DDI-DrugBank.d213.s0|0-5|Iodine|brand
DDI-DrugBank.d213.s0|7-8|or|drug
DDI-DrugBank.d213.s0|10-15|iodine|drug
DDI-DrugBank.d213.s0|17-22|excess|drug
DDI-DrugBank.d213.s0|24-26|may|drug
DDI-DrugBank.d213.s0|28-35|decrease|drug
DDI-DrugBank.d213.s0|37-39|the|drug
DDI-DrugBank.d213.s0|41-46|effect|drug
DDI-DrugBank.d213.s0|48-49|of|drug
DDI-DrugBank.d213.s0|51-61|Carbimazole|drug
DDI-DrugBank.d213.s0|62-62|,|drug
DDI-DrugBank.d213.s0|64-66|and|drug
DDI-DrugBank.d213.s0|68-69|an|drug
DDI-DrugBank.d213.s0|71-76|iodine|drug
DDI-DrugBank.d213.s0|78-87|deficiency|drug
DDI-DrugBank.d213.s0|89-91|can|drug
DDI-DrugBank.d213.s0|93-100|increase|drug
DDI-DrugBank.d213.s0|102-104|the|drug
DDI-DrugBank.d213.s0|106-111|effect|drug
DDI-DrugBank.d213.s0|113-114|of|drug
DDI-DrugBank.d213.s0|116-126|Carbimazole|drug
DDI-DrugBank.d213.s0|127-127|.|drug
DDI-DrugBank.d213.s1|0-4|Serum|group
DDI-DrugBank.d213.s1|6-18|concentration|drug
DDI-DrugBank.d213.s1|20-21|of|drug
DDI-DrugBank.d213.s1|23-29|digoxin|drug
DDI-DrugBank.d213.s1|31-33|and|drug
DDI-DrugBank.d213.s1|35-43|digitoxin|drug
DDI-DrugBank.d213.s1|45-47|may|drug
DDI-DrugBank.d213.s1|49-56|increase|drug
DDI-DrugBank.d213.s1|58-61|when|drug
DDI-DrugBank.d213.s1|63-70|patients|drug
DDI-DrugBank.d213.s1|72-75|take|drug
DDI-DrugBank.d213.s1|77-87|antithyroid|drug
DDI-DrugBank.d213.s1|89-94|agents|drug
DDI-DrugBank.d213.s1|95-95|.|drug
DDI-DrugBank.d213.s2|0-0|A|drug
DDI-DrugBank.d213.s2|2-9|decrease|drug
DDI-DrugBank.d213.s2|11-12|of|drug
DDI-DrugBank.d213.s2|14-16|the|drug
DDI-DrugBank.d213.s2|18-23|dosage|drug
DDI-DrugBank.d213.s2|25-27|may|drug
DDI-DrugBank.d213.s2|29-30|be|drug
DDI-DrugBank.d213.s2|32-40|necessary|drug
DDI-DrugBank.d213.s2|42-45|when|drug
DDI-DrugBank.d213.s2|47-53|patient|drug
DDI-DrugBank.d213.s2|55-61|becomes|drug
DDI-DrugBank.d213.s2|63-71|euthyroid|drug
DDI-DrugBank.d213.s2|72-72|.|drug
DDI-DrugBank.d213.s3|0-10|Antithyroid|drug
DDI-DrugBank.d213.s3|12-17|agents|drug
DDI-DrugBank.d213.s3|19-21|may|drug
DDI-DrugBank.d213.s3|23-30|decrease|drug
DDI-DrugBank.d213.s3|32-40|thyroidal|drug
DDI-DrugBank.d213.s3|42-47|uptake|drug
DDI-DrugBank.d213.s3|49-50|of|drug
DDI-DrugBank.d213.s3|52-57|sodium|drug
DDI-DrugBank.d213.s3|59-64|iodide|drug
DDI-DrugBank.d213.s3|66-69|I131|drug
DDI-DrugBank.d213.s3|70-70|,|drug
DDI-DrugBank.d213.s3|72-72|a|drug
DDI-DrugBank.d213.s3|74-80|rebound|drug
DDI-DrugBank.d213.s3|82-83|in|drug
DDI-DrugBank.d213.s3|85-90|uptake|drug
DDI-DrugBank.d213.s3|92-94|may|drug
DDI-DrugBank.d213.s3|96-100|occur|drug
DDI-DrugBank.d213.s3|102-103|up|drug
DDI-DrugBank.d213.s3|105-106|to|drug
DDI-DrugBank.d213.s3|108-108|5|drug
DDI-DrugBank.d213.s3|110-113|days|drug
DDI-DrugBank.d213.s3|115-119|after|drug
DDI-DrugBank.d213.s3|121-126|sudden|drug
DDI-DrugBank.d213.s3|128-137|withdrawal|drug
DDI-DrugBank.d213.s3|139-140|of|drug
DDI-DrugBank.d213.s3|142-152|Carbimazole|drug
DDI-DrugBank.d213.s3|153-153|.|drug
DDI-DrugBank.d213.s4|0-7|Patients|drug
DDI-DrugBank.d213.s4|9-16|response|drug
DDI-DrugBank.d213.s4|18-19|to|drug
DDI-DrugBank.d213.s4|21-24|oral|drug
DDI-DrugBank.d213.s4|26-39|anticoagulants|drug
DDI-DrugBank.d213.s4|41-43|may|drug
DDI-DrugBank.d213.s4|45-46|be|drug
DDI-DrugBank.d213.s4|48-55|affected|drug
DDI-DrugBank.d213.s4|57-58|by|drug
DDI-DrugBank.d213.s4|60-66|his/her|drug
DDI-DrugBank.d213.s4|68-74|thyroid|drug
DDI-DrugBank.d213.s4|76-78|and|drug
DDI-DrugBank.d213.s4|80-88|metabolic|drug
DDI-DrugBank.d213.s4|90-95|status|drug
DDI-DrugBank.d213.s4|96-96|.|drug
DDI-DrugBank.d213.s5|0-1|An|drug
DDI-DrugBank.d213.s5|3-12|evaluation|drug
DDI-DrugBank.d213.s5|14-15|of|drug
DDI-DrugBank.d213.s5|17-27|prothrombin|drug
DDI-DrugBank.d213.s5|29-32|time|drug
DDI-DrugBank.d213.s5|34-36|and|drug
DDI-DrugBank.d213.s5|38-39|an|drug
DDI-DrugBank.d213.s5|41-50|adjustment|drug
DDI-DrugBank.d213.s5|52-53|of|drug
DDI-DrugBank.d213.s5|55-67|anticoagulant|drug
DDI-DrugBank.d213.s5|69-74|dosage|drug
DDI-DrugBank.d213.s5|76-78|are|drug
DDI-DrugBank.d213.s5|80-90|recommended|drug
DDI-DrugBank.d416.s0|0-4|Renal|drug
DDI-DrugBank.d416.s0|6-14|clearance|drug
DDI-DrugBank.d416.s0|16-27|measurements|drug
DDI-DrugBank.d416.s0|29-30|of|drug
DDI-DrugBank.d416.s0|32-34|PAH|drug
DDI-DrugBank.d416.s0|36-38|can|drug
DDI-DrugBank.d416.s0|39-41|not|drug
DDI-DrugBank.d416.s0|43-44|be|drug
DDI-DrugBank.d416.s0|46-49|made|drug
DDI-DrugBank.d416.s0|51-54|with|drug
DDI-DrugBank.d416.s0|56-58|any|drug
DDI-DrugBank.d416.s0|60-70|significant|drug
DDI-DrugBank.d416.s0|72-79|accuracy|drug
DDI-DrugBank.d416.s0|81-82|in|drug
DDI-DrugBank.d416.s0|84-91|patients|drug
DDI-DrugBank.d416.s0|93-101|receiving|drug
DDI-DrugBank.d416.s0|103-114|sulfonamides|drug
DDI-DrugBank.d416.s0|115-115|,|drug
DDI-DrugBank.d416.s0|117-124|procaine|drug
DDI-DrugBank.d416.s0|125-125|,|drug
DDI-DrugBank.d416.s0|127-128|or|drug
DDI-DrugBank.d416.s0|130-144|thiazolesulfone|drug
DDI-DrugBank.d416.s0|145-145|.|drug
DDI-DrugBank.d416.s1|0-4|These|drug
DDI-DrugBank.d416.s1|6-14|compounds|drug
DDI-DrugBank.d416.s1|16-24|interfere|drug
DDI-DrugBank.d416.s1|26-29|with|drug
DDI-DrugBank.d416.s1|31-38|chemical|drug
DDI-DrugBank.d416.s1|40-44|color|drug
DDI-DrugBank.d416.s1|46-56|development|drug
DDI-DrugBank.d416.s1|58-66|essential|drug
DDI-DrugBank.d416.s1|68-69|to|drug
DDI-DrugBank.d416.s1|71-73|the|drug
DDI-DrugBank.d416.s1|75-84|analytical|drug
DDI-DrugBank.d416.s1|86-95|procedures|drug
DDI-DrugBank.d416.s1|96-96|.|drug
DDI-DrugBank.d416.s2|0-9|Probenecid|brand
DDI-DrugBank.d416.s2|11-19|depresses|drug
DDI-DrugBank.d416.s2|21-27|tubular|drug
DDI-DrugBank.d416.s2|29-37|secretion|drug
DDI-DrugBank.d416.s2|39-40|of|drug
DDI-DrugBank.d416.s2|42-48|certain|drug
DDI-DrugBank.d416.s2|50-53|weak|drug
DDI-DrugBank.d416.s2|55-59|acids|drug
DDI-DrugBank.d416.s2|61-64|such|drug
DDI-DrugBank.d416.s2|66-67|as|drug
DDI-DrugBank.d416.s2|69-71|PAH|drug
DDI-DrugBank.d416.s2|72-72|.|drug
DDI-DrugBank.d416.s3|0-8|Therefore|drug
DDI-DrugBank.d416.s3|9-9|,|drug
DDI-DrugBank.d416.s3|11-18|patients|drug
DDI-DrugBank.d416.s3|20-28|receiving|drug
DDI-DrugBank.d416.s3|30-39|probenecid|drug
DDI-DrugBank.d416.s3|41-44|will|drug
DDI-DrugBank.d416.s3|46-49|have|drug
DDI-DrugBank.d416.s3|51-61|erroneously|drug
DDI-DrugBank.d416.s3|63-65|low|drug
DDI-DrugBank.d416.s3|67-70|ERPF|drug
DDI-DrugBank.d416.s3|72-74|and|drug
DDI-DrugBank.d416.s3|76-77|Tm|drug
DDI-DrugBank.d416.s3|79-81|PAH|drug
DDI-DrugBank.d416.s3|83-88|values|drug
DDI-DrugBank.d416.s3|89-89|.|drug
DDI-DrugBank.d694.s0|0-6|Digoxin|brand
DDI-DrugBank.d694.s0|7-7|:|drug
DDI-DrugBank.d694.s0|9-13|There|drug
DDI-DrugBank.d694.s0|15-17|was|drug
DDI-DrugBank.d694.s0|19-19|a|drug
DDI-DrugBank.d694.s0|21-26|slight|drug
DDI-DrugBank.d694.s0|28-35|increase|drug
DDI-DrugBank.d694.s0|37-38|in|drug
DDI-DrugBank.d694.s0|40-42|the|drug
DDI-DrugBank.d694.s0|44-47|area|drug
DDI-DrugBank.d694.s0|49-53|under|drug
DDI-DrugBank.d694.s0|55-57|the|drug
DDI-DrugBank.d694.s0|59-63|curve|drug
DDI-DrugBank.d694.s0|65-65|(|drug
DDI-DrugBank.d694.s0|66-68|AUC|drug
DDI-DrugBank.d694.s0|69-69|,|drug
DDI-DrugBank.d694.s0|71-72|11|drug
DDI-DrugBank.d694.s0|73-73|%|drug
DDI-DrugBank.d694.s0|74-74|)|drug
DDI-DrugBank.d694.s0|76-78|and|drug
DDI-DrugBank.d694.s0|80-83|mean|drug
DDI-DrugBank.d694.s0|85-88|peak|drug
DDI-DrugBank.d694.s0|90-93|drug|drug
DDI-DrugBank.d694.s0|95-107|concentration|drug
DDI-DrugBank.d694.s0|109-109|(|drug
DDI-DrugBank.d694.s0|110-113|Cmax|drug
DDI-DrugBank.d694.s0|114-114|,|drug
DDI-DrugBank.d694.s0|116-117|18|drug
DDI-DrugBank.d694.s0|118-118|%|drug
DDI-DrugBank.d694.s0|119-119|)|drug
DDI-DrugBank.d694.s0|121-122|of|drug
DDI-DrugBank.d694.s0|124-130|digoxin|drug
DDI-DrugBank.d694.s0|132-135|with|drug
DDI-DrugBank.d694.s0|137-139|the|drug
DDI-DrugBank.d694.s0|141-157|co-administration|drug
DDI-DrugBank.d694.s0|159-160|of|drug
DDI-DrugBank.d694.s0|162-164|100|drug
DDI-DrugBank.d694.s0|166-167|mg|drug
DDI-DrugBank.d694.s0|169-179|sitagliptin|drug
DDI-DrugBank.d694.s0|181-183|for|drug
DDI-DrugBank.d694.s0|185-186|10|drug
DDI-DrugBank.d694.s0|188-191|days|drug
DDI-DrugBank.d694.s0|192-192|.|drug
DDI-DrugBank.d694.s1|0-7|Patients|drug
DDI-DrugBank.d694.s1|9-17|receiving|drug
DDI-DrugBank.d694.s1|19-25|digoxin|drug
DDI-DrugBank.d694.s1|27-32|should|drug
DDI-DrugBank.d694.s1|34-35|be|drug
DDI-DrugBank.d694.s1|37-45|monitored|drug
DDI-DrugBank.d694.s1|47-59|appropriately|drug
DDI-DrugBank.d694.s1|60-60|.|drug
DDI-DrugBank.d694.s2|0-1|No|drug
DDI-DrugBank.d694.s2|3-8|dosage|drug
DDI-DrugBank.d694.s2|10-19|adjustment|drug
DDI-DrugBank.d694.s2|21-22|of|drug
DDI-DrugBank.d694.s2|24-30|digoxin|drug
DDI-DrugBank.d694.s2|32-33|or|drug
DDI-DrugBank.d694.s2|35-41|JANUVIA|drug
DDI-DrugBank.d694.s2|43-44|is|drug
DDI-DrugBank.d694.s2|46-56|recommended|drug
DDI-DrugBank.d694.s2|57-57|.|drug
DDI-DrugBank.d44.s0|0-1|No|drug
DDI-DrugBank.d44.s0|3-8|formal|drug
DDI-DrugBank.d44.s0|10-13|drug|drug
DDI-DrugBank.d44.s0|15-25|interaction|drug
DDI-DrugBank.d44.s0|27-33|studies|drug
DDI-DrugBank.d44.s0|35-38|have|drug
DDI-DrugBank.d44.s0|40-43|been|drug
DDI-DrugBank.d44.s0|45-53|performed|drug
DDI-DrugBank.d44.s0|55-58|with|drug
DDI-DrugBank.d44.s0|60-66|RAPTIVA|drug
DDI-DrugBank.d44.s0|67-67|.|drug
DDI-DrugBank.d44.s1|0-6|RAPTIVA|drug
DDI-DrugBank.d44.s1|8-13|should|drug
DDI-DrugBank.d44.s1|15-17|not|drug
DDI-DrugBank.d44.s1|19-20|be|drug
DDI-DrugBank.d44.s1|22-25|used|drug
DDI-DrugBank.d44.s1|27-30|with|drug
DDI-DrugBank.d44.s1|32-36|other|drug
DDI-DrugBank.d44.s1|38-54|immunosuppressive|drug
DDI-DrugBank.d44.s1|56-60|drugs|drug
DDI-DrugBank.d44.s1|61-61|.|drug
DDI-DrugBank.d44.s2|0-8|Acellular|drug
DDI-DrugBank.d44.s2|9-9|,|drug
DDI-DrugBank.d44.s2|11-14|live|drug
DDI-DrugBank.d44.s2|16-18|and|drug
DDI-DrugBank.d44.s2|20-34|live-attenuated|drug
DDI-DrugBank.d44.s2|36-43|vaccines|drug
DDI-DrugBank.d44.s2|45-50|should|drug
DDI-DrugBank.d44.s2|52-54|not|drug
DDI-DrugBank.d44.s2|56-57|be|drug
DDI-DrugBank.d44.s2|59-70|administered|drug
DDI-DrugBank.d44.s2|72-77|during|drug
DDI-DrugBank.d44.s2|79-85|RAPTIVA|drug
DDI-DrugBank.d44.s2|87-95|treatment|drug
DDI-DrugBank.d44.s2|96-96|.|drug
DDI-DrugBank.d44.s3|0-14|Drug/Laboratory|drug
DDI-DrugBank.d44.s3|16-19|Test|drug
DDI-DrugBank.d44.s3|21-32|Interactions|drug
DDI-DrugBank.d44.s3|34-42|Increases|drug
DDI-DrugBank.d44.s3|44-45|in|drug
DDI-DrugBank.d44.s3|47-56|lymphocyte|drug
DDI-DrugBank.d44.s3|58-63|counts|drug
DDI-DrugBank.d44.s3|65-71|related|drug
DDI-DrugBank.d44.s3|73-74|to|drug
DDI-DrugBank.d44.s3|76-78|the|drug
DDI-DrugBank.d44.s3|80-92|pharmacologic|drug
DDI-DrugBank.d44.s3|94-102|mechanism|drug
DDI-DrugBank.d44.s3|104-105|of|drug
DDI-DrugBank.d44.s3|107-112|action|drug
DDI-DrugBank.d44.s3|114-116|are|drug
DDI-DrugBank.d44.s3|118-127|frequently|drug
DDI-DrugBank.d44.s3|129-136|observed|drug
DDI-DrugBank.d44.s3|138-143|during|drug
DDI-DrugBank.d44.s3|145-151|RAPTIVA|drug
DDI-DrugBank.d44.s3|153-161|treatment|drug
DDI-DrugBank.d44.s3|162-162|.|drug
DDI-DrugBank.d237.s0|0-8|Cisapride|drug
DDI-DrugBank.d237.s0|10-11|is|drug
DDI-DrugBank.d237.s0|13-23|metabolized|drug
DDI-DrugBank.d237.s0|25-30|mainly|drug
DDI-DrugBank.d237.s0|32-34|via|drug
DDI-DrugBank.d237.s0|36-38|the|drug
DDI-DrugBank.d237.s0|40-49|cytochrome|drug
DDI-DrugBank.d237.s0|51-54|P450|drug
DDI-DrugBank.d237.s0|56-58|3A4|drug
DDI-DrugBank.d237.s0|60-65|enzyme|drug
DDI-DrugBank.d237.s0|66-66|.|drug
DDI-DrugBank.d237.s1|0-1|In|drug
DDI-DrugBank.d237.s1|3-6|some|drug
DDI-DrugBank.d237.s1|8-12|cases|drug
DDI-DrugBank.d237.s1|14-18|where|drug
DDI-DrugBank.d237.s1|20-26|serious|drug
DDI-DrugBank.d237.s1|28-38|ventricular|drug
DDI-DrugBank.d237.s1|40-50|arrhythmias|drug
DDI-DrugBank.d237.s1|51-51|,|drug
DDI-DrugBank.d237.s1|53-54|QT|drug
DDI-DrugBank.d237.s1|56-67|prolongation|drug
DDI-DrugBank.d237.s1|68-68|,|drug
DDI-DrugBank.d237.s1|70-72|and|drug
DDI-DrugBank.d237.s1|74-81|torsades|drug
DDI-DrugBank.d237.s1|83-84|de|drug
DDI-DrugBank.d237.s1|86-92|pointes|drug
DDI-DrugBank.d237.s1|94-97|have|drug
DDI-DrugBank.d237.s1|99-106|occurred|drug
DDI-DrugBank.d237.s1|108-111|when|drug
DDI-DrugBank.d237.s1|113-121|cisapride|drug
DDI-DrugBank.d237.s1|123-125|was|drug
DDI-DrugBank.d237.s1|127-131|taken|drug
DDI-DrugBank.d237.s1|133-134|in|drug
DDI-DrugBank.d237.s1|136-146|conjunction|drug
DDI-DrugBank.d237.s1|148-151|with|drug
DDI-DrugBank.d237.s1|153-155|one|drug
DDI-DrugBank.d237.s1|157-158|of|drug
DDI-DrugBank.d237.s1|160-162|the|drug
DDI-DrugBank.d237.s1|164-173|cytochrome|drug
DDI-DrugBank.d237.s1|175-178|P450|drug
DDI-DrugBank.d237.s1|180-182|3A4|drug
DDI-DrugBank.d237.s1|184-193|inhibitors|drug
DDI-DrugBank.d237.s1|194-194|,|drug
DDI-DrugBank.d237.s1|196-203|elevated|drug
DDI-DrugBank.d237.s1|205-209|blood|drug
DDI-DrugBank.d237.s1|211-219|cisapride|drug
DDI-DrugBank.d237.s1|221-226|levels|drug
DDI-DrugBank.d237.s1|228-231|were|drug
DDI-DrugBank.d237.s1|233-237|noted|drug
DDI-DrugBank.d237.s1|239-240|at|drug
DDI-DrugBank.d237.s1|242-244|the|drug
DDI-DrugBank.d237.s1|246-249|time|drug
DDI-DrugBank.d237.s1|251-252|of|drug
DDI-DrugBank.d237.s1|254-256|the|drug
DDI-DrugBank.d237.s1|258-259|QT|drug
DDI-DrugBank.d237.s1|261-272|prolongation|drug
DDI-DrugBank.d237.s1|273-273|.|drug
DDI-DrugBank.d237.s2|0-10|Antibiotics|drug
DDI-DrugBank.d237.s2|11-11|:|drug
DDI-DrugBank.d237.s2|13-14|In|drug
DDI-DrugBank.d237.s2|16-20|vitro|drug
DDI-DrugBank.d237.s2|22-27|and/or|drug
DDI-DrugBank.d237.s2|29-30|in|drug
DDI-DrugBank.d237.s2|32-35|vivo|drug
DDI-DrugBank.d237.s2|37-40|data|drug
DDI-DrugBank.d237.s2|42-45|show|drug
DDI-DrugBank.d237.s2|47-50|that|drug
DDI-DrugBank.d237.s2|52-65|clarithromycin|drug
DDI-DrugBank.d237.s2|66-66|,|drug
DDI-DrugBank.d237.s2|68-79|erythromycin|drug
DDI-DrugBank.d237.s2|80-80|,|drug
DDI-DrugBank.d237.s2|82-84|and|drug
DDI-DrugBank.d237.s2|86-99|troleandomycin|drug
DDI-DrugBank.d237.s2|101-108|markedly|drug
DDI-DrugBank.d237.s2|110-116|inhibit|drug
DDI-DrugBank.d237.s2|118-120|the|drug
DDI-DrugBank.d237.s2|122-131|metabolism|drug
DDI-DrugBank.d237.s2|133-134|of|drug
DDI-DrugBank.d237.s2|136-144|cisapride|drug
DDI-DrugBank.d237.s2|145-145|,|drug
DDI-DrugBank.d237.s2|147-151|which|drug
DDI-DrugBank.d237.s2|153-155|can|drug
DDI-DrugBank.d237.s2|157-162|result|drug
DDI-DrugBank.d237.s2|164-165|in|drug
DDI-DrugBank.d237.s2|167-168|an|drug
DDI-DrugBank.d237.s2|170-177|increase|drug
DDI-DrugBank.d237.s2|179-180|in|drug
DDI-DrugBank.d237.s2|182-187|plasma|drug
DDI-DrugBank.d237.s2|189-197|cisapride|drug
DDI-DrugBank.d237.s2|199-204|levels|drug
DDI-DrugBank.d237.s2|206-208|and|drug
DDI-DrugBank.d237.s2|210-221|prolongation|drug
DDI-DrugBank.d237.s2|223-224|of|drug
DDI-DrugBank.d237.s2|226-228|the|drug
DDI-DrugBank.d237.s2|230-231|QT|drug
DDI-DrugBank.d237.s2|233-240|interval|drug
DDI-DrugBank.d237.s2|242-243|on|drug
DDI-DrugBank.d237.s2|245-247|the|drug
DDI-DrugBank.d237.s2|249-251|ECG|drug
DDI-DrugBank.d237.s2|252-252|.|drug
DDI-DrugBank.d237.s3|0-15|Anticholinergics|drug
DDI-DrugBank.d237.s3|16-16|:|drug
DDI-DrugBank.d237.s3|18-27|Concurrent|drug
DDI-DrugBank.d237.s3|29-42|administration|drug
DDI-DrugBank.d237.s3|44-45|of|drug
DDI-DrugBank.d237.s3|47-53|certain|drug
DDI-DrugBank.d237.s3|55-69|anticholinergic|drug
DDI-DrugBank.d237.s3|71-79|compounds|drug
DDI-DrugBank.d237.s3|80-80|,|drug
DDI-DrugBank.d237.s3|82-85|such|drug
DDI-DrugBank.d237.s3|87-88|as|drug
DDI-DrugBank.d237.s3|90-99|belladonna|drug
DDI-DrugBank.d237.s3|101-109|alkaloids|drug
DDI-DrugBank.d237.s3|111-113|and|drug
DDI-DrugBank.d237.s3|115-125|dicyclomine|drug
DDI-DrugBank.d237.s3|126-126|,|drug
DDI-DrugBank.d237.s3|128-132|would|drug
DDI-DrugBank.d237.s3|134-135|be|drug
DDI-DrugBank.d237.s3|137-144|expected|drug
DDI-DrugBank.d237.s3|146-147|to|drug
DDI-DrugBank.d237.s3|149-158|compromise|drug
DDI-DrugBank.d237.s3|160-162|the|drug
DDI-DrugBank.d237.s3|164-173|beneficial|drug
DDI-DrugBank.d237.s3|175-181|effects|drug
DDI-DrugBank.d237.s3|183-184|of|drug
DDI-DrugBank.d237.s3|186-194|cisapride|drug
DDI-DrugBank.d237.s3|195-195|.|drug
DDI-DrugBank.d237.s4|0-13|Anticoagulants|group
DDI-DrugBank.d237.s4|15-15|(|drug
DDI-DrugBank.d237.s4|16-19|Oral|drug
DDI-DrugBank.d237.s4|20-20|)|drug
DDI-DrugBank.d237.s4|21-21|:|drug
DDI-DrugBank.d237.s4|23-24|In|drug
DDI-DrugBank.d237.s4|26-33|patients|drug
DDI-DrugBank.d237.s4|35-43|receiving|drug
DDI-DrugBank.d237.s4|45-48|oral|drug
DDI-DrugBank.d237.s4|50-63|anticoagulants|drug
DDI-DrugBank.d237.s4|64-64|,|drug
DDI-DrugBank.d237.s4|66-68|the|drug
DDI-DrugBank.d237.s4|70-80|coagulation|drug
DDI-DrugBank.d237.s4|82-86|times|drug
DDI-DrugBank.d237.s4|88-91|were|drug
DDI-DrugBank.d237.s4|93-101|increased|drug
DDI-DrugBank.d237.s4|103-104|in|drug
DDI-DrugBank.d237.s4|106-109|some|drug
DDI-DrugBank.d237.s4|111-115|cases|drug
DDI-DrugBank.d237.s4|116-116|.|drug
DDI-DrugBank.d237.s5|0-1|It|drug
DDI-DrugBank.d237.s5|3-4|is|drug
DDI-DrugBank.d237.s5|6-14|advisable|drug
DDI-DrugBank.d237.s5|16-17|to|drug
DDI-DrugBank.d237.s5|19-23|check|drug
DDI-DrugBank.d237.s5|25-35|coagulation|drug
DDI-DrugBank.d237.s5|37-40|time|drug
DDI-DrugBank.d237.s5|42-47|within|drug
DDI-DrugBank.d237.s5|49-51|the|drug
DDI-DrugBank.d237.s5|53-57|first|drug
DDI-DrugBank.d237.s5|59-61|few|drug
DDI-DrugBank.d237.s5|63-66|days|drug
DDI-DrugBank.d237.s5|68-72|after|drug
DDI-DrugBank.d237.s5|74-76|the|drug
DDI-DrugBank.d237.s5|78-82|start|drug
DDI-DrugBank.d237.s5|84-86|and|drug
DDI-DrugBank.d237.s5|88-102|discontinuation|drug
DDI-DrugBank.d237.s5|104-105|of|drug
DDI-DrugBank.d237.s5|107-115|cisapride|drug
DDI-DrugBank.d237.s5|117-123|therapy|drug
DDI-DrugBank.d237.s5|124-124|,|drug
DDI-DrugBank.d237.s5|126-129|with|drug
DDI-DrugBank.d237.s5|131-132|an|drug
DDI-DrugBank.d237.s5|134-144|appropriate|drug
DDI-DrugBank.d237.s5|146-155|adjustment|drug
DDI-DrugBank.d237.s5|157-158|of|drug
DDI-DrugBank.d237.s5|160-162|the|drug
DDI-DrugBank.d237.s5|164-176|anticoagulant|drug
DDI-DrugBank.d237.s5|178-181|dose|drug
DDI-DrugBank.d237.s5|182-182|,|drug
DDI-DrugBank.d237.s5|184-185|if|drug
DDI-DrugBank.d237.s5|187-195|necessary|drug
DDI-DrugBank.d237.s5|196-196|.|drug
DDI-DrugBank.d237.s6|0-14|Antidepressants|drug
DDI-DrugBank.d237.s6|15-15|:|drug
DDI-DrugBank.d237.s6|17-18|In|drug
DDI-DrugBank.d237.s6|20-24|vitro|drug
DDI-DrugBank.d237.s6|26-29|data|drug
DDI-DrugBank.d237.s6|31-38|indicate|drug
DDI-DrugBank.d237.s6|40-43|that|drug
DDI-DrugBank.d237.s6|45-54|nefazodone|drug
DDI-DrugBank.d237.s6|56-63|inhibits|drug
DDI-DrugBank.d237.s6|65-67|the|drug
DDI-DrugBank.d237.s6|69-78|metabolism|drug
DDI-DrugBank.d237.s6|80-81|of|drug
DDI-DrugBank.d237.s6|83-91|cisapride|drug
DDI-DrugBank.d237.s6|92-92|,|drug
DDI-DrugBank.d237.s6|94-98|which|drug
DDI-DrugBank.d237.s6|100-102|can|drug
DDI-DrugBank.d237.s6|104-109|result|drug
DDI-DrugBank.d237.s6|111-112|in|drug
DDI-DrugBank.d237.s6|114-115|an|drug
DDI-DrugBank.d237.s6|117-124|increase|drug
DDI-DrugBank.d237.s6|126-127|in|drug
DDI-DrugBank.d237.s6|129-134|plasma|drug
DDI-DrugBank.d237.s6|136-144|cisapride|drug
DDI-DrugBank.d237.s6|146-151|levels|drug
DDI-DrugBank.d237.s6|153-155|and|drug
DDI-DrugBank.d237.s6|157-168|prolongation|drug
DDI-DrugBank.d237.s6|170-171|of|drug
DDI-DrugBank.d237.s6|173-175|the|drug
DDI-DrugBank.d237.s6|177-178|QT|drug
DDI-DrugBank.d237.s6|180-187|interval|drug
DDI-DrugBank.d237.s6|189-190|on|drug
DDI-DrugBank.d237.s6|192-194|the|drug
DDI-DrugBank.d237.s6|196-198|ECG|drug
DDI-DrugBank.d237.s6|199-199|.|drug
DDI-DrugBank.d237.s7|0-10|Antifungals|drug
DDI-DrugBank.d237.s7|11-11|:|drug
DDI-DrugBank.d237.s7|13-14|In|drug
DDI-DrugBank.d237.s7|16-20|vitro|drug
DDI-DrugBank.d237.s7|22-27|and/or|drug
DDI-DrugBank.d237.s7|29-30|in|drug
DDI-DrugBank.d237.s7|32-35|vivo|drug
DDI-DrugBank.d237.s7|37-40|data|drug
DDI-DrugBank.d237.s7|42-49|indicate|drug
DDI-DrugBank.d237.s7|51-54|that|drug
DDI-DrugBank.d237.s7|56-66|fluconazole|drug
DDI-DrugBank.d237.s7|67-67|,|drug
DDI-DrugBank.d237.s7|69-80|itraconazole|drug
DDI-DrugBank.d237.s7|81-81|,|drug
DDI-DrugBank.d237.s7|83-85|and|drug
DDI-DrugBank.d237.s7|87-90|oral|drug
DDI-DrugBank.d237.s7|92-103|ketoconazole|drug
DDI-DrugBank.d237.s7|105-112|markedly|drug
DDI-DrugBank.d237.s7|114-120|inhibit|drug
DDI-DrugBank.d237.s7|122-124|the|drug
DDI-DrugBank.d237.s7|126-135|metabolism|drug
DDI-DrugBank.d237.s7|137-138|of|drug
DDI-DrugBank.d237.s7|140-148|cisapride|drug
DDI-DrugBank.d237.s7|149-149|,|drug
DDI-DrugBank.d237.s7|151-155|which|drug
DDI-DrugBank.d237.s7|157-159|can|drug
DDI-DrugBank.d237.s7|161-166|result|drug
DDI-DrugBank.d237.s7|168-169|in|drug
DDI-DrugBank.d237.s7|171-172|an|drug
DDI-DrugBank.d237.s7|174-181|increase|drug
DDI-DrugBank.d237.s7|183-184|in|drug
DDI-DrugBank.d237.s7|186-191|plasma|drug
DDI-DrugBank.d237.s7|193-201|cisapride|drug
DDI-DrugBank.d237.s7|203-208|levels|drug
DDI-DrugBank.d237.s7|210-212|and|drug
DDI-DrugBank.d237.s7|214-225|prolongation|drug
DDI-DrugBank.d237.s7|227-228|of|drug
DDI-DrugBank.d237.s7|230-232|the|drug
DDI-DrugBank.d237.s7|234-235|QT|drug
DDI-DrugBank.d237.s7|237-244|interval|drug
DDI-DrugBank.d237.s7|246-247|on|drug
DDI-DrugBank.d237.s7|249-251|the|drug
DDI-DrugBank.d237.s7|253-255|ECG|drug
DDI-DrugBank.d237.s7|256-256|.|drug
DDI-DrugBank.d237.s8|0-4|Human|drug
DDI-DrugBank.d237.s8|6-20|pharmacokinetic|drug
DDI-DrugBank.d237.s8|22-25|data|drug
DDI-DrugBank.d237.s8|27-34|indicate|drug
DDI-DrugBank.d237.s8|36-39|that|drug
DDI-DrugBank.d237.s8|41-44|oral|drug
DDI-DrugBank.d237.s8|46-57|ketoconazole|drug
DDI-DrugBank.d237.s8|59-66|markedly|drug
DDI-DrugBank.d237.s8|68-75|inhibits|drug
DDI-DrugBank.d237.s8|77-79|the|drug
DDI-DrugBank.d237.s8|81-90|metabolism|drug
DDI-DrugBank.d237.s8|92-93|of|drug
DDI-DrugBank.d237.s8|95-103|cisapride|drug
DDI-DrugBank.d237.s8|104-104|,|drug
DDI-DrugBank.d237.s8|106-114|resulting|drug
DDI-DrugBank.d237.s8|116-117|in|drug
DDI-DrugBank.d237.s8|119-119|a|drug
DDI-DrugBank.d237.s8|121-124|mean|drug
DDI-DrugBank.d237.s8|126-135|eight-fold|drug
DDI-DrugBank.d237.s8|137-144|increase|drug
DDI-DrugBank.d237.s8|146-147|in|drug
DDI-DrugBank.d237.s8|149-151|AUC|drug
DDI-DrugBank.d237.s8|153-154|of|drug
DDI-DrugBank.d237.s8|156-164|cisapride|drug
DDI-DrugBank.d237.s8|165-165|.|drug
DDI-DrugBank.d237.s9|0-0|A|drug
DDI-DrugBank.d237.s9|2-6|study|drug
DDI-DrugBank.d237.s9|8-9|in|drug
DDI-DrugBank.d237.s9|11-12|14|drug
DDI-DrugBank.d237.s9|14-19|normal|drug
DDI-DrugBank.d237.s9|21-24|male|drug
DDI-DrugBank.d237.s9|26-28|and|drug
DDI-DrugBank.d237.s9|30-35|female|drug
DDI-DrugBank.d237.s9|37-46|volunteers|drug
DDI-DrugBank.d237.s9|48-55|suggests|drug
DDI-DrugBank.d237.s9|57-60|that|drug
DDI-DrugBank.d237.s9|62-77|coadministration|drug
DDI-DrugBank.d237.s9|79-80|of|drug
DDI-DrugBank.d237.s9|82-90|cisapride|drug
DDI-DrugBank.d237.s9|92-94|and|drug
DDI-DrugBank.d237.s9|96-107|ketoconazole|drug
DDI-DrugBank.d237.s9|109-111|can|drug
DDI-DrugBank.d237.s9|113-118|result|drug
DDI-DrugBank.d237.s9|120-121|in|drug
DDI-DrugBank.d237.s9|123-134|prolongation|drug
DDI-DrugBank.d237.s9|136-137|of|drug
DDI-DrugBank.d237.s9|139-141|the|drug
DDI-DrugBank.d237.s9|143-144|QT|drug
DDI-DrugBank.d237.s9|146-153|interval|drug
DDI-DrugBank.d237.s9|155-156|on|drug
DDI-DrugBank.d237.s9|158-160|the|drug
DDI-DrugBank.d237.s9|162-164|ECG|drug
DDI-DrugBank.d237.s9|165-165|.|drug
DDI-DrugBank.d237.s10|0-1|H2|drug
DDI-DrugBank.d237.s10|3-10|Receptor|drug
DDI-DrugBank.d237.s10|12-22|Antagonists|drug
DDI-DrugBank.d237.s10|23-23|:|drug
DDI-DrugBank.d237.s10|25-34|Cimetidine|brand
DDI-DrugBank.d237.s10|36-51|coadministration|drug
DDI-DrugBank.d237.s10|53-57|leads|drug
DDI-DrugBank.d237.s10|59-60|to|drug
DDI-DrugBank.d237.s10|62-63|an|drug
DDI-DrugBank.d237.s10|65-73|increased|drug
DDI-DrugBank.d237.s10|75-78|peak|drug
DDI-DrugBank.d237.s10|80-85|plasma|drug
DDI-DrugBank.d237.s10|87-99|concentration|drug
DDI-DrugBank.d237.s10|101-103|and|drug
DDI-DrugBank.d237.s10|105-107|AUC|drug
DDI-DrugBank.d237.s10|109-110|of|drug
DDI-DrugBank.d237.s10|112-120|cisapride|drug
DDI-DrugBank.d237.s10|121-121|,|drug
DDI-DrugBank.d237.s10|123-127|there|drug
DDI-DrugBank.d237.s10|129-130|is|drug
DDI-DrugBank.d237.s10|132-133|no|drug
DDI-DrugBank.d237.s10|135-140|effect|drug
DDI-DrugBank.d237.s10|142-143|on|drug
DDI-DrugBank.d237.s10|145-153|cisapride|drug
DDI-DrugBank.d237.s10|155-164|absorption|drug
DDI-DrugBank.d237.s10|166-169|when|drug
DDI-DrugBank.d237.s10|171-172|it|drug
DDI-DrugBank.d237.s10|174-175|is|drug
DDI-DrugBank.d237.s10|177-190|coadministered|drug
DDI-DrugBank.d237.s10|192-195|with|drug
DDI-DrugBank.d237.s10|197-206|ranitidine|drug
DDI-DrugBank.d237.s10|207-207|.|drug
DDI-DrugBank.d237.s11|0-2|The|drug
DDI-DrugBank.d237.s11|4-19|gastrointestinal|drug
DDI-DrugBank.d237.s11|21-30|absorption|drug
DDI-DrugBank.d237.s11|32-33|of|drug
DDI-DrugBank.d237.s11|35-44|cimetidine|drug
DDI-DrugBank.d237.s11|46-48|and|drug
DDI-DrugBank.d237.s11|50-59|ranitidine|drug
DDI-DrugBank.d237.s11|61-62|is|drug
DDI-DrugBank.d237.s11|64-74|accelerated|drug
DDI-DrugBank.d237.s11|76-79|when|drug
DDI-DrugBank.d237.s11|81-84|they|drug
DDI-DrugBank.d237.s11|86-88|are|drug
DDI-DrugBank.d237.s11|90-103|coadministered|drug
DDI-DrugBank.d237.s11|105-108|with|drug
DDI-DrugBank.d237.s11|110-118|cisapride|drug
DDI-DrugBank.d237.s11|119-119|.|drug
DDI-DrugBank.d237.s12|0-7|Protease|drug
DDI-DrugBank.d237.s12|9-18|Inhibitors|drug
DDI-DrugBank.d237.s12|19-19|:|drug
DDI-DrugBank.d237.s12|21-22|In|drug
DDI-DrugBank.d237.s12|24-28|vitro|drug
DDI-DrugBank.d237.s12|30-33|data|drug
DDI-DrugBank.d237.s12|35-42|indicate|drug
DDI-DrugBank.d237.s12|44-47|that|drug
DDI-DrugBank.d237.s12|49-57|indinavir|drug
DDI-DrugBank.d237.s12|59-61|and|drug
DDI-DrugBank.d237.s12|63-71|ritonavir|drug
DDI-DrugBank.d237.s12|73-80|markedly|drug
DDI-DrugBank.d237.s12|82-88|inhibit|drug
DDI-DrugBank.d237.s12|90-92|the|drug
DDI-DrugBank.d237.s12|94-103|metabolism|drug
DDI-DrugBank.d237.s12|105-106|of|drug
DDI-DrugBank.d237.s12|108-116|cisapride|drug
DDI-DrugBank.d237.s12|118-122|which|drug
DDI-DrugBank.d237.s12|124-126|can|drug
DDI-DrugBank.d237.s12|128-133|result|drug
DDI-DrugBank.d237.s12|135-136|in|drug
DDI-DrugBank.d237.s12|138-139|an|drug
DDI-DrugBank.d237.s12|141-148|increase|drug
DDI-DrugBank.d237.s12|150-151|in|drug
DDI-DrugBank.d237.s12|153-158|plasma|drug
DDI-DrugBank.d237.s12|160-168|cisapride|drug
DDI-DrugBank.d237.s12|170-175|levels|drug
DDI-DrugBank.d237.s12|177-179|and|drug
DDI-DrugBank.d237.s12|181-192|prolongation|drug
DDI-DrugBank.d237.s12|194-195|of|drug
DDI-DrugBank.d237.s12|197-199|the|drug
DDI-DrugBank.d237.s12|201-202|QT|drug
DDI-DrugBank.d237.s12|204-211|interval|drug
DDI-DrugBank.d237.s12|213-214|on|drug
DDI-DrugBank.d237.s12|216-218|the|drug
DDI-DrugBank.d237.s12|220-222|ECG|drug
DDI-DrugBank.d237.s12|223-223|.|drug
DDI-DrugBank.d237.s13|0-4|Other|drug
DDI-DrugBank.d237.s13|5-5|:|drug
DDI-DrugBank.d237.s13|7-22|Coadministration|drug
DDI-DrugBank.d237.s13|24-25|of|drug
DDI-DrugBank.d237.s13|27-36|grapefruit|drug
DDI-DrugBank.d237.s13|38-42|juice|drug
DDI-DrugBank.d237.s13|44-47|with|drug
DDI-DrugBank.d237.s13|49-57|cisapride|drug
DDI-DrugBank.d237.s13|59-67|increases|drug
DDI-DrugBank.d237.s13|69-71|the|drug
DDI-DrugBank.d237.s13|73-87|bioavailability|drug
DDI-DrugBank.d237.s13|89-90|of|drug
DDI-DrugBank.d237.s13|92-100|cisapride|drug
DDI-DrugBank.d237.s13|102-104|and|drug
DDI-DrugBank.d237.s13|106-116|concomitant|drug
DDI-DrugBank.d237.s13|118-120|use|drug
DDI-DrugBank.d237.s13|122-127|should|drug
DDI-DrugBank.d237.s13|129-130|be|drug
DDI-DrugBank.d237.s13|132-138|avoided|drug
DDI-DrugBank.d237.s13|139-139|.|drug
DDI-DrugBank.d237.s14|0-8|Cisapride|drug
DDI-DrugBank.d237.s14|10-15|should|drug
DDI-DrugBank.d237.s14|17-19|not|drug
DDI-DrugBank.d237.s14|21-22|be|drug
DDI-DrugBank.d237.s14|24-27|used|drug
DDI-DrugBank.d237.s14|29-41|concomitantly|drug
DDI-DrugBank.d237.s14|43-46|with|drug
DDI-DrugBank.d237.s14|48-52|other|drug
DDI-DrugBank.d237.s14|54-58|drugs|drug
DDI-DrugBank.d237.s14|60-64|known|drug
DDI-DrugBank.d237.s14|66-67|to|drug
DDI-DrugBank.d237.s14|69-75|prolong|drug
DDI-DrugBank.d237.s14|77-79|the|drug
DDI-DrugBank.d237.s14|81-82|QT|drug
DDI-DrugBank.d237.s14|84-91|interval|drug
DDI-DrugBank.d237.s14|92-92|:|drug
DDI-DrugBank.d237.s14|94-100|certain|drug
DDI-DrugBank.d237.s14|102-116|antiarrhythmics|drug
DDI-DrugBank.d237.s14|117-117|,|drug
DDI-DrugBank.d237.s14|119-127|including|drug
DDI-DrugBank.d237.s14|129-133|those|drug
DDI-DrugBank.d237.s14|135-136|of|drug
DDI-DrugBank.d237.s14|138-142|Class|drug
DDI-DrugBank.d237.s14|144-145|IA|drug
DDI-DrugBank.d237.s14|147-147|(|drug
DDI-DrugBank.d237.s14|148-151|such|drug
DDI-DrugBank.d237.s14|153-154|as|drug
DDI-DrugBank.d237.s14|156-164|quinidine|drug
DDI-DrugBank.d237.s14|166-168|and|drug
DDI-DrugBank.d237.s14|170-181|procainamide|drug
DDI-DrugBank.d237.s14|182-182|)|drug
DDI-DrugBank.d237.s14|184-186|and|drug
DDI-DrugBank.d237.s14|188-192|Class|drug
DDI-DrugBank.d237.s14|194-196|III|drug
DDI-DrugBank.d237.s14|198-198|(|drug
DDI-DrugBank.d237.s14|199-202|such|drug
DDI-DrugBank.d237.s14|204-205|as|drug
DDI-DrugBank.d237.s14|207-213|sotalol|drug
DDI-DrugBank.d237.s14|214-214|)|drug
DDI-DrugBank.d237.s14|215-215|;|drug
DDI-DrugBank.d237.s15|0-8|tricyclic|drug
DDI-DrugBank.d237.s15|10-24|antidepressants|drug
DDI-DrugBank.d237.s15|26-26|(|drug
DDI-DrugBank.d237.s15|27-30|such|drug
DDI-DrugBank.d237.s15|32-33|as|drug
DDI-DrugBank.d237.s15|35-47|amitriptyline|drug
DDI-DrugBank.d237.s15|48-48|)|drug
DDI-DrugBank.d237.s15|49-49|;|drug
DDI-DrugBank.d237.s16|0-6|certain|drug
DDI-DrugBank.d237.s16|8-18|tetracyclic|drug
DDI-DrugBank.d237.s16|20-34|antidepressants|drug
DDI-DrugBank.d237.s16|36-36|(|drug
DDI-DrugBank.d237.s16|37-40|such|drug
DDI-DrugBank.d237.s16|42-43|as|drug
DDI-DrugBank.d237.s16|45-55|maprotiline|drug
DDI-DrugBank.d237.s16|56-56|)|drug
DDI-DrugBank.d237.s16|57-57|;|drug
DDI-DrugBank.d237.s17|0-6|certain|drug
DDI-DrugBank.d237.s17|8-20|antipsychotic|drug
DDI-DrugBank.d237.s17|22-32|medications|drug
DDI-DrugBank.d237.s17|34-34|(|drug
DDI-DrugBank.d237.s17|35-38|such|drug
DDI-DrugBank.d237.s17|40-41|as|drug
DDI-DrugBank.d237.s17|43-52|sertindole|drug
DDI-DrugBank.d237.s17|53-53|)|drug
DDI-DrugBank.d237.s17|54-54|;|drug
DDI-DrugBank.d237.s18|0-9|astemizole|drug
DDI-DrugBank.d237.s18|10-10|,|drug
DDI-DrugBank.d237.s18|12-19|bepridil|drug
DDI-DrugBank.d237.s18|20-20|,|drug
DDI-DrugBank.d237.s18|22-33|sparfloxacin|drug
DDI-DrugBank.d237.s18|34-34|,|drug
DDI-DrugBank.d237.s18|36-38|and|drug
DDI-DrugBank.d237.s18|40-49|terodiline|drug
DDI-DrugBank.d237.s18|50-50|.|drug
DDI-DrugBank.d237.s19|0-2|The|drug
DDI-DrugBank.d237.s19|4-12|preceding|drug
DDI-DrugBank.d237.s19|14-18|lists|drug
DDI-DrugBank.d237.s19|20-21|of|drug
DDI-DrugBank.d237.s19|23-27|drugs|drug
DDI-DrugBank.d237.s19|29-31|are|drug
DDI-DrugBank.d237.s19|33-35|not|drug
DDI-DrugBank.d237.s19|37-49|comprehensive|drug
DDI-DrugBank.d237.s19|50-50|.|drug
DDI-DrugBank.d237.s20|0-2|The|drug
DDI-DrugBank.d237.s20|4-15|acceleration|drug
DDI-DrugBank.d237.s20|17-18|of|drug
DDI-DrugBank.d237.s20|20-26|gastric|drug
DDI-DrugBank.d237.s20|28-35|emptying|drug
DDI-DrugBank.d237.s20|37-38|by|drug
DDI-DrugBank.d237.s20|40-48|cisapride|drug
DDI-DrugBank.d237.s20|50-54|could|drug
DDI-DrugBank.d237.s20|56-61|affect|drug
DDI-DrugBank.d237.s20|63-65|the|drug
DDI-DrugBank.d237.s20|67-70|rate|drug
DDI-DrugBank.d237.s20|72-73|of|drug
DDI-DrugBank.d237.s20|75-84|absorption|drug
DDI-DrugBank.d237.s20|86-87|of|drug
DDI-DrugBank.d237.s20|89-93|other|drug
DDI-DrugBank.d237.s20|95-99|drugs|drug
DDI-DrugBank.d237.s20|100-100|.|drug
DDI-DrugBank.d237.s21|0-7|Patients|drug
DDI-DrugBank.d237.s21|9-17|receiving|drug
DDI-DrugBank.d237.s21|19-24|narrow|drug
DDI-DrugBank.d237.s21|26-36|therapeutic|drug
DDI-DrugBank.d237.s21|38-42|ratio|drug
DDI-DrugBank.d237.s21|44-48|drugs|drug
DDI-DrugBank.d237.s21|50-51|or|drug
DDI-DrugBank.d237.s21|53-57|other|drug
DDI-DrugBank.d237.s21|59-63|drugs|drug
DDI-DrugBank.d237.s21|65-68|that|drug
DDI-DrugBank.d237.s21|70-76|require|drug
DDI-DrugBank.d237.s21|78-84|careful|drug
DDI-DrugBank.d237.s21|86-94|titration|drug
DDI-DrugBank.d237.s21|96-101|should|drug
DDI-DrugBank.d237.s21|103-104|be|drug
DDI-DrugBank.d237.s21|106-113|followed|drug
DDI-DrugBank.d237.s21|115-121|closely|drug
DDI-DrugBank.d237.s21|122-122|;|drug
DDI-DrugBank.d237.s22|0-1|if|drug
DDI-DrugBank.d237.s22|3-8|plasma|drug
DDI-DrugBank.d237.s22|10-15|levels|drug
DDI-DrugBank.d237.s22|17-19|are|drug
DDI-DrugBank.d237.s22|21-25|being|drug
DDI-DrugBank.d237.s22|27-35|monitored|drug
DDI-DrugBank.d237.s22|36-36|,|drug
DDI-DrugBank.d237.s22|38-41|they|drug
DDI-DrugBank.d237.s22|43-48|should|drug
DDI-DrugBank.d237.s22|50-51|be|drug
DDI-DrugBank.d237.s22|53-62|reassessed|drug
DDI-DrugBank.d237.s22|63-63|.|drug
DDI-DrugBank.d433.s0|0-1|No|drug
DDI-DrugBank.d433.s0|3-8|formal|drug
DDI-DrugBank.d433.s0|10-13|drug|drug
DDI-DrugBank.d433.s0|15-25|interaction|drug
DDI-DrugBank.d433.s0|27-33|studies|drug
DDI-DrugBank.d433.s0|35-38|have|drug
DDI-DrugBank.d433.s0|40-43|been|drug
DDI-DrugBank.d433.s0|45-53|conducted|drug
DDI-DrugBank.d433.s0|55-58|with|drug
DDI-DrugBank.d433.s0|60-64|Rebif|brand
DDI-DrugBank.d433.s0|66-66|.|drug
DDI-DrugBank.d433.s1|0-2|Due|drug
DDI-DrugBank.d433.s1|4-5|to|drug
DDI-DrugBank.d433.s1|7-9|its|drug
DDI-DrugBank.d433.s1|11-19|potential|drug
DDI-DrugBank.d433.s1|21-22|to|drug
DDI-DrugBank.d433.s1|24-28|cause|drug
DDI-DrugBank.d433.s1|30-40|neutropenia|drug
DDI-DrugBank.d433.s1|42-44|and|drug
DDI-DrugBank.d433.s1|46-56|lymphopenia|drug
DDI-DrugBank.d433.s1|57-57|,|drug
DDI-DrugBank.d433.s1|59-64|proper|drug
DDI-DrugBank.d433.s1|66-75|monitoring|drug
DDI-DrugBank.d433.s1|77-78|of|drug
DDI-DrugBank.d433.s1|80-87|patients|drug
DDI-DrugBank.d433.s1|89-90|is|drug
DDI-DrugBank.d433.s1|92-99|required|drug
DDI-DrugBank.d433.s1|101-102|if|drug
DDI-DrugBank.d433.s1|104-108|Rebif|brand
DDI-DrugBank.d433.s1|111-112|is|drug
DDI-DrugBank.d433.s1|114-118|given|drug
DDI-DrugBank.d433.s1|120-121|in|drug
DDI-DrugBank.d433.s1|123-133|combination|drug
DDI-DrugBank.d433.s1|135-138|with|drug
DDI-DrugBank.d433.s1|140-155|myelosuppressive|drug
DDI-DrugBank.d433.s1|157-162|agents|drug
DDI-DrugBank.d433.s1|163-163|.|drug
DDI-DrugBank.d433.s2|0-3|Also|drug
DDI-DrugBank.d433.s2|4-4|,|drug
DDI-DrugBank.d433.s2|6-8|the|drug
DDI-DrugBank.d433.s2|10-18|potential|drug
DDI-DrugBank.d433.s2|20-22|for|drug
DDI-DrugBank.d433.s2|24-30|hepatic|drug
DDI-DrugBank.d433.s2|32-37|injury|drug
DDI-DrugBank.d433.s2|39-44|should|drug
DDI-DrugBank.d433.s2|46-47|be|drug
DDI-DrugBank.d433.s2|49-58|considered|drug
DDI-DrugBank.d433.s2|60-63|when|drug
DDI-DrugBank.d433.s2|65-69|Rebif|brand
DDI-DrugBank.d433.s2|72-73|is|drug
DDI-DrugBank.d433.s2|75-78|used|drug
DDI-DrugBank.d433.s2|80-81|in|drug
DDI-DrugBank.d433.s2|83-93|combination|drug
DDI-DrugBank.d433.s2|95-98|with|drug
DDI-DrugBank.d433.s2|100-104|other|drug
DDI-DrugBank.d433.s2|106-113|products|drug
DDI-DrugBank.d433.s2|115-124|associated|drug
DDI-DrugBank.d433.s2|126-129|with|drug
DDI-DrugBank.d433.s2|131-137|hepatic|drug
DDI-DrugBank.d433.s2|139-144|injury|drug
DDI-DrugBank.d433.s2|145-145|,|drug
DDI-DrugBank.d433.s2|147-148|or|drug
DDI-DrugBank.d433.s2|150-153|when|drug
DDI-DrugBank.d433.s2|155-157|new|drug
DDI-DrugBank.d433.s2|159-164|agents|drug
DDI-DrugBank.d433.s2|166-168|are|drug
DDI-DrugBank.d433.s2|170-174|added|drug
DDI-DrugBank.d433.s2|176-177|to|drug
DDI-DrugBank.d433.s2|179-181|the|drug
DDI-DrugBank.d433.s2|183-189|regimen|drug
DDI-DrugBank.d433.s2|191-192|of|drug
DDI-DrugBank.d433.s2|194-201|patients|drug
DDI-DrugBank.d433.s2|203-209|already|drug
DDI-DrugBank.d433.s2|211-212|on|drug
DDI-DrugBank.d433.s2|214-218|Rebif|brand
DDI-DrugBank.d433.s2|220-220|.|drug
DDI-DrugBank.d736.s0|0-10|Hypokalemia|drug
DDI-DrugBank.d736.s0|12-14|can|drug
DDI-DrugBank.d736.s0|16-24|sensitize|drug
DDI-DrugBank.d736.s0|26-27|or|drug
DDI-DrugBank.d736.s0|29-38|exaggerate|drug
DDI-DrugBank.d736.s0|40-42|the|drug
DDI-DrugBank.d736.s0|44-51|response|drug
DDI-DrugBank.d736.s0|53-54|of|drug
DDI-DrugBank.d736.s0|56-58|the|drug
DDI-DrugBank.d736.s0|60-64|heart|drug
DDI-DrugBank.d736.s0|66-67|to|drug
DDI-DrugBank.d736.s0|69-71|the|drug
DDI-DrugBank.d736.s0|73-77|toxic|drug
DDI-DrugBank.d736.s0|79-85|effects|drug
DDI-DrugBank.d736.s0|87-88|of|drug
DDI-DrugBank.d736.s0|90-98|digitalis|drug
DDI-DrugBank.d736.s0|100-100|(|drug
DDI-DrugBank.d736.s0|101-104|e.g.|drug
DDI-DrugBank.d736.s0|105-105|,|drug
DDI-DrugBank.d736.s0|107-115|increased|drug
DDI-DrugBank.d736.s0|117-127|ventricular|drug
DDI-DrugBank.d736.s0|129-140|irritability|drug
DDI-DrugBank.d736.s0|141-141|)|drug
DDI-DrugBank.d736.s0|142-142|.|drug
DDI-DrugBank.d736.s1|0-10|Hypokalemia|drug
DDI-DrugBank.d736.s1|12-14|may|drug
DDI-DrugBank.d736.s1|16-22|develop|drug
DDI-DrugBank.d736.s1|24-29|during|drug
DDI-DrugBank.d736.s1|31-41|concomitant|drug
DDI-DrugBank.d736.s1|43-45|use|drug
DDI-DrugBank.d736.s1|47-48|of|drug
DDI-DrugBank.d736.s1|50-57|steroids|drug
DDI-DrugBank.d736.s1|59-60|or|drug
DDI-DrugBank.d736.s1|62-65|ACTH|drug
DDI-DrugBank.d736.s1|66-66|.|drug
DDI-DrugBank.d736.s2|0-6|Insulin|drug
DDI-DrugBank.d736.s2|8-19|requirements|drug
DDI-DrugBank.d736.s2|21-22|in|drug
DDI-DrugBank.d736.s2|24-31|diabetic|drug
DDI-DrugBank.d736.s2|33-40|patients|drug
DDI-DrugBank.d736.s2|42-44|may|drug
DDI-DrugBank.d736.s2|46-47|be|drug
DDI-DrugBank.d736.s2|49-57|increased|drug
DDI-DrugBank.d736.s2|58-58|,|drug
DDI-DrugBank.d736.s2|60-68|decreased|drug
DDI-DrugBank.d736.s2|69-69|,|drug
DDI-DrugBank.d736.s2|71-72|or|drug
DDI-DrugBank.d736.s2|74-82|unchanged|drug
DDI-DrugBank.d736.s2|83-83|.|drug
DDI-DrugBank.d736.s3|0-8|Thiazides|group
DDI-DrugBank.d736.s3|10-12|may|drug
DDI-DrugBank.d736.s3|14-21|decrease|drug
DDI-DrugBank.d736.s3|23-30|arterial|drug
DDI-DrugBank.d736.s3|32-45|responsiveness|drug
DDI-DrugBank.d736.s3|47-48|to|drug
DDI-DrugBank.d736.s3|50-63|norepinephrine|drug
DDI-DrugBank.d736.s3|64-64|.|drug
DDI-DrugBank.d736.s4|0-3|This|drug
DDI-DrugBank.d736.s4|5-14|diminution|drug
DDI-DrugBank.d736.s4|16-17|is|drug
DDI-DrugBank.d736.s4|19-21|not|drug
DDI-DrugBank.d736.s4|23-32|sufficient|drug
DDI-DrugBank.d736.s4|34-35|to|drug
DDI-DrugBank.d736.s4|37-44|preclude|drug
DDI-DrugBank.d736.s4|46-58|effectiveness|drug
DDI-DrugBank.d736.s4|60-61|of|drug
DDI-DrugBank.d736.s4|63-65|the|drug
DDI-DrugBank.d736.s4|67-73|pressor|drug
DDI-DrugBank.d736.s4|75-79|agent|drug
DDI-DrugBank.d736.s4|81-83|for|drug
DDI-DrugBank.d736.s4|85-95|therapeutic|drug
DDI-DrugBank.d736.s4|97-99|use|drug
DDI-DrugBank.d736.s4|100-100|.|drug
DDI-DrugBank.d736.s5|0-7|Thiazide|drug
DDI-DrugBank.d736.s5|9-13|drugs|drug
DDI-DrugBank.d736.s5|15-17|may|drug
DDI-DrugBank.d736.s5|19-26|increase|drug
DDI-DrugBank.d736.s5|28-30|the|drug
DDI-DrugBank.d736.s5|32-45|responsiveness|drug
DDI-DrugBank.d736.s5|47-48|of|drug
DDI-DrugBank.d736.s5|50-61|tubocurarine|drug
DDI-DrugBank.d736.s5|62-62|.|drug
DDI-DrugBank.d736.s6|0-6|Lithium|brand
DDI-DrugBank.d736.s6|8-12|renal|drug
DDI-DrugBank.d736.s6|14-22|clearance|drug
DDI-DrugBank.d736.s6|24-25|is|drug
DDI-DrugBank.d736.s6|27-33|reduced|drug
DDI-DrugBank.d736.s6|35-36|by|drug
DDI-DrugBank.d736.s6|38-46|thiazides|drug
DDI-DrugBank.d736.s6|47-47|,|drug
DDI-DrugBank.d736.s6|49-58|increasing|drug
DDI-DrugBank.d736.s6|60-62|the|drug
DDI-DrugBank.d736.s6|64-67|risk|drug
DDI-DrugBank.d736.s6|69-70|of|drug
DDI-DrugBank.d736.s6|72-78|lithium|drug
DDI-DrugBank.d736.s6|80-87|toxicity|drug
DDI-DrugBank.d736.s6|88-88|.|drug
DDI-DrugBank.d736.s7|0-8|Thiazides|group
DDI-DrugBank.d736.s7|10-12|may|drug
DDI-DrugBank.d736.s7|14-16|add|drug
DDI-DrugBank.d736.s7|18-19|to|drug
DDI-DrugBank.d736.s7|21-22|or|drug
DDI-DrugBank.d736.s7|24-33|potentiate|drug
DDI-DrugBank.d736.s7|35-37|the|drug
DDI-DrugBank.d736.s7|39-44|action|drug
DDI-DrugBank.d736.s7|46-47|of|drug
DDI-DrugBank.d736.s7|49-53|other|drug
DDI-DrugBank.d736.s7|55-70|antihypertensive|drug
DDI-DrugBank.d736.s7|72-76|drugs|drug
DDI-DrugBank.d736.s7|77-77|.|drug
DDI-DrugBank.d736.s8|0-11|Potentiation|drug
DDI-DrugBank.d736.s8|13-18|occurs|drug
DDI-DrugBank.d736.s8|20-23|with|drug
DDI-DrugBank.d736.s8|25-34|ganglionic|drug
DDI-DrugBank.d736.s8|36-37|or|drug
DDI-DrugBank.d736.s8|39-48|peripheral|drug
DDI-DrugBank.d736.s8|50-59|adrenergic|drug
DDI-DrugBank.d736.s8|61-68|blocking|drug
DDI-DrugBank.d736.s8|70-74|drugs|drug
DDI-DrugBank.d736.s8|75-75|.|drug
DDI-DrugBank.d704.s0|0-8|Drug-Drug|drug
DDI-DrugBank.d704.s0|10-21|Interactions|drug
DDI-DrugBank.d704.s0|22-22|:|drug
DDI-DrugBank.d704.s0|24-26|The|drug
DDI-DrugBank.d704.s0|28-42|pharmacokinetic|drug
DDI-DrugBank.d704.s0|44-46|and|drug
DDI-DrugBank.d704.s0|48-62|pharmacodynamic|drug
DDI-DrugBank.d704.s0|64-75|interactions|drug
DDI-DrugBank.d704.s0|77-83|between|drug
DDI-DrugBank.d704.s0|85-90|FLOMAX|drug
DDI-DrugBank.d704.s0|92-99|capsules|drug
DDI-DrugBank.d704.s0|101-103|and|drug
DDI-DrugBank.d704.s0|105-109|other|drug
DDI-DrugBank.d704.s0|111-126|alpha-adrenergic|drug
DDI-DrugBank.d704.s0|128-135|blocking|drug
DDI-DrugBank.d704.s0|137-142|agents|drug
DDI-DrugBank.d704.s0|144-147|have|drug
DDI-DrugBank.d704.s0|149-151|not|drug
DDI-DrugBank.d704.s0|153-156|been|drug
DDI-DrugBank.d704.s0|158-167|determined|drug
DDI-DrugBank.d704.s0|168-168|.|drug
DDI-DrugBank.d704.s1|0-6|However|drug
DDI-DrugBank.d704.s1|7-7|,|drug
DDI-DrugBank.d704.s1|9-20|interactions|drug
DDI-DrugBank.d704.s1|22-24|may|drug
DDI-DrugBank.d704.s1|26-27|be|drug
DDI-DrugBank.d704.s1|29-36|expected|drug
DDI-DrugBank.d704.s1|38-40|and|drug
DDI-DrugBank.d704.s1|42-47|FLOMAX|drug
DDI-DrugBank.d704.s1|49-56|capsules|drug
DDI-DrugBank.d704.s1|58-63|should|drug
DDI-DrugBank.d704.s1|65-67|NOT|drug
DDI-DrugBank.d704.s1|69-70|be|drug
DDI-DrugBank.d704.s1|72-75|used|drug
DDI-DrugBank.d704.s1|77-78|in|drug
DDI-DrugBank.d704.s1|80-90|combination|drug
DDI-DrugBank.d704.s1|92-95|with|drug
DDI-DrugBank.d704.s1|97-101|other|drug
DDI-DrugBank.d704.s1|103-118|alpha-adrenergic|drug
DDI-DrugBank.d704.s1|120-127|blocking|drug
DDI-DrugBank.d704.s1|129-134|agents|drug
DDI-DrugBank.d704.s1|135-135|.|drug
DDI-DrugBank.d704.s2|0-2|The|drug
DDI-DrugBank.d704.s2|4-18|pharmacokinetic|drug
DDI-DrugBank.d704.s2|20-30|interaction|drug
DDI-DrugBank.d704.s2|32-38|between|drug
DDI-DrugBank.d704.s2|40-49|cimetidine|drug
DDI-DrugBank.d704.s2|51-53|and|drug
DDI-DrugBank.d704.s2|55-60|FLOMAX|drug
DDI-DrugBank.d704.s2|62-69|capsules|drug
DDI-DrugBank.d704.s2|71-73|was|drug
DDI-DrugBank.d704.s2|75-86|investigated|drug
DDI-DrugBank.d704.s2|87-87|.|drug
DDI-DrugBank.d704.s3|0-2|The|drug
DDI-DrugBank.d704.s3|4-10|results|drug
DDI-DrugBank.d704.s3|12-19|indicate|drug
DDI-DrugBank.d704.s3|21-31|significant|drug
DDI-DrugBank.d704.s3|33-39|changes|drug
DDI-DrugBank.d704.s3|41-42|in|drug
DDI-DrugBank.d704.s3|44-53|tamsulosin|drug
DDI-DrugBank.d704.s3|55-57|HCI|drug
DDI-DrugBank.d704.s3|59-67|clearance|drug
DDI-DrugBank.d704.s3|69-69|(|drug
DDI-DrugBank.d704.s3|70-71|26|drug
DDI-DrugBank.d704.s3|72-72|%|drug
DDI-DrugBank.d704.s3|74-81|decrease|drug
DDI-DrugBank.d704.s3|82-82|)|drug
DDI-DrugBank.d704.s3|84-86|and|drug
DDI-DrugBank.d704.s3|88-90|AUC|drug
DDI-DrugBank.d704.s3|92-92|(|drug
DDI-DrugBank.d704.s3|93-94|44|drug
DDI-DrugBank.d704.s3|95-95|%|drug
DDI-DrugBank.d704.s3|97-104|increase|drug
DDI-DrugBank.d704.s3|105-105|)|drug
DDI-DrugBank.d704.s3|106-106|.|drug
DDI-DrugBank.d704.s4|0-8|Therefore|drug
DDI-DrugBank.d704.s4|9-9|,|drug
DDI-DrugBank.d704.s4|11-16|FLOMAX|drug
DDI-DrugBank.d704.s4|18-25|capsules|drug
DDI-DrugBank.d704.s4|27-32|should|drug
DDI-DrugBank.d704.s4|34-35|be|drug
DDI-DrugBank.d704.s4|37-40|used|drug
DDI-DrugBank.d704.s4|42-45|with|drug
DDI-DrugBank.d704.s4|47-53|caution|drug
DDI-DrugBank.d704.s4|55-56|in|drug
DDI-DrugBank.d704.s4|58-68|combination|drug
DDI-DrugBank.d704.s4|70-73|with|drug
DDI-DrugBank.d704.s4|75-84|cimetidine|drug
DDI-DrugBank.d704.s4|85-85|,|drug
DDI-DrugBank.d704.s4|87-98|particularly|drug
DDI-DrugBank.d704.s4|100-101|at|drug
DDI-DrugBank.d704.s4|103-107|doses|drug
DDI-DrugBank.d704.s4|109-114|higher|drug
DDI-DrugBank.d704.s4|116-119|than|drug
DDI-DrugBank.d704.s4|121-123|0.4|drug
DDI-DrugBank.d704.s4|125-126|mg|drug
DDI-DrugBank.d704.s4|127-127|.|drug
DDI-DrugBank.d704.s5|0-6|Results|drug
DDI-DrugBank.d704.s5|8-11|from|drug
DDI-DrugBank.d704.s5|13-19|limited|drug
DDI-DrugBank.d704.s5|21-22|in|drug
DDI-DrugBank.d704.s5|24-28|vitro|drug
DDI-DrugBank.d704.s5|30-32|and|drug
DDI-DrugBank.d704.s5|34-35|in|drug
DDI-DrugBank.d704.s5|37-40|vivo|drug
DDI-DrugBank.d704.s5|42-50|drug-drug|drug
DDI-DrugBank.d704.s5|52-62|interaction|drug
DDI-DrugBank.d704.s5|64-70|studies|drug
DDI-DrugBank.d704.s5|72-78|between|drug
DDI-DrugBank.d704.s5|80-89|tamsulosin|drug
DDI-DrugBank.d704.s5|91-93|HCI|drug
DDI-DrugBank.d704.s5|95-97|and|drug
DDI-DrugBank.d704.s5|99-106|warfarin|drug
DDI-DrugBank.d704.s5|108-110|are|drug
DDI-DrugBank.d704.s5|112-123|inconclusive|drug
DDI-DrugBank.d704.s5|124-124|.|drug
DDI-DrugBank.d704.s6|0-8|Therefore|drug
DDI-DrugBank.d704.s6|9-9|,|drug
DDI-DrugBank.d704.s6|11-17|caution|drug
DDI-DrugBank.d704.s6|19-24|should|drug
DDI-DrugBank.d704.s6|26-27|be|drug
DDI-DrugBank.d704.s6|29-37|exercised|drug
DDI-DrugBank.d704.s6|39-42|with|drug
DDI-DrugBank.d704.s6|44-54|concomitant|drug
DDI-DrugBank.d704.s6|56-69|administration|drug
DDI-DrugBank.d704.s6|71-72|of|drug
DDI-DrugBank.d704.s6|74-81|warfarin|drug
DDI-DrugBank.d704.s6|83-85|and|drug
DDI-DrugBank.d704.s6|87-92|FLOMAX|drug
DDI-DrugBank.d704.s6|94-101|capsules|drug
DDI-DrugBank.d704.s6|102-102|.|drug
DDI-DrugBank.d759.s0|0-6|Limited|drug
DDI-DrugBank.d759.s0|8-15|evidence|drug
DDI-DrugBank.d759.s0|17-24|suggests|drug
DDI-DrugBank.d759.s0|26-29|that|drug
DDI-DrugBank.d759.s0|31-38|ascorbic|drug
DDI-DrugBank.d759.s0|40-43|acid|drug
DDI-DrugBank.d759.s0|45-47|may|drug
DDI-DrugBank.d759.s0|49-57|influence|drug
DDI-DrugBank.d759.s0|59-61|the|drug
DDI-DrugBank.d759.s0|63-71|intensity|drug
DDI-DrugBank.d759.s0|73-75|and|drug
DDI-DrugBank.d759.s0|77-84|duration|drug
DDI-DrugBank.d759.s0|86-87|of|drug
DDI-DrugBank.d759.s0|89-94|action|drug
DDI-DrugBank.d759.s0|96-97|of|drug
DDI-DrugBank.d759.s0|99-116|bishydroxycoumarin|drug
DDI-DrugBank.d759.s0|117-117|.|drug
DDI-DrugBank.d253.s0|0-14|Beta-adrenergic|drug
DDI-DrugBank.d253.s0|16-23|blocking|drug
DDI-DrugBank.d253.s0|25-30|agents|drug
DDI-DrugBank.d253.s0|31-31|:|drug
DDI-DrugBank.d253.s0|33-42|concurrent|drug
DDI-DrugBank.d253.s0|44-46|use|drug
DDI-DrugBank.d253.s0|48-50|may|drug
DDI-DrugBank.d253.s0|52-56|blunt|drug
DDI-DrugBank.d253.s0|58-60|the|drug
DDI-DrugBank.d253.s0|62-69|response|drug
DDI-DrugBank.d253.s0|71-72|to|drug
DDI-DrugBank.d253.s0|74-83|arbutamine|drug
DDI-DrugBank.d253.s0|84-84|.|drug
DDI-DrugBank.d253.s1|0-14|Beta-adrenergic|drug
DDI-DrugBank.d253.s1|16-23|blocking|drug
DDI-DrugBank.d253.s1|25-30|agents|drug
DDI-DrugBank.d253.s1|32-37|should|drug
DDI-DrugBank.d253.s1|39-40|be|drug
DDI-DrugBank.d253.s1|42-50|withdrawn|drug
DDI-DrugBank.d253.s1|52-53|at|drug
DDI-DrugBank.d253.s1|55-59|least|drug
DDI-DrugBank.d253.s1|61-62|48|drug
DDI-DrugBank.d253.s1|64-68|hours|drug
DDI-DrugBank.d253.s1|70-75|before|drug
DDI-DrugBank.d253.s1|77-86|conducting|drug
DDI-DrugBank.d253.s1|88-89|an|drug
DDI-DrugBank.d253.s1|91-109|arbutamine-mediated|drug
DDI-DrugBank.d253.s1|111-116|stress|drug
DDI-DrugBank.d253.s1|118-121|test|drug
DDI-DrugBank.d253.s1|122-122|.|drug
DDI-DrugBank.d253.s2|0-13|Antiarrhythmic|drug
DDI-DrugBank.d253.s2|15-20|agents|drug
DDI-DrugBank.d253.s2|21-21|,|drug
DDI-DrugBank.d253.s2|23-27|class|drug
DDI-DrugBank.d253.s2|29-29|I|drug
DDI-DrugBank.d253.s2|31-31|(|drug
DDI-DrugBank.d253.s2|32-35|such|drug
DDI-DrugBank.d253.s2|37-38|as|drug
DDI-DrugBank.d253.s2|40-49|flecainide|drug
DDI-DrugBank.d253.s2|50-50|,|drug
DDI-DrugBank.d253.s2|52-60|lidocaine|drug
DDI-DrugBank.d253.s2|61-61|,|drug
DDI-DrugBank.d253.s2|63-64|or|drug
DDI-DrugBank.d253.s2|66-74|quinidine|drug
DDI-DrugBank.d253.s2|75-75|)|drug
DDI-DrugBank.d253.s2|76-76|:|drug
DDI-DrugBank.d253.s2|78-87|concurrent|drug
DDI-DrugBank.d253.s2|89-91|use|drug
DDI-DrugBank.d253.s2|93-96|with|drug
DDI-DrugBank.d253.s2|98-107|arbutamine|drug
DDI-DrugBank.d253.s2|109-111|may|drug
DDI-DrugBank.d253.s2|113-116|have|drug
DDI-DrugBank.d253.s2|118-118|a|drug
DDI-DrugBank.d253.s2|120-132|proarrhythmic|drug
DDI-DrugBank.d253.s2|134-139|effect|drug
DDI-DrugBank.d253.s2|140-140|.|drug
DDI-DrugBank.d253.s3|0-14|Antidepressants|drug
DDI-DrugBank.d253.s3|16-16|(|drug
DDI-DrugBank.d253.s3|17-25|tricyclic|drug
DDI-DrugBank.d253.s3|26-26|)|drug
DDI-DrugBank.d253.s3|27-27|,|drug
DDI-DrugBank.d253.s3|29-36|atropine|drug
DDI-DrugBank.d253.s3|38-39|or|drug
DDI-DrugBank.d253.s3|41-45|other|drug
DDI-DrugBank.d253.s3|47-61|anticholinergic|drug
DDI-DrugBank.d253.s3|63-68|agents|drug
DDI-DrugBank.d253.s3|69-69|,|drug
DDI-DrugBank.d253.s3|71-72|or|drug
DDI-DrugBank.d253.s3|74-82|digitalis|drug
DDI-DrugBank.d253.s3|84-93|glycosides|drug
DDI-DrugBank.d253.s3|94-94|:|drug
DDI-DrugBank.d253.s3|96-105|concurrent|drug
DDI-DrugBank.d253.s3|107-109|use|drug
DDI-DrugBank.d253.s3|111-114|with|drug
DDI-DrugBank.d253.s3|116-125|arbutamine|drug
DDI-DrugBank.d253.s3|127-129|may|drug
DDI-DrugBank.d253.s3|131-137|produce|drug
DDI-DrugBank.d253.s3|139-146|additive|drug
DDI-DrugBank.d253.s3|148-156|inotropic|drug
DDI-DrugBank.d253.s3|158-163|and/or|drug
DDI-DrugBank.d253.s3|165-176|chronotropic|drug
DDI-DrugBank.d253.s3|178-184|effects|drug
DDI-DrugBank.d253.s3|185-185|.|drug
DDI-DrugBank.d78.s0|0-7|Antacids|group
DDI-DrugBank.d78.s0|8-8|,|drug
DDI-DrugBank.d78.s0|10-19|Sucralfate|brand
DDI-DrugBank.d78.s0|20-20|,|drug
DDI-DrugBank.d78.s0|22-26|Metal|drug
DDI-DrugBank.d78.s0|28-34|Cations|drug
DDI-DrugBank.d78.s0|35-35|,|drug
DDI-DrugBank.d78.s0|37-49|Multivitamins|brand
DDI-DrugBank.d78.s0|51-60|Quinolones|group
DDI-DrugBank.d78.s0|62-65|form|drug
DDI-DrugBank.d78.s0|67-74|chelates|drug
DDI-DrugBank.d78.s0|76-79|with|drug
DDI-DrugBank.d78.s0|81-88|alkaline|drug
DDI-DrugBank.d78.s0|90-94|earth|drug
DDI-DrugBank.d78.s0|96-98|and|drug
DDI-DrugBank.d78.s0|100-109|transition|drug
DDI-DrugBank.d78.s0|111-115|metal|drug
DDI-DrugBank.d78.s0|117-123|cations|drug
DDI-DrugBank.d78.s0|124-124|.|drug
DDI-DrugBank.d78.s1|0-13|Administration|drug
DDI-DrugBank.d78.s1|15-16|of|drug
DDI-DrugBank.d78.s1|18-27|quinolones|drug
DDI-DrugBank.d78.s1|29-32|with|drug
DDI-DrugBank.d78.s1|34-41|antacids|drug
DDI-DrugBank.d78.s1|43-52|containing|drug
DDI-DrugBank.d78.s1|54-61|aluminum|drug
DDI-DrugBank.d78.s1|62-62|,|drug
DDI-DrugBank.d78.s1|64-72|magnesium|drug
DDI-DrugBank.d78.s1|73-73|,|drug
DDI-DrugBank.d78.s1|75-76|or|drug
DDI-DrugBank.d78.s1|78-84|calcium|drug
DDI-DrugBank.d78.s1|85-85|,|drug
DDI-DrugBank.d78.s1|87-90|with|drug
DDI-DrugBank.d78.s1|92-101|sucralfate|drug
DDI-DrugBank.d78.s1|102-102|,|drug
DDI-DrugBank.d78.s1|104-107|with|drug
DDI-DrugBank.d78.s1|109-113|metal|drug
DDI-DrugBank.d78.s1|115-121|cations|drug
DDI-DrugBank.d78.s1|123-126|such|drug
DDI-DrugBank.d78.s1|128-129|as|drug
DDI-DrugBank.d78.s1|131-134|iron|drug
DDI-DrugBank.d78.s1|135-135|,|drug
DDI-DrugBank.d78.s1|137-138|or|drug
DDI-DrugBank.d78.s1|140-143|with|drug
DDI-DrugBank.d78.s1|145-157|multivitamins|drug
DDI-DrugBank.d78.s1|159-168|containing|drug
DDI-DrugBank.d78.s1|170-173|iron|drug
DDI-DrugBank.d78.s1|175-176|or|drug
DDI-DrugBank.d78.s1|178-181|zinc|drug
DDI-DrugBank.d78.s1|182-182|,|drug
DDI-DrugBank.d78.s1|184-185|or|drug
DDI-DrugBank.d78.s1|187-190|with|drug
DDI-DrugBank.d78.s1|192-203|formulations|drug
DDI-DrugBank.d78.s1|205-214|containing|drug
DDI-DrugBank.d78.s1|216-223|divalent|drug
DDI-DrugBank.d78.s1|225-227|and|drug
DDI-DrugBank.d78.s1|229-237|trivalent|drug
DDI-DrugBank.d78.s1|239-245|cations|drug
DDI-DrugBank.d78.s1|247-250|such|drug
DDI-DrugBank.d78.s1|252-253|as|drug
DDI-DrugBank.d78.s1|255-259|VIDEX|drug
DDI-DrugBank.d78.s1|261-261|(|drug
DDI-DrugBank.d78.s1|262-271|didanosine|drug
DDI-DrugBank.d78.s1|272-272|)|drug
DDI-DrugBank.d78.s1|274-290|chewable/buffered|drug
DDI-DrugBank.d78.s1|292-298|tablets|drug
DDI-DrugBank.d78.s1|300-301|or|drug
DDI-DrugBank.d78.s1|303-305|the|drug
DDI-DrugBank.d78.s1|307-315|pediatric|drug
DDI-DrugBank.d78.s1|317-322|powder|drug
DDI-DrugBank.d78.s1|324-326|for|drug
DDI-DrugBank.d78.s1|328-331|oral|drug
DDI-DrugBank.d78.s1|333-340|solution|drug
DDI-DrugBank.d78.s1|341-341|,|drug
DDI-DrugBank.d78.s1|343-345|may|drug
DDI-DrugBank.d78.s1|347-359|substantially|drug
DDI-DrugBank.d78.s1|361-369|interfere|drug
DDI-DrugBank.d78.s1|371-374|with|drug
DDI-DrugBank.d78.s1|376-378|the|drug
DDI-DrugBank.d78.s1|380-389|absorption|drug
DDI-DrugBank.d78.s1|391-392|of|drug
DDI-DrugBank.d78.s1|394-403|quinolones|drug
DDI-DrugBank.d78.s1|404-404|,|drug
DDI-DrugBank.d78.s1|406-414|resulting|drug
DDI-DrugBank.d78.s1|416-417|in|drug
DDI-DrugBank.d78.s1|419-426|systemic|drug
DDI-DrugBank.d78.s1|428-441|concentrations|drug
DDI-DrugBank.d78.s1|443-454|considerably|drug
DDI-DrugBank.d78.s1|456-460|lower|drug
DDI-DrugBank.d78.s1|462-465|than|drug
DDI-DrugBank.d78.s1|467-473|desired|drug
DDI-DrugBank.d78.s1|474-474|.|drug
DDI-DrugBank.d78.s2|0-4|These|drug
DDI-DrugBank.d78.s2|6-11|agents|drug
DDI-DrugBank.d78.s2|13-18|should|drug
DDI-DrugBank.d78.s2|20-22|not|drug
DDI-DrugBank.d78.s2|24-25|be|drug
DDI-DrugBank.d78.s2|27-31|taken|drug
DDI-DrugBank.d78.s2|33-38|within|drug
DDI-DrugBank.d78.s2|40-40|4|drug
DDI-DrugBank.d78.s2|42-46|hours|drug
DDI-DrugBank.d78.s2|48-53|before|drug
DDI-DrugBank.d78.s2|55-56|or|drug
DDI-DrugBank.d78.s2|58-58|4|drug
DDI-DrugBank.d78.s2|60-64|hours|drug
DDI-DrugBank.d78.s2|66-70|after|drug
DDI-DrugBank.d78.s2|72-84|grepafloxacin|drug
DDI-DrugBank.d78.s2|86-99|administration|drug
DDI-DrugBank.d78.s2|100-100|.|drug
DDI-DrugBank.d78.s3|0-7|Caffeine|brand
DDI-DrugBank.d78.s3|9-19|Theobromine|drug
DDI-DrugBank.d78.s3|21-33|Grepafloxacin|drug
DDI-DrugBank.d78.s3|34-34|,|drug
DDI-DrugBank.d78.s3|36-39|like|drug
DDI-DrugBank.d78.s3|41-45|other|drug
DDI-DrugBank.d78.s3|47-56|quinolones|drug
DDI-DrugBank.d78.s3|57-57|,|drug
DDI-DrugBank.d78.s3|59-61|may|drug
DDI-DrugBank.d78.s3|63-69|inhibit|drug
DDI-DrugBank.d78.s3|71-73|the|drug
DDI-DrugBank.d78.s3|75-84|metabolism|drug
DDI-DrugBank.d78.s3|86-87|of|drug
DDI-DrugBank.d78.s3|89-96|caffeine|drug
DDI-DrugBank.d78.s3|98-100|and|drug
DDI-DrugBank.d78.s3|102-112|theobromine|drug
DDI-DrugBank.d78.s3|113-113|.|drug
DDI-DrugBank.d78.s4|0-4|These|drug
DDI-DrugBank.d78.s4|6-15|stimulants|drug
DDI-DrugBank.d78.s4|17-19|are|drug
DDI-DrugBank.d78.s4|21-28|commonly|drug
DDI-DrugBank.d78.s4|30-34|found|drug
DDI-DrugBank.d78.s4|36-37|in|drug
DDI-DrugBank.d78.s4|39-44|coffee|drug
DDI-DrugBank.d78.s4|46-48|and|drug
DDI-DrugBank.d78.s4|50-52|tea|drug
DDI-DrugBank.d78.s4|53-53|,|drug
DDI-DrugBank.d78.s4|55-66|respectively|drug
DDI-DrugBank.d78.s4|67-67|.|drug
DDI-DrugBank.d78.s5|0-1|In|drug
DDI-DrugBank.d78.s5|3-6|some|drug
DDI-DrugBank.d78.s5|8-15|patients|drug
DDI-DrugBank.d78.s5|16-16|,|drug
DDI-DrugBank.d78.s5|18-21|this|drug
DDI-DrugBank.d78.s5|23-25|may|drug
DDI-DrugBank.d78.s5|27-30|lead|drug
DDI-DrugBank.d78.s5|32-33|to|drug
DDI-DrugBank.d78.s5|35-41|reduced|drug
DDI-DrugBank.d78.s5|43-51|clearance|drug
DDI-DrugBank.d78.s5|52-52|,|drug
DDI-DrugBank.d78.s5|54-65|prolongation|drug
DDI-DrugBank.d78.s5|67-68|of|drug
DDI-DrugBank.d78.s5|70-75|plasma|drug
DDI-DrugBank.d78.s5|77-85|half-life|drug
DDI-DrugBank.d78.s5|86-86|,|drug
DDI-DrugBank.d78.s5|88-90|and|drug
DDI-DrugBank.d78.s5|92-99|enhanced|drug
DDI-DrugBank.d78.s5|101-107|effects|drug
DDI-DrugBank.d78.s5|109-110|of|drug
DDI-DrugBank.d78.s5|112-119|caffeine|drug
DDI-DrugBank.d78.s5|121-123|and|drug
DDI-DrugBank.d78.s5|125-135|theobromine|drug
DDI-DrugBank.d78.s5|136-136|.|drug
DDI-DrugBank.d78.s6|0-11|Theophylline|brand
DDI-DrugBank.d78.s6|12-12|:|drug
DDI-DrugBank.d78.s6|14-26|Grepafloxacin|drug
DDI-DrugBank.d78.s6|28-29|is|drug
DDI-DrugBank.d78.s6|31-31|a|drug
DDI-DrugBank.d78.s6|33-43|competitive|drug
DDI-DrugBank.d78.s6|45-53|inhibitor|drug
DDI-DrugBank.d78.s6|55-56|of|drug
DDI-DrugBank.d78.s6|58-60|the|drug
DDI-DrugBank.d78.s6|62-71|metabolism|drug
DDI-DrugBank.d78.s6|73-74|of|drug
DDI-DrugBank.d78.s6|76-87|theophylline|drug
DDI-DrugBank.d78.s6|88-88|.|drug
DDI-DrugBank.d78.s7|0-4|Serum|group
DDI-DrugBank.d78.s7|6-17|theophylline|drug
DDI-DrugBank.d78.s7|19-32|concentrations|drug
DDI-DrugBank.d78.s7|34-41|increase|drug
DDI-DrugBank.d78.s7|43-46|when|drug
DDI-DrugBank.d78.s7|48-60|grepafloxacin|drug
DDI-DrugBank.d78.s7|62-63|is|drug
DDI-DrugBank.d78.s7|65-73|initiated|drug
DDI-DrugBank.d78.s7|75-76|in|drug
DDI-DrugBank.d78.s7|78-78|a|drug
DDI-DrugBank.d78.s7|80-86|patient|drug
DDI-DrugBank.d78.s7|88-97|maintained|drug
DDI-DrugBank.d78.s7|99-100|on|drug
DDI-DrugBank.d78.s7|102-113|theophylline|drug
DDI-DrugBank.d78.s7|114-114|.|drug
DDI-DrugBank.d78.s8|0-3|When|drug
DDI-DrugBank.d78.s8|5-14|initiating|drug
DDI-DrugBank.d78.s8|16-16|a|drug
DDI-DrugBank.d78.s8|18-26|multi-day|drug
DDI-DrugBank.d78.s8|28-33|course|drug
DDI-DrugBank.d78.s8|35-36|of|drug
DDI-DrugBank.d78.s8|38-50|grepafloxacin|drug
DDI-DrugBank.d78.s8|52-53|in|drug
DDI-DrugBank.d78.s8|55-55|a|drug
DDI-DrugBank.d78.s8|57-63|patient|drug
DDI-DrugBank.d78.s8|65-74|maintained|drug
DDI-DrugBank.d78.s8|76-77|on|drug
DDI-DrugBank.d78.s8|79-90|theophylline|drug
DDI-DrugBank.d78.s8|91-91|,|drug
DDI-DrugBank.d78.s8|93-95|the|drug
DDI-DrugBank.d78.s8|97-108|theophylline|drug
DDI-DrugBank.d78.s8|110-120|maintenance|drug
DDI-DrugBank.d78.s8|122-125|dose|drug
DDI-DrugBank.d78.s8|127-132|should|drug
DDI-DrugBank.d78.s8|134-135|be|drug
DDI-DrugBank.d78.s8|137-142|halved|drug
DDI-DrugBank.d78.s8|144-146|for|drug
DDI-DrugBank.d78.s8|148-150|the|drug
DDI-DrugBank.d78.s8|152-157|period|drug
DDI-DrugBank.d78.s8|159-160|of|drug
DDI-DrugBank.d78.s8|162-171|concurrent|drug
DDI-DrugBank.d78.s8|173-175|use|drug
DDI-DrugBank.d78.s8|177-178|of|drug
DDI-DrugBank.d78.s8|180-192|grepafloxacin|drug
DDI-DrugBank.d78.s8|194-196|and|drug
DDI-DrugBank.d78.s8|198-207|monitoring|drug
DDI-DrugBank.d78.s8|209-210|of|drug
DDI-DrugBank.d78.s8|212-216|serum|drug
DDI-DrugBank.d78.s8|218-229|theophylline|drug
DDI-DrugBank.d78.s8|231-244|concentrations|drug
DDI-DrugBank.d78.s8|246-251|should|drug
DDI-DrugBank.d78.s8|253-254|be|drug
DDI-DrugBank.d78.s8|256-264|initiated|drug
DDI-DrugBank.d78.s8|266-267|as|drug
DDI-DrugBank.d78.s8|269-269|a|drug
DDI-DrugBank.d78.s8|271-275|guide|drug
DDI-DrugBank.d78.s8|277-278|to|drug
DDI-DrugBank.d78.s8|280-286|further|drug
DDI-DrugBank.d78.s8|288-293|dosage|drug
DDI-DrugBank.d78.s8|295-305|adjustments|drug
DDI-DrugBank.d78.s8|306-306|.|drug
DDI-DrugBank.d78.s9|0-7|Warfarin|brand
DDI-DrugBank.d78.s9|8-8|:|drug
DDI-DrugBank.d78.s9|10-11|In|drug
DDI-DrugBank.d78.s9|13-20|subjects|drug
DDI-DrugBank.d78.s9|22-30|receiving|drug
DDI-DrugBank.d78.s9|32-39|warfarin|drug
DDI-DrugBank.d78.s9|40-40|,|drug
DDI-DrugBank.d78.s9|42-43|no|drug
DDI-DrugBank.d78.s9|45-55|significant|drug
DDI-DrugBank.d78.s9|57-62|change|drug
DDI-DrugBank.d78.s9|64-65|in|drug
DDI-DrugBank.d78.s9|67-74|clotting|drug
DDI-DrugBank.d78.s9|76-79|time|drug
DDI-DrugBank.d78.s9|81-83|was|drug
DDI-DrugBank.d78.s9|85-92|observed|drug
DDI-DrugBank.d78.s9|94-97|when|drug
DDI-DrugBank.d78.s9|99-111|grepafloxacin|drug
DDI-DrugBank.d78.s9|113-115|was|drug
DDI-DrugBank.d78.s9|117-130|coadministered|drug
DDI-DrugBank.d78.s9|131-131|.|drug
DDI-DrugBank.d78.s10|0-6|However|drug
DDI-DrugBank.d78.s10|7-7|,|drug
DDI-DrugBank.d78.s10|9-15|because|drug
DDI-DrugBank.d78.s10|17-20|some|drug
DDI-DrugBank.d78.s10|22-31|quinolones|drug
DDI-DrugBank.d78.s10|33-36|have|drug
DDI-DrugBank.d78.s10|38-41|been|drug
DDI-DrugBank.d78.s10|43-50|reported|drug
DDI-DrugBank.d78.s10|52-53|to|drug
DDI-DrugBank.d78.s10|55-61|enhance|drug
DDI-DrugBank.d78.s10|63-65|the|drug
DDI-DrugBank.d78.s10|67-73|effects|drug
DDI-DrugBank.d78.s10|75-76|of|drug
DDI-DrugBank.d78.s10|78-85|warfarin|drug
DDI-DrugBank.d78.s10|87-88|or|drug
DDI-DrugBank.d78.s10|90-92|its|drug
DDI-DrugBank.d78.s10|94-104|derivatives|drug
DDI-DrugBank.d78.s10|105-105|,|drug
DDI-DrugBank.d78.s10|107-117|prothrombin|drug
DDI-DrugBank.d78.s10|119-122|time|drug
DDI-DrugBank.d78.s10|124-125|or|drug
DDI-DrugBank.d78.s10|127-131|other|drug
DDI-DrugBank.d78.s10|133-140|suitable|drug
DDI-DrugBank.d78.s10|142-156|anticoagulation|drug
DDI-DrugBank.d78.s10|158-161|test|drug
DDI-DrugBank.d78.s10|163-168|should|drug
DDI-DrugBank.d78.s10|170-171|be|drug
DDI-DrugBank.d78.s10|173-181|monitored|drug
DDI-DrugBank.d78.s10|183-189|closely|drug
DDI-DrugBank.d78.s10|191-192|if|drug
DDI-DrugBank.d78.s10|194-194|a|drug
DDI-DrugBank.d78.s10|196-204|quinolone|drug
DDI-DrugBank.d78.s10|206-218|antimicrobial|drug
DDI-DrugBank.d78.s10|220-221|is|drug
DDI-DrugBank.d78.s10|223-234|administered|drug
DDI-DrugBank.d78.s10|236-239|with|drug
DDI-DrugBank.d78.s10|241-248|warfarin|drug
DDI-DrugBank.d78.s10|250-251|or|drug
DDI-DrugBank.d78.s10|253-255|its|drug
DDI-DrugBank.d78.s10|257-267|derivatives|drug
DDI-DrugBank.d78.s10|268-268|.|drug
DDI-DrugBank.d78.s11|0-4|Drugs|drug
DDI-DrugBank.d78.s11|6-16|Metabolized|drug
DDI-DrugBank.d78.s11|18-19|by|drug
DDI-DrugBank.d78.s11|21-30|Cytochrome|drug
DDI-DrugBank.d78.s11|32-35|P450|drug
DDI-DrugBank.d78.s11|37-43|Enzymes|group
DDI-DrugBank.d78.s11|45-47|The|drug
DDI-DrugBank.d78.s11|49-52|drug|drug
DDI-DrugBank.d78.s11|54-64|interaction|drug
DDI-DrugBank.d78.s11|66-70|study|drug
DDI-DrugBank.d78.s11|72-81|evaluating|drug
DDI-DrugBank.d78.s11|83-85|the|drug
DDI-DrugBank.d78.s11|87-92|effect|drug
DDI-DrugBank.d78.s11|94-95|of|drug
DDI-DrugBank.d78.s11|97-109|grepafloxacin|drug
DDI-DrugBank.d78.s11|111-112|on|drug
DDI-DrugBank.d78.s11|114-125|theophylline|drug
DDI-DrugBank.d78.s11|127-135|indicates|drug
DDI-DrugBank.d78.s11|137-140|that|drug
DDI-DrugBank.d78.s11|142-154|grepafloxacin|drug
DDI-DrugBank.d78.s11|156-163|inhibits|drug
DDI-DrugBank.d78.s11|165-176|theophylline|drug
DDI-DrugBank.d78.s11|178-187|metabolism|drug
DDI-DrugBank.d78.s11|188-188|,|drug
DDI-DrugBank.d78.s11|190-194|which|drug
DDI-DrugBank.d78.s11|196-197|is|drug
DDI-DrugBank.d78.s11|199-206|mediated|drug
DDI-DrugBank.d78.s11|208-209|by|drug
DDI-DrugBank.d78.s11|211-216|CYP1A2|drug
DDI-DrugBank.d78.s11|217-217|.|drug
DDI-DrugBank.d78.s12|0-4|While|drug
DDI-DrugBank.d78.s12|6-7|no|drug
DDI-DrugBank.d78.s12|9-16|clinical|drug
DDI-DrugBank.d78.s12|18-24|studies|drug
DDI-DrugBank.d78.s12|26-29|have|drug
DDI-DrugBank.d78.s12|31-34|been|drug
DDI-DrugBank.d78.s12|36-44|conducted|drug
DDI-DrugBank.d78.s12|46-47|to|drug
DDI-DrugBank.d78.s12|49-56|evaluate|drug
DDI-DrugBank.d78.s12|58-60|the|drug
DDI-DrugBank.d78.s12|62-67|effect|drug
DDI-DrugBank.d78.s12|69-70|of|drug
DDI-DrugBank.d78.s12|72-84|grepafloxacin|drug
DDI-DrugBank.d78.s12|86-87|on|drug
DDI-DrugBank.d78.s12|89-91|the|drug
DDI-DrugBank.d78.s12|93-102|metabolism|drug
DDI-DrugBank.d78.s12|104-105|of|drug
DDI-DrugBank.d78.s12|107-111|C.P.A|drug
DDI-DrugBank.d78.s12|112-112|.|drug
DDI-DrugBank.d78.s13|0-9|substrates|drug
DDI-DrugBank.d78.s13|10-10|,|drug
DDI-DrugBank.d78.s13|12-13|in|drug
DDI-DrugBank.d78.s13|15-19|vitro|drug
DDI-DrugBank.d78.s13|21-24|data|drug
DDI-DrugBank.d78.s13|26-32|suggest|drug
DDI-DrugBank.d78.s13|34-40|similar|drug
DDI-DrugBank.d78.s13|42-48|effects|drug
DDI-DrugBank.d78.s13|50-51|of|drug
DDI-DrugBank.d78.s13|53-65|grepafloxacin|drug
DDI-DrugBank.d78.s13|67-68|in|drug
DDI-DrugBank.d78.s13|70-75|CYP3A4|drug
DDI-DrugBank.d78.s13|77-84|mediated|drug
DDI-DrugBank.d78.s13|86-95|metabolism|drug
DDI-DrugBank.d78.s13|97-99|and|drug
DDI-DrugBank.d78.s13|101-112|theophylline|drug
DDI-DrugBank.d78.s13|114-123|metabolism|drug
DDI-DrugBank.d78.s13|124-124|.|drug
DDI-DrugBank.d78.s14|0-1|In|drug
DDI-DrugBank.d78.s14|3-10|addition|drug
DDI-DrugBank.d78.s14|11-11|,|drug
DDI-DrugBank.d78.s14|13-17|other|drug
DDI-DrugBank.d78.s14|19-28|quinolones|drug
DDI-DrugBank.d78.s14|30-33|have|drug
DDI-DrugBank.d78.s14|35-38|been|drug
DDI-DrugBank.d78.s14|40-47|reported|drug
DDI-DrugBank.d78.s14|49-50|to|drug
DDI-DrugBank.d78.s14|52-59|decrease|drug
DDI-DrugBank.d78.s14|61-63|the|drug
DDI-DrugBank.d78.s14|65-79|CYP3A4-mediated|drug
DDI-DrugBank.d78.s14|81-90|metabolism|drug
DDI-DrugBank.d78.s14|92-93|of|drug
DDI-DrugBank.d78.s14|95-106|cyclosporine|drug
DDI-DrugBank.d78.s14|107-107|.|drug
DDI-DrugBank.d78.s15|0-4|Other|drug
DDI-DrugBank.d78.s15|6-10|drugs|drug
DDI-DrugBank.d78.s15|12-22|metabolized|drug
DDI-DrugBank.d78.s15|24-25|by|drug
DDI-DrugBank.d78.s15|27-31|C.P.A|drug
DDI-DrugBank.d78.s15|32-32|.|drug
DDI-DrugBank.d78.s16|0-6|include|drug
DDI-DrugBank.d78.s16|8-18|terfenadine|drug
DDI-DrugBank.d78.s16|19-19|,|drug
DDI-DrugBank.d78.s16|21-30|astemizole|drug
DDI-DrugBank.d78.s16|31-31|,|drug
DDI-DrugBank.d78.s16|33-41|cisapride|drug
DDI-DrugBank.d78.s16|42-42|,|drug
DDI-DrugBank.d78.s16|44-52|midazolam|drug
DDI-DrugBank.d78.s16|53-53|,|drug
DDI-DrugBank.d78.s16|55-57|and|drug
DDI-DrugBank.d78.s16|59-67|triazolam|drug
DDI-DrugBank.d78.s16|68-68|.|drug
DDI-DrugBank.d78.s17|0-2|The|drug
DDI-DrugBank.d78.s17|4-11|clinical|drug
DDI-DrugBank.d78.s17|13-21|relevance|drug
DDI-DrugBank.d78.s17|23-24|of|drug
DDI-DrugBank.d78.s17|26-28|the|drug
DDI-DrugBank.d78.s17|30-38|potential|drug
DDI-DrugBank.d78.s17|40-45|effect|drug
DDI-DrugBank.d78.s17|47-48|of|drug
DDI-DrugBank.d78.s17|50-62|grepafloxacin|drug
DDI-DrugBank.d78.s17|64-65|on|drug
DDI-DrugBank.d78.s17|67-69|the|drug
DDI-DrugBank.d78.s17|71-80|metabolism|drug
DDI-DrugBank.d78.s17|82-83|of|drug
DDI-DrugBank.d78.s17|85-90|C.P.A|drug
DDI-DrugBank.d78.s17|92-101|.|drug
DDI-DrugBank.d78.s17|103-104|substrates|drug
DDI-DrugBank.d78.s17|106-108|is|drug
DDI-DrugBank.d78.s17|110-114|not|drug
DDI-DrugBank.d78.s17|115-115|known|drug
DDI-DrugBank.d78.s18|0-7|Patients|drug
DDI-DrugBank.d78.s18|9-17|receiving|drug
DDI-DrugBank.d78.s18|19-28|concurrent|drug
DDI-DrugBank.d78.s18|30-43|administration|drug
DDI-DrugBank.d78.s18|45-46|of|drug
DDI-DrugBank.d78.s18|48-57|substrates|drug
DDI-DrugBank.d78.s18|59-60|of|drug
DDI-DrugBank.d78.s18|62-67|C.P.A|drug
DDI-DrugBank.d78.s18|69-72|.|drug
DDI-DrugBank.d78.s18|74-76|were|drug
DDI-DrugBank.d78.s18|78-85|not|drug
DDI-DrugBank.d78.s18|87-90|excluded|drug
DDI-DrugBank.d78.s18|92-99|from|drug
DDI-DrugBank.d78.s18|101-106|clinical|drug
DDI-DrugBank.d78.s18|108-109|trials|drug
DDI-DrugBank.d78.s18|111-123|of|drug
DDI-DrugBank.d78.s18|124-124|grepafloxacin|drug
DDI-DrugBank.d78.s19|0-11|Nonsteroidal|drug
DDI-DrugBank.d78.s19|13-29|Anti-inflammatory|drug
DDI-DrugBank.d78.s19|31-35|Drugs|drug
DDI-DrugBank.d78.s19|37-37|(|drug
DDI-DrugBank.d78.s19|38-43|NSAIDs|drug
DDI-DrugBank.d78.s19|44-44|)|drug
DDI-DrugBank.d78.s19|45-45|:|drug
DDI-DrugBank.d78.s19|47-49|The|drug
DDI-DrugBank.d78.s19|51-61|concomitant|drug
DDI-DrugBank.d78.s19|63-76|administration|drug
DDI-DrugBank.d78.s19|78-79|of|drug
DDI-DrugBank.d78.s19|81-81|a|drug
DDI-DrugBank.d78.s19|83-94|nonsteroidal|drug
DDI-DrugBank.d78.s19|96-99|anti|drug
DDI-DrugBank.d78.s19|101-112|inflammatory|drug
DDI-DrugBank.d78.s19|114-117|drug|drug
DDI-DrugBank.d78.s19|119-122|with|drug
DDI-DrugBank.d78.s19|124-124|a|drug
DDI-DrugBank.d78.s19|126-134|quinolone|drug
DDI-DrugBank.d78.s19|136-138|may|drug
DDI-DrugBank.d78.s19|140-147|increase|drug
DDI-DrugBank.d78.s19|149-151|the|drug
DDI-DrugBank.d78.s19|153-157|risks|drug
DDI-DrugBank.d78.s19|159-160|of|drug
DDI-DrugBank.d78.s19|162-164|CNS|drug
DDI-DrugBank.d78.s19|166-176|stimulation|drug
DDI-DrugBank.d78.s19|178-180|and|drug
DDI-DrugBank.d78.s19|182-192|convulsions|drug
DDI-DrugBank.d78.s19|193-193|.|drug
DDI-DrugBank.d78.s20|0-11|Antidiabetic|drug
DDI-DrugBank.d78.s20|13-18|Agents|drug
DDI-DrugBank.d78.s20|19-19|:|drug
DDI-DrugBank.d78.s20|21-32|Disturbances|drug
DDI-DrugBank.d78.s20|34-35|of|drug
DDI-DrugBank.d78.s20|37-41|blood|drug
DDI-DrugBank.d78.s20|43-49|glucose|drug
DDI-DrugBank.d78.s20|50-50|,|drug
DDI-DrugBank.d78.s20|52-60|including|drug
DDI-DrugBank.d78.s20|62-74|hyperglycemia|drug
DDI-DrugBank.d78.s20|76-78|and|drug
DDI-DrugBank.d78.s20|80-91|hypoglycemia|drug
DDI-DrugBank.d78.s20|92-92|,|drug
DDI-DrugBank.d78.s20|94-97|have|drug
DDI-DrugBank.d78.s20|99-102|been|drug
DDI-DrugBank.d78.s20|104-111|reported|drug
DDI-DrugBank.d78.s20|113-114|in|drug
DDI-DrugBank.d78.s20|116-123|patients|drug
DDI-DrugBank.d78.s20|125-131|treated|drug
DDI-DrugBank.d78.s20|133-145|concomitantly|drug
DDI-DrugBank.d78.s20|147-150|with|drug
DDI-DrugBank.d78.s20|152-161|quinolones|drug
DDI-DrugBank.d78.s20|163-165|and|drug
DDI-DrugBank.d78.s20|167-168|an|drug
DDI-DrugBank.d78.s20|170-181|antidiabetic|drug
DDI-DrugBank.d78.s20|183-187|agent|drug
DDI-DrugBank.d78.s20|188-188|.|drug
DDI-DrugBank.d78.s21|0-8|Therefore|drug
DDI-DrugBank.d78.s21|9-9|,|drug
DDI-DrugBank.d78.s21|11-17|careful|drug
DDI-DrugBank.d78.s21|19-28|monitoring|drug
DDI-DrugBank.d78.s21|30-31|of|drug
DDI-DrugBank.d78.s21|33-37|blood|drug
DDI-DrugBank.d78.s21|39-45|glucose|drug
DDI-DrugBank.d78.s21|47-48|is|drug
DDI-DrugBank.d78.s21|50-60|recommended|drug
DDI-DrugBank.d78.s21|62-65|when|drug
DDI-DrugBank.d78.s21|67-71|these|drug
DDI-DrugBank.d78.s21|73-78|agents|drug
DDI-DrugBank.d78.s21|80-82|are|drug
DDI-DrugBank.d78.s21|84-97|coadministered|drug
DDI-DrugBank.d78.s21|98-98|.|drug
DDI-DrugBank.d252.s0|0-7|Although|drug
DDI-DrugBank.d252.s0|9-15|BETAGAN|drug
DDI-DrugBank.d252.s0|17-20|used|drug
DDI-DrugBank.d252.s0|22-26|alone|drug
DDI-DrugBank.d252.s0|28-30|has|drug
DDI-DrugBank.d252.s0|32-37|little|drug
DDI-DrugBank.d252.s0|39-40|or|drug
DDI-DrugBank.d252.s0|42-43|no|drug
DDI-DrugBank.d252.s0|45-50|effect|drug
DDI-DrugBank.d252.s0|52-53|on|drug
DDI-DrugBank.d252.s0|55-59|pupil|drug
DDI-DrugBank.d252.s0|61-64|size|drug
DDI-DrugBank.d252.s0|65-65|,|drug
DDI-DrugBank.d252.s0|67-75|mydriasis|drug
DDI-DrugBank.d252.s0|77-85|resulting|drug
DDI-DrugBank.d252.s0|87-90|from|drug
DDI-DrugBank.d252.s0|92-102|concomitant|drug
DDI-DrugBank.d252.s0|104-110|therapy|drug
DDI-DrugBank.d252.s0|112-115|with|drug
DDI-DrugBank.d252.s0|117-123|BETAGAN|drug
DDI-DrugBank.d252.s0|125-127|and|drug
DDI-DrugBank.d252.s0|129-139|epinephrine|drug
DDI-DrugBank.d252.s0|141-143|may|drug
DDI-DrugBank.d252.s0|145-149|occur|drug
DDI-DrugBank.d252.s0|150-150|.|drug
DDI-DrugBank.d252.s1|0-4|Close|drug
DDI-DrugBank.d252.s1|6-16|observation|drug
DDI-DrugBank.d252.s1|18-19|of|drug
DDI-DrugBank.d252.s1|21-23|the|drug
DDI-DrugBank.d252.s1|25-31|patient|drug
DDI-DrugBank.d252.s1|33-34|is|drug
DDI-DrugBank.d252.s1|36-46|recommended|drug
DDI-DrugBank.d252.s1|48-51|when|drug
DDI-DrugBank.d252.s1|53-53|a|drug
DDI-DrugBank.d252.s1|55-66|beta-blocker|drug
DDI-DrugBank.d252.s1|68-69|is|drug
DDI-DrugBank.d252.s1|71-82|administered|drug
DDI-DrugBank.d252.s1|84-85|to|drug
DDI-DrugBank.d252.s1|87-94|patients|drug
DDI-DrugBank.d252.s1|96-104|receiving|drug
DDI-DrugBank.d252.s1|106-128|catecholamine-depleting|drug
DDI-DrugBank.d252.s1|130-134|drugs|drug
DDI-DrugBank.d252.s1|136-139|such|drug
DDI-DrugBank.d252.s1|141-142|as|drug
DDI-DrugBank.d252.s1|144-152|reserpine|drug
DDI-DrugBank.d252.s1|153-153|,|drug
DDI-DrugBank.d252.s1|155-161|because|drug
DDI-DrugBank.d252.s1|163-164|of|drug
DDI-DrugBank.d252.s1|166-173|possible|drug
DDI-DrugBank.d252.s1|175-182|additive|drug
DDI-DrugBank.d252.s1|184-190|effects|drug
DDI-DrugBank.d252.s1|192-194|and|drug
DDI-DrugBank.d252.s1|196-198|the|drug
DDI-DrugBank.d252.s1|200-209|production|drug
DDI-DrugBank.d252.s1|211-212|of|drug
DDI-DrugBank.d252.s1|214-224|hypotension|drug
DDI-DrugBank.d252.s1|226-231|and/or|drug
DDI-DrugBank.d252.s1|233-238|marked|drug
DDI-DrugBank.d252.s1|240-250|bradycardia|drug
DDI-DrugBank.d252.s1|251-251|,|drug
DDI-DrugBank.d252.s1|253-257|which|drug
DDI-DrugBank.d252.s1|259-261|may|drug
DDI-DrugBank.d252.s1|263-269|produce|drug
DDI-DrugBank.d252.s1|271-277|vertigo|drug
DDI-DrugBank.d252.s1|278-278|,|drug
DDI-DrugBank.d252.s1|280-286|syncope|drug
DDI-DrugBank.d252.s1|288-289|or|drug
DDI-DrugBank.d252.s1|291-298|postural|drug
DDI-DrugBank.d252.s1|300-310|hypotension|drug
DDI-DrugBank.d252.s1|311-311|.|drug
DDI-DrugBank.d252.s2|0-7|Patients|drug
DDI-DrugBank.d252.s2|9-17|receiving|drug
DDI-DrugBank.d252.s2|19-33|beta-adrenergic|drug
DDI-DrugBank.d252.s2|35-42|blocking|drug
DDI-DrugBank.d252.s2|44-49|agents|drug
DDI-DrugBank.d252.s2|51-55|along|drug
DDI-DrugBank.d252.s2|57-60|with|drug
DDI-DrugBank.d252.s2|62-67|either|drug
DDI-DrugBank.d252.s2|69-72|oral|drug
DDI-DrugBank.d252.s2|74-75|or|drug
DDI-DrugBank.d252.s2|77-87|intravenous|drug
DDI-DrugBank.d252.s2|89-95|calcium|drug
DDI-DrugBank.d252.s2|97-107|antagonists|drug
DDI-DrugBank.d252.s2|109-114|should|drug
DDI-DrugBank.d252.s2|116-117|be|drug
DDI-DrugBank.d252.s2|119-127|monitored|drug
DDI-DrugBank.d252.s2|129-131|for|drug
DDI-DrugBank.d252.s2|133-140|possible|drug
DDI-DrugBank.d252.s2|142-157|atrioventricular|drug
DDI-DrugBank.d252.s2|159-168|conduction|drug
DDI-DrugBank.d252.s2|170-181|disturbances|drug
DDI-DrugBank.d252.s2|182-182|,|drug
DDI-DrugBank.d252.s2|184-187|left|drug
DDI-DrugBank.d252.s2|189-199|ventricular|drug
DDI-DrugBank.d252.s2|201-207|failure|drug
DDI-DrugBank.d252.s2|209-211|and|drug
DDI-DrugBank.d252.s2|213-223|hypotension|drug
DDI-DrugBank.d252.s2|224-224|.|drug
DDI-DrugBank.d252.s3|0-1|In|drug
DDI-DrugBank.d252.s3|3-10|patients|drug
DDI-DrugBank.d252.s3|12-15|with|drug
DDI-DrugBank.d252.s3|17-24|impaired|drug
DDI-DrugBank.d252.s3|26-32|cardiac|drug
DDI-DrugBank.d252.s3|34-41|function|drug
DDI-DrugBank.d252.s3|42-42|,|drug
DDI-DrugBank.d252.s3|44-55|simultaneous|drug
DDI-DrugBank.d252.s3|57-59|use|drug
DDI-DrugBank.d252.s3|61-66|should|drug
DDI-DrugBank.d252.s3|68-69|be|drug
DDI-DrugBank.d252.s3|71-77|avoided|drug
DDI-DrugBank.d252.s3|79-88|altogether|drug
DDI-DrugBank.d252.s3|89-89|.|drug
DDI-DrugBank.d252.s4|0-2|The|drug
DDI-DrugBank.d252.s4|4-14|concomitant|drug
DDI-DrugBank.d252.s4|16-18|use|drug
DDI-DrugBank.d252.s4|20-21|of|drug
DDI-DrugBank.d252.s4|23-37|beta-adrenergic|drug
DDI-DrugBank.d252.s4|39-46|blocking|drug
DDI-DrugBank.d252.s4|48-53|agents|drug
DDI-DrugBank.d252.s4|55-58|with|drug
DDI-DrugBank.d252.s4|60-68|digitalis|drug
DDI-DrugBank.d252.s4|70-72|and|drug
DDI-DrugBank.d252.s4|74-80|calcium|drug
DDI-DrugBank.d252.s4|82-92|antagonists|drug
DDI-DrugBank.d252.s4|94-96|may|drug
DDI-DrugBank.d252.s4|98-101|have|drug
DDI-DrugBank.d252.s4|103-110|additive|drug
DDI-DrugBank.d252.s4|112-118|effects|drug
DDI-DrugBank.d252.s4|120-121|on|drug
DDI-DrugBank.d252.s4|123-132|prolonging|drug
DDI-DrugBank.d252.s4|134-149|atrioventricular|drug
DDI-DrugBank.d252.s4|151-160|conduction|drug
DDI-DrugBank.d252.s4|162-165|time|drug
DDI-DrugBank.d252.s4|166-166|.|drug
DDI-DrugBank.d252.s5|0-20|Phenothiazine-related|drug
DDI-DrugBank.d252.s5|22-30|compounds|drug
DDI-DrugBank.d252.s5|32-34|and|drug
DDI-DrugBank.d252.s5|36-50|beta-adrenergic|drug
DDI-DrugBank.d252.s5|52-59|blocking|drug
DDI-DrugBank.d252.s5|61-66|agents|drug
DDI-DrugBank.d252.s5|68-70|may|drug
DDI-DrugBank.d252.s5|72-75|have|drug
DDI-DrugBank.d252.s5|77-84|additive|drug
DDI-DrugBank.d252.s5|86-96|hypotensite|drug
DDI-DrugBank.d252.s5|98-104|effects|drug
DDI-DrugBank.d252.s5|106-108|due|drug
DDI-DrugBank.d252.s5|110-111|to|drug
DDI-DrugBank.d252.s5|113-115|the|drug
DDI-DrugBank.d252.s5|117-126|inhibition|drug
DDI-DrugBank.d252.s5|128-129|of|drug
DDI-DrugBank.d252.s5|131-134|each|drug
DDI-DrugBank.d252.s5|136-140|other|drug
DDI-DrugBank.d252.s5|142-142|s|drug
DDI-DrugBank.d252.s5|144-153|metabolism|drug
DDI-DrugBank.d252.s5|154-154|.|drug
DDI-DrugBank.d97.s0|0-8|Indinavir|drug
DDI-DrugBank.d97.s0|10-11|is|drug
DDI-DrugBank.d97.s0|13-14|an|drug
DDI-DrugBank.d97.s0|16-24|inhibitor|drug
DDI-DrugBank.d97.s0|26-27|of|drug
DDI-DrugBank.d97.s0|29-31|the|drug
DDI-DrugBank.d97.s0|33-42|cytochrome|drug
DDI-DrugBank.d97.s0|44-47|P450|drug
DDI-DrugBank.d97.s0|49-55|isoform|drug
DDI-DrugBank.d97.s0|57-62|CYP3A4|drug
DDI-DrugBank.d97.s0|63-63|.|drug
DDI-DrugBank.d97.s1|0-15|Coadministration|drug
DDI-DrugBank.d97.s1|17-18|of|drug
DDI-DrugBank.d97.s1|20-27|CRIXIVAN|drug
DDI-DrugBank.d97.s1|29-31|and|drug
DDI-DrugBank.d97.s1|33-37|drugs|drug
DDI-DrugBank.d97.s1|39-47|primarily|drug
DDI-DrugBank.d97.s1|49-59|metabolized|drug
DDI-DrugBank.d97.s1|61-62|by|drug
DDI-DrugBank.d97.s1|64-69|CYP3A4|drug
DDI-DrugBank.d97.s1|71-73|may|drug
DDI-DrugBank.d97.s1|75-80|result|drug
DDI-DrugBank.d97.s1|82-83|in|drug
DDI-DrugBank.d97.s1|85-93|increased|drug
DDI-DrugBank.d97.s1|95-100|plasma|drug
DDI-DrugBank.d97.s1|102-115|concentrations|drug
DDI-DrugBank.d97.s1|117-118|of|drug
DDI-DrugBank.d97.s1|120-122|the|drug
DDI-DrugBank.d97.s1|124-128|other|drug
DDI-DrugBank.d97.s1|130-133|drug|drug
DDI-DrugBank.d97.s1|134-134|,|drug
DDI-DrugBank.d97.s1|136-140|which|drug
DDI-DrugBank.d97.s1|142-146|could|drug
DDI-DrugBank.d97.s1|148-155|increase|drug
DDI-DrugBank.d97.s1|157-158|or|drug
DDI-DrugBank.d97.s1|160-166|prolong|drug
DDI-DrugBank.d97.s1|168-170|its|drug
DDI-DrugBank.d97.s1|172-182|therapeutic|drug
DDI-DrugBank.d97.s1|184-186|and|drug
DDI-DrugBank.d97.s1|188-194|adverse|drug
DDI-DrugBank.d97.s1|196-202|effects|drug
DDI-DrugBank.d97.s1|203-203|.|drug
DDI-DrugBank.d97.s2|0-8|Indinavir|drug
DDI-DrugBank.d97.s2|10-11|is|drug
DDI-DrugBank.d97.s2|13-23|metabolized|drug
DDI-DrugBank.d97.s2|25-26|by|drug
DDI-DrugBank.d97.s2|28-33|CYP3A4|drug
DDI-DrugBank.d97.s2|34-34|.|drug
DDI-DrugBank.d97.s3|0-4|Drugs|drug
DDI-DrugBank.d97.s3|6-9|that|drug
DDI-DrugBank.d97.s3|11-16|induce|drug
DDI-DrugBank.d97.s3|18-23|CYP3A4|drug
DDI-DrugBank.d97.s3|25-32|activity|drug
DDI-DrugBank.d97.s3|34-38|would|drug
DDI-DrugBank.d97.s3|40-41|be|drug
DDI-DrugBank.d97.s3|43-50|expected|drug
DDI-DrugBank.d97.s3|52-53|to|drug
DDI-DrugBank.d97.s3|55-62|increase|drug
DDI-DrugBank.d97.s3|64-66|the|drug
DDI-DrugBank.d97.s3|68-76|clearance|drug
DDI-DrugBank.d97.s3|78-79|of|drug
DDI-DrugBank.d97.s3|81-89|indinavir|drug
DDI-DrugBank.d97.s3|90-90|,|drug
DDI-DrugBank.d97.s3|92-100|resulting|drug
DDI-DrugBank.d97.s3|102-103|in|drug
DDI-DrugBank.d97.s3|105-111|lowered|drug
DDI-DrugBank.d97.s3|113-118|plasma|drug
DDI-DrugBank.d97.s3|120-133|concentrations|drug
DDI-DrugBank.d97.s3|135-136|of|drug
DDI-DrugBank.d97.s3|138-146|indinavir|drug
DDI-DrugBank.d97.s3|147-147|.|drug
DDI-DrugBank.d97.s4|0-15|Coadministration|drug
DDI-DrugBank.d97.s4|17-18|of|drug
DDI-DrugBank.d97.s4|20-27|CRIXIVAN|drug
DDI-DrugBank.d97.s4|29-31|and|drug
DDI-DrugBank.d97.s4|33-37|other|drug
DDI-DrugBank.d97.s4|39-43|drugs|drug
DDI-DrugBank.d97.s4|45-48|that|drug
DDI-DrugBank.d97.s4|50-56|inhibit|drug
DDI-DrugBank.d97.s4|58-63|CYP3A4|drug
DDI-DrugBank.d97.s4|65-67|may|drug
DDI-DrugBank.d97.s4|69-76|decrease|drug
DDI-DrugBank.d97.s4|78-80|the|drug
DDI-DrugBank.d97.s4|82-90|clearance|drug
DDI-DrugBank.d97.s4|92-93|of|drug
DDI-DrugBank.d97.s4|95-103|indinavir|drug
DDI-DrugBank.d97.s4|105-107|and|drug
DDI-DrugBank.d97.s4|109-111|may|drug
DDI-DrugBank.d97.s4|113-118|result|drug
DDI-DrugBank.d97.s4|120-121|in|drug
DDI-DrugBank.d97.s4|123-131|increased|drug
DDI-DrugBank.d97.s4|133-138|plasma|drug
DDI-DrugBank.d97.s4|140-153|concentrations|drug
DDI-DrugBank.d97.s4|155-156|of|drug
DDI-DrugBank.d97.s4|158-166|indinavir|drug
DDI-DrugBank.d97.s4|167-167|.|drug
DDI-DrugBank.d97.s5|0-4|Table|drug
DDI-DrugBank.d97.s5|6-6|8|drug
DDI-DrugBank.d97.s6|0-4|Drugs|drug
DDI-DrugBank.d97.s6|6-9|That|drug
DDI-DrugBank.d97.s6|11-16|Should|drug
DDI-DrugBank.d97.s6|18-20|Not|drug
DDI-DrugBank.d97.s6|22-23|Be|drug
DDI-DrugBank.d97.s6|25-38|Coadministered|drug
DDI-DrugBank.d97.s6|40-43|with|drug
DDI-DrugBank.d97.s6|45-52|CRIXIVAN|drug
DDI-DrugBank.d97.s7|0-3|Drug|drug
DDI-DrugBank.d97.s7|5-9|Class|drug
DDI-DrugBank.d97.s7|10-10|:|drug
DDI-DrugBank.d97.s7|12-15|Drug|drug
DDI-DrugBank.d97.s7|17-20|Name|drug
DDI-DrugBank.d97.s7|22-29|Clinical|drug
DDI-DrugBank.d97.s7|31-37|Comment|drug
DDI-DrugBank.d97.s8|0-14|Antiarrhythmics|drug
DDI-DrugBank.d97.s8|15-15|:|drug
DDI-DrugBank.d97.s8|17-26|amiodarone|drug
DDI-DrugBank.d97.s9|0-14|CONTRAINDICATED|drug
DDI-DrugBank.d97.s9|16-18|due|drug
DDI-DrugBank.d97.s9|20-21|to|drug
DDI-DrugBank.d97.s9|23-31|potential|drug
DDI-DrugBank.d97.s9|33-35|for|drug
DDI-DrugBank.d97.s9|37-43|serious|drug
DDI-DrugBank.d97.s9|45-50|and/or|drug
DDI-DrugBank.d97.s9|52-67|life-threatening|drug
DDI-DrugBank.d97.s9|69-77|reactions|drug
DDI-DrugBank.d97.s9|79-82|such|drug
DDI-DrugBank.d97.s9|84-85|as|drug
DDI-DrugBank.d97.s9|87-93|cardiac|drug
DDI-DrugBank.d97.s9|95-105|arrhythmias|drug
DDI-DrugBank.d97.s9|106-106|.|drug
DDI-DrugBank.d97.s10|0-4|Ergot|drug
DDI-DrugBank.d97.s10|6-16|derivatives|drug
DDI-DrugBank.d97.s10|17-17|:|drug
DDI-DrugBank.d97.s10|19-35|dihydroergotamine|drug
DDI-DrugBank.d97.s10|36-36|,|drug
DDI-DrugBank.d97.s10|38-47|ergonovine|drug
DDI-DrugBank.d97.s10|48-48|,|drug
DDI-DrugBank.d97.s10|50-59|ergotamine|drug
DDI-DrugBank.d97.s10|60-60|,|drug
DDI-DrugBank.d97.s10|62-77|methylergonovine|drug
DDI-DrugBank.d97.s11|0-14|CONTRAINDICATED|drug
DDI-DrugBank.d97.s11|16-18|due|drug
DDI-DrugBank.d97.s11|20-21|to|drug
DDI-DrugBank.d97.s11|23-31|potential|drug
DDI-DrugBank.d97.s11|33-35|for|drug
DDI-DrugBank.d97.s11|37-43|serious|drug
DDI-DrugBank.d97.s11|45-50|and/or|drug
DDI-DrugBank.d97.s11|52-67|life-threatening|drug
DDI-DrugBank.d97.s11|69-77|reactions|drug
DDI-DrugBank.d97.s11|79-82|such|drug
DDI-DrugBank.d97.s11|84-85|as|drug
DDI-DrugBank.d97.s11|87-91|acute|drug
DDI-DrugBank.d97.s11|93-97|ergot|drug
DDI-DrugBank.d97.s11|99-106|toxicity|drug
DDI-DrugBank.d97.s11|108-120|characterized|drug
DDI-DrugBank.d97.s11|122-123|by|drug
DDI-DrugBank.d97.s11|125-134|peripheral|drug
DDI-DrugBank.d97.s11|136-144|vasospasm|drug
DDI-DrugBank.d97.s11|146-148|and|drug
DDI-DrugBank.d97.s11|150-157|ischemia|drug
DDI-DrugBank.d97.s11|159-160|of|drug
DDI-DrugBank.d97.s11|162-164|the|drug
DDI-DrugBank.d97.s11|166-176|extremities|drug
DDI-DrugBank.d97.s11|178-180|and|drug
DDI-DrugBank.d97.s11|182-186|other|drug
DDI-DrugBank.d97.s11|188-194|tissues|drug
DDI-DrugBank.d97.s11|195-195|.|drug
DDI-DrugBank.d97.s12|0-17|Sedative/hypnotics|drug
DDI-DrugBank.d97.s12|18-18|:|drug
DDI-DrugBank.d97.s12|20-28|midazolam|drug
DDI-DrugBank.d97.s12|29-29|,|drug
DDI-DrugBank.d97.s12|31-39|triazolam|drug
DDI-DrugBank.d97.s13|0-14|CONTRAINDICATED|drug
DDI-DrugBank.d97.s13|16-18|due|drug
DDI-DrugBank.d97.s13|20-21|to|drug
DDI-DrugBank.d97.s13|23-31|potential|drug
DDI-DrugBank.d97.s13|33-35|for|drug
DDI-DrugBank.d97.s13|37-43|serious|drug
DDI-DrugBank.d97.s13|45-50|and/or|drug
DDI-DrugBank.d97.s13|52-67|life-threatening|drug
DDI-DrugBank.d97.s13|69-77|reactions|drug
DDI-DrugBank.d97.s13|79-82|such|drug
DDI-DrugBank.d97.s13|84-85|as|drug
DDI-DrugBank.d97.s13|87-95|prolonged|drug
DDI-DrugBank.d97.s13|97-98|or|drug
DDI-DrugBank.d97.s13|100-108|increased|drug
DDI-DrugBank.d97.s13|110-117|sedation|drug
DDI-DrugBank.d97.s13|119-120|or|drug
DDI-DrugBank.d97.s13|122-132|respiratory|drug
DDI-DrugBank.d97.s13|134-143|depression|drug
DDI-DrugBank.d97.s13|144-144|.|drug
DDI-DrugBank.d97.s14|0-1|GI|drug
DDI-DrugBank.d97.s14|3-10|motility|drug
DDI-DrugBank.d97.s14|12-17|agents|drug
DDI-DrugBank.d97.s14|18-18|:|drug
DDI-DrugBank.d97.s14|20-28|cisapride|drug
DDI-DrugBank.d97.s15|0-14|CONTRAINDICATED|drug
DDI-DrugBank.d97.s15|16-18|due|drug
DDI-DrugBank.d97.s15|20-21|to|drug
DDI-DrugBank.d97.s15|23-31|potential|drug
DDI-DrugBank.d97.s15|33-35|for|drug
DDI-DrugBank.d97.s15|37-43|serious|drug
DDI-DrugBank.d97.s15|45-50|and/or|drug
DDI-DrugBank.d97.s15|52-67|life-threatening|drug
DDI-DrugBank.d97.s15|69-77|reactions|drug
DDI-DrugBank.d97.s15|79-82|such|drug
DDI-DrugBank.d97.s15|84-85|as|drug
DDI-DrugBank.d97.s15|87-93|cardiac|drug
DDI-DrugBank.d97.s15|95-105|arrhythmias|drug
DDI-DrugBank.d97.s15|106-106|.|drug
DDI-DrugBank.d97.s16|0-10|Neuroleptic|drug
DDI-DrugBank.d97.s16|11-11|:|drug
DDI-DrugBank.d97.s16|13-20|pimozide|drug
DDI-DrugBank.d97.s17|0-14|CONTRAINDICATED|drug
DDI-DrugBank.d97.s17|16-18|due|drug
DDI-DrugBank.d97.s17|20-21|to|drug
DDI-DrugBank.d97.s17|23-31|potential|drug
DDI-DrugBank.d97.s17|33-35|for|drug
DDI-DrugBank.d97.s17|37-43|serious|drug
DDI-DrugBank.d97.s17|45-50|and/or|drug
DDI-DrugBank.d97.s17|52-67|life-threatening|drug
DDI-DrugBank.d97.s17|69-77|reactions|drug
DDI-DrugBank.d97.s17|79-82|such|drug
DDI-DrugBank.d97.s17|84-85|as|drug
DDI-DrugBank.d97.s17|87-93|cardiac|drug
DDI-DrugBank.d97.s17|95-105|arrhythmias|drug
DDI-DrugBank.d97.s17|106-106|.|drug
DDI-DrugBank.d97.s18|0-5|Herbal|brand
DDI-DrugBank.d97.s18|7-14|products|drug
DDI-DrugBank.d97.s18|15-15|:|drug
DDI-DrugBank.d97.s18|17-19|St.|drug
DDI-DrugBank.d97.s18|21-24|John|drug
DDI-DrugBank.d97.s18|26-26|s|drug
DDI-DrugBank.d97.s18|28-31|wort|drug
DDI-DrugBank.d97.s18|33-33|(|drug
DDI-DrugBank.d97.s18|34-42|Hypericum|brand
DDI-DrugBank.d97.s18|44-53|perforatum|drug
DDI-DrugBank.d97.s18|54-54|)|drug
DDI-DrugBank.d97.s19|0-2|May|drug
DDI-DrugBank.d97.s19|4-7|lead|drug
DDI-DrugBank.d97.s19|9-10|to|drug
DDI-DrugBank.d97.s19|12-15|loss|drug
DDI-DrugBank.d97.s19|17-18|of|drug
DDI-DrugBank.d97.s19|20-28|virologic|drug
DDI-DrugBank.d97.s19|30-37|response|drug
DDI-DrugBank.d97.s19|39-41|and|drug
DDI-DrugBank.d97.s19|43-50|possible|drug
DDI-DrugBank.d97.s19|52-61|resistance|drug
DDI-DrugBank.d97.s19|63-64|to|drug
DDI-DrugBank.d97.s19|66-73|CRIXIVAN|drug
DDI-DrugBank.d97.s19|75-76|or|drug
DDI-DrugBank.d97.s19|78-79|to|drug
DDI-DrugBank.d97.s19|81-83|the|drug
DDI-DrugBank.d97.s19|85-89|class|drug
DDI-DrugBank.d97.s19|91-92|of|drug
DDI-DrugBank.d97.s19|94-101|protease|drug
DDI-DrugBank.d97.s19|103-112|inhibitors|drug
DDI-DrugBank.d97.s19|113-113|.|drug
DDI-DrugBank.d97.s20|0-16|Antimycobacterial|drug
DDI-DrugBank.d97.s20|17-17|:|drug
DDI-DrugBank.d97.s20|19-26|rifampin|drug
DDI-DrugBank.d97.s21|0-2|May|drug
DDI-DrugBank.d97.s21|4-7|lead|drug
DDI-DrugBank.d97.s21|9-10|to|drug
DDI-DrugBank.d97.s21|12-15|loss|drug
DDI-DrugBank.d97.s21|17-18|of|drug
DDI-DrugBank.d97.s21|20-28|virologic|drug
DDI-DrugBank.d97.s21|30-37|response|drug
DDI-DrugBank.d97.s21|39-41|and|drug
DDI-DrugBank.d97.s21|43-50|possible|drug
DDI-DrugBank.d97.s21|52-61|resistance|drug
DDI-DrugBank.d97.s21|63-64|to|drug
DDI-DrugBank.d97.s21|66-73|CRIXIVAN|drug
DDI-DrugBank.d97.s21|75-76|or|drug
DDI-DrugBank.d97.s21|78-79|to|drug
DDI-DrugBank.d97.s21|81-83|the|drug
DDI-DrugBank.d97.s21|85-89|class|drug
DDI-DrugBank.d97.s21|91-92|of|drug
DDI-DrugBank.d97.s21|94-101|protease|drug
DDI-DrugBank.d97.s21|103-112|inhibitors|drug
DDI-DrugBank.d97.s21|114-115|or|drug
DDI-DrugBank.d97.s21|117-121|other|drug
DDI-DrugBank.d97.s21|123-136|coadministered|drug
DDI-DrugBank.d97.s21|138-151|antiretroviral|drug
DDI-DrugBank.d97.s21|153-158|agents|drug
DDI-DrugBank.d97.s21|159-159|.|drug
DDI-DrugBank.d97.s22|0-6|HMG-CoA|drug
DDI-DrugBank.d97.s22|8-16|Reductase|drug
DDI-DrugBank.d97.s22|18-27|inhibitors|drug
DDI-DrugBank.d97.s22|28-28|:|drug
DDI-DrugBank.d97.s22|30-39|lovastatin|drug
DDI-DrugBank.d97.s22|40-40|,|drug
DDI-DrugBank.d97.s22|42-52|simvastatin|drug
DDI-DrugBank.d97.s23|0-8|Potential|drug
DDI-DrugBank.d97.s23|10-12|for|drug
DDI-DrugBank.d97.s23|14-20|serious|drug
DDI-DrugBank.d97.s23|22-30|reactions|drug
DDI-DrugBank.d97.s23|32-35|such|drug
DDI-DrugBank.d97.s23|37-38|as|drug
DDI-DrugBank.d97.s23|40-43|risk|drug
DDI-DrugBank.d97.s23|45-46|of|drug
DDI-DrugBank.d97.s23|48-55|myopathy|drug
DDI-DrugBank.d97.s23|57-65|including|drug
DDI-DrugBank.d97.s23|67-80|rhabdomyolysis|drug
DDI-DrugBank.d97.s23|81-81|.|drug
DDI-DrugBank.d97.s24|0-7|Protease|drug
DDI-DrugBank.d97.s24|9-17|inhibitor|drug
DDI-DrugBank.d97.s24|18-18|:|drug
DDI-DrugBank.d97.s24|20-29|atazanavir|drug
DDI-DrugBank.d97.s25|0-3|Both|drug
DDI-DrugBank.d97.s25|5-12|CRIXIVAN|drug
DDI-DrugBank.d97.s25|14-16|and|drug
DDI-DrugBank.d97.s25|18-27|atazanavir|drug
DDI-DrugBank.d97.s25|29-31|are|drug
DDI-DrugBank.d97.s25|33-42|associated|drug
DDI-DrugBank.d97.s25|44-47|with|drug
DDI-DrugBank.d97.s25|49-56|indirect|drug
DDI-DrugBank.d97.s25|58-58|(|drug
DDI-DrugBank.d97.s25|59-70|unconjugated|drug
DDI-DrugBank.d97.s25|71-71|)|drug
DDI-DrugBank.d97.s25|73-90|hyperbilirubinemia|drug
DDI-DrugBank.d97.s25|91-91|.|drug
DDI-DrugBank.d97.s26|0-11|Combinations|drug
DDI-DrugBank.d97.s26|13-14|of|drug
DDI-DrugBank.d97.s26|16-20|these|drug
DDI-DrugBank.d97.s26|22-26|drugs|drug
DDI-DrugBank.d97.s26|28-31|have|drug
DDI-DrugBank.d97.s26|33-35|not|drug
DDI-DrugBank.d97.s26|37-40|been|drug
DDI-DrugBank.d97.s26|42-48|studied|drug
DDI-DrugBank.d97.s26|50-52|and|drug
DDI-DrugBank.d97.s26|54-69|coadministration|drug
DDI-DrugBank.d97.s26|71-72|of|drug
DDI-DrugBank.d97.s26|74-81|CRIXIVAN|drug
DDI-DrugBank.d97.s26|83-85|and|drug
DDI-DrugBank.d97.s26|87-96|atazanavir|drug
DDI-DrugBank.d97.s26|98-99|is|drug
DDI-DrugBank.d97.s26|101-103|not|drug
DDI-DrugBank.d97.s26|105-115|recommended|drug
DDI-DrugBank.d97.s26|116-116|.|drug
DDI-DrugBank.d97.s27|0-4|Table|drug
DDI-DrugBank.d97.s27|6-6|9|drug
DDI-DrugBank.d97.s28|0-10|Established|drug
DDI-DrugBank.d97.s28|12-14|and|drug
DDI-DrugBank.d97.s28|16-20|Other|drug
DDI-DrugBank.d97.s28|22-32|Potentially|drug
DDI-DrugBank.d97.s28|34-44|Significant|drug
DDI-DrugBank.d97.s28|46-49|Drug|drug
DDI-DrugBank.d97.s28|51-62|Interactions|drug
DDI-DrugBank.d97.s28|63-63|:|drug
DDI-DrugBank.d97.s28|65-74|Alteration|drug
DDI-DrugBank.d97.s28|76-77|in|drug
DDI-DrugBank.d97.s28|79-82|Dose|drug
DDI-DrugBank.d97.s28|84-85|or|drug
DDI-DrugBank.d97.s28|87-93|Regimen|brand
DDI-DrugBank.d97.s28|95-97|May|drug
DDI-DrugBank.d97.s28|99-100|Be|drug
DDI-DrugBank.d97.s28|102-112|Recommended|drug
DDI-DrugBank.d97.s28|114-118|Based|drug
DDI-DrugBank.d97.s28|120-121|on|drug
DDI-DrugBank.d97.s28|123-126|Drug|drug
DDI-DrugBank.d97.s28|128-138|Interaction|drug
DDI-DrugBank.d97.s28|140-146|Studies|drug
DDI-DrugBank.d97.s28|148-149|or|drug
DDI-DrugBank.d97.s28|151-159|Predicted|drug
DDI-DrugBank.d97.s28|161-171|Interaction|drug
DDI-DrugBank.d97.s29|0-3|Drug|drug
DDI-DrugBank.d97.s29|5-8|Name|drug
DDI-DrugBank.d97.s30|0-5|Effect|drug
DDI-DrugBank.d97.s31|0-7|Clinical|drug
DDI-DrugBank.d97.s31|9-15|Comment|drug
DDI-DrugBank.d97.s32|0-2|HIV|drug
DDI-DrugBank.d97.s32|4-12|Antiviral|drug
DDI-DrugBank.d97.s32|14-19|Agents|drug
DDI-DrugBank.d97.s33|0-10|Delavirdine|drug
DDI-DrugBank.d97.s34|0-8|indinavir|drug
DDI-DrugBank.d97.s34|10-22|concentration|drug
DDI-DrugBank.d97.s35|0-3|Dose|drug
DDI-DrugBank.d97.s35|5-13|reduction|drug
DDI-DrugBank.d97.s35|15-16|of|drug
DDI-DrugBank.d97.s35|18-25|CRIXIVAN|drug
DDI-DrugBank.d97.s35|27-28|to|drug
DDI-DrugBank.d97.s35|30-32|600|drug
DDI-DrugBank.d97.s35|34-35|mg|drug
DDI-DrugBank.d97.s35|37-41|every|drug
DDI-DrugBank.d97.s35|43-43|8|drug
DDI-DrugBank.d97.s35|45-49|hours|drug
DDI-DrugBank.d97.s35|51-56|should|drug
DDI-DrugBank.d97.s35|58-59|be|drug
DDI-DrugBank.d97.s35|61-70|considered|drug
DDI-DrugBank.d97.s35|72-75|when|drug
DDI-DrugBank.d97.s35|77-82|taking|drug
DDI-DrugBank.d97.s35|84-94|delavirdine|drug
DDI-DrugBank.d97.s35|96-98|400|drug
DDI-DrugBank.d97.s35|100-101|mg|drug
DDI-DrugBank.d97.s35|103-107|three|drug
DDI-DrugBank.d97.s35|109-113|times|drug
DDI-DrugBank.d97.s35|115-115|a|drug
DDI-DrugBank.d97.s35|117-119|day|drug
DDI-DrugBank.d97.s35|120-120|.|drug
DDI-DrugBank.d97.s36|0-9|Didanosine|brand
DDI-DrugBank.d97.s37|0-8|Indinavir|drug
DDI-DrugBank.d97.s37|10-12|and|drug
DDI-DrugBank.d97.s37|14-23|didanosine|drug
DDI-DrugBank.d97.s37|25-36|formulations|drug
DDI-DrugBank.d97.s37|38-47|containing|drug
DDI-DrugBank.d97.s37|49-54|buffer|drug
DDI-DrugBank.d97.s37|56-61|should|drug
DDI-DrugBank.d97.s37|63-64|be|drug
DDI-DrugBank.d97.s37|66-77|administered|drug
DDI-DrugBank.d97.s37|79-80|at|drug
DDI-DrugBank.d97.s37|82-86|least|drug
DDI-DrugBank.d97.s37|88-90|one|drug
DDI-DrugBank.d97.s37|92-95|hour|drug
DDI-DrugBank.d97.s37|97-101|apart|drug
DDI-DrugBank.d97.s37|103-104|on|drug
DDI-DrugBank.d97.s37|106-107|an|drug
DDI-DrugBank.d97.s37|109-113|empty|drug
DDI-DrugBank.d97.s37|115-121|stomach|drug
DDI-DrugBank.d97.s37|122-122|.|drug
DDI-DrugBank.d97.s38|0-8|Efavirenz|brand
DDI-DrugBank.d97.s39|0-8|indinavir|drug
DDI-DrugBank.d97.s39|10-22|concentration|drug
DDI-DrugBank.d97.s40|0-2|The|drug
DDI-DrugBank.d97.s40|4-10|optimal|drug
DDI-DrugBank.d97.s40|12-15|dose|drug
DDI-DrugBank.d97.s40|17-18|of|drug
DDI-DrugBank.d97.s40|20-28|indinavir|drug
DDI-DrugBank.d97.s40|29-29|,|drug
DDI-DrugBank.d97.s40|31-34|when|drug
DDI-DrugBank.d97.s40|36-40|given|drug
DDI-DrugBank.d97.s40|42-43|in|drug
DDI-DrugBank.d97.s40|45-55|combination|drug
DDI-DrugBank.d97.s40|57-60|with|drug
DDI-DrugBank.d97.s40|62-70|efavirenz|drug
DDI-DrugBank.d97.s40|71-71|,|drug
DDI-DrugBank.d97.s40|73-74|is|drug
DDI-DrugBank.d97.s40|76-78|not|drug
DDI-DrugBank.d97.s40|80-84|known|drug
DDI-DrugBank.d97.s40|85-85|.|drug
DDI-DrugBank.d97.s41|0-9|Increasing|drug
DDI-DrugBank.d97.s41|11-13|the|drug
DDI-DrugBank.d97.s41|15-23|indinavir|drug
DDI-DrugBank.d97.s41|25-28|dose|drug
DDI-DrugBank.d97.s41|30-31|to|drug
DDI-DrugBank.d97.s41|33-36|1000|drug
DDI-DrugBank.d97.s41|38-39|mg|drug
DDI-DrugBank.d97.s41|41-45|every|drug
DDI-DrugBank.d97.s41|47-47|8|drug
DDI-DrugBank.d97.s41|49-53|hours|drug
DDI-DrugBank.d97.s41|55-58|does|drug
DDI-DrugBank.d97.s41|60-62|not|drug
DDI-DrugBank.d97.s41|64-73|compensate|drug
DDI-DrugBank.d97.s41|75-77|for|drug
DDI-DrugBank.d97.s41|79-81|the|drug
DDI-DrugBank.d97.s41|83-91|increased|drug
DDI-DrugBank.d97.s41|93-101|indinavir|drug
DDI-DrugBank.d97.s41|103-112|metabolism|drug
DDI-DrugBank.d97.s41|114-116|due|drug
DDI-DrugBank.d97.s41|118-119|to|drug
DDI-DrugBank.d97.s41|121-129|efavirenz|drug
DDI-DrugBank.d97.s41|130-130|.|drug
DDI-DrugBank.d97.s42|0-9|Nelfinavir|drug
DDI-DrugBank.d97.s43|0-8|indinavir|drug
DDI-DrugBank.d97.s43|10-22|concentration|drug
DDI-DrugBank.d97.s44|0-2|The|drug
DDI-DrugBank.d97.s44|4-14|appropriate|drug
DDI-DrugBank.d97.s44|16-20|doses|drug
DDI-DrugBank.d97.s44|22-24|for|drug
DDI-DrugBank.d97.s44|26-29|this|drug
DDI-DrugBank.d97.s44|31-41|combination|drug
DDI-DrugBank.d97.s44|42-42|,|drug
DDI-DrugBank.d97.s44|44-47|with|drug
DDI-DrugBank.d97.s44|49-55|respect|drug
DDI-DrugBank.d97.s44|57-58|to|drug
DDI-DrugBank.d97.s44|60-67|efficacy|drug
DDI-DrugBank.d97.s44|69-71|and|drug
DDI-DrugBank.d97.s44|73-78|safety|drug
DDI-DrugBank.d97.s44|79-79|,|drug
DDI-DrugBank.d97.s44|81-84|have|drug
DDI-DrugBank.d97.s44|86-88|not|drug
DDI-DrugBank.d97.s44|90-93|been|drug
DDI-DrugBank.d97.s44|95-105|established|drug
DDI-DrugBank.d97.s44|106-106|.|drug
DDI-DrugBank.d97.s45|0-9|Nevirapine|brand
DDI-DrugBank.d97.s46|0-8|indinavir|drug
DDI-DrugBank.d97.s46|10-22|concentration|drug
DDI-DrugBank.d97.s47|0-8|Indinavir|drug
DDI-DrugBank.d97.s47|10-23|concentrations|drug
DDI-DrugBank.d97.s47|25-27|may|drug
DDI-DrugBank.d97.s47|29-30|be|drug
DDI-DrugBank.d97.s47|32-40|decreased|drug
DDI-DrugBank.d97.s47|42-43|in|drug
DDI-DrugBank.d97.s47|45-47|the|drug
DDI-DrugBank.d97.s47|49-56|presence|drug
DDI-DrugBank.d97.s47|58-59|of|drug
DDI-DrugBank.d97.s47|61-70|nevirapine|drug
DDI-DrugBank.d97.s47|71-71|.|drug
DDI-DrugBank.d97.s48|0-2|The|drug
DDI-DrugBank.d97.s48|4-14|appropriate|drug
DDI-DrugBank.d97.s48|16-20|doses|drug
DDI-DrugBank.d97.s48|22-24|for|drug
DDI-DrugBank.d97.s48|26-29|this|drug
DDI-DrugBank.d97.s48|31-41|combination|drug
DDI-DrugBank.d97.s48|42-42|,|drug
DDI-DrugBank.d97.s48|44-47|with|drug
DDI-DrugBank.d97.s48|49-55|respect|drug
DDI-DrugBank.d97.s48|57-58|to|drug
DDI-DrugBank.d97.s48|60-67|efficacy|drug
DDI-DrugBank.d97.s48|69-71|and|drug
DDI-DrugBank.d97.s48|73-78|safety|drug
DDI-DrugBank.d97.s48|79-79|,|drug
DDI-DrugBank.d97.s48|81-84|have|drug
DDI-DrugBank.d97.s48|86-88|not|drug
DDI-DrugBank.d97.s48|90-93|been|drug
DDI-DrugBank.d97.s48|95-105|established|drug
DDI-DrugBank.d97.s48|106-106|.|drug
DDI-DrugBank.d97.s49|0-8|Ritonavir|brand
DDI-DrugBank.d97.s50|0-8|indinavir|drug
DDI-DrugBank.d97.s50|10-22|concentration|drug
DDI-DrugBank.d97.s50|26-34|ritonavir|drug
DDI-DrugBank.d97.s50|36-48|concentration|drug
DDI-DrugBank.d97.s51|0-2|The|drug
DDI-DrugBank.d97.s51|4-14|appropriate|drug
DDI-DrugBank.d97.s51|16-20|doses|drug
DDI-DrugBank.d97.s51|22-24|for|drug
DDI-DrugBank.d97.s51|26-29|this|drug
DDI-DrugBank.d97.s51|31-41|combination|drug
DDI-DrugBank.d97.s51|42-42|,|drug
DDI-DrugBank.d97.s51|44-47|with|drug
DDI-DrugBank.d97.s51|49-55|respect|drug
DDI-DrugBank.d97.s51|57-58|to|drug
DDI-DrugBank.d97.s51|60-67|efficacy|drug
DDI-DrugBank.d97.s51|69-71|and|drug
DDI-DrugBank.d97.s51|73-78|safety|drug
DDI-DrugBank.d97.s51|79-79|,|drug
DDI-DrugBank.d97.s51|81-84|have|drug
DDI-DrugBank.d97.s51|86-88|not|drug
DDI-DrugBank.d97.s51|90-93|been|drug
DDI-DrugBank.d97.s51|95-105|established|drug
DDI-DrugBank.d97.s51|106-106|.|drug
DDI-DrugBank.d97.s52|0-10|Preliminary|drug
DDI-DrugBank.d97.s52|12-19|clinical|drug
DDI-DrugBank.d97.s52|21-24|data|drug
DDI-DrugBank.d97.s52|26-32|suggest|drug
DDI-DrugBank.d97.s52|34-37|that|drug
DDI-DrugBank.d97.s52|39-41|the|drug
DDI-DrugBank.d97.s52|43-51|incidence|drug
DDI-DrugBank.d97.s52|53-54|of|drug
DDI-DrugBank.d97.s52|56-70|nephrolithiasis|drug
DDI-DrugBank.d97.s52|72-73|is|drug
DDI-DrugBank.d97.s52|75-80|higher|drug
DDI-DrugBank.d97.s52|82-83|in|drug
DDI-DrugBank.d97.s52|85-92|patients|drug
DDI-DrugBank.d97.s52|94-102|receiving|drug
DDI-DrugBank.d97.s52|104-112|indinavir|drug
DDI-DrugBank.d97.s52|114-115|in|drug
DDI-DrugBank.d97.s52|117-127|combination|drug
DDI-DrugBank.d97.s52|129-132|with|drug
DDI-DrugBank.d97.s52|134-142|ritonavir|drug
DDI-DrugBank.d97.s52|144-147|than|drug
DDI-DrugBank.d97.s52|149-153|those|drug
DDI-DrugBank.d97.s52|155-163|receiving|drug
DDI-DrugBank.d97.s52|165-172|CRIXIVAN|drug
DDI-DrugBank.d97.s52|174-176|800|drug
DDI-DrugBank.d97.s52|178-179|mg|drug
DDI-DrugBank.d97.s52|181-183|q8h|drug
DDI-DrugBank.d97.s52|184-184|.|drug
DDI-DrugBank.d97.s53|0-9|Saquinavir|drug
DDI-DrugBank.d97.s54|0-9|saquinavir|drug
DDI-DrugBank.d97.s54|11-23|concentration|drug
DDI-DrugBank.d97.s55|0-2|The|drug
DDI-DrugBank.d97.s55|4-14|appropriate|drug
DDI-DrugBank.d97.s55|16-20|doses|drug
DDI-DrugBank.d97.s55|22-24|for|drug
DDI-DrugBank.d97.s55|26-29|this|drug
DDI-DrugBank.d97.s55|31-41|combination|drug
DDI-DrugBank.d97.s55|42-42|,|drug
DDI-DrugBank.d97.s55|44-47|with|drug
DDI-DrugBank.d97.s55|49-55|respect|drug
DDI-DrugBank.d97.s55|57-58|to|drug
DDI-DrugBank.d97.s55|60-67|efficacy|drug
DDI-DrugBank.d97.s55|69-71|and|drug
DDI-DrugBank.d97.s55|73-78|safety|drug
DDI-DrugBank.d97.s55|79-79|,|drug
DDI-DrugBank.d97.s55|81-84|have|drug
DDI-DrugBank.d97.s55|86-88|not|drug
DDI-DrugBank.d97.s55|90-93|been|drug
DDI-DrugBank.d97.s55|95-105|established|drug
DDI-DrugBank.d97.s55|106-106|.|drug
DDI-DrugBank.d97.s56|0-4|Other|drug
DDI-DrugBank.d97.s56|6-11|Agents|drug
DDI-DrugBank.d97.s57|0-14|Antiarrhythmics|drug
DDI-DrugBank.d97.s57|15-15|:|drug
DDI-DrugBank.d97.s57|17-24|bepridil|drug
DDI-DrugBank.d97.s57|25-25|,|drug
DDI-DrugBank.d97.s57|27-35|lidocaine|drug
DDI-DrugBank.d97.s57|37-37|(|drug
DDI-DrugBank.d97.s57|38-45|systemic|drug
DDI-DrugBank.d97.s57|46-46|)|drug
DDI-DrugBank.d97.s57|48-50|and|drug
DDI-DrugBank.d97.s57|52-60|quinidine|drug
DDI-DrugBank.d97.s58|0-13|antiarrhythmic|drug
DDI-DrugBank.d97.s58|15-20|agents|drug
DDI-DrugBank.d97.s58|22-34|concentration|drug
DDI-DrugBank.d97.s59|0-6|Caution|drug
DDI-DrugBank.d97.s59|8-9|is|drug
DDI-DrugBank.d97.s59|11-19|warranted|drug
DDI-DrugBank.d97.s59|21-23|and|drug
DDI-DrugBank.d97.s59|25-35|therapeutic|drug
DDI-DrugBank.d97.s59|37-49|concentration|drug
DDI-DrugBank.d97.s59|51-60|monitoring|drug
DDI-DrugBank.d97.s59|62-63|is|drug
DDI-DrugBank.d97.s59|65-75|recommended|drug
DDI-DrugBank.d97.s59|77-79|for|drug
DDI-DrugBank.d97.s59|81-95|antiarrhythmics|drug
DDI-DrugBank.d97.s59|97-100|when|drug
DDI-DrugBank.d97.s59|102-115|coadministered|drug
DDI-DrugBank.d97.s59|117-120|with|drug
DDI-DrugBank.d97.s59|122-129|CRIXIVAN|drug
DDI-DrugBank.d97.s59|130-130|.|drug
DDI-DrugBank.d97.s60|0-14|Anticonvulsants|group
DDI-DrugBank.d97.s60|15-15|:|drug
DDI-DrugBank.d97.s60|17-29|carbamazepine|drug
DDI-DrugBank.d97.s60|30-30|,|drug
DDI-DrugBank.d97.s60|32-44|phenobarbital|drug
DDI-DrugBank.d97.s60|45-45|,|drug
DDI-DrugBank.d97.s60|47-55|phenytoin|drug
DDI-DrugBank.d97.s61|0-8|indinavir|drug
DDI-DrugBank.d97.s61|10-22|concentration|drug
DDI-DrugBank.d97.s62|0-2|Use|drug
DDI-DrugBank.d97.s62|4-7|with|drug
DDI-DrugBank.d97.s62|9-15|caution|drug
DDI-DrugBank.d97.s62|16-16|.|drug
DDI-DrugBank.d97.s63|0-7|CRIXIVAN|drug
DDI-DrugBank.d97.s63|9-11|may|drug
DDI-DrugBank.d97.s63|13-15|not|drug
DDI-DrugBank.d97.s63|17-18|be|drug
DDI-DrugBank.d97.s63|20-28|effective|drug
DDI-DrugBank.d97.s63|30-32|due|drug
DDI-DrugBank.d97.s63|34-35|to|drug
DDI-DrugBank.d97.s63|37-45|decreased|drug
DDI-DrugBank.d97.s63|47-55|indinavir|drug
DDI-DrugBank.d97.s63|57-70|concentrations|drug
DDI-DrugBank.d97.s63|72-73|in|drug
DDI-DrugBank.d97.s63|75-82|patients|drug
DDI-DrugBank.d97.s63|84-89|taking|drug
DDI-DrugBank.d97.s63|91-95|these|drug
DDI-DrugBank.d97.s63|97-102|agents|drug
DDI-DrugBank.d97.s63|104-116|concomitantly|drug
DDI-DrugBank.d97.s63|117-117|.|drug
DDI-DrugBank.d97.s64|0-6|Calcium|brand
DDI-DrugBank.d97.s64|8-14|Channel|drug
DDI-DrugBank.d97.s64|16-23|Blockers|drug
DDI-DrugBank.d97.s64|24-24|,|drug
DDI-DrugBank.d97.s64|26-40|Dihydropyridine|drug
DDI-DrugBank.d97.s64|41-41|:|drug
DDI-DrugBank.d97.s64|43-46|e.g.|drug
DDI-DrugBank.d97.s64|47-47|,|drug
DDI-DrugBank.d97.s64|49-58|felodipine|drug
DDI-DrugBank.d97.s64|59-59|,|drug
DDI-DrugBank.d97.s64|61-70|nifedipine|drug
DDI-DrugBank.d97.s64|71-71|,|drug
DDI-DrugBank.d97.s64|73-83|nicardipine|drug
DDI-DrugBank.d97.s65|0-14|dihydropyridine|drug
DDI-DrugBank.d97.s65|16-22|calcium|drug
DDI-DrugBank.d97.s65|24-30|channel|drug
DDI-DrugBank.d97.s65|32-39|blockers|drug
DDI-DrugBank.d97.s65|41-53|concentration|drug
DDI-DrugBank.d97.s66|0-6|Caution|drug
DDI-DrugBank.d97.s66|8-9|is|drug
DDI-DrugBank.d97.s66|11-19|warranted|drug
DDI-DrugBank.d97.s66|21-23|and|drug
DDI-DrugBank.d97.s66|25-32|clinical|drug
DDI-DrugBank.d97.s66|34-43|monitoring|drug
DDI-DrugBank.d97.s66|45-46|of|drug
DDI-DrugBank.d97.s66|48-55|patients|drug
DDI-DrugBank.d97.s66|57-58|is|drug
DDI-DrugBank.d97.s66|60-70|recommended|drug
DDI-DrugBank.d97.s66|71-71|.|drug
DDI-DrugBank.d97.s67|0-13|Clarithromycin|brand
DDI-DrugBank.d97.s68|0-13|clarithromycin|drug
DDI-DrugBank.d97.s68|15-27|concentration|drug
DDI-DrugBank.d97.s68|31-39|indinavir|drug
DDI-DrugBank.d97.s68|41-53|concentration|drug
DDI-DrugBank.d97.s69|0-2|The|drug
DDI-DrugBank.d97.s69|4-14|appropriate|drug
DDI-DrugBank.d97.s69|16-20|doses|drug
DDI-DrugBank.d97.s69|22-24|for|drug
DDI-DrugBank.d97.s69|26-29|this|drug
DDI-DrugBank.d97.s69|31-41|combination|drug
DDI-DrugBank.d97.s69|42-42|,|drug
DDI-DrugBank.d97.s69|44-47|with|drug
DDI-DrugBank.d97.s69|49-55|respect|drug
DDI-DrugBank.d97.s69|57-58|to|drug
DDI-DrugBank.d97.s69|60-67|efficacy|drug
DDI-DrugBank.d97.s69|69-71|and|drug
DDI-DrugBank.d97.s69|73-78|safety|drug
DDI-DrugBank.d97.s69|79-79|,|drug
DDI-DrugBank.d97.s69|81-84|have|drug
DDI-DrugBank.d97.s69|86-88|not|drug
DDI-DrugBank.d97.s69|90-93|been|drug
DDI-DrugBank.d97.s69|95-105|established|drug
DDI-DrugBank.d97.s69|106-106|.|drug
DDI-DrugBank.d97.s70|0-6|HMG-CoA|drug
DDI-DrugBank.d97.s70|8-16|Reductase|drug
DDI-DrugBank.d97.s70|18-26|Inhibitor|drug
DDI-DrugBank.d97.s70|27-27|:|drug
DDI-DrugBank.d97.s70|29-40|atorvastatin|drug
DDI-DrugBank.d97.s71|0-11|atorvastatin|drug
DDI-DrugBank.d97.s71|13-25|concentration|drug
DDI-DrugBank.d97.s72|0-2|Use|drug
DDI-DrugBank.d97.s72|4-9|lowest|drug
DDI-DrugBank.d97.s72|11-18|possible|drug
DDI-DrugBank.d97.s72|20-23|dose|drug
DDI-DrugBank.d97.s72|25-26|of|drug
DDI-DrugBank.d97.s72|28-39|atorvastatin|drug
DDI-DrugBank.d97.s72|41-44|with|drug
DDI-DrugBank.d97.s72|46-52|careful|drug
DDI-DrugBank.d97.s72|54-63|monitoring|drug
DDI-DrugBank.d97.s72|64-64|,|drug
DDI-DrugBank.d97.s72|66-67|or|drug
DDI-DrugBank.d97.s72|69-76|consider|drug
DDI-DrugBank.d97.s72|78-84|HMG-CoA|drug
DDI-DrugBank.d97.s72|86-94|reductase|drug
DDI-DrugBank.d97.s72|96-105|inhibitors|drug
DDI-DrugBank.d97.s72|107-110|that|drug
DDI-DrugBank.d97.s72|112-114|are|drug
DDI-DrugBank.d97.s72|116-118|not|drug
DDI-DrugBank.d97.s72|120-128|primarily|drug
DDI-DrugBank.d97.s72|130-140|metabolized|drug
DDI-DrugBank.d97.s72|142-143|by|drug
DDI-DrugBank.d97.s72|145-150|CYP3A4|drug
DDI-DrugBank.d97.s72|151-151|,|drug
DDI-DrugBank.d97.s72|153-156|such|drug
DDI-DrugBank.d97.s72|158-159|as|drug
DDI-DrugBank.d97.s72|161-171|pravastatin|drug
DDI-DrugBank.d97.s72|172-172|,|drug
DDI-DrugBank.d97.s72|174-184|fluvastatin|drug
DDI-DrugBank.d97.s72|185-185|,|drug
DDI-DrugBank.d97.s72|187-188|or|drug
DDI-DrugBank.d97.s72|190-201|rosuvastatin|drug
DDI-DrugBank.d97.s72|203-204|in|drug
DDI-DrugBank.d97.s72|206-216|combination|drug
DDI-DrugBank.d97.s72|218-221|with|drug
DDI-DrugBank.d97.s72|223-230|CRIXIVAN|drug
DDI-DrugBank.d97.s72|231-231|.|drug
DDI-DrugBank.d97.s73|0-17|Immunosuppressants|drug
DDI-DrugBank.d97.s73|18-18|:|drug
DDI-DrugBank.d97.s73|20-31|cyclosporine|drug
DDI-DrugBank.d97.s73|32-32|,|drug
DDI-DrugBank.d97.s73|34-43|tacrolimus|drug
DDI-DrugBank.d97.s73|44-44|,|drug
DDI-DrugBank.d97.s73|46-54|sirolimus|drug
DDI-DrugBank.d97.s74|0-16|immunosuppressant|drug
DDI-DrugBank.d97.s74|18-23|agents|drug
DDI-DrugBank.d97.s74|25-37|concentration|drug
DDI-DrugBank.d97.s75|0-5|Plasma|drug
DDI-DrugBank.d97.s75|7-20|concentrations|drug
DDI-DrugBank.d97.s75|22-24|may|drug
DDI-DrugBank.d97.s75|26-27|be|drug
DDI-DrugBank.d97.s75|29-37|increased|drug
DDI-DrugBank.d97.s75|39-40|by|drug
DDI-DrugBank.d97.s75|42-49|CRIXIVAN|drug
DDI-DrugBank.d97.s75|50-50|.|drug
DDI-DrugBank.d97.s76|0-11|Itraconazole|brand
DDI-DrugBank.d97.s77|0-8|indinavir|drug
DDI-DrugBank.d97.s77|10-22|concentration|drug
DDI-DrugBank.d97.s78|0-3|Dose|drug
DDI-DrugBank.d97.s78|5-13|reduction|drug
DDI-DrugBank.d97.s78|15-16|of|drug
DDI-DrugBank.d97.s78|18-25|CRIXIVAN|drug
DDI-DrugBank.d97.s78|27-28|to|drug
DDI-DrugBank.d97.s78|30-32|600|drug
DDI-DrugBank.d97.s78|34-35|mg|drug
DDI-DrugBank.d97.s78|37-41|every|drug
DDI-DrugBank.d97.s78|43-43|8|drug
DDI-DrugBank.d97.s78|45-49|hours|drug
DDI-DrugBank.d97.s78|51-52|is|drug
DDI-DrugBank.d97.s78|54-64|recommended|drug
DDI-DrugBank.d97.s78|66-69|when|drug
DDI-DrugBank.d97.s78|71-83|administering|drug
DDI-DrugBank.d97.s78|85-96|itraconazole|drug
DDI-DrugBank.d97.s78|98-109|concurrently|drug
DDI-DrugBank.d97.s78|110-110|.|drug
DDI-DrugBank.d97.s79|0-11|Ketoconazole|brand
DDI-DrugBank.d97.s80|0-8|indinavir|drug
DDI-DrugBank.d97.s80|10-22|concentration|drug
DDI-DrugBank.d97.s81|0-3|Dose|drug
DDI-DrugBank.d97.s81|5-13|reduction|drug
DDI-DrugBank.d97.s81|15-16|of|drug
DDI-DrugBank.d97.s81|18-25|CRIXIVAN|drug
DDI-DrugBank.d97.s81|27-28|to|drug
DDI-DrugBank.d97.s81|30-32|600|drug
DDI-DrugBank.d97.s81|34-35|mg|drug
DDI-DrugBank.d97.s81|37-41|every|drug
DDI-DrugBank.d97.s81|43-43|8|drug
DDI-DrugBank.d97.s81|45-49|hours|drug
DDI-DrugBank.d97.s81|51-56|should|drug
DDI-DrugBank.d97.s81|58-59|be|drug
DDI-DrugBank.d97.s81|61-70|considered|drug
DDI-DrugBank.d97.s81|71-71|.|drug
DDI-DrugBank.d97.s82|0-8|Rifabutin|brand
DDI-DrugBank.d97.s83|0-8|indinavir|drug
DDI-DrugBank.d97.s83|10-22|concentration|drug
DDI-DrugBank.d97.s83|26-34|rifabutin|drug
DDI-DrugBank.d97.s83|36-48|concentration|drug
DDI-DrugBank.d97.s84|0-3|Dose|drug
DDI-DrugBank.d97.s84|5-13|reduction|drug
DDI-DrugBank.d97.s84|15-16|of|drug
DDI-DrugBank.d97.s84|18-26|rifabutin|drug
DDI-DrugBank.d97.s84|28-29|to|drug
DDI-DrugBank.d97.s84|31-34|half|drug
DDI-DrugBank.d97.s84|36-38|the|drug
DDI-DrugBank.d97.s84|40-47|standard|drug
DDI-DrugBank.d97.s84|49-52|dose|drug
DDI-DrugBank.d97.s84|54-56|and|drug
DDI-DrugBank.d97.s84|58-58|a|drug
DDI-DrugBank.d97.s84|60-63|dose|drug
DDI-DrugBank.d97.s84|65-72|increase|drug
DDI-DrugBank.d97.s84|74-75|of|drug
DDI-DrugBank.d97.s84|77-84|CRIXIVAN|drug
DDI-DrugBank.d97.s84|86-87|to|drug
DDI-DrugBank.d97.s84|89-92|1000|drug
DDI-DrugBank.d97.s84|94-95|mg|drug
DDI-DrugBank.d97.s84|97-97|(|drug
DDI-DrugBank.d97.s84|98-102|three|drug
DDI-DrugBank.d97.s84|104-109|333-mg|drug
DDI-DrugBank.d97.s84|111-118|capsules|drug
DDI-DrugBank.d97.s84|119-119|)|drug
DDI-DrugBank.d97.s84|121-125|every|drug
DDI-DrugBank.d97.s84|127-127|8|drug
DDI-DrugBank.d97.s84|129-133|hours|drug
DDI-DrugBank.d97.s84|135-137|are|drug
DDI-DrugBank.d97.s84|139-149|recommended|drug
DDI-DrugBank.d97.s84|151-154|when|drug
DDI-DrugBank.d97.s84|156-164|rifabutin|drug
DDI-DrugBank.d97.s84|166-168|and|drug
DDI-DrugBank.d97.s84|170-177|CRIXIVAN|drug
DDI-DrugBank.d97.s84|179-181|are|drug
DDI-DrugBank.d97.s84|183-196|coadministered|drug
DDI-DrugBank.d97.s84|197-197|.|drug
DDI-DrugBank.d97.s85|0-9|Sildenafil|brand
DDI-DrugBank.d97.s86|0-9|sildenafil|drug
DDI-DrugBank.d97.s86|11-23|concentration|drug
DDI-DrugBank.d97.s87|0-9|Sildenafil|brand
DDI-DrugBank.d97.s87|11-14|dose|drug
DDI-DrugBank.d97.s87|16-21|should|drug
DDI-DrugBank.d97.s87|23-25|not|drug
DDI-DrugBank.d97.s87|27-32|exceed|drug
DDI-DrugBank.d97.s87|34-34|a|drug
DDI-DrugBank.d97.s87|36-42|maximum|drug
DDI-DrugBank.d97.s87|44-45|of|drug
DDI-DrugBank.d97.s87|47-48|25|drug
DDI-DrugBank.d97.s87|50-51|mg|drug
DDI-DrugBank.d97.s87|53-54|in|drug
DDI-DrugBank.d97.s87|56-56|a|drug
DDI-DrugBank.d97.s87|58-60|48-|drug
DDI-DrugBank.d97.s87|62-65|hour|drug
DDI-DrugBank.d97.s87|67-72|period|drug
DDI-DrugBank.d97.s87|74-75|in|drug
DDI-DrugBank.d97.s87|77-84|patients|drug
DDI-DrugBank.d97.s87|86-94|receiving|drug
DDI-DrugBank.d97.s87|96-106|concomitant|drug
DDI-DrugBank.d97.s87|108-116|indinavir|drug
DDI-DrugBank.d97.s87|118-124|therapy|drug
DDI-DrugBank.d97.s87|125-125|.|drug
DDI-DrugBank.d97.s88|0-8|Tadalafil|brand
DDI-DrugBank.d97.s89|0-8|tadalafil|drug
DDI-DrugBank.d97.s89|10-22|concentration|drug
DDI-DrugBank.d97.s90|0-8|Tadalafil|brand
DDI-DrugBank.d97.s90|10-13|dose|drug
DDI-DrugBank.d97.s90|15-20|should|drug
DDI-DrugBank.d97.s90|22-24|not|drug
DDI-DrugBank.d97.s90|26-31|exceed|drug
DDI-DrugBank.d97.s90|33-33|a|drug
DDI-DrugBank.d97.s90|35-41|maximum|drug
DDI-DrugBank.d97.s90|43-44|of|drug
DDI-DrugBank.d97.s90|46-47|10|drug
DDI-DrugBank.d97.s90|49-50|mg|drug
DDI-DrugBank.d97.s90|52-53|in|drug
DDI-DrugBank.d97.s90|55-55|a|drug
DDI-DrugBank.d97.s90|57-59|72-|drug
DDI-DrugBank.d97.s90|61-64|hour|drug
DDI-DrugBank.d97.s90|66-71|period|drug
DDI-DrugBank.d97.s90|73-74|in|drug
DDI-DrugBank.d97.s90|76-83|patients|drug
DDI-DrugBank.d97.s90|85-93|receiving|drug
DDI-DrugBank.d97.s90|95-105|concomitant|drug
DDI-DrugBank.d97.s90|107-115|indinavir|drug
DDI-DrugBank.d97.s90|117-123|therapy|drug
DDI-DrugBank.d97.s90|124-124|.|drug
DDI-DrugBank.d97.s91|0-9|Vardenafil|brand
DDI-DrugBank.d97.s92|0-9|vardenafil|drug
DDI-DrugBank.d97.s92|11-23|concentration|drug
DDI-DrugBank.d97.s93|0-9|Vardenafil|brand
DDI-DrugBank.d97.s93|11-14|dose|drug
DDI-DrugBank.d97.s93|16-21|should|drug
DDI-DrugBank.d97.s93|23-25|not|drug
DDI-DrugBank.d97.s93|27-32|exceed|drug
DDI-DrugBank.d97.s93|34-34|a|drug
DDI-DrugBank.d97.s93|36-42|maximum|drug
DDI-DrugBank.d97.s93|44-45|of|drug
DDI-DrugBank.d97.s93|47-49|2.5|drug
DDI-DrugBank.d97.s93|51-52|mg|drug
DDI-DrugBank.d97.s93|54-55|in|drug
DDI-DrugBank.d97.s93|57-57|a|drug
DDI-DrugBank.d97.s93|59-65|24-hour|drug
DDI-DrugBank.d97.s93|67-72|period|drug
DDI-DrugBank.d97.s93|74-75|in|drug
DDI-DrugBank.d97.s93|77-84|patients|drug
DDI-DrugBank.d97.s93|86-94|receiving|drug
DDI-DrugBank.d97.s93|96-106|concomitant|drug
DDI-DrugBank.d97.s93|108-116|indinavir|drug
DDI-DrugBank.d97.s93|118-124|therapy|drug
DDI-DrugBank.d97.s93|125-125|.|drug
DDI-DrugBank.d97.s94|0-3|Note|drug
DDI-DrugBank.d97.s94|4-4|:|drug
DDI-DrugBank.d97.s95|0-0|=|drug
DDI-DrugBank.d97.s95|2-9|increase|drug
DDI-DrugBank.d97.s95|10-10|;|drug
DDI-DrugBank.d97.s96|0-0|=|drug
DDI-DrugBank.d97.s96|2-9|decrease|drug
DDI-MedLine.d44.s0|0-6|Effects|drug
DDI-MedLine.d44.s0|8-9|of|drug
DDI-MedLine.d44.s0|11-20|etofibrate|drug
DDI-MedLine.d44.s0|22-25|upon|drug
DDI-MedLine.d44.s0|27-29|the|drug
DDI-MedLine.d44.s0|31-40|metabolism|drug
DDI-MedLine.d44.s0|42-43|of|drug
DDI-MedLine.d44.s0|45-60|chylomicron-like|drug
DDI-MedLine.d44.s0|62-70|emulsions|drug
DDI-MedLine.d44.s0|72-73|in|drug
DDI-MedLine.d44.s0|75-82|patients|drug
DDI-MedLine.d44.s0|84-87|with|drug
DDI-MedLine.d44.s0|89-96|coronary|drug
DDI-MedLine.d44.s0|98-103|artery|drug
DDI-MedLine.d44.s0|105-111|disease|drug
DDI-MedLine.d44.s0|112-112|.|drug
DDI-MedLine.d44.s1|0-3|Slow|drug
DDI-MedLine.d44.s1|5-15|chylomicron|drug
DDI-MedLine.d44.s1|17-29|intravascular|drug
DDI-MedLine.d44.s1|31-40|catabolism|drug
DDI-MedLine.d44.s1|42-44|has|drug
DDI-MedLine.d44.s1|46-49|been|drug
DDI-MedLine.d44.s1|51-60|associated|drug
DDI-MedLine.d44.s1|62-65|with|drug
DDI-MedLine.d44.s1|67-74|coronary|drug
DDI-MedLine.d44.s1|76-81|artery|drug
DDI-MedLine.d44.s1|83-89|disease|drug
DDI-MedLine.d44.s1|91-93|and|drug
DDI-MedLine.d44.s1|95-103|screening|drug
DDI-MedLine.d44.s1|105-107|for|drug
DDI-MedLine.d44.s1|109-113|drugs|drug
DDI-MedLine.d44.s1|115-118|that|drug
DDI-MedLine.d44.s1|120-122|can|drug
DDI-MedLine.d44.s1|124-131|speed-up|drug
DDI-MedLine.d44.s1|133-136|this|drug
DDI-MedLine.d44.s1|138-144|process|drug
DDI-MedLine.d44.s1|146-148|can|drug
DDI-MedLine.d44.s1|150-151|be|drug
DDI-MedLine.d44.s1|153-161|important|drug
DDI-MedLine.d44.s1|162-162|.|drug
DDI-MedLine.d44.s2|0-1|In|drug
DDI-MedLine.d44.s2|3-6|this|drug
DDI-MedLine.d44.s2|8-12|study|drug
DDI-MedLine.d44.s2|13-13|,|drug
DDI-MedLine.d44.s2|15-17|the|drug
DDI-MedLine.d44.s2|19-25|effects|drug
DDI-MedLine.d44.s2|27-28|of|drug
DDI-MedLine.d44.s2|30-39|etofibrate|drug
DDI-MedLine.d44.s2|41-44|upon|drug
DDI-MedLine.d44.s2|46-56|chylomicron|drug
DDI-MedLine.d44.s2|58-67|metabolism|drug
DDI-MedLine.d44.s2|69-71|was|drug
DDI-MedLine.d44.s2|73-78|tested|drug
DDI-MedLine.d44.s2|80-81|by|drug
DDI-MedLine.d44.s2|83-95|determination|drug
DDI-MedLine.d44.s2|97-98|of|drug
DDI-MedLine.d44.s2|100-102|the|drug
DDI-MedLine.d44.s2|104-109|plasma|drug
DDI-MedLine.d44.s2|111-118|kinetics|drug
DDI-MedLine.d44.s2|120-121|of|drug
DDI-MedLine.d44.s2|123-123|a|drug
DDI-MedLine.d44.s2|125-140|chylomicron-like|drug
DDI-MedLine.d44.s2|142-149|emulsion|drug
DDI-MedLine.d44.s2|151-155|model|drug
DDI-MedLine.d44.s2|157-158|in|drug
DDI-MedLine.d44.s2|160-161|12|drug
DDI-MedLine.d44.s2|163-170|patients|drug
DDI-MedLine.d44.s2|172-175|with|drug
DDI-MedLine.d44.s2|177-184|coronary|drug
DDI-MedLine.d44.s2|186-191|artery|drug
DDI-MedLine.d44.s2|193-199|disease|drug
DDI-MedLine.d44.s2|200-200|,|drug
DDI-MedLine.d44.s2|202-205|aged|drug
DDI-MedLine.d44.s2|207-213|59+/-11|drug
DDI-MedLine.d44.s2|215-219|years|drug
DDI-MedLine.d44.s2|220-220|,|drug
DDI-MedLine.d44.s2|222-222|(|drug
DDI-MedLine.d44.s2|223-227|total|drug
DDI-MedLine.d44.s2|229-239|cholesterol|drug
DDI-MedLine.d44.s2|240-240|:|drug
DDI-MedLine.d44.s2|242-249|240+/-41|drug
DDI-MedLine.d44.s2|251-255|mg/dl|drug
DDI-MedLine.d44.s2|256-256|;|drug
DDI-MedLine.d44.s2|258-270|triglycerides|drug
DDI-MedLine.d44.s2|271-271|:|drug
DDI-MedLine.d44.s2|273-280|188+/-42|drug
DDI-MedLine.d44.s2|282-286|mg/dl|drug
DDI-MedLine.d44.s2|287-287|)|drug
DDI-MedLine.d44.s2|289-297|submitted|drug
DDI-MedLine.d44.s2|299-300|to|drug
DDI-MedLine.d44.s2|302-302|a|drug
DDI-MedLine.d44.s2|304-313|randomized|drug
DDI-MedLine.d44.s2|314-314|,|drug
DDI-MedLine.d44.s2|316-324|crossover|drug
DDI-MedLine.d44.s2|325-325|,|drug
DDI-MedLine.d44.s2|327-338|double-blind|drug
DDI-MedLine.d44.s2|339-339|,|drug
DDI-MedLine.d44.s2|341-358|placebo-controlled|drug
DDI-MedLine.d44.s2|360-364|study|drug
DDI-MedLine.d44.s2|366-369|with|drug
DDI-MedLine.d44.s2|371-384|administration|drug
DDI-MedLine.d44.s2|386-387|of|drug
DDI-MedLine.d44.s2|389-389|1|drug
DDI-MedLine.d44.s2|391-391|g|drug
DDI-MedLine.d44.s2|393-395|per|drug
DDI-MedLine.d44.s2|397-399|day|drug
DDI-MedLine.d44.s2|401-410|etofibrate|drug
DDI-MedLine.d44.s2|412-413|or|drug
DDI-MedLine.d44.s2|415-421|placebo|drug
DDI-MedLine.d44.s2|423-425|for|drug
DDI-MedLine.d44.s2|427-433|1-month|drug
DDI-MedLine.d44.s2|434-434|.|drug
DDI-MedLine.d44.s3|0-0|A|drug
DDI-MedLine.d44.s3|2-8|1-month|drug
DDI-MedLine.d44.s3|10-16|washout|drug
DDI-MedLine.d44.s3|18-23|period|drug
DDI-MedLine.d44.s3|25-27|was|drug
DDI-MedLine.d44.s3|29-36|inserted|drug
DDI-MedLine.d44.s3|38-44|between|drug
DDI-MedLine.d44.s3|46-48|the|drug
DDI-MedLine.d44.s3|50-58|treatment|drug
DDI-MedLine.d44.s3|60-66|periods|drug
DDI-MedLine.d44.s3|67-67|.|drug
DDI-MedLine.d44.s4|0-7|Patients|drug
DDI-MedLine.d44.s4|9-12|were|drug
DDI-MedLine.d44.s4|14-26|intravenously|drug
DDI-MedLine.d44.s4|28-35|injected|drug
DDI-MedLine.d44.s4|37-37|a|drug
DDI-MedLine.d44.s4|39-54|chylomicron-like|drug
DDI-MedLine.d44.s4|56-63|emulsion|drug
DDI-MedLine.d44.s4|65-70|doubly|drug
DDI-MedLine.d44.s4|72-78|labeled|drug
DDI-MedLine.d44.s4|80-83|with|drug
DDI-MedLine.d44.s4|85-99|14C-cholesteryl|drug
DDI-MedLine.d44.s4|101-106|oleate|drug
DDI-MedLine.d44.s4|108-110|and|drug
DDI-MedLine.d44.s4|112-122|3H-triolein|drug
DDI-MedLine.d44.s4|124-125|at|drug
DDI-MedLine.d44.s4|127-134|baseline|drug
DDI-MedLine.d44.s4|136-138|and|drug
DDI-MedLine.d44.s4|140-144|after|drug
DDI-MedLine.d44.s4|146-155|treatments|drug
DDI-MedLine.d44.s4|156-156|.|drug
DDI-MedLine.d44.s5|0-4|After|drug
DDI-MedLine.d44.s5|6-15|etofibrate|drug
DDI-MedLine.d44.s5|17-25|treatment|drug
DDI-MedLine.d44.s5|26-26|,|drug
DDI-MedLine.d44.s5|28-32|there|drug
DDI-MedLine.d44.s5|34-36|was|drug
DDI-MedLine.d44.s5|38-45|decrease|drug
DDI-MedLine.d44.s5|47-48|of|drug
DDI-MedLine.d44.s5|50-54|total|drug
DDI-MedLine.d44.s5|56-66|cholesterol|drug
DDI-MedLine.d44.s5|68-70|and|drug
DDI-MedLine.d44.s5|72-83|triglyceride|drug
DDI-MedLine.d44.s5|85-90|plasma|drug
DDI-MedLine.d44.s5|92-97|levels|drug
DDI-MedLine.d44.s5|99-101|and|drug
DDI-MedLine.d44.s5|103-103|a|drug
DDI-MedLine.d44.s5|105-109|trend|drug
DDI-MedLine.d44.s5|111-112|to|drug
DDI-MedLine.d44.s5|114-121|increase|drug
DDI-MedLine.d44.s5|123-134|high-density|drug
DDI-MedLine.d44.s5|136-146|lipoprotein|drug
DDI-MedLine.d44.s5|148-158|cholesterol|drug
DDI-MedLine.d44.s5|160-165|plasma|drug
DDI-MedLine.d44.s5|167-172|levels|drug
DDI-MedLine.d44.s5|173-173|.|drug
DDI-MedLine.d44.s6|0-9|Etofibrate|drug
DDI-MedLine.d44.s6|11-18|elicited|drug
DDI-MedLine.d44.s6|20-21|62|drug
DDI-MedLine.d44.s6|22-22|%|drug
DDI-MedLine.d44.s6|24-34|enhancement|drug
DDI-MedLine.d44.s6|36-37|of|drug
DDI-MedLine.d44.s6|39-50|post-heparin|drug
DDI-MedLine.d44.s6|52-60|lipolytic|drug
DDI-MedLine.d44.s6|62-69|activity|drug
DDI-MedLine.d44.s6|71-73|and|drug
DDI-MedLine.d44.s6|75-77|100|drug
DDI-MedLine.d44.s6|78-78|%|drug
DDI-MedLine.d44.s6|80-87|increase|drug
DDI-MedLine.d44.s6|89-90|of|drug
DDI-MedLine.d44.s6|92-106|3H-triglyceride|drug
DDI-MedLine.d44.s6|108-117|fractional|drug
DDI-MedLine.d44.s6|119-127|clearance|drug
DDI-MedLine.d44.s6|129-132|rate|drug
DDI-MedLine.d44.s6|134-141|compared|drug
DDI-MedLine.d44.s6|143-146|with|drug
DDI-MedLine.d44.s6|148-154|placebo|drug
DDI-MedLine.d44.s6|156-164|treatment|drug
DDI-MedLine.d44.s6|165-165|.|drug
DDI-MedLine.d44.s7|0-14|14C-cholesterol|drug
DDI-MedLine.d44.s7|16-20|ester|drug
DDI-MedLine.d44.s7|22-31|fractional|drug
DDI-MedLine.d44.s7|33-41|clearance|drug
DDI-MedLine.d44.s7|43-46|rate|drug
DDI-MedLine.d44.s7|48-50|was|drug
DDI-MedLine.d44.s7|52-54|260|drug
DDI-MedLine.d44.s7|55-55|%|drug
DDI-MedLine.d44.s7|57-63|greater|drug
DDI-MedLine.d44.s7|65-69|after|drug
DDI-MedLine.d44.s7|71-80|etofibrate|drug
DDI-MedLine.d44.s7|82-85|than|drug
DDI-MedLine.d44.s7|87-91|after|drug
DDI-MedLine.d44.s7|93-99|placebo|drug
DDI-MedLine.d44.s7|100-100|.|drug
DDI-MedLine.d44.s8|0-8|Therefore|drug
DDI-MedLine.d44.s8|9-9|,|drug
DDI-MedLine.d44.s8|11-11|a|drug
DDI-MedLine.d44.s8|13-18|potent|drug
DDI-MedLine.d44.s8|20-25|effect|drug
DDI-MedLine.d44.s8|27-28|of|drug
DDI-MedLine.d44.s8|30-39|etofibrate|drug
DDI-MedLine.d44.s8|41-42|on|drug
DDI-MedLine.d44.s8|44-47|both|drug
DDI-MedLine.d44.s8|49-59|chylomicron|drug
DDI-MedLine.d44.s8|61-69|lipolysis|drug
DDI-MedLine.d44.s8|71-73|and|drug
DDI-MedLine.d44.s8|75-81|remnant|drug
DDI-MedLine.d44.s8|83-89|removal|drug
DDI-MedLine.d44.s8|91-93|was|drug
DDI-MedLine.d44.s8|95-102|achieved|drug
DDI-MedLine.d44.s8|103-103|,|drug
DDI-MedLine.d44.s8|105-114|indicating|drug
DDI-MedLine.d44.s8|116-119|that|drug
DDI-MedLine.d44.s8|121-124|this|drug
DDI-MedLine.d44.s8|126-129|drug|drug
DDI-MedLine.d44.s8|131-133|can|drug
DDI-MedLine.d44.s8|135-136|be|drug
DDI-MedLine.d44.s8|138-141|used|drug
DDI-MedLine.d44.s8|143-144|to|drug
DDI-MedLine.d44.s8|146-152|improve|drug
DDI-MedLine.d44.s8|154-157|this|drug
DDI-MedLine.d44.s8|159-168|metabolism|drug
DDI-MedLine.d44.s8|170-171|in|drug
DDI-MedLine.d44.s8|173-178|future|drug
DDI-MedLine.d44.s8|180-190|prospective|drug
DDI-MedLine.d44.s8|192-198|studies|drug
DDI-MedLine.d44.s8|199-199|.|drug
DDI-DrugBank.d152.s0|0-6|Certain|drug
DDI-DrugBank.d152.s0|8-16|endocrine|drug
DDI-DrugBank.d152.s0|18-20|and|drug
DDI-DrugBank.d152.s0|22-26|liver|drug
DDI-DrugBank.d152.s0|28-35|function|drug
DDI-DrugBank.d152.s0|37-41|tests|drug
DDI-DrugBank.d152.s0|43-45|may|drug
DDI-DrugBank.d152.s0|47-48|be|drug
DDI-DrugBank.d152.s0|50-57|affected|drug
DDI-DrugBank.d152.s0|59-60|by|drug
DDI-DrugBank.d152.s0|62-80|estrogen-containing|drug
DDI-DrugBank.d152.s0|82-85|oral|drug
DDI-DrugBank.d152.s0|87-100|contraceptives|drug
DDI-DrugBank.d152.s0|101-101|.|drug
DDI-DrugBank.d152.s1|0-2|The|drug
DDI-DrugBank.d152.s1|4-12|following|drug
DDI-DrugBank.d152.s1|14-20|similar|drug
DDI-DrugBank.d152.s1|22-28|changes|drug
DDI-DrugBank.d152.s1|30-32|may|drug
DDI-DrugBank.d152.s1|34-35|be|drug
DDI-DrugBank.d152.s1|37-44|expected|drug
DDI-DrugBank.d152.s1|46-49|with|drug
DDI-DrugBank.d152.s1|51-56|larger|drug
DDI-DrugBank.d152.s1|58-62|doses|drug
DDI-DrugBank.d152.s1|64-65|of|drug
DDI-DrugBank.d152.s1|67-74|estrogen|drug
DDI-DrugBank.d152.s1|75-75|:|drug
DDI-DrugBank.d152.s1|77-85|Increased|drug
DDI-DrugBank.d152.s1|87-105|sulfobromophthalein|drug
DDI-DrugBank.d152.s1|107-115|retention|drug
DDI-DrugBank.d152.s1|116-116|;|drug
DDI-DrugBank.d152.s2|0-8|increased|drug
DDI-DrugBank.d152.s2|10-20|prothrombin|drug
DDI-DrugBank.d152.s2|22-24|and|drug
DDI-DrugBank.d152.s2|26-32|factors|drug
DDI-DrugBank.d152.s2|34-36|VII|drug
DDI-DrugBank.d152.s2|37-37|,|drug
DDI-DrugBank.d152.s2|39-42|VIII|drug
DDI-DrugBank.d152.s2|43-43|,|drug
DDI-DrugBank.d152.s2|45-46|IX|drug
DDI-DrugBank.d152.s2|47-47|,|drug
DDI-DrugBank.d152.s2|49-51|and|drug
DDI-DrugBank.d152.s2|53-53|X|drug
DDI-DrugBank.d152.s2|54-54|;|drug
DDI-DrugBank.d152.s3|0-8|decreased|drug
DDI-DrugBank.d152.s3|10-21|antithrombin|drug
DDI-DrugBank.d152.s3|23-23|3|drug
DDI-DrugBank.d152.s3|24-24|;|drug
DDI-DrugBank.d152.s4|0-8|increased|drug
DDI-DrugBank.d152.s4|10-31|norepinephrine-induced|drug
DDI-DrugBank.d152.s4|33-38|platel|drug
DDI-DrugBank.d152.s4|40-41|et|drug
DDI-DrugBank.d152.s4|43-53|aggregation|drug
DDI-DrugBank.d152.s4|54-54|;|drug
DDI-DrugBank.d152.s5|0-8|increased|drug
DDI-DrugBank.d152.s5|10-16|thyroid|drug
DDI-DrugBank.d152.s5|18-24|binding|drug
DDI-DrugBank.d152.s5|26-33|globulin|drug
DDI-DrugBank.d152.s5|35-35|(|drug
DDI-DrugBank.d152.s5|36-38|TBG|drug
DDI-DrugBank.d152.s5|39-39|)|drug
DDI-DrugBank.d152.s5|41-47|leading|drug
DDI-DrugBank.d152.s5|49-50|to|drug
DDI-DrugBank.d152.s5|52-60|increased|drug
DDI-DrugBank.d152.s5|62-72|circulating|drug
DDI-DrugBank.d152.s5|74-78|total|drug
DDI-DrugBank.d152.s5|80-86|thyroid|drug
DDI-DrugBank.d152.s5|88-94|hormone|drug
DDI-DrugBank.d152.s5|95-95|,|drug
DDI-DrugBank.d152.s5|97-98|as|drug
DDI-DrugBank.d152.s5|100-107|measured|drug
DDI-DrugBank.d152.s5|109-110|by|drug
DDI-DrugBank.d152.s5|112-114|PBI|drug
DDI-DrugBank.d152.s5|115-115|,|drug
DDI-DrugBank.d152.s5|117-118|T4|drug
DDI-DrugBank.d152.s5|120-121|by|drug
DDI-DrugBank.d152.s5|123-128|column|drug
DDI-DrugBank.d152.s5|129-129|,|drug
DDI-DrugBank.d152.s5|131-132|or|drug
DDI-DrugBank.d152.s5|134-135|T4|drug
DDI-DrugBank.d152.s5|137-138|by|drug
DDI-DrugBank.d152.s5|140-155|radioimmunoassay|drug
DDI-DrugBank.d152.s5|156-156|.|drug
DDI-DrugBank.d152.s6|0-3|Free|drug
DDI-DrugBank.d152.s6|5-6|T3|drug
DDI-DrugBank.d152.s6|8-12|resin|drug
DDI-DrugBank.d152.s6|14-19|uptake|drug
DDI-DrugBank.d152.s6|21-22|is|drug
DDI-DrugBank.d152.s6|24-32|decreased|drug
DDI-DrugBank.d152.s6|33-33|,|drug
DDI-DrugBank.d152.s6|35-44|reflecting|drug
DDI-DrugBank.d152.s6|46-48|the|drug
DDI-DrugBank.d152.s6|50-57|elevated|drug
DDI-DrugBank.d152.s6|59-61|TBG|drug
DDI-DrugBank.d152.s6|62-62|;|drug
DDI-DrugBank.d152.s7|0-3|free|drug
DDI-DrugBank.d152.s7|5-6|T4|drug
DDI-DrugBank.d152.s7|8-20|concentration|drug
DDI-DrugBank.d152.s7|22-23|is|drug
DDI-DrugBank.d152.s7|25-33|unaltered|drug
DDI-DrugBank.d152.s7|34-34|:|drug
DDI-DrugBank.d152.s7|36-43|impaired|drug
DDI-DrugBank.d152.s7|45-51|glucose|drug
DDI-DrugBank.d152.s7|53-61|tolerance|drug
DDI-DrugBank.d152.s7|62-62|;|drug
DDI-DrugBank.d152.s8|0-8|decreased|drug
DDI-DrugBank.d152.s8|10-21|pregnanediol|drug
DDI-DrugBank.d152.s8|23-31|excretion|drug
DDI-DrugBank.d152.s8|32-32|;|drug
DDI-DrugBank.d152.s9|0-6|reduced|drug
DDI-DrugBank.d152.s9|8-15|response|drug
DDI-DrugBank.d152.s9|17-18|to|drug
DDI-DrugBank.d152.s9|20-29|metyrapone|drug
DDI-DrugBank.d152.s9|31-34|test|drug
DDI-DrugBank.d152.s9|35-35|;|drug
DDI-DrugBank.d152.s10|0-6|reduced|drug
DDI-DrugBank.d152.s10|8-12|serum|drug
DDI-DrugBank.d152.s10|14-19|folate|drug
DDI-DrugBank.d152.s10|21-33|concentration|drug
DDI-DrugBank.d152.s10|34-34|;|drug
DDI-DrugBank.d152.s11|0-8|increased|drug
DDI-DrugBank.d152.s11|10-14|serum|drug
DDI-DrugBank.d152.s11|16-27|triglyceride|drug
DDI-DrugBank.d152.s11|29-31|and|drug
DDI-DrugBank.d152.s11|33-44|phospholipid|drug
DDI-DrugBank.d152.s11|46-58|concentration|drug
DDI-DrugBank.d152.s11|59-59|.|drug
DDI-DrugBank.d302.s0|0-3|http|drug
DDI-DrugBank.d302.s0|4-4|:|drug
DDI-DrugBank.d302.s0|5-53|//www.rxlist.com/cgi/generic3/guanethidine_od.htm|drug
DDI-MedLine.d181.s0|0-3|Drug|drug
DDI-MedLine.d181.s0|5-15|interaction|drug
DDI-MedLine.d181.s0|17-18|of|drug
DDI-MedLine.d181.s0|20-32|levothyroxine|drug
DDI-MedLine.d181.s0|34-37|with|drug
DDI-MedLine.d181.s0|39-44|infant|drug
DDI-MedLine.d181.s0|46-50|colic|drug
DDI-MedLine.d181.s0|52-56|drops|drug
DDI-MedLine.d181.s0|57-57|.|drug
DDI-MedLine.d181.s1|0-6|Infacol|brand
DDI-MedLine.d181.s1|8-8|(|drug
DDI-MedLine.d181.s1|9-14|Forest|drug
DDI-MedLine.d181.s1|16-27|Laboratories|drug
DDI-MedLine.d181.s1|29-30|UK|drug
DDI-MedLine.d181.s1|31-31|,|drug
DDI-MedLine.d181.s1|33-36|Kent|drug
DDI-MedLine.d181.s1|37-37|,|drug
DDI-MedLine.d181.s1|39-40|UK|drug
DDI-MedLine.d181.s1|41-41|)|drug
DDI-MedLine.d181.s1|43-44|is|drug
DDI-MedLine.d181.s1|46-46|a|drug
DDI-MedLine.d181.s1|48-53|widely|drug
DDI-MedLine.d181.s1|55-63|available|drug
DDI-MedLine.d181.s1|65-80|over-the-counter|drug
DDI-MedLine.d181.s1|82-92|preparation|drug
DDI-MedLine.d181.s1|94-97|used|drug
DDI-MedLine.d181.s1|99-100|to|drug
DDI-MedLine.d181.s1|102-108|relieve|drug
DDI-MedLine.d181.s1|110-114|colic|drug
DDI-MedLine.d181.s1|116-123|symptoms|drug
DDI-MedLine.d181.s1|125-126|in|drug
DDI-MedLine.d181.s1|128-135|neonates|drug
DDI-MedLine.d181.s1|137-139|and|drug
DDI-MedLine.d181.s1|141-147|infants|drug
DDI-MedLine.d181.s1|148-148|.|drug
DDI-MedLine.d181.s2|0-2|The|drug
DDI-MedLine.d181.s2|4-9|active|drug
DDI-MedLine.d181.s2|11-20|ingredient|drug
DDI-MedLine.d181.s2|22-23|is|drug
DDI-MedLine.d181.s2|25-34|simeticone|drug
DDI-MedLine.d181.s2|35-35|.|drug
DDI-MedLine.d181.s3|0-1|No|drug
DDI-MedLine.d181.s3|3-6|drug|drug
DDI-MedLine.d181.s3|8-19|interactions|drug
DDI-MedLine.d181.s3|21-24|with|drug
DDI-MedLine.d181.s3|26-35|simeticone|drug
DDI-MedLine.d181.s3|37-39|are|drug
DDI-MedLine.d181.s3|41-50|documented|drug
DDI-MedLine.d181.s3|52-53|in|drug
DDI-MedLine.d181.s3|55-57|the|drug
DDI-MedLine.d181.s3|59-65|current|drug
DDI-MedLine.d181.s3|67-73|summary|drug
DDI-MedLine.d181.s3|75-76|of|drug
DDI-MedLine.d181.s3|78-84|product|drug
DDI-MedLine.d181.s3|86-100|characteristics|drug
DDI-MedLine.d181.s3|101-101|.|drug
DDI-MedLine.d181.s4|0-2|The|drug
DDI-MedLine.d181.s4|4-10|authors|drug
DDI-MedLine.d181.s4|12-17|report|drug
DDI-MedLine.d181.s4|19-21|the|drug
DDI-MedLine.d181.s4|23-26|case|drug
DDI-MedLine.d181.s4|28-29|of|drug
DDI-MedLine.d181.s4|31-32|an|drug
DDI-MedLine.d181.s4|34-39|infant|drug
DDI-MedLine.d181.s4|41-44|with|drug
DDI-MedLine.d181.s4|46-54|confirmed|drug
DDI-MedLine.d181.s4|56-65|congenital|drug
DDI-MedLine.d181.s4|67-80|hypothyroidism|drug
DDI-MedLine.d181.s4|82-83|on|drug
DDI-MedLine.d181.s4|85-97|levothyroxine|drug
DDI-MedLine.d181.s4|99-101|who|drug
DDI-MedLine.d181.s4|103-113|experienced|drug
DDI-MedLine.d181.s4|115-115|a|drug
DDI-MedLine.d181.s4|117-124|possible|drug
DDI-MedLine.d181.s4|126-129|drug|drug
DDI-MedLine.d181.s4|131-141|interaction|drug
DDI-MedLine.d181.s4|143-146|with|drug
DDI-MedLine.d181.s4|148-157|simeticone|drug
DDI-MedLine.d181.s4|158-158|.|drug
DDI-MedLine.d181.s5|0-6|Despite|drug
DDI-MedLine.d181.s5|8-15|adequate|drug
DDI-MedLine.d181.s5|17-29|levothyroxine|drug
DDI-MedLine.d181.s5|31-36|dosage|drug
DDI-MedLine.d181.s5|37-37|,|drug
DDI-MedLine.d181.s5|39-45|thyroid|drug
DDI-MedLine.d181.s5|47-57|stimulating|drug
DDI-MedLine.d181.s5|59-65|hormone|drug
DDI-MedLine.d181.s5|67-67|(|drug
DDI-MedLine.d181.s5|68-70|TSH|drug
DDI-MedLine.d181.s5|71-71|)|drug
DDI-MedLine.d181.s5|73-75|was|drug
DDI-MedLine.d181.s5|77-80|high|drug
DDI-MedLine.d181.s5|81-81|,|drug
DDI-MedLine.d181.s5|83-92|suggesting|drug
DDI-MedLine.d181.s5|94-107|undertreatment|drug
DDI-MedLine.d181.s5|108-108|.|drug
DDI-MedLine.d181.s6|0-10|Questioning|drug
DDI-MedLine.d181.s6|12-19|revealed|drug
DDI-MedLine.d181.s6|21-23|the|drug
DDI-MedLine.d181.s6|25-29|child|drug
DDI-MedLine.d181.s6|31-33|was|drug
DDI-MedLine.d181.s6|35-40|taking|drug
DDI-MedLine.d181.s6|42-48|Infacol|brand
DDI-MedLine.d181.s6|50-54|drops|drug
DDI-MedLine.d181.s6|56-61|before|drug
DDI-MedLine.d181.s6|63-67|feeds|drug
DDI-MedLine.d181.s6|69-73|while|drug
DDI-MedLine.d181.s6|75-76|on|drug
DDI-MedLine.d181.s6|78-90|levothyroxine|drug
DDI-MedLine.d181.s6|91-91|.|drug
DDI-MedLine.d181.s7|0-2|The|drug
DDI-MedLine.d181.s7|4-8|colic|drug
DDI-MedLine.d181.s7|10-14|drops|drug
DDI-MedLine.d181.s7|16-19|were|drug
DDI-MedLine.d181.s7|21-31|immediately|drug
DDI-MedLine.d181.s7|33-44|discontinued|drug
DDI-MedLine.d181.s7|46-48|and|drug
DDI-MedLine.d181.s7|50-52|TSH|drug
DDI-MedLine.d181.s7|54-61|promptly|drug
DDI-MedLine.d181.s7|63-72|normalised|drug
DDI-MedLine.d181.s7|74-77|with|drug
DDI-MedLine.d181.s7|79-79|a|drug
DDI-MedLine.d181.s7|81-89|reduction|drug
DDI-MedLine.d181.s7|91-92|in|drug
DDI-MedLine.d181.s7|94-102|thyroxine|drug
DDI-MedLine.d181.s7|104-114|requirement|drug
DDI-MedLine.d181.s7|116-117|to|drug
DDI-MedLine.d181.s7|119-120|an|drug
DDI-MedLine.d181.s7|122-124|age|drug
DDI-MedLine.d181.s7|126-136|appropriate|drug
DDI-MedLine.d181.s7|138-143|dosage|drug
DDI-MedLine.d181.s7|144-144|.|drug
DDI-MedLine.d181.s8|0-3|Drug|drug
DDI-MedLine.d181.s8|5-15|interaction|drug
DDI-MedLine.d181.s8|17-18|of|drug
DDI-MedLine.d181.s8|20-28|thyroxine|drug
DDI-MedLine.d181.s8|30-33|with|drug
DDI-MedLine.d181.s8|35-44|simeticone|drug
DDI-MedLine.d181.s8|46-48|has|drug
DDI-MedLine.d181.s8|50-52|not|drug
DDI-MedLine.d181.s8|54-57|been|drug
DDI-MedLine.d181.s8|59-66|reported|drug
DDI-MedLine.d181.s8|68-77|previously|drug
DDI-MedLine.d181.s8|79-81|and|drug
DDI-MedLine.d181.s8|83-84|is|drug
DDI-MedLine.d181.s8|86-88|not|drug
DDI-MedLine.d181.s8|90-95|listed|drug
DDI-MedLine.d181.s8|97-98|in|drug
DDI-MedLine.d181.s8|100-102|the|drug
DDI-MedLine.d181.s8|104-110|British|drug
DDI-MedLine.d181.s8|112-119|National|drug
DDI-MedLine.d181.s8|121-129|Formulary|drug
DDI-MedLine.d181.s8|131-133|for|drug
DDI-MedLine.d181.s8|135-142|Children|drug
DDI-MedLine.d181.s8|143-143|.|drug
DDI-MedLine.d181.s9|0-9|Clinicians|drug
DDI-MedLine.d181.s9|11-13|and|drug
DDI-MedLine.d181.s9|15-21|parents|drug
DDI-MedLine.d181.s9|23-26|need|drug
DDI-MedLine.d181.s9|28-29|to|drug
DDI-MedLine.d181.s9|31-32|be|drug
DDI-MedLine.d181.s9|34-38|aware|drug
DDI-MedLine.d181.s9|40-41|of|drug
DDI-MedLine.d181.s9|43-46|this|drug
DDI-MedLine.d181.s9|48-58|interaction|drug
DDI-MedLine.d181.s9|60-61|to|drug
DDI-MedLine.d181.s9|63-67|avoid|drug
DDI-MedLine.d181.s9|69-79|unnecessary|drug
DDI-MedLine.d181.s9|81-94|undertreatment|drug
DDI-MedLine.d181.s9|96-98|and|drug
DDI-MedLine.d181.s9|100-106|prevent|drug
DDI-MedLine.d181.s9|108-116|potential|drug
DDI-MedLine.d181.s9|118-126|long-term|drug
DDI-MedLine.d181.s9|128-139|neurological|drug
DDI-MedLine.d181.s9|141-148|sequelae|drug
DDI-MedLine.d181.s9|149-149|.|drug
DDI-DrugBank.d439.s0|0-12|Corticotropin|drug
DDI-DrugBank.d439.s0|14-16|may|drug
DDI-DrugBank.d439.s0|18-27|accentuate|drug
DDI-DrugBank.d439.s0|29-31|the|drug
DDI-DrugBank.d439.s0|33-43|electrolyte|drug
DDI-DrugBank.d439.s0|45-48|loss|drug
DDI-DrugBank.d439.s0|50-59|associated|drug
DDI-DrugBank.d439.s0|61-64|with|drug
DDI-DrugBank.d439.s0|66-73|diuretic|drug
DDI-DrugBank.d439.s0|75-81|therapy|drug
DDI-DrugBank.d439.s0|82-82|.|drug
DDI-DrugBank.d632.s0|0-2|Due|drug
DDI-DrugBank.d632.s0|4-5|to|drug
DDI-DrugBank.d632.s0|7-9|its|drug
DDI-DrugBank.d632.s0|11-17|effects|drug
DDI-DrugBank.d632.s0|19-20|on|drug
DDI-DrugBank.d632.s0|22-28|gastric|drug
DDI-DrugBank.d632.s0|30-37|emptying|drug
DDI-DrugBank.d632.s0|38-38|,|drug
DDI-DrugBank.d632.s0|40-45|SYMLIN|drug
DDI-DrugBank.d632.s0|47-53|therapy|drug
DDI-DrugBank.d632.s0|55-60|should|drug
DDI-DrugBank.d632.s0|62-64|not|drug
DDI-DrugBank.d632.s0|66-67|be|drug
DDI-DrugBank.d632.s0|69-78|considered|drug
DDI-DrugBank.d632.s0|80-82|for|drug
DDI-DrugBank.d632.s0|84-91|patients|drug
DDI-DrugBank.d632.s0|93-98|taking|drug
DDI-DrugBank.d632.s0|100-104|drugs|drug
DDI-DrugBank.d632.s0|106-109|that|drug
DDI-DrugBank.d632.s0|111-115|alter|drug
DDI-DrugBank.d632.s0|117-132|gastrointestinal|drug
DDI-DrugBank.d632.s0|134-141|motility|drug
DDI-DrugBank.d632.s0|143-143|(|drug
DDI-DrugBank.d632.s0|144-147|e.g.|drug
DDI-DrugBank.d632.s0|148-148|,|drug
DDI-DrugBank.d632.s0|150-164|anticholinergic|drug
DDI-DrugBank.d632.s0|166-171|agents|drug
DDI-DrugBank.d632.s0|173-176|such|drug
DDI-DrugBank.d632.s0|178-179|as|drug
DDI-DrugBank.d632.s0|181-188|atropine|drug
DDI-DrugBank.d632.s0|189-189|)|drug
DDI-DrugBank.d632.s0|191-193|and|drug
DDI-DrugBank.d632.s0|195-200|agents|drug
DDI-DrugBank.d632.s0|202-205|that|drug
DDI-DrugBank.d632.s0|207-210|slow|drug
DDI-DrugBank.d632.s0|212-214|the|drug
DDI-DrugBank.d632.s0|216-225|intestinal|drug
DDI-DrugBank.d632.s0|227-236|absorption|drug
DDI-DrugBank.d632.s0|238-239|of|drug
DDI-DrugBank.d632.s0|241-249|nutrients|drug
DDI-DrugBank.d632.s0|251-251|(|drug
DDI-DrugBank.d632.s0|252-255|e.g.|drug
DDI-DrugBank.d632.s0|256-256|,|drug
DDI-DrugBank.d632.s0|258-262|alpha|drug
DDI-DrugBank.d632.s0|264-274|glucosidase|drug
DDI-DrugBank.d632.s0|276-285|inhibitors|drug
DDI-DrugBank.d632.s0|286-286|)|drug
DDI-DrugBank.d632.s0|287-287|.|drug
DDI-DrugBank.d632.s1|0-7|Patients|drug
DDI-DrugBank.d632.s1|9-13|using|drug
DDI-DrugBank.d632.s1|15-19|these|drug
DDI-DrugBank.d632.s1|21-25|drugs|drug
DDI-DrugBank.d632.s1|27-30|have|drug
DDI-DrugBank.d632.s1|32-34|not|drug
DDI-DrugBank.d632.s1|36-39|been|drug
DDI-DrugBank.d632.s1|41-47|studied|drug
DDI-DrugBank.d632.s1|49-50|in|drug
DDI-DrugBank.d632.s1|52-59|clinical|drug
DDI-DrugBank.d632.s1|61-66|trials|drug
DDI-DrugBank.d632.s1|67-67|.|drug
DDI-DrugBank.d632.s2|0-5|SYMLIN|drug
DDI-DrugBank.d632.s2|7-9|has|drug
DDI-DrugBank.d632.s2|11-13|the|drug
DDI-DrugBank.d632.s2|15-23|potential|drug
DDI-DrugBank.d632.s2|25-26|to|drug
DDI-DrugBank.d632.s2|28-32|delay|drug
DDI-DrugBank.d632.s2|34-36|the|drug
DDI-DrugBank.d632.s2|38-47|absorption|drug
DDI-DrugBank.d632.s2|49-50|of|drug
DDI-DrugBank.d632.s2|52-64|concomitantly|drug
DDI-DrugBank.d632.s2|66-77|administered|drug
DDI-DrugBank.d632.s2|79-82|oral|drug
DDI-DrugBank.d632.s2|84-94|medications|drug
DDI-DrugBank.d632.s2|95-95|.|drug
DDI-DrugBank.d632.s3|0-3|When|drug
DDI-DrugBank.d632.s3|5-7|the|drug
DDI-DrugBank.d632.s3|9-13|rapid|drug
DDI-DrugBank.d632.s3|15-19|onset|drug
DDI-DrugBank.d632.s3|21-22|of|drug
DDI-DrugBank.d632.s3|24-24|a|drug
DDI-DrugBank.d632.s3|26-36|concomitant|drug
DDI-DrugBank.d632.s3|38-43|orally|drug
DDI-DrugBank.d632.s3|45-56|administered|drug
DDI-DrugBank.d632.s3|58-62|agent|drug
DDI-DrugBank.d632.s3|64-65|is|drug
DDI-DrugBank.d632.s3|67-67|a|drug
DDI-DrugBank.d632.s3|69-76|critical|drug
DDI-DrugBank.d632.s3|78-88|determinant|drug
DDI-DrugBank.d632.s3|90-91|of|drug
DDI-DrugBank.d632.s3|93-105|effectiveness|drug
DDI-DrugBank.d632.s3|107-107|(|drug
DDI-DrugBank.d632.s3|108-111|such|drug
DDI-DrugBank.d632.s3|113-114|as|drug
DDI-DrugBank.d632.s3|116-125|analgesics|drug
DDI-DrugBank.d632.s3|126-126|)|drug
DDI-DrugBank.d632.s3|127-127|,|drug
DDI-DrugBank.d632.s3|129-131|the|drug
DDI-DrugBank.d632.s3|133-137|agent|drug
DDI-DrugBank.d632.s3|139-144|should|drug
DDI-DrugBank.d632.s3|146-147|be|drug
DDI-DrugBank.d632.s3|149-160|administered|drug
DDI-DrugBank.d632.s3|162-163|at|drug
DDI-DrugBank.d632.s3|165-169|least|drug
DDI-DrugBank.d632.s3|171-171|1|drug
DDI-DrugBank.d632.s3|173-176|hour|drug
DDI-DrugBank.d632.s3|178-182|prior|drug
DDI-DrugBank.d632.s3|184-185|to|drug
DDI-DrugBank.d632.s3|187-188|or|drug
DDI-DrugBank.d632.s3|190-190|2|drug
DDI-DrugBank.d632.s3|192-196|hours|drug
DDI-DrugBank.d632.s3|198-202|after|drug
DDI-DrugBank.d632.s3|204-209|SYMLIN|drug
DDI-DrugBank.d632.s3|211-219|injection|drug
DDI-DrugBank.d632.s3|220-220|.|drug
DDI-DrugBank.d632.s4|0-1|In|drug
DDI-DrugBank.d632.s4|3-10|clinical|drug
DDI-DrugBank.d632.s4|12-17|trials|drug
DDI-DrugBank.d632.s4|18-18|,|drug
DDI-DrugBank.d632.s4|20-22|the|drug
DDI-DrugBank.d632.s4|24-34|concomitant|drug
DDI-DrugBank.d632.s4|36-38|use|drug
DDI-DrugBank.d632.s4|40-41|of|drug
DDI-DrugBank.d632.s4|43-55|sulfonylureas|drug
DDI-DrugBank.d632.s4|57-58|or|drug
DDI-DrugBank.d632.s4|60-69|biguanides|drug
DDI-DrugBank.d632.s4|71-73|did|drug
DDI-DrugBank.d632.s4|75-77|not|drug
DDI-DrugBank.d632.s4|79-83|alter|drug
DDI-DrugBank.d632.s4|85-87|the|drug
DDI-DrugBank.d632.s4|89-95|adverse|drug
DDI-DrugBank.d632.s4|97-101|event|drug
DDI-DrugBank.d632.s4|103-109|profile|drug
DDI-DrugBank.d632.s4|111-112|of|drug
DDI-DrugBank.d632.s4|114-119|SYMLIN|drug
DDI-DrugBank.d632.s4|120-120|.|drug
DDI-DrugBank.d632.s5|0-1|No|drug
DDI-DrugBank.d632.s5|3-8|formal|drug
DDI-DrugBank.d632.s5|10-20|interaction|drug
DDI-DrugBank.d632.s5|22-28|studies|drug
DDI-DrugBank.d632.s5|30-33|have|drug
DDI-DrugBank.d632.s5|35-38|been|drug
DDI-DrugBank.d632.s5|40-48|performed|drug
DDI-DrugBank.d632.s5|50-51|to|drug
DDI-DrugBank.d632.s5|53-58|assess|drug
DDI-DrugBank.d632.s5|60-62|the|drug
DDI-DrugBank.d632.s5|64-69|effect|drug
DDI-DrugBank.d632.s5|71-72|of|drug
DDI-DrugBank.d632.s5|74-79|SYMLIN|drug
DDI-DrugBank.d632.s5|81-82|on|drug
DDI-DrugBank.d632.s5|84-86|the|drug
DDI-DrugBank.d632.s5|88-95|kinetics|drug
DDI-DrugBank.d632.s5|97-98|of|drug
DDI-DrugBank.d632.s5|100-103|oral|drug
DDI-DrugBank.d632.s5|105-116|antidiabetic|drug
DDI-DrugBank.d632.s5|118-123|agents|drug
DDI-DrugBank.d632.s5|124-124|.|drug
DDI-DrugBank.d632.s6|0-5|Mixing|drug
DDI-DrugBank.d632.s6|7-12|SYMLIN|drug
DDI-DrugBank.d632.s6|14-16|and|drug
DDI-DrugBank.d632.s6|18-24|Insulin|drug
DDI-DrugBank.d632.s6|26-28|The|drug
DDI-DrugBank.d632.s6|30-44|pharmacokinetic|drug
DDI-DrugBank.d632.s6|46-55|parameters|drug
DDI-DrugBank.d632.s6|57-58|of|drug
DDI-DrugBank.d632.s6|60-65|SYMLIN|drug
DDI-DrugBank.d632.s6|67-70|were|drug
DDI-DrugBank.d632.s6|72-78|altered|drug
DDI-DrugBank.d632.s6|80-83|when|drug
DDI-DrugBank.d632.s6|85-89|mixed|drug
DDI-DrugBank.d632.s6|91-94|with|drug
DDI-DrugBank.d632.s6|96-102|regular|drug
DDI-DrugBank.d632.s6|103-103|,|drug
DDI-DrugBank.d632.s6|105-107|NPH|drug
DDI-DrugBank.d632.s6|108-108|,|drug
DDI-DrugBank.d632.s6|110-112|and|drug
DDI-DrugBank.d632.s6|114-118|70/30|drug
DDI-DrugBank.d632.s6|120-127|premixed|drug
DDI-DrugBank.d632.s6|129-140|formulations|drug
DDI-DrugBank.d632.s6|142-143|of|drug
DDI-DrugBank.d632.s6|145-155|recombinant|drug
DDI-DrugBank.d632.s6|157-161|human|drug
DDI-DrugBank.d632.s6|163-169|insulin|drug
DDI-DrugBank.d632.s6|171-181|immediately|drug
DDI-DrugBank.d632.s6|183-187|prior|drug
DDI-DrugBank.d632.s6|189-190|to|drug
DDI-DrugBank.d632.s6|192-200|injection|drug
DDI-DrugBank.d632.s6|201-201|.|drug
DDI-DrugBank.d632.s7|0-3|Thus|drug
DDI-DrugBank.d632.s7|4-4|,|drug
DDI-DrugBank.d632.s7|6-11|SYMLIN|drug
DDI-DrugBank.d632.s7|13-15|and|drug
DDI-DrugBank.d632.s7|17-23|insulin|drug
DDI-DrugBank.d632.s7|25-30|should|drug
DDI-DrugBank.d632.s7|32-34|not|drug
DDI-DrugBank.d632.s7|36-37|be|drug
DDI-DrugBank.d632.s7|39-43|mixed|drug
DDI-DrugBank.d632.s7|45-47|and|drug
DDI-DrugBank.d632.s7|49-52|must|drug
DDI-DrugBank.d632.s7|54-55|be|drug
DDI-DrugBank.d632.s7|57-68|administered|drug
DDI-DrugBank.d632.s7|70-79|separately|drug
DDI-DrugBank.d632.s7|80-80|.|drug
DDI-DrugBank.d81.s0|0-12|Nitroglycerin|brand
DDI-DrugBank.d81.s0|13-13|:|drug
DDI-DrugBank.d81.s0|15-22|DynaCirc|brand
DDI-DrugBank.d81.s0|25-25|(|drug
DDI-DrugBank.d81.s0|26-35|isradipine|drug
DDI-DrugBank.d81.s0|36-36|)|drug
DDI-DrugBank.d81.s0|38-40|has|drug
DDI-DrugBank.d81.s0|42-45|been|drug
DDI-DrugBank.d81.s0|47-52|safely|drug
DDI-DrugBank.d81.s0|54-67|coadministered|drug
DDI-DrugBank.d81.s0|69-72|with|drug
DDI-DrugBank.d81.s0|74-86|nitroglycerin|drug
DDI-DrugBank.d81.s0|87-87|.|drug
DDI-DrugBank.d81.s1|0-18|Hydrochlorothiazide|brand
DDI-DrugBank.d81.s1|19-19|:|drug
DDI-DrugBank.d81.s1|21-21|A|drug
DDI-DrugBank.d81.s1|23-27|study|drug
DDI-DrugBank.d81.s1|29-30|in|drug
DDI-DrugBank.d81.s1|32-37|normal|drug
DDI-DrugBank.d81.s1|39-45|healthy|drug
DDI-DrugBank.d81.s1|47-56|volunteers|drug
DDI-DrugBank.d81.s1|58-60|has|drug
DDI-DrugBank.d81.s1|62-66|shown|drug
DDI-DrugBank.d81.s1|68-71|that|drug
DDI-DrugBank.d81.s1|73-83|concomitant|drug
DDI-DrugBank.d81.s1|85-98|administration|drug
DDI-DrugBank.d81.s1|100-101|of|drug
DDI-DrugBank.d81.s1|103-110|DynaCirc|brand
DDI-DrugBank.d81.s1|113-113|(|drug
DDI-DrugBank.d81.s1|114-123|isradipine|drug
DDI-DrugBank.d81.s1|124-124|)|drug
DDI-DrugBank.d81.s1|126-128|and|drug
DDI-DrugBank.d81.s1|130-148|hydrochlorothiazide|drug
DDI-DrugBank.d81.s1|150-153|does|drug
DDI-DrugBank.d81.s1|155-157|not|drug
DDI-DrugBank.d81.s1|159-164|result|drug
DDI-DrugBank.d81.s1|166-167|in|drug
DDI-DrugBank.d81.s1|169-175|altered|drug
DDI-DrugBank.d81.s1|177-192|pharmacoktnetics|drug
DDI-DrugBank.d81.s1|194-195|of|drug
DDI-DrugBank.d81.s1|197-202|either|drug
DDI-DrugBank.d81.s1|204-207|drug|drug
DDI-DrugBank.d81.s1|208-208|.|drug
DDI-DrugBank.d81.s2|0-1|In|drug
DDI-DrugBank.d81.s2|3-3|a|drug
DDI-DrugBank.d81.s2|5-9|study|drug
DDI-DrugBank.d81.s2|11-12|in|drug
DDI-DrugBank.d81.s2|14-25|hypertensive|drug
DDI-DrugBank.d81.s2|27-34|patients|drug
DDI-DrugBank.d81.s2|35-35|,|drug
DDI-DrugBank.d81.s2|37-44|addition|drug
DDI-DrugBank.d81.s2|46-47|of|drug
DDI-DrugBank.d81.s2|49-58|isradipine|drug
DDI-DrugBank.d81.s2|60-61|to|drug
DDI-DrugBank.d81.s2|63-70|existing|drug
DDI-DrugBank.d81.s2|72-90|hydrochlorothiazide|drug
DDI-DrugBank.d81.s2|92-98|therapy|drug
DDI-DrugBank.d81.s2|100-102|did|drug
DDI-DrugBank.d81.s2|104-106|not|drug
DDI-DrugBank.d81.s2|108-113|result|drug
DDI-DrugBank.d81.s2|115-116|in|drug
DDI-DrugBank.d81.s2|118-120|any|drug
DDI-DrugBank.d81.s2|122-131|unexpected|drug
DDI-DrugBank.d81.s2|133-139|adverse|drug
DDI-DrugBank.d81.s2|141-147|effects|drug
DDI-DrugBank.d81.s2|148-148|,|drug
DDI-DrugBank.d81.s2|150-152|and|drug
DDI-DrugBank.d81.s2|154-163|isradipine|drug
DDI-DrugBank.d81.s2|165-167|had|drug
DDI-DrugBank.d81.s2|169-170|an|drug
DDI-DrugBank.d81.s2|172-181|additional|drug
DDI-DrugBank.d81.s2|183-198|antihypertensive|drug
DDI-DrugBank.d81.s2|200-205|effect|drug
DDI-DrugBank.d81.s2|206-206|.|drug
DDI-DrugBank.d81.s3|0-10|Propranolol|brand
DDI-DrugBank.d81.s3|11-11|:|drug
DDI-DrugBank.d81.s3|13-14|In|drug
DDI-DrugBank.d81.s3|16-16|a|drug
DDI-DrugBank.d81.s3|18-23|single|drug
DDI-DrugBank.d81.s3|25-28|dose|drug
DDI-DrugBank.d81.s3|30-34|study|drug
DDI-DrugBank.d81.s3|36-37|in|drug
DDI-DrugBank.d81.s3|39-44|normal|drug
DDI-DrugBank.d81.s3|46-55|volunteers|drug
DDI-DrugBank.d81.s3|56-56|,|drug
DDI-DrugBank.d81.s3|58-73|coadministration|drug
DDI-DrugBank.d81.s3|75-76|of|drug
DDI-DrugBank.d81.s3|78-88|propranolol|drug
DDI-DrugBank.d81.s3|90-92|had|drug
DDI-DrugBank.d81.s3|94-94|a|drug
DDI-DrugBank.d81.s3|96-100|small|drug
DDI-DrugBank.d81.s3|102-107|effect|drug
DDI-DrugBank.d81.s3|109-110|on|drug
DDI-DrugBank.d81.s3|112-114|the|drug
DDI-DrugBank.d81.s3|116-119|rate|drug
DDI-DrugBank.d81.s3|121-123|but|drug
DDI-DrugBank.d81.s3|125-126|no|drug
DDI-DrugBank.d81.s3|128-133|effect|drug
DDI-DrugBank.d81.s3|135-136|on|drug
DDI-DrugBank.d81.s3|138-140|the|drug
DDI-DrugBank.d81.s3|142-147|extent|drug
DDI-DrugBank.d81.s3|149-150|of|drug
DDI-DrugBank.d81.s3|152-161|isradipine|drug
DDI-DrugBank.d81.s3|163-177|bioavailability|drug
DDI-DrugBank.d81.s3|178-178|.|drug
DDI-DrugBank.d81.s4|0-10|Significant|drug
DDI-DrugBank.d81.s4|12-20|increases|drug
DDI-DrugBank.d81.s4|22-23|In|drug
DDI-DrugBank.d81.s4|25-27|AUC|drug
DDI-DrugBank.d81.s4|29-29|(|drug
DDI-DrugBank.d81.s4|30-31|27|drug
DDI-DrugBank.d81.s4|32-32|%|drug
DDI-DrugBank.d81.s4|33-33|)|drug
DDI-DrugBank.d81.s4|35-37|and|drug
DDI-DrugBank.d81.s4|39-42|Cmax|drug
DDI-DrugBank.d81.s4|44-44|(|drug
DDI-DrugBank.d81.s4|45-46|58|drug
DDI-DrugBank.d81.s4|47-47|%|drug
DDI-DrugBank.d81.s4|48-48|)|drug
DDI-DrugBank.d81.s4|50-52|and|drug
DDI-DrugBank.d81.s4|54-62|decreases|drug
DDI-DrugBank.d81.s4|64-65|in|drug
DDI-DrugBank.d81.s4|67-70|tmax|drug
DDI-DrugBank.d81.s4|72-72|(|drug
DDI-DrugBank.d81.s4|73-74|23|drug
DDI-DrugBank.d81.s4|75-75|%|drug
DDI-DrugBank.d81.s4|76-76|)|drug
DDI-DrugBank.d81.s4|78-79|of|drug
DDI-DrugBank.d81.s4|81-91|propranolol|drug
DDI-DrugBank.d81.s4|93-96|were|drug
DDI-DrugBank.d81.s4|98-102|noted|drug
DDI-DrugBank.d81.s4|104-105|in|drug
DDI-DrugBank.d81.s4|107-110|this|drug
DDI-DrugBank.d81.s4|112-116|study|drug
DDI-DrugBank.d81.s4|117-117|.|drug
DDI-DrugBank.d81.s5|0-6|However|drug
DDI-DrugBank.d81.s5|7-7|,|drug
DDI-DrugBank.d81.s5|9-19|concomitant|drug
DDI-DrugBank.d81.s5|21-34|administration|drug
DDI-DrugBank.d81.s5|36-37|of|drug
DDI-DrugBank.d81.s5|39-39|5|drug
DDI-DrugBank.d81.s5|41-42|mg|drug
DDI-DrugBank.d81.s5|44-49|b.i.d|drug
DDI-DrugBank.d81.s5|51-60|.|drug
DDI-DrugBank.d81.s5|62-64|isradipine|drug
DDI-DrugBank.d81.s5|66-67|and|drug
DDI-DrugBank.d81.s5|69-70|40|drug
DDI-DrugBank.d81.s5|72-76|mg|drug
DDI-DrugBank.d81.s5|77-77|b.i.d|drug
DDI-DrugBank.d81.s6|0-10|propranolol|drug
DDI-DrugBank.d81.s6|12-13|to|drug
DDI-DrugBank.d81.s6|15-21|healthy|drug
DDI-DrugBank.d81.s6|23-32|volunteers|drug
DDI-DrugBank.d81.s6|34-38|under|drug
DDI-DrugBank.d81.s6|40-51|steady-state|drug
DDI-DrugBank.d81.s6|53-62|conditions|drug
DDI-DrugBank.d81.s6|64-66|had|drug
DDI-DrugBank.d81.s6|68-69|no|drug
DDI-DrugBank.d81.s6|71-78|relevant|drug
DDI-DrugBank.d81.s6|80-85|effect|drug
DDI-DrugBank.d81.s6|87-88|on|drug
DDI-DrugBank.d81.s6|90-95|either|drug
DDI-DrugBank.d81.s6|97-100|drug|drug
DDI-DrugBank.d81.s6|102-102|s|drug
DDI-DrugBank.d81.s6|104-118|bioavailability|drug
DDI-DrugBank.d81.s6|119-119|,|drug
DDI-DrugBank.d81.s6|121-123|AUC|drug
DDI-DrugBank.d81.s6|125-127|and|drug
DDI-DrugBank.d81.s6|129-132|Cmax|drug
DDI-DrugBank.d81.s6|133-133|,|drug
DDI-DrugBank.d81.s6|135-145|differences|drug
DDI-DrugBank.d81.s6|147-150|were|drug
DDI-DrugBank.d81.s6|153-154|20|drug
DDI-DrugBank.d81.s6|155-155|%|drug
DDI-DrugBank.d81.s6|157-163|between|drug
DDI-DrugBank.d81.s6|165-174|isradipine|drug
DDI-DrugBank.d81.s6|176-180|given|drug
DDI-DrugBank.d81.s6|182-187|singly|drug
DDI-DrugBank.d81.s6|189-191|and|drug
DDI-DrugBank.d81.s6|193-194|in|drug
DDI-DrugBank.d81.s6|196-206|combination|drug
DDI-DrugBank.d81.s6|208-211|with|drug
DDI-DrugBank.d81.s6|213-223|propranolol|drug
DDI-DrugBank.d81.s6|224-224|,|drug
DDI-DrugBank.d81.s6|226-228|and|drug
DDI-DrugBank.d81.s6|230-236|between|drug
DDI-DrugBank.d81.s6|238-248|propranolol|drug
DDI-DrugBank.d81.s6|250-254|given|drug
DDI-DrugBank.d81.s6|256-261|singly|drug
DDI-DrugBank.d81.s6|263-265|and|drug
DDI-DrugBank.d81.s6|267-268|in|drug
DDI-DrugBank.d81.s6|270-280|combination|drug
DDI-DrugBank.d81.s6|282-285|with|drug
DDI-DrugBank.d81.s6|287-296|isradipine|drug
DDI-DrugBank.d81.s6|297-297|.|drug
DDI-DrugBank.d81.s7|0-9|Cimetidine|brand
DDI-DrugBank.d81.s7|10-10|:|drug
DDI-DrugBank.d81.s7|12-13|In|drug
DDI-DrugBank.d81.s7|15-15|a|drug
DDI-DrugBank.d81.s7|17-21|study|drug
DDI-DrugBank.d81.s7|23-24|in|drug
DDI-DrugBank.d81.s7|26-32|healthy|drug
DDI-DrugBank.d81.s7|34-43|volunteers|drug
DDI-DrugBank.d81.s7|44-44|,|drug
DDI-DrugBank.d81.s7|46-46|a|drug
DDI-DrugBank.d81.s7|48-55|one-week|drug
DDI-DrugBank.d81.s7|57-62|course|drug
DDI-DrugBank.d81.s7|64-65|of|drug
DDI-DrugBank.d81.s7|67-76|cimetidine|drug
DDI-DrugBank.d81.s7|78-79|at|drug
DDI-DrugBank.d81.s7|81-83|400|drug
DDI-DrugBank.d81.s7|85-86|mg|drug
DDI-DrugBank.d81.s7|88-93|b.i.d|drug
DDI-DrugBank.d81.s7|95-98|.|drug
DDI-DrugBank.d81.s7|100-100|with|drug
DDI-DrugBank.d81.s7|102-107|a|drug
DDI-DrugBank.d81.s7|109-109|single|drug
DDI-DrugBank.d81.s7|111-112|5|drug
DDI-DrugBank.d81.s7|114-117|mg|drug
DDI-DrugBank.d81.s7|119-120|dose|drug
DDI-DrugBank.d81.s7|122-131|of|drug
DDI-DrugBank.d81.s7|133-134|isradipine|drug
DDI-DrugBank.d81.s7|136-138|on|drug
DDI-DrugBank.d81.s7|140-144|the|drug
DDI-DrugBank.d81.s7|146-148|sixth|drug
DDI-DrugBank.d81.s7|150-155|day|drug
DDI-DrugBank.d81.s7|157-158|showed|drug
DDI-DrugBank.d81.s7|160-167|an|drug
DDI-DrugBank.d81.s7|169-170|increase|drug
DDI-DrugBank.d81.s7|172-181|in|drug
DDI-DrugBank.d81.s7|183-186|isradipine|drug
DDI-DrugBank.d81.s7|188-191|mean|drug
DDI-DrugBank.d81.s7|193-198|peak|drug
DDI-DrugBank.d81.s7|200-213|plasma|drug
DDI-DrugBank.d81.s7|215-215|concentrations|drug
DDI-DrugBank.d81.s7|216-217|(|drug
DDI-DrugBank.d81.s7|218-218|36|drug
DDI-DrugBank.d81.s7|219-219|%|drug
DDI-DrugBank.d81.s7|221-223|)|drug
DDI-DrugBank.d81.s7|225-235|and|drug
DDI-DrugBank.d81.s7|237-244|significant|drug
DDI-DrugBank.d81.s7|246-247|increase|drug
DDI-DrugBank.d81.s7|249-252|in|drug
DDI-DrugBank.d81.s7|254-258|area|drug
DDI-DrugBank.d81.s7|260-262|under|drug
DDI-DrugBank.d81.s7|264-268|the|drug
DDI-DrugBank.d81.s7|270-270|curve|drug
DDI-DrugBank.d81.s7|271-272|(|drug
DDI-DrugBank.d81.s7|273-273|50|drug
DDI-DrugBank.d81.s7|274-274|%|drug
DDI-DrugBank.d81.s7|275-275|)|drug
DDI-DrugBank.d81.s8|0-1|If|drug
DDI-DrugBank.d81.s8|3-12|isradipine|drug
DDI-DrugBank.d81.s8|14-20|therapy|drug
DDI-DrugBank.d81.s8|22-23|is|drug
DDI-DrugBank.d81.s8|25-33|initiated|drug
DDI-DrugBank.d81.s8|35-36|in|drug
DDI-DrugBank.d81.s8|38-38|a|drug
DDI-DrugBank.d81.s8|40-46|patient|drug
DDI-DrugBank.d81.s8|48-56|currently|drug
DDI-DrugBank.d81.s8|58-66|receiving|drug
DDI-DrugBank.d81.s8|68-77|cimetidine|drug
DDI-DrugBank.d81.s8|79-85|careful|drug
DDI-DrugBank.d81.s8|87-96|monitoring|drug
DDI-DrugBank.d81.s8|98-100|for|drug
DDI-DrugBank.d81.s8|102-108|adverse|drug
DDI-DrugBank.d81.s8|110-118|reactions|drug
DDI-DrugBank.d81.s8|120-121|is|drug
DDI-DrugBank.d81.s8|123-129|advised|drug
DDI-DrugBank.d81.s8|131-133|and|drug
DDI-DrugBank.d81.s8|135-142|downward|drug
DDI-DrugBank.d81.s8|144-147|dose|drug
DDI-DrugBank.d81.s8|149-158|adjustment|drug
DDI-DrugBank.d81.s8|160-162|may|drug
DDI-DrugBank.d81.s8|164-165|be|drug
DDI-DrugBank.d81.s8|167-174|required|drug
DDI-DrugBank.d81.s8|175-175|.|drug
DDI-DrugBank.d81.s9|0-9|Rifampicin|drug
DDI-DrugBank.d81.s9|10-10|:|drug
DDI-DrugBank.d81.s9|12-13|In|drug
DDI-DrugBank.d81.s9|15-15|a|drug
DDI-DrugBank.d81.s9|17-21|study|drug
DDI-DrugBank.d81.s9|23-24|in|drug
DDI-DrugBank.d81.s9|26-32|healthy|drug
DDI-DrugBank.d81.s9|34-43|volunteers|drug
DDI-DrugBank.d81.s9|44-44|,|drug
DDI-DrugBank.d81.s9|46-46|a|drug
DDI-DrugBank.d81.s9|48-54|six-day|drug
DDI-DrugBank.d81.s9|56-61|course|drug
DDI-DrugBank.d81.s9|63-64|of|drug
DDI-DrugBank.d81.s9|66-75|rifampicin|drug
DDI-DrugBank.d81.s9|77-78|at|drug
DDI-DrugBank.d81.s9|80-82|600|drug
DDI-DrugBank.d81.s9|84-89|mg/day|drug
DDI-DrugBank.d81.s9|91-98|followed|drug
DDI-DrugBank.d81.s9|100-101|by|drug
DDI-DrugBank.d81.s9|103-103|a|drug
DDI-DrugBank.d81.s9|105-110|single|drug
DDI-DrugBank.d81.s9|112-112|5|drug
DDI-DrugBank.d81.s9|114-115|mg|drug
DDI-DrugBank.d81.s9|117-120|dose|drug
DDI-DrugBank.d81.s9|122-123|of|drug
DDI-DrugBank.d81.s9|125-134|isradipine|drug
DDI-DrugBank.d81.s9|136-143|resulted|drug
DDI-DrugBank.d81.s9|145-146|in|drug
DDI-DrugBank.d81.s9|148-148|a|drug
DDI-DrugBank.d81.s9|150-158|reduction|drug
DDI-DrugBank.d81.s9|160-161|in|drug
DDI-DrugBank.d81.s9|163-172|isradipine|drug
DDI-DrugBank.d81.s9|174-179|levels|drug
DDI-DrugBank.d81.s9|181-182|to|drug
DDI-DrugBank.d81.s9|184-188|below|drug
DDI-DrugBank.d81.s9|190-199|detectable|drug
DDI-DrugBank.d81.s9|201-206|limits|drug
DDI-DrugBank.d81.s9|207-207|.|drug
DDI-DrugBank.d81.s10|0-1|If|drug
DDI-DrugBank.d81.s10|3-12|rifampicin|drug
DDI-DrugBank.d81.s10|14-20|therapy|drug
DDI-DrugBank.d81.s10|22-23|is|drug
DDI-DrugBank.d81.s10|25-32|required|drug
DDI-DrugBank.d81.s10|33-33|,|drug
DDI-DrugBank.d81.s10|35-44|isradipine|drug
DDI-DrugBank.d81.s10|46-59|concentrations|drug
DDI-DrugBank.d81.s10|61-63|and|drug
DDI-DrugBank.d81.s10|65-75|therapeutic|drug
DDI-DrugBank.d81.s10|77-83|effects|drug
DDI-DrugBank.d81.s10|85-87|are|drug
DDI-DrugBank.d81.s10|89-94|likely|drug
DDI-DrugBank.d81.s10|96-97|to|drug
DDI-DrugBank.d81.s10|99-100|be|drug
DDI-DrugBank.d81.s10|102-109|markedly|drug
DDI-DrugBank.d81.s10|111-117|reduced|drug
DDI-DrugBank.d81.s10|119-120|or|drug
DDI-DrugBank.d81.s10|122-130|abolished|drug
DDI-DrugBank.d81.s10|132-133|as|drug
DDI-DrugBank.d81.s10|135-135|a|drug
DDI-DrugBank.d81.s10|137-147|consequence|drug
DDI-DrugBank.d81.s10|149-150|of|drug
DDI-DrugBank.d81.s10|152-160|increased|drug
DDI-DrugBank.d81.s10|162-171|metabolism|drug
DDI-DrugBank.d81.s10|173-175|and|drug
DDI-DrugBank.d81.s10|177-182|higher|drug
DDI-DrugBank.d81.s10|184-192|clearance|drug
DDI-DrugBank.d81.s10|194-195|of|drug
DDI-DrugBank.d81.s10|197-206|isradipine|drug
DDI-DrugBank.d81.s10|207-207|.|drug
DDI-DrugBank.d81.s11|0-7|Warfarin|brand
DDI-DrugBank.d81.s11|8-8|:|drug
DDI-DrugBank.d81.s11|10-11|In|drug
DDI-DrugBank.d81.s11|13-13|a|drug
DDI-DrugBank.d81.s11|15-19|study|drug
DDI-DrugBank.d81.s11|21-22|in|drug
DDI-DrugBank.d81.s11|24-30|healthy|drug
DDI-DrugBank.d81.s11|32-41|volunteers|drug
DDI-DrugBank.d81.s11|42-42|,|drug
DDI-DrugBank.d81.s11|44-45|no|drug
DDI-DrugBank.d81.s11|47-56|clinically|drug
DDI-DrugBank.d81.s11|58-65|relevant|drug
DDI-DrugBank.d81.s11|67-81|pharmacokinetic|drug
DDI-DrugBank.d81.s11|83-84|or|drug
DDI-DrugBank.d81.s11|86-100|pharmacodynamic|drug
DDI-DrugBank.d81.s11|102-112|interaction|drug
DDI-DrugBank.d81.s11|114-120|between|drug
DDI-DrugBank.d81.s11|122-131|isradipine|drug
DDI-DrugBank.d81.s11|133-135|and|drug
DDI-DrugBank.d81.s11|137-143|racemic|drug
DDI-DrugBank.d81.s11|145-152|warfarin|drug
DDI-DrugBank.d81.s11|154-156|was|drug
DDI-DrugBank.d81.s11|158-161|seen|drug
DDI-DrugBank.d81.s11|163-166|when|drug
DDI-DrugBank.d81.s11|168-170|two|drug
DDI-DrugBank.d81.s11|172-177|single|drug
DDI-DrugBank.d81.s11|179-182|oral|drug
DDI-DrugBank.d81.s11|184-188|doses|drug
DDI-DrugBank.d81.s11|190-191|of|drug
DDI-DrugBank.d81.s11|193-200|warfarin|drug
DDI-DrugBank.d81.s11|202-202|(|drug
DDI-DrugBank.d81.s11|203-205|0.7|drug
DDI-DrugBank.d81.s11|207-211|mg/kg|drug
DDI-DrugBank.d81.s11|213-216|body|drug
DDI-DrugBank.d81.s11|218-223|weight|drug
DDI-DrugBank.d81.s11|224-224|)|drug
DDI-DrugBank.d81.s11|226-229|were|drug
DDI-DrugBank.d81.s11|231-242|administered|drug
DDI-DrugBank.d81.s11|244-249|during|drug
DDI-DrugBank.d81.s11|251-252|11|drug
DDI-DrugBank.d81.s11|254-257|days|drug
DDI-DrugBank.d81.s11|259-260|of|drug
DDI-DrugBank.d81.s11|262-273|multipledose|drug
DDI-DrugBank.d81.s11|275-283|treatment|drug
DDI-DrugBank.d81.s11|285-288|with|drug
DDI-DrugBank.d81.s11|290-290|5|drug
DDI-DrugBank.d81.s11|292-293|mg|drug
DDI-DrugBank.d81.s11|295-300|b.i.d|drug
DDI-DrugBank.d81.s11|302-311|.|drug
DDI-DrugBank.d81.s11|312-312|isradipine|drug
DDI-DrugBank.d81.s12|0-6|Neither|drug
DDI-DrugBank.d81.s12|8-14|racemic|drug
DDI-DrugBank.d81.s12|16-23|warfarin|drug
DDI-DrugBank.d81.s12|25-27|nor|drug
DDI-DrugBank.d81.s12|29-38|isradipine|drug
DDI-DrugBank.d81.s12|40-46|binding|drug
DDI-DrugBank.d81.s12|48-49|to|drug
DDI-DrugBank.d81.s12|51-56|plasma|drug
DDI-DrugBank.d81.s12|58-65|proteins|drug
DDI-DrugBank.d81.s12|67-68|in|drug
DDI-DrugBank.d81.s12|70-74|vitro|drug
DDI-DrugBank.d81.s12|76-78|was|drug
DDI-DrugBank.d81.s12|80-86|altered|drug
DDI-DrugBank.d81.s12|88-89|by|drug
DDI-DrugBank.d81.s12|91-93|the|drug
DDI-DrugBank.d81.s12|95-102|addition|drug
DDI-DrugBank.d81.s12|104-105|of|drug
DDI-DrugBank.d81.s12|107-109|the|drug
DDI-DrugBank.d81.s12|111-115|other|drug
DDI-DrugBank.d81.s12|117-120|drug|drug
DDI-DrugBank.d81.s12|121-121|.|drug
DDI-DrugBank.d81.s13|0-6|Digoxin|brand
DDI-DrugBank.d81.s13|7-7|:|drug
DDI-DrugBank.d81.s13|9-11|The|drug
DDI-DrugBank.d81.s13|13-23|concomitant|drug
DDI-DrugBank.d81.s13|25-38|administration|drug
DDI-DrugBank.d81.s13|40-41|of|drug
DDI-DrugBank.d81.s13|43-50|DynaCirc|brand
DDI-DrugBank.d81.s13|53-53|(|drug
DDI-DrugBank.d81.s13|54-63|isradipine|drug
DDI-DrugBank.d81.s13|64-64|)|drug
DDI-DrugBank.d81.s13|66-68|and|drug
DDI-DrugBank.d81.s13|70-76|digoxin|drug
DDI-DrugBank.d81.s13|78-79|in|drug
DDI-DrugBank.d81.s13|81-81|a|drug
DDI-DrugBank.d81.s13|83-93|single-dose|drug
DDI-DrugBank.d81.s13|95-109|pharmacokinetic|drug
DDI-DrugBank.d81.s13|111-115|study|drug
DDI-DrugBank.d81.s13|117-119|did|drug
DDI-DrugBank.d81.s13|121-123|not|drug
DDI-DrugBank.d81.s13|125-130|affect|drug
DDI-DrugBank.d81.s13|132-136|renal|drug
DDI-DrugBank.d81.s13|137-137|,|drug
DDI-DrugBank.d81.s13|139-146|nonrenal|drug
DDI-DrugBank.d81.s13|148-150|and|drug
DDI-DrugBank.d81.s13|152-156|total|drug
DDI-DrugBank.d81.s13|158-161|body|drug
DDI-DrugBank.d81.s13|163-171|clearance|drug
DDI-DrugBank.d81.s13|173-174|of|drug
DDI-DrugBank.d81.s13|176-182|digoxin|drug
DDI-DrugBank.d81.s13|183-183|.|drug
DDI-DrugBank.d81.s14|0-7|Fentanyl|brand
DDI-DrugBank.d81.s14|9-18|Anesthesia|drug
DDI-DrugBank.d81.s14|19-19|:|drug
DDI-DrugBank.d81.s14|21-26|Severe|drug
DDI-DrugBank.d81.s14|28-38|hypotension|drug
DDI-DrugBank.d81.s14|40-42|has|drug
DDI-DrugBank.d81.s14|44-47|been|drug
DDI-DrugBank.d81.s14|49-56|reported|drug
DDI-DrugBank.d81.s14|58-63|during|drug
DDI-DrugBank.d81.s14|65-72|fentanyl|drug
DDI-DrugBank.d81.s14|74-83|anesthesia|drug
DDI-DrugBank.d81.s14|85-88|with|drug
DDI-DrugBank.d81.s14|90-100|concomitant|drug
DDI-DrugBank.d81.s14|102-104|use|drug
DDI-DrugBank.d81.s14|106-107|of|drug
DDI-DrugBank.d81.s14|109-109|a|drug
DDI-DrugBank.d81.s14|111-114|beta|drug
DDI-DrugBank.d81.s14|116-122|blocker|drug
DDI-DrugBank.d81.s14|124-126|and|drug
DDI-DrugBank.d81.s14|128-128|a|drug
DDI-DrugBank.d81.s14|130-136|calcium|drug
DDI-DrugBank.d81.s14|138-144|channel|drug
DDI-DrugBank.d81.s14|146-152|blocker|drug
DDI-DrugBank.d81.s14|153-153|.|drug
DDI-DrugBank.d81.s15|0-3|Even|drug
DDI-DrugBank.d81.s15|5-10|though|drug
DDI-DrugBank.d81.s15|12-15|such|drug
DDI-DrugBank.d81.s15|17-28|interactions|drug
DDI-DrugBank.d81.s15|30-33|have|drug
DDI-DrugBank.d81.s15|35-37|not|drug
DDI-DrugBank.d81.s15|39-42|been|drug
DDI-DrugBank.d81.s15|44-47|seen|drug
DDI-DrugBank.d81.s15|49-50|in|drug
DDI-DrugBank.d81.s15|52-59|clinical|drug
DDI-DrugBank.d81.s15|61-67|studies|drug
DDI-DrugBank.d81.s15|69-72|with|drug
DDI-DrugBank.d81.s15|74-81|DynaCirc|brand
DDI-DrugBank.d81.s15|84-84|(|drug
DDI-DrugBank.d81.s15|85-94|isradipine|drug
DDI-DrugBank.d81.s15|95-95|)|drug
DDI-DrugBank.d81.s15|96-96|,|drug
DDI-DrugBank.d81.s15|98-99|an|drug
DDI-DrugBank.d81.s15|101-109|increased|drug
DDI-DrugBank.d81.s15|111-116|volume|drug
DDI-DrugBank.d81.s15|118-119|of|drug
DDI-DrugBank.d81.s15|121-131|circulating|drug
DDI-DrugBank.d81.s15|133-138|fluids|drug
DDI-DrugBank.d81.s15|140-144|might|drug
DDI-DrugBank.d81.s15|146-147|be|drug
DDI-DrugBank.d81.s15|149-156|required|drug
DDI-DrugBank.d81.s15|158-159|if|drug
DDI-DrugBank.d81.s15|161-164|such|drug
DDI-DrugBank.d81.s15|166-167|an|drug
DDI-DrugBank.d81.s15|169-179|interaction|drug
DDI-DrugBank.d81.s15|181-184|were|drug
DDI-DrugBank.d81.s15|186-187|to|drug
DDI-DrugBank.d81.s15|189-193|occur|drug
DDI-DrugBank.d81.s15|194-194|.|drug
DDI-DrugBank.d245.s0|0-2|The|drug
DDI-DrugBank.d245.s0|4-15|hypoglycemic|drug
DDI-DrugBank.d245.s0|17-22|action|drug
DDI-DrugBank.d245.s0|24-25|of|drug
DDI-DrugBank.d245.s0|27-38|sulfonylurea|drug
DDI-DrugBank.d245.s0|40-42|may|drug
DDI-DrugBank.d245.s0|44-45|be|drug
DDI-DrugBank.d245.s0|47-57|potentiated|drug
DDI-DrugBank.d245.s0|59-60|by|drug
DDI-DrugBank.d245.s0|62-68|certain|drug
DDI-DrugBank.d245.s0|70-74|drugs|drug
DDI-DrugBank.d245.s0|76-84|including|drug
DDI-DrugBank.d245.s0|86-97|nonsteroidal|drug
DDI-DrugBank.d245.s0|99-115|anti-inflammatory|drug
DDI-DrugBank.d245.s0|117-122|agents|drug
DDI-DrugBank.d245.s0|124-126|and|drug
DDI-DrugBank.d245.s0|128-132|other|drug
DDI-DrugBank.d245.s0|134-138|drugs|drug
DDI-DrugBank.d245.s0|140-143|that|drug
DDI-DrugBank.d245.s0|145-147|are|drug
DDI-DrugBank.d245.s0|149-154|highly|drug
DDI-DrugBank.d245.s0|156-162|protein|drug
DDI-DrugBank.d245.s0|164-168|bound|drug
DDI-DrugBank.d245.s0|169-169|,|drug
DDI-DrugBank.d245.s0|171-181|salicylates|drug
DDI-DrugBank.d245.s0|182-182|,|drug
DDI-DrugBank.d245.s0|184-195|sulfonamides|drug
DDI-DrugBank.d245.s0|196-196|,|drug
DDI-DrugBank.d245.s0|198-212|chloramphenicol|drug
DDI-DrugBank.d245.s0|213-213|,|drug
DDI-DrugBank.d245.s0|215-224|probenecid|drug
DDI-DrugBank.d245.s0|225-225|,|drug
DDI-DrugBank.d245.s0|227-235|coumarins|drug
DDI-DrugBank.d245.s0|236-236|,|drug
DDI-DrugBank.d245.s0|238-246|monoamine|drug
DDI-DrugBank.d245.s0|248-254|oxidase|drug
DDI-DrugBank.d245.s0|256-265|inhibitors|drug
DDI-DrugBank.d245.s0|266-266|,|drug
DDI-DrugBank.d245.s0|268-270|and|drug
DDI-DrugBank.d245.s0|272-275|beta|drug
DDI-DrugBank.d245.s0|277-286|adrenergic|drug
DDI-DrugBank.d245.s0|288-295|blocking|drug
DDI-DrugBank.d245.s0|297-302|agents|drug
DDI-DrugBank.d245.s0|303-303|.|drug
DDI-DrugBank.d245.s1|0-3|When|drug
DDI-DrugBank.d245.s1|5-8|such|drug
DDI-DrugBank.d245.s1|10-14|drugs|drug
DDI-DrugBank.d245.s1|16-18|are|drug
DDI-DrugBank.d245.s1|20-31|administered|drug
DDI-DrugBank.d245.s1|33-34|to|drug
DDI-DrugBank.d245.s1|36-36|a|drug
DDI-DrugBank.d245.s1|38-44|patient|drug
DDI-DrugBank.d245.s1|46-54|receiving|drug
DDI-DrugBank.d245.s1|56-64|DIABINESE|drug
DDI-DrugBank.d245.s1|65-65|,|drug
DDI-DrugBank.d245.s1|67-69|the|drug
DDI-DrugBank.d245.s1|71-77|patient|drug
DDI-DrugBank.d245.s1|79-84|should|drug
DDI-DrugBank.d245.s1|86-87|be|drug
DDI-DrugBank.d245.s1|89-96|observed|drug
DDI-DrugBank.d245.s1|98-104|closely|drug
DDI-DrugBank.d245.s1|106-108|for|drug
DDI-DrugBank.d245.s1|110-121|hypoglycemia|drug
DDI-DrugBank.d245.s1|122-122|.|drug
DDI-DrugBank.d245.s2|0-3|When|drug
DDI-DrugBank.d245.s2|5-8|such|drug
DDI-DrugBank.d245.s2|10-14|drugs|drug
DDI-DrugBank.d245.s2|16-18|are|drug
DDI-DrugBank.d245.s2|20-28|withdrawn|drug
DDI-DrugBank.d245.s2|30-33|from|drug
DDI-DrugBank.d245.s2|35-35|a|drug
DDI-DrugBank.d245.s2|37-43|patient|drug
DDI-DrugBank.d245.s2|45-53|receiving|drug
DDI-DrugBank.d245.s2|55-63|DIABINESE|drug
DDI-DrugBank.d245.s2|64-64|,|drug
DDI-DrugBank.d245.s2|66-68|the|drug
DDI-DrugBank.d245.s2|70-76|patient|drug
DDI-DrugBank.d245.s2|78-83|should|drug
DDI-DrugBank.d245.s2|85-86|be|drug
DDI-DrugBank.d245.s2|88-95|observed|drug
DDI-DrugBank.d245.s2|97-103|closely|drug
DDI-DrugBank.d245.s2|105-107|for|drug
DDI-DrugBank.d245.s2|109-112|loss|drug
DDI-DrugBank.d245.s2|114-115|of|drug
DDI-DrugBank.d245.s2|117-123|control|drug
DDI-DrugBank.d245.s2|124-124|.|drug
DDI-DrugBank.d245.s3|0-6|Certain|drug
DDI-DrugBank.d245.s3|8-12|drugs|drug
DDI-DrugBank.d245.s3|14-17|tend|drug
DDI-DrugBank.d245.s3|19-20|to|drug
DDI-DrugBank.d245.s3|22-28|produce|drug
DDI-DrugBank.d245.s3|30-42|hyperglycemia|drug
DDI-DrugBank.d245.s3|44-46|and|drug
DDI-DrugBank.d245.s3|48-50|may|drug
DDI-DrugBank.d245.s3|52-55|lead|drug
DDI-DrugBank.d245.s3|57-58|to|drug
DDI-DrugBank.d245.s3|60-63|loss|drug
DDI-DrugBank.d245.s3|65-66|of|drug
DDI-DrugBank.d245.s3|68-74|control|drug
DDI-DrugBank.d245.s3|75-75|.|drug
DDI-DrugBank.d245.s4|0-4|These|drug
DDI-DrugBank.d245.s4|6-10|drugs|drug
DDI-DrugBank.d245.s4|12-18|include|drug
DDI-DrugBank.d245.s4|20-22|the|drug
DDI-DrugBank.d245.s4|24-32|thiazides|drug
DDI-DrugBank.d245.s4|34-36|and|drug
DDI-DrugBank.d245.s4|38-42|other|drug
DDI-DrugBank.d245.s4|44-52|diuretics|drug
DDI-DrugBank.d245.s4|53-53|,|drug
DDI-DrugBank.d245.s4|55-69|corticosteroids|drug
DDI-DrugBank.d245.s4|70-70|,|drug
DDI-DrugBank.d245.s4|72-85|phenothiazines|drug
DDI-DrugBank.d245.s4|86-86|,|drug
DDI-DrugBank.d245.s4|88-94|thyroid|drug
DDI-DrugBank.d245.s4|96-103|products|drug
DDI-DrugBank.d245.s4|104-104|,|drug
DDI-DrugBank.d245.s4|106-114|estrogens|drug
DDI-DrugBank.d245.s4|115-115|,|drug
DDI-DrugBank.d245.s4|117-120|oral|drug
DDI-DrugBank.d245.s4|122-135|contraceptives|drug
DDI-DrugBank.d245.s4|136-136|,|drug
DDI-DrugBank.d245.s4|138-146|phenytoin|drug
DDI-DrugBank.d245.s4|147-147|,|drug
DDI-DrugBank.d245.s4|149-157|nicotinic|drug
DDI-DrugBank.d245.s4|159-162|acid|drug
DDI-DrugBank.d245.s4|163-163|,|drug
DDI-DrugBank.d245.s4|165-180|sympathomimetics|drug
DDI-DrugBank.d245.s4|181-181|,|drug
DDI-DrugBank.d245.s4|183-189|calcium|drug
DDI-DrugBank.d245.s4|191-197|channel|drug
DDI-DrugBank.d245.s4|199-206|blocking|drug
DDI-DrugBank.d245.s4|208-212|drugs|drug
DDI-DrugBank.d245.s4|213-213|,|drug
DDI-DrugBank.d245.s4|215-217|and|drug
DDI-DrugBank.d245.s4|219-227|isoniazid|drug
DDI-DrugBank.d245.s4|228-228|.|drug
DDI-DrugBank.d245.s5|0-3|When|drug
DDI-DrugBank.d245.s5|5-8|such|drug
DDI-DrugBank.d245.s5|10-14|drugs|drug
DDI-DrugBank.d245.s5|16-18|are|drug
DDI-DrugBank.d245.s5|20-31|administered|drug
DDI-DrugBank.d245.s5|33-34|to|drug
DDI-DrugBank.d245.s5|36-36|a|drug
DDI-DrugBank.d245.s5|38-44|patient|drug
DDI-DrugBank.d245.s5|46-54|receiving|drug
DDI-DrugBank.d245.s5|56-64|DIABINESE|drug
DDI-DrugBank.d245.s5|65-65|,|drug
DDI-DrugBank.d245.s5|67-69|the|drug
DDI-DrugBank.d245.s5|71-77|patient|drug
DDI-DrugBank.d245.s5|79-84|should|drug
DDI-DrugBank.d245.s5|86-87|be|drug
DDI-DrugBank.d245.s5|89-95|closely|drug
DDI-DrugBank.d245.s5|97-104|observed|drug
DDI-DrugBank.d245.s5|106-108|for|drug
DDI-DrugBank.d245.s5|110-113|loss|drug
DDI-DrugBank.d245.s5|115-116|of|drug
DDI-DrugBank.d245.s5|118-124|control|drug
DDI-DrugBank.d245.s5|125-125|.|drug
DDI-DrugBank.d245.s6|0-3|When|drug
DDI-DrugBank.d245.s6|5-8|such|drug
DDI-DrugBank.d245.s6|10-14|drugs|drug
DDI-DrugBank.d245.s6|16-18|are|drug
DDI-DrugBank.d245.s6|20-28|withdrawn|drug
DDI-DrugBank.d245.s6|30-33|from|drug
DDI-DrugBank.d245.s6|35-35|a|drug
DDI-DrugBank.d245.s6|37-43|patient|drug
DDI-DrugBank.d245.s6|45-53|receiving|drug
DDI-DrugBank.d245.s6|55-63|DIABINESE|drug
DDI-DrugBank.d245.s6|64-64|,|drug
DDI-DrugBank.d245.s6|66-68|the|drug
DDI-DrugBank.d245.s6|70-76|patient|drug
DDI-DrugBank.d245.s6|78-83|should|drug
DDI-DrugBank.d245.s6|85-86|be|drug
DDI-DrugBank.d245.s6|88-95|observed|drug
DDI-DrugBank.d245.s6|97-103|closely|drug
DDI-DrugBank.d245.s6|105-107|for|drug
DDI-DrugBank.d245.s6|109-120|hypoglycemia|drug
DDI-DrugBank.d245.s6|121-121|.|drug
DDI-DrugBank.d245.s7|0-4|Since|drug
DDI-DrugBank.d245.s7|6-11|animal|drug
DDI-DrugBank.d245.s7|13-19|studies|drug
DDI-DrugBank.d245.s7|21-27|suggest|drug
DDI-DrugBank.d245.s7|29-32|that|drug
DDI-DrugBank.d245.s7|34-36|the|drug
DDI-DrugBank.d245.s7|38-43|action|drug
DDI-DrugBank.d245.s7|45-46|of|drug
DDI-DrugBank.d245.s7|48-59|barbiturates|drug
DDI-DrugBank.d245.s7|61-63|may|drug
DDI-DrugBank.d245.s7|65-66|be|drug
DDI-DrugBank.d245.s7|68-76|prolonged|drug
DDI-DrugBank.d245.s7|78-79|by|drug
DDI-DrugBank.d245.s7|81-87|therapy|drug
DDI-DrugBank.d245.s7|89-92|with|drug
DDI-DrugBank.d245.s7|94-107|chlorpropamide|drug
DDI-DrugBank.d245.s7|108-108|,|drug
DDI-DrugBank.d245.s7|110-121|barbiturates|drug
DDI-DrugBank.d245.s7|123-128|should|drug
DDI-DrugBank.d245.s7|130-131|be|drug
DDI-DrugBank.d245.s7|133-140|employed|drug
DDI-DrugBank.d245.s7|142-145|with|drug
DDI-DrugBank.d245.s7|147-153|caution|drug
DDI-DrugBank.d245.s7|154-154|.|drug
DDI-DrugBank.d245.s8|0-1|In|drug
DDI-DrugBank.d245.s8|3-6|some|drug
DDI-DrugBank.d245.s8|8-15|patients|drug
DDI-DrugBank.d245.s8|16-16|,|drug
DDI-DrugBank.d245.s8|18-18|a|drug
DDI-DrugBank.d245.s8|20-34|disulfiram-like|drug
DDI-DrugBank.d245.s8|36-43|reaction|drug
DDI-DrugBank.d245.s8|45-47|may|drug
DDI-DrugBank.d245.s8|49-50|be|drug
DDI-DrugBank.d245.s8|52-59|produced|drug
DDI-DrugBank.d245.s8|61-62|by|drug
DDI-DrugBank.d245.s8|64-66|the|drug
DDI-DrugBank.d245.s8|68-76|ingestion|drug
DDI-DrugBank.d245.s8|78-79|of|drug
DDI-DrugBank.d245.s8|81-87|alcohol|drug
DDI-DrugBank.d245.s8|88-88|.|drug
DDI-DrugBank.d245.s9|0-0|A|drug
DDI-DrugBank.d245.s9|2-10|potential|drug
DDI-DrugBank.d245.s9|12-22|interaction|drug
DDI-DrugBank.d245.s9|24-30|between|drug
DDI-DrugBank.d245.s9|32-35|oral|drug
DDI-DrugBank.d245.s9|37-46|miconazole|drug
DDI-DrugBank.d245.s9|48-50|and|drug
DDI-DrugBank.d245.s9|52-55|oral|drug
DDI-DrugBank.d245.s9|57-68|hypoglycemic|drug
DDI-DrugBank.d245.s9|70-75|agents|drug
DDI-DrugBank.d245.s9|77-83|leading|drug
DDI-DrugBank.d245.s9|85-86|to|drug
DDI-DrugBank.d245.s9|88-93|severe|drug
DDI-DrugBank.d245.s9|95-106|hypoglycemia|drug
DDI-DrugBank.d245.s9|108-110|has|drug
DDI-DrugBank.d245.s9|112-115|been|drug
DDI-DrugBank.d245.s9|117-124|reported|drug
DDI-DrugBank.d245.s9|125-125|.|drug
DDI-DrugBank.d245.s10|0-6|Whether|drug
DDI-DrugBank.d245.s10|8-11|this|drug
DDI-DrugBank.d245.s10|13-23|interaction|drug
DDI-DrugBank.d245.s10|25-28|also|drug
DDI-DrugBank.d245.s10|30-35|occurs|drug
DDI-DrugBank.d245.s10|37-40|with|drug
DDI-DrugBank.d245.s10|42-44|the|drug
DDI-DrugBank.d245.s10|46-56|intravenous|drug
DDI-DrugBank.d245.s10|57-57|,|drug
DDI-DrugBank.d245.s10|59-65|topical|drug
DDI-DrugBank.d245.s10|66-66|,|drug
DDI-DrugBank.d245.s10|68-69|or|drug
DDI-DrugBank.d245.s10|71-77|vaginal|drug
DDI-DrugBank.d245.s10|79-90|preparations|drug
DDI-DrugBank.d245.s10|92-93|of|drug
DDI-DrugBank.d245.s10|95-104|miconazole|drug
DDI-DrugBank.d245.s10|106-107|is|drug
DDI-DrugBank.d245.s10|109-111|not|drug
DDI-DrugBank.d245.s10|113-117|known|drug
DDI-DrugBank.d245.s10|118-118|.|drug
DDI-MedLine.d73.s0|0-12|Neurochemical|drug
DDI-MedLine.d73.s0|14-16|and|drug
DDI-MedLine.d73.s0|18-27|functional|drug
DDI-MedLine.d73.s0|29-40|consequences|drug
DDI-MedLine.d73.s0|42-50|following|drug
DDI-MedLine.d73.s0|52-95|1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine|drug
DDI-MedLine.d73.s0|97-97|(|drug
DDI-MedLine.d73.s0|98-101|MPTP|drug
DDI-MedLine.d73.s0|102-102|)|drug
DDI-MedLine.d73.s0|104-106|and|drug
DDI-MedLine.d73.s0|108-122|methamphetamine|drug
DDI-MedLine.d73.s0|123-123|.|drug
DDI-MedLine.d73.s1|0-2|The|drug
DDI-MedLine.d73.s1|4-16|neurochemical|drug
DDI-MedLine.d73.s1|18-20|and|drug
DDI-MedLine.d73.s1|22-31|functional|drug
DDI-MedLine.d73.s1|33-44|consequences|drug
DDI-MedLine.d73.s1|46-54|following|drug
DDI-MedLine.d73.s1|56-59|MPTP|drug
DDI-MedLine.d73.s1|61-74|administration|drug
DDI-MedLine.d73.s1|76-77|to|drug
DDI-MedLine.d73.s1|79-81|the|drug
DDI-MedLine.d73.s1|83-85|rat|drug
DDI-MedLine.d73.s1|87-90|were|drug
DDI-MedLine.d73.s1|92-100|evaluated|drug
DDI-MedLine.d73.s1|102-104|and|drug
DDI-MedLine.d73.s1|106-113|compared|drug
DDI-MedLine.d73.s1|115-116|to|drug
DDI-MedLine.d73.s1|118-124|similar|drug
DDI-MedLine.d73.s1|126-132|effects|drug
DDI-MedLine.d73.s1|134-142|following|drug
DDI-MedLine.d73.s1|144-158|methamphetamine|drug
DDI-MedLine.d73.s1|160-173|administration|drug
DDI-MedLine.d73.s1|174-174|.|drug
DDI-MedLine.d73.s2|0-1|It|drug
DDI-MedLine.d73.s2|3-5|was|drug
DDI-MedLine.d73.s2|7-14|observed|drug
DDI-MedLine.d73.s2|16-19|that|drug
DDI-MedLine.d73.s2|21-24|MPTP|drug
DDI-MedLine.d73.s2|26-32|induced|drug
DDI-MedLine.d73.s2|34-37|long|drug
DDI-MedLine.d73.s2|39-45|lasting|drug
DDI-MedLine.d73.s2|47-56|depletions|drug
DDI-MedLine.d73.s2|58-59|of|drug
DDI-MedLine.d73.s2|61-68|striatal|drug
DDI-MedLine.d73.s2|70-77|dopamine|drug
DDI-MedLine.d73.s2|79-92|concentrations|drug
DDI-MedLine.d73.s2|94-96|and|drug
DDI-MedLine.d73.s2|98-101|this|drug
DDI-MedLine.d73.s2|103-112|neurotoxic|drug
DDI-MedLine.d73.s2|114-119|effect|drug
DDI-MedLine.d73.s2|121-125|could|drug
DDI-MedLine.d73.s2|127-128|be|drug
DDI-MedLine.d73.s2|130-138|prevented|drug
DDI-MedLine.d73.s2|140-141|by|drug
DDI-MedLine.d73.s2|143-151|pargyline|drug
DDI-MedLine.d73.s2|153-164|pretreatment|drug
DDI-MedLine.d73.s2|165-165|.|drug
DDI-MedLine.d73.s3|0-2|The|drug
DDI-MedLine.d73.s3|4-15|MPTP-induced|drug
DDI-MedLine.d73.s3|17-24|neuronal|drug
DDI-MedLine.d73.s3|26-31|damage|drug
DDI-MedLine.d73.s3|33-40|produced|drug
DDI-MedLine.d73.s3|42-42|a|drug
DDI-MedLine.d73.s3|44-52|tolerance|drug
DDI-MedLine.d73.s3|54-55|to|drug
DDI-MedLine.d73.s3|57-59|the|drug
DDI-MedLine.d73.s3|61-70|disruptive|drug
DDI-MedLine.d73.s3|72-78|effects|drug
DDI-MedLine.d73.s3|80-81|of|drug
DDI-MedLine.d73.s3|83-93|amphetamine|drug
DDI-MedLine.d73.s3|95-97|and|drug
DDI-MedLine.d73.s3|99-99|a|drug
DDI-MedLine.d73.s3|101-116|supersensitivity|drug
DDI-MedLine.d73.s3|118-119|to|drug
DDI-MedLine.d73.s3|121-123|the|drug
DDI-MedLine.d73.s3|125-134|disruptive|drug
DDI-MedLine.d73.s3|136-142|effects|drug
DDI-MedLine.d73.s3|144-145|of|drug
DDI-MedLine.d73.s3|147-157|apomorphine|drug
DDI-MedLine.d73.s3|159-160|in|drug
DDI-MedLine.d73.s3|162-165|rats|drug
DDI-MedLine.d73.s3|167-176|responding|drug
DDI-MedLine.d73.s3|178-179|in|drug
DDI-MedLine.d73.s3|181-181|a|drug
DDI-MedLine.d73.s3|183-190|schedule|drug
DDI-MedLine.d73.s3|192-201|controlled|drug
DDI-MedLine.d73.s3|203-210|paradigm|drug
DDI-MedLine.d73.s3|211-211|.|drug
DDI-MedLine.d73.s4|0-14|Methamphetamine|drug
DDI-MedLine.d73.s4|15-15|,|drug
DDI-MedLine.d73.s4|17-20|like|drug
DDI-MedLine.d73.s4|22-25|MPTP|drug
DDI-MedLine.d73.s4|26-26|,|drug
DDI-MedLine.d73.s4|28-35|produced|drug
DDI-MedLine.d73.s4|37-46|depletions|drug
DDI-MedLine.d73.s4|48-49|of|drug
DDI-MedLine.d73.s4|51-58|striatal|drug
DDI-MedLine.d73.s4|60-67|dopamine|drug
DDI-MedLine.d73.s4|69-71|but|drug
DDI-MedLine.d73.s4|73-77|these|drug
DDI-MedLine.d73.s4|79-85|actions|drug
DDI-MedLine.d73.s4|87-90|were|drug
DDI-MedLine.d73.s4|92-102|potentiated|drug
DDI-MedLine.d73.s4|104-105|by|drug
DDI-MedLine.d73.s4|107-115|pargyline|drug
DDI-MedLine.d73.s4|117-128|pretreatment|drug
DDI-MedLine.d73.s4|129-129|.|drug
DDI-MedLine.d73.s5|0-4|These|drug
DDI-MedLine.d73.s5|6-17|observations|drug
DDI-MedLine.d73.s5|19-21|are|drug
DDI-MedLine.d73.s5|23-31|discussed|drug
DDI-MedLine.d73.s5|33-34|in|drug
DDI-MedLine.d73.s5|36-44|reference|drug
DDI-MedLine.d73.s5|46-47|to|drug
DDI-MedLine.d73.s5|49-56|possible|drug
DDI-MedLine.d73.s5|58-68|deleterious|drug
DDI-MedLine.d73.s5|70-76|effects|drug
DDI-MedLine.d73.s5|78-86|following|drug
DDI-MedLine.d73.s5|88-90|the|drug
DDI-MedLine.d73.s5|92-105|administration|drug
DDI-MedLine.d73.s5|107-108|of|drug
DDI-MedLine.d73.s5|110-118|pargyline|drug
DDI-MedLine.d73.s5|120-121|to|drug
DDI-MedLine.d73.s5|123-130|patients|drug
DDI-MedLine.d73.s5|132-135|with|drug
DDI-MedLine.d73.s5|137-145|Parkinson|drug
DDI-MedLine.d73.s5|146-147|'s|drug
DDI-MedLine.d73.s5|149-155|Disease|drug
DDI-MedLine.d73.s5|156-156|.|drug
DDI-DrugBank.d429.s0|0-7|Antacids|group
DDI-DrugBank.d429.s0|9-11|and|drug
DDI-DrugBank.d429.s0|13-18|kaolin|drug
DDI-DrugBank.d429.s0|19-19|:|drug
DDI-DrugBank.d429.s0|21-28|Antacids|group
DDI-DrugBank.d429.s0|30-32|and|drug
DDI-DrugBank.d429.s0|34-39|kaolin|drug
DDI-DrugBank.d429.s0|41-43|can|drug
DDI-DrugBank.d429.s0|45-50|reduce|drug
DDI-DrugBank.d429.s0|52-61|absorption|drug
DDI-DrugBank.d429.s0|63-64|of|drug
DDI-DrugBank.d429.s0|66-76|chloroquine|drug
DDI-DrugBank.d429.s0|77-77|;|drug
DDI-DrugBank.d429.s1|0-1|an|drug
DDI-DrugBank.d429.s1|3-10|interval|drug
DDI-DrugBank.d429.s1|12-13|of|drug
DDI-DrugBank.d429.s1|15-16|at|drug
DDI-DrugBank.d429.s1|18-22|least|drug
DDI-DrugBank.d429.s1|24-24|4|drug
DDI-DrugBank.d429.s1|26-30|hours|drug
DDI-DrugBank.d429.s1|32-38|between|drug
DDI-DrugBank.d429.s1|40-45|intake|drug
DDI-DrugBank.d429.s1|47-48|of|drug
DDI-DrugBank.d429.s1|50-54|these|drug
DDI-DrugBank.d429.s1|56-61|agents|drug
DDI-DrugBank.d429.s1|63-65|and|drug
DDI-DrugBank.d429.s1|67-77|chloroquine|drug
DDI-DrugBank.d429.s1|79-84|should|drug
DDI-DrugBank.d429.s1|86-87|be|drug
DDI-DrugBank.d429.s1|89-96|observed|drug
DDI-DrugBank.d429.s1|97-97|.|drug
DDI-DrugBank.d429.s2|0-9|Cimetidine|brand
DDI-DrugBank.d429.s2|10-10|:|drug
DDI-DrugBank.d429.s2|12-21|Cimetidine|brand
DDI-DrugBank.d429.s2|23-25|can|drug
DDI-DrugBank.d429.s2|27-33|inhibit|drug
DDI-DrugBank.d429.s2|35-37|the|drug
DDI-DrugBank.d429.s2|39-48|metabolism|drug
DDI-DrugBank.d429.s2|50-51|of|drug
DDI-DrugBank.d429.s2|53-63|chloroquine|drug
DDI-DrugBank.d429.s2|64-64|,|drug
DDI-DrugBank.d429.s2|66-75|increasing|drug
DDI-DrugBank.d429.s2|77-79|its|drug
DDI-DrugBank.d429.s2|81-86|plasma|drug
DDI-DrugBank.d429.s2|88-92|level|drug
DDI-DrugBank.d429.s2|93-93|.|drug
DDI-DrugBank.d429.s3|0-10|Concomitant|drug
DDI-DrugBank.d429.s3|12-14|use|drug
DDI-DrugBank.d429.s3|16-17|of|drug
DDI-DrugBank.d429.s3|19-28|cimetidine|drug
DDI-DrugBank.d429.s3|30-35|should|drug
DDI-DrugBank.d429.s3|37-38|be|drug
DDI-DrugBank.d429.s3|40-46|avoided|drug
DDI-DrugBank.d429.s3|47-47|.|drug
DDI-DrugBank.d429.s4|0-9|Ampicillin|brand
DDI-DrugBank.d429.s4|10-10|:|drug
DDI-DrugBank.d429.s4|12-13|In|drug
DDI-DrugBank.d429.s4|15-15|a|drug
DDI-DrugBank.d429.s4|17-21|study|drug
DDI-DrugBank.d429.s4|23-24|of|drug
DDI-DrugBank.d429.s4|26-32|healthy|drug
DDI-DrugBank.d429.s4|34-43|volunteers|drug
DDI-DrugBank.d429.s4|44-44|,|drug
DDI-DrugBank.d429.s4|46-56|chloroquine|drug
DDI-DrugBank.d429.s4|58-70|significantly|drug
DDI-DrugBank.d429.s4|72-78|reduced|drug
DDI-DrugBank.d429.s4|80-82|the|drug
DDI-DrugBank.d429.s4|84-98|bioavailability|drug
DDI-DrugBank.d429.s4|100-101|of|drug
DDI-DrugBank.d429.s4|103-112|ampicillin|drug
DDI-DrugBank.d429.s4|113-113|.|drug
DDI-DrugBank.d429.s5|0-1|An|drug
DDI-DrugBank.d429.s5|3-10|interval|drug
DDI-DrugBank.d429.s5|12-13|of|drug
DDI-DrugBank.d429.s5|15-16|at|drug
DDI-DrugBank.d429.s5|18-22|least|drug
DDI-DrugBank.d429.s5|24-26|two|drug
DDI-DrugBank.d429.s5|28-32|hours|drug
DDI-DrugBank.d429.s5|34-40|between|drug
DDI-DrugBank.d429.s5|42-47|intake|drug
DDI-DrugBank.d429.s5|49-50|of|drug
DDI-DrugBank.d429.s5|52-55|this|drug
DDI-DrugBank.d429.s5|57-61|agent|drug
DDI-DrugBank.d429.s5|63-65|and|drug
DDI-DrugBank.d429.s5|67-77|chloroquine|drug
DDI-DrugBank.d429.s5|79-84|should|drug
DDI-DrugBank.d429.s5|86-87|be|drug
DDI-DrugBank.d429.s5|89-96|observed|drug
DDI-DrugBank.d429.s5|97-97|.|drug
DDI-DrugBank.d429.s6|0-10|Cyclosporin|drug
DDI-DrugBank.d429.s6|11-11|:|drug
DDI-DrugBank.d429.s6|13-17|After|drug
DDI-DrugBank.d429.s6|19-30|introduction|drug
DDI-DrugBank.d429.s6|32-33|of|drug
DDI-DrugBank.d429.s6|35-45|chloroquine|drug
DDI-DrugBank.d429.s6|47-47|(|drug
DDI-DrugBank.d429.s6|48-51|oral|drug
DDI-DrugBank.d429.s6|53-56|form|drug
DDI-DrugBank.d429.s6|57-57|)|drug
DDI-DrugBank.d429.s6|58-58|,|drug
DDI-DrugBank.d429.s6|60-60|a|drug
DDI-DrugBank.d429.s6|62-67|sudden|drug
DDI-DrugBank.d429.s6|69-76|increase|drug
DDI-DrugBank.d429.s6|78-79|in|drug
DDI-DrugBank.d429.s6|81-85|serum|drug
DDI-DrugBank.d429.s6|87-97|cyclosporin|drug
DDI-DrugBank.d429.s6|99-103|level|drug
DDI-DrugBank.d429.s6|105-107|has|drug
DDI-DrugBank.d429.s6|109-112|been|drug
DDI-DrugBank.d429.s6|114-121|reported|drug
DDI-DrugBank.d429.s6|122-122|.|drug
DDI-DrugBank.d429.s7|0-8|Therefore|drug
DDI-DrugBank.d429.s7|9-9|,|drug
DDI-DrugBank.d429.s7|11-15|close|drug
DDI-DrugBank.d429.s7|17-26|monitoring|drug
DDI-DrugBank.d429.s7|28-29|of|drug
DDI-DrugBank.d429.s7|31-35|serum|drug
DDI-DrugBank.d429.s7|37-47|cyclosporin|drug
DDI-DrugBank.d429.s7|49-53|level|drug
DDI-DrugBank.d429.s7|55-56|is|drug
DDI-DrugBank.d429.s7|58-68|recommended|drug
DDI-DrugBank.d429.s7|70-72|and|drug
DDI-DrugBank.d429.s7|73-73|,|drug
DDI-DrugBank.d429.s7|75-76|if|drug
DDI-DrugBank.d429.s7|78-86|necessary|drug
DDI-DrugBank.d429.s7|87-87|,|drug
DDI-DrugBank.d429.s7|89-99|chloroquine|drug
DDI-DrugBank.d429.s7|101-106|should|drug
DDI-DrugBank.d429.s7|108-109|be|drug
DDI-DrugBank.d429.s7|111-122|discontinued|drug
DDI-DrugBank.d429.s7|123-123|.|drug
DDI-DrugBank.d186.s0|0-1|An|drug
DDI-DrugBank.d186.s0|3-17|encephalopathic|drug
DDI-DrugBank.d186.s0|19-26|syndrome|drug
DDI-DrugBank.d186.s0|28-28|(|drug
DDI-DrugBank.d186.s0|29-41|characterized|drug
DDI-DrugBank.d186.s0|43-44|by|drug
DDI-DrugBank.d186.s0|46-53|weakness|drug
DDI-DrugBank.d186.s0|54-54|,|drug
DDI-DrugBank.d186.s0|56-63|lethargy|drug
DDI-DrugBank.d186.s0|64-64|,|drug
DDI-DrugBank.d186.s0|66-70|fever|drug
DDI-DrugBank.d186.s0|71-71|,|drug
DDI-DrugBank.d186.s0|73-85|tremulousness|drug
DDI-DrugBank.d186.s0|87-89|and|drug
DDI-DrugBank.d186.s0|91-99|confusion|drug
DDI-DrugBank.d186.s0|100-100|,|drug
DDI-DrugBank.d186.s0|102-115|extrapyramidal|drug
DDI-DrugBank.d186.s0|117-124|symptoms|drug
DDI-DrugBank.d186.s0|125-125|,|drug
DDI-DrugBank.d186.s0|127-138|leukocytosis|drug
DDI-DrugBank.d186.s0|139-139|,|drug
DDI-DrugBank.d186.s0|141-148|elevated|drug
DDI-DrugBank.d186.s0|150-154|serum|drug
DDI-DrugBank.d186.s0|156-162|enzymes|drug
DDI-DrugBank.d186.s0|163-163|,|drug
DDI-DrugBank.d186.s0|165-167|BUN|drug
DDI-DrugBank.d186.s0|168-168|,|drug
DDI-DrugBank.d186.s0|170-172|and|drug
DDI-DrugBank.d186.s0|174-176|FBS|drug
DDI-DrugBank.d186.s0|177-177|)|drug
DDI-DrugBank.d186.s0|179-186|followed|drug
DDI-DrugBank.d186.s0|188-189|by|drug
DDI-DrugBank.d186.s0|191-202|irreversible|drug
DDI-DrugBank.d186.s0|204-208|brain|drug
DDI-DrugBank.d186.s0|210-215|damage|drug
DDI-DrugBank.d186.s0|217-219|has|drug
DDI-DrugBank.d186.s0|221-228|occurred|drug
DDI-DrugBank.d186.s0|230-231|in|drug
DDI-DrugBank.d186.s0|233-233|a|drug
DDI-DrugBank.d186.s0|235-237|few|drug
DDI-DrugBank.d186.s0|239-246|patients|drug
DDI-DrugBank.d186.s0|248-254|treated|drug
DDI-DrugBank.d186.s0|256-259|with|drug
DDI-DrugBank.d186.s0|261-267|lithium|drug
DDI-DrugBank.d186.s0|269-272|plus|drug
DDI-DrugBank.d186.s0|274-279|HALDOL|drug
DDI-DrugBank.d186.s0|280-280|.|drug
DDI-DrugBank.d186.s1|0-0|A|drug
DDI-DrugBank.d186.s1|2-7|causal|drug
DDI-DrugBank.d186.s1|9-20|relationship|drug
DDI-DrugBank.d186.s1|22-28|between|drug
DDI-DrugBank.d186.s1|30-34|these|drug
DDI-DrugBank.d186.s1|36-41|events|drug
DDI-DrugBank.d186.s1|43-45|and|drug
DDI-DrugBank.d186.s1|47-49|the|drug
DDI-DrugBank.d186.s1|51-61|concomitant|drug
DDI-DrugBank.d186.s1|63-76|administration|drug
DDI-DrugBank.d186.s1|78-79|of|drug
DDI-DrugBank.d186.s1|81-87|lithium|drug
DDI-DrugBank.d186.s1|89-91|and|drug
DDI-DrugBank.d186.s1|93-98|HALDOL|drug
DDI-DrugBank.d186.s1|100-102|has|drug
DDI-DrugBank.d186.s1|104-106|not|drug
DDI-DrugBank.d186.s1|108-111|been|drug
DDI-DrugBank.d186.s1|113-123|established|drug
DDI-DrugBank.d186.s1|124-124|;|drug
DDI-DrugBank.d186.s2|0-6|however|drug
DDI-DrugBank.d186.s2|7-7|,|drug
DDI-DrugBank.d186.s2|9-16|patients|drug
DDI-DrugBank.d186.s2|18-26|receiving|drug
DDI-DrugBank.d186.s2|28-31|such|drug
DDI-DrugBank.d186.s2|33-40|combined|drug
DDI-DrugBank.d186.s2|42-48|therapy|drug
DDI-DrugBank.d186.s2|50-55|should|drug
DDI-DrugBank.d186.s2|57-58|be|drug
DDI-DrugBank.d186.s2|60-68|monitored|drug
DDI-DrugBank.d186.s2|70-76|closely|drug
DDI-DrugBank.d186.s2|78-80|for|drug
DDI-DrugBank.d186.s2|82-86|early|drug
DDI-DrugBank.d186.s2|88-95|evidence|drug
DDI-DrugBank.d186.s2|97-98|of|drug
DDI-DrugBank.d186.s2|100-111|neurological|drug
DDI-DrugBank.d186.s2|113-120|toxicity|drug
DDI-DrugBank.d186.s2|122-124|and|drug
DDI-DrugBank.d186.s2|126-134|treatment|drug
DDI-DrugBank.d186.s2|136-147|discontinued|drug
DDI-DrugBank.d186.s2|149-156|promptly|drug
DDI-DrugBank.d186.s2|158-159|if|drug
DDI-DrugBank.d186.s2|161-164|such|drug
DDI-DrugBank.d186.s2|166-170|signs|drug
DDI-DrugBank.d186.s2|172-177|appear|drug
DDI-DrugBank.d186.s2|178-178|.|drug
DDI-DrugBank.d186.s3|0-1|As|drug
DDI-DrugBank.d186.s3|3-6|with|drug
DDI-DrugBank.d186.s3|8-12|other|drug
DDI-DrugBank.d186.s3|14-26|antipsychotic|drug
DDI-DrugBank.d186.s3|28-33|agents|drug
DDI-DrugBank.d186.s3|34-34|,|drug
DDI-DrugBank.d186.s3|36-37|it|drug
DDI-DrugBank.d186.s3|39-44|should|drug
DDI-DrugBank.d186.s3|46-47|be|drug
DDI-DrugBank.d186.s3|49-53|noted|drug
DDI-DrugBank.d186.s3|55-58|that|drug
DDI-DrugBank.d186.s3|60-65|HALDOL|drug
DDI-DrugBank.d186.s3|67-69|may|drug
DDI-DrugBank.d186.s3|71-72|be|drug
DDI-DrugBank.d186.s3|74-80|capable|drug
DDI-DrugBank.d186.s3|82-83|of|drug
DDI-DrugBank.d186.s3|85-96|potentiating|drug
DDI-DrugBank.d186.s3|98-100|CNS|drug
DDI-DrugBank.d186.s3|102-112|depressants|drug
DDI-DrugBank.d186.s3|114-117|such|drug
DDI-DrugBank.d186.s3|119-120|as|drug
DDI-DrugBank.d186.s3|122-132|anesthetics|drug
DDI-DrugBank.d186.s3|133-133|,|drug
DDI-DrugBank.d186.s3|135-141|opiates|drug
DDI-DrugBank.d186.s3|142-142|,|drug
DDI-DrugBank.d186.s3|144-146|and|drug
DDI-DrugBank.d186.s3|148-154|alcohol|drug
DDI-DrugBank.d186.s3|155-155|.|drug
DDI-DrugBank.d186.s4|0-1|In|drug
DDI-DrugBank.d186.s4|3-3|a|drug
DDI-DrugBank.d186.s4|5-9|study|drug
DDI-DrugBank.d186.s4|11-12|of|drug
DDI-DrugBank.d186.s4|14-15|12|drug
DDI-DrugBank.d186.s4|17-29|schizophrenic|drug
DDI-DrugBank.d186.s4|31-38|patients|drug
DDI-DrugBank.d186.s4|40-53|coadministered|drug
DDI-DrugBank.d186.s4|55-58|oral|drug
DDI-DrugBank.d186.s4|60-70|haloperidol|drug
DDI-DrugBank.d186.s4|72-74|and|drug
DDI-DrugBank.d186.s4|76-83|rifampin|drug
DDI-DrugBank.d186.s4|84-84|,|drug
DDI-DrugBank.d186.s4|86-91|plasma|drug
DDI-DrugBank.d186.s4|93-103|haloperidol|drug
DDI-DrugBank.d186.s4|105-110|levels|drug
DDI-DrugBank.d186.s4|112-115|were|drug
DDI-DrugBank.d186.s4|117-125|decreased|drug
DDI-DrugBank.d186.s4|127-128|by|drug
DDI-DrugBank.d186.s4|130-130|a|drug
DDI-DrugBank.d186.s4|132-135|mean|drug
DDI-DrugBank.d186.s4|137-138|of|drug
DDI-DrugBank.d186.s4|140-141|70|drug
DDI-DrugBank.d186.s4|142-142|%|drug
DDI-DrugBank.d186.s4|144-146|and|drug
DDI-DrugBank.d186.s4|148-151|mean|drug
DDI-DrugBank.d186.s4|153-158|scores|drug
DDI-DrugBank.d186.s4|160-161|on|drug
DDI-DrugBank.d186.s4|163-165|the|drug
DDI-DrugBank.d186.s4|167-171|Brief|drug
DDI-DrugBank.d186.s4|173-183|Psychiatric|drug
DDI-DrugBank.d186.s4|185-190|Rating|drug
DDI-DrugBank.d186.s4|192-196|Scale|drug
DDI-DrugBank.d186.s4|198-201|were|drug
DDI-DrugBank.d186.s4|203-211|increased|drug
DDI-DrugBank.d186.s4|213-216|from|drug
DDI-DrugBank.d186.s4|218-225|baseline|drug
DDI-DrugBank.d186.s4|226-226|.|drug
DDI-DrugBank.d186.s5|0-1|In|drug
DDI-DrugBank.d186.s5|3-3|5|drug
DDI-DrugBank.d186.s5|5-9|other|drug
DDI-DrugBank.d186.s5|11-23|schizophrenic|drug
DDI-DrugBank.d186.s5|25-32|patients|drug
DDI-DrugBank.d186.s5|34-40|treated|drug
DDI-DrugBank.d186.s5|42-45|with|drug
DDI-DrugBank.d186.s5|47-50|oral|drug
DDI-DrugBank.d186.s5|52-62|haloperidol|drug
DDI-DrugBank.d186.s5|64-66|and|drug
DDI-DrugBank.d186.s5|68-75|rifampin|drug
DDI-DrugBank.d186.s5|76-76|,|drug
DDI-DrugBank.d186.s5|78-92|discontinuation|drug
DDI-DrugBank.d186.s5|94-95|of|drug
DDI-DrugBank.d186.s5|97-104|rifampin|drug
DDI-DrugBank.d186.s5|106-113|produced|drug
DDI-DrugBank.d186.s5|115-115|a|drug
DDI-DrugBank.d186.s5|117-120|mean|drug
DDI-DrugBank.d186.s5|122-129|3.3-fold|drug
DDI-DrugBank.d186.s5|131-138|increase|drug
DDI-DrugBank.d186.s5|140-141|in|drug
DDI-DrugBank.d186.s5|143-153|haloperidol|drug
DDI-DrugBank.d186.s5|155-168|concentrations|drug
DDI-DrugBank.d186.s5|169-169|.|drug
DDI-DrugBank.d186.s6|0-3|Thus|drug
DDI-DrugBank.d186.s6|4-4|,|drug
DDI-DrugBank.d186.s6|6-12|careful|drug
DDI-DrugBank.d186.s6|14-23|monitoring|drug
DDI-DrugBank.d186.s6|25-26|of|drug
DDI-DrugBank.d186.s6|28-35|clinical|drug
DDI-DrugBank.d186.s6|37-42|status|drug
DDI-DrugBank.d186.s6|44-45|is|drug
DDI-DrugBank.d186.s6|47-55|warranted|drug
DDI-DrugBank.d186.s6|57-60|when|drug
DDI-DrugBank.d186.s6|62-69|rifampin|drug
DDI-DrugBank.d186.s6|71-72|is|drug
DDI-DrugBank.d186.s6|74-85|administered|drug
DDI-DrugBank.d186.s6|87-88|or|drug
DDI-DrugBank.d186.s6|90-101|discontinued|drug
DDI-DrugBank.d186.s6|103-104|in|drug
DDI-DrugBank.d186.s6|106-124|haloperidol-treated|drug
DDI-DrugBank.d186.s6|126-133|patients|drug
DDI-DrugBank.d186.s6|134-134|.|drug
DDI-DrugBank.d41.s0|0-13|Cholestyramine|brand
DDI-DrugBank.d41.s0|15-17|and|drug
DDI-DrugBank.d41.s0|19-26|Charcoal|brand
DDI-DrugBank.d41.s0|28-41|Administration|drug
DDI-DrugBank.d41.s0|43-44|of|drug
DDI-DrugBank.d41.s0|46-59|cholestyramine|drug
DDI-DrugBank.d41.s0|61-62|or|drug
DDI-DrugBank.d41.s0|64-72|activated|drug
DDI-DrugBank.d41.s0|74-81|charcoal|drug
DDI-DrugBank.d41.s0|83-84|in|drug
DDI-DrugBank.d41.s0|86-93|patients|drug
DDI-DrugBank.d41.s0|95-95|(|drug
DDI-DrugBank.d41.s0|96-99|n=13|drug
DDI-DrugBank.d41.s0|100-100|)|drug
DDI-DrugBank.d41.s0|102-104|and|drug
DDI-DrugBank.d41.s0|106-115|volunteers|drug
DDI-DrugBank.d41.s0|117-117|(|drug
DDI-DrugBank.d41.s0|118-121|n=96|drug
DDI-DrugBank.d41.s0|122-122|)|drug
DDI-DrugBank.d41.s0|124-131|resulted|drug
DDI-DrugBank.d41.s0|133-134|in|drug
DDI-DrugBank.d41.s0|136-136|a|drug
DDI-DrugBank.d41.s0|138-142|rapid|drug
DDI-DrugBank.d41.s0|144-146|and|drug
DDI-DrugBank.d41.s0|148-158|significant|drug
DDI-DrugBank.d41.s0|160-167|decrease|drug
DDI-DrugBank.d41.s0|169-170|in|drug
DDI-DrugBank.d41.s0|172-177|plasma|drug
DDI-DrugBank.d41.s0|179-180|M1|drug
DDI-DrugBank.d41.s0|182-182|(|drug
DDI-DrugBank.d41.s0|183-185|the|drug
DDI-DrugBank.d41.s0|187-192|active|drug
DDI-DrugBank.d41.s0|194-203|metabolite|drug
DDI-DrugBank.d41.s0|205-206|of|drug
DDI-DrugBank.d41.s0|208-218|leflunomide|drug
DDI-DrugBank.d41.s0|219-219|)|drug
DDI-DrugBank.d41.s0|221-233|concentration|drug
DDI-DrugBank.d41.s0|235-235|.|drug
DDI-DrugBank.d41.s1|0-10|Hepatotoxic|drug
DDI-DrugBank.d41.s1|12-16|Drugs|drug
DDI-DrugBank.d41.s1|18-26|Increased|drug
DDI-DrugBank.d41.s1|28-31|side|drug
DDI-DrugBank.d41.s1|33-39|effects|drug
DDI-DrugBank.d41.s1|41-43|may|drug
DDI-DrugBank.d41.s1|45-49|occur|drug
DDI-DrugBank.d41.s1|51-54|when|drug
DDI-DrugBank.d41.s1|56-66|leflunomide|drug
DDI-DrugBank.d41.s1|68-69|is|drug
DDI-DrugBank.d41.s1|71-75|given|drug
DDI-DrugBank.d41.s1|77-89|concomitantly|drug
DDI-DrugBank.d41.s1|91-94|with|drug
DDI-DrugBank.d41.s1|96-106|hepatotoxic|drug
DDI-DrugBank.d41.s1|108-117|substances|drug
DDI-DrugBank.d41.s1|118-118|.|drug
DDI-DrugBank.d41.s2|0-3|This|drug
DDI-DrugBank.d41.s2|5-6|is|drug
DDI-DrugBank.d41.s2|8-11|also|drug
DDI-DrugBank.d41.s2|13-14|to|drug
DDI-DrugBank.d41.s2|16-17|be|drug
DDI-DrugBank.d41.s2|19-28|considered|drug
DDI-DrugBank.d41.s2|30-33|when|drug
DDI-DrugBank.d41.s2|35-45|leflunomide|drug
DDI-DrugBank.d41.s2|47-55|treatment|drug
DDI-DrugBank.d41.s2|57-58|is|drug
DDI-DrugBank.d41.s2|60-67|followed|drug
DDI-DrugBank.d41.s2|69-70|by|drug
DDI-DrugBank.d41.s2|72-75|such|drug
DDI-DrugBank.d41.s2|77-81|drugs|drug
DDI-DrugBank.d41.s2|83-89|without|drug
DDI-DrugBank.d41.s2|91-91|a|drug
DDI-DrugBank.d41.s2|93-96|drug|drug
DDI-DrugBank.d41.s2|98-108|elimination|drug
DDI-DrugBank.d41.s2|110-118|procedure|drug
DDI-DrugBank.d41.s2|119-119|.|drug
DDI-DrugBank.d41.s3|0-1|In|drug
DDI-DrugBank.d41.s3|3-3|a|drug
DDI-DrugBank.d41.s3|5-9|small|drug
DDI-DrugBank.d41.s3|11-11|(|drug
DDI-DrugBank.d41.s3|12-15|n=30|drug
DDI-DrugBank.d41.s3|16-16|)|drug
DDI-DrugBank.d41.s3|18-28|combination|drug
DDI-DrugBank.d41.s3|30-34|study|drug
DDI-DrugBank.d41.s3|36-37|of|drug
DDI-DrugBank.d41.s3|39-43|ARAVA|drug
DDI-DrugBank.d41.s3|45-48|with|drug
DDI-DrugBank.d41.s3|50-61|methotrexate|drug
DDI-DrugBank.d41.s3|62-62|,|drug
DDI-DrugBank.d41.s3|64-64|a|drug
DDI-DrugBank.d41.s3|66-67|2-|drug
DDI-DrugBank.d41.s3|69-70|to|drug
DDI-DrugBank.d41.s3|72-77|3-fold|drug
DDI-DrugBank.d41.s3|79-87|elevation|drug
DDI-DrugBank.d41.s3|89-90|in|drug
DDI-DrugBank.d41.s3|92-96|liver|drug
DDI-DrugBank.d41.s3|98-104|enzymes|drug
DDI-DrugBank.d41.s3|106-108|was|drug
DDI-DrugBank.d41.s3|110-113|seen|drug
DDI-DrugBank.d41.s3|115-116|in|drug
DDI-DrugBank.d41.s3|118-118|5|drug
DDI-DrugBank.d41.s3|120-121|of|drug
DDI-DrugBank.d41.s3|123-124|30|drug
DDI-DrugBank.d41.s3|126-133|patients|drug
DDI-DrugBank.d41.s3|134-134|.|drug
DDI-DrugBank.d41.s4|0-2|All|drug
DDI-DrugBank.d41.s4|4-13|elevations|drug
DDI-DrugBank.d41.s4|15-22|resolved|drug
DDI-DrugBank.d41.s4|23-23|,|drug
DDI-DrugBank.d41.s4|25-25|2|drug
DDI-DrugBank.d41.s4|27-30|with|drug
DDI-DrugBank.d41.s4|32-43|continuation|drug
DDI-DrugBank.d41.s4|45-46|of|drug
DDI-DrugBank.d41.s4|48-51|both|drug
DDI-DrugBank.d41.s4|53-57|drugs|drug
DDI-DrugBank.d41.s4|59-61|and|drug
DDI-DrugBank.d41.s4|63-63|3|drug
DDI-DrugBank.d41.s4|65-69|after|drug
DDI-DrugBank.d41.s4|71-85|discontinuation|drug
DDI-DrugBank.d41.s4|87-88|of|drug
DDI-DrugBank.d41.s4|90-100|leflunomide|drug
DDI-DrugBank.d41.s4|101-101|.|drug
DDI-DrugBank.d41.s5|0-0|A|drug
DDI-DrugBank.d41.s5|3-8|3-fold|drug
DDI-DrugBank.d41.s5|10-17|increase|drug
DDI-DrugBank.d41.s5|19-21|was|drug
DDI-DrugBank.d41.s5|23-26|seen|drug
DDI-DrugBank.d41.s5|28-29|in|drug
DDI-DrugBank.d41.s5|31-37|another|drug
DDI-DrugBank.d41.s5|39-39|5|drug
DDI-DrugBank.d41.s5|41-48|patients|drug
DDI-DrugBank.d41.s5|49-49|.|drug
DDI-DrugBank.d41.s6|0-2|All|drug
DDI-DrugBank.d41.s6|4-5|of|drug
DDI-DrugBank.d41.s6|7-11|these|drug
DDI-DrugBank.d41.s6|13-16|also|drug
DDI-DrugBank.d41.s6|18-25|resolved|drug
DDI-DrugBank.d41.s6|26-26|,|drug
DDI-DrugBank.d41.s6|28-28|2|drug
DDI-DrugBank.d41.s6|30-33|with|drug
DDI-DrugBank.d41.s6|35-46|continuation|drug
DDI-DrugBank.d41.s6|48-49|of|drug
DDI-DrugBank.d41.s6|51-54|both|drug
DDI-DrugBank.d41.s6|56-60|drugs|drug
DDI-DrugBank.d41.s6|62-64|and|drug
DDI-DrugBank.d41.s6|66-66|3|drug
DDI-DrugBank.d41.s6|68-72|after|drug
DDI-DrugBank.d41.s6|74-88|discontinuation|drug
DDI-DrugBank.d41.s6|90-91|of|drug
DDI-DrugBank.d41.s6|93-103|leflunomide|drug
DDI-DrugBank.d41.s6|104-104|.|drug
DDI-DrugBank.d41.s7|0-4|Three|drug
DDI-DrugBank.d41.s7|6-13|patients|drug
DDI-DrugBank.d41.s7|15-17|met|drug
DDI-DrugBank.d41.s7|19-21|ACR|drug
DDI-DrugBank.d41.s7|23-30|criteria|drug
DDI-DrugBank.d41.s7|32-34|for|drug
DDI-DrugBank.d41.s7|36-40|liver|drug
DDI-DrugBank.d41.s7|42-47|biopsy|drug
DDI-DrugBank.d41.s7|49-49|(|drug
DDI-DrugBank.d41.s7|50-50|1|drug
DDI-DrugBank.d41.s7|51-51|:|drug
DDI-DrugBank.d41.s7|53-59|Roegnik|drug
DDI-DrugBank.d41.s7|61-65|Grade|drug
DDI-DrugBank.d41.s7|67-67|I|drug
DDI-DrugBank.d41.s7|68-68|,|drug
DDI-DrugBank.d41.s7|70-70|2|drug
DDI-DrugBank.d41.s7|71-71|:|drug
DDI-DrugBank.d41.s7|73-79|Roegnik|drug
DDI-DrugBank.d41.s7|81-85|Grade|drug
DDI-DrugBank.d41.s7|87-90|IIIa|drug
DDI-DrugBank.d41.s7|91-91|)|drug
DDI-DrugBank.d41.s7|92-92|.|drug
DDI-DrugBank.d41.s8|0-1|No|drug
DDI-DrugBank.d41.s8|3-17|pharmacokinetic|drug
DDI-DrugBank.d41.s8|19-29|interaction|drug
DDI-DrugBank.d41.s8|31-33|was|drug
DDI-DrugBank.d41.s8|35-44|identified|drug
DDI-DrugBank.d41.s8|45-45|.|drug
DDI-DrugBank.d41.s9|0-5|NSAIDs|drug
DDI-DrugBank.d41.s9|6-6|:|drug
DDI-DrugBank.d41.s9|8-9|In|drug
DDI-DrugBank.d41.s9|11-12|in|drug
DDI-DrugBank.d41.s9|14-18|vitro|drug
DDI-DrugBank.d41.s9|20-26|studies|drug
DDI-DrugBank.d41.s9|27-27|,|drug
DDI-DrugBank.d41.s9|29-30|M1|drug
DDI-DrugBank.d41.s9|32-34|was|drug
DDI-DrugBank.d41.s9|36-40|shown|drug
DDI-DrugBank.d41.s9|42-43|to|drug
DDI-DrugBank.d41.s9|45-49|cause|drug
DDI-DrugBank.d41.s9|51-59|increases|drug
DDI-DrugBank.d41.s9|61-67|ranging|drug
DDI-DrugBank.d41.s9|69-72|from|drug
DDI-DrugBank.d41.s9|74-75|13|drug
DDI-DrugBank.d41.s9|77-77|-|drug
DDI-DrugBank.d41.s9|79-80|50|drug
DDI-DrugBank.d41.s9|81-81|%|drug
DDI-DrugBank.d41.s9|83-84|in|drug
DDI-DrugBank.d41.s9|86-88|the|drug
DDI-DrugBank.d41.s9|90-93|free|drug
DDI-DrugBank.d41.s9|95-102|fraction|drug
DDI-DrugBank.d41.s9|104-105|of|drug
DDI-DrugBank.d41.s9|107-116|diclofenac|drug
DDI-DrugBank.d41.s9|118-120|and|drug
DDI-DrugBank.d41.s9|122-130|ibuprofen|drug
DDI-DrugBank.d41.s9|132-133|at|drug
DDI-DrugBank.d41.s9|135-148|concentrations|drug
DDI-DrugBank.d41.s9|150-151|in|drug
DDI-DrugBank.d41.s9|153-155|the|drug
DDI-DrugBank.d41.s9|157-164|clinical|drug
DDI-DrugBank.d41.s9|166-170|range|drug
DDI-DrugBank.d41.s9|171-171|.|drug
DDI-DrugBank.d41.s10|0-2|The|drug
DDI-DrugBank.d41.s10|4-11|clinical|drug
DDI-DrugBank.d41.s10|13-24|significance|drug
DDI-DrugBank.d41.s10|26-27|of|drug
DDI-DrugBank.d41.s10|29-32|this|drug
DDI-DrugBank.d41.s10|34-40|finding|drug
DDI-DrugBank.d41.s10|42-43|is|drug
DDI-DrugBank.d41.s10|45-51|unknown|drug
DDI-DrugBank.d41.s10|52-52|;|drug
DDI-DrugBank.d41.s11|0-6|however|drug
DDI-DrugBank.d41.s11|7-7|,|drug
DDI-DrugBank.d41.s11|9-13|there|drug
DDI-DrugBank.d41.s11|15-17|was|drug
DDI-DrugBank.d41.s11|19-27|extensive|drug
DDI-DrugBank.d41.s11|29-39|concomitant|drug
DDI-DrugBank.d41.s11|41-43|use|drug
DDI-DrugBank.d41.s11|45-46|of|drug
DDI-DrugBank.d41.s11|48-53|NSAIDs|drug
DDI-DrugBank.d41.s11|55-56|in|drug
DDI-DrugBank.d41.s11|58-65|clinical|drug
DDI-DrugBank.d41.s11|67-73|studies|drug
DDI-DrugBank.d41.s11|75-77|and|drug
DDI-DrugBank.d41.s11|79-80|no|drug
DDI-DrugBank.d41.s11|82-93|differential|drug
DDI-DrugBank.d41.s11|95-100|effect|drug
DDI-DrugBank.d41.s11|102-104|was|drug
DDI-DrugBank.d41.s11|106-113|observed|drug
DDI-DrugBank.d41.s11|114-114|.|drug
DDI-DrugBank.d41.s12|0-10|Tolbutamide|brand
DDI-DrugBank.d41.s12|11-11|:|drug
DDI-DrugBank.d41.s12|13-14|In|drug
DDI-DrugBank.d41.s12|16-17|in|drug
DDI-DrugBank.d41.s12|19-23|vitro|drug
DDI-DrugBank.d41.s12|25-31|studies|drug
DDI-DrugBank.d41.s12|32-32|,|drug
DDI-DrugBank.d41.s12|34-35|M1|drug
DDI-DrugBank.d41.s12|37-39|was|drug
DDI-DrugBank.d41.s12|41-45|shown|drug
DDI-DrugBank.d41.s12|47-48|to|drug
DDI-DrugBank.d41.s12|50-54|cause|drug
DDI-DrugBank.d41.s12|56-64|increases|drug
DDI-DrugBank.d41.s12|66-72|ranging|drug
DDI-DrugBank.d41.s12|74-77|from|drug
DDI-DrugBank.d41.s12|79-80|13|drug
DDI-DrugBank.d41.s12|82-82|-|drug
DDI-DrugBank.d41.s12|84-85|50|drug
DDI-DrugBank.d41.s12|86-86|%|drug
DDI-DrugBank.d41.s12|88-89|in|drug
DDI-DrugBank.d41.s12|91-93|the|drug
DDI-DrugBank.d41.s12|95-98|free|drug
DDI-DrugBank.d41.s12|100-107|fraction|drug
DDI-DrugBank.d41.s12|109-110|of|drug
DDI-DrugBank.d41.s12|112-122|tolbutamide|drug
DDI-DrugBank.d41.s12|124-125|at|drug
DDI-DrugBank.d41.s12|127-140|concentrations|drug
DDI-DrugBank.d41.s12|142-143|in|drug
DDI-DrugBank.d41.s12|145-147|the|drug
DDI-DrugBank.d41.s12|149-156|clinical|drug
DDI-DrugBank.d41.s12|158-162|range|drug
DDI-DrugBank.d41.s12|163-163|.|drug
DDI-DrugBank.d41.s13|0-2|The|drug
DDI-DrugBank.d41.s13|4-11|clinical|drug
DDI-DrugBank.d41.s13|13-24|significance|drug
DDI-DrugBank.d41.s13|26-27|of|drug
DDI-DrugBank.d41.s13|29-32|this|drug
DDI-DrugBank.d41.s13|34-40|finding|drug
DDI-DrugBank.d41.s13|42-43|is|drug
DDI-DrugBank.d41.s13|45-51|unknown|drug
DDI-DrugBank.d41.s13|52-52|.|drug
DDI-DrugBank.d41.s14|0-7|Rifampin|brand
DDI-DrugBank.d41.s14|8-8|:|drug
DDI-DrugBank.d41.s14|10-18|Following|drug
DDI-DrugBank.d41.s14|20-30|concomitant|drug
DDI-DrugBank.d41.s14|32-45|administration|drug
DDI-DrugBank.d41.s14|47-48|of|drug
DDI-DrugBank.d41.s14|50-50|a|drug
DDI-DrugBank.d41.s14|52-57|single|drug
DDI-DrugBank.d41.s14|59-62|dose|drug
DDI-DrugBank.d41.s14|64-65|of|drug
DDI-DrugBank.d41.s14|67-71|ARAVA|drug
DDI-DrugBank.d41.s14|73-74|to|drug
DDI-DrugBank.d41.s14|76-83|subjects|drug
DDI-DrugBank.d41.s14|85-93|receiving|drug
DDI-DrugBank.d41.s14|95-102|multiple|drug
DDI-DrugBank.d41.s14|104-108|doses|drug
DDI-DrugBank.d41.s14|110-111|of|drug
DDI-DrugBank.d41.s14|113-120|rifampin|drug
DDI-DrugBank.d41.s14|121-121|,|drug
DDI-DrugBank.d41.s14|123-124|M1|drug
DDI-DrugBank.d41.s14|126-129|peak|drug
DDI-DrugBank.d41.s14|131-136|levels|drug
DDI-DrugBank.d41.s14|138-141|were|drug
DDI-DrugBank.d41.s14|143-151|increased|drug
DDI-DrugBank.d41.s14|153-153|(|drug
DDI-DrugBank.d41.s14|154-156|~40|drug
DDI-DrugBank.d41.s14|157-157|%|drug
DDI-DrugBank.d41.s14|158-158|)|drug
DDI-DrugBank.d41.s14|160-163|over|drug
DDI-DrugBank.d41.s14|165-169|those|drug
DDI-DrugBank.d41.s14|171-174|seen|drug
DDI-DrugBank.d41.s14|176-179|when|drug
DDI-DrugBank.d41.s14|181-185|ARAVA|drug
DDI-DrugBank.d41.s14|187-189|was|drug
DDI-DrugBank.d41.s14|191-195|given|drug
DDI-DrugBank.d41.s14|197-201|alone|drug
DDI-DrugBank.d41.s14|202-202|.|drug
DDI-DrugBank.d41.s15|0-6|Because|drug
DDI-DrugBank.d41.s15|8-9|of|drug
DDI-DrugBank.d41.s15|11-13|the|drug
DDI-DrugBank.d41.s15|15-23|potential|drug
DDI-DrugBank.d41.s15|25-27|for|drug
DDI-DrugBank.d41.s15|29-33|ARAVA|drug
DDI-DrugBank.d41.s15|35-40|levels|drug
DDI-DrugBank.d41.s15|42-43|to|drug
DDI-DrugBank.d41.s15|45-52|continue|drug
DDI-DrugBank.d41.s15|54-55|to|drug
DDI-DrugBank.d41.s15|57-64|increase|drug
DDI-DrugBank.d41.s15|66-69|with|drug
DDI-DrugBank.d41.s15|71-78|multiple|drug
DDI-DrugBank.d41.s15|80-85|dosing|drug
DDI-DrugBank.d41.s15|86-86|,|drug
DDI-DrugBank.d41.s15|88-94|caution|drug
DDI-DrugBank.d41.s15|96-101|should|drug
DDI-DrugBank.d41.s15|103-104|be|drug
DDI-DrugBank.d41.s15|106-109|used|drug
DDI-DrugBank.d41.s15|111-112|if|drug
DDI-DrugBank.d41.s15|114-121|patients|drug
DDI-DrugBank.d41.s15|123-125|are|drug
DDI-DrugBank.d41.s15|127-128|to|drug
DDI-DrugBank.d41.s15|130-131|be|drug
DDI-DrugBank.d41.s15|133-141|receiving|drug
DDI-DrugBank.d41.s15|143-146|both|drug
DDI-DrugBank.d41.s15|148-152|ARAVA|drug
DDI-DrugBank.d41.s15|154-156|and|drug
DDI-DrugBank.d41.s15|158-165|rifampin|drug
DDI-DrugBank.d41.s15|166-166|.|drug
DDI-DrugBank.d41.s16|0-7|Warfarin|brand
DDI-DrugBank.d41.s16|8-8|:|drug
DDI-DrugBank.d41.s16|10-18|Increased|drug
DDI-DrugBank.d41.s16|20-22|INR|drug
DDI-DrugBank.d41.s16|24-24|(|drug
DDI-DrugBank.d41.s16|25-37|International|drug
DDI-DrugBank.d41.s16|39-48|Normalized|drug
DDI-DrugBank.d41.s16|50-54|Ratio|drug
DDI-DrugBank.d41.s16|55-55|)|drug
DDI-DrugBank.d41.s16|57-60|when|drug
DDI-DrugBank.d41.s16|62-66|ARAVA|drug
DDI-DrugBank.d41.s16|68-70|and|drug
DDI-DrugBank.d41.s16|72-79|warfarin|drug
DDI-DrugBank.d41.s16|81-84|were|drug
DDI-DrugBank.d41.s16|86-100|co-administered|drug
DDI-DrugBank.d41.s16|102-104|has|drug
DDI-DrugBank.d41.s16|106-109|been|drug
DDI-DrugBank.d41.s16|111-116|rarely|drug
DDI-DrugBank.d41.s16|118-125|reported|drug
DDI-DrugBank.d41.s16|126-126|.|drug
DDI-DrugBank.d101.s0|0-5|Steady|drug
DDI-DrugBank.d101.s0|7-11|state|drug
DDI-DrugBank.d101.s0|13-18|plasma|drug
DDI-DrugBank.d101.s0|20-28|digitoxin|drug
DDI-DrugBank.d101.s0|30-43|concentrations|drug
DDI-DrugBank.d101.s0|45-47|did|drug
DDI-DrugBank.d101.s0|49-51|not|drug
DDI-DrugBank.d101.s0|53-58|appear|drug
DDI-DrugBank.d101.s0|60-61|to|drug
DDI-DrugBank.d101.s0|63-68|change|drug
DDI-DrugBank.d101.s0|69-69|.|drug
DDI-DrugBank.d101.s1|0-8|Therefore|drug
DDI-DrugBank.d101.s1|9-9|,|drug
DDI-DrugBank.d101.s1|11-20|monitoring|drug
DDI-DrugBank.d101.s1|22-23|of|drug
DDI-DrugBank.d101.s1|25-30|plasma|drug
DDI-DrugBank.d101.s1|32-38|digoxin|drug
DDI-DrugBank.d101.s1|40-45|levels|drug
DDI-DrugBank.d101.s1|47-49|may|drug
DDI-DrugBank.d101.s1|51-52|be|drug
DDI-DrugBank.d101.s1|54-62|indicated|drug
DDI-DrugBank.d101.s1|64-65|in|drug
DDI-DrugBank.d101.s1|67-74|patients|drug
DDI-DrugBank.d101.s1|76-84|receiving|drug
DDI-DrugBank.d101.s1|86-92|similar|drug
DDI-DrugBank.d101.s1|94-104|combination|drug
DDI-DrugBank.d101.s1|106-117|chemotherapy|drug
DDI-DrugBank.d101.s1|119-126|regimens|drug
DDI-DrugBank.d101.s1|127-127|.|drug
DDI-DrugBank.d101.s2|0-2|The|drug
DDI-DrugBank.d101.s2|4-14|utilization|drug
DDI-DrugBank.d101.s2|16-17|of|drug
DDI-DrugBank.d101.s2|19-27|digitoxin|drug
DDI-DrugBank.d101.s2|29-31|for|drug
DDI-DrugBank.d101.s2|33-36|such|drug
DDI-DrugBank.d101.s2|38-45|patients|drug
DDI-DrugBank.d101.s2|47-49|may|drug
DDI-DrugBank.d101.s2|51-52|be|drug
DDI-DrugBank.d101.s2|54-63|considered|drug
DDI-DrugBank.d101.s2|65-66|as|drug
DDI-DrugBank.d101.s2|68-69|an|drug
DDI-DrugBank.d101.s2|71-81|alternative|drug
DDI-DrugBank.d101.s2|82-82|.|drug
DDI-DrugBank.d101.s3|0-3|Also|drug
DDI-DrugBank.d101.s3|5-15|flucytosine|drug
DDI-DrugBank.d101.s3|16-16|.|drug
DDI-MedLine.d193.s0|0-9|Ticagrelor|brand
DDI-MedLine.d193.s0|11-11|(|drug
DDI-MedLine.d193.s0|12-19|Brilinta|brand
DDI-MedLine.d193.s0|20-20|)|drug
DDI-MedLine.d193.s0|21-22|--|drug
DDI-MedLine.d193.s0|23-28|better|drug
DDI-MedLine.d193.s0|30-33|than|drug
DDI-MedLine.d193.s0|35-45|clopidogrel|drug
DDI-MedLine.d193.s0|47-47|(|drug
DDI-MedLine.d193.s0|48-53|Plavix|brand
DDI-MedLine.d193.s0|54-54|)|drug
DDI-MedLine.d193.s1|0-2|The|drug
DDI-MedLine.d193.s1|4-6|FDA|drug
DDI-MedLine.d193.s1|8-10|has|drug
DDI-MedLine.d193.s1|12-19|approved|drug
DDI-MedLine.d193.s1|21-30|ticagrelor|drug
DDI-MedLine.d193.s1|32-32|(|drug
DDI-MedLine.d193.s1|33-52|Brilinta-AstraZeneca|drug
DDI-MedLine.d193.s1|53-53|)|drug
DDI-MedLine.d193.s1|54-54|,|drug
DDI-MedLine.d193.s1|56-57|an|drug
DDI-MedLine.d193.s1|59-62|oral|drug
DDI-MedLine.d193.s1|64-75|antiplatelet|drug
DDI-MedLine.d193.s1|77-80|drug|drug
DDI-MedLine.d193.s1|81-81|,|drug
DDI-MedLine.d193.s1|83-85|for|drug
DDI-MedLine.d193.s1|87-89|use|drug
DDI-MedLine.d193.s1|91-94|with|drug
DDI-MedLine.d193.s1|96-103|low-dose|drug
DDI-MedLine.d193.s1|105-111|aspirin|drug
DDI-MedLine.d193.s1|113-114|to|drug
DDI-MedLine.d193.s1|116-121|reduce|drug
DDI-MedLine.d193.s1|123-125|the|drug
DDI-MedLine.d193.s1|127-130|rate|drug
DDI-MedLine.d193.s1|132-133|of|drug
DDI-MedLine.d193.s1|135-144|thrombotic|drug
DDI-MedLine.d193.s1|146-159|cardiovascular|drug
DDI-MedLine.d193.s1|161-166|events|drug
DDI-MedLine.d193.s1|168-169|in|drug
DDI-MedLine.d193.s1|171-178|patients|drug
DDI-MedLine.d193.s1|180-183|with|drug
DDI-MedLine.d193.s1|185-189|acute|drug
DDI-MedLine.d193.s1|191-198|coronary|drug
DDI-MedLine.d193.s1|200-207|syndrome|drug
DDI-MedLine.d193.s1|209-209|(|drug
DDI-MedLine.d193.s1|210-212|ACS|drug
DDI-MedLine.d193.s1|213-213|)|drug
DDI-MedLine.d193.s1|214-214|.|drug
DDI-MedLine.d193.s2|0-1|It|drug
DDI-MedLine.d193.s2|3-6|will|drug
DDI-MedLine.d193.s2|8-14|compete|drug
DDI-MedLine.d193.s2|16-19|with|drug
DDI-MedLine.d193.s2|21-31|clopidogrel|drug
DDI-MedLine.d193.s2|33-33|(|drug
DDI-MedLine.d193.s2|34-39|Plavix|brand
DDI-MedLine.d193.s2|40-40|)|drug
DDI-MedLine.d193.s2|42-44|and|drug
DDI-MedLine.d193.s2|46-54|prasugrel|drug
DDI-MedLine.d193.s2|56-56|(|drug
DDI-MedLine.d193.s2|57-63|Effient|brand
DDI-MedLine.d193.s2|64-64|)|drug
DDI-MedLine.d193.s2|66-68|for|drug
DDI-MedLine.d193.s2|70-73|such|drug
DDI-MedLine.d193.s2|75-77|use|drug
DDI-MedLine.d193.s2|78-78|.|drug
DDI-MedLine.d193.s3|0-10|Clopidogrel|brand
DDI-MedLine.d193.s3|12-13|is|drug
DDI-MedLine.d193.s3|15-22|expected|drug
DDI-MedLine.d193.s3|24-25|to|drug
DDI-MedLine.d193.s3|27-32|become|drug
DDI-MedLine.d193.s3|34-42|available|drug
DDI-MedLine.d193.s3|44-54|generically|drug
DDI-MedLine.d193.s3|56-57|in|drug
DDI-MedLine.d193.s3|59-61|the|drug
DDI-MedLine.d193.s3|63-64|US|drug
DDI-MedLine.d193.s3|66-71|within|drug
DDI-MedLine.d193.s3|73-75|the|drug
DDI-MedLine.d193.s3|77-80|next|drug
DDI-MedLine.d193.s3|82-84|few|drug
DDI-MedLine.d193.s3|86-91|months|drug
DDI-MedLine.d193.s3|92-92|.|drug
DDI-DrugBank.d357.s0|0-3|5HT3|drug
DDI-DrugBank.d357.s0|5-15|Antagonists|drug
DDI-DrugBank.d357.s0|16-16|:|drug
DDI-DrugBank.d357.s0|18-22|Based|drug
DDI-DrugBank.d357.s0|24-25|on|drug
DDI-DrugBank.d357.s0|27-33|reports|drug
DDI-DrugBank.d357.s0|35-36|of|drug
DDI-DrugBank.d357.s0|38-45|profound|drug
DDI-DrugBank.d357.s0|47-57|hypotension|drug
DDI-DrugBank.d357.s0|59-61|and|drug
DDI-DrugBank.d357.s0|63-66|loss|drug
DDI-DrugBank.d357.s0|68-69|of|drug
DDI-DrugBank.d357.s0|71-83|consciousness|drug
DDI-DrugBank.d357.s0|85-88|when|drug
DDI-DrugBank.d357.s0|90-100|apomorphine|drug
DDI-DrugBank.d357.s0|102-104|was|drug
DDI-DrugBank.d357.s0|106-117|administered|drug
DDI-DrugBank.d357.s0|119-122|with|drug
DDI-DrugBank.d357.s0|124-134|ondansetron|drug
DDI-DrugBank.d357.s0|135-135|,|drug
DDI-DrugBank.d357.s0|137-139|the|drug
DDI-DrugBank.d357.s0|141-151|concomitant|drug
DDI-DrugBank.d357.s0|153-155|use|drug
DDI-DrugBank.d357.s0|157-158|of|drug
DDI-DrugBank.d357.s0|160-170|apomorphine|drug
DDI-DrugBank.d357.s0|172-175|with|drug
DDI-DrugBank.d357.s0|177-181|drugs|drug
DDI-DrugBank.d357.s0|183-184|of|drug
DDI-DrugBank.d357.s0|186-188|the|drug
DDI-DrugBank.d357.s0|190-193|5HT3|drug
DDI-DrugBank.d357.s0|195-204|antagonist|drug
DDI-DrugBank.d357.s0|206-210|class|drug
DDI-DrugBank.d357.s0|212-212|(|drug
DDI-DrugBank.d357.s0|213-221|including|drug
DDI-DrugBank.d357.s0|222-222|,|drug
DDI-DrugBank.d357.s0|224-226|for|drug
DDI-DrugBank.d357.s0|228-234|example|drug
DDI-DrugBank.d357.s0|235-235|,|drug
DDI-DrugBank.d357.s0|237-247|ondansetron|drug
DDI-DrugBank.d357.s0|248-248|,|drug
DDI-DrugBank.d357.s0|250-260|granisetron|drug
DDI-DrugBank.d357.s0|261-261|,|drug
DDI-DrugBank.d357.s0|263-272|dolasetron|drug
DDI-DrugBank.d357.s0|273-273|,|drug
DDI-DrugBank.d357.s0|275-286|palonosetron|drug
DDI-DrugBank.d357.s0|287-287|,|drug
DDI-DrugBank.d357.s0|289-291|and|drug
DDI-DrugBank.d357.s0|293-301|alosetron|drug
DDI-DrugBank.d357.s0|302-302|)|drug
DDI-DrugBank.d357.s0|304-305|is|drug
DDI-DrugBank.d357.s0|307-321|contraindicated|drug
DDI-DrugBank.d357.s0|323-323|.|drug
DDI-DrugBank.d357.s1|0-15|Antihypertensive|drug
DDI-DrugBank.d357.s1|17-27|Medications|drug
DDI-DrugBank.d357.s1|29-31|and|drug
DDI-DrugBank.d357.s1|33-44|Vasodilators|drug
DDI-DrugBank.d357.s1|45-45|:|drug
DDI-DrugBank.d357.s1|47-49|The|drug
DDI-DrugBank.d357.s1|51-59|following|drug
DDI-DrugBank.d357.s1|61-67|adverse|drug
DDI-DrugBank.d357.s1|69-74|events|drug
DDI-DrugBank.d357.s1|76-79|were|drug
DDI-DrugBank.d357.s1|81-91|experienced|drug
DDI-DrugBank.d357.s1|93-96|more|drug
DDI-DrugBank.d357.s1|98-105|commonly|drug
DDI-DrugBank.d357.s1|107-108|in|drug
DDI-DrugBank.d357.s1|110-117|patients|drug
DDI-DrugBank.d357.s1|119-127|receiving|drug
DDI-DrugBank.d357.s1|129-139|concomitant|drug
DDI-DrugBank.d357.s1|141-156|antihypertensive|drug
DDI-DrugBank.d357.s1|158-168|medications|drug
DDI-DrugBank.d357.s1|170-171|or|drug
DDI-DrugBank.d357.s1|173-184|vasodilators|drug
DDI-DrugBank.d357.s1|186-186|(|drug
DDI-DrugBank.d357.s1|187-187|n|drug
DDI-DrugBank.d357.s1|189-189|=|drug
DDI-DrugBank.d357.s1|191-192|94|drug
DDI-DrugBank.d357.s1|193-193|)|drug
DDI-DrugBank.d357.s1|195-202|compared|drug
DDI-DrugBank.d357.s1|204-205|to|drug
DDI-DrugBank.d357.s1|207-214|patients|drug
DDI-DrugBank.d357.s1|216-218|not|drug
DDI-DrugBank.d357.s1|220-228|receiving|drug
DDI-DrugBank.d357.s1|230-234|these|drug
DDI-DrugBank.d357.s1|236-246|concomitant|drug
DDI-DrugBank.d357.s1|248-252|drugs|drug
DDI-DrugBank.d357.s1|254-254|(|drug
DDI-DrugBank.d357.s1|255-255|n|drug
DDI-DrugBank.d357.s1|257-257|=|drug
DDI-DrugBank.d357.s1|259-261|456|drug
DDI-DrugBank.d357.s1|262-262|)|drug
DDI-DrugBank.d357.s1|263-263|:|drug
DDI-DrugBank.d357.s1|265-275|hypotension|drug
DDI-DrugBank.d357.s1|277-278|10|drug
DDI-DrugBank.d357.s1|279-279|%|drug
DDI-DrugBank.d357.s1|281-282|vs|drug
DDI-DrugBank.d357.s1|284-284|4|drug
DDI-DrugBank.d357.s1|285-285|%|drug
DDI-DrugBank.d357.s1|286-286|,|drug
DDI-DrugBank.d357.s1|288-297|myocardial|drug
DDI-DrugBank.d357.s1|299-308|infarction|drug
DDI-DrugBank.d357.s1|310-310|3|drug
DDI-DrugBank.d357.s1|311-311|%|drug
DDI-DrugBank.d357.s1|313-314|vs|drug
DDI-DrugBank.d357.s1|316-316|1|drug
DDI-DrugBank.d357.s1|317-317|%|drug
DDI-DrugBank.d357.s1|318-318|,|drug
DDI-DrugBank.d357.s1|320-326|serious|drug
DDI-DrugBank.d357.s1|328-336|pneumonia|drug
DDI-DrugBank.d357.s1|338-338|5|drug
DDI-DrugBank.d357.s1|339-339|%|drug
DDI-DrugBank.d357.s1|341-342|vs|drug
DDI-DrugBank.d357.s1|344-344|3|drug
DDI-DrugBank.d357.s1|345-345|%|drug
DDI-DrugBank.d357.s1|346-346|,|drug
DDI-DrugBank.d357.s1|348-354|serious|drug
DDI-DrugBank.d357.s1|356-360|falls|drug
DDI-DrugBank.d357.s1|362-362|9|drug
DDI-DrugBank.d357.s1|363-363|%|drug
DDI-DrugBank.d357.s1|365-366|vs|drug
DDI-DrugBank.d357.s1|368-368|3|drug
DDI-DrugBank.d357.s1|369-369|%|drug
DDI-DrugBank.d357.s1|370-370|,|drug
DDI-DrugBank.d357.s1|372-374|and|drug
DDI-DrugBank.d357.s1|376-379|bone|drug
DDI-DrugBank.d357.s1|381-383|and|drug
DDI-DrugBank.d357.s1|385-389|joint|drug
DDI-DrugBank.d357.s1|391-398|injuries|drug
DDI-DrugBank.d357.s1|400-400|6|drug
DDI-DrugBank.d357.s1|401-401|%|drug
DDI-DrugBank.d357.s1|403-404|vs|drug
DDI-DrugBank.d357.s1|406-406|2|drug
DDI-DrugBank.d357.s1|407-407|%|drug
DDI-DrugBank.d357.s1|408-408|.|drug
DDI-DrugBank.d357.s2|0-2|The|drug
DDI-DrugBank.d357.s2|4-12|mechanism|drug
DDI-DrugBank.d357.s2|14-23|underlying|drug
DDI-DrugBank.d357.s2|25-28|many|drug
DDI-DrugBank.d357.s2|30-31|of|drug
DDI-DrugBank.d357.s2|33-37|these|drug
DDI-DrugBank.d357.s2|39-44|events|drug
DDI-DrugBank.d357.s2|46-47|is|drug
DDI-DrugBank.d357.s2|49-55|unknown|drug
DDI-DrugBank.d357.s2|56-56|,|drug
DDI-DrugBank.d357.s2|58-60|but|drug
DDI-DrugBank.d357.s2|62-64|may|drug
DDI-DrugBank.d357.s2|66-74|represent|drug
DDI-DrugBank.d357.s2|76-84|increased|drug
DDI-DrugBank.d357.s2|86-96|hypotension|drug
DDI-DrugBank.d357.s2|98-98|.|drug
DDI-DrugBank.d357.s3|0-7|Dopamine|brand
DDI-DrugBank.d357.s3|9-19|Antagonists|drug
DDI-DrugBank.d357.s3|20-20|:|drug
DDI-DrugBank.d357.s3|22-26|Since|drug
DDI-DrugBank.d357.s3|28-38|apomorphine|drug
DDI-DrugBank.d357.s3|40-41|is|drug
DDI-DrugBank.d357.s3|43-43|a|drug
DDI-DrugBank.d357.s3|45-52|dopamine|drug
DDI-DrugBank.d357.s3|54-60|agonist|drug
DDI-DrugBank.d357.s3|61-61|,|drug
DDI-DrugBank.d357.s3|63-64|it|drug
DDI-DrugBank.d357.s3|66-67|is|drug
DDI-DrugBank.d357.s3|69-76|possible|drug
DDI-DrugBank.d357.s3|78-81|that|drug
DDI-DrugBank.d357.s3|83-90|dopamine|drug
DDI-DrugBank.d357.s3|92-102|antagonists|drug
DDI-DrugBank.d357.s3|103-103|,|drug
DDI-DrugBank.d357.s3|105-108|such|drug
DDI-DrugBank.d357.s3|110-111|as|drug
DDI-DrugBank.d357.s3|113-115|the|drug
DDI-DrugBank.d357.s3|117-128|neuroleptics|drug
DDI-DrugBank.d357.s3|130-130|(|drug
DDI-DrugBank.d357.s3|131-144|phenothiazines|drug
DDI-DrugBank.d357.s3|145-145|,|drug
DDI-DrugBank.d357.s3|147-160|butyrophenones|drug
DDI-DrugBank.d357.s3|161-161|,|drug
DDI-DrugBank.d357.s3|163-175|thioxanthenes|drug
DDI-DrugBank.d357.s3|176-176|)|drug
DDI-DrugBank.d357.s3|178-179|or|drug
DDI-DrugBank.d357.s3|181-194|metoclopramide|drug
DDI-DrugBank.d357.s3|195-195|,|drug
DDI-DrugBank.d357.s3|197-199|may|drug
DDI-DrugBank.d357.s3|201-208|diminish|drug
DDI-DrugBank.d357.s3|210-212|the|drug
DDI-DrugBank.d357.s3|214-226|effectiveness|drug
DDI-DrugBank.d357.s3|228-229|of|drug
DDI-DrugBank.d357.s3|231-236|APOKYN|drug
DDI-DrugBank.d357.s3|237-237|.|drug
DDI-DrugBank.d357.s4|0-7|Patients|drug
DDI-DrugBank.d357.s4|9-12|with|drug
DDI-DrugBank.d357.s4|14-18|major|drug
DDI-DrugBank.d357.s4|20-28|psychotic|drug
DDI-DrugBank.d357.s4|30-38|disorders|drug
DDI-DrugBank.d357.s4|39-39|,|drug
DDI-DrugBank.d357.s4|41-47|treated|drug
DDI-DrugBank.d357.s4|49-52|with|drug
DDI-DrugBank.d357.s4|54-65|neuroleptics|drug
DDI-DrugBank.d357.s4|66-66|,|drug
DDI-DrugBank.d357.s4|68-73|should|drug
DDI-DrugBank.d357.s4|75-76|be|drug
DDI-DrugBank.d357.s4|78-84|treated|drug
DDI-DrugBank.d357.s4|86-89|with|drug
DDI-DrugBank.d357.s4|91-98|dopamine|drug
DDI-DrugBank.d357.s4|100-107|agonists|drug
DDI-DrugBank.d357.s4|109-112|only|drug
DDI-DrugBank.d357.s4|114-115|if|drug
DDI-DrugBank.d357.s4|117-119|the|drug
DDI-DrugBank.d357.s4|121-129|potential|drug
DDI-DrugBank.d357.s4|131-138|benefits|drug
DDI-DrugBank.d357.s4|140-147|outweigh|drug
DDI-DrugBank.d357.s4|149-151|the|drug
DDI-DrugBank.d357.s4|153-157|risks|drug
DDI-DrugBank.d357.s4|158-158|.|drug
DDI-DrugBank.d357.s5|0-4|Drugs|drug
DDI-DrugBank.d357.s5|6-15|Prolonging|drug
DDI-DrugBank.d357.s5|17-19|the|drug
DDI-DrugBank.d357.s5|21-26|QT/QTc|drug
DDI-DrugBank.d357.s5|28-35|Interval|drug
DDI-DrugBank.d357.s5|37-43|Caution|drug
DDI-DrugBank.d357.s5|45-50|should|drug
DDI-DrugBank.d357.s5|52-53|be|drug
DDI-DrugBank.d357.s5|55-63|exercised|drug
DDI-DrugBank.d357.s5|65-68|when|drug
DDI-DrugBank.d357.s5|70-80|prescribing|drug
DDI-DrugBank.d357.s5|82-92|apomorphine|drug
DDI-DrugBank.d357.s5|94-106|concomitantly|drug
DDI-DrugBank.d357.s5|108-111|with|drug
DDI-DrugBank.d357.s5|113-117|drugs|drug
DDI-DrugBank.d357.s5|119-122|that|drug
DDI-DrugBank.d357.s5|124-130|prolong|drug
DDI-DrugBank.d357.s5|132-134|the|drug
DDI-DrugBank.d357.s5|136-141|QT/QTc|drug
DDI-DrugBank.d357.s5|143-150|interval|drug
DDI-DrugBank.d357.s5|151-151|.|drug
DDI-DrugBank.d357.s6|0-14|Drug/Laboratory|drug
DDI-DrugBank.d357.s6|16-19|Test|drug
DDI-DrugBank.d357.s6|21-32|Interactions|drug
DDI-DrugBank.d357.s6|34-38|There|drug
DDI-DrugBank.d357.s6|40-42|are|drug
DDI-DrugBank.d357.s6|44-45|no|drug
DDI-DrugBank.d357.s6|47-51|known|drug
DDI-DrugBank.d357.s6|53-64|interactions|drug
DDI-DrugBank.d357.s6|66-72|between|drug
DDI-DrugBank.d357.s6|74-79|APOKYN|drug
DDI-DrugBank.d357.s6|81-83|and|drug
DDI-DrugBank.d357.s6|85-94|laboratory|drug
DDI-DrugBank.d357.s6|96-100|tests|drug
DDI-DrugBank.d357.s6|101-101|.|drug
DDI-DrugBank.d371.s0|0-4|There|drug
DDI-DrugBank.d371.s0|6-9|have|drug
DDI-DrugBank.d371.s0|11-14|been|drug
DDI-DrugBank.d371.s0|16-17|no|drug
DDI-DrugBank.d371.s0|19-24|formal|drug
DDI-DrugBank.d371.s0|26-33|clinical|drug
DDI-DrugBank.d371.s0|35-41|studies|drug
DDI-DrugBank.d371.s0|43-44|to|drug
DDI-DrugBank.d371.s0|46-53|evaluate|drug
DDI-DrugBank.d371.s0|55-57|the|drug
DDI-DrugBank.d371.s0|59-62|drug|drug
DDI-DrugBank.d371.s0|64-75|interactions|drug
DDI-DrugBank.d371.s0|77-78|of|drug
DDI-DrugBank.d371.s0|80-87|TAXOTERE|drug
DDI-DrugBank.d371.s0|89-92|with|drug
DDI-DrugBank.d371.s0|94-98|other|drug
DDI-DrugBank.d371.s0|100-110|medications|drug
DDI-DrugBank.d371.s0|111-111|.|drug
DDI-DrugBank.d371.s1|0-1|In|drug
DDI-DrugBank.d371.s1|3-7|vitro|drug
DDI-DrugBank.d371.s1|9-15|studies|drug
DDI-DrugBank.d371.s1|17-20|have|drug
DDI-DrugBank.d371.s1|22-26|shown|drug
DDI-DrugBank.d371.s1|28-31|that|drug
DDI-DrugBank.d371.s1|33-35|the|drug
DDI-DrugBank.d371.s1|37-46|metabolism|drug
DDI-DrugBank.d371.s1|48-49|of|drug
DDI-DrugBank.d371.s1|51-59|docetaxel|drug
DDI-DrugBank.d371.s1|61-63|may|drug
DDI-DrugBank.d371.s1|65-66|be|drug
DDI-DrugBank.d371.s1|68-75|modified|drug
DDI-DrugBank.d371.s1|77-78|by|drug
DDI-DrugBank.d371.s1|80-82|the|drug
DDI-DrugBank.d371.s1|84-94|concomitant|drug
DDI-DrugBank.d371.s1|96-109|administration|drug
DDI-DrugBank.d371.s1|111-112|of|drug
DDI-DrugBank.d371.s1|114-122|compounds|drug
DDI-DrugBank.d371.s1|124-127|that|drug
DDI-DrugBank.d371.s1|129-134|induce|drug
DDI-DrugBank.d371.s1|135-135|,|drug
DDI-DrugBank.d371.s1|137-143|inhibit|drug
DDI-DrugBank.d371.s1|144-144|,|drug
DDI-DrugBank.d371.s1|146-147|or|drug
DDI-DrugBank.d371.s1|149-151|are|drug
DDI-DrugBank.d371.s1|153-163|metabolized|drug
DDI-DrugBank.d371.s1|165-166|by|drug
DDI-DrugBank.d371.s1|168-177|cytochrome|drug
DDI-DrugBank.d371.s1|179-182|P450|drug
DDI-DrugBank.d371.s1|184-186|3A4|drug
DDI-DrugBank.d371.s1|187-187|,|drug
DDI-DrugBank.d371.s1|189-192|such|drug
DDI-DrugBank.d371.s1|194-195|as|drug
DDI-DrugBank.d371.s1|197-208|cyclosporine|drug
DDI-DrugBank.d371.s1|209-209|,|drug
DDI-DrugBank.d371.s1|211-221|terfenadine|drug
DDI-DrugBank.d371.s1|222-222|,|drug
DDI-DrugBank.d371.s1|224-235|ketoconazole|drug
DDI-DrugBank.d371.s1|236-236|,|drug
DDI-DrugBank.d371.s1|238-249|erythromycin|drug
DDI-DrugBank.d371.s1|250-250|,|drug
DDI-DrugBank.d371.s1|252-254|and|drug
DDI-DrugBank.d371.s1|256-269|troleandomycin|drug
DDI-DrugBank.d371.s1|270-270|.|drug
DDI-DrugBank.d371.s2|0-6|Caution|drug
DDI-DrugBank.d371.s2|8-13|should|drug
DDI-DrugBank.d371.s2|15-16|be|drug
DDI-DrugBank.d371.s2|18-26|exercised|drug
DDI-DrugBank.d371.s2|28-31|with|drug
DDI-DrugBank.d371.s2|33-37|these|drug
DDI-DrugBank.d371.s2|39-43|drugs|drug
DDI-DrugBank.d371.s2|45-48|when|drug
DDI-DrugBank.d371.s2|50-57|treating|drug
DDI-DrugBank.d371.s2|59-66|patients|drug
DDI-DrugBank.d371.s2|68-76|receiving|drug
DDI-DrugBank.d371.s2|78-85|TAXOTERE|drug
DDI-DrugBank.d371.s2|87-88|as|drug
DDI-DrugBank.d371.s2|90-94|there|drug
DDI-DrugBank.d371.s2|96-97|is|drug
DDI-DrugBank.d371.s2|99-99|a|drug
DDI-DrugBank.d371.s2|101-109|potential|drug
DDI-DrugBank.d371.s2|111-113|for|drug
DDI-DrugBank.d371.s2|115-115|a|drug
DDI-DrugBank.d371.s2|117-127|significant|drug
DDI-DrugBank.d371.s2|129-139|interaction|drug
DDI-DrugBank.d371.s2|140-140|.|drug
DDI-DrugBank.d756.s0|0-6|Dosages|drug
DDI-DrugBank.d756.s0|8-9|of|drug
DDI-DrugBank.d756.s0|11-23|concomitantly|drug
DDI-DrugBank.d756.s0|25-36|administered|drug
DDI-DrugBank.d756.s0|38-44|opioids|drug
DDI-DrugBank.d756.s0|46-51|should|drug
DDI-DrugBank.d756.s0|53-54|be|drug
DDI-DrugBank.d756.s0|56-62|reduced|drug
DDI-DrugBank.d756.s0|64-65|by|drug
DDI-DrugBank.d756.s0|67-79|approximately|drug
DDI-DrugBank.d756.s0|81-84|half|drug
DDI-DrugBank.d756.s0|85-85|,|drug
DDI-DrugBank.d756.s0|87-93|because|drug
DDI-DrugBank.d756.s0|95-109|levomepromazine|drug
DDI-DrugBank.d756.s0|111-119|amplifies|drug
DDI-DrugBank.d756.s0|121-123|the|drug
DDI-DrugBank.d756.s0|125-135|therapeutic|drug
DDI-DrugBank.d756.s0|137-143|actions|drug
DDI-DrugBank.d756.s0|145-147|and|drug
DDI-DrugBank.d756.s0|149-160|side-effects|drug
DDI-DrugBank.d756.s0|162-163|of|drug
DDI-DrugBank.d756.s0|165-171|opioids|drug
DDI-DrugBank.d756.s0|172-172|.|drug
DDI-DrugBank.d756.s1|0-10|Combination|drug
DDI-DrugBank.d756.s1|12-15|with|drug
DDI-DrugBank.d756.s1|17-24|tramadol|drug
DDI-DrugBank.d756.s1|26-26|(|drug
DDI-DrugBank.d756.s1|27-32|Ultram|brand
DDI-DrugBank.d756.s1|33-33|)|drug
DDI-DrugBank.d756.s1|35-36|is|drug
DDI-DrugBank.d756.s1|38-47|associated|drug
DDI-DrugBank.d756.s1|49-52|with|drug
DDI-DrugBank.d756.s1|54-62|increased|drug
DDI-DrugBank.d756.s1|64-67|risk|drug
DDI-DrugBank.d756.s1|69-70|of|drug
DDI-DrugBank.d756.s1|72-79|seizures|drug
DDI-DrugBank.d756.s1|80-80|.|drug
DDI-DrugBank.d756.s2|0-7|Additive|drug
DDI-DrugBank.d756.s2|9-16|sedative|drug
DDI-DrugBank.d756.s2|18-24|effects|drug
DDI-DrugBank.d756.s2|26-28|and|drug
DDI-DrugBank.d756.s2|30-40|confusional|drug
DDI-DrugBank.d756.s2|42-47|states|drug
DDI-DrugBank.d756.s2|49-51|may|drug
DDI-DrugBank.d756.s2|53-58|emerge|drug
DDI-DrugBank.d756.s2|60-61|if|drug
DDI-DrugBank.d756.s2|63-77|levomepromazine|drug
DDI-DrugBank.d756.s2|79-80|is|drug
DDI-DrugBank.d756.s2|82-86|given|drug
DDI-DrugBank.d756.s2|88-91|with|drug
DDI-DrugBank.d756.s2|93-107|benzodiazepines|drug
DDI-DrugBank.d756.s2|109-110|or|drug
DDI-DrugBank.d756.s2|112-123|barbiturates|drug
DDI-DrugBank.d756.s2|124-124|.|drug
DDI-DrugBank.d756.s3|0-3|This|drug
DDI-DrugBank.d756.s3|5-7|may|drug
DDI-DrugBank.d756.s3|9-10|be|drug
DDI-DrugBank.d756.s3|12-18|avoided|drug
DDI-DrugBank.d756.s3|20-21|by|drug
DDI-DrugBank.d756.s3|23-27|using|drug
DDI-DrugBank.d756.s3|29-31|the|drug
DDI-DrugBank.d756.s3|33-38|lowest|drug
DDI-DrugBank.d756.s3|40-43|dose|drug
DDI-DrugBank.d756.s3|45-52|possible|drug
DDI-DrugBank.d756.s3|54-57|with|drug
DDI-DrugBank.d756.s3|59-61|the|drug
DDI-DrugBank.d756.s3|63-72|substances|drug
DDI-DrugBank.d756.s3|74-75|in|drug
DDI-DrugBank.d756.s3|77-84|question|drug
DDI-DrugBank.d756.s3|85-85|.|drug
DDI-DrugBank.d756.s4|0-4|Exert|drug
DDI-DrugBank.d756.s4|6-15|particular|drug
DDI-DrugBank.d756.s4|17-23|caution|drug
DDI-DrugBank.d756.s4|25-26|in|drug
DDI-DrugBank.d756.s4|28-36|combining|drug
DDI-DrugBank.d756.s4|38-52|levomepromazine|drug
DDI-DrugBank.d756.s4|54-57|with|drug
DDI-DrugBank.d756.s4|59-63|other|drug
DDI-DrugBank.d756.s4|65-79|anticholinergic|drug
DDI-DrugBank.d756.s4|81-85|drugs|drug
DDI-DrugBank.d756.s4|87-87|(|drug
DDI-DrugBank.d756.s4|88-96|tricyclic|drug
DDI-DrugBank.d756.s4|98-112|antidepressants|drug
DDI-DrugBank.d756.s4|114-116|and|drug
DDI-DrugBank.d756.s4|118-140|antiparkinsonian-agents|drug
DDI-DrugBank.d756.s4|141-141|)|drug
DDI-DrugBank.d756.s4|142-142|:|drug
DDI-DrugBank.d756.s4|144-155|Particularly|drug
DDI-DrugBank.d756.s4|157-159|the|drug
DDI-DrugBank.d756.s4|161-167|elderly|drug
DDI-DrugBank.d756.s4|169-171|may|drug
DDI-DrugBank.d756.s4|173-179|develop|drug
DDI-DrugBank.d756.s4|181-188|delirium|drug
DDI-DrugBank.d756.s4|189-189|,|drug
DDI-DrugBank.d756.s4|191-194|high|drug
DDI-DrugBank.d756.s4|196-200|fever|drug
DDI-DrugBank.d756.s4|201-201|,|drug
DDI-DrugBank.d756.s4|203-208|severe|drug
DDI-DrugBank.d756.s4|210-220|obstipation|drug
DDI-DrugBank.d756.s4|221-221|,|drug
DDI-DrugBank.d756.s4|223-226|even|drug
DDI-DrugBank.d756.s4|228-232|ileus|drug
DDI-DrugBank.d756.s4|234-236|and|drug
DDI-DrugBank.d756.s4|238-245|glaucoma|drug
DDI-DrugBank.d756.s4|246-246|.|drug
DDI-DrugBank.d756.s5|0-5|Reduce|drug
DDI-DrugBank.d756.s5|7-10|both|drug
DDI-DrugBank.d756.s5|12-14|the|drug
DDI-DrugBank.d756.s5|16-19|dose|drug
DDI-DrugBank.d756.s5|21-22|of|drug
DDI-DrugBank.d756.s5|24-38|levomepromazine|drug
DDI-DrugBank.d756.s5|40-42|and|drug
DDI-DrugBank.d756.s5|44-46|the|drug
DDI-DrugBank.d756.s5|48-51|dose|drug
DDI-DrugBank.d756.s5|53-54|of|drug
DDI-DrugBank.d756.s5|56-58|the|drug
DDI-DrugBank.d756.s5|60-64|other|drug
DDI-DrugBank.d756.s5|66-69|drug|drug
DDI-DrugBank.d756.s5|70-70|.|drug
DDI-DrugBank.d756.s6|0-1|If|drug
DDI-DrugBank.d756.s6|3-10|possible|drug
DDI-DrugBank.d756.s6|11-11|,|drug
DDI-DrugBank.d756.s6|13-17|avoid|drug
DDI-DrugBank.d756.s6|19-22|such|drug
DDI-DrugBank.d756.s6|24-35|combinations|drug
DDI-DrugBank.d756.s6|36-36|.|drug
DDI-DrugBank.d756.s7|0-7|Caffeine|brand
DDI-DrugBank.d756.s7|9-14|and/or|drug
DDI-DrugBank.d756.s7|16-26|stimulantes|drug
DDI-DrugBank.d756.s7|28-29|of|drug
DDI-DrugBank.d756.s7|31-33|the|drug
DDI-DrugBank.d756.s7|35-55|ephedrine/amphetamine|drug
DDI-DrugBank.d756.s7|57-60|type|drug
DDI-DrugBank.d756.s7|62-64|may|drug
DDI-DrugBank.d756.s7|66-75|counteract|drug
DDI-DrugBank.d756.s7|77-79|the|drug
DDI-DrugBank.d756.s7|81-88|specific|drug
DDI-DrugBank.d756.s7|90-96|actions|drug
DDI-DrugBank.d756.s7|98-99|of|drug
DDI-DrugBank.d756.s7|101-115|levomepromazine|drug
DDI-DrugBank.d756.s7|116-116|.|drug
DDI-DrugBank.d756.s8|0-10|Concomitant|drug
DDI-DrugBank.d756.s8|12-14|use|drug
DDI-DrugBank.d756.s8|16-17|of|drug
DDI-DrugBank.d756.s8|19-23|these|drug
DDI-DrugBank.d756.s8|25-34|substances|drug
DDI-DrugBank.d756.s8|36-41|should|drug
DDI-DrugBank.d756.s8|43-44|be|drug
DDI-DrugBank.d756.s8|46-52|avoided|drug
DDI-DrugBank.d756.s8|53-53|.|drug
DDI-DrugBank.d756.s9|0-5|Coffee|brand
DDI-DrugBank.d756.s9|7-9|and|drug
DDI-DrugBank.d756.s9|11-15|black|drug
DDI-DrugBank.d756.s9|17-19|tea|drug
DDI-DrugBank.d756.s9|21-26|should|drug
DDI-DrugBank.d756.s9|28-29|be|drug
DDI-DrugBank.d756.s9|31-37|avoided|drug
DDI-DrugBank.d756.s9|39-45|because|drug
DDI-DrugBank.d756.s9|47-50|they|drug
DDI-DrugBank.d756.s9|52-59|decrease|drug
DDI-DrugBank.d756.s9|61-63|the|drug
DDI-DrugBank.d756.s9|65-74|absorption|drug
DDI-DrugBank.d756.s9|76-77|of|drug
DDI-DrugBank.d756.s9|79-93|levomepromazine|drug
DDI-DrugBank.d756.s9|95-106|considerably|drug
DDI-DrugBank.d756.s9|107-107|.|drug
DDI-DrugBank.d756.s10|0-2|The|drug
DDI-DrugBank.d756.s10|4-7|same|drug
DDI-DrugBank.d756.s10|9-10|is|drug
DDI-DrugBank.d756.s10|12-15|true|drug
DDI-DrugBank.d756.s10|17-19|for|drug
DDI-DrugBank.d756.s10|21-28|antacids|drug
DDI-DrugBank.d756.s10|29-29|;|drug
DDI-DrugBank.d756.s11|0-4|these|drug
DDI-DrugBank.d756.s11|6-11|should|drug
DDI-DrugBank.d756.s11|13-14|be|drug
DDI-DrugBank.d756.s11|16-20|given|drug
DDI-DrugBank.d756.s11|22-22|1|drug
DDI-DrugBank.d756.s11|24-25|to|drug
DDI-DrugBank.d756.s11|27-27|2|drug
DDI-DrugBank.d756.s11|29-33|hours|drug
DDI-DrugBank.d756.s11|35-40|before|drug
DDI-DrugBank.d756.s11|42-43|or|drug
DDI-DrugBank.d756.s11|45-49|after|drug
DDI-DrugBank.d756.s11|51-54|oral|drug
DDI-DrugBank.d756.s11|56-69|administration|drug
DDI-DrugBank.d756.s11|71-72|of|drug
DDI-DrugBank.d756.s11|74-89|leveomepromazine|drug
DDI-DrugBank.d756.s11|90-90|.|drug
DDI-DrugBank.d739.s0|0-10|Montelukast|brand
DDI-DrugBank.d739.s0|12-13|at|drug
DDI-DrugBank.d739.s0|15-15|a|drug
DDI-DrugBank.d739.s0|17-20|Dose|drug
DDI-DrugBank.d739.s0|22-23|of|drug
DDI-DrugBank.d739.s0|25-26|10|drug
DDI-DrugBank.d739.s0|28-29|mg|drug
DDI-DrugBank.d739.s0|31-34|Once|drug
DDI-DrugBank.d739.s0|36-40|Daily|drug
DDI-DrugBank.d739.s0|42-46|Dosed|drug
DDI-DrugBank.d739.s0|48-49|to|drug
DDI-DrugBank.d739.s0|51-65|Pharmacokinetic|drug
DDI-DrugBank.d739.s0|67-72|Steady|drug
DDI-DrugBank.d739.s0|74-78|State|drug
DDI-DrugBank.d739.s0|81-81|-|drug
DDI-DrugBank.d739.s0|83-85|did|drug
DDI-DrugBank.d739.s0|87-89|not|drug
DDI-DrugBank.d739.s0|91-95|cause|drug
DDI-DrugBank.d739.s0|97-106|clinically|drug
DDI-DrugBank.d739.s0|108-118|significant|drug
DDI-DrugBank.d739.s0|120-126|changes|drug
DDI-DrugBank.d739.s0|128-129|in|drug
DDI-DrugBank.d739.s0|131-133|the|drug
DDI-DrugBank.d739.s0|135-142|kinetics|drug
DDI-DrugBank.d739.s0|144-145|of|drug
DDI-DrugBank.d739.s0|147-147|a|drug
DDI-DrugBank.d739.s0|149-154|single|drug
DDI-DrugBank.d739.s0|156-166|intravenous|drug
DDI-DrugBank.d739.s0|168-171|dose|drug
DDI-DrugBank.d739.s0|173-174|of|drug
DDI-DrugBank.d739.s0|176-187|theophylline|drug
DDI-DrugBank.d739.s0|189-189|(|drug
DDI-DrugBank.d739.s0|190-202|predominantly|drug
DDI-DrugBank.d739.s0|204-204|a|drug
DDI-DrugBank.d739.s0|206-215|cytochrome|drug
DDI-DrugBank.d739.s0|217-220|P450|drug
DDI-DrugBank.d739.s0|222-224|1A2|drug
DDI-DrugBank.d739.s0|226-234|substrate|drug
DDI-DrugBank.d739.s0|235-235|)|drug
DDI-DrugBank.d739.s0|236-236|.|drug
DDI-DrugBank.d739.s1|0-0|-|drug
DDI-DrugBank.d739.s1|2-4|did|drug
DDI-DrugBank.d739.s1|6-8|not|drug
DDI-DrugBank.d739.s1|10-15|change|drug
DDI-DrugBank.d739.s1|17-19|the|drug
DDI-DrugBank.d739.s1|21-35|pharmacokinetic|drug
DDI-DrugBank.d739.s1|37-43|profile|drug
DDI-DrugBank.d739.s1|45-46|of|drug
DDI-DrugBank.d739.s1|48-55|warfarin|drug
DDI-DrugBank.d739.s1|57-57|(|drug
DDI-DrugBank.d739.s1|58-58|a|drug
DDI-DrugBank.d739.s1|60-68|substrate|drug
DDI-DrugBank.d739.s1|70-71|of|drug
DDI-DrugBank.d739.s1|73-83|cytochromes|drug
DDI-DrugBank.d739.s1|85-88|P450|drug
DDI-DrugBank.d739.s1|90-92|2A6|drug
DDI-DrugBank.d739.s1|94-96|and|drug
DDI-DrugBank.d739.s1|98-100|2C9|drug
DDI-DrugBank.d739.s1|101-101|)|drug
DDI-DrugBank.d739.s1|103-104|or|drug
DDI-DrugBank.d739.s1|106-114|influence|drug
DDI-DrugBank.d739.s1|116-118|the|drug
DDI-DrugBank.d739.s1|120-125|effect|drug
DDI-DrugBank.d739.s1|127-128|of|drug
DDI-DrugBank.d739.s1|130-130|a|drug
DDI-DrugBank.d739.s1|132-137|single|drug
DDI-DrugBank.d739.s1|139-143|30-mg|drug
DDI-DrugBank.d739.s1|145-148|oral|drug
DDI-DrugBank.d739.s1|150-153|dose|drug
DDI-DrugBank.d739.s1|155-156|of|drug
DDI-DrugBank.d739.s1|158-165|warfarin|drug
DDI-DrugBank.d739.s1|167-168|on|drug
DDI-DrugBank.d739.s1|170-180|prothrombin|drug
DDI-DrugBank.d739.s1|182-185|time|drug
DDI-DrugBank.d739.s1|187-188|or|drug
DDI-DrugBank.d739.s1|190-192|the|drug
DDI-DrugBank.d739.s1|194-196|INR|drug
DDI-DrugBank.d739.s1|198-198|(|drug
DDI-DrugBank.d739.s1|199-211|International|drug
DDI-DrugBank.d739.s1|213-222|Normalized|drug
DDI-DrugBank.d739.s1|224-228|Ratio|drug
DDI-DrugBank.d739.s1|229-229|)|drug
DDI-DrugBank.d739.s1|230-230|.|drug
DDI-DrugBank.d739.s2|0-0|-|drug
DDI-DrugBank.d739.s2|2-4|did|drug
DDI-DrugBank.d739.s2|6-8|not|drug
DDI-DrugBank.d739.s2|10-15|change|drug
DDI-DrugBank.d739.s2|17-19|the|drug
DDI-DrugBank.d739.s2|21-35|pharmacokinetic|drug
DDI-DrugBank.d739.s2|37-43|profile|drug
DDI-DrugBank.d739.s2|45-46|or|drug
DDI-DrugBank.d739.s2|48-54|urinary|drug
DDI-DrugBank.d739.s2|56-64|excretion|drug
DDI-DrugBank.d739.s2|66-67|of|drug
DDI-DrugBank.d739.s2|69-82|immunoreactive|drug
DDI-DrugBank.d739.s2|84-90|digoxin|drug
DDI-DrugBank.d739.s2|91-91|.|drug
DDI-DrugBank.d739.s3|0-0|-|drug
DDI-DrugBank.d739.s3|2-4|did|drug
DDI-DrugBank.d739.s3|6-8|not|drug
DDI-DrugBank.d739.s3|10-15|change|drug
DDI-DrugBank.d739.s3|17-19|the|drug
DDI-DrugBank.d739.s3|21-26|plasma|drug
DDI-DrugBank.d739.s3|28-40|concentration|drug
DDI-DrugBank.d739.s3|42-48|profile|drug
DDI-DrugBank.d739.s3|50-51|of|drug
DDI-DrugBank.d739.s3|53-63|terfenadine|drug
DDI-DrugBank.d739.s3|65-65|(|drug
DDI-DrugBank.d739.s3|66-66|a|drug
DDI-DrugBank.d739.s3|68-76|substrate|drug
DDI-DrugBank.d739.s3|78-79|of|drug
DDI-DrugBank.d739.s3|81-90|cytochrome|drug
DDI-DrugBank.d739.s3|92-95|P450|drug
DDI-DrugBank.d739.s3|97-99|3A4|drug
DDI-DrugBank.d739.s3|100-100|)|drug
DDI-DrugBank.d739.s3|102-103|or|drug
DDI-DrugBank.d739.s3|105-116|fexofenadine|drug
DDI-DrugBank.d739.s3|117-117|,|drug
DDI-DrugBank.d739.s3|119-121|its|drug
DDI-DrugBank.d739.s3|123-134|carboxylated|drug
DDI-DrugBank.d739.s3|136-145|metabolite|drug
DDI-DrugBank.d739.s3|146-146|,|drug
DDI-DrugBank.d739.s3|148-150|and|drug
DDI-DrugBank.d739.s3|152-154|did|drug
DDI-DrugBank.d739.s3|156-158|not|drug
DDI-DrugBank.d739.s3|160-166|prolong|drug
DDI-DrugBank.d739.s3|168-170|the|drug
DDI-DrugBank.d739.s3|172-174|QTc|drug
DDI-DrugBank.d739.s3|176-183|interval|drug
DDI-DrugBank.d739.s3|185-193|following|drug
DDI-DrugBank.d739.s3|195-211|co-administration|drug
DDI-DrugBank.d739.s3|213-216|with|drug
DDI-DrugBank.d739.s3|218-228|terfenadine|drug
DDI-DrugBank.d739.s3|230-231|60|drug
DDI-DrugBank.d739.s3|233-234|mg|drug
DDI-DrugBank.d739.s3|236-240|twice|drug
DDI-DrugBank.d739.s3|242-246|daily|drug
DDI-DrugBank.d739.s3|247-247|.|drug
DDI-DrugBank.d739.s4|0-10|Montelukast|brand
DDI-DrugBank.d739.s4|12-13|at|drug
DDI-DrugBank.d739.s4|15-19|Doses|drug
DDI-DrugBank.d739.s4|21-22|of|drug
DDI-DrugBank.d739.s4|27-29|100|drug
DDI-DrugBank.d739.s4|31-32|mg|drug
DDI-DrugBank.d739.s4|34-38|Daily|drug
DDI-DrugBank.d739.s4|40-44|Dosed|drug
DDI-DrugBank.d739.s4|46-47|to|drug
DDI-DrugBank.d739.s4|49-63|Pharmacokinetic|drug
DDI-DrugBank.d739.s4|65-70|Steady|drug
DDI-DrugBank.d739.s4|72-76|State|drug
DDI-DrugBank.d739.s4|77-77|:|drug
DDI-DrugBank.d739.s4|80-80|-|drug
DDI-DrugBank.d739.s4|82-84|did|drug
DDI-DrugBank.d739.s4|86-88|not|drug
DDI-DrugBank.d739.s4|90-102|significantly|drug
DDI-DrugBank.d739.s4|104-108|alter|drug
DDI-DrugBank.d739.s4|110-112|the|drug
DDI-DrugBank.d739.s4|114-119|plasma|drug
DDI-DrugBank.d739.s4|121-134|concentrations|drug
DDI-DrugBank.d739.s4|136-137|of|drug
DDI-DrugBank.d739.s4|139-144|either|drug
DDI-DrugBank.d739.s4|146-154|component|drug
DDI-DrugBank.d739.s4|156-157|of|drug
DDI-DrugBank.d739.s4|159-160|an|drug
DDI-DrugBank.d739.s4|162-165|oral|drug
DDI-DrugBank.d739.s4|167-179|contraceptive|drug
DDI-DrugBank.d739.s4|181-190|containing|drug
DDI-DrugBank.d739.s4|192-204|norethindrone|drug
DDI-DrugBank.d739.s4|206-206|1|drug
DDI-DrugBank.d739.s4|208-217|mg/ethinyl|drug
DDI-DrugBank.d739.s4|219-227|estradiol|drug
DDI-DrugBank.d739.s4|229-230|35|drug
DDI-DrugBank.d739.s4|232-234|mcg|drug
DDI-DrugBank.d739.s4|235-235|.|drug
DDI-DrugBank.d739.s5|0-0|-|drug
DDI-DrugBank.d739.s5|2-4|did|drug
DDI-DrugBank.d739.s5|6-8|not|drug
DDI-DrugBank.d739.s5|10-14|cause|drug
DDI-DrugBank.d739.s5|16-18|any|drug
DDI-DrugBank.d739.s5|20-29|clinically|drug
DDI-DrugBank.d739.s5|31-41|significant|drug
DDI-DrugBank.d739.s5|43-48|change|drug
DDI-DrugBank.d739.s5|50-51|in|drug
DDI-DrugBank.d739.s5|53-58|plasma|drug
DDI-DrugBank.d739.s5|60-67|profiles|drug
DDI-DrugBank.d739.s5|69-70|of|drug
DDI-DrugBank.d739.s5|72-81|prednisone|drug
DDI-DrugBank.d739.s5|83-84|or|drug
DDI-DrugBank.d739.s5|86-97|prednisolone|drug
DDI-DrugBank.d739.s5|99-107|following|drug
DDI-DrugBank.d739.s5|109-122|administration|drug
DDI-DrugBank.d739.s5|124-125|of|drug
DDI-DrugBank.d739.s5|127-132|either|drug
DDI-DrugBank.d739.s5|134-137|oral|drug
DDI-DrugBank.d739.s5|139-148|prednisone|drug
DDI-DrugBank.d739.s5|150-151|or|drug
DDI-DrugBank.d739.s5|153-163|intravenous|drug
DDI-DrugBank.d739.s5|165-176|prednisolone|drug
DDI-DrugBank.d739.s5|177-177|.|drug
DDI-DrugBank.d739.s6|0-12|Phenobarbital|brand
DDI-DrugBank.d739.s6|13-13|,|drug
DDI-DrugBank.d739.s6|15-19|which|drug
DDI-DrugBank.d739.s6|21-27|induces|drug
DDI-DrugBank.d739.s6|29-35|hepatic|drug
DDI-DrugBank.d739.s6|37-46|metabolism|drug
DDI-DrugBank.d739.s6|47-47|,|drug
DDI-DrugBank.d739.s6|49-57|decreased|drug
DDI-DrugBank.d739.s6|59-61|the|drug
DDI-DrugBank.d739.s6|63-65|AUC|drug
DDI-DrugBank.d739.s6|67-68|of|drug
DDI-DrugBank.d739.s6|70-80|montelukast|drug
DDI-DrugBank.d739.s6|82-94|approximately|drug
DDI-DrugBank.d739.s6|96-97|40|drug
DDI-DrugBank.d739.s6|98-98|%|drug
DDI-DrugBank.d739.s6|100-108|following|drug
DDI-DrugBank.d739.s6|110-110|a|drug
DDI-DrugBank.d739.s6|112-117|single|drug
DDI-DrugBank.d739.s6|119-123|10-mg|drug
DDI-DrugBank.d739.s6|125-128|dose|drug
DDI-DrugBank.d739.s6|130-131|of|drug
DDI-DrugBank.d739.s6|133-143|montelukast|drug
DDI-DrugBank.d739.s6|144-144|.|drug
DDI-DrugBank.d739.s7|0-1|No|drug
DDI-DrugBank.d739.s7|3-8|dosage|drug
DDI-DrugBank.d739.s7|10-19|adjustment|drug
DDI-DrugBank.d739.s7|21-23|for|drug
DDI-DrugBank.d739.s7|25-35|montelukast|drug
DDI-DrugBank.d739.s7|37-38|is|drug
DDI-DrugBank.d739.s7|40-50|recommended|drug
DDI-DrugBank.d739.s7|51-51|.|drug
DDI-DrugBank.d739.s8|0-1|It|drug
DDI-DrugBank.d739.s8|3-4|is|drug
DDI-DrugBank.d739.s8|6-15|reasonable|drug
DDI-DrugBank.d739.s8|17-18|to|drug
DDI-DrugBank.d739.s8|20-25|employ|drug
DDI-DrugBank.d739.s8|27-37|appropriate|drug
DDI-DrugBank.d739.s8|39-46|clinical|drug
DDI-DrugBank.d739.s8|48-57|monitoring|drug
DDI-DrugBank.d739.s8|59-62|when|drug
DDI-DrugBank.d739.s8|64-69|potent|drug
DDI-DrugBank.d739.s8|71-80|cytochrome|drug
DDI-DrugBank.d739.s8|82-85|P450|drug
DDI-DrugBank.d739.s8|87-92|enzyme|drug
DDI-DrugBank.d739.s8|94-101|inducers|drug
DDI-DrugBank.d739.s8|102-102|,|drug
DDI-DrugBank.d739.s8|104-107|such|drug
DDI-DrugBank.d739.s8|109-110|as|drug
DDI-DrugBank.d739.s8|112-124|phenobarbital|drug
DDI-DrugBank.d739.s8|126-127|or|drug
DDI-DrugBank.d739.s8|129-136|rifampin|drug
DDI-DrugBank.d739.s8|137-137|,|drug
DDI-DrugBank.d739.s8|139-141|are|drug
DDI-DrugBank.d739.s8|143-157|co-administered|drug
DDI-DrugBank.d739.s8|159-162|with|drug
DDI-DrugBank.d739.s8|164-174|montelukast|drug
DDI-DrugBank.d739.s8|175-175|.|drug
DDI-DrugBank.d739.s9|0-10|Montelukast|brand
DDI-DrugBank.d739.s9|12-14|has|drug
DDI-DrugBank.d739.s9|16-19|been|drug
DDI-DrugBank.d739.s9|21-32|administered|drug
DDI-DrugBank.d739.s9|34-37|with|drug
DDI-DrugBank.d739.s9|39-43|other|drug
DDI-DrugBank.d739.s9|45-53|therapies|drug
DDI-DrugBank.d739.s9|55-63|routinely|drug
DDI-DrugBank.d739.s9|65-68|used|drug
DDI-DrugBank.d739.s9|70-71|in|drug
DDI-DrugBank.d739.s9|73-75|the|drug
DDI-DrugBank.d739.s9|77-87|prophylaxis|drug
DDI-DrugBank.d739.s9|89-91|and|drug
DDI-DrugBank.d739.s9|93-99|chronic|drug
DDI-DrugBank.d739.s9|101-109|treatment|drug
DDI-DrugBank.d739.s9|111-112|of|drug
DDI-DrugBank.d739.s9|114-119|asthma|drug
DDI-DrugBank.d739.s9|121-124|with|drug
DDI-DrugBank.d739.s9|126-127|no|drug
DDI-DrugBank.d739.s9|129-136|apparent|drug
DDI-DrugBank.d739.s9|138-145|increase|drug
DDI-DrugBank.d739.s9|147-148|in|drug
DDI-DrugBank.d739.s9|150-156|adverse|drug
DDI-DrugBank.d739.s9|158-166|reactions|drug
DDI-DrugBank.d739.s9|167-167|.|drug
DDI-DrugBank.d739.s10|0-1|In|drug
DDI-DrugBank.d739.s10|3-18|drug-interaction|drug
DDI-DrugBank.d739.s10|20-26|studies|drug
DDI-DrugBank.d739.s10|27-27|,|drug
DDI-DrugBank.d739.s10|29-31|the|drug
DDI-DrugBank.d739.s10|33-43|recommended|drug
DDI-DrugBank.d739.s10|45-52|clinical|drug
DDI-DrugBank.d739.s10|54-57|dose|drug
DDI-DrugBank.d739.s10|59-60|of|drug
DDI-DrugBank.d739.s10|62-72|montelukast|drug
DDI-DrugBank.d739.s10|74-76|did|drug
DDI-DrugBank.d739.s10|78-80|not|drug
DDI-DrugBank.d739.s10|82-85|have|drug
DDI-DrugBank.d739.s10|87-96|clinically|drug
DDI-DrugBank.d739.s10|98-106|important|drug
DDI-DrugBank.d739.s10|108-114|effects|drug
DDI-DrugBank.d739.s10|116-117|on|drug
DDI-DrugBank.d739.s10|119-121|the|drug
DDI-DrugBank.d739.s10|123-138|pharmacokinetics|drug
DDI-DrugBank.d739.s10|140-141|of|drug
DDI-DrugBank.d739.s10|143-145|the|drug
DDI-DrugBank.d739.s10|147-155|following|drug
DDI-DrugBank.d739.s10|157-161|drugs|drug
DDI-DrugBank.d739.s10|162-162|:|drug
DDI-DrugBank.d739.s10|164-175|theophylline|drug
DDI-DrugBank.d739.s10|176-176|,|drug
DDI-DrugBank.d739.s10|178-187|prednisone|drug
DDI-DrugBank.d739.s10|188-188|,|drug
DDI-DrugBank.d739.s10|190-201|prednisolone|drug
DDI-DrugBank.d739.s10|202-202|,|drug
DDI-DrugBank.d739.s10|204-207|oral|drug
DDI-DrugBank.d739.s10|209-222|contraceptives|drug
DDI-DrugBank.d739.s10|224-224|(|drug
DDI-DrugBank.d739.s10|225-237|norethindrone|drug
DDI-DrugBank.d739.s10|239-239|1|drug
DDI-DrugBank.d739.s10|241-250|mg/ethinyl|drug
DDI-DrugBank.d739.s10|252-260|estradiol|drug
DDI-DrugBank.d739.s10|262-263|35|drug
DDI-DrugBank.d739.s10|265-267|mcg|drug
DDI-DrugBank.d739.s10|268-268|)|drug
DDI-DrugBank.d739.s10|269-269|,|drug
DDI-DrugBank.d739.s10|271-281|terfenadine|drug
DDI-DrugBank.d739.s10|282-282|,|drug
DDI-DrugBank.d739.s10|284-290|digoxin|drug
DDI-DrugBank.d739.s10|291-291|,|drug
DDI-DrugBank.d739.s10|293-295|and|drug
DDI-DrugBank.d739.s10|297-304|warfarin|drug
DDI-DrugBank.d739.s10|305-305|.|drug
DDI-DrugBank.d739.s11|0-7|Although|drug
DDI-DrugBank.d739.s11|9-18|additional|drug
DDI-DrugBank.d739.s11|20-27|specific|drug
DDI-DrugBank.d739.s11|29-39|interaction|drug
DDI-DrugBank.d739.s11|41-47|studies|drug
DDI-DrugBank.d739.s11|49-52|were|drug
DDI-DrugBank.d739.s11|54-56|not|drug
DDI-DrugBank.d739.s11|58-66|performed|drug
DDI-DrugBank.d739.s11|67-67|,|drug
DDI-DrugBank.d739.s11|69-79|montelukast|drug
DDI-DrugBank.d739.s11|81-83|was|drug
DDI-DrugBank.d739.s11|85-88|used|drug
DDI-DrugBank.d739.s11|90-102|concomitantly|drug
DDI-DrugBank.d739.s11|104-107|with|drug
DDI-DrugBank.d739.s11|109-109|a|drug
DDI-DrugBank.d739.s11|111-114|wide|drug
DDI-DrugBank.d739.s11|116-120|range|drug
DDI-DrugBank.d739.s11|122-123|of|drug
DDI-DrugBank.d739.s11|125-132|commonly|drug
DDI-DrugBank.d739.s11|134-143|prescribed|drug
DDI-DrugBank.d739.s11|145-149|drugs|drug
DDI-DrugBank.d739.s11|151-152|in|drug
DDI-DrugBank.d739.s11|154-161|clinical|drug
DDI-DrugBank.d739.s11|163-169|studies|drug
DDI-DrugBank.d739.s11|171-177|without|drug
DDI-DrugBank.d739.s11|179-186|evidence|drug
DDI-DrugBank.d739.s11|188-189|of|drug
DDI-DrugBank.d739.s11|191-198|clinical|drug
DDI-DrugBank.d739.s11|200-206|adverse|drug
DDI-DrugBank.d739.s11|208-219|interactions|drug
DDI-DrugBank.d739.s11|220-220|.|drug
DDI-DrugBank.d739.s12|0-4|These|drug
DDI-DrugBank.d739.s12|6-16|medications|drug
DDI-DrugBank.d739.s12|18-25|included|drug
DDI-DrugBank.d739.s12|27-33|thyroid|drug
DDI-DrugBank.d739.s12|35-42|hormones|drug
DDI-DrugBank.d739.s12|43-43|,|drug
DDI-DrugBank.d739.s12|45-52|sedative|drug
DDI-DrugBank.d739.s12|54-62|hypnotics|drug
DDI-DrugBank.d739.s12|63-63|,|drug
DDI-DrugBank.d739.s12|65-77|non-steroidal|drug
DDI-DrugBank.d739.s12|79-95|anti-inflammatory|drug
DDI-DrugBank.d739.s12|97-102|agents|drug
DDI-DrugBank.d739.s12|103-103|,|drug
DDI-DrugBank.d739.s12|105-119|benzodiazepines|drug
DDI-DrugBank.d739.s12|120-120|,|drug
DDI-DrugBank.d739.s12|122-124|and|drug
DDI-DrugBank.d739.s12|126-138|decongestants|drug
DDI-DrugBank.d739.s12|139-139|.|drug
DDI-DrugBank.d739.s13|0-12|Phenobarbital|brand
DDI-DrugBank.d739.s13|13-13|,|drug
DDI-DrugBank.d739.s13|15-19|which|drug
DDI-DrugBank.d739.s13|21-27|induces|drug
DDI-DrugBank.d739.s13|29-35|hepatic|drug
DDI-DrugBank.d739.s13|37-46|metabolism|drug
DDI-DrugBank.d739.s13|47-47|,|drug
DDI-DrugBank.d739.s13|49-57|decreased|drug
DDI-DrugBank.d739.s13|59-61|the|drug
DDI-DrugBank.d739.s13|63-65|AUC|drug
DDI-DrugBank.d739.s13|67-68|of|drug
DDI-DrugBank.d739.s13|70-80|montelukast|drug
DDI-DrugBank.d739.s13|82-94|approximately|drug
DDI-DrugBank.d739.s13|96-97|40|drug
DDI-DrugBank.d739.s13|98-98|%|drug
DDI-DrugBank.d739.s13|100-108|following|drug
DDI-DrugBank.d739.s13|110-110|a|drug
DDI-DrugBank.d739.s13|112-117|single|drug
DDI-DrugBank.d739.s13|119-123|10-mg|drug
DDI-DrugBank.d739.s13|125-128|dose|drug
DDI-DrugBank.d739.s13|130-131|of|drug
DDI-DrugBank.d739.s13|133-143|montelukast|drug
DDI-DrugBank.d739.s13|144-144|.|drug
DDI-DrugBank.d739.s14|0-1|No|drug
DDI-DrugBank.d739.s14|3-8|dosage|drug
DDI-DrugBank.d739.s14|10-19|adjustment|drug
DDI-DrugBank.d739.s14|21-23|for|drug
DDI-DrugBank.d739.s14|25-35|montelukast|drug
DDI-DrugBank.d739.s14|37-38|is|drug
DDI-DrugBank.d739.s14|40-50|recommended|drug
DDI-DrugBank.d739.s14|51-51|.|drug
DDI-DrugBank.d739.s15|0-1|It|drug
DDI-DrugBank.d739.s15|3-4|is|drug
DDI-DrugBank.d739.s15|6-15|reasonable|drug
DDI-DrugBank.d739.s15|17-18|to|drug
DDI-DrugBank.d739.s15|20-25|employ|drug
DDI-DrugBank.d739.s15|27-37|appropriate|drug
DDI-DrugBank.d739.s15|39-46|clinical|drug
DDI-DrugBank.d739.s15|48-57|monitoring|drug
DDI-DrugBank.d739.s15|59-62|when|drug
DDI-DrugBank.d739.s15|64-69|potent|drug
DDI-DrugBank.d739.s15|71-80|cytochrome|drug
DDI-DrugBank.d739.s15|82-85|P450|drug
DDI-DrugBank.d739.s15|87-92|enzyme|drug
DDI-DrugBank.d739.s15|94-101|inducers|drug
DDI-DrugBank.d739.s15|102-102|,|drug
DDI-DrugBank.d739.s15|104-107|such|drug
DDI-DrugBank.d739.s15|109-110|as|drug
DDI-DrugBank.d739.s15|112-124|phenobarbital|drug
DDI-DrugBank.d739.s15|126-127|or|drug
DDI-DrugBank.d739.s15|129-136|rifampin|drug
DDI-DrugBank.d739.s15|137-137|,|drug
DDI-DrugBank.d739.s15|139-141|are|drug
DDI-DrugBank.d739.s15|143-157|co-administered|drug
DDI-DrugBank.d739.s15|159-162|with|drug
DDI-DrugBank.d739.s15|164-174|montelukast|drug
DDI-DrugBank.d739.s15|175-175|.|drug
DDI-DrugBank.d761.s0|0-6|Alcohol|brand
DDI-DrugBank.d761.s0|7-7|:|drug
DDI-DrugBank.d761.s0|9-10|In|drug
DDI-DrugBank.d761.s0|12-12|a|drug
DDI-DrugBank.d761.s0|14-26|multiple-dose|drug
DDI-DrugBank.d761.s0|28-32|study|drug
DDI-DrugBank.d761.s0|34-35|in|drug
DDI-DrugBank.d761.s0|37-38|30|drug
DDI-DrugBank.d761.s0|40-45|normal|drug
DDI-DrugBank.d761.s0|47-52|weight|drug
DDI-DrugBank.d761.s0|54-61|subjects|drug
DDI-DrugBank.d761.s0|62-62|,|drug
DDI-DrugBank.d761.s0|64-79|coadministration|drug
DDI-DrugBank.d761.s0|81-82|of|drug
DDI-DrugBank.d761.s0|84-90|XENICAL|drug
DDI-DrugBank.d761.s0|92-94|and|drug
DDI-DrugBank.d761.s0|96-97|40|drug
DDI-DrugBank.d761.s0|99-103|grams|drug
DDI-DrugBank.d761.s0|105-106|of|drug
DDI-DrugBank.d761.s0|108-114|alcohol|drug
DDI-DrugBank.d761.s0|116-116|(|drug
DDI-DrugBank.d761.s0|117-120|e.g.|drug
DDI-DrugBank.d761.s0|121-121|,|drug
DDI-DrugBank.d761.s0|123-135|approximately|drug
DDI-DrugBank.d761.s0|137-137|3|drug
DDI-DrugBank.d761.s0|139-145|glasses|drug
DDI-DrugBank.d761.s0|147-148|of|drug
DDI-DrugBank.d761.s0|150-153|wine|drug
DDI-DrugBank.d761.s0|154-154|)|drug
DDI-DrugBank.d761.s0|156-158|did|drug
DDI-DrugBank.d761.s0|160-162|not|drug
DDI-DrugBank.d761.s0|164-169|result|drug
DDI-DrugBank.d761.s0|171-172|in|drug
DDI-DrugBank.d761.s0|174-183|alteration|drug
DDI-DrugBank.d761.s0|185-186|of|drug
DDI-DrugBank.d761.s0|188-194|alcohol|drug
DDI-DrugBank.d761.s0|196-211|pharmacokinetics|drug
DDI-DrugBank.d761.s0|212-212|,|drug
DDI-DrugBank.d761.s0|214-221|orlistat|drug
DDI-DrugBank.d761.s0|223-238|pharmacodynamics|drug
DDI-DrugBank.d761.s0|240-240|(|drug
DDI-DrugBank.d761.s0|241-245|fecal|drug
DDI-DrugBank.d761.s0|247-249|fat|drug
DDI-DrugBank.d761.s0|251-259|excretion|drug
DDI-DrugBank.d761.s0|260-260|)|drug
DDI-DrugBank.d761.s0|261-261|,|drug
DDI-DrugBank.d761.s0|263-264|or|drug
DDI-DrugBank.d761.s0|266-273|systemic|drug
DDI-DrugBank.d761.s0|275-282|exposure|drug
DDI-DrugBank.d761.s0|284-285|to|drug
DDI-DrugBank.d761.s0|287-294|orlistat|drug
DDI-DrugBank.d761.s0|295-295|.|drug
DDI-DrugBank.d761.s1|0-11|Cyclosporine|brand
DDI-DrugBank.d761.s1|12-12|:|drug
DDI-DrugBank.d761.s1|14-24|Preliminary|drug
DDI-DrugBank.d761.s1|26-29|data|drug
DDI-DrugBank.d761.s1|31-34|from|drug
DDI-DrugBank.d761.s1|36-36|a|drug
DDI-DrugBank.d761.s1|38-44|XENICAL|drug
DDI-DrugBank.d761.s1|46-48|and|drug
DDI-DrugBank.d761.s1|50-61|cyclosporine|drug
DDI-DrugBank.d761.s1|63-66|drug|drug
DDI-DrugBank.d761.s1|68-78|interaction|drug
DDI-DrugBank.d761.s1|80-84|study|drug
DDI-DrugBank.d761.s1|86-93|indicate|drug
DDI-DrugBank.d761.s1|95-95|a|drug
DDI-DrugBank.d761.s1|97-105|reduction|drug
DDI-DrugBank.d761.s1|107-108|in|drug
DDI-DrugBank.d761.s1|110-121|cyclosporine|drug
DDI-DrugBank.d761.s1|123-128|plasma|drug
DDI-DrugBank.d761.s1|130-135|levels|drug
DDI-DrugBank.d761.s1|137-140|when|drug
DDI-DrugBank.d761.s1|142-148|XENICAL|drug
DDI-DrugBank.d761.s1|150-152|was|drug
DDI-DrugBank.d761.s1|154-167|coadministered|drug
DDI-DrugBank.d761.s1|169-172|with|drug
DDI-DrugBank.d761.s1|174-185|cyclosporine|drug
DDI-DrugBank.d761.s1|186-186|.|drug
DDI-DrugBank.d761.s2|0-6|Digoxin|brand
DDI-DrugBank.d761.s2|7-7|:|drug
DDI-DrugBank.d761.s2|9-10|In|drug
DDI-DrugBank.d761.s2|12-13|12|drug
DDI-DrugBank.d761.s2|15-27|normal-weight|drug
DDI-DrugBank.d761.s2|29-36|subjects|drug
DDI-DrugBank.d761.s2|38-46|receiving|drug
DDI-DrugBank.d761.s2|48-54|XENICAL|drug
DDI-DrugBank.d761.s2|56-58|120|drug
DDI-DrugBank.d761.s2|60-61|mg|drug
DDI-DrugBank.d761.s2|63-67|three|drug
DDI-DrugBank.d761.s2|69-73|times|drug
DDI-DrugBank.d761.s2|75-75|a|drug
DDI-DrugBank.d761.s2|77-79|day|drug
DDI-DrugBank.d761.s2|81-83|for|drug
DDI-DrugBank.d761.s2|85-85|6|drug
DDI-DrugBank.d761.s2|87-90|days|drug
DDI-DrugBank.d761.s2|91-91|,|drug
DDI-DrugBank.d761.s2|93-99|XENICAL|drug
DDI-DrugBank.d761.s2|101-103|did|drug
DDI-DrugBank.d761.s2|105-107|not|drug
DDI-DrugBank.d761.s2|109-113|alter|drug
DDI-DrugBank.d761.s2|115-117|the|drug
DDI-DrugBank.d761.s2|119-134|pharmacokinetics|drug
DDI-DrugBank.d761.s2|136-137|of|drug
DDI-DrugBank.d761.s2|139-139|a|drug
DDI-DrugBank.d761.s2|141-146|single|drug
DDI-DrugBank.d761.s2|148-151|dose|drug
DDI-DrugBank.d761.s2|153-154|of|drug
DDI-DrugBank.d761.s2|156-162|digoxin|drug
DDI-DrugBank.d761.s2|163-163|.|drug
DDI-DrugBank.d761.s3|0-10|Fat-soluble|drug
DDI-DrugBank.d761.s3|12-18|Vitamin|drug
DDI-DrugBank.d761.s3|20-30|Supplements|group
DDI-DrugBank.d761.s3|32-34|and|drug
DDI-DrugBank.d761.s3|36-44|Analogues|drug
DDI-DrugBank.d761.s3|45-45|:|drug
DDI-DrugBank.d761.s3|47-47|A|drug
DDI-DrugBank.d761.s3|49-63|pharmacokinetic|drug
DDI-DrugBank.d761.s3|65-75|interaction|drug
DDI-DrugBank.d761.s3|77-81|study|drug
DDI-DrugBank.d761.s3|83-88|showed|drug
DDI-DrugBank.d761.s3|90-90|a|drug
DDI-DrugBank.d761.s3|92-93|30|drug
DDI-DrugBank.d761.s3|94-94|%|drug
DDI-DrugBank.d761.s3|96-104|reduction|drug
DDI-DrugBank.d761.s3|106-107|in|drug
DDI-DrugBank.d761.s3|109-121|beta-carotene|drug
DDI-DrugBank.d761.s3|123-132|supplement|drug
DDI-DrugBank.d761.s3|134-143|absorption|drug
DDI-DrugBank.d761.s3|145-148|when|drug
DDI-DrugBank.d761.s3|150-162|concomitantly|drug
DDI-DrugBank.d761.s3|164-175|administered|drug
DDI-DrugBank.d761.s3|177-180|with|drug
DDI-DrugBank.d761.s3|182-188|XENICAL|drug
DDI-DrugBank.d761.s3|189-189|.|drug
DDI-DrugBank.d761.s4|0-6|XENICAL|drug
DDI-DrugBank.d761.s4|8-16|inhibited|drug
DDI-DrugBank.d761.s4|18-27|absorption|drug
DDI-DrugBank.d761.s4|29-30|of|drug
DDI-DrugBank.d761.s4|32-32|a|drug
DDI-DrugBank.d761.s4|34-40|vitamin|drug
DDI-DrugBank.d761.s4|42-42|E|drug
DDI-DrugBank.d761.s4|44-50|acetate|drug
DDI-DrugBank.d761.s4|52-61|supplement|drug
DDI-DrugBank.d761.s4|63-64|by|drug
DDI-DrugBank.d761.s4|66-78|approximately|drug
DDI-DrugBank.d761.s4|80-81|60|drug
DDI-DrugBank.d761.s4|82-82|%|drug
DDI-DrugBank.d761.s4|83-83|.|drug
DDI-DrugBank.d761.s5|0-2|The|drug
DDI-DrugBank.d761.s5|4-9|effect|drug
DDI-DrugBank.d761.s5|11-12|of|drug
DDI-DrugBank.d761.s5|14-21|orlistat|drug
DDI-DrugBank.d761.s5|23-24|on|drug
DDI-DrugBank.d761.s5|26-28|the|drug
DDI-DrugBank.d761.s5|30-39|absorption|drug
DDI-DrugBank.d761.s5|41-42|of|drug
DDI-DrugBank.d761.s5|44-55|supplemental|drug
DDI-DrugBank.d761.s5|57-63|vitamin|drug
DDI-DrugBank.d761.s5|65-65|D|drug
DDI-DrugBank.d761.s5|66-66|,|drug
DDI-DrugBank.d761.s5|68-74|vitamin|drug
DDI-DrugBank.d761.s5|76-76|A|drug
DDI-DrugBank.d761.s5|77-77|,|drug
DDI-DrugBank.d761.s5|79-81|and|drug
DDI-DrugBank.d761.s5|83-103|nutritionally-derived|drug
DDI-DrugBank.d761.s5|105-111|vitamin|drug
DDI-DrugBank.d761.s5|113-113|K|drug
DDI-DrugBank.d761.s5|115-116|is|drug
DDI-DrugBank.d761.s5|118-120|not|drug
DDI-DrugBank.d761.s5|122-126|known|drug
DDI-DrugBank.d761.s5|128-129|at|drug
DDI-DrugBank.d761.s5|131-134|this|drug
DDI-DrugBank.d761.s5|136-139|time|drug
DDI-DrugBank.d761.s5|140-140|.|drug
DDI-DrugBank.d761.s6|0-8|Glyburide|brand
DDI-DrugBank.d761.s6|9-9|:|drug
DDI-DrugBank.d761.s6|11-12|In|drug
DDI-DrugBank.d761.s6|14-15|12|drug
DDI-DrugBank.d761.s6|17-29|normal-weight|drug
DDI-DrugBank.d761.s6|31-38|subjects|drug
DDI-DrugBank.d761.s6|40-48|receiving|drug
DDI-DrugBank.d761.s6|50-57|orlistat|drug
DDI-DrugBank.d761.s6|59-60|80|drug
DDI-DrugBank.d761.s6|62-63|mg|drug
DDI-DrugBank.d761.s6|65-69|three|drug
DDI-DrugBank.d761.s6|71-75|times|drug
DDI-DrugBank.d761.s6|77-77|a|drug
DDI-DrugBank.d761.s6|79-81|day|drug
DDI-DrugBank.d761.s6|83-85|for|drug
DDI-DrugBank.d761.s6|87-87|5|drug
DDI-DrugBank.d761.s6|89-92|days|drug
DDI-DrugBank.d761.s6|93-93|,|drug
DDI-DrugBank.d761.s6|95-102|orlistat|drug
DDI-DrugBank.d761.s6|104-106|did|drug
DDI-DrugBank.d761.s6|108-110|not|drug
DDI-DrugBank.d761.s6|112-116|alter|drug
DDI-DrugBank.d761.s6|118-120|the|drug
DDI-DrugBank.d761.s6|122-137|pharmacokinetics|drug
DDI-DrugBank.d761.s6|139-140|or|drug
DDI-DrugBank.d761.s6|142-157|pharmacodynamics|drug
DDI-DrugBank.d761.s6|159-159|(|drug
DDI-DrugBank.d761.s6|160-164|blood|drug
DDI-DrugBank.d761.s6|166-181|glucose-lowering|drug
DDI-DrugBank.d761.s6|182-182|)|drug
DDI-DrugBank.d761.s6|184-185|of|drug
DDI-DrugBank.d761.s6|187-195|glyburide|drug
DDI-DrugBank.d761.s6|196-196|.|drug
DDI-DrugBank.d761.s7|0-9|Nifedipine|brand
DDI-DrugBank.d761.s7|11-11|(|drug
DDI-DrugBank.d761.s7|12-27|extended-release|drug
DDI-DrugBank.d761.s7|29-35|tablets|drug
DDI-DrugBank.d761.s7|36-36|)|drug
DDI-DrugBank.d761.s7|37-37|:|drug
DDI-DrugBank.d761.s7|39-40|In|drug
DDI-DrugBank.d761.s7|42-43|17|drug
DDI-DrugBank.d761.s7|45-57|normal-weight|drug
DDI-DrugBank.d761.s7|59-66|subjects|drug
DDI-DrugBank.d761.s7|68-76|receiving|drug
DDI-DrugBank.d761.s7|78-84|XENICAL|drug
DDI-DrugBank.d761.s7|86-88|120|drug
DDI-DrugBank.d761.s7|90-91|mg|drug
DDI-DrugBank.d761.s7|93-97|three|drug
DDI-DrugBank.d761.s7|99-103|times|drug
DDI-DrugBank.d761.s7|105-105|a|drug
DDI-DrugBank.d761.s7|107-109|day|drug
DDI-DrugBank.d761.s7|111-113|for|drug
DDI-DrugBank.d761.s7|115-115|6|drug
DDI-DrugBank.d761.s7|117-120|days|drug
DDI-DrugBank.d761.s7|121-121|,|drug
DDI-DrugBank.d761.s7|123-129|XENICAL|drug
DDI-DrugBank.d761.s7|131-133|did|drug
DDI-DrugBank.d761.s7|135-137|not|drug
DDI-DrugBank.d761.s7|139-143|alter|drug
DDI-DrugBank.d761.s7|145-147|the|drug
DDI-DrugBank.d761.s7|149-163|bioavailability|drug
DDI-DrugBank.d761.s7|165-166|of|drug
DDI-DrugBank.d761.s7|168-177|nifedipine|drug
DDI-DrugBank.d761.s7|179-179|(|drug
DDI-DrugBank.d761.s7|180-195|extended-release|drug
DDI-DrugBank.d761.s7|197-203|tablets|drug
DDI-DrugBank.d761.s7|204-204|)|drug
DDI-DrugBank.d761.s7|205-205|.|drug
DDI-DrugBank.d761.s8|0-3|Oral|drug
DDI-DrugBank.d761.s8|5-18|Contraceptives|drug
DDI-DrugBank.d761.s8|19-19|:|drug
DDI-DrugBank.d761.s8|21-22|In|drug
DDI-DrugBank.d761.s8|24-25|20|drug
DDI-DrugBank.d761.s8|27-39|normal-weight|drug
DDI-DrugBank.d761.s8|41-46|female|drug
DDI-DrugBank.d761.s8|48-55|subjects|drug
DDI-DrugBank.d761.s8|56-56|,|drug
DDI-DrugBank.d761.s8|58-60|the|drug
DDI-DrugBank.d761.s8|62-70|treatment|drug
DDI-DrugBank.d761.s8|72-73|of|drug
DDI-DrugBank.d761.s8|75-81|XENICAL|drug
DDI-DrugBank.d761.s8|83-85|120|drug
DDI-DrugBank.d761.s8|87-88|mg|drug
DDI-DrugBank.d761.s8|90-94|three|drug
DDI-DrugBank.d761.s8|96-100|times|drug
DDI-DrugBank.d761.s8|102-102|a|drug
DDI-DrugBank.d761.s8|104-106|day|drug
DDI-DrugBank.d761.s8|108-110|for|drug
DDI-DrugBank.d761.s8|112-113|23|drug
DDI-DrugBank.d761.s8|115-118|days|drug
DDI-DrugBank.d761.s8|120-127|resulted|drug
DDI-DrugBank.d761.s8|129-130|in|drug
DDI-DrugBank.d761.s8|132-133|no|drug
DDI-DrugBank.d761.s8|135-141|changes|drug
DDI-DrugBank.d761.s8|143-144|in|drug
DDI-DrugBank.d761.s8|146-148|the|drug
DDI-DrugBank.d761.s8|150-170|ovulation-suppressing|drug
DDI-DrugBank.d761.s8|172-177|action|drug
DDI-DrugBank.d761.s8|179-180|of|drug
DDI-DrugBank.d761.s8|182-185|oral|drug
DDI-DrugBank.d761.s8|187-200|contraceptives|drug
DDI-DrugBank.d761.s8|201-201|.|drug
DDI-DrugBank.d761.s9|0-8|Phenytoin|brand
DDI-DrugBank.d761.s9|9-9|:|drug
DDI-DrugBank.d761.s9|11-12|In|drug
DDI-DrugBank.d761.s9|14-15|12|drug
DDI-DrugBank.d761.s9|17-29|normal-weight|drug
DDI-DrugBank.d761.s9|31-38|subjects|drug
DDI-DrugBank.d761.s9|40-48|receiving|drug
DDI-DrugBank.d761.s9|50-56|XENICAL|drug
DDI-DrugBank.d761.s9|58-60|120|drug
DDI-DrugBank.d761.s9|62-63|mg|drug
DDI-DrugBank.d761.s9|65-69|three|drug
DDI-DrugBank.d761.s9|71-75|times|drug
DDI-DrugBank.d761.s9|77-77|a|drug
DDI-DrugBank.d761.s9|79-81|day|drug
DDI-DrugBank.d761.s9|83-85|for|drug
DDI-DrugBank.d761.s9|87-87|7|drug
DDI-DrugBank.d761.s9|89-92|days|drug
DDI-DrugBank.d761.s9|93-93|,|drug
DDI-DrugBank.d761.s9|95-101|XENICAL|drug
DDI-DrugBank.d761.s9|103-105|did|drug
DDI-DrugBank.d761.s9|107-109|not|drug
DDI-DrugBank.d761.s9|111-115|alter|drug
DDI-DrugBank.d761.s9|117-119|the|drug
DDI-DrugBank.d761.s9|121-136|pharmacokinetics|drug
DDI-DrugBank.d761.s9|138-139|of|drug
DDI-DrugBank.d761.s9|141-141|a|drug
DDI-DrugBank.d761.s9|143-148|single|drug
DDI-DrugBank.d761.s9|150-155|300-mg|drug
DDI-DrugBank.d761.s9|157-160|dose|drug
DDI-DrugBank.d761.s9|162-163|of|drug
DDI-DrugBank.d761.s9|165-173|phenytoin|drug
DDI-DrugBank.d761.s9|174-174|.|drug
DDI-DrugBank.d761.s10|0-10|Pravastatin|brand
DDI-DrugBank.d761.s10|11-11|:|drug
DDI-DrugBank.d761.s10|13-14|In|drug
DDI-DrugBank.d761.s10|16-16|a|drug
DDI-DrugBank.d761.s10|18-22|2-way|drug
DDI-DrugBank.d761.s10|24-32|crossover|drug
DDI-DrugBank.d761.s10|34-38|study|drug
DDI-DrugBank.d761.s10|40-41|of|drug
DDI-DrugBank.d761.s10|43-44|24|drug
DDI-DrugBank.d761.s10|46-58|normal-weight|drug
DDI-DrugBank.d761.s10|59-59|,|drug
DDI-DrugBank.d761.s10|61-66|mildly|drug
DDI-DrugBank.d761.s10|68-87|hypercholesterolemic|drug
DDI-DrugBank.d761.s10|89-96|patients|drug
DDI-DrugBank.d761.s10|98-106|receiving|drug
DDI-DrugBank.d761.s10|108-114|XENICAL|drug
DDI-DrugBank.d761.s10|116-118|120|drug
DDI-DrugBank.d761.s10|120-121|mg|drug
DDI-DrugBank.d761.s10|123-127|three|drug
DDI-DrugBank.d761.s10|129-133|times|drug
DDI-DrugBank.d761.s10|135-135|a|drug
DDI-DrugBank.d761.s10|137-139|day|drug
DDI-DrugBank.d761.s10|141-143|for|drug
DDI-DrugBank.d761.s10|145-145|6|drug
DDI-DrugBank.d761.s10|147-150|days|drug
DDI-DrugBank.d761.s10|151-151|,|drug
DDI-DrugBank.d761.s10|153-159|XENICAL|drug
DDI-DrugBank.d761.s10|161-163|did|drug
DDI-DrugBank.d761.s10|165-167|not|drug
DDI-DrugBank.d761.s10|169-174|affect|drug
DDI-DrugBank.d761.s10|176-178|the|drug
DDI-DrugBank.d761.s10|180-195|pharmacokinetics|drug
DDI-DrugBank.d761.s10|197-198|of|drug
DDI-DrugBank.d761.s10|200-210|pravastatin|drug
DDI-DrugBank.d761.s10|211-211|.|drug
DDI-DrugBank.d761.s11|0-7|Warfarin|brand
DDI-DrugBank.d761.s11|8-8|:|drug
DDI-DrugBank.d761.s11|10-11|In|drug
DDI-DrugBank.d761.s11|13-14|12|drug
DDI-DrugBank.d761.s11|16-28|normal-weight|drug
DDI-DrugBank.d761.s11|30-37|subjects|drug
DDI-DrugBank.d761.s11|38-38|,|drug
DDI-DrugBank.d761.s11|40-53|administration|drug
DDI-DrugBank.d761.s11|55-56|of|drug
DDI-DrugBank.d761.s11|58-64|XENICAL|drug
DDI-DrugBank.d761.s11|66-68|120|drug
DDI-DrugBank.d761.s11|70-71|mg|drug
DDI-DrugBank.d761.s11|73-77|three|drug
DDI-DrugBank.d761.s11|79-83|times|drug
DDI-DrugBank.d761.s11|85-85|a|drug
DDI-DrugBank.d761.s11|87-89|day|drug
DDI-DrugBank.d761.s11|91-93|for|drug
DDI-DrugBank.d761.s11|95-96|16|drug
DDI-DrugBank.d761.s11|98-101|days|drug
DDI-DrugBank.d761.s11|103-105|did|drug
DDI-DrugBank.d761.s11|107-109|not|drug
DDI-DrugBank.d761.s11|111-116|result|drug
DDI-DrugBank.d761.s11|118-119|in|drug
DDI-DrugBank.d761.s11|121-123|any|drug
DDI-DrugBank.d761.s11|125-130|change|drug
DDI-DrugBank.d761.s11|132-133|in|drug
DDI-DrugBank.d761.s11|135-140|either|drug
DDI-DrugBank.d761.s11|142-149|warfarin|drug
DDI-DrugBank.d761.s11|151-166|pharmacokinetics|drug
DDI-DrugBank.d761.s11|168-168|(|drug
DDI-DrugBank.d761.s11|169-172|both|drug
DDI-DrugBank.d761.s11|174-175|R-|drug
DDI-DrugBank.d761.s11|177-179|and|drug
DDI-DrugBank.d761.s11|181-193|S-enantiomers|drug
DDI-DrugBank.d761.s11|194-194|)|drug
DDI-DrugBank.d761.s11|196-197|or|drug
DDI-DrugBank.d761.s11|199-214|pharmacodynamics|drug
DDI-DrugBank.d761.s11|216-216|(|drug
DDI-DrugBank.d761.s11|217-227|prothrombin|drug
DDI-DrugBank.d761.s11|229-232|time|drug
DDI-DrugBank.d761.s11|234-236|and|drug
DDI-DrugBank.d761.s11|238-242|serum|drug
DDI-DrugBank.d761.s11|244-249|Factor|drug
DDI-DrugBank.d761.s11|251-253|VII|drug
DDI-DrugBank.d761.s11|254-254|)|drug
DDI-DrugBank.d761.s11|255-255|.|drug
DDI-DrugBank.d761.s12|0-7|Although|drug
DDI-DrugBank.d761.s12|9-25|undercarboxylated|drug
DDI-DrugBank.d761.s12|27-37|osteocalcin|drug
DDI-DrugBank.d761.s12|38-38|,|drug
DDI-DrugBank.d761.s12|40-40|a|drug
DDI-DrugBank.d761.s12|42-47|marker|drug
DDI-DrugBank.d761.s12|49-50|of|drug
DDI-DrugBank.d761.s12|52-58|vitamin|drug
DDI-DrugBank.d761.s12|60-60|K|drug
DDI-DrugBank.d761.s12|62-72|nutritional|drug
DDI-DrugBank.d761.s12|74-79|status|drug
DDI-DrugBank.d761.s12|80-80|,|drug
DDI-DrugBank.d761.s12|82-84|was|drug
DDI-DrugBank.d761.s12|86-94|unaltered|drug
DDI-DrugBank.d761.s12|96-99|with|drug
DDI-DrugBank.d761.s12|101-107|XENICAL|drug
DDI-DrugBank.d761.s12|109-122|administration|drug
DDI-DrugBank.d761.s12|123-123|,|drug
DDI-DrugBank.d761.s12|125-131|vitamin|drug
DDI-DrugBank.d761.s12|133-133|K|drug
DDI-DrugBank.d761.s12|135-140|levels|drug
DDI-DrugBank.d761.s12|142-147|tended|drug
DDI-DrugBank.d761.s12|149-150|to|drug
DDI-DrugBank.d761.s12|152-158|decline|drug
DDI-DrugBank.d761.s12|160-161|in|drug
DDI-DrugBank.d761.s12|163-170|subjects|drug
DDI-DrugBank.d761.s12|172-177|taking|drug
DDI-DrugBank.d761.s12|179-185|XENICAL|drug
DDI-DrugBank.d761.s12|186-186|.|drug
DDI-DrugBank.d761.s13|0-8|Therefore|drug
DDI-DrugBank.d761.s13|9-9|,|drug
DDI-DrugBank.d761.s13|11-12|as|drug
DDI-DrugBank.d761.s13|14-20|vitamin|drug
DDI-DrugBank.d761.s13|22-22|K|drug
DDI-DrugBank.d761.s13|24-33|absorption|drug
DDI-DrugBank.d761.s13|35-37|may|drug
DDI-DrugBank.d761.s13|39-40|be|drug
DDI-DrugBank.d761.s13|42-50|decreased|drug
DDI-DrugBank.d761.s13|52-55|with|drug
DDI-DrugBank.d761.s13|57-63|XENICAL|drug
DDI-DrugBank.d761.s13|64-64|,|drug
DDI-DrugBank.d761.s13|66-73|patients|drug
DDI-DrugBank.d761.s13|75-76|on|drug
DDI-DrugBank.d761.s13|78-84|chronic|drug
DDI-DrugBank.d761.s13|86-91|stable|drug
DDI-DrugBank.d761.s13|93-97|doses|drug
DDI-DrugBank.d761.s13|99-100|of|drug
DDI-DrugBank.d761.s13|102-109|warfarin|drug
DDI-DrugBank.d761.s13|111-113|who|drug
DDI-DrugBank.d761.s13|115-117|are|drug
DDI-DrugBank.d761.s13|119-128|prescribed|drug
DDI-DrugBank.d761.s13|130-136|XENICAL|drug
DDI-DrugBank.d761.s13|138-143|should|drug
DDI-DrugBank.d761.s13|145-146|be|drug
DDI-DrugBank.d761.s13|148-156|monitored|drug
DDI-DrugBank.d761.s13|158-164|closely|drug
DDI-DrugBank.d761.s13|166-168|for|drug
DDI-DrugBank.d761.s13|170-176|changes|drug
DDI-DrugBank.d761.s13|178-179|in|drug
DDI-DrugBank.d761.s13|181-191|coagulation|drug
DDI-DrugBank.d761.s13|193-202|parameters|drug
DDI-DrugBank.d761.s13|203-203|.|drug
DDI-DrugBank.d359.s0|0-7|PEGANONE|drug
DDI-DrugBank.d359.s0|9-12|used|drug
DDI-DrugBank.d359.s0|14-15|in|drug
DDI-DrugBank.d359.s0|17-27|combination|drug
DDI-DrugBank.d359.s0|29-32|with|drug
DDI-DrugBank.d359.s0|34-38|other|drug
DDI-DrugBank.d359.s0|40-44|drugs|drug
DDI-DrugBank.d359.s0|46-50|known|drug
DDI-DrugBank.d359.s0|52-53|to|drug
DDI-DrugBank.d359.s0|55-63|adversely|drug
DDI-DrugBank.d359.s0|65-70|affect|drug
DDI-DrugBank.d359.s0|72-74|the|drug
DDI-DrugBank.d359.s0|76-88|hematopoietic|drug
DDI-DrugBank.d359.s0|90-95|system|drug
DDI-DrugBank.d359.s0|97-102|should|drug
DDI-DrugBank.d359.s0|104-105|be|drug
DDI-DrugBank.d359.s0|107-113|avoided|drug
DDI-DrugBank.d359.s0|115-116|if|drug
DDI-DrugBank.d359.s0|118-125|possible|drug
DDI-DrugBank.d359.s0|126-126|.|drug
DDI-DrugBank.d359.s1|0-11|Considerable|drug
DDI-DrugBank.d359.s1|13-19|caution|drug
DDI-DrugBank.d359.s1|21-26|should|drug
DDI-DrugBank.d359.s1|28-29|be|drug
DDI-DrugBank.d359.s1|31-39|exercised|drug
DDI-DrugBank.d359.s1|41-42|if|drug
DDI-DrugBank.d359.s1|44-51|PEGANONE|drug
DDI-DrugBank.d359.s1|53-54|is|drug
DDI-DrugBank.d359.s1|56-67|administered|drug
DDI-DrugBank.d359.s1|69-80|concurrently|drug
DDI-DrugBank.d359.s1|82-85|with|drug
DDI-DrugBank.d359.s1|87-95|Phenurone|drug
DDI-DrugBank.d359.s1|97-97|(|drug
DDI-DrugBank.d359.s1|98-108|phenacemide|drug
DDI-DrugBank.d359.s1|109-109|)|drug
DDI-DrugBank.d359.s1|111-115|since|drug
DDI-DrugBank.d359.s1|117-124|paranoid|drug
DDI-DrugBank.d359.s1|126-133|symptoms|drug
DDI-DrugBank.d359.s1|135-138|have|drug
DDI-DrugBank.d359.s1|140-143|been|drug
DDI-DrugBank.d359.s1|145-152|reported|drug
DDI-DrugBank.d359.s1|154-159|during|drug
DDI-DrugBank.d359.s1|161-167|therapy|drug
DDI-DrugBank.d359.s1|169-172|with|drug
DDI-DrugBank.d359.s1|174-177|this|drug
DDI-DrugBank.d359.s1|179-189|combination|drug
DDI-DrugBank.d359.s1|190-190|.|drug
DDI-DrugBank.d359.s2|0-0|A|drug
DDI-DrugBank.d359.s2|2-8|two-way|drug
DDI-DrugBank.d359.s2|10-20|interaction|drug
DDI-DrugBank.d359.s2|22-28|between|drug
DDI-DrugBank.d359.s2|30-32|the|drug
DDI-DrugBank.d359.s2|34-42|hydantoin|drug
DDI-DrugBank.d359.s2|44-56|antiepileptic|drug
DDI-DrugBank.d359.s2|57-57|,|drug
DDI-DrugBank.d359.s2|59-67|phenytoin|drug
DDI-DrugBank.d359.s2|68-68|,|drug
DDI-DrugBank.d359.s2|70-72|and|drug
DDI-DrugBank.d359.s2|74-76|the|drug
DDI-DrugBank.d359.s2|78-85|coumarin|drug
DDI-DrugBank.d359.s2|87-100|anticoagulants|drug
DDI-DrugBank.d359.s2|102-104|has|drug
DDI-DrugBank.d359.s2|106-109|been|drug
DDI-DrugBank.d359.s2|111-119|suggested|drug
DDI-DrugBank.d359.s2|120-120|.|drug
DDI-DrugBank.d359.s3|0-9|Presumably|drug
DDI-DrugBank.d359.s3|10-10|,|drug
DDI-DrugBank.d359.s3|12-20|phenytoin|drug
DDI-DrugBank.d359.s3|22-25|acts|drug
DDI-DrugBank.d359.s3|27-28|as|drug
DDI-DrugBank.d359.s3|30-30|a|drug
DDI-DrugBank.d359.s3|32-41|stimulator|drug
DDI-DrugBank.d359.s3|43-44|of|drug
DDI-DrugBank.d359.s3|46-53|coumarin|drug
DDI-DrugBank.d359.s3|55-64|metabolism|drug
DDI-DrugBank.d359.s3|66-68|and|drug
DDI-DrugBank.d359.s3|70-72|has|drug
DDI-DrugBank.d359.s3|74-77|been|drug
DDI-DrugBank.d359.s3|79-86|reported|drug
DDI-DrugBank.d359.s3|88-89|to|drug
DDI-DrugBank.d359.s3|91-95|cause|drug
DDI-DrugBank.d359.s3|97-105|decreased|drug
DDI-DrugBank.d359.s3|107-111|serum|drug
DDI-DrugBank.d359.s3|113-118|levels|drug
DDI-DrugBank.d359.s3|120-121|of|drug
DDI-DrugBank.d359.s3|123-125|the|drug
DDI-DrugBank.d359.s3|127-134|coumarin|drug
DDI-DrugBank.d359.s3|136-149|anticoagulants|drug
DDI-DrugBank.d359.s3|151-153|and|drug
DDI-DrugBank.d359.s3|155-163|increased|drug
DDI-DrugBank.d359.s3|165-188|prothrombin-proconvertin|drug
DDI-DrugBank.d359.s3|190-203|concentrations|drug
DDI-DrugBank.d359.s3|204-204|.|drug
DDI-DrugBank.d359.s4|0-9|Conversely|drug
DDI-DrugBank.d359.s4|10-10|,|drug
DDI-DrugBank.d359.s4|12-14|the|drug
DDI-DrugBank.d359.s4|16-23|coumarin|drug
DDI-DrugBank.d359.s4|25-38|anticoagulants|drug
DDI-DrugBank.d359.s4|40-43|have|drug
DDI-DrugBank.d359.s4|45-48|been|drug
DDI-DrugBank.d359.s4|50-57|reported|drug
DDI-DrugBank.d359.s4|59-60|to|drug
DDI-DrugBank.d359.s4|62-69|increase|drug
DDI-DrugBank.d359.s4|71-73|the|drug
DDI-DrugBank.d359.s4|75-79|serum|drug
DDI-DrugBank.d359.s4|81-86|levels|drug
DDI-DrugBank.d359.s4|88-90|and|drug
DDI-DrugBank.d359.s4|92-98|prolong|drug
DDI-DrugBank.d359.s4|100-102|the|drug
DDI-DrugBank.d359.s4|104-108|serum|drug
DDI-DrugBank.d359.s4|110-118|half-life|drug
DDI-DrugBank.d359.s4|120-121|of|drug
DDI-DrugBank.d359.s4|123-131|phenytoin|drug
DDI-DrugBank.d359.s4|133-134|by|drug
DDI-DrugBank.d359.s4|136-145|inhibiting|drug
DDI-DrugBank.d359.s4|147-149|its|drug
DDI-DrugBank.d359.s4|151-160|metabolism|drug
DDI-DrugBank.d359.s4|161-161|.|drug
DDI-DrugBank.d359.s5|0-7|Although|drug
DDI-DrugBank.d359.s5|9-13|there|drug
DDI-DrugBank.d359.s5|15-16|is|drug
DDI-DrugBank.d359.s5|18-19|no|drug
DDI-DrugBank.d359.s5|21-33|documentation|drug
DDI-DrugBank.d359.s5|35-36|of|drug
DDI-DrugBank.d359.s5|38-41|such|drug
DDI-DrugBank.d359.s5|42-42|,|drug
DDI-DrugBank.d359.s5|44-44|a|drug
DDI-DrugBank.d359.s5|46-52|similar|drug
DDI-DrugBank.d359.s5|54-64|interaction|drug
DDI-DrugBank.d359.s5|66-72|between|drug
DDI-DrugBank.d359.s5|74-81|ethotoin|drug
DDI-DrugBank.d359.s5|83-85|and|drug
DDI-DrugBank.d359.s5|87-89|the|drug
DDI-DrugBank.d359.s5|91-98|coumarin|drug
DDI-DrugBank.d359.s5|100-113|anticoagulants|drug
DDI-DrugBank.d359.s5|115-117|may|drug
DDI-DrugBank.d359.s5|119-123|occur|drug
DDI-DrugBank.d359.s5|124-124|.|drug
DDI-DrugBank.d359.s6|0-6|Caution|drug
DDI-DrugBank.d359.s6|8-9|is|drug
DDI-DrugBank.d359.s6|11-19|therefore|drug
DDI-DrugBank.d359.s6|21-27|advised|drug
DDI-DrugBank.d359.s6|29-32|when|drug
DDI-DrugBank.d359.s6|34-46|administering|drug
DDI-DrugBank.d359.s6|48-55|PEGANONE|drug
DDI-DrugBank.d359.s6|57-58|to|drug
DDI-DrugBank.d359.s6|60-67|patients|drug
DDI-DrugBank.d359.s6|69-77|receiving|drug
DDI-DrugBank.d359.s6|79-86|coumarin|drug
DDI-DrugBank.d359.s6|88-101|anticoagulants|drug
DDI-DrugBank.d359.s6|102-102|.|drug
DDI-DrugBank.d308.s0|0-2|THE|drug
DDI-DrugBank.d308.s0|4-15|POTENTIATING|drug
DDI-DrugBank.d308.s0|17-22|ACTION|drug
DDI-DrugBank.d308.s0|24-25|OF|drug
DDI-DrugBank.d308.s0|27-37|HYDROXYZINE|drug
DDI-DrugBank.d308.s0|39-42|MUST|drug
DDI-DrugBank.d308.s0|44-45|BE|drug
DDI-DrugBank.d308.s0|47-56|CONSIDERED|drug
DDI-DrugBank.d308.s0|58-61|WHEN|drug
DDI-DrugBank.d308.s0|63-65|THE|drug
DDI-DrugBank.d308.s0|67-70|DRUG|drug
DDI-DrugBank.d308.s0|72-73|IS|drug
DDI-DrugBank.d308.s0|75-78|USED|drug
DDI-DrugBank.d308.s0|80-81|IN|drug
DDI-DrugBank.d308.s0|83-93|CONJUNCTION|drug
DDI-DrugBank.d308.s0|95-98|WITH|drug
DDI-DrugBank.d308.s0|100-106|CENTRAL|drug
DDI-DrugBank.d308.s0|108-114|NERVOUS|drug
DDI-DrugBank.d308.s0|116-121|SYSTEM|drug
DDI-DrugBank.d308.s0|123-133|DEPRESSANTS|drug
DDI-DrugBank.d308.s0|135-138|SUCH|drug
DDI-DrugBank.d308.s0|140-141|AS|drug
DDI-DrugBank.d308.s0|143-151|NARCOTICS|drug
DDI-DrugBank.d308.s0|152-152|,|drug
DDI-DrugBank.d308.s0|154-165|NON-NARCOTIC|drug
DDI-DrugBank.d308.s0|167-176|ANALGESICS|drug
DDI-DrugBank.d308.s0|178-180|AND|drug
DDI-DrugBank.d308.s0|182-193|BARBITURATES|drug
DDI-DrugBank.d308.s0|194-194|.|drug
DDI-DrugBank.d308.s1|0-8|Therefore|drug
DDI-DrugBank.d308.s1|10-13|when|drug
DDI-DrugBank.d308.s1|15-21|central|drug
DDI-DrugBank.d308.s1|23-29|nervous|drug
DDI-DrugBank.d308.s1|31-36|system|drug
DDI-DrugBank.d308.s1|38-48|depressants|drug
DDI-DrugBank.d308.s1|50-52|are|drug
DDI-DrugBank.d308.s1|54-65|administered|drug
DDI-DrugBank.d308.s1|67-79|concomitantly|drug
DDI-DrugBank.d308.s1|81-84|with|drug
DDI-DrugBank.d308.s1|86-96|hydroxyzine|drug
DDI-DrugBank.d308.s1|98-102|their|drug
DDI-DrugBank.d308.s1|104-109|dosage|drug
DDI-DrugBank.d308.s1|111-116|should|drug
DDI-DrugBank.d308.s1|118-119|be|drug
DDI-DrugBank.d308.s1|121-127|reduced|drug
DDI-DrugBank.d308.s1|128-128|.|drug
DDI-DrugBank.d308.s2|0-4|Since|drug
DDI-DrugBank.d308.s2|6-15|drowsiness|drug
DDI-DrugBank.d308.s2|17-19|may|drug
DDI-DrugBank.d308.s2|21-25|occur|drug
DDI-DrugBank.d308.s2|27-30|with|drug
DDI-DrugBank.d308.s2|32-34|use|drug
DDI-DrugBank.d308.s2|36-37|of|drug
DDI-DrugBank.d308.s2|39-42|this|drug
DDI-DrugBank.d308.s2|44-47|drug|drug
DDI-DrugBank.d308.s2|48-48|,|drug
DDI-DrugBank.d308.s2|50-57|patients|drug
DDI-DrugBank.d308.s2|59-64|should|drug
DDI-DrugBank.d308.s2|66-67|be|drug
DDI-DrugBank.d308.s2|69-74|warned|drug
DDI-DrugBank.d308.s2|76-77|of|drug
DDI-DrugBank.d308.s2|79-82|this|drug
DDI-DrugBank.d308.s2|84-94|possibility|drug
DDI-DrugBank.d308.s2|96-98|and|drug
DDI-DrugBank.d308.s2|100-108|cautioned|drug
DDI-DrugBank.d308.s2|110-116|against|drug
DDI-DrugBank.d308.s2|118-124|driving|drug
DDI-DrugBank.d308.s2|126-126|a|drug
DDI-DrugBank.d308.s2|128-130|car|drug
DDI-DrugBank.d308.s2|132-133|or|drug
DDI-DrugBank.d308.s2|135-143|operating|drug
DDI-DrugBank.d308.s2|145-153|dangerous|drug
DDI-DrugBank.d308.s2|155-163|machinery|drug
DDI-DrugBank.d308.s2|165-169|while|drug
DDI-DrugBank.d308.s2|171-176|taking|drug
DDI-DrugBank.d308.s2|178-183|Atarax|brand
DDI-DrugBank.d308.s2|184-184|.|drug
DDI-DrugBank.d308.s3|0-7|Patients|drug
DDI-DrugBank.d308.s3|9-14|should|drug
DDI-DrugBank.d308.s3|16-17|be|drug
DDI-DrugBank.d308.s3|19-25|advised|drug
DDI-DrugBank.d308.s3|27-33|against|drug
DDI-DrugBank.d308.s3|35-37|the|drug
DDI-DrugBank.d308.s3|39-50|simultaneous|drug
DDI-DrugBank.d308.s3|52-54|use|drug
DDI-DrugBank.d308.s3|56-57|of|drug
DDI-DrugBank.d308.s3|59-63|other|drug
DDI-DrugBank.d308.s3|65-67|CNS|drug
DDI-DrugBank.d308.s3|69-78|depressant|drug
DDI-DrugBank.d308.s3|80-84|drugs|drug
DDI-DrugBank.d308.s3|85-85|,|drug
DDI-DrugBank.d308.s3|87-89|and|drug
DDI-DrugBank.d308.s3|91-99|cautioned|drug
DDI-DrugBank.d308.s3|101-104|that|drug
DDI-DrugBank.d308.s3|106-108|the|drug
DDI-DrugBank.d308.s3|110-115|effect|drug
DDI-DrugBank.d308.s3|117-118|of|drug
DDI-DrugBank.d308.s3|120-126|alcohol|drug
DDI-DrugBank.d308.s3|128-130|may|drug
DDI-DrugBank.d308.s3|132-133|be|drug
DDI-DrugBank.d308.s3|135-143|increased|drug
DDI-DrugBank.d308.s3|144-144|.|drug
DDI-DrugBank.d227.s0|0-9|Isoflurane|brand
DDI-DrugBank.d227.s0|11-21|potentiates|drug
DDI-DrugBank.d227.s0|23-25|the|drug
DDI-DrugBank.d227.s0|27-32|muscle|drug
DDI-DrugBank.d227.s0|34-41|relaxant|drug
DDI-DrugBank.d227.s0|43-48|effect|drug
DDI-DrugBank.d227.s0|50-51|of|drug
DDI-DrugBank.d227.s0|53-55|all|drug
DDI-DrugBank.d227.s0|57-62|muscle|drug
DDI-DrugBank.d227.s0|64-72|relaxants|drug
DDI-DrugBank.d227.s0|73-73|,|drug
DDI-DrugBank.d227.s0|75-78|most|drug
DDI-DrugBank.d227.s0|80-86|notably|drug
DDI-DrugBank.d227.s0|88-102|nondepolarizing|drug
DDI-DrugBank.d227.s0|104-109|muscle|drug
DDI-DrugBank.d227.s0|111-119|relaxants|drug
DDI-DrugBank.d227.s0|120-120|,|drug
DDI-DrugBank.d227.s0|122-124|and|drug
DDI-DrugBank.d227.s0|126-128|MAC|drug
DDI-DrugBank.d227.s0|130-130|(|drug
DDI-DrugBank.d227.s0|131-137|minimum|drug
DDI-DrugBank.d227.s0|139-146|alveolar|drug
DDI-DrugBank.d227.s0|148-160|concentration|drug
DDI-DrugBank.d227.s0|161-161|)|drug
DDI-DrugBank.d227.s0|163-164|is|drug
DDI-DrugBank.d227.s0|166-172|reduced|drug
DDI-DrugBank.d227.s0|174-175|by|drug
DDI-DrugBank.d227.s0|177-187|concomitant|drug
DDI-DrugBank.d227.s0|189-202|administration|drug
DDI-DrugBank.d227.s0|204-205|of|drug
DDI-DrugBank.d227.s0|207-207|N|drug
DDI-DrugBank.d227.s0|209-210|2O|drug
DDI-DrugBank.d227.s0|211-211|.|drug
DDI-DrugBank.d227.s1|0-2|See|drug
DDI-DrugBank.d227.s1|4-11|CLINICAL|drug
DDI-DrugBank.d227.s1|13-24|PHARMACOLOGY|drug
DDI-DrugBank.d227.s1|25-25|.|drug
DDI-DrugBank.d124.s0|0-3|DRUG|drug
DDI-DrugBank.d124.s0|5-16|INTERACTIONS|drug
DDI-DrugBank.d124.s1|0-6|Several|drug
DDI-DrugBank.d124.s1|8-11|drug|drug
DDI-DrugBank.d124.s1|13-23|interaction|drug
DDI-DrugBank.d124.s1|25-31|studies|drug
DDI-DrugBank.d124.s1|33-36|have|drug
DDI-DrugBank.d124.s1|38-41|been|drug
DDI-DrugBank.d124.s1|43-51|completed|drug
DDI-DrugBank.d124.s1|53-56|with|drug
DDI-DrugBank.d124.s1|58-61|both|drug
DDI-DrugBank.d124.s1|63-70|INVIRASE|drug
DDI-DrugBank.d124.s1|72-74|and|drug
DDI-DrugBank.d124.s1|76-84|FORTOVASE|drug
DDI-DrugBank.d124.s1|85-85|.|drug
DDI-DrugBank.d124.s2|0-11|Observations|drug
DDI-DrugBank.d124.s2|13-16|from|drug
DDI-DrugBank.d124.s2|18-21|drug|drug
DDI-DrugBank.d124.s2|23-33|interaction|drug
DDI-DrugBank.d124.s2|35-41|studies|drug
DDI-DrugBank.d124.s2|43-46|with|drug
DDI-DrugBank.d124.s2|48-56|FORTOVASE|drug
DDI-DrugBank.d124.s2|58-60|may|drug
DDI-DrugBank.d124.s2|62-64|not|drug
DDI-DrugBank.d124.s2|66-67|be|drug
DDI-DrugBank.d124.s2|69-78|predictive|drug
DDI-DrugBank.d124.s2|80-82|for|drug
DDI-DrugBank.d124.s2|84-91|INVIRASE|drug
DDI-DrugBank.d124.s2|92-92|.|drug
DDI-DrugBank.d124.s3|0-6|Because|drug
DDI-DrugBank.d124.s3|8-16|ritonavir|drug
DDI-DrugBank.d124.s3|18-19|is|drug
DDI-DrugBank.d124.s3|21-34|coadministered|drug
DDI-DrugBank.d124.s3|35-35|,|drug
DDI-DrugBank.d124.s3|37-47|prescribers|drug
DDI-DrugBank.d124.s3|49-54|should|drug
DDI-DrugBank.d124.s3|56-59|also|drug
DDI-DrugBank.d124.s3|61-65|refer|drug
DDI-DrugBank.d124.s3|67-68|to|drug
DDI-DrugBank.d124.s3|70-72|the|drug
DDI-DrugBank.d124.s3|74-84|prescribing|drug
DDI-DrugBank.d124.s3|86-96|information|drug
DDI-DrugBank.d124.s3|98-100|for|drug
DDI-DrugBank.d124.s3|102-110|ritonavir|drug
DDI-DrugBank.d124.s3|112-120|regarding|drug
DDI-DrugBank.d124.s3|122-125|drug|drug
DDI-DrugBank.d124.s3|127-138|interactions|drug
DDI-DrugBank.d124.s3|140-149|associated|drug
DDI-DrugBank.d124.s3|151-154|with|drug
DDI-DrugBank.d124.s3|156-159|this|drug
DDI-DrugBank.d124.s3|161-165|agent|drug
DDI-DrugBank.d124.s3|166-166|.|drug
DDI-DrugBank.d124.s4|0-2|The|drug
DDI-DrugBank.d124.s4|4-13|metabolism|drug
DDI-DrugBank.d124.s4|15-16|of|drug
DDI-DrugBank.d124.s4|18-27|saquinavir|drug
DDI-DrugBank.d124.s4|29-30|is|drug
DDI-DrugBank.d124.s4|32-39|mediated|drug
DDI-DrugBank.d124.s4|41-42|by|drug
DDI-DrugBank.d124.s4|44-53|cytochrome|drug
DDI-DrugBank.d124.s4|55-58|P450|drug
DDI-DrugBank.d124.s4|59-59|,|drug
DDI-DrugBank.d124.s4|61-64|with|drug
DDI-DrugBank.d124.s4|66-68|the|drug
DDI-DrugBank.d124.s4|70-77|specific|drug
DDI-DrugBank.d124.s4|79-87|isoenzyme|drug
DDI-DrugBank.d124.s4|89-94|CYP3A4|drug
DDI-DrugBank.d124.s4|96-106|responsible|drug
DDI-DrugBank.d124.s4|108-110|for|drug
DDI-DrugBank.d124.s4|112-113|90|drug
DDI-DrugBank.d124.s4|114-114|%|drug
DDI-DrugBank.d124.s4|116-117|of|drug
DDI-DrugBank.d124.s4|119-121|the|drug
DDI-DrugBank.d124.s4|123-129|hepatic|drug
DDI-DrugBank.d124.s4|131-140|metabolism|drug
DDI-DrugBank.d124.s4|141-141|.|drug
DDI-DrugBank.d124.s5|0-11|Additionally|drug
DDI-DrugBank.d124.s5|12-12|,|drug
DDI-DrugBank.d124.s5|14-23|saquinavir|drug
DDI-DrugBank.d124.s5|25-26|is|drug
DDI-DrugBank.d124.s5|28-28|a|drug
DDI-DrugBank.d124.s5|30-38|substrate|drug
DDI-DrugBank.d124.s5|40-42|for|drug
DDI-DrugBank.d124.s5|44-57|P-Glycoprotein|drug
DDI-DrugBank.d124.s5|59-59|(|drug
DDI-DrugBank.d124.s5|60-62|Pgp|drug
DDI-DrugBank.d124.s5|63-63|)|drug
DDI-DrugBank.d124.s5|64-64|.|drug
DDI-DrugBank.d124.s6|0-8|Therefore|drug
DDI-DrugBank.d124.s6|9-9|,|drug
DDI-DrugBank.d124.s6|11-15|drugs|drug
DDI-DrugBank.d124.s6|17-20|that|drug
DDI-DrugBank.d124.s6|22-27|affect|drug
DDI-DrugBank.d124.s6|29-34|CYP3A4|drug
DDI-DrugBank.d124.s6|36-41|and/or|drug
DDI-DrugBank.d124.s6|43-45|Pgp|drug
DDI-DrugBank.d124.s6|46-46|,|drug
DDI-DrugBank.d124.s6|48-50|may|drug
DDI-DrugBank.d124.s6|52-57|modify|drug
DDI-DrugBank.d124.s6|59-61|the|drug
DDI-DrugBank.d124.s6|63-78|pharmacokinetics|drug
DDI-DrugBank.d124.s6|80-81|of|drug
DDI-DrugBank.d124.s6|83-92|saquinavir|drug
DDI-DrugBank.d124.s6|93-93|.|drug
DDI-DrugBank.d124.s7|0-8|Similarly|drug
DDI-DrugBank.d124.s7|9-9|,|drug
DDI-DrugBank.d124.s7|11-20|saquinavir|drug
DDI-DrugBank.d124.s7|22-26|might|drug
DDI-DrugBank.d124.s7|28-31|also|drug
DDI-DrugBank.d124.s7|33-38|modify|drug
DDI-DrugBank.d124.s7|40-42|the|drug
DDI-DrugBank.d124.s7|44-59|pharmacokinetics|drug
DDI-DrugBank.d124.s7|61-62|of|drug
DDI-DrugBank.d124.s7|64-68|other|drug
DDI-DrugBank.d124.s7|70-74|drugs|drug
DDI-DrugBank.d124.s7|76-79|that|drug
DDI-DrugBank.d124.s7|81-83|are|drug
DDI-DrugBank.d124.s7|85-94|substrates|drug
DDI-DrugBank.d124.s7|96-98|for|drug
DDI-DrugBank.d124.s7|100-105|CYP3A4|drug
DDI-DrugBank.d124.s7|107-108|or|drug
DDI-DrugBank.d124.s7|110-112|Pgp|drug
DDI-DrugBank.d124.s7|113-113|.|drug
DDI-DrugBank.d124.s8|0-4|Drugs|drug
DDI-DrugBank.d124.s8|6-9|that|drug
DDI-DrugBank.d124.s8|11-13|are|drug
DDI-DrugBank.d124.s8|15-29|contraindicated|drug
DDI-DrugBank.d124.s8|31-42|specifically|drug
DDI-DrugBank.d124.s8|44-46|due|drug
DDI-DrugBank.d124.s8|48-49|to|drug
DDI-DrugBank.d124.s8|51-53|the|drug
DDI-DrugBank.d124.s8|55-62|expected|drug
DDI-DrugBank.d124.s8|64-72|magnitude|drug
DDI-DrugBank.d124.s8|74-75|of|drug
DDI-DrugBank.d124.s8|77-87|interaction|drug
DDI-DrugBank.d124.s8|89-91|and|drug
DDI-DrugBank.d124.s8|93-101|potential|drug
DDI-DrugBank.d124.s8|103-105|for|drug
DDI-DrugBank.d124.s8|107-113|serious|drug
DDI-DrugBank.d124.s8|115-121|adverse|drug
DDI-DrugBank.d124.s8|123-128|events|drug
DDI-DrugBank.d124.s8|130-132|are|drug
DDI-DrugBank.d124.s8|134-139|listed|drug
DDI-DrugBank.d124.s8|141-157|CONTRAINDICATIONS|drug
DDI-DrugBank.d124.s8|158-158|.|drug
DDI-DrugBank.d124.s9|0-9|Additional|drug
DDI-DrugBank.d124.s9|11-15|drugs|drug
DDI-DrugBank.d124.s9|17-20|that|drug
DDI-DrugBank.d124.s9|22-24|are|drug
DDI-DrugBank.d124.s9|26-28|not|drug
DDI-DrugBank.d124.s9|30-40|recommended|drug
DDI-DrugBank.d124.s9|42-44|for|drug
DDI-DrugBank.d124.s9|46-61|coadministration|drug
DDI-DrugBank.d124.s9|63-66|with|drug
DDI-DrugBank.d124.s9|68-75|INVIRASE|drug
DDI-DrugBank.d124.s9|77-79|and|drug
DDI-DrugBank.d124.s9|81-89|ritonavir|drug
DDI-DrugBank.d124.s9|91-93|are|drug
DDI-DrugBank.d124.s9|95-102|included|drug
DDI-DrugBank.d124.s9|104-108|below|drug
DDI-DrugBank.d124.s9|109-109|.|drug
DDI-DrugBank.d124.s10|0-4|These|drug
DDI-DrugBank.d124.s10|6-20|recommendations|drug
DDI-DrugBank.d124.s10|22-24|are|drug
DDI-DrugBank.d124.s10|26-30|based|drug
DDI-DrugBank.d124.s10|32-33|on|drug
DDI-DrugBank.d124.s10|35-40|either|drug
DDI-DrugBank.d124.s10|42-45|drug|drug
DDI-DrugBank.d124.s10|47-57|interaction|drug
DDI-DrugBank.d124.s10|59-65|studies|drug
DDI-DrugBank.d124.s10|67-68|or|drug
DDI-DrugBank.d124.s10|70-78|predicted|drug
DDI-DrugBank.d124.s10|80-91|interactions|drug
DDI-DrugBank.d124.s10|93-95|due|drug
DDI-DrugBank.d124.s10|97-98|to|drug
DDI-DrugBank.d124.s10|100-102|the|drug
DDI-DrugBank.d124.s10|104-111|expected|drug
DDI-DrugBank.d124.s10|113-121|magnitude|drug
DDI-DrugBank.d124.s10|123-124|of|drug
DDI-DrugBank.d124.s10|126-136|interaction|drug
DDI-DrugBank.d124.s10|138-140|and|drug
DDI-DrugBank.d124.s10|142-150|potential|drug
DDI-DrugBank.d124.s10|152-154|for|drug
DDI-DrugBank.d124.s10|156-162|serious|drug
DDI-DrugBank.d124.s10|164-169|events|drug
DDI-DrugBank.d124.s10|171-172|or|drug
DDI-DrugBank.d124.s10|174-177|loss|drug
DDI-DrugBank.d124.s10|179-180|of|drug
DDI-DrugBank.d124.s10|182-189|efficacy|drug
DDI-DrugBank.d124.s10|190-190|.|drug
DDI-DrugBank.d124.s11|0-3|With|drug
DDI-DrugBank.d124.s11|5-8|some|drug
DDI-DrugBank.d124.s11|10-15|agents|drug
DDI-DrugBank.d124.s11|16-16|,|drug
DDI-DrugBank.d124.s11|18-20|the|drug
DDI-DrugBank.d124.s11|22-31|metabolism|drug
DDI-DrugBank.d124.s11|33-35|may|drug
DDI-DrugBank.d124.s11|37-38|be|drug
DDI-DrugBank.d124.s11|40-46|induced|drug
DDI-DrugBank.d124.s11|47-47|,|drug
DDI-DrugBank.d124.s11|49-57|resulting|drug
DDI-DrugBank.d124.s11|59-60|in|drug
DDI-DrugBank.d124.s11|62-70|decreased|drug
DDI-DrugBank.d124.s11|72-85|concentrations|drug
DDI-DrugBank.d124.s11|86-86|.|drug
DDI-DrugBank.d124.s12|0-4|Drugs|drug
DDI-DrugBank.d124.s12|6-9|That|drug
DDI-DrugBank.d124.s12|11-16|Should|drug
DDI-DrugBank.d124.s12|18-20|Not|drug
DDI-DrugBank.d124.s12|22-23|Be|drug
DDI-DrugBank.d124.s12|25-38|Coadministered|drug
DDI-DrugBank.d124.s12|40-43|With|drug
DDI-DrugBank.d124.s12|45-62|INVIRASE/Ritonavir|drug
DDI-DrugBank.d124.s13|0-3|Drug|drug
DDI-DrugBank.d124.s13|5-9|Class|drug
DDI-DrugBank.d124.s13|10-10|:|drug
DDI-DrugBank.d124.s13|12-15|Drug|drug
DDI-DrugBank.d124.s13|17-20|Name|drug
DDI-DrugBank.d124.s13|22-29|Clinical|drug
DDI-DrugBank.d124.s13|31-37|Comment|drug
DDI-DrugBank.d124.s14|0-14|Antiarrhythmics|drug
DDI-DrugBank.d124.s14|15-15|:|drug
DDI-DrugBank.d124.s14|17-26|Amiodarone|brand
DDI-DrugBank.d124.s14|27-27|,|drug
DDI-DrugBank.d124.s14|29-36|bepridil|drug
DDI-DrugBank.d124.s14|37-37|,|drug
DDI-DrugBank.d124.s14|39-48|flecainide|drug
DDI-DrugBank.d124.s14|49-49|,|drug
DDI-DrugBank.d124.s14|51-61|propafenone|drug
DDI-DrugBank.d124.s14|62-62|,|drug
DDI-DrugBank.d124.s14|64-72|quinidine|drug
DDI-DrugBank.d124.s14|74-88|CONTRAINDICATED|drug
DDI-DrugBank.d124.s14|90-92|due|drug
DDI-DrugBank.d124.s14|94-95|to|drug
DDI-DrugBank.d124.s14|97-105|potential|drug
DDI-DrugBank.d124.s14|107-109|for|drug
DDI-DrugBank.d124.s14|111-117|serious|drug
DDI-DrugBank.d124.s14|119-124|and/or|drug
DDI-DrugBank.d124.s14|126-141|life-threatening|drug
DDI-DrugBank.d124.s14|143-151|reactions|drug
DDI-DrugBank.d124.s14|152-152|.|drug
DDI-DrugBank.d124.s15|0-13|Antihistamines|drug
DDI-DrugBank.d124.s15|14-14|:|drug
DDI-DrugBank.d124.s15|16-26|astemizole|drug
DDI-DrugBank.d124.s15|27-27|*|drug
DDI-DrugBank.d124.s15|29-40|,|drug
DDI-DrugBank.d124.s15|42-56|terfenadine|drug
DDI-DrugBank.d124.s15|58-60|*|drug
DDI-DrugBank.d124.s15|62-63|CONTRAINDICATED|drug
DDI-DrugBank.d124.s15|65-73|due|drug
DDI-DrugBank.d124.s15|75-77|to|drug
DDI-DrugBank.d124.s15|79-85|potential|drug
DDI-DrugBank.d124.s15|87-92|for|drug
DDI-DrugBank.d124.s15|94-109|serious|drug
DDI-DrugBank.d124.s15|111-117|and/or|drug
DDI-DrugBank.d124.s15|119-129|life-threatening|drug
DDI-DrugBank.d124.s15|130-130|cardiac|drug
DDI-DrugBank.d124.s16|0-4|Ergot|drug
DDI-DrugBank.d124.s16|6-16|Derivatives|drug
DDI-DrugBank.d124.s16|17-17|:|drug
DDI-DrugBank.d124.s16|19-35|Dihydroergotamine|drug
DDI-DrugBank.d124.s16|36-36|,|drug
DDI-DrugBank.d124.s16|38-47|ergonovine|drug
DDI-DrugBank.d124.s16|48-48|,|drug
DDI-DrugBank.d124.s16|50-59|ergotamine|drug
DDI-DrugBank.d124.s16|60-60|,|drug
DDI-DrugBank.d124.s16|62-77|methylergonovine|drug
DDI-DrugBank.d124.s16|79-93|CONTRAINDICATED|drug
DDI-DrugBank.d124.s16|95-97|due|drug
DDI-DrugBank.d124.s16|99-100|to|drug
DDI-DrugBank.d124.s16|102-110|potential|drug
DDI-DrugBank.d124.s16|112-114|for|drug
DDI-DrugBank.d124.s16|116-122|serious|drug
DDI-DrugBank.d124.s16|124-126|and|drug
DDI-DrugBank.d124.s16|128-143|life-threatening|drug
DDI-DrugBank.d124.s16|145-153|reactions|drug
DDI-DrugBank.d124.s16|155-158|such|drug
DDI-DrugBank.d124.s16|160-161|as|drug
DDI-DrugBank.d124.s16|163-167|acute|drug
DDI-DrugBank.d124.s16|169-173|ergot|drug
DDI-DrugBank.d124.s16|175-182|toxicity|drug
DDI-DrugBank.d124.s16|184-196|characterized|drug
DDI-DrugBank.d124.s16|198-199|by|drug
DDI-DrugBank.d124.s16|201-210|peripheral|drug
DDI-DrugBank.d124.s16|212-220|vasospasm|drug
DDI-DrugBank.d124.s16|222-224|and|drug
DDI-DrugBank.d124.s16|226-233|ischemia|drug
DDI-DrugBank.d124.s16|235-236|of|drug
DDI-DrugBank.d124.s16|238-240|the|drug
DDI-DrugBank.d124.s16|242-252|extremities|drug
DDI-DrugBank.d124.s16|254-256|and|drug
DDI-DrugBank.d124.s16|258-262|other|drug
DDI-DrugBank.d124.s16|264-270|tissues|drug
DDI-DrugBank.d124.s16|271-271|.|drug
DDI-DrugBank.d124.s17|0-16|Antimycobacterial|drug
DDI-DrugBank.d124.s17|18-23|Agents|drug
DDI-DrugBank.d124.s17|24-24|:|drug
DDI-DrugBank.d124.s17|26-33|rifampin|drug
DDI-DrugBank.d124.s17|35-49|CONTRAINDICATED|drug
DDI-DrugBank.d124.s17|51-55|since|drug
DDI-DrugBank.d124.s17|57-59|the|drug
DDI-DrugBank.d124.s17|61-76|coadministration|drug
DDI-DrugBank.d124.s17|78-79|of|drug
DDI-DrugBank.d124.s17|81-84|this|drug
DDI-DrugBank.d124.s17|86-92|product|drug
DDI-DrugBank.d124.s17|94-97|with|drug
DDI-DrugBank.d124.s17|99-108|saquinavir|drug
DDI-DrugBank.d124.s17|110-111|in|drug
DDI-DrugBank.d124.s17|113-114|an|drug
DDI-DrugBank.d124.s17|116-129|antiretroviral|drug
DDI-DrugBank.d124.s17|131-137|regimen|drug
DDI-DrugBank.d124.s17|139-145|reduces|drug
DDI-DrugBank.d124.s17|147-149|the|drug
DDI-DrugBank.d124.s17|151-156|plasma|drug
DDI-DrugBank.d124.s17|158-171|concentrations|drug
DDI-DrugBank.d124.s17|173-174|of|drug
DDI-DrugBank.d124.s17|176-185|saquinavir|drug
DDI-DrugBank.d124.s17|186-186|.|drug
DDI-DrugBank.d124.s18|0-5|Garlic|brand
DDI-DrugBank.d124.s18|7-14|Capsules|drug
DDI-DrugBank.d124.s18|16-21|Garlic|brand
DDI-DrugBank.d124.s18|23-30|capsules|drug
DDI-DrugBank.d124.s18|32-37|should|drug
DDI-DrugBank.d124.s18|39-41|not|drug
DDI-DrugBank.d124.s18|43-44|be|drug
DDI-DrugBank.d124.s18|46-49|used|drug
DDI-DrugBank.d124.s18|51-55|while|drug
DDI-DrugBank.d124.s18|57-62|taking|drug
DDI-DrugBank.d124.s18|64-73|saquinavir|drug
DDI-DrugBank.d124.s18|75-75|(|drug
DDI-DrugBank.d124.s18|76-84|FORTOVASE|drug
DDI-DrugBank.d124.s18|85-85|)|drug
DDI-DrugBank.d124.s18|87-88|as|drug
DDI-DrugBank.d124.s18|90-92|the|drug
DDI-DrugBank.d124.s18|94-97|sole|drug
DDI-DrugBank.d124.s18|99-106|protease|drug
DDI-DrugBank.d124.s18|108-116|inhibitor|drug
DDI-DrugBank.d124.s18|118-120|due|drug
DDI-DrugBank.d124.s18|122-123|to|drug
DDI-DrugBank.d124.s18|125-127|the|drug
DDI-DrugBank.d124.s18|129-132|risk|drug
DDI-DrugBank.d124.s18|134-135|of|drug
DDI-DrugBank.d124.s18|137-145|decreased|drug
DDI-DrugBank.d124.s18|147-156|saquinavir|drug
DDI-DrugBank.d124.s18|158-163|plasma|drug
DDI-DrugBank.d124.s18|165-178|concentrations|drug
DDI-DrugBank.d124.s18|179-179|.|drug
DDI-DrugBank.d124.s19|0-1|No|drug
DDI-DrugBank.d124.s19|3-6|data|drug
DDI-DrugBank.d124.s19|8-10|are|drug
DDI-DrugBank.d124.s19|12-20|available|drug
DDI-DrugBank.d124.s19|22-24|for|drug
DDI-DrugBank.d124.s19|26-28|the|drug
DDI-DrugBank.d124.s19|30-45|coadministration|drug
DDI-DrugBank.d124.s19|47-48|of|drug
DDI-DrugBank.d124.s19|50-67|INVIRASE/ritonavir|drug
DDI-DrugBank.d124.s19|69-70|or|drug
DDI-DrugBank.d124.s19|72-90|FORTOVASE/ritonavir|drug
DDI-DrugBank.d124.s19|92-94|and|drug
DDI-DrugBank.d124.s19|96-101|garlic|drug
DDI-DrugBank.d124.s19|103-110|capsules|drug
DDI-DrugBank.d124.s19|111-111|.|drug
DDI-DrugBank.d124.s20|0-1|GI|drug
DDI-DrugBank.d124.s20|3-10|Motility|drug
DDI-DrugBank.d124.s20|12-16|Agent|drug
DDI-DrugBank.d124.s20|17-17|:|drug
DDI-DrugBank.d124.s20|19-28|cisapride|drug
DDI-DrugBank.d124.s20|30-44|*|drug
DDI-DrugBank.d124.s20|46-48|CONTRAINDICATED|drug
DDI-DrugBank.d124.s20|50-51|due|drug
DDI-DrugBank.d124.s20|53-61|to|drug
DDI-DrugBank.d124.s20|63-65|potential|drug
DDI-DrugBank.d124.s20|67-73|for|drug
DDI-DrugBank.d124.s20|75-80|serious|drug
DDI-DrugBank.d124.s20|82-97|and/or|drug
DDI-DrugBank.d124.s20|99-107|life-threatening|drug
DDI-DrugBank.d124.s20|109-112|reactions|drug
DDI-DrugBank.d124.s20|114-115|such|drug
DDI-DrugBank.d124.s20|117-123|as|drug
DDI-DrugBank.d124.s20|125-135|cardiac|drug
DDI-DrugBank.d124.s20|136-136|arrhythmias|drug
DDI-DrugBank.d124.s21|0-5|Herbal|brand
DDI-DrugBank.d124.s21|7-14|Products|drug
DDI-DrugBank.d124.s21|15-15|:|drug
DDI-DrugBank.d124.s21|17-19|St.|drug
DDI-DrugBank.d124.s21|21-24|John|drug
DDI-DrugBank.d124.s21|26-26|s|drug
DDI-DrugBank.d124.s21|28-31|wort|drug
DDI-DrugBank.d124.s21|33-33|(|drug
DDI-DrugBank.d124.s21|34-42|hypericum|drug
DDI-DrugBank.d124.s21|44-53|perforatum|drug
DDI-DrugBank.d124.s21|54-54|)|drug
DDI-DrugBank.d124.s21|56-62|WARNING|drug
DDI-DrugBank.d124.s21|64-79|coadministration|drug
DDI-DrugBank.d124.s21|81-83|may|drug
DDI-DrugBank.d124.s21|85-88|lead|drug
DDI-DrugBank.d124.s21|90-91|to|drug
DDI-DrugBank.d124.s21|93-96|loss|drug
DDI-DrugBank.d124.s21|98-99|of|drug
DDI-DrugBank.d124.s21|101-109|virologic|drug
DDI-DrugBank.d124.s21|111-118|response|drug
DDI-DrugBank.d124.s21|120-122|and|drug
DDI-DrugBank.d124.s21|124-131|possible|drug
DDI-DrugBank.d124.s21|133-142|resistance|drug
DDI-DrugBank.d124.s21|144-145|to|drug
DDI-DrugBank.d124.s21|147-154|INVIRASE|drug
DDI-DrugBank.d124.s21|156-157|or|drug
DDI-DrugBank.d124.s21|159-160|to|drug
DDI-DrugBank.d124.s21|162-164|the|drug
DDI-DrugBank.d124.s21|166-170|class|drug
DDI-DrugBank.d124.s21|172-173|of|drug
DDI-DrugBank.d124.s21|175-182|protease|drug
DDI-DrugBank.d124.s21|184-193|inhibitors|drug
DDI-DrugBank.d124.s21|194-194|.|drug
DDI-DrugBank.d124.s22|0-6|HMG-CoA|drug
DDI-DrugBank.d124.s22|8-16|Reductase|drug
DDI-DrugBank.d124.s22|18-27|Inhibitors|drug
DDI-DrugBank.d124.s22|28-28|:|drug
DDI-DrugBank.d124.s22|30-39|lovastatin|drug
DDI-DrugBank.d124.s22|40-40|,|drug
DDI-DrugBank.d124.s22|42-52|simvastatin|drug
DDI-DrugBank.d124.s22|54-60|WARNING|drug
DDI-DrugBank.d124.s22|62-70|potential|drug
DDI-DrugBank.d124.s22|72-74|for|drug
DDI-DrugBank.d124.s22|76-82|serious|drug
DDI-DrugBank.d124.s22|84-92|reactions|drug
DDI-DrugBank.d124.s22|94-97|such|drug
DDI-DrugBank.d124.s22|99-100|as|drug
DDI-DrugBank.d124.s22|102-105|risk|drug
DDI-DrugBank.d124.s22|107-108|of|drug
DDI-DrugBank.d124.s22|110-117|myopathy|drug
DDI-DrugBank.d124.s22|119-127|including|drug
DDI-DrugBank.d124.s22|129-142|rhabdomyolysis|drug
DDI-DrugBank.d124.s22|143-143|.|drug
DDI-DrugBank.d124.s23|0-18|Sedatives/Hypnotics|drug
DDI-DrugBank.d124.s23|19-19|:|drug
DDI-DrugBank.d124.s23|21-29|triazolam|drug
DDI-DrugBank.d124.s23|30-30|,|drug
DDI-DrugBank.d124.s23|32-40|midazolam|drug
DDI-DrugBank.d124.s23|42-56|CONTRAINDICATED|drug
DDI-DrugBank.d124.s23|58-60|due|drug
DDI-DrugBank.d124.s23|62-63|to|drug
DDI-DrugBank.d124.s23|65-73|potential|drug
DDI-DrugBank.d124.s23|75-77|for|drug
DDI-DrugBank.d124.s23|79-85|serious|drug
DDI-DrugBank.d124.s23|87-92|and/or|drug
DDI-DrugBank.d124.s23|94-109|life-threatening|drug
DDI-DrugBank.d124.s23|111-119|reactions|drug
DDI-DrugBank.d124.s23|121-124|such|drug
DDI-DrugBank.d124.s23|126-127|as|drug
DDI-DrugBank.d124.s23|129-137|prolonged|drug
DDI-DrugBank.d124.s23|139-140|or|drug
DDI-DrugBank.d124.s23|142-150|increased|drug
DDI-DrugBank.d124.s23|152-159|sedation|drug
DDI-DrugBank.d124.s23|161-162|or|drug
DDI-DrugBank.d124.s23|164-174|respiratory|drug
DDI-DrugBank.d124.s23|176-185|depression|drug
DDI-DrugBank.d124.s23|186-186|.|drug
DDI-DrugBank.d124.s24|0-0|*|drug
DDI-DrugBank.d124.s24|2-3|No|drug
DDI-DrugBank.d124.s24|5-10|longer|drug
DDI-DrugBank.d124.s24|12-19|marketed|drug
DDI-DrugBank.d124.s24|21-22|in|drug
DDI-DrugBank.d124.s24|24-26|the|drug
DDI-DrugBank.d124.s24|28-29|US|drug
DDI-DrugBank.d124.s24|30-30|.|drug
DDI-DrugBank.d124.s25|0-4|Drugs|drug
DDI-DrugBank.d124.s25|6-9|That|drug
DDI-DrugBank.d124.s25|11-13|Are|drug
DDI-DrugBank.d124.s25|15-20|Mainly|drug
DDI-DrugBank.d124.s25|22-32|Metabolized|drug
DDI-DrugBank.d124.s25|34-35|by|drug
DDI-DrugBank.d124.s25|37-42|CYP3A4|drug
DDI-DrugBank.d124.s26|0-7|Although|drug
DDI-DrugBank.d124.s26|9-16|specific|drug
DDI-DrugBank.d124.s26|18-24|studies|drug
DDI-DrugBank.d124.s26|26-29|have|drug
DDI-DrugBank.d124.s26|31-33|not|drug
DDI-DrugBank.d124.s26|35-38|been|drug
DDI-DrugBank.d124.s26|40-48|performed|drug
DDI-DrugBank.d124.s26|49-49|,|drug
DDI-DrugBank.d124.s26|51-66|coadministration|drug
DDI-DrugBank.d124.s26|68-71|with|drug
DDI-DrugBank.d124.s26|73-77|drugs|drug
DDI-DrugBank.d124.s26|79-82|that|drug
DDI-DrugBank.d124.s26|84-86|are|drug
DDI-DrugBank.d124.s26|88-93|mainly|drug
DDI-DrugBank.d124.s26|95-105|metabolized|drug
DDI-DrugBank.d124.s26|107-108|by|drug
DDI-DrugBank.d124.s26|110-115|CYP3A4|drug
DDI-DrugBank.d124.s26|117-117|(|drug
DDI-DrugBank.d124.s26|118-119|eg|drug
DDI-DrugBank.d124.s26|120-120|,|drug
DDI-DrugBank.d124.s26|122-128|calcium|drug
DDI-DrugBank.d124.s26|130-136|channel|drug
DDI-DrugBank.d124.s26|138-145|blockers|drug
DDI-DrugBank.d124.s26|146-146|,|drug
DDI-DrugBank.d124.s26|148-154|dapsone|drug
DDI-DrugBank.d124.s26|155-155|,|drug
DDI-DrugBank.d124.s26|157-168|disopyramide|drug
DDI-DrugBank.d124.s26|169-169|,|drug
DDI-DrugBank.d124.s26|171-177|quinine|drug
DDI-DrugBank.d124.s26|178-178|,|drug
DDI-DrugBank.d124.s26|180-189|amiodarone|drug
DDI-DrugBank.d124.s26|190-190|,|drug
DDI-DrugBank.d124.s26|192-200|quinidine|drug
DDI-DrugBank.d124.s26|201-201|,|drug
DDI-DrugBank.d124.s26|203-210|warfarin|drug
DDI-DrugBank.d124.s26|211-211|,|drug
DDI-DrugBank.d124.s26|213-222|tacrolimus|drug
DDI-DrugBank.d124.s26|223-223|,|drug
DDI-DrugBank.d124.s26|225-236|cyclosporine|drug
DDI-DrugBank.d124.s26|237-237|,|drug
DDI-DrugBank.d124.s26|239-243|ergot|drug
DDI-DrugBank.d124.s26|245-255|derivatives|drug
DDI-DrugBank.d124.s26|256-256|,|drug
DDI-DrugBank.d124.s26|258-265|pimozide|drug
DDI-DrugBank.d124.s26|266-266|,|drug
DDI-DrugBank.d124.s26|268-280|carbamazepine|drug
DDI-DrugBank.d124.s26|281-281|,|drug
DDI-DrugBank.d124.s26|283-290|fentanyl|drug
DDI-DrugBank.d124.s26|291-291|,|drug
DDI-DrugBank.d124.s26|293-302|alfentanyl|drug
DDI-DrugBank.d124.s26|303-303|,|drug
DDI-DrugBank.d124.s26|305-314|alprazolam|drug
DDI-DrugBank.d124.s26|315-315|,|drug
DDI-DrugBank.d124.s26|317-319|and|drug
DDI-DrugBank.d124.s26|321-329|triazolam|drug
DDI-DrugBank.d124.s26|330-330|)|drug
DDI-DrugBank.d124.s26|332-334|may|drug
DDI-DrugBank.d124.s26|336-339|have|drug
DDI-DrugBank.d124.s26|341-348|elevated|drug
DDI-DrugBank.d124.s26|350-355|plasma|drug
DDI-DrugBank.d124.s26|357-370|concentrations|drug
DDI-DrugBank.d124.s26|372-375|when|drug
DDI-DrugBank.d124.s26|377-390|coadministered|drug
DDI-DrugBank.d124.s26|392-395|with|drug
DDI-DrugBank.d124.s26|397-406|saquinavir|drug
DDI-DrugBank.d124.s26|407-407|;|drug
DDI-DrugBank.d124.s27|0-8|therefore|drug
DDI-DrugBank.d124.s27|9-9|,|drug
DDI-DrugBank.d124.s27|11-15|these|drug
DDI-DrugBank.d124.s27|17-28|combinations|drug
DDI-DrugBank.d124.s27|30-35|should|drug
DDI-DrugBank.d124.s27|37-38|be|drug
DDI-DrugBank.d124.s27|40-43|used|drug
DDI-DrugBank.d124.s27|45-48|with|drug
DDI-DrugBank.d124.s27|50-56|caution|drug
DDI-DrugBank.d124.s27|57-57|.|drug
DDI-DrugBank.d124.s28|0-4|Since|drug
DDI-DrugBank.d124.s28|6-13|INVIRASE|drug
DDI-DrugBank.d124.s28|15-16|is|drug
DDI-DrugBank.d124.s28|18-31|coadministered|drug
DDI-DrugBank.d124.s28|33-36|with|drug
DDI-DrugBank.d124.s28|38-46|ritonavir|drug
DDI-DrugBank.d124.s28|47-47|,|drug
DDI-DrugBank.d124.s28|49-51|the|drug
DDI-DrugBank.d124.s28|53-61|ritonavir|drug
DDI-DrugBank.d124.s28|63-67|label|drug
DDI-DrugBank.d124.s28|69-74|should|drug
DDI-DrugBank.d124.s28|76-77|be|drug
DDI-DrugBank.d124.s28|79-86|reviewed|drug
DDI-DrugBank.d124.s28|88-90|for|drug
DDI-DrugBank.d124.s28|92-101|additional|drug
DDI-DrugBank.d124.s28|103-107|drugs|drug
DDI-DrugBank.d124.s28|109-112|that|drug
DDI-DrugBank.d124.s28|114-119|should|drug
DDI-DrugBank.d124.s28|121-123|not|drug
DDI-DrugBank.d124.s28|125-126|be|drug
DDI-DrugBank.d124.s28|128-141|coadministered|drug
DDI-DrugBank.d124.s28|142-142|.|drug
DDI-DrugBank.d124.s29|0-7|Inducers|drug
DDI-DrugBank.d124.s29|9-10|of|drug
DDI-DrugBank.d124.s29|12-17|CYP3A4|drug
DDI-DrugBank.d124.s30|0-15|Coadministration|drug
DDI-DrugBank.d124.s30|17-20|with|drug
DDI-DrugBank.d124.s30|22-30|compounds|drug
DDI-DrugBank.d124.s30|32-35|that|drug
DDI-DrugBank.d124.s30|37-39|are|drug
DDI-DrugBank.d124.s30|41-46|potent|drug
DDI-DrugBank.d124.s30|48-55|inducers|drug
DDI-DrugBank.d124.s30|57-58|of|drug
DDI-DrugBank.d124.s30|60-65|CYP3A4|drug
DDI-DrugBank.d124.s30|67-67|(|drug
DDI-DrugBank.d124.s30|68-69|eg|drug
DDI-DrugBank.d124.s30|70-70|,|drug
DDI-DrugBank.d124.s30|72-84|phenobarbital|drug
DDI-DrugBank.d124.s30|85-85|,|drug
DDI-DrugBank.d124.s30|87-95|phenytoin|drug
DDI-DrugBank.d124.s30|96-96|,|drug
DDI-DrugBank.d124.s30|98-110|dexamethasone|drug
DDI-DrugBank.d124.s30|111-111|,|drug
DDI-DrugBank.d124.s30|113-125|carbamazepine|drug
DDI-DrugBank.d124.s30|126-126|)|drug
DDI-DrugBank.d124.s30|128-130|may|drug
DDI-DrugBank.d124.s30|132-137|result|drug
DDI-DrugBank.d124.s30|139-140|in|drug
DDI-DrugBank.d124.s30|142-150|decreased|drug
DDI-DrugBank.d124.s30|152-157|plasma|drug
DDI-DrugBank.d124.s30|159-164|levels|drug
DDI-DrugBank.d124.s30|166-167|of|drug
DDI-DrugBank.d124.s30|169-178|saquinavir|drug
DDI-DrugBank.d124.s30|179-179|.|drug
DDI-DrugBank.d30.s0|0-1|No|drug
DDI-DrugBank.d30.s0|3-13|significant|drug
DDI-DrugBank.d30.s0|15-23|drug-drug|drug
DDI-DrugBank.d30.s0|25-39|pharmacokinetic|drug
DDI-DrugBank.d30.s0|41-52|interactions|drug
DDI-DrugBank.d30.s0|54-57|have|drug
DDI-DrugBank.d30.s0|59-62|been|drug
DDI-DrugBank.d30.s0|64-68|found|drug
DDI-DrugBank.d30.s0|70-71|in|drug
DDI-DrugBank.d30.s0|73-83|interaction|drug
DDI-DrugBank.d30.s0|85-91|studies|drug
DDI-DrugBank.d30.s0|93-96|with|drug
DDI-DrugBank.d30.s0|98-116|hydrochlorothiazide|drug
DDI-DrugBank.d30.s0|117-117|,|drug
DDI-DrugBank.d30.s0|119-125|digoxin|drug
DDI-DrugBank.d30.s0|126-126|,|drug
DDI-DrugBank.d30.s0|128-135|warfarin|drug
DDI-DrugBank.d30.s0|136-136|,|drug
DDI-DrugBank.d30.s0|138-147|cimetidine|drug
DDI-DrugBank.d30.s0|149-151|and|drug
DDI-DrugBank.d30.s0|153-165|phenobarbital|drug
DDI-DrugBank.d30.s0|166-166|.|drug
DDI-DrugBank.d30.s1|0-7|Rifampin|brand
DDI-DrugBank.d30.s1|8-8|,|drug
DDI-DrugBank.d30.s1|10-11|an|drug
DDI-DrugBank.d30.s1|13-19|inducer|drug
DDI-DrugBank.d30.s1|21-22|of|drug
DDI-DrugBank.d30.s1|24-27|drug|drug
DDI-DrugBank.d30.s1|29-38|metabolism|drug
DDI-DrugBank.d30.s1|39-39|,|drug
DDI-DrugBank.d30.s1|41-49|decreased|drug
DDI-DrugBank.d30.s1|51-53|the|drug
DDI-DrugBank.d30.s1|55-68|concentrations|drug
DDI-DrugBank.d30.s1|70-71|of|drug
DDI-DrugBank.d30.s1|73-80|losartan|drug
DDI-DrugBank.d30.s1|82-84|and|drug
DDI-DrugBank.d30.s1|86-88|its|drug
DDI-DrugBank.d30.s1|90-95|active|drug
DDI-DrugBank.d30.s1|97-106|metabolite|drug
DDI-DrugBank.d30.s1|107-107|.|drug
DDI-DrugBank.d30.s2|0-1|In|drug
DDI-DrugBank.d30.s2|3-8|humans|drug
DDI-DrugBank.d30.s2|9-9|,|drug
DDI-DrugBank.d30.s2|11-13|two|drug
DDI-DrugBank.d30.s2|15-24|inhibitors|drug
DDI-DrugBank.d30.s2|26-27|of|drug
DDI-DrugBank.d30.s2|29-32|P450|drug
DDI-DrugBank.d30.s2|34-36|3A4|drug
DDI-DrugBank.d30.s2|38-41|have|drug
DDI-DrugBank.d30.s2|43-46|been|drug
DDI-DrugBank.d30.s2|48-54|studied|drug
DDI-DrugBank.d30.s2|55-55|.|drug
DDI-DrugBank.d30.s3|0-11|Ketoconazole|brand
DDI-DrugBank.d30.s3|13-15|did|drug
DDI-DrugBank.d30.s3|17-19|not|drug
DDI-DrugBank.d30.s3|21-26|affect|drug
DDI-DrugBank.d30.s3|28-30|the|drug
DDI-DrugBank.d30.s3|32-41|conversion|drug
DDI-DrugBank.d30.s3|43-44|of|drug
DDI-DrugBank.d30.s3|46-53|losartan|drug
DDI-DrugBank.d30.s3|55-56|to|drug
DDI-DrugBank.d30.s3|58-60|the|drug
DDI-DrugBank.d30.s3|62-67|active|drug
DDI-DrugBank.d30.s3|69-78|metabolite|drug
DDI-DrugBank.d30.s3|80-84|after|drug
DDI-DrugBank.d30.s3|86-96|intravenous|drug
DDI-DrugBank.d30.s3|98-111|administration|drug
DDI-DrugBank.d30.s3|113-114|of|drug
DDI-DrugBank.d30.s3|116-123|losartan|drug
DDI-DrugBank.d30.s3|124-124|,|drug
DDI-DrugBank.d30.s3|126-128|and|drug
DDI-DrugBank.d30.s3|130-141|erythromycin|drug
DDI-DrugBank.d30.s3|143-145|had|drug
DDI-DrugBank.d30.s3|147-148|no|drug
DDI-DrugBank.d30.s3|150-159|clinically|drug
DDI-DrugBank.d30.s3|161-171|significant|drug
DDI-DrugBank.d30.s3|173-178|effect|drug
DDI-DrugBank.d30.s3|180-184|after|drug
DDI-DrugBank.d30.s3|186-189|oral|drug
DDI-DrugBank.d30.s3|191-204|administration|drug
DDI-DrugBank.d30.s3|205-205|.|drug
DDI-DrugBank.d30.s4|0-10|Fluconazole|brand
DDI-DrugBank.d30.s4|11-11|,|drug
DDI-DrugBank.d30.s4|13-14|an|drug
DDI-DrugBank.d30.s4|16-24|inhibitor|drug
DDI-DrugBank.d30.s4|26-27|of|drug
DDI-DrugBank.d30.s4|29-32|P450|drug
DDI-DrugBank.d30.s4|34-36|2C9|drug
DDI-DrugBank.d30.s4|37-37|,|drug
DDI-DrugBank.d30.s4|39-47|decreased|drug
DDI-DrugBank.d30.s4|49-54|active|drug
DDI-DrugBank.d30.s4|56-65|metabolite|drug
DDI-DrugBank.d30.s4|67-79|concentration|drug
DDI-DrugBank.d30.s4|81-83|and|drug
DDI-DrugBank.d30.s4|85-93|increased|drug
DDI-DrugBank.d30.s4|95-102|losartan|drug
DDI-DrugBank.d30.s4|104-116|concentration|drug
DDI-DrugBank.d30.s4|117-117|.|drug
DDI-DrugBank.d30.s5|0-2|The|drug
DDI-DrugBank.d30.s5|4-18|pharmacodynamic|drug
DDI-DrugBank.d30.s5|20-31|consequences|drug
DDI-DrugBank.d30.s5|33-34|of|drug
DDI-DrugBank.d30.s5|36-46|concomitant|drug
DDI-DrugBank.d30.s5|48-50|use|drug
DDI-DrugBank.d30.s5|52-53|of|drug
DDI-DrugBank.d30.s5|55-62|losartan|drug
DDI-DrugBank.d30.s5|64-66|and|drug
DDI-DrugBank.d30.s5|68-77|inhibitors|drug
DDI-DrugBank.d30.s5|79-80|of|drug
DDI-DrugBank.d30.s5|82-85|P450|drug
DDI-DrugBank.d30.s5|87-89|2C9|drug
DDI-DrugBank.d30.s5|91-94|have|drug
DDI-DrugBank.d30.s5|96-98|not|drug
DDI-DrugBank.d30.s5|100-103|been|drug
DDI-DrugBank.d30.s5|105-112|examined|drug
DDI-DrugBank.d30.s5|113-113|.|drug
DDI-DrugBank.d30.s6|0-7|Subjects|drug
DDI-DrugBank.d30.s6|9-11|who|drug
DDI-DrugBank.d30.s6|13-14|do|drug
DDI-DrugBank.d30.s6|16-18|not|drug
DDI-DrugBank.d30.s6|20-29|metabolize|drug
DDI-DrugBank.d30.s6|31-38|losartan|drug
DDI-DrugBank.d30.s6|40-41|to|drug
DDI-DrugBank.d30.s6|43-48|active|drug
DDI-DrugBank.d30.s6|50-59|metabolite|drug
DDI-DrugBank.d30.s6|61-64|have|drug
DDI-DrugBank.d30.s6|66-69|been|drug
DDI-DrugBank.d30.s6|71-75|shown|drug
DDI-DrugBank.d30.s6|77-78|to|drug
DDI-DrugBank.d30.s6|80-83|have|drug
DDI-DrugBank.d30.s6|85-85|a|drug
DDI-DrugBank.d30.s6|87-94|specific|drug
DDI-DrugBank.d30.s6|95-95|,|drug
DDI-DrugBank.d30.s6|97-100|rare|drug
DDI-DrugBank.d30.s6|102-107|defect|drug
DDI-DrugBank.d30.s6|109-110|in|drug
DDI-DrugBank.d30.s6|112-121|cytochrome|drug
DDI-DrugBank.d30.s6|123-126|P450|drug
DDI-DrugBank.d30.s6|128-130|2C9|drug
DDI-DrugBank.d30.s6|131-131|.|drug
DDI-DrugBank.d30.s7|0-4|These|drug
DDI-DrugBank.d30.s7|6-9|data|drug
DDI-DrugBank.d30.s7|11-17|suggest|drug
DDI-DrugBank.d30.s7|19-22|that|drug
DDI-DrugBank.d30.s7|24-26|the|drug
DDI-DrugBank.d30.s7|28-37|conversion|drug
DDI-DrugBank.d30.s7|39-40|of|drug
DDI-DrugBank.d30.s7|42-49|losartan|drug
DDI-DrugBank.d30.s7|51-52|to|drug
DDI-DrugBank.d30.s7|54-56|its|drug
DDI-DrugBank.d30.s7|58-63|active|drug
DDI-DrugBank.d30.s7|65-74|metabolite|drug
DDI-DrugBank.d30.s7|76-77|is|drug
DDI-DrugBank.d30.s7|79-86|mediated|drug
DDI-DrugBank.d30.s7|88-96|primarily|drug
DDI-DrugBank.d30.s7|98-99|by|drug
DDI-DrugBank.d30.s7|101-104|P450|drug
DDI-DrugBank.d30.s7|106-108|2C9|drug
DDI-DrugBank.d30.s7|110-112|and|drug
DDI-DrugBank.d30.s7|114-116|not|drug
DDI-DrugBank.d30.s7|118-121|P450|drug
DDI-DrugBank.d30.s7|123-125|3A4|drug
DDI-DrugBank.d30.s7|126-126|.|drug
DDI-DrugBank.d30.s8|0-1|As|drug
DDI-DrugBank.d30.s8|3-6|with|drug
DDI-DrugBank.d30.s8|8-12|other|drug
DDI-DrugBank.d30.s8|14-18|drugs|drug
DDI-DrugBank.d30.s8|20-23|that|drug
DDI-DrugBank.d30.s8|25-29|block|drug
DDI-DrugBank.d30.s8|31-41|angiotensin|drug
DDI-DrugBank.d30.s8|43-44|II|drug
DDI-DrugBank.d30.s8|46-47|or|drug
DDI-DrugBank.d30.s8|49-51|its|drug
DDI-DrugBank.d30.s8|53-59|effects|drug
DDI-DrugBank.d30.s8|60-60|,|drug
DDI-DrugBank.d30.s8|62-72|concomitant|drug
DDI-DrugBank.d30.s8|74-76|use|drug
DDI-DrugBank.d30.s8|78-79|of|drug
DDI-DrugBank.d30.s8|81-97|potassium-sparing|drug
DDI-DrugBank.d30.s8|99-107|diuretics|drug
DDI-DrugBank.d30.s8|109-109|(|drug
DDI-DrugBank.d30.s8|110-113|e.g.|drug
DDI-DrugBank.d30.s8|114-114|,|drug
DDI-DrugBank.d30.s8|116-129|spironolactone|drug
DDI-DrugBank.d30.s8|130-130|,|drug
DDI-DrugBank.d30.s8|132-142|triamterene|drug
DDI-DrugBank.d30.s8|143-143|,|drug
DDI-DrugBank.d30.s8|145-153|amiloride|drug
DDI-DrugBank.d30.s8|154-154|)|drug
DDI-DrugBank.d30.s8|155-155|,|drug
DDI-DrugBank.d30.s8|157-165|potassium|drug
DDI-DrugBank.d30.s8|167-177|supplements|drug
DDI-DrugBank.d30.s8|178-178|,|drug
DDI-DrugBank.d30.s8|180-181|or|drug
DDI-DrugBank.d30.s8|183-186|salt|drug
DDI-DrugBank.d30.s8|188-198|substitutes|drug
DDI-DrugBank.d30.s8|200-209|containing|drug
DDI-DrugBank.d30.s8|211-219|potassium|drug
DDI-DrugBank.d30.s8|221-223|may|drug
DDI-DrugBank.d30.s8|225-228|lead|drug
DDI-DrugBank.d30.s8|230-231|to|drug
DDI-DrugBank.d30.s8|233-241|increases|drug
DDI-DrugBank.d30.s8|243-244|in|drug
DDI-DrugBank.d30.s8|246-250|serum|drug
DDI-DrugBank.d30.s8|252-260|potassium|drug
DDI-DrugBank.d30.s8|261-261|.|drug
DDI-DrugBank.d30.s9|0-1|As|drug
DDI-DrugBank.d30.s9|3-6|with|drug
DDI-DrugBank.d30.s9|8-12|other|drug
DDI-DrugBank.d30.s9|14-29|antihypertensive|drug
DDI-DrugBank.d30.s9|31-36|agents|drug
DDI-DrugBank.d30.s9|37-37|,|drug
DDI-DrugBank.d30.s9|39-41|the|drug
DDI-DrugBank.d30.s9|43-58|antihypertensive|drug
DDI-DrugBank.d30.s9|60-65|effect|drug
DDI-DrugBank.d30.s9|67-68|of|drug
DDI-DrugBank.d30.s9|70-77|losartan|drug
DDI-DrugBank.d30.s9|79-81|may|drug
DDI-DrugBank.d30.s9|83-84|be|drug
DDI-DrugBank.d30.s9|86-92|blunted|drug
DDI-DrugBank.d30.s9|94-95|by|drug
DDI-DrugBank.d30.s9|97-99|the|drug
DDI-DrugBank.d30.s9|101-113|non-steroidal|drug
DDI-DrugBank.d30.s9|115-131|anti-inflammatory|drug
DDI-DrugBank.d30.s9|133-136|drug|drug
DDI-DrugBank.d30.s9|138-149|indomethacin|drug
DDI-DrugBank.d30.s10|0-0|.|drug
DDI-DrugBank.d287.s0|0-9|Cevimeline|brand
DDI-DrugBank.d287.s0|11-16|should|drug
DDI-DrugBank.d287.s0|18-19|be|drug
DDI-DrugBank.d287.s0|21-32|administered|drug
DDI-DrugBank.d287.s0|34-37|with|drug
DDI-DrugBank.d287.s0|39-45|caution|drug
DDI-DrugBank.d287.s0|47-48|to|drug
DDI-DrugBank.d287.s0|50-57|patients|drug
DDI-DrugBank.d287.s0|59-64|taking|drug
DDI-DrugBank.d287.s0|66-69|beta|drug
DDI-DrugBank.d287.s0|71-80|adrenergic|drug
DDI-DrugBank.d287.s0|82-92|antagonists|drug
DDI-DrugBank.d287.s0|93-93|,|drug
DDI-DrugBank.d287.s0|95-101|because|drug
DDI-DrugBank.d287.s0|103-104|of|drug
DDI-DrugBank.d287.s0|106-108|the|drug
DDI-DrugBank.d287.s0|110-120|possibility|drug
DDI-DrugBank.d287.s0|122-123|of|drug
DDI-DrugBank.d287.s0|125-134|conduction|drug
DDI-DrugBank.d287.s0|136-147|disturbances|drug
DDI-DrugBank.d287.s0|148-148|.|drug
DDI-DrugBank.d287.s1|0-4|Drugs|drug
DDI-DrugBank.d287.s1|6-9|with|drug
DDI-DrugBank.d287.s1|11-29|parasympathomimetic|drug
DDI-DrugBank.d287.s1|31-37|effects|drug
DDI-DrugBank.d287.s1|39-50|administered|drug
DDI-DrugBank.d287.s1|52-63|concurrently|drug
DDI-DrugBank.d287.s1|65-68|with|drug
DDI-DrugBank.d287.s1|70-79|cevimeline|drug
DDI-DrugBank.d287.s1|81-83|can|drug
DDI-DrugBank.d287.s1|85-86|be|drug
DDI-DrugBank.d287.s1|88-95|expected|drug
DDI-DrugBank.d287.s1|97-98|to|drug
DDI-DrugBank.d287.s1|100-103|have|drug
DDI-DrugBank.d287.s1|105-112|additive|drug
DDI-DrugBank.d287.s1|114-120|effects|drug
DDI-DrugBank.d287.s1|121-121|.|drug
DDI-DrugBank.d287.s2|0-9|Cevimeline|brand
DDI-DrugBank.d287.s2|11-15|might|drug
DDI-DrugBank.d287.s2|17-25|interfere|drug
DDI-DrugBank.d287.s2|27-30|with|drug
DDI-DrugBank.d287.s2|32-40|desirable|drug
DDI-DrugBank.d287.s2|42-55|antimuscarinic|drug
DDI-DrugBank.d287.s2|57-63|effects|drug
DDI-DrugBank.d287.s2|65-66|of|drug
DDI-DrugBank.d287.s2|68-72|drugs|drug
DDI-DrugBank.d287.s2|74-77|used|drug
DDI-DrugBank.d287.s2|79-91|concomitantly|drug
DDI-DrugBank.d287.s2|92-92|.|drug
DDI-DrugBank.d287.s3|0-4|Drugs|drug
DDI-DrugBank.d287.s3|6-10|which|drug
DDI-DrugBank.d287.s3|12-18|inhibit|drug
DDI-DrugBank.d287.s3|20-25|CYP2D6|drug
DDI-DrugBank.d287.s3|27-29|and|drug
DDI-DrugBank.d287.s3|31-38|CYP3A3/4|drug
DDI-DrugBank.d287.s3|40-43|also|drug
DDI-DrugBank.d287.s3|45-51|inhibit|drug
DDI-DrugBank.d287.s3|53-55|the|drug
DDI-DrugBank.d287.s3|57-66|metabolism|drug
DDI-DrugBank.d287.s3|68-69|of|drug
DDI-DrugBank.d287.s3|71-80|cevimeline|drug
DDI-DrugBank.d287.s3|81-81|.|drug
DDI-DrugBank.d287.s4|0-9|Cevimeline|brand
DDI-DrugBank.d287.s4|11-16|should|drug
DDI-DrugBank.d287.s4|18-19|be|drug
DDI-DrugBank.d287.s4|21-24|used|drug
DDI-DrugBank.d287.s4|26-29|with|drug
DDI-DrugBank.d287.s4|31-37|caution|drug
DDI-DrugBank.d287.s4|39-40|in|drug
DDI-DrugBank.d287.s4|42-52|individuals|drug
DDI-DrugBank.d287.s4|54-58|known|drug
DDI-DrugBank.d287.s4|60-61|or|drug
DDI-DrugBank.d287.s4|63-71|suspected|drug
DDI-DrugBank.d287.s4|73-74|to|drug
DDI-DrugBank.d287.s4|76-77|be|drug
DDI-DrugBank.d287.s4|79-87|deficient|drug
DDI-DrugBank.d287.s4|89-90|in|drug
DDI-DrugBank.d287.s4|92-97|CYP2D6|drug
DDI-DrugBank.d287.s4|99-106|activity|drug
DDI-DrugBank.d287.s4|107-107|,|drug
DDI-DrugBank.d287.s4|109-113|based|drug
DDI-DrugBank.d287.s4|115-116|on|drug
DDI-DrugBank.d287.s4|118-125|previous|drug
DDI-DrugBank.d287.s4|127-136|experience|drug
DDI-DrugBank.d287.s4|137-137|,|drug
DDI-DrugBank.d287.s4|139-140|as|drug
DDI-DrugBank.d287.s4|142-145|they|drug
DDI-DrugBank.d287.s4|147-149|may|drug
DDI-DrugBank.d287.s4|151-152|be|drug
DDI-DrugBank.d287.s4|154-155|at|drug
DDI-DrugBank.d287.s4|157-157|a|drug
DDI-DrugBank.d287.s4|159-164|higher|drug
DDI-DrugBank.d287.s4|166-169|risk|drug
DDI-DrugBank.d287.s4|171-172|of|drug
DDI-DrugBank.d287.s4|174-180|adverse|drug
DDI-DrugBank.d287.s4|182-187|events|drug
DDI-DrugBank.d287.s4|188-188|.|drug
DDI-DrugBank.d287.s5|0-1|In|drug
DDI-DrugBank.d287.s5|3-4|an|drug
DDI-DrugBank.d287.s5|6-7|in|drug
DDI-DrugBank.d287.s5|9-13|vitro|drug
DDI-DrugBank.d287.s5|15-19|study|drug
DDI-DrugBank.d287.s5|20-20|,|drug
DDI-DrugBank.d287.s5|22-31|cytochrome|drug
DDI-DrugBank.d287.s5|33-36|P450|drug
DDI-DrugBank.d287.s5|38-45|isozymes|drug
DDI-DrugBank.d287.s5|47-49|1A2|drug
DDI-DrugBank.d287.s5|50-50|,|drug
DDI-DrugBank.d287.s5|52-54|2A6|drug
DDI-DrugBank.d287.s5|55-55|,|drug
DDI-DrugBank.d287.s5|57-59|2C9|drug
DDI-DrugBank.d287.s5|60-60|,|drug
DDI-DrugBank.d287.s5|62-65|2C19|drug
DDI-DrugBank.d287.s5|66-66|,|drug
DDI-DrugBank.d287.s5|68-70|2D6|drug
DDI-DrugBank.d287.s5|71-71|,|drug
DDI-DrugBank.d287.s5|73-75|2E1|drug
DDI-DrugBank.d287.s5|76-76|,|drug
DDI-DrugBank.d287.s5|78-80|and|drug
DDI-DrugBank.d287.s5|82-84|3A4|drug
DDI-DrugBank.d287.s5|86-89|were|drug
DDI-DrugBank.d287.s5|91-93|not|drug
DDI-DrugBank.d287.s5|95-103|inhibited|drug
DDI-DrugBank.d287.s5|105-106|by|drug
DDI-DrugBank.d287.s5|108-115|exposure|drug
DDI-DrugBank.d287.s5|117-118|to|drug
DDI-DrugBank.d287.s5|120-129|cevimeline|drug
DDI-DrugBank.d287.s5|130-130|.|drug
DDI-DrugBank.d549.s0|0-1|In|drug
DDI-DrugBank.d549.s0|3-9|studies|drug
DDI-DrugBank.d549.s0|11-12|in|drug
DDI-DrugBank.d549.s0|14-19|normal|drug
DDI-DrugBank.d549.s0|21-30|volunteers|drug
DDI-DrugBank.d549.s0|31-31|,|drug
DDI-DrugBank.d549.s0|33-37|there|drug
DDI-DrugBank.d549.s0|39-41|was|drug
DDI-DrugBank.d549.s0|43-44|no|drug
DDI-DrugBank.d549.s0|46-60|pharmacodynamic|drug
DDI-DrugBank.d549.s0|62-72|interaction|drug
DDI-DrugBank.d549.s0|74-80|between|drug
DDI-DrugBank.d549.s0|82-92|intravenous|drug
DDI-DrugBank.d549.s0|94-101|iloprost|drug
DDI-DrugBank.d549.s0|103-105|and|drug
DDI-DrugBank.d549.s0|107-112|either|drug
DDI-DrugBank.d549.s0|114-123|nifedipine|drug
DDI-DrugBank.d549.s0|124-124|,|drug
DDI-DrugBank.d549.s0|126-134|diltiazem|drug
DDI-DrugBank.d549.s0|135-135|,|drug
DDI-DrugBank.d549.s0|137-138|or|drug
DDI-DrugBank.d549.s0|140-148|captopril|drug
DDI-DrugBank.d549.s0|149-149|.|drug
DDI-DrugBank.d549.s1|0-6|However|drug
DDI-DrugBank.d549.s1|7-7|,|drug
DDI-DrugBank.d549.s1|9-16|iloprost|drug
DDI-DrugBank.d549.s1|18-20|has|drug
DDI-DrugBank.d549.s1|22-24|the|drug
DDI-DrugBank.d549.s1|26-34|potential|drug
DDI-DrugBank.d549.s1|36-37|to|drug
DDI-DrugBank.d549.s1|39-46|increase|drug
DDI-DrugBank.d549.s1|48-50|the|drug
DDI-DrugBank.d549.s1|52-62|hypotensive|drug
DDI-DrugBank.d549.s1|64-69|effect|drug
DDI-DrugBank.d549.s1|71-72|of|drug
DDI-DrugBank.d549.s1|74-85|vasodilators|drug
DDI-DrugBank.d549.s1|87-89|and|drug
DDI-DrugBank.d549.s1|91-106|antihypertensive|drug
DDI-DrugBank.d549.s1|108-113|agents|drug
DDI-DrugBank.d549.s1|114-114|.|drug
DDI-DrugBank.d549.s2|0-4|Since|drug
DDI-DrugBank.d549.s2|6-13|iloprost|drug
DDI-DrugBank.d549.s2|15-22|inhibits|drug
DDI-DrugBank.d549.s2|24-31|platelet|drug
DDI-DrugBank.d549.s2|33-40|function|drug
DDI-DrugBank.d549.s2|41-41|,|drug
DDI-DrugBank.d549.s2|43-47|there|drug
DDI-DrugBank.d549.s2|49-50|is|drug
DDI-DrugBank.d549.s2|52-52|a|drug
DDI-DrugBank.d549.s2|54-62|potential|drug
DDI-DrugBank.d549.s2|64-66|for|drug
DDI-DrugBank.d549.s2|68-76|increased|drug
DDI-DrugBank.d549.s2|78-81|risk|drug
DDI-DrugBank.d549.s2|83-84|of|drug
DDI-DrugBank.d549.s2|86-93|bleeding|drug
DDI-DrugBank.d549.s2|94-94|,|drug
DDI-DrugBank.d549.s2|96-107|particularly|drug
DDI-DrugBank.d549.s2|109-110|in|drug
DDI-DrugBank.d549.s2|112-119|patients|drug
DDI-DrugBank.d549.s2|121-130|maintained|drug
DDI-DrugBank.d549.s2|132-133|on|drug
DDI-DrugBank.d549.s2|135-148|anticoagulants|drug
DDI-DrugBank.d549.s2|149-149|.|drug
DDI-DrugBank.d549.s3|0-5|During|drug
DDI-DrugBank.d549.s3|7-14|clinical|drug
DDI-DrugBank.d549.s3|16-21|trials|drug
DDI-DrugBank.d549.s3|22-22|,|drug
DDI-DrugBank.d549.s3|24-31|iloprost|drug
DDI-DrugBank.d549.s3|33-35|was|drug
DDI-DrugBank.d549.s3|37-40|used|drug
DDI-DrugBank.d549.s3|42-53|concurrently|drug
DDI-DrugBank.d549.s3|55-58|with|drug
DDI-DrugBank.d549.s3|60-73|anticoagulants|drug
DDI-DrugBank.d549.s3|74-74|,|drug
DDI-DrugBank.d549.s3|76-84|diuretics|drug
DDI-DrugBank.d549.s3|85-85|,|drug
DDI-DrugBank.d549.s3|87-93|cardiac|drug
DDI-DrugBank.d549.s3|95-104|glycosides|drug
DDI-DrugBank.d549.s3|105-105|,|drug
DDI-DrugBank.d549.s3|107-113|calcium|drug
DDI-DrugBank.d549.s3|115-121|channel|drug
DDI-DrugBank.d549.s3|123-130|blockers|drug
DDI-DrugBank.d549.s3|131-131|,|drug
DDI-DrugBank.d549.s3|133-142|analgesics|drug
DDI-DrugBank.d549.s3|143-143|,|drug
DDI-DrugBank.d549.s3|145-156|antipyretics|drug
DDI-DrugBank.d549.s3|157-157|,|drug
DDI-DrugBank.d549.s3|159-170|nonsteroidal|drug
DDI-DrugBank.d549.s3|172-189|antiinflammatories|drug
DDI-DrugBank.d549.s3|190-190|,|drug
DDI-DrugBank.d549.s3|192-206|corticosteroids|drug
DDI-DrugBank.d549.s3|207-207|,|drug
DDI-DrugBank.d549.s3|209-211|and|drug
DDI-DrugBank.d549.s3|213-217|other|drug
DDI-DrugBank.d549.s3|219-229|medications|drug
DDI-DrugBank.d549.s3|230-230|.|drug
DDI-DrugBank.d549.s4|0-10|Intravenous|drug
DDI-DrugBank.d549.s4|12-19|infusion|drug
DDI-DrugBank.d549.s4|21-22|of|drug
DDI-DrugBank.d549.s4|24-31|iloprost|drug
DDI-DrugBank.d549.s4|33-35|had|drug
DDI-DrugBank.d549.s4|37-38|no|drug
DDI-DrugBank.d549.s4|40-45|effect|drug
DDI-DrugBank.d549.s4|47-48|on|drug
DDI-DrugBank.d549.s4|50-52|the|drug
DDI-DrugBank.d549.s4|54-69|pharmacokinetics|drug
DDI-DrugBank.d549.s4|71-72|of|drug
DDI-DrugBank.d549.s4|74-80|digoxin|drug
DDI-DrugBank.d549.s4|81-81|.|drug
DDI-DrugBank.d549.s5|0-14|Acetylsalicylic|drug
DDI-DrugBank.d549.s5|16-19|acid|drug
DDI-DrugBank.d549.s5|21-23|did|drug
DDI-DrugBank.d549.s5|25-27|not|drug
DDI-DrugBank.d549.s5|29-33|alter|drug
DDI-DrugBank.d549.s5|35-37|the|drug
DDI-DrugBank.d549.s5|39-47|clearance|drug
DDI-DrugBank.d549.s5|49-49|(|drug
DDI-DrugBank.d549.s5|50-65|pharmacokinetics|drug
DDI-DrugBank.d549.s5|66-66|)|drug
DDI-DrugBank.d549.s5|68-69|of|drug
DDI-DrugBank.d549.s5|71-78|iloprost|drug
DDI-DrugBank.d549.s5|79-79|.|drug
DDI-DrugBank.d549.s6|0-7|Although|drug
DDI-DrugBank.d549.s6|9-16|clinical|drug
DDI-DrugBank.d549.s6|18-24|studies|drug
DDI-DrugBank.d549.s6|26-29|have|drug
DDI-DrugBank.d549.s6|31-33|not|drug
DDI-DrugBank.d549.s6|35-38|been|drug
DDI-DrugBank.d549.s6|40-48|conducted|drug
DDI-DrugBank.d549.s6|49-49|,|drug
DDI-DrugBank.d549.s6|51-52|in|drug
DDI-DrugBank.d549.s6|54-58|vitro|drug
DDI-DrugBank.d549.s6|60-66|studies|drug
DDI-DrugBank.d549.s6|68-69|of|drug
DDI-DrugBank.d549.s6|71-78|iloprost|drug
DDI-DrugBank.d549.s6|80-87|indicate|drug
DDI-DrugBank.d549.s6|89-92|that|drug
DDI-DrugBank.d549.s6|94-95|no|drug
DDI-DrugBank.d549.s6|97-104|relevant|drug
DDI-DrugBank.d549.s6|106-115|inhibition|drug
DDI-DrugBank.d549.s6|117-118|of|drug
DDI-DrugBank.d549.s6|120-129|cytochrome|drug
DDI-DrugBank.d549.s6|131-134|P450|drug
DDI-DrugBank.d549.s6|136-139|drug|drug
DDI-DrugBank.d549.s6|141-150|metabolism|drug
DDI-DrugBank.d549.s6|152-156|would|drug
DDI-DrugBank.d549.s6|158-159|be|drug
DDI-DrugBank.d549.s6|161-168|expected|drug
DDI-DrugBank.d549.s6|169-169|.|drug
DDI-DrugBank.d95.s0|0-11|Cyclosporine|brand
DDI-DrugBank.d95.s0|13-13|-|drug
DDI-DrugBank.d95.s0|15-24|L-arginine|drug
DDI-DrugBank.d95.s0|26-28|may|drug
DDI-DrugBank.d95.s0|30-39|counteract|drug
DDI-DrugBank.d95.s0|41-43|the|drug
DDI-DrugBank.d95.s0|45-57|antinaturetic|drug
DDI-DrugBank.d95.s0|59-64|effect|drug
DDI-DrugBank.d95.s0|66-67|of|drug
DDI-DrugBank.d95.s0|69-79|cyclosporin|drug
DDI-DrugBank.d95.s0|80-80|.|drug
DDI-DrugBank.d95.s1|0-8|Ibuprofen|brand
DDI-DrugBank.d95.s1|10-10|-|drug
DDI-DrugBank.d95.s1|12-21|L-arginine|drug
DDI-DrugBank.d95.s1|23-25|may|drug
DDI-DrugBank.d95.s1|27-34|increase|drug
DDI-DrugBank.d95.s1|36-38|the|drug
DDI-DrugBank.d95.s1|40-49|absorption|drug
DDI-DrugBank.d95.s1|51-52|of|drug
DDI-DrugBank.d95.s1|54-62|ibuprofen|drug
DDI-DrugBank.d95.s1|64-65|if|drug
DDI-DrugBank.d95.s1|67-71|taken|drug
DDI-DrugBank.d95.s1|73-85|concomitantly|drug
DDI-DrugBank.d95.s1|86-86|.|drug
DDI-DrugBank.d95.s2|0-6|Organic|drug
DDI-DrugBank.d95.s2|8-15|nitrates|drug
DDI-DrugBank.d95.s2|17-17|-|drug
DDI-DrugBank.d95.s2|19-28|L-arginine|drug
DDI-DrugBank.d95.s2|30-40|supplements|drug
DDI-DrugBank.d95.s2|42-54|theoretically|drug
DDI-DrugBank.d95.s2|56-58|may|drug
DDI-DrugBank.d95.s2|60-69|potentiate|drug
DDI-DrugBank.d95.s2|71-73|the|drug
DDI-DrugBank.d95.s2|75-81|effects|drug
DDI-DrugBank.d95.s2|83-84|of|drug
DDI-DrugBank.d95.s2|86-92|organic|drug
DDI-DrugBank.d95.s2|94-101|nitrates|drug
DDI-DrugBank.d95.s2|103-104|if|drug
DDI-DrugBank.d95.s2|106-110|taken|drug
DDI-DrugBank.d95.s2|112-124|concomitantly|drug
DDI-DrugBank.d95.s2|125-125|.|drug
DDI-DrugBank.d95.s3|0-9|Sildenafil|brand
DDI-DrugBank.d95.s3|11-17|citrate|drug
DDI-DrugBank.d95.s3|19-19|-|drug
DDI-DrugBank.d95.s3|21-33|Theoretically|drug
DDI-DrugBank.d95.s3|34-34|,|drug
DDI-DrugBank.d95.s3|36-45|L-arginine|drug
DDI-DrugBank.d95.s3|47-57|supplements|drug
DDI-DrugBank.d95.s3|59-63|taken|drug
DDI-DrugBank.d95.s3|65-77|concomitantly|drug
DDI-DrugBank.d95.s3|79-82|with|drug
DDI-DrugBank.d95.s3|84-93|sildenafil|drug
DDI-DrugBank.d95.s3|95-101|citrate|drug
DDI-DrugBank.d95.s3|102-102|,|drug
DDI-DrugBank.d95.s3|104-106|may|drug
DDI-DrugBank.d95.s3|108-117|potentiate|drug
DDI-DrugBank.d95.s3|119-121|the|drug
DDI-DrugBank.d95.s3|123-129|effects|drug
DDI-DrugBank.d95.s3|131-132|of|drug
DDI-DrugBank.d95.s3|134-136|the|drug
DDI-DrugBank.d95.s3|138-141|drug|drug
DDI-DrugBank.d95.s3|142-142|.|drug
DDI-DrugBank.d622.s0|0-3|When|drug
DDI-DrugBank.d622.s0|5-12|atropine|drug
DDI-DrugBank.d622.s0|14-16|and|drug
DDI-DrugBank.d622.s0|18-28|pralidoxime|drug
DDI-DrugBank.d622.s0|30-32|are|drug
DDI-DrugBank.d622.s0|34-37|used|drug
DDI-DrugBank.d622.s0|39-46|together|drug
DDI-DrugBank.d622.s0|47-47|,|drug
DDI-DrugBank.d622.s0|49-51|the|drug
DDI-DrugBank.d622.s0|53-57|signs|drug
DDI-DrugBank.d622.s0|59-60|of|drug
DDI-DrugBank.d622.s0|62-75|atropinization|drug
DDI-DrugBank.d622.s0|77-77|(|drug
DDI-DrugBank.d622.s0|78-85|flushing|drug
DDI-DrugBank.d622.s0|86-86|,|drug
DDI-DrugBank.d622.s0|88-96|mydriasis|drug
DDI-DrugBank.d622.s0|97-97|,|drug
DDI-DrugBank.d622.s0|99-109|tachycardia|drug
DDI-DrugBank.d622.s0|110-110|,|drug
DDI-DrugBank.d622.s0|112-118|dryness|drug
DDI-DrugBank.d622.s0|120-121|of|drug
DDI-DrugBank.d622.s0|123-125|the|drug
DDI-DrugBank.d622.s0|127-131|mouth|drug
DDI-DrugBank.d622.s0|133-135|and|drug
DDI-DrugBank.d622.s0|137-140|nose|drug
DDI-DrugBank.d622.s0|141-141|)|drug
DDI-DrugBank.d622.s0|143-145|may|drug
DDI-DrugBank.d622.s0|147-151|occur|drug
DDI-DrugBank.d622.s0|153-159|earlier|drug
DDI-DrugBank.d622.s0|161-164|than|drug
DDI-DrugBank.d622.s0|166-170|might|drug
DDI-DrugBank.d622.s0|172-173|be|drug
DDI-DrugBank.d622.s0|175-182|expected|drug
DDI-DrugBank.d622.s0|184-187|when|drug
DDI-DrugBank.d622.s0|189-196|atropine|drug
DDI-DrugBank.d622.s0|198-199|is|drug
DDI-DrugBank.d622.s0|201-204|used|drug
DDI-DrugBank.d622.s0|206-210|alone|drug
DDI-DrugBank.d622.s0|211-211|.|drug
DDI-DrugBank.d622.s1|0-3|This|drug
DDI-DrugBank.d622.s1|5-6|is|drug
DDI-DrugBank.d622.s1|8-17|especially|drug
DDI-DrugBank.d622.s1|19-22|true|drug
DDI-DrugBank.d622.s1|24-25|if|drug
DDI-DrugBank.d622.s1|27-29|the|drug
DDI-DrugBank.d622.s1|31-35|total|drug
DDI-DrugBank.d622.s1|37-40|dose|drug
DDI-DrugBank.d622.s1|42-43|of|drug
DDI-DrugBank.d622.s1|45-52|atropine|drug
DDI-DrugBank.d622.s1|54-56|has|drug
DDI-DrugBank.d622.s1|58-61|been|drug
DDI-DrugBank.d622.s1|63-67|large|drug
DDI-DrugBank.d622.s1|69-71|and|drug
DDI-DrugBank.d622.s1|73-75|the|drug
DDI-DrugBank.d622.s1|77-90|administration|drug
DDI-DrugBank.d622.s1|92-93|of|drug
DDI-DrugBank.d622.s1|95-105|pralidoxime|drug
DDI-DrugBank.d622.s1|107-109|has|drug
DDI-DrugBank.d622.s1|111-114|been|drug
DDI-DrugBank.d622.s1|116-122|delayed|drug
DDI-DrugBank.d622.s1|123-123|.|drug
DDI-DrugBank.d622.s2|0-0|2|drug
DDI-DrugBank.d622.s2|2-2|-|drug
DDI-DrugBank.d622.s2|4-4|4|drug
DDI-DrugBank.d622.s2|6-8|The|drug
DDI-DrugBank.d622.s2|10-18|following|drug
DDI-DrugBank.d622.s2|20-30|precautions|drug
DDI-DrugBank.d622.s2|32-37|should|drug
DDI-DrugBank.d622.s2|39-40|be|drug
DDI-DrugBank.d622.s2|42-45|kept|drug
DDI-DrugBank.d622.s2|47-48|in|drug
DDI-DrugBank.d622.s2|50-53|mind|drug
DDI-DrugBank.d622.s2|55-56|in|drug
DDI-DrugBank.d622.s2|58-60|the|drug
DDI-DrugBank.d622.s2|62-70|treatment|drug
DDI-DrugBank.d622.s2|72-73|of|drug
DDI-DrugBank.d622.s2|75-92|anticholinesterase|drug
DDI-DrugBank.d622.s2|94-102|poisoning|drug
DDI-DrugBank.d622.s2|103-103|,|drug
DDI-DrugBank.d622.s2|105-112|although|drug
DDI-DrugBank.d622.s2|114-117|they|drug
DDI-DrugBank.d622.s2|119-120|do|drug
DDI-DrugBank.d622.s2|122-124|not|drug
DDI-DrugBank.d622.s2|126-129|bear|drug
DDI-DrugBank.d622.s2|131-138|directly|drug
DDI-DrugBank.d622.s2|140-141|on|drug
DDI-DrugBank.d622.s2|143-145|the|drug
DDI-DrugBank.d622.s2|147-149|use|drug
DDI-DrugBank.d622.s2|151-152|of|drug
DDI-DrugBank.d622.s2|154-164|pralidoxime|drug
DDI-DrugBank.d622.s2|165-165|:|drug
DDI-DrugBank.d622.s2|167-171|since|drug
DDI-DrugBank.d622.s2|173-184|barbiturates|drug
DDI-DrugBank.d622.s2|186-188|are|drug
DDI-DrugBank.d622.s2|190-200|potentiated|drug
DDI-DrugBank.d622.s2|202-203|by|drug
DDI-DrugBank.d622.s2|205-207|the|drug
DDI-DrugBank.d622.s2|209-227|anticholinesterases|drug
DDI-DrugBank.d622.s2|228-228|,|drug
DDI-DrugBank.d622.s2|230-233|they|drug
DDI-DrugBank.d622.s2|235-240|should|drug
DDI-DrugBank.d622.s2|242-243|be|drug
DDI-DrugBank.d622.s2|245-248|used|drug
DDI-DrugBank.d622.s2|250-259|cautiously|drug
DDI-DrugBank.d622.s2|261-262|in|drug
DDI-DrugBank.d622.s2|264-266|the|drug
DDI-DrugBank.d622.s2|268-276|treatment|drug
DDI-DrugBank.d622.s2|278-279|of|drug
DDI-DrugBank.d622.s2|281-291|convulsions|drug
DDI-DrugBank.d622.s2|292-292|;|drug
DDI-DrugBank.d622.s3|0-7|morphine|drug
DDI-DrugBank.d622.s3|8-8|,|drug
DDI-DrugBank.d622.s3|10-21|theophylline|drug
DDI-DrugBank.d622.s3|22-22|,|drug
DDI-DrugBank.d622.s3|24-36|aminophylline|drug
DDI-DrugBank.d622.s3|37-37|,|drug
DDI-DrugBank.d622.s3|39-53|succinylcholine|drug
DDI-DrugBank.d622.s3|54-54|,|drug
DDI-DrugBank.d622.s3|56-64|reserpine|drug
DDI-DrugBank.d622.s3|65-65|,|drug
DDI-DrugBank.d622.s3|67-69|and|drug
DDI-DrugBank.d622.s3|71-88|phenothiazine-type|drug
DDI-DrugBank.d622.s3|90-102|tranquilizers|drug
DDI-DrugBank.d622.s3|104-109|should|drug
DDI-DrugBank.d622.s3|111-112|be|drug
DDI-DrugBank.d622.s3|114-120|avoided|drug
DDI-DrugBank.d622.s3|122-123|in|drug
DDI-DrugBank.d622.s3|125-132|patients|drug
DDI-DrugBank.d622.s3|134-137|with|drug
DDI-DrugBank.d622.s3|139-153|organophosphate|drug
DDI-DrugBank.d622.s3|155-163|poisoning|drug
DDI-DrugBank.d622.s3|164-164|.|drug
DDI-DrugBank.d328.s0|0-2|The|drug
DDI-DrugBank.d328.s0|4-7|drug|drug
DDI-DrugBank.d328.s0|9-19|interaction|drug
DDI-DrugBank.d328.s0|21-27|studies|drug
DDI-DrugBank.d328.s0|29-32|with|drug
DDI-DrugBank.d328.s0|34-43|valdecoxib|drug
DDI-DrugBank.d328.s0|45-48|were|drug
DDI-DrugBank.d328.s0|50-58|performed|drug
DDI-DrugBank.d328.s0|60-63|both|drug
DDI-DrugBank.d328.s0|65-68|with|drug
DDI-DrugBank.d328.s0|70-79|valdecoxib|drug
DDI-DrugBank.d328.s0|81-83|and|drug
DDI-DrugBank.d328.s0|85-85|a|drug
DDI-DrugBank.d328.s0|87-93|rapidly|drug
DDI-DrugBank.d328.s0|95-104|hydrolyzed|drug
DDI-DrugBank.d328.s0|106-116|intravenous|drug
DDI-DrugBank.d328.s0|118-124|prodrug|drug
DDI-DrugBank.d328.s0|126-129|form|drug
DDI-DrugBank.d328.s0|130-130|.|drug
DDI-DrugBank.d328.s1|0-2|The|drug
DDI-DrugBank.d328.s1|4-10|results|drug
DDI-DrugBank.d328.s1|12-15|from|drug
DDI-DrugBank.d328.s1|17-22|trials|drug
DDI-DrugBank.d328.s1|24-28|using|drug
DDI-DrugBank.d328.s1|30-32|the|drug
DDI-DrugBank.d328.s1|34-44|intravenous|drug
DDI-DrugBank.d328.s1|46-52|prodrug|drug
DDI-DrugBank.d328.s1|54-56|are|drug
DDI-DrugBank.d328.s1|58-65|reported|drug
DDI-DrugBank.d328.s1|67-68|in|drug
DDI-DrugBank.d328.s1|70-73|this|drug
DDI-DrugBank.d328.s1|75-81|section|drug
DDI-DrugBank.d328.s1|83-84|as|drug
DDI-DrugBank.d328.s1|86-89|they|drug
DDI-DrugBank.d328.s1|91-96|relate|drug
DDI-DrugBank.d328.s1|98-99|to|drug
DDI-DrugBank.d328.s1|101-103|the|drug
DDI-DrugBank.d328.s1|105-108|role|drug
DDI-DrugBank.d328.s1|110-111|of|drug
DDI-DrugBank.d328.s1|113-122|valdecoxib|drug
DDI-DrugBank.d328.s1|124-125|in|drug
DDI-DrugBank.d328.s1|127-130|drug|drug
DDI-DrugBank.d328.s1|132-143|interactions|drug
DDI-DrugBank.d328.s1|144-144|.|drug
DDI-DrugBank.d328.s2|0-6|General|drug
DDI-DrugBank.d328.s2|7-7|:|drug
DDI-DrugBank.d328.s2|9-10|In|drug
DDI-DrugBank.d328.s2|12-17|humans|drug
DDI-DrugBank.d328.s2|18-18|,|drug
DDI-DrugBank.d328.s2|20-29|valdecoxib|drug
DDI-DrugBank.d328.s2|31-40|metabolism|drug
DDI-DrugBank.d328.s2|42-43|is|drug
DDI-DrugBank.d328.s2|45-57|predominantly|drug
DDI-DrugBank.d328.s2|59-66|mediated|drug
DDI-DrugBank.d328.s2|68-70|via|drug
DDI-DrugBank.d328.s2|72-74|CYP|drug
DDI-DrugBank.d328.s2|76-78|3A4|drug
DDI-DrugBank.d328.s2|80-82|and|drug
DDI-DrugBank.d328.s2|84-86|2C9|drug
DDI-DrugBank.d328.s2|88-91|with|drug
DDI-DrugBank.d328.s2|93-107|glucuronidation|drug
DDI-DrugBank.d328.s2|109-113|being|drug
DDI-DrugBank.d328.s2|115-115|a|drug
DDI-DrugBank.d328.s2|117-123|further|drug
DDI-DrugBank.d328.s2|125-125|(|drug
DDI-DrugBank.d328.s2|126-127|20|drug
DDI-DrugBank.d328.s2|128-128|%|drug
DDI-DrugBank.d328.s2|129-129|)|drug
DDI-DrugBank.d328.s2|131-135|route|drug
DDI-DrugBank.d328.s2|137-138|of|drug
DDI-DrugBank.d328.s2|140-149|metabolism|drug
DDI-DrugBank.d328.s2|150-150|.|drug
DDI-DrugBank.d328.s3|0-1|In|drug
DDI-DrugBank.d328.s3|3-7|vitro|drug
DDI-DrugBank.d328.s3|9-15|studies|drug
DDI-DrugBank.d328.s3|17-24|indicate|drug
DDI-DrugBank.d328.s3|26-29|that|drug
DDI-DrugBank.d328.s3|31-40|valdecoxib|drug
DDI-DrugBank.d328.s3|42-43|is|drug
DDI-DrugBank.d328.s3|45-45|a|drug
DDI-DrugBank.d328.s3|47-54|moderate|drug
DDI-DrugBank.d328.s3|56-64|inhibitor|drug
DDI-DrugBank.d328.s3|66-67|of|drug
DDI-DrugBank.d328.s3|69-71|CYP|drug
DDI-DrugBank.d328.s3|73-76|2C19|drug
DDI-DrugBank.d328.s3|78-78|(|drug
DDI-DrugBank.d328.s3|79-82|IC50|drug
DDI-DrugBank.d328.s3|84-84|=|drug
DDI-DrugBank.d328.s3|86-86|6|drug
DDI-DrugBank.d328.s3|89-92|g/mL|drug
DDI-DrugBank.d328.s3|94-95|or|drug
DDI-DrugBank.d328.s3|97-98|19|drug
DDI-DrugBank.d328.s3|101-101|M|drug
DDI-DrugBank.d328.s3|102-102|)|drug
DDI-DrugBank.d328.s3|104-106|and|drug
DDI-DrugBank.d328.s3|108-110|2C9|drug
DDI-DrugBank.d328.s3|112-112|(|drug
DDI-DrugBank.d328.s3|113-116|IC50|drug
DDI-DrugBank.d328.s3|118-118|=|drug
DDI-DrugBank.d328.s3|120-121|13|drug
DDI-DrugBank.d328.s3|124-127|g/mL|drug
DDI-DrugBank.d328.s3|129-130|or|drug
DDI-DrugBank.d328.s3|132-133|41|drug
DDI-DrugBank.d328.s3|136-136|M|drug
DDI-DrugBank.d328.s3|137-137|)|drug
DDI-DrugBank.d328.s3|138-138|,|drug
DDI-DrugBank.d328.s3|140-142|and|drug
DDI-DrugBank.d328.s3|144-144|a|drug
DDI-DrugBank.d328.s3|146-149|weak|drug
DDI-DrugBank.d328.s3|151-159|inhibitor|drug
DDI-DrugBank.d328.s3|161-162|of|drug
DDI-DrugBank.d328.s3|164-166|CYP|drug
DDI-DrugBank.d328.s3|168-170|2D6|drug
DDI-DrugBank.d328.s3|172-172|(|drug
DDI-DrugBank.d328.s3|173-176|IC50|drug
DDI-DrugBank.d328.s3|178-178|=|drug
DDI-DrugBank.d328.s3|180-181|31|drug
DDI-DrugBank.d328.s3|184-187|g/mL|drug
DDI-DrugBank.d328.s3|189-190|or|drug
DDI-DrugBank.d328.s3|192-194|100|drug
DDI-DrugBank.d328.s3|197-197|M|drug
DDI-DrugBank.d328.s3|198-198|)|drug
DDI-DrugBank.d328.s3|200-202|and|drug
DDI-DrugBank.d328.s3|204-206|3A4|drug
DDI-DrugBank.d328.s3|208-208|(|drug
DDI-DrugBank.d328.s3|209-212|IC50|drug
DDI-DrugBank.d328.s3|214-214|=|drug
DDI-DrugBank.d328.s3|216-217|44|drug
DDI-DrugBank.d328.s3|220-223|g/mL|drug
DDI-DrugBank.d328.s3|225-226|or|drug
DDI-DrugBank.d328.s3|228-230|141|drug
DDI-DrugBank.d328.s3|233-233|M|drug
DDI-DrugBank.d328.s3|235-235|)|drug
DDI-DrugBank.d328.s3|236-237|..|drug
DDI-DrugBank.d328.s4|0-6|Aspirin|brand
DDI-DrugBank.d328.s4|7-7|:|drug
DDI-DrugBank.d328.s4|9-19|Concomitant|drug
DDI-DrugBank.d328.s4|21-34|administration|drug
DDI-DrugBank.d328.s4|36-37|of|drug
DDI-DrugBank.d328.s4|39-45|aspirin|drug
DDI-DrugBank.d328.s4|47-50|with|drug
DDI-DrugBank.d328.s4|52-61|valdecoxib|drug
DDI-DrugBank.d328.s4|63-65|may|drug
DDI-DrugBank.d328.s4|67-72|result|drug
DDI-DrugBank.d328.s4|74-75|in|drug
DDI-DrugBank.d328.s4|77-78|an|drug
DDI-DrugBank.d328.s4|80-88|increased|drug
DDI-DrugBank.d328.s4|90-93|risk|drug
DDI-DrugBank.d328.s4|95-96|of|drug
DDI-DrugBank.d328.s4|98-99|GI|drug
DDI-DrugBank.d328.s4|101-110|ulceration|drug
DDI-DrugBank.d328.s4|112-114|and|drug
DDI-DrugBank.d328.s4|116-128|complications|drug
DDI-DrugBank.d328.s4|130-137|compared|drug
DDI-DrugBank.d328.s4|139-140|to|drug
DDI-DrugBank.d328.s4|142-151|valdecoxib|drug
DDI-DrugBank.d328.s4|153-157|alone|drug
DDI-DrugBank.d328.s4|158-158|.|drug
DDI-DrugBank.d328.s5|0-6|Because|drug
DDI-DrugBank.d328.s5|8-9|of|drug
DDI-DrugBank.d328.s5|11-13|its|drug
DDI-DrugBank.d328.s5|15-18|lack|drug
DDI-DrugBank.d328.s5|20-21|of|drug
DDI-DrugBank.d328.s5|23-35|anti-platelet|drug
DDI-DrugBank.d328.s5|37-42|effect|drug
DDI-DrugBank.d328.s5|44-53|valdecoxib|drug
DDI-DrugBank.d328.s5|55-56|is|drug
DDI-DrugBank.d328.s5|58-60|not|drug
DDI-DrugBank.d328.s5|62-62|a|drug
DDI-DrugBank.d328.s5|64-73|substitute|drug
DDI-DrugBank.d328.s5|75-77|for|drug
DDI-DrugBank.d328.s5|79-85|aspirin|drug
DDI-DrugBank.d328.s5|87-89|for|drug
DDI-DrugBank.d328.s5|91-104|cardiovascular|drug
DDI-DrugBank.d328.s5|106-116|prophylaxis|drug
DDI-DrugBank.d328.s5|117-117|.|drug
DDI-DrugBank.d328.s6|0-1|In|drug
DDI-DrugBank.d328.s6|3-3|a|drug
DDI-DrugBank.d328.s6|5-12|parallel|drug
DDI-DrugBank.d328.s6|14-18|group|drug
DDI-DrugBank.d328.s6|20-23|drug|drug
DDI-DrugBank.d328.s6|25-35|interaction|drug
DDI-DrugBank.d328.s6|37-41|study|drug
DDI-DrugBank.d328.s6|43-51|comparing|drug
DDI-DrugBank.d328.s6|53-55|the|drug
DDI-DrugBank.d328.s6|57-67|intravenous|drug
DDI-DrugBank.d328.s6|69-75|prodrug|drug
DDI-DrugBank.d328.s6|77-80|form|drug
DDI-DrugBank.d328.s6|82-83|of|drug
DDI-DrugBank.d328.s6|85-94|valdecoxib|drug
DDI-DrugBank.d328.s6|96-97|at|drug
DDI-DrugBank.d328.s6|99-100|40|drug
DDI-DrugBank.d328.s6|102-103|mg|drug
DDI-DrugBank.d328.s6|105-107|BID|drug
DDI-DrugBank.d328.s6|109-109|(|drug
DDI-DrugBank.d328.s6|110-113|n=10|drug
DDI-DrugBank.d328.s6|114-114|)|drug
DDI-DrugBank.d328.s6|116-117|vs|drug
DDI-DrugBank.d328.s6|119-125|placebo|drug
DDI-DrugBank.d328.s6|127-127|(|drug
DDI-DrugBank.d328.s6|128-130|n=9|drug
DDI-DrugBank.d328.s6|131-131|)|drug
DDI-DrugBank.d328.s6|132-132|,|drug
DDI-DrugBank.d328.s6|134-143|valdecoxib|drug
DDI-DrugBank.d328.s6|145-147|had|drug
DDI-DrugBank.d328.s6|149-150|no|drug
DDI-DrugBank.d328.s6|152-157|effect|drug
DDI-DrugBank.d328.s6|159-160|on|drug
DDI-DrugBank.d328.s6|162-163|in|drug
DDI-DrugBank.d328.s6|165-169|vitro|drug
DDI-DrugBank.d328.s6|171-186|aspirin-mediated|drug
DDI-DrugBank.d328.s6|188-197|inhibition|drug
DDI-DrugBank.d328.s6|199-200|of|drug
DDI-DrugBank.d328.s6|202-214|arachidonate-|drug
DDI-DrugBank.d328.s6|216-217|or|drug
DDI-DrugBank.d328.s6|219-237|collagen-stimulated|drug
DDI-DrugBank.d328.s6|239-246|platelet|drug
DDI-DrugBank.d328.s6|248-258|aggregation|drug
DDI-DrugBank.d328.s6|259-259|.|drug
DDI-DrugBank.d328.s7|0-11|Methotrexate|brand
DDI-DrugBank.d328.s7|12-12|:|drug
DDI-DrugBank.d328.s7|14-23|Valdecoxib|drug
DDI-DrugBank.d328.s7|25-26|10|drug
DDI-DrugBank.d328.s7|28-29|mg|drug
DDI-DrugBank.d328.s7|31-33|BID|drug
DDI-DrugBank.d328.s7|35-37|did|drug
DDI-DrugBank.d328.s7|39-41|not|drug
DDI-DrugBank.d328.s7|43-46|show|drug
DDI-DrugBank.d328.s7|48-48|a|drug
DDI-DrugBank.d328.s7|50-60|significant|drug
DDI-DrugBank.d328.s7|62-67|effect|drug
DDI-DrugBank.d328.s7|69-70|on|drug
DDI-DrugBank.d328.s7|72-74|the|drug
DDI-DrugBank.d328.s7|76-81|plasma|drug
DDI-DrugBank.d328.s7|83-90|exposure|drug
DDI-DrugBank.d328.s7|92-93|or|drug
DDI-DrugBank.d328.s7|95-99|renal|drug
DDI-DrugBank.d328.s7|101-109|clearance|drug
DDI-DrugBank.d328.s7|111-112|of|drug
DDI-DrugBank.d328.s7|114-125|methotrexate|drug
DDI-DrugBank.d328.s7|126-126|.|drug
DDI-DrugBank.d328.s8|0-13|ACE-inhibitors|drug
DDI-DrugBank.d328.s8|14-14|:|drug
DDI-DrugBank.d328.s8|15-21|Reports|drug
DDI-DrugBank.d328.s8|23-29|suggest|drug
DDI-DrugBank.d328.s8|31-34|that|drug
DDI-DrugBank.d328.s8|36-41|NSAIDs|drug
DDI-DrugBank.d328.s8|43-45|may|drug
DDI-DrugBank.d328.s8|47-54|diminish|drug
DDI-DrugBank.d328.s8|56-58|the|drug
DDI-DrugBank.d328.s8|60-75|antihypertensive|drug
DDI-DrugBank.d328.s8|77-82|effect|drug
DDI-DrugBank.d328.s8|84-85|of|drug
DDI-DrugBank.d328.s8|87-100|ACE-inhibitors|drug
DDI-DrugBank.d328.s8|101-101|.|drug
DDI-DrugBank.d328.s9|0-3|This|drug
DDI-DrugBank.d328.s9|5-15|interaction|drug
DDI-DrugBank.d328.s9|17-22|should|drug
DDI-DrugBank.d328.s9|24-25|be|drug
DDI-DrugBank.d328.s9|27-31|given|drug
DDI-DrugBank.d328.s9|33-45|consideration|drug
DDI-DrugBank.d328.s9|47-48|in|drug
DDI-DrugBank.d328.s9|50-57|patients|drug
DDI-DrugBank.d328.s9|59-64|taking|drug
DDI-DrugBank.d328.s9|66-71|BEXTRA|drug
DDI-DrugBank.d328.s9|73-85|concomitantly|drug
DDI-DrugBank.d328.s9|87-90|with|drug
DDI-DrugBank.d328.s9|92-105|ACE-inhibitors|drug
DDI-DrugBank.d328.s9|106-106|.|drug
DDI-DrugBank.d328.s10|0-9|Furosemide|brand
DDI-DrugBank.d328.s10|10-10|:|drug
DDI-DrugBank.d328.s10|12-19|Clinical|drug
DDI-DrugBank.d328.s10|21-27|studies|drug
DDI-DrugBank.d328.s10|28-28|,|drug
DDI-DrugBank.d328.s10|30-31|as|drug
DDI-DrugBank.d328.s10|33-36|well|drug
DDI-DrugBank.d328.s10|38-39|as|drug
DDI-DrugBank.d328.s10|41-54|post-marketing|drug
DDI-DrugBank.d328.s10|56-67|observations|drug
DDI-DrugBank.d328.s10|68-68|,|drug
DDI-DrugBank.d328.s10|70-73|have|drug
DDI-DrugBank.d328.s10|75-79|shown|drug
DDI-DrugBank.d328.s10|81-84|that|drug
DDI-DrugBank.d328.s10|86-91|NSAIDs|drug
DDI-DrugBank.d328.s10|93-95|can|drug
DDI-DrugBank.d328.s10|97-102|reduce|drug
DDI-DrugBank.d328.s10|104-106|the|drug
DDI-DrugBank.d328.s10|108-118|natriuretic|drug
DDI-DrugBank.d328.s10|120-125|effect|drug
DDI-DrugBank.d328.s10|127-128|of|drug
DDI-DrugBank.d328.s10|130-139|furosemide|drug
DDI-DrugBank.d328.s10|141-143|and|drug
DDI-DrugBank.d328.s10|145-153|thiazides|drug
DDI-DrugBank.d328.s10|155-156|in|drug
DDI-DrugBank.d328.s10|158-161|some|drug
DDI-DrugBank.d328.s10|163-170|patients|drug
DDI-DrugBank.d328.s10|171-171|.|drug
DDI-DrugBank.d328.s11|0-3|This|drug
DDI-DrugBank.d328.s11|5-12|response|drug
DDI-DrugBank.d328.s11|14-16|has|drug
DDI-DrugBank.d328.s11|18-21|been|drug
DDI-DrugBank.d328.s11|23-32|attributed|drug
DDI-DrugBank.d328.s11|34-35|to|drug
DDI-DrugBank.d328.s11|37-46|inhibition|drug
DDI-DrugBank.d328.s11|48-49|of|drug
DDI-DrugBank.d328.s11|51-55|renal|drug
DDI-DrugBank.d328.s11|57-69|prostaglandin|drug
DDI-DrugBank.d328.s11|71-79|synthesis|drug
DDI-DrugBank.d328.s11|80-80|.|drug
DDI-DrugBank.d328.s12|0-14|Anticonvulsants|group
DDI-DrugBank.d328.s12|16-16|(|drug
DDI-DrugBank.d328.s12|17-25|Phenytoin|brand
DDI-DrugBank.d328.s12|26-26|)|drug
DDI-DrugBank.d328.s12|27-27|:|drug
DDI-DrugBank.d328.s12|29-34|Steady|drug
DDI-DrugBank.d328.s12|36-40|state|drug
DDI-DrugBank.d328.s12|42-47|plasma|drug
DDI-DrugBank.d328.s12|49-56|exposure|drug
DDI-DrugBank.d328.s12|58-58|(|drug
DDI-DrugBank.d328.s12|59-61|AUC|drug
DDI-DrugBank.d328.s12|62-62|)|drug
DDI-DrugBank.d328.s12|64-65|of|drug
DDI-DrugBank.d328.s12|67-76|valdecoxib|drug
DDI-DrugBank.d328.s12|78-78|(|drug
DDI-DrugBank.d328.s12|79-80|40|drug
DDI-DrugBank.d328.s12|82-83|mg|drug
DDI-DrugBank.d328.s12|85-87|BID|drug
DDI-DrugBank.d328.s12|89-91|for|drug
DDI-DrugBank.d328.s12|93-94|12|drug
DDI-DrugBank.d328.s12|96-99|days|drug
DDI-DrugBank.d328.s12|100-100|)|drug
DDI-DrugBank.d328.s12|102-104|was|drug
DDI-DrugBank.d328.s12|106-114|decreased|drug
DDI-DrugBank.d328.s12|116-117|by|drug
DDI-DrugBank.d328.s12|119-120|27|drug
DDI-DrugBank.d328.s12|121-121|%|drug
DDI-DrugBank.d328.s12|123-126|when|drug
DDI-DrugBank.d328.s12|128-142|co-administered|drug
DDI-DrugBank.d328.s12|144-147|with|drug
DDI-DrugBank.d328.s12|149-156|multiple|drug
DDI-DrugBank.d328.s12|158-162|doses|drug
DDI-DrugBank.d328.s12|164-164|(|drug
DDI-DrugBank.d328.s12|165-167|300|drug
DDI-DrugBank.d328.s12|169-170|mg|drug
DDI-DrugBank.d328.s12|172-173|QD|drug
DDI-DrugBank.d328.s12|175-177|for|drug
DDI-DrugBank.d328.s12|179-180|12|drug
DDI-DrugBank.d328.s12|182-185|days|drug
DDI-DrugBank.d328.s12|186-186|)|drug
DDI-DrugBank.d328.s12|188-189|of|drug
DDI-DrugBank.d328.s12|191-199|phenytoin|drug
DDI-DrugBank.d328.s12|201-201|(|drug
DDI-DrugBank.d328.s12|202-202|a|drug
DDI-DrugBank.d328.s12|204-206|CYP|drug
DDI-DrugBank.d328.s12|208-210|3A4|drug
DDI-DrugBank.d328.s12|212-218|inducer|drug
DDI-DrugBank.d328.s12|219-219|)|drug
DDI-DrugBank.d328.s12|220-220|.|drug
DDI-DrugBank.d328.s13|0-7|Patients|drug
DDI-DrugBank.d328.s13|9-15|already|drug
DDI-DrugBank.d328.s13|17-26|stabilized|drug
DDI-DrugBank.d328.s13|28-29|on|drug
DDI-DrugBank.d328.s13|31-40|valdecoxib|drug
DDI-DrugBank.d328.s13|42-47|should|drug
DDI-DrugBank.d328.s13|49-50|be|drug
DDI-DrugBank.d328.s13|52-58|closely|drug
DDI-DrugBank.d328.s13|60-68|monitored|drug
DDI-DrugBank.d328.s13|70-72|for|drug
DDI-DrugBank.d328.s13|74-77|loss|drug
DDI-DrugBank.d328.s13|79-80|of|drug
DDI-DrugBank.d328.s13|82-88|symptom|drug
DDI-DrugBank.d328.s13|90-96|control|drug
DDI-DrugBank.d328.s13|98-101|with|drug
DDI-DrugBank.d328.s13|103-111|phenytoin|drug
DDI-DrugBank.d328.s13|113-128|coadministration|drug
DDI-DrugBank.d328.s13|129-129|.|drug
DDI-DrugBank.d328.s14|0-9|Valdecoxib|drug
DDI-DrugBank.d328.s14|11-13|did|drug
DDI-DrugBank.d328.s14|15-17|not|drug
DDI-DrugBank.d328.s14|19-22|have|drug
DDI-DrugBank.d328.s14|24-24|a|drug
DDI-DrugBank.d328.s14|26-38|statistically|drug
DDI-DrugBank.d328.s14|40-50|significant|drug
DDI-DrugBank.d328.s14|52-57|effect|drug
DDI-DrugBank.d328.s14|59-60|on|drug
DDI-DrugBank.d328.s14|62-64|the|drug
DDI-DrugBank.d328.s14|66-81|pharmacokinetics|drug
DDI-DrugBank.d328.s14|83-84|of|drug
DDI-DrugBank.d328.s14|86-94|phenytoin|drug
DDI-DrugBank.d328.s14|96-96|(|drug
DDI-DrugBank.d328.s14|97-97|a|drug
DDI-DrugBank.d328.s14|99-101|CYP|drug
DDI-DrugBank.d328.s14|103-105|2C9|drug
DDI-DrugBank.d328.s14|107-109|and|drug
DDI-DrugBank.d328.s14|111-113|CYP|drug
DDI-DrugBank.d328.s14|115-118|2C19|drug
DDI-DrugBank.d328.s14|120-128|substrate|drug
DDI-DrugBank.d328.s14|129-129|)|drug
DDI-DrugBank.d328.s14|130-130|.|drug
DDI-DrugBank.d328.s15|0-3|Drug|drug
DDI-DrugBank.d328.s15|5-15|interaction|drug
DDI-DrugBank.d328.s15|17-23|studies|drug
DDI-DrugBank.d328.s15|25-28|with|drug
DDI-DrugBank.d328.s15|30-34|other|drug
DDI-DrugBank.d328.s15|36-50|anticonvulsants|drug
DDI-DrugBank.d328.s15|52-55|have|drug
DDI-DrugBank.d328.s15|57-59|not|drug
DDI-DrugBank.d328.s15|61-64|been|drug
DDI-DrugBank.d328.s15|66-74|conducted|drug
DDI-DrugBank.d328.s15|75-75|.|drug
DDI-DrugBank.d328.s16|0-6|Routine|drug
DDI-DrugBank.d328.s16|8-17|monitoring|drug
DDI-DrugBank.d328.s16|19-24|should|drug
DDI-DrugBank.d328.s16|26-27|be|drug
DDI-DrugBank.d328.s16|29-37|performed|drug
DDI-DrugBank.d328.s16|39-42|when|drug
DDI-DrugBank.d328.s16|44-50|therapy|drug
DDI-DrugBank.d328.s16|52-55|with|drug
DDI-DrugBank.d328.s16|57-62|BEXTRA|drug
DDI-DrugBank.d328.s16|64-65|is|drug
DDI-DrugBank.d328.s16|67-72|either|drug
DDI-DrugBank.d328.s16|74-82|initiated|drug
DDI-DrugBank.d328.s16|84-85|or|drug
DDI-DrugBank.d328.s16|87-98|discontinued|drug
DDI-DrugBank.d328.s16|100-101|in|drug
DDI-DrugBank.d328.s16|103-110|patients|drug
DDI-DrugBank.d328.s16|112-113|on|drug
DDI-DrugBank.d328.s16|115-128|anticonvulsant|drug
DDI-DrugBank.d328.s16|130-136|therapy|drug
DDI-DrugBank.d328.s16|137-137|.|drug
DDI-DrugBank.d328.s17|0-15|Dextromethorphan|drug
DDI-DrugBank.d328.s17|16-16|:|drug
DDI-DrugBank.d328.s17|18-33|Dextromethorphan|drug
DDI-DrugBank.d328.s17|35-36|is|drug
DDI-DrugBank.d328.s17|38-46|primarily|drug
DDI-DrugBank.d328.s17|48-58|metabolized|drug
DDI-DrugBank.d328.s17|60-61|by|drug
DDI-DrugBank.d328.s17|63-65|CYP|drug
DDI-DrugBank.d328.s17|67-69|2D6|drug
DDI-DrugBank.d328.s17|71-73|and|drug
DDI-DrugBank.d328.s17|75-76|to|drug
DDI-DrugBank.d328.s17|78-78|a|drug
DDI-DrugBank.d328.s17|80-85|lesser|drug
DDI-DrugBank.d328.s17|87-92|extent|drug
DDI-DrugBank.d328.s17|94-95|by|drug
DDI-DrugBank.d328.s17|97-99|3A4|drug
DDI-DrugBank.d328.s17|100-100|.|drug
DDI-DrugBank.d328.s18|0-15|Coadministration|drug
DDI-DrugBank.d328.s18|17-20|with|drug
DDI-DrugBank.d328.s18|22-31|valdecoxib|drug
DDI-DrugBank.d328.s18|33-33|(|drug
DDI-DrugBank.d328.s18|34-35|40|drug
DDI-DrugBank.d328.s18|37-38|mg|drug
DDI-DrugBank.d328.s18|40-42|BID|drug
DDI-DrugBank.d328.s18|44-46|for|drug
DDI-DrugBank.d328.s18|48-48|7|drug
DDI-DrugBank.d328.s18|50-53|days|drug
DDI-DrugBank.d328.s18|54-54|)|drug
DDI-DrugBank.d328.s18|56-63|resulted|drug
DDI-DrugBank.d328.s18|65-66|in|drug
DDI-DrugBank.d328.s18|68-68|a|drug
DDI-DrugBank.d328.s18|70-80|significant|drug
DDI-DrugBank.d328.s18|82-89|increase|drug
DDI-DrugBank.d328.s18|91-92|in|drug
DDI-DrugBank.d328.s18|94-109|dextromethorphan|drug
DDI-DrugBank.d328.s18|111-116|plasma|drug
DDI-DrugBank.d328.s18|118-123|levels|drug
DDI-DrugBank.d328.s18|125-134|suggesting|drug
DDI-DrugBank.d328.s18|136-139|that|drug
DDI-DrugBank.d328.s18|140-140|,|drug
DDI-DrugBank.d328.s18|142-143|at|drug
DDI-DrugBank.d328.s18|145-149|these|drug
DDI-DrugBank.d328.s18|151-155|doses|drug
DDI-DrugBank.d328.s18|156-156|,|drug
DDI-DrugBank.d328.s18|158-167|valdecoxib|drug
DDI-DrugBank.d328.s18|169-170|is|drug
DDI-DrugBank.d328.s18|172-172|a|drug
DDI-DrugBank.d328.s18|174-177|weak|drug
DDI-DrugBank.d328.s18|179-187|inhibitor|drug
DDI-DrugBank.d328.s18|189-190|of|drug
DDI-DrugBank.d328.s18|192-194|2D6|drug
DDI-DrugBank.d328.s18|195-195|.|drug
DDI-DrugBank.d328.s19|0-3|Even|drug
DDI-DrugBank.d328.s19|5-6|so|drug
DDI-DrugBank.d328.s19|8-23|dextromethorphan|drug
DDI-DrugBank.d328.s19|25-30|plasma|drug
DDI-DrugBank.d328.s19|32-45|concentrations|drug
DDI-DrugBank.d328.s19|47-48|in|drug
DDI-DrugBank.d328.s19|50-52|the|drug
DDI-DrugBank.d328.s19|54-61|presence|drug
DDI-DrugBank.d328.s19|63-64|of|drug
DDI-DrugBank.d328.s19|66-69|high|drug
DDI-DrugBank.d328.s19|71-75|doses|drug
DDI-DrugBank.d328.s19|77-78|of|drug
DDI-DrugBank.d328.s19|80-89|valdecoxib|drug
DDI-DrugBank.d328.s19|91-94|were|drug
DDI-DrugBank.d328.s19|96-101|almost|drug
DDI-DrugBank.d328.s19|103-108|5-fold|drug
DDI-DrugBank.d328.s19|110-114|lower|drug
DDI-DrugBank.d328.s19|116-119|than|drug
DDI-DrugBank.d328.s19|121-125|those|drug
DDI-DrugBank.d328.s19|127-130|seen|drug
DDI-DrugBank.d328.s19|132-133|in|drug
DDI-DrugBank.d328.s19|135-137|CYP|drug
DDI-DrugBank.d328.s19|139-141|2D6|drug
DDI-DrugBank.d328.s19|143-146|poor|drug
DDI-DrugBank.d328.s19|148-159|metabolizers|drug
DDI-DrugBank.d328.s19|161-170|suggesting|drug
DDI-DrugBank.d328.s19|172-175|that|drug
DDI-DrugBank.d328.s19|177-180|dose|drug
DDI-DrugBank.d328.s19|182-191|adjustment|drug
DDI-DrugBank.d328.s19|193-194|is|drug
DDI-DrugBank.d328.s19|196-198|not|drug
DDI-DrugBank.d328.s19|200-208|necessary|drug
DDI-DrugBank.d328.s19|209-209|.|drug
DDI-DrugBank.d328.s20|0-6|Lithium|brand
DDI-DrugBank.d328.s20|7-7|:|drug
DDI-DrugBank.d328.s20|9-18|Valdecoxib|drug
DDI-DrugBank.d328.s20|20-21|40|drug
DDI-DrugBank.d328.s20|23-24|mg|drug
DDI-DrugBank.d328.s20|26-28|BID|drug
DDI-DrugBank.d328.s20|30-32|for|drug
DDI-DrugBank.d328.s20|34-34|7|drug
DDI-DrugBank.d328.s20|36-39|days|drug
DDI-DrugBank.d328.s20|41-48|produced|drug
DDI-DrugBank.d328.s20|50-60|significant|drug
DDI-DrugBank.d328.s20|62-70|decreases|drug
DDI-DrugBank.d328.s20|72-73|in|drug
DDI-DrugBank.d328.s20|75-81|lithium|drug
DDI-DrugBank.d328.s20|83-87|serum|drug
DDI-DrugBank.d328.s20|89-97|clearance|drug
DDI-DrugBank.d328.s20|99-99|(|drug
DDI-DrugBank.d328.s20|100-101|25|drug
DDI-DrugBank.d328.s20|102-102|%|drug
DDI-DrugBank.d328.s20|103-103|)|drug
DDI-DrugBank.d328.s20|105-107|and|drug
DDI-DrugBank.d328.s20|109-113|renal|drug
DDI-DrugBank.d328.s20|115-123|clearance|drug
DDI-DrugBank.d328.s20|125-125|(|drug
DDI-DrugBank.d328.s20|126-127|30|drug
DDI-DrugBank.d328.s20|128-128|%|drug
DDI-DrugBank.d328.s20|129-129|)|drug
DDI-DrugBank.d328.s20|131-134|with|drug
DDI-DrugBank.d328.s20|136-136|a|drug
DDI-DrugBank.d328.s20|138-139|34|drug
DDI-DrugBank.d328.s20|140-140|%|drug
DDI-DrugBank.d328.s20|142-147|higher|drug
DDI-DrugBank.d328.s20|149-153|serum|drug
DDI-DrugBank.d328.s20|155-162|exposure|drug
DDI-DrugBank.d328.s20|164-171|compared|drug
DDI-DrugBank.d328.s20|173-174|to|drug
DDI-DrugBank.d328.s20|176-182|lithium|drug
DDI-DrugBank.d328.s20|184-188|alone|drug
DDI-DrugBank.d328.s20|189-189|.|drug
DDI-DrugBank.d328.s21|0-6|Lithium|brand
DDI-DrugBank.d328.s21|8-12|serum|drug
DDI-DrugBank.d328.s21|14-27|concentrations|drug
DDI-DrugBank.d328.s21|29-34|should|drug
DDI-DrugBank.d328.s21|36-37|be|drug
DDI-DrugBank.d328.s21|39-47|monitored|drug
DDI-DrugBank.d328.s21|49-55|closely|drug
DDI-DrugBank.d328.s21|57-60|when|drug
DDI-DrugBank.d328.s21|62-71|initiating|drug
DDI-DrugBank.d328.s21|73-74|or|drug
DDI-DrugBank.d328.s21|76-83|changing|drug
DDI-DrugBank.d328.s21|85-91|therapy|drug
DDI-DrugBank.d328.s21|93-96|with|drug
DDI-DrugBank.d328.s21|98-103|BEXTRA|drug
DDI-DrugBank.d328.s21|105-106|in|drug
DDI-DrugBank.d328.s21|108-115|patients|drug
DDI-DrugBank.d328.s21|117-125|receiving|drug
DDI-DrugBank.d328.s21|127-133|lithium|drug
DDI-DrugBank.d328.s21|134-134|.|drug
DDI-DrugBank.d328.s22|0-6|Lithium|brand
DDI-DrugBank.d328.s22|8-16|carbonate|drug
DDI-DrugBank.d328.s22|18-18|(|drug
DDI-DrugBank.d328.s22|19-21|450|drug
DDI-DrugBank.d328.s22|23-24|mg|drug
DDI-DrugBank.d328.s22|26-28|BID|drug
DDI-DrugBank.d328.s22|30-32|for|drug
DDI-DrugBank.d328.s22|34-34|7|drug
DDI-DrugBank.d328.s22|36-39|days|drug
DDI-DrugBank.d328.s22|40-40|)|drug
DDI-DrugBank.d328.s22|42-44|had|drug
DDI-DrugBank.d328.s22|46-47|no|drug
DDI-DrugBank.d328.s22|49-54|effect|drug
DDI-DrugBank.d328.s22|56-57|on|drug
DDI-DrugBank.d328.s22|59-68|valdecoxib|drug
DDI-DrugBank.d328.s22|70-85|pharmacokinetics|drug
DDI-DrugBank.d328.s22|86-86|.|drug
DDI-DrugBank.d328.s23|0-7|Warfarin|brand
DDI-DrugBank.d328.s23|8-8|:|drug
DDI-DrugBank.d328.s23|10-12|The|drug
DDI-DrugBank.d328.s23|14-19|effect|drug
DDI-DrugBank.d328.s23|21-22|of|drug
DDI-DrugBank.d328.s23|24-33|valdecoxib|drug
DDI-DrugBank.d328.s23|35-36|on|drug
DDI-DrugBank.d328.s23|38-40|the|drug
DDI-DrugBank.d328.s23|42-54|anticoagulant|drug
DDI-DrugBank.d328.s23|56-61|effect|drug
DDI-DrugBank.d328.s23|63-64|of|drug
DDI-DrugBank.d328.s23|66-73|warfarin|drug
DDI-DrugBank.d328.s23|75-75|(|drug
DDI-DrugBank.d328.s23|76-76|1|drug
DDI-DrugBank.d328.s23|78-78|-|drug
DDI-DrugBank.d328.s23|80-80|8|drug
DDI-DrugBank.d328.s23|82-87|mg/day|drug
DDI-DrugBank.d328.s23|88-88|)|drug
DDI-DrugBank.d328.s23|90-92|was|drug
DDI-DrugBank.d328.s23|94-100|studied|drug
DDI-DrugBank.d328.s23|102-103|in|drug
DDI-DrugBank.d328.s23|105-111|healthy|drug
DDI-DrugBank.d328.s23|113-120|subjects|drug
DDI-DrugBank.d328.s23|122-123|by|drug
DDI-DrugBank.d328.s23|125-140|coadministration|drug
DDI-DrugBank.d328.s23|142-143|of|drug
DDI-DrugBank.d328.s23|145-150|BEXTRA|drug
DDI-DrugBank.d328.s23|152-153|40|drug
DDI-DrugBank.d328.s23|155-156|mg|drug
DDI-DrugBank.d328.s23|158-160|BID|drug
DDI-DrugBank.d328.s23|162-164|for|drug
DDI-DrugBank.d328.s23|166-166|7|drug
DDI-DrugBank.d328.s23|168-171|days|drug
DDI-DrugBank.d328.s23|172-172|.|drug
DDI-DrugBank.d328.s24|0-9|Valdecoxib|drug
DDI-DrugBank.d328.s24|11-16|caused|drug
DDI-DrugBank.d328.s24|18-18|a|drug
DDI-DrugBank.d328.s24|20-32|statistically|drug
DDI-DrugBank.d328.s24|34-44|significant|drug
DDI-DrugBank.d328.s24|46-53|increase|drug
DDI-DrugBank.d328.s24|55-56|in|drug
DDI-DrugBank.d328.s24|58-63|plasma|drug
DDI-DrugBank.d328.s24|65-73|exposures|drug
DDI-DrugBank.d328.s24|75-76|of|drug
DDI-DrugBank.d328.s24|78-87|R-warfarin|drug
DDI-DrugBank.d328.s24|89-91|and|drug
DDI-DrugBank.d328.s24|93-102|S-warfarin|drug
DDI-DrugBank.d328.s24|104-104|(|drug
DDI-DrugBank.d328.s24|105-106|12|drug
DDI-DrugBank.d328.s24|107-107|%|drug
DDI-DrugBank.d328.s24|109-111|and|drug
DDI-DrugBank.d328.s24|113-114|15|drug
DDI-DrugBank.d328.s24|115-115|%|drug
DDI-DrugBank.d328.s24|116-116|,|drug
DDI-DrugBank.d328.s24|118-129|respectively|drug
DDI-DrugBank.d328.s24|130-130|)|drug
DDI-DrugBank.d328.s24|131-131|,|drug
DDI-DrugBank.d328.s24|133-135|and|drug
DDI-DrugBank.d328.s24|137-138|in|drug
DDI-DrugBank.d328.s24|140-142|the|drug
DDI-DrugBank.d328.s24|144-158|pharmacodynamic|drug
DDI-DrugBank.d328.s24|160-166|effects|drug
DDI-DrugBank.d328.s24|168-168|(|drug
DDI-DrugBank.d328.s24|169-179|prothrombin|drug
DDI-DrugBank.d328.s24|181-184|time|drug
DDI-DrugBank.d328.s24|185-185|,|drug
DDI-DrugBank.d328.s24|187-194|measured|drug
DDI-DrugBank.d328.s24|196-197|as|drug
DDI-DrugBank.d328.s24|199-201|INR|drug
DDI-DrugBank.d328.s24|202-202|)|drug
DDI-DrugBank.d328.s24|204-205|of|drug
DDI-DrugBank.d328.s24|207-214|warfarin|drug
DDI-DrugBank.d328.s24|215-215|.|drug
DDI-DrugBank.d328.s25|0-4|While|drug
DDI-DrugBank.d328.s25|6-9|mean|drug
DDI-DrugBank.d328.s25|11-13|INR|drug
DDI-DrugBank.d328.s25|15-20|values|drug
DDI-DrugBank.d328.s25|22-25|were|drug
DDI-DrugBank.d328.s25|27-30|only|drug
DDI-DrugBank.d328.s25|32-39|slightly|drug
DDI-DrugBank.d328.s25|41-49|increased|drug
DDI-DrugBank.d328.s25|51-54|with|drug
DDI-DrugBank.d328.s25|56-71|coadministration|drug
DDI-DrugBank.d328.s25|73-74|of|drug
DDI-DrugBank.d328.s25|76-85|valdecoxib|drug
DDI-DrugBank.d328.s25|86-86|,|drug
DDI-DrugBank.d328.s25|88-90|the|drug
DDI-DrugBank.d328.s25|92-101|day-to-day|drug
DDI-DrugBank.d328.s25|103-113|variability|drug
DDI-DrugBank.d328.s25|115-116|in|drug
DDI-DrugBank.d328.s25|118-127|individual|drug
DDI-DrugBank.d328.s25|129-131|INR|drug
DDI-DrugBank.d328.s25|133-138|values|drug
DDI-DrugBank.d328.s25|140-142|was|drug
DDI-DrugBank.d328.s25|144-152|increased|drug
DDI-DrugBank.d328.s25|153-153|.|drug
DDI-DrugBank.d328.s26|0-12|Anticoagulant|drug
DDI-DrugBank.d328.s26|14-20|therapy|drug
DDI-DrugBank.d328.s26|22-27|should|drug
DDI-DrugBank.d328.s26|29-30|be|drug
DDI-DrugBank.d328.s26|32-40|monitored|drug
DDI-DrugBank.d328.s26|41-41|,|drug
DDI-DrugBank.d328.s26|43-54|particularly|drug
DDI-DrugBank.d328.s26|56-61|during|drug
DDI-DrugBank.d328.s26|63-65|the|drug
DDI-DrugBank.d328.s26|67-71|first|drug
DDI-DrugBank.d328.s26|73-75|few|drug
DDI-DrugBank.d328.s26|77-81|weeks|drug
DDI-DrugBank.d328.s26|82-82|,|drug
DDI-DrugBank.d328.s26|84-88|after|drug
DDI-DrugBank.d328.s26|90-99|initiating|drug
DDI-DrugBank.d328.s26|101-107|therapy|drug
DDI-DrugBank.d328.s26|109-112|with|drug
DDI-DrugBank.d328.s26|114-119|BEXTRA|drug
DDI-DrugBank.d328.s26|121-122|in|drug
DDI-DrugBank.d328.s26|124-131|patients|drug
DDI-DrugBank.d328.s26|133-141|receiving|drug
DDI-DrugBank.d328.s26|143-150|warfarin|drug
DDI-DrugBank.d328.s26|152-153|or|drug
DDI-DrugBank.d328.s26|155-161|similar|drug
DDI-DrugBank.d328.s26|163-168|agents|drug
DDI-DrugBank.d328.s26|169-169|.|drug
DDI-DrugBank.d328.s27|0-10|Fluconazole|brand
DDI-DrugBank.d328.s27|12-14|and|drug
DDI-DrugBank.d328.s27|16-27|Ketoconazole|brand
DDI-DrugBank.d328.s27|28-28|:|drug
DDI-DrugBank.d328.s27|30-41|Ketoconazole|brand
DDI-DrugBank.d328.s27|43-45|and|drug
DDI-DrugBank.d328.s27|47-57|fluconazole|drug
DDI-DrugBank.d328.s27|59-61|are|drug
DDI-DrugBank.d328.s27|63-75|predominantly|drug
DDI-DrugBank.d328.s27|77-79|CYP|drug
DDI-DrugBank.d328.s27|81-83|3A4|drug
DDI-DrugBank.d328.s27|85-87|and|drug
DDI-DrugBank.d328.s27|89-91|2C9|drug
DDI-DrugBank.d328.s27|93-102|inhibitors|drug
DDI-DrugBank.d328.s27|103-103|,|drug
DDI-DrugBank.d328.s27|105-116|respectively|drug
DDI-DrugBank.d328.s27|117-117|.|drug
DDI-DrugBank.d328.s28|0-10|Concomitant|drug
DDI-DrugBank.d328.s28|12-17|single|drug
DDI-DrugBank.d328.s28|19-22|dose|drug
DDI-DrugBank.d328.s28|24-37|administration|drug
DDI-DrugBank.d328.s28|39-40|of|drug
DDI-DrugBank.d328.s28|42-51|valdecoxib|drug
DDI-DrugBank.d328.s28|53-54|20|drug
DDI-DrugBank.d328.s28|56-57|mg|drug
DDI-DrugBank.d328.s28|59-62|with|drug
DDI-DrugBank.d328.s28|64-71|multiple|drug
DDI-DrugBank.d328.s28|73-77|doses|drug
DDI-DrugBank.d328.s28|79-80|of|drug
DDI-DrugBank.d328.s28|82-93|ketoconazole|drug
DDI-DrugBank.d328.s28|95-97|and|drug
DDI-DrugBank.d328.s28|99-109|fluconazole|drug
DDI-DrugBank.d328.s28|111-118|produced|drug
DDI-DrugBank.d328.s28|120-120|a|drug
DDI-DrugBank.d328.s28|122-132|significant|drug
DDI-DrugBank.d328.s28|134-141|increase|drug
DDI-DrugBank.d328.s28|143-144|in|drug
DDI-DrugBank.d328.s28|146-153|exposure|drug
DDI-DrugBank.d328.s28|155-156|of|drug
DDI-DrugBank.d328.s28|158-167|valdecoxib|drug
DDI-DrugBank.d328.s28|168-168|.|drug
DDI-DrugBank.d328.s29|0-5|Plasma|drug
DDI-DrugBank.d328.s29|7-14|exposure|drug
DDI-DrugBank.d328.s29|16-16|(|drug
DDI-DrugBank.d328.s29|17-19|AUC|drug
DDI-DrugBank.d328.s29|20-20|)|drug
DDI-DrugBank.d328.s29|22-23|to|drug
DDI-DrugBank.d328.s29|25-34|valdecoxib|drug
DDI-DrugBank.d328.s29|36-38|was|drug
DDI-DrugBank.d328.s29|40-48|increased|drug
DDI-DrugBank.d328.s29|50-51|62|drug
DDI-DrugBank.d328.s29|52-52|%|drug
DDI-DrugBank.d328.s29|54-57|when|drug
DDI-DrugBank.d328.s29|59-72|coadministered|drug
DDI-DrugBank.d328.s29|74-77|with|drug
DDI-DrugBank.d328.s29|79-89|fluconazole|drug
DDI-DrugBank.d328.s29|91-93|and|drug
DDI-DrugBank.d328.s29|95-96|38|drug
DDI-DrugBank.d328.s29|97-97|%|drug
DDI-DrugBank.d328.s29|99-102|when|drug
DDI-DrugBank.d328.s29|104-117|coadministered|drug
DDI-DrugBank.d328.s29|119-122|with|drug
DDI-DrugBank.d328.s29|124-135|ketoconazole|drug
DDI-DrugBank.d328.s29|136-136|.|drug
DDI-DrugBank.d328.s30|0-8|Glyburide|brand
DDI-DrugBank.d328.s30|9-9|:|drug
DDI-DrugBank.d328.s30|11-19|Glyburide|brand
DDI-DrugBank.d328.s30|21-22|is|drug
DDI-DrugBank.d328.s30|24-24|a|drug
DDI-DrugBank.d328.s30|26-28|CYP|drug
DDI-DrugBank.d328.s30|30-32|2C9|drug
DDI-DrugBank.d328.s30|34-42|substrate|drug
DDI-DrugBank.d328.s30|43-43|.|drug
DDI-DrugBank.d328.s31|0-15|Coadministration|drug
DDI-DrugBank.d328.s31|17-18|of|drug
DDI-DrugBank.d328.s31|20-29|valdecoxib|drug
DDI-DrugBank.d328.s31|31-31|(|drug
DDI-DrugBank.d328.s31|32-33|10|drug
DDI-DrugBank.d328.s31|35-36|mg|drug
DDI-DrugBank.d328.s31|38-40|BID|drug
DDI-DrugBank.d328.s31|42-44|for|drug
DDI-DrugBank.d328.s31|46-46|7|drug
DDI-DrugBank.d328.s31|48-51|days|drug
DDI-DrugBank.d328.s31|52-52|)|drug
DDI-DrugBank.d328.s31|54-57|with|drug
DDI-DrugBank.d328.s31|59-67|glyburide|drug
DDI-DrugBank.d328.s31|69-69|(|drug
DDI-DrugBank.d328.s31|70-70|5|drug
DDI-DrugBank.d328.s31|72-73|mg|drug
DDI-DrugBank.d328.s31|75-76|QD|drug
DDI-DrugBank.d328.s31|78-79|or|drug
DDI-DrugBank.d328.s31|81-82|10|drug
DDI-DrugBank.d328.s31|84-85|mg|drug
DDI-DrugBank.d328.s31|87-89|BID|drug
DDI-DrugBank.d328.s31|90-90|)|drug
DDI-DrugBank.d328.s31|92-94|did|drug
DDI-DrugBank.d328.s31|96-98|not|drug
DDI-DrugBank.d328.s31|100-105|affect|drug
DDI-DrugBank.d328.s31|107-109|the|drug
DDI-DrugBank.d328.s31|111-126|pharmacokinetics|drug
DDI-DrugBank.d328.s31|128-128|(|drug
DDI-DrugBank.d328.s31|129-136|exposure|drug
DDI-DrugBank.d328.s31|137-137|)|drug
DDI-DrugBank.d328.s31|139-140|of|drug
DDI-DrugBank.d328.s31|142-150|glyburide|drug
DDI-DrugBank.d328.s31|151-151|.|drug
DDI-DrugBank.d328.s32|0-15|Coadministration|drug
DDI-DrugBank.d328.s32|17-18|of|drug
DDI-DrugBank.d328.s32|20-29|valdecoxib|drug
DDI-DrugBank.d328.s32|31-31|(|drug
DDI-DrugBank.d328.s32|32-33|40|drug
DDI-DrugBank.d328.s32|35-36|mg|drug
DDI-DrugBank.d328.s32|38-40|BID|drug
DDI-DrugBank.d328.s32|42-42|(|drug
DDI-DrugBank.d328.s32|43-45|day|drug
DDI-DrugBank.d328.s32|47-47|1|drug
DDI-DrugBank.d328.s32|48-48|)|drug
DDI-DrugBank.d328.s32|50-52|and|drug
DDI-DrugBank.d328.s32|54-55|40|drug
DDI-DrugBank.d328.s32|57-58|mg|drug
DDI-DrugBank.d328.s32|60-61|QD|drug
DDI-DrugBank.d328.s32|63-63|(|drug
DDI-DrugBank.d328.s32|64-67|days|drug
DDI-DrugBank.d328.s32|69-71|2-7|drug
DDI-DrugBank.d328.s32|72-72|)|drug
DDI-DrugBank.d328.s32|73-73|)|drug
DDI-DrugBank.d328.s32|75-78|with|drug
DDI-DrugBank.d328.s32|80-88|glyburide|drug
DDI-DrugBank.d328.s32|90-90|(|drug
DDI-DrugBank.d328.s32|91-91|5|drug
DDI-DrugBank.d328.s32|93-94|mg|drug
DDI-DrugBank.d328.s32|96-97|QD|drug
DDI-DrugBank.d328.s32|98-98|)|drug
DDI-DrugBank.d328.s32|100-102|did|drug
DDI-DrugBank.d328.s32|104-106|not|drug
DDI-DrugBank.d328.s32|108-113|affect|drug
DDI-DrugBank.d328.s32|115-120|either|drug
DDI-DrugBank.d328.s32|122-124|the|drug
DDI-DrugBank.d328.s32|126-141|pharmacokinetics|drug
DDI-DrugBank.d328.s32|143-143|(|drug
DDI-DrugBank.d328.s32|144-151|exposure|drug
DDI-DrugBank.d328.s32|152-152|)|drug
DDI-DrugBank.d328.s32|154-155|or|drug
DDI-DrugBank.d328.s32|157-159|the|drug
DDI-DrugBank.d328.s32|161-176|pharmacodynamics|drug
DDI-DrugBank.d328.s32|178-178|(|drug
DDI-DrugBank.d328.s32|179-183|blood|drug
DDI-DrugBank.d328.s32|185-191|glucose|drug
DDI-DrugBank.d328.s32|193-195|and|drug
DDI-DrugBank.d328.s32|197-203|insulin|drug
DDI-DrugBank.d328.s32|205-210|levels|drug
DDI-DrugBank.d328.s32|211-211|)|drug
DDI-DrugBank.d328.s32|213-214|of|drug
DDI-DrugBank.d328.s32|216-224|glyburide|drug
DDI-DrugBank.d328.s32|225-225|.|drug
DDI-DrugBank.d328.s33|0-15|Coadministration|drug
DDI-DrugBank.d328.s33|17-18|of|drug
DDI-DrugBank.d328.s33|20-29|valdecoxib|drug
DDI-DrugBank.d328.s33|31-31|(|drug
DDI-DrugBank.d328.s33|32-33|40|drug
DDI-DrugBank.d328.s33|35-36|mg|drug
DDI-DrugBank.d328.s33|38-40|BID|drug
DDI-DrugBank.d328.s33|42-42|(|drug
DDI-DrugBank.d328.s33|43-45|day|drug
DDI-DrugBank.d328.s33|47-47|1|drug
DDI-DrugBank.d328.s33|48-48|)|drug
DDI-DrugBank.d328.s33|50-52|and|drug
DDI-DrugBank.d328.s33|54-55|40|drug
DDI-DrugBank.d328.s33|57-58|mg|drug
DDI-DrugBank.d328.s33|60-61|QD|drug
DDI-DrugBank.d328.s33|63-63|(|drug
DDI-DrugBank.d328.s33|64-67|days|drug
DDI-DrugBank.d328.s33|69-71|2-7|drug
DDI-DrugBank.d328.s33|72-72|)|drug
DDI-DrugBank.d328.s33|73-73|)|drug
DDI-DrugBank.d328.s33|75-78|with|drug
DDI-DrugBank.d328.s33|80-88|glyburide|drug
DDI-DrugBank.d328.s33|90-90|(|drug
DDI-DrugBank.d328.s33|91-92|10|drug
DDI-DrugBank.d328.s33|94-95|mg|drug
DDI-DrugBank.d328.s33|97-105|glyburide|drug
DDI-DrugBank.d328.s33|107-109|BID|drug
DDI-DrugBank.d328.s33|110-110|)|drug
DDI-DrugBank.d328.s33|112-119|resulted|drug
DDI-DrugBank.d328.s33|121-122|in|drug
DDI-DrugBank.d328.s33|124-125|21|drug
DDI-DrugBank.d328.s33|126-126|%|drug
DDI-DrugBank.d328.s33|128-135|increase|drug
DDI-DrugBank.d328.s33|137-138|in|drug
DDI-DrugBank.d328.s33|140-148|glyburide|drug
DDI-DrugBank.d328.s33|150-156|AUC0-12|drug
DDI-DrugBank.d328.s33|158-160|and|drug
DDI-DrugBank.d328.s33|162-162|a|drug
DDI-DrugBank.d328.s33|164-165|16|drug
DDI-DrugBank.d328.s33|166-166|%|drug
DDI-DrugBank.d328.s33|168-175|increase|drug
DDI-DrugBank.d328.s33|177-178|in|drug
DDI-DrugBank.d328.s33|180-188|glyburide|drug
DDI-DrugBank.d328.s33|190-193|Cmax|drug
DDI-DrugBank.d328.s33|195-201|leading|drug
DDI-DrugBank.d328.s33|203-204|to|drug
DDI-DrugBank.d328.s33|206-206|a|drug
DDI-DrugBank.d328.s33|208-209|16|drug
DDI-DrugBank.d328.s33|210-210|%|drug
DDI-DrugBank.d328.s33|212-219|decrease|drug
DDI-DrugBank.d328.s33|221-222|in|drug
DDI-DrugBank.d328.s33|224-230|glucose|drug
DDI-DrugBank.d328.s33|232-238|AUC0-24|drug
DDI-DrugBank.d328.s33|239-239|.|drug
DDI-DrugBank.d328.s34|0-6|Insulin|drug
DDI-DrugBank.d328.s34|8-17|parameters|drug
DDI-DrugBank.d328.s34|19-22|were|drug
DDI-DrugBank.d328.s34|24-26|not|drug
DDI-DrugBank.d328.s34|28-35|affected|drug
DDI-DrugBank.d328.s34|36-36|.|drug
DDI-DrugBank.d328.s35|0-6|Because|drug
DDI-DrugBank.d328.s35|8-14|changes|drug
DDI-DrugBank.d328.s35|16-17|in|drug
DDI-DrugBank.d328.s35|19-25|glucose|drug
DDI-DrugBank.d328.s35|27-40|concentrations|drug
DDI-DrugBank.d328.s35|42-45|with|drug
DDI-DrugBank.d328.s35|47-56|valdecoxib|drug
DDI-DrugBank.d328.s35|58-73|coadministration|drug
DDI-DrugBank.d328.s35|75-78|were|drug
DDI-DrugBank.d328.s35|80-85|within|drug
DDI-DrugBank.d328.s35|87-89|the|drug
DDI-DrugBank.d328.s35|91-96|normal|drug
DDI-DrugBank.d328.s35|98-108|variability|drug
DDI-DrugBank.d328.s35|110-112|and|drug
DDI-DrugBank.d328.s35|114-123|individual|drug
DDI-DrugBank.d328.s35|125-131|glucose|drug
DDI-DrugBank.d328.s35|133-146|concentrations|drug
DDI-DrugBank.d328.s35|148-151|were|drug
DDI-DrugBank.d328.s35|153-157|above|drug
DDI-DrugBank.d328.s35|159-160|or|drug
DDI-DrugBank.d328.s35|162-165|near|drug
DDI-DrugBank.d328.s35|167-168|70|drug
DDI-DrugBank.d328.s35|170-174|mg/dL|drug
DDI-DrugBank.d328.s35|175-175|,|drug
DDI-DrugBank.d328.s35|177-180|dose|drug
DDI-DrugBank.d328.s35|182-191|adjustment|drug
DDI-DrugBank.d328.s35|193-195|for|drug
DDI-DrugBank.d328.s35|197-205|glyburide|drug
DDI-DrugBank.d328.s35|207-207|(|drug
DDI-DrugBank.d328.s35|208-208|5|drug
DDI-DrugBank.d328.s35|210-211|mg|drug
DDI-DrugBank.d328.s35|213-214|QD|drug
DDI-DrugBank.d328.s35|216-218|and|drug
DDI-DrugBank.d328.s35|220-221|10|drug
DDI-DrugBank.d328.s35|223-224|mg|drug
DDI-DrugBank.d328.s35|226-228|BID|drug
DDI-DrugBank.d328.s35|229-229|)|drug
DDI-DrugBank.d328.s35|231-234|with|drug
DDI-DrugBank.d328.s35|236-245|valdecoxib|drug
DDI-DrugBank.d328.s35|247-262|coadministration|drug
DDI-DrugBank.d328.s35|264-264|(|drug
DDI-DrugBank.d328.s35|265-266|up|drug
DDI-DrugBank.d328.s35|268-269|to|drug
DDI-DrugBank.d328.s35|271-272|40|drug
DDI-DrugBank.d328.s35|274-275|mg|drug
DDI-DrugBank.d328.s35|277-278|QD|drug
DDI-DrugBank.d328.s35|279-279|)|drug
DDI-DrugBank.d328.s35|281-282|is|drug
DDI-DrugBank.d328.s35|284-286|not|drug
DDI-DrugBank.d328.s35|288-296|indicated|drug
DDI-DrugBank.d328.s35|297-297|.|drug
DDI-DrugBank.d328.s36|0-15|Coadministration|drug
DDI-DrugBank.d328.s36|17-18|of|drug
DDI-DrugBank.d328.s36|20-28|glyburide|drug
DDI-DrugBank.d328.s36|30-33|with|drug
DDI-DrugBank.d328.s36|35-39|doses|drug
DDI-DrugBank.d328.s36|41-46|higher|drug
DDI-DrugBank.d328.s36|48-51|than|drug
DDI-DrugBank.d328.s36|53-54|40|drug
DDI-DrugBank.d328.s36|56-57|mg|drug
DDI-DrugBank.d328.s36|59-68|valdecoxib|drug
DDI-DrugBank.d328.s36|70-70|(|drug
DDI-DrugBank.d328.s36|71-74|e.g.|drug
DDI-DrugBank.d328.s36|75-75|,|drug
DDI-DrugBank.d328.s36|77-78|40|drug
DDI-DrugBank.d328.s36|80-81|mg|drug
DDI-DrugBank.d328.s36|83-85|BID|drug
DDI-DrugBank.d328.s36|86-86|)|drug
DDI-DrugBank.d328.s36|88-91|have|drug
DDI-DrugBank.d328.s36|93-95|not|drug
DDI-DrugBank.d328.s36|97-100|been|drug
DDI-DrugBank.d328.s36|102-108|studied|drug
DDI-DrugBank.d328.s36|109-109|.|drug
DDI-DrugBank.d328.s37|0-9|Omeprazole|brand
DDI-DrugBank.d328.s37|10-10|:|drug
DDI-DrugBank.d328.s37|12-21|Omeprazole|brand
DDI-DrugBank.d328.s37|23-24|is|drug
DDI-DrugBank.d328.s37|26-26|a|drug
DDI-DrugBank.d328.s37|28-30|CYP|drug
DDI-DrugBank.d328.s37|32-34|3A4|drug
DDI-DrugBank.d328.s37|36-44|substrate|drug
DDI-DrugBank.d328.s37|46-48|and|drug
DDI-DrugBank.d328.s37|50-52|CYP|drug
DDI-DrugBank.d328.s37|54-57|2C19|drug
DDI-DrugBank.d328.s37|59-67|substrate|drug
DDI-DrugBank.d328.s37|69-71|and|drug
DDI-DrugBank.d328.s37|73-81|inhibitor|drug
DDI-DrugBank.d328.s37|82-82|.|drug
DDI-DrugBank.d328.s38|0-9|Valdecoxib|drug
DDI-DrugBank.d328.s38|11-16|steady|drug
DDI-DrugBank.d328.s38|18-22|state|drug
DDI-DrugBank.d328.s38|24-29|plasma|drug
DDI-DrugBank.d328.s38|31-44|concentrations|drug
DDI-DrugBank.d328.s38|46-46|(|drug
DDI-DrugBank.d328.s38|47-48|40|drug
DDI-DrugBank.d328.s38|50-51|mg|drug
DDI-DrugBank.d328.s38|53-55|BID|drug
DDI-DrugBank.d328.s38|56-56|)|drug
DDI-DrugBank.d328.s38|58-61|were|drug
DDI-DrugBank.d328.s38|63-65|not|drug
DDI-DrugBank.d328.s38|67-74|affected|drug
DDI-DrugBank.d328.s38|76-88|significantly|drug
DDI-DrugBank.d328.s38|90-93|with|drug
DDI-DrugBank.d328.s38|95-102|multiple|drug
DDI-DrugBank.d328.s38|104-108|doses|drug
DDI-DrugBank.d328.s38|110-111|of|drug
DDI-DrugBank.d328.s38|113-122|omeprazole|drug
DDI-DrugBank.d328.s38|124-124|(|drug
DDI-DrugBank.d328.s38|125-126|40|drug
DDI-DrugBank.d328.s38|128-129|mg|drug
DDI-DrugBank.d328.s38|131-132|QD|drug
DDI-DrugBank.d328.s38|133-133|)|drug
DDI-DrugBank.d328.s38|134-134|.|drug
DDI-DrugBank.d328.s39|0-15|Coadministration|drug
DDI-DrugBank.d328.s39|17-20|with|drug
DDI-DrugBank.d328.s39|22-31|valdecoxib|drug
DDI-DrugBank.d328.s39|33-41|increased|drug
DDI-DrugBank.d328.s39|43-50|exposure|drug
DDI-DrugBank.d328.s39|52-53|of|drug
DDI-DrugBank.d328.s39|55-64|omeprazole|drug
DDI-DrugBank.d328.s39|66-66|(|drug
DDI-DrugBank.d328.s39|67-69|AUC|drug
DDI-DrugBank.d328.s39|70-70|)|drug
DDI-DrugBank.d328.s39|72-73|by|drug
DDI-DrugBank.d328.s39|75-76|46|drug
DDI-DrugBank.d328.s39|77-77|%|drug
DDI-DrugBank.d328.s39|78-78|.|drug
DDI-DrugBank.d328.s40|0-4|Drugs|drug
DDI-DrugBank.d328.s40|6-10|whose|drug
DDI-DrugBank.d328.s40|12-21|absorption|drug
DDI-DrugBank.d328.s40|23-24|is|drug
DDI-DrugBank.d328.s40|26-34|sensitive|drug
DDI-DrugBank.d328.s40|36-37|to|drug
DDI-DrugBank.d328.s40|39-40|pH|drug
DDI-DrugBank.d328.s40|42-44|may|drug
DDI-DrugBank.d328.s40|46-47|be|drug
DDI-DrugBank.d328.s40|49-58|negatively|drug
DDI-DrugBank.d328.s40|60-67|impacted|drug
DDI-DrugBank.d328.s40|69-70|by|drug
DDI-DrugBank.d328.s40|72-82|concomitant|drug
DDI-DrugBank.d328.s40|84-97|administration|drug
DDI-DrugBank.d328.s40|99-100|of|drug
DDI-DrugBank.d328.s40|102-111|omeprazole|drug
DDI-DrugBank.d328.s40|113-115|and|drug
DDI-DrugBank.d328.s40|117-126|valdecoxib|drug
DDI-DrugBank.d328.s40|127-127|.|drug
DDI-DrugBank.d328.s41|0-6|However|drug
DDI-DrugBank.d328.s41|7-7|,|drug
DDI-DrugBank.d328.s41|9-15|because|drug
DDI-DrugBank.d328.s41|17-22|higher|drug
DDI-DrugBank.d328.s41|24-28|doses|drug
DDI-DrugBank.d328.s41|30-30|(|drug
DDI-DrugBank.d328.s41|31-32|up|drug
DDI-DrugBank.d328.s41|34-35|to|drug
DDI-DrugBank.d328.s41|37-39|360|drug
DDI-DrugBank.d328.s41|41-42|mg|drug
DDI-DrugBank.d328.s41|44-45|QD|drug
DDI-DrugBank.d328.s41|46-46|)|drug
DDI-DrugBank.d328.s41|48-49|of|drug
DDI-DrugBank.d328.s41|51-60|omeprazole|drug
DDI-DrugBank.d328.s41|62-64|are|drug
DDI-DrugBank.d328.s41|66-74|tolerated|drug
DDI-DrugBank.d328.s41|76-77|in|drug
DDI-DrugBank.d328.s41|79-95|Zollinger-Ellison|drug
DDI-DrugBank.d328.s41|97-97|(|drug
DDI-DrugBank.d328.s41|98-99|ZE|drug
DDI-DrugBank.d328.s41|100-100|)|drug
DDI-DrugBank.d328.s41|102-109|patients|drug
DDI-DrugBank.d328.s41|110-110|,|drug
DDI-DrugBank.d328.s41|112-113|no|drug
DDI-DrugBank.d328.s41|115-118|dose|drug
DDI-DrugBank.d328.s41|120-129|adjustment|drug
DDI-DrugBank.d328.s41|131-133|for|drug
DDI-DrugBank.d328.s41|135-144|omeprazole|drug
DDI-DrugBank.d328.s41|146-147|is|drug
DDI-DrugBank.d328.s41|149-159|recommended|drug
DDI-DrugBank.d328.s41|161-162|at|drug
DDI-DrugBank.d328.s41|164-170|current|drug
DDI-DrugBank.d328.s41|172-176|doses|drug
DDI-DrugBank.d328.s41|177-177|.|drug
DDI-DrugBank.d328.s42|0-15|Coadministration|drug
DDI-DrugBank.d328.s42|17-18|of|drug
DDI-DrugBank.d328.s42|20-29|valdecoxib|drug
DDI-DrugBank.d328.s42|31-34|with|drug
DDI-DrugBank.d328.s42|36-40|doses|drug
DDI-DrugBank.d328.s42|42-47|higher|drug
DDI-DrugBank.d328.s42|49-52|than|drug
DDI-DrugBank.d328.s42|54-55|40|drug
DDI-DrugBank.d328.s42|57-58|mg|drug
DDI-DrugBank.d328.s42|60-61|QD|drug
DDI-DrugBank.d328.s42|63-72|omeprazole|drug
DDI-DrugBank.d328.s42|74-76|has|drug
DDI-DrugBank.d328.s42|78-80|not|drug
DDI-DrugBank.d328.s42|82-85|been|drug
DDI-DrugBank.d328.s42|87-93|studied|drug
DDI-DrugBank.d328.s42|94-94|.|drug
DDI-DrugBank.d328.s43|0-3|Oral|drug
DDI-DrugBank.d328.s43|5-18|Contraceptives|drug
DDI-DrugBank.d328.s43|19-19|:|drug
DDI-DrugBank.d328.s43|21-30|Valdecoxib|drug
DDI-DrugBank.d328.s43|32-32|(|drug
DDI-DrugBank.d328.s43|33-34|40|drug
DDI-DrugBank.d328.s43|36-37|mg|drug
DDI-DrugBank.d328.s43|39-41|BID|drug
DDI-DrugBank.d328.s43|42-42|)|drug
DDI-DrugBank.d328.s43|44-46|did|drug
DDI-DrugBank.d328.s43|48-50|not|drug
DDI-DrugBank.d328.s43|52-57|induce|drug
DDI-DrugBank.d328.s43|59-61|the|drug
DDI-DrugBank.d328.s43|63-72|metabolism|drug
DDI-DrugBank.d328.s43|74-75|of|drug
DDI-DrugBank.d328.s43|77-79|the|drug
DDI-DrugBank.d328.s43|81-91|combination|drug
DDI-DrugBank.d328.s43|93-96|oral|drug
DDI-DrugBank.d328.s43|98-110|contraceptive|drug
DDI-DrugBank.d328.s43|112-132|norethindrone/ethinyl|drug
DDI-DrugBank.d328.s43|134-142|estradiol|drug
DDI-DrugBank.d328.s43|144-144|(|drug
DDI-DrugBank.d328.s43|145-145|1|drug
DDI-DrugBank.d328.s43|147-148|mg|drug
DDI-DrugBank.d328.s43|150-152|/35|drug
DDI-DrugBank.d328.s43|154-156|mcg|drug
DDI-DrugBank.d328.s43|158-168|combination|drug
DDI-DrugBank.d328.s43|169-169|,|drug
DDI-DrugBank.d328.s43|171-181|Ortho-Novum|drug
DDI-DrugBank.d328.s43|183-186|1/35|drug
DDI-DrugBank.d328.s43|188-188|)|drug
DDI-DrugBank.d328.s43|189-189|.|drug
DDI-DrugBank.d328.s44|0-15|Coadministration|drug
DDI-DrugBank.d328.s44|17-18|of|drug
DDI-DrugBank.d328.s44|20-29|valdecoxib|drug
DDI-DrugBank.d328.s44|31-33|and|drug
DDI-DrugBank.d328.s44|35-45|Ortho-Novum|drug
DDI-DrugBank.d328.s44|47-50|1/35|drug
DDI-DrugBank.d328.s44|53-61|increased|drug
DDI-DrugBank.d328.s44|63-65|the|drug
DDI-DrugBank.d328.s44|67-74|exposure|drug
DDI-DrugBank.d328.s44|76-77|of|drug
DDI-DrugBank.d328.s44|79-91|norethindrone|drug
DDI-DrugBank.d328.s44|93-95|and|drug
DDI-DrugBank.d328.s44|97-103|ethinyl|drug
DDI-DrugBank.d328.s44|105-113|estradiol|drug
DDI-DrugBank.d328.s44|115-116|by|drug
DDI-DrugBank.d328.s44|118-119|20|drug
DDI-DrugBank.d328.s44|120-120|%|drug
DDI-DrugBank.d328.s44|122-124|and|drug
DDI-DrugBank.d328.s44|126-127|34|drug
DDI-DrugBank.d328.s44|128-128|%|drug
DDI-DrugBank.d328.s44|129-129|,|drug
DDI-DrugBank.d328.s44|131-142|respectively|drug
DDI-DrugBank.d328.s44|143-143|.|drug
DDI-DrugBank.d328.s45|0-7|Although|drug
DDI-DrugBank.d328.s45|9-13|there|drug
DDI-DrugBank.d328.s45|15-16|is|drug
DDI-DrugBank.d328.s45|18-23|little|drug
DDI-DrugBank.d328.s45|25-28|risk|drug
DDI-DrugBank.d328.s45|30-32|for|drug
DDI-DrugBank.d328.s45|34-37|loss|drug
DDI-DrugBank.d328.s45|39-40|of|drug
DDI-DrugBank.d328.s45|42-54|contraceptive|drug
DDI-DrugBank.d328.s45|56-63|efficacy|drug
DDI-DrugBank.d328.s45|64-64|,|drug
DDI-DrugBank.d328.s45|66-68|the|drug
DDI-DrugBank.d328.s45|70-77|clinical|drug
DDI-DrugBank.d328.s45|79-90|significance|drug
DDI-DrugBank.d328.s45|92-93|of|drug
DDI-DrugBank.d328.s45|95-99|these|drug
DDI-DrugBank.d328.s45|101-109|increased|drug
DDI-DrugBank.d328.s45|111-119|exposures|drug
DDI-DrugBank.d328.s45|121-122|in|drug
DDI-DrugBank.d328.s45|124-128|terms|drug
DDI-DrugBank.d328.s45|130-131|of|drug
DDI-DrugBank.d328.s45|133-138|safety|drug
DDI-DrugBank.d328.s45|140-141|is|drug
DDI-DrugBank.d328.s45|143-145|not|drug
DDI-DrugBank.d328.s45|147-151|known|drug
DDI-DrugBank.d328.s45|152-152|.|drug
DDI-DrugBank.d328.s46|0-4|These|drug
DDI-DrugBank.d328.s46|6-14|increased|drug
DDI-DrugBank.d328.s46|16-24|exposures|drug
DDI-DrugBank.d328.s46|26-27|of|drug
DDI-DrugBank.d328.s46|29-41|norethindrone|drug
DDI-DrugBank.d328.s46|43-45|and|drug
DDI-DrugBank.d328.s46|47-53|ethinyl|drug
DDI-DrugBank.d328.s46|55-63|estradiol|drug
DDI-DrugBank.d328.s46|65-70|should|drug
DDI-DrugBank.d328.s46|72-73|be|drug
DDI-DrugBank.d328.s46|75-79|taken|drug
DDI-DrugBank.d328.s46|81-84|into|drug
DDI-DrugBank.d328.s46|86-98|consideration|drug
DDI-DrugBank.d328.s46|100-103|when|drug
DDI-DrugBank.d328.s46|105-113|selecting|drug
DDI-DrugBank.d328.s46|115-116|an|drug
DDI-DrugBank.d328.s46|118-121|oral|drug
DDI-DrugBank.d328.s46|123-135|contraceptive|drug
DDI-DrugBank.d328.s46|137-139|for|drug
DDI-DrugBank.d328.s46|141-145|women|drug
DDI-DrugBank.d328.s46|147-152|taking|drug
DDI-DrugBank.d328.s46|154-163|valdecoxib|drug
DDI-DrugBank.d328.s46|164-164|.|drug
DDI-DrugBank.d328.s47|0-7|Diazepam|brand
DDI-DrugBank.d328.s47|8-8|:|drug
DDI-DrugBank.d328.s47|10-17|Diazepam|brand
DDI-DrugBank.d328.s47|19-19|(|drug
DDI-DrugBank.d328.s47|20-25|Valium|brand
DDI-DrugBank.d328.s47|26-26|)|drug
DDI-DrugBank.d328.s47|28-29|is|drug
DDI-DrugBank.d328.s47|31-31|a|drug
DDI-DrugBank.d328.s47|33-35|CYP|drug
DDI-DrugBank.d328.s47|37-39|3A4|drug
DDI-DrugBank.d328.s47|41-43|and|drug
DDI-DrugBank.d328.s47|45-47|CYP|drug
DDI-DrugBank.d328.s47|49-52|2C19|drug
DDI-DrugBank.d328.s47|54-62|substrate|drug
DDI-DrugBank.d328.s47|63-63|.|drug
DDI-DrugBank.d328.s48|0-5|Plasma|drug
DDI-DrugBank.d328.s48|7-14|exposure|drug
DDI-DrugBank.d328.s48|16-17|of|drug
DDI-DrugBank.d328.s48|19-26|diazepam|drug
DDI-DrugBank.d328.s48|28-28|(|drug
DDI-DrugBank.d328.s48|29-30|10|drug
DDI-DrugBank.d328.s48|32-33|mg|drug
DDI-DrugBank.d328.s48|35-37|BID|drug
DDI-DrugBank.d328.s48|38-38|)|drug
DDI-DrugBank.d328.s48|40-42|was|drug
DDI-DrugBank.d328.s48|44-52|increased|drug
DDI-DrugBank.d328.s48|54-55|by|drug
DDI-DrugBank.d328.s48|57-58|28|drug
DDI-DrugBank.d328.s48|59-59|%|drug
DDI-DrugBank.d328.s48|61-69|following|drug
DDI-DrugBank.d328.s48|71-84|administration|drug
DDI-DrugBank.d328.s48|86-87|of|drug
DDI-DrugBank.d328.s48|89-98|valdecoxib|drug
DDI-DrugBank.d328.s48|100-100|(|drug
DDI-DrugBank.d328.s48|101-102|40|drug
DDI-DrugBank.d328.s48|104-105|mg|drug
DDI-DrugBank.d328.s48|107-109|BID|drug
DDI-DrugBank.d328.s48|110-110|)|drug
DDI-DrugBank.d328.s48|112-114|for|drug
DDI-DrugBank.d328.s48|116-117|12|drug
DDI-DrugBank.d328.s48|119-122|days|drug
DDI-DrugBank.d328.s48|123-123|,|drug
DDI-DrugBank.d328.s48|125-129|while|drug
DDI-DrugBank.d328.s48|131-136|plasma|drug
DDI-DrugBank.d328.s48|138-145|exposure|drug
DDI-DrugBank.d328.s48|147-148|of|drug
DDI-DrugBank.d328.s48|150-159|valdecoxib|drug
DDI-DrugBank.d328.s48|161-161|(|drug
DDI-DrugBank.d328.s48|162-163|40|drug
DDI-DrugBank.d328.s48|165-166|mg|drug
DDI-DrugBank.d328.s48|168-170|BID|drug
DDI-DrugBank.d328.s48|171-171|)|drug
DDI-DrugBank.d328.s48|173-175|was|drug
DDI-DrugBank.d328.s48|177-179|not|drug
DDI-DrugBank.d328.s48|181-193|substantially|drug
DDI-DrugBank.d328.s48|195-203|increased|drug
DDI-DrugBank.d328.s48|205-213|following|drug
DDI-DrugBank.d328.s48|215-228|administration|drug
DDI-DrugBank.d328.s48|230-231|of|drug
DDI-DrugBank.d328.s48|233-240|diazepam|drug
DDI-DrugBank.d328.s48|242-242|(|drug
DDI-DrugBank.d328.s48|243-244|10|drug
DDI-DrugBank.d328.s48|246-247|mg|drug
DDI-DrugBank.d328.s48|249-251|BID|drug
DDI-DrugBank.d328.s48|252-252|)|drug
DDI-DrugBank.d328.s48|254-256|for|drug
DDI-DrugBank.d328.s48|258-259|12|drug
DDI-DrugBank.d328.s48|261-264|days|drug
DDI-DrugBank.d328.s48|265-265|.|drug
DDI-DrugBank.d328.s49|0-7|Although|drug
DDI-DrugBank.d328.s49|9-11|the|drug
DDI-DrugBank.d328.s49|13-21|magnitude|drug
DDI-DrugBank.d328.s49|23-24|of|drug
DDI-DrugBank.d328.s49|26-32|changes|drug
DDI-DrugBank.d328.s49|34-35|in|drug
DDI-DrugBank.d328.s49|37-44|diazepam|drug
DDI-DrugBank.d328.s49|46-51|plasma|drug
DDI-DrugBank.d328.s49|53-60|exposure|drug
DDI-DrugBank.d328.s49|62-65|when|drug
DDI-DrugBank.d328.s49|67-80|coadministered|drug
DDI-DrugBank.d328.s49|82-85|with|drug
DDI-DrugBank.d328.s49|87-96|valdecoxib|drug
DDI-DrugBank.d328.s49|98-101|were|drug
DDI-DrugBank.d328.s49|103-105|not|drug
DDI-DrugBank.d328.s49|107-116|sufficient|drug
DDI-DrugBank.d328.s49|118-119|to|drug
DDI-DrugBank.d328.s49|121-127|warrant|drug
DDI-DrugBank.d328.s49|129-134|dosage|drug
DDI-DrugBank.d328.s49|136-146|adjustments|drug
DDI-DrugBank.d328.s49|147-147|,|drug
DDI-DrugBank.d328.s49|149-156|patients|drug
DDI-DrugBank.d328.s49|158-160|may|drug
DDI-DrugBank.d328.s49|162-171|experience|drug
DDI-DrugBank.d328.s49|173-180|enhanced|drug
DDI-DrugBank.d328.s49|182-189|sedative|drug
DDI-DrugBank.d328.s49|191-194|side|drug
DDI-DrugBank.d328.s49|196-202|effects|drug
DDI-DrugBank.d328.s49|204-209|caused|drug
DDI-DrugBank.d328.s49|211-212|by|drug
DDI-DrugBank.d328.s49|214-222|increased|drug
DDI-DrugBank.d328.s49|224-231|exposure|drug
DDI-DrugBank.d328.s49|233-234|of|drug
DDI-DrugBank.d328.s49|236-243|diazepam|drug
DDI-DrugBank.d328.s49|245-249|under|drug
DDI-DrugBank.d328.s49|251-254|this|drug
DDI-DrugBank.d328.s49|256-267|circumstance|drug
DDI-DrugBank.d328.s49|268-268|.|drug
DDI-DrugBank.d328.s50|0-7|Patients|drug
DDI-DrugBank.d328.s50|9-14|should|drug
DDI-DrugBank.d328.s50|16-17|be|drug
DDI-DrugBank.d328.s50|19-27|cautioned|drug
DDI-DrugBank.d328.s50|29-35|against|drug
DDI-DrugBank.d328.s50|37-44|engaging|drug
DDI-DrugBank.d328.s50|46-47|in|drug
DDI-DrugBank.d328.s50|49-57|hazardous|drug
DDI-DrugBank.d328.s50|59-68|activities|drug
DDI-DrugBank.d328.s50|70-78|requiring|drug
DDI-DrugBank.d328.s50|80-87|complete|drug
DDI-DrugBank.d328.s50|89-94|mental|drug
DDI-DrugBank.d328.s50|96-104|alertness|drug
DDI-DrugBank.d328.s50|106-109|such|drug
DDI-DrugBank.d328.s50|111-112|as|drug
DDI-DrugBank.d328.s50|114-122|operating|drug
DDI-DrugBank.d328.s50|124-132|machinery|drug
DDI-DrugBank.d328.s50|134-135|or|drug
DDI-DrugBank.d328.s50|137-143|driving|drug
DDI-DrugBank.d328.s50|145-145|a|drug
DDI-DrugBank.d328.s50|147-151|motor|drug
DDI-DrugBank.d328.s50|153-159|vehicle|drug
DDI-DrugBank.d328.s50|160-160|.|drug
DDI-DrugBank.d69.s0|0-2|Use|drug
DDI-DrugBank.d69.s0|4-5|of|drug
DDI-DrugBank.d69.s0|7-16|Cerubidine|brand
DDI-DrugBank.d69.s0|18-19|in|drug
DDI-DrugBank.d69.s0|21-21|a|drug
DDI-DrugBank.d69.s0|23-29|patient|drug
DDI-DrugBank.d69.s0|31-33|who|drug
DDI-DrugBank.d69.s0|35-37|has|drug
DDI-DrugBank.d69.s0|39-48|previously|drug
DDI-DrugBank.d69.s0|50-57|received|drug
DDI-DrugBank.d69.s0|59-69|doxorubicin|drug
DDI-DrugBank.d69.s0|71-79|increases|drug
DDI-DrugBank.d69.s0|81-83|the|drug
DDI-DrugBank.d69.s0|85-88|risk|drug
DDI-DrugBank.d69.s0|90-91|of|drug
DDI-DrugBank.d69.s0|93-106|cardiotoxicity|drug
DDI-DrugBank.d69.s0|107-107|.|drug
DDI-DrugBank.d69.s1|0-9|Cerubidine|brand
DDI-DrugBank.d69.s1|11-16|should|drug
DDI-DrugBank.d69.s1|18-20|not|drug
DDI-DrugBank.d69.s1|22-23|be|drug
DDI-DrugBank.d69.s1|25-28|used|drug
DDI-DrugBank.d69.s1|30-31|in|drug
DDI-DrugBank.d69.s1|33-40|patients|drug
DDI-DrugBank.d69.s1|42-44|who|drug
DDI-DrugBank.d69.s1|46-49|have|drug
DDI-DrugBank.d69.s1|51-60|previously|drug
DDI-DrugBank.d69.s1|62-69|received|drug
DDI-DrugBank.d69.s1|71-73|the|drug
DDI-DrugBank.d69.s1|75-85|recommended|drug
DDI-DrugBank.d69.s1|87-93|maximum|drug
DDI-DrugBank.d69.s1|95-104|cumulative|drug
DDI-DrugBank.d69.s1|106-110|doses|drug
DDI-DrugBank.d69.s1|112-113|of|drug
DDI-DrugBank.d69.s1|115-125|doxorubicin|drug
DDI-DrugBank.d69.s1|127-128|or|drug
DDI-DrugBank.d69.s1|130-139|Cerubidine|brand
DDI-DrugBank.d69.s1|140-140|.|drug
DDI-DrugBank.d69.s2|0-15|Cyclophosphamide|brand
DDI-DrugBank.d69.s2|17-20|used|drug
DDI-DrugBank.d69.s2|22-33|concurrently|drug
DDI-DrugBank.d69.s2|35-38|with|drug
DDI-DrugBank.d69.s2|40-49|Cerubidine|brand
DDI-DrugBank.d69.s2|51-53|may|drug
DDI-DrugBank.d69.s2|55-58|also|drug
DDI-DrugBank.d69.s2|60-65|result|drug
DDI-DrugBank.d69.s2|67-68|in|drug
DDI-DrugBank.d69.s2|70-78|increased|drug
DDI-DrugBank.d69.s2|80-93|cardiotoxicity|drug
DDI-DrugBank.d69.s2|94-94|.|drug
DDI-DrugBank.d69.s3|0-5|Dosage|drug
DDI-DrugBank.d69.s3|7-15|reduction|drug
DDI-DrugBank.d69.s3|17-18|of|drug
DDI-DrugBank.d69.s3|20-29|Cerubidine|brand
DDI-DrugBank.d69.s3|31-33|may|drug
DDI-DrugBank.d69.s3|35-36|be|drug
DDI-DrugBank.d69.s3|38-45|required|drug
DDI-DrugBank.d69.s3|47-50|when|drug
DDI-DrugBank.d69.s3|52-55|used|drug
DDI-DrugBank.d69.s3|57-68|concurrently|drug
DDI-DrugBank.d69.s3|70-73|with|drug
DDI-DrugBank.d69.s3|75-79|other|drug
DDI-DrugBank.d69.s3|81-96|myelosuppressive|drug
DDI-DrugBank.d69.s3|98-103|agents|drug
DDI-DrugBank.d69.s3|104-104|.|drug
DDI-DrugBank.d69.s4|0-10|Hepatotoxic|drug
DDI-DrugBank.d69.s4|12-22|medications|drug
DDI-DrugBank.d69.s4|23-23|,|drug
DDI-DrugBank.d69.s4|25-28|such|drug
DDI-DrugBank.d69.s4|30-31|as|drug
DDI-DrugBank.d69.s4|33-41|high-dose|drug
DDI-DrugBank.d69.s4|43-54|methotrexate|drug
DDI-DrugBank.d69.s4|55-55|,|drug
DDI-DrugBank.d69.s4|57-59|may|drug
DDI-DrugBank.d69.s4|61-66|impair|drug
DDI-DrugBank.d69.s4|68-72|liver|drug
DDI-DrugBank.d69.s4|74-81|function|drug
DDI-DrugBank.d69.s4|83-85|and|drug
DDI-DrugBank.d69.s4|87-94|increase|drug
DDI-DrugBank.d69.s4|96-98|the|drug
DDI-DrugBank.d69.s4|100-103|risk|drug
DDI-DrugBank.d69.s4|105-106|of|drug
DDI-DrugBank.d69.s4|108-115|toxicity|drug
DDI-DrugBank.d69.s4|116-116|.|drug
DDI-DrugBank.d19.s0|0-9|Disulfiram|brand
DDI-DrugBank.d19.s0|11-17|appears|drug
DDI-DrugBank.d19.s0|19-20|to|drug
DDI-DrugBank.d19.s0|22-29|decrease|drug
DDI-DrugBank.d19.s0|31-33|the|drug
DDI-DrugBank.d19.s0|35-38|rate|drug
DDI-DrugBank.d19.s0|40-41|at|drug
DDI-DrugBank.d19.s0|43-47|which|drug
DDI-DrugBank.d19.s0|49-55|certain|drug
DDI-DrugBank.d19.s0|57-61|drugs|drug
DDI-DrugBank.d19.s0|63-65|are|drug
DDI-DrugBank.d19.s0|67-77|metabolized|drug
DDI-DrugBank.d19.s0|79-81|and|drug
DDI-DrugBank.d19.s0|83-91|therefore|drug
DDI-DrugBank.d19.s0|93-95|may|drug
DDI-DrugBank.d19.s0|97-104|increase|drug
DDI-DrugBank.d19.s0|106-108|the|drug
DDI-DrugBank.d19.s0|110-114|blood|drug
DDI-DrugBank.d19.s0|116-121|levels|drug
DDI-DrugBank.d19.s0|123-125|and|drug
DDI-DrugBank.d19.s0|127-129|the|drug
DDI-DrugBank.d19.s0|131-141|possibility|drug
DDI-DrugBank.d19.s0|143-144|of|drug
DDI-DrugBank.d19.s0|146-153|clinical|drug
DDI-DrugBank.d19.s0|155-162|toxicity|drug
DDI-DrugBank.d19.s0|164-165|of|drug
DDI-DrugBank.d19.s0|167-171|drugs|drug
DDI-DrugBank.d19.s0|173-177|given|drug
DDI-DrugBank.d19.s0|179-191|concomitantly|drug
DDI-DrugBank.d19.s0|192-192|.|drug
DDI-DrugBank.d19.s1|0-9|DISULFIRAM|drug
DDI-DrugBank.d19.s1|11-16|SHOULD|drug
DDI-DrugBank.d19.s1|18-19|BE|drug
DDI-DrugBank.d19.s1|21-24|USED|drug
DDI-DrugBank.d19.s1|26-29|WITH|drug
DDI-DrugBank.d19.s1|31-37|CAUTION|drug
DDI-DrugBank.d19.s1|39-40|IN|drug
DDI-DrugBank.d19.s1|42-46|THOSE|drug
DDI-DrugBank.d19.s1|48-55|PATIENTS|drug
DDI-DrugBank.d19.s1|57-65|REVEIVING|drug
DDI-DrugBank.d19.s1|67-75|PHENYTOIN|drug
DDI-DrugBank.d19.s1|77-79|AND|drug
DDI-DrugBank.d19.s1|81-83|ITS|drug
DDI-DrugBank.d19.s1|85-93|CONGENERS|drug
DDI-DrugBank.d19.s1|94-94|.|drug
DDI-DrugBank.d19.s2|0-4|SINCE|drug
DDI-DrugBank.d19.s2|6-8|THE|drug
DDI-DrugBank.d19.s2|10-20|CONCOMITANT|drug
DDI-DrugBank.d19.s2|22-35|ADMINISTRATION|drug
DDI-DrugBank.d19.s2|37-38|OF|drug
DDI-DrugBank.d19.s2|40-44|THESE|drug
DDI-DrugBank.d19.s2|46-48|TWO|drug
DDI-DrugBank.d19.s2|50-54|DRUGS|drug
DDI-DrugBank.d19.s2|56-58|CAN|drug
DDI-DrugBank.d19.s2|60-63|LEAD|drug
DDI-DrugBank.d19.s2|65-66|TO|drug
DDI-DrugBank.d19.s2|68-76|PHENYTOIN|drug
DDI-DrugBank.d19.s2|78-89|INTOXICATION|drug
DDI-DrugBank.d19.s2|90-90|,|drug
DDI-DrugBank.d19.s2|92-96|PRIOR|drug
DDI-DrugBank.d19.s2|98-99|TO|drug
DDI-DrugBank.d19.s2|101-113|ADMINISTERING|drug
DDI-DrugBank.d19.s2|115-124|DISULFIRAM|drug
DDI-DrugBank.d19.s2|126-127|TO|drug
DDI-DrugBank.d19.s2|129-129|A|drug
DDI-DrugBank.d19.s2|131-137|PATIENT|drug
DDI-DrugBank.d19.s2|139-140|ON|drug
DDI-DrugBank.d19.s2|142-150|PHENYTOIN|drug
DDI-DrugBank.d19.s2|152-158|THERAPY|drug
DDI-DrugBank.d19.s2|159-159|,|drug
DDI-DrugBank.d19.s2|161-161|A|drug
DDI-DrugBank.d19.s2|163-170|BASELINE|drug
DDI-DrugBank.d19.s2|172-180|PHENYTOIN|drug
DDI-DrugBank.d19.s2|182-186|SERUM|drug
DDI-DrugBank.d19.s2|188-192|LEVEL|drug
DDI-DrugBank.d19.s2|194-199|SHOULD|drug
DDI-DrugBank.d19.s2|201-202|BE|drug
DDI-DrugBank.d19.s2|204-211|OBTAINED|drug
DDI-DrugBank.d19.s2|212-212|.|drug
DDI-DrugBank.d19.s3|0-9|SUBSEQUENT|drug
DDI-DrugBank.d19.s3|11-12|TO|drug
DDI-DrugBank.d19.s3|14-23|INITIATION|drug
DDI-DrugBank.d19.s3|25-26|OF|drug
DDI-DrugBank.d19.s3|28-37|DISULFIRAM|drug
DDI-DrugBank.d19.s3|39-45|THERAPY|drug
DDI-DrugBank.d19.s3|46-46|.|drug
DDI-DrugBank.d19.s4|0-4|SERUM|drug
DDI-DrugBank.d19.s4|6-11|LEVELS|drug
DDI-DrugBank.d19.s4|13-14|OF|drug
DDI-DrugBank.d19.s4|16-24|PHENYTOIN|drug
DDI-DrugBank.d19.s4|26-31|SHOULD|drug
DDI-DrugBank.d19.s4|33-34|BE|drug
DDI-DrugBank.d19.s4|36-45|DETERMINED|drug
DDI-DrugBank.d19.s4|47-48|ON|drug
DDI-DrugBank.d19.s4|50-58|DIFFERENT|drug
DDI-DrugBank.d19.s4|60-63|DAYS|drug
DDI-DrugBank.d19.s4|65-67|FOR|drug
DDI-DrugBank.d19.s4|69-76|EVIDENCE|drug
DDI-DrugBank.d19.s4|78-79|OF|drug
DDI-DrugBank.d19.s4|81-82|AN|drug
DDI-DrugBank.d19.s4|84-91|INCREASE|drug
DDI-DrugBank.d19.s4|93-94|OR|drug
DDI-DrugBank.d19.s4|96-98|FOR|drug
DDI-DrugBank.d19.s4|100-100|A|drug
DDI-DrugBank.d19.s4|102-111|CONTINUING|drug
DDI-DrugBank.d19.s4|113-116|RISE|drug
DDI-DrugBank.d19.s4|118-119|IN|drug
DDI-DrugBank.d19.s4|121-126|LEVELS|drug
DDI-DrugBank.d19.s4|127-127|.|drug
DDI-DrugBank.d19.s5|0-8|INCREASED|drug
DDI-DrugBank.d19.s5|10-18|PHENYTOIN|drug
DDI-DrugBank.d19.s5|20-25|LEVELS|drug
DDI-DrugBank.d19.s5|27-32|SHOULD|drug
DDI-DrugBank.d19.s5|34-35|BE|drug
DDI-DrugBank.d19.s5|37-43|TREATED|drug
DDI-DrugBank.d19.s5|45-48|WITH|drug
DDI-DrugBank.d19.s5|50-60|APPROPRIATE|drug
DDI-DrugBank.d19.s5|62-67|DOSAGE|drug
DDI-DrugBank.d19.s5|69-78|ADJUSTMENT|drug
DDI-DrugBank.d19.s5|79-79|.|drug
DDI-DrugBank.d19.s6|0-1|It|drug
DDI-DrugBank.d19.s6|3-5|may|drug
DDI-DrugBank.d19.s6|7-8|be|drug
DDI-DrugBank.d19.s6|10-18|necessary|drug
DDI-DrugBank.d19.s6|20-21|to|drug
DDI-DrugBank.d19.s6|23-28|adjust|drug
DDI-DrugBank.d19.s6|30-32|the|drug
DDI-DrugBank.d19.s6|34-39|dosage|drug
DDI-DrugBank.d19.s6|41-42|of|drug
DDI-DrugBank.d19.s6|44-47|oral|drug
DDI-DrugBank.d19.s6|49-62|anticoagulants|drug
DDI-DrugBank.d19.s6|64-67|upon|drug
DDI-DrugBank.d19.s6|69-77|beginning|drug
DDI-DrugBank.d19.s6|79-80|or|drug
DDI-DrugBank.d19.s6|82-89|stopping|drug
DDI-DrugBank.d19.s6|91-101|disulfiram|drug
DDI-DrugBank.d19.s6|103-107|.|drug
DDI-DrugBank.d19.s6|109-118|since|drug
DDI-DrugBank.d19.s6|120-122|disulfiram|drug
DDI-DrugBank.d19.s6|124-130|may|drug
DDI-DrugBank.d19.s6|132-142|prolong|drug
DDI-DrugBank.d19.s6|144-147|prothrombin|drug
DDI-DrugBank.d19.s6|148-148|time|drug
DDI-DrugBank.d19.s7|0-7|Patients|drug
DDI-DrugBank.d19.s7|9-14|taking|drug
DDI-DrugBank.d19.s7|16-24|isoniazid|drug
DDI-DrugBank.d19.s7|26-29|when|drug
DDI-DrugBank.d19.s7|31-40|disulfiram|drug
DDI-DrugBank.d19.s7|42-43|is|drug
DDI-DrugBank.d19.s7|45-49|given|drug
DDI-DrugBank.d19.s7|51-56|should|drug
DDI-DrugBank.d19.s7|58-59|be|drug
DDI-DrugBank.d19.s7|61-68|observed|drug
DDI-DrugBank.d19.s7|70-72|for|drug
DDI-DrugBank.d19.s7|74-76|the|drug
DDI-DrugBank.d19.s7|78-87|appearance|drug
DDI-DrugBank.d19.s7|89-90|of|drug
DDI-DrugBank.d19.s7|92-99|unsteady|drug
DDI-DrugBank.d19.s7|101-104|gait|drug
DDI-DrugBank.d19.s7|106-107|or|drug
DDI-DrugBank.d19.s7|109-114|marked|drug
DDI-DrugBank.d19.s7|116-122|changes|drug
DDI-DrugBank.d19.s7|124-125|in|drug
DDI-DrugBank.d19.s7|127-132|mental|drug
DDI-DrugBank.d19.s7|134-139|status|drug
DDI-DrugBank.d19.s7|140-140|;|drug
DDI-DrugBank.d19.s8|0-2|the|drug
DDI-DrugBank.d19.s8|4-13|disulfiram|drug
DDI-DrugBank.d19.s8|15-20|should|drug
DDI-DrugBank.d19.s8|22-23|be|drug
DDI-DrugBank.d19.s8|25-36|discontinued|drug
DDI-DrugBank.d19.s8|38-39|if|drug
DDI-DrugBank.d19.s8|41-44|such|drug
DDI-DrugBank.d19.s8|46-50|signs|drug
DDI-DrugBank.d19.s8|52-57|appear|drug
DDI-DrugBank.d19.s8|58-58|.|drug
DDI-DrugBank.d19.s9|0-1|In|drug
DDI-DrugBank.d19.s9|3-6|rats|drug
DDI-DrugBank.d19.s9|7-7|,|drug
DDI-DrugBank.d19.s9|9-20|simultaneous|drug
DDI-DrugBank.d19.s9|22-30|ingestion|drug
DDI-DrugBank.d19.s9|32-33|of|drug
DDI-DrugBank.d19.s9|35-44|disulfiram|drug
DDI-DrugBank.d19.s9|46-48|and|drug
DDI-DrugBank.d19.s9|50-56|nitrite|drug
DDI-DrugBank.d19.s9|58-59|in|drug
DDI-DrugBank.d19.s9|61-63|the|drug
DDI-DrugBank.d19.s9|65-68|diet|drug
DDI-DrugBank.d19.s9|70-72|for|drug
DDI-DrugBank.d19.s9|74-75|78|drug
DDI-DrugBank.d19.s9|77-81|weeks|drug
DDI-DrugBank.d19.s9|83-85|has|drug
DDI-DrugBank.d19.s9|87-90|been|drug
DDI-DrugBank.d19.s9|92-99|reported|drug
DDI-DrugBank.d19.s9|101-102|to|drug
DDI-DrugBank.d19.s9|104-108|cause|drug
DDI-DrugBank.d19.s9|110-115|tumors|drug
DDI-DrugBank.d19.s9|116-116|,|drug
DDI-DrugBank.d19.s9|118-120|and|drug
DDI-DrugBank.d19.s9|122-123|it|drug
DDI-DrugBank.d19.s9|125-127|has|drug
DDI-DrugBank.d19.s9|129-132|been|drug
DDI-DrugBank.d19.s9|134-142|suggested|drug
DDI-DrugBank.d19.s9|144-147|that|drug
DDI-DrugBank.d19.s9|149-158|disulfiram|drug
DDI-DrugBank.d19.s9|160-162|may|drug
DDI-DrugBank.d19.s9|164-168|react|drug
DDI-DrugBank.d19.s9|170-173|with|drug
DDI-DrugBank.d19.s9|175-182|nitrites|drug
DDI-DrugBank.d19.s9|184-185|in|drug
DDI-DrugBank.d19.s9|187-189|the|drug
DDI-DrugBank.d19.s9|191-193|rat|drug
DDI-DrugBank.d19.s9|195-201|stomach|drug
DDI-DrugBank.d19.s9|203-204|to|drug
DDI-DrugBank.d19.s9|206-209|form|drug
DDI-DrugBank.d19.s9|211-211|a|drug
DDI-DrugBank.d19.s9|213-223|nitrosamine|drug
DDI-DrugBank.d19.s9|224-224|,|drug
DDI-DrugBank.d19.s9|226-230|which|drug
DDI-DrugBank.d19.s9|232-233|is|drug
DDI-DrugBank.d19.s9|235-245|tumorigenic|drug
DDI-DrugBank.d19.s9|246-246|.|drug
DDI-DrugBank.d19.s10|0-9|Disulfiram|brand
DDI-DrugBank.d19.s10|11-15|alone|drug
DDI-DrugBank.d19.s10|17-18|in|drug
DDI-DrugBank.d19.s10|20-22|the|drug
DDI-DrugBank.d19.s10|24-26|rat|drug
DDI-DrugBank.d19.s10|28-28|s|drug
DDI-DrugBank.d19.s10|30-33|diet|drug
DDI-DrugBank.d19.s10|35-37|did|drug
DDI-DrugBank.d19.s10|39-41|not|drug
DDI-DrugBank.d19.s10|43-46|lead|drug
DDI-DrugBank.d19.s10|48-49|to|drug
DDI-DrugBank.d19.s10|51-54|such|drug
DDI-DrugBank.d19.s10|56-61|tumors|drug
DDI-DrugBank.d19.s10|62-62|.|drug
DDI-DrugBank.d19.s11|0-2|The|drug
DDI-DrugBank.d19.s11|4-12|relevance|drug
DDI-DrugBank.d19.s11|14-15|of|drug
DDI-DrugBank.d19.s11|17-20|this|drug
DDI-DrugBank.d19.s11|22-28|finding|drug
DDI-DrugBank.d19.s11|30-31|to|drug
DDI-DrugBank.d19.s11|33-38|humans|drug
DDI-DrugBank.d19.s11|40-41|is|drug
DDI-DrugBank.d19.s11|43-45|not|drug
DDI-DrugBank.d19.s11|47-51|known|drug
DDI-DrugBank.d19.s11|53-54|at|drug
DDI-DrugBank.d19.s11|56-59|this|drug
DDI-DrugBank.d19.s11|61-64|time|drug
DDI-DrugBank.d19.s11|65-65|.|drug
DDI-DrugBank.d278.s0|0-9|Enoxaparin|drug
DDI-DrugBank.d278.s0|11-15|dosed|drug
DDI-DrugBank.d278.s0|17-18|as|drug
DDI-DrugBank.d278.s0|20-20|a|drug
DDI-DrugBank.d278.s0|22-24|1.0|drug
DDI-DrugBank.d278.s0|26-30|mg/kg|drug
DDI-DrugBank.d278.s0|32-43|subcutaneous|drug
DDI-DrugBank.d278.s0|45-53|injection|drug
DDI-DrugBank.d278.s0|55-58|q12h|drug
DDI-DrugBank.d278.s0|60-62|for|drug
DDI-DrugBank.d278.s0|64-67|four|drug
DDI-DrugBank.d278.s0|69-73|doses|drug
DDI-DrugBank.d278.s0|75-77|did|drug
DDI-DrugBank.d278.s0|79-81|not|drug
DDI-DrugBank.d278.s0|83-87|alter|drug
DDI-DrugBank.d278.s0|89-91|the|drug
DDI-DrugBank.d278.s0|93-108|pharmacokinetics|drug
DDI-DrugBank.d278.s0|110-111|of|drug
DDI-DrugBank.d278.s0|113-124|eptifibatide|drug
DDI-DrugBank.d278.s0|126-127|or|drug
DDI-DrugBank.d278.s0|129-131|the|drug
DDI-DrugBank.d278.s0|133-137|level|drug
DDI-DrugBank.d278.s0|139-140|of|drug
DDI-DrugBank.d278.s0|142-149|platelet|drug
DDI-DrugBank.d278.s0|151-161|aggregation|drug
DDI-DrugBank.d278.s0|163-164|in|drug
DDI-DrugBank.d278.s0|166-172|healthy|drug
DDI-DrugBank.d278.s0|174-179|adults|drug
DDI-DrugBank.d278.s0|180-180|.|drug
DDI-MedLine.d47.s0|0-7|Activity|drug
DDI-MedLine.d47.s0|9-10|of|drug
DDI-MedLine.d47.s0|12-18|buforin|drug
DDI-MedLine.d47.s0|20-21|II|drug
DDI-MedLine.d47.s0|23-27|alone|drug
DDI-MedLine.d47.s0|29-31|and|drug
DDI-MedLine.d47.s0|33-34|in|drug
DDI-MedLine.d47.s0|36-46|combination|drug
DDI-MedLine.d47.s0|48-51|with|drug
DDI-MedLine.d47.s0|53-64|azithromycin|drug
DDI-MedLine.d47.s0|66-68|and|drug
DDI-MedLine.d47.s0|70-80|minocycline|drug
DDI-MedLine.d47.s0|82-88|against|drug
DDI-MedLine.d47.s0|90-104|Cryptosporidium|drug
DDI-MedLine.d47.s0|106-111|parvum|drug
DDI-MedLine.d47.s0|113-114|in|drug
DDI-MedLine.d47.s0|116-119|cell|drug
DDI-MedLine.d47.s0|121-127|culture|drug
DDI-MedLine.d47.s0|128-128|.|drug
DDI-MedLine.d47.s1|0-2|The|drug
DDI-MedLine.d47.s1|4-5|in|drug
DDI-MedLine.d47.s1|7-11|vitro|drug
DDI-MedLine.d47.s1|13-32|anti-cryptosporidial|drug
DDI-MedLine.d47.s1|34-41|activity|drug
DDI-MedLine.d47.s1|43-44|of|drug
DDI-MedLine.d47.s1|46-52|buforin|drug
DDI-MedLine.d47.s1|54-55|II|drug
DDI-MedLine.d47.s1|57-61|alone|drug
DDI-MedLine.d47.s1|63-65|and|drug
DDI-MedLine.d47.s1|67-68|in|drug
DDI-MedLine.d47.s1|70-80|combination|drug
DDI-MedLine.d47.s1|82-85|with|drug
DDI-MedLine.d47.s1|87-98|azithromycin|drug
DDI-MedLine.d47.s1|100-102|and|drug
DDI-MedLine.d47.s1|104-114|minocycline|drug
DDI-MedLine.d47.s1|116-118|was|drug
DDI-MedLine.d47.s1|120-131|investigated|drug
DDI-MedLine.d47.s1|132-132|.|drug
DDI-MedLine.d47.s2|0-6|Buforin|drug
DDI-MedLine.d47.s2|8-9|II|drug
DDI-MedLine.d47.s2|11-16|showed|drug
DDI-MedLine.d47.s2|18-25|moderate|drug
DDI-MedLine.d47.s2|27-34|activity|drug
DDI-MedLine.d47.s2|35-35|,|drug
DDI-MedLine.d47.s2|37-41|which|drug
DDI-MedLine.d47.s2|43-51|increased|drug
DDI-MedLine.d47.s2|53-56|with|drug
DDI-MedLine.d47.s2|58-67|increasing|drug
DDI-MedLine.d47.s2|69-81|concentration|drug
DDI-MedLine.d47.s2|83-84|to|drug
DDI-MedLine.d47.s2|86-89|55.7|drug
DDI-MedLine.d47.s2|90-90|%|drug
DDI-MedLine.d47.s2|92-102|suppression|drug
DDI-MedLine.d47.s2|104-105|of|drug
DDI-MedLine.d47.s2|107-112|growth|drug
DDI-MedLine.d47.s2|114-115|at|drug
DDI-MedLine.d47.s2|117-118|20|drug
DDI-MedLine.d47.s2|120-125|microM|drug
DDI-MedLine.d47.s2|126-126|.|drug
DDI-MedLine.d47.s3|0-7|Moreover|drug
DDI-MedLine.d47.s3|8-8|,|drug
DDI-MedLine.d47.s3|10-12|its|drug
DDI-MedLine.d47.s3|14-21|activity|drug
DDI-MedLine.d47.s3|23-25|was|drug
DDI-MedLine.d47.s3|27-34|enhanced|drug
DDI-MedLine.d47.s3|36-39|when|drug
DDI-MedLine.d47.s3|41-42|it|drug
DDI-MedLine.d47.s3|44-46|was|drug
DDI-MedLine.d47.s3|48-55|combined|drug
DDI-MedLine.d47.s3|57-60|with|drug
DDI-MedLine.d47.s3|62-67|either|drug
DDI-MedLine.d47.s3|69-80|azithromycin|drug
DDI-MedLine.d47.s3|82-83|or|drug
DDI-MedLine.d47.s3|85-95|minocycline|drug
DDI-MedLine.d47.s3|97-100|with|drug
DDI-MedLine.d47.s3|102-103|90|drug
DDI-MedLine.d47.s3|104-104|%|drug
DDI-MedLine.d47.s3|106-113|parasite|drug
DDI-MedLine.d47.s3|115-123|reduction|drug
DDI-MedLine.d47.s3|125-126|at|drug
DDI-MedLine.d47.s3|128-130|the|drug
DDI-MedLine.d47.s3|132-138|highest|drug
DDI-MedLine.d47.s3|140-152|concentration|drug
DDI-MedLine.d47.s3|154-159|tested|drug
DDI-MedLine.d47.s3|160-160|.|drug
DDI-MedLine.d47.s4|0-6|Buforin|drug
DDI-MedLine.d47.s4|8-9|II|drug
DDI-MedLine.d47.s4|11-13|may|drug
DDI-MedLine.d47.s4|15-16|be|drug
DDI-MedLine.d47.s4|18-23|active|drug
DDI-MedLine.d47.s4|25-26|in|drug
DDI-MedLine.d47.s4|28-37|inhibiting|drug
DDI-MedLine.d47.s4|39-53|Cryptosporidium|drug
DDI-MedLine.d47.s4|55-60|parvum|drug
DDI-MedLine.d47.s4|62-67|growth|drug
DDI-MedLine.d47.s4|69-70|in|drug
DDI-MedLine.d47.s4|72-76|vitro|drug
DDI-MedLine.d47.s4|78-81|upon|drug
DDI-MedLine.d47.s4|83-93|combination|drug
DDI-MedLine.d47.s4|95-98|with|drug
DDI-MedLine.d47.s4|100-105|either|drug
DDI-MedLine.d47.s4|107-118|azithromycin|drug
DDI-MedLine.d47.s4|120-121|or|drug
DDI-MedLine.d47.s4|123-133|minocycline|drug
DDI-MedLine.d47.s4|134-134|.|drug
DDI-DrugBank.d520.s0|0-2|The|drug
DDI-DrugBank.d520.s0|4-8|renal|drug
DDI-DrugBank.d520.s0|10-16|effects|drug
DDI-DrugBank.d520.s0|18-19|of|drug
DDI-DrugBank.d520.s0|21-31|nephrotoxic|drug
DDI-DrugBank.d520.s0|33-41|compounds|drug
DDI-DrugBank.d520.s0|43-45|may|drug
DDI-DrugBank.d520.s0|47-48|be|drug
DDI-DrugBank.d520.s0|50-60|potentiated|drug
DDI-DrugBank.d520.s0|62-63|by|drug
DDI-DrugBank.d520.s0|65-75|Carboplatin|brand
DDI-DrugBank.d520.s0|76-76|.|drug
DDI-DrugBank.d14.s0|0-2|The|drug
DDI-DrugBank.d14.s0|4-15|vasodilating|drug
DDI-DrugBank.d14.s0|17-23|effects|drug
DDI-DrugBank.d14.s0|25-26|of|drug
DDI-DrugBank.d14.s0|28-40|nitroglycerin|drug
DDI-DrugBank.d14.s0|42-44|may|drug
DDI-DrugBank.d14.s0|46-47|be|drug
DDI-DrugBank.d14.s0|49-56|additive|drug
DDI-DrugBank.d14.s0|58-61|with|drug
DDI-DrugBank.d14.s0|63-67|those|drug
DDI-DrugBank.d14.s0|69-70|of|drug
DDI-DrugBank.d14.s0|72-76|other|drug
DDI-DrugBank.d14.s0|78-89|vasodilators|drug
DDI-DrugBank.d14.s0|90-90|.|drug
DDI-DrugBank.d14.s1|0-6|Alcohol|brand
DDI-DrugBank.d14.s1|7-7|,|drug
DDI-DrugBank.d14.s1|9-10|in|drug
DDI-DrugBank.d14.s1|12-21|particular|drug
DDI-DrugBank.d14.s1|22-22|,|drug
DDI-DrugBank.d14.s1|24-26|has|drug
DDI-DrugBank.d14.s1|28-31|been|drug
DDI-DrugBank.d14.s1|33-37|found|drug
DDI-DrugBank.d14.s1|39-40|to|drug
DDI-DrugBank.d14.s1|42-48|exhibit|drug
DDI-DrugBank.d14.s1|50-57|additive|drug
DDI-DrugBank.d14.s1|59-65|effects|drug
DDI-DrugBank.d14.s1|67-68|of|drug
DDI-DrugBank.d14.s1|70-73|this|drug
DDI-DrugBank.d14.s1|75-81|variety|drug
DDI-DrugBank.d14.s1|82-82|.|drug
DDI-DrugBank.d14.s2|0-5|Marked|drug
DDI-DrugBank.d14.s2|7-17|symptomatic|drug
DDI-DrugBank.d14.s2|19-29|orthostatic|drug
DDI-DrugBank.d14.s2|31-41|hypotension|drug
DDI-DrugBank.d14.s2|43-45|has|drug
DDI-DrugBank.d14.s2|47-50|been|drug
DDI-DrugBank.d14.s2|52-59|reported|drug
DDI-DrugBank.d14.s2|61-64|when|drug
DDI-DrugBank.d14.s2|66-72|calcium|drug
DDI-DrugBank.d14.s2|74-80|channel|drug
DDI-DrugBank.d14.s2|82-89|blockers|drug
DDI-DrugBank.d14.s2|91-93|and|drug
DDI-DrugBank.d14.s2|95-101|organic|drug
DDI-DrugBank.d14.s2|103-110|nitrates|drug
DDI-DrugBank.d14.s2|112-115|were|drug
DDI-DrugBank.d14.s2|117-120|used|drug
DDI-DrugBank.d14.s2|122-123|in|drug
DDI-DrugBank.d14.s2|125-135|combination|drug
DDI-DrugBank.d14.s2|136-136|.|drug
DDI-DrugBank.d14.s3|0-3|Dose|drug
DDI-DrugBank.d14.s3|5-15|adjustments|drug
DDI-DrugBank.d14.s3|17-18|of|drug
DDI-DrugBank.d14.s3|20-25|either|drug
DDI-DrugBank.d14.s3|27-31|class|drug
DDI-DrugBank.d14.s3|33-34|of|drug
DDI-DrugBank.d14.s3|36-41|agents|drug
DDI-DrugBank.d14.s3|43-45|may|drug
DDI-DrugBank.d14.s3|47-48|be|drug
DDI-DrugBank.d14.s3|50-58|necessary|drug
DDI-DrugBank.d14.s3|59-59|.|drug
DDI-MedLine.d31.s0|0-5|Cancer|drug
DDI-MedLine.d31.s0|7-8|in|drug
DDI-MedLine.d31.s0|10-12|the|drug
DDI-MedLine.d31.s0|14-20|elderly|drug
DDI-MedLine.d31.s0|21-21|:|drug
DDI-MedLine.d31.s0|23-27|basic|drug
DDI-MedLine.d31.s0|29-35|science|drug
DDI-MedLine.d31.s0|37-39|and|drug
DDI-MedLine.d31.s0|41-48|clinical|drug
DDI-MedLine.d31.s0|50-56|aspects|drug
DDI-MedLine.d31.s0|57-57|.|drug
DDI-MedLine.d31.s1|0-2|The|drug
DDI-MedLine.d31.s1|4-12|incidence|drug
DDI-MedLine.d31.s1|14-15|of|drug
DDI-MedLine.d31.s1|17-22|cancer|drug
DDI-MedLine.d31.s1|24-32|increases|drug
DDI-MedLine.d31.s1|34-46|progressively|drug
DDI-MedLine.d31.s1|48-51|with|drug
DDI-MedLine.d31.s1|53-55|age|drug
DDI-MedLine.d31.s1|56-56|.|drug
DDI-MedLine.d31.s2|0-13|Rearrangements|drug
DDI-MedLine.d31.s2|15-16|of|drug
DDI-MedLine.d31.s2|18-24|genomes|drug
DDI-MedLine.d31.s2|26-29|have|drug
DDI-MedLine.d31.s2|31-34|been|drug
DDI-MedLine.d31.s2|36-40|found|drug
DDI-MedLine.d31.s2|42-43|to|drug
DDI-MedLine.d31.s2|45-53|accompany|drug
DDI-MedLine.d31.s2|55-62|cellular|drug
DDI-MedLine.d31.s2|64-68|aging|drug
DDI-MedLine.d31.s2|69-69|.|drug
DDI-MedLine.d31.s3|0-4|These|drug
DDI-MedLine.d31.s3|6-12|factors|drug
DDI-MedLine.d31.s3|13-13|,|drug
DDI-MedLine.d31.s3|15-16|in|drug
DDI-MedLine.d31.s3|18-24|concert|drug
DDI-MedLine.d31.s3|26-29|with|drug
DDI-MedLine.d31.s3|31-43|age-dependent|drug
DDI-MedLine.d31.s3|45-55|alterations|drug
DDI-MedLine.d31.s3|57-58|in|drug
DDI-MedLine.d31.s3|60-65|immune|drug
DDI-MedLine.d31.s3|67-74|function|drug
DDI-MedLine.d31.s3|76-78|and|drug
DDI-MedLine.d31.s3|80-83|host|drug
DDI-MedLine.d31.s3|85-91|defense|drug
DDI-MedLine.d31.s3|92-92|,|drug
DDI-MedLine.d31.s3|94-96|may|drug
DDI-MedLine.d31.s3|98-101|help|drug
DDI-MedLine.d31.s3|103-104|to|drug
DDI-MedLine.d31.s3|106-112|explain|drug
DDI-MedLine.d31.s3|114-116|the|drug
DDI-MedLine.d31.s3|118-126|increased|drug
DDI-MedLine.d31.s3|128-131|risk|drug
DDI-MedLine.d31.s3|133-134|of|drug
DDI-MedLine.d31.s3|136-144|malignant|drug
DDI-MedLine.d31.s3|146-152|disease|drug
DDI-MedLine.d31.s3|154-155|in|drug
DDI-MedLine.d31.s3|157-160|aged|drug
DDI-MedLine.d31.s3|162-168|persons|drug
DDI-MedLine.d31.s3|169-169|.|drug
DDI-MedLine.d31.s4|0-2|The|drug
DDI-MedLine.d31.s4|4-11|clinical|drug
DDI-MedLine.d31.s4|13-24|presentation|drug
DDI-MedLine.d31.s4|26-28|and|drug
DDI-MedLine.d31.s4|30-36|natural|drug
DDI-MedLine.d31.s4|38-44|history|drug
DDI-MedLine.d31.s4|46-47|of|drug
DDI-MedLine.d31.s4|49-57|neoplasia|drug
DDI-MedLine.d31.s4|59-61|are|drug
DDI-MedLine.d31.s4|63-66|also|drug
DDI-MedLine.d31.s4|68-75|affected|drug
DDI-MedLine.d31.s4|77-78|by|drug
DDI-MedLine.d31.s4|80-84|aging|drug
DDI-MedLine.d31.s4|85-85|.|drug
DDI-MedLine.d31.s5|0-3|This|drug
DDI-MedLine.d31.s5|5-14|conference|drug
DDI-MedLine.d31.s5|16-22|reviews|drug
DDI-MedLine.d31.s5|24-29|recent|drug
DDI-MedLine.d31.s5|31-42|developments|drug
DDI-MedLine.d31.s5|44-45|in|drug
DDI-MedLine.d31.s5|47-51|these|drug
DDI-MedLine.d31.s5|53-57|areas|drug
DDI-MedLine.d31.s5|58-58|,|drug
DDI-MedLine.d31.s5|60-67|examines|drug
DDI-MedLine.d31.s5|69-71|the|drug
DDI-MedLine.d31.s5|73-79|effects|drug
DDI-MedLine.d31.s5|81-82|of|drug
DDI-MedLine.d31.s5|84-87|drug|drug
DDI-MedLine.d31.s5|89-91|use|drug
DDI-MedLine.d31.s5|93-94|in|drug
DDI-MedLine.d31.s5|96-98|the|drug
DDI-MedLine.d31.s5|100-106|elderly|drug
DDI-MedLine.d31.s5|108-110|and|drug
DDI-MedLine.d31.s5|112-123|implications|drug
DDI-MedLine.d31.s5|125-127|for|drug
DDI-MedLine.d31.s5|129-138|management|drug
DDI-MedLine.d31.s5|139-139|,|drug
DDI-MedLine.d31.s5|141-143|and|drug
DDI-MedLine.d31.s5|145-153|discusses|drug
DDI-MedLine.d31.s5|155-161|current|drug
DDI-MedLine.d31.s5|163-173|information|drug
DDI-MedLine.d31.s5|175-176|on|drug
DDI-MedLine.d31.s5|178-180|how|drug
DDI-MedLine.d31.s5|182-184|age|drug
DDI-MedLine.d31.s5|186-188|may|drug
DDI-MedLine.d31.s5|190-198|influence|drug
DDI-MedLine.d31.s5|200-202|the|drug
DDI-MedLine.d31.s5|204-211|response|drug
DDI-MedLine.d31.s5|213-214|of|drug
DDI-MedLine.d31.s5|216-221|cancer|drug
DDI-MedLine.d31.s5|223-224|to|drug
DDI-MedLine.d31.s5|226-232|therapy|drug
DDI-MedLine.d31.s5|233-233|.|drug
DDI-DrugBank.d105.s0|0-13|Anticoagulants|group
DDI-DrugBank.d105.s0|15-23|including|drug
DDI-DrugBank.d105.s0|25-32|coumarin|drug
DDI-DrugBank.d105.s0|34-44|derivatives|drug
DDI-DrugBank.d105.s0|45-45|,|drug
DDI-DrugBank.d105.s0|47-56|indandione|drug
DDI-DrugBank.d105.s0|58-68|derivatives|drug
DDI-DrugBank.d105.s0|69-69|,|drug
DDI-DrugBank.d105.s0|71-73|and|drug
DDI-DrugBank.d105.s0|75-82|platelet|drug
DDI-DrugBank.d105.s0|84-94|aggregation|drug
DDI-DrugBank.d105.s0|96-105|inhibitors|drug
DDI-DrugBank.d105.s0|107-110|such|drug
DDI-DrugBank.d105.s0|112-113|as|drug
DDI-DrugBank.d105.s0|115-126|nonsteroidal|drug
DDI-DrugBank.d105.s0|128-144|anti-inflammatory|drug
DDI-DrugBank.d105.s0|146-150|drugs|drug
DDI-DrugBank.d105.s0|152-152|(|drug
DDI-DrugBank.d105.s0|153-158|NSAIDs|drug
DDI-DrugBank.d105.s0|159-159|)|drug
DDI-DrugBank.d105.s0|160-160|,|drug
DDI-DrugBank.d105.s0|162-164|and|drug
DDI-DrugBank.d105.s0|166-172|aspirin|drug
DDI-DrugBank.d105.s0|174-176|may|drug
DDI-DrugBank.d105.s0|178-185|increase|drug
DDI-DrugBank.d105.s0|187-189|the|drug
DDI-DrugBank.d105.s0|191-194|risk|drug
DDI-DrugBank.d105.s0|196-197|of|drug
DDI-DrugBank.d105.s0|199-206|bleeding|drug
DDI-DrugBank.d105.s0|208-211|when|drug
DDI-DrugBank.d105.s0|213-224|administered|drug
DDI-DrugBank.d105.s0|226-238|concomitantly|drug
DDI-DrugBank.d105.s0|240-243|with|drug
DDI-DrugBank.d105.s0|245-253|ardeparin|drug
DDI-DrugBank.d105.s0|254-254|.|drug
DDI-DrugBank.d153.s0|0-2|The|drug
DDI-DrugBank.d153.s0|4-17|administration|drug
DDI-DrugBank.d153.s0|19-20|of|drug
DDI-DrugBank.d153.s0|22-26|local|drug
DDI-DrugBank.d153.s0|28-37|anesthetic|drug
DDI-DrugBank.d153.s0|39-47|solutions|drug
DDI-DrugBank.d153.s0|49-58|containing|drug
DDI-DrugBank.d153.s0|60-70|epinephrine|drug
DDI-DrugBank.d153.s0|72-73|or|drug
DDI-DrugBank.d153.s0|75-88|norepinephrine|drug
DDI-DrugBank.d153.s0|90-91|to|drug
DDI-DrugBank.d153.s0|93-100|patients|drug
DDI-DrugBank.d153.s0|102-110|receiving|drug
DDI-DrugBank.d153.s0|112-120|monoamine|drug
DDI-DrugBank.d153.s0|122-128|oxidase|drug
DDI-DrugBank.d153.s0|130-139|inhibitors|drug
DDI-DrugBank.d153.s0|141-142|or|drug
DDI-DrugBank.d153.s0|144-152|tricyclic|drug
DDI-DrugBank.d153.s0|154-168|antidepressants|drug
DDI-DrugBank.d153.s0|170-172|may|drug
DDI-DrugBank.d153.s0|174-180|produce|drug
DDI-DrugBank.d153.s0|182-187|severe|drug
DDI-DrugBank.d153.s0|188-188|,|drug
DDI-DrugBank.d153.s0|190-198|prolonged|drug
DDI-DrugBank.d153.s0|200-211|hypertension|drug
DDI-DrugBank.d153.s0|212-212|.|drug
DDI-DrugBank.d153.s1|0-9|Concurrent|drug
DDI-DrugBank.d153.s1|11-13|use|drug
DDI-DrugBank.d153.s1|15-16|of|drug
DDI-DrugBank.d153.s1|18-22|these|drug
DDI-DrugBank.d153.s1|24-29|agents|drug
DDI-DrugBank.d153.s1|31-36|should|drug
DDI-DrugBank.d153.s1|38-46|generally|drug
DDI-DrugBank.d153.s1|48-49|be|drug
DDI-DrugBank.d153.s1|51-57|avoided|drug
DDI-DrugBank.d153.s1|58-58|.|drug
DDI-DrugBank.d153.s2|0-1|In|drug
DDI-DrugBank.d153.s2|3-12|situations|drug
DDI-DrugBank.d153.s2|14-15|in|drug
DDI-DrugBank.d153.s2|17-21|which|drug
DDI-DrugBank.d153.s2|23-32|concurrent|drug
DDI-DrugBank.d153.s2|34-40|therapy|drug
DDI-DrugBank.d153.s2|42-43|is|drug
DDI-DrugBank.d153.s2|45-53|necessary|drug
DDI-DrugBank.d153.s2|54-54|,|drug
DDI-DrugBank.d153.s2|56-62|careful|drug
DDI-DrugBank.d153.s2|64-70|patient|drug
DDI-DrugBank.d153.s2|72-81|monitoring|drug
DDI-DrugBank.d153.s2|83-84|is|drug
DDI-DrugBank.d153.s2|86-94|essential|drug
DDI-DrugBank.d153.s2|95-95|.|drug
DDI-DrugBank.d153.s3|0-9|Concurrent|drug
DDI-DrugBank.d153.s3|11-24|administration|drug
DDI-DrugBank.d153.s3|26-27|of|drug
DDI-DrugBank.d153.s3|29-39|vasopressor|drug
DDI-DrugBank.d153.s3|41-45|drugs|drug
DDI-DrugBank.d153.s3|47-49|and|drug
DDI-DrugBank.d153.s3|51-52|of|drug
DDI-DrugBank.d153.s3|54-63|ergot-type|drug
DDI-DrugBank.d153.s3|65-72|oxytocic|drug
DDI-DrugBank.d153.s3|74-78|drugs|drug
DDI-DrugBank.d153.s3|80-82|may|drug
DDI-DrugBank.d153.s3|84-88|cause|drug
DDI-DrugBank.d153.s3|90-95|severe|drug
DDI-DrugBank.d153.s3|96-96|,|drug
DDI-DrugBank.d153.s3|98-107|persistent|drug
DDI-DrugBank.d153.s3|109-120|hypertension|drug
DDI-DrugBank.d153.s3|122-123|or|drug
DDI-DrugBank.d153.s3|125-139|cerebrovascular|drug
DDI-DrugBank.d153.s3|141-149|accidents|drug
DDI-DrugBank.d153.s3|150-150|.|drug
DDI-DrugBank.d153.s4|0-13|Phenothiazines|group
DDI-DrugBank.d153.s4|15-17|and|drug
DDI-DrugBank.d153.s4|19-32|butyrophenones|drug
DDI-DrugBank.d153.s4|34-36|may|drug
DDI-DrugBank.d153.s4|38-43|reduce|drug
DDI-DrugBank.d153.s4|45-46|or|drug
DDI-DrugBank.d153.s4|48-54|reverse|drug
DDI-DrugBank.d153.s4|56-58|the|drug
DDI-DrugBank.d153.s4|60-66|pressor|drug
DDI-DrugBank.d153.s4|68-73|effect|drug
DDI-DrugBank.d153.s4|75-76|of|drug
DDI-DrugBank.d153.s4|78-88|epinephrine|drug
DDI-DrugBank.d153.s4|89-89|.|drug
DDI-DrugBank.d197.s0|0-6|General|drug
DDI-DrugBank.d197.s0|8-9|In|drug
DDI-DrugBank.d197.s0|11-15|vitro|drug
DDI-DrugBank.d197.s0|17-23|studies|drug
DDI-DrugBank.d197.s0|25-26|in|drug
DDI-DrugBank.d197.s0|28-32|human|drug
DDI-DrugBank.d197.s0|34-38|liver|drug
DDI-DrugBank.d197.s0|40-49|microsomes|drug
DDI-DrugBank.d197.s0|51-62|demonstrated|drug
DDI-DrugBank.d197.s0|64-65|no|drug
DDI-DrugBank.d197.s0|67-74|evidence|drug
DDI-DrugBank.d197.s0|76-77|of|drug
DDI-DrugBank.d197.s0|79-88|cytochrome|drug
DDI-DrugBank.d197.s0|90-102|P450-mediated|drug
DDI-DrugBank.d197.s0|104-107|drug|drug
DDI-DrugBank.d197.s0|109-120|interactions|drug
DDI-DrugBank.d197.s0|122-125|that|drug
DDI-DrugBank.d197.s0|127-129|are|drug
DDI-DrugBank.d197.s0|131-136|likely|drug
DDI-DrugBank.d197.s0|138-139|to|drug
DDI-DrugBank.d197.s0|141-142|be|drug
DDI-DrugBank.d197.s0|144-145|of|drug
DDI-DrugBank.d197.s0|147-154|clinical|drug
DDI-DrugBank.d197.s0|156-164|relevance|drug
DDI-DrugBank.d197.s0|165-165|.|drug
DDI-DrugBank.d197.s1|0-38|Anesthetics/Sedatives/Hypnotics/Opioids|drug
DDI-DrugBank.d197.s1|39-39|:|drug
DDI-DrugBank.d197.s1|41-57|Co-administration|drug
DDI-DrugBank.d197.s1|59-60|of|drug
DDI-DrugBank.d197.s1|62-69|PRECEDEX|drug
DDI-DrugBank.d197.s1|71-74|with|drug
DDI-DrugBank.d197.s1|76-86|anesthetics|drug
DDI-DrugBank.d197.s1|87-87|,|drug
DDI-DrugBank.d197.s1|89-97|sedatives|drug
DDI-DrugBank.d197.s1|98-98|,|drug
DDI-DrugBank.d197.s1|100-108|hypnotics|drug
DDI-DrugBank.d197.s1|109-109|,|drug
DDI-DrugBank.d197.s1|111-113|and|drug
DDI-DrugBank.d197.s1|115-121|opioids|drug
DDI-DrugBank.d197.s1|123-124|is|drug
DDI-DrugBank.d197.s1|126-131|likely|drug
DDI-DrugBank.d197.s1|133-134|to|drug
DDI-DrugBank.d197.s1|136-139|lead|drug
DDI-DrugBank.d197.s1|141-142|to|drug
DDI-DrugBank.d197.s1|144-145|an|drug
DDI-DrugBank.d197.s1|147-157|enhancement|drug
DDI-DrugBank.d197.s1|159-160|of|drug
DDI-DrugBank.d197.s1|162-168|effects|drug
DDI-DrugBank.d197.s1|169-169|.|drug
DDI-DrugBank.d197.s2|0-7|Specific|drug
DDI-DrugBank.d197.s2|9-15|studies|drug
DDI-DrugBank.d197.s2|17-20|have|drug
DDI-DrugBank.d197.s2|22-30|confirmed|drug
DDI-DrugBank.d197.s2|32-36|these|drug
DDI-DrugBank.d197.s2|38-44|effects|drug
DDI-DrugBank.d197.s2|46-49|with|drug
DDI-DrugBank.d197.s2|51-61|sevoflurane|drug
DDI-DrugBank.d197.s2|62-62|,|drug
DDI-DrugBank.d197.s2|64-73|isoflurane|drug
DDI-DrugBank.d197.s2|74-74|,|drug
DDI-DrugBank.d197.s2|76-83|propofol|drug
DDI-DrugBank.d197.s2|84-84|,|drug
DDI-DrugBank.d197.s2|86-95|alfentanil|drug
DDI-DrugBank.d197.s2|96-96|,|drug
DDI-DrugBank.d197.s2|98-100|and|drug
DDI-DrugBank.d197.s2|102-110|midazolam|drug
DDI-DrugBank.d197.s2|111-111|.|drug
DDI-DrugBank.d197.s3|0-1|No|drug
DDI-DrugBank.d197.s3|3-17|pharmacokinetic|drug
DDI-DrugBank.d197.s3|19-30|interactions|drug
DDI-DrugBank.d197.s3|32-38|between|drug
DDI-DrugBank.d197.s3|40-54|dexmedetomidine|drug
DDI-DrugBank.d197.s3|56-58|and|drug
DDI-DrugBank.d197.s3|60-69|isoflurane|drug
DDI-DrugBank.d197.s3|70-70|,|drug
DDI-DrugBank.d197.s3|72-79|propofol|drug
DDI-DrugBank.d197.s3|80-80|,|drug
DDI-DrugBank.d197.s3|82-91|alfentanil|drug
DDI-DrugBank.d197.s3|92-92|,|drug
DDI-DrugBank.d197.s3|94-96|and|drug
DDI-DrugBank.d197.s3|98-106|midazolam|drug
DDI-DrugBank.d197.s3|108-111|have|drug
DDI-DrugBank.d197.s3|113-116|been|drug
DDI-DrugBank.d197.s3|118-129|demonstrated|drug
DDI-DrugBank.d197.s3|130-130|.|drug
DDI-DrugBank.d197.s4|0-6|However|drug
DDI-DrugBank.d197.s4|7-7|,|drug
DDI-DrugBank.d197.s4|9-11|due|drug
DDI-DrugBank.d197.s4|13-14|to|drug
DDI-DrugBank.d197.s4|16-23|possible|drug
DDI-DrugBank.d197.s4|25-39|pharmacodynamic|drug
DDI-DrugBank.d197.s4|41-52|interactions|drug
DDI-DrugBank.d197.s4|53-53|,|drug
DDI-DrugBank.d197.s4|55-58|when|drug
DDI-DrugBank.d197.s4|60-74|co-administered|drug
DDI-DrugBank.d197.s4|76-79|with|drug
DDI-DrugBank.d197.s4|81-88|PRECEDEX|drug
DDI-DrugBank.d197.s4|89-89|,|drug
DDI-DrugBank.d197.s4|91-91|a|drug
DDI-DrugBank.d197.s4|93-101|reduction|drug
DDI-DrugBank.d197.s4|103-104|in|drug
DDI-DrugBank.d197.s4|106-111|dosage|drug
DDI-DrugBank.d197.s4|113-114|of|drug
DDI-DrugBank.d197.s4|116-123|PRECEDEX|drug
DDI-DrugBank.d197.s4|125-126|on|drug
DDI-DrugBank.d197.s4|128-130|the|drug
DDI-DrugBank.d197.s4|132-142|concomitant|drug
DDI-DrugBank.d197.s4|144-153|anesthetic|drug
DDI-DrugBank.d197.s4|154-154|,|drug
DDI-DrugBank.d197.s4|156-163|sedative|drug
DDI-DrugBank.d197.s4|164-164|,|drug
DDI-DrugBank.d197.s4|166-173|hypnotic|drug
DDI-DrugBank.d197.s4|175-176|or|drug
DDI-DrugBank.d197.s4|178-183|opioid|drug
DDI-DrugBank.d197.s4|185-187|may|drug
DDI-DrugBank.d197.s4|189-190|be|drug
DDI-DrugBank.d197.s4|192-199|required|drug
DDI-DrugBank.d197.s4|200-200|.|drug
DDI-DrugBank.d197.s5|0-12|Neuromuscular|drug
DDI-DrugBank.d197.s5|14-21|Blockers|drug
DDI-DrugBank.d197.s5|22-22|:|drug
DDI-DrugBank.d197.s5|24-25|In|drug
DDI-DrugBank.d197.s5|27-29|one|drug
DDI-DrugBank.d197.s5|31-35|study|drug
DDI-DrugBank.d197.s5|37-38|of|drug
DDI-DrugBank.d197.s5|40-41|10|drug
DDI-DrugBank.d197.s5|43-49|healthy|drug
DDI-DrugBank.d197.s5|51-60|volunteers|drug
DDI-DrugBank.d197.s5|61-61|,|drug
DDI-DrugBank.d197.s5|63-76|administration|drug
DDI-DrugBank.d197.s5|78-79|of|drug
DDI-DrugBank.d197.s5|81-88|PRECEDEX|drug
DDI-DrugBank.d197.s5|90-92|for|drug
DDI-DrugBank.d197.s5|94-95|45|drug
DDI-DrugBank.d197.s5|97-103|minutes|drug
DDI-DrugBank.d197.s5|105-106|at|drug
DDI-DrugBank.d197.s5|108-108|a|drug
DDI-DrugBank.d197.s5|110-115|plasma|drug
DDI-DrugBank.d197.s5|117-129|concentration|drug
DDI-DrugBank.d197.s5|131-132|of|drug
DDI-DrugBank.d197.s5|134-134|1|drug
DDI-DrugBank.d197.s5|136-136|(|drug
DDI-DrugBank.d197.s5|137-139|one|drug
DDI-DrugBank.d197.s5|140-140|)|drug
DDI-DrugBank.d197.s5|142-146|ng/mL|drug
DDI-DrugBank.d197.s5|148-155|resulted|drug
DDI-DrugBank.d197.s5|157-158|in|drug
DDI-DrugBank.d197.s5|160-161|no|drug
DDI-DrugBank.d197.s5|163-172|clinically|drug
DDI-DrugBank.d197.s5|174-183|meaningful|drug
DDI-DrugBank.d197.s5|185-193|increases|drug
DDI-DrugBank.d197.s5|195-196|in|drug
DDI-DrugBank.d197.s5|198-200|the|drug
DDI-DrugBank.d197.s5|202-210|magnitude|drug
DDI-DrugBank.d197.s5|212-213|or|drug
DDI-DrugBank.d197.s5|215-227|neuromuscular|drug
DDI-DrugBank.d197.s5|229-236|blockade|drug
DDI-DrugBank.d197.s5|238-247|associated|drug
DDI-DrugBank.d197.s5|249-252|with|drug
DDI-DrugBank.d197.s5|254-263|rocuronium|drug
DDI-DrugBank.d197.s5|265-278|administration|drug
DDI-DrugBank.d197.s5|279-279|.|drug
DDI-DrugBank.d255.s0|0-4|There|drug
DDI-DrugBank.d255.s0|6-8|are|drug
DDI-DrugBank.d255.s0|10-11|no|drug
DDI-DrugBank.d255.s0|13-17|known|drug
DDI-DrugBank.d255.s0|19-27|drug/drug|drug
DDI-DrugBank.d255.s0|29-40|interactions|drug
DDI-DrugBank.d255.s0|42-45|with|drug
DDI-DrugBank.d255.s0|47-58|chlorambucil|drug
DDI-DrugBank.d255.s0|59-59|.|drug
DDI-DrugBank.d104.s0|0-11|Fenfluramine|drug
DDI-DrugBank.d104.s0|13-15|may|drug
DDI-DrugBank.d104.s0|17-24|increase|drug
DDI-DrugBank.d104.s0|26-33|slightly|drug
DDI-DrugBank.d104.s0|35-37|the|drug
DDI-DrugBank.d104.s0|39-44|effect|drug
DDI-DrugBank.d104.s0|46-47|of|drug
DDI-DrugBank.d104.s0|49-64|antihypertensive|drug
DDI-DrugBank.d104.s0|66-70|drugs|drug
DDI-DrugBank.d104.s0|71-71|,|drug
DDI-DrugBank.d104.s0|73-76|e.g.|drug
DDI-DrugBank.d104.s0|77-77|,|drug
DDI-DrugBank.d104.s0|79-90|guanethidine|drug
DDI-DrugBank.d104.s0|91-91|,|drug
DDI-DrugBank.d104.s0|93-102|methyldopa|drug
DDI-DrugBank.d104.s0|103-103|,|drug
DDI-DrugBank.d104.s0|105-113|reserpine|drug
DDI-DrugBank.d104.s0|114-114|.|drug
DDI-DrugBank.d104.s1|0-4|Other|drug
DDI-DrugBank.d104.s1|6-8|CNS|drug
DDI-DrugBank.d104.s1|10-19|depressant|drug
DDI-DrugBank.d104.s1|21-25|drugs|drug
DDI-DrugBank.d104.s1|27-32|should|drug
DDI-DrugBank.d104.s1|34-35|be|drug
DDI-DrugBank.d104.s1|37-40|used|drug
DDI-DrugBank.d104.s1|42-45|with|drug
DDI-DrugBank.d104.s1|47-53|caution|drug
DDI-DrugBank.d104.s1|55-56|in|drug
DDI-DrugBank.d104.s1|58-65|patients|drug
DDI-DrugBank.d104.s1|67-72|taking|drug
DDI-DrugBank.d104.s1|74-85|fenfluramine|drug
DDI-DrugBank.d104.s1|86-86|,|drug
DDI-DrugBank.d104.s1|88-92|since|drug
DDI-DrugBank.d104.s1|94-96|the|drug
DDI-DrugBank.d104.s1|98-104|effects|drug
DDI-DrugBank.d104.s1|106-108|may|drug
DDI-DrugBank.d104.s1|110-111|be|drug
DDI-DrugBank.d104.s1|113-120|additive|drug
DDI-DrugBank.d104.s1|121-121|.|drug
DDI-DrugBank.d397.s0|0-11|Erythromycin|brand
DDI-DrugBank.d397.s0|13-15|use|drug
DDI-DrugBank.d397.s0|17-18|in|drug
DDI-DrugBank.d397.s0|20-27|patients|drug
DDI-DrugBank.d397.s0|29-31|who|drug
DDI-DrugBank.d397.s0|33-35|are|drug
DDI-DrugBank.d397.s0|37-45|receiving|drug
DDI-DrugBank.d397.s0|47-50|high|drug
DDI-DrugBank.d397.s0|52-56|doses|drug
DDI-DrugBank.d397.s0|58-59|of|drug
DDI-DrugBank.d397.s0|61-72|theophylline|drug
DDI-DrugBank.d397.s0|74-76|may|drug
DDI-DrugBank.d397.s0|78-79|be|drug
DDI-DrugBank.d397.s0|81-90|associated|drug
DDI-DrugBank.d397.s0|92-95|with|drug
DDI-DrugBank.d397.s0|97-98|an|drug
DDI-DrugBank.d397.s0|100-107|increase|drug
DDI-DrugBank.d397.s0|109-110|in|drug
DDI-DrugBank.d397.s0|112-116|serum|drug
DDI-DrugBank.d397.s0|118-129|theophylline|drug
DDI-DrugBank.d397.s0|131-136|levels|drug
DDI-DrugBank.d397.s0|138-140|and|drug
DDI-DrugBank.d397.s0|142-150|potential|drug
DDI-DrugBank.d397.s0|152-163|theophylline|drug
DDI-DrugBank.d397.s0|165-172|toxicity|drug
DDI-DrugBank.d397.s0|173-173|.|drug
DDI-DrugBank.d397.s1|0-1|In|drug
DDI-DrugBank.d397.s1|3-6|case|drug
DDI-DrugBank.d397.s1|8-9|of|drug
DDI-DrugBank.d397.s1|11-22|theophylline|drug
DDI-DrugBank.d397.s1|24-31|toxicity|drug
DDI-DrugBank.d397.s1|33-38|and/or|drug
DDI-DrugBank.d397.s1|40-47|elevated|drug
DDI-DrugBank.d397.s1|49-53|serum|drug
DDI-DrugBank.d397.s1|55-66|theophylline|drug
DDI-DrugBank.d397.s1|68-73|levels|drug
DDI-DrugBank.d397.s1|74-74|,|drug
DDI-DrugBank.d397.s1|76-78|the|drug
DDI-DrugBank.d397.s1|80-83|dose|drug
DDI-DrugBank.d397.s1|85-86|of|drug
DDI-DrugBank.d397.s1|88-99|theophylline|drug
DDI-DrugBank.d397.s1|101-106|should|drug
DDI-DrugBank.d397.s1|108-109|be|drug
DDI-DrugBank.d397.s1|111-117|reduced|drug
DDI-DrugBank.d397.s1|119-123|while|drug
DDI-DrugBank.d397.s1|125-127|the|drug
DDI-DrugBank.d397.s1|129-135|patient|drug
DDI-DrugBank.d397.s1|137-138|is|drug
DDI-DrugBank.d397.s1|140-148|receiving|drug
DDI-DrugBank.d397.s1|150-160|concomitant|drug
DDI-DrugBank.d397.s1|162-173|erythromycin|drug
DDI-DrugBank.d397.s1|175-181|therapy|drug
DDI-DrugBank.d397.s1|182-182|.|drug
DDI-DrugBank.d397.s2|0-10|Concomitant|drug
DDI-DrugBank.d397.s2|12-25|administration|drug
DDI-DrugBank.d397.s2|27-28|of|drug
DDI-DrugBank.d397.s2|30-41|erythromycin|drug
DDI-DrugBank.d397.s2|43-45|and|drug
DDI-DrugBank.d397.s2|47-53|digoxin|drug
DDI-DrugBank.d397.s2|55-57|has|drug
DDI-DrugBank.d397.s2|59-62|been|drug
DDI-DrugBank.d397.s2|64-71|reported|drug
DDI-DrugBank.d397.s2|73-74|to|drug
DDI-DrugBank.d397.s2|76-81|result|drug
DDI-DrugBank.d397.s2|83-84|in|drug
DDI-DrugBank.d397.s2|86-93|elevated|drug
DDI-DrugBank.d397.s2|95-101|digoxin|drug
DDI-DrugBank.d397.s2|103-107|serum|drug
DDI-DrugBank.d397.s2|109-114|levels|drug
DDI-DrugBank.d397.s2|115-115|.|drug
DDI-DrugBank.d397.s3|0-4|There|drug
DDI-DrugBank.d397.s3|6-9|have|drug
DDI-DrugBank.d397.s3|11-14|been|drug
DDI-DrugBank.d397.s3|16-22|reports|drug
DDI-DrugBank.d397.s3|24-25|of|drug
DDI-DrugBank.d397.s3|27-35|increased|drug
DDI-DrugBank.d397.s3|37-49|anticoagulant|drug
DDI-DrugBank.d397.s3|51-57|effects|drug
DDI-DrugBank.d397.s3|59-62|when|drug
DDI-DrugBank.d397.s3|64-75|erythromycin|drug
DDI-DrugBank.d397.s3|77-79|and|drug
DDI-DrugBank.d397.s3|81-84|oral|drug
DDI-DrugBank.d397.s3|86-99|anticoagulants|drug
DDI-DrugBank.d397.s3|101-104|were|drug
DDI-DrugBank.d397.s3|106-109|used|drug
DDI-DrugBank.d397.s3|111-123|concomitantly|drug
DDI-DrugBank.d397.s3|124-124|.|drug
DDI-DrugBank.d397.s4|0-8|Increased|drug
DDI-DrugBank.d397.s4|10-24|anticoagulation|drug
DDI-DrugBank.d397.s4|26-32|effects|drug
DDI-DrugBank.d397.s4|34-36|due|drug
DDI-DrugBank.d397.s4|38-39|to|drug
DDI-DrugBank.d397.s4|41-52|interactions|drug
DDI-DrugBank.d397.s4|54-55|of|drug
DDI-DrugBank.d397.s4|57-68|erythromycin|drug
DDI-DrugBank.d397.s4|70-73|with|drug
DDI-DrugBank.d397.s4|75-81|various|drug
DDI-DrugBank.d397.s4|83-86|oral|drug
DDI-DrugBank.d397.s4|88-101|anticoagulents|drug
DDI-DrugBank.d397.s4|103-105|may|drug
DDI-DrugBank.d397.s4|107-108|be|drug
DDI-DrugBank.d397.s4|110-113|more|drug
DDI-DrugBank.d397.s4|115-124|pronounced|drug
DDI-DrugBank.d397.s4|126-127|in|drug
DDI-DrugBank.d397.s4|129-131|the|drug
DDI-DrugBank.d397.s4|133-139|elderly|drug
DDI-DrugBank.d397.s4|140-140|.|drug
DDI-DrugBank.d397.s5|0-9|Concurrent|drug
DDI-DrugBank.d397.s5|11-13|use|drug
DDI-DrugBank.d397.s5|15-16|of|drug
DDI-DrugBank.d397.s5|18-29|erythromycin|drug
DDI-DrugBank.d397.s5|31-33|and|drug
DDI-DrugBank.d397.s5|35-44|ergotamine|drug
DDI-DrugBank.d397.s5|46-47|or|drug
DDI-DrugBank.d397.s5|49-65|dihydroergotamine|drug
DDI-DrugBank.d397.s5|67-69|has|drug
DDI-DrugBank.d397.s5|71-74|been|drug
DDI-DrugBank.d397.s5|76-85|associated|drug
DDI-DrugBank.d397.s5|87-88|in|drug
DDI-DrugBank.d397.s5|90-93|some|drug
DDI-DrugBank.d397.s5|95-102|patients|drug
DDI-DrugBank.d397.s5|104-107|with|drug
DDI-DrugBank.d397.s5|109-113|acute|drug
DDI-DrugBank.d397.s5|115-119|ergot|drug
DDI-DrugBank.d397.s5|121-128|toxicity|drug
DDI-DrugBank.d397.s5|130-142|characterized|drug
DDI-DrugBank.d397.s5|144-145|by|drug
DDI-DrugBank.d397.s5|147-152|severe|drug
DDI-DrugBank.d397.s5|154-163|peripheral|drug
DDI-DrugBank.d397.s5|165-173|vasospasm|drug
DDI-DrugBank.d397.s5|175-177|and|drug
DDI-DrugBank.d397.s5|179-189|dysesthesia|drug
DDI-DrugBank.d397.s5|190-190|.|drug
DDI-DrugBank.d397.s6|0-11|Erythromycin|brand
DDI-DrugBank.d397.s6|13-15|has|drug
DDI-DrugBank.d397.s6|17-20|been|drug
DDI-DrugBank.d397.s6|22-29|reported|drug
DDI-DrugBank.d397.s6|31-32|to|drug
DDI-DrugBank.d397.s6|34-41|decrease|drug
DDI-DrugBank.d397.s6|43-45|the|drug
DDI-DrugBank.d397.s6|47-55|clearance|drug
DDI-DrugBank.d397.s6|57-58|of|drug
DDI-DrugBank.d397.s6|60-68|triazolam|drug
DDI-DrugBank.d397.s6|70-72|and|drug
DDI-DrugBank.d397.s6|74-82|midazolam|drug
DDI-DrugBank.d397.s6|84-86|and|drug
DDI-DrugBank.d397.s6|88-91|thus|drug
DDI-DrugBank.d397.s6|93-95|may|drug
DDI-DrugBank.d397.s6|97-104|increase|drug
DDI-DrugBank.d397.s6|106-108|the|drug
DDI-DrugBank.d397.s6|110-122|pharmacologic|drug
DDI-DrugBank.d397.s6|124-129|effect|drug
DDI-DrugBank.d397.s6|131-132|of|drug
DDI-DrugBank.d397.s6|134-138|these|drug
DDI-DrugBank.d397.s6|140-154|benzodiazepines|drug
DDI-DrugBank.d397.s6|155-155|.|drug
DDI-DrugBank.d397.s7|0-2|The|drug
DDI-DrugBank.d397.s7|4-6|use|drug
DDI-DrugBank.d397.s7|8-9|of|drug
DDI-DrugBank.d397.s7|11-22|erythromycin|drug
DDI-DrugBank.d397.s7|24-25|in|drug
DDI-DrugBank.d397.s7|27-34|patients|drug
DDI-DrugBank.d397.s7|36-47|concurrently|drug
DDI-DrugBank.d397.s7|49-54|taking|drug
DDI-DrugBank.d397.s7|56-60|drugs|drug
DDI-DrugBank.d397.s7|62-72|metabolized|drug
DDI-DrugBank.d397.s7|74-75|by|drug
DDI-DrugBank.d397.s7|77-79|the|drug
DDI-DrugBank.d397.s7|81-90|cytochrome|drug
DDI-DrugBank.d397.s7|92-95|P450|drug
DDI-DrugBank.d397.s7|97-102|system|drug
DDI-DrugBank.d397.s7|104-106|may|drug
DDI-DrugBank.d397.s7|108-109|be|drug
DDI-DrugBank.d397.s7|111-120|associated|drug
DDI-DrugBank.d397.s7|122-125|with|drug
DDI-DrugBank.d397.s7|127-136|elevations|drug
DDI-DrugBank.d397.s7|138-139|in|drug
DDI-DrugBank.d397.s7|141-145|serum|drug
DDI-DrugBank.d397.s7|147-152|levels|drug
DDI-DrugBank.d397.s7|154-155|of|drug
DDI-DrugBank.d397.s7|157-161|these|drug
DDI-DrugBank.d397.s7|163-167|other|drug
DDI-DrugBank.d397.s7|169-173|drugs|drug
DDI-DrugBank.d397.s7|174-174|.|drug
DDI-DrugBank.d397.s8|0-4|There|drug
DDI-DrugBank.d397.s8|6-9|have|drug
DDI-DrugBank.d397.s8|11-14|been|drug
DDI-DrugBank.d397.s8|16-22|reports|drug
DDI-DrugBank.d397.s8|24-25|of|drug
DDI-DrugBank.d397.s8|27-38|interactions|drug
DDI-DrugBank.d397.s8|40-41|of|drug
DDI-DrugBank.d397.s8|43-54|erythromycin|drug
DDI-DrugBank.d397.s8|56-59|with|drug
DDI-DrugBank.d397.s8|61-73|carbamazepine|drug
DDI-DrugBank.d397.s8|74-74|,|drug
DDI-DrugBank.d397.s8|76-87|cyclosporine|drug
DDI-DrugBank.d397.s8|88-88|,|drug
DDI-DrugBank.d397.s8|90-99|tacrolimus|drug
DDI-DrugBank.d397.s8|100-100|,|drug
DDI-DrugBank.d397.s8|102-113|hexobarbital|drug
DDI-DrugBank.d397.s8|114-114|,|drug
DDI-DrugBank.d397.s8|116-124|phenytoin|drug
DDI-DrugBank.d397.s8|125-125|,|drug
DDI-DrugBank.d397.s8|127-136|alfentanil|drug
DDI-DrugBank.d397.s8|137-137|,|drug
DDI-DrugBank.d397.s8|139-147|cisapride|drug
DDI-DrugBank.d397.s8|148-148|,|drug
DDI-DrugBank.d397.s8|150-161|disopyramide|drug
DDI-DrugBank.d397.s8|162-162|,|drug
DDI-DrugBank.d397.s8|164-173|lovastatin|drug
DDI-DrugBank.d397.s8|174-174|,|drug
DDI-DrugBank.d397.s8|176-188|bromocriptine|drug
DDI-DrugBank.d397.s8|189-189|,|drug
DDI-DrugBank.d397.s8|191-199|valproate|drug
DDI-DrugBank.d397.s8|200-200|,|drug
DDI-DrugBank.d397.s8|202-212|terfenadine|drug
DDI-DrugBank.d397.s8|213-213|,|drug
DDI-DrugBank.d397.s8|215-217|and|drug
DDI-DrugBank.d397.s8|219-228|astemizole|drug
DDI-DrugBank.d397.s8|229-229|.|drug
DDI-DrugBank.d397.s9|0-4|Serum|group
DDI-DrugBank.d397.s9|6-19|concentrations|drug
DDI-DrugBank.d397.s9|21-22|of|drug
DDI-DrugBank.d397.s9|24-28|drugs|drug
DDI-DrugBank.d397.s9|30-40|metabolized|drug
DDI-DrugBank.d397.s9|42-43|by|drug
DDI-DrugBank.d397.s9|45-47|the|drug
DDI-DrugBank.d397.s9|49-58|cytochrome|drug
DDI-DrugBank.d397.s9|60-63|P450|drug
DDI-DrugBank.d397.s9|65-70|system|drug
DDI-DrugBank.d397.s9|72-77|should|drug
DDI-DrugBank.d397.s9|79-80|be|drug
DDI-DrugBank.d397.s9|82-90|monitored|drug
DDI-DrugBank.d397.s9|92-98|closely|drug
DDI-DrugBank.d397.s9|100-101|in|drug
DDI-DrugBank.d397.s9|103-110|patients|drug
DDI-DrugBank.d397.s9|112-123|concurrently|drug
DDI-DrugBank.d397.s9|125-133|receiving|drug
DDI-DrugBank.d397.s9|135-146|erythromycin|drug
DDI-DrugBank.d397.s9|147-147|.|drug
DDI-DrugBank.d397.s10|0-11|Erythromycin|brand
DDI-DrugBank.d397.s10|13-15|has|drug
DDI-DrugBank.d397.s10|17-20|been|drug
DDI-DrugBank.d397.s10|22-29|reported|drug
DDI-DrugBank.d397.s10|31-32|to|drug
DDI-DrugBank.d397.s10|34-46|significantly|drug
DDI-DrugBank.d397.s10|48-52|alter|drug
DDI-DrugBank.d397.s10|54-56|the|drug
DDI-DrugBank.d397.s10|58-67|metabolism|drug
DDI-DrugBank.d397.s10|69-70|of|drug
DDI-DrugBank.d397.s10|72-82|nonsedating|drug
DDI-DrugBank.d397.s10|84-97|antihistamines|drug
DDI-DrugBank.d397.s10|99-109|terfenadine|drug
DDI-DrugBank.d397.s10|111-113|and|drug
DDI-DrugBank.d397.s10|115-124|astemizole|drug
DDI-DrugBank.d397.s10|126-129|when|drug
DDI-DrugBank.d397.s10|131-135|taken|drug
DDI-DrugBank.d397.s10|137-149|concomitantly|drug
DDI-DrugBank.d397.s10|150-150|.|drug
DDI-DrugBank.d397.s11|0-3|Rare|drug
DDI-DrugBank.d397.s11|5-9|cases|drug
DDI-DrugBank.d397.s11|11-12|of|drug
DDI-DrugBank.d397.s11|14-20|serious|drug
DDI-DrugBank.d397.s11|22-35|cardiovascular|drug
DDI-DrugBank.d397.s11|37-43|adverse|drug
DDI-DrugBank.d397.s11|45-50|events|drug
DDI-DrugBank.d397.s11|51-51|,|drug
DDI-DrugBank.d397.s11|53-61|including|drug
DDI-DrugBank.d397.s11|63-82|electrocardiographic|drug
DDI-DrugBank.d397.s11|84-89|QT/QTc|drug
DDI-DrugBank.d397.s11|91-98|interval|drug
DDI-DrugBank.d397.s11|100-111|prolongation|drug
DDI-DrugBank.d397.s11|112-112|,|drug
DDI-DrugBank.d397.s11|114-120|cardiac|drug
DDI-DrugBank.d397.s11|122-127|arrest|drug
DDI-DrugBank.d397.s11|128-128|,|drug
DDI-DrugBank.d397.s11|130-137|torsades|drug
DDI-DrugBank.d397.s11|139-140|de|drug
DDI-DrugBank.d397.s11|142-148|pointes|drug
DDI-DrugBank.d397.s11|149-149|,|drug
DDI-DrugBank.d397.s11|151-153|and|drug
DDI-DrugBank.d397.s11|155-159|other|drug
DDI-DrugBank.d397.s11|161-171|ventricular|drug
DDI-DrugBank.d397.s11|173-183|arrhythmias|drug
DDI-DrugBank.d397.s11|185-188|have|drug
DDI-DrugBank.d397.s11|190-193|been|drug
DDI-DrugBank.d397.s11|195-202|observed|drug
DDI-DrugBank.d397.s11|203-203|.|drug
DDI-DrugBank.d397.s12|0-1|In|drug
DDI-DrugBank.d397.s12|3-10|addition|drug
DDI-DrugBank.d397.s12|11-11|,|drug
DDI-DrugBank.d397.s12|13-18|deaths|drug
DDI-DrugBank.d397.s12|20-23|have|drug
DDI-DrugBank.d397.s12|25-28|been|drug
DDI-DrugBank.d397.s12|30-37|reported|drug
DDI-DrugBank.d397.s12|39-44|rarely|drug
DDI-DrugBank.d397.s12|46-49|with|drug
DDI-DrugBank.d397.s12|51-61|concomitant|drug
DDI-DrugBank.d397.s12|63-76|administration|drug
DDI-DrugBank.d397.s12|78-79|of|drug
DDI-DrugBank.d397.s12|81-91|terfenadine|drug
DDI-DrugBank.d397.s12|93-95|and|drug
DDI-DrugBank.d397.s12|97-108|erythromycin|drug
DDI-DrugBank.d397.s12|109-109|.|drug
DDI-DrugBank.d397.s13|0-4|There|drug
DDI-DrugBank.d397.s13|6-9|have|drug
DDI-DrugBank.d397.s13|11-14|been|drug
DDI-DrugBank.d397.s13|16-28|postmarketing|drug
DDI-DrugBank.d397.s13|30-36|reports|drug
DDI-DrugBank.d397.s13|38-39|of|drug
DDI-DrugBank.d397.s13|41-44|drug|drug
DDI-DrugBank.d397.s13|46-57|interactions|drug
DDI-DrugBank.d397.s13|59-62|when|drug
DDI-DrugBank.d397.s13|64-75|erythromycin|drug
DDI-DrugBank.d397.s13|77-78|is|drug
DDI-DrugBank.d397.s13|80-93|coadministered|drug
DDI-DrugBank.d397.s13|95-98|with|drug
DDI-DrugBank.d397.s13|100-108|cisapride|drug
DDI-DrugBank.d397.s13|109-109|,|drug
DDI-DrugBank.d397.s13|111-119|resulting|drug
DDI-DrugBank.d397.s13|121-122|in|drug
DDI-DrugBank.d397.s13|124-125|QT|drug
DDI-DrugBank.d397.s13|127-138|prolongation|drug
DDI-DrugBank.d397.s13|139-139|,|drug
DDI-DrugBank.d397.s13|141-147|cardiac|drug
DDI-DrugBank.d397.s13|149-158|arrythmias|drug
DDI-DrugBank.d397.s13|159-159|,|drug
DDI-DrugBank.d397.s13|161-171|ventricular|drug
DDI-DrugBank.d397.s13|173-183|tachycardia|drug
DDI-DrugBank.d397.s13|184-184|,|drug
DDI-DrugBank.d397.s13|186-196|ventricular|drug
DDI-DrugBank.d397.s13|198-208|fibrulation|drug
DDI-DrugBank.d397.s13|209-209|,|drug
DDI-DrugBank.d397.s13|211-213|and|drug
DDI-DrugBank.d397.s13|215-222|torsades|drug
DDI-DrugBank.d397.s13|224-225|de|drug
DDI-DrugBank.d397.s13|227-233|pointes|drug
DDI-DrugBank.d397.s13|234-234|,|drug
DDI-DrugBank.d397.s13|236-239|most|drug
DDI-DrugBank.d397.s13|241-244|like|drug
DDI-DrugBank.d397.s13|246-248|due|drug
DDI-DrugBank.d397.s13|250-251|to|drug
DDI-DrugBank.d397.s13|253-262|inhibition|drug
DDI-DrugBank.d397.s13|264-265|of|drug
DDI-DrugBank.d397.s13|267-273|hepatic|drug
DDI-DrugBank.d397.s13|275-284|metabolism|drug
DDI-DrugBank.d397.s13|286-287|of|drug
DDI-DrugBank.d397.s13|289-297|cisapride|drug
DDI-DrugBank.d397.s13|299-300|by|drug
DDI-DrugBank.d397.s13|302-313|erythromycin|drug
DDI-DrugBank.d397.s13|314-314|.|drug
DDI-DrugBank.d397.s14|0-9|Fatalities|drug
DDI-DrugBank.d397.s14|11-14|have|drug
DDI-DrugBank.d397.s14|16-19|been|drug
DDI-DrugBank.d397.s14|21-28|reported|drug
DDI-DrugBank.d397.s14|29-29|.|drug
DDI-DrugBank.d397.s15|0-7|Patients|drug
DDI-DrugBank.d397.s15|9-17|receiving|drug
DDI-DrugBank.d397.s15|19-29|concomitant|drug
DDI-DrugBank.d397.s15|31-40|lovastatin|drug
DDI-DrugBank.d397.s15|42-44|and|drug
DDI-DrugBank.d397.s15|46-57|erythromycin|drug
DDI-DrugBank.d397.s15|59-64|should|drug
DDI-DrugBank.d397.s15|66-67|be|drug
DDI-DrugBank.d397.s15|69-77|carefully|drug
DDI-DrugBank.d397.s15|79-87|monitored|drug
DDI-DrugBank.d397.s15|88-88|;|drug
DDI-DrugBank.d397.s16|0-4|cases|drug
DDI-DrugBank.d397.s16|6-7|of|drug
DDI-DrugBank.d397.s16|9-22|rhabdomyolysis|drug
DDI-DrugBank.d397.s16|24-27|have|drug
DDI-DrugBank.d397.s16|29-32|been|drug
DDI-DrugBank.d397.s16|34-41|reported|drug
DDI-DrugBank.d397.s16|43-44|in|drug
DDI-DrugBank.d397.s16|46-54|seriously|drug
DDI-DrugBank.d397.s16|56-58|ill|drug
DDI-DrugBank.d397.s16|60-67|patients|drug
DDI-DrugBank.d397.s16|68-68|.|drug
DDI-DrugBank.d8.s0|0-3|Both|drug
DDI-DrugBank.d8.s0|5-7|the|drug
DDI-DrugBank.d8.s0|9-17|magnitude|drug
DDI-DrugBank.d8.s0|19-21|and|drug
DDI-DrugBank.d8.s0|23-30|duration|drug
DDI-DrugBank.d8.s0|32-33|of|drug
DDI-DrugBank.d8.s0|35-41|central|drug
DDI-DrugBank.d8.s0|43-49|nervous|drug
DDI-DrugBank.d8.s0|51-56|system|drug
DDI-DrugBank.d8.s0|58-60|and|drug
DDI-DrugBank.d8.s0|62-75|cardiovascular|drug
DDI-DrugBank.d8.s0|77-83|effects|drug
DDI-DrugBank.d8.s0|85-87|may|drug
DDI-DrugBank.d8.s0|89-90|be|drug
DDI-DrugBank.d8.s0|92-99|enhanced|drug
DDI-DrugBank.d8.s0|101-104|when|drug
DDI-DrugBank.d8.s0|106-112|ALFENTA|drug
DDI-DrugBank.d8.s0|114-115|is|drug
DDI-DrugBank.d8.s0|117-128|administered|drug
DDI-DrugBank.d8.s0|130-131|in|drug
DDI-DrugBank.d8.s0|133-143|combination|drug
DDI-DrugBank.d8.s0|145-148|with|drug
DDI-DrugBank.d8.s0|150-154|other|drug
DDI-DrugBank.d8.s0|156-158|CNS|drug
DDI-DrugBank.d8.s0|160-170|depressants|drug
DDI-DrugBank.d8.s0|172-175|such|drug
DDI-DrugBank.d8.s0|177-178|as|drug
DDI-DrugBank.d8.s0|180-191|barbiturates|drug
DDI-DrugBank.d8.s0|192-192|,|drug
DDI-DrugBank.d8.s0|194-206|tranquilizers|drug
DDI-DrugBank.d8.s0|207-207|,|drug
DDI-DrugBank.d8.s0|209-215|opioids|drug
DDI-DrugBank.d8.s0|216-216|,|drug
DDI-DrugBank.d8.s0|218-219|or|drug
DDI-DrugBank.d8.s0|221-230|inhalation|drug
DDI-DrugBank.d8.s0|232-238|general|drug
DDI-DrugBank.d8.s0|240-250|anesthetics|drug
DDI-DrugBank.d8.s0|251-251|.|drug
DDI-DrugBank.d8.s1|0-12|Postoperative|drug
DDI-DrugBank.d8.s1|14-24|respiratory|drug
DDI-DrugBank.d8.s1|26-35|depression|drug
DDI-DrugBank.d8.s1|37-39|may|drug
DDI-DrugBank.d8.s1|41-42|be|drug
DDI-DrugBank.d8.s1|44-51|enhanced|drug
DDI-DrugBank.d8.s1|53-54|or|drug
DDI-DrugBank.d8.s1|56-64|prolonged|drug
DDI-DrugBank.d8.s1|66-67|by|drug
DDI-DrugBank.d8.s1|69-73|these|drug
DDI-DrugBank.d8.s1|75-80|agents|drug
DDI-DrugBank.d8.s1|81-81|.|drug
DDI-DrugBank.d8.s2|0-1|In|drug
DDI-DrugBank.d8.s2|3-6|such|drug
DDI-DrugBank.d8.s2|8-12|cases|drug
DDI-DrugBank.d8.s2|14-15|of|drug
DDI-DrugBank.d8.s2|17-24|combined|drug
DDI-DrugBank.d8.s2|26-34|treatment|drug
DDI-DrugBank.d8.s2|35-35|,|drug
DDI-DrugBank.d8.s2|37-39|the|drug
DDI-DrugBank.d8.s2|41-44|dose|drug
DDI-DrugBank.d8.s2|46-47|of|drug
DDI-DrugBank.d8.s2|49-51|one|drug
DDI-DrugBank.d8.s2|53-54|or|drug
DDI-DrugBank.d8.s2|56-59|both|drug
DDI-DrugBank.d8.s2|61-66|agents|drug
DDI-DrugBank.d8.s2|68-73|should|drug
DDI-DrugBank.d8.s2|75-76|be|drug
DDI-DrugBank.d8.s2|78-84|reduced|drug
DDI-DrugBank.d8.s2|85-85|.|drug
DDI-DrugBank.d8.s3|0-6|Limited|drug
DDI-DrugBank.d8.s3|8-15|clinical|drug
DDI-DrugBank.d8.s3|17-26|experience|drug
DDI-DrugBank.d8.s3|28-36|indicates|drug
DDI-DrugBank.d8.s3|38-41|that|drug
DDI-DrugBank.d8.s3|43-54|requirements|drug
DDI-DrugBank.d8.s3|56-58|for|drug
DDI-DrugBank.d8.s3|60-67|volatile|drug
DDI-DrugBank.d8.s3|69-78|inhalation|drug
DDI-DrugBank.d8.s3|80-90|anesthetics|drug
DDI-DrugBank.d8.s3|92-94|are|drug
DDI-DrugBank.d8.s3|96-102|reduced|drug
DDI-DrugBank.d8.s3|104-105|by|drug
DDI-DrugBank.d8.s3|107-108|30|drug
DDI-DrugBank.d8.s3|110-111|to|drug
DDI-DrugBank.d8.s3|113-114|50|drug
DDI-DrugBank.d8.s3|115-115|%|drug
DDI-DrugBank.d8.s3|117-119|for|drug
DDI-DrugBank.d8.s3|121-123|the|drug
DDI-DrugBank.d8.s3|125-129|first|drug
DDI-DrugBank.d8.s3|131-135|sixty|drug
DDI-DrugBank.d8.s3|137-137|(|drug
DDI-DrugBank.d8.s3|138-139|60|drug
DDI-DrugBank.d8.s3|140-140|)|drug
DDI-DrugBank.d8.s3|142-148|minutes|drug
DDI-DrugBank.d8.s3|150-158|following|drug
DDI-DrugBank.d8.s3|160-166|ALFENTA|drug
DDI-DrugBank.d8.s3|168-176|induction|drug
DDI-DrugBank.d8.s3|178-180|The|drug
DDI-DrugBank.d8.s3|182-192|concomitant|drug
DDI-DrugBank.d8.s3|194-196|use|drug
DDI-DrugBank.d8.s3|198-199|of|drug
DDI-DrugBank.d8.s3|201-212|erythromycin|drug
DDI-DrugBank.d8.s3|214-217|with|drug
DDI-DrugBank.d8.s3|219-225|ALFENTA|drug
DDI-DrugBank.d8.s3|227-229|can|drug
DDI-DrugBank.d8.s3|231-243|significantly|drug
DDI-DrugBank.d8.s3|245-251|inhibit|drug
DDI-DrugBank.d8.s3|253-259|ALFENTA|drug
DDI-DrugBank.d8.s3|261-269|clearance|drug
DDI-DrugBank.d8.s3|271-273|and|drug
DDI-DrugBank.d8.s3|275-277|may|drug
DDI-DrugBank.d8.s3|279-286|increase|drug
DDI-DrugBank.d8.s3|288-290|the|drug
DDI-DrugBank.d8.s3|292-295|risk|drug
DDI-DrugBank.d8.s3|297-298|of|drug
DDI-DrugBank.d8.s3|300-308|prolonged|drug
DDI-DrugBank.d8.s3|310-311|or|drug
DDI-DrugBank.d8.s3|313-319|delayed|drug
DDI-DrugBank.d8.s3|321-331|respiratory|drug
DDI-DrugBank.d8.s3|333-342|depression|drug
DDI-DrugBank.d8.s3|343-343|.|drug
DDI-DrugBank.d8.s4|0-9|Cimetidine|brand
DDI-DrugBank.d8.s4|11-17|reduces|drug
DDI-DrugBank.d8.s4|19-21|the|drug
DDI-DrugBank.d8.s4|23-31|clearance|drug
DDI-DrugBank.d8.s4|33-34|of|drug
DDI-DrugBank.d8.s4|36-42|ALFENTA|drug
DDI-DrugBank.d8.s4|43-43|.|drug
DDI-DrugBank.d8.s5|0-8|Therefore|drug
DDI-DrugBank.d8.s5|10-16|smaller|drug
DDI-DrugBank.d8.s5|18-24|ALFENTA|drug
DDI-DrugBank.d8.s5|26-30|doses|drug
DDI-DrugBank.d8.s5|32-35|will|drug
DDI-DrugBank.d8.s5|37-38|be|drug
DDI-DrugBank.d8.s5|40-47|required|drug
DDI-DrugBank.d8.s5|49-52|with|drug
DDI-DrugBank.d8.s5|54-62|prolonged|drug
DDI-DrugBank.d8.s5|64-77|administration|drug
DDI-DrugBank.d8.s5|79-81|and|drug
DDI-DrugBank.d8.s5|83-85|the|drug
DDI-DrugBank.d8.s5|87-94|duration|drug
DDI-DrugBank.d8.s5|96-97|of|drug
DDI-DrugBank.d8.s5|99-104|action|drug
DDI-DrugBank.d8.s5|106-107|of|drug
DDI-DrugBank.d8.s5|109-115|ALFENTA|drug
DDI-DrugBank.d8.s5|117-118|my|drug
DDI-DrugBank.d8.s5|120-121|be|drug
DDI-DrugBank.d8.s5|123-130|extended|drug
DDI-DrugBank.d8.s5|131-131|.|drug
DDI-DrugBank.d8.s6|0-12|Perioperative|drug
DDI-DrugBank.d8.s6|14-27|administration|drug
DDI-DrugBank.d8.s6|29-30|of|drug
DDI-DrugBank.d8.s6|32-36|drugs|drug
DDI-DrugBank.d8.s6|38-46|affecting|drug
DDI-DrugBank.d8.s6|48-54|hepatic|drug
DDI-DrugBank.d8.s6|56-60|blood|drug
DDI-DrugBank.d8.s6|62-65|flow|drug
DDI-DrugBank.d8.s6|67-68|or|drug
DDI-DrugBank.d8.s6|70-75|enzyme|drug
DDI-DrugBank.d8.s6|77-84|function|drug
DDI-DrugBank.d8.s6|86-88|may|drug
DDI-DrugBank.d8.s6|90-95|reduce|drug
DDI-DrugBank.d8.s6|97-102|plasma|drug
DDI-DrugBank.d8.s6|104-112|clearance|drug
DDI-DrugBank.d8.s6|114-116|and|drug
DDI-DrugBank.d8.s6|118-124|prolong|drug
DDI-DrugBank.d8.s6|126-133|recovery|drug
DDI-DrugBank.d8.s6|134-134|.|drug
DDI-DrugBank.d446.s0|0-15|Chlorotrianisene|drug
DDI-DrugBank.d446.s0|17-19|may|drug
DDI-DrugBank.d446.s0|21-28|interact|drug
DDI-DrugBank.d446.s0|30-33|with|drug
DDI-DrugBank.d446.s0|35-49|antidepressants|drug
DDI-DrugBank.d446.s0|50-50|,|drug
DDI-DrugBank.d446.s0|52-58|aspirin|drug
DDI-DrugBank.d446.s0|59-59|,|drug
DDI-DrugBank.d446.s0|61-72|barbiturates|drug
DDI-DrugBank.d446.s0|73-73|,|drug
DDI-DrugBank.d446.s0|75-87|bromocriptine|drug
DDI-DrugBank.d446.s0|88-88|,|drug
DDI-DrugBank.d446.s0|90-96|calcium|drug
DDI-DrugBank.d446.s0|98-108|supplements|drug
DDI-DrugBank.d446.s0|109-109|,|drug
DDI-DrugBank.d446.s0|111-125|corticosteroids|drug
DDI-DrugBank.d446.s0|126-126|,|drug
DDI-DrugBank.d446.s0|128-140|corticotropin|drug
DDI-DrugBank.d446.s0|141-141|,|drug
DDI-DrugBank.d446.s0|143-154|cyclosporine|drug
DDI-DrugBank.d446.s0|155-155|,|drug
DDI-DrugBank.d446.s0|157-166|dantrolene|drug
DDI-DrugBank.d446.s0|167-167|,|drug
DDI-DrugBank.d446.s0|169-176|nicotine|drug
DDI-DrugBank.d446.s0|177-177|,|drug
DDI-DrugBank.d446.s0|179-188|somatropin|drug
DDI-DrugBank.d446.s0|189-189|,|drug
DDI-DrugBank.d446.s0|191-199|tamoxifen|drug
DDI-DrugBank.d446.s0|200-200|,|drug
DDI-DrugBank.d446.s0|202-204|and|drug
DDI-DrugBank.d446.s0|206-213|warfarin|drug
DDI-DrugBank.d446.s0|214-214|.|drug
DDI-DrugBank.d715.s0|0-6|Caution|drug
DDI-DrugBank.d715.s0|8-13|should|drug
DDI-DrugBank.d715.s0|15-16|be|drug
DDI-DrugBank.d715.s0|18-25|observed|drug
DDI-DrugBank.d715.s0|27-28|in|drug
DDI-DrugBank.d715.s0|30-42|administering|drug
DDI-DrugBank.d715.s0|44-49|DEMSER|drug
DDI-DrugBank.d715.s0|51-52|to|drug
DDI-DrugBank.d715.s0|54-61|patients|drug
DDI-DrugBank.d715.s0|63-71|receiving|drug
DDI-DrugBank.d715.s0|73-86|phenothiazines|drug
DDI-DrugBank.d715.s0|88-89|or|drug
DDI-DrugBank.d715.s0|91-101|haloperidol|drug
DDI-DrugBank.d715.s0|103-109|because|drug
DDI-DrugBank.d715.s0|111-113|the|drug
DDI-DrugBank.d715.s0|115-128|extrapyramidal|drug
DDI-DrugBank.d715.s0|130-136|effects|drug
DDI-DrugBank.d715.s0|138-139|of|drug
DDI-DrugBank.d715.s0|141-145|these|drug
DDI-DrugBank.d715.s0|147-151|drugs|drug
DDI-DrugBank.d715.s0|153-155|can|drug
DDI-DrugBank.d715.s0|157-158|be|drug
DDI-DrugBank.d715.s0|160-167|expected|drug
DDI-DrugBank.d715.s0|169-170|to|drug
DDI-DrugBank.d715.s0|172-173|be|drug
DDI-DrugBank.d715.s0|175-185|potentiated|drug
DDI-DrugBank.d715.s0|187-188|by|drug
DDI-DrugBank.d715.s0|190-199|inhibition|drug
DDI-DrugBank.d715.s0|201-202|of|drug
DDI-DrugBank.d715.s0|204-216|catecholamine|drug
DDI-DrugBank.d715.s0|218-226|synthesis|drug
DDI-DrugBank.d715.s0|227-227|.|drug
DDI-DrugBank.d715.s1|0-9|Concurrent|drug
DDI-DrugBank.d715.s1|11-13|use|drug
DDI-DrugBank.d715.s1|15-16|of|drug
DDI-DrugBank.d715.s1|18-23|DEMSER|drug
DDI-DrugBank.d715.s1|25-28|with|drug
DDI-DrugBank.d715.s1|30-36|alcohol|drug
DDI-DrugBank.d715.s1|38-39|or|drug
DDI-DrugBank.d715.s1|41-45|other|drug
DDI-DrugBank.d715.s1|47-49|CNS|drug
DDI-DrugBank.d715.s1|51-61|depressants|drug
DDI-DrugBank.d715.s1|63-65|can|drug
DDI-DrugBank.d715.s1|67-74|increase|drug
DDI-DrugBank.d715.s1|76-80|their|drug
DDI-DrugBank.d715.s1|82-89|sedative|drug
DDI-DrugBank.d715.s1|91-97|effects|drug
DDI-DrugBank.d715.s1|98-98|.|drug
DDI-MedLine.d59.s0|0-0|A|drug
DDI-MedLine.d59.s0|2-9|proposed|drug
DDI-MedLine.d59.s0|11-19|mechanism|drug
DDI-MedLine.d59.s0|21-23|for|drug
DDI-MedLine.d59.s0|25-27|the|drug
DDI-MedLine.d59.s0|29-40|potentiation|drug
DDI-MedLine.d59.s0|42-43|of|drug
DDI-MedLine.d59.s0|45-57|cAMP-mediated|drug
DDI-MedLine.d59.s0|59-62|acid|drug
DDI-MedLine.d59.s0|64-72|secretion|drug
DDI-MedLine.d59.s0|74-75|by|drug
DDI-MedLine.d59.s0|77-85|carbachol|drug
DDI-MedLine.d59.s0|86-86|.|drug
DDI-MedLine.d59.s1|0-3|Acid|drug
DDI-MedLine.d59.s1|5-13|secretion|drug
DDI-MedLine.d59.s1|15-16|in|drug
DDI-MedLine.d59.s1|18-25|isolated|drug
DDI-MedLine.d59.s1|27-32|rabbit|drug
DDI-MedLine.d59.s1|34-40|gastric|drug
DDI-MedLine.d59.s1|42-47|glands|drug
DDI-MedLine.d59.s1|49-51|was|drug
DDI-MedLine.d59.s1|53-61|monitored|drug
DDI-MedLine.d59.s1|63-64|by|drug
DDI-MedLine.d59.s1|66-68|the|drug
DDI-MedLine.d59.s1|70-81|accumulation|drug
DDI-MedLine.d59.s1|83-84|of|drug
DDI-MedLine.d59.s1|86-86|[|drug
DDI-MedLine.d59.s1|87-87|(|drug
DDI-MedLine.d59.s1|88-89|14|drug
DDI-MedLine.d59.s1|90-90|)|drug
DDI-MedLine.d59.s1|91-91|C|drug
DDI-MedLine.d59.s1|92-92|]|drug
DDI-MedLine.d59.s1|93-103|aminopyrine|drug
DDI-MedLine.d59.s1|104-104|.|drug
DDI-MedLine.d59.s2|0-10|Stimulation|drug
DDI-MedLine.d59.s2|12-13|of|drug
DDI-MedLine.d59.s2|15-17|the|drug
DDI-MedLine.d59.s2|19-24|glands|drug
DDI-MedLine.d59.s2|26-29|with|drug
DDI-MedLine.d59.s2|31-39|carbachol|drug
DDI-MedLine.d59.s2|41-55|synergistically|drug
DDI-MedLine.d59.s2|57-65|augmented|drug
DDI-MedLine.d59.s2|67-69|the|drug
DDI-MedLine.d59.s2|71-78|response|drug
DDI-MedLine.d59.s2|80-81|to|drug
DDI-MedLine.d59.s2|83-91|dibutyryl|drug
DDI-MedLine.d59.s2|93-96|cAMP|drug
DDI-MedLine.d59.s2|97-97|.|drug
DDI-MedLine.d59.s3|0-2|The|drug
DDI-MedLine.d59.s3|4-15|augmentation|drug
DDI-MedLine.d59.s3|17-25|persisted|drug
DDI-MedLine.d59.s3|27-30|even|drug
DDI-MedLine.d59.s3|32-36|after|drug
DDI-MedLine.d59.s3|38-46|carbachol|drug
DDI-MedLine.d59.s3|48-50|was|drug
DDI-MedLine.d59.s3|52-57|washed|drug
DDI-MedLine.d59.s3|59-61|out|drug
DDI-MedLine.d59.s3|63-65|and|drug
DDI-MedLine.d59.s3|67-69|was|drug
DDI-MedLine.d59.s3|71-79|resistant|drug
DDI-MedLine.d59.s3|81-82|to|drug
DDI-MedLine.d59.s3|84-91|chelated|drug
DDI-MedLine.d59.s3|93-105|extracellular|drug
DDI-MedLine.d59.s3|107-108|Ca|drug
DDI-MedLine.d59.s3|109-109|(|drug
DDI-MedLine.d59.s3|110-111|2+|drug
DDI-MedLine.d59.s3|112-112|)|drug
DDI-MedLine.d59.s3|114-116|and|drug
DDI-MedLine.d59.s3|118-119|to|drug
DDI-MedLine.d59.s3|121-130|inhibitors|drug
DDI-MedLine.d59.s3|132-133|of|drug
DDI-MedLine.d59.s3|135-140|either|drug
DDI-MedLine.d59.s3|142-148|protein|drug
DDI-MedLine.d59.s3|150-155|kinase|drug
DDI-MedLine.d59.s3|157-157|C|drug
DDI-MedLine.d59.s3|159-160|or|drug
DDI-MedLine.d59.s3|162-171|calmodulin|drug
DDI-MedLine.d59.s3|173-178|kinase|drug
DDI-MedLine.d59.s3|180-181|II|drug
DDI-MedLine.d59.s3|182-182|.|drug
DDI-MedLine.d59.s4|0-11|Cytochalasin|drug
DDI-MedLine.d59.s4|13-13|D|drug
DDI-MedLine.d59.s4|15-16|at|drug
DDI-MedLine.d59.s4|18-19|10|drug
DDI-MedLine.d59.s4|21-26|microM|drug
DDI-MedLine.d59.s4|28-41|preferentially|drug
DDI-MedLine.d59.s4|43-49|blocked|drug
DDI-MedLine.d59.s4|51-53|the|drug
DDI-MedLine.d59.s4|55-63|secretory|drug
DDI-MedLine.d59.s4|65-70|effect|drug
DDI-MedLine.d59.s4|72-73|of|drug
DDI-MedLine.d59.s4|75-83|carbachol|drug
DDI-MedLine.d59.s4|85-87|and|drug
DDI-MedLine.d59.s4|89-91|its|drug
DDI-MedLine.d59.s4|93-101|synergism|drug
DDI-MedLine.d59.s4|103-106|with|drug
DDI-MedLine.d59.s4|108-111|cAMP|drug
DDI-MedLine.d59.s4|112-112|,|drug
DDI-MedLine.d59.s4|114-120|whereas|drug
DDI-MedLine.d59.s4|122-123|it|drug
DDI-MedLine.d59.s4|125-127|had|drug
DDI-MedLine.d59.s4|129-130|no|drug
DDI-MedLine.d59.s4|132-137|effect|drug
DDI-MedLine.d59.s4|139-140|on|drug
DDI-MedLine.d59.s4|142-151|histamine-|drug
DDI-MedLine.d59.s4|153-154|or|drug
DDI-MedLine.d59.s4|156-170|cAMP-stimulated|drug
DDI-MedLine.d59.s4|172-175|acid|drug
DDI-MedLine.d59.s4|177-185|secretion|drug
DDI-MedLine.d59.s4|187-192|within|drug
DDI-MedLine.d59.s4|194-195|15|drug
DDI-MedLine.d59.s4|197-199|min|drug
DDI-MedLine.d59.s4|200-200|.|drug
DDI-MedLine.d59.s5|0-11|Cytochalasin|drug
DDI-MedLine.d59.s5|13-13|D|drug
DDI-MedLine.d59.s5|15-23|inhibited|drug
DDI-MedLine.d59.s5|25-27|the|drug
DDI-MedLine.d59.s5|29-48|carbachol-stimulated|drug
DDI-MedLine.d59.s5|50-62|intracellular|drug
DDI-MedLine.d59.s5|64-65|Ca|drug
DDI-MedLine.d59.s5|66-66|(|drug
DDI-MedLine.d59.s5|67-68|2+|drug
DDI-MedLine.d59.s5|69-69|)|drug
DDI-MedLine.d59.s5|71-83|concentration|drug
DDI-MedLine.d59.s5|85-85|(|drug
DDI-MedLine.d59.s5|86-86|[|drug
DDI-MedLine.d59.s5|87-88|Ca|drug
DDI-MedLine.d59.s5|89-89|(|drug
DDI-MedLine.d59.s5|90-91|2+|drug
DDI-MedLine.d59.s5|92-92|)|drug
DDI-MedLine.d59.s5|93-93|]|drug
DDI-MedLine.d59.s5|94-94|(|drug
DDI-MedLine.d59.s5|95-95|i|drug
DDI-MedLine.d59.s5|96-96|)|drug
DDI-MedLine.d59.s5|97-97|)|drug
DDI-MedLine.d59.s5|99-106|increase|drug
DDI-MedLine.d59.s5|108-110|due|drug
DDI-MedLine.d59.s5|112-113|to|drug
DDI-MedLine.d59.s5|115-121|release|drug
DDI-MedLine.d59.s5|123-126|from|drug
DDI-MedLine.d59.s5|128-130|the|drug
DDI-MedLine.d59.s5|132-133|Ca|drug
DDI-MedLine.d59.s5|134-134|(|drug
DDI-MedLine.d59.s5|135-136|2+|drug
DDI-MedLine.d59.s5|137-137|)|drug
DDI-MedLine.d59.s5|139-143|store|drug
DDI-MedLine.d59.s5|144-144|.|drug
DDI-MedLine.d59.s6|0-8|Treatment|drug
DDI-MedLine.d59.s6|10-11|of|drug
DDI-MedLine.d59.s6|13-15|the|drug
DDI-MedLine.d59.s6|17-22|glands|drug
DDI-MedLine.d59.s6|24-27|with|drug
DDI-MedLine.d59.s6|29-40|cytochalasin|drug
DDI-MedLine.d59.s6|42-42|D|drug
DDI-MedLine.d59.s6|44-56|redistributed|drug
DDI-MedLine.d59.s6|58-61|type|drug
DDI-MedLine.d59.s6|63-63|3|drug
DDI-MedLine.d59.s6|65-72|inositol|drug
DDI-MedLine.d59.s6|74-92|1,4,5-trisphosphate|drug
DDI-MedLine.d59.s6|94-101|receptor|drug
DDI-MedLine.d59.s6|103-103|(|drug
DDI-MedLine.d59.s6|104-106|the|drug
DDI-MedLine.d59.s6|108-112|major|drug
DDI-MedLine.d59.s6|114-120|subtype|drug
DDI-MedLine.d59.s6|122-123|in|drug
DDI-MedLine.d59.s6|125-127|the|drug
DDI-MedLine.d59.s6|129-136|parietal|drug
DDI-MedLine.d59.s6|138-141|cell|drug
DDI-MedLine.d59.s6|142-142|)|drug
DDI-MedLine.d59.s6|144-147|from|drug
DDI-MedLine.d59.s6|149-151|the|drug
DDI-MedLine.d59.s6|153-160|fraction|drug
DDI-MedLine.d59.s6|162-171|containing|drug
DDI-MedLine.d59.s6|173-181|membranes|drug
DDI-MedLine.d59.s6|183-184|of|drug
DDI-MedLine.d59.s6|186-190|large|drug
DDI-MedLine.d59.s6|192-195|size|drug
DDI-MedLine.d59.s6|197-198|to|drug
DDI-MedLine.d59.s6|200-202|the|drug
DDI-MedLine.d59.s6|204-213|microsomal|drug
DDI-MedLine.d59.s6|215-222|fraction|drug
DDI-MedLine.d59.s6|223-223|,|drug
DDI-MedLine.d59.s6|225-234|suggesting|drug
DDI-MedLine.d59.s6|236-236|a|drug
DDI-MedLine.d59.s6|238-249|dissociation|drug
DDI-MedLine.d59.s6|251-252|of|drug
DDI-MedLine.d59.s6|254-256|the|drug
DDI-MedLine.d59.s6|258-262|store|drug
DDI-MedLine.d59.s6|264-267|from|drug
DDI-MedLine.d59.s6|269-271|the|drug
DDI-MedLine.d59.s6|273-278|plasma|drug
DDI-MedLine.d59.s6|280-287|membrane|drug
DDI-MedLine.d59.s6|288-288|.|drug
DDI-MedLine.d59.s7|0-4|These|drug
DDI-MedLine.d59.s7|6-13|findings|drug
DDI-MedLine.d59.s7|15-21|suggest|drug
DDI-MedLine.d59.s7|23-26|that|drug
DDI-MedLine.d59.s7|28-40|intracellular|drug
DDI-MedLine.d59.s7|42-43|Ca|drug
DDI-MedLine.d59.s7|44-44|(|drug
DDI-MedLine.d59.s7|45-46|2+|drug
DDI-MedLine.d59.s7|47-47|)|drug
DDI-MedLine.d59.s7|49-55|release|drug
DDI-MedLine.d59.s7|57-58|by|drug
DDI-MedLine.d59.s7|60-70|cholinergic|drug
DDI-MedLine.d59.s7|72-82|stimulation|drug
DDI-MedLine.d59.s7|84-85|is|drug
DDI-MedLine.d59.s7|87-94|critical|drug
DDI-MedLine.d59.s7|96-98|for|drug
DDI-MedLine.d59.s7|100-110|determining|drug
DDI-MedLine.d59.s7|112-120|synergism|drug
DDI-MedLine.d59.s7|122-125|with|drug
DDI-MedLine.d59.s7|127-130|cAMP|drug
DDI-MedLine.d59.s7|132-133|in|drug
DDI-MedLine.d59.s7|135-142|parietal|drug
DDI-MedLine.d59.s7|144-147|cell|drug
DDI-MedLine.d59.s7|149-158|activation|drug
DDI-MedLine.d59.s7|160-162|and|drug
DDI-MedLine.d59.s7|164-167|that|drug
DDI-MedLine.d59.s7|169-178|functional|drug
DDI-MedLine.d59.s7|180-187|coupling|drug
DDI-MedLine.d59.s7|189-195|between|drug
DDI-MedLine.d59.s7|197-199|the|drug
DDI-MedLine.d59.s7|201-202|Ca|drug
DDI-MedLine.d59.s7|203-203|(|drug
DDI-MedLine.d59.s7|204-205|2+|drug
DDI-MedLine.d59.s7|206-206|)|drug
DDI-MedLine.d59.s7|208-212|store|drug
DDI-MedLine.d59.s7|214-216|and|drug
DDI-MedLine.d59.s7|218-220|the|drug
DDI-MedLine.d59.s7|222-229|receptor|drug
DDI-MedLine.d59.s7|231-232|is|drug
DDI-MedLine.d59.s7|234-243|maintained|drug
DDI-MedLine.d59.s7|245-246|by|drug
DDI-MedLine.d59.s7|248-252|actin|drug
DDI-MedLine.d59.s7|254-267|microfilaments|drug
DDI-MedLine.d59.s7|268-268|.|drug
DDI-DrugBank.d671.s0|0-2|The|drug
DDI-DrugBank.d671.s0|4-14|interaction|drug
DDI-DrugBank.d671.s0|16-17|of|drug
DDI-DrugBank.d671.s0|19-24|CYLERT|drug
DDI-DrugBank.d671.s0|26-26|(|drug
DDI-DrugBank.d671.s0|27-34|pemoline|drug
DDI-DrugBank.d671.s0|35-35|)|drug
DDI-DrugBank.d671.s0|37-40|with|drug
DDI-DrugBank.d671.s0|42-46|other|drug
DDI-DrugBank.d671.s0|48-52|drugs|drug
DDI-DrugBank.d671.s0|54-56|has|drug
DDI-DrugBank.d671.s0|58-60|not|drug
DDI-DrugBank.d671.s0|62-65|been|drug
DDI-DrugBank.d671.s0|67-73|studied|drug
DDI-DrugBank.d671.s0|75-76|in|drug
DDI-DrugBank.d671.s0|78-83|humans|drug
DDI-DrugBank.d671.s0|84-84|.|drug
DDI-DrugBank.d671.s1|0-7|Patients|drug
DDI-DrugBank.d671.s1|9-11|who|drug
DDI-DrugBank.d671.s1|13-15|are|drug
DDI-DrugBank.d671.s1|17-25|receiving|drug
DDI-DrugBank.d671.s1|27-32|CYLERT|drug
DDI-DrugBank.d671.s1|34-45|concurrently|drug
DDI-DrugBank.d671.s1|47-50|with|drug
DDI-DrugBank.d671.s1|52-56|other|drug
DDI-DrugBank.d671.s1|58-62|drugs|drug
DDI-DrugBank.d671.s1|63-63|,|drug
DDI-DrugBank.d671.s1|65-74|especially|drug
DDI-DrugBank.d671.s1|76-80|drugs|drug
DDI-DrugBank.d671.s1|82-85|with|drug
DDI-DrugBank.d671.s1|87-89|CNS|drug
DDI-DrugBank.d671.s1|91-98|activity|drug
DDI-DrugBank.d671.s1|99-99|,|drug
DDI-DrugBank.d671.s1|101-106|should|drug
DDI-DrugBank.d671.s1|108-109|be|drug
DDI-DrugBank.d671.s1|111-119|monitored|drug
DDI-DrugBank.d671.s1|121-129|carefully|drug
DDI-DrugBank.d671.s1|130-130|.|drug
DDI-DrugBank.d671.s2|0-8|Decreased|drug
DDI-DrugBank.d671.s2|10-16|seizure|drug
DDI-DrugBank.d671.s2|18-26|threshold|drug
DDI-DrugBank.d671.s2|28-30|has|drug
DDI-DrugBank.d671.s2|32-35|been|drug
DDI-DrugBank.d671.s2|37-44|reported|drug
DDI-DrugBank.d671.s2|46-47|in|drug
DDI-DrugBank.d671.s2|49-56|patients|drug
DDI-DrugBank.d671.s2|58-66|receiving|drug
DDI-DrugBank.d671.s2|68-73|CYLERT|drug
DDI-DrugBank.d671.s2|75-87|concomitantly|drug
DDI-DrugBank.d671.s2|89-92|with|drug
DDI-DrugBank.d671.s2|94-106|antiepileptic|drug
DDI-DrugBank.d671.s2|108-118|medications|drug
DDI-DrugBank.d671.s2|119-119|.|drug
DDI-DrugBank.d181.s0|0-7|Oxytocin|brand
DDI-DrugBank.d181.s0|9-10|or|drug
DDI-DrugBank.d181.s0|12-16|other|drug
DDI-DrugBank.d181.s0|18-26|oxytocics|drug
DDI-DrugBank.d181.s0|28-28|(|drug
DDI-DrugBank.d181.s0|29-38|concurrent|drug
DDI-DrugBank.d181.s0|40-42|use|drug
DDI-DrugBank.d181.s0|44-47|with|drug
DDI-DrugBank.d181.s0|49-57|dinoprost|drug
DDI-DrugBank.d181.s0|59-61|may|drug
DDI-DrugBank.d181.s0|63-68|result|drug
DDI-DrugBank.d181.s0|70-71|in|drug
DDI-DrugBank.d181.s0|73-79|uterine|drug
DDI-DrugBank.d181.s0|81-90|hypertonus|drug
DDI-DrugBank.d181.s0|91-91|,|drug
DDI-DrugBank.d181.s0|93-100|possibly|drug
DDI-DrugBank.d181.s0|102-108|causing|drug
DDI-DrugBank.d181.s0|110-116|uterine|drug
DDI-DrugBank.d181.s0|118-124|rupture|drug
DDI-DrugBank.d181.s0|126-127|or|drug
DDI-DrugBank.d181.s0|129-136|cervical|drug
DDI-DrugBank.d181.s0|138-147|laceration|drug
DDI-DrugBank.d181.s0|148-148|,|drug
DDI-DrugBank.d181.s0|150-159|especially|drug
DDI-DrugBank.d181.s0|161-162|in|drug
DDI-DrugBank.d181.s0|164-166|the|drug
DDI-DrugBank.d181.s0|168-174|absence|drug
DDI-DrugBank.d181.s0|176-177|of|drug
DDI-DrugBank.d181.s0|179-186|adequate|drug
DDI-DrugBank.d181.s0|188-195|cervical|drug
DDI-DrugBank.d181.s0|197-206|dilatation|drug
DDI-DrugBank.d181.s0|207-207|;|drug
DDI-DrugBank.d181.s1|0-7|although|drug
DDI-DrugBank.d181.s1|9-20|combinations|drug
DDI-DrugBank.d181.s1|22-24|are|drug
DDI-DrugBank.d181.s1|26-34|sometimes|drug
DDI-DrugBank.d181.s1|36-39|used|drug
DDI-DrugBank.d181.s1|41-43|for|drug
DDI-DrugBank.d181.s1|45-55|therapeutic|drug
DDI-DrugBank.d181.s1|57-65|advantage|drug
DDI-DrugBank.d181.s1|66-66|,|drug
DDI-DrugBank.d181.s1|68-71|when|drug
DDI-DrugBank.d181.s1|73-76|used|drug
DDI-DrugBank.d181.s1|78-89|concurrently|drug
DDI-DrugBank.d181.s1|90-90|,|drug
DDI-DrugBank.d181.s1|92-98|patient|drug
DDI-DrugBank.d181.s1|100-105|should|drug
DDI-DrugBank.d181.s1|107-108|be|drug
DDI-DrugBank.d181.s1|110-116|closely|drug
DDI-DrugBank.d181.s1|118-126|monitored|drug
DDI-DrugBank.d181.s1|127-127|.|drug
DDI-DrugBank.d317.s0|0-14|DRUG/LABORATORY|drug
DDI-DrugBank.d317.s0|16-19|TEST|drug
DDI-DrugBank.d317.s0|21-32|INTERACTIONS|drug
DDI-DrugBank.d317.s0|34-34|1|drug
DDI-DrugBank.d317.s0|35-35|.|drug
DDI-DrugBank.d317.s1|0-10|Accelerated|drug
DDI-DrugBank.d317.s1|12-22|prothrombin|drug
DDI-DrugBank.d317.s1|24-27|time|drug
DDI-DrugBank.d317.s1|28-28|,|drug
DDI-DrugBank.d317.s1|30-36|partial|drug
DDI-DrugBank.d317.s1|38-51|thromboplastin|drug
DDI-DrugBank.d317.s1|53-56|time|drug
DDI-DrugBank.d317.s1|57-57|,|drug
DDI-DrugBank.d317.s1|59-61|and|drug
DDI-DrugBank.d317.s1|63-70|platelet|drug
DDI-DrugBank.d317.s1|72-82|aggregation|drug
DDI-DrugBank.d317.s1|84-87|time|drug
DDI-DrugBank.d317.s1|88-88|;|drug
DDI-DrugBank.d317.s2|0-8|increased|drug
DDI-DrugBank.d317.s2|10-17|platelet|drug
DDI-DrugBank.d317.s2|19-23|count|drug
DDI-DrugBank.d317.s2|24-24|;|drug
DDI-DrugBank.d317.s3|0-8|increased|drug
DDI-DrugBank.d317.s3|10-16|factors|drug
DDI-DrugBank.d317.s3|18-19|II|drug
DDI-DrugBank.d317.s3|20-20|,|drug
DDI-DrugBank.d317.s3|22-24|VII|drug
DDI-DrugBank.d317.s3|26-32|antigen|drug
DDI-DrugBank.d317.s3|33-33|,|drug
DDI-DrugBank.d317.s3|35-38|VIII|drug
DDI-DrugBank.d317.s3|40-46|antigen|drug
DDI-DrugBank.d317.s3|47-47|,|drug
DDI-DrugBank.d317.s3|49-52|VIII|drug
DDI-DrugBank.d317.s3|54-62|coagulant|drug
DDI-DrugBank.d317.s3|64-71|activity|drug
DDI-DrugBank.d317.s3|72-72|,|drug
DDI-DrugBank.d317.s3|74-75|IX|drug
DDI-DrugBank.d317.s3|76-76|,|drug
DDI-DrugBank.d317.s3|78-78|X|drug
DDI-DrugBank.d317.s3|79-79|,|drug
DDI-DrugBank.d317.s3|81-83|XII|drug
DDI-DrugBank.d317.s3|84-84|,|drug
DDI-DrugBank.d317.s3|86-90|VII-X|drug
DDI-DrugBank.d317.s3|92-98|complex|drug
DDI-DrugBank.d317.s3|99-99|,|drug
DDI-DrugBank.d317.s3|101-108|II-VII-X|drug
DDI-DrugBank.d317.s3|110-116|complex|drug
DDI-DrugBank.d317.s3|117-117|,|drug
DDI-DrugBank.d317.s3|119-121|and|drug
DDI-DrugBank.d317.s3|123-142|beta-thromboglobulin|drug
DDI-DrugBank.d317.s3|143-143|;|drug
DDI-DrugBank.d317.s4|0-8|decreased|drug
DDI-DrugBank.d317.s4|10-15|levels|drug
DDI-DrugBank.d317.s4|17-18|of|drug
DDI-DrugBank.d317.s4|20-30|anti-factor|drug
DDI-DrugBank.d317.s4|32-33|Xa|drug
DDI-DrugBank.d317.s4|35-37|and|drug
DDI-DrugBank.d317.s4|39-50|antithrombin|drug
DDI-DrugBank.d317.s4|52-54|III|drug
DDI-DrugBank.d317.s4|55-55|,|drug
DDI-DrugBank.d317.s4|57-65|decreased|drug
DDI-DrugBank.d317.s4|67-78|antithrombin|drug
DDI-DrugBank.d317.s4|80-82|III|drug
DDI-DrugBank.d317.s4|84-91|activity|drug
DDI-DrugBank.d317.s4|92-92|;|drug
DDI-DrugBank.d317.s5|0-8|increased|drug
DDI-DrugBank.d317.s5|10-15|levels|drug
DDI-DrugBank.d317.s5|17-18|of|drug
DDI-DrugBank.d317.s5|20-29|fibrinogen|drug
DDI-DrugBank.d317.s5|31-33|and|drug
DDI-DrugBank.d317.s5|35-44|fibrinogen|drug
DDI-DrugBank.d317.s5|46-53|activity|drug
DDI-DrugBank.d317.s5|54-54|;|drug
DDI-DrugBank.d317.s6|0-8|increased|drug
DDI-DrugBank.d317.s6|10-20|plasminogen|drug
DDI-DrugBank.d317.s6|22-28|antigen|drug
DDI-DrugBank.d317.s6|30-32|and|drug
DDI-DrugBank.d317.s6|34-41|activity|drug
DDI-DrugBank.d317.s6|42-42|.|drug
DDI-DrugBank.d317.s7|0-0|2|drug
DDI-DrugBank.d317.s7|1-1|.|drug
DDI-DrugBank.d317.s8|0-8|Increased|drug
DDI-DrugBank.d317.s8|10-24|thyroid-binding|drug
DDI-DrugBank.d317.s8|26-33|globulin|drug
DDI-DrugBank.d317.s8|35-35|(|drug
DDI-DrugBank.d317.s8|36-38|TBG|drug
DDI-DrugBank.d317.s8|39-39|)|drug
DDI-DrugBank.d317.s8|41-46|levels|drug
DDI-DrugBank.d317.s8|48-54|leading|drug
DDI-DrugBank.d317.s8|56-57|to|drug
DDI-DrugBank.d317.s8|59-67|increased|drug
DDI-DrugBank.d317.s8|69-79|circulating|drug
DDI-DrugBank.d317.s8|81-85|total|drug
DDI-DrugBank.d317.s8|87-93|thyroid|drug
DDI-DrugBank.d317.s8|95-101|hormone|drug
DDI-DrugBank.d317.s8|103-108|levels|drug
DDI-DrugBank.d317.s8|110-111|as|drug
DDI-DrugBank.d317.s8|113-120|measured|drug
DDI-DrugBank.d317.s8|122-123|by|drug
DDI-DrugBank.d317.s8|125-137|protein-bound|drug
DDI-DrugBank.d317.s8|139-144|iodine|drug
DDI-DrugBank.d317.s8|146-146|(|drug
DDI-DrugBank.d317.s8|147-149|PBI|drug
DDI-DrugBank.d317.s8|150-150|)|drug
DDI-DrugBank.d317.s8|151-151|,|drug
DDI-DrugBank.d317.s8|153-154|T4|drug
DDI-DrugBank.d317.s8|156-161|levels|drug
DDI-DrugBank.d317.s8|163-163|(|drug
DDI-DrugBank.d317.s8|164-165|by|drug
DDI-DrugBank.d317.s8|167-172|column|drug
DDI-DrugBank.d317.s8|174-175|or|drug
DDI-DrugBank.d317.s8|177-178|by|drug
DDI-DrugBank.d317.s8|180-195|radioimmunoassay|drug
DDI-DrugBank.d317.s8|196-196|)|drug
DDI-DrugBank.d317.s8|198-199|or|drug
DDI-DrugBank.d317.s8|201-202|T3|drug
DDI-DrugBank.d317.s8|204-209|levels|drug
DDI-DrugBank.d317.s8|211-212|by|drug
DDI-DrugBank.d317.s8|214-229|radioimmunoassay|drug
DDI-DrugBank.d317.s8|230-230|.|drug
DDI-DrugBank.d317.s9|0-1|T3|drug
DDI-DrugBank.d317.s9|3-7|resin|drug
DDI-DrugBank.d317.s9|9-14|uptake|drug
DDI-DrugBank.d317.s9|16-17|is|drug
DDI-DrugBank.d317.s9|19-27|decreased|drug
DDI-DrugBank.d317.s9|28-28|,|drug
DDI-DrugBank.d317.s9|30-39|reflecting|drug
DDI-DrugBank.d317.s9|41-43|the|drug
DDI-DrugBank.d317.s9|45-52|elevated|drug
DDI-DrugBank.d317.s9|54-56|TBG|drug
DDI-DrugBank.d317.s9|57-57|.|drug
DDI-DrugBank.d317.s10|0-3|Free|drug
DDI-DrugBank.d317.s10|5-6|T4|drug
DDI-DrugBank.d317.s10|8-10|and|drug
DDI-DrugBank.d317.s10|12-15|free|drug
DDI-DrugBank.d317.s10|17-18|T3|drug
DDI-DrugBank.d317.s10|20-33|concentrations|drug
DDI-DrugBank.d317.s10|35-37|are|drug
DDI-DrugBank.d317.s10|39-47|unaltered|drug
DDI-DrugBank.d317.s10|48-48|.|drug
DDI-DrugBank.d317.s11|0-7|Patients|drug
DDI-DrugBank.d317.s11|9-10|on|drug
DDI-DrugBank.d317.s11|12-18|thyroid|drug
DDI-DrugBank.d317.s11|20-30|replacement|drug
DDI-DrugBank.d317.s11|32-38|therapy|drug
DDI-DrugBank.d317.s11|40-42|may|drug
DDI-DrugBank.d317.s11|44-50|require|drug
DDI-DrugBank.d317.s11|52-57|higher|drug
DDI-DrugBank.d317.s11|59-63|doses|drug
DDI-DrugBank.d317.s11|65-66|of|drug
DDI-DrugBank.d317.s11|68-74|thyroid|drug
DDI-DrugBank.d317.s11|76-82|hormone|drug
DDI-DrugBank.d317.s11|83-83|.|drug
DDI-DrugBank.d317.s12|0-0|3|drug
DDI-DrugBank.d317.s12|1-1|.|drug
DDI-DrugBank.d317.s13|0-4|Other|drug
DDI-DrugBank.d317.s13|6-12|binding|drug
DDI-DrugBank.d317.s13|14-21|proteins|drug
DDI-DrugBank.d317.s13|23-25|may|drug
DDI-DrugBank.d317.s13|27-28|be|drug
DDI-DrugBank.d317.s13|30-37|elevated|drug
DDI-DrugBank.d317.s13|39-40|in|drug
DDI-DrugBank.d317.s13|42-46|serum|drug
DDI-DrugBank.d317.s13|47-47|,|drug
DDI-DrugBank.d317.s13|49-49|(|drug
DDI-DrugBank.d317.s13|50-53|i.e.|drug
DDI-DrugBank.d317.s13|54-54|,|drug
DDI-DrugBank.d317.s13|56-69|corticosteroid|drug
DDI-DrugBank.d317.s13|71-77|binding|drug
DDI-DrugBank.d317.s13|79-86|globulin|drug
DDI-DrugBank.d317.s13|88-88|(|drug
DDI-DrugBank.d317.s13|89-91|CBG|drug
DDI-DrugBank.d317.s13|92-92|)|drug
DDI-DrugBank.d317.s13|93-93|,|drug
DDI-DrugBank.d317.s13|95-97|sex|drug
DDI-DrugBank.d317.s13|99-105|hormone|drug
DDI-DrugBank.d317.s13|107-113|binding|drug
DDI-DrugBank.d317.s13|115-122|globulin|drug
DDI-DrugBank.d317.s13|124-124|(|drug
DDI-DrugBank.d317.s13|125-128|SHBG|drug
DDI-DrugBank.d317.s13|129-129|)|drug
DDI-DrugBank.d317.s13|130-130|)|drug
DDI-DrugBank.d317.s13|132-138|leading|drug
DDI-DrugBank.d317.s13|140-141|to|drug
DDI-DrugBank.d317.s13|143-151|increased|drug
DDI-DrugBank.d317.s13|153-157|total|drug
DDI-DrugBank.d317.s13|159-169|circulating|drug
DDI-DrugBank.d317.s13|171-185|corticosteroids|drug
DDI-DrugBank.d317.s13|187-189|and|drug
DDI-DrugBank.d317.s13|191-193|sex|drug
DDI-DrugBank.d317.s13|195-202|steroids|drug
DDI-DrugBank.d317.s13|203-203|,|drug
DDI-DrugBank.d317.s13|205-216|respectively|drug
DDI-DrugBank.d317.s13|217-217|.|drug
DDI-DrugBank.d317.s14|0-3|Free|drug
DDI-DrugBank.d317.s14|5-11|hormone|drug
DDI-DrugBank.d317.s14|13-26|concentrations|drug
DDI-DrugBank.d317.s14|28-30|may|drug
DDI-DrugBank.d317.s14|32-33|be|drug
DDI-DrugBank.d317.s14|35-43|decreased|drug
DDI-DrugBank.d317.s14|44-44|.|drug
DDI-DrugBank.d317.s15|0-4|Other|drug
DDI-DrugBank.d317.s15|6-11|plasma|drug
DDI-DrugBank.d317.s15|13-20|proteins|drug
DDI-DrugBank.d317.s15|22-24|may|drug
DDI-DrugBank.d317.s15|26-27|be|drug
DDI-DrugBank.d317.s15|29-37|increased|drug
DDI-DrugBank.d317.s15|39-39|(|drug
DDI-DrugBank.d317.s15|40-60|angiotensinogen/renin|drug
DDI-DrugBank.d317.s15|62-70|substrate|drug
DDI-DrugBank.d317.s15|71-71|,|drug
DDI-DrugBank.d317.s15|73-91|alpha-1-antitrypsin|drug
DDI-DrugBank.d317.s15|92-92|,|drug
DDI-DrugBank.d317.s15|94-106|ceruloplasmin|drug
DDI-DrugBank.d317.s15|107-107|)|drug
DDI-DrugBank.d317.s15|108-108|.|drug
DDI-DrugBank.d317.s16|0-0|4|drug
DDI-DrugBank.d317.s16|1-1|.|drug
DDI-DrugBank.d317.s17|0-8|Increased|drug
DDI-DrugBank.d317.s17|10-15|plasma|drug
DDI-DrugBank.d317.s17|17-19|HDL|drug
DDI-DrugBank.d317.s17|21-23|and|drug
DDI-DrugBank.d317.s17|25-28|HDL2|drug
DDI-DrugBank.d317.s17|30-40|cholesterol|drug
DDI-DrugBank.d317.s17|42-52|subfraction|drug
DDI-DrugBank.d317.s17|54-67|concentrations|drug
DDI-DrugBank.d317.s17|68-68|,|drug
DDI-DrugBank.d317.s17|70-76|reduced|drug
DDI-DrugBank.d317.s17|78-80|LDL|drug
DDI-DrugBank.d317.s17|82-92|cholesterol|drug
DDI-DrugBank.d317.s17|94-106|concentration|drug
DDI-DrugBank.d317.s17|107-107|,|drug
DDI-DrugBank.d317.s17|109-117|increased|drug
DDI-DrugBank.d317.s17|119-130|triglyceride|drug
DDI-DrugBank.d317.s17|132-137|levels|drug
DDI-DrugBank.d317.s17|138-138|.|drug
DDI-DrugBank.d317.s18|0-0|5|drug
DDI-DrugBank.d317.s18|1-1|.|drug
DDI-DrugBank.d317.s19|0-7|Impaired|drug
DDI-DrugBank.d317.s19|9-15|glucose|drug
DDI-DrugBank.d317.s19|17-25|tolerance|drug
DDI-DrugBank.d317.s19|26-26|.|drug
DDI-DrugBank.d317.s20|0-0|6|drug
DDI-DrugBank.d317.s20|1-1|.|drug
DDI-DrugBank.d317.s21|0-6|Reduced|drug
DDI-DrugBank.d317.s21|8-15|response|drug
DDI-DrugBank.d317.s21|17-18|to|drug
DDI-DrugBank.d317.s21|20-29|metyrapone|drug
DDI-DrugBank.d317.s21|31-34|test|drug
DDI-DrugBank.d317.s21|35-35|.|drug
DDI-DrugBank.d635.s0|0-4|Other|drug
DDI-DrugBank.d635.s0|6-17|short-acting|drug
DDI-DrugBank.d635.s0|19-22|beta|drug
DDI-DrugBank.d635.s0|24-33|adrenergic|drug
DDI-DrugBank.d635.s0|35-41|aerosol|drug
DDI-DrugBank.d635.s0|43-57|bronchodilators|drug
DDI-DrugBank.d635.s0|59-64|should|drug
DDI-DrugBank.d635.s0|66-68|not|drug
DDI-DrugBank.d635.s0|70-71|be|drug
DDI-DrugBank.d635.s0|73-76|used|drug
DDI-DrugBank.d635.s0|78-90|concomitantly|drug
DDI-DrugBank.d635.s0|92-95|with|drug
DDI-DrugBank.d635.s0|97-102|MAXAIR|drug
DDI-DrugBank.d635.s0|104-112|AUTOHALER|drug
DDI-DrugBank.d635.s0|114-120|because|drug
DDI-DrugBank.d635.s0|122-125|they|drug
DDI-DrugBank.d635.s0|127-129|may|drug
DDI-DrugBank.d635.s0|131-134|have|drug
DDI-DrugBank.d635.s0|136-143|additive|drug
DDI-DrugBank.d635.s0|145-151|effects|drug
DDI-DrugBank.d635.s0|152-152|.|drug
DDI-DrugBank.d766.s0|0-4|Since|drug
DDI-DrugBank.d766.s0|6-17|trimetrexate|drug
DDI-DrugBank.d766.s0|19-20|is|drug
DDI-DrugBank.d766.s0|22-32|metabolized|drug
DDI-DrugBank.d766.s0|34-35|by|drug
DDI-DrugBank.d766.s0|37-37|a|drug
DDI-DrugBank.d766.s0|39-42|P450|drug
DDI-DrugBank.d766.s0|44-49|enzyme|drug
DDI-DrugBank.d766.s0|51-56|system|drug
DDI-DrugBank.d766.s0|57-57|,|drug
DDI-DrugBank.d766.s0|59-63|drugs|drug
DDI-DrugBank.d766.s0|65-68|that|drug
DDI-DrugBank.d766.s0|70-75|induce|drug
DDI-DrugBank.d766.s0|77-78|or|drug
DDI-DrugBank.d766.s0|80-86|inhibit|drug
DDI-DrugBank.d766.s0|88-91|this|drug
DDI-DrugBank.d766.s0|93-96|drug|drug
DDI-DrugBank.d766.s0|98-109|metabolizing|drug
DDI-DrugBank.d766.s0|111-116|enzyme|drug
DDI-DrugBank.d766.s0|118-123|system|drug
DDI-DrugBank.d766.s0|125-127|may|drug
DDI-DrugBank.d766.s0|129-134|elicit|drug
DDI-DrugBank.d766.s0|136-144|important|drug
DDI-DrugBank.d766.s0|146-154|drug-drug|drug
DDI-DrugBank.d766.s0|156-167|interactions|drug
DDI-DrugBank.d766.s0|169-172|that|drug
DDI-DrugBank.d766.s0|174-176|may|drug
DDI-DrugBank.d766.s0|178-182|alter|drug
DDI-DrugBank.d766.s0|184-195|trimetrexate|drug
DDI-DrugBank.d766.s0|197-202|plasma|drug
DDI-DrugBank.d766.s0|204-217|concentrations|drug
DDI-DrugBank.d766.s0|218-218|.|drug
DDI-DrugBank.d766.s1|0-5|Agents|drug
DDI-DrugBank.d766.s1|7-10|that|drug
DDI-DrugBank.d766.s1|12-16|might|drug
DDI-DrugBank.d766.s1|18-19|be|drug
DDI-DrugBank.d766.s1|21-34|coadministered|drug
DDI-DrugBank.d766.s1|36-39|with|drug
DDI-DrugBank.d766.s1|41-52|trimetrexate|drug
DDI-DrugBank.d766.s1|54-55|in|drug
DDI-DrugBank.d766.s1|57-60|AIDS|drug
DDI-DrugBank.d766.s1|62-69|patients|drug
DDI-DrugBank.d766.s1|71-73|for|drug
DDI-DrugBank.d766.s1|75-79|other|drug
DDI-DrugBank.d766.s1|81-91|indications|drug
DDI-DrugBank.d766.s1|93-96|that|drug
DDI-DrugBank.d766.s1|98-102|could|drug
DDI-DrugBank.d766.s1|104-109|elicit|drug
DDI-DrugBank.d766.s1|111-114|this|drug
DDI-DrugBank.d766.s1|116-123|activity|drug
DDI-DrugBank.d766.s1|125-131|include|drug
DDI-DrugBank.d766.s1|133-144|erythromycin|drug
DDI-DrugBank.d766.s1|145-145|,|drug
DDI-DrugBank.d766.s1|147-154|rifampin|drug
DDI-DrugBank.d766.s1|155-155|,|drug
DDI-DrugBank.d766.s1|157-165|rifabutin|drug
DDI-DrugBank.d766.s1|166-166|,|drug
DDI-DrugBank.d766.s1|168-179|ketoconazole|drug
DDI-DrugBank.d766.s1|180-180|,|drug
DDI-DrugBank.d766.s1|182-184|and|drug
DDI-DrugBank.d766.s1|186-196|fluconazole|drug
DDI-DrugBank.d766.s1|197-197|.|drug
DDI-DrugBank.d766.s2|0-1|In|drug
DDI-DrugBank.d766.s2|3-7|vitro|drug
DDI-DrugBank.d766.s2|9-17|perfusion|drug
DDI-DrugBank.d766.s2|19-20|of|drug
DDI-DrugBank.d766.s2|22-29|isolated|drug
DDI-DrugBank.d766.s2|31-33|rat|drug
DDI-DrugBank.d766.s2|35-39|liver|drug
DDI-DrugBank.d766.s2|41-43|has|drug
DDI-DrugBank.d766.s2|45-49|shown|drug
DDI-DrugBank.d766.s2|51-54|that|drug
DDI-DrugBank.d766.s2|56-65|cimetidine|drug
DDI-DrugBank.d766.s2|67-72|caused|drug
DDI-DrugBank.d766.s2|74-74|a|drug
DDI-DrugBank.d766.s2|76-86|significant|drug
DDI-DrugBank.d766.s2|88-96|reduction|drug
DDI-DrugBank.d766.s2|98-99|in|drug
DDI-DrugBank.d766.s2|101-112|trimetrexate|drug
DDI-DrugBank.d766.s2|114-123|metabolism|drug
DDI-DrugBank.d766.s2|125-127|and|drug
DDI-DrugBank.d766.s2|129-132|that|drug
DDI-DrugBank.d766.s2|134-146|acetaminophen|drug
DDI-DrugBank.d766.s2|148-154|altered|drug
DDI-DrugBank.d766.s2|156-158|the|drug
DDI-DrugBank.d766.s2|160-167|relative|drug
DDI-DrugBank.d766.s2|169-181|concentration|drug
DDI-DrugBank.d766.s2|183-184|of|drug
DDI-DrugBank.d766.s2|186-197|trimetrexate|drug
DDI-DrugBank.d766.s2|199-209|metabolites|drug
DDI-DrugBank.d766.s2|211-218|possibly|drug
DDI-DrugBank.d766.s2|220-221|by|drug
DDI-DrugBank.d766.s2|223-231|competing|drug
DDI-DrugBank.d766.s2|233-235|for|drug
DDI-DrugBank.d766.s2|237-243|sulfate|drug
DDI-DrugBank.d766.s2|245-255|metabolites|drug
DDI-DrugBank.d766.s2|256-256|.|drug
DDI-DrugBank.d766.s3|0-4|Based|drug
DDI-DrugBank.d766.s3|6-7|on|drug
DDI-DrugBank.d766.s3|9-10|an|drug
DDI-DrugBank.d766.s3|12-13|in|drug
DDI-DrugBank.d766.s3|15-19|vitro|drug
DDI-DrugBank.d766.s3|21-23|rat|drug
DDI-DrugBank.d766.s3|25-29|liver|drug
DDI-DrugBank.d766.s3|31-35|model|drug
DDI-DrugBank.d766.s3|36-36|,|drug
DDI-DrugBank.d766.s3|38-45|nitrogen|drug
DDI-DrugBank.d766.s3|47-57|substituted|drug
DDI-DrugBank.d766.s3|59-67|imidazole|drug
DDI-DrugBank.d766.s3|69-73|drugs|drug
DDI-DrugBank.d766.s3|75-75|(|drug
DDI-DrugBank.d766.s3|76-87|clotrimazole|drug
DDI-DrugBank.d766.s3|88-88|,|drug
DDI-DrugBank.d766.s3|90-101|ketoconazole|drug
DDI-DrugBank.d766.s3|102-102|,|drug
DDI-DrugBank.d766.s3|104-113|miconazole|drug
DDI-DrugBank.d766.s3|114-114|)|drug
DDI-DrugBank.d766.s3|116-119|were|drug
DDI-DrugBank.d766.s3|121-126|potent|drug
DDI-DrugBank.d766.s3|127-127|,|drug
DDI-DrugBank.d766.s3|129-143|non-competitive|drug
DDI-DrugBank.d766.s3|145-154|inhibitors|drug
DDI-DrugBank.d766.s3|156-157|of|drug
DDI-DrugBank.d766.s3|159-170|trimetrexate|drug
DDI-DrugBank.d766.s3|172-181|metabolism|drug
DDI-DrugBank.d766.s3|182-182|.|drug
DDI-DrugBank.d766.s4|0-7|Patients|drug
DDI-DrugBank.d766.s4|9-17|medicated|drug
DDI-DrugBank.d766.s4|19-22|with|drug
DDI-DrugBank.d766.s4|24-28|these|drug
DDI-DrugBank.d766.s4|30-34|drugs|drug
DDI-DrugBank.d766.s4|36-38|and|drug
DDI-DrugBank.d766.s4|40-51|trimetrexate|drug
DDI-DrugBank.d766.s4|53-58|should|drug
DDI-DrugBank.d766.s4|60-61|be|drug
DDI-DrugBank.d766.s4|63-71|carefully|drug
DDI-DrugBank.d766.s4|73-81|monitored|drug
DDI-DrugBank.d766.s4|82-82|.|drug
DDI-DrugBank.d489.s0|0-2|The|drug
DDI-DrugBank.d489.s0|4-12|following|drug
DDI-DrugBank.d489.s0|14-18|drugs|drug
DDI-DrugBank.d489.s0|20-23|have|drug
DDI-DrugBank.d489.s0|25-28|been|drug
DDI-DrugBank.d489.s0|30-43|coadministered|drug
DDI-DrugBank.d489.s0|45-48|with|drug
DDI-DrugBank.d489.s0|50-56|Kerlone|brand
DDI-DrugBank.d489.s0|58-60|and|drug
DDI-DrugBank.d489.s0|62-65|have|drug
DDI-DrugBank.d489.s0|67-69|not|drug
DDI-DrugBank.d489.s0|71-77|altered|drug
DDI-DrugBank.d489.s0|79-81|its|drug
DDI-DrugBank.d489.s0|83-98|pharmacokinetics|drug
DDI-DrugBank.d489.s0|99-99|:|drug
DDI-DrugBank.d489.s0|101-110|cimetidine|drug
DDI-DrugBank.d489.s0|111-111|,|drug
DDI-DrugBank.d489.s0|113-122|nifedipine|drug
DDI-DrugBank.d489.s0|123-123|,|drug
DDI-DrugBank.d489.s0|125-138|chlorthalidone|drug
DDI-DrugBank.d489.s0|139-139|,|drug
DDI-DrugBank.d489.s0|141-143|and|drug
DDI-DrugBank.d489.s0|145-163|hydrochlorothiazide|drug
DDI-DrugBank.d489.s0|164-164|.|drug
DDI-DrugBank.d489.s1|0-10|Concomitant|drug
DDI-DrugBank.d489.s1|12-25|administration|drug
DDI-DrugBank.d489.s1|27-28|of|drug
DDI-DrugBank.d489.s1|30-36|Kerlone|brand
DDI-DrugBank.d489.s1|38-41|with|drug
DDI-DrugBank.d489.s1|43-45|the|drug
DDI-DrugBank.d489.s1|47-50|oral|drug
DDI-DrugBank.d489.s1|52-64|anticoagulant|drug
DDI-DrugBank.d489.s1|66-73|warfarin|drug
DDI-DrugBank.d489.s1|75-77|has|drug
DDI-DrugBank.d489.s1|79-82|been|drug
DDI-DrugBank.d489.s1|84-88|shown|drug
DDI-DrugBank.d489.s1|90-92|not|drug
DDI-DrugBank.d489.s1|94-95|to|drug
DDI-DrugBank.d489.s1|97-106|potentiate|drug
DDI-DrugBank.d489.s1|108-110|the|drug
DDI-DrugBank.d489.s1|112-124|anticoagulant|drug
DDI-DrugBank.d489.s1|126-131|effect|drug
DDI-DrugBank.d489.s1|133-134|of|drug
DDI-DrugBank.d489.s1|136-143|warfarin|drug
DDI-DrugBank.d489.s1|144-144|.|drug
DDI-DrugBank.d489.s2|0-22|Catecholamine-depleting|drug
DDI-DrugBank.d489.s2|24-28|drugs|drug
DDI-DrugBank.d489.s2|30-30|(|drug
DDI-DrugBank.d489.s2|31-34|e.g.|drug
DDI-DrugBank.d489.s2|35-35|,|drug
DDI-DrugBank.d489.s2|37-45|reserpine|drug
DDI-DrugBank.d489.s2|46-46|)|drug
DDI-DrugBank.d489.s2|48-50|may|drug
DDI-DrugBank.d489.s2|52-55|have|drug
DDI-DrugBank.d489.s2|57-58|an|drug
DDI-DrugBank.d489.s2|60-67|additive|drug
DDI-DrugBank.d489.s2|69-74|effect|drug
DDI-DrugBank.d489.s2|76-79|when|drug
DDI-DrugBank.d489.s2|81-85|given|drug
DDI-DrugBank.d489.s2|87-90|with|drug
DDI-DrugBank.d489.s2|92-104|beta-blocking|drug
DDI-DrugBank.d489.s2|106-111|agents|drug
DDI-DrugBank.d489.s2|112-112|.|drug
DDI-DrugBank.d489.s3|0-7|Patients|drug
DDI-DrugBank.d489.s3|9-15|treated|drug
DDI-DrugBank.d489.s3|17-20|with|drug
DDI-DrugBank.d489.s3|22-22|a|drug
DDI-DrugBank.d489.s3|24-38|beta-adrenergic|drug
DDI-DrugBank.d489.s3|40-47|receptor|drug
DDI-DrugBank.d489.s3|49-56|blocking|drug
DDI-DrugBank.d489.s3|58-62|agent|drug
DDI-DrugBank.d489.s3|64-67|plus|drug
DDI-DrugBank.d489.s3|69-69|a|drug
DDI-DrugBank.d489.s3|71-83|catecholamine|drug
DDI-DrugBank.d489.s3|85-92|depletor|drug
DDI-DrugBank.d489.s3|94-99|should|drug
DDI-DrugBank.d489.s3|101-109|therefore|drug
DDI-DrugBank.d489.s3|111-112|be|drug
DDI-DrugBank.d489.s3|114-120|closely|drug
DDI-DrugBank.d489.s3|122-129|observed|drug
DDI-DrugBank.d489.s3|131-133|for|drug
DDI-DrugBank.d489.s3|135-142|evidence|drug
DDI-DrugBank.d489.s3|144-145|of|drug
DDI-DrugBank.d489.s3|147-157|hypotension|drug
DDI-DrugBank.d489.s3|159-160|or|drug
DDI-DrugBank.d489.s3|162-167|marked|drug
DDI-DrugBank.d489.s3|169-179|bradycardia|drug
DDI-DrugBank.d489.s3|180-180|,|drug
DDI-DrugBank.d489.s3|182-186|which|drug
DDI-DrugBank.d489.s3|188-190|may|drug
DDI-DrugBank.d489.s3|192-198|produce|drug
DDI-DrugBank.d489.s3|200-206|vertigo|drug
DDI-DrugBank.d489.s3|207-207|,|drug
DDI-DrugBank.d489.s3|209-215|syncope|drug
DDI-DrugBank.d489.s3|216-216|,|drug
DDI-DrugBank.d489.s3|218-219|or|drug
DDI-DrugBank.d489.s3|221-228|postural|drug
DDI-DrugBank.d489.s3|230-240|hypotension|drug
DDI-DrugBank.d489.s3|241-241|.|drug
DDI-DrugBank.d489.s4|0-5|Should|drug
DDI-DrugBank.d489.s4|7-8|it|drug
DDI-DrugBank.d489.s4|10-11|be|drug
DDI-DrugBank.d489.s4|13-19|decided|drug
DDI-DrugBank.d489.s4|21-22|to|drug
DDI-DrugBank.d489.s4|24-34|discontinue|drug
DDI-DrugBank.d489.s4|36-42|therapy|drug
DDI-DrugBank.d489.s4|44-45|in|drug
DDI-DrugBank.d489.s4|47-54|patients|drug
DDI-DrugBank.d489.s4|56-64|receiving|drug
DDI-DrugBank.d489.s4|66-78|beta-blockers|drug
DDI-DrugBank.d489.s4|80-82|and|drug
DDI-DrugBank.d489.s4|84-92|clonidine|drug
DDI-DrugBank.d489.s4|94-105|concurrently|drug
DDI-DrugBank.d489.s4|106-106|,|drug
DDI-DrugBank.d489.s4|108-110|the|drug
DDI-DrugBank.d489.s4|112-123|beta-blocker|drug
DDI-DrugBank.d489.s4|125-130|should|drug
DDI-DrugBank.d489.s4|132-133|be|drug
DDI-DrugBank.d489.s4|135-146|discontinued|drug
DDI-DrugBank.d489.s4|148-153|slowly|drug
DDI-DrugBank.d489.s4|155-158|over|drug
DDI-DrugBank.d489.s4|160-166|several|drug
DDI-DrugBank.d489.s4|168-171|days|drug
DDI-DrugBank.d489.s4|173-178|before|drug
DDI-DrugBank.d489.s4|180-182|the|drug
DDI-DrugBank.d489.s4|184-190|gradual|drug
DDI-DrugBank.d489.s4|192-201|withdrawal|drug
DDI-DrugBank.d489.s4|203-204|of|drug
DDI-DrugBank.d489.s4|206-214|clonidine|drug
DDI-DrugBank.d489.s4|215-215|.|drug
DDI-DrugBank.d489.s5|0-9|Literature|drug
DDI-DrugBank.d489.s5|11-17|reports|drug
DDI-DrugBank.d489.s5|19-25|suggest|drug
DDI-DrugBank.d489.s5|27-30|that|drug
DDI-DrugBank.d489.s5|32-35|oral|drug
DDI-DrugBank.d489.s5|37-43|calcium|drug
DDI-DrugBank.d489.s5|45-55|antagonists|drug
DDI-DrugBank.d489.s5|57-59|may|drug
DDI-DrugBank.d489.s5|61-62|be|drug
DDI-DrugBank.d489.s5|64-67|used|drug
DDI-DrugBank.d489.s5|69-70|in|drug
DDI-DrugBank.d489.s5|72-82|combination|drug
DDI-DrugBank.d489.s5|84-87|with|drug
DDI-DrugBank.d489.s5|89-103|beta-adrenergic|drug
DDI-DrugBank.d489.s5|105-112|blocking|drug
DDI-DrugBank.d489.s5|114-119|agents|drug
DDI-DrugBank.d489.s5|121-124|when|drug
DDI-DrugBank.d489.s5|126-130|heart|drug
DDI-DrugBank.d489.s5|132-139|function|drug
DDI-DrugBank.d489.s5|141-142|is|drug
DDI-DrugBank.d489.s5|144-149|normal|drug
DDI-DrugBank.d489.s5|150-150|,|drug
DDI-DrugBank.d489.s5|152-154|but|drug
DDI-DrugBank.d489.s5|156-161|should|drug
DDI-DrugBank.d489.s5|163-164|be|drug
DDI-DrugBank.d489.s5|166-172|avoided|drug
DDI-DrugBank.d489.s5|174-175|in|drug
DDI-DrugBank.d489.s5|177-184|patients|drug
DDI-DrugBank.d489.s5|186-189|with|drug
DDI-DrugBank.d489.s5|191-198|impaired|drug
DDI-DrugBank.d489.s5|200-206|cardiac|drug
DDI-DrugBank.d489.s5|208-215|function|drug
DDI-DrugBank.d489.s5|216-216|.|drug
DDI-DrugBank.d489.s6|0-10|Hypotension|drug
DDI-DrugBank.d489.s6|11-11|,|drug
DDI-DrugBank.d489.s6|13-14|AV|drug
DDI-DrugBank.d489.s6|16-25|conduction|drug
DDI-DrugBank.d489.s6|27-38|disturbances|drug
DDI-DrugBank.d489.s6|39-39|,|drug
DDI-DrugBank.d489.s6|41-43|and|drug
DDI-DrugBank.d489.s6|45-48|left|drug
DDI-DrugBank.d489.s6|50-60|ventricular|drug
DDI-DrugBank.d489.s6|62-68|failure|drug
DDI-DrugBank.d489.s6|70-73|have|drug
DDI-DrugBank.d489.s6|75-78|been|drug
DDI-DrugBank.d489.s6|80-87|reported|drug
DDI-DrugBank.d489.s6|89-90|in|drug
DDI-DrugBank.d489.s6|92-95|some|drug
DDI-DrugBank.d489.s6|97-104|patients|drug
DDI-DrugBank.d489.s6|106-114|receiving|drug
DDI-DrugBank.d489.s6|116-130|beta-adrenergic|drug
DDI-DrugBank.d489.s6|132-139|blocking|drug
DDI-DrugBank.d489.s6|141-146|agents|drug
DDI-DrugBank.d489.s6|148-151|when|drug
DDI-DrugBank.d489.s6|153-154|an|drug
DDI-DrugBank.d489.s6|156-159|oral|drug
DDI-DrugBank.d489.s6|161-167|calcium|drug
DDI-DrugBank.d489.s6|169-178|antagonist|drug
DDI-DrugBank.d489.s6|180-182|was|drug
DDI-DrugBank.d489.s6|184-188|added|drug
DDI-DrugBank.d489.s6|190-191|to|drug
DDI-DrugBank.d489.s6|193-195|the|drug
DDI-DrugBank.d489.s6|197-205|treatment|drug
DDI-DrugBank.d489.s6|207-213|regimen|drug
DDI-DrugBank.d489.s6|214-214|.|drug
DDI-DrugBank.d489.s7|0-10|Hypotension|drug
DDI-DrugBank.d489.s7|12-14|was|drug
DDI-DrugBank.d489.s7|16-19|more|drug
DDI-DrugBank.d489.s7|21-26|likely|drug
DDI-DrugBank.d489.s7|28-29|to|drug
DDI-DrugBank.d489.s7|31-35|occur|drug
DDI-DrugBank.d489.s7|37-38|if|drug
DDI-DrugBank.d489.s7|40-42|the|drug
DDI-DrugBank.d489.s7|44-50|calcium|drug
DDI-DrugBank.d489.s7|52-61|antagonist|drug
DDI-DrugBank.d489.s7|63-66|were|drug
DDI-DrugBank.d489.s7|68-68|a|drug
DDI-DrugBank.d489.s7|70-84|dihydropyridine|drug
DDI-DrugBank.d489.s7|86-95|derivative|drug
DDI-DrugBank.d489.s7|96-96|,|drug
DDI-DrugBank.d489.s7|98-101|e.g.|drug
DDI-DrugBank.d489.s7|102-102|,|drug
DDI-DrugBank.d489.s7|104-113|nifedipine|drug
DDI-DrugBank.d489.s7|114-114|,|drug
DDI-DrugBank.d489.s7|116-120|while|drug
DDI-DrugBank.d489.s7|122-125|left|drug
DDI-DrugBank.d489.s7|127-137|ventricular|drug
DDI-DrugBank.d489.s7|139-145|failure|drug
DDI-DrugBank.d489.s7|147-149|and|drug
DDI-DrugBank.d489.s7|151-152|AV|drug
DDI-DrugBank.d489.s7|154-163|conduction|drug
DDI-DrugBank.d489.s7|165-176|disturbances|drug
DDI-DrugBank.d489.s7|177-177|,|drug
DDI-DrugBank.d489.s7|179-187|including|drug
DDI-DrugBank.d489.s7|189-196|complete|drug
DDI-DrugBank.d489.s7|198-202|heart|drug
DDI-DrugBank.d489.s7|204-208|block|drug
DDI-DrugBank.d489.s7|209-209|,|drug
DDI-DrugBank.d489.s7|211-214|were|drug
DDI-DrugBank.d489.s7|216-219|more|drug
DDI-DrugBank.d489.s7|221-226|likely|drug
DDI-DrugBank.d489.s7|228-229|to|drug
DDI-DrugBank.d489.s7|231-235|occur|drug
DDI-DrugBank.d489.s7|237-240|with|drug
DDI-DrugBank.d489.s7|242-247|either|drug
DDI-DrugBank.d489.s7|249-257|verapamil|drug
DDI-DrugBank.d489.s7|259-260|or|drug
DDI-DrugBank.d489.s7|262-270|diltiazem|drug
DDI-DrugBank.d489.s7|271-271|.|drug
DDI-DrugBank.d489.s8|0-3|Risk|drug
DDI-DrugBank.d489.s8|5-6|of|drug
DDI-DrugBank.d489.s8|8-19|Anaphylactic|drug
DDI-DrugBank.d489.s8|21-28|Reaction|drug
DDI-DrugBank.d489.s8|29-29|:|drug
DDI-DrugBank.d489.s8|31-38|Although|drug
DDI-DrugBank.d489.s8|40-41|it|drug
DDI-DrugBank.d489.s8|43-44|is|drug
DDI-DrugBank.d489.s8|46-50|known|drug
DDI-DrugBank.d489.s8|52-55|that|drug
DDI-DrugBank.d489.s8|57-64|patients|drug
DDI-DrugBank.d489.s8|66-67|on|drug
DDI-DrugBank.d489.s8|69-81|beta-blockers|drug
DDI-DrugBank.d489.s8|83-85|may|drug
DDI-DrugBank.d489.s8|87-88|be|drug
DDI-DrugBank.d489.s8|90-99|refractory|drug
DDI-DrugBank.d489.s8|101-102|to|drug
DDI-DrugBank.d489.s8|104-114|epinephrine|drug
DDI-DrugBank.d489.s8|116-117|in|drug
DDI-DrugBank.d489.s8|119-121|the|drug
DDI-DrugBank.d489.s8|123-131|treatment|drug
DDI-DrugBank.d489.s8|133-134|of|drug
DDI-DrugBank.d489.s8|136-147|anaphylactic|drug
DDI-DrugBank.d489.s8|149-153|shock|drug
DDI-DrugBank.d489.s8|154-154|,|drug
DDI-DrugBank.d489.s8|156-168|beta-blockers|drug
DDI-DrugBank.d489.s8|170-172|can|drug
DDI-DrugBank.d489.s8|173-173|,|drug
DDI-DrugBank.d489.s8|175-176|in|drug
DDI-DrugBank.d489.s8|178-185|addition|drug
DDI-DrugBank.d489.s8|186-186|,|drug
DDI-DrugBank.d489.s8|188-196|interfere|drug
DDI-DrugBank.d489.s8|198-201|with|drug
DDI-DrugBank.d489.s8|203-205|the|drug
DDI-DrugBank.d489.s8|207-216|modulation|drug
DDI-DrugBank.d489.s8|218-219|of|drug
DDI-DrugBank.d489.s8|221-228|allergic|drug
DDI-DrugBank.d489.s8|230-237|reaction|drug
DDI-DrugBank.d489.s8|239-241|and|drug
DDI-DrugBank.d489.s8|243-246|lead|drug
DDI-DrugBank.d489.s8|248-249|to|drug
DDI-DrugBank.d489.s8|251-252|an|drug
DDI-DrugBank.d489.s8|254-262|increased|drug
DDI-DrugBank.d489.s8|264-271|severity|drug
DDI-DrugBank.d489.s8|273-278|and/or|drug
DDI-DrugBank.d489.s8|280-288|frequency|drug
DDI-DrugBank.d489.s8|290-291|of|drug
DDI-DrugBank.d489.s8|293-299|attacks|drug
DDI-DrugBank.d489.s8|300-300|.|drug
DDI-DrugBank.d489.s9|0-5|Severe|drug
DDI-DrugBank.d489.s9|7-14|allergic|drug
DDI-DrugBank.d489.s9|16-24|reactions|drug
DDI-DrugBank.d489.s9|26-34|including|drug
DDI-DrugBank.d489.s9|36-46|anaphylaxis|drug
DDI-DrugBank.d489.s9|48-51|have|drug
DDI-DrugBank.d489.s9|53-56|been|drug
DDI-DrugBank.d489.s9|58-65|reported|drug
DDI-DrugBank.d489.s9|67-68|in|drug
DDI-DrugBank.d489.s9|70-77|patients|drug
DDI-DrugBank.d489.s9|79-85|exposed|drug
DDI-DrugBank.d489.s9|87-88|to|drug
DDI-DrugBank.d489.s9|90-90|a|drug
DDI-DrugBank.d489.s9|92-98|variety|drug
DDI-DrugBank.d489.s9|100-101|of|drug
DDI-DrugBank.d489.s9|103-111|allergens|drug
DDI-DrugBank.d489.s9|113-118|either|drug
DDI-DrugBank.d489.s9|120-121|by|drug
DDI-DrugBank.d489.s9|123-130|repeated|drug
DDI-DrugBank.d489.s9|132-140|challenge|drug
DDI-DrugBank.d489.s9|141-141|,|drug
DDI-DrugBank.d489.s9|143-144|or|drug
DDI-DrugBank.d489.s9|146-155|accidental|drug
DDI-DrugBank.d489.s9|157-163|contact|drug
DDI-DrugBank.d489.s9|164-164|,|drug
DDI-DrugBank.d489.s9|166-168|and|drug
DDI-DrugBank.d489.s9|170-173|with|drug
DDI-DrugBank.d489.s9|175-184|diagnostic|drug
DDI-DrugBank.d489.s9|186-187|or|drug
DDI-DrugBank.d489.s9|189-199|therapeutic|drug
DDI-DrugBank.d489.s9|201-206|agents|drug
DDI-DrugBank.d489.s9|208-212|while|drug
DDI-DrugBank.d489.s9|214-222|receiving|drug
DDI-DrugBank.d489.s9|224-236|beta-blockers|drug
DDI-DrugBank.d489.s9|237-237|.|drug
DDI-DrugBank.d489.s10|0-3|Such|drug
DDI-DrugBank.d489.s10|5-12|patients|drug
DDI-DrugBank.d489.s10|14-16|may|drug
DDI-DrugBank.d489.s10|18-19|be|drug
DDI-DrugBank.d489.s10|21-32|unresponsive|drug
DDI-DrugBank.d489.s10|34-35|to|drug
DDI-DrugBank.d489.s10|37-39|the|drug
DDI-DrugBank.d489.s10|41-45|usual|drug
DDI-DrugBank.d489.s10|47-51|doses|drug
DDI-DrugBank.d489.s10|53-54|of|drug
DDI-DrugBank.d489.s10|56-66|epinephrine|drug
DDI-DrugBank.d489.s10|68-71|used|drug
DDI-DrugBank.d489.s10|73-74|to|drug
DDI-DrugBank.d489.s10|76-80|treat|drug
DDI-DrugBank.d489.s10|82-89|allergic|drug
DDI-DrugBank.d489.s10|91-98|reaction|drug
DDI-DrugBank.d489.s10|99-99|.|drug
DDI-MedLine.d1.s0|0-0|[|drug
DDI-MedLine.d1.s0|1-4|Drug|drug
DDI-MedLine.d1.s0|6-14|treatment|drug
DDI-MedLine.d1.s0|16-17|of|drug
DDI-MedLine.d1.s0|19-26|erection|drug
DDI-MedLine.d1.s0|28-36|disorders|drug
DDI-MedLine.d1.s0|38-39|in|drug
DDI-MedLine.d1.s0|41-48|patients|drug
DDI-MedLine.d1.s0|50-53|with|drug
DDI-MedLine.d1.s0|55-68|cardiovascular|drug
DDI-MedLine.d1.s0|70-76|disease|drug
DDI-MedLine.d1.s0|77-77|]|drug
DDI-MedLine.d1.s0|79-86|Erectile|drug
DDI-MedLine.d1.s0|88-98|dysfunction|drug
DDI-MedLine.d1.s0|100-101|is|drug
DDI-MedLine.d1.s0|103-103|a|drug
DDI-MedLine.d1.s0|105-112|frequent|drug
DDI-MedLine.d1.s0|114-122|condition|drug
DDI-MedLine.d1.s0|124-125|in|drug
DDI-MedLine.d1.s0|127-140|cardiovascular|drug
DDI-MedLine.d1.s0|142-149|patients|drug
DDI-MedLine.d1.s0|150-150|.|drug
DDI-MedLine.d1.s1|0-4|Since|drug
DDI-MedLine.d1.s1|6-8|the|drug
DDI-MedLine.d1.s1|10-16|arrival|drug
DDI-MedLine.d1.s1|18-19|of|drug
DDI-MedLine.d1.s1|21-24|oral|drug
DDI-MedLine.d1.s1|26-44|erection-supporting|drug
DDI-MedLine.d1.s1|46-55|medication|drug
DDI-MedLine.d1.s1|56-56|,|drug
DDI-MedLine.d1.s1|58-65|patients|drug
DDI-MedLine.d1.s1|67-70|want|drug
DDI-MedLine.d1.s1|72-73|to|drug
DDI-MedLine.d1.s1|75-78|know|drug
DDI-MedLine.d1.s1|80-82|how|drug
DDI-MedLine.d1.s1|84-87|safe|drug
DDI-MedLine.d1.s1|89-94|sexual|drug
DDI-MedLine.d1.s1|96-103|activity|drug
DDI-MedLine.d1.s1|105-106|is|drug
DDI-MedLine.d1.s1|108-109|in|drug
DDI-MedLine.d1.s1|111-124|cardiovascular|drug
DDI-MedLine.d1.s1|126-132|disease|drug
DDI-MedLine.d1.s1|134-135|in|drug
DDI-MedLine.d1.s1|137-143|general|drug
DDI-MedLine.d1.s1|145-147|and|drug
DDI-MedLine.d1.s1|149-154|during|drug
DDI-MedLine.d1.s1|156-158|use|drug
DDI-MedLine.d1.s1|160-161|of|drug
DDI-MedLine.d1.s1|163-181|erection-supporting|drug
DDI-MedLine.d1.s1|183-192|medication|drug
DDI-MedLine.d1.s1|194-195|in|drug
DDI-MedLine.d1.s1|197-206|particular|drug
DDI-MedLine.d1.s1|207-207|.|drug
DDI-MedLine.d1.s2|0-5|Sexual|drug
DDI-MedLine.d1.s2|7-17|intercourse|drug
DDI-MedLine.d1.s2|19-22|with|drug
DDI-MedLine.d1.s2|24-24|a|drug
DDI-MedLine.d1.s2|26-31|steady|drug
DDI-MedLine.d1.s2|33-39|partner|drug
DDI-MedLine.d1.s2|41-46|causes|drug
DDI-MedLine.d1.s2|48-49|no|drug
DDI-MedLine.d1.s2|51-54|more|drug
DDI-MedLine.d1.s2|56-69|cardiovascular|drug
DDI-MedLine.d1.s2|71-74|risk|drug
DDI-MedLine.d1.s2|76-79|than|drug
DDI-MedLine.d1.s2|81-86|normal|drug
DDI-MedLine.d1.s2|88-92|daily|drug
DDI-MedLine.d1.s2|94-103|activities|drug
DDI-MedLine.d1.s2|105-108|such|drug
DDI-MedLine.d1.s2|110-111|as|drug
DDI-MedLine.d1.s2|113-119|ironing|drug
DDI-MedLine.d1.s2|120-120|,|drug
DDI-MedLine.d1.s2|122-122|2|drug
DDI-MedLine.d1.s2|124-133|kilometers|drug
DDI-MedLine.d1.s2|135-136|of|drug
DDI-MedLine.d1.s2|138-144|walking|drug
DDI-MedLine.d1.s2|146-152|without|drug
DDI-MedLine.d1.s2|154-161|climbing|drug
DDI-MedLine.d1.s2|162-162|,|drug
DDI-MedLine.d1.s2|164-175|paperhanging|drug
DDI-MedLine.d1.s2|176-176|,|drug
DDI-MedLine.d1.s2|178-184|playing|drug
DDI-MedLine.d1.s2|186-189|golf|drug
DDI-MedLine.d1.s2|191-192|or|drug
DDI-MedLine.d1.s2|194-202|gardening|drug
DDI-MedLine.d1.s2|203-203|.|drug
DDI-MedLine.d1.s3|0-2|The|drug
DDI-MedLine.d1.s3|4-11|relative|drug
DDI-MedLine.d1.s3|13-16|risk|drug
DDI-MedLine.d1.s3|18-19|of|drug
DDI-MedLine.d1.s3|21-30|myocardial|drug
DDI-MedLine.d1.s3|32-41|infarction|drug
DDI-MedLine.d1.s3|43-48|during|drug
DDI-MedLine.d1.s3|50-55|sexual|drug
DDI-MedLine.d1.s3|57-64|activity|drug
DDI-MedLine.d1.s3|66-67|is|drug
DDI-MedLine.d1.s3|69-71|not|drug
DDI-MedLine.d1.s3|73-85|significantly|drug
DDI-MedLine.d1.s3|87-92|higher|drug
DDI-MedLine.d1.s3|94-97|than|drug
DDI-MedLine.d1.s3|99-101|for|drug
DDI-MedLine.d1.s3|103-109|healthy|drug
DDI-MedLine.d1.s3|111-117|persons|drug
DDI-MedLine.d1.s3|118-118|.|drug
DDI-MedLine.d1.s4|0-2|The|drug
DDI-MedLine.d1.s4|4-12|incidence|drug
DDI-MedLine.d1.s4|14-15|of|drug
DDI-MedLine.d1.s4|17-30|cardiovascular|drug
DDI-MedLine.d1.s4|32-40|morbidity|drug
DDI-MedLine.d1.s4|42-44|and|drug
DDI-MedLine.d1.s4|46-54|mortality|drug
DDI-MedLine.d1.s4|56-57|is|drug
DDI-MedLine.d1.s4|59-61|not|drug
DDI-MedLine.d1.s4|63-68|higher|drug
DDI-MedLine.d1.s4|70-74|among|drug
DDI-MedLine.d1.s4|76-80|users|drug
DDI-MedLine.d1.s4|82-83|of|drug
DDI-MedLine.d1.s4|85-94|sildenafil|drug
DDI-MedLine.d1.s4|95-95|.|drug
DDI-MedLine.d1.s5|0-9|Sildenafil|brand
DDI-MedLine.d1.s5|11-12|is|drug
DDI-MedLine.d1.s5|14-28|contraindicated|drug
DDI-MedLine.d1.s5|30-31|in|drug
DDI-MedLine.d1.s5|33-40|patients|drug
DDI-MedLine.d1.s5|42-46|using|drug
DDI-MedLine.d1.s5|48-58|long-acting|drug
DDI-MedLine.d1.s5|60-67|nitrates|drug
DDI-MedLine.d1.s5|69-70|or|drug
DDI-MedLine.d1.s5|72-74|who|drug
DDI-MedLine.d1.s5|76-78|may|drug
DDI-MedLine.d1.s5|80-83|need|drug
DDI-MedLine.d1.s5|85-86|to|drug
DDI-MedLine.d1.s5|88-90|use|drug
DDI-MedLine.d1.s5|92-103|short-acting|drug
DDI-MedLine.d1.s5|105-112|nitrates|drug
DDI-MedLine.d1.s5|113-113|,|drug
DDI-MedLine.d1.s5|115-121|because|drug
DDI-MedLine.d1.s5|123-125|the|drug
DDI-MedLine.d1.s5|127-137|combination|drug
DDI-MedLine.d1.s5|139-141|may|drug
DDI-MedLine.d1.s5|143-147|cause|drug
DDI-MedLine.d1.s5|149-149|a|drug
DDI-MedLine.d1.s5|151-155|sharp|drug
DDI-MedLine.d1.s5|157-160|fall|drug
DDI-MedLine.d1.s5|162-163|of|drug
DDI-MedLine.d1.s5|165-167|the|drug
DDI-MedLine.d1.s5|169-173|blood|drug
DDI-MedLine.d1.s5|175-182|pressure|drug
DDI-MedLine.d1.s5|183-183|.|drug
DDI-MedLine.d1.s6|0-1|No|drug
DDI-MedLine.d1.s6|3-14|interactions|drug
DDI-MedLine.d1.s6|16-19|have|drug
DDI-MedLine.d1.s6|21-24|been|drug
DDI-MedLine.d1.s6|26-33|observed|drug
DDI-MedLine.d1.s6|35-38|with|drug
DDI-MedLine.d1.s6|40-52|beta-receptor|drug
DDI-MedLine.d1.s6|54-61|blockers|drug
DDI-MedLine.d1.s6|62-62|,|drug
DDI-MedLine.d1.s6|64-70|calcium|drug
DDI-MedLine.d1.s6|72-82|antagonists|drug
DDI-MedLine.d1.s6|83-83|,|drug
DDI-MedLine.d1.s6|85-92|thiazide|drug
DDI-MedLine.d1.s6|94-96|and|drug
DDI-MedLine.d1.s6|98-101|loop|drug
DDI-MedLine.d1.s6|103-111|diuretics|drug
DDI-MedLine.d1.s6|113-115|and|drug
DDI-MedLine.d1.s6|117-119|ACE|drug
DDI-MedLine.d1.s6|121-130|inhibitors|drug
DDI-MedLine.d1.s6|131-131|.|drug
DDI-MedLine.d1.s7|0-5|Before|drug
DDI-MedLine.d1.s7|7-17|prescribing|drug
DDI-MedLine.d1.s7|19-19|a|drug
DDI-MedLine.d1.s7|21-31|symptomatic|drug
DDI-MedLine.d1.s7|33-33|(|drug
DDI-MedLine.d1.s7|34-47|pharmaceutical|drug
DDI-MedLine.d1.s7|48-48|)|drug
DDI-MedLine.d1.s7|50-58|treatment|drug
DDI-MedLine.d1.s7|60-62|for|drug
DDI-MedLine.d1.s7|64-71|patients|drug
DDI-MedLine.d1.s7|73-76|with|drug
DDI-MedLine.d1.s7|78-79|an|drug
DDI-MedLine.d1.s7|81-88|erection|drug
DDI-MedLine.d1.s7|90-97|disorder|drug
DDI-MedLine.d1.s7|98-98|,|drug
DDI-MedLine.d1.s7|100-108|attention|drug
DDI-MedLine.d1.s7|110-115|should|drug
DDI-MedLine.d1.s7|117-118|be|drug
DDI-MedLine.d1.s7|120-124|given|drug
DDI-MedLine.d1.s7|126-128|tot|drug
DDI-MedLine.d1.s7|130-132|the|drug
DDI-MedLine.d1.s7|134-144|sexological|drug
DDI-MedLine.d1.s7|145-145|,|drug
DDI-MedLine.d1.s7|147-159|psychological|drug
DDI-MedLine.d1.s7|161-163|and|drug
DDI-MedLine.d1.s7|165-171|medical|drug
DDI-MedLine.d1.s7|173-183|backgrounds|drug
DDI-MedLine.d1.s7|185-186|of|drug
DDI-MedLine.d1.s7|188-190|the|drug
DDI-MedLine.d1.s7|192-199|disorder|drug
DDI-MedLine.d1.s7|200-200|.|drug
DDI-MedLine.d1.s8|0-8|Secondary|drug
DDI-MedLine.d1.s8|10-19|prevention|drug
DDI-MedLine.d1.s8|21-22|of|drug
DDI-MedLine.d1.s8|24-38|atherosclerotic|drug
DDI-MedLine.d1.s8|40-43|risk|drug
DDI-MedLine.d1.s8|45-51|factors|drug
DDI-MedLine.d1.s8|53-54|is|drug
DDI-MedLine.d1.s8|56-59|also|drug
DDI-MedLine.d1.s8|61-69|important|drug
DDI-MedLine.d1.s8|70-70|:|drug
DDI-MedLine.d1.s8|72-81|regulation|drug
DDI-MedLine.d1.s8|83-84|of|drug
DDI-MedLine.d1.s8|86-90|blood|drug
DDI-MedLine.d1.s8|92-99|pressure|drug
DDI-MedLine.d1.s8|101-103|and|drug
DDI-MedLine.d1.s8|105-109|blood|drug
DDI-MedLine.d1.s8|111-115|sugar|drug
DDI-MedLine.d1.s8|117-121|level|drug
DDI-MedLine.d1.s8|122-122|,|drug
DDI-MedLine.d1.s8|124-138|hyperlipidaemia|drug
DDI-MedLine.d1.s8|140-142|and|drug
DDI-MedLine.d1.s8|144-150|obesity|drug
DDI-MedLine.d1.s8|151-151|,|drug
DDI-MedLine.d1.s8|153-154|as|drug
DDI-MedLine.d1.s8|156-159|well|drug
DDI-MedLine.d1.s8|161-162|as|drug
DDI-MedLine.d1.s8|164-164|a|drug
DDI-MedLine.d1.s8|166-171|change|drug
DDI-MedLine.d1.s8|173-174|of|drug
DDI-MedLine.d1.s8|176-184|lifestyle|drug
DDI-MedLine.d1.s8|186-186|(|drug
DDI-MedLine.d1.s8|187-192|giving|drug
DDI-MedLine.d1.s8|194-195|up|drug
DDI-MedLine.d1.s8|197-203|smoking|drug
DDI-MedLine.d1.s8|204-204|,|drug
DDI-MedLine.d1.s8|206-213|adapting|drug
DDI-MedLine.d1.s8|215-216|of|drug
DDI-MedLine.d1.s8|218-221|diet|drug
DDI-MedLine.d1.s8|223-225|and|drug
DDI-MedLine.d1.s8|227-230|more|drug
DDI-MedLine.d1.s8|232-239|physical|drug
DDI-MedLine.d1.s8|241-248|exertion|drug
DDI-MedLine.d1.s8|249-249|)|drug
DDI-MedLine.d1.s8|250-250|.|drug
DDI-MedLine.d1.s9|0-7|Patients|drug
DDI-MedLine.d1.s9|9-12|with|drug
DDI-MedLine.d1.s9|14-14|a|drug
DDI-MedLine.d1.s9|16-19|very|drug
DDI-MedLine.d1.s9|21-23|low|drug
DDI-MedLine.d1.s9|25-31|cardiac|drug
DDI-MedLine.d1.s9|33-40|capacity|drug
DDI-MedLine.d1.s9|42-47|should|drug
DDI-MedLine.d1.s9|49-50|be|drug
DDI-MedLine.d1.s9|52-58|advised|drug
DDI-MedLine.d1.s9|60-61|to|drug
DDI-MedLine.d1.s9|63-69|refrain|drug
DDI-MedLine.d1.s9|71-74|from|drug
DDI-MedLine.d1.s9|76-84|treatment|drug
DDI-MedLine.d1.s9|86-87|of|drug
DDI-MedLine.d1.s9|89-91|the|drug
DDI-MedLine.d1.s9|93-100|erection|drug
DDI-MedLine.d1.s9|102-109|disorder|drug
DDI-MedLine.d1.s9|110-110|.|drug
DDI-DrugBank.d580.s0|0-1|In|drug
DDI-DrugBank.d580.s0|3-10|clinical|drug
DDI-DrugBank.d580.s0|12-18|studies|drug
DDI-DrugBank.d580.s0|19-19|,|drug
DDI-DrugBank.d580.s0|21-23|the|drug
DDI-DrugBank.d580.s0|25-34|concurrent|drug
DDI-DrugBank.d580.s0|36-49|administration|drug
DDI-DrugBank.d580.s0|51-52|of|drug
DDI-DrugBank.d580.s0|54-56|the|drug
DDI-DrugBank.d580.s0|58-64|ASMANEX|drug
DDI-DrugBank.d580.s0|66-75|TWISTHALER|drug
DDI-DrugBank.d580.s0|80-86|inhaler|drug
DDI-DrugBank.d580.s0|88-90|and|drug
DDI-DrugBank.d580.s0|92-96|other|drug
DDI-DrugBank.d580.s0|98-102|drugs|drug
DDI-DrugBank.d580.s0|104-111|commonly|drug
DDI-DrugBank.d580.s0|113-116|used|drug
DDI-DrugBank.d580.s0|118-119|in|drug
DDI-DrugBank.d580.s0|121-123|the|drug
DDI-DrugBank.d580.s0|125-133|treatment|drug
DDI-DrugBank.d580.s0|135-136|of|drug
DDI-DrugBank.d580.s0|138-143|asthma|drug
DDI-DrugBank.d580.s0|145-147|was|drug
DDI-DrugBank.d580.s0|149-151|not|drug
DDI-DrugBank.d580.s0|153-162|associated|drug
DDI-DrugBank.d580.s0|164-167|with|drug
DDI-DrugBank.d580.s0|169-171|any|drug
DDI-DrugBank.d580.s0|173-179|unusual|drug
DDI-DrugBank.d580.s0|181-187|adverse|drug
DDI-DrugBank.d580.s0|189-194|events|drug
DDI-DrugBank.d580.s0|195-195|.|drug
DDI-DrugBank.d580.s1|0-6|However|drug
DDI-DrugBank.d580.s1|7-7|,|drug
DDI-DrugBank.d580.s1|9-20|ketoconazole|drug
DDI-DrugBank.d580.s1|21-21|,|drug
DDI-DrugBank.d580.s1|23-23|a|drug
DDI-DrugBank.d580.s1|25-30|potent|drug
DDI-DrugBank.d580.s1|32-40|inhibitor|drug
DDI-DrugBank.d580.s1|42-43|of|drug
DDI-DrugBank.d580.s1|45-54|cytochrome|drug
DDI-DrugBank.d580.s1|56-59|P450|drug
DDI-DrugBank.d580.s1|61-63|3A4|drug
DDI-DrugBank.d580.s1|64-64|,|drug
DDI-DrugBank.d580.s1|66-68|may|drug
DDI-DrugBank.d580.s1|70-77|increase|drug
DDI-DrugBank.d580.s1|79-84|plasma|drug
DDI-DrugBank.d580.s1|86-91|levels|drug
DDI-DrugBank.d580.s1|93-94|of|drug
DDI-DrugBank.d580.s1|96-105|mometasone|drug
DDI-DrugBank.d580.s1|107-113|furoate|drug
DDI-DrugBank.d580.s1|115-120|during|drug
DDI-DrugBank.d580.s1|122-132|concomitant|drug
DDI-DrugBank.d580.s1|134-139|dosing|drug
DDI-DrugBank.d580.s1|140-140|.|drug
DDI-DrugBank.d465.s0|0-2|The|drug
DDI-DrugBank.d465.s0|4-15|vasodilating|drug
DDI-DrugBank.d465.s0|17-23|effects|drug
DDI-DrugBank.d465.s0|25-26|of|drug
DDI-DrugBank.d465.s0|28-37|isosorbide|drug
DDI-DrugBank.d465.s0|39-47|dinitrate|drug
DDI-DrugBank.d465.s0|49-51|may|drug
DDI-DrugBank.d465.s0|53-54|be|drug
DDI-DrugBank.d465.s0|56-63|additive|drug
DDI-DrugBank.d465.s0|65-68|with|drug
DDI-DrugBank.d465.s0|70-74|those|drug
DDI-DrugBank.d465.s0|76-77|of|drug
DDI-DrugBank.d465.s0|79-83|other|drug
DDI-DrugBank.d465.s0|85-96|vasodilators|drug
DDI-DrugBank.d465.s0|97-97|.|drug
DDI-DrugBank.d465.s1|0-6|Alcohol|brand
DDI-DrugBank.d465.s1|7-7|,|drug
DDI-DrugBank.d465.s1|9-10|in|drug
DDI-DrugBank.d465.s1|12-21|particular|drug
DDI-DrugBank.d465.s1|22-22|,|drug
DDI-DrugBank.d465.s1|24-26|has|drug
DDI-DrugBank.d465.s1|28-31|been|drug
DDI-DrugBank.d465.s1|33-37|found|drug
DDI-DrugBank.d465.s1|39-40|to|drug
DDI-DrugBank.d465.s1|42-48|exhibit|drug
DDI-DrugBank.d465.s1|50-57|additive|drug
DDI-DrugBank.d465.s1|59-65|effects|drug
DDI-DrugBank.d465.s1|67-68|of|drug
DDI-DrugBank.d465.s1|70-73|this|drug
DDI-DrugBank.d465.s1|75-81|variety|drug
DDI-DrugBank.d465.s1|82-82|.|drug
DDI-DrugBank.d590.s0|0-15|Coadministration|drug
DDI-DrugBank.d590.s0|17-18|of|drug
DDI-DrugBank.d590.s0|20-25|TRITEC|drug
DDI-DrugBank.d590.s0|27-30|with|drug
DDI-DrugBank.d590.s0|32-45|clarithromycin|drug
DDI-DrugBank.d590.s0|47-54|resulted|drug
DDI-DrugBank.d590.s0|56-57|in|drug
DDI-DrugBank.d590.s0|59-67|increased|drug
DDI-DrugBank.d590.s0|69-74|plasma|drug
DDI-DrugBank.d590.s0|76-85|ranitidine|drug
DDI-DrugBank.d590.s0|87-100|concentrations|drug
DDI-DrugBank.d590.s0|102-102|(|drug
DDI-DrugBank.d590.s0|103-104|57|drug
DDI-DrugBank.d590.s0|105-105|%|drug
DDI-DrugBank.d590.s0|106-106|)|drug
DDI-DrugBank.d590.s0|107-107|,|drug
DDI-DrugBank.d590.s0|109-117|increased|drug
DDI-DrugBank.d590.s0|119-124|plasma|drug
DDI-DrugBank.d590.s0|126-132|bismuth|drug
DDI-DrugBank.d590.s0|134-139|trough|drug
DDI-DrugBank.d590.s0|141-154|concentrations|drug
DDI-DrugBank.d590.s0|156-156|(|drug
DDI-DrugBank.d590.s0|157-158|48|drug
DDI-DrugBank.d590.s0|159-159|%|drug
DDI-DrugBank.d590.s0|160-160|)|drug
DDI-DrugBank.d590.s0|161-161|,|drug
DDI-DrugBank.d590.s0|163-165|and|drug
DDI-DrugBank.d590.s0|167-175|increased|drug
DDI-DrugBank.d590.s0|177-179|14-|drug
DDI-DrugBank.d590.s0|181-188|hydroxy-|drug
DDI-DrugBank.d590.s0|190-203|clarithromycin|drug
DDI-DrugBank.d590.s0|205-210|plasma|drug
DDI-DrugBank.d590.s0|212-225|concentrations|drug
DDI-DrugBank.d590.s0|227-227|(|drug
DDI-DrugBank.d590.s0|228-229|31|drug
DDI-DrugBank.d590.s0|230-230|%|drug
DDI-DrugBank.d590.s0|231-231|)|drug
DDI-DrugBank.d590.s0|232-232|.|drug
DDI-DrugBank.d590.s1|0-15|Coadministration|drug
DDI-DrugBank.d590.s1|17-20|with|drug
DDI-DrugBank.d590.s1|22-28|aspirin|drug
DDI-DrugBank.d590.s1|30-36|results|drug
DDI-DrugBank.d590.s1|38-39|in|drug
DDI-DrugBank.d590.s1|41-41|a|drug
DDI-DrugBank.d590.s1|43-48|slight|drug
DDI-DrugBank.d590.s1|50-57|decrease|drug
DDI-DrugBank.d590.s1|59-60|in|drug
DDI-DrugBank.d590.s1|62-64|the|drug
DDI-DrugBank.d590.s1|66-69|rate|drug
DDI-DrugBank.d590.s1|71-72|of|drug
DDI-DrugBank.d590.s1|74-83|salicylate|drug
DDI-DrugBank.d590.s1|85-94|absorption|drug
DDI-DrugBank.d590.s1|96-99|that|drug
DDI-DrugBank.d590.s1|101-102|is|drug
DDI-DrugBank.d590.s1|104-113|clinically|drug
DDI-DrugBank.d590.s1|115-125|unimportant|drug
DDI-DrugBank.d590.s1|126-126|.|drug
DDI-DrugBank.d590.s2|0-15|Coadministration|drug
DDI-DrugBank.d590.s2|17-20|with|drug
DDI-DrugBank.d590.s2|22-22|a|drug
DDI-DrugBank.d590.s2|24-27|high|drug
DDI-DrugBank.d590.s2|29-32|dose|drug
DDI-DrugBank.d590.s2|34-35|of|drug
DDI-DrugBank.d590.s2|37-43|antacid|drug
DDI-DrugBank.d590.s2|45-45|(|drug
DDI-DrugBank.d590.s2|46-48|170|drug
DDI-DrugBank.d590.s2|50-52|mEq|drug
DDI-DrugBank.d590.s2|53-53|)|drug
DDI-DrugBank.d590.s2|55-61|results|drug
DDI-DrugBank.d590.s2|63-64|in|drug
DDI-DrugBank.d590.s2|66-66|a|drug
DDI-DrugBank.d590.s2|68-69|28|drug
DDI-DrugBank.d590.s2|70-70|%|drug
DDI-DrugBank.d590.s2|72-79|decrease|drug
DDI-DrugBank.d590.s2|81-82|in|drug
DDI-DrugBank.d590.s2|84-89|plasma|drug
DDI-DrugBank.d590.s2|91-104|concentrations|drug
DDI-DrugBank.d590.s2|106-107|of|drug
DDI-DrugBank.d590.s2|109-118|ranitidine|drug
DDI-DrugBank.d590.s2|120-122|and|drug
DDI-DrugBank.d590.s2|124-126|may|drug
DDI-DrugBank.d590.s2|128-135|decrease|drug
DDI-DrugBank.d590.s2|137-142|plasma|drug
DDI-DrugBank.d590.s2|144-157|concentrations|drug
DDI-DrugBank.d590.s2|159-160|of|drug
DDI-DrugBank.d590.s2|162-168|bismuth|drug
DDI-DrugBank.d590.s2|170-173|from|drug
DDI-DrugBank.d590.s2|175-180|TRITEC|drug
DDI-DrugBank.d590.s2|181-181|.|drug
DDI-DrugBank.d590.s3|0-4|These|drug
DDI-DrugBank.d590.s3|6-12|effects|drug
DDI-DrugBank.d590.s3|14-16|are|drug
DDI-DrugBank.d590.s3|18-27|clinically|drug
DDI-DrugBank.d590.s3|29-41|insignificant|drug
DDI-DrugBank.d590.s3|42-42|.|drug
DDI-DrugBank.d590.s4|0-2|For|drug
DDI-DrugBank.d590.s4|4-14|information|drug
DDI-DrugBank.d590.s4|16-17|on|drug
DDI-DrugBank.d590.s4|19-22|drug|drug
DDI-DrugBank.d590.s4|24-35|interactions|drug
DDI-DrugBank.d590.s4|37-46|associated|drug
DDI-DrugBank.d590.s4|48-51|with|drug
DDI-DrugBank.d590.s4|53-62|ranitidine|drug
DDI-DrugBank.d590.s4|63-63|,|drug
DDI-DrugBank.d590.s4|65-69|refer|drug
DDI-DrugBank.d590.s4|71-72|to|drug
DDI-DrugBank.d590.s4|74-76|the|drug
DDI-DrugBank.d590.s4|78-83|ZANTAC|drug
DDI-DrugBank.d590.s4|89-95|package|drug
DDI-DrugBank.d590.s4|97-102|insert|drug
DDI-DrugBank.d590.s4|103-103|.|drug
DDI-DrugBank.d531.s0|0-8|Efavirenz|brand
DDI-DrugBank.d531.s0|10-12|has|drug
DDI-DrugBank.d531.s0|14-17|been|drug
DDI-DrugBank.d531.s0|19-23|shown|drug
DDI-DrugBank.d531.s0|25-26|in|drug
DDI-DrugBank.d531.s0|28-31|vivo|drug
DDI-DrugBank.d531.s0|33-34|to|drug
DDI-DrugBank.d531.s0|36-41|induce|drug
DDI-DrugBank.d531.s0|43-48|CYP3A4|drug
DDI-DrugBank.d531.s0|49-49|.|drug
DDI-DrugBank.d531.s1|0-4|Other|drug
DDI-DrugBank.d531.s1|6-14|compounds|drug
DDI-DrugBank.d531.s1|16-19|that|drug
DDI-DrugBank.d531.s1|21-23|are|drug
DDI-DrugBank.d531.s1|25-34|substrates|drug
DDI-DrugBank.d531.s1|36-37|of|drug
DDI-DrugBank.d531.s1|39-44|CYP3A4|drug
DDI-DrugBank.d531.s1|46-48|may|drug
DDI-DrugBank.d531.s1|50-53|have|drug
DDI-DrugBank.d531.s1|55-63|decreased|drug
DDI-DrugBank.d531.s1|65-70|plasma|drug
DDI-DrugBank.d531.s1|72-85|concentrations|drug
DDI-DrugBank.d531.s1|87-90|when|drug
DDI-DrugBank.d531.s1|92-105|coadministered|drug
DDI-DrugBank.d531.s1|107-110|with|drug
DDI-DrugBank.d531.s1|112-118|SUSTIVA|drug
DDI-DrugBank.d531.s1|120-120|(|drug
DDI-DrugBank.d531.s1|121-129|efavirenz|drug
DDI-DrugBank.d531.s1|130-130|)|drug
DDI-DrugBank.d531.s1|131-131|.|drug
DDI-DrugBank.d531.s2|0-1|In|drug
DDI-DrugBank.d531.s2|3-7|vitro|drug
DDI-DrugBank.d531.s2|9-15|studies|drug
DDI-DrugBank.d531.s2|17-20|have|drug
DDI-DrugBank.d531.s2|22-33|demonstrated|drug
DDI-DrugBank.d531.s2|35-38|that|drug
DDI-DrugBank.d531.s2|40-48|efavirenz|drug
DDI-DrugBank.d531.s2|50-57|inhibits|drug
DDI-DrugBank.d531.s2|59-61|2C9|drug
DDI-DrugBank.d531.s2|62-62|,|drug
DDI-DrugBank.d531.s2|64-67|2C19|drug
DDI-DrugBank.d531.s2|68-68|,|drug
DDI-DrugBank.d531.s2|70-72|and|drug
DDI-DrugBank.d531.s2|74-76|3A4|drug
DDI-DrugBank.d531.s2|78-85|isozymes|drug
DDI-DrugBank.d531.s2|87-88|in|drug
DDI-DrugBank.d531.s2|90-92|the|drug
DDI-DrugBank.d531.s2|94-98|range|drug
DDI-DrugBank.d531.s2|100-101|of|drug
DDI-DrugBank.d531.s2|103-110|observed|drug
DDI-DrugBank.d531.s2|112-120|efavirenz|drug
DDI-DrugBank.d531.s2|122-127|plasma|drug
DDI-DrugBank.d531.s2|129-142|concentrations|drug
DDI-DrugBank.d531.s2|143-143|.|drug
DDI-DrugBank.d531.s3|0-15|Coadministration|drug
DDI-DrugBank.d531.s3|17-18|of|drug
DDI-DrugBank.d531.s3|20-28|efavirenz|drug
DDI-DrugBank.d531.s3|30-33|with|drug
DDI-DrugBank.d531.s3|35-39|drugs|drug
DDI-DrugBank.d531.s3|41-49|primarily|drug
DDI-DrugBank.d531.s3|51-61|metabolized|drug
DDI-DrugBank.d531.s3|63-64|by|drug
DDI-DrugBank.d531.s3|66-70|these|drug
DDI-DrugBank.d531.s3|72-79|isozymes|drug
DDI-DrugBank.d531.s3|81-83|may|drug
DDI-DrugBank.d531.s3|85-90|result|drug
DDI-DrugBank.d531.s3|92-93|in|drug
DDI-DrugBank.d531.s3|95-101|altered|drug
DDI-DrugBank.d531.s3|103-108|plasma|drug
DDI-DrugBank.d531.s3|110-123|concentrations|drug
DDI-DrugBank.d531.s3|125-126|of|drug
DDI-DrugBank.d531.s3|128-130|the|drug
DDI-DrugBank.d531.s3|132-145|coadministered|drug
DDI-DrugBank.d531.s3|147-150|drug|drug
DDI-DrugBank.d531.s3|151-151|.|drug
DDI-DrugBank.d531.s4|0-8|Therefore|drug
DDI-DrugBank.d531.s4|9-9|,|drug
DDI-DrugBank.d531.s4|11-21|appropriate|drug
DDI-DrugBank.d531.s4|23-26|dose|drug
DDI-DrugBank.d531.s4|28-38|adjustments|drug
DDI-DrugBank.d531.s4|40-42|may|drug
DDI-DrugBank.d531.s4|44-45|be|drug
DDI-DrugBank.d531.s4|47-55|necessary|drug
DDI-DrugBank.d531.s4|57-59|for|drug
DDI-DrugBank.d531.s4|61-65|these|drug
DDI-DrugBank.d531.s4|67-71|drugs|drug
DDI-DrugBank.d531.s4|72-72|.|drug
DDI-DrugBank.d531.s5|0-4|Drugs|drug
DDI-DrugBank.d531.s5|6-10|which|drug
DDI-DrugBank.d531.s5|12-17|induce|drug
DDI-DrugBank.d531.s5|19-24|CYP3A4|drug
DDI-DrugBank.d531.s5|26-33|activity|drug
DDI-DrugBank.d531.s5|35-35|(|drug
DDI-DrugBank.d531.s5|36-37|eg|drug
DDI-DrugBank.d531.s5|38-38|,|drug
DDI-DrugBank.d531.s5|40-52|phenobarbital|drug
DDI-DrugBank.d531.s5|53-53|,|drug
DDI-DrugBank.d531.s5|55-62|rifampin|drug
DDI-DrugBank.d531.s5|63-63|,|drug
DDI-DrugBank.d531.s5|65-73|rifabutin|drug
DDI-DrugBank.d531.s5|74-74|)|drug
DDI-DrugBank.d531.s5|76-80|would|drug
DDI-DrugBank.d531.s5|82-83|be|drug
DDI-DrugBank.d531.s5|85-92|expected|drug
DDI-DrugBank.d531.s5|94-95|to|drug
DDI-DrugBank.d531.s5|97-104|increase|drug
DDI-DrugBank.d531.s5|106-108|the|drug
DDI-DrugBank.d531.s5|110-118|clearance|drug
DDI-DrugBank.d531.s5|120-121|of|drug
DDI-DrugBank.d531.s5|123-131|efavirenz|drug
DDI-DrugBank.d531.s5|133-141|resulting|drug
DDI-DrugBank.d531.s5|143-144|in|drug
DDI-DrugBank.d531.s5|146-152|lowered|drug
DDI-DrugBank.d531.s5|154-159|plasma|drug
DDI-DrugBank.d531.s5|161-174|concentrations|drug
DDI-DrugBank.d531.s5|175-175|.|drug
DDI-DrugBank.d531.s6|0-3|Drug|drug
DDI-DrugBank.d531.s6|5-16|interactions|drug
DDI-DrugBank.d531.s6|18-21|with|drug
DDI-DrugBank.d531.s6|23-29|SUSTIVA|drug
DDI-DrugBank.d531.s6|31-33|are|drug
DDI-DrugBank.d531.s6|35-44|summarized|drug
DDI-DrugBank.d531.s6|46-47|in|drug
DDI-DrugBank.d531.s6|49-53|Table|drug
DDI-DrugBank.d531.s6|55-55|5|drug
DDI-DrugBank.d531.s6|56-56|.|drug
DDI-DrugBank.d531.s7|0-4|Table|drug
DDI-DrugBank.d531.s7|6-7|5a|drug
DDI-DrugBank.d531.s7|8-8|:|drug
DDI-DrugBank.d531.s7|10-14|Drugs|drug
DDI-DrugBank.d531.s7|16-19|That|drug
DDI-DrugBank.d531.s7|21-26|Should|drug
DDI-DrugBank.d531.s7|28-30|Not|drug
DDI-DrugBank.d531.s7|32-33|Be|drug
DDI-DrugBank.d531.s7|35-48|Coadministered|drug
DDI-DrugBank.d531.s7|50-53|With|drug
DDI-DrugBank.d531.s7|55-61|SUSTIVA|drug
DDI-DrugBank.d531.s8|0-3|Drug|drug
DDI-DrugBank.d531.s8|5-9|Class|drug
DDI-DrugBank.d531.s9|0-4|Drugs|drug
DDI-DrugBank.d531.s9|6-11|Within|drug
DDI-DrugBank.d531.s9|13-17|Class|drug
DDI-DrugBank.d531.s9|19-21|Not|drug
DDI-DrugBank.d531.s9|23-24|To|drug
DDI-DrugBank.d531.s9|26-27|Be|drug
DDI-DrugBank.d531.s9|29-42|Coadministered|drug
DDI-DrugBank.d531.s9|44-47|With|drug
DDI-DrugBank.d531.s9|49-55|SUSTIVA|drug
DDI-DrugBank.d531.s10|0-13|Antihistamines|drug
DDI-DrugBank.d531.s10|14-14|:|drug
DDI-DrugBank.d531.s10|16-30|Benzodiazepines|drug
DDI-DrugBank.d531.s10|32-33|GI|drug
DDI-DrugBank.d531.s10|35-42|Motility|drug
DDI-DrugBank.d531.s10|44-49|Agents|drug
DDI-DrugBank.d531.s10|51-63|Anti-Migraine|drug
DDI-DrugBank.d531.s10|65-74|Antifungal|brand
DDI-DrugBank.d531.s11|0-9|astemizole|drug
DDI-DrugBank.d531.s11|11-19|midazolam|drug
DDI-DrugBank.d531.s11|20-20|,|drug
DDI-DrugBank.d531.s11|22-30|triazolam|drug
DDI-DrugBank.d531.s11|32-40|cisapride|drug
DDI-DrugBank.d531.s11|42-46|ergot|drug
DDI-DrugBank.d531.s11|48-58|derivatives|drug
DDI-DrugBank.d531.s11|60-71|voriconazole|drug
DDI-DrugBank.d531.s12|0-10|Established|drug
DDI-DrugBank.d531.s12|12-15|Drug|drug
DDI-DrugBank.d531.s12|17-28|Interactions|drug
DDI-DrugBank.d531.s14|0-3|Drug|drug
DDI-DrugBank.d531.s14|5-8|Name|drug
DDI-DrugBank.d531.s15|0-5|Effect|drug
DDI-DrugBank.d531.s16|0-7|Clinical|drug
DDI-DrugBank.d531.s16|9-15|Comment|drug
DDI-DrugBank.d531.s17|0-9|Atazanavir|brand
DDI-DrugBank.d531.s18|0-9|atazanavir|drug
DDI-DrugBank.d531.s19|0-3|When|drug
DDI-DrugBank.d531.s19|5-18|coadministered|drug
DDI-DrugBank.d531.s19|20-23|with|drug
DDI-DrugBank.d531.s19|25-31|SUSTIVA|drug
DDI-DrugBank.d531.s19|33-34|in|drug
DDI-DrugBank.d531.s19|36-50|treatment-naive|drug
DDI-DrugBank.d531.s19|52-59|patients|drug
DDI-DrugBank.d531.s19|60-60|,|drug
DDI-DrugBank.d531.s19|62-64|the|drug
DDI-DrugBank.d531.s19|66-76|recommended|drug
DDI-DrugBank.d531.s19|78-81|dose|drug
DDI-DrugBank.d531.s19|83-84|of|drug
DDI-DrugBank.d531.s19|86-95|atazanavir|drug
DDI-DrugBank.d531.s19|97-98|is|drug
DDI-DrugBank.d531.s19|100-102|300|drug
DDI-DrugBank.d531.s19|104-105|mg|drug
DDI-DrugBank.d531.s19|107-110|with|drug
DDI-DrugBank.d531.s19|112-120|ritonavir|drug
DDI-DrugBank.d531.s19|122-124|100|drug
DDI-DrugBank.d531.s19|126-127|mg|drug
DDI-DrugBank.d531.s19|129-131|and|drug
DDI-DrugBank.d531.s19|133-139|SUSTIVA|drug
DDI-DrugBank.d531.s19|141-143|600|drug
DDI-DrugBank.d531.s19|145-146|mg|drug
DDI-DrugBank.d531.s19|148-148|(|drug
DDI-DrugBank.d531.s19|149-151|all|drug
DDI-DrugBank.d531.s19|153-156|once|drug
DDI-DrugBank.d531.s19|158-162|daily|drug
DDI-DrugBank.d531.s19|163-163|)|drug
DDI-DrugBank.d531.s19|164-164|.|drug
DDI-DrugBank.d531.s20|0-5|Dosing|drug
DDI-DrugBank.d531.s20|7-21|recommendations|drug
DDI-DrugBank.d531.s20|23-25|for|drug
DDI-DrugBank.d531.s20|27-33|SUSTIVA|drug
DDI-DrugBank.d531.s20|35-37|and|drug
DDI-DrugBank.d531.s20|39-48|atazanavir|drug
DDI-DrugBank.d531.s20|50-51|in|drug
DDI-DrugBank.d531.s20|53-73|treatment-experienced|drug
DDI-DrugBank.d531.s20|75-82|patients|drug
DDI-DrugBank.d531.s20|84-87|have|drug
DDI-DrugBank.d531.s20|89-91|not|drug
DDI-DrugBank.d531.s20|93-96|been|drug
DDI-DrugBank.d531.s20|98-108|established|drug
DDI-DrugBank.d531.s20|109-109|.|drug
DDI-DrugBank.d531.s21|0-10|Established|drug
DDI-DrugBank.d531.s21|12-15|Drug|drug
DDI-DrugBank.d531.s21|17-28|Interactions|drug
DDI-DrugBank.d531.s21|30-30|(|drug
DDI-DrugBank.d531.s21|31-39|continued|drug
DDI-DrugBank.d531.s21|40-40|)|drug
DDI-DrugBank.d531.s22|0-3|Drug|drug
DDI-DrugBank.d531.s22|5-8|Name|drug
DDI-DrugBank.d531.s23|0-5|Effect|drug
DDI-DrugBank.d531.s24|0-7|Clinical|drug
DDI-DrugBank.d531.s24|9-15|Comment|drug
DDI-DrugBank.d531.s25|0-13|Clarithromycin|brand
DDI-DrugBank.d531.s26|0-13|clarithromycin|drug
DDI-DrugBank.d531.s26|15-27|concentration|drug
DDI-DrugBank.d531.s27|0-5|Plasma|drug
DDI-DrugBank.d531.s27|7-20|concentrations|drug
DDI-DrugBank.d531.s27|22-30|decreased|drug
DDI-DrugBank.d531.s27|32-33|by|drug
DDI-DrugBank.d531.s27|35-41|SUSTIVA|drug
DDI-DrugBank.d531.s27|42-42|;|drug
DDI-DrugBank.d531.s28|0-7|clinical|drug
DDI-DrugBank.d531.s28|9-20|significance|drug
DDI-DrugBank.d531.s28|22-28|unknown|drug
DDI-DrugBank.d531.s28|29-29|.|drug
DDI-DrugBank.d531.s29|0-1|In|drug
DDI-DrugBank.d531.s29|3-12|uninfected|drug
DDI-DrugBank.d531.s29|14-23|volunteers|drug
DDI-DrugBank.d531.s29|24-24|,|drug
DDI-DrugBank.d531.s29|26-27|46|drug
DDI-DrugBank.d531.s29|28-28|%|drug
DDI-DrugBank.d531.s29|30-38|developed|drug
DDI-DrugBank.d531.s29|40-43|rash|drug
DDI-DrugBank.d531.s29|45-49|while|drug
DDI-DrugBank.d531.s29|51-59|receiving|drug
DDI-DrugBank.d531.s29|61-67|SUSTIVA|drug
DDI-DrugBank.d531.s29|69-71|and|drug
DDI-DrugBank.d531.s29|73-86|clarithromycin|drug
DDI-DrugBank.d531.s29|87-87|.|drug
DDI-DrugBank.d531.s30|0-1|No|drug
DDI-DrugBank.d531.s30|3-6|dose|drug
DDI-DrugBank.d531.s30|8-17|adjustment|drug
DDI-DrugBank.d531.s30|19-20|of|drug
DDI-DrugBank.d531.s30|22-28|SUSTIVA|drug
DDI-DrugBank.d531.s30|30-31|is|drug
DDI-DrugBank.d531.s30|33-43|recommended|drug
DDI-DrugBank.d531.s30|45-48|when|drug
DDI-DrugBank.d531.s30|50-54|given|drug
DDI-DrugBank.d531.s30|56-59|with|drug
DDI-DrugBank.d531.s30|61-74|clarithromycin|drug
DDI-DrugBank.d531.s30|75-75|.|drug
DDI-DrugBank.d531.s31|0-11|Alternatives|drug
DDI-DrugBank.d531.s31|13-14|to|drug
DDI-DrugBank.d531.s31|16-29|clarithromycin|drug
DDI-DrugBank.d531.s31|30-30|,|drug
DDI-DrugBank.d531.s31|32-35|such|drug
DDI-DrugBank.d531.s31|37-38|as|drug
DDI-DrugBank.d531.s31|40-51|azithromycin|drug
DDI-DrugBank.d531.s31|52-52|,|drug
DDI-DrugBank.d531.s31|54-59|should|drug
DDI-DrugBank.d531.s31|61-62|be|drug
DDI-DrugBank.d531.s31|64-73|considered|drug
DDI-DrugBank.d531.s31|74-74|.|drug
DDI-DrugBank.d531.s32|0-4|Other|drug
DDI-DrugBank.d531.s32|6-14|macrolide|drug
DDI-DrugBank.d531.s32|16-26|antibiotics|drug
DDI-DrugBank.d531.s32|27-27|,|drug
DDI-DrugBank.d531.s32|29-32|such|drug
DDI-DrugBank.d531.s32|34-35|as|drug
DDI-DrugBank.d531.s32|37-48|erythromycin|drug
DDI-DrugBank.d531.s32|49-49|,|drug
DDI-DrugBank.d531.s32|51-54|have|drug
DDI-DrugBank.d531.s32|56-58|not|drug
DDI-DrugBank.d531.s32|60-63|been|drug
DDI-DrugBank.d531.s32|65-71|studied|drug
DDI-DrugBank.d531.s32|73-74|in|drug
DDI-DrugBank.d531.s32|76-86|combination|drug
DDI-DrugBank.d531.s32|88-91|with|drug
DDI-DrugBank.d531.s32|93-99|SUSTIVA|drug
DDI-DrugBank.d531.s32|100-100|.|drug
DDI-DrugBank.d531.s34|0-4|14-OH|drug
DDI-DrugBank.d531.s34|6-15|metabolite|drug
DDI-DrugBank.d531.s34|17-29|concentration|drug
DDI-DrugBank.d531.s35|0-8|Indinavir|drug
DDI-DrugBank.d531.s36|0-8|indinavir|drug
DDI-DrugBank.d531.s36|10-22|concentration|drug
DDI-DrugBank.d531.s37|0-2|The|drug
DDI-DrugBank.d531.s37|4-10|optimal|drug
DDI-DrugBank.d531.s37|12-15|dose|drug
DDI-DrugBank.d531.s37|17-18|of|drug
DDI-DrugBank.d531.s37|20-28|indinavir|drug
DDI-DrugBank.d531.s37|29-29|,|drug
DDI-DrugBank.d531.s37|31-34|when|drug
DDI-DrugBank.d531.s37|36-40|given|drug
DDI-DrugBank.d531.s37|42-43|in|drug
DDI-DrugBank.d531.s37|45-55|combination|drug
DDI-DrugBank.d531.s37|57-60|with|drug
DDI-DrugBank.d531.s37|62-68|SUSTIVA|drug
DDI-DrugBank.d531.s37|69-69|,|drug
DDI-DrugBank.d531.s37|71-72|is|drug
DDI-DrugBank.d531.s37|74-76|not|drug
DDI-DrugBank.d531.s37|78-82|known|drug
DDI-DrugBank.d531.s37|83-83|.|drug
DDI-DrugBank.d531.s38|0-9|Increasing|drug
DDI-DrugBank.d531.s38|11-13|the|drug
DDI-DrugBank.d531.s38|15-23|indinavir|drug
DDI-DrugBank.d531.s38|25-28|dose|drug
DDI-DrugBank.d531.s38|30-31|to|drug
DDI-DrugBank.d531.s38|33-36|1000|drug
DDI-DrugBank.d531.s38|38-39|mg|drug
DDI-DrugBank.d531.s38|41-45|every|drug
DDI-DrugBank.d531.s38|47-47|8|drug
DDI-DrugBank.d531.s38|49-53|hours|drug
DDI-DrugBank.d531.s38|55-58|does|drug
DDI-DrugBank.d531.s38|60-62|not|drug
DDI-DrugBank.d531.s38|64-73|compensate|drug
DDI-DrugBank.d531.s38|75-77|for|drug
DDI-DrugBank.d531.s38|79-81|the|drug
DDI-DrugBank.d531.s38|83-91|increased|drug
DDI-DrugBank.d531.s38|93-101|indinavir|drug
DDI-DrugBank.d531.s38|103-112|metabolism|drug
DDI-DrugBank.d531.s38|114-116|due|drug
DDI-DrugBank.d531.s38|118-119|to|drug
DDI-DrugBank.d531.s38|121-127|SUSTIVA|drug
DDI-DrugBank.d531.s38|128-128|.|drug
DDI-DrugBank.d531.s39|0-3|When|drug
DDI-DrugBank.d531.s39|5-13|indinavir|drug
DDI-DrugBank.d531.s39|15-16|at|drug
DDI-DrugBank.d531.s39|18-19|an|drug
DDI-DrugBank.d531.s39|21-29|increased|drug
DDI-DrugBank.d531.s39|31-34|dose|drug
DDI-DrugBank.d531.s39|36-36|(|drug
DDI-DrugBank.d531.s39|37-40|1000|drug
DDI-DrugBank.d531.s39|42-43|mg|drug
DDI-DrugBank.d531.s39|45-49|every|drug
DDI-DrugBank.d531.s39|51-51|8|drug
DDI-DrugBank.d531.s39|53-57|hours|drug
DDI-DrugBank.d531.s39|58-58|)|drug
DDI-DrugBank.d531.s39|60-62|was|drug
DDI-DrugBank.d531.s39|64-68|given|drug
DDI-DrugBank.d531.s39|70-73|with|drug
DDI-DrugBank.d531.s39|75-81|SUSTIVA|drug
DDI-DrugBank.d531.s39|83-83|(|drug
DDI-DrugBank.d531.s39|84-86|600|drug
DDI-DrugBank.d531.s39|88-89|mg|drug
DDI-DrugBank.d531.s39|91-94|once|drug
DDI-DrugBank.d531.s39|96-100|daily|drug
DDI-DrugBank.d531.s39|101-101|)|drug
DDI-DrugBank.d531.s39|102-102|,|drug
DDI-DrugBank.d531.s39|104-106|the|drug
DDI-DrugBank.d531.s39|108-116|indinavir|drug
DDI-DrugBank.d531.s39|118-120|AUC|drug
DDI-DrugBank.d531.s39|122-124|and|drug
DDI-DrugBank.d531.s39|126-129|Cmin|drug
DDI-DrugBank.d531.s39|131-134|were|drug
DDI-DrugBank.d531.s39|136-144|decreased|drug
DDI-DrugBank.d531.s39|146-147|on|drug
DDI-DrugBank.d531.s39|149-155|average|drug
DDI-DrugBank.d531.s39|157-158|by|drug
DDI-DrugBank.d531.s39|160-164|33-46|drug
DDI-DrugBank.d531.s39|165-165|%|drug
DDI-DrugBank.d531.s39|167-169|and|drug
DDI-DrugBank.d531.s39|171-175|39-57|drug
DDI-DrugBank.d531.s39|176-176|%|drug
DDI-DrugBank.d531.s39|177-177|,|drug
DDI-DrugBank.d531.s39|179-190|respectively|drug
DDI-DrugBank.d531.s39|191-191|,|drug
DDI-DrugBank.d531.s39|193-200|compared|drug
DDI-DrugBank.d531.s39|202-203|to|drug
DDI-DrugBank.d531.s39|205-208|when|drug
DDI-DrugBank.d531.s39|210-218|indinavir|drug
DDI-DrugBank.d531.s39|220-220|(|drug
DDI-DrugBank.d531.s39|221-223|800|drug
DDI-DrugBank.d531.s39|225-226|mg|drug
DDI-DrugBank.d531.s39|228-232|every|drug
DDI-DrugBank.d531.s39|234-234|8|drug
DDI-DrugBank.d531.s39|236-240|hours|drug
DDI-DrugBank.d531.s39|241-241|)|drug
DDI-DrugBank.d531.s39|243-245|was|drug
DDI-DrugBank.d531.s39|247-251|given|drug
DDI-DrugBank.d531.s39|253-257|alone|drug
DDI-DrugBank.d531.s39|258-258|.|drug
DDI-DrugBank.d531.s40|0-18|Lopinavir/ritonavir|drug
DDI-DrugBank.d531.s41|0-8|lopinavir|drug
DDI-DrugBank.d531.s41|10-22|concentration|drug
DDI-DrugBank.d531.s42|0-0|A|drug
DDI-DrugBank.d531.s42|2-5|dose|drug
DDI-DrugBank.d531.s42|7-14|increase|drug
DDI-DrugBank.d531.s42|16-17|of|drug
DDI-DrugBank.d531.s42|19-37|lopinavir/ritonavir|drug
DDI-DrugBank.d531.s42|39-40|to|drug
DDI-DrugBank.d531.s42|42-48|533/133|drug
DDI-DrugBank.d531.s42|50-51|mg|drug
DDI-DrugBank.d531.s42|53-53|(|drug
DDI-DrugBank.d531.s42|54-54|4|drug
DDI-DrugBank.d531.s42|56-63|capsules|drug
DDI-DrugBank.d531.s42|65-66|or|drug
DDI-DrugBank.d531.s42|68-70|6.5|drug
DDI-DrugBank.d531.s42|72-73|mL|drug
DDI-DrugBank.d531.s42|74-74|)|drug
DDI-DrugBank.d531.s42|76-80|twice|drug
DDI-DrugBank.d531.s42|82-86|daily|drug
DDI-DrugBank.d531.s42|88-92|taken|drug
DDI-DrugBank.d531.s42|94-97|with|drug
DDI-DrugBank.d531.s42|99-102|food|drug
DDI-DrugBank.d531.s42|104-105|is|drug
DDI-DrugBank.d531.s42|107-117|recommended|drug
DDI-DrugBank.d531.s42|119-122|when|drug
DDI-DrugBank.d531.s42|124-127|used|drug
DDI-DrugBank.d531.s42|129-130|in|drug
DDI-DrugBank.d531.s42|132-142|combination|drug
DDI-DrugBank.d531.s42|144-147|with|drug
DDI-DrugBank.d531.s42|149-155|SUSTIVA|drug
DDI-DrugBank.d531.s42|156-156|.|drug
DDI-DrugBank.d531.s43|0-8|Methadone|brand
DDI-DrugBank.d531.s44|0-8|methadone|drug
DDI-DrugBank.d531.s44|10-22|concentration|drug
DDI-DrugBank.d531.s45|0-15|Coadministration|drug
DDI-DrugBank.d531.s45|17-18|in|drug
DDI-DrugBank.d531.s45|20-31|HIV-infected|drug
DDI-DrugBank.d531.s45|33-43|individuals|drug
DDI-DrugBank.d531.s45|45-48|with|drug
DDI-DrugBank.d531.s45|50-50|a|drug
DDI-DrugBank.d531.s45|52-58|history|drug
DDI-DrugBank.d531.s45|60-61|of|drug
DDI-DrugBank.d531.s45|63-71|injection|drug
DDI-DrugBank.d531.s45|73-76|drug|drug
DDI-DrugBank.d531.s45|78-80|use|drug
DDI-DrugBank.d531.s45|82-89|resulted|drug
DDI-DrugBank.d531.s45|91-92|in|drug
DDI-DrugBank.d531.s45|94-102|decreased|drug
DDI-DrugBank.d531.s45|104-109|plasma|drug
DDI-DrugBank.d531.s45|111-116|levels|drug
DDI-DrugBank.d531.s45|118-119|of|drug
DDI-DrugBank.d531.s45|121-129|methadone|drug
DDI-DrugBank.d531.s45|131-133|and|drug
DDI-DrugBank.d531.s45|135-139|signs|drug
DDI-DrugBank.d531.s45|141-142|of|drug
DDI-DrugBank.d531.s45|144-149|opiate|drug
DDI-DrugBank.d531.s45|151-160|withdrawal|drug
DDI-DrugBank.d531.s45|161-161|.|drug
DDI-DrugBank.d531.s46|0-8|Methadone|brand
DDI-DrugBank.d531.s46|10-13|dose|drug
DDI-DrugBank.d531.s46|15-17|was|drug
DDI-DrugBank.d531.s46|19-27|increased|drug
DDI-DrugBank.d531.s46|29-30|by|drug
DDI-DrugBank.d531.s46|32-32|a|drug
DDI-DrugBank.d531.s46|34-37|mean|drug
DDI-DrugBank.d531.s46|39-40|of|drug
DDI-DrugBank.d531.s46|42-43|22|drug
DDI-DrugBank.d531.s46|44-44|%|drug
DDI-DrugBank.d531.s46|46-47|to|drug
DDI-DrugBank.d531.s46|49-57|alleviate|drug
DDI-DrugBank.d531.s46|59-68|withdrawal|drug
DDI-DrugBank.d531.s46|70-77|symptoms|drug
DDI-DrugBank.d531.s46|78-78|.|drug
DDI-DrugBank.d531.s47|0-7|Patients|drug
DDI-DrugBank.d531.s47|9-14|should|drug
DDI-DrugBank.d531.s47|16-17|be|drug
DDI-DrugBank.d531.s47|19-27|monitored|drug
DDI-DrugBank.d531.s47|29-31|for|drug
DDI-DrugBank.d531.s47|33-37|signs|drug
DDI-DrugBank.d531.s47|39-40|of|drug
DDI-DrugBank.d531.s47|42-51|withdrawal|drug
DDI-DrugBank.d531.s47|53-55|and|drug
DDI-DrugBank.d531.s47|57-61|their|drug
DDI-DrugBank.d531.s47|63-71|methadone|drug
DDI-DrugBank.d531.s47|73-76|dose|drug
DDI-DrugBank.d531.s47|78-86|increased|drug
DDI-DrugBank.d531.s47|88-89|as|drug
DDI-DrugBank.d531.s47|91-98|required|drug
DDI-DrugBank.d531.s47|100-101|to|drug
DDI-DrugBank.d531.s47|103-111|alleviate|drug
DDI-DrugBank.d531.s47|113-122|withdrawal|drug
DDI-DrugBank.d531.s47|124-131|symptoms|drug
DDI-DrugBank.d531.s47|132-132|.|drug
DDI-DrugBank.d531.s48|0-6|Ethinyl|drug
DDI-DrugBank.d531.s48|8-16|estradiol|drug
DDI-DrugBank.d531.s49|0-6|ethinyl|drug
DDI-DrugBank.d531.s49|8-16|estradiol|drug
DDI-DrugBank.d531.s49|18-30|concentration|drug
DDI-DrugBank.d531.s50|0-5|Plasma|drug
DDI-DrugBank.d531.s50|7-20|concentrations|drug
DDI-DrugBank.d531.s50|22-30|increased|drug
DDI-DrugBank.d531.s50|32-33|by|drug
DDI-DrugBank.d531.s50|35-41|SUSTIVA|drug
DDI-DrugBank.d531.s50|43-43|(|drug
DDI-DrugBank.d531.s50|44-52|efavirenz|drug
DDI-DrugBank.d531.s50|53-53|)|drug
DDI-DrugBank.d531.s50|54-54|;|drug
DDI-DrugBank.d531.s51|0-7|clinical|drug
DDI-DrugBank.d531.s51|9-20|significance|drug
DDI-DrugBank.d531.s51|22-28|unknown|drug
DDI-DrugBank.d531.s51|29-29|.|drug
DDI-DrugBank.d531.s52|0-6|Because|drug
DDI-DrugBank.d531.s52|8-10|the|drug
DDI-DrugBank.d531.s52|12-20|potential|drug
DDI-DrugBank.d531.s52|22-32|interaction|drug
DDI-DrugBank.d531.s52|34-35|of|drug
DDI-DrugBank.d531.s52|37-45|efavirenz|drug
DDI-DrugBank.d531.s52|47-50|with|drug
DDI-DrugBank.d531.s52|52-55|oral|drug
DDI-DrugBank.d531.s52|57-70|contraceptives|drug
DDI-DrugBank.d531.s52|72-74|has|drug
DDI-DrugBank.d531.s52|76-78|not|drug
DDI-DrugBank.d531.s52|80-83|been|drug
DDI-DrugBank.d531.s52|85-89|fully|drug
DDI-DrugBank.d531.s52|91-103|characterized|drug
DDI-DrugBank.d531.s52|104-104|,|drug
DDI-DrugBank.d531.s52|106-106|a|drug
DDI-DrugBank.d531.s52|108-115|reliable|drug
DDI-DrugBank.d531.s52|117-122|method|drug
DDI-DrugBank.d531.s52|124-125|of|drug
DDI-DrugBank.d531.s52|127-133|barrier|drug
DDI-DrugBank.d531.s52|135-147|contraception|drug
DDI-DrugBank.d531.s52|149-154|should|drug
DDI-DrugBank.d531.s52|156-157|be|drug
DDI-DrugBank.d531.s52|159-162|used|drug
DDI-DrugBank.d531.s52|164-165|in|drug
DDI-DrugBank.d531.s52|167-174|addition|drug
DDI-DrugBank.d531.s52|176-177|to|drug
DDI-DrugBank.d531.s52|179-182|oral|drug
DDI-DrugBank.d531.s52|184-197|contraceptives|drug
DDI-DrugBank.d531.s52|198-198|.|drug
DDI-DrugBank.d531.s53|0-8|Rifabutin|brand
DDI-DrugBank.d531.s54|0-8|rifabutin|drug
DDI-DrugBank.d531.s54|10-22|concentration|drug
DDI-DrugBank.d531.s55|0-7|Increase|drug
DDI-DrugBank.d531.s55|9-13|daily|drug
DDI-DrugBank.d531.s55|15-18|dose|drug
DDI-DrugBank.d531.s55|20-21|of|drug
DDI-DrugBank.d531.s55|23-31|rifabutin|drug
DDI-DrugBank.d531.s55|33-34|by|drug
DDI-DrugBank.d531.s55|36-37|50|drug
DDI-DrugBank.d531.s55|38-38|%|drug
DDI-DrugBank.d531.s55|39-39|.|drug
DDI-DrugBank.d531.s56|0-7|Consider|drug
DDI-DrugBank.d531.s56|9-16|doubling|drug
DDI-DrugBank.d531.s56|18-20|the|drug
DDI-DrugBank.d531.s56|22-30|rifabutin|drug
DDI-DrugBank.d531.s56|32-35|dose|drug
DDI-DrugBank.d531.s56|37-38|in|drug
DDI-DrugBank.d531.s56|40-47|regimens|drug
DDI-DrugBank.d531.s56|49-53|where|drug
DDI-DrugBank.d531.s56|55-63|rifabutin|drug
DDI-DrugBank.d531.s56|65-66|is|drug
DDI-DrugBank.d531.s56|68-72|given|drug
DDI-DrugBank.d531.s56|74-74|2|drug
DDI-DrugBank.d531.s56|76-77|or|drug
DDI-DrugBank.d531.s56|79-79|3|drug
DDI-DrugBank.d531.s56|81-85|times|drug
DDI-DrugBank.d531.s56|87-87|a|drug
DDI-DrugBank.d531.s56|89-92|week|drug
DDI-DrugBank.d531.s56|93-93|.|drug
DDI-DrugBank.d531.s57|0-7|Rifampin|brand
DDI-DrugBank.d531.s58|0-8|efavirenz|drug
DDI-DrugBank.d531.s58|10-22|concentration|drug
DDI-DrugBank.d531.s59|0-7|Clinical|drug
DDI-DrugBank.d531.s59|9-20|significance|drug
DDI-DrugBank.d531.s59|22-23|of|drug
DDI-DrugBank.d531.s59|25-31|reduced|drug
DDI-DrugBank.d531.s59|33-41|efavirenz|drug
DDI-DrugBank.d531.s59|43-56|concentrations|drug
DDI-DrugBank.d531.s59|58-64|unknown|drug
DDI-DrugBank.d531.s59|65-65|.|drug
DDI-DrugBank.d531.s60|0-8|Ritonavir|brand
DDI-DrugBank.d531.s61|0-8|ritonavir|drug
DDI-DrugBank.d531.s61|10-22|concentration|drug
DDI-DrugBank.d531.s62|0-10|Combination|drug
DDI-DrugBank.d531.s62|12-14|was|drug
DDI-DrugBank.d531.s62|16-25|associated|drug
DDI-DrugBank.d531.s62|27-30|with|drug
DDI-DrugBank.d531.s62|32-32|a|drug
DDI-DrugBank.d531.s62|34-39|higher|drug
DDI-DrugBank.d531.s62|41-49|frequency|drug
DDI-DrugBank.d531.s62|51-52|of|drug
DDI-DrugBank.d531.s62|54-60|adverse|drug
DDI-DrugBank.d531.s62|62-69|clinical|drug
DDI-DrugBank.d531.s62|71-81|experiences|drug
DDI-DrugBank.d531.s62|83-83|(|drug
DDI-DrugBank.d531.s62|84-85|eg|drug
DDI-DrugBank.d531.s62|86-86|,|drug
DDI-DrugBank.d531.s62|88-96|dizziness|drug
DDI-DrugBank.d531.s62|97-97|,|drug
DDI-DrugBank.d531.s62|99-104|nausea|drug
DDI-DrugBank.d531.s62|105-105|,|drug
DDI-DrugBank.d531.s62|107-117|paresthesia|drug
DDI-DrugBank.d531.s62|118-118|)|drug
DDI-DrugBank.d531.s62|120-122|and|drug
DDI-DrugBank.d531.s62|124-133|laboratory|drug
DDI-DrugBank.d531.s62|135-147|abnormalities|drug
DDI-DrugBank.d531.s62|149-149|(|drug
DDI-DrugBank.d531.s62|150-157|elevated|drug
DDI-DrugBank.d531.s62|159-163|liver|drug
DDI-DrugBank.d531.s62|165-171|enzymes|drug
DDI-DrugBank.d531.s62|172-172|)|drug
DDI-DrugBank.d531.s62|173-173|.|drug
DDI-DrugBank.d531.s63|0-9|Monitoring|drug
DDI-DrugBank.d531.s63|11-12|of|drug
DDI-DrugBank.d531.s63|14-18|liver|drug
DDI-DrugBank.d531.s63|20-26|enzymes|drug
DDI-DrugBank.d531.s63|28-29|is|drug
DDI-DrugBank.d531.s63|31-41|recommended|drug
DDI-DrugBank.d531.s63|43-46|when|drug
DDI-DrugBank.d531.s63|48-54|SUSTIVA|drug
DDI-DrugBank.d531.s63|56-57|is|drug
DDI-DrugBank.d531.s63|59-62|used|drug
DDI-DrugBank.d531.s63|64-65|in|drug
DDI-DrugBank.d531.s63|67-77|combination|drug
DDI-DrugBank.d531.s63|79-82|with|drug
DDI-DrugBank.d531.s63|84-92|ritonavir|drug
DDI-DrugBank.d531.s63|93-93|.|drug
DDI-DrugBank.d531.s64|0-8|efavirenz|drug
DDI-DrugBank.d531.s64|10-22|concentration|drug
DDI-DrugBank.d531.s65|0-9|Saquinavir|drug
DDI-DrugBank.d531.s66|0-9|saquinavir|drug
DDI-DrugBank.d531.s66|11-23|concentration|drug
DDI-DrugBank.d531.s67|0-5|Should|drug
DDI-DrugBank.d531.s67|7-9|not|drug
DDI-DrugBank.d531.s67|11-12|be|drug
DDI-DrugBank.d531.s67|14-17|used|drug
DDI-DrugBank.d531.s67|19-20|as|drug
DDI-DrugBank.d531.s67|22-25|sole|drug
DDI-DrugBank.d531.s67|27-34|protease|drug
DDI-DrugBank.d531.s67|36-44|inhibitor|drug
DDI-DrugBank.d531.s67|46-47|in|drug
DDI-DrugBank.d531.s67|49-59|combination|drug
DDI-DrugBank.d531.s67|61-64|with|drug
DDI-DrugBank.d531.s67|66-72|SUSTIVA|drug
DDI-DrugBank.d531.s67|73-73|.|drug
DDI-DrugBank.d531.s68|0-9|Sertraline|brand
DDI-DrugBank.d531.s69|0-9|sertraline|drug
DDI-DrugBank.d531.s69|11-23|concentration|drug
DDI-DrugBank.d531.s70|0-8|Increases|drug
DDI-DrugBank.d531.s70|10-11|in|drug
DDI-DrugBank.d531.s70|13-22|sertraline|drug
DDI-DrugBank.d531.s70|24-27|dose|drug
DDI-DrugBank.d531.s70|29-34|should|drug
DDI-DrugBank.d531.s70|36-37|be|drug
DDI-DrugBank.d531.s70|39-44|guided|drug
DDI-DrugBank.d531.s70|46-47|by|drug
DDI-DrugBank.d531.s70|49-56|clinical|drug
DDI-DrugBank.d531.s70|58-65|response|drug
DDI-DrugBank.d531.s70|66-66|.|drug
DDI-DrugBank.d531.s71|0-4|Other|drug
DDI-DrugBank.d531.s71|6-16|Potentially|drug
DDI-DrugBank.d531.s71|18-27|Clinically|drug
DDI-DrugBank.d531.s71|29-39|Significant|drug
DDI-DrugBank.d531.s71|41-44|Drug|drug
DDI-DrugBank.d531.s71|46-47|or|drug
DDI-DrugBank.d531.s71|49-54|Herbal|brand
DDI-DrugBank.d531.s71|56-62|Product|drug
DDI-DrugBank.d531.s71|64-75|Interactions|drug
DDI-DrugBank.d531.s71|77-80|With|drug
DDI-DrugBank.d531.s71|82-89|SUSTIVAb|drug
DDI-DrugBank.d531.s72|0-13|Anticoagulants|group
DDI-DrugBank.d531.s72|14-14|:|drug
DDI-DrugBank.d531.s72|16-23|Warfarin|brand
DDI-DrugBank.d531.s73|0-5|Plasma|drug
DDI-DrugBank.d531.s73|7-20|concentrations|drug
DDI-DrugBank.d531.s73|22-24|and|drug
DDI-DrugBank.d531.s73|26-32|effects|drug
DDI-DrugBank.d531.s73|34-44|potentially|drug
DDI-DrugBank.d531.s73|46-54|increased|drug
DDI-DrugBank.d531.s73|56-57|or|drug
DDI-DrugBank.d531.s73|59-67|decreased|drug
DDI-DrugBank.d531.s73|69-70|by|drug
DDI-DrugBank.d531.s73|72-78|SUSTIVA|drug
DDI-DrugBank.d531.s73|79-79|.|drug
DDI-DrugBank.d531.s74|0-14|Anticonvulsants|group
DDI-DrugBank.d531.s74|15-15|:|drug
DDI-DrugBank.d531.s74|17-25|Phenytoin|brand
DDI-DrugBank.d531.s74|27-39|Phenobarbital|brand
DDI-DrugBank.d531.s74|41-53|Carbamazepine|brand
DDI-DrugBank.d531.s75|0-8|Potential|drug
DDI-DrugBank.d531.s75|10-12|for|drug
DDI-DrugBank.d531.s75|14-22|reduction|drug
DDI-DrugBank.d531.s75|24-25|in|drug
DDI-DrugBank.d531.s75|27-40|anticonvulsant|drug
DDI-DrugBank.d531.s75|42-47|and/or|drug
DDI-DrugBank.d531.s75|49-57|efavirenz|drug
DDI-DrugBank.d531.s75|59-64|plasma|drug
DDI-DrugBank.d531.s75|66-71|levels|drug
DDI-DrugBank.d531.s75|72-72|;|drug
DDI-DrugBank.d531.s76|0-7|periodic|drug
DDI-DrugBank.d531.s76|9-18|monitoring|drug
DDI-DrugBank.d531.s76|20-21|of|drug
DDI-DrugBank.d531.s76|23-36|anticonvulsant|drug
DDI-DrugBank.d531.s76|38-43|plasma|drug
DDI-DrugBank.d531.s76|45-50|levels|drug
DDI-DrugBank.d531.s76|52-57|should|drug
DDI-DrugBank.d531.s76|59-60|be|drug
DDI-DrugBank.d531.s76|62-70|conducted|drug
DDI-DrugBank.d531.s76|71-71|.|drug
DDI-DrugBank.d531.s77|0-10|Antifungals|drug
DDI-DrugBank.d531.s77|11-11|:|drug
DDI-DrugBank.d531.s77|13-24|Itraconazole|brand
DDI-DrugBank.d531.s77|26-37|Ketoconazole|brand
DDI-DrugBank.d531.s78|0-3|Drug|drug
DDI-DrugBank.d531.s78|5-15|interaction|drug
DDI-DrugBank.d531.s78|17-23|studies|drug
DDI-DrugBank.d531.s78|25-28|with|drug
DDI-DrugBank.d531.s78|30-36|SUSTIVA|drug
DDI-DrugBank.d531.s78|38-40|and|drug
DDI-DrugBank.d531.s78|42-46|these|drug
DDI-DrugBank.d531.s78|48-56|imidazole|drug
DDI-DrugBank.d531.s78|58-60|and|drug
DDI-DrugBank.d531.s78|62-69|triazole|drug
DDI-DrugBank.d531.s78|71-81|antifungals|drug
DDI-DrugBank.d531.s78|83-86|have|drug
DDI-DrugBank.d531.s78|88-90|not|drug
DDI-DrugBank.d531.s78|92-95|been|drug
DDI-DrugBank.d531.s78|97-105|conducted|drug
DDI-DrugBank.d531.s78|106-106|.|drug
DDI-DrugBank.d531.s79|0-6|SUSTIVA|drug
DDI-DrugBank.d531.s79|8-10|has|drug
DDI-DrugBank.d531.s79|12-14|the|drug
DDI-DrugBank.d531.s79|16-24|potential|drug
DDI-DrugBank.d531.s79|26-27|to|drug
DDI-DrugBank.d531.s79|29-36|decrease|drug
DDI-DrugBank.d531.s79|38-43|plasma|drug
DDI-DrugBank.d531.s79|45-58|concentrations|drug
DDI-DrugBank.d531.s79|60-61|of|drug
DDI-DrugBank.d531.s79|63-74|itraconazole|drug
DDI-DrugBank.d531.s79|76-78|and|drug
DDI-DrugBank.d531.s79|80-91|ketoconazole|drug
DDI-DrugBank.d531.s79|92-92|.|drug
DDI-DrugBank.d531.s80|0-7|Anti-HIV|drug
DDI-DrugBank.d531.s80|9-16|protease|drug
DDI-DrugBank.d531.s80|18-27|inhibitors|drug
DDI-DrugBank.d531.s80|28-28|:|drug
DDI-DrugBank.d531.s80|30-49|Saquinavir/ritonavir|drug
DDI-DrugBank.d531.s80|51-61|combination|drug
DDI-DrugBank.d531.s81|0-1|No|drug
DDI-DrugBank.d531.s81|3-17|pharmacokinetic|drug
DDI-DrugBank.d531.s81|19-22|data|drug
DDI-DrugBank.d531.s81|24-26|are|drug
DDI-DrugBank.d531.s81|28-36|available|drug
DDI-DrugBank.d531.s81|37-37|.|drug
DDI-DrugBank.d531.s82|0-9|Amprenavir|drug
DDI-DrugBank.d531.s83|0-9|SUSTIVAhas|drug
DDI-DrugBank.d531.s83|11-13|the|drug
DDI-DrugBank.d531.s83|15-23|potential|drug
DDI-DrugBank.d531.s83|25-26|to|drug
DDI-DrugBank.d531.s83|28-35|decrease|drug
DDI-DrugBank.d531.s83|37-41|serum|drug
DDI-DrugBank.d531.s83|43-56|concentrations|drug
DDI-DrugBank.d531.s83|58-59|of|drug
DDI-DrugBank.d531.s83|61-70|amprenavir|drug
DDI-DrugBank.d531.s83|71-71|.|drug
DDI-DrugBank.d531.s84|0-13|Non-nucleoside|drug
DDI-DrugBank.d531.s84|15-21|reverse|drug
DDI-DrugBank.d531.s84|23-35|transcriptase|drug
DDI-DrugBank.d531.s84|37-46|inhibitors|drug
DDI-DrugBank.d531.s85|0-1|No|drug
DDI-DrugBank.d531.s85|3-9|studies|drug
DDI-DrugBank.d531.s85|11-14|have|drug
DDI-DrugBank.d531.s85|16-19|been|drug
DDI-DrugBank.d531.s85|21-29|performed|drug
DDI-DrugBank.d531.s85|31-34|with|drug
DDI-DrugBank.d531.s85|36-40|other|drug
DDI-DrugBank.d531.s85|42-47|NNRTIs|drug
DDI-DrugBank.d531.s85|48-48|.|drug
DDI-DrugBank.d531.s86|0-2|St.|drug
DDI-DrugBank.d531.s86|4-7|John|drug
DDI-DrugBank.d531.s86|9-9|s|drug
DDI-DrugBank.d531.s86|11-14|wort|drug
DDI-DrugBank.d531.s86|16-16|(|drug
DDI-DrugBank.d531.s86|17-25|Hypericum|brand
DDI-DrugBank.d531.s86|27-36|perforatum|drug
DDI-DrugBank.d531.s86|37-37|)|drug
DDI-DrugBank.d531.s87|0-7|Expected|drug
DDI-DrugBank.d531.s87|9-10|to|drug
DDI-DrugBank.d531.s87|12-24|substantially|drug
DDI-DrugBank.d531.s87|26-33|decrease|drug
DDI-DrugBank.d531.s87|35-40|plasma|drug
DDI-DrugBank.d531.s87|42-47|levels|drug
DDI-DrugBank.d531.s87|49-50|of|drug
DDI-DrugBank.d531.s87|52-60|efavirenz|drug
DDI-DrugBank.d531.s87|61-61|;|drug
DDI-DrugBank.d531.s87|62-64|has|drug
DDI-DrugBank.d531.s87|66-68|not|drug
DDI-DrugBank.d531.s87|70-73|been|drug
DDI-DrugBank.d531.s87|75-81|studied|drug
DDI-DrugBank.d531.s87|83-84|in|drug
DDI-DrugBank.d531.s87|86-96|combination|drug
DDI-DrugBank.d531.s87|98-101|with|drug
DDI-DrugBank.d531.s87|103-109|SUSTIVA|drug
DDI-DrugBank.d531.s87|110-110|.|drug
DDI-DrugBank.d531.s88|0-0|a|drug
DDI-DrugBank.d531.s88|2-4|See|drug
DDI-DrugBank.d531.s88|6-11|Tables|drug
DDI-DrugBank.d531.s88|13-13|1|drug
DDI-DrugBank.d531.s88|15-17|and|drug
DDI-DrugBank.d531.s88|19-19|2|drug
DDI-DrugBank.d531.s88|20-20|.|drug
DDI-DrugBank.d531.s89|0-0|b|drug
DDI-DrugBank.d531.s89|2-5|This|drug
DDI-DrugBank.d531.s89|7-11|table|drug
DDI-DrugBank.d531.s89|13-14|is|drug
DDI-DrugBank.d531.s89|16-18|not|drug
DDI-DrugBank.d531.s89|20-32|all-inclusive|drug
DDI-DrugBank.d531.s89|33-33|.|drug
DDI-DrugBank.d531.s90|0-4|Other|drug
DDI-DrugBank.d531.s90|6-10|Drugs|drug
DDI-DrugBank.d531.s90|11-11|:|drug
DDI-DrugBank.d531.s90|13-17|Based|drug
DDI-DrugBank.d531.s90|19-20|on|drug
DDI-DrugBank.d531.s90|22-24|the|drug
DDI-DrugBank.d531.s90|26-32|results|drug
DDI-DrugBank.d531.s90|34-35|of|drug
DDI-DrugBank.d531.s90|37-40|drug|drug
DDI-DrugBank.d531.s90|42-52|interaction|drug
DDI-DrugBank.d531.s90|54-60|studies|drug
DDI-DrugBank.d531.s90|61-61|,|drug
DDI-DrugBank.d531.s90|63-64|no|drug
DDI-DrugBank.d531.s90|66-71|dosage|drug
DDI-DrugBank.d531.s90|73-82|adjustment|drug
DDI-DrugBank.d531.s90|84-85|is|drug
DDI-DrugBank.d531.s90|87-97|recommended|drug
DDI-DrugBank.d531.s90|99-102|when|drug
DDI-DrugBank.d531.s90|104-110|SUSTIVA|drug
DDI-DrugBank.d531.s90|112-112|(|drug
DDI-DrugBank.d531.s90|113-121|efavirenz|drug
DDI-DrugBank.d531.s90|122-122|)|drug
DDI-DrugBank.d531.s90|124-125|is|drug
DDI-DrugBank.d531.s90|127-131|given|drug
DDI-DrugBank.d531.s90|133-136|with|drug
DDI-DrugBank.d531.s90|138-140|the|drug
DDI-DrugBank.d531.s90|142-150|following|drug
DDI-DrugBank.d531.s90|151-151|:|drug
DDI-DrugBank.d531.s90|153-170|aluminum/magnesium|drug
DDI-DrugBank.d531.s90|172-180|hydroxide|drug
DDI-DrugBank.d531.s90|182-189|antacids|drug
DDI-DrugBank.d531.s90|190-190|,|drug
DDI-DrugBank.d531.s90|192-203|azithromycin|drug
DDI-DrugBank.d531.s90|204-204|,|drug
DDI-DrugBank.d531.s90|206-215|cetirizine|drug
DDI-DrugBank.d531.s90|216-216|,|drug
DDI-DrugBank.d531.s90|218-227|famotidine|drug
DDI-DrugBank.d531.s90|228-228|,|drug
DDI-DrugBank.d531.s90|230-240|fluconazole|drug
DDI-DrugBank.d531.s90|241-241|,|drug
DDI-DrugBank.d531.s90|243-252|lamivudine|drug
DDI-DrugBank.d531.s90|253-253|,|drug
DDI-DrugBank.d531.s90|255-263|lorazepam|drug
DDI-DrugBank.d531.s90|264-264|,|drug
DDI-DrugBank.d531.s90|266-275|nelfinavir|drug
DDI-DrugBank.d531.s90|276-276|,|drug
DDI-DrugBank.d531.s90|278-287|paroxetine|drug
DDI-DrugBank.d531.s90|288-288|,|drug
DDI-DrugBank.d531.s90|290-292|and|drug
DDI-DrugBank.d531.s90|294-303|zidovudine|drug
DDI-DrugBank.d531.s90|304-304|.|drug
DDI-DrugBank.d531.s91|0-7|Specific|drug
DDI-DrugBank.d531.s91|9-12|drug|drug
DDI-DrugBank.d531.s91|14-24|interaction|drug
DDI-DrugBank.d531.s91|26-32|studies|drug
DDI-DrugBank.d531.s91|34-37|have|drug
DDI-DrugBank.d531.s91|39-41|not|drug
DDI-DrugBank.d531.s91|43-46|been|drug
DDI-DrugBank.d531.s91|48-56|performed|drug
DDI-DrugBank.d531.s91|58-61|with|drug
DDI-DrugBank.d531.s91|63-69|SUSTIVA|drug
DDI-DrugBank.d531.s91|71-73|and|drug
DDI-DrugBank.d531.s91|75-79|NRTIs|drug
DDI-DrugBank.d531.s91|81-85|other|drug
DDI-DrugBank.d531.s91|87-90|than|drug
DDI-DrugBank.d531.s91|92-101|lamivudine|drug
DDI-DrugBank.d531.s91|103-105|and|drug
DDI-DrugBank.d531.s91|107-116|zidovudine|drug
DDI-DrugBank.d531.s91|117-117|.|drug
DDI-DrugBank.d531.s92|0-9|Clinically|drug
DDI-DrugBank.d531.s92|11-21|significant|drug
DDI-DrugBank.d531.s92|23-34|interactions|drug
DDI-DrugBank.d531.s92|36-40|would|drug
DDI-DrugBank.d531.s92|42-44|not|drug
DDI-DrugBank.d531.s92|46-47|be|drug
DDI-DrugBank.d531.s92|49-56|expected|drug
DDI-DrugBank.d531.s92|58-62|since|drug
DDI-DrugBank.d531.s92|64-66|the|drug
DDI-DrugBank.d531.s92|68-72|NRTIs|drug
DDI-DrugBank.d531.s92|74-76|are|drug
DDI-DrugBank.d531.s92|78-88|metabolized|drug
DDI-DrugBank.d531.s92|90-92|via|drug
DDI-DrugBank.d531.s92|94-94|a|drug
DDI-DrugBank.d531.s92|96-104|different|drug
DDI-DrugBank.d531.s92|106-110|route|drug
DDI-DrugBank.d531.s92|112-115|than|drug
DDI-DrugBank.d531.s92|117-125|efavirenz|drug
DDI-DrugBank.d531.s92|127-129|and|drug
DDI-DrugBank.d531.s92|131-135|would|drug
DDI-DrugBank.d531.s92|137-138|be|drug
DDI-DrugBank.d531.s92|140-147|unlikely|drug
DDI-DrugBank.d531.s92|149-150|to|drug
DDI-DrugBank.d531.s92|152-158|compete|drug
DDI-DrugBank.d531.s92|160-162|for|drug
DDI-DrugBank.d531.s92|164-166|the|drug
DDI-DrugBank.d531.s92|168-171|same|drug
DDI-DrugBank.d531.s92|173-181|metabolic|drug
DDI-DrugBank.d531.s92|183-189|enzymes|drug
DDI-DrugBank.d531.s92|191-193|and|drug
DDI-DrugBank.d531.s92|195-205|elimination|drug
DDI-DrugBank.d531.s92|207-214|pathways|drug
DDI-DrugBank.d531.s92|215-215|.|drug
DDI-DrugBank.d223.s0|0-4|Drugs|drug
DDI-DrugBank.d223.s0|6-16|Metabolized|drug
DDI-DrugBank.d223.s0|18-19|by|drug
DDI-DrugBank.d223.s0|21-24|P450|drug
DDI-DrugBank.d223.s0|26-28|2D6|drug
DDI-DrugBank.d223.s0|29-29|:|drug
DDI-DrugBank.d223.s0|31-33|The|drug
DDI-DrugBank.d223.s0|35-45|biochemical|drug
DDI-DrugBank.d223.s0|47-54|activity|drug
DDI-DrugBank.d223.s0|56-57|of|drug
DDI-DrugBank.d223.s0|59-61|the|drug
DDI-DrugBank.d223.s0|63-66|drug|drug
DDI-DrugBank.d223.s0|68-79|metabolizing|drug
DDI-DrugBank.d223.s0|81-87|isozyme|drug
DDI-DrugBank.d223.s0|89-98|cytochrome|drug
DDI-DrugBank.d223.s0|100-103|P450|drug
DDI-DrugBank.d223.s0|105-107|2D6|drug
DDI-DrugBank.d223.s0|109-109|(|drug
DDI-DrugBank.d223.s0|110-120|debrisoquin|drug
DDI-DrugBank.d223.s0|122-132|hydroxylase|drug
DDI-DrugBank.d223.s0|133-133|)|drug
DDI-DrugBank.d223.s0|135-136|is|drug
DDI-DrugBank.d223.s0|138-144|reduced|drug
DDI-DrugBank.d223.s0|146-147|in|drug
DDI-DrugBank.d223.s0|149-149|a|drug
DDI-DrugBank.d223.s0|151-156|subset|drug
DDI-DrugBank.d223.s0|158-159|of|drug
DDI-DrugBank.d223.s0|161-163|the|drug
DDI-DrugBank.d223.s0|165-173|Caucasian|drug
DDI-DrugBank.d223.s0|175-184|population|drug
DDI-DrugBank.d223.s0|186-186|(|drug
DDI-DrugBank.d223.s0|187-191|about|drug
DDI-DrugBank.d223.s0|193-196|7-10|drug
DDI-DrugBank.d223.s0|197-197|%|drug
DDI-DrugBank.d223.s0|199-200|of|drug
DDI-DrugBank.d223.s0|202-211|Caucasians|drug
DDI-DrugBank.d223.s0|213-215|are|drug
DDI-DrugBank.d223.s0|217-225|so-called|drug
DDI-DrugBank.d223.s0|227-230|poor|drug
DDI-DrugBank.d223.s0|232-243|metabolizers|drug
DDI-DrugBank.d223.s0|244-244|)|drug
DDI-DrugBank.d223.s0|245-245|;|drug
DDI-DrugBank.d223.s1|0-7|reliable|drug
DDI-DrugBank.d223.s1|9-17|estimates|drug
DDI-DrugBank.d223.s1|19-20|of|drug
DDI-DrugBank.d223.s1|22-24|the|drug
DDI-DrugBank.d223.s1|26-35|prevalence|drug
DDI-DrugBank.d223.s1|37-38|of|drug
DDI-DrugBank.d223.s1|40-46|reduced|drug
DDI-DrugBank.d223.s1|48-51|P450|drug
DDI-DrugBank.d223.s1|53-55|2D6|drug
DDI-DrugBank.d223.s1|57-63|isozyme|drug
DDI-DrugBank.d223.s1|65-72|activity|drug
DDI-DrugBank.d223.s1|74-78|among|drug
DDI-DrugBank.d223.s1|80-84|Asian|drug
DDI-DrugBank.d223.s1|85-85|,|drug
DDI-DrugBank.d223.s1|87-93|African|drug
DDI-DrugBank.d223.s1|95-97|and|drug
DDI-DrugBank.d223.s1|99-103|other|drug
DDI-DrugBank.d223.s1|105-115|populations|drug
DDI-DrugBank.d223.s1|117-119|are|drug
DDI-DrugBank.d223.s1|121-123|not|drug
DDI-DrugBank.d223.s1|125-127|yet|drug
DDI-DrugBank.d223.s1|129-137|available|drug
DDI-DrugBank.d223.s1|138-138|.|drug
DDI-DrugBank.d223.s2|0-3|Poor|drug
DDI-DrugBank.d223.s2|5-16|metabolizers|drug
DDI-DrugBank.d223.s2|18-21|have|drug
DDI-DrugBank.d223.s2|23-28|higher|drug
DDI-DrugBank.d223.s2|30-33|than|drug
DDI-DrugBank.d223.s2|35-42|expected|drug
DDI-DrugBank.d223.s2|44-49|plasma|drug
DDI-DrugBank.d223.s2|51-64|concentrations|drug
DDI-DrugBank.d223.s2|66-67|of|drug
DDI-DrugBank.d223.s2|69-77|tricyclic|drug
DDI-DrugBank.d223.s2|79-93|antidepressants|drug
DDI-DrugBank.d223.s2|95-95|(|drug
DDI-DrugBank.d223.s2|96-99|TCAs|drug
DDI-DrugBank.d223.s2|100-100|)|drug
DDI-DrugBank.d223.s2|102-105|when|drug
DDI-DrugBank.d223.s2|107-111|given|drug
DDI-DrugBank.d223.s2|113-117|usual|drug
DDI-DrugBank.d223.s2|119-123|doses|drug
DDI-DrugBank.d223.s2|124-124|.|drug
DDI-DrugBank.d223.s3|0-8|Depending|drug
DDI-DrugBank.d223.s3|10-11|on|drug
DDI-DrugBank.d223.s3|13-15|the|drug
DDI-DrugBank.d223.s3|17-24|fraction|drug
DDI-DrugBank.d223.s3|26-27|of|drug
DDI-DrugBank.d223.s3|29-32|drug|drug
DDI-DrugBank.d223.s3|34-44|metabolized|drug
DDI-DrugBank.d223.s3|46-47|by|drug
DDI-DrugBank.d223.s3|49-52|P450|drug
DDI-DrugBank.d223.s3|54-56|2D6|drug
DDI-DrugBank.d223.s3|57-57|,|drug
DDI-DrugBank.d223.s3|59-61|the|drug
DDI-DrugBank.d223.s3|63-70|increase|drug
DDI-DrugBank.d223.s3|72-73|in|drug
DDI-DrugBank.d223.s3|75-80|plasma|drug
DDI-DrugBank.d223.s3|82-94|concentration|drug
DDI-DrugBank.d223.s3|96-98|may|drug
DDI-DrugBank.d223.s3|100-101|be|drug
DDI-DrugBank.d223.s3|103-107|small|drug
DDI-DrugBank.d223.s3|108-108|,|drug
DDI-DrugBank.d223.s3|110-111|or|drug
DDI-DrugBank.d223.s3|113-117|quite|drug
DDI-DrugBank.d223.s3|119-123|large|drug
DDI-DrugBank.d223.s3|125-125|(|drug
DDI-DrugBank.d223.s3|126-131|8-fold|drug
DDI-DrugBank.d223.s3|133-140|increase|drug
DDI-DrugBank.d223.s3|142-143|in|drug
DDI-DrugBank.d223.s3|145-150|plasma|drug
DDI-DrugBank.d223.s3|152-154|AUC|drug
DDI-DrugBank.d223.s3|156-157|of|drug
DDI-DrugBank.d223.s3|159-161|the|drug
DDI-DrugBank.d223.s3|163-165|TCA|drug
DDI-DrugBank.d223.s3|166-166|)|drug
DDI-DrugBank.d223.s3|167-167|.|drug
DDI-DrugBank.d223.s4|0-1|In|drug
DDI-DrugBank.d223.s4|3-10|addition|drug
DDI-DrugBank.d223.s4|11-11|,|drug
DDI-DrugBank.d223.s4|13-19|certain|drug
DDI-DrugBank.d223.s4|21-25|drugs|drug
DDI-DrugBank.d223.s4|27-33|inhibit|drug
DDI-DrugBank.d223.s4|35-37|the|drug
DDI-DrugBank.d223.s4|39-46|activity|drug
DDI-DrugBank.d223.s4|48-49|of|drug
DDI-DrugBank.d223.s4|51-54|this|drug
DDI-DrugBank.d223.s4|56-62|isozyme|drug
DDI-DrugBank.d223.s4|64-66|and|drug
DDI-DrugBank.d223.s4|68-71|make|drug
DDI-DrugBank.d223.s4|73-78|normal|drug
DDI-DrugBank.d223.s4|80-91|metabolizers|drug
DDI-DrugBank.d223.s4|93-100|resemble|drug
DDI-DrugBank.d223.s4|102-105|poor|drug
DDI-DrugBank.d223.s4|107-118|metabolizers|drug
DDI-DrugBank.d223.s4|119-119|.|drug
DDI-DrugBank.d223.s5|0-1|An|drug
DDI-DrugBank.d223.s5|3-12|individual|drug
DDI-DrugBank.d223.s5|14-16|who|drug
DDI-DrugBank.d223.s5|18-19|is|drug
DDI-DrugBank.d223.s5|21-26|stable|drug
DDI-DrugBank.d223.s5|28-29|on|drug
DDI-DrugBank.d223.s5|31-31|a|drug
DDI-DrugBank.d223.s5|33-37|given|drug
DDI-DrugBank.d223.s5|39-42|dose|drug
DDI-DrugBank.d223.s5|44-45|of|drug
DDI-DrugBank.d223.s5|47-49|TCA|drug
DDI-DrugBank.d223.s5|51-53|may|drug
DDI-DrugBank.d223.s5|55-60|become|drug
DDI-DrugBank.d223.s5|62-69|abruptly|drug
DDI-DrugBank.d223.s5|71-75|toxic|drug
DDI-DrugBank.d223.s5|77-80|when|drug
DDI-DrugBank.d223.s5|82-86|given|drug
DDI-DrugBank.d223.s5|88-90|one|drug
DDI-DrugBank.d223.s5|92-93|of|drug
DDI-DrugBank.d223.s5|95-99|these|drug
DDI-DrugBank.d223.s5|101-110|inhibiting|drug
DDI-DrugBank.d223.s5|112-116|drugs|drug
DDI-DrugBank.d223.s5|118-119|as|drug
DDI-DrugBank.d223.s5|121-131|concomitant|drug
DDI-DrugBank.d223.s5|133-139|therapy|drug
DDI-DrugBank.d223.s5|140-140|.|drug
DDI-DrugBank.d223.s6|0-2|The|drug
DDI-DrugBank.d223.s6|4-8|drugs|drug
DDI-DrugBank.d223.s6|10-13|that|drug
DDI-DrugBank.d223.s6|15-21|inhibit|drug
DDI-DrugBank.d223.s6|23-32|cytochrome|drug
DDI-DrugBank.d223.s6|34-37|P450|drug
DDI-DrugBank.d223.s6|39-41|2D6|drug
DDI-DrugBank.d223.s6|43-49|include|drug
DDI-DrugBank.d223.s6|51-54|some|drug
DDI-DrugBank.d223.s6|56-59|that|drug
DDI-DrugBank.d223.s6|61-63|are|drug
DDI-DrugBank.d223.s6|65-67|not|drug
DDI-DrugBank.d223.s6|69-79|metabolized|drug
DDI-DrugBank.d223.s6|81-82|by|drug
DDI-DrugBank.d223.s6|84-86|the|drug
DDI-DrugBank.d223.s6|88-93|enzyme|drug
DDI-DrugBank.d223.s6|95-95|(|drug
DDI-DrugBank.d223.s6|96-104|quinidine|drug
DDI-DrugBank.d223.s6|105-105|;|drug
DDI-DrugBank.d223.s7|0-9|cimetidine|drug
DDI-DrugBank.d223.s7|10-10|)|drug
DDI-DrugBank.d223.s7|12-14|and|drug
DDI-DrugBank.d223.s7|16-19|many|drug
DDI-DrugBank.d223.s7|21-24|that|drug
DDI-DrugBank.d223.s7|26-28|are|drug
DDI-DrugBank.d223.s7|30-39|substrates|drug
DDI-DrugBank.d223.s7|41-43|for|drug
DDI-DrugBank.d223.s7|45-48|P450|drug
DDI-DrugBank.d223.s7|50-52|2D6|drug
DDI-DrugBank.d223.s7|54-54|(|drug
DDI-DrugBank.d223.s7|55-58|many|drug
DDI-DrugBank.d223.s7|60-64|other|drug
DDI-DrugBank.d223.s7|66-80|antidepressants|drug
DDI-DrugBank.d223.s7|81-81|,|drug
DDI-DrugBank.d223.s7|83-96|phenothiazines|drug
DDI-DrugBank.d223.s7|97-97|,|drug
DDI-DrugBank.d223.s7|99-101|and|drug
DDI-DrugBank.d223.s7|103-105|the|drug
DDI-DrugBank.d223.s7|107-110|Type|drug
DDI-DrugBank.d223.s7|112-113|1C|drug
DDI-DrugBank.d223.s7|115-129|antiarrhythmics|drug
DDI-DrugBank.d223.s7|131-141|propafenone|drug
DDI-DrugBank.d223.s7|143-145|and|drug
DDI-DrugBank.d223.s7|147-156|flecainide|drug
DDI-DrugBank.d223.s7|157-157|)|drug
DDI-DrugBank.d223.s7|158-158|.|drug
DDI-DrugBank.d223.s8|0-4|While|drug
DDI-DrugBank.d223.s8|6-8|all|drug
DDI-DrugBank.d223.s8|10-12|the|drug
DDI-DrugBank.d223.s8|14-22|selective|drug
DDI-DrugBank.d223.s8|24-32|serotonin|drug
DDI-DrugBank.d223.s8|34-41|reuptake|drug
DDI-DrugBank.d223.s8|43-52|inhibitors|drug
DDI-DrugBank.d223.s8|54-54|(|drug
DDI-DrugBank.d223.s8|55-59|SSRIs|drug
DDI-DrugBank.d223.s8|60-60|)|drug
DDI-DrugBank.d223.s8|61-61|,|drug
DDI-DrugBank.d223.s8|63-66|e.g.|drug
DDI-DrugBank.d223.s8|67-67|,|drug
DDI-DrugBank.d223.s8|69-78|citalopram|drug
DDI-DrugBank.d223.s8|79-79|,|drug
DDI-DrugBank.d223.s8|81-92|escitalopram|drug
DDI-DrugBank.d223.s8|93-93|,|drug
DDI-DrugBank.d223.s8|95-104|fluoxetine|drug
DDI-DrugBank.d223.s8|105-105|,|drug
DDI-DrugBank.d223.s8|107-116|sertraline|drug
DDI-DrugBank.d223.s8|117-117|,|drug
DDI-DrugBank.d223.s8|119-121|and|drug
DDI-DrugBank.d223.s8|123-132|paroxetine|drug
DDI-DrugBank.d223.s8|133-133|,|drug
DDI-DrugBank.d223.s8|135-141|inhibit|drug
DDI-DrugBank.d223.s8|143-146|P450|drug
DDI-DrugBank.d223.s8|148-150|2D6|drug
DDI-DrugBank.d223.s8|151-151|,|drug
DDI-DrugBank.d223.s8|153-156|they|drug
DDI-DrugBank.d223.s8|158-160|may|drug
DDI-DrugBank.d223.s8|162-165|vary|drug
DDI-DrugBank.d223.s8|167-168|in|drug
DDI-DrugBank.d223.s8|170-172|the|drug
DDI-DrugBank.d223.s8|174-179|extent|drug
DDI-DrugBank.d223.s8|181-182|of|drug
DDI-DrugBank.d223.s8|184-193|inhibition|drug
DDI-DrugBank.d223.s8|194-194|.|drug
DDI-DrugBank.d223.s9|0-2|The|drug
DDI-DrugBank.d223.s9|4-9|extent|drug
DDI-DrugBank.d223.s9|11-12|to|drug
DDI-DrugBank.d223.s9|14-18|which|drug
DDI-DrugBank.d223.s9|20-27|SSRI-TCA|drug
DDI-DrugBank.d223.s9|29-40|interactions|drug
DDI-DrugBank.d223.s9|42-44|may|drug
DDI-DrugBank.d223.s9|46-49|pose|drug
DDI-DrugBank.d223.s9|51-58|clinical|drug
DDI-DrugBank.d223.s9|60-67|problems|drug
DDI-DrugBank.d223.s9|69-72|will|drug
DDI-DrugBank.d223.s9|74-79|depend|drug
DDI-DrugBank.d223.s9|81-82|on|drug
DDI-DrugBank.d223.s9|84-86|the|drug
DDI-DrugBank.d223.s9|88-93|degree|drug
DDI-DrugBank.d223.s9|95-96|of|drug
DDI-DrugBank.d223.s9|98-107|inhibition|drug
DDI-DrugBank.d223.s9|109-111|and|drug
DDI-DrugBank.d223.s9|113-115|the|drug
DDI-DrugBank.d223.s9|117-132|pharmacokinetics|drug
DDI-DrugBank.d223.s9|134-135|of|drug
DDI-DrugBank.d223.s9|137-139|the|drug
DDI-DrugBank.d223.s9|141-144|SSRI|drug
DDI-DrugBank.d223.s9|146-153|involved|drug
DDI-DrugBank.d223.s9|154-154|.|drug
DDI-DrugBank.d223.s10|0-11|Nevertheless|drug
DDI-DrugBank.d223.s10|12-12|,|drug
DDI-DrugBank.d223.s10|14-20|caution|drug
DDI-DrugBank.d223.s10|22-23|is|drug
DDI-DrugBank.d223.s10|25-33|indicated|drug
DDI-DrugBank.d223.s10|35-36|in|drug
DDI-DrugBank.d223.s10|38-40|the|drug
DDI-DrugBank.d223.s10|42-58|co-administration|drug
DDI-DrugBank.d223.s10|60-61|of|drug
DDI-DrugBank.d223.s10|63-66|TCAs|drug
DDI-DrugBank.d223.s10|68-71|with|drug
DDI-DrugBank.d223.s10|73-75|any|drug
DDI-DrugBank.d223.s10|77-78|of|drug
DDI-DrugBank.d223.s10|80-82|the|drug
DDI-DrugBank.d223.s10|84-88|SSRIs|drug
DDI-DrugBank.d223.s10|90-92|and|drug
DDI-DrugBank.d223.s10|94-97|also|drug
DDI-DrugBank.d223.s10|99-100|in|drug
DDI-DrugBank.d223.s10|102-110|switching|drug
DDI-DrugBank.d223.s10|112-115|from|drug
DDI-DrugBank.d223.s10|117-119|one|drug
DDI-DrugBank.d223.s10|121-125|class|drug
DDI-DrugBank.d223.s10|127-128|to|drug
DDI-DrugBank.d223.s10|130-132|the|drug
DDI-DrugBank.d223.s10|134-138|other|drug
DDI-DrugBank.d223.s10|139-139|.|drug
DDI-DrugBank.d223.s11|0-1|Of|drug
DDI-DrugBank.d223.s11|3-12|particular|drug
DDI-DrugBank.d223.s11|14-23|importance|drug
DDI-DrugBank.d223.s11|24-24|,|drug
DDI-DrugBank.d223.s11|26-35|sufficient|drug
DDI-DrugBank.d223.s11|37-40|time|drug
DDI-DrugBank.d223.s11|42-45|must|drug
DDI-DrugBank.d223.s11|47-52|elapse|drug
DDI-DrugBank.d223.s11|54-59|before|drug
DDI-DrugBank.d223.s11|61-70|initiating|drug
DDI-DrugBank.d223.s11|72-74|TCA|drug
DDI-DrugBank.d223.s11|76-84|treatment|drug
DDI-DrugBank.d223.s11|86-87|in|drug
DDI-DrugBank.d223.s11|89-89|a|drug
DDI-DrugBank.d223.s11|91-97|patient|drug
DDI-DrugBank.d223.s11|99-103|being|drug
DDI-DrugBank.d223.s11|105-113|withdrawn|drug
DDI-DrugBank.d223.s11|115-118|from|drug
DDI-DrugBank.d223.s11|120-129|fluoxetine|drug
DDI-DrugBank.d223.s11|130-130|,|drug
DDI-DrugBank.d223.s11|132-136|given|drug
DDI-DrugBank.d223.s11|138-140|the|drug
DDI-DrugBank.d223.s11|142-145|long|drug
DDI-DrugBank.d223.s11|147-155|half-life|drug
DDI-DrugBank.d223.s11|157-158|of|drug
DDI-DrugBank.d223.s11|160-162|the|drug
DDI-DrugBank.d223.s11|164-169|parent|drug
DDI-DrugBank.d223.s11|171-173|and|drug
DDI-DrugBank.d223.s11|175-180|active|drug
DDI-DrugBank.d223.s11|182-191|metabolite|drug
DDI-DrugBank.d223.s11|193-193|(|drug
DDI-DrugBank.d223.s11|194-195|at|drug
DDI-DrugBank.d223.s11|197-201|least|drug
DDI-DrugBank.d223.s11|203-203|5|drug
DDI-DrugBank.d223.s11|205-209|weeks|drug
DDI-DrugBank.d223.s11|211-213|may|drug
DDI-DrugBank.d223.s11|215-216|be|drug
DDI-DrugBank.d223.s11|218-226|necessary|drug
DDI-DrugBank.d223.s11|227-227|)|drug
DDI-DrugBank.d223.s11|228-228|.|drug
DDI-DrugBank.d223.s12|0-10|Concomitant|drug
DDI-DrugBank.d223.s12|12-14|use|drug
DDI-DrugBank.d223.s12|16-17|of|drug
DDI-DrugBank.d223.s12|19-27|tricyclic|drug
DDI-DrugBank.d223.s12|29-43|antidepressants|drug
DDI-DrugBank.d223.s12|45-48|with|drug
DDI-DrugBank.d223.s12|50-54|drugs|drug
DDI-DrugBank.d223.s12|56-59|that|drug
DDI-DrugBank.d223.s12|61-63|can|drug
DDI-DrugBank.d223.s12|65-71|inhibit|drug
DDI-DrugBank.d223.s12|73-82|cytochrome|drug
DDI-DrugBank.d223.s12|84-87|P450|drug
DDI-DrugBank.d223.s12|89-91|2D6|drug
DDI-DrugBank.d223.s12|93-95|may|drug
DDI-DrugBank.d223.s12|97-103|require|drug
DDI-DrugBank.d223.s12|105-109|lower|drug
DDI-DrugBank.d223.s12|111-115|doses|drug
DDI-DrugBank.d223.s12|117-120|than|drug
DDI-DrugBank.d223.s12|122-128|usually|drug
DDI-DrugBank.d223.s12|130-139|prescribed|drug
DDI-DrugBank.d223.s12|141-143|for|drug
DDI-DrugBank.d223.s12|145-150|either|drug
DDI-DrugBank.d223.s12|152-154|the|drug
DDI-DrugBank.d223.s12|156-164|tricyclic|drug
DDI-DrugBank.d223.s12|166-179|antidepressant|drug
DDI-DrugBank.d223.s12|181-182|or|drug
DDI-DrugBank.d223.s12|184-186|the|drug
DDI-DrugBank.d223.s12|188-192|other|drug
DDI-DrugBank.d223.s12|194-197|drug|drug
DDI-DrugBank.d223.s12|198-198|.|drug
DDI-DrugBank.d223.s13|0-10|Furthermore|drug
DDI-DrugBank.d223.s13|11-11|,|drug
DDI-DrugBank.d223.s13|13-20|whenever|drug
DDI-DrugBank.d223.s13|22-24|one|drug
DDI-DrugBank.d223.s13|26-27|of|drug
DDI-DrugBank.d223.s13|29-33|these|drug
DDI-DrugBank.d223.s13|35-39|other|drug
DDI-DrugBank.d223.s13|41-45|drugs|drug
DDI-DrugBank.d223.s13|47-48|is|drug
DDI-DrugBank.d223.s13|50-58|withdrawn|drug
DDI-DrugBank.d223.s13|60-63|from|drug
DDI-DrugBank.d223.s13|65-74|co-therapy|drug
DDI-DrugBank.d223.s13|75-75|,|drug
DDI-DrugBank.d223.s13|77-78|an|drug
DDI-DrugBank.d223.s13|80-88|increased|drug
DDI-DrugBank.d223.s13|90-93|dose|drug
DDI-DrugBank.d223.s13|95-96|of|drug
DDI-DrugBank.d223.s13|98-106|tricyclic|drug
DDI-DrugBank.d223.s13|108-121|antidepressant|drug
DDI-DrugBank.d223.s13|123-125|may|drug
DDI-DrugBank.d223.s13|127-128|be|drug
DDI-DrugBank.d223.s13|130-137|required|drug
DDI-DrugBank.d223.s13|138-138|.|drug
DDI-DrugBank.d223.s14|0-1|It|drug
DDI-DrugBank.d223.s14|3-4|is|drug
DDI-DrugBank.d223.s14|6-14|desirable|drug
DDI-DrugBank.d223.s14|16-17|to|drug
DDI-DrugBank.d223.s14|19-25|monitor|drug
DDI-DrugBank.d223.s14|27-29|TCA|drug
DDI-DrugBank.d223.s14|31-36|plasma|drug
DDI-DrugBank.d223.s14|38-43|levels|drug
DDI-DrugBank.d223.s14|45-52|whenever|drug
DDI-DrugBank.d223.s14|54-54|a|drug
DDI-DrugBank.d223.s14|56-58|TCA|drug
DDI-DrugBank.d223.s14|60-61|is|drug
DDI-DrugBank.d223.s14|63-67|going|drug
DDI-DrugBank.d223.s14|69-70|to|drug
DDI-DrugBank.d223.s14|72-73|be|drug
DDI-DrugBank.d223.s14|75-89|co-administered|drug
DDI-DrugBank.d223.s14|91-94|with|drug
DDI-DrugBank.d223.s14|96-102|another|drug
DDI-DrugBank.d223.s14|104-107|drug|drug
DDI-DrugBank.d223.s14|109-113|known|drug
DDI-DrugBank.d223.s14|115-116|to|drug
DDI-DrugBank.d223.s14|118-119|be|drug
DDI-DrugBank.d223.s14|121-122|an|drug
DDI-DrugBank.d223.s14|124-132|inhibitor|drug
DDI-DrugBank.d223.s14|134-135|of|drug
DDI-DrugBank.d223.s14|137-140|P450|drug
DDI-DrugBank.d223.s14|142-144|2D6|drug
DDI-DrugBank.d223.s14|145-145|.|drug
DDI-DrugBank.d223.s15|0-6|Doxepin|brand
DDI-DrugBank.d223.s15|8-9|is|drug
DDI-DrugBank.d223.s15|11-19|primarily|drug
DDI-DrugBank.d223.s15|21-31|metabolized|drug
DDI-DrugBank.d223.s15|33-34|by|drug
DDI-DrugBank.d223.s15|36-41|CYP2D6|drug
DDI-DrugBank.d223.s15|43-43|(|drug
DDI-DrugBank.d223.s15|44-47|with|drug
DDI-DrugBank.d223.s15|49-54|CYP1A2|drug
DDI-DrugBank.d223.s15|57-59|and|drug
DDI-DrugBank.d223.s15|62-67|CYP3A4|drug
DDI-DrugBank.d223.s15|69-70|as|drug
DDI-DrugBank.d223.s15|72-76|minor|drug
DDI-DrugBank.d223.s15|78-85|pathways|drug
DDI-DrugBank.d223.s15|86-86|)|drug
DDI-DrugBank.d223.s15|87-87|.|drug
DDI-DrugBank.d223.s16|0-9|Inhibitors|drug
DDI-DrugBank.d223.s16|11-12|or|drug
DDI-DrugBank.d223.s16|14-23|substrates|drug
DDI-DrugBank.d223.s16|25-26|of|drug
DDI-DrugBank.d223.s16|28-33|CYP2D6|drug
DDI-DrugBank.d223.s16|35-35|(|drug
DDI-DrugBank.d223.s16|36-39|i.e.|drug
DDI-DrugBank.d223.s16|40-40|,|drug
DDI-DrugBank.d223.s16|42-50|quinidine|drug
DDI-DrugBank.d223.s16|51-51|,|drug
DDI-DrugBank.d223.s16|53-61|selective|drug
DDI-DrugBank.d223.s16|63-71|serotonin|drug
DDI-DrugBank.d223.s16|73-80|reuptake|drug
DDI-DrugBank.d223.s16|82-91|inhibitors|drug
DDI-DrugBank.d223.s16|93-93|[|drug
DDI-DrugBank.d223.s16|94-98|SSRIs|drug
DDI-DrugBank.d223.s16|99-99|]|drug
DDI-DrugBank.d223.s16|100-100|)|drug
DDI-DrugBank.d223.s16|102-104|may|drug
DDI-DrugBank.d223.s16|106-113|increase|drug
DDI-DrugBank.d223.s16|115-117|the|drug
DDI-DrugBank.d223.s16|119-124|plasma|drug
DDI-DrugBank.d223.s16|126-138|concentration|drug
DDI-DrugBank.d223.s16|140-141|of|drug
DDI-DrugBank.d223.s16|143-149|doxepin|drug
DDI-DrugBank.d223.s16|151-154|when|drug
DDI-DrugBank.d223.s16|156-167|administered|drug
DDI-DrugBank.d223.s16|169-181|concomitantly|drug
DDI-DrugBank.d223.s16|182-182|.|drug
DDI-DrugBank.d223.s17|0-2|The|drug
DDI-DrugBank.d223.s17|4-9|extent|drug
DDI-DrugBank.d223.s17|11-12|of|drug
DDI-DrugBank.d223.s17|14-24|interaction|drug
DDI-DrugBank.d223.s17|26-32|depends|drug
DDI-DrugBank.d223.s17|34-35|on|drug
DDI-DrugBank.d223.s17|37-39|the|drug
DDI-DrugBank.d223.s17|41-51|variability|drug
DDI-DrugBank.d223.s17|53-54|of|drug
DDI-DrugBank.d223.s17|56-61|effect|drug
DDI-DrugBank.d223.s17|63-64|on|drug
DDI-DrugBank.d223.s17|66-71|CYP2D6|drug
DDI-DrugBank.d223.s17|72-72|.|drug
DDI-DrugBank.d223.s18|0-2|The|drug
DDI-DrugBank.d223.s18|4-11|clinical|drug
DDI-DrugBank.d223.s18|13-24|significance|drug
DDI-DrugBank.d223.s18|26-27|of|drug
DDI-DrugBank.d223.s18|29-32|this|drug
DDI-DrugBank.d223.s18|34-44|interaction|drug
DDI-DrugBank.d223.s18|46-49|with|drug
DDI-DrugBank.d223.s18|51-57|doxepin|drug
DDI-DrugBank.d223.s18|59-61|has|drug
DDI-DrugBank.d223.s18|63-65|not|drug
DDI-DrugBank.d223.s18|67-70|been|drug
DDI-DrugBank.d223.s18|72-85|systematically|drug
DDI-DrugBank.d223.s18|87-95|evaluated|drug
DDI-DrugBank.d223.s18|96-96|.|drug
DDI-DrugBank.d223.s19|0-2|MAO|drug
DDI-DrugBank.d223.s19|4-13|Inhibitors|drug
DDI-DrugBank.d223.s19|14-14|:|drug
DDI-DrugBank.d223.s19|16-22|Serious|drug
DDI-DrugBank.d223.s19|24-27|side|drug
DDI-DrugBank.d223.s19|29-35|effects|drug
DDI-DrugBank.d223.s19|37-39|and|drug
DDI-DrugBank.d223.s19|41-44|even|drug
DDI-DrugBank.d223.s19|46-50|death|drug
DDI-DrugBank.d223.s19|52-55|have|drug
DDI-DrugBank.d223.s19|57-60|been|drug
DDI-DrugBank.d223.s19|62-69|reported|drug
DDI-DrugBank.d223.s19|71-79|following|drug
DDI-DrugBank.d223.s19|81-83|the|drug
DDI-DrugBank.d223.s19|85-95|concomitant|drug
DDI-DrugBank.d223.s19|97-99|use|drug
DDI-DrugBank.d223.s19|101-102|of|drug
DDI-DrugBank.d223.s19|104-110|certain|drug
DDI-DrugBank.d223.s19|112-116|drugs|drug
DDI-DrugBank.d223.s19|118-121|with|drug
DDI-DrugBank.d223.s19|123-125|MAO|drug
DDI-DrugBank.d223.s19|127-136|inhibitors|drug
DDI-DrugBank.d223.s19|137-137|.|drug
DDI-DrugBank.d223.s20|0-8|Therefore|drug
DDI-DrugBank.d223.s20|9-9|,|drug
DDI-DrugBank.d223.s20|11-13|MAO|drug
DDI-DrugBank.d223.s20|15-24|inhibitors|drug
DDI-DrugBank.d223.s20|26-31|should|drug
DDI-DrugBank.d223.s20|33-34|be|drug
DDI-DrugBank.d223.s20|36-47|discontinued|drug
DDI-DrugBank.d223.s20|49-50|at|drug
DDI-DrugBank.d223.s20|52-56|least|drug
DDI-DrugBank.d223.s20|58-60|two|drug
DDI-DrugBank.d223.s20|62-66|weeks|drug
DDI-DrugBank.d223.s20|68-72|prior|drug
DDI-DrugBank.d223.s20|74-75|to|drug
DDI-DrugBank.d223.s20|77-79|the|drug
DDI-DrugBank.d223.s20|81-88|cautious|drug
DDI-DrugBank.d223.s20|90-99|initiation|drug
DDI-DrugBank.d223.s20|101-102|of|drug
DDI-DrugBank.d223.s20|104-110|therapy|drug
DDI-DrugBank.d223.s20|112-115|with|drug
DDI-DrugBank.d223.s20|117-124|SINEQUAN|drug
DDI-DrugBank.d223.s20|125-125|.|drug
DDI-DrugBank.d223.s21|0-2|The|drug
DDI-DrugBank.d223.s21|4-8|exact|drug
DDI-DrugBank.d223.s21|10-15|length|drug
DDI-DrugBank.d223.s21|17-18|of|drug
DDI-DrugBank.d223.s21|20-23|time|drug
DDI-DrugBank.d223.s21|25-27|may|drug
DDI-DrugBank.d223.s21|29-32|vary|drug
DDI-DrugBank.d223.s21|34-36|and|drug
DDI-DrugBank.d223.s21|38-39|is|drug
DDI-DrugBank.d223.s21|41-49|dependent|drug
DDI-DrugBank.d223.s21|51-54|upon|drug
DDI-DrugBank.d223.s21|56-58|the|drug
DDI-DrugBank.d223.s21|60-69|particular|drug
DDI-DrugBank.d223.s21|71-73|MAO|drug
DDI-DrugBank.d223.s21|75-83|inhibitor|drug
DDI-DrugBank.d223.s21|85-89|being|drug
DDI-DrugBank.d223.s21|91-94|used|drug
DDI-DrugBank.d223.s21|95-95|,|drug
DDI-DrugBank.d223.s21|97-99|the|drug
DDI-DrugBank.d223.s21|101-106|length|drug
DDI-DrugBank.d223.s21|108-109|of|drug
DDI-DrugBank.d223.s21|111-114|time|drug
DDI-DrugBank.d223.s21|116-117|it|drug
DDI-DrugBank.d223.s21|119-121|has|drug
DDI-DrugBank.d223.s21|123-126|been|drug
DDI-DrugBank.d223.s21|128-139|administered|drug
DDI-DrugBank.d223.s21|140-140|,|drug
DDI-DrugBank.d223.s21|142-144|and|drug
DDI-DrugBank.d223.s21|146-148|the|drug
DDI-DrugBank.d223.s21|150-155|dosage|drug
DDI-DrugBank.d223.s21|157-164|involved|drug
DDI-DrugBank.d223.s21|165-165|.|drug
DDI-DrugBank.d223.s22|0-9|Cimetidine|brand
DDI-DrugBank.d223.s22|10-10|:|drug
DDI-DrugBank.d223.s22|12-21|Cimetidine|brand
DDI-DrugBank.d223.s22|23-25|has|drug
DDI-DrugBank.d223.s22|27-30|been|drug
DDI-DrugBank.d223.s22|32-39|reported|drug
DDI-DrugBank.d223.s22|41-42|to|drug
DDI-DrugBank.d223.s22|44-50|produce|drug
DDI-DrugBank.d223.s22|52-61|clinically|drug
DDI-DrugBank.d223.s22|63-73|significant|drug
DDI-DrugBank.d223.s22|75-86|fluctuations|drug
DDI-DrugBank.d223.s22|88-89|in|drug
DDI-DrugBank.d223.s22|91-102|steady-state|drug
DDI-DrugBank.d223.s22|104-108|serum|drug
DDI-DrugBank.d223.s22|110-123|concentrations|drug
DDI-DrugBank.d223.s22|125-126|of|drug
DDI-DrugBank.d223.s22|128-134|various|drug
DDI-DrugBank.d223.s22|136-144|tricyclic|drug
DDI-DrugBank.d223.s22|146-160|antidepressants|drug
DDI-DrugBank.d223.s22|161-161|.|drug
DDI-DrugBank.d223.s23|0-6|Serious|drug
DDI-DrugBank.d223.s23|8-22|anticholinergic|drug
DDI-DrugBank.d223.s23|24-31|symptoms|drug
DDI-DrugBank.d223.s23|33-33|(|drug
DDI-DrugBank.d223.s23|34-37|i.e.|drug
DDI-DrugBank.d223.s23|38-38|,|drug
DDI-DrugBank.d223.s23|40-45|severe|drug
DDI-DrugBank.d223.s23|47-49|dry|drug
DDI-DrugBank.d223.s23|51-55|mouth|drug
DDI-DrugBank.d223.s23|56-56|,|drug
DDI-DrugBank.d223.s23|58-64|urinary|drug
DDI-DrugBank.d223.s23|66-74|retention|drug
DDI-DrugBank.d223.s23|76-78|and|drug
DDI-DrugBank.d223.s23|80-86|blurred|drug
DDI-DrugBank.d223.s23|88-93|vision|drug
DDI-DrugBank.d223.s23|94-94|)|drug
DDI-DrugBank.d223.s23|96-99|have|drug
DDI-DrugBank.d223.s23|101-104|been|drug
DDI-DrugBank.d223.s23|106-115|associated|drug
DDI-DrugBank.d223.s23|117-120|with|drug
DDI-DrugBank.d223.s23|122-131|elevations|drug
DDI-DrugBank.d223.s23|133-134|in|drug
DDI-DrugBank.d223.s23|136-138|the|drug
DDI-DrugBank.d223.s23|140-144|serum|drug
DDI-DrugBank.d223.s23|146-151|levels|drug
DDI-DrugBank.d223.s23|153-154|of|drug
DDI-DrugBank.d223.s23|156-164|tricyclic|drug
DDI-DrugBank.d223.s23|166-179|antidepressant|drug
DDI-DrugBank.d223.s23|181-184|when|drug
DDI-DrugBank.d223.s23|186-195|cimetidine|drug
DDI-DrugBank.d223.s23|197-203|therapy|drug
DDI-DrugBank.d223.s23|205-206|is|drug
DDI-DrugBank.d223.s23|208-216|initiated|drug
DDI-DrugBank.d223.s23|217-217|.|drug
DDI-DrugBank.d223.s24|0-11|Additionally|drug
DDI-DrugBank.d223.s24|12-12|,|drug
DDI-DrugBank.d223.s24|14-19|higher|drug
DDI-DrugBank.d223.s24|21-24|than|drug
DDI-DrugBank.d223.s24|26-33|expected|drug
DDI-DrugBank.d223.s24|35-43|tricyclic|drug
DDI-DrugBank.d223.s24|45-58|antidepressant|drug
DDI-DrugBank.d223.s24|60-65|levels|drug
DDI-DrugBank.d223.s24|67-70|have|drug
DDI-DrugBank.d223.s24|72-75|been|drug
DDI-DrugBank.d223.s24|77-84|observed|drug
DDI-DrugBank.d223.s24|86-89|when|drug
DDI-DrugBank.d223.s24|91-94|they|drug
DDI-DrugBank.d223.s24|96-98|are|drug
DDI-DrugBank.d223.s24|100-104|begun|drug
DDI-DrugBank.d223.s24|106-107|in|drug
DDI-DrugBank.d223.s24|109-116|patients|drug
DDI-DrugBank.d223.s24|118-124|already|drug
DDI-DrugBank.d223.s24|126-131|taking|drug
DDI-DrugBank.d223.s24|133-142|cimetidine|drug
DDI-DrugBank.d223.s24|143-143|.|drug
DDI-DrugBank.d223.s25|0-1|In|drug
DDI-DrugBank.d223.s25|3-10|patients|drug
DDI-DrugBank.d223.s25|12-14|who|drug
DDI-DrugBank.d223.s25|16-19|have|drug
DDI-DrugBank.d223.s25|21-24|been|drug
DDI-DrugBank.d223.s25|26-33|reported|drug
DDI-DrugBank.d223.s25|35-36|to|drug
DDI-DrugBank.d223.s25|38-39|be|drug
DDI-DrugBank.d223.s25|41-44|well|drug
DDI-DrugBank.d223.s25|46-55|controlled|drug
DDI-DrugBank.d223.s25|57-58|on|drug
DDI-DrugBank.d223.s25|60-68|tricyclic|drug
DDI-DrugBank.d223.s25|70-84|antidepressants|drug
DDI-DrugBank.d223.s25|86-94|receiving|drug
DDI-DrugBank.d223.s25|96-105|concurrent|drug
DDI-DrugBank.d223.s25|107-116|cimetidine|drug
DDI-DrugBank.d223.s25|118-124|therapy|drug
DDI-DrugBank.d223.s25|125-125|,|drug
DDI-DrugBank.d223.s25|127-141|discontinuation|drug
DDI-DrugBank.d223.s25|143-144|of|drug
DDI-DrugBank.d223.s25|146-155|cimetidine|drug
DDI-DrugBank.d223.s25|157-159|has|drug
DDI-DrugBank.d223.s25|161-164|been|drug
DDI-DrugBank.d223.s25|166-173|reported|drug
DDI-DrugBank.d223.s25|175-176|to|drug
DDI-DrugBank.d223.s25|178-185|decrease|drug
DDI-DrugBank.d223.s25|187-197|established|drug
DDI-DrugBank.d223.s25|199-210|steady-state|drug
DDI-DrugBank.d223.s25|212-216|serum|drug
DDI-DrugBank.d223.s25|218-226|tricyclic|drug
DDI-DrugBank.d223.s25|228-241|antidepressant|drug
DDI-DrugBank.d223.s25|243-248|levels|drug
DDI-DrugBank.d223.s25|250-252|and|drug
DDI-DrugBank.d223.s25|254-263|compromise|drug
DDI-DrugBank.d223.s25|265-269|their|drug
DDI-DrugBank.d223.s25|271-281|therapeutic|drug
DDI-DrugBank.d223.s25|283-289|effects|drug
DDI-DrugBank.d223.s25|290-290|.|drug
DDI-DrugBank.d223.s26|0-6|Alcohol|brand
DDI-DrugBank.d223.s26|7-7|:|drug
DDI-DrugBank.d223.s26|9-10|It|drug
DDI-DrugBank.d223.s26|12-17|should|drug
DDI-DrugBank.d223.s26|19-20|be|drug
DDI-DrugBank.d223.s26|22-26|borne|drug
DDI-DrugBank.d223.s26|28-29|in|drug
DDI-DrugBank.d223.s26|31-34|mind|drug
DDI-DrugBank.d223.s26|36-39|that|drug
DDI-DrugBank.d223.s26|41-47|alcohol|drug
DDI-DrugBank.d223.s26|49-57|ingestion|drug
DDI-DrugBank.d223.s26|59-61|may|drug
DDI-DrugBank.d223.s26|63-70|increase|drug
DDI-DrugBank.d223.s26|72-74|the|drug
DDI-DrugBank.d223.s26|76-81|danger|drug
DDI-DrugBank.d223.s26|83-90|inherent|drug
DDI-DrugBank.d223.s26|92-93|in|drug
DDI-DrugBank.d223.s26|95-97|any|drug
DDI-DrugBank.d223.s26|99-109|intentional|drug
DDI-DrugBank.d223.s26|111-112|or|drug
DDI-DrugBank.d223.s26|114-126|unintentional|drug
DDI-DrugBank.d223.s26|128-135|SINEQUAN|drug
DDI-DrugBank.d223.s26|137-146|overdosage|drug
DDI-DrugBank.d223.s26|147-147|.|drug
DDI-DrugBank.d223.s27|0-3|This|drug
DDI-DrugBank.d223.s27|5-6|is|drug
DDI-DrugBank.d223.s27|8-17|especially|drug
DDI-DrugBank.d223.s27|19-27|important|drug
DDI-DrugBank.d223.s27|29-30|in|drug
DDI-DrugBank.d223.s27|32-39|patients|drug
DDI-DrugBank.d223.s27|41-43|who|drug
DDI-DrugBank.d223.s27|45-47|may|drug
DDI-DrugBank.d223.s27|49-51|use|drug
DDI-DrugBank.d223.s27|53-59|alcohol|drug
DDI-DrugBank.d223.s27|61-71|excessively|drug
DDI-DrugBank.d223.s27|72-72|.|drug
DDI-DrugBank.d223.s28|0-9|Tolazamide|brand
DDI-DrugBank.d223.s28|10-10|:|drug
DDI-DrugBank.d223.s28|12-12|A|drug
DDI-DrugBank.d223.s28|14-17|case|drug
DDI-DrugBank.d223.s28|19-20|of|drug
DDI-DrugBank.d223.s28|22-27|severe|drug
DDI-DrugBank.d223.s28|29-40|hypoglycemia|drug
DDI-DrugBank.d223.s28|42-44|has|drug
DDI-DrugBank.d223.s28|46-49|been|drug
DDI-DrugBank.d223.s28|51-58|reported|drug
DDI-DrugBank.d223.s28|60-61|in|drug
DDI-DrugBank.d223.s28|63-63|a|drug
DDI-DrugBank.d223.s28|65-68|type|drug
DDI-DrugBank.d223.s28|70-71|II|drug
DDI-DrugBank.d223.s28|73-80|diabetic|drug
DDI-DrugBank.d223.s28|82-88|patient|drug
DDI-DrugBank.d223.s28|90-99|maintained|drug
DDI-DrugBank.d223.s28|101-102|on|drug
DDI-DrugBank.d223.s28|104-113|tolazamide|drug
DDI-DrugBank.d223.s28|115-115|(|drug
DDI-DrugBank.d223.s28|116-116|1|drug
DDI-DrugBank.d223.s28|118-123|gm/day|drug
DDI-DrugBank.d223.s28|124-124|)|drug
DDI-DrugBank.d223.s28|126-127|11|drug
DDI-DrugBank.d223.s28|129-132|days|drug
DDI-DrugBank.d223.s28|134-138|after|drug
DDI-DrugBank.d223.s28|140-142|the|drug
DDI-DrugBank.d223.s28|144-151|addition|drug
DDI-DrugBank.d223.s28|153-154|of|drug
DDI-DrugBank.d223.s28|156-162|doxepin|drug
DDI-DrugBank.d223.s28|164-164|(|drug
DDI-DrugBank.d223.s28|165-166|75|drug
DDI-DrugBank.d223.s28|168-173|mg/day|drug
DDI-DrugBank.d223.s28|174-174|)|drug
DDI-DrugBank.d223.s28|175-175|.|drug
DDI-DrugBank.d654.s0|0-16|Co-administration|drug
DDI-DrugBank.d654.s0|18-19|of|drug
DDI-DrugBank.d654.s0|21-24|oral|drug
DDI-DrugBank.d654.s0|26-37|ketoconazole|drug
DDI-DrugBank.d654.s0|39-41|200|drug
DDI-DrugBank.d654.s0|43-44|mg|drug
DDI-DrugBank.d654.s0|46-50|twice|drug
DDI-DrugBank.d654.s0|52-56|daily|drug
DDI-DrugBank.d654.s0|58-66|increased|drug
DDI-DrugBank.d654.s0|68-78|retapamulin|drug
DDI-DrugBank.d654.s0|80-88|geometric|drug
DDI-DrugBank.d654.s0|90-93|mean|drug
DDI-DrugBank.d654.s0|95-97|AUC|drug
DDI-DrugBank.d654.s0|98-98|(|drug
DDI-DrugBank.d654.s0|99-102|0-24|drug
DDI-DrugBank.d654.s0|103-103|)|drug
DDI-DrugBank.d654.s0|105-107|and|drug
DDI-DrugBank.d654.s0|109-112|Cmax|drug
DDI-DrugBank.d654.s0|114-115|by|drug
DDI-DrugBank.d654.s0|117-118|81|drug
DDI-DrugBank.d654.s0|119-119|%|drug
DDI-DrugBank.d654.s0|121-125|after|drug
DDI-DrugBank.d654.s0|127-133|topical|drug
DDI-DrugBank.d654.s0|135-145|application|drug
DDI-DrugBank.d654.s0|147-148|of|drug
DDI-DrugBank.d654.s0|150-160|retapamulin|drug
DDI-DrugBank.d654.s0|162-169|ointment|drug
DDI-DrugBank.d654.s0|170-170|,|drug
DDI-DrugBank.d654.s0|172-172|1|drug
DDI-DrugBank.d654.s0|173-173|%|drug
DDI-DrugBank.d654.s0|175-176|on|drug
DDI-DrugBank.d654.s0|178-180|the|drug
DDI-DrugBank.d654.s0|182-188|abraded|drug
DDI-DrugBank.d654.s0|190-193|skin|drug
DDI-DrugBank.d654.s0|195-196|of|drug
DDI-DrugBank.d654.s0|198-204|healthy|drug
DDI-DrugBank.d654.s0|206-210|adult|drug
DDI-DrugBank.d654.s0|212-216|males|drug
DDI-DrugBank.d654.s0|217-217|.|drug
DDI-DrugBank.d654.s1|0-2|Due|drug
DDI-DrugBank.d654.s1|4-5|to|drug
DDI-DrugBank.d654.s1|7-9|low|drug
DDI-DrugBank.d654.s1|11-18|systemic|drug
DDI-DrugBank.d654.s1|20-27|exposure|drug
DDI-DrugBank.d654.s1|29-30|to|drug
DDI-DrugBank.d654.s1|32-42|retapamulin|drug
DDI-DrugBank.d654.s1|44-52|following|drug
DDI-DrugBank.d654.s1|54-60|topical|drug
DDI-DrugBank.d654.s1|62-72|application|drug
DDI-DrugBank.d654.s1|74-75|in|drug
DDI-DrugBank.d654.s1|77-84|patients|drug
DDI-DrugBank.d654.s1|85-85|,|drug
DDI-DrugBank.d654.s1|87-92|dosage|drug
DDI-DrugBank.d654.s1|94-104|adjustments|drug
DDI-DrugBank.d654.s1|106-108|for|drug
DDI-DrugBank.d654.s1|110-120|retapamulin|drug
DDI-DrugBank.d654.s1|122-124|are|drug
DDI-DrugBank.d654.s1|126-136|unnecessary|drug
DDI-DrugBank.d654.s1|138-141|when|drug
DDI-DrugBank.d654.s1|143-157|co-administered|drug
DDI-DrugBank.d654.s1|159-162|with|drug
DDI-DrugBank.d654.s1|164-169|CYP3A4|drug
DDI-DrugBank.d654.s1|171-180|inhibitors|drug
DDI-DrugBank.d654.s1|181-181|,|drug
DDI-DrugBank.d654.s1|183-186|such|drug
DDI-DrugBank.d654.s1|188-189|as|drug
DDI-DrugBank.d654.s1|191-202|ketoconazole|drug
DDI-DrugBank.d654.s1|203-203|.|drug
DDI-DrugBank.d654.s2|0-4|Based|drug
DDI-DrugBank.d654.s2|6-7|on|drug
DDI-DrugBank.d654.s2|9-10|in|drug
DDI-DrugBank.d654.s2|12-16|vitro|drug
DDI-DrugBank.d654.s2|18-21|P450|drug
DDI-DrugBank.d654.s2|23-32|inhibition|drug
DDI-DrugBank.d654.s2|34-40|studies|drug
DDI-DrugBank.d654.s2|42-44|and|drug
DDI-DrugBank.d654.s2|46-48|the|drug
DDI-DrugBank.d654.s2|50-52|low|drug
DDI-DrugBank.d654.s2|54-61|systemic|drug
DDI-DrugBank.d654.s2|63-70|exposure|drug
DDI-DrugBank.d654.s2|72-79|observed|drug
DDI-DrugBank.d654.s2|81-89|following|drug
DDI-DrugBank.d654.s2|91-97|topical|drug
DDI-DrugBank.d654.s2|99-109|application|drug
DDI-DrugBank.d654.s2|111-112|of|drug
DDI-DrugBank.d654.s2|114-120|ALTABAX|drug
DDI-DrugBank.d654.s2|121-121|,|drug
DDI-DrugBank.d654.s2|123-133|retapamulin|drug
DDI-DrugBank.d654.s2|135-136|is|drug
DDI-DrugBank.d654.s2|138-145|unlikely|drug
DDI-DrugBank.d654.s2|147-148|to|drug
DDI-DrugBank.d654.s2|150-155|affect|drug
DDI-DrugBank.d654.s2|157-159|the|drug
DDI-DrugBank.d654.s2|161-170|metabolism|drug
DDI-DrugBank.d654.s2|172-173|of|drug
DDI-DrugBank.d654.s2|175-179|other|drug
DDI-DrugBank.d654.s2|181-184|P450|drug
DDI-DrugBank.d654.s2|186-195|substrates|drug
DDI-DrugBank.d654.s2|196-196|.|drug
DDI-DrugBank.d654.s3|0-2|The|drug
DDI-DrugBank.d654.s3|4-9|effect|drug
DDI-DrugBank.d654.s3|11-12|of|drug
DDI-DrugBank.d654.s3|14-23|concurrent|drug
DDI-DrugBank.d654.s3|25-35|application|drug
DDI-DrugBank.d654.s3|37-38|of|drug
DDI-DrugBank.d654.s3|40-46|ALTABAX|drug
DDI-DrugBank.d654.s3|48-50|and|drug
DDI-DrugBank.d654.s3|52-56|other|drug
DDI-DrugBank.d654.s3|58-64|topical|drug
DDI-DrugBank.d654.s3|66-73|products|drug
DDI-DrugBank.d654.s3|75-76|to|drug
DDI-DrugBank.d654.s3|78-80|the|drug
DDI-DrugBank.d654.s3|82-85|same|drug
DDI-DrugBank.d654.s3|87-90|area|drug
DDI-DrugBank.d654.s3|92-93|of|drug
DDI-DrugBank.d654.s3|95-98|skin|drug
DDI-DrugBank.d654.s3|100-102|has|drug
DDI-DrugBank.d654.s3|104-106|not|drug
DDI-DrugBank.d654.s3|108-111|been|drug
DDI-DrugBank.d654.s3|113-119|studied|drug
DDI-DrugBank.d654.s3|120-120|.|drug
DDI-DrugBank.d639.s0|0-16|Co-administration|drug
DDI-DrugBank.d639.s0|18-19|of|drug
DDI-DrugBank.d639.s0|21-26|SUTENT|drug
DDI-DrugBank.d639.s0|28-31|with|drug
DDI-DrugBank.d639.s0|33-38|strong|drug
DDI-DrugBank.d639.s0|40-49|inhibitors|drug
DDI-DrugBank.d639.s0|51-52|of|drug
DDI-DrugBank.d639.s0|54-56|the|drug
DDI-DrugBank.d639.s0|58-63|CYP3A4|drug
DDI-DrugBank.d639.s0|65-70|family|drug
DDI-DrugBank.d639.s0|72-72|(|drug
DDI-DrugBank.d639.s0|73-76|e.g.|drug
DDI-DrugBank.d639.s0|77-77|,|drug
DDI-DrugBank.d639.s0|79-90|ketoconazole|drug
DDI-DrugBank.d639.s0|91-91|,|drug
DDI-DrugBank.d639.s0|93-104|itraconazole|drug
DDI-DrugBank.d639.s0|105-105|,|drug
DDI-DrugBank.d639.s0|107-120|clarithromycin|drug
DDI-DrugBank.d639.s0|121-121|,|drug
DDI-DrugBank.d639.s0|123-132|atazanavir|drug
DDI-DrugBank.d639.s0|133-133|,|drug
DDI-DrugBank.d639.s0|135-143|indinavir|drug
DDI-DrugBank.d639.s0|144-144|,|drug
DDI-DrugBank.d639.s0|146-155|nefazodone|drug
DDI-DrugBank.d639.s0|156-156|,|drug
DDI-DrugBank.d639.s0|158-167|nelfinavir|drug
DDI-DrugBank.d639.s0|168-168|,|drug
DDI-DrugBank.d639.s0|170-178|ritonavir|drug
DDI-DrugBank.d639.s0|179-179|,|drug
DDI-DrugBank.d639.s0|181-190|saquinavir|drug
DDI-DrugBank.d639.s0|191-191|,|drug
DDI-DrugBank.d639.s0|193-205|telithromycin|drug
DDI-DrugBank.d639.s0|206-206|,|drug
DDI-DrugBank.d639.s0|208-219|voriconizole|drug
DDI-DrugBank.d639.s0|220-220|)|drug
DDI-DrugBank.d639.s0|222-224|may|drug
DDI-DrugBank.d639.s0|226-234|increases|drug
DDI-DrugBank.d639.s0|236-244|sunitinib|drug
DDI-DrugBank.d639.s0|246-259|concentrations|drug
DDI-DrugBank.d639.s0|260-260|.|drug
DDI-DrugBank.d639.s1|0-9|Grapefruit|brand
DDI-DrugBank.d639.s1|11-13|may|drug
DDI-DrugBank.d639.s1|15-18|also|drug
DDI-DrugBank.d639.s1|20-27|increase|drug
DDI-DrugBank.d639.s1|29-34|plasma|drug
DDI-DrugBank.d639.s1|36-49|concentrations|drug
DDI-DrugBank.d639.s1|51-52|of|drug
DDI-DrugBank.d639.s1|54-59|SUTENT|drug
DDI-DrugBank.d639.s1|60-60|.|drug
DDI-DrugBank.d639.s2|0-16|Co-administration|drug
DDI-DrugBank.d639.s2|18-19|of|drug
DDI-DrugBank.d639.s2|21-26|SUTENT|drug
DDI-DrugBank.d639.s2|28-31|with|drug
DDI-DrugBank.d639.s2|33-40|inducers|drug
DDI-DrugBank.d639.s2|42-43|of|drug
DDI-DrugBank.d639.s2|45-47|the|drug
DDI-DrugBank.d639.s2|49-54|CYP3A4|drug
DDI-DrugBank.d639.s2|56-61|family|drug
DDI-DrugBank.d639.s2|63-63|(|drug
DDI-DrugBank.d639.s2|64-67|e.g.|drug
DDI-DrugBank.d639.s2|68-68|,|drug
DDI-DrugBank.d639.s2|70-82|dexamethasone|drug
DDI-DrugBank.d639.s2|83-83|,|drug
DDI-DrugBank.d639.s2|85-93|phenytoin|drug
DDI-DrugBank.d639.s2|94-94|,|drug
DDI-DrugBank.d639.s2|96-108|carbamazepine|drug
DDI-DrugBank.d639.s2|109-109|,|drug
DDI-DrugBank.d639.s2|111-118|rifampin|drug
DDI-DrugBank.d639.s2|119-119|,|drug
DDI-DrugBank.d639.s2|121-129|rifabutin|drug
DDI-DrugBank.d639.s2|130-130|,|drug
DDI-DrugBank.d639.s2|132-141|rifapentin|drug
DDI-DrugBank.d639.s2|142-142|,|drug
DDI-DrugBank.d639.s2|144-156|phenobarbital|drug
DDI-DrugBank.d639.s2|157-157|,|drug
DDI-DrugBank.d639.s2|159-161|St.|drug
DDI-DrugBank.d639.s2|163-167|Johns|drug
DDI-DrugBank.d639.s2|169-172|Wort|drug
DDI-DrugBank.d639.s2|173-173|)|drug
DDI-DrugBank.d639.s2|175-177|may|drug
DDI-DrugBank.d639.s2|179-186|decrease|drug
DDI-DrugBank.d639.s2|188-196|sunitinib|drug
DDI-DrugBank.d639.s2|198-211|concentrations|drug
DDI-DrugBank.d639.s2|212-212|.|drug
DDI-DrugBank.d639.s3|0-1|St|drug
DDI-DrugBank.d639.s3|2-2|.|drug
DDI-DrugBank.d639.s4|0-4|Johns|drug
DDI-DrugBank.d639.s4|6-9|Wort|drug
DDI-DrugBank.d639.s4|11-13|may|drug
DDI-DrugBank.d639.s4|15-22|decrease|drug
DDI-DrugBank.d639.s4|24-29|SUTENT|drug
DDI-DrugBank.d639.s4|31-36|plasma|drug
DDI-DrugBank.d639.s4|38-51|concentrations|drug
DDI-DrugBank.d639.s4|53-65|unpredictably|drug
DDI-DrugBank.d639.s4|66-66|.|drug
DDI-DrugBank.d639.s5|0-7|Patients|drug
DDI-DrugBank.d639.s5|9-17|receiving|drug
DDI-DrugBank.d639.s5|19-24|SUTENT|drug
DDI-DrugBank.d639.s5|26-31|should|drug
DDI-DrugBank.d639.s5|33-35|not|drug
DDI-DrugBank.d639.s5|37-40|take|drug
DDI-DrugBank.d639.s5|42-43|St|drug
DDI-DrugBank.d639.s5|44-44|.|drug
DDI-DrugBank.d639.s6|0-4|Johns|drug
DDI-DrugBank.d639.s6|6-9|Wort|drug
DDI-DrugBank.d639.s6|11-23|concomitantly|drug
DDI-DrugBank.d639.s6|24-24|.|drug
DDI-DrugBank.d639.s7|0-5|SUTENT|drug
DDI-DrugBank.d639.s7|7-10|dose|drug
DDI-DrugBank.d639.s7|12-23|modification|drug
DDI-DrugBank.d639.s7|25-26|is|drug
DDI-DrugBank.d639.s7|28-38|recommended|drug
DDI-DrugBank.d639.s7|40-41|in|drug
DDI-DrugBank.d639.s7|43-50|patients|drug
DDI-DrugBank.d639.s7|52-56|using|drug
DDI-DrugBank.d639.s7|58-68|concomitant|drug
DDI-DrugBank.d639.s7|70-75|CYP3A4|drug
DDI-DrugBank.d639.s7|77-86|inhibitors|drug
DDI-DrugBank.d639.s7|88-89|or|drug
DDI-DrugBank.d639.s7|91-98|inducers|drug
DDI-DrugBank.d639.s7|99-99|.|drug
DDI-DrugBank.d723.s0|0-4|Other|drug
DDI-DrugBank.d723.s0|6-8|eye|drug
DDI-DrugBank.d723.s0|10-14|drops|drug
DDI-DrugBank.d723.s0|16-17|or|drug
DDI-DrugBank.d723.s0|19-29|medications|drug
DDI-DrugBank.d723.s0|31-34|such|drug
DDI-DrugBank.d723.s0|36-37|as|drug
DDI-DrugBank.d723.s0|39-51|acetylcholine|drug
DDI-DrugBank.d723.s0|53-60|chloride|drug
DDI-DrugBank.d723.s0|62-62|(|drug
DDI-DrugBank.d723.s0|63-69|Miochol|drug
DDI-DrugBank.d723.s0|70-70|)|drug
DDI-DrugBank.d723.s0|72-74|and|drug
DDI-DrugBank.d723.s0|76-84|carbachol|drug
DDI-DrugBank.d723.s0|86-86|(|drug
DDI-DrugBank.d723.s0|87-95|Carboptic|drug
DDI-DrugBank.d723.s0|96-96|,|drug
DDI-DrugBank.d723.s0|98-103|Isopto|drug
DDI-DrugBank.d723.s0|105-113|Carbachol|brand
DDI-DrugBank.d723.s0|114-114|)|drug
DDI-DrugBank.d723.s0|116-118|may|drug
DDI-DrugBank.d723.s0|120-127|decrease|drug
DDI-DrugBank.d723.s0|129-131|the|drug
DDI-DrugBank.d723.s0|133-139|effects|drug
DDI-DrugBank.d723.s0|141-142|of|drug
DDI-DrugBank.d723.s0|144-151|suprofen|drug
DDI-DrugBank.d723.s0|153-162|ophthalmic|drug
DDI-DrugBank.d723.s0|163-163|.|drug
DDI-DrugBank.d746.s0|0-6|ARAMINE|drug
DDI-DrugBank.d746.s0|8-13|should|drug
DDI-DrugBank.d746.s0|15-16|be|drug
DDI-DrugBank.d746.s0|18-21|used|drug
DDI-DrugBank.d746.s0|23-26|with|drug
DDI-DrugBank.d746.s0|28-34|caution|drug
DDI-DrugBank.d746.s0|36-37|in|drug
DDI-DrugBank.d746.s0|39-49|digitalized|drug
DDI-DrugBank.d746.s0|51-58|patients|drug
DDI-DrugBank.d746.s0|59-59|,|drug
DDI-DrugBank.d746.s0|61-65|since|drug
DDI-DrugBank.d746.s0|67-69|the|drug
DDI-DrugBank.d746.s0|71-81|combination|drug
DDI-DrugBank.d746.s0|83-84|of|drug
DDI-DrugBank.d746.s0|86-94|digitalis|drug
DDI-DrugBank.d746.s0|96-98|and|drug
DDI-DrugBank.d746.s0|100-114|sympathomimetic|drug
DDI-DrugBank.d746.s0|116-121|amines|drug
DDI-DrugBank.d746.s0|123-125|may|drug
DDI-DrugBank.d746.s0|127-131|cause|drug
DDI-DrugBank.d746.s0|133-139|ectopic|drug
DDI-DrugBank.d746.s0|141-151|arrhythmias|drug
DDI-DrugBank.d746.s0|152-152|.|drug
DDI-DrugBank.d746.s1|0-8|Monoamine|drug
DDI-DrugBank.d746.s1|10-16|oxidase|drug
DDI-DrugBank.d746.s1|18-27|inhibitors|drug
DDI-DrugBank.d746.s1|29-30|or|drug
DDI-DrugBank.d746.s1|32-40|tricyclic|drug
DDI-DrugBank.d746.s1|42-56|antidepressants|drug
DDI-DrugBank.d746.s1|58-60|may|drug
DDI-DrugBank.d746.s1|62-71|potentiate|drug
DDI-DrugBank.d746.s1|73-75|the|drug
DDI-DrugBank.d746.s1|77-82|action|drug
DDI-DrugBank.d746.s1|84-85|of|drug
DDI-DrugBank.d746.s1|87-101|sympathomimetic|drug
DDI-DrugBank.d746.s1|103-108|amines|drug
DDI-DrugBank.d746.s1|109-109|.|drug
DDI-DrugBank.d746.s2|0-8|Therefore|drug
DDI-DrugBank.d746.s2|9-9|,|drug
DDI-DrugBank.d746.s2|11-14|when|drug
DDI-DrugBank.d746.s2|16-25|initiating|drug
DDI-DrugBank.d746.s2|27-33|pressor|drug
DDI-DrugBank.d746.s2|35-41|therapy|drug
DDI-DrugBank.d746.s2|43-44|in|drug
DDI-DrugBank.d746.s2|46-53|patients|drug
DDI-DrugBank.d746.s2|55-63|receiving|drug
DDI-DrugBank.d746.s2|65-69|these|drug
DDI-DrugBank.d746.s2|71-75|drugs|drug
DDI-DrugBank.d746.s2|76-76|,|drug
DDI-DrugBank.d746.s2|78-80|the|drug
DDI-DrugBank.d746.s2|82-88|initial|drug
DDI-DrugBank.d746.s2|90-93|dose|drug
DDI-DrugBank.d746.s2|95-100|should|drug
DDI-DrugBank.d746.s2|102-103|be|drug
DDI-DrugBank.d746.s2|105-109|small|drug
DDI-DrugBank.d746.s2|111-113|and|drug
DDI-DrugBank.d746.s2|115-119|given|drug
DDI-DrugBank.d746.s2|121-124|with|drug
DDI-DrugBank.d746.s2|126-132|caution|drug
DDI-DrugBank.d746.s2|133-133|.|drug
DDI-DrugBank.d22.s0|0-13|Aminosalicylic|drug
DDI-DrugBank.d22.s0|15-18|acid|drug
DDI-DrugBank.d22.s0|20-22|may|drug
DDI-DrugBank.d22.s0|24-31|decrease|drug
DDI-DrugBank.d22.s0|33-35|the|drug
DDI-DrugBank.d22.s0|37-42|amount|drug
DDI-DrugBank.d22.s0|44-45|of|drug
DDI-DrugBank.d22.s0|47-53|digoxin|drug
DDI-DrugBank.d22.s0|55-55|(|drug
DDI-DrugBank.d22.s0|56-62|Lanoxin|brand
DDI-DrugBank.d22.s0|63-63|,|drug
DDI-DrugBank.d22.s0|65-74|Lanoxicaps|brand
DDI-DrugBank.d22.s0|75-75|)|drug
DDI-DrugBank.d22.s0|77-80|that|drug
DDI-DrugBank.d22.s0|82-85|gets|drug
DDI-DrugBank.d22.s0|87-94|absorbed|drug
DDI-DrugBank.d22.s0|96-99|into|drug
DDI-DrugBank.d22.s0|101-104|your|drug
DDI-DrugBank.d22.s0|106-109|body|drug
DDI-DrugBank.d22.s0|110-110|.|drug
DDI-DrugBank.d22.s1|0-1|In|drug
DDI-DrugBank.d22.s1|3-5|the|drug
DDI-DrugBank.d22.s1|7-10|case|drug
DDI-DrugBank.d22.s1|12-15|that|drug
DDI-DrugBank.d22.s1|17-19|you|drug
DDI-DrugBank.d22.s1|21-23|are|drug
DDI-DrugBank.d22.s1|25-30|taking|drug
DDI-DrugBank.d22.s1|32-38|digoxin|drug
DDI-DrugBank.d22.s1|40-44|while|drug
DDI-DrugBank.d22.s1|46-51|taking|drug
DDI-DrugBank.d22.s1|53-66|aminosalicylic|drug
DDI-DrugBank.d22.s1|68-71|acid|drug
DDI-DrugBank.d22.s1|72-72|,|drug
DDI-DrugBank.d22.s1|74-79|higher|drug
DDI-DrugBank.d22.s1|81-85|doses|drug
DDI-DrugBank.d22.s1|87-88|of|drug
DDI-DrugBank.d22.s1|90-96|digoxin|drug
DDI-DrugBank.d22.s1|98-100|may|drug
DDI-DrugBank.d22.s1|102-103|be|drug
DDI-DrugBank.d22.s1|105-110|needed|drug
DDI-DrugBank.d22.s1|111-111|.|drug
DDI-DrugBank.d22.s2|0-13|Aminosalicylic|drug
DDI-DrugBank.d22.s2|15-18|acid|drug
DDI-DrugBank.d22.s2|20-22|may|drug
DDI-DrugBank.d22.s2|24-27|also|drug
DDI-DrugBank.d22.s2|29-36|decrease|drug
DDI-DrugBank.d22.s2|38-40|the|drug
DDI-DrugBank.d22.s2|42-51|absorption|drug
DDI-DrugBank.d22.s2|53-54|of|drug
DDI-DrugBank.d22.s2|56-62|vitamin|drug
DDI-DrugBank.d22.s2|64-66|B12|drug
DDI-DrugBank.d22.s2|67-67|,|drug
DDI-DrugBank.d22.s2|69-73|which|drug
DDI-DrugBank.d22.s2|75-77|can|drug
DDI-DrugBank.d22.s2|79-82|lead|drug
DDI-DrugBank.d22.s2|84-85|to|drug
DDI-DrugBank.d22.s2|87-87|a|drug
DDI-DrugBank.d22.s2|89-98|deficiency|drug
DDI-DrugBank.d22.s2|99-99|.|drug
DDI-DrugBank.d22.s3|0-8|Therefore|drug
DDI-DrugBank.d22.s3|10-12|you|drug
DDI-DrugBank.d22.s3|14-16|may|drug
DDI-DrugBank.d22.s3|18-21|need|drug
DDI-DrugBank.d22.s3|23-24|to|drug
DDI-DrugBank.d22.s3|26-29|take|drug
DDI-DrugBank.d22.s3|31-31|a|drug
DDI-DrugBank.d22.s3|33-39|vitamin|drug
DDI-DrugBank.d22.s3|41-43|B12|drug
DDI-DrugBank.d22.s3|45-54|supplement|drug
DDI-DrugBank.d22.s3|56-60|while|drug
DDI-DrugBank.d22.s3|62-67|taking|drug
DDI-DrugBank.d22.s3|69-82|aminosalicylic|drug
DDI-DrugBank.d22.s3|84-87|acid|drug
DDI-DrugBank.d22.s3|88-88|.|drug
DDI-DrugBank.d185.s0|0-0|A|drug
DDI-DrugBank.d185.s0|2-10|drug-drug|drug
DDI-DrugBank.d185.s0|12-22|interaction|drug
DDI-DrugBank.d185.s0|24-28|study|drug
DDI-DrugBank.d185.s0|30-38|evaluated|drug
DDI-DrugBank.d185.s0|40-42|the|drug
DDI-DrugBank.d185.s0|44-49|effect|drug
DDI-DrugBank.d185.s0|51-52|of|drug
DDI-DrugBank.d185.s0|54-56|the|drug
DDI-DrugBank.d185.s0|58-60|use|drug
DDI-DrugBank.d185.s0|62-63|of|drug
DDI-DrugBank.d185.s0|65-70|ACZONE|drug
DDI-DrugBank.d185.s0|72-74|Gel|drug
DDI-DrugBank.d185.s0|75-75|,|drug
DDI-DrugBank.d185.s0|77-77|5|drug
DDI-DrugBank.d185.s0|78-78|%|drug
DDI-DrugBank.d185.s0|79-79|,|drug
DDI-DrugBank.d185.s0|81-82|in|drug
DDI-DrugBank.d185.s0|84-94|combination|drug
DDI-DrugBank.d185.s0|96-99|with|drug
DDI-DrugBank.d185.s0|101-106|double|drug
DDI-DrugBank.d185.s0|108-115|strength|drug
DDI-DrugBank.d185.s0|117-117|(|drug
DDI-DrugBank.d185.s0|118-120|160|drug
DDI-DrugBank.d185.s0|122-127|mg/800|drug
DDI-DrugBank.d185.s0|129-130|mg|drug
DDI-DrugBank.d185.s0|131-131|)|drug
DDI-DrugBank.d185.s0|133-161|trimethoprim/sulfamethoxazole|drug
DDI-DrugBank.d185.s0|163-163|(|drug
DDI-DrugBank.d185.s0|164-170|TMP/SMX|drug
DDI-DrugBank.d185.s0|171-171|)|drug
DDI-DrugBank.d185.s0|172-172|.|drug
DDI-DrugBank.d185.s1|0-5|During|drug
DDI-DrugBank.d185.s1|7-23|co-administration|drug
DDI-DrugBank.d185.s1|24-24|,|drug
DDI-DrugBank.d185.s1|26-33|systemic|drug
DDI-DrugBank.d185.s1|35-40|levels|drug
DDI-DrugBank.d185.s1|42-43|of|drug
DDI-DrugBank.d185.s1|45-47|TMP|drug
DDI-DrugBank.d185.s1|49-51|and|drug
DDI-DrugBank.d185.s1|53-55|SMX|drug
DDI-DrugBank.d185.s1|57-60|were|drug
DDI-DrugBank.d185.s1|62-72|essentially|drug
DDI-DrugBank.d185.s1|74-82|unchanged|drug
DDI-DrugBank.d185.s1|83-83|.|drug
DDI-DrugBank.d185.s2|0-6|Notably|drug
DDI-DrugBank.d185.s2|7-7|,|drug
DDI-DrugBank.d185.s2|9-16|systemic|drug
DDI-DrugBank.d185.s2|18-25|exposure|drug
DDI-DrugBank.d185.s2|27-27|(|drug
DDI-DrugBank.d185.s2|28-34|AUC0-12|drug
DDI-DrugBank.d185.s2|35-35|)|drug
DDI-DrugBank.d185.s2|37-38|of|drug
DDI-DrugBank.d185.s2|40-46|dapsone|drug
DDI-DrugBank.d185.s2|48-60|hydroxylamine|drug
DDI-DrugBank.d185.s2|62-62|(|drug
DDI-DrugBank.d185.s2|63-65|DHA|drug
DDI-DrugBank.d185.s2|66-66|)|drug
DDI-DrugBank.d185.s2|68-70|was|drug
DDI-DrugBank.d185.s2|72-75|more|drug
DDI-DrugBank.d185.s2|77-80|than|drug
DDI-DrugBank.d185.s2|82-88|doubled|drug
DDI-DrugBank.d185.s2|90-91|in|drug
DDI-DrugBank.d185.s2|93-95|the|drug
DDI-DrugBank.d185.s2|97-104|presence|drug
DDI-DrugBank.d185.s2|106-107|of|drug
DDI-DrugBank.d185.s2|109-115|TMP/SMX|drug
DDI-DrugBank.d185.s2|116-116|.|drug
DDI-DrugBank.d185.s3|0-7|Exposure|drug
DDI-DrugBank.d185.s3|9-12|from|drug
DDI-DrugBank.d185.s3|14-16|the|drug
DDI-DrugBank.d185.s3|18-25|proposed|drug
DDI-DrugBank.d185.s3|27-33|topical|drug
DDI-DrugBank.d185.s3|35-38|dose|drug
DDI-DrugBank.d185.s3|40-41|is|drug
DDI-DrugBank.d185.s3|43-47|about|drug
DDI-DrugBank.d185.s3|49-49|1|drug
DDI-DrugBank.d185.s3|50-50|%|drug
DDI-DrugBank.d185.s3|52-53|of|drug
DDI-DrugBank.d185.s3|55-58|that|drug
DDI-DrugBank.d185.s3|60-63|from|drug
DDI-DrugBank.d185.s3|65-67|the|drug
DDI-DrugBank.d185.s3|69-71|100|drug
DDI-DrugBank.d185.s3|73-74|mg|drug
DDI-DrugBank.d185.s3|76-79|oral|drug
DDI-DrugBank.d185.s3|81-84|dose|drug
DDI-DrugBank.d185.s3|85-85|,|drug
DDI-DrugBank.d185.s3|87-90|even|drug
DDI-DrugBank.d185.s3|92-95|when|drug
DDI-DrugBank.d185.s3|97-111|co-administered|drug
DDI-DrugBank.d185.s3|113-116|with|drug
DDI-DrugBank.d185.s3|118-124|TMP/SMX|drug
DDI-DrugBank.d185.s3|125-125|.|drug
DDI-DrugBank.d185.s4|0-6|Certain|drug
DDI-DrugBank.d185.s4|8-18|concomitant|drug
DDI-DrugBank.d185.s4|20-30|medications|drug
DDI-DrugBank.d185.s4|32-32|(|drug
DDI-DrugBank.d185.s4|33-36|such|drug
DDI-DrugBank.d185.s4|38-39|as|drug
DDI-DrugBank.d185.s4|41-48|rifampin|drug
DDI-DrugBank.d185.s4|49-49|,|drug
DDI-DrugBank.d185.s4|51-65|anticonvulsants|drug
DDI-DrugBank.d185.s4|66-66|,|drug
DDI-DrugBank.d185.s4|68-69|St|drug
DDI-DrugBank.d185.s4|70-70|.|drug
DDI-DrugBank.d185.s5|0-3|John|drug
DDI-DrugBank.d185.s5|5-5|s|drug
DDI-DrugBank.d185.s5|7-10|wort|drug
DDI-DrugBank.d185.s5|11-11|)|drug
DDI-DrugBank.d185.s5|13-15|may|drug
DDI-DrugBank.d185.s5|17-24|increase|drug
DDI-DrugBank.d185.s5|26-28|the|drug
DDI-DrugBank.d185.s5|30-38|formation|drug
DDI-DrugBank.d185.s5|40-41|of|drug
DDI-DrugBank.d185.s5|43-49|dapsone|drug
DDI-DrugBank.d185.s5|51-63|hydroxylamine|drug
DDI-DrugBank.d185.s5|64-64|,|drug
DDI-DrugBank.d185.s5|66-66|a|drug
DDI-DrugBank.d185.s5|68-77|metabolite|drug
DDI-DrugBank.d185.s5|79-80|of|drug
DDI-DrugBank.d185.s5|82-88|dapsone|drug
DDI-DrugBank.d185.s5|90-99|associated|drug
DDI-DrugBank.d185.s5|101-104|with|drug
DDI-DrugBank.d185.s5|106-114|hemolysis|drug
DDI-DrugBank.d185.s5|115-115|.|drug
DDI-DrugBank.d185.s6|0-3|With|drug
DDI-DrugBank.d185.s6|5-8|oral|drug
DDI-DrugBank.d185.s6|10-16|dapsone|drug
DDI-DrugBank.d185.s6|18-26|treatment|drug
DDI-DrugBank.d185.s6|27-27|,|drug
DDI-DrugBank.d185.s6|29-33|folic|drug
DDI-DrugBank.d185.s6|35-38|acid|drug
DDI-DrugBank.d185.s6|40-50|antagonists|drug
DDI-DrugBank.d185.s6|52-55|such|drug
DDI-DrugBank.d185.s6|57-58|as|drug
DDI-DrugBank.d185.s6|60-72|pyrimethamine|drug
DDI-DrugBank.d185.s6|74-77|have|drug
DDI-DrugBank.d185.s6|79-82|been|drug
DDI-DrugBank.d185.s6|84-88|noted|drug
DDI-DrugBank.d185.s6|90-91|to|drug
DDI-DrugBank.d185.s6|93-100|possibly|drug
DDI-DrugBank.d185.s6|102-109|increase|drug
DDI-DrugBank.d185.s6|111-113|the|drug
DDI-DrugBank.d185.s6|115-124|likelihood|drug
DDI-DrugBank.d185.s6|126-127|of|drug
DDI-DrugBank.d185.s6|129-139|hematologic|drug
DDI-DrugBank.d185.s6|141-149|reactions|drug
DDI-DrugBank.d185.s7|0-0|.|drug
DDI-DrugBank.d418.s0|0-1|No|drug
DDI-DrugBank.d418.s0|3-8|formal|drug
DDI-DrugBank.d418.s0|10-13|drug|drug
DDI-DrugBank.d418.s0|15-25|interaction|drug
DDI-DrugBank.d418.s0|27-33|studies|drug
DDI-DrugBank.d418.s0|35-38|have|drug
DDI-DrugBank.d418.s0|40-43|been|drug
DDI-DrugBank.d418.s0|45-53|conducted|drug
DDI-DrugBank.d418.s0|55-58|with|drug
DDI-DrugBank.d418.s0|60-67|Cyanokit|brand
DDI-DrugBank.d418.s0|68-68|.|drug
DDI-DrugBank.d65.s0|0-12|Sulfacetamide|brand
DDI-DrugBank.d65.s0|14-25|preparations|drug
DDI-DrugBank.d65.s0|27-29|are|drug
DDI-DrugBank.d65.s0|31-42|incompatible|drug
DDI-DrugBank.d65.s0|44-47|with|drug
DDI-DrugBank.d65.s0|49-54|silver|drug
DDI-DrugBank.d65.s0|56-67|preparations|drug
DDI-DrugBank.d65.s0|68-68|.|drug
DDI-DrugBank.d525.s0|0-9|Eprosartan|drug
DDI-DrugBank.d525.s0|11-13|has|drug
DDI-DrugBank.d525.s0|15-18|been|drug
DDI-DrugBank.d525.s0|20-24|shown|drug
DDI-DrugBank.d525.s0|26-27|to|drug
DDI-DrugBank.d525.s0|29-32|have|drug
DDI-DrugBank.d525.s0|34-35|no|drug
DDI-DrugBank.d525.s0|37-42|effect|drug
DDI-DrugBank.d525.s0|44-45|on|drug
DDI-DrugBank.d525.s0|47-49|the|drug
DDI-DrugBank.d525.s0|51-66|pharmacokinetics|drug
DDI-DrugBank.d525.s0|68-69|of|drug
DDI-DrugBank.d525.s0|71-77|digoxin|drug
DDI-DrugBank.d525.s0|79-81|and|drug
DDI-DrugBank.d525.s0|83-85|the|drug
DDI-DrugBank.d525.s0|87-102|pharmacodynamics|drug
DDI-DrugBank.d525.s0|104-105|of|drug
DDI-DrugBank.d525.s0|107-114|warfarin|drug
DDI-DrugBank.d525.s0|116-118|and|drug
DDI-DrugBank.d525.s0|120-128|glyburide|drug
DDI-DrugBank.d525.s0|129-129|.|drug
DDI-DrugBank.d525.s1|0-3|Thus|drug
DDI-DrugBank.d525.s1|5-6|no|drug
DDI-DrugBank.d525.s1|8-13|dosing|drug
DDI-DrugBank.d525.s1|15-25|adjustments|drug
DDI-DrugBank.d525.s1|27-29|are|drug
DDI-DrugBank.d525.s1|31-39|necessary|drug
DDI-DrugBank.d525.s1|41-46|during|drug
DDI-DrugBank.d525.s1|48-58|concomitant|drug
DDI-DrugBank.d525.s1|60-62|use|drug
DDI-DrugBank.d525.s1|64-67|with|drug
DDI-DrugBank.d525.s1|69-73|these|drug
DDI-DrugBank.d525.s1|75-80|agents|drug
DDI-DrugBank.d525.s1|81-81|.|drug
DDI-DrugBank.d525.s2|0-6|Because|drug
DDI-DrugBank.d525.s2|8-17|eprosartan|drug
DDI-DrugBank.d525.s2|19-20|is|drug
DDI-DrugBank.d525.s2|22-24|not|drug
DDI-DrugBank.d525.s2|26-36|metabolized|drug
DDI-DrugBank.d525.s2|38-39|by|drug
DDI-DrugBank.d525.s2|41-43|the|drug
DDI-DrugBank.d525.s2|45-54|cytochrome|drug
DDI-DrugBank.d525.s2|56-59|P450|drug
DDI-DrugBank.d525.s2|61-66|system|drug
DDI-DrugBank.d525.s2|67-67|,|drug
DDI-DrugBank.d525.s2|69-78|inhibitors|drug
DDI-DrugBank.d525.s2|80-81|of|drug
DDI-DrugBank.d525.s2|83-88|CYP450|drug
DDI-DrugBank.d525.s2|90-95|enzyme|drug
DDI-DrugBank.d525.s2|97-101|would|drug
DDI-DrugBank.d525.s2|103-105|not|drug
DDI-DrugBank.d525.s2|107-108|be|drug
DDI-DrugBank.d525.s2|110-117|expected|drug
DDI-DrugBank.d525.s2|119-120|to|drug
DDI-DrugBank.d525.s2|122-127|affect|drug
DDI-DrugBank.d525.s2|129-131|its|drug
DDI-DrugBank.d525.s2|133-142|metabolism|drug
DDI-DrugBank.d525.s2|143-143|,|drug
DDI-DrugBank.d525.s2|145-147|and|drug
DDI-DrugBank.d525.s2|149-160|ketoconazole|drug
DDI-DrugBank.d525.s2|162-164|and|drug
DDI-DrugBank.d525.s2|166-176|fluconazole|drug
DDI-DrugBank.d525.s2|177-177|,|drug
DDI-DrugBank.d525.s2|179-184|potent|drug
DDI-DrugBank.d525.s2|186-195|inhibitors|drug
DDI-DrugBank.d525.s2|197-198|of|drug
DDI-DrugBank.d525.s2|200-204|CYP3A|drug
DDI-DrugBank.d525.s2|206-208|and|drug
DDI-DrugBank.d525.s2|210-212|2C9|drug
DDI-DrugBank.d525.s2|213-213|,|drug
DDI-DrugBank.d525.s2|215-226|respectively|drug
DDI-DrugBank.d525.s2|227-227|,|drug
DDI-DrugBank.d525.s2|229-232|have|drug
DDI-DrugBank.d525.s2|234-237|been|drug
DDI-DrugBank.d525.s2|239-243|shown|drug
DDI-DrugBank.d525.s2|245-246|to|drug
DDI-DrugBank.d525.s2|248-251|have|drug
DDI-DrugBank.d525.s2|253-254|no|drug
DDI-DrugBank.d525.s2|256-261|effect|drug
DDI-DrugBank.d525.s2|263-264|on|drug
DDI-DrugBank.d525.s2|266-275|eprosartan|drug
DDI-DrugBank.d525.s2|277-292|pharmacokinetics|drug
DDI-DrugBank.d525.s2|293-293|.|drug
DDI-DrugBank.d525.s3|0-9|Ranitidine|brand
DDI-DrugBank.d525.s3|11-14|also|drug
DDI-DrugBank.d525.s3|16-18|has|drug
DDI-DrugBank.d525.s3|20-21|no|drug
DDI-DrugBank.d525.s3|23-28|effect|drug
DDI-DrugBank.d525.s3|30-31|on|drug
DDI-DrugBank.d525.s3|33-42|eprosartan|drug
DDI-DrugBank.d525.s3|44-59|pharmacokinetics|drug
DDI-DrugBank.d525.s3|60-60|.|drug
DDI-DrugBank.d525.s4|0-9|Eprosartan|drug
DDI-DrugBank.d525.s4|11-11|(|drug
DDI-DrugBank.d525.s4|12-13|up|drug
DDI-DrugBank.d525.s4|15-16|to|drug
DDI-DrugBank.d525.s4|18-20|400|drug
DDI-DrugBank.d525.s4|22-23|mg|drug
DDI-DrugBank.d525.s4|25-30|b.i.d|drug
DDI-DrugBank.d525.s4|32-33|.|drug
DDI-DrugBank.d525.s4|35-37|or|drug
DDI-DrugBank.d525.s4|39-40|800|drug
DDI-DrugBank.d525.s4|42-45|mg|drug
DDI-DrugBank.d525.s4|46-46|q.d|drug
DDI-DrugBank.d525.s4|48-52|.|drug
DDI-DrugBank.d525.s4|54-57|)|drug
DDI-DrugBank.d525.s4|59-62|doses|drug
DDI-DrugBank.d525.s4|64-69|have|drug
DDI-DrugBank.d525.s4|71-74|been|drug
DDI-DrugBank.d525.s4|76-88|safely|drug
DDI-DrugBank.d525.s4|90-93|used|drug
DDI-DrugBank.d525.s4|95-95|concomitantly|drug
DDI-DrugBank.d525.s4|97-104|with|drug
DDI-DrugBank.d525.s4|106-113|a|drug
DDI-DrugBank.d525.s4|115-115|thiazide|drug
DDI-DrugBank.d525.s4|116-134|diuretic|drug
DDI-DrugBank.d525.s4|135-135|(|drug
DDI-DrugBank.d525.s4|136-136|hydrochlorothiazide|drug
DDI-DrugBank.d525.s5|0-9|Eprosartan|drug
DDI-DrugBank.d525.s5|11-15|doses|drug
DDI-DrugBank.d525.s5|17-18|of|drug
DDI-DrugBank.d525.s5|20-21|up|drug
DDI-DrugBank.d525.s5|23-24|to|drug
DDI-DrugBank.d525.s5|26-28|300|drug
DDI-DrugBank.d525.s5|30-31|mg|drug
DDI-DrugBank.d525.s5|33-38|b.i.d|drug
DDI-DrugBank.d525.s5|40-43|.|drug
DDI-DrugBank.d525.s5|45-48|have|drug
DDI-DrugBank.d525.s5|50-55|been|drug
DDI-DrugBank.d525.s5|57-60|safely|drug
DDI-DrugBank.d525.s5|62-74|used|drug
DDI-DrugBank.d525.s5|76-79|concomitantly|drug
DDI-DrugBank.d525.s5|81-97|with|drug
DDI-DrugBank.d525.s5|99-105|sustained-release|drug
DDI-DrugBank.d525.s5|107-113|calcium|drug
DDI-DrugBank.d525.s5|115-122|channel|drug
DDI-DrugBank.d525.s5|124-124|blockers|drug
DDI-DrugBank.d525.s5|125-141|(|drug
DDI-DrugBank.d525.s5|143-152|sustained-release|drug
DDI-DrugBank.d525.s5|153-153|nifedipine|drug
DDI-DrugBank.d525.s5|155-158|)|drug
DDI-DrugBank.d525.s5|160-161|with|drug
DDI-DrugBank.d525.s5|163-172|no|drug
DDI-DrugBank.d525.s5|174-184|clinically|drug
DDI-DrugBank.d525.s5|186-192|significant|drug
DDI-DrugBank.d525.s5|194-205|adverse|drug
DDI-DrugBank.d525.s5|206-206|interactions|drug
DDI-DrugBank.d250.s0|0-6|Certain|drug
DDI-DrugBank.d250.s0|8-12|other|drug
DDI-DrugBank.d250.s0|14-24|antibiotics|drug
DDI-DrugBank.d250.s0|26-26|(|drug
DDI-DrugBank.d250.s0|27-41|aminoglycosides|drug
DDI-DrugBank.d250.s0|43-45|and|drug
DDI-DrugBank.d250.s0|47-55|polymyxin|drug
DDI-DrugBank.d250.s0|56-56|)|drug
DDI-DrugBank.d250.s0|58-61|have|drug
DDI-DrugBank.d250.s0|63-66|also|drug
DDI-DrugBank.d250.s0|68-71|been|drug
DDI-DrugBank.d250.s0|73-80|reported|drug
DDI-DrugBank.d250.s0|82-83|to|drug
DDI-DrugBank.d250.s0|85-93|interfere|drug
DDI-DrugBank.d250.s0|95-98|with|drug
DDI-DrugBank.d250.s0|100-102|the|drug
DDI-DrugBank.d250.s0|104-108|nerve|drug
DDI-DrugBank.d250.s0|110-121|transmission|drug
DDI-DrugBank.d250.s0|123-124|at|drug
DDI-DrugBank.d250.s0|126-128|the|drug
DDI-DrugBank.d250.s0|130-142|neuromuscular|drug
DDI-DrugBank.d250.s0|144-151|junction|drug
DDI-DrugBank.d250.s0|152-152|.|drug
DDI-DrugBank.d250.s1|0-4|Based|drug
DDI-DrugBank.d250.s1|6-7|on|drug
DDI-DrugBank.d250.s1|9-12|this|drug
DDI-DrugBank.d250.s1|14-21|reported|drug
DDI-DrugBank.d250.s1|23-30|activity|drug
DDI-DrugBank.d250.s1|31-31|,|drug
DDI-DrugBank.d250.s1|33-36|they|drug
DDI-DrugBank.d250.s1|38-43|should|drug
DDI-DrugBank.d250.s1|45-47|not|drug
DDI-DrugBank.d250.s1|49-50|be|drug
DDI-DrugBank.d250.s1|52-56|given|drug
DDI-DrugBank.d250.s1|58-70|concomitantly|drug
DDI-DrugBank.d250.s1|72-75|with|drug
DDI-DrugBank.d250.s1|77-86|Coly-Mycin|drug
DDI-DrugBank.d250.s1|88-88|M|drug
DDI-DrugBank.d250.s1|90-99|Parenteral|drug
DDI-DrugBank.d250.s1|101-106|except|drug
DDI-DrugBank.d250.s1|108-111|with|drug
DDI-DrugBank.d250.s1|113-115|the|drug
DDI-DrugBank.d250.s1|117-124|greatest|drug
DDI-DrugBank.d250.s1|126-132|caution|drug
DDI-DrugBank.d250.s1|133-133|.|drug
DDI-DrugBank.d250.s2|0-9|Curariform|drug
DDI-DrugBank.d250.s2|11-16|muscle|drug
DDI-DrugBank.d250.s2|18-26|relaxants|drug
DDI-DrugBank.d250.s2|28-28|(|drug
DDI-DrugBank.d250.s2|29-30|eg|drug
DDI-DrugBank.d250.s2|31-31|,|drug
DDI-DrugBank.d250.s2|33-44|tubocurarine|drug
DDI-DrugBank.d250.s2|45-45|)|drug
DDI-DrugBank.d250.s2|47-49|and|drug
DDI-DrugBank.d250.s2|51-55|other|drug
DDI-DrugBank.d250.s2|57-61|drugs|drug
DDI-DrugBank.d250.s2|62-62|,|drug
DDI-DrugBank.d250.s2|64-72|including|drug
DDI-DrugBank.d250.s2|74-78|ether|drug
DDI-DrugBank.d250.s2|79-79|,|drug
DDI-DrugBank.d250.s2|81-95|succinylcholine|drug
DDI-DrugBank.d250.s2|96-96|,|drug
DDI-DrugBank.d250.s2|98-106|gallamine|drug
DDI-DrugBank.d250.s2|107-107|,|drug
DDI-DrugBank.d250.s2|109-121|decamethonium|drug
DDI-DrugBank.d250.s2|123-125|and|drug
DDI-DrugBank.d250.s2|127-132|sodium|drug
DDI-DrugBank.d250.s2|134-140|citrate|drug
DDI-DrugBank.d250.s2|141-141|,|drug
DDI-DrugBank.d250.s2|143-152|potentiate|drug
DDI-DrugBank.d250.s2|154-156|the|drug
DDI-DrugBank.d250.s2|158-170|neuromuscular|drug
DDI-DrugBank.d250.s2|172-179|blocking|drug
DDI-DrugBank.d250.s2|181-186|effect|drug
DDI-DrugBank.d250.s2|188-190|and|drug
DDI-DrugBank.d250.s2|192-197|should|drug
DDI-DrugBank.d250.s2|199-200|be|drug
DDI-DrugBank.d250.s2|202-205|used|drug
DDI-DrugBank.d250.s2|207-210|with|drug
DDI-DrugBank.d250.s2|212-218|extreme|drug
DDI-DrugBank.d250.s2|220-226|caution|drug
DDI-DrugBank.d250.s2|228-229|in|drug
DDI-DrugBank.d250.s2|231-238|patients|drug
DDI-DrugBank.d250.s2|240-244|being|drug
DDI-DrugBank.d250.s2|246-252|treated|drug
DDI-DrugBank.d250.s2|254-257|with|drug
DDI-DrugBank.d250.s2|259-268|Coly-Mycin|drug
DDI-DrugBank.d250.s2|270-270|M|drug
DDI-DrugBank.d250.s2|272-281|Parenteral|drug
DDI-DrugBank.d250.s2|282-282|.|drug
DDI-DrugBank.d250.s3|0-5|Sodium|group
DDI-DrugBank.d250.s3|7-17|cephalothin|drug
DDI-DrugBank.d250.s3|19-21|may|drug
DDI-DrugBank.d250.s3|23-29|enhance|drug
DDI-DrugBank.d250.s3|31-33|the|drug
DDI-DrugBank.d250.s3|35-48|nephrotoxicity|drug
DDI-DrugBank.d250.s3|50-51|of|drug
DDI-DrugBank.d250.s3|53-62|Coly-Mycin|drug
DDI-DrugBank.d250.s3|64-64|M|drug
DDI-DrugBank.d250.s3|66-75|Parenteral|drug
DDI-DrugBank.d250.s3|76-76|.|drug
DDI-DrugBank.d250.s4|0-2|The|drug
DDI-DrugBank.d250.s4|4-14|concomitant|drug
DDI-DrugBank.d250.s4|16-18|use|drug
DDI-DrugBank.d250.s4|20-21|of|drug
DDI-DrugBank.d250.s4|23-28|sodium|drug
DDI-DrugBank.d250.s4|30-40|cephalothin|drug
DDI-DrugBank.d250.s4|42-44|and|drug
DDI-DrugBank.d250.s4|46-55|Coly-Mycin|drug
DDI-DrugBank.d250.s4|57-57|M|drug
DDI-DrugBank.d250.s4|59-68|Parenteral|drug
DDI-DrugBank.d250.s4|70-75|should|drug
DDI-DrugBank.d250.s4|77-78|be|drug
DDI-DrugBank.d250.s4|80-86|avoided|drug
DDI-DrugBank.d250.s4|87-87|.|drug
DDI-DrugBank.d320.s0|0-9|Chirocaine|drug
DDI-DrugBank.d320.s0|13-18|should|drug
DDI-DrugBank.d320.s0|20-21|be|drug
DDI-DrugBank.d320.s0|23-26|used|drug
DDI-DrugBank.d320.s0|28-31|with|drug
DDI-DrugBank.d320.s0|33-39|caution|drug
DDI-DrugBank.d320.s0|41-42|in|drug
DDI-DrugBank.d320.s0|44-51|patients|drug
DDI-DrugBank.d320.s0|53-61|receiving|drug
DDI-DrugBank.d320.s0|63-67|other|drug
DDI-DrugBank.d320.s0|69-73|local|drug
DDI-DrugBank.d320.s0|75-85|anesthetics|drug
DDI-DrugBank.d320.s0|87-88|or|drug
DDI-DrugBank.d320.s0|90-95|agents|drug
DDI-DrugBank.d320.s0|97-108|structurally|drug
DDI-DrugBank.d320.s0|110-116|related|drug
DDI-DrugBank.d320.s0|118-119|to|drug
DDI-DrugBank.d320.s0|121-130|amide-type|drug
DDI-DrugBank.d320.s0|132-136|local|drug
DDI-DrugBank.d320.s0|138-148|anesthetics|drug
DDI-DrugBank.d320.s0|150-154|since|drug
DDI-DrugBank.d320.s0|156-158|the|drug
DDI-DrugBank.d320.s0|160-164|toxic|drug
DDI-DrugBank.d320.s0|166-172|effects|drug
DDI-DrugBank.d320.s0|174-175|of|drug
DDI-DrugBank.d320.s0|177-181|these|drug
DDI-DrugBank.d320.s0|183-187|drugs|drug
DDI-DrugBank.d320.s0|189-193|could|drug
DDI-DrugBank.d320.s0|195-196|be|drug
DDI-DrugBank.d320.s0|198-205|additive|drug
DDI-DrugBank.d320.s0|206-206|.|drug
DDI-DrugBank.d320.s1|0-1|In|drug
DDI-DrugBank.d320.s1|3-7|vitro|drug
DDI-DrugBank.d320.s1|9-15|studies|drug
DDI-DrugBank.d320.s1|17-24|indicate|drug
DDI-DrugBank.d320.s1|26-31|CYP3A4|drug
DDI-DrugBank.d320.s1|33-39|isoform|drug
DDI-DrugBank.d320.s1|41-43|and|drug
DDI-DrugBank.d320.s1|45-50|CYP1A2|drug
DDI-DrugBank.d320.s1|52-58|isoform|drug
DDI-DrugBank.d320.s1|60-66|mediate|drug
DDI-DrugBank.d320.s1|68-70|the|drug
DDI-DrugBank.d320.s1|72-81|metabolism|drug
DDI-DrugBank.d320.s1|83-84|of|drug
DDI-DrugBank.d320.s1|86-100|levobupivacaine|drug
DDI-DrugBank.d320.s1|102-103|to|drug
DDI-DrugBank.d320.s1|105-112|desbutyl|drug
DDI-DrugBank.d320.s1|114-128|levobupivacaine|drug
DDI-DrugBank.d320.s1|130-132|and|drug
DDI-DrugBank.d320.s1|134-142|3-hydroxy|drug
DDI-DrugBank.d320.s1|144-158|levobupivacaine|drug
DDI-DrugBank.d320.s1|159-159|,|drug
DDI-DrugBank.d320.s1|161-172|respectively|drug
DDI-DrugBank.d320.s1|173-173|.|drug
DDI-DrugBank.d320.s2|0-3|Thus|drug
DDI-DrugBank.d320.s2|5-10|agents|drug
DDI-DrugBank.d320.s2|12-17|likely|drug
DDI-DrugBank.d320.s2|19-20|to|drug
DDI-DrugBank.d320.s2|22-23|be|drug
DDI-DrugBank.d320.s2|25-37|concomitantly|drug
DDI-DrugBank.d320.s2|39-50|administered|drug
DDI-DrugBank.d320.s2|52-55|with|drug
DDI-DrugBank.d320.s2|57-66|Chirocaine|drug
DDI-DrugBank.d320.s2|68-71|that|drug
DDI-DrugBank.d320.s2|73-75|are|drug
DDI-DrugBank.d320.s2|77-87|metabolized|drug
DDI-DrugBank.d320.s2|89-90|by|drug
DDI-DrugBank.d320.s2|92-95|this|drug
DDI-DrugBank.d320.s2|97-105|isoenzyme|drug
DDI-DrugBank.d320.s2|107-112|family|drug
DDI-DrugBank.d320.s2|114-116|may|drug
DDI-DrugBank.d320.s2|118-128|potentially|drug
DDI-DrugBank.d320.s2|130-137|interact|drug
DDI-DrugBank.d320.s2|139-142|with|drug
DDI-DrugBank.d320.s2|144-153|Chirocaine|drug
DDI-DrugBank.d320.s2|154-154|.|drug
DDI-DrugBank.d320.s3|0-7|Although|drug
DDI-DrugBank.d320.s3|9-10|no|drug
DDI-DrugBank.d320.s3|12-19|clinical|drug
DDI-DrugBank.d320.s3|21-27|studies|drug
DDI-DrugBank.d320.s3|29-32|have|drug
DDI-DrugBank.d320.s3|34-37|been|drug
DDI-DrugBank.d320.s3|39-47|conducted|drug
DDI-DrugBank.d320.s3|48-48|,|drug
DDI-DrugBank.d320.s3|50-51|it|drug
DDI-DrugBank.d320.s3|53-54|is|drug
DDI-DrugBank.d320.s3|56-61|likely|drug
DDI-DrugBank.d320.s3|63-66|that|drug
DDI-DrugBank.d320.s3|68-70|the|drug
DDI-DrugBank.d320.s3|72-81|metabolism|drug
DDI-DrugBank.d320.s3|83-84|of|drug
DDI-DrugBank.d320.s3|86-100|levobupivacaine|drug
DDI-DrugBank.d320.s3|102-104|may|drug
DDI-DrugBank.d320.s3|106-107|be|drug
DDI-DrugBank.d320.s3|109-116|affected|drug
DDI-DrugBank.d320.s3|118-119|by|drug
DDI-DrugBank.d320.s3|121-123|the|drug
DDI-DrugBank.d320.s3|125-129|known|drug
DDI-DrugBank.d320.s3|131-136|CYP3A4|drug
DDI-DrugBank.d320.s3|138-145|inducers|drug
DDI-DrugBank.d320.s3|147-147|(|drug
DDI-DrugBank.d320.s3|148-151|such|drug
DDI-DrugBank.d320.s3|153-154|as|drug
DDI-DrugBank.d320.s3|156-164|phenytoin|drug
DDI-DrugBank.d320.s3|165-165|,|drug
DDI-DrugBank.d320.s3|167-179|phenobarbital|drug
DDI-DrugBank.d320.s3|180-180|,|drug
DDI-DrugBank.d320.s3|182-189|rifampin|drug
DDI-DrugBank.d320.s3|190-190|)|drug
DDI-DrugBank.d320.s3|191-191|,|drug
DDI-DrugBank.d320.s3|193-198|CYP3A4|drug
DDI-DrugBank.d320.s3|200-209|inhibitors|drug
DDI-DrugBank.d320.s3|211-211|(|drug
DDI-DrugBank.d320.s3|212-216|azole|drug
DDI-DrugBank.d320.s3|218-229|antimycotics|drug
DDI-DrugBank.d320.s3|231-234|e.g.|drug
DDI-DrugBank.d320.s3|235-235|,|drug
DDI-DrugBank.d320.s3|237-248|ketoconazole|drug
DDI-DrugBank.d320.s3|249-249|;|drug
DDI-DrugBank.d320.s4|0-6|certain|drug
DDI-DrugBank.d320.s4|8-15|protease|drug
DDI-DrugBank.d320.s4|17-26|inhibitors|drug
DDI-DrugBank.d320.s4|28-31|e.g.|drug
DDI-DrugBank.d320.s4|32-32|,|drug
DDI-DrugBank.d320.s4|34-42|ritanovir|drug
DDI-DrugBank.d320.s4|43-43|;|drug
DDI-DrugBank.d320.s5|0-8|macrolide|drug
DDI-DrugBank.d320.s5|10-20|antibiotics|drug
DDI-DrugBank.d320.s5|22-25|e.g.|drug
DDI-DrugBank.d320.s5|26-26|,|drug
DDI-DrugBank.d320.s5|28-39|erythromycin|drug
DDI-DrugBank.d320.s5|40-40|;|drug
DDI-DrugBank.d320.s6|0-2|and|drug
DDI-DrugBank.d320.s6|4-10|calcium|drug
DDI-DrugBank.d320.s6|12-18|channel|drug
DDI-DrugBank.d320.s6|20-30|antagonists|drug
DDI-DrugBank.d320.s6|32-35|e.g.|drug
DDI-DrugBank.d320.s6|36-36|,|drug
DDI-DrugBank.d320.s6|38-46|verapamil|drug
DDI-DrugBank.d320.s6|47-47|)|drug
DDI-DrugBank.d320.s6|48-48|,|drug
DDI-DrugBank.d320.s6|50-55|CYP1A2|drug
DDI-DrugBank.d320.s6|57-64|inducers|drug
DDI-DrugBank.d320.s6|66-66|(|drug
DDI-DrugBank.d320.s6|67-76|omeprazole|drug
DDI-DrugBank.d320.s6|77-77|)|drug
DDI-DrugBank.d320.s6|79-81|and|drug
DDI-DrugBank.d320.s6|83-88|CYP1A2|drug
DDI-DrugBank.d320.s6|90-99|inhibitors|drug
DDI-DrugBank.d320.s6|101-101|(|drug
DDI-DrugBank.d320.s6|102-112|furafylline|drug
DDI-DrugBank.d320.s6|114-116|and|drug
DDI-DrugBank.d320.s6|118-131|clarithromycin|drug
DDI-DrugBank.d320.s6|132-132|)|drug
DDI-DrugBank.d320.s6|133-133|.|drug
DDI-DrugBank.d320.s7|0-5|Dosage|drug
DDI-DrugBank.d320.s7|7-16|adjustment|drug
DDI-DrugBank.d320.s7|18-20|may|drug
DDI-DrugBank.d320.s7|22-23|be|drug
DDI-DrugBank.d320.s7|25-33|warranted|drug
DDI-DrugBank.d320.s7|35-38|when|drug
DDI-DrugBank.d320.s7|40-54|levobupivacaine|drug
DDI-DrugBank.d320.s7|56-57|is|drug
DDI-DrugBank.d320.s7|59-70|concurrently|drug
DDI-DrugBank.d320.s7|72-83|administered|drug
DDI-DrugBank.d320.s7|85-88|with|drug
DDI-DrugBank.d320.s7|90-95|CYP3A4|drug
DDI-DrugBank.d320.s7|97-106|inhibitors|drug
DDI-DrugBank.d320.s7|108-110|and|drug
DDI-DrugBank.d320.s7|112-117|CYP1A2|drug
DDI-DrugBank.d320.s7|119-128|inhibitors|drug
DDI-DrugBank.d320.s7|130-131|as|drug
DDI-DrugBank.d320.s7|133-140|systemic|drug
DDI-DrugBank.d320.s7|142-156|levobupivacaine|drug
DDI-DrugBank.d320.s7|158-163|levels|drug
DDI-DrugBank.d320.s7|165-167|may|drug
DDI-DrugBank.d320.s7|169-172|rise|drug
DDI-DrugBank.d320.s7|174-182|resulting|drug
DDI-DrugBank.d320.s7|184-185|in|drug
DDI-DrugBank.d320.s7|187-194|toxicity|drug
DDI-DrugBank.d320.s7|195-195|.|drug
DDI-DrugBank.d109.s0|0-24|Ketoconazole/Itraconazole|drug
DDI-DrugBank.d109.s0|25-25|,|drug
DDI-DrugBank.d109.s0|27-36|Macrolides|group
DDI-DrugBank.d109.s0|37-37|,|drug
DDI-DrugBank.d109.s0|39-47|Including|drug
DDI-DrugBank.d109.s0|49-60|Erythromycin|brand
DDI-DrugBank.d241.s0|0-9|Additional|drug
DDI-DrugBank.d241.s0|11-20|reductions|drug
DDI-DrugBank.d241.s0|22-23|in|drug
DDI-DrugBank.d241.s0|25-29|blood|drug
DDI-DrugBank.d241.s0|31-38|pressure|drug
DDI-DrugBank.d241.s0|40-42|may|drug
DDI-DrugBank.d241.s0|44-48|occur|drug
DDI-DrugBank.d241.s0|50-53|when|drug
DDI-DrugBank.d241.s0|55-60|FLOLAN|drug
DDI-DrugBank.d241.s0|62-63|is|drug
DDI-DrugBank.d241.s0|65-76|administered|drug
DDI-DrugBank.d241.s0|78-81|with|drug
DDI-DrugBank.d241.s0|83-91|diuretics|drug
DDI-DrugBank.d241.s0|92-92|,|drug
DDI-DrugBank.d241.s0|94-109|antihypertensive|drug
DDI-DrugBank.d241.s0|111-116|agents|drug
DDI-DrugBank.d241.s0|117-117|,|drug
DDI-DrugBank.d241.s0|119-120|or|drug
DDI-DrugBank.d241.s0|122-126|other|drug
DDI-DrugBank.d241.s0|128-139|vasodilators|drug
DDI-DrugBank.d241.s0|140-140|.|drug
DDI-DrugBank.d241.s1|0-3|When|drug
DDI-DrugBank.d241.s1|5-9|other|drug
DDI-DrugBank.d241.s1|11-22|antiplatelet|drug
DDI-DrugBank.d241.s1|24-29|agents|drug
DDI-DrugBank.d241.s1|31-32|or|drug
DDI-DrugBank.d241.s1|34-47|anticoagulants|drug
DDI-DrugBank.d241.s1|49-51|are|drug
DDI-DrugBank.d241.s1|53-56|used|drug
DDI-DrugBank.d241.s1|58-70|concomitantly|drug
DDI-DrugBank.d241.s1|71-71|,|drug
DDI-DrugBank.d241.s1|73-77|there|drug
DDI-DrugBank.d241.s1|79-80|is|drug
DDI-DrugBank.d241.s1|82-84|the|drug
DDI-DrugBank.d241.s1|86-94|potential|drug
DDI-DrugBank.d241.s1|96-98|for|drug
DDI-DrugBank.d241.s1|100-105|FLOLAN|drug
DDI-DrugBank.d241.s1|107-108|to|drug
DDI-DrugBank.d241.s1|110-117|increase|drug
DDI-DrugBank.d241.s1|119-121|the|drug
DDI-DrugBank.d241.s1|123-126|risk|drug
DDI-DrugBank.d241.s1|128-129|of|drug
DDI-DrugBank.d241.s1|131-138|bleeding|drug
DDI-DrugBank.d241.s1|139-139|.|drug
DDI-DrugBank.d241.s2|0-6|However|drug
DDI-DrugBank.d241.s2|7-7|,|drug
DDI-DrugBank.d241.s2|9-16|patients|drug
DDI-DrugBank.d241.s2|18-26|receiving|drug
DDI-DrugBank.d241.s2|28-36|infusions|drug
DDI-DrugBank.d241.s2|38-39|of|drug
DDI-DrugBank.d241.s2|41-46|FLOLAN|drug
DDI-DrugBank.d241.s2|48-49|in|drug
DDI-DrugBank.d241.s2|51-58|clinical|drug
DDI-DrugBank.d241.s2|60-65|trials|drug
DDI-DrugBank.d241.s2|67-70|were|drug
DDI-DrugBank.d241.s2|72-81|maintained|drug
DDI-DrugBank.d241.s2|83-84|on|drug
DDI-DrugBank.d241.s2|86-99|anticoagulants|drug
DDI-DrugBank.d241.s2|101-107|without|drug
DDI-DrugBank.d241.s2|109-116|evidence|drug
DDI-DrugBank.d241.s2|118-119|of|drug
DDI-DrugBank.d241.s2|121-129|increased|drug
DDI-DrugBank.d241.s2|131-138|bleeding|drug
DDI-DrugBank.d241.s2|139-139|.|drug
DDI-DrugBank.d241.s3|0-1|In|drug
DDI-DrugBank.d241.s3|3-10|clinical|drug
DDI-DrugBank.d241.s3|12-17|trials|drug
DDI-DrugBank.d241.s3|18-18|,|drug
DDI-DrugBank.d241.s3|20-25|FLOLAN|drug
DDI-DrugBank.d241.s3|27-29|was|drug
DDI-DrugBank.d241.s3|31-34|used|drug
DDI-DrugBank.d241.s3|36-39|with|drug
DDI-DrugBank.d241.s3|41-47|digoxin|drug
DDI-DrugBank.d241.s3|48-48|,|drug
DDI-DrugBank.d241.s3|50-58|diuretics|drug
DDI-DrugBank.d241.s3|59-59|,|drug
DDI-DrugBank.d241.s3|61-74|anticoagulants|drug
DDI-DrugBank.d241.s3|75-75|,|drug
DDI-DrugBank.d241.s3|77-80|oral|drug
DDI-DrugBank.d241.s3|82-93|vasodilators|drug
DDI-DrugBank.d241.s3|94-94|,|drug
DDI-DrugBank.d241.s3|96-98|and|drug
DDI-DrugBank.d241.s3|100-111|supplemental|drug
DDI-DrugBank.d241.s3|113-121|oxygen.In|drug
DDI-DrugBank.d241.s3|123-123|a|drug
DDI-DrugBank.d241.s3|125-139|pharmacokinetic|drug
DDI-DrugBank.d241.s3|141-148|substudy|drug
DDI-DrugBank.d241.s3|150-151|in|drug
DDI-DrugBank.d241.s3|153-160|patients|drug
DDI-DrugBank.d241.s3|162-165|with|drug
DDI-DrugBank.d241.s3|167-176|congestive|drug
DDI-DrugBank.d241.s3|178-182|heart|drug
DDI-DrugBank.d241.s3|184-190|failure|drug
DDI-DrugBank.d241.s3|192-200|receiving|drug
DDI-DrugBank.d241.s3|202-211|furosemide|drug
DDI-DrugBank.d241.s3|213-214|or|drug
DDI-DrugBank.d241.s3|216-222|digoxin|drug
DDI-DrugBank.d241.s3|224-225|in|drug
DDI-DrugBank.d241.s3|227-230|whom|drug
DDI-DrugBank.d241.s3|232-238|therapy|drug
DDI-DrugBank.d241.s3|240-243|with|drug
DDI-DrugBank.d241.s3|245-250|FLOLAN|drug
DDI-DrugBank.d241.s3|252-254|was|drug
DDI-DrugBank.d241.s3|256-264|initiated|drug
DDI-DrugBank.d241.s3|265-265|,|drug
DDI-DrugBank.d241.s3|267-274|apparent|drug
DDI-DrugBank.d241.s3|276-279|oral|drug
DDI-DrugBank.d241.s3|281-289|clearance|drug
DDI-DrugBank.d241.s3|291-296|values|drug
DDI-DrugBank.d241.s3|298-300|for|drug
DDI-DrugBank.d241.s3|302-311|furosemide|drug
DDI-DrugBank.d241.s3|313-313|(|drug
DDI-DrugBank.d241.s3|314-314|n|drug
DDI-DrugBank.d241.s3|316-316|=|drug
DDI-DrugBank.d241.s3|318-319|23|drug
DDI-DrugBank.d241.s3|320-320|)|drug
DDI-DrugBank.d241.s3|322-324|and|drug
DDI-DrugBank.d241.s3|326-332|digoxin|drug
DDI-DrugBank.d241.s3|334-334|(|drug
DDI-DrugBank.d241.s3|335-335|n|drug
DDI-DrugBank.d241.s3|337-337|=|drug
DDI-DrugBank.d241.s3|339-340|30|drug
DDI-DrugBank.d241.s3|341-341|)|drug
DDI-DrugBank.d241.s3|343-346|were|drug
DDI-DrugBank.d241.s3|348-356|decreased|drug
DDI-DrugBank.d241.s3|358-359|by|drug
DDI-DrugBank.d241.s3|361-362|13|drug
DDI-DrugBank.d241.s3|363-363|%|drug
DDI-DrugBank.d241.s3|365-367|and|drug
DDI-DrugBank.d241.s3|369-370|15|drug
DDI-DrugBank.d241.s3|371-371|%|drug
DDI-DrugBank.d241.s3|372-372|,|drug
DDI-DrugBank.d241.s3|374-385|respectively|drug
DDI-DrugBank.d241.s3|386-386|,|drug
DDI-DrugBank.d241.s3|388-389|on|drug
DDI-DrugBank.d241.s3|391-393|the|drug
DDI-DrugBank.d241.s3|395-400|second|drug
DDI-DrugBank.d241.s3|402-404|day|drug
DDI-DrugBank.d241.s3|406-407|of|drug
DDI-DrugBank.d241.s3|409-415|therapy|drug
DDI-DrugBank.d241.s3|417-419|and|drug
DDI-DrugBank.d241.s3|421-423|had|drug
DDI-DrugBank.d241.s3|425-432|returned|drug
DDI-DrugBank.d241.s3|434-435|to|drug
DDI-DrugBank.d241.s3|437-444|baseline|drug
DDI-DrugBank.d241.s3|446-451|values|drug
DDI-DrugBank.d241.s3|453-454|by|drug
DDI-DrugBank.d241.s3|456-458|day|drug
DDI-DrugBank.d241.s3|460-461|87|drug
DDI-DrugBank.d241.s3|462-462|.|drug
DDI-DrugBank.d241.s4|0-2|The|drug
DDI-DrugBank.d241.s4|4-9|change|drug
DDI-DrugBank.d241.s4|11-12|in|drug
DDI-DrugBank.d241.s4|14-23|furosemide|drug
DDI-DrugBank.d241.s4|25-33|clearance|drug
DDI-DrugBank.d241.s4|35-39|value|drug
DDI-DrugBank.d241.s4|41-42|is|drug
DDI-DrugBank.d241.s4|44-46|not|drug
DDI-DrugBank.d241.s4|48-53|likely|drug
DDI-DrugBank.d241.s4|55-56|to|drug
DDI-DrugBank.d241.s4|58-59|be|drug
DDI-DrugBank.d241.s4|61-70|clinically|drug
DDI-DrugBank.d241.s4|72-82|significant|drug
DDI-DrugBank.d241.s4|83-83|.|drug
DDI-DrugBank.d241.s5|0-6|However|drug
DDI-DrugBank.d241.s5|7-7|,|drug
DDI-DrugBank.d241.s5|9-16|patients|drug
DDI-DrugBank.d241.s5|18-19|on|drug
DDI-DrugBank.d241.s5|21-27|digoxin|drug
DDI-DrugBank.d241.s5|29-31|may|drug
DDI-DrugBank.d241.s5|33-36|show|drug
DDI-DrugBank.d241.s5|38-47|elevations|drug
DDI-DrugBank.d241.s5|49-50|of|drug
DDI-DrugBank.d241.s5|52-58|digoxin|drug
DDI-DrugBank.d241.s5|60-73|concentrations|drug
DDI-DrugBank.d241.s5|75-79|after|drug
DDI-DrugBank.d241.s5|81-90|initiation|drug
DDI-DrugBank.d241.s5|92-93|of|drug
DDI-DrugBank.d241.s5|95-101|therapy|drug
DDI-DrugBank.d241.s5|103-106|with|drug
DDI-DrugBank.d241.s5|108-113|FLOLAN|drug
DDI-DrugBank.d241.s5|114-114|,|drug
DDI-DrugBank.d241.s5|116-120|which|drug
DDI-DrugBank.d241.s5|122-124|may|drug
DDI-DrugBank.d241.s5|126-127|be|drug
DDI-DrugBank.d241.s5|129-138|clinically|drug
DDI-DrugBank.d241.s5|140-150|significant|drug
DDI-DrugBank.d241.s5|152-153|in|drug
DDI-DrugBank.d241.s5|155-162|patients|drug
DDI-DrugBank.d241.s5|164-168|prone|drug
DDI-DrugBank.d241.s5|170-171|to|drug
DDI-DrugBank.d241.s5|173-179|digoxin|drug
DDI-DrugBank.d241.s5|181-188|toxicity|drug
DDI-DrugBank.d241.s5|189-189|.|drug
DDI-MedLine.d43.s0|0-4|Tumor|drug
DDI-MedLine.d43.s0|6-14|phenotype|drug
DDI-MedLine.d43.s0|16-18|and|drug
DDI-MedLine.d43.s0|20-33|susceptibility|drug
DDI-MedLine.d43.s0|35-36|to|drug
DDI-MedLine.d43.s0|38-48|progression|drug
DDI-MedLine.d43.s0|50-51|as|drug
DDI-MedLine.d43.s0|53-54|an|drug
DDI-MedLine.d43.s0|56-65|expression|drug
DDI-MedLine.d43.s0|67-68|of|drug
DDI-MedLine.d43.s0|70-83|subpopulations|drug
DDI-MedLine.d43.s0|85-86|of|drug
DDI-MedLine.d43.s0|88-96|initiated|drug
DDI-MedLine.d43.s0|98-103|murine|drug
DDI-MedLine.d43.s0|105-109|cells|drug
DDI-MedLine.d43.s0|110-110|.|drug
DDI-MedLine.d43.s1|0-8|Currently|drug
DDI-MedLine.d43.s1|9-9|,|drug
DDI-MedLine.d43.s1|11-12|it|drug
DDI-MedLine.d43.s1|14-15|is|drug
DDI-MedLine.d43.s1|17-25|conceived|drug
DDI-MedLine.d43.s1|27-30|that|drug
DDI-MedLine.d43.s1|32-32|a|drug
DDI-MedLine.d43.s1|34-39|number|drug
DDI-MedLine.d43.s1|41-42|of|drug
DDI-MedLine.d43.s1|44-49|events|drug
DDI-MedLine.d43.s1|50-50|,|drug
DDI-MedLine.d43.s1|52-53|or|drug
DDI-MedLine.d43.s1|55-58|hits|drug
DDI-MedLine.d43.s1|59-59|,|drug
DDI-MedLine.d43.s1|61-63|are|drug
DDI-MedLine.d43.s1|65-72|required|drug
DDI-MedLine.d43.s1|74-76|for|drug
DDI-MedLine.d43.s1|78-80|the|drug
DDI-MedLine.d43.s1|82-90|induction|drug
DDI-MedLine.d43.s1|92-93|of|drug
DDI-MedLine.d43.s1|95-100|tumors|drug
DDI-MedLine.d43.s1|102-103|by|drug
DDI-MedLine.d43.s1|105-112|chemical|drug
DDI-MedLine.d43.s1|114-119|agents|drug
DDI-MedLine.d43.s1|120-120|.|drug
DDI-MedLine.d43.s2|0-2|The|drug
DDI-MedLine.d43.s2|4-8|first|drug
DDI-MedLine.d43.s2|10-14|phase|drug
DDI-MedLine.d43.s2|16-17|of|drug
DDI-MedLine.d43.s2|19-22|this|drug
DDI-MedLine.d43.s2|24-31|sequence|drug
DDI-MedLine.d43.s2|32-32|,|drug
DDI-MedLine.d43.s2|34-43|initiation|drug
DDI-MedLine.d43.s2|44-44|,|drug
DDI-MedLine.d43.s2|46-47|is|drug
DDI-MedLine.d43.s2|49-58|considered|drug
DDI-MedLine.d43.s2|60-61|to|drug
DDI-MedLine.d43.s2|63-68|result|drug
DDI-MedLine.d43.s2|70-73|from|drug
DDI-MedLine.d43.s2|75-76|at|drug
DDI-MedLine.d43.s2|78-82|least|drug
DDI-MedLine.d43.s2|84-86|one|drug
DDI-MedLine.d43.s2|88-92|event|drug
DDI-MedLine.d43.s2|94-95|in|drug
DDI-MedLine.d43.s2|97-99|the|drug
DDI-MedLine.d43.s2|101-107|genetic|drug
DDI-MedLine.d43.s2|109-117|apparatus|drug
DDI-MedLine.d43.s2|118-118|.|drug
DDI-MedLine.d43.s3|0-7|Analyses|drug
DDI-MedLine.d43.s3|9-10|of|drug
DDI-MedLine.d43.s3|12-15|this|drug
DDI-MedLine.d43.s3|17-24|sequence|drug
DDI-MedLine.d43.s3|25-25|,|drug
DDI-MedLine.d43.s3|27-33|however|drug
DDI-MedLine.d43.s3|34-34|,|drug
DDI-MedLine.d43.s3|36-42|usually|drug
DDI-MedLine.d43.s3|44-47|give|drug
DDI-MedLine.d43.s3|49-54|little|drug
DDI-MedLine.d43.s3|56-68|consideration|drug
DDI-MedLine.d43.s3|70-71|to|drug
DDI-MedLine.d43.s3|73-75|the|drug
DDI-MedLine.d43.s3|77-82|nature|drug
DDI-MedLine.d43.s3|84-85|of|drug
DDI-MedLine.d43.s3|87-89|the|drug
DDI-MedLine.d43.s3|91-96|target|drug
DDI-MedLine.d43.s3|98-101|cell|drug
DDI-MedLine.d43.s3|103-104|or|drug
DDI-MedLine.d43.s3|106-107|to|drug
DDI-MedLine.d43.s3|109-111|the|drug
DDI-MedLine.d43.s3|113-127|characteristics|drug
DDI-MedLine.d43.s3|129-130|of|drug
DDI-MedLine.d43.s3|132-134|the|drug
DDI-MedLine.d43.s3|136-144|resultant|drug
DDI-MedLine.d43.s3|146-151|tumors|drug
DDI-MedLine.d43.s3|152-152|.|drug
DDI-MedLine.d43.s4|0-13|Vesselinovitch|drug
DDI-MedLine.d43.s4|15-16|et|drug
DDI-MedLine.d43.s4|18-19|al|drug
DDI-MedLine.d43.s4|20-20|.|drug
DDI-MedLine.d43.s5|0-0|(|drug
DDI-MedLine.d43.s5|1-6|Cancer|drug
DDI-MedLine.d43.s5|8-11|Res.|drug
DDI-MedLine.d43.s5|12-12|,|drug
DDI-MedLine.d43.s5|14-15|38|drug
DDI-MedLine.d43.s5|16-16|:|drug
DDI-MedLine.d43.s5|18-26|2003-2010|drug
DDI-MedLine.d43.s5|27-27|,|drug
DDI-MedLine.d43.s5|29-32|1978|drug
DDI-MedLine.d43.s5|33-33|)|drug
DDI-MedLine.d43.s5|35-38|have|drug
DDI-MedLine.d43.s5|40-47|reported|drug
DDI-MedLine.d43.s5|49-52|that|drug
DDI-MedLine.d43.s5|54-54|a|drug
DDI-MedLine.d43.s5|56-61|single|drug
DDI-MedLine.d43.s5|62-62|,|drug
DDI-MedLine.d43.s5|64-68|small|drug
DDI-MedLine.d43.s5|70-74|pulse|drug
DDI-MedLine.d43.s5|76-77|of|drug
DDI-MedLine.d43.s5|79-88|carcinogen|drug
DDI-MedLine.d43.s5|90-92|can|drug
DDI-MedLine.d43.s5|94-99|induce|drug
DDI-MedLine.d43.s5|101-105|early|drug
DDI-MedLine.d43.s5|107-109|and|drug
DDI-MedLine.d43.s5|111-118|numerous|drug
DDI-MedLine.d43.s5|120-124|liver|drug
DDI-MedLine.d43.s5|126-131|tumors|drug
DDI-MedLine.d43.s5|133-136|when|drug
DDI-MedLine.d43.s5|138-149|administered|drug
DDI-MedLine.d43.s5|151-160|neonatally|drug
DDI-MedLine.d43.s5|162-163|to|drug
DDI-MedLine.d43.s5|165-168|mice|drug
DDI-MedLine.d43.s5|170-173|with|drug
DDI-MedLine.d43.s5|175-175|a|drug
DDI-MedLine.d43.s5|177-183|genetic|drug
DDI-MedLine.d43.s5|185-198|predisposition|drug
DDI-MedLine.d43.s5|200-201|to|drug
DDI-MedLine.d43.s5|203-221|hepatotumorigenesis|drug
DDI-MedLine.d43.s5|222-222|.|drug
DDI-MedLine.d43.s6|0-1|In|drug
DDI-MedLine.d43.s6|3-5|the|drug
DDI-MedLine.d43.s6|7-13|current|drug
DDI-MedLine.d43.s6|15-19|study|drug
DDI-MedLine.d43.s6|20-20|,|drug
DDI-MedLine.d43.s6|22-24|the|drug
DDI-MedLine.d43.s6|26-39|nonpredisposed|drug
DDI-MedLine.d43.s6|41-46|strain|drug
DDI-MedLine.d43.s6|48-55|C57BL/6N|drug
DDI-MedLine.d43.s6|57-59|was|drug
DDI-MedLine.d43.s6|61-64|also|drug
DDI-MedLine.d43.s6|66-70|shown|drug
DDI-MedLine.d43.s6|72-73|to|drug
DDI-MedLine.d43.s6|75-76|be|drug
DDI-MedLine.d43.s6|78-83|highly|drug
DDI-MedLine.d43.s6|85-95|susceptible|drug
DDI-MedLine.d43.s6|97-98|to|drug
DDI-MedLine.d43.s6|100-117|diethylnitrosamine|drug
DDI-MedLine.d43.s6|119-124|during|drug
DDI-MedLine.d43.s6|126-128|the|drug
DDI-MedLine.d43.s6|130-137|neonatal|drug
DDI-MedLine.d43.s6|139-144|period|drug
DDI-MedLine.d43.s6|145-145|.|drug
DDI-MedLine.d43.s7|0-7|C57BL/6N|drug
DDI-MedLine.d43.s7|9-20|demonstrated|drug
DDI-MedLine.d43.s7|22-26|large|drug
DDI-MedLine.d43.s7|28-34|numbers|drug
DDI-MedLine.d43.s7|36-37|of|drug
DDI-MedLine.d43.s7|39-41|two|drug
DDI-MedLine.d43.s7|43-44|of|drug
DDI-MedLine.d43.s7|46-48|the|drug
DDI-MedLine.d43.s7|50-54|three|drug
DDI-MedLine.d43.s7|56-60|types|drug
DDI-MedLine.d43.s7|62-63|of|drug
DDI-MedLine.d43.s7|65-69|liver|drug
DDI-MedLine.d43.s7|71-76|tumors|drug
DDI-MedLine.d43.s7|78-81|seen|drug
DDI-MedLine.d43.s7|83-84|in|drug
DDI-MedLine.d43.s7|86-91|livers|drug
DDI-MedLine.d43.s7|93-94|of|drug
DDI-MedLine.d43.s7|96-106|genetically|drug
DDI-MedLine.d43.s7|108-118|predisposed|drug
DDI-MedLine.d43.s7|120-123|mice|drug
DDI-MedLine.d43.s7|124-124|,|drug
DDI-MedLine.d43.s7|126-128|one|drug
DDI-MedLine.d43.s7|130-131|of|drug
DDI-MedLine.d43.s7|133-137|which|drug
DDI-MedLine.d43.s7|139-146|required|drug
DDI-MedLine.d43.s7|148-150|the|drug
DDI-MedLine.d43.s7|152-161|additional|drug
DDI-MedLine.d43.s7|163-170|stimulus|drug
DDI-MedLine.d43.s7|172-173|of|drug
DDI-MedLine.d43.s7|175-181|dietary|drug
DDI-MedLine.d43.s7|183-195|phenobarbital|drug
DDI-MedLine.d43.s7|197-199|for|drug
DDI-MedLine.d43.s7|201-206|growth|drug
DDI-MedLine.d43.s7|207-207|.|drug
DDI-MedLine.d43.s8|0-5|Tumors|drug
DDI-MedLine.d43.s8|7-8|of|drug
DDI-MedLine.d43.s8|10-13|more|drug
DDI-MedLine.d43.s8|15-23|malignant|drug
DDI-MedLine.d43.s8|25-33|phenotype|drug
DDI-MedLine.d43.s8|35-38|were|drug
DDI-MedLine.d43.s8|40-51|demonstrated|drug
DDI-MedLine.d43.s8|53-56|only|drug
DDI-MedLine.d43.s8|58-59|in|drug
DDI-MedLine.d43.s8|61-71|genetically|drug
DDI-MedLine.d43.s8|73-83|predisposed|drug
DDI-MedLine.d43.s8|85-88|mice|drug
DDI-MedLine.d43.s8|90-90|(|drug
DDI-MedLine.d43.s8|91-98|C57BL/6N|drug
DDI-MedLine.d43.s8|100-100|X|drug
DDI-MedLine.d43.s8|102-108|C3H/HeN|drug
DDI-MedLine.d43.s8|110-111|F1|drug
DDI-MedLine.d43.s8|112-112|)|drug
DDI-MedLine.d43.s8|114-117|that|drug
DDI-MedLine.d43.s8|119-126|received|drug
DDI-MedLine.d43.s8|128-130|one|drug
DDI-MedLine.d43.s8|132-135|dose|drug
DDI-MedLine.d43.s8|137-138|of|drug
DDI-MedLine.d43.s8|140-149|carcinogen|drug
DDI-MedLine.d43.s8|150-150|.|drug
DDI-MedLine.d43.s9|0-4|These|drug
DDI-MedLine.d43.s9|6-13|findings|drug
DDI-MedLine.d43.s9|15-21|suggest|drug
DDI-MedLine.d43.s9|23-26|that|drug
DDI-MedLine.d43.s9|28-30|the|drug
DDI-MedLine.d43.s9|32-40|phenotype|drug
DDI-MedLine.d43.s9|42-43|of|drug
DDI-MedLine.d43.s9|45-45|a|drug
DDI-MedLine.d43.s9|47-51|tumor|drug
DDI-MedLine.d43.s9|53-56|that|drug
DDI-MedLine.d43.s9|58-64|results|drug
DDI-MedLine.d43.s9|66-69|from|drug
DDI-MedLine.d43.s9|71-71|a|drug
DDI-MedLine.d43.s9|73-77|pulse|drug
DDI-MedLine.d43.s9|79-80|of|drug
DDI-MedLine.d43.s9|82-82|a|drug
DDI-MedLine.d43.s9|84-91|chemical|drug
DDI-MedLine.d43.s9|93-102|carcinogen|drug
DDI-MedLine.d43.s9|104-106|may|drug
DDI-MedLine.d43.s9|108-113|depend|drug
DDI-MedLine.d43.s9|115-118|upon|drug
DDI-MedLine.d43.s9|120-122|the|drug
DDI-MedLine.d43.s9|124-129|target|drug
DDI-MedLine.d43.s9|131-134|cell|drug
DDI-MedLine.d43.s9|135-135|.|drug
DDI-MedLine.d43.s10|0-2|The|drug
DDI-MedLine.d43.s10|4-12|initiated|drug
DDI-MedLine.d43.s10|14-18|cells|drug
DDI-MedLine.d43.s10|20-23|that|drug
DDI-MedLine.d43.s10|25-30|result|drug
DDI-MedLine.d43.s10|32-35|from|drug
DDI-MedLine.d43.s10|37-40|this|drug
DDI-MedLine.d43.s10|42-44|hit|drug
DDI-MedLine.d43.s10|46-48|may|drug
DDI-MedLine.d43.s10|50-53|vary|drug
DDI-MedLine.d43.s10|55-58|from|drug
DDI-MedLine.d43.s10|60-64|those|drug
DDI-MedLine.d43.s10|66-69|that|drug
DDI-MedLine.d43.s10|71-81|demonstrate|drug
DDI-MedLine.d43.s10|83-86|very|drug
DDI-MedLine.d43.s10|88-93|little|drug
DDI-MedLine.d43.s10|95-105|progression|drug
DDI-MedLine.d43.s10|107-108|in|drug
DDI-MedLine.d43.s10|110-113|cell|drug
DDI-MedLine.d43.s10|115-118|type|drug
DDI-MedLine.d43.s10|120-122|and|drug
DDI-MedLine.d43.s10|124-126|may|drug
DDI-MedLine.d43.s10|128-129|or|drug
DDI-MedLine.d43.s10|131-133|may|drug
DDI-MedLine.d43.s10|135-137|not|drug
DDI-MedLine.d43.s10|139-145|require|drug
DDI-MedLine.d43.s10|147-155|exogenous|drug
DDI-MedLine.d43.s10|157-167|enhancement|drug
DDI-MedLine.d43.s10|169-170|of|drug
DDI-MedLine.d43.s10|172-177|growth|drug
DDI-MedLine.d43.s10|179-180|to|drug
DDI-MedLine.d43.s10|182-186|those|drug
DDI-MedLine.d43.s10|188-191|that|drug
DDI-MedLine.d43.s10|193-195|can|drug
DDI-MedLine.d43.s10|197-204|progress|drug
DDI-MedLine.d43.s10|206-209|very|drug
DDI-MedLine.d43.s10|211-217|rapidly|drug
DDI-MedLine.d43.s10|219-220|to|drug
DDI-MedLine.d43.s10|222-226|fully|drug
DDI-MedLine.d43.s10|228-236|malignant|drug
DDI-MedLine.d43.s10|238-245|behavior|drug
DDI-MedLine.d43.s10|246-246|.|drug
DDI-MedLine.d43.s11|0-2|The|drug
DDI-MedLine.d43.s11|4-9|latter|drug
DDI-MedLine.d43.s11|11-15|might|drug
DDI-MedLine.d43.s11|17-21|arise|drug
DDI-MedLine.d43.s11|23-26|from|drug
DDI-MedLine.d43.s11|28-28|a|drug
DDI-MedLine.d43.s11|30-32|hit|drug
DDI-MedLine.d43.s11|34-35|in|drug
DDI-MedLine.d43.s11|37-37|a|drug
DDI-MedLine.d43.s11|39-49|genetically|drug
DDI-MedLine.d43.s11|51-59|initiated|drug
DDI-MedLine.d43.s11|61-64|cell|drug
DDI-MedLine.d43.s11|65-65|,|drug
DDI-MedLine.d43.s11|67-69|the|drug
DDI-MedLine.d43.s11|71-76|result|drug
DDI-MedLine.d43.s11|78-79|of|drug
DDI-MedLine.d43.s11|81-85|which|drug
DDI-MedLine.d43.s11|87-88|is|drug
DDI-MedLine.d43.s11|90-90|a|drug
DDI-MedLine.d43.s11|92-95|more|drug
DDI-MedLine.d43.s11|97-101|rapid|drug
DDI-MedLine.d43.s11|103-113|progression|drug
DDI-MedLine.d43.s11|115-116|in|drug
DDI-MedLine.d43.s11|118-122|tumor|drug
DDI-MedLine.d43.s11|124-127|type|drug
DDI-MedLine.d43.s11|128-128|.|drug
DDI-MedLine.d86.s0|0-14|Pharmacokinetic|drug
DDI-MedLine.d86.s0|16-26|interaction|drug
DDI-MedLine.d86.s0|28-34|between|drug
DDI-MedLine.d86.s0|36-41|single|drug
DDI-MedLine.d86.s0|43-46|oral|drug
DDI-MedLine.d86.s0|48-52|doses|drug
DDI-MedLine.d86.s0|54-55|of|drug
DDI-MedLine.d86.s0|57-65|diltiazem|drug
DDI-MedLine.d86.s0|67-69|and|drug
DDI-MedLine.d86.s0|71-79|sirolimus|drug
DDI-MedLine.d86.s0|81-82|in|drug
DDI-MedLine.d86.s0|84-90|healthy|drug
DDI-MedLine.d86.s0|92-101|volunteers|drug
DDI-MedLine.d86.s0|102-102|.|drug
DDI-MedLine.d86.s1|0-2|AIM|drug
DDI-MedLine.d86.s1|4-6|AND|drug
DDI-MedLine.d86.s1|8-17|BACKGROUND|drug
DDI-MedLine.d86.s1|18-18|:|drug
DDI-MedLine.d86.s1|20-22|The|drug
DDI-MedLine.d86.s1|24-38|pharmacokinetic|drug
DDI-MedLine.d86.s1|40-50|interaction|drug
DDI-MedLine.d86.s1|52-58|between|drug
DDI-MedLine.d86.s1|60-68|sirolimus|drug
DDI-MedLine.d86.s1|69-69|,|drug
DDI-MedLine.d86.s1|71-71|a|drug
DDI-MedLine.d86.s1|73-81|macrolide|drug
DDI-MedLine.d86.s1|83-99|immunosuppressant|drug
DDI-MedLine.d86.s1|101-111|metabolized|drug
DDI-MedLine.d86.s1|113-114|by|drug
DDI-MedLine.d86.s1|116-121|CYP3A4|drug
DDI-MedLine.d86.s1|122-122|,|drug
DDI-MedLine.d86.s1|124-126|and|drug
DDI-MedLine.d86.s1|128-130|the|drug
DDI-MedLine.d86.s1|132-138|calcium|drug
DDI-MedLine.d86.s1|140-146|channel|drug
DDI-MedLine.d86.s1|148-154|blocker|drug
DDI-MedLine.d86.s1|156-164|diltiazem|drug
DDI-MedLine.d86.s1|166-168|was|drug
DDI-MedLine.d86.s1|170-176|studied|drug
DDI-MedLine.d86.s1|178-179|in|drug
DDI-MedLine.d86.s1|181-182|18|drug
DDI-MedLine.d86.s1|184-190|healthy|drug
DDI-MedLine.d86.s1|192-199|subjects|drug
DDI-MedLine.d86.s1|200-200|.|drug
DDI-MedLine.d86.s2|0-6|Several|drug
DDI-MedLine.d86.s2|8-17|clinically|drug
DDI-MedLine.d86.s2|19-27|important|drug
DDI-MedLine.d86.s2|29-40|interactions|drug
DDI-MedLine.d86.s2|42-45|have|drug
DDI-MedLine.d86.s2|47-56|previously|drug
DDI-MedLine.d86.s2|58-61|been|drug
DDI-MedLine.d86.s2|63-70|reported|drug
DDI-MedLine.d86.s2|72-74|for|drug
DDI-MedLine.d86.s2|76-80|other|drug
DDI-MedLine.d86.s2|82-98|immunosuppressive|drug
DDI-MedLine.d86.s2|100-104|drugs|drug
DDI-MedLine.d86.s2|106-109|that|drug
DDI-MedLine.d86.s2|111-113|are|drug
DDI-MedLine.d86.s2|115-125|metabolized|drug
DDI-MedLine.d86.s2|127-128|by|drug
DDI-MedLine.d86.s2|130-132|the|drug
DDI-MedLine.d86.s2|134-137|same|drug
DDI-MedLine.d86.s2|139-144|enzyme|drug
DDI-MedLine.d86.s2|146-148|and|drug
DDI-MedLine.d86.s2|150-152|for|drug
DDI-MedLine.d86.s2|154-160|calcium|drug
DDI-MedLine.d86.s2|162-172|antagonists|drug
DDI-MedLine.d86.s2|173-173|.|drug
DDI-MedLine.d86.s3|0-6|METHODS|drug
DDI-MedLine.d86.s3|7-7|:|drug
DDI-MedLine.d86.s3|9-15|Healthy|drug
DDI-MedLine.d86.s3|17-24|subjects|drug
DDI-MedLine.d86.s3|26-28|who|drug
DDI-MedLine.d86.s3|30-33|were|drug
DDI-MedLine.d86.s3|35-36|20|drug
DDI-MedLine.d86.s3|38-39|to|drug
DDI-MedLine.d86.s3|41-42|43|drug
DDI-MedLine.d86.s3|44-48|years|drug
DDI-MedLine.d86.s3|50-52|old|drug
DDI-MedLine.d86.s3|54-65|participated|drug
DDI-MedLine.d86.s3|67-68|in|drug
DDI-MedLine.d86.s3|70-71|an|drug
DDI-MedLine.d86.s3|73-76|open|drug
DDI-MedLine.d86.s3|77-77|,|drug
DDI-MedLine.d86.s3|79-90|three-period|drug
DDI-MedLine.d86.s3|91-91|,|drug
DDI-MedLine.d86.s3|93-102|randomized|drug
DDI-MedLine.d86.s3|103-103|,|drug
DDI-MedLine.d86.s3|105-113|crossover|drug
DDI-MedLine.d86.s3|115-119|study|drug
DDI-MedLine.d86.s3|121-122|of|drug
DDI-MedLine.d86.s3|124-126|the|drug
DDI-MedLine.d86.s3|128-143|pharmacokinetics|drug
DDI-MedLine.d86.s3|145-146|of|drug
DDI-MedLine.d86.s3|148-148|a|drug
DDI-MedLine.d86.s3|150-155|single|drug
DDI-MedLine.d86.s3|157-161|10-mg|drug
DDI-MedLine.d86.s3|163-166|oral|drug
DDI-MedLine.d86.s3|168-171|dose|drug
DDI-MedLine.d86.s3|173-174|of|drug
DDI-MedLine.d86.s3|176-184|sirolimus|drug
DDI-MedLine.d86.s3|185-185|,|drug
DDI-MedLine.d86.s3|187-187|a|drug
DDI-MedLine.d86.s3|189-194|single|drug
DDI-MedLine.d86.s3|196-199|oral|drug
DDI-MedLine.d86.s3|201-206|120-mg|drug
DDI-MedLine.d86.s3|208-211|dose|drug
DDI-MedLine.d86.s3|213-214|of|drug
DDI-MedLine.d86.s3|216-224|diltiazem|drug
DDI-MedLine.d86.s3|225-225|,|drug
DDI-MedLine.d86.s3|227-229|and|drug
DDI-MedLine.d86.s3|231-233|the|drug
DDI-MedLine.d86.s3|235-237|two|drug
DDI-MedLine.d86.s3|239-243|drugs|drug
DDI-MedLine.d86.s3|245-249|given|drug
DDI-MedLine.d86.s3|251-258|together|drug
DDI-MedLine.d86.s3|259-259|.|drug
DDI-MedLine.d86.s4|0-2|The|drug
DDI-MedLine.d86.s4|4-8|three|drug
DDI-MedLine.d86.s4|10-14|study|drug
DDI-MedLine.d86.s4|16-22|periods|drug
DDI-MedLine.d86.s4|24-27|were|drug
DDI-MedLine.d86.s4|29-37|separated|drug
DDI-MedLine.d86.s4|39-40|by|drug
DDI-MedLine.d86.s4|42-42|a|drug
DDI-MedLine.d86.s4|44-49|21-day|drug
DDI-MedLine.d86.s4|51-57|washout|drug
DDI-MedLine.d86.s4|59-63|phase|drug
DDI-MedLine.d86.s4|64-64|.|drug
DDI-MedLine.d86.s5|0-6|RESULTS|drug
DDI-MedLine.d86.s5|7-7|:|drug
DDI-MedLine.d86.s5|9-11|The|drug
DDI-MedLine.d86.s5|13-21|geometric|drug
DDI-MedLine.d86.s5|23-26|mean|drug
DDI-MedLine.d86.s5|28-28|(|drug
DDI-MedLine.d86.s5|29-30|90|drug
DDI-MedLine.d86.s5|31-31|%|drug
DDI-MedLine.d86.s5|33-42|confidence|drug
DDI-MedLine.d86.s5|44-51|interval|drug
DDI-MedLine.d86.s5|52-52|)|drug
DDI-MedLine.d86.s5|54-58|whole|drug
DDI-MedLine.d86.s5|60-64|blood|drug
DDI-MedLine.d86.s5|66-74|sirolimus|drug
DDI-MedLine.d86.s5|76-79|area|drug
DDI-MedLine.d86.s5|81-85|under|drug
DDI-MedLine.d86.s5|87-89|the|drug
DDI-MedLine.d86.s5|91-96|plasma|drug
DDI-MedLine.d86.s5|98-110|concentration|drug
DDI-MedLine.d86.s5|112-121|time-curve|drug
DDI-MedLine.d86.s5|123-131|increased|drug
DDI-MedLine.d86.s5|133-134|60|drug
DDI-MedLine.d86.s5|135-135|%|drug
DDI-MedLine.d86.s5|137-137|(|drug
DDI-MedLine.d86.s5|138-139|35|drug
DDI-MedLine.d86.s5|140-140|%|drug
DDI-MedLine.d86.s5|141-143|-90|drug
DDI-MedLine.d86.s5|144-144|%|drug
DDI-MedLine.d86.s5|145-145|)|drug
DDI-MedLine.d86.s5|146-146|,|drug
DDI-MedLine.d86.s5|148-151|from|drug
DDI-MedLine.d86.s5|153-155|736|drug
DDI-MedLine.d86.s5|157-158|to|drug
DDI-MedLine.d86.s5|160-163|1178|drug
DDI-MedLine.d86.s5|165-166|ng|drug
DDI-MedLine.d86.s5|168-168|x|drug
DDI-MedLine.d86.s5|170-173|h/mL|drug
DDI-MedLine.d86.s5|174-174|,|drug
DDI-MedLine.d86.s5|176-178|and|drug
DDI-MedLine.d86.s5|180-186|maximum|drug
DDI-MedLine.d86.s5|188-200|concentration|drug
DDI-MedLine.d86.s5|202-210|increased|drug
DDI-MedLine.d86.s5|212-213|43|drug
DDI-MedLine.d86.s5|214-214|%|drug
DDI-MedLine.d86.s5|216-216|(|drug
DDI-MedLine.d86.s5|217-218|14|drug
DDI-MedLine.d86.s5|219-219|%|drug
DDI-MedLine.d86.s5|220-222|-81|drug
DDI-MedLine.d86.s5|223-223|%|drug
DDI-MedLine.d86.s5|224-224|)|drug
DDI-MedLine.d86.s5|225-225|,|drug
DDI-MedLine.d86.s5|227-230|from|drug
DDI-MedLine.d86.s5|232-233|67|drug
DDI-MedLine.d86.s5|235-236|to|drug
DDI-MedLine.d86.s5|238-239|96|drug
DDI-MedLine.d86.s5|241-245|ng/mL|drug
DDI-MedLine.d86.s5|246-246|,|drug
DDI-MedLine.d86.s5|248-251|with|drug
DDI-MedLine.d86.s5|253-261|diltiazem|drug
DDI-MedLine.d86.s5|263-278|coadministration|drug
DDI-MedLine.d86.s5|279-279|,|drug
DDI-MedLine.d86.s5|281-287|whereas|drug
DDI-MedLine.d86.s5|289-291|the|drug
DDI-MedLine.d86.s5|293-296|mean|drug
DDI-MedLine.d86.s5|298-308|elimination|drug
DDI-MedLine.d86.s5|310-318|half-life|drug
DDI-MedLine.d86.s5|320-321|of|drug
DDI-MedLine.d86.s5|323-331|sirolimus|drug
DDI-MedLine.d86.s5|333-341|decreased|drug
DDI-MedLine.d86.s5|343-350|slightly|drug
DDI-MedLine.d86.s5|351-351|,|drug
DDI-MedLine.d86.s5|353-356|from|drug
DDI-MedLine.d86.s5|358-359|79|drug
DDI-MedLine.d86.s5|361-362|to|drug
DDI-MedLine.d86.s5|364-365|67|drug
DDI-MedLine.d86.s5|367-371|hours|drug
DDI-MedLine.d86.s5|372-372|.|drug
DDI-MedLine.d86.s6|0-7|Apparent|drug
DDI-MedLine.d86.s6|9-12|oral|drug
DDI-MedLine.d86.s6|14-22|clearance|drug
DDI-MedLine.d86.s6|24-26|and|drug
DDI-MedLine.d86.s6|28-33|volume|drug
DDI-MedLine.d86.s6|35-36|of|drug
DDI-MedLine.d86.s6|38-49|distribution|drug
DDI-MedLine.d86.s6|51-52|of|drug
DDI-MedLine.d86.s6|54-62|sirolimus|drug
DDI-MedLine.d86.s6|64-72|decreased|drug
DDI-MedLine.d86.s6|74-77|with|drug
DDI-MedLine.d86.s6|79-80|38|drug
DDI-MedLine.d86.s6|81-81|%|drug
DDI-MedLine.d86.s6|83-85|and|drug
DDI-MedLine.d86.s6|87-88|45|drug
DDI-MedLine.d86.s6|89-89|%|drug
DDI-MedLine.d86.s6|90-90|,|drug
DDI-MedLine.d86.s6|92-103|respectively|drug
DDI-MedLine.d86.s6|104-104|,|drug
DDI-MedLine.d86.s6|106-109|when|drug
DDI-MedLine.d86.s6|111-119|sirolimus|drug
DDI-MedLine.d86.s6|121-123|was|drug
DDI-MedLine.d86.s6|125-129|given|drug
DDI-MedLine.d86.s6|131-134|with|drug
DDI-MedLine.d86.s6|136-144|diltiazem|drug
DDI-MedLine.d86.s6|145-145|.|drug
DDI-MedLine.d86.s7|0-2|The|drug
DDI-MedLine.d86.s7|4-9|plasma|drug
DDI-MedLine.d86.s7|11-17|maximum|drug
DDI-MedLine.d86.s7|19-31|concentration|drug
DDI-MedLine.d86.s7|33-35|and|drug
DDI-MedLine.d86.s7|37-40|area|drug
DDI-MedLine.d86.s7|42-46|under|drug
DDI-MedLine.d86.s7|48-50|the|drug
DDI-MedLine.d86.s7|52-57|plasma|drug
DDI-MedLine.d86.s7|59-76|concentration-time|drug
DDI-MedLine.d86.s7|78-82|curve|drug
DDI-MedLine.d86.s7|84-85|of|drug
DDI-MedLine.d86.s7|87-95|diltiazem|drug
DDI-MedLine.d86.s7|96-96|,|drug
DDI-MedLine.d86.s7|98-115|desacetyldiltiazem|drug
DDI-MedLine.d86.s7|116-116|,|drug
DDI-MedLine.d86.s7|118-120|and|drug
DDI-MedLine.d86.s7|122-139|desmethyldiltiazem|drug
DDI-MedLine.d86.s7|141-144|were|drug
DDI-MedLine.d86.s7|146-154|unchanged|drug
DDI-MedLine.d86.s7|156-160|after|drug
DDI-MedLine.d86.s7|162-177|coadministration|drug
DDI-MedLine.d86.s7|179-180|of|drug
DDI-MedLine.d86.s7|182-190|sirolimus|drug
DDI-MedLine.d86.s7|191-191|,|drug
DDI-MedLine.d86.s7|193-195|and|drug
DDI-MedLine.d86.s7|197-198|no|drug
DDI-MedLine.d86.s7|200-211|potentiation|drug
DDI-MedLine.d86.s7|213-214|of|drug
DDI-MedLine.d86.s7|216-218|the|drug
DDI-MedLine.d86.s7|220-226|effects|drug
DDI-MedLine.d86.s7|228-229|of|drug
DDI-MedLine.d86.s7|231-239|diltiazem|drug
DDI-MedLine.d86.s7|241-242|on|drug
DDI-MedLine.d86.s7|244-252|diastolic|drug
DDI-MedLine.d86.s7|254-255|or|drug
DDI-MedLine.d86.s7|257-264|systolic|drug
DDI-MedLine.d86.s7|266-270|blood|drug
DDI-MedLine.d86.s7|272-279|pressure|drug
DDI-MedLine.d86.s7|281-282|or|drug
DDI-MedLine.d86.s7|284-285|on|drug
DDI-MedLine.d86.s7|287-289|the|drug
DDI-MedLine.d86.s7|291-310|electrocardiographic|drug
DDI-MedLine.d86.s7|312-321|parameters|drug
DDI-MedLine.d86.s7|323-325|was|drug
DDI-MedLine.d86.s7|327-330|seen|drug
DDI-MedLine.d86.s7|331-331|.|drug
DDI-MedLine.d86.s8|0-10|CONCLUSIONS|drug
DDI-MedLine.d86.s8|11-11|:|drug
DDI-MedLine.d86.s8|13-23|Single-dose|drug
DDI-MedLine.d86.s8|25-33|diltiazem|drug
DDI-MedLine.d86.s8|35-50|coadministration|drug
DDI-MedLine.d86.s8|52-56|leads|drug
DDI-MedLine.d86.s8|58-59|to|drug
DDI-MedLine.d86.s8|61-66|higher|drug
DDI-MedLine.d86.s8|68-76|sirolimus|drug
DDI-MedLine.d86.s8|78-85|exposure|drug
DDI-MedLine.d86.s8|86-86|,|drug
DDI-MedLine.d86.s8|88-97|presumably|drug
DDI-MedLine.d86.s8|99-100|by|drug
DDI-MedLine.d86.s8|102-111|inhibition|drug
DDI-MedLine.d86.s8|113-114|of|drug
DDI-MedLine.d86.s8|116-118|the|drug
DDI-MedLine.d86.s8|120-129|first-pass|drug
DDI-MedLine.d86.s8|131-140|metabolism|drug
DDI-MedLine.d86.s8|142-143|of|drug
DDI-MedLine.d86.s8|145-153|sirolimus|drug
DDI-MedLine.d86.s8|154-154|.|drug
DDI-MedLine.d86.s9|0-6|Because|drug
DDI-MedLine.d86.s9|8-9|of|drug
DDI-MedLine.d86.s9|11-13|the|drug
DDI-MedLine.d86.s9|15-24|pronounced|drug
DDI-MedLine.d86.s9|26-37|intersubject|drug
DDI-MedLine.d86.s9|39-49|variability|drug
DDI-MedLine.d86.s9|51-52|in|drug
DDI-MedLine.d86.s9|54-56|the|drug
DDI-MedLine.d86.s9|58-63|extent|drug
DDI-MedLine.d86.s9|65-66|of|drug
DDI-MedLine.d86.s9|68-70|the|drug
DDI-MedLine.d86.s9|72-90|sirolimus-diltiazem|drug
DDI-MedLine.d86.s9|92-102|interaction|drug
DDI-MedLine.d86.s9|103-103|,|drug
DDI-MedLine.d86.s9|105-109|whole|drug
DDI-MedLine.d86.s9|111-115|blood|drug
DDI-MedLine.d86.s9|117-125|sirolimus|drug
DDI-MedLine.d86.s9|127-140|concentrations|drug
DDI-MedLine.d86.s9|142-147|should|drug
DDI-MedLine.d86.s9|149-150|be|drug
DDI-MedLine.d86.s9|152-160|monitored|drug
DDI-MedLine.d86.s9|162-168|closely|drug
DDI-MedLine.d86.s9|170-171|in|drug
DDI-MedLine.d86.s9|173-180|patients|drug
DDI-MedLine.d86.s9|182-188|treated|drug
DDI-MedLine.d86.s9|190-193|with|drug
DDI-MedLine.d86.s9|195-197|the|drug
DDI-MedLine.d86.s9|199-201|two|drug
DDI-MedLine.d86.s9|203-207|drugs|drug
DDI-MedLine.d86.s9|208-208|.|drug
DDI-DrugBank.d17.s0|0-13|Anticoagulants|group
DDI-DrugBank.d17.s0|14-14|,|drug
DDI-DrugBank.d17.s0|16-19|oral|drug
DDI-DrugBank.d17.s1|0-0|(|drug
DDI-DrugBank.d17.s1|1-7|Effects|drug
DDI-DrugBank.d17.s1|9-11|may|drug
DDI-DrugBank.d17.s1|13-14|be|drug
DDI-DrugBank.d17.s1|16-24|decreased|drug
DDI-DrugBank.d17.s1|26-29|when|drug
DDI-DrugBank.d17.s1|31-34|used|drug
DDI-DrugBank.d17.s1|36-47|concurrently|drug
DDI-DrugBank.d17.s1|49-52|with|drug
DDI-DrugBank.d17.s1|54-61|thiazide|drug
DDI-DrugBank.d17.s1|63-71|diuretics|drug
DDI-DrugBank.d17.s1|72-72|;|drug
DDI-DrugBank.d17.s2|0-5|dosage|drug
DDI-DrugBank.d17.s2|7-17|adjustments|drug
DDI-DrugBank.d17.s2|19-21|may|drug
DDI-DrugBank.d17.s2|23-24|be|drug
DDI-DrugBank.d17.s2|26-34|necessary|drug
DDI-DrugBank.d17.s2|35-35|.|drug
DDI-DrugBank.d17.s2|36-36|)|drug
DDI-DrugBank.d17.s3|0-7|Antigout|drug
DDI-DrugBank.d17.s3|9-19|medications|drug
DDI-DrugBank.d17.s4|0-0|(|drug
DDI-DrugBank.d17.s4|1-8|Thiazide|drug
DDI-DrugBank.d17.s4|10-18|diuretics|drug
DDI-DrugBank.d17.s4|20-22|may|drug
DDI-DrugBank.d17.s4|24-28|raise|drug
DDI-DrugBank.d17.s4|30-32|the|drug
DDI-DrugBank.d17.s4|34-38|level|drug
DDI-DrugBank.d17.s4|40-41|of|drug
DDI-DrugBank.d17.s4|43-47|blood|drug
DDI-DrugBank.d17.s4|49-52|uric|drug
DDI-DrugBank.d17.s4|54-57|acid|drug
DDI-DrugBank.d17.s4|58-58|;|drug
DDI-DrugBank.d17.s5|0-5|dosage|drug
DDI-DrugBank.d17.s5|7-16|adjustment|drug
DDI-DrugBank.d17.s5|18-19|of|drug
DDI-DrugBank.d17.s5|21-28|antigout|drug
DDI-DrugBank.d17.s5|30-40|medications|drug
DDI-DrugBank.d17.s5|42-44|may|drug
DDI-DrugBank.d17.s5|46-47|be|drug
DDI-DrugBank.d17.s5|49-57|necessary|drug
DDI-DrugBank.d17.s5|59-60|to|drug
DDI-DrugBank.d17.s5|62-68|control|drug
DDI-DrugBank.d17.s5|70-82|hyperuricemia|drug
DDI-DrugBank.d17.s5|84-86|and|drug
DDI-DrugBank.d17.s5|88-91|gout|drug
DDI-DrugBank.d17.s5|92-92|.|drug
DDI-DrugBank.d17.s5|93-93|)|drug
DDI-DrugBank.d17.s6|0-15|Antihypertensive|drug
DDI-DrugBank.d17.s6|17-27|medications|drug
DDI-DrugBank.d17.s6|28-28|,|drug
DDI-DrugBank.d17.s6|30-34|other|drug
DDI-DrugBank.d17.s6|35-35|,|drug
DDI-DrugBank.d17.s6|37-46|especially|drug
DDI-DrugBank.d17.s6|48-56|diazoxide|drug
DDI-DrugBank.d17.s6|57-57|,|drug
DDI-DrugBank.d17.s6|59-60|or|drug
DDI-DrugBank.d17.s6|62-74|preanesthetic|drug
DDI-DrugBank.d17.s6|76-78|and|drug
DDI-DrugBank.d17.s6|80-89|anesthetic|drug
DDI-DrugBank.d17.s6|91-96|agents|drug
DDI-DrugBank.d17.s6|98-101|used|drug
DDI-DrugBank.d17.s6|103-104|in|drug
DDI-DrugBank.d17.s6|106-112|surgery|drug
DDI-DrugBank.d17.s6|114-115|or|drug
DDI-DrugBank.d17.s6|117-131|skeletal-muscle|drug
DDI-DrugBank.d17.s6|133-141|relaxants|drug
DDI-DrugBank.d17.s6|142-142|,|drug
DDI-DrugBank.d17.s6|144-158|nondepolarizing|drug
DDI-DrugBank.d17.s6|159-159|,|drug
DDI-DrugBank.d17.s6|161-164|used|drug
DDI-DrugBank.d17.s6|166-167|in|drug
DDI-DrugBank.d17.s6|169-175|surgery|drug
DDI-DrugBank.d17.s7|0-0|(|drug
DDI-DrugBank.d17.s7|1-7|Effects|drug
DDI-DrugBank.d17.s7|9-11|may|drug
DDI-DrugBank.d17.s7|13-14|be|drug
DDI-DrugBank.d17.s7|16-26|potentiated|drug
DDI-DrugBank.d17.s7|28-31|when|drug
DDI-DrugBank.d17.s7|33-36|used|drug
DDI-DrugBank.d17.s7|38-49|concurrently|drug
DDI-DrugBank.d17.s7|51-54|with|drug
DDI-DrugBank.d17.s7|56-63|thiazide|drug
DDI-DrugBank.d17.s7|65-73|diuretics|drug
DDI-DrugBank.d17.s7|74-74|;|drug
DDI-DrugBank.d17.s8|0-5|dosage|drug
DDI-DrugBank.d17.s8|7-17|adjustments|drug
DDI-DrugBank.d17.s8|19-21|may|drug
DDI-DrugBank.d17.s8|23-24|be|drug
DDI-DrugBank.d17.s8|26-34|necessary|drug
DDI-DrugBank.d17.s8|35-35|.|drug
DDI-DrugBank.d17.s8|36-36|)|drug
DDI-DrugBank.d17.s9|0-11|Amphotericin|drug
DDI-DrugBank.d17.s9|13-13|B|drug
DDI-DrugBank.d17.s9|15-16|or|drug
DDI-DrugBank.d17.s9|18-32|Corticosteroids|group
DDI-DrugBank.d17.s9|34-35|or|drug
DDI-DrugBank.d17.s9|37-49|Corticotropin|drug
DDI-DrugBank.d17.s9|51-51|(|drug
DDI-DrugBank.d17.s9|52-55|ACTH|drug
DDI-DrugBank.d17.s9|56-56|)|drug
DDI-DrugBank.d17.s10|0-0|(|drug
DDI-DrugBank.d17.s10|1-10|Concurrent|drug
DDI-DrugBank.d17.s10|12-14|use|drug
DDI-DrugBank.d17.s10|16-19|with|drug
DDI-DrugBank.d17.s10|21-28|thiazide|drug
DDI-DrugBank.d17.s10|30-38|diuretics|drug
DDI-DrugBank.d17.s10|40-42|may|drug
DDI-DrugBank.d17.s10|44-52|intensify|drug
DDI-DrugBank.d17.s10|54-64|electrolyte|drug
DDI-DrugBank.d17.s10|66-74|imbalance|drug
DDI-DrugBank.d17.s10|75-75|,|drug
DDI-DrugBank.d17.s10|77-88|particularly|drug
DDI-DrugBank.d17.s10|90-100|hypokalemia|drug
DDI-DrugBank.d17.s10|101-101|.|drug
DDI-DrugBank.d17.s10|102-102|)|drug
DDI-DrugBank.d17.s11|0-6|Cardiac|drug
DDI-DrugBank.d17.s11|8-17|glycosides|drug
DDI-DrugBank.d17.s12|0-0|(|drug
DDI-DrugBank.d17.s12|1-10|Concurrent|drug
DDI-DrugBank.d17.s12|12-14|use|drug
DDI-DrugBank.d17.s12|16-19|with|drug
DDI-DrugBank.d17.s12|21-28|thiazide|drug
DDI-DrugBank.d17.s12|30-38|diuretics|drug
DDI-DrugBank.d17.s12|40-42|may|drug
DDI-DrugBank.d17.s12|44-50|enhance|drug
DDI-DrugBank.d17.s12|52-54|the|drug
DDI-DrugBank.d17.s12|56-66|possibility|drug
DDI-DrugBank.d17.s12|68-69|of|drug
DDI-DrugBank.d17.s12|71-79|digitalis|drug
DDI-DrugBank.d17.s12|81-88|toxicity|drug
DDI-DrugBank.d17.s12|90-99|associated|drug
DDI-DrugBank.d17.s12|101-104|with|drug
DDI-DrugBank.d17.s12|106-116|hypokalemia|drug
DDI-DrugBank.d17.s12|117-117|.|drug
DDI-DrugBank.d17.s12|118-118|)|drug
DDI-DrugBank.d17.s13|0-9|Colestipol|drug
DDI-DrugBank.d17.s14|0-0|(|drug
DDI-DrugBank.d17.s14|1-3|May|drug
DDI-DrugBank.d17.s14|5-11|inhibit|drug
DDI-DrugBank.d17.s14|13-28|gastrointestinal|drug
DDI-DrugBank.d17.s14|30-39|absorption|drug
DDI-DrugBank.d17.s14|41-42|of|drug
DDI-DrugBank.d17.s14|44-46|the|drug
DDI-DrugBank.d17.s14|48-55|thiazide|drug
DDI-DrugBank.d17.s14|57-65|diuretics|drug
DDI-DrugBank.d17.s14|66-66|;|drug
DDI-DrugBank.d17.s15|0-13|administration|drug
DDI-DrugBank.d17.s15|15-15|1|drug
DDI-DrugBank.d17.s15|17-20|hour|drug
DDI-DrugBank.d17.s15|22-27|before|drug
DDI-DrugBank.d17.s15|29-30|or|drug
DDI-DrugBank.d17.s15|32-32|4|drug
DDI-DrugBank.d17.s15|34-38|hours|drug
DDI-DrugBank.d17.s15|40-44|after|drug
DDI-DrugBank.d17.s15|46-55|colestipol|drug
DDI-DrugBank.d17.s15|57-58|is|drug
DDI-DrugBank.d17.s15|60-70|recommended|drug
DDI-DrugBank.d17.s15|71-71|.|drug
DDI-DrugBank.d17.s15|72-72|)|drug
DDI-DrugBank.d17.s16|0-12|Hypoglycemics|drug
DDI-DrugBank.d17.s17|0-0|(|drug
DDI-DrugBank.d17.s17|1-8|Thiazide|drug
DDI-DrugBank.d17.s17|10-18|diuretics|drug
DDI-DrugBank.d17.s17|20-22|may|drug
DDI-DrugBank.d17.s17|24-28|raise|drug
DDI-DrugBank.d17.s17|30-34|blood|drug
DDI-DrugBank.d17.s17|36-42|glucose|drug
DDI-DrugBank.d17.s17|44-49|levels|drug
DDI-DrugBank.d17.s17|50-50|;|drug
DDI-DrugBank.d17.s18|0-2|for|drug
DDI-DrugBank.d17.s18|4-14|adult-onset|drug
DDI-DrugBank.d17.s18|16-24|diabetics|drug
DDI-DrugBank.d17.s18|25-25|,|drug
DDI-DrugBank.d17.s18|27-32|dosage|drug
DDI-DrugBank.d17.s18|34-43|adjustment|drug
DDI-DrugBank.d17.s18|45-46|of|drug
DDI-DrugBank.d17.s18|48-59|hypoglycemic|drug
DDI-DrugBank.d17.s18|61-71|medications|drug
DDI-DrugBank.d17.s18|73-75|may|drug
DDI-DrugBank.d17.s18|77-78|be|drug
DDI-DrugBank.d17.s18|80-88|necessary|drug
DDI-DrugBank.d17.s18|90-95|during|drug
DDI-DrugBank.d17.s18|97-99|and|drug
DDI-DrugBank.d17.s18|101-105|after|drug
DDI-DrugBank.d17.s18|107-114|thiazide|drug
DDI-DrugBank.d17.s18|116-123|diuretic|drug
DDI-DrugBank.d17.s18|125-131|therapy|drug
DDI-DrugBank.d17.s18|132-132|;|drug
DDI-DrugBank.d17.s19|0-6|insulin|drug
DDI-DrugBank.d17.s19|8-19|requirements|drug
DDI-DrugBank.d17.s19|21-23|may|drug
DDI-DrugBank.d17.s19|25-26|be|drug
DDI-DrugBank.d17.s19|28-36|increased|drug
DDI-DrugBank.d17.s19|37-37|,|drug
DDI-DrugBank.d17.s19|39-47|decreased|drug
DDI-DrugBank.d17.s19|48-48|,|drug
DDI-DrugBank.d17.s19|50-51|or|drug
DDI-DrugBank.d17.s19|53-61|unchanged|drug
DDI-DrugBank.d17.s19|62-62|.|drug
DDI-DrugBank.d17.s19|63-63|)|drug
DDI-DrugBank.d17.s20|0-6|Lithium|brand
DDI-DrugBank.d17.s20|8-12|salts|drug
DDI-DrugBank.d17.s21|0-0|(|drug
DDI-DrugBank.d17.s21|1-10|Concurrent|drug
DDI-DrugBank.d17.s21|12-14|use|drug
DDI-DrugBank.d17.s21|16-19|with|drug
DDI-DrugBank.d17.s21|21-28|thiazide|drug
DDI-DrugBank.d17.s21|30-38|diuretics|drug
DDI-DrugBank.d17.s21|40-41|is|drug
DDI-DrugBank.d17.s21|43-45|not|drug
DDI-DrugBank.d17.s21|47-57|recommended|drug
DDI-DrugBank.d17.s21|58-58|,|drug
DDI-DrugBank.d17.s21|60-61|as|drug
DDI-DrugBank.d17.s21|63-66|they|drug
DDI-DrugBank.d17.s21|68-70|may|drug
DDI-DrugBank.d17.s21|72-78|provoke|drug
DDI-DrugBank.d17.s21|80-86|lithium|drug
DDI-DrugBank.d17.s21|88-95|toxicity|drug
DDI-DrugBank.d17.s21|97-103|because|drug
DDI-DrugBank.d17.s21|105-106|of|drug
DDI-DrugBank.d17.s21|108-114|reduced|drug
DDI-DrugBank.d17.s21|116-120|renal|drug
DDI-DrugBank.d17.s21|122-130|clearance|drug
DDI-DrugBank.d17.s21|131-131|.|drug
DDI-DrugBank.d17.s21|132-132|)|drug
DDI-DrugBank.d17.s22|0-10|Methenamine|drug
DDI-DrugBank.d17.s23|0-0|(|drug
DDI-DrugBank.d17.s23|1-13|Effectiveness|drug
DDI-DrugBank.d17.s23|15-17|may|drug
DDI-DrugBank.d17.s23|19-20|be|drug
DDI-DrugBank.d17.s23|22-30|decreased|drug
DDI-DrugBank.d17.s23|32-35|when|drug
DDI-DrugBank.d17.s23|37-40|used|drug
DDI-DrugBank.d17.s23|42-53|concurrently|drug
DDI-DrugBank.d17.s23|55-58|with|drug
DDI-DrugBank.d17.s23|60-67|thiazide|drug
DDI-DrugBank.d17.s23|69-77|diuretics|drug
DDI-DrugBank.d17.s23|79-85|because|drug
DDI-DrugBank.d17.s23|87-88|of|drug
DDI-DrugBank.d17.s23|90-103|alkalinization|drug
DDI-DrugBank.d17.s23|105-106|of|drug
DDI-DrugBank.d17.s23|108-110|the|drug
DDI-DrugBank.d17.s23|112-116|urine|drug
DDI-DrugBank.d17.s23|117-117|.|drug
DDI-DrugBank.d17.s23|118-118|)|drug
DDI-DrugBank.d17.s24|0-11|Nonsteroidal|drug
DDI-DrugBank.d17.s24|13-29|anti-inflammatory|drug
DDI-DrugBank.d17.s24|31-36|agents|drug
DDI-DrugBank.d17.s25|0-0|(|drug
DDI-DrugBank.d17.s25|1-2|In|drug
DDI-DrugBank.d17.s25|4-7|some|drug
DDI-DrugBank.d17.s25|9-16|patients|drug
DDI-DrugBank.d17.s25|17-17|,|drug
DDI-DrugBank.d17.s25|19-21|the|drug
DDI-DrugBank.d17.s25|23-31|steroidal|drug
DDI-DrugBank.d17.s25|33-49|anti-inflammatory|drug
DDI-DrugBank.d17.s25|51-55|agent|drug
DDI-DrugBank.d17.s25|57-59|can|drug
DDI-DrugBank.d17.s25|61-66|reduce|drug
DDI-DrugBank.d17.s25|68-70|the|drug
DDI-DrugBank.d17.s25|72-79|diuretic|drug
DDI-DrugBank.d17.s25|80-80|,|drug
DDI-DrugBank.d17.s25|82-92|natriuretic|drug
DDI-DrugBank.d17.s25|93-93|,|drug
DDI-DrugBank.d17.s25|95-97|and|drug
DDI-DrugBank.d17.s25|99-114|antihypertensive|drug
DDI-DrugBank.d17.s25|116-122|effects|drug
DDI-DrugBank.d17.s25|124-125|of|drug
DDI-DrugBank.d17.s25|127-130|loop|drug
DDI-DrugBank.d17.s25|131-131|,|drug
DDI-DrugBank.d17.s25|133-141|potassium|drug
DDI-DrugBank.d17.s25|143-149|sparing|drug
DDI-DrugBank.d17.s25|150-150|,|drug
DDI-DrugBank.d17.s25|152-154|and|drug
DDI-DrugBank.d17.s25|156-163|thiazide|drug
DDI-DrugBank.d17.s25|165-173|diuretics|drug
DDI-DrugBank.d17.s25|174-174|.|drug
DDI-DrugBank.d17.s26|0-8|Therefore|drug
DDI-DrugBank.d17.s26|9-9|,|drug
DDI-DrugBank.d17.s26|11-14|when|drug
DDI-DrugBank.d17.s26|16-33|hydroflumethiazide|drug
DDI-DrugBank.d17.s26|35-37|and|drug
DDI-DrugBank.d17.s26|39-50|nonsteroidal|drug
DDI-DrugBank.d17.s26|52-68|anti-inflammatory|drug
DDI-DrugBank.d17.s26|70-75|agents|drug
DDI-DrugBank.d17.s26|77-79|are|drug
DDI-DrugBank.d17.s26|81-84|used|drug
DDI-DrugBank.d17.s26|86-98|concomitantly|drug
DDI-DrugBank.d17.s26|99-99|,|drug
DDI-DrugBank.d17.s26|101-103|the|drug
DDI-DrugBank.d17.s26|105-111|patient|drug
DDI-DrugBank.d17.s26|113-118|should|drug
DDI-DrugBank.d17.s26|120-121|be|drug
DDI-DrugBank.d17.s26|123-130|observed|drug
DDI-DrugBank.d17.s26|132-138|closely|drug
DDI-DrugBank.d17.s26|140-141|to|drug
DDI-DrugBank.d17.s26|143-151|determine|drug
DDI-DrugBank.d17.s26|153-154|if|drug
DDI-DrugBank.d17.s26|156-158|the|drug
DDI-DrugBank.d17.s26|160-166|desired|drug
DDI-DrugBank.d17.s26|168-173|effect|drug
DDI-DrugBank.d17.s26|175-176|of|drug
DDI-DrugBank.d17.s26|178-180|the|drug
DDI-DrugBank.d17.s26|182-189|diuretic|drug
DDI-DrugBank.d17.s26|191-192|is|drug
DDI-DrugBank.d17.s26|194-201|obtained|drug
DDI-DrugBank.d17.s26|202-202|.|drug
DDI-DrugBank.d17.s26|203-203|)|drug
DDI-DrugBank.d17.s27|0-13|Norepinephrine|brand
DDI-DrugBank.d17.s28|0-0|(|drug
DDI-DrugBank.d17.s28|1-9|Thiazides|group
DDI-DrugBank.d17.s28|11-13|may|drug
DDI-DrugBank.d17.s28|15-22|decrease|drug
DDI-DrugBank.d17.s28|24-31|arterial|drug
DDI-DrugBank.d17.s28|33-46|responsiveness|drug
DDI-DrugBank.d17.s28|48-49|to|drug
DDI-DrugBank.d17.s28|51-64|norepinephrine|drug
DDI-DrugBank.d17.s28|65-65|.|drug
DDI-DrugBank.d17.s29|0-3|This|drug
DDI-DrugBank.d17.s29|5-14|diminution|drug
DDI-DrugBank.d17.s29|16-17|is|drug
DDI-DrugBank.d17.s29|19-21|not|drug
DDI-DrugBank.d17.s29|23-32|sufficient|drug
DDI-DrugBank.d17.s29|34-35|to|drug
DDI-DrugBank.d17.s29|37-44|preclude|drug
DDI-DrugBank.d17.s29|46-58|effectiveness|drug
DDI-DrugBank.d17.s29|60-61|of|drug
DDI-DrugBank.d17.s29|63-65|the|drug
DDI-DrugBank.d17.s29|67-73|pressor|drug
DDI-DrugBank.d17.s29|75-79|agent|drug
DDI-DrugBank.d17.s29|81-83|for|drug
DDI-DrugBank.d17.s29|85-95|therapeutic|drug
DDI-DrugBank.d17.s29|97-99|use|drug
DDI-DrugBank.d17.s29|100-100|.|drug
DDI-DrugBank.d17.s29|101-101|)|drug
DDI-DrugBank.d17.s30|0-11|Tubocurarine|drug
DDI-DrugBank.d17.s31|0-0|(|drug
DDI-DrugBank.d17.s31|1-8|Thiazide|drug
DDI-DrugBank.d17.s31|10-14|drugs|drug
DDI-DrugBank.d17.s31|16-18|may|drug
DDI-DrugBank.d17.s31|20-27|increase|drug
DDI-DrugBank.d17.s31|29-31|the|drug
DDI-DrugBank.d17.s31|33-46|responsiveness|drug
DDI-DrugBank.d17.s31|48-49|to|drug
DDI-DrugBank.d17.s31|51-62|tubocurarine|drug
DDI-DrugBank.d17.s31|63-63|.|drug
DDI-DrugBank.d17.s31|64-64|)|drug
DDI-DrugBank.d17.s32|0-9|DIAGNOSTIC|drug
DDI-DrugBank.d17.s32|11-22|INTERFERENCE|drug
DDI-DrugBank.d17.s32|24-27|With|drug
DDI-DrugBank.d17.s32|29-36|expected|drug
DDI-DrugBank.d17.s32|38-48|physiologic|drug
DDI-DrugBank.d17.s32|50-56|effects|drug
DDI-DrugBank.d17.s32|57-57|:|drug
DDI-DrugBank.d17.s32|59-63|Blood|group
DDI-DrugBank.d17.s32|65-67|and|drug
DDI-DrugBank.d17.s32|69-73|urine|drug
DDI-DrugBank.d17.s32|75-81|glucose|drug
DDI-DrugBank.d17.s32|83-88|levels|drug
DDI-DrugBank.d17.s32|90-90|(|drug
DDI-DrugBank.d17.s32|91-97|usually|drug
DDI-DrugBank.d17.s32|99-102|only|drug
DDI-DrugBank.d17.s32|104-105|in|drug
DDI-DrugBank.d17.s32|107-114|patients|drug
DDI-DrugBank.d17.s32|116-119|with|drug
DDI-DrugBank.d17.s32|121-121|a|drug
DDI-DrugBank.d17.s32|123-136|predisposition|drug
DDI-DrugBank.d17.s32|138-140|for|drug
DDI-DrugBank.d17.s32|142-148|glucose|drug
DDI-DrugBank.d17.s32|150-160|intolerance|drug
DDI-DrugBank.d17.s32|161-161|)|drug
DDI-DrugBank.d17.s32|163-165|and|drug
DDI-DrugBank.d17.s32|167-171|Serum|group
DDI-DrugBank.d17.s32|173-181|bilirubin|drug
DDI-DrugBank.d17.s32|183-188|levels|drug
DDI-DrugBank.d17.s32|190-190|(|drug
DDI-DrugBank.d17.s32|191-192|by|drug
DDI-DrugBank.d17.s32|194-205|displacement|drug
DDI-DrugBank.d17.s32|207-210|from|drug
DDI-DrugBank.d17.s32|212-218|albumin|drug
DDI-DrugBank.d17.s32|220-226|binding|drug
DDI-DrugBank.d17.s32|227-227|)|drug
DDI-DrugBank.d17.s32|229-231|and|drug
DDI-DrugBank.d17.s32|233-237|Serum|group
DDI-DrugBank.d17.s32|239-245|calcium|drug
DDI-DrugBank.d17.s32|247-252|levels|drug
DDI-DrugBank.d17.s32|254-254|(|drug
DDI-DrugBank.d17.s32|255-262|thiazide|drug
DDI-DrugBank.d17.s32|264-272|diuretics|drug
DDI-DrugBank.d17.s32|274-279|should|drug
DDI-DrugBank.d17.s32|281-282|be|drug
DDI-DrugBank.d17.s32|284-295|discontinued|drug
DDI-DrugBank.d17.s32|297-302|before|drug
DDI-DrugBank.d17.s32|304-323|parathyroid-function|drug
DDI-DrugBank.d17.s32|325-329|tests|drug
DDI-DrugBank.d17.s32|331-333|are|drug
DDI-DrugBank.d17.s32|335-341|carried|drug
DDI-DrugBank.d17.s32|343-345|out|drug
DDI-DrugBank.d17.s32|346-346|)|drug
DDI-DrugBank.d17.s32|348-350|and|drug
DDI-DrugBank.d17.s32|352-356|Serum|group
DDI-DrugBank.d17.s32|358-361|uric|drug
DDI-DrugBank.d17.s32|363-366|acid|drug
DDI-DrugBank.d17.s32|368-373|levels|drug
DDI-DrugBank.d17.s32|375-375|(|drug
DDI-DrugBank.d17.s32|376-378|may|drug
DDI-DrugBank.d17.s32|380-381|be|drug
DDI-DrugBank.d17.s32|383-391|increased|drug
DDI-DrugBank.d17.s32|392-392|)|drug
DDI-DrugBank.d17.s32|394-398|Serum|group
DDI-DrugBank.d17.s32|400-408|magnesium|drug
DDI-DrugBank.d17.s32|409-409|,|drug
DDI-DrugBank.d17.s32|411-419|potassium|drug
DDI-DrugBank.d17.s32|420-420|,|drug
DDI-DrugBank.d17.s32|422-424|and|drug
DDI-DrugBank.d17.s32|426-431|sodium|drug
DDI-DrugBank.d17.s32|433-438|levels|drug
DDI-DrugBank.d17.s32|440-440|(|drug
DDI-DrugBank.d17.s32|441-443|may|drug
DDI-DrugBank.d17.s32|445-446|be|drug
DDI-DrugBank.d17.s32|448-456|decreased|drug
DDI-DrugBank.d17.s32|457-457|;|drug
DDI-DrugBank.d17.s33|0-4|serum|drug
DDI-DrugBank.d17.s33|6-14|magnesium|drug
DDI-DrugBank.d17.s33|16-21|levels|drug
DDI-DrugBank.d17.s33|23-25|may|drug
DDI-DrugBank.d17.s33|27-34|increase|drug
DDI-DrugBank.d17.s33|36-37|in|drug
DDI-DrugBank.d17.s33|39-44|uremic|drug
DDI-DrugBank.d17.s33|46-53|patients|drug
DDI-DrugBank.d17.s33|54-54|)|drug
DDI-DrugBank.d17.s33|56-60|Serum|group
DDI-DrugBank.d17.s33|62-74|protein-bound|drug
DDI-DrugBank.d17.s33|76-81|iodine|drug
DDI-DrugBank.d17.s33|83-83|(|drug
DDI-DrugBank.d17.s33|84-86|PBI|drug
DDI-DrugBank.d17.s33|87-87|)|drug
DDI-DrugBank.d17.s33|89-94|levels|drug
DDI-DrugBank.d17.s33|96-96|(|drug
DDI-DrugBank.d17.s33|97-99|may|drug
DDI-DrugBank.d17.s33|101-102|be|drug
DDI-DrugBank.d17.s33|104-112|decreased|drug
DDI-DrugBank.d17.s33|113-113|)|drug
DDI-DrugBank.d17.s33|115-123|Thiazides|group
DDI-DrugBank.d17.s33|125-130|should|drug
DDI-DrugBank.d17.s33|132-133|be|drug
DDI-DrugBank.d17.s33|135-146|discontinued|drug
DDI-DrugBank.d17.s33|148-153|before|drug
DDI-DrugBank.d17.s33|155-162|carrying|drug
DDI-DrugBank.d17.s33|164-166|out|drug
DDI-DrugBank.d17.s33|168-172|tests|drug
DDI-DrugBank.d17.s33|174-176|for|drug
DDI-DrugBank.d17.s33|178-188|parathyroid|drug
DDI-DrugBank.d17.s33|190-197|function|drug
DDI-DrugBank.d17.s33|198-198|.|drug
DDI-MedLine.d74.s0|0-8|Responses|drug
DDI-MedLine.d74.s0|10-11|to|drug
DDI-MedLine.d74.s0|13-20|arginine|drug
DDI-MedLine.d74.s0|22-23|of|drug
DDI-MedLine.d74.s0|25-27|the|drug
DDI-MedLine.d74.s0|29-36|perfused|drug
DDI-MedLine.d74.s0|38-45|pancreas|drug
DDI-MedLine.d74.s0|47-48|of|drug
DDI-MedLine.d74.s0|50-52|the|drug
DDI-MedLine.d74.s0|54-64|genetically|drug
DDI-MedLine.d74.s0|66-73|diabetic|drug
DDI-MedLine.d74.s0|75-81|Chinese|drug
DDI-MedLine.d74.s0|83-89|hamster|drug
DDI-MedLine.d74.s0|90-90|.|drug
DDI-MedLine.d74.s1|0-9|Nonketotic|drug
DDI-MedLine.d74.s1|10-10|,|drug
DDI-MedLine.d74.s1|12-22|genetically|drug
DDI-MedLine.d74.s1|24-31|diabetic|drug
DDI-MedLine.d74.s1|33-38|Cinese|drug
DDI-MedLine.d74.s1|40-47|hamsters|drug
DDI-MedLine.d74.s1|49-52|show|drug
DDI-MedLine.d74.s1|54-62|subnormal|drug
DDI-MedLine.d74.s1|64-73|pancreatic|drug
DDI-MedLine.d74.s1|75-81|insulin|drug
DDI-MedLine.d74.s1|83-89|release|drug
DDI-MedLine.d74.s1|91-93|and|drug
DDI-MedLine.d74.s1|95-102|impaired|drug
DDI-MedLine.d74.s1|104-114|suppression|drug
DDI-MedLine.d74.s1|116-117|of|drug
DDI-MedLine.d74.s1|119-126|glucagon|drug
DDI-MedLine.d74.s1|128-129|in|drug
DDI-MedLine.d74.s1|131-138|response|drug
DDI-MedLine.d74.s1|140-141|to|drug
DDI-MedLine.d74.s1|143-149|glucose|drug
DDI-MedLine.d74.s1|150-150|.|drug
DDI-MedLine.d74.s2|0-1|To|drug
DDI-MedLine.d74.s2|3-7|study|drug
DDI-MedLine.d74.s2|9-11|the|drug
DDI-MedLine.d74.s2|13-22|pancreatic|drug
DDI-MedLine.d74.s2|24-30|effects|drug
DDI-MedLine.d74.s2|32-33|of|drug
DDI-MedLine.d74.s2|35-39|other|drug
DDI-MedLine.d74.s2|41-46|agents|drug
DDI-MedLine.d74.s2|47-47|,|drug
DDI-MedLine.d74.s2|49-55|dynamic|drug
DDI-MedLine.d74.s2|57-63|insulin|drug
DDI-MedLine.d74.s2|65-67|and|drug
DDI-MedLine.d74.s2|69-76|glucagon|drug
DDI-MedLine.d74.s2|78-84|release|drug
DDI-MedLine.d74.s2|86-88|was|drug
DDI-MedLine.d74.s2|90-97|measured|drug
DDI-MedLine.d74.s2|99-102|from|drug
DDI-MedLine.d74.s2|104-106|the|drug
DDI-MedLine.d74.s2|108-109|in|drug
DDI-MedLine.d74.s2|111-115|vitro|drug
DDI-MedLine.d74.s2|117-124|perfused|drug
DDI-MedLine.d74.s2|126-135|pancreases|drug
DDI-MedLine.d74.s2|137-138|of|drug
DDI-MedLine.d74.s2|140-145|normal|drug
DDI-MedLine.d74.s2|147-149|and|drug
DDI-MedLine.d74.s2|151-158|diabetic|drug
DDI-MedLine.d74.s2|160-166|Chinese|drug
DDI-MedLine.d74.s2|168-175|hamsters|drug
DDI-MedLine.d74.s2|177-178|in|drug
DDI-MedLine.d74.s2|180-187|response|drug
DDI-MedLine.d74.s2|189-190|to|drug
DDI-MedLine.d74.s2|192-198|various|drug
DDI-MedLine.d74.s2|200-211|combinations|drug
DDI-MedLine.d74.s2|213-214|of|drug
DDI-MedLine.d74.s2|216-223|arginine|drug
DDI-MedLine.d74.s2|225-225|(|drug
DDI-MedLine.d74.s2|226-229|20mM|drug
DDI-MedLine.d74.s2|230-230|)|drug
DDI-MedLine.d74.s2|231-231|,|drug
DDI-MedLine.d74.s2|233-239|glucose|drug
DDI-MedLine.d74.s2|241-241|(|drug
DDI-MedLine.d74.s2|242-244|100|drug
DDI-MedLine.d74.s2|246-247|or|drug
DDI-MedLine.d74.s2|249-251|150|drug
DDI-MedLine.d74.s2|253-255|mg.|drug
DDI-MedLine.d74.s2|257-259|per|drug
DDI-MedLine.d74.s2|261-263|100|drug
DDI-MedLine.d74.s2|265-267|ml|drug
DDI-MedLine.d74.s2|268-268|.|drug
DDI-MedLine.d74.s2|269-269|)|drug
DDI-MedLine.d74.s2|271-273|,|drug
DDI-MedLine.d74.s2|275-286|and|drug
DDI-MedLine.d74.s2|288-288|theophylline|drug
DDI-MedLine.d74.s2|289-290|(|drug
DDI-MedLine.d74.s2|292-293|10|drug
DDI-MedLine.d74.s2|294-294|mM|drug
DDI-MedLine.d74.s2|295-295|)|drug
DDI-MedLine.d74.s3|0-11|Theophylline|brand
DDI-MedLine.d74.s3|13-17|alone|drug
DDI-MedLine.d74.s3|19-24|caused|drug
DDI-MedLine.d74.s3|26-34|identical|drug
DDI-MedLine.d74.s3|36-42|insulin|drug
DDI-MedLine.d74.s3|44-46|and|drug
DDI-MedLine.d74.s3|48-55|glucagon|drug
DDI-MedLine.d74.s3|57-63|release|drug
DDI-MedLine.d74.s3|65-66|in|drug
DDI-MedLine.d74.s3|68-76|diabetics|drug
DDI-MedLine.d74.s3|78-80|and|drug
DDI-MedLine.d74.s3|82-88|normals|drug
DDI-MedLine.d74.s3|89-89|.|drug
DDI-MedLine.d74.s4|0-6|Glucose|brand
DDI-MedLine.d74.s4|7-7|,|drug
DDI-MedLine.d74.s4|9-13|alone|drug
DDI-MedLine.d74.s4|15-17|and|drug
DDI-MedLine.d74.s4|19-20|in|drug
DDI-MedLine.d74.s4|22-24|the|drug
DDI-MedLine.d74.s4|26-33|presence|drug
DDI-MedLine.d74.s4|35-36|of|drug
DDI-MedLine.d74.s4|38-49|theophylline|drug
DDI-MedLine.d74.s4|50-50|,|drug
DDI-MedLine.d74.s4|52-57|caused|drug
DDI-MedLine.d74.s4|59-67|subnormal|drug
DDI-MedLine.d74.s4|69-75|insulin|drug
DDI-MedLine.d74.s4|77-83|release|drug
DDI-MedLine.d74.s4|85-87|and|drug
DDI-MedLine.d74.s4|89-92|less|drug
DDI-MedLine.d74.s4|94-104|suppression|drug
DDI-MedLine.d74.s4|106-107|of|drug
DDI-MedLine.d74.s4|109-116|glucagon|drug
DDI-MedLine.d74.s4|118-124|release|drug
DDI-MedLine.d74.s4|126-127|in|drug
DDI-MedLine.d74.s4|129-131|the|drug
DDI-MedLine.d74.s4|133-142|diabectics|drug
DDI-MedLine.d74.s4|144-147|than|drug
DDI-MedLine.d74.s4|149-150|in|drug
DDI-MedLine.d74.s4|152-154|the|drug
DDI-MedLine.d74.s4|156-162|normals|drug
DDI-MedLine.d74.s4|163-163|.|drug
DDI-MedLine.d74.s5|0-7|Arginine|brand
DDI-MedLine.d74.s5|8-8|,|drug
DDI-MedLine.d74.s5|10-11|in|drug
DDI-MedLine.d74.s5|13-15|the|drug
DDI-MedLine.d74.s5|17-24|presence|drug
DDI-MedLine.d74.s5|26-27|of|drug
DDI-MedLine.d74.s5|29-35|glucose|drug
DDI-MedLine.d74.s5|37-39|and|drug
DDI-MedLine.d74.s5|41-52|theophylline|drug
DDI-MedLine.d74.s5|53-53|,|drug
DDI-MedLine.d74.s5|55-60|caused|drug
DDI-MedLine.d74.s5|62-70|excessive|drug
DDI-MedLine.d74.s5|72-79|glucagon|drug
DDI-MedLine.d74.s5|81-87|release|drug
DDI-MedLine.d74.s5|89-91|but|drug
DDI-MedLine.d74.s5|93-98|nearly|drug
DDI-MedLine.d74.s5|100-105|normal|drug
DDI-MedLine.d74.s5|107-113|insulin|drug
DDI-MedLine.d74.s5|115-121|release|drug
DDI-MedLine.d74.s5|123-124|in|drug
DDI-MedLine.d74.s5|126-128|the|drug
DDI-MedLine.d74.s5|130-138|diabetics|drug
DDI-MedLine.d74.s5|139-139|.|drug
DDI-MedLine.d74.s6|0-7|Arginine|brand
DDI-MedLine.d74.s6|8-8|,|drug
DDI-MedLine.d74.s6|10-11|in|drug
DDI-MedLine.d74.s6|13-15|the|drug
DDI-MedLine.d74.s6|17-23|absence|drug
DDI-MedLine.d74.s6|25-26|of|drug
DDI-MedLine.d74.s6|28-34|glucose|drug
DDI-MedLine.d74.s6|36-37|or|drug
DDI-MedLine.d74.s6|39-50|theophylline|drug
DDI-MedLine.d74.s6|51-51|,|drug
DDI-MedLine.d74.s6|53-58|caused|drug
DDI-MedLine.d74.s6|60-68|excessive|drug
DDI-MedLine.d74.s6|70-77|glucagon|drug
DDI-MedLine.d74.s6|79-85|release|drug
DDI-MedLine.d74.s6|87-88|in|drug
DDI-MedLine.d74.s6|90-92|the|drug
DDI-MedLine.d74.s6|94-102|diabetics|drug
DDI-MedLine.d74.s6|104-106|and|drug
DDI-MedLine.d74.s6|108-119|undetectable|drug
DDI-MedLine.d74.s6|121-127|insulin|drug
DDI-MedLine.d74.s6|129-135|release|drug
DDI-MedLine.d74.s6|137-138|in|drug
DDI-MedLine.d74.s6|140-145|either|drug
DDI-MedLine.d74.s6|147-155|diabetics|drug
DDI-MedLine.d74.s6|157-158|or|drug
DDI-MedLine.d74.s6|160-166|normals|drug
DDI-MedLine.d74.s6|167-167|.|drug
DDI-MedLine.d74.s7|0-9|Pancreatic|drug
DDI-MedLine.d74.s7|11-17|content|drug
DDI-MedLine.d74.s7|19-23|after|drug
DDI-MedLine.d74.s7|25-33|perfusion|drug
DDI-MedLine.d74.s7|35-37|did|drug
DDI-MedLine.d74.s7|39-41|not|drug
DDI-MedLine.d74.s7|43-51|correlate|drug
DDI-MedLine.d74.s7|53-56|with|drug
DDI-MedLine.d74.s7|58-64|release|drug
DDI-MedLine.d74.s7|66-71|during|drug
DDI-MedLine.d74.s7|73-81|perfusion|drug
DDI-MedLine.d74.s7|82-82|.|drug
DDI-MedLine.d74.s8|0-7|Infusion|drug
DDI-MedLine.d74.s8|9-10|of|drug
DDI-MedLine.d74.s8|12-19|arginine|drug
DDI-MedLine.d74.s8|21-25|alone|drug
DDI-MedLine.d74.s8|27-34|markedly|drug
DDI-MedLine.d74.s8|36-44|decreased|drug
DDI-MedLine.d74.s8|46-48|the|drug
DDI-MedLine.d74.s8|50-55|amount|drug
DDI-MedLine.d74.s8|57-58|of|drug
DDI-MedLine.d74.s8|60-70|extractable|drug
DDI-MedLine.d74.s8|72-81|pancreatic|drug
DDI-MedLine.d74.s8|83-89|insulin|drug
DDI-MedLine.d74.s8|91-93|and|drug
DDI-MedLine.d74.s8|95-102|glucagon|drug
DDI-MedLine.d74.s8|103-103|.|drug
DDI-MedLine.d74.s9|0-4|These|drug
DDI-MedLine.d74.s9|6-12|results|drug
DDI-MedLine.d74.s9|14-21|indicate|drug
DDI-MedLine.d74.s9|23-26|that|drug
DDI-MedLine.d74.s9|28-30|the|drug
DDI-MedLine.d74.s9|32-41|pancreatic|drug
DDI-MedLine.d74.s9|43-47|alpha|drug
DDI-MedLine.d74.s9|49-52|cell|drug
DDI-MedLine.d74.s9|54-55|of|drug
DDI-MedLine.d74.s9|57-59|the|drug
DDI-MedLine.d74.s9|61-68|diabetic|drug
DDI-MedLine.d74.s9|70-76|Chinese|drug
DDI-MedLine.d74.s9|78-84|hamster|drug
DDI-MedLine.d74.s9|86-93|responds|drug
DDI-MedLine.d74.s9|95-105|excessively|drug
DDI-MedLine.d74.s9|107-108|to|drug
DDI-MedLine.d74.s9|110-117|arginine|drug
DDI-MedLine.d74.s9|118-118|,|drug
DDI-MedLine.d74.s9|120-121|as|drug
DDI-MedLine.d74.s9|123-124|is|drug
DDI-MedLine.d74.s9|126-129|seen|drug
DDI-MedLine.d74.s9|131-132|in|drug
DDI-MedLine.d74.s9|134-136|the|drug
DDI-MedLine.d74.s9|138-142|human|drug
DDI-MedLine.d74.s9|144-151|diabetic|drug
DDI-MedLine.d74.s9|152-152|.|drug
DDI-MedLine.d74.s10|0-3|This|drug
DDI-MedLine.d74.s10|5-10|defect|drug
DDI-MedLine.d74.s10|12-13|is|drug
DDI-MedLine.d74.s10|15-17|not|drug
DDI-MedLine.d74.s10|19-25|related|drug
DDI-MedLine.d74.s10|27-28|to|drug
DDI-MedLine.d74.s10|30-34|acute|drug
DDI-MedLine.d74.s10|36-42|insulin|drug
DDI-MedLine.d74.s10|44-50|release|drug
DDI-MedLine.d74.s10|52-53|or|drug
DDI-MedLine.d74.s10|55-57|the|drug
DDI-MedLine.d74.s10|59-66|presence|drug
DDI-MedLine.d74.s10|68-69|of|drug
DDI-MedLine.d74.s10|71-77|glucose|drug
DDI-MedLine.d74.s10|78-78|.|drug
DDI-MedLine.d74.s11|0-6|Further|drug
DDI-MedLine.d74.s11|7-7|,|drug
DDI-MedLine.d74.s11|9-13|these|drug
DDI-MedLine.d74.s11|15-21|results|drug
DDI-MedLine.d74.s11|23-29|confirm|drug
DDI-MedLine.d74.s11|31-34|that|drug
DDI-MedLine.d74.s11|36-38|the|drug
DDI-MedLine.d74.s11|40-47|diabetic|drug
DDI-MedLine.d74.s11|49-55|Chinese|drug
DDI-MedLine.d74.s11|57-63|hamster|drug
DDI-MedLine.d74.s11|64-65|'s|drug
DDI-MedLine.d74.s11|67-71|alpha|drug
DDI-MedLine.d74.s11|73-75|and|drug
DDI-MedLine.d74.s11|77-80|beta|drug
DDI-MedLine.d74.s11|82-86|cells|drug
DDI-MedLine.d74.s11|88-94|respond|drug
DDI-MedLine.d74.s11|96-103|normally|drug
DDI-MedLine.d74.s11|105-106|to|drug
DDI-MedLine.d74.s11|108-119|theophylline|drug
DDI-MedLine.d74.s11|120-120|,|drug
DDI-MedLine.d74.s11|122-124|but|drug
DDI-MedLine.d74.s11|126-128|are|drug
DDI-MedLine.d74.s11|130-139|relatively|drug
DDI-MedLine.d74.s11|141-151|insensitive|drug
DDI-MedLine.d74.s11|153-154|to|drug
DDI-MedLine.d74.s11|156-162|glucose|drug
DDI-MedLine.d74.s11|163-163|.|drug
DDI-DrugBank.d744.s0|0-10|Acromegalic|drug
DDI-DrugBank.d744.s0|12-19|patients|drug
DDI-DrugBank.d744.s0|21-24|with|drug
DDI-DrugBank.d744.s0|26-33|diabetes|drug
DDI-DrugBank.d744.s0|35-42|mellitus|drug
DDI-DrugBank.d744.s0|44-48|being|drug
DDI-DrugBank.d744.s0|50-56|treated|drug
DDI-DrugBank.d744.s0|58-61|with|drug
DDI-DrugBank.d744.s0|63-69|insulin|drug
DDI-DrugBank.d744.s0|71-76|and/or|drug
DDI-DrugBank.d744.s0|78-81|oral|drug
DDI-DrugBank.d744.s0|83-94|hypoglycemic|drug
DDI-DrugBank.d744.s0|96-101|agents|drug
DDI-DrugBank.d744.s0|103-105|may|drug
DDI-DrugBank.d744.s0|107-113|require|drug
DDI-DrugBank.d744.s0|115-118|dose|drug
DDI-DrugBank.d744.s0|120-129|reductions|drug
DDI-DrugBank.d744.s0|131-132|of|drug
DDI-DrugBank.d744.s0|134-138|these|drug
DDI-DrugBank.d744.s0|140-150|therapeutic|drug
DDI-DrugBank.d744.s0|152-157|agents|drug
DDI-DrugBank.d744.s0|159-163|after|drug
DDI-DrugBank.d744.s0|165-167|the|drug
DDI-DrugBank.d744.s0|169-178|initiation|drug
DDI-DrugBank.d744.s0|180-181|of|drug
DDI-DrugBank.d744.s0|183-189|therapy|drug
DDI-DrugBank.d744.s0|191-194|with|drug
DDI-DrugBank.d744.s0|196-203|SOMAVERT|drug
DDI-DrugBank.d744.s0|204-204|.|drug
DDI-DrugBank.d744.s1|0-1|In|drug
DDI-DrugBank.d744.s1|3-10|clinical|drug
DDI-DrugBank.d744.s1|12-18|studies|drug
DDI-DrugBank.d744.s1|19-19|,|drug
DDI-DrugBank.d744.s1|21-28|patients|drug
DDI-DrugBank.d744.s1|30-31|on|drug
DDI-DrugBank.d744.s1|33-39|opioids|drug
DDI-DrugBank.d744.s1|41-45|often|drug
DDI-DrugBank.d744.s1|47-52|needed|drug
DDI-DrugBank.d744.s1|54-59|higher|drug
DDI-DrugBank.d744.s1|61-65|serum|drug
DDI-DrugBank.d744.s1|67-77|pegvisomant|drug
DDI-DrugBank.d744.s1|79-92|concentrations|drug
DDI-DrugBank.d744.s1|94-95|to|drug
DDI-DrugBank.d744.s1|97-103|achieve|drug
DDI-DrugBank.d744.s1|105-115|appropriate|drug
DDI-DrugBank.d744.s1|117-121|IGF-I|drug
DDI-DrugBank.d744.s1|123-133|suppression|drug
DDI-DrugBank.d744.s1|135-142|compared|drug
DDI-DrugBank.d744.s1|144-147|with|drug
DDI-DrugBank.d744.s1|149-156|patients|drug
DDI-DrugBank.d744.s1|158-160|not|drug
DDI-DrugBank.d744.s1|162-170|receiving|drug
DDI-DrugBank.d744.s1|172-178|opioids|drug
DDI-DrugBank.d744.s1|179-179|.|drug
DDI-DrugBank.d744.s2|0-2|The|drug
DDI-DrugBank.d744.s2|4-12|mechanism|drug
DDI-DrugBank.d744.s2|14-15|of|drug
DDI-DrugBank.d744.s2|17-20|this|drug
DDI-DrugBank.d744.s2|22-32|interaction|drug
DDI-DrugBank.d744.s2|34-35|is|drug
DDI-DrugBank.d744.s2|37-39|not|drug
DDI-DrugBank.d744.s2|41-45|known|drug
DDI-DrugBank.d744.s2|46-46|.|drug
DDI-DrugBank.d171.s0|0-6|Tagamet|brand
DDI-DrugBank.d171.s0|7-7|,|drug
DDI-DrugBank.d171.s0|9-18|apparently|drug
DDI-DrugBank.d171.s0|20-26|through|drug
DDI-DrugBank.d171.s0|28-29|an|drug
DDI-DrugBank.d171.s0|31-36|effect|drug
DDI-DrugBank.d171.s0|38-39|on|drug
DDI-DrugBank.d171.s0|41-47|certain|drug
DDI-DrugBank.d171.s0|49-58|microsomal|drug
DDI-DrugBank.d171.s0|60-65|enzyme|drug
DDI-DrugBank.d171.s0|67-73|systems|drug
DDI-DrugBank.d171.s0|74-74|,|drug
DDI-DrugBank.d171.s0|76-78|has|drug
DDI-DrugBank.d171.s0|80-83|been|drug
DDI-DrugBank.d171.s0|85-92|reported|drug
DDI-DrugBank.d171.s0|94-95|to|drug
DDI-DrugBank.d171.s0|97-102|reduce|drug
DDI-DrugBank.d171.s0|104-106|the|drug
DDI-DrugBank.d171.s0|108-114|hepatic|drug
DDI-DrugBank.d171.s0|116-125|metabolism|drug
DDI-DrugBank.d171.s0|127-128|of|drug
DDI-DrugBank.d171.s0|130-142|warfarin-type|drug
DDI-DrugBank.d171.s0|144-157|anticoagulants|drug
DDI-DrugBank.d171.s0|158-158|,|drug
DDI-DrugBank.d171.s0|160-168|phenytoin|drug
DDI-DrugBank.d171.s0|169-169|,|drug
DDI-DrugBank.d171.s0|171-181|propranolol|drug
DDI-DrugBank.d171.s0|182-182|,|drug
DDI-DrugBank.d171.s0|184-193|nifedipine|drug
DDI-DrugBank.d171.s0|194-194|,|drug
DDI-DrugBank.d171.s0|196-211|chlordiazepoxide|drug
DDI-DrugBank.d171.s0|212-212|,|drug
DDI-DrugBank.d171.s0|214-221|diazepam|drug
DDI-DrugBank.d171.s0|222-222|,|drug
DDI-DrugBank.d171.s0|224-230|certain|drug
DDI-DrugBank.d171.s0|232-240|tricyclic|drug
DDI-DrugBank.d171.s0|242-256|antidepressants|drug
DDI-DrugBank.d171.s0|257-257|,|drug
DDI-DrugBank.d171.s0|259-267|lidocaine|drug
DDI-DrugBank.d171.s0|268-268|,|drug
DDI-DrugBank.d171.s0|270-281|theophylline|drug
DDI-DrugBank.d171.s0|283-285|and|drug
DDI-DrugBank.d171.s0|287-299|metronidazole|drug
DDI-DrugBank.d171.s0|300-300|,|drug
DDI-DrugBank.d171.s0|302-308|thereby|drug
DDI-DrugBank.d171.s0|310-317|delaying|drug
DDI-DrugBank.d171.s0|319-329|elimination|drug
DDI-DrugBank.d171.s0|331-333|and|drug
DDI-DrugBank.d171.s0|335-344|increasing|drug
DDI-DrugBank.d171.s0|346-350|blood|drug
DDI-DrugBank.d171.s0|352-357|levels|drug
DDI-DrugBank.d171.s0|359-360|of|drug
DDI-DrugBank.d171.s0|362-366|these|drug
DDI-DrugBank.d171.s0|368-372|drugs|drug
DDI-DrugBank.d171.s0|373-373|.|drug
DDI-DrugBank.d171.s1|0-9|Clinically|drug
DDI-DrugBank.d171.s1|11-21|significant|drug
DDI-DrugBank.d171.s1|23-29|effects|drug
DDI-DrugBank.d171.s1|31-34|have|drug
DDI-DrugBank.d171.s1|36-39|been|drug
DDI-DrugBank.d171.s1|41-48|reported|drug
DDI-DrugBank.d171.s1|50-53|with|drug
DDI-DrugBank.d171.s1|55-57|the|drug
DDI-DrugBank.d171.s1|59-66|warfarin|drug
DDI-DrugBank.d171.s1|68-81|anticoagulants|drug
DDI-DrugBank.d171.s1|82-82|;|drug
DDI-DrugBank.d171.s2|0-8|therefore|drug
DDI-DrugBank.d171.s2|9-9|,|drug
DDI-DrugBank.d171.s2|11-15|close|drug
DDI-DrugBank.d171.s2|17-26|monitoring|drug
DDI-DrugBank.d171.s2|28-29|of|drug
DDI-DrugBank.d171.s2|31-41|prothrombin|drug
DDI-DrugBank.d171.s2|43-46|time|drug
DDI-DrugBank.d171.s2|48-49|is|drug
DDI-DrugBank.d171.s2|51-61|recommended|drug
DDI-DrugBank.d171.s2|62-62|,|drug
DDI-DrugBank.d171.s2|64-66|and|drug
DDI-DrugBank.d171.s2|68-77|adjustment|drug
DDI-DrugBank.d171.s2|79-80|of|drug
DDI-DrugBank.d171.s2|82-84|the|drug
DDI-DrugBank.d171.s2|86-98|anticoagulant|drug
DDI-DrugBank.d171.s2|100-103|dose|drug
DDI-DrugBank.d171.s2|105-107|may|drug
DDI-DrugBank.d171.s2|109-110|be|drug
DDI-DrugBank.d171.s2|112-120|necessary|drug
DDI-DrugBank.d171.s2|122-125|when|drug
DDI-DrugBank.d171.s2|127-133|Tagamet|brand
DDI-DrugBank.d171.s2|135-136|is|drug
DDI-DrugBank.d171.s2|138-149|administered|drug
DDI-DrugBank.d171.s2|151-163|concomitantly|drug
DDI-DrugBank.d171.s2|164-164|.|drug
DDI-DrugBank.d171.s3|0-10|Interaction|drug
DDI-DrugBank.d171.s3|12-15|with|drug
DDI-DrugBank.d171.s3|17-25|phenytoin|drug
DDI-DrugBank.d171.s3|26-26|,|drug
DDI-DrugBank.d171.s3|28-36|lidocaine|drug
DDI-DrugBank.d171.s3|38-40|and|drug
DDI-DrugBank.d171.s3|42-53|theophylline|drug
DDI-DrugBank.d171.s3|55-57|has|drug
DDI-DrugBank.d171.s3|59-62|also|drug
DDI-DrugBank.d171.s3|64-67|been|drug
DDI-DrugBank.d171.s3|69-76|reported|drug
DDI-DrugBank.d171.s3|78-79|to|drug
DDI-DrugBank.d171.s3|81-87|produce|drug
DDI-DrugBank.d171.s3|89-95|adverse|drug
DDI-DrugBank.d171.s3|97-104|clinical|drug
DDI-DrugBank.d171.s3|106-112|effects|drug
DDI-DrugBank.d171.s3|113-113|.|drug
DDI-DrugBank.d171.s4|0-6|However|drug
DDI-DrugBank.d171.s4|7-7|,|drug
DDI-DrugBank.d171.s4|9-9|a|drug
DDI-DrugBank.d171.s4|11-19|crossover|drug
DDI-DrugBank.d171.s4|21-25|study|drug
DDI-DrugBank.d171.s4|27-28|in|drug
DDI-DrugBank.d171.s4|30-36|healthy|drug
DDI-DrugBank.d171.s4|38-45|subjects|drug
DDI-DrugBank.d171.s4|47-55|receiving|drug
DDI-DrugBank.d171.s4|57-62|either|drug
DDI-DrugBank.d171.s4|64-70|Tagamet|brand
DDI-DrugBank.d171.s4|72-74|300|drug
DDI-DrugBank.d171.s4|76-77|mg|drug
DDI-DrugBank.d171.s4|79-84|q.i.d|drug
DDI-DrugBank.d171.s4|86-87|.|drug
DDI-DrugBank.d171.s4|89-91|or|drug
DDI-DrugBank.d171.s4|93-94|800|drug
DDI-DrugBank.d171.s4|96-99|mg|drug
DDI-DrugBank.d171.s4|101-113|h.s|drug
DDI-DrugBank.d171.s4|115-118|.|drug
DDI-DrugBank.d171.s4|120-120|concomitantly|drug
DDI-DrugBank.d171.s4|122-124|with|drug
DDI-DrugBank.d171.s4|126-127|a|drug
DDI-DrugBank.d171.s4|129-134|300|drug
DDI-DrugBank.d171.s4|136-141|mg|drug
DDI-DrugBank.d171.s4|143-144|b.i.d|drug
DDI-DrugBank.d171.s4|146-157|.|drug
DDI-DrugBank.d171.s4|159-159|dosage|drug
DDI-DrugBank.d171.s4|160-167|of|drug
DDI-DrugBank.d171.s4|169-169|theophylline|drug
DDI-DrugBank.d171.s4|171-173|(|drug
DDI-DrugBank.d171.s4|175-189|Theo-Dur|drug
DDI-DrugBank.d171.s4|190-190|,|drug
DDI-DrugBank.d171.s4|192-195|Key|drug
DDI-DrugBank.d171.s4|196-196|Pharmaceuticals|drug
DDI-DrugBank.d171.s4|198-209|,|drug
DDI-DrugBank.d171.s4|211-214|Inc.|drug
DDI-DrugBank.d171.s4|216-225|)|drug
DDI-DrugBank.d171.s4|227-228|demonstrated|drug
DDI-DrugBank.d171.s4|230-241|less|drug
DDI-DrugBank.d171.s4|243-254|alteration|drug
DDI-DrugBank.d171.s4|256-259|in|drug
DDI-DrugBank.d171.s4|261-265|steady-state|drug
DDI-DrugBank.d171.s4|267-272|theophylline|drug
DDI-DrugBank.d171.s4|274-277|peak|drug
DDI-DrugBank.d171.s4|279-281|serum|drug
DDI-DrugBank.d171.s4|283-285|levels|drug
DDI-DrugBank.d171.s4|287-288|with|drug
DDI-DrugBank.d171.s4|290-293|the|drug
DDI-DrugBank.d171.s4|295-301|800|drug
DDI-DrugBank.d171.s4|302-302|mg|drug
DDI-DrugBank.d171.s4|304-315|h.s|drug
DDI-DrugBank.d171.s4|317-318|.|drug
DDI-DrugBank.d171.s4|320-327|regimen|drug
DDI-DrugBank.d171.s4|329-332|,|drug
DDI-DrugBank.d171.s4|334-335|particularly|drug
DDI-DrugBank.d171.s4|337-341|in|drug
DDI-DrugBank.d171.s4|343-345|subjects|drug
DDI-DrugBank.d171.s4|347-351|aged|drug
DDI-DrugBank.d171.s4|352-352|54|drug
DDI-DrugBank.d171.s5|0-3|Data|drug
DDI-DrugBank.d171.s5|5-10|beyond|drug
DDI-DrugBank.d171.s5|12-13|10|drug
DDI-DrugBank.d171.s5|15-18|days|drug
DDI-DrugBank.d171.s5|20-22|are|drug
DDI-DrugBank.d171.s5|24-26|not|drug
DDI-DrugBank.d171.s5|28-36|available|drug
DDI-DrugBank.d171.s5|37-37|.|drug
DDI-DrugBank.d171.s6|0-0|(|drug
DDI-DrugBank.d171.s6|1-4|Note|drug
DDI-DrugBank.d171.s6|5-5|:|drug
DDI-DrugBank.d171.s6|7-9|All|drug
DDI-DrugBank.d171.s6|11-18|patients|drug
DDI-DrugBank.d171.s6|20-28|receiving|drug
DDI-DrugBank.d171.s6|30-41|theophylline|drug
DDI-DrugBank.d171.s6|43-48|should|drug
DDI-DrugBank.d171.s6|50-51|be|drug
DDI-DrugBank.d171.s6|53-61|monitored|drug
DDI-DrugBank.d171.s6|63-75|appropriately|drug
DDI-DrugBank.d171.s6|76-76|,|drug
DDI-DrugBank.d171.s6|78-87|regardless|drug
DDI-DrugBank.d171.s6|89-90|of|drug
DDI-DrugBank.d171.s6|92-102|concomitant|drug
DDI-DrugBank.d171.s6|104-107|drug|drug
DDI-DrugBank.d171.s6|109-115|therapy|drug
DDI-DrugBank.d171.s6|116-116|.|drug
DDI-DrugBank.d171.s6|117-117|)|drug
DDI-DrugBank.d171.s7|0-5|Dosage|drug
DDI-DrugBank.d171.s7|7-8|of|drug
DDI-DrugBank.d171.s7|10-12|the|drug
DDI-DrugBank.d171.s7|14-18|drugs|drug
DDI-DrugBank.d171.s7|20-28|mentioned|drug
DDI-DrugBank.d171.s7|30-34|above|drug
DDI-DrugBank.d171.s7|36-38|and|drug
DDI-DrugBank.d171.s7|40-44|other|drug
DDI-DrugBank.d171.s7|46-54|similarly|drug
DDI-DrugBank.d171.s7|56-66|metabolized|drug
DDI-DrugBank.d171.s7|68-72|drugs|drug
DDI-DrugBank.d171.s7|73-73|,|drug
DDI-DrugBank.d171.s7|75-86|particularly|drug
DDI-DrugBank.d171.s7|88-92|those|drug
DDI-DrugBank.d171.s7|94-95|of|drug
DDI-DrugBank.d171.s7|97-99|low|drug
DDI-DrugBank.d171.s7|101-111|therapeutic|drug
DDI-DrugBank.d171.s7|113-117|ratio|drug
DDI-DrugBank.d171.s7|119-120|or|drug
DDI-DrugBank.d171.s7|122-123|in|drug
DDI-DrugBank.d171.s7|125-132|patients|drug
DDI-DrugBank.d171.s7|134-137|with|drug
DDI-DrugBank.d171.s7|139-143|renal|drug
DDI-DrugBank.d171.s7|145-150|and/or|drug
DDI-DrugBank.d171.s7|152-158|hepatic|drug
DDI-DrugBank.d171.s7|160-169|impairment|drug
DDI-DrugBank.d171.s7|170-170|,|drug
DDI-DrugBank.d171.s7|172-174|may|drug
DDI-DrugBank.d171.s7|176-182|require|drug
DDI-DrugBank.d171.s7|184-193|adjustment|drug
DDI-DrugBank.d171.s7|195-198|when|drug
DDI-DrugBank.d171.s7|200-207|starting|drug
DDI-DrugBank.d171.s7|209-210|or|drug
DDI-DrugBank.d171.s7|212-219|stopping|drug
DDI-DrugBank.d171.s7|221-233|concomitantly|drug
DDI-DrugBank.d171.s7|235-246|administered|drug
DDI-DrugBank.d171.s7|248-254|Tagamet|brand
DDI-DrugBank.d171.s7|256-257|to|drug
DDI-DrugBank.d171.s7|259-266|maintain|drug
DDI-DrugBank.d171.s7|268-274|optimum|drug
DDI-DrugBank.d171.s7|276-286|therapeutic|drug
DDI-DrugBank.d171.s7|288-292|blood|drug
DDI-DrugBank.d171.s7|294-299|levels|drug
DDI-DrugBank.d171.s7|300-300|.|drug
DDI-DrugBank.d171.s8|0-9|Alteration|drug
DDI-DrugBank.d171.s8|11-12|of|drug
DDI-DrugBank.d171.s8|14-15|pH|drug
DDI-DrugBank.d171.s8|17-19|may|drug
DDI-DrugBank.d171.s8|21-26|affect|drug
DDI-DrugBank.d171.s8|28-37|absorption|drug
DDI-DrugBank.d171.s8|39-40|of|drug
DDI-DrugBank.d171.s8|42-48|certain|drug
DDI-DrugBank.d171.s8|50-54|drugs|drug
DDI-DrugBank.d171.s8|56-56|(|drug
DDI-DrugBank.d171.s8|57-60|e.g.|drug
DDI-DrugBank.d171.s8|61-61|,|drug
DDI-DrugBank.d171.s8|63-74|ketoconazole|drug
DDI-DrugBank.d171.s8|75-75|)|drug
DDI-DrugBank.d171.s8|76-76|.|drug
DDI-DrugBank.d171.s9|0-1|If|drug
DDI-DrugBank.d171.s9|3-7|these|drug
DDI-DrugBank.d171.s9|9-16|products|drug
DDI-DrugBank.d171.s9|18-20|are|drug
DDI-DrugBank.d171.s9|22-27|needed|drug
DDI-DrugBank.d171.s9|28-28|,|drug
DDI-DrugBank.d171.s9|30-33|they|drug
DDI-DrugBank.d171.s9|35-40|should|drug
DDI-DrugBank.d171.s9|42-43|be|drug
DDI-DrugBank.d171.s9|45-49|given|drug
DDI-DrugBank.d171.s9|51-52|at|drug
DDI-DrugBank.d171.s9|54-58|least|drug
DDI-DrugBank.d171.s9|60-60|2|drug
DDI-DrugBank.d171.s9|62-66|hours|drug
DDI-DrugBank.d171.s9|68-73|before|drug
DDI-DrugBank.d171.s9|75-84|cimetidine|drug
DDI-DrugBank.d171.s9|86-99|administration|drug
DDI-DrugBank.d171.s9|100-100|.|drug
DDI-DrugBank.d171.s10|0-9|Additional|drug
DDI-DrugBank.d171.s10|11-18|clinical|drug
DDI-DrugBank.d171.s10|20-29|experience|drug
DDI-DrugBank.d171.s10|31-33|may|drug
DDI-DrugBank.d171.s10|35-40|reveal|drug
DDI-DrugBank.d171.s10|42-46|other|drug
DDI-DrugBank.d171.s10|48-52|drugs|drug
DDI-DrugBank.d171.s10|54-61|affected|drug
DDI-DrugBank.d171.s10|63-64|by|drug
DDI-DrugBank.d171.s10|66-68|the|drug
DDI-DrugBank.d171.s10|70-80|concomitant|drug
DDI-DrugBank.d171.s10|82-95|administration|drug
DDI-DrugBank.d171.s10|97-98|of|drug
DDI-DrugBank.d171.s10|100-106|Tagamet|brand
DDI-DrugBank.d171.s10|107-107|.|drug
DDI-DrugBank.d110.s0|0-2|The|drug
DDI-DrugBank.d110.s0|4-17|administration|drug
DDI-DrugBank.d110.s0|19-20|of|drug
DDI-DrugBank.d110.s0|22-26|local|drug
DDI-DrugBank.d110.s0|28-37|anesthetic|drug
DDI-DrugBank.d110.s0|39-47|solutions|drug
DDI-DrugBank.d110.s0|49-58|containing|drug
DDI-DrugBank.d110.s0|60-70|epinephrine|drug
DDI-DrugBank.d110.s0|72-73|or|drug
DDI-DrugBank.d110.s0|75-88|norepinephrine|drug
DDI-DrugBank.d110.s0|90-91|to|drug
DDI-DrugBank.d110.s0|93-100|patients|drug
DDI-DrugBank.d110.s0|102-110|receiving|drug
DDI-DrugBank.d110.s0|112-120|monoamine|drug
DDI-DrugBank.d110.s0|122-128|oxidase|drug
DDI-DrugBank.d110.s0|130-139|inhibitors|drug
DDI-DrugBank.d110.s0|140-140|,|drug
DDI-DrugBank.d110.s0|142-150|tricyclic|drug
DDI-DrugBank.d110.s0|152-166|antidepressants|drug
DDI-DrugBank.d110.s0|168-169|or|drug
DDI-DrugBank.d110.s0|171-184|phenothiazines|drug
DDI-DrugBank.d110.s0|186-188|may|drug
DDI-DrugBank.d110.s0|190-196|produce|drug
DDI-DrugBank.d110.s0|198-203|severe|drug
DDI-DrugBank.d110.s0|204-204|,|drug
DDI-DrugBank.d110.s0|206-214|prolonged|drug
DDI-DrugBank.d110.s0|216-226|hypotension|drug
DDI-DrugBank.d110.s0|228-229|or|drug
DDI-DrugBank.d110.s0|231-242|hypertension|drug
DDI-DrugBank.d110.s0|243-243|.|drug
DDI-DrugBank.d110.s1|0-9|Concurrent|drug
DDI-DrugBank.d110.s1|11-13|use|drug
DDI-DrugBank.d110.s1|15-16|of|drug
DDI-DrugBank.d110.s1|18-22|these|drug
DDI-DrugBank.d110.s1|24-29|agents|drug
DDI-DrugBank.d110.s1|31-36|should|drug
DDI-DrugBank.d110.s1|38-46|generally|drug
DDI-DrugBank.d110.s1|48-49|be|drug
DDI-DrugBank.d110.s1|51-57|avoided|drug
DDI-DrugBank.d110.s1|58-58|.|drug
DDI-DrugBank.d110.s2|0-1|In|drug
DDI-DrugBank.d110.s2|3-12|situations|drug
DDI-DrugBank.d110.s2|14-17|when|drug
DDI-DrugBank.d110.s2|19-28|concurrent|drug
DDI-DrugBank.d110.s2|30-36|therapy|drug
DDI-DrugBank.d110.s2|38-39|is|drug
DDI-DrugBank.d110.s2|41-49|necessary|drug
DDI-DrugBank.d110.s2|50-50|,|drug
DDI-DrugBank.d110.s2|52-58|careful|drug
DDI-DrugBank.d110.s2|60-66|patient|drug
DDI-DrugBank.d110.s2|68-77|monitoring|drug
DDI-DrugBank.d110.s2|79-80|is|drug
DDI-DrugBank.d110.s2|82-90|essential|drug
DDI-DrugBank.d110.s2|91-91|.|drug
DDI-DrugBank.d110.s3|0-9|Concurrent|drug
DDI-DrugBank.d110.s3|11-24|administration|drug
DDI-DrugBank.d110.s3|26-27|of|drug
DDI-DrugBank.d110.s3|29-39|vasopressor|drug
DDI-DrugBank.d110.s3|41-45|drugs|drug
DDI-DrugBank.d110.s3|47-47|(|drug
DDI-DrugBank.d110.s3|48-50|for|drug
DDI-DrugBank.d110.s3|52-54|the|drug
DDI-DrugBank.d110.s3|56-64|treatment|drug
DDI-DrugBank.d110.s3|66-67|of|drug
DDI-DrugBank.d110.s3|69-79|hypotension|drug
DDI-DrugBank.d110.s3|81-87|related|drug
DDI-DrugBank.d110.s3|89-90|to|drug
DDI-DrugBank.d110.s3|92-100|obstetric|drug
DDI-DrugBank.d110.s3|102-107|blocks|drug
DDI-DrugBank.d110.s3|108-108|)|drug
DDI-DrugBank.d110.s3|110-112|and|drug
DDI-DrugBank.d110.s3|114-123|ergot-type|drug
DDI-DrugBank.d110.s3|125-132|oxytocic|drug
DDI-DrugBank.d110.s3|134-138|drugs|drug
DDI-DrugBank.d110.s3|140-142|may|drug
DDI-DrugBank.d110.s3|144-148|cause|drug
DDI-DrugBank.d110.s3|150-155|severe|drug
DDI-DrugBank.d110.s3|156-156|,|drug
DDI-DrugBank.d110.s3|158-167|persistent|drug
DDI-DrugBank.d110.s3|169-180|hypertension|drug
DDI-DrugBank.d110.s3|182-183|or|drug
DDI-DrugBank.d110.s3|185-199|cerebrovascular|drug
DDI-DrugBank.d110.s3|201-209|accidents|drug
DDI-DrugBank.d110.s3|210-210|.|drug
DDI-DrugBank.d110.s4|0-2|The|drug
DDI-DrugBank.d110.s4|4-20|para-aminobenzoic|drug
DDI-DrugBank.d110.s4|22-25|acid|drug
DDI-DrugBank.d110.s4|27-36|metabolite|drug
DDI-DrugBank.d110.s4|38-39|of|drug
DDI-DrugBank.d110.s4|41-54|chloroprocaine|drug
DDI-DrugBank.d110.s4|56-63|inhibits|drug
DDI-DrugBank.d110.s4|65-67|the|drug
DDI-DrugBank.d110.s4|69-74|action|drug
DDI-DrugBank.d110.s4|76-77|of|drug
DDI-DrugBank.d110.s4|79-90|sulfonamides|drug
DDI-DrugBank.d110.s4|91-91|.|drug
DDI-DrugBank.d110.s5|0-8|Therefore|drug
DDI-DrugBank.d110.s5|9-9|,|drug
DDI-DrugBank.d110.s5|11-24|chloroprocaine|drug
DDI-DrugBank.d110.s5|26-31|should|drug
DDI-DrugBank.d110.s5|33-35|not|drug
DDI-DrugBank.d110.s5|37-38|be|drug
DDI-DrugBank.d110.s5|40-43|used|drug
DDI-DrugBank.d110.s5|45-46|in|drug
DDI-DrugBank.d110.s5|48-50|any|drug
DDI-DrugBank.d110.s5|52-60|condition|drug
DDI-DrugBank.d110.s5|62-63|in|drug
DDI-DrugBank.d110.s5|65-69|which|drug
DDI-DrugBank.d110.s5|71-71|a|drug
DDI-DrugBank.d110.s5|73-83|sulfonamide|drug
DDI-DrugBank.d110.s5|85-88|drug|drug
DDI-DrugBank.d110.s5|90-91|is|drug
DDI-DrugBank.d110.s5|93-97|being|drug
DDI-DrugBank.d110.s5|99-106|employed|drug
DDI-DrugBank.d110.s5|107-107|.|drug
DDI-DrugBank.d449.s0|0-16|Co-administration|drug
DDI-DrugBank.d449.s0|18-21|with|drug
DDI-DrugBank.d449.s0|23-32|antifungal|drug
DDI-DrugBank.d449.s0|34-39|agents|drug
DDI-DrugBank.d449.s0|41-44|such|drug
DDI-DrugBank.d449.s0|46-47|as|drug
DDI-DrugBank.d449.s0|49-60|ketoconazole|drug
DDI-DrugBank.d449.s0|62-63|or|drug
DDI-DrugBank.d449.s0|65-76|itraconazole|drug
DDI-DrugBank.d449.s0|78-79|is|drug
DDI-DrugBank.d449.s0|81-83|not|drug
DDI-DrugBank.d449.s0|85-95|recommended|drug
DDI-DrugBank.d449.s0|96-96|.|drug
DDI-DrugBank.d449.s1|0-9|Nafazodone|drug
DDI-DrugBank.d449.s1|10-10|,|drug
DDI-DrugBank.d449.s1|12-22|fluvoxamine|drug
DDI-DrugBank.d449.s1|23-23|,|drug
DDI-DrugBank.d449.s1|25-34|cimetidine|drug
DDI-DrugBank.d449.s1|36-36|(|drug
DDI-DrugBank.d449.s1|37-44|consider|drug
DDI-DrugBank.d449.s1|46-50|Xanax|brand
DDI-DrugBank.d449.s1|52-55|dose|drug
DDI-DrugBank.d449.s1|57-65|reduction|drug
DDI-DrugBank.d449.s1|66-66|)|drug
DDI-DrugBank.d449.s1|67-67|.|drug
DDI-DrugBank.d449.s2|0-9|Fluoxetine|brand
DDI-DrugBank.d449.s2|10-10|,|drug
DDI-DrugBank.d449.s2|12-14|OCs|drug
DDI-DrugBank.d449.s2|15-15|,|drug
DDI-DrugBank.d449.s2|17-26|sertraline|drug
DDI-DrugBank.d449.s2|27-27|,|drug
DDI-DrugBank.d449.s2|29-37|diltiazem|drug
DDI-DrugBank.d449.s2|38-38|,|drug
DDI-DrugBank.d449.s2|40-48|macrolide|drug
DDI-DrugBank.d449.s2|50-60|antibiotics|drug
DDI-DrugBank.d449.s2|62-62|(|drug
DDI-DrugBank.d449.s2|63-70|exercise|drug
DDI-DrugBank.d449.s2|72-78|caution|drug
DDI-DrugBank.d449.s2|79-79|)|drug
DDI-DrugBank.d449.s2|80-80|.|drug
DDI-DrugBank.d367.s0|0-3|Most|drug
DDI-DrugBank.d367.s0|5-5|(|drug
DDI-DrugBank.d367.s0|6-7|98|drug
DDI-DrugBank.d367.s0|8-8|%|drug
DDI-DrugBank.d367.s0|9-9|)|drug
DDI-DrugBank.d367.s0|11-12|of|drug
DDI-DrugBank.d367.s0|14-19|plasma|drug
DDI-DrugBank.d367.s0|21-29|doxazosin|drug
DDI-DrugBank.d367.s0|31-32|is|drug
DDI-DrugBank.d367.s0|34-40|protein|drug
DDI-DrugBank.d367.s0|42-46|bound|drug
DDI-DrugBank.d367.s0|47-47|.|drug
DDI-DrugBank.d367.s1|0-1|In|drug
DDI-DrugBank.d367.s1|3-7|vitro|drug
DDI-DrugBank.d367.s1|9-12|data|drug
DDI-DrugBank.d367.s1|14-15|in|drug
DDI-DrugBank.d367.s1|17-21|human|drug
DDI-DrugBank.d367.s1|23-28|plasma|drug
DDI-DrugBank.d367.s1|30-37|indicate|drug
DDI-DrugBank.d367.s1|39-42|that|drug
DDI-DrugBank.d367.s1|44-52|doxazosin|drug
DDI-DrugBank.d367.s1|54-61|mesylate|drug
DDI-DrugBank.d367.s1|63-65|has|drug
DDI-DrugBank.d367.s1|67-68|no|drug
DDI-DrugBank.d367.s1|70-75|effect|drug
DDI-DrugBank.d367.s1|77-78|on|drug
DDI-DrugBank.d367.s1|80-86|protein|drug
DDI-DrugBank.d367.s1|88-94|binding|drug
DDI-DrugBank.d367.s1|96-97|of|drug
DDI-DrugBank.d367.s1|99-105|digoxin|drug
DDI-DrugBank.d367.s1|106-106|,|drug
DDI-DrugBank.d367.s1|108-115|warfarin|drug
DDI-DrugBank.d367.s1|116-116|,|drug
DDI-DrugBank.d367.s1|118-126|phenytoin|drug
DDI-DrugBank.d367.s1|128-129|or|drug
DDI-DrugBank.d367.s1|131-142|indomethacin|drug
DDI-DrugBank.d367.s1|143-143|.|drug
DDI-DrugBank.d367.s2|0-4|There|drug
DDI-DrugBank.d367.s2|6-7|is|drug
DDI-DrugBank.d367.s2|9-10|no|drug
DDI-DrugBank.d367.s2|12-22|information|drug
DDI-DrugBank.d367.s2|24-25|on|drug
DDI-DrugBank.d367.s2|27-29|the|drug
DDI-DrugBank.d367.s2|31-36|effect|drug
DDI-DrugBank.d367.s2|38-39|of|drug
DDI-DrugBank.d367.s2|41-45|other|drug
DDI-DrugBank.d367.s2|47-52|highly|drug
DDI-DrugBank.d367.s2|54-59|plasma|drug
DDI-DrugBank.d367.s2|61-67|protein|drug
DDI-DrugBank.d367.s2|69-73|bound|drug
DDI-DrugBank.d367.s2|75-79|drugs|drug
DDI-DrugBank.d367.s2|81-82|on|drug
DDI-DrugBank.d367.s2|84-92|doxazosin|drug
DDI-DrugBank.d367.s2|94-100|binding|drug
DDI-DrugBank.d367.s2|101-101|.|drug
DDI-DrugBank.d367.s3|0-8|Doxazosin|brand
DDI-DrugBank.d367.s3|10-17|mesylate|drug
DDI-DrugBank.d367.s3|19-21|has|drug
DDI-DrugBank.d367.s3|23-26|been|drug
DDI-DrugBank.d367.s3|28-39|administered|drug
DDI-DrugBank.d367.s3|41-47|without|drug
DDI-DrugBank.d367.s3|49-51|any|drug
DDI-DrugBank.d367.s3|53-60|evidence|drug
DDI-DrugBank.d367.s3|62-63|of|drug
DDI-DrugBank.d367.s3|65-66|an|drug
DDI-DrugBank.d367.s3|68-74|adverse|drug
DDI-DrugBank.d367.s3|76-79|drug|drug
DDI-DrugBank.d367.s3|81-91|interaction|drug
DDI-DrugBank.d367.s3|93-94|to|drug
DDI-DrugBank.d367.s3|96-103|patients|drug
DDI-DrugBank.d367.s3|105-113|receiving|drug
DDI-DrugBank.d367.s3|115-122|thiazide|drug
DDI-DrugBank.d367.s3|124-132|diuretics|drug
DDI-DrugBank.d367.s3|133-133|,|drug
DDI-DrugBank.d367.s3|135-147|beta-blocking|drug
DDI-DrugBank.d367.s3|149-154|agents|drug
DDI-DrugBank.d367.s3|155-155|,|drug
DDI-DrugBank.d367.s3|157-159|and|drug
DDI-DrugBank.d367.s3|161-172|nonsteroidal|drug
DDI-DrugBank.d367.s3|174-190|anti-inflammatory|drug
DDI-DrugBank.d367.s3|192-196|drugs|drug
DDI-DrugBank.d367.s3|197-197|.|drug
DDI-DrugBank.d367.s4|0-1|In|drug
DDI-DrugBank.d367.s4|3-3|a|drug
DDI-DrugBank.d367.s4|5-22|placebo-controlled|drug
DDI-DrugBank.d367.s4|24-28|trial|drug
DDI-DrugBank.d367.s4|30-31|in|drug
DDI-DrugBank.d367.s4|33-38|normal|drug
DDI-DrugBank.d367.s4|40-49|volunteers|drug
DDI-DrugBank.d367.s4|50-50|,|drug
DDI-DrugBank.d367.s4|52-54|the|drug
DDI-DrugBank.d367.s4|56-69|administration|drug
DDI-DrugBank.d367.s4|71-72|of|drug
DDI-DrugBank.d367.s4|74-74|a|drug
DDI-DrugBank.d367.s4|76-81|single|drug
DDI-DrugBank.d367.s4|83-83|1|drug
DDI-DrugBank.d367.s4|85-86|mg|drug
DDI-DrugBank.d367.s4|88-91|dose|drug
DDI-DrugBank.d367.s4|93-94|of|drug
DDI-DrugBank.d367.s4|96-104|doxazosin|drug
DDI-DrugBank.d367.s4|106-107|on|drug
DDI-DrugBank.d367.s4|109-111|day|drug
DDI-DrugBank.d367.s4|113-113|1|drug
DDI-DrugBank.d367.s4|115-116|of|drug
DDI-DrugBank.d367.s4|118-118|a|drug
DDI-DrugBank.d367.s4|120-127|four-day|drug
DDI-DrugBank.d367.s4|129-135|regimen|drug
DDI-DrugBank.d367.s4|137-138|of|drug
DDI-DrugBank.d367.s4|140-143|oral|drug
DDI-DrugBank.d367.s4|145-154|cimetidine|drug
DDI-DrugBank.d367.s4|156-156|(|drug
DDI-DrugBank.d367.s4|157-159|400|drug
DDI-DrugBank.d367.s4|161-162|mg|drug
DDI-DrugBank.d367.s4|164-168|twice|drug
DDI-DrugBank.d367.s4|170-174|daily|drug
DDI-DrugBank.d367.s4|175-175|)|drug
DDI-DrugBank.d367.s4|177-184|resulted|drug
DDI-DrugBank.d367.s4|186-187|in|drug
DDI-DrugBank.d367.s4|189-189|a|drug
DDI-DrugBank.d367.s4|191-192|10|drug
DDI-DrugBank.d367.s4|193-193|%|drug
DDI-DrugBank.d367.s4|195-202|increase|drug
DDI-DrugBank.d367.s4|204-205|in|drug
DDI-DrugBank.d367.s4|207-210|mean|drug
DDI-DrugBank.d367.s4|212-214|AUC|drug
DDI-DrugBank.d367.s4|216-217|of|drug
DDI-DrugBank.d367.s4|219-227|doxazosin|drug
DDI-DrugBank.d367.s4|229-229|(|drug
DDI-DrugBank.d367.s4|230-236|p=0.006|drug
DDI-DrugBank.d367.s4|237-237|)|drug
DDI-DrugBank.d367.s4|238-238|,|drug
DDI-DrugBank.d367.s4|240-242|and|drug
DDI-DrugBank.d367.s4|244-244|a|drug
DDI-DrugBank.d367.s4|246-251|slight|drug
DDI-DrugBank.d367.s4|253-255|but|drug
DDI-DrugBank.d367.s4|257-259|not|drug
DDI-DrugBank.d367.s4|261-273|statistically|drug
DDI-DrugBank.d367.s4|275-285|significant|drug
DDI-DrugBank.d367.s4|287-294|increase|drug
DDI-DrugBank.d367.s4|296-297|in|drug
DDI-DrugBank.d367.s4|299-302|mean|drug
DDI-DrugBank.d367.s4|304-307|Cmax|drug
DDI-DrugBank.d367.s4|309-311|and|drug
DDI-DrugBank.d367.s4|313-316|mean|drug
DDI-DrugBank.d367.s4|318-326|half-life|drug
DDI-DrugBank.d367.s4|328-329|of|drug
DDI-DrugBank.d367.s4|331-339|doxazosin|drug
DDI-DrugBank.d367.s4|340-340|.|drug
DDI-DrugBank.d367.s5|0-2|The|drug
DDI-DrugBank.d367.s5|4-11|clinical|drug
DDI-DrugBank.d367.s5|13-24|significance|drug
DDI-DrugBank.d367.s5|26-27|of|drug
DDI-DrugBank.d367.s5|29-32|this|drug
DDI-DrugBank.d367.s5|34-41|increase|drug
DDI-DrugBank.d367.s5|43-44|in|drug
DDI-DrugBank.d367.s5|46-54|doxazosin|drug
DDI-DrugBank.d367.s5|56-58|AUC|drug
DDI-DrugBank.d367.s5|60-61|is|drug
DDI-DrugBank.d367.s5|63-69|unknown|drug
DDI-DrugBank.d367.s5|70-70|.|drug
DDI-DrugBank.d367.s6|0-1|In|drug
DDI-DrugBank.d367.s6|3-10|clinical|drug
DDI-DrugBank.d367.s6|12-17|trials|drug
DDI-DrugBank.d367.s6|18-18|,|drug
DDI-DrugBank.d367.s6|20-28|doxazosin|drug
DDI-DrugBank.d367.s6|30-37|mesylate|drug
DDI-DrugBank.d367.s6|39-45|tablets|drug
DDI-DrugBank.d367.s6|47-50|have|drug
DDI-DrugBank.d367.s6|52-55|been|drug
DDI-DrugBank.d367.s6|57-68|administered|drug
DDI-DrugBank.d367.s6|70-71|to|drug
DDI-DrugBank.d367.s6|73-80|patients|drug
DDI-DrugBank.d367.s6|82-83|on|drug
DDI-DrugBank.d367.s6|85-85|a|drug
DDI-DrugBank.d367.s6|87-93|variety|drug
DDI-DrugBank.d367.s6|95-96|of|drug
DDI-DrugBank.d367.s6|98-108|concomitant|drug
DDI-DrugBank.d367.s6|110-120|medications|drug
DDI-DrugBank.d367.s6|121-121|;|drug
DDI-DrugBank.d367.s7|0-4|while|drug
DDI-DrugBank.d367.s7|6-7|no|drug
DDI-DrugBank.d367.s7|9-14|formal|drug
DDI-DrugBank.d367.s7|16-26|interaction|drug
DDI-DrugBank.d367.s7|28-34|studies|drug
DDI-DrugBank.d367.s7|36-39|have|drug
DDI-DrugBank.d367.s7|41-44|been|drug
DDI-DrugBank.d367.s7|46-54|conducted|drug
DDI-DrugBank.d367.s7|55-55|,|drug
DDI-DrugBank.d367.s7|57-58|no|drug
DDI-DrugBank.d367.s7|60-71|interactions|drug
DDI-DrugBank.d367.s7|73-76|were|drug
DDI-DrugBank.d367.s7|78-85|observed|drug
DDI-DrugBank.d367.s7|86-86|.|drug
DDI-DrugBank.d367.s8|0-8|Doxazosin|brand
DDI-DrugBank.d367.s8|10-17|mesylate|drug
DDI-DrugBank.d367.s8|19-25|tablets|drug
DDI-DrugBank.d367.s8|27-30|have|drug
DDI-DrugBank.d367.s8|32-35|been|drug
DDI-DrugBank.d367.s8|37-40|used|drug
DDI-DrugBank.d367.s8|42-45|with|drug
DDI-DrugBank.d367.s8|47-49|the|drug
DDI-DrugBank.d367.s8|51-59|following|drug
DDI-DrugBank.d367.s8|61-65|drugs|drug
DDI-DrugBank.d367.s8|67-68|or|drug
DDI-DrugBank.d367.s8|70-73|drug|drug
DDI-DrugBank.d367.s8|75-81|classes|drug
DDI-DrugBank.d367.s8|82-82|:|drug
DDI-DrugBank.d367.s8|84-84|1|drug
DDI-DrugBank.d367.s8|85-85|.|drug
DDI-DrugBank.d367.s9|0-26|Analgesic/anti-inflammatory|drug
DDI-DrugBank.d367.s9|28-28|(|drug
DDI-DrugBank.d367.s9|29-32|e.g.|drug
DDI-DrugBank.d367.s9|33-33|,|drug
DDI-DrugBank.d367.s9|35-47|acetaminophen|drug
DDI-DrugBank.d367.s9|48-48|,|drug
DDI-DrugBank.d367.s9|50-56|aspirin|drug
DDI-DrugBank.d367.s9|57-57|,|drug
DDI-DrugBank.d367.s9|59-65|codeine|drug
DDI-DrugBank.d367.s9|67-69|and|drug
DDI-DrugBank.d367.s9|71-77|codeine|drug
DDI-DrugBank.d367.s9|79-90|combinations|drug
DDI-DrugBank.d367.s9|91-91|,|drug
DDI-DrugBank.d367.s9|93-101|ibuprofen|drug
DDI-DrugBank.d367.s9|102-102|,|drug
DDI-DrugBank.d367.s9|104-115|indomethacin|drug
DDI-DrugBank.d367.s9|116-116|)|drug
DDI-DrugBank.d367.s9|117-117|.|drug
DDI-DrugBank.d367.s10|0-0|2|drug
DDI-DrugBank.d367.s10|1-1|.|drug
DDI-DrugBank.d367.s11|0-10|Antibiotics|drug
DDI-DrugBank.d367.s11|12-12|(|drug
DDI-DrugBank.d367.s11|13-16|e.g.|drug
DDI-DrugBank.d367.s11|17-17|,|drug
DDI-DrugBank.d367.s11|19-30|erythromycin|drug
DDI-DrugBank.d367.s11|31-31|,|drug
DDI-DrugBank.d367.s11|33-44|trimethoprim|drug
DDI-DrugBank.d367.s11|46-48|and|drug
DDI-DrugBank.d367.s11|50-65|sulfamethoxazole|drug
DDI-DrugBank.d367.s11|66-66|,|drug
DDI-DrugBank.d367.s11|68-78|amoxicillin|drug
DDI-DrugBank.d367.s11|79-79|)|drug
DDI-DrugBank.d367.s11|80-80|.|drug
DDI-DrugBank.d367.s12|0-0|3|drug
DDI-DrugBank.d367.s12|1-1|.|drug
DDI-DrugBank.d367.s13|0-13|Antihistamines|drug
DDI-DrugBank.d367.s13|15-15|(|drug
DDI-DrugBank.d367.s13|16-19|e.g.|drug
DDI-DrugBank.d367.s13|20-20|,|drug
DDI-DrugBank.d367.s13|22-37|chlorpheniramine|drug
DDI-DrugBank.d367.s13|38-38|)|drug
DDI-DrugBank.d367.s13|39-39|.|drug
DDI-DrugBank.d367.s14|0-0|4|drug
DDI-DrugBank.d367.s14|1-1|.|drug
DDI-DrugBank.d367.s15|0-13|Cardiovascular|drug
DDI-DrugBank.d367.s15|15-20|agents|drug
DDI-DrugBank.d367.s15|22-22|(|drug
DDI-DrugBank.d367.s15|23-26|e.g.|drug
DDI-DrugBank.d367.s15|27-27|,|drug
DDI-DrugBank.d367.s15|29-36|atenolol|drug
DDI-DrugBank.d367.s15|37-37|,|drug
DDI-DrugBank.d367.s15|39-57|hydrochlorothiazide|drug
DDI-DrugBank.d367.s15|58-58|,|drug
DDI-DrugBank.d367.s15|60-70|propranolol|drug
DDI-DrugBank.d367.s15|71-71|)|drug
DDI-DrugBank.d367.s15|72-72|.|drug
DDI-DrugBank.d367.s16|0-0|5|drug
DDI-DrugBank.d367.s16|1-1|.|drug
DDI-DrugBank.d367.s17|0-14|Corticosteroids|group
DDI-DrugBank.d367.s17|15-15|.|drug
DDI-DrugBank.d367.s18|0-0|6|drug
DDI-DrugBank.d367.s18|1-1|.|drug
DDI-DrugBank.d367.s19|0-15|Gastrointestinal|drug
DDI-DrugBank.d367.s19|17-22|agents|drug
DDI-DrugBank.d367.s19|24-24|(|drug
DDI-DrugBank.d367.s19|25-28|e.g.|drug
DDI-DrugBank.d367.s19|29-29|,|drug
DDI-DrugBank.d367.s19|31-38|antacids|drug
DDI-DrugBank.d367.s19|39-39|)|drug
DDI-DrugBank.d367.s19|40-40|.|drug
DDI-DrugBank.d367.s20|0-0|7|drug
DDI-DrugBank.d367.s20|1-1|.|drug
DDI-DrugBank.d367.s21|0-12|Hypoglycemics|drug
DDI-DrugBank.d367.s21|14-16|and|drug
DDI-DrugBank.d367.s21|18-26|endocrine|drug
DDI-DrugBank.d367.s21|28-32|drugs|drug
DDI-DrugBank.d367.s21|33-33|.|drug
DDI-DrugBank.d367.s22|0-0|8|drug
DDI-DrugBank.d367.s22|1-1|.|drug
DDI-DrugBank.d367.s23|0-8|Sedatives|drug
DDI-DrugBank.d367.s23|10-12|and|drug
DDI-DrugBank.d367.s23|14-26|tranquilizers|drug
DDI-DrugBank.d367.s23|28-28|(|drug
DDI-DrugBank.d367.s23|29-32|e.g.|drug
DDI-DrugBank.d367.s23|33-33|,|drug
DDI-DrugBank.d367.s23|35-42|diazepam|drug
DDI-DrugBank.d367.s23|43-43|)|drug
DDI-DrugBank.d367.s23|44-44|.|drug
DDI-DrugBank.d367.s24|0-0|9|drug
DDI-DrugBank.d367.s24|1-1|.|drug
DDI-DrugBank.d367.s25|0-3|Cold|brand
DDI-DrugBank.d367.s25|5-7|and|drug
DDI-DrugBank.d367.s25|9-11|flu|drug
DDI-DrugBank.d367.s25|13-20|remedies|drug
DDI-DrugBank.d367.s25|21-21|.|drug
DDI-DrugBank.d454.s0|0-0|-|drug
DDI-DrugBank.d454.s0|2-11|Lofexidine|drug
DDI-DrugBank.d454.s0|13-15|may|drug
DDI-DrugBank.d454.s0|17-23|enhance|drug
DDI-DrugBank.d454.s0|25-27|the|drug
DDI-DrugBank.d454.s0|29-31|CNS|drug
DDI-DrugBank.d454.s0|33-42|depressive|drug
DDI-DrugBank.d454.s0|44-50|effects|drug
DDI-DrugBank.d454.s0|52-53|of|drug
DDI-DrugBank.d454.s0|55-61|alcohol|drug
DDI-DrugBank.d454.s0|62-62|,|drug
DDI-DrugBank.d454.s0|64-75|barbiturates|drug
DDI-DrugBank.d454.s0|77-79|and|drug
DDI-DrugBank.d454.s0|81-85|other|drug
DDI-DrugBank.d454.s0|87-95|sedatives|drug
DDI-DrugBank.d454.s1|0-0|.|drug
DDI-DrugBank.d454.s2|0-0|-|drug
DDI-DrugBank.d454.s2|2-11|Lofexidine|drug
DDI-DrugBank.d454.s2|13-15|may|drug
DDI-DrugBank.d454.s2|17-23|enhance|drug
DDI-DrugBank.d454.s2|25-27|the|drug
DDI-DrugBank.d454.s2|29-35|effects|drug
DDI-DrugBank.d454.s2|37-38|of|drug
DDI-DrugBank.d454.s2|40-56|anti-hypertensive|drug
DDI-DrugBank.d454.s2|58-61|drug|drug
DDI-DrugBank.d454.s2|63-69|therapy|drug
DDI-DrugBank.d454.s3|0-0|.|drug
DDI-DrugBank.d454.s4|0-0|-|drug
DDI-DrugBank.d454.s4|2-12|Concomitant|drug
DDI-DrugBank.d454.s4|14-16|use|drug
DDI-DrugBank.d454.s4|18-19|of|drug
DDI-DrugBank.d454.s4|21-29|tricyclic|drug
DDI-DrugBank.d454.s4|31-45|antidepressants|drug
DDI-DrugBank.d454.s4|47-49|may|drug
DDI-DrugBank.d454.s4|51-56|reduce|drug
DDI-DrugBank.d454.s4|58-60|the|drug
DDI-DrugBank.d454.s4|62-69|efficacy|drug
DDI-DrugBank.d454.s4|71-72|of|drug
DDI-DrugBank.d454.s4|74-83|lofexidine|drug
DDI-DrugBank.d454.s4|84-84|.|drug
DDI-MedLine.d118.s0|0-8|Sirolimus|brand
DDI-MedLine.d118.s0|9-9|:|drug
DDI-MedLine.d118.s0|11-19|mammalian|drug
DDI-MedLine.d118.s0|21-26|target|drug
DDI-MedLine.d118.s0|28-29|of|drug
DDI-MedLine.d118.s0|31-39|rapamycin|drug
DDI-MedLine.d118.s0|41-49|inhibitor|drug
DDI-MedLine.d118.s0|51-52|to|drug
DDI-MedLine.d118.s0|54-60|prevent|drug
DDI-MedLine.d118.s0|62-67|kidney|drug
DDI-MedLine.d118.s0|69-77|rejection|drug
DDI-MedLine.d118.s0|78-78|.|drug
DDI-MedLine.d118.s1|0-6|Current|drug
DDI-MedLine.d118.s1|8-24|immunosuppressive|drug
DDI-MedLine.d118.s1|26-34|therapies|drug
DDI-MedLine.d118.s1|36-38|are|drug
DDI-MedLine.d118.s1|40-48|effective|drug
DDI-MedLine.d118.s1|50-52|but|drug
DDI-MedLine.d118.s1|54-56|can|drug
DDI-MedLine.d118.s1|58-59|be|drug
DDI-MedLine.d118.s1|61-70|associated|drug
DDI-MedLine.d118.s1|72-75|with|drug
DDI-MedLine.d118.s1|77-87|significant|drug
DDI-MedLine.d118.s1|89-95|adverse|drug
DDI-MedLine.d118.s1|97-105|reactions|drug
DDI-MedLine.d118.s1|106-106|.|drug
DDI-MedLine.d118.s2|0-8|Sirolimus|brand
DDI-MedLine.d118.s2|10-14|works|drug
DDI-MedLine.d118.s2|16-26|differently|drug
DDI-MedLine.d118.s2|28-31|from|drug
DDI-MedLine.d118.s2|33-35|the|drug
DDI-MedLine.d118.s2|37-54|immunosuppressants|drug
DDI-MedLine.d118.s2|56-64|currently|drug
DDI-MedLine.d118.s2|66-74|available|drug
DDI-MedLine.d118.s2|75-75|,|drug
DDI-MedLine.d118.s2|77-79|and|drug
DDI-MedLine.d118.s2|81-86|except|drug
DDI-MedLine.d118.s2|88-90|for|drug
DDI-MedLine.d118.s2|92-100|increased|drug
DDI-MedLine.d118.s2|102-106|lipid|drug
DDI-MedLine.d118.s2|108-113|levels|drug
DDI-MedLine.d118.s2|114-114|,|drug
DDI-MedLine.d118.s2|116-118|the|drug
DDI-MedLine.d118.s2|120-126|adverse|drug
DDI-MedLine.d118.s2|128-135|reaction|drug
DDI-MedLine.d118.s2|137-143|profile|drug
DDI-MedLine.d118.s2|145-146|of|drug
DDI-MedLine.d118.s2|148-156|sirolimus|drug
DDI-MedLine.d118.s2|158-161|does|drug
DDI-MedLine.d118.s2|163-165|not|drug
DDI-MedLine.d118.s2|167-172|appear|drug
DDI-MedLine.d118.s2|174-175|to|drug
DDI-MedLine.d118.s2|177-183|overlap|drug
DDI-MedLine.d118.s2|185-186|to|drug
DDI-MedLine.d118.s2|188-190|any|drug
DDI-MedLine.d118.s2|192-196|great|drug
DDI-MedLine.d118.s2|198-203|extent|drug
DDI-MedLine.d118.s2|205-208|with|drug
DDI-MedLine.d118.s2|210-213|that|drug
DDI-MedLine.d118.s2|215-224|associated|drug
DDI-MedLine.d118.s2|226-229|with|drug
DDI-MedLine.d118.s2|231-242|cyclosporine|drug
DDI-MedLine.d118.s2|244-245|or|drug
DDI-MedLine.d118.s2|247-256|tacrolimus|drug
DDI-MedLine.d118.s2|257-257|.|drug
DDI-MedLine.d118.s3|0-4|While|drug
DDI-MedLine.d118.s3|6-15|additional|drug
DDI-MedLine.d118.s3|17-24|research|drug
DDI-MedLine.d118.s3|26-27|is|drug
DDI-MedLine.d118.s3|29-34|needed|drug
DDI-MedLine.d118.s3|35-35|,|drug
DDI-MedLine.d118.s3|37-39|the|drug
DDI-MedLine.d118.s3|41-47|initial|drug
DDI-MedLine.d118.s3|49-56|clinical|drug
DDI-MedLine.d118.s3|58-61|data|drug
DDI-MedLine.d118.s3|63-64|in|drug
DDI-MedLine.d118.s3|66-71|kidney|drug
DDI-MedLine.d118.s3|73-82|recipients|drug
DDI-MedLine.d118.s3|84-90|suggest|drug
DDI-MedLine.d118.s3|92-95|that|drug
DDI-MedLine.d118.s3|97-105|sirolimus|drug
DDI-MedLine.d118.s3|106-106|,|drug
DDI-MedLine.d118.s3|108-109|in|drug
DDI-MedLine.d118.s3|111-121|combination|drug
DDI-MedLine.d118.s3|123-126|with|drug
DDI-MedLine.d118.s3|128-139|cyclosporine|drug
DDI-MedLine.d118.s3|141-142|or|drug
DDI-MedLine.d118.s3|144-153|tacrolimus|drug
DDI-MedLine.d118.s3|154-154|,|drug
DDI-MedLine.d118.s3|156-160|might|drug
DDI-MedLine.d118.s3|162-165|have|drug
DDI-MedLine.d118.s3|167-169|the|drug
DDI-MedLine.d118.s3|171-179|potential|drug
DDI-MedLine.d118.s3|181-182|to|drug
DDI-MedLine.d118.s3|184-189|reduce|drug
DDI-MedLine.d118.s3|191-193|the|drug
DDI-MedLine.d118.s3|195-203|frequency|drug
DDI-MedLine.d118.s3|205-206|of|drug
DDI-MedLine.d118.s3|208-216|rejection|drug
DDI-MedLine.d118.s3|218-225|episodes|drug
DDI-MedLine.d118.s3|226-226|,|drug
DDI-MedLine.d118.s3|228-233|permit|drug
DDI-MedLine.d118.s3|235-244|reductions|drug
DDI-MedLine.d118.s3|246-247|in|drug
DDI-MedLine.d118.s3|249-260|cyclosporine|drug
DDI-MedLine.d118.s3|262-263|or|drug
DDI-MedLine.d118.s3|265-274|tacrolimus|drug
DDI-MedLine.d118.s3|276-281|dosage|drug
DDI-MedLine.d118.s3|282-282|,|drug
DDI-MedLine.d118.s3|284-286|and|drug
DDI-MedLine.d118.s3|288-293|permit|drug
DDI-MedLine.d118.s3|295-301|steroid|drug
DDI-MedLine.d118.s3|303-312|withdrawal|drug
DDI-MedLine.d118.s3|314-314|(|drug
DDI-MedLine.d118.s3|315-319|Kelly|drug
DDI-MedLine.d118.s3|320-320|,|drug
DDI-MedLine.d118.s3|322-325|1999|drug
DDI-MedLine.d118.s3|326-326|)|drug
DDI-MedLine.d118.s3|327-327|.|drug
DDI-DrugBank.d269.s0|0-9|Inhibitors|drug
DDI-DrugBank.d269.s0|11-12|of|drug
DDI-DrugBank.d269.s0|14-19|CYP2D6|drug
DDI-DrugBank.d269.s0|20-20|;|drug
DDI-DrugBank.d269.s1|0-3|poor|drug
DDI-DrugBank.d269.s1|5-16|metabolizers|drug
DDI-DrugBank.d269.s1|18-19|of|drug
DDI-DrugBank.d269.s1|21-31|debrisoquin|drug
DDI-DrugBank.d269.s1|32-32|:|drug
DDI-DrugBank.d269.s1|34-45|Interactions|drug
DDI-DrugBank.d269.s1|47-48|of|drug
DDI-DrugBank.d269.s1|50-59|carvedilol|drug
DDI-DrugBank.d269.s1|61-64|with|drug
DDI-DrugBank.d269.s1|66-71|strong|drug
DDI-DrugBank.d269.s1|73-82|inhibitors|drug
DDI-DrugBank.d269.s1|84-85|of|drug
DDI-DrugBank.d269.s1|87-92|CYP2D6|drug
DDI-DrugBank.d269.s1|94-94|(|drug
DDI-DrugBank.d269.s1|95-98|such|drug
DDI-DrugBank.d269.s1|100-101|as|drug
DDI-DrugBank.d269.s1|103-111|quinidine|drug
DDI-DrugBank.d269.s1|112-112|,|drug
DDI-DrugBank.d269.s1|114-123|fluoxetine|drug
DDI-DrugBank.d269.s1|124-124|,|drug
DDI-DrugBank.d269.s1|126-135|paroxetine|drug
DDI-DrugBank.d269.s1|136-136|,|drug
DDI-DrugBank.d269.s1|138-140|and|drug
DDI-DrugBank.d269.s1|142-152|propafenone|drug
DDI-DrugBank.d269.s1|153-153|)|drug
DDI-DrugBank.d269.s1|155-158|have|drug
DDI-DrugBank.d269.s1|160-162|not|drug
DDI-DrugBank.d269.s1|164-167|been|drug
DDI-DrugBank.d269.s1|169-175|studied|drug
DDI-DrugBank.d269.s1|176-176|,|drug
DDI-DrugBank.d269.s1|178-180|but|drug
DDI-DrugBank.d269.s1|182-186|these|drug
DDI-DrugBank.d269.s1|188-192|drugs|drug
DDI-DrugBank.d269.s1|194-198|would|drug
DDI-DrugBank.d269.s1|200-201|be|drug
DDI-DrugBank.d269.s1|203-210|expected|drug
DDI-DrugBank.d269.s1|212-213|to|drug
DDI-DrugBank.d269.s1|215-222|increase|drug
DDI-DrugBank.d269.s1|224-228|blood|drug
DDI-DrugBank.d269.s1|230-235|levels|drug
DDI-DrugBank.d269.s1|237-238|of|drug
DDI-DrugBank.d269.s1|240-242|the|drug
DDI-DrugBank.d269.s1|244-244|R|drug
DDI-DrugBank.d269.s1|245-245|(|drug
DDI-DrugBank.d269.s1|246-246|+|drug
DDI-DrugBank.d269.s1|247-247|)|drug
DDI-DrugBank.d269.s1|249-258|enantiomer|drug
DDI-DrugBank.d269.s1|260-261|of|drug
DDI-DrugBank.d269.s1|263-272|carvedilol|drug
DDI-DrugBank.d269.s1|274-274|.|drug
DDI-DrugBank.d269.s2|0-12|Retrospective|drug
DDI-DrugBank.d269.s2|14-21|analysis|drug
DDI-DrugBank.d269.s2|23-24|of|drug
DDI-DrugBank.d269.s2|26-29|side|drug
DDI-DrugBank.d269.s2|31-37|effects|drug
DDI-DrugBank.d269.s2|39-40|in|drug
DDI-DrugBank.d269.s2|42-49|clinical|drug
DDI-DrugBank.d269.s2|51-56|trials|drug
DDI-DrugBank.d269.s2|58-63|showed|drug
DDI-DrugBank.d269.s2|65-68|that|drug
DDI-DrugBank.d269.s2|70-73|poor|drug
DDI-DrugBank.d269.s2|75-77|2D6|drug
DDI-DrugBank.d269.s2|79-90|metabolizers|drug
DDI-DrugBank.d269.s2|92-94|had|drug
DDI-DrugBank.d269.s2|96-96|a|drug
DDI-DrugBank.d269.s2|98-103|higher|drug
DDI-DrugBank.d269.s2|105-108|rate|drug
DDI-DrugBank.d269.s2|110-111|of|drug
DDI-DrugBank.d269.s2|113-121|dizziness|drug
DDI-DrugBank.d269.s2|123-128|during|drug
DDI-DrugBank.d269.s2|130-141|up-titration|drug
DDI-DrugBank.d269.s2|142-142|,|drug
DDI-DrugBank.d269.s2|144-153|presumably|drug
DDI-DrugBank.d269.s2|155-163|resulting|drug
DDI-DrugBank.d269.s2|165-168|from|drug
DDI-DrugBank.d269.s2|170-181|vasodilating|drug
DDI-DrugBank.d269.s2|183-189|effects|drug
DDI-DrugBank.d269.s2|191-192|of|drug
DDI-DrugBank.d269.s2|194-196|the|drug
DDI-DrugBank.d269.s2|198-203|higher|drug
DDI-DrugBank.d269.s2|205-218|concentrations|drug
DDI-DrugBank.d269.s2|220-221|of|drug
DDI-DrugBank.d269.s2|223-225|the|drug
DDI-DrugBank.d269.s2|227-236|a-blocking|drug
DDI-DrugBank.d269.s2|238-238|R|drug
DDI-DrugBank.d269.s2|239-239|(|drug
DDI-DrugBank.d269.s2|240-240|+|drug
DDI-DrugBank.d269.s2|241-241|)|drug
DDI-DrugBank.d269.s2|243-252|enantiomer|drug
DDI-DrugBank.d269.s2|253-253|.|drug
DDI-DrugBank.d269.s3|0-22|Catecholamine-depleting|drug
DDI-DrugBank.d269.s3|24-29|Agents|drug
DDI-DrugBank.d269.s3|30-30|:|drug
DDI-DrugBank.d269.s3|32-39|Patients|drug
DDI-DrugBank.d269.s3|41-46|taking|drug
DDI-DrugBank.d269.s3|48-51|both|drug
DDI-DrugBank.d269.s3|53-58|agents|drug
DDI-DrugBank.d269.s3|60-63|with|drug
DDI-DrugBank.d269.s3|65-74|b-blocking|drug
DDI-DrugBank.d269.s3|76-85|properties|drug
DDI-DrugBank.d269.s3|87-89|and|drug
DDI-DrugBank.d269.s3|91-91|a|drug
DDI-DrugBank.d269.s3|93-96|drug|drug
DDI-DrugBank.d269.s3|98-101|that|drug
DDI-DrugBank.d269.s3|103-105|can|drug
DDI-DrugBank.d269.s3|107-113|deplete|drug
DDI-DrugBank.d269.s3|115-128|catecholamines|drug
DDI-DrugBank.d269.s3|130-130|(|drug
DDI-DrugBank.d269.s3|131-134|e.g.|drug
DDI-DrugBank.d269.s3|135-135|,|drug
DDI-DrugBank.d269.s3|137-145|reserpine|drug
DDI-DrugBank.d269.s3|147-149|and|drug
DDI-DrugBank.d269.s3|151-159|monoamine|drug
DDI-DrugBank.d269.s3|161-167|oxidase|drug
DDI-DrugBank.d269.s3|169-178|inhibitors|drug
DDI-DrugBank.d269.s3|179-179|)|drug
DDI-DrugBank.d269.s3|181-186|should|drug
DDI-DrugBank.d269.s3|188-189|be|drug
DDI-DrugBank.d269.s3|191-198|observed|drug
DDI-DrugBank.d269.s3|200-206|closely|drug
DDI-DrugBank.d269.s3|208-210|for|drug
DDI-DrugBank.d269.s3|212-216|signs|drug
DDI-DrugBank.d269.s3|218-219|of|drug
DDI-DrugBank.d269.s3|221-231|hypotension|drug
DDI-DrugBank.d269.s3|233-238|and/or|drug
DDI-DrugBank.d269.s3|240-245|severe|drug
DDI-DrugBank.d269.s3|247-257|bradycardia|drug
DDI-DrugBank.d269.s3|258-258|.|drug
DDI-DrugBank.d269.s4|0-8|Clonidine|brand
DDI-DrugBank.d269.s4|9-9|:|drug
DDI-DrugBank.d269.s4|11-21|Concomitant|drug
DDI-DrugBank.d269.s4|23-36|administration|drug
DDI-DrugBank.d269.s4|38-39|of|drug
DDI-DrugBank.d269.s4|41-49|clonidine|drug
DDI-DrugBank.d269.s4|51-54|with|drug
DDI-DrugBank.d269.s4|56-61|agents|drug
DDI-DrugBank.d269.s4|63-66|with|drug
DDI-DrugBank.d269.s4|68-77|b-blocking|drug
DDI-DrugBank.d269.s4|79-88|properties|drug
DDI-DrugBank.d269.s4|90-92|may|drug
DDI-DrugBank.d269.s4|94-103|potentiate|drug
DDI-DrugBank.d269.s4|105-119|blood-pressure-|drug
DDI-DrugBank.d269.s4|121-123|and|drug
DDI-DrugBank.d269.s4|125-143|heart-rate-lowering|drug
DDI-DrugBank.d269.s4|145-151|effects|drug
DDI-DrugBank.d269.s4|152-152|.|drug
DDI-DrugBank.d269.s5|0-3|When|drug
DDI-DrugBank.d269.s5|5-15|concomitant|drug
DDI-DrugBank.d269.s5|17-25|treatment|drug
DDI-DrugBank.d269.s5|27-30|with|drug
DDI-DrugBank.d269.s5|32-37|agents|drug
DDI-DrugBank.d269.s5|39-42|with|drug
DDI-DrugBank.d269.s5|44-53|b-blocking|drug
DDI-DrugBank.d269.s5|55-64|properties|drug
DDI-DrugBank.d269.s5|66-68|and|drug
DDI-DrugBank.d269.s5|70-78|clonidine|drug
DDI-DrugBank.d269.s5|80-81|is|drug
DDI-DrugBank.d269.s5|83-84|to|drug
DDI-DrugBank.d269.s5|86-87|be|drug
DDI-DrugBank.d269.s5|89-98|terminated|drug
DDI-DrugBank.d269.s5|99-99|,|drug
DDI-DrugBank.d269.s5|101-103|the|drug
DDI-DrugBank.d269.s5|105-114|b-blocking|drug
DDI-DrugBank.d269.s5|116-120|agent|drug
DDI-DrugBank.d269.s5|122-127|should|drug
DDI-DrugBank.d269.s5|129-130|be|drug
DDI-DrugBank.d269.s5|132-143|discontinued|drug
DDI-DrugBank.d269.s5|145-149|first|drug
DDI-DrugBank.d269.s5|150-150|.|drug
DDI-DrugBank.d269.s6|0-8|Clonidine|brand
DDI-DrugBank.d269.s6|10-16|therapy|drug
DDI-DrugBank.d269.s6|18-20|can|drug
DDI-DrugBank.d269.s6|22-25|then|drug
DDI-DrugBank.d269.s6|27-28|be|drug
DDI-DrugBank.d269.s6|30-41|discontinued|drug
DDI-DrugBank.d269.s6|43-49|several|drug
DDI-DrugBank.d269.s6|51-54|days|drug
DDI-DrugBank.d269.s6|56-60|later|drug
DDI-DrugBank.d269.s6|62-63|by|drug
DDI-DrugBank.d269.s6|65-73|gradually|drug
DDI-DrugBank.d269.s6|75-84|decreasing|drug
DDI-DrugBank.d269.s6|86-88|the|drug
DDI-DrugBank.d269.s6|90-95|dosage|drug
DDI-DrugBank.d269.s6|96-96|.|drug
DDI-DrugBank.d269.s7|0-11|Cyclosporine|brand
DDI-DrugBank.d269.s7|12-12|:|drug
DDI-DrugBank.d269.s7|14-19|Modest|drug
DDI-DrugBank.d269.s7|21-29|increases|drug
DDI-DrugBank.d269.s7|31-32|in|drug
DDI-DrugBank.d269.s7|34-37|mean|drug
DDI-DrugBank.d269.s7|39-44|trough|drug
DDI-DrugBank.d269.s7|46-57|cyclosporine|drug
DDI-DrugBank.d269.s7|59-72|concentrations|drug
DDI-DrugBank.d269.s7|74-77|were|drug
DDI-DrugBank.d269.s7|79-86|observed|drug
DDI-DrugBank.d269.s7|88-96|following|drug
DDI-DrugBank.d269.s7|98-107|initiation|drug
DDI-DrugBank.d269.s7|109-110|of|drug
DDI-DrugBank.d269.s7|112-121|carvedilol|drug
DDI-DrugBank.d269.s7|123-131|treatment|drug
DDI-DrugBank.d269.s7|133-134|in|drug
DDI-DrugBank.d269.s7|136-137|21|drug
DDI-DrugBank.d269.s7|139-143|renal|drug
DDI-DrugBank.d269.s7|145-154|transplant|drug
DDI-DrugBank.d269.s7|156-163|patients|drug
DDI-DrugBank.d269.s7|165-173|suffering|drug
DDI-DrugBank.d269.s7|175-178|from|drug
DDI-DrugBank.d269.s7|180-186|chronic|drug
DDI-DrugBank.d269.s7|188-195|vascular|drug
DDI-DrugBank.d269.s7|197-205|rejection|drug
DDI-DrugBank.d269.s7|206-206|.|drug
DDI-DrugBank.d269.s8|0-1|In|drug
DDI-DrugBank.d269.s8|3-7|about|drug
DDI-DrugBank.d269.s8|9-10|30|drug
DDI-DrugBank.d269.s8|11-11|%|drug
DDI-DrugBank.d269.s8|13-14|of|drug
DDI-DrugBank.d269.s8|16-23|patients|drug
DDI-DrugBank.d269.s8|24-24|,|drug
DDI-DrugBank.d269.s8|26-28|the|drug
DDI-DrugBank.d269.s8|30-33|dose|drug
DDI-DrugBank.d269.s8|35-36|of|drug
DDI-DrugBank.d269.s8|38-49|cyclosporine|drug
DDI-DrugBank.d269.s8|51-53|had|drug
DDI-DrugBank.d269.s8|55-56|to|drug
DDI-DrugBank.d269.s8|58-59|be|drug
DDI-DrugBank.d269.s8|61-67|reduced|drug
DDI-DrugBank.d269.s8|69-70|in|drug
DDI-DrugBank.d269.s8|72-76|order|drug
DDI-DrugBank.d269.s8|78-79|to|drug
DDI-DrugBank.d269.s8|81-88|maintain|drug
DDI-DrugBank.d269.s8|90-101|cyclosporine|drug
DDI-DrugBank.d269.s8|103-116|concentrations|drug
DDI-DrugBank.d269.s8|118-123|within|drug
DDI-DrugBank.d269.s8|125-127|the|drug
DDI-DrugBank.d269.s8|129-139|therapeutic|drug
DDI-DrugBank.d269.s8|141-145|range|drug
DDI-DrugBank.d269.s8|146-146|,|drug
DDI-DrugBank.d269.s8|148-152|while|drug
DDI-DrugBank.d269.s8|154-155|in|drug
DDI-DrugBank.d269.s8|157-159|the|drug
DDI-DrugBank.d269.s8|161-169|remainder|drug
DDI-DrugBank.d269.s8|171-172|no|drug
DDI-DrugBank.d269.s8|174-183|adjustment|drug
DDI-DrugBank.d269.s8|185-187|was|drug
DDI-DrugBank.d269.s8|189-194|needed|drug
DDI-DrugBank.d269.s8|195-195|.|drug
DDI-DrugBank.d269.s9|0-1|On|drug
DDI-DrugBank.d269.s9|3-5|the|drug
DDI-DrugBank.d269.s9|7-13|average|drug
DDI-DrugBank.d269.s9|15-17|for|drug
DDI-DrugBank.d269.s9|19-21|the|drug
DDI-DrugBank.d269.s9|23-27|group|drug
DDI-DrugBank.d269.s9|28-28|,|drug
DDI-DrugBank.d269.s9|30-32|the|drug
DDI-DrugBank.d269.s9|34-37|dose|drug
DDI-DrugBank.d269.s9|39-40|of|drug
DDI-DrugBank.d269.s9|42-53|cyclosporine|drug
DDI-DrugBank.d269.s9|55-57|was|drug
DDI-DrugBank.d269.s9|59-65|reduced|drug
DDI-DrugBank.d269.s9|67-71|about|drug
DDI-DrugBank.d269.s9|73-74|20|drug
DDI-DrugBank.d269.s9|75-75|%|drug
DDI-DrugBank.d269.s9|77-78|in|drug
DDI-DrugBank.d269.s9|80-84|these|drug
DDI-DrugBank.d269.s9|86-93|patients|drug
DDI-DrugBank.d269.s9|94-94|.|drug
DDI-DrugBank.d269.s10|0-2|Due|drug
DDI-DrugBank.d269.s10|4-5|to|drug
DDI-DrugBank.d269.s10|7-10|wide|drug
DDI-DrugBank.d269.s10|12-26|interindividual|drug
DDI-DrugBank.d269.s10|28-38|variability|drug
DDI-DrugBank.d269.s10|40-41|in|drug
DDI-DrugBank.d269.s10|43-45|the|drug
DDI-DrugBank.d269.s10|47-50|dose|drug
DDI-DrugBank.d269.s10|52-61|adjustment|drug
DDI-DrugBank.d269.s10|63-70|required|drug
DDI-DrugBank.d269.s10|71-71|,|drug
DDI-DrugBank.d269.s10|73-74|it|drug
DDI-DrugBank.d269.s10|76-77|is|drug
DDI-DrugBank.d269.s10|79-89|recommended|drug
DDI-DrugBank.d269.s10|91-94|that|drug
DDI-DrugBank.d269.s10|96-107|cyclosporine|drug
DDI-DrugBank.d269.s10|109-122|concentrations|drug
DDI-DrugBank.d269.s10|124-125|be|drug
DDI-DrugBank.d269.s10|127-135|monitored|drug
DDI-DrugBank.d269.s10|137-143|closely|drug
DDI-DrugBank.d269.s10|145-149|after|drug
DDI-DrugBank.d269.s10|151-160|initiation|drug
DDI-DrugBank.d269.s10|162-163|of|drug
DDI-DrugBank.d269.s10|165-174|carvedilol|drug
DDI-DrugBank.d269.s10|176-182|therapy|drug
DDI-DrugBank.d269.s10|184-186|and|drug
DDI-DrugBank.d269.s10|188-191|that|drug
DDI-DrugBank.d269.s10|193-195|the|drug
DDI-DrugBank.d269.s10|197-200|dose|drug
DDI-DrugBank.d269.s10|202-203|of|drug
DDI-DrugBank.d269.s10|205-216|cyclosporine|drug
DDI-DrugBank.d269.s10|218-219|be|drug
DDI-DrugBank.d269.s10|221-228|adjusted|drug
DDI-DrugBank.d269.s10|230-231|as|drug
DDI-DrugBank.d269.s10|233-243|appropriate|drug
DDI-DrugBank.d269.s10|244-244|.|drug
DDI-DrugBank.d269.s11|0-6|Digoxin|brand
DDI-DrugBank.d269.s11|7-7|:|drug
DDI-DrugBank.d269.s11|9-15|Digoxin|brand
DDI-DrugBank.d269.s11|17-30|concentrations|drug
DDI-DrugBank.d269.s11|32-34|are|drug
DDI-DrugBank.d269.s11|36-44|increased|drug
DDI-DrugBank.d269.s11|46-47|by|drug
DDI-DrugBank.d269.s11|49-53|about|drug
DDI-DrugBank.d269.s11|55-56|15|drug
DDI-DrugBank.d269.s11|57-57|%|drug
DDI-DrugBank.d269.s11|59-62|when|drug
DDI-DrugBank.d269.s11|64-70|digoxin|drug
DDI-DrugBank.d269.s11|72-74|and|drug
DDI-DrugBank.d269.s11|76-85|carvedilol|drug
DDI-DrugBank.d269.s11|87-89|are|drug
DDI-DrugBank.d269.s11|91-102|administered|drug
DDI-DrugBank.d269.s11|104-116|concomitantly|drug
DDI-DrugBank.d269.s11|117-117|.|drug
DDI-DrugBank.d269.s12|0-3|Both|drug
DDI-DrugBank.d269.s12|5-11|digoxin|drug
DDI-DrugBank.d269.s12|13-15|and|drug
DDI-DrugBank.d269.s12|17-21|COREG|drug
DDI-DrugBank.d269.s12|23-26|slow|drug
DDI-DrugBank.d269.s12|28-29|AV|drug
DDI-DrugBank.d269.s12|31-40|conduction|drug
DDI-DrugBank.d269.s12|41-41|.|drug
DDI-DrugBank.d269.s13|0-8|Therefore|drug
DDI-DrugBank.d269.s13|9-9|,|drug
DDI-DrugBank.d269.s13|11-19|increased|drug
DDI-DrugBank.d269.s13|21-30|monitoring|drug
DDI-DrugBank.d269.s13|32-33|of|drug
DDI-DrugBank.d269.s13|35-41|digoxin|drug
DDI-DrugBank.d269.s13|43-44|is|drug
DDI-DrugBank.d269.s13|46-56|recommended|drug
DDI-DrugBank.d269.s13|58-61|when|drug
DDI-DrugBank.d269.s13|63-72|initiating|drug
DDI-DrugBank.d269.s13|73-73|,|drug
DDI-DrugBank.d269.s13|75-83|adjusting|drug
DDI-DrugBank.d269.s13|84-84|,|drug
DDI-DrugBank.d269.s13|86-87|or|drug
DDI-DrugBank.d269.s13|89-101|discontinuing|drug
DDI-DrugBank.d269.s13|103-107|COREG|drug
DDI-DrugBank.d269.s13|108-108|.|drug
DDI-DrugBank.d269.s14|0-7|Inducers|drug
DDI-DrugBank.d269.s14|9-11|and|drug
DDI-DrugBank.d269.s14|13-22|Inhibitors|drug
DDI-DrugBank.d269.s14|24-25|of|drug
DDI-DrugBank.d269.s14|27-33|Hepatic|drug
DDI-DrugBank.d269.s14|35-44|Metabolism|drug
DDI-DrugBank.d269.s14|45-45|:|drug
DDI-DrugBank.d269.s14|47-54|Rifampin|brand
DDI-DrugBank.d269.s14|56-62|reduced|drug
DDI-DrugBank.d269.s14|64-69|plasma|drug
DDI-DrugBank.d269.s14|71-84|concentrations|drug
DDI-DrugBank.d269.s14|86-87|of|drug
DDI-DrugBank.d269.s14|89-98|carvedilol|drug
DDI-DrugBank.d269.s14|100-101|by|drug
DDI-DrugBank.d269.s14|103-107|about|drug
DDI-DrugBank.d269.s14|109-110|70|drug
DDI-DrugBank.d269.s14|111-111|%|drug
DDI-DrugBank.d269.s14|112-112|.|drug
DDI-DrugBank.d269.s15|0-9|Cimetidine|brand
DDI-DrugBank.d269.s15|11-19|increased|drug
DDI-DrugBank.d269.s15|21-23|AUC|drug
DDI-DrugBank.d269.s15|25-26|by|drug
DDI-DrugBank.d269.s15|28-32|about|drug
DDI-DrugBank.d269.s15|34-35|30|drug
DDI-DrugBank.d269.s15|36-36|%|drug
DDI-DrugBank.d269.s15|38-40|but|drug
DDI-DrugBank.d269.s15|42-47|caused|drug
DDI-DrugBank.d269.s15|49-50|no|drug
DDI-DrugBank.d269.s15|52-57|change|drug
DDI-DrugBank.d269.s15|59-60|in|drug
DDI-DrugBank.d269.s15|62-65|Cmax|drug
DDI-DrugBank.d269.s15|66-66|.|drug
DDI-DrugBank.d269.s16|0-6|Calcium|brand
DDI-DrugBank.d269.s16|8-14|Channel|drug
DDI-DrugBank.d269.s16|16-23|Blockers|drug
DDI-DrugBank.d269.s16|24-24|:|drug
DDI-DrugBank.d269.s16|26-33|Isolated|drug
DDI-DrugBank.d269.s16|35-39|cases|drug
DDI-DrugBank.d269.s16|41-42|of|drug
DDI-DrugBank.d269.s16|44-53|conduction|drug
DDI-DrugBank.d269.s16|55-65|disturbance|drug
DDI-DrugBank.d269.s16|67-67|(|drug
DDI-DrugBank.d269.s16|68-73|rarely|drug
DDI-DrugBank.d269.s16|75-78|with|drug
DDI-DrugBank.d269.s16|80-90|hemodynamic|drug
DDI-DrugBank.d269.s16|92-101|compromise|drug
DDI-DrugBank.d269.s16|102-102|)|drug
DDI-DrugBank.d269.s16|104-107|have|drug
DDI-DrugBank.d269.s16|109-112|been|drug
DDI-DrugBank.d269.s16|114-121|observed|drug
DDI-DrugBank.d269.s16|123-126|when|drug
DDI-DrugBank.d269.s16|128-132|COREG|drug
DDI-DrugBank.d269.s16|134-135|is|drug
DDI-DrugBank.d269.s16|137-151|co-administered|drug
DDI-DrugBank.d269.s16|153-156|with|drug
DDI-DrugBank.d269.s16|158-166|diltiazem|drug
DDI-DrugBank.d269.s16|167-167|.|drug
DDI-DrugBank.d269.s17|0-1|As|drug
DDI-DrugBank.d269.s17|3-6|with|drug
DDI-DrugBank.d269.s17|8-12|other|drug
DDI-DrugBank.d269.s17|14-19|agents|drug
DDI-DrugBank.d269.s17|21-24|with|drug
DDI-DrugBank.d269.s17|26-35|b-blocking|drug
DDI-DrugBank.d269.s17|37-46|properties|drug
DDI-DrugBank.d269.s17|47-47|,|drug
DDI-DrugBank.d269.s17|49-50|if|drug
DDI-DrugBank.d269.s17|52-56|COREG|drug
DDI-DrugBank.d269.s17|58-59|is|drug
DDI-DrugBank.d269.s17|61-62|to|drug
DDI-DrugBank.d269.s17|64-65|be|drug
DDI-DrugBank.d269.s17|67-78|administered|drug
DDI-DrugBank.d269.s17|80-85|orally|drug
DDI-DrugBank.d269.s17|87-90|with|drug
DDI-DrugBank.d269.s17|92-98|calcium|drug
DDI-DrugBank.d269.s17|100-106|channel|drug
DDI-DrugBank.d269.s17|108-115|blockers|drug
DDI-DrugBank.d269.s17|117-118|of|drug
DDI-DrugBank.d269.s17|120-122|the|drug
DDI-DrugBank.d269.s17|124-132|verapamil|drug
DDI-DrugBank.d269.s17|134-135|or|drug
DDI-DrugBank.d269.s17|137-145|diltiazem|drug
DDI-DrugBank.d269.s17|147-150|type|drug
DDI-DrugBank.d269.s17|151-151|,|drug
DDI-DrugBank.d269.s17|153-154|it|drug
DDI-DrugBank.d269.s17|156-157|is|drug
DDI-DrugBank.d269.s17|159-169|recommended|drug
DDI-DrugBank.d269.s17|171-174|that|drug
DDI-DrugBank.d269.s17|176-178|ECG|drug
DDI-DrugBank.d269.s17|180-182|and|drug
DDI-DrugBank.d269.s17|184-188|blood|drug
DDI-DrugBank.d269.s17|190-197|pressure|drug
DDI-DrugBank.d269.s17|199-200|be|drug
DDI-DrugBank.d269.s17|202-210|monitored|drug
DDI-DrugBank.d269.s17|211-211|.|drug
DDI-DrugBank.d269.s18|0-6|Insulin|drug
DDI-DrugBank.d269.s18|8-9|or|drug
DDI-DrugBank.d269.s18|11-14|Oral|drug
DDI-DrugBank.d269.s18|16-28|Hypoglycemics|drug
DDI-DrugBank.d269.s18|29-29|:|drug
DDI-DrugBank.d269.s18|31-36|Agents|drug
DDI-DrugBank.d269.s18|38-41|with|drug
DDI-DrugBank.d269.s18|43-52|b-blocking|drug
DDI-DrugBank.d269.s18|54-63|properties|drug
DDI-DrugBank.d269.s18|65-67|may|drug
DDI-DrugBank.d269.s18|69-75|enhance|drug
DDI-DrugBank.d269.s18|77-79|the|drug
DDI-DrugBank.d269.s18|81-100|blood-sugar-reducing|drug
DDI-DrugBank.d269.s18|102-107|effect|drug
DDI-DrugBank.d269.s18|109-110|of|drug
DDI-DrugBank.d269.s18|112-118|insulin|drug
DDI-DrugBank.d269.s18|120-122|and|drug
DDI-DrugBank.d269.s18|124-127|oral|drug
DDI-DrugBank.d269.s18|129-141|hypoglycemics|drug
DDI-DrugBank.d269.s18|142-142|.|drug
DDI-DrugBank.d269.s19|0-8|Therefore|drug
DDI-DrugBank.d269.s19|9-9|,|drug
DDI-DrugBank.d269.s19|11-12|in|drug
DDI-DrugBank.d269.s19|14-21|patients|drug
DDI-DrugBank.d269.s19|23-28|taking|drug
DDI-DrugBank.d269.s19|30-36|insulin|drug
DDI-DrugBank.d269.s19|38-39|or|drug
DDI-DrugBank.d269.s19|41-44|oral|drug
DDI-DrugBank.d269.s19|46-58|hypoglycemics|drug
DDI-DrugBank.d269.s19|59-59|,|drug
DDI-DrugBank.d269.s19|61-67|regular|drug
DDI-DrugBank.d269.s19|69-78|monitoring|drug
DDI-DrugBank.d269.s19|80-81|of|drug
DDI-DrugBank.d269.s19|83-87|blood|drug
DDI-DrugBank.d269.s19|89-95|glucose|drug
DDI-DrugBank.d269.s19|97-98|is|drug
DDI-DrugBank.d269.s19|100-110|recommended|drug
DDI-DrugBank.d269.s19|111-111|.|drug
DDI-DrugBank.d530.s0|0-12|Non-selective|drug
DDI-DrugBank.d530.s0|14-22|monoamine|drug
DDI-DrugBank.d530.s0|24-30|oxidase|drug
DDI-DrugBank.d530.s0|32-32|(|drug
DDI-DrugBank.d530.s0|33-35|MAO|drug
DDI-DrugBank.d530.s0|36-36|)|drug
DDI-DrugBank.d530.s0|38-47|inhibitors|drug
DDI-DrugBank.d530.s0|49-49|-|drug
DDI-DrugBank.d530.s0|51-59|including|drug
DDI-DrugBank.d530.s0|61-70|phenelzine|drug
DDI-DrugBank.d530.s0|72-78|sulfate|drug
DDI-DrugBank.d530.s0|79-79|,|drug
DDI-DrugBank.d530.s0|81-95|tranylcypromine|drug
DDI-DrugBank.d530.s0|97-103|sulfate|drug
DDI-DrugBank.d530.s0|105-107|and|drug
DDI-DrugBank.d530.s0|109-117|pargyline|drug
DDI-DrugBank.d530.s0|119-121|HC1|drug
DDI-DrugBank.d530.s0|122-122|.|drug
DDI-DrugBank.d530.s1|0-10|Concomitant|drug
DDI-DrugBank.d530.s1|12-14|use|drug
DDI-DrugBank.d530.s1|16-17|of|drug
DDI-DrugBank.d530.s1|19-33|L-phenylalanine|drug
DDI-DrugBank.d530.s1|35-37|and|drug
DDI-DrugBank.d530.s1|39-51|non-selective|drug
DDI-DrugBank.d530.s1|53-55|MAO|drug
DDI-DrugBank.d530.s1|57-66|inhibitors|drug
DDI-DrugBank.d530.s1|68-70|may|drug
DDI-DrugBank.d530.s1|72-76|cause|drug
DDI-DrugBank.d530.s1|78-89|hypertension|drug
DDI-DrugBank.d530.s1|90-90|.|drug
DDI-DrugBank.d530.s2|0-9|Selegiline|brand
DDI-DrugBank.d530.s2|11-11|-|drug
DDI-DrugBank.d530.s2|13-27|L-phenylalanine|drug
DDI-DrugBank.d530.s2|29-31|and|drug
DDI-DrugBank.d530.s2|33-35|the|drug
DDI-DrugBank.d530.s2|37-45|selective|drug
DDI-DrugBank.d530.s2|47-49|MAO|drug
DDI-DrugBank.d530.s2|51-59|inhibitor|drug
DDI-DrugBank.d530.s2|61-70|selegiline|drug
DDI-DrugBank.d530.s2|72-74|may|drug
DDI-DrugBank.d530.s2|76-79|have|drug
DDI-DrugBank.d530.s2|81-91|synergistic|drug
DDI-DrugBank.d530.s2|93-106|antidepressant|drug
DDI-DrugBank.d530.s2|108-115|activity|drug
DDI-DrugBank.d530.s2|117-118|if|drug
DDI-DrugBank.d530.s2|120-123|used|drug
DDI-DrugBank.d530.s2|125-137|concomitantly|drug
DDI-DrugBank.d530.s2|138-138|.|drug
DDI-DrugBank.d530.s3|0-10|Neuroleptic|drug
DDI-DrugBank.d530.s3|12-16|Drugs|drug
DDI-DrugBank.d530.s3|18-18|-|drug
DDI-DrugBank.d530.s3|20-34|L-phenylalanine|drug
DDI-DrugBank.d530.s3|36-38|may|drug
DDI-DrugBank.d530.s3|40-49|potentiate|drug
DDI-DrugBank.d530.s3|51-53|the|drug
DDI-DrugBank.d530.s3|55-61|tardive|drug
DDI-DrugBank.d530.s3|63-72|dyskinesia|drug
DDI-DrugBank.d530.s3|74-77|side|drug
DDI-DrugBank.d530.s3|79-87|reactions|drug
DDI-DrugBank.d530.s3|89-90|of|drug
DDI-DrugBank.d530.s3|92-102|neuroleptic|drug
DDI-DrugBank.d530.s3|104-108|drugs|drug
DDI-DrugBank.d530.s3|110-111|if|drug
DDI-DrugBank.d530.s3|113-116|used|drug
DDI-DrugBank.d530.s3|118-130|concomitantly|drug
DDI-DrugBank.d530.s3|132-135|with|drug
DDI-DrugBank.d530.s3|137-140|them|drug
DDI-DrugBank.d530.s3|141-141|.|drug
DDI-DrugBank.d395.s0|0-6|Bismuth|brand
DDI-DrugBank.d395.s0|7-7|:|drug
DDI-DrugBank.d395.s0|9-15|Bismuth|brand
DDI-DrugBank.d395.s0|17-29|subsalicylate|drug
DDI-DrugBank.d395.s0|30-30|,|drug
DDI-DrugBank.d395.s0|32-36|given|drug
DDI-DrugBank.d395.s0|38-50|concomitantly|drug
DDI-DrugBank.d395.s0|52-55|with|drug
DDI-DrugBank.d395.s0|57-64|enoxacin|drug
DDI-DrugBank.d395.s0|66-67|or|drug
DDI-DrugBank.d395.s0|69-70|60|drug
DDI-DrugBank.d395.s0|72-78|minutes|drug
DDI-DrugBank.d395.s0|80-88|following|drug
DDI-DrugBank.d395.s0|90-97|enoxacin|drug
DDI-DrugBank.d395.s0|99-112|administration|drug
DDI-DrugBank.d395.s0|113-113|,|drug
DDI-DrugBank.d395.s0|115-123|decreased|drug
DDI-DrugBank.d395.s0|125-132|enoxacin|drug
DDI-DrugBank.d395.s0|134-148|bioavailability|drug
DDI-DrugBank.d395.s0|150-151|by|drug
DDI-DrugBank.d395.s0|153-165|approximately|drug
DDI-DrugBank.d395.s0|167-168|25|drug
DDI-DrugBank.d395.s0|169-169|%|drug
DDI-DrugBank.d395.s0|170-170|.|drug
DDI-DrugBank.d395.s1|0-3|Thus|drug
DDI-DrugBank.d395.s1|4-4|,|drug
DDI-DrugBank.d395.s1|6-16|concomitant|drug
DDI-DrugBank.d395.s1|18-31|administration|drug
DDI-DrugBank.d395.s1|33-34|of|drug
DDI-DrugBank.d395.s1|36-43|enoxacin|drug
DDI-DrugBank.d395.s1|45-47|and|drug
DDI-DrugBank.d395.s1|49-55|bismuth|drug
DDI-DrugBank.d395.s1|57-69|subsalicylate|drug
DDI-DrugBank.d395.s1|71-76|should|drug
DDI-DrugBank.d395.s1|78-79|be|drug
DDI-DrugBank.d395.s1|81-87|avoided|drug
DDI-DrugBank.d395.s1|88-88|.|drug
DDI-DrugBank.d395.s2|0-7|Caffeine|brand
DDI-DrugBank.d395.s2|8-8|:|drug
DDI-DrugBank.d395.s2|10-17|Enoxacin|drug
DDI-DrugBank.d395.s2|19-20|is|drug
DDI-DrugBank.d395.s2|22-22|a|drug
DDI-DrugBank.d395.s2|24-29|potent|drug
DDI-DrugBank.d395.s2|31-39|inhibitor|drug
DDI-DrugBank.d395.s2|41-42|of|drug
DDI-DrugBank.d395.s2|44-46|the|drug
DDI-DrugBank.d395.s2|48-57|cytochrome|drug
DDI-DrugBank.d395.s2|59-63|P-450|drug
DDI-DrugBank.d395.s2|65-72|isozymes|drug
DDI-DrugBank.d395.s2|74-84|responsible|drug
DDI-DrugBank.d395.s2|86-88|for|drug
DDI-DrugBank.d395.s2|90-92|the|drug
DDI-DrugBank.d395.s2|94-103|metabolism|drug
DDI-DrugBank.d395.s2|105-106|of|drug
DDI-DrugBank.d395.s2|108-122|methylxanthines|drug
DDI-DrugBank.d395.s2|123-123|.|drug
DDI-DrugBank.d395.s3|0-1|In|drug
DDI-DrugBank.d395.s3|3-3|a|drug
DDI-DrugBank.d395.s3|5-17|multiple-dose|drug
DDI-DrugBank.d395.s3|19-23|study|drug
DDI-DrugBank.d395.s3|24-24|,|drug
DDI-DrugBank.d395.s3|26-33|enoxacin|drug
DDI-DrugBank.d395.s3|35-40|caused|drug
DDI-DrugBank.d395.s3|42-42|a|drug
DDI-DrugBank.d395.s3|44-55|dose-related|drug
DDI-DrugBank.d395.s3|57-64|increase|drug
DDI-DrugBank.d395.s3|66-67|in|drug
DDI-DrugBank.d395.s3|69-71|the|drug
DDI-DrugBank.d395.s3|73-76|mean|drug
DDI-DrugBank.d395.s3|78-88|elimination|drug
DDI-DrugBank.d395.s3|90-98|half-life|drug
DDI-DrugBank.d395.s3|100-101|of|drug
DDI-DrugBank.d395.s3|103-110|caffeine|drug
DDI-DrugBank.d395.s3|111-111|,|drug
DDI-DrugBank.d395.s3|113-119|thereby|drug
DDI-DrugBank.d395.s3|121-130|decreasing|drug
DDI-DrugBank.d395.s3|132-134|the|drug
DDI-DrugBank.d395.s3|136-144|clearance|drug
DDI-DrugBank.d395.s3|146-147|of|drug
DDI-DrugBank.d395.s3|149-156|caffeine|drug
DDI-DrugBank.d395.s3|158-159|by|drug
DDI-DrugBank.d395.s3|161-162|up|drug
DDI-DrugBank.d395.s3|164-165|to|drug
DDI-DrugBank.d395.s3|167-168|80|drug
DDI-DrugBank.d395.s3|169-169|%|drug
DDI-DrugBank.d395.s3|171-173|and|drug
DDI-DrugBank.d395.s3|175-181|leading|drug
DDI-DrugBank.d395.s3|183-184|to|drug
DDI-DrugBank.d395.s3|186-186|a|drug
DDI-DrugBank.d395.s3|188-196|five-fold|drug
DDI-DrugBank.d395.s3|198-205|increase|drug
DDI-DrugBank.d395.s3|207-208|in|drug
DDI-DrugBank.d395.s3|210-212|the|drug
DDI-DrugBank.d395.s3|214-216|AUC|drug
DDI-DrugBank.d395.s3|218-220|and|drug
DDI-DrugBank.d395.s3|222-224|the|drug
DDI-DrugBank.d395.s3|226-234|half-life|drug
DDI-DrugBank.d395.s3|236-237|of|drug
DDI-DrugBank.d395.s3|239-246|caffeine|drug
DDI-DrugBank.d395.s3|247-247|.|drug
DDI-DrugBank.d395.s4|0-5|Trough|drug
DDI-DrugBank.d395.s4|7-12|plasma|drug
DDI-DrugBank.d395.s4|14-21|enoxacin|drug
DDI-DrugBank.d395.s4|23-28|levels|drug
DDI-DrugBank.d395.s4|30-33|were|drug
DDI-DrugBank.d395.s4|35-38|also|drug
DDI-DrugBank.d395.s4|40-41|20|drug
DDI-DrugBank.d395.s4|42-42|%|drug
DDI-DrugBank.d395.s4|44-49|higher|drug
DDI-DrugBank.d395.s4|51-54|when|drug
DDI-DrugBank.d395.s4|56-63|caffeine|drug
DDI-DrugBank.d395.s4|65-67|and|drug
DDI-DrugBank.d395.s4|69-76|enoxacin|drug
DDI-DrugBank.d395.s4|78-81|were|drug
DDI-DrugBank.d395.s4|83-94|administered|drug
DDI-DrugBank.d395.s4|96-108|concomitantly|drug
DDI-DrugBank.d395.s4|109-109|.|drug
DDI-DrugBank.d395.s5|0-15|Caffeine-related|drug
DDI-DrugBank.d395.s5|17-23|adverse|drug
DDI-DrugBank.d395.s5|25-31|effects|drug
DDI-DrugBank.d395.s5|33-36|have|drug
DDI-DrugBank.d395.s5|38-45|occurred|drug
DDI-DrugBank.d395.s5|47-48|in|drug
DDI-DrugBank.d395.s5|50-57|patients|drug
DDI-DrugBank.d395.s5|59-67|consuming|drug
DDI-DrugBank.d395.s5|69-76|caffeine|drug
DDI-DrugBank.d395.s5|78-82|while|drug
DDI-DrugBank.d395.s5|84-85|on|drug
DDI-DrugBank.d395.s5|87-93|therapy|drug
DDI-DrugBank.d395.s5|95-98|with|drug
DDI-DrugBank.d395.s5|100-107|enoxacin|drug
DDI-DrugBank.d395.s5|108-108|.|drug
DDI-DrugBank.d395.s6|0-11|Cyclosporine|brand
DDI-DrugBank.d395.s6|12-12|:|drug
DDI-DrugBank.d395.s6|14-21|Elevated|drug
DDI-DrugBank.d395.s6|23-27|serum|drug
DDI-DrugBank.d395.s6|29-34|levels|drug
DDI-DrugBank.d395.s6|36-37|of|drug
DDI-DrugBank.d395.s6|39-50|cyclosporine|drug
DDI-DrugBank.d395.s6|52-55|have|drug
DDI-DrugBank.d395.s6|57-60|been|drug
DDI-DrugBank.d395.s6|62-69|reported|drug
DDI-DrugBank.d395.s6|71-74|with|drug
DDI-DrugBank.d395.s6|76-86|concomitant|drug
DDI-DrugBank.d395.s6|88-90|use|drug
DDI-DrugBank.d395.s6|92-93|of|drug
DDI-DrugBank.d395.s6|95-106|cyclosporine|drug
DDI-DrugBank.d395.s6|108-111|with|drug
DDI-DrugBank.d395.s6|113-117|other|drug
DDI-DrugBank.d395.s6|119-125|members|drug
DDI-DrugBank.d395.s6|127-128|of|drug
DDI-DrugBank.d395.s6|130-132|the|drug
DDI-DrugBank.d395.s6|134-142|quinolone|drug
DDI-DrugBank.d395.s6|144-148|class|drug
DDI-DrugBank.d395.s6|149-149|.|drug
DDI-DrugBank.d395.s7|0-6|Digoxin|brand
DDI-DrugBank.d395.s7|7-7|:|drug
DDI-DrugBank.d395.s7|9-16|Enoxacin|drug
DDI-DrugBank.d395.s7|18-20|may|drug
DDI-DrugBank.d395.s7|22-26|raise|drug
DDI-DrugBank.d395.s7|28-32|serum|drug
DDI-DrugBank.d395.s7|34-40|digoxin|drug
DDI-DrugBank.d395.s7|42-47|levels|drug
DDI-DrugBank.d395.s7|49-50|in|drug
DDI-DrugBank.d395.s7|52-55|some|drug
DDI-DrugBank.d395.s7|57-67|individuals|drug
DDI-DrugBank.d395.s7|68-68|.|drug
DDI-DrugBank.d395.s8|0-1|If|drug
DDI-DrugBank.d395.s8|3-7|signs|drug
DDI-DrugBank.d395.s8|9-11|and|drug
DDI-DrugBank.d395.s8|13-20|symptoms|drug
DDI-DrugBank.d395.s8|22-31|suggestive|drug
DDI-DrugBank.d395.s8|33-34|of|drug
DDI-DrugBank.d395.s8|36-42|digoxin|drug
DDI-DrugBank.d395.s8|44-51|toxicity|drug
DDI-DrugBank.d395.s8|53-57|occur|drug
DDI-DrugBank.d395.s8|59-62|when|drug
DDI-DrugBank.d395.s8|64-71|enoxacin|drug
DDI-DrugBank.d395.s8|73-75|and|drug
DDI-DrugBank.d395.s8|77-83|digoxin|drug
DDI-DrugBank.d395.s8|85-87|are|drug
DDI-DrugBank.d395.s8|89-93|given|drug
DDI-DrugBank.d395.s8|95-107|concomitantly|drug
DDI-DrugBank.d395.s8|108-108|,|drug
DDI-DrugBank.d395.s8|110-119|physicians|drug
DDI-DrugBank.d395.s8|121-123|are|drug
DDI-DrugBank.d395.s8|125-131|advised|drug
DDI-DrugBank.d395.s8|133-134|to|drug
DDI-DrugBank.d395.s8|136-141|obtain|drug
DDI-DrugBank.d395.s8|143-147|serum|drug
DDI-DrugBank.d395.s8|149-155|digoxin|drug
DDI-DrugBank.d395.s8|157-162|levels|drug
DDI-DrugBank.d395.s8|164-166|and|drug
DDI-DrugBank.d395.s8|168-173|adjust|drug
DDI-DrugBank.d395.s8|175-181|digoxin|drug
DDI-DrugBank.d395.s8|183-187|doses|drug
DDI-DrugBank.d395.s8|189-201|appropriately|drug
DDI-DrugBank.d395.s8|202-202|.|drug
DDI-DrugBank.d395.s9|0-12|Non-steroidal|drug
DDI-DrugBank.d395.s9|14-30|anti-inflammatory|drug
DDI-DrugBank.d395.s9|32-37|agents|drug
DDI-DrugBank.d395.s9|38-38|:|drug
DDI-DrugBank.d395.s9|40-47|Seizures|drug
DDI-DrugBank.d395.s9|49-52|have|drug
DDI-DrugBank.d395.s9|54-57|been|drug
DDI-DrugBank.d395.s9|59-66|reported|drug
DDI-DrugBank.d395.s9|68-69|in|drug
DDI-DrugBank.d395.s9|71-78|patients|drug
DDI-DrugBank.d395.s9|80-85|taking|drug
DDI-DrugBank.d395.s9|87-94|enoxacin|drug
DDI-DrugBank.d395.s9|96-108|concomitantly|drug
DDI-DrugBank.d395.s9|110-113|with|drug
DDI-DrugBank.d395.s9|115-117|the|drug
DDI-DrugBank.d395.s9|119-130|nonsteroidal|drug
DDI-DrugBank.d395.s9|132-148|anti-inflammatory|drug
DDI-DrugBank.d395.s9|150-153|drug|drug
DDI-DrugBank.d395.s9|155-162|fenbufen|drug
DDI-DrugBank.d395.s9|163-163|.|drug
DDI-DrugBank.d395.s10|0-5|Animal|drug
DDI-DrugBank.d395.s10|7-13|studies|drug
DDI-DrugBank.d395.s10|15-18|also|drug
DDI-DrugBank.d395.s10|20-26|suggest|drug
DDI-DrugBank.d395.s10|28-29|an|drug
DDI-DrugBank.d395.s10|31-39|increased|drug
DDI-DrugBank.d395.s10|41-49|potential|drug
DDI-DrugBank.d395.s10|51-53|for|drug
DDI-DrugBank.d395.s10|55-62|seizures|drug
DDI-DrugBank.d395.s10|64-67|when|drug
DDI-DrugBank.d395.s10|69-73|these|drug
DDI-DrugBank.d395.s10|75-77|two|drug
DDI-DrugBank.d395.s10|79-83|drugs|drug
DDI-DrugBank.d395.s10|85-87|are|drug
DDI-DrugBank.d395.s10|89-93|given|drug
DDI-DrugBank.d395.s10|95-107|concomitantly|drug
DDI-DrugBank.d395.s10|108-108|.|drug
DDI-DrugBank.d395.s11|0-7|Fenbufen|drug
DDI-DrugBank.d395.s11|9-10|is|drug
DDI-DrugBank.d395.s11|12-14|not|drug
DDI-DrugBank.d395.s11|16-23|approved|drug
DDI-DrugBank.d395.s11|25-26|in|drug
DDI-DrugBank.d395.s11|28-30|the|drug
DDI-DrugBank.d395.s11|32-37|United|drug
DDI-DrugBank.d395.s11|39-44|States|drug
DDI-DrugBank.d395.s11|46-47|at|drug
DDI-DrugBank.d395.s11|49-52|this|drug
DDI-DrugBank.d395.s11|54-57|time|drug
DDI-DrugBank.d395.s11|58-58|.|drug
DDI-DrugBank.d395.s12|0-9|Sucralfate|brand
DDI-DrugBank.d395.s12|11-13|and|drug
DDI-DrugBank.d395.s12|15-22|antacids|drug
DDI-DrugBank.d395.s12|23-23|:|drug
DDI-DrugBank.d395.s12|25-34|Quinolones|group
DDI-DrugBank.d395.s12|36-39|form|drug
DDI-DrugBank.d395.s12|41-48|chelates|drug
DDI-DrugBank.d395.s12|50-53|with|drug
DDI-DrugBank.d395.s12|55-59|metal|drug
DDI-DrugBank.d395.s12|61-67|cations|drug
DDI-DrugBank.d395.s12|68-68|.|drug
DDI-DrugBank.d395.s13|0-8|Therefore|drug
DDI-DrugBank.d395.s13|9-9|,|drug
DDI-DrugBank.d395.s13|11-24|administration|drug
DDI-DrugBank.d395.s13|26-27|of|drug
DDI-DrugBank.d395.s13|29-38|quinolones|drug
DDI-DrugBank.d395.s13|40-43|with|drug
DDI-DrugBank.d395.s13|45-52|antacids|drug
DDI-DrugBank.d395.s13|54-63|containing|drug
DDI-DrugBank.d395.s13|65-71|calcium|drug
DDI-DrugBank.d395.s13|72-72|,|drug
DDI-DrugBank.d395.s13|74-82|magnesium|drug
DDI-DrugBank.d395.s13|83-83|,|drug
DDI-DrugBank.d395.s13|85-86|or|drug
DDI-DrugBank.d395.s13|88-95|aluminum|drug
DDI-DrugBank.d395.s13|96-96|;|drug
DDI-DrugBank.d395.s14|0-3|with|drug
DDI-DrugBank.d395.s14|5-14|sucralfate|drug
DDI-DrugBank.d395.s14|15-15|;|drug
DDI-DrugBank.d395.s15|0-3|with|drug
DDI-DrugBank.d395.s15|5-12|divalent|drug
DDI-DrugBank.d395.s15|14-15|or|drug
DDI-DrugBank.d395.s15|17-25|trivalent|drug
DDI-DrugBank.d395.s15|27-33|cations|drug
DDI-DrugBank.d395.s15|35-38|such|drug
DDI-DrugBank.d395.s15|40-41|as|drug
DDI-DrugBank.d395.s15|43-46|iron|drug
DDI-DrugBank.d395.s15|47-47|;|drug
DDI-DrugBank.d395.s16|0-1|or|drug
DDI-DrugBank.d395.s16|3-6|with|drug
DDI-DrugBank.d395.s16|8-20|multivitamins|drug
DDI-DrugBank.d395.s16|22-31|containing|drug
DDI-DrugBank.d395.s16|33-36|zinc|drug
DDI-DrugBank.d395.s16|38-40|may|drug
DDI-DrugBank.d395.s16|42-54|substantially|drug
DDI-DrugBank.d395.s16|56-64|interfere|drug
DDI-DrugBank.d395.s16|66-69|with|drug
DDI-DrugBank.d395.s16|71-74|drug|drug
DDI-DrugBank.d395.s16|76-85|absorption|drug
DDI-DrugBank.d395.s16|87-89|and|drug
DDI-DrugBank.d395.s16|91-96|result|drug
DDI-DrugBank.d395.s16|98-99|in|drug
DDI-DrugBank.d395.s16|101-112|insufficient|drug
DDI-DrugBank.d395.s16|114-119|plasma|drug
DDI-DrugBank.d395.s16|121-123|and|drug
DDI-DrugBank.d395.s16|125-130|tissue|drug
DDI-DrugBank.d395.s16|132-140|quinolone|drug
DDI-DrugBank.d395.s16|142-155|concentrations|drug
DDI-DrugBank.d395.s16|156-156|.|drug
DDI-DrugBank.d395.s17|0-7|Antacids|group
DDI-DrugBank.d395.s17|9-18|containing|drug
DDI-DrugBank.d395.s17|20-27|aluminum|drug
DDI-DrugBank.d395.s17|29-37|hydroxide|drug
DDI-DrugBank.d395.s17|39-41|and|drug
DDI-DrugBank.d395.s17|43-51|magnesium|drug
DDI-DrugBank.d395.s17|53-61|hydroxide|drug
DDI-DrugBank.d395.s17|63-68|reduce|drug
DDI-DrugBank.d395.s17|70-72|the|drug
DDI-DrugBank.d395.s17|74-77|oral|drug
DDI-DrugBank.d395.s17|79-88|absorption|drug
DDI-DrugBank.d395.s17|90-91|of|drug
DDI-DrugBank.d395.s17|93-100|enoxacin|drug
DDI-DrugBank.d395.s17|102-103|by|drug
DDI-DrugBank.d395.s17|105-106|75|drug
DDI-DrugBank.d395.s17|107-107|%|drug
DDI-DrugBank.d395.s17|108-108|.|drug
DDI-DrugBank.d395.s18|0-2|The|drug
DDI-DrugBank.d395.s18|4-7|oral|drug
DDI-DrugBank.d395.s18|9-23|bioavailability|drug
DDI-DrugBank.d395.s18|25-26|of|drug
DDI-DrugBank.d395.s18|28-35|enoxacin|drug
DDI-DrugBank.d395.s18|37-38|is|drug
DDI-DrugBank.d395.s18|40-46|reduced|drug
DDI-DrugBank.d395.s18|48-49|by|drug
DDI-DrugBank.d395.s18|51-52|60|drug
DDI-DrugBank.d395.s18|53-53|%|drug
DDI-DrugBank.d395.s18|55-58|with|drug
DDI-DrugBank.d395.s18|60-75|coadministration|drug
DDI-DrugBank.d395.s18|77-78|of|drug
DDI-DrugBank.d395.s18|80-89|ranitidine|drug
DDI-DrugBank.d395.s18|90-90|.|drug
DDI-DrugBank.d395.s19|0-4|These|drug
DDI-DrugBank.d395.s19|6-11|agents|drug
DDI-DrugBank.d395.s19|13-18|should|drug
DDI-DrugBank.d395.s19|20-22|not|drug
DDI-DrugBank.d395.s19|24-25|be|drug
DDI-DrugBank.d395.s19|27-31|taken|drug
DDI-DrugBank.d395.s19|33-35|for|drug
DDI-DrugBank.d395.s19|37-37|8|drug
DDI-DrugBank.d395.s19|39-43|hours|drug
DDI-DrugBank.d395.s19|45-50|before|drug
DDI-DrugBank.d395.s19|52-53|or|drug
DDI-DrugBank.d395.s19|55-57|for|drug
DDI-DrugBank.d395.s19|59-59|2|drug
DDI-DrugBank.d395.s19|61-65|hours|drug
DDI-DrugBank.d395.s19|67-71|after|drug
DDI-DrugBank.d395.s19|73-80|enoxacin|drug
DDI-DrugBank.d395.s19|82-95|administration|drug
DDI-DrugBank.d395.s19|96-96|.|drug
DDI-DrugBank.d395.s20|0-11|Theophylline|brand
DDI-DrugBank.d395.s20|12-12|:|drug
DDI-DrugBank.d395.s20|14-21|Enoxacin|drug
DDI-DrugBank.d395.s20|23-24|is|drug
DDI-DrugBank.d395.s20|26-26|a|drug
DDI-DrugBank.d395.s20|28-33|potent|drug
DDI-DrugBank.d395.s20|35-43|inhibitor|drug
DDI-DrugBank.d395.s20|45-46|of|drug
DDI-DrugBank.d395.s20|48-50|the|drug
DDI-DrugBank.d395.s20|52-61|cytochrome|drug
DDI-DrugBank.d395.s20|63-67|P-450|drug
DDI-DrugBank.d395.s20|69-76|isozymes|drug
DDI-DrugBank.d395.s20|78-88|responsible|drug
DDI-DrugBank.d395.s20|90-92|for|drug
DDI-DrugBank.d395.s20|94-96|the|drug
DDI-DrugBank.d395.s20|98-107|metabolism|drug
DDI-DrugBank.d395.s20|109-110|of|drug
DDI-DrugBank.d395.s20|112-126|methylxanthines|drug
DDI-DrugBank.d395.s20|127-127|.|drug
DDI-DrugBank.d395.s21|0-7|Enoxacin|drug
DDI-DrugBank.d395.s21|9-18|interferes|drug
DDI-DrugBank.d395.s21|20-23|with|drug
DDI-DrugBank.d395.s21|25-27|the|drug
DDI-DrugBank.d395.s21|29-38|metabolism|drug
DDI-DrugBank.d395.s21|40-41|of|drug
DDI-DrugBank.d395.s21|43-54|theophylline|drug
DDI-DrugBank.d395.s21|56-64|resulting|drug
DDI-DrugBank.d395.s21|66-67|in|drug
DDI-DrugBank.d395.s21|69-69|a|drug
DDI-DrugBank.d395.s21|71-72|42|drug
DDI-DrugBank.d395.s21|73-73|%|drug
DDI-DrugBank.d395.s21|75-76|to|drug
DDI-DrugBank.d395.s21|78-79|74|drug
DDI-DrugBank.d395.s21|80-80|%|drug
DDI-DrugBank.d395.s21|82-93|dose-related|drug
DDI-DrugBank.d395.s21|95-102|decrease|drug
DDI-DrugBank.d395.s21|104-105|in|drug
DDI-DrugBank.d395.s21|107-118|theophylline|drug
DDI-DrugBank.d395.s21|120-128|clearance|drug
DDI-DrugBank.d395.s21|130-132|and|drug
DDI-DrugBank.d395.s21|134-134|a|drug
DDI-DrugBank.d395.s21|136-145|subsequent|drug
DDI-DrugBank.d395.s21|147-149|260|drug
DDI-DrugBank.d395.s21|150-150|%|drug
DDI-DrugBank.d395.s21|152-153|to|drug
DDI-DrugBank.d395.s21|155-157|350|drug
DDI-DrugBank.d395.s21|158-158|%|drug
DDI-DrugBank.d395.s21|160-167|increase|drug
DDI-DrugBank.d395.s21|169-170|in|drug
DDI-DrugBank.d395.s21|172-176|serum|drug
DDI-DrugBank.d395.s21|178-189|theophylline|drug
DDI-DrugBank.d395.s21|191-196|levels|drug
DDI-DrugBank.d395.s21|197-197|.|drug
DDI-DrugBank.d395.s22|0-19|Theophylline-related|drug
DDI-DrugBank.d395.s22|21-27|adverse|drug
DDI-DrugBank.d395.s22|29-35|effects|drug
DDI-DrugBank.d395.s22|37-40|have|drug
DDI-DrugBank.d395.s22|42-49|occurred|drug
DDI-DrugBank.d395.s22|51-52|in|drug
DDI-DrugBank.d395.s22|54-61|patients|drug
DDI-DrugBank.d395.s22|63-66|when|drug
DDI-DrugBank.d395.s22|68-79|theophylline|drug
DDI-DrugBank.d395.s22|81-83|and|drug
DDI-DrugBank.d395.s22|85-92|enoxacin|drug
DDI-DrugBank.d395.s22|94-97|were|drug
DDI-DrugBank.d395.s22|99-112|coadministered|drug
DDI-DrugBank.d395.s22|113-113|.|drug
DDI-DrugBank.d395.s23|0-7|Warfarin|brand
DDI-DrugBank.d395.s23|8-8|:|drug
DDI-DrugBank.d395.s23|10-19|Quinolones|group
DDI-DrugBank.d395.s23|20-20|,|drug
DDI-DrugBank.d395.s23|22-30|including|drug
DDI-DrugBank.d395.s23|32-39|enoxacin|drug
DDI-DrugBank.d395.s23|40-40|,|drug
DDI-DrugBank.d395.s23|42-49|decrease|drug
DDI-DrugBank.d395.s23|51-53|the|drug
DDI-DrugBank.d395.s23|55-63|clearance|drug
DDI-DrugBank.d395.s23|65-66|of|drug
DDI-DrugBank.d395.s23|68-77|R-warfarin|drug
DDI-DrugBank.d395.s23|78-78|,|drug
DDI-DrugBank.d395.s23|80-82|the|drug
DDI-DrugBank.d395.s23|84-87|less|drug
DDI-DrugBank.d395.s23|89-94|active|drug
DDI-DrugBank.d395.s23|96-101|isomer|drug
DDI-DrugBank.d395.s23|103-104|of|drug
DDI-DrugBank.d395.s23|106-112|racemic|drug
DDI-DrugBank.d395.s23|114-121|warfarin|drug
DDI-DrugBank.d395.s23|122-122|.|drug
DDI-DrugBank.d395.s24|0-7|Enoxacin|drug
DDI-DrugBank.d395.s24|9-12|does|drug
DDI-DrugBank.d395.s24|14-16|not|drug
DDI-DrugBank.d395.s24|18-23|affect|drug
DDI-DrugBank.d395.s24|25-27|the|drug
DDI-DrugBank.d395.s24|29-37|clearance|drug
DDI-DrugBank.d395.s24|39-40|of|drug
DDI-DrugBank.d395.s24|42-44|the|drug
DDI-DrugBank.d395.s24|46-51|active|drug
DDI-DrugBank.d395.s24|53-60|S-isomer|drug
DDI-DrugBank.d395.s24|61-61|,|drug
DDI-DrugBank.d395.s24|63-65|and|drug
DDI-DrugBank.d395.s24|67-73|changes|drug
DDI-DrugBank.d395.s24|75-76|in|drug
DDI-DrugBank.d395.s24|78-85|clotting|drug
DDI-DrugBank.d395.s24|87-90|time|drug
DDI-DrugBank.d395.s24|92-95|have|drug
DDI-DrugBank.d395.s24|97-99|not|drug
DDI-DrugBank.d395.s24|101-104|been|drug
DDI-DrugBank.d395.s24|106-113|observed|drug
DDI-DrugBank.d395.s24|115-118|when|drug
DDI-DrugBank.d395.s24|120-127|enoxacin|drug
DDI-DrugBank.d395.s24|129-131|and|drug
DDI-DrugBank.d395.s24|133-140|warfarin|drug
DDI-DrugBank.d395.s24|142-145|were|drug
DDI-DrugBank.d395.s24|147-160|coadministered|drug
DDI-DrugBank.d395.s24|161-161|.|drug
DDI-DrugBank.d395.s25|0-11|Nevertheless|drug
DDI-DrugBank.d395.s25|12-12|,|drug
DDI-DrugBank.d395.s25|14-16|the|drug
DDI-DrugBank.d395.s25|18-28|prothrombin|drug
DDI-DrugBank.d395.s25|30-33|time|drug
DDI-DrugBank.d395.s25|35-36|or|drug
DDI-DrugBank.d395.s25|38-42|other|drug
DDI-DrugBank.d395.s25|44-51|suitable|drug
DDI-DrugBank.d395.s25|53-63|coagulation|drug
DDI-DrugBank.d395.s25|65-68|test|drug
DDI-DrugBank.d395.s25|70-75|should|drug
DDI-DrugBank.d395.s25|77-78|be|drug
DDI-DrugBank.d395.s25|80-88|monitored|drug
DDI-DrugBank.d395.s25|90-93|when|drug
DDI-DrugBank.d395.s25|95-102|warfarin|drug
DDI-DrugBank.d395.s25|104-105|or|drug
DDI-DrugBank.d395.s25|107-109|its|drug
DDI-DrugBank.d395.s25|111-121|derivatives|drug
DDI-DrugBank.d395.s25|123-125|and|drug
DDI-DrugBank.d395.s25|127-134|enoxacin|drug
DDI-DrugBank.d395.s25|136-138|are|drug
DDI-DrugBank.d395.s25|140-144|given|drug
DDI-DrugBank.d395.s25|146-158|concomitantly|drug
DDI-DrugBank.d395.s25|159-159|.|drug
DDI-MedLine.d138.s0|0-10|Interaction|drug
DDI-MedLine.d138.s0|12-18|between|drug
DDI-MedLine.d138.s0|20-27|oxytocin|drug
DDI-MedLine.d138.s0|29-31|and|drug
DDI-MedLine.d138.s0|33-44|antidiuretic|drug
DDI-MedLine.d138.s0|46-52|hormone|drug
DDI-MedLine.d138.s0|54-56|and|drug
DDI-MedLine.d138.s0|58-60|its|drug
DDI-MedLine.d138.s0|62-67|effect|drug
DDI-MedLine.d138.s0|69-70|on|drug
DDI-MedLine.d138.s0|72-74|the|drug
DDI-MedLine.d138.s0|76-79|milk|drug
DDI-MedLine.d138.s0|81-89|secretion|drug
DDI-MedLine.d138.s0|91-92|by|drug
DDI-MedLine.d138.s0|94-100|alveoli|drug
DDI-MedLine.d138.s0|102-103|of|drug
DDI-MedLine.d138.s0|105-107|the|drug
DDI-MedLine.d138.s0|109-115|mammary|drug
DDI-MedLine.d138.s0|117-121|gland|drug
DDI-MedLine.d138.s0|123-124|of|drug
DDI-MedLine.d138.s0|126-134|lactating|drug
DDI-MedLine.d138.s0|136-139|rats|drug
DDI-MedLine.d138.s0|140-140|.|drug
DDI-MedLine.d138.s1|0-10|Interaction|drug
DDI-MedLine.d138.s1|12-18|between|drug
DDI-MedLine.d138.s1|20-28|exogenous|drug
DDI-MedLine.d138.s1|30-32|and|drug
DDI-MedLine.d138.s1|34-43|endogenous|drug
DDI-MedLine.d138.s1|45-52|oxytocin|drug
DDI-MedLine.d138.s1|54-56|and|drug
DDI-MedLine.d138.s1|58-68|vasopressin|drug
DDI-MedLine.d138.s1|70-72|was|drug
DDI-MedLine.d138.s1|74-78|found|drug
DDI-MedLine.d138.s1|80-81|to|drug
DDI-MedLine.d138.s1|83-88|affect|drug
DDI-MedLine.d138.s1|90-92|the|drug
DDI-MedLine.d138.s1|94-102|mechanism|drug
DDI-MedLine.d138.s1|104-105|of|drug
DDI-MedLine.d138.s1|107-110|milk|drug
DDI-MedLine.d138.s1|112-119|ejection|drug
DDI-MedLine.d138.s1|121-122|by|drug
DDI-MedLine.d138.s1|124-126|the|drug
DDI-MedLine.d138.s1|128-134|alveoli|drug
DDI-MedLine.d138.s1|136-137|of|drug
DDI-MedLine.d138.s1|139-141|the|drug
DDI-MedLine.d138.s1|143-149|mammary|drug
DDI-MedLine.d138.s1|151-155|gland|drug
DDI-MedLine.d138.s1|157-158|in|drug
DDI-MedLine.d138.s1|160-168|lactating|drug
DDI-MedLine.d138.s1|170-173|rats|drug
DDI-MedLine.d138.s1|174-174|.|drug
DDI-MedLine.d138.s2|0-9|Inhibition|drug
DDI-MedLine.d138.s2|11-13|and|drug
DDI-MedLine.d138.s2|15-25|stimulation|drug
DDI-MedLine.d138.s2|27-28|of|drug
DDI-MedLine.d138.s2|30-32|the|drug
DDI-MedLine.d138.s2|34-39|effect|drug
DDI-MedLine.d138.s2|41-42|of|drug
DDI-MedLine.d138.s2|44-51|oxytocin|drug
DDI-MedLine.d138.s2|53-54|on|drug
DDI-MedLine.d138.s2|56-59|milk|drug
DDI-MedLine.d138.s2|61-68|ejection|drug
DDI-MedLine.d138.s2|70-71|by|drug
DDI-MedLine.d138.s2|73-83|vasopressin|drug
DDI-MedLine.d138.s2|85-87|was|drug
DDI-MedLine.d138.s2|89-100|demonstrated|drug
DDI-MedLine.d138.s2|101-101|.|drug
DDI-MedLine.d138.s3|0-1|On|drug
DDI-MedLine.d138.s3|3-5|the|drug
DDI-MedLine.d138.s3|7-11|basis|drug
DDI-MedLine.d138.s3|13-14|of|drug
DDI-MedLine.d138.s3|16-18|the|drug
DDI-MedLine.d138.s3|20-29|principles|drug
DDI-MedLine.d138.s3|31-38|observed|drug
DDI-MedLine.d138.s3|40-42|the|drug
DDI-MedLine.d138.s3|44-57|concentrations|drug
DDI-MedLine.d138.s3|59-60|fo|drug
DDI-MedLine.d138.s3|62-66|these|drug
DDI-MedLine.d138.s3|68-75|hormones|drug
DDI-MedLine.d138.s3|77-80|were|drug
DDI-MedLine.d138.s3|82-93|investigated|drug
DDI-MedLine.d138.s3|95-96|in|drug
DDI-MedLine.d138.s3|98-100|the|drug
DDI-MedLine.d138.s3|102-107|plasma|drug
DDI-MedLine.d138.s3|109-110|of|drug
DDI-MedLine.d138.s3|112-115|dogs|drug
DDI-MedLine.d138.s3|117-124|deprived|drug
DDI-MedLine.d138.s3|126-127|of|drug
DDI-MedLine.d138.s3|129-133|water|drug
DDI-MedLine.d138.s3|135-137|for|drug
DDI-MedLine.d138.s3|139-139|3|drug
DDI-MedLine.d138.s3|141-144|days|drug
DDI-MedLine.d138.s3|146-148|and|drug
DDI-MedLine.d138.s3|150-153|then|drug
DDI-MedLine.d138.s3|155-161|allowed|drug
DDI-MedLine.d138.s3|163-164|to|drug
DDI-MedLine.d138.s3|166-170|drink|drug
DDI-MedLine.d138.s3|171-171|.|drug
DDI-DrugBank.d546.s0|0-3|Drug|drug
DDI-DrugBank.d546.s0|5-16|Interactions|drug
DDI-DrugBank.d546.s0|18-21|with|drug
DDI-DrugBank.d546.s0|23-35|Beta-Blockers|drug
DDI-DrugBank.d546.s0|36-36|:|drug
DDI-DrugBank.d546.s0|38-48|Concomitant|drug
DDI-DrugBank.d546.s0|50-52|use|drug
DDI-DrugBank.d546.s0|54-55|of|drug
DDI-DrugBank.d546.s0|57-66|fenoldopam|drug
DDI-DrugBank.d546.s0|68-71|with|drug
DDI-DrugBank.d546.s0|73-85|beta-blockers|drug
DDI-DrugBank.d546.s0|87-92|should|drug
DDI-DrugBank.d546.s0|94-95|be|drug
DDI-DrugBank.d546.s0|97-103|avoided|drug
DDI-DrugBank.d546.s0|104-104|.|drug
DDI-DrugBank.d546.s1|0-1|If|drug
DDI-DrugBank.d546.s1|3-5|the|drug
DDI-DrugBank.d546.s1|7-11|drugs|drug
DDI-DrugBank.d546.s1|13-15|are|drug
DDI-DrugBank.d546.s1|17-20|used|drug
DDI-DrugBank.d546.s1|22-29|together|drug
DDI-DrugBank.d546.s1|30-30|,|drug
DDI-DrugBank.d546.s1|32-38|caution|drug
DDI-DrugBank.d546.s1|40-45|should|drug
DDI-DrugBank.d546.s1|47-48|be|drug
DDI-DrugBank.d546.s1|50-58|exercised|drug
DDI-DrugBank.d546.s1|60-66|because|drug
DDI-DrugBank.d546.s1|68-77|unexpected|drug
DDI-DrugBank.d546.s1|79-89|hypotension|drug
DDI-DrugBank.d546.s1|91-95|could|drug
DDI-DrugBank.d546.s1|97-102|result|drug
DDI-DrugBank.d546.s1|104-107|from|drug
DDI-DrugBank.d546.s1|109-120|beta-blocker|drug
DDI-DrugBank.d546.s1|122-131|inhibition|drug
DDI-DrugBank.d546.s1|133-134|of|drug
DDI-DrugBank.d546.s1|136-138|the|drug
DDI-DrugBank.d546.s1|140-150|sympathetic|drug
DDI-DrugBank.d546.s1|152-157|reflex|drug
DDI-DrugBank.d546.s1|159-166|response|drug
DDI-DrugBank.d546.s1|168-169|to|drug
DDI-DrugBank.d546.s1|171-180|fenoldopam|drug
DDI-DrugBank.d546.s1|181-181|.|drug
DDI-DrugBank.d546.s2|0-3|Drug|drug
DDI-DrugBank.d546.s2|5-16|Interactions|drug
DDI-DrugBank.d546.s2|17-17|,|drug
DDI-DrugBank.d546.s2|19-25|General|drug
DDI-DrugBank.d546.s2|26-26|:|drug
DDI-DrugBank.d546.s2|28-35|Although|drug
DDI-DrugBank.d546.s2|37-41|there|drug
DDI-DrugBank.d546.s2|43-46|have|drug
DDI-DrugBank.d546.s2|48-51|been|drug
DDI-DrugBank.d546.s2|53-54|no|drug
DDI-DrugBank.d546.s2|56-61|formal|drug
DDI-DrugBank.d546.s2|63-73|interaction|drug
DDI-DrugBank.d546.s2|75-81|studies|drug
DDI-DrugBank.d546.s2|82-82|,|drug
DDI-DrugBank.d546.s2|84-94|intravenous|drug
DDI-DrugBank.d546.s2|96-105|fenoldopam|drug
DDI-DrugBank.d546.s2|107-109|has|drug
DDI-DrugBank.d546.s2|111-114|been|drug
DDI-DrugBank.d546.s2|116-127|administered|drug
DDI-DrugBank.d546.s2|129-134|safely|drug
DDI-DrugBank.d546.s2|136-139|with|drug
DDI-DrugBank.d546.s2|141-145|drugs|drug
DDI-DrugBank.d546.s2|147-150|such|drug
DDI-DrugBank.d546.s2|152-153|as|drug
DDI-DrugBank.d546.s2|155-163|digitalis|drug
DDI-DrugBank.d546.s2|165-167|and|drug
DDI-DrugBank.d546.s2|169-178|sublingual|drug
DDI-DrugBank.d546.s2|180-192|nitroglycerin|drug
DDI-DrugBank.d546.s2|193-193|.|drug
DDI-DrugBank.d546.s3|0-4|There|drug
DDI-DrugBank.d546.s3|6-7|is|drug
DDI-DrugBank.d546.s3|9-15|limited|drug
DDI-DrugBank.d546.s3|17-26|experience|drug
DDI-DrugBank.d546.s3|28-31|with|drug
DDI-DrugBank.d546.s3|33-43|concomitant|drug
DDI-DrugBank.d546.s3|45-60|antihypertensive|drug
DDI-DrugBank.d546.s3|62-67|agents|drug
DDI-DrugBank.d546.s3|69-72|such|drug
DDI-DrugBank.d546.s3|74-75|as|drug
DDI-DrugBank.d546.s3|77-90|alpha-blockers|drug
DDI-DrugBank.d546.s3|91-91|,|drug
DDI-DrugBank.d546.s3|93-99|calcium|drug
DDI-DrugBank.d546.s3|101-116|channel-blockers|drug
DDI-DrugBank.d546.s3|117-117|,|drug
DDI-DrugBank.d546.s3|119-121|ACE|drug
DDI-DrugBank.d546.s3|123-132|inhibitors|drug
DDI-DrugBank.d546.s3|133-133|,|drug
DDI-DrugBank.d546.s3|135-137|and|drug
DDI-DrugBank.d546.s3|139-147|diuretics|drug
DDI-DrugBank.d546.s3|149-149|(|drug
DDI-DrugBank.d546.s3|150-153|both|drug
DDI-DrugBank.d546.s3|155-167|thiazide-like|drug
DDI-DrugBank.d546.s3|169-171|and|drug
DDI-DrugBank.d546.s3|173-176|loop|drug
DDI-DrugBank.d546.s3|177-177|)|drug
DDI-DrugBank.d546.s3|178-178|.|drug
DDI-DrugBank.d107.s0|0-10|Hypotension|drug
DDI-DrugBank.d107.s0|11-11|:|drug
DDI-DrugBank.d107.s0|13-20|Patients|drug
DDI-DrugBank.d107.s0|22-23|on|drug
DDI-DrugBank.d107.s0|25-32|Diuretic|drug
DDI-DrugBank.d107.s0|34-40|Therapy|drug
DDI-DrugBank.d107.s0|41-41|:|drug
DDI-DrugBank.d107.s0|43-50|Patients|drug
DDI-DrugBank.d107.s0|52-53|on|drug
DDI-DrugBank.d107.s0|55-63|diuretics|drug
DDI-DrugBank.d107.s0|65-67|and|drug
DDI-DrugBank.d107.s0|69-78|especially|drug
DDI-DrugBank.d107.s0|80-84|those|drug
DDI-DrugBank.d107.s0|86-87|in|drug
DDI-DrugBank.d107.s0|89-92|whom|drug
DDI-DrugBank.d107.s0|94-101|diuretic|drug
DDI-DrugBank.d107.s0|103-109|therapy|drug
DDI-DrugBank.d107.s0|111-113|was|drug
DDI-DrugBank.d107.s0|115-122|recently|drug
DDI-DrugBank.d107.s0|124-133|instituted|drug
DDI-DrugBank.d107.s0|134-134|,|drug
DDI-DrugBank.d107.s0|136-138|may|drug
DDI-DrugBank.d107.s0|140-151|occasionally|drug
DDI-DrugBank.d107.s0|153-162|experience|drug
DDI-DrugBank.d107.s0|164-165|an|drug
DDI-DrugBank.d107.s0|167-175|excessive|drug
DDI-DrugBank.d107.s0|177-185|reduction|drug
DDI-DrugBank.d107.s0|187-188|of|drug
DDI-DrugBank.d107.s0|190-194|blood|drug
DDI-DrugBank.d107.s0|196-203|pressure|drug
DDI-DrugBank.d107.s0|205-209|after|drug
DDI-DrugBank.d107.s0|211-220|initiation|drug
DDI-DrugBank.d107.s0|222-223|of|drug
DDI-DrugBank.d107.s0|225-231|therapy|drug
DDI-DrugBank.d107.s0|233-236|with|drug
DDI-DrugBank.d107.s0|238-246|enalapril|drug
DDI-DrugBank.d107.s0|248-249|or|drug
DDI-DrugBank.d107.s0|251-261|enalaprilat|drug
DDI-DrugBank.d107.s0|262-262|.|drug
DDI-DrugBank.d107.s1|0-2|The|drug
DDI-DrugBank.d107.s1|4-14|possibility|drug
DDI-DrugBank.d107.s1|16-17|of|drug
DDI-DrugBank.d107.s1|19-29|hypotensive|drug
DDI-DrugBank.d107.s1|31-37|effects|drug
DDI-DrugBank.d107.s1|39-42|with|drug
DDI-DrugBank.d107.s1|44-52|enalapril|drug
DDI-DrugBank.d107.s1|54-55|or|drug
DDI-DrugBank.d107.s1|57-67|enalaprilat|drug
DDI-DrugBank.d107.s1|69-71|can|drug
DDI-DrugBank.d107.s1|73-74|be|drug
DDI-DrugBank.d107.s1|76-84|minimized|drug
DDI-DrugBank.d107.s1|86-87|by|drug
DDI-DrugBank.d107.s1|89-94|either|drug
DDI-DrugBank.d107.s1|96-108|discontinuing|drug
DDI-DrugBank.d107.s1|110-112|the|drug
DDI-DrugBank.d107.s1|114-121|diuretic|drug
DDI-DrugBank.d107.s1|123-124|or|drug
DDI-DrugBank.d107.s1|126-135|increasing|drug
DDI-DrugBank.d107.s1|137-139|the|drug
DDI-DrugBank.d107.s1|141-144|salt|drug
DDI-DrugBank.d107.s1|146-151|intake|drug
DDI-DrugBank.d107.s1|153-157|prior|drug
DDI-DrugBank.d107.s1|159-160|to|drug
DDI-DrugBank.d107.s1|162-171|initiation|drug
DDI-DrugBank.d107.s1|173-174|of|drug
DDI-DrugBank.d107.s1|176-184|treatment|drug
DDI-DrugBank.d107.s1|186-189|with|drug
DDI-DrugBank.d107.s1|191-199|enalapril|drug
DDI-DrugBank.d107.s1|201-202|or|drug
DDI-DrugBank.d107.s1|204-214|enalaprilat|drug
DDI-DrugBank.d107.s1|215-215|.|drug
DDI-DrugBank.d107.s2|0-1|If|drug
DDI-DrugBank.d107.s2|3-4|it|drug
DDI-DrugBank.d107.s2|6-7|is|drug
DDI-DrugBank.d107.s2|9-17|necessary|drug
DDI-DrugBank.d107.s2|19-20|to|drug
DDI-DrugBank.d107.s2|22-29|continue|drug
DDI-DrugBank.d107.s2|31-33|the|drug
DDI-DrugBank.d107.s2|35-42|diuretic|drug
DDI-DrugBank.d107.s2|43-43|,|drug
DDI-DrugBank.d107.s2|45-51|provide|drug
DDI-DrugBank.d107.s2|53-57|close|drug
DDI-DrugBank.d107.s2|59-65|medical|drug
DDI-DrugBank.d107.s2|67-77|supervision|drug
DDI-DrugBank.d107.s2|79-83|after|drug
DDI-DrugBank.d107.s2|85-87|the|drug
DDI-DrugBank.d107.s2|89-95|initial|drug
DDI-DrugBank.d107.s2|97-100|dose|drug
DDI-DrugBank.d107.s2|102-104|for|drug
DDI-DrugBank.d107.s2|106-107|at|drug
DDI-DrugBank.d107.s2|109-113|least|drug
DDI-DrugBank.d107.s2|115-117|two|drug
DDI-DrugBank.d107.s2|119-123|hours|drug
DDI-DrugBank.d107.s2|125-127|and|drug
DDI-DrugBank.d107.s2|129-133|until|drug
DDI-DrugBank.d107.s2|135-139|blood|drug
DDI-DrugBank.d107.s2|141-148|pressure|drug
DDI-DrugBank.d107.s2|150-152|has|drug
DDI-DrugBank.d107.s2|154-163|stabilized|drug
DDI-DrugBank.d107.s2|165-167|for|drug
DDI-DrugBank.d107.s2|169-170|at|drug
DDI-DrugBank.d107.s2|172-176|least|drug
DDI-DrugBank.d107.s2|178-179|an|drug
DDI-DrugBank.d107.s2|181-190|additional|drug
DDI-DrugBank.d107.s2|192-197|hour|drug
DDI-DrugBank.d107.s3|0-5|Agents|drug
DDI-DrugBank.d107.s3|7-13|Causing|drug
DDI-DrugBank.d107.s3|15-19|Renin|drug
DDI-DrugBank.d107.s3|21-27|Release|brand
DDI-DrugBank.d107.s3|28-28|:|drug
DDI-DrugBank.d107.s3|30-32|The|drug
DDI-DrugBank.d107.s3|34-49|antihypertensive|drug
DDI-DrugBank.d107.s3|51-56|effect|drug
DDI-DrugBank.d107.s3|58-59|of|drug
DDI-DrugBank.d107.s3|61-69|enalapril|drug
DDI-DrugBank.d107.s3|71-73|and|drug
DDI-DrugBank.d107.s3|75-83|enalapril|drug
DDI-DrugBank.d107.s3|85-86|IV|drug
DDI-DrugBank.d107.s3|88-89|is|drug
DDI-DrugBank.d107.s3|91-99|augmented|drug
DDI-DrugBank.d107.s3|101-102|by|drug
DDI-DrugBank.d107.s3|104-119|antihypertensive|drug
DDI-DrugBank.d107.s3|121-126|agents|drug
DDI-DrugBank.d107.s3|128-131|that|drug
DDI-DrugBank.d107.s3|133-137|cause|drug
DDI-DrugBank.d107.s3|139-143|renin|drug
DDI-DrugBank.d107.s3|145-151|release|drug
DDI-DrugBank.d107.s3|153-153|(|drug
DDI-DrugBank.d107.s3|154-157|e.g.|drug
DDI-DrugBank.d107.s3|158-158|,|drug
DDI-DrugBank.d107.s3|160-168|diuretics|drug
DDI-DrugBank.d107.s3|169-169|)|drug
DDI-DrugBank.d107.s3|170-170|.|drug
DDI-DrugBank.d107.s4|0-12|Non-steroidal|drug
DDI-DrugBank.d107.s4|14-30|Anti-inflammatory|drug
DDI-DrugBank.d107.s4|32-37|Agents|drug
DDI-DrugBank.d107.s4|38-38|:|drug
DDI-DrugBank.d107.s4|40-41|In|drug
DDI-DrugBank.d107.s4|43-46|some|drug
DDI-DrugBank.d107.s4|48-55|patients|drug
DDI-DrugBank.d107.s4|57-60|with|drug
DDI-DrugBank.d107.s4|62-72|compromised|drug
DDI-DrugBank.d107.s4|74-78|renal|drug
DDI-DrugBank.d107.s4|80-87|function|drug
DDI-DrugBank.d107.s4|89-91|who|drug
DDI-DrugBank.d107.s4|93-95|are|drug
DDI-DrugBank.d107.s4|97-101|being|drug
DDI-DrugBank.d107.s4|103-109|treated|drug
DDI-DrugBank.d107.s4|111-114|with|drug
DDI-DrugBank.d107.s4|116-127|nonsteroidal|drug
DDI-DrugBank.d107.s4|129-145|anti-inflammatory|drug
DDI-DrugBank.d107.s4|147-151|drugs|drug
DDI-DrugBank.d107.s4|152-152|,|drug
DDI-DrugBank.d107.s4|154-156|the|drug
DDI-DrugBank.d107.s4|158-174|co-administration|drug
DDI-DrugBank.d107.s4|176-177|of|drug
DDI-DrugBank.d107.s4|179-187|enalapril|drug
DDI-DrugBank.d107.s4|189-191|may|drug
DDI-DrugBank.d107.s4|193-198|result|drug
DDI-DrugBank.d107.s4|200-201|in|drug
DDI-DrugBank.d107.s4|203-203|a|drug
DDI-DrugBank.d107.s4|205-211|further|drug
DDI-DrugBank.d107.s4|213-225|deterioration|drug
DDI-DrugBank.d107.s4|227-228|of|drug
DDI-DrugBank.d107.s4|230-234|renal|drug
DDI-DrugBank.d107.s4|236-243|function|drug
DDI-DrugBank.d107.s4|244-244|.|drug
DDI-DrugBank.d107.s5|0-4|These|drug
DDI-DrugBank.d107.s5|6-12|effects|drug
DDI-DrugBank.d107.s5|14-16|are|drug
DDI-DrugBank.d107.s5|18-24|usually|drug
DDI-DrugBank.d107.s5|26-35|reversible|drug
DDI-DrugBank.d107.s5|36-36|.|drug
DDI-DrugBank.d107.s6|0-1|In|drug
DDI-DrugBank.d107.s6|3-3|a|drug
DDI-DrugBank.d107.s6|5-12|clinical|drug
DDI-DrugBank.d107.s6|14-25|pharmacology|drug
DDI-DrugBank.d107.s6|27-31|study|drug
DDI-DrugBank.d107.s6|32-32|,|drug
DDI-DrugBank.d107.s6|34-45|indomethacin|drug
DDI-DrugBank.d107.s6|47-48|or|drug
DDI-DrugBank.d107.s6|50-57|sulindac|drug
DDI-DrugBank.d107.s6|59-61|was|drug
DDI-DrugBank.d107.s6|63-74|administered|drug
DDI-DrugBank.d107.s6|76-77|to|drug
DDI-DrugBank.d107.s6|79-90|hypertensive|drug
DDI-DrugBank.d107.s6|92-99|patients|drug
DDI-DrugBank.d107.s6|101-109|receiving|drug
DDI-DrugBank.d107.s6|111-117|VASOTEC|drug
DDI-DrugBank.d107.s6|118-118|.|drug
DDI-DrugBank.d107.s7|0-1|In|drug
DDI-DrugBank.d107.s7|3-6|this|drug
DDI-DrugBank.d107.s7|8-12|study|drug
DDI-DrugBank.d107.s7|14-18|there|drug
DDI-DrugBank.d107.s7|20-22|was|drug
DDI-DrugBank.d107.s7|24-25|no|drug
DDI-DrugBank.d107.s7|27-34|evidence|drug
DDI-DrugBank.d107.s7|36-37|of|drug
DDI-DrugBank.d107.s7|39-39|a|drug
DDI-DrugBank.d107.s7|41-48|blunting|drug
DDI-DrugBank.d107.s7|50-51|of|drug
DDI-DrugBank.d107.s7|53-55|the|drug
DDI-DrugBank.d107.s7|57-72|antihypertensive|drug
DDI-DrugBank.d107.s7|74-79|action|drug
DDI-DrugBank.d107.s7|81-82|of|drug
DDI-DrugBank.d107.s7|84-90|VASOTEC|drug
DDI-DrugBank.d107.s7|91-91|.|drug
DDI-DrugBank.d107.s8|0-6|However|drug
DDI-DrugBank.d107.s8|7-7|,|drug
DDI-DrugBank.d107.s8|9-15|reports|drug
DDI-DrugBank.d107.s8|17-23|suggest|drug
DDI-DrugBank.d107.s8|25-28|that|drug
DDI-DrugBank.d107.s8|30-35|NSAIDs|drug
DDI-DrugBank.d107.s8|37-39|may|drug
DDI-DrugBank.d107.s8|41-48|diminish|drug
DDI-DrugBank.d107.s8|50-52|the|drug
DDI-DrugBank.d107.s8|54-69|antihypertensive|drug
DDI-DrugBank.d107.s8|71-76|effect|drug
DDI-DrugBank.d107.s8|78-79|of|drug
DDI-DrugBank.d107.s8|81-83|ACE|drug
DDI-DrugBank.d107.s8|85-94|inhibitors|drug
DDI-DrugBank.d107.s8|95-95|.|drug
DDI-DrugBank.d107.s9|0-3|This|drug
DDI-DrugBank.d107.s9|5-15|interaction|drug
DDI-DrugBank.d107.s9|17-22|should|drug
DDI-DrugBank.d107.s9|24-25|be|drug
DDI-DrugBank.d107.s9|27-31|given|drug
DDI-DrugBank.d107.s9|33-45|consideration|drug
DDI-DrugBank.d107.s9|47-48|in|drug
DDI-DrugBank.d107.s9|50-57|patients|drug
DDI-DrugBank.d107.s9|59-64|taking|drug
DDI-DrugBank.d107.s9|66-71|NSAIDs|drug
DDI-DrugBank.d107.s9|73-85|concomitantly|drug
DDI-DrugBank.d107.s9|87-90|with|drug
DDI-DrugBank.d107.s9|92-94|ACE|drug
DDI-DrugBank.d107.s9|96-105|inhibitors|drug
DDI-DrugBank.d107.s9|106-106|.|drug
DDI-DrugBank.d107.s10|0-4|Other|drug
DDI-DrugBank.d107.s10|6-19|Cardiovascular|drug
DDI-DrugBank.d107.s10|21-26|Agents|drug
DDI-DrugBank.d107.s10|27-27|:|drug
DDI-DrugBank.d107.s10|29-37|Enalapril|brand
DDI-DrugBank.d107.s10|39-41|and|drug
DDI-DrugBank.d107.s10|43-51|enalapril|drug
DDI-DrugBank.d107.s10|53-54|IV|drug
DDI-DrugBank.d107.s10|56-59|have|drug
DDI-DrugBank.d107.s10|61-64|been|drug
DDI-DrugBank.d107.s10|66-69|used|drug
DDI-DrugBank.d107.s10|71-83|concomitantly|drug
DDI-DrugBank.d107.s10|85-88|with|drug
DDI-DrugBank.d107.s10|90-93|beta|drug
DDI-DrugBank.d107.s10|95-113|adrenergic-blocking|drug
DDI-DrugBank.d107.s10|115-120|agents|drug
DDI-DrugBank.d107.s10|121-121|,|drug
DDI-DrugBank.d107.s10|123-132|methyldopa|drug
DDI-DrugBank.d107.s10|133-133|,|drug
DDI-DrugBank.d107.s10|135-142|nitrates|drug
DDI-DrugBank.d107.s10|143-143|,|drug
DDI-DrugBank.d107.s10|145-160|calcium-blocking|drug
DDI-DrugBank.d107.s10|162-167|agents|drug
DDI-DrugBank.d107.s10|168-168|,|drug
DDI-DrugBank.d107.s10|170-180|hydralazine|drug
DDI-DrugBank.d107.s10|181-181|,|drug
DDI-DrugBank.d107.s10|183-190|prazosin|drug
DDI-DrugBank.d107.s10|192-194|and|drug
DDI-DrugBank.d107.s10|196-202|digoxin|drug
DDI-DrugBank.d107.s10|204-210|without|drug
DDI-DrugBank.d107.s10|212-219|evidence|drug
DDI-DrugBank.d107.s10|221-222|of|drug
DDI-DrugBank.d107.s10|224-233|clinically|drug
DDI-DrugBank.d107.s10|235-245|significant|drug
DDI-DrugBank.d107.s10|247-253|adverse|drug
DDI-DrugBank.d107.s10|255-266|interactions|drug
DDI-DrugBank.d107.s10|267-267|.|drug
DDI-DrugBank.d107.s11|0-8|Enalapril|brand
DDI-DrugBank.d107.s11|10-11|IV|drug
DDI-DrugBank.d107.s11|13-15|has|drug
DDI-DrugBank.d107.s11|17-20|been|drug
DDI-DrugBank.d107.s11|22-25|used|drug
DDI-DrugBank.d107.s11|27-39|concomitantly|drug
DDI-DrugBank.d107.s11|41-44|with|drug
DDI-DrugBank.d107.s11|46-54|digitalis|drug
DDI-DrugBank.d107.s11|56-62|without|drug
DDI-DrugBank.d107.s11|64-71|evidence|drug
DDI-DrugBank.d107.s11|73-74|of|drug
DDI-DrugBank.d107.s11|76-85|clinically|drug
DDI-DrugBank.d107.s11|87-97|significant|drug
DDI-DrugBank.d107.s11|99-105|adverse|drug
DDI-DrugBank.d107.s11|107-115|reactions|drug
DDI-DrugBank.d107.s11|116-116|.|drug
DDI-DrugBank.d107.s12|0-5|Agents|drug
DDI-DrugBank.d107.s12|7-16|Increasing|drug
DDI-DrugBank.d107.s12|18-22|Serum|group
DDI-DrugBank.d107.s12|24-32|Potassium|drug
DDI-DrugBank.d107.s12|33-33|:|drug
DDI-DrugBank.d107.s12|35-43|Enalapril|brand
DDI-DrugBank.d107.s12|45-47|and|drug
DDI-DrugBank.d107.s12|49-57|enalapril|drug
DDI-DrugBank.d107.s12|59-60|IV|drug
DDI-DrugBank.d107.s12|62-70|attenuate|drug
DDI-DrugBank.d107.s12|72-80|potassium|drug
DDI-DrugBank.d107.s12|82-85|loss|drug
DDI-DrugBank.d107.s12|87-92|caused|drug
DDI-DrugBank.d107.s12|94-95|by|drug
DDI-DrugBank.d107.s12|97-109|thiazide-type|drug
DDI-DrugBank.d107.s12|111-119|diuretics|drug
DDI-DrugBank.d107.s12|120-120|.|drug
DDI-DrugBank.d107.s13|0-16|Potassium-sparing|drug
DDI-DrugBank.d107.s13|18-26|diuretics|drug
DDI-DrugBank.d107.s13|28-28|(|drug
DDI-DrugBank.d107.s13|29-32|e.g.|drug
DDI-DrugBank.d107.s13|33-33|,|drug
DDI-DrugBank.d107.s13|35-48|spironolactone|drug
DDI-DrugBank.d107.s13|49-49|,|drug
DDI-DrugBank.d107.s13|51-61|triamterene|drug
DDI-DrugBank.d107.s13|62-62|,|drug
DDI-DrugBank.d107.s13|64-65|or|drug
DDI-DrugBank.d107.s13|67-75|amiloride|drug
DDI-DrugBank.d107.s13|76-76|)|drug
DDI-DrugBank.d107.s13|77-77|,|drug
DDI-DrugBank.d107.s13|79-87|potassium|drug
DDI-DrugBank.d107.s13|89-99|supplements|drug
DDI-DrugBank.d107.s13|100-100|,|drug
DDI-DrugBank.d107.s13|102-103|or|drug
DDI-DrugBank.d107.s13|105-124|potassium-containing|drug
DDI-DrugBank.d107.s13|126-129|salt|drug
DDI-DrugBank.d107.s13|131-141|substitutes|drug
DDI-DrugBank.d107.s13|143-145|may|drug
DDI-DrugBank.d107.s13|147-150|lead|drug
DDI-DrugBank.d107.s13|152-153|to|drug
DDI-DrugBank.d107.s13|155-165|significant|drug
DDI-DrugBank.d107.s13|167-175|increases|drug
DDI-DrugBank.d107.s13|177-178|in|drug
DDI-DrugBank.d107.s13|180-184|serum|drug
DDI-DrugBank.d107.s13|186-194|potassium|drug
DDI-DrugBank.d107.s13|195-195|.|drug
DDI-DrugBank.d107.s14|0-8|Therefore|drug
DDI-DrugBank.d107.s14|9-9|,|drug
DDI-DrugBank.d107.s14|11-12|if|drug
DDI-DrugBank.d107.s14|14-24|concomitant|drug
DDI-DrugBank.d107.s14|26-28|use|drug
DDI-DrugBank.d107.s14|30-31|of|drug
DDI-DrugBank.d107.s14|33-37|these|drug
DDI-DrugBank.d107.s14|39-44|agents|drug
DDI-DrugBank.d107.s14|46-47|is|drug
DDI-DrugBank.d107.s14|49-57|indicated|drug
DDI-DrugBank.d107.s14|59-65|because|drug
DDI-DrugBank.d107.s14|67-68|of|drug
DDI-DrugBank.d107.s14|70-81|demonstrated|drug
DDI-DrugBank.d107.s14|83-93|hypokalemia|drug
DDI-DrugBank.d107.s14|94-94|,|drug
DDI-DrugBank.d107.s14|96-99|they|drug
DDI-DrugBank.d107.s14|101-106|should|drug
DDI-DrugBank.d107.s14|108-109|be|drug
DDI-DrugBank.d107.s14|111-114|used|drug
DDI-DrugBank.d107.s14|116-119|with|drug
DDI-DrugBank.d107.s14|121-127|caution|drug
DDI-DrugBank.d107.s14|129-131|and|drug
DDI-DrugBank.d107.s14|133-136|with|drug
DDI-DrugBank.d107.s14|138-145|frequent|drug
DDI-DrugBank.d107.s14|147-156|monitoring|drug
DDI-DrugBank.d107.s14|158-159|of|drug
DDI-DrugBank.d107.s14|161-165|serum|drug
DDI-DrugBank.d107.s14|167-175|potassium|drug
DDI-DrugBank.d107.s14|176-176|.|drug
DDI-DrugBank.d107.s15|0-8|Potassium|drug
DDI-DrugBank.d107.s15|10-16|sparing|drug
DDI-DrugBank.d107.s15|18-23|agents|drug
DDI-DrugBank.d107.s15|25-30|should|drug
DDI-DrugBank.d107.s15|32-40|generally|drug
DDI-DrugBank.d107.s15|42-44|not|drug
DDI-DrugBank.d107.s15|46-47|be|drug
DDI-DrugBank.d107.s15|49-52|used|drug
DDI-DrugBank.d107.s15|54-55|in|drug
DDI-DrugBank.d107.s15|57-64|patients|drug
DDI-DrugBank.d107.s15|66-69|with|drug
DDI-DrugBank.d107.s15|71-75|heart|drug
DDI-DrugBank.d107.s15|77-83|failure|drug
DDI-DrugBank.d107.s15|85-93|receiving|drug
DDI-DrugBank.d107.s15|95-103|enalapril|drug
DDI-DrugBank.d107.s15|104-104|.|drug
DDI-DrugBank.d107.s16|0-6|Lithium|brand
DDI-DrugBank.d107.s16|7-7|:|drug
DDI-DrugBank.d107.s16|9-15|Lithium|brand
DDI-DrugBank.d107.s16|17-24|toxicity|drug
DDI-DrugBank.d107.s16|26-28|has|drug
DDI-DrugBank.d107.s16|30-33|been|drug
DDI-DrugBank.d107.s16|35-42|reported|drug
DDI-DrugBank.d107.s16|44-45|in|drug
DDI-DrugBank.d107.s16|47-54|patients|drug
DDI-DrugBank.d107.s16|56-64|receiving|drug
DDI-DrugBank.d107.s16|66-72|lithium|drug
DDI-DrugBank.d107.s16|74-86|concomitantly|drug
DDI-DrugBank.d107.s16|88-91|with|drug
DDI-DrugBank.d107.s16|93-97|drugs|drug
DDI-DrugBank.d107.s16|99-103|which|drug
DDI-DrugBank.d107.s16|105-109|cause|drug
DDI-DrugBank.d107.s16|111-121|elimination|drug
DDI-DrugBank.d107.s16|123-124|of|drug
DDI-DrugBank.d107.s16|126-131|sodium|drug
DDI-DrugBank.d107.s16|132-132|,|drug
DDI-DrugBank.d107.s16|134-142|including|drug
DDI-DrugBank.d107.s16|144-146|ACE|drug
DDI-DrugBank.d107.s16|148-157|inhibitors|drug
DDI-DrugBank.d107.s16|158-158|.|drug
DDI-DrugBank.d107.s17|0-1|It|drug
DDI-DrugBank.d107.s17|3-4|is|drug
DDI-DrugBank.d107.s17|6-16|recommended|drug
DDI-DrugBank.d107.s17|18-21|that|drug
DDI-DrugBank.d107.s17|23-27|serum|drug
DDI-DrugBank.d107.s17|29-35|lithium|drug
DDI-DrugBank.d107.s17|37-42|levels|drug
DDI-DrugBank.d107.s17|44-45|be|drug
DDI-DrugBank.d107.s17|47-55|monitored|drug
DDI-DrugBank.d107.s17|57-66|frequently|drug
DDI-DrugBank.d107.s17|68-69|if|drug
DDI-DrugBank.d107.s17|71-79|enalapril|drug
DDI-DrugBank.d107.s17|81-82|is|drug
DDI-DrugBank.d107.s17|84-95|administered|drug
DDI-DrugBank.d107.s17|97-109|concomitantly|drug
DDI-DrugBank.d107.s17|111-114|with|drug
DDI-DrugBank.d107.s17|116-122|lithium|drug
DDI-DrugBank.d107.s17|123-123|.|drug
DDI-MedLine.d29.s0|0-5|Effect|drug
DDI-MedLine.d29.s0|7-8|of|drug
DDI-MedLine.d29.s0|10-19|probenecid|drug
DDI-MedLine.d29.s0|21-22|on|drug
DDI-MedLine.d29.s0|24-26|the|drug
DDI-MedLine.d29.s0|28-35|apparent|drug
DDI-MedLine.d29.s0|37-42|volume|drug
DDI-MedLine.d29.s0|44-45|of|drug
DDI-MedLine.d29.s0|47-58|distribution|drug
DDI-MedLine.d29.s0|60-62|and|drug
DDI-MedLine.d29.s0|64-74|elimination|drug
DDI-MedLine.d29.s0|76-77|of|drug
DDI-MedLine.d29.s0|79-89|cloxacillin|drug
DDI-MedLine.d29.s0|90-90|.|drug
DDI-MedLine.d29.s1|0-8|According|drug
DDI-MedLine.d29.s1|10-11|to|drug
DDI-MedLine.d29.s1|13-19|Gibaldi|drug
DDI-MedLine.d29.s1|21-22|et|drug
DDI-MedLine.d29.s1|24-25|al|drug
DDI-MedLine.d29.s1|26-26|.|drug
DDI-MedLine.d29.s2|0-0|(|drug
DDI-MedLine.d29.s2|1-4|1968|drug
DDI-MedLine.d29.s2|5-5|,|drug
DDI-MedLine.d29.s2|7-10|1970|drug
DDI-MedLine.d29.s2|11-11|)|drug
DDI-MedLine.d29.s2|12-12|,|drug
DDI-MedLine.d29.s2|14-16|the|drug
DDI-MedLine.d29.s2|18-23|higher|drug
DDI-MedLine.d29.s2|25-29|serum|drug
DDI-MedLine.d29.s2|31-44|concentrations|drug
DDI-MedLine.d29.s2|46-47|of|drug
DDI-MedLine.d29.s2|49-59|penicillins|drug
DDI-MedLine.d29.s2|61-63|and|drug
DDI-MedLine.d29.s2|65-77|cephaloridine|drug
DDI-MedLine.d29.s2|79-85|reached|drug
DDI-MedLine.d29.s2|87-91|after|drug
DDI-MedLine.d29.s2|93-106|administration|drug
DDI-MedLine.d29.s2|108-109|of|drug
DDI-MedLine.d29.s2|111-120|probenecid|drug
DDI-MedLine.d29.s2|122-124|are|drug
DDI-MedLine.d29.s2|126-128|due|drug
DDI-MedLine.d29.s2|130-132|not|drug
DDI-MedLine.d29.s2|134-137|only|drug
DDI-MedLine.d29.s2|139-140|to|drug
DDI-MedLine.d29.s2|142-147|slower|drug
DDI-MedLine.d29.s2|149-153|renal|drug
DDI-MedLine.d29.s2|155-165|elimination|drug
DDI-MedLine.d29.s2|167-169|but|drug
DDI-MedLine.d29.s2|171-174|also|drug
DDI-MedLine.d29.s2|176-177|to|drug
DDI-MedLine.d29.s2|179-180|an|drug
DDI-MedLine.d29.s2|182-188|altered|drug
DDI-MedLine.d29.s2|190-201|distribution|drug
DDI-MedLine.d29.s2|203-204|in|drug
DDI-MedLine.d29.s2|206-208|the|drug
DDI-MedLine.d29.s2|210-213|body|drug
DDI-MedLine.d29.s2|214-214|.|drug
DDI-MedLine.d29.s3|0-1|To|drug
DDI-MedLine.d29.s3|3-11|determine|drug
DDI-MedLine.d29.s3|13-19|whether|drug
DDI-MedLine.d29.s3|21-30|probenecid|drug
DDI-MedLine.d29.s3|32-34|has|drug
DDI-MedLine.d29.s3|36-36|a|drug
DDI-MedLine.d29.s3|38-43|direct|drug
DDI-MedLine.d29.s3|45-50|effect|drug
DDI-MedLine.d29.s3|52-53|on|drug
DDI-MedLine.d29.s3|55-57|the|drug
DDI-MedLine.d29.s3|59-70|distribution|drug
DDI-MedLine.d29.s3|72-73|of|drug
DDI-MedLine.d29.s3|75-85|cloxacillin|drug
DDI-MedLine.d29.s3|86-86|,|drug
DDI-MedLine.d29.s3|88-90|the|drug
DDI-MedLine.d29.s3|92-102|elimination|drug
DDI-MedLine.d29.s3|104-106|and|drug
DDI-MedLine.d29.s3|108-119|distribution|drug
DDI-MedLine.d29.s3|121-122|of|drug
DDI-MedLine.d29.s3|124-134|cloxacillin|drug
DDI-MedLine.d29.s3|136-138|was|drug
DDI-MedLine.d29.s3|140-146|studied|drug
DDI-MedLine.d29.s3|148-149|in|drug
DDI-MedLine.d29.s3|151-153|six|drug
DDI-MedLine.d29.s3|155-162|patients|drug
DDI-MedLine.d29.s3|163-163|,|drug
DDI-MedLine.d29.s3|165-168|five|drug
DDI-MedLine.d29.s3|170-176|lacking|drug
DDI-MedLine.d29.s3|178-183|kidney|drug
DDI-MedLine.d29.s3|185-192|function|drug
DDI-MedLine.d29.s3|194-196|and|drug
DDI-MedLine.d29.s3|198-200|one|drug
DDI-MedLine.d29.s3|202-205|with|drug
DDI-MedLine.d29.s3|207-207|a|drug
DDI-MedLine.d29.s3|209-217|partially|drug
DDI-MedLine.d29.s3|219-226|impaired|drug
DDI-MedLine.d29.s3|228-232|renal|drug
DDI-MedLine.d29.s3|234-241|function|drug
DDI-MedLine.d29.s3|242-242|,|drug
DDI-MedLine.d29.s3|244-245|in|drug
DDI-MedLine.d29.s3|247-249|the|drug
DDI-MedLine.d29.s3|251-258|presence|drug
DDI-MedLine.d29.s3|260-261|or|drug
DDI-MedLine.d29.s3|263-269|absence|drug
DDI-MedLine.d29.s3|271-272|of|drug
DDI-MedLine.d29.s3|274-283|probenecid|drug
DDI-MedLine.d29.s3|284-284|.|drug
DDI-MedLine.d29.s4|0-1|No|drug
DDI-MedLine.d29.s4|3-13|significant|drug
DDI-MedLine.d29.s4|15-24|difference|drug
DDI-MedLine.d29.s4|26-28|was|drug
DDI-MedLine.d29.s4|30-34|found|drug
DDI-MedLine.d29.s4|36-42|between|drug
DDI-MedLine.d29.s4|44-46|the|drug
DDI-MedLine.d29.s4|48-51|mean|drug
DDI-MedLine.d29.s4|53-58|values|drug
DDI-MedLine.d29.s4|60-61|of|drug
DDI-MedLine.d29.s4|63-65|the|drug
DDI-MedLine.d29.s4|67-72|volume|drug
DDI-MedLine.d29.s4|74-75|of|drug
DDI-MedLine.d29.s4|77-88|distribution|drug
DDI-MedLine.d29.s4|90-91|of|drug
DDI-MedLine.d29.s4|93-103|cloxacillin|drug
DDI-MedLine.d29.s4|105-108|with|drug
DDI-MedLine.d29.s4|110-112|and|drug
DDI-MedLine.d29.s4|114-120|without|drug
DDI-MedLine.d29.s4|122-131|probenecid|drug
DDI-MedLine.d29.s4|133-133|(|drug
DDI-MedLine.d29.s4|134-137|13.0|drug
DDI-MedLine.d29.s4|139-141|and|drug
DDI-MedLine.d29.s4|143-146|12.6|drug
DDI-MedLine.d29.s4|148-153|liters|drug
DDI-MedLine.d29.s4|154-154|,|drug
DDI-MedLine.d29.s4|156-167|respectively|drug
DDI-MedLine.d29.s4|168-168|)|drug
DDI-MedLine.d29.s4|169-169|.|drug
DDI-MedLine.d29.s5|0-3|Thus|drug
DDI-MedLine.d29.s5|4-4|,|drug
DDI-MedLine.d29.s5|6-8|the|drug
DDI-MedLine.d29.s5|10-19|hypothesis|drug
DDI-MedLine.d29.s5|21-22|of|drug
DDI-MedLine.d29.s5|24-30|Gibaldi|drug
DDI-MedLine.d29.s5|32-33|et|drug
DDI-MedLine.d29.s5|35-36|al|drug
DDI-MedLine.d29.s5|37-37|.|drug
DDI-MedLine.d29.s6|0-4|could|drug
DDI-MedLine.d29.s6|6-8|not|drug
DDI-MedLine.d29.s6|10-11|be|drug
DDI-MedLine.d29.s6|13-21|confirmed|drug
DDI-MedLine.d29.s6|23-25|for|drug
DDI-MedLine.d29.s6|27-37|cloxacillin|drug
DDI-MedLine.d29.s6|39-40|in|drug
DDI-MedLine.d29.s6|42-49|patients|drug
DDI-MedLine.d29.s6|51-57|lacking|drug
DDI-MedLine.d29.s6|59-64|kidney|drug
DDI-MedLine.d29.s6|66-73|function|drug
DDI-MedLine.d29.s6|74-74|.|drug
DDI-MedLine.d29.s7|0-1|In|drug
DDI-MedLine.d29.s7|3-7|spite|drug
DDI-MedLine.d29.s7|9-10|of|drug
DDI-MedLine.d29.s7|12-14|the|drug
DDI-MedLine.d29.s7|16-22|absence|drug
DDI-MedLine.d29.s7|24-25|of|drug
DDI-MedLine.d29.s7|27-32|kidney|drug
DDI-MedLine.d29.s7|34-41|function|drug
DDI-MedLine.d29.s7|42-42|,|drug
DDI-MedLine.d29.s7|44-46|the|drug
DDI-MedLine.d29.s7|48-52|value|drug
DDI-MedLine.d29.s7|54-55|of|drug
DDI-MedLine.d29.s7|57-59|the|drug
DDI-MedLine.d29.s7|61-71|elimination|drug
DDI-MedLine.d29.s7|73-76|rate|drug
DDI-MedLine.d29.s7|78-85|constant|drug
DDI-MedLine.d29.s7|87-89|was|drug
DDI-MedLine.d29.s7|91-103|significantly|drug
DDI-MedLine.d29.s7|105-113|decreased|drug
DDI-MedLine.d29.s7|115-116|in|drug
DDI-MedLine.d29.s7|118-120|the|drug
DDI-MedLine.d29.s7|122-129|presence|drug
DDI-MedLine.d29.s7|131-132|of|drug
DDI-MedLine.d29.s7|134-143|probenecid|drug
DDI-MedLine.d29.s7|145-145|(|drug
DDI-MedLine.d29.s7|146-149|from|drug
DDI-MedLine.d29.s7|151-155|0.326|drug
DDI-MedLine.d29.s7|157-158|to|drug
DDI-MedLine.d29.s7|160-166|0.263/h|drug
DDI-MedLine.d29.s7|167-167|)|drug
DDI-MedLine.d29.s7|168-168|.|drug
DDI-MedLine.d29.s8|0-3|This|drug
DDI-MedLine.d29.s8|5-9|might|drug
DDI-MedLine.d29.s8|11-12|be|drug
DDI-MedLine.d29.s8|14-22|explained|drug
DDI-MedLine.d29.s8|24-25|by|drug
DDI-MedLine.d29.s8|27-27|a|drug
DDI-MedLine.d29.s8|29-36|blockade|drug
DDI-MedLine.d29.s8|38-39|by|drug
DDI-MedLine.d29.s8|41-50|probenecid|drug
DDI-MedLine.d29.s8|52-53|of|drug
DDI-MedLine.d29.s8|55-57|the|drug
DDI-MedLine.d29.s8|59-69|elimination|drug
DDI-MedLine.d29.s8|71-72|of|drug
DDI-MedLine.d29.s8|74-84|cloxacillin|drug
DDI-MedLine.d29.s8|86-87|by|drug
DDI-MedLine.d29.s8|89-91|the|drug
DDI-MedLine.d29.s8|93-97|liver|drug
DDI-MedLine.d29.s8|98-98|.|drug
DDI-DrugBank.d318.s0|0-3|When|drug
DDI-DrugBank.d318.s0|5-16|administered|drug
DDI-DrugBank.d318.s0|18-29|concurrently|drug
DDI-DrugBank.d318.s0|30-30|,|drug
DDI-DrugBank.d318.s0|32-34|the|drug
DDI-DrugBank.d318.s0|36-44|following|drug
DDI-DrugBank.d318.s0|46-50|drugs|drug
DDI-DrugBank.d318.s0|52-54|may|drug
DDI-DrugBank.d318.s0|56-63|interact|drug
DDI-DrugBank.d318.s0|65-68|with|drug
DDI-DrugBank.d318.s0|70-81|amphotericin|drug
DDI-DrugBank.d318.s0|83-83|B|drug
DDI-DrugBank.d318.s0|84-84|:|drug
DDI-DrugBank.d318.s0|86-99|Antineoplastic|drug
DDI-DrugBank.d318.s0|101-106|agents|drug
DDI-DrugBank.d318.s0|107-107|:|drug
DDI-DrugBank.d318.s0|109-111|may|drug
DDI-DrugBank.d318.s0|113-119|enhance|drug
DDI-DrugBank.d318.s0|121-123|the|drug
DDI-DrugBank.d318.s0|125-133|potential|drug
DDI-DrugBank.d318.s0|135-137|for|drug
DDI-DrugBank.d318.s0|139-143|renal|drug
DDI-DrugBank.d318.s0|145-152|toxicity|drug
DDI-DrugBank.d318.s0|153-153|,|drug
DDI-DrugBank.d318.s0|155-166|bronchospasm|drug
DDI-DrugBank.d318.s0|168-170|and|drug
DDI-DrugBank.d318.s0|172-182|hypotension|drug
DDI-DrugBank.d318.s0|183-183|.|drug
DDI-DrugBank.d318.s1|0-13|Antineoplastic|drug
DDI-DrugBank.d318.s1|15-20|agents|drug
DDI-DrugBank.d318.s1|22-22|(|drug
DDI-DrugBank.d318.s1|23-24|e.|drug
DDI-DrugBank.d318.s1|26-27|g.|drug
DDI-DrugBank.d318.s1|28-28|,|drug
DDI-DrugBank.d318.s1|30-37|nitrogen|drug
DDI-DrugBank.d318.s1|39-45|mustard|drug
DDI-DrugBank.d318.s1|46-46|,|drug
DDI-DrugBank.d318.s1|48-51|etc|drug
DDI-DrugBank.d318.s1|52-52|.|drug
DDI-DrugBank.d318.s1|54-59|)|drug
DDI-DrugBank.d318.s1|61-62|should|drug
DDI-DrugBank.d318.s1|64-68|be|drug
DDI-DrugBank.d318.s1|70-82|given|drug
DDI-DrugBank.d318.s1|84-87|concomitantly|drug
DDI-DrugBank.d318.s1|89-92|only|drug
DDI-DrugBank.d318.s1|94-98|with|drug
DDI-DrugBank.d318.s1|100-106|great|drug
DDI-DrugBank.d318.s1|107-107|caution|drug
DDI-DrugBank.d318.s2|0-14|Corticosteroids|group
DDI-DrugBank.d318.s2|16-18|and|drug
DDI-DrugBank.d318.s2|20-32|Corticotropin|drug
DDI-DrugBank.d318.s2|34-34|(|drug
DDI-DrugBank.d318.s2|35-38|ACTH|drug
DDI-DrugBank.d318.s2|39-39|)|drug
DDI-DrugBank.d318.s2|40-40|:|drug
DDI-DrugBank.d318.s2|42-44|may|drug
DDI-DrugBank.d318.s2|46-55|potentiate|drug
DDI-DrugBank.d318.s2|57-68|amphotericin|drug
DDI-DrugBank.d318.s2|70-71|B-|drug
DDI-DrugBank.d318.s2|73-79|induced|drug
DDI-DrugBank.d318.s2|81-91|hypokalemia|drug
DDI-DrugBank.d318.s2|93-97|which|drug
DDI-DrugBank.d318.s2|99-101|may|drug
DDI-DrugBank.d318.s2|103-112|predispose|drug
DDI-DrugBank.d318.s2|114-116|the|drug
DDI-DrugBank.d318.s2|118-124|patient|drug
DDI-DrugBank.d318.s2|126-127|to|drug
DDI-DrugBank.d318.s2|129-135|cardiac|drug
DDI-DrugBank.d318.s2|137-147|dysfunction|drug
DDI-DrugBank.d318.s2|148-148|.|drug
DDI-DrugBank.d318.s3|0-4|Avoid|drug
DDI-DrugBank.d318.s3|6-16|concomitant|drug
DDI-DrugBank.d318.s3|18-20|use|drug
DDI-DrugBank.d318.s3|22-27|unless|drug
DDI-DrugBank.d318.s3|29-37|necessary|drug
DDI-DrugBank.d318.s3|39-40|to|drug
DDI-DrugBank.d318.s3|42-48|control|drug
DDI-DrugBank.d318.s3|50-53|side|drug
DDI-DrugBank.d318.s3|55-61|effects|drug
DDI-DrugBank.d318.s3|63-64|of|drug
DDI-DrugBank.d318.s3|66-77|amphotericin|drug
DDI-DrugBank.d318.s3|79-79|B|drug
DDI-DrugBank.d318.s3|80-80|.|drug
DDI-DrugBank.d318.s4|0-1|If|drug
DDI-DrugBank.d318.s4|3-6|used|drug
DDI-DrugBank.d318.s4|8-20|concomitantly|drug
DDI-DrugBank.d318.s4|21-21|,|drug
DDI-DrugBank.d318.s4|23-29|closely|drug
DDI-DrugBank.d318.s4|31-37|monitor|drug
DDI-DrugBank.d318.s4|39-43|serum|drug
DDI-DrugBank.d318.s4|45-56|electrolytes|drug
DDI-DrugBank.d318.s4|58-60|and|drug
DDI-DrugBank.d318.s4|62-68|cardiac|drug
DDI-DrugBank.d318.s4|70-77|function|drug
DDI-DrugBank.d318.s4|78-78|.|drug
DDI-DrugBank.d318.s5|0-8|Digitalis|drug
DDI-DrugBank.d318.s5|10-19|glycosides|drug
DDI-DrugBank.d318.s5|20-20|:|drug
DDI-DrugBank.d318.s5|22-33|amphotericin|drug
DDI-DrugBank.d318.s5|35-43|B-induced|drug
DDI-DrugBank.d318.s5|45-55|hypokalemia|drug
DDI-DrugBank.d318.s5|57-59|may|drug
DDI-DrugBank.d318.s5|61-70|potentiate|drug
DDI-DrugBank.d318.s5|72-80|digitalis|drug
DDI-DrugBank.d318.s5|82-89|toxicity|drug
DDI-DrugBank.d318.s5|90-90|.|drug
DDI-DrugBank.d318.s6|0-4|Serum|group
DDI-DrugBank.d318.s6|6-14|potassium|drug
DDI-DrugBank.d318.s6|16-21|levels|drug
DDI-DrugBank.d318.s6|23-25|and|drug
DDI-DrugBank.d318.s6|27-33|cardiac|drug
DDI-DrugBank.d318.s6|35-42|function|drug
DDI-DrugBank.d318.s6|44-49|should|drug
DDI-DrugBank.d318.s6|51-52|be|drug
DDI-DrugBank.d318.s6|54-60|closely|drug
DDI-DrugBank.d318.s6|62-70|monitored|drug
DDI-DrugBank.d318.s6|72-74|and|drug
DDI-DrugBank.d318.s6|76-78|any|drug
DDI-DrugBank.d318.s6|80-86|deficit|drug
DDI-DrugBank.d318.s6|88-95|promptly|drug
DDI-DrugBank.d318.s6|97-105|corrected|drug
DDI-DrugBank.d318.s6|106-106|.|drug
DDI-DrugBank.d318.s7|0-10|Flucytosine|brand
DDI-DrugBank.d318.s7|11-11|:|drug
DDI-DrugBank.d318.s7|13-17|while|drug
DDI-DrugBank.d318.s7|19-19|a|drug
DDI-DrugBank.d318.s7|21-31|synergistic|drug
DDI-DrugBank.d318.s7|33-44|relationship|drug
DDI-DrugBank.d318.s7|46-49|with|drug
DDI-DrugBank.d318.s7|51-62|amphotericin|drug
DDI-DrugBank.d318.s7|64-64|B|drug
DDI-DrugBank.d318.s7|66-68|has|drug
DDI-DrugBank.d318.s7|70-73|been|drug
DDI-DrugBank.d318.s7|75-82|reported|drug
DDI-DrugBank.d318.s7|83-83|,|drug
DDI-DrugBank.d318.s7|85-95|concomitant|drug
DDI-DrugBank.d318.s7|97-99|use|drug
DDI-DrugBank.d318.s7|101-103|may|drug
DDI-DrugBank.d318.s7|105-112|increase|drug
DDI-DrugBank.d318.s7|114-116|the|drug
DDI-DrugBank.d318.s7|118-125|toxicity|drug
DDI-DrugBank.d318.s7|127-128|of|drug
DDI-DrugBank.d318.s7|130-140|flucytosine|drug
DDI-DrugBank.d318.s7|142-143|by|drug
DDI-DrugBank.d318.s7|145-152|possibly|drug
DDI-DrugBank.d318.s7|154-163|increasing|drug
DDI-DrugBank.d318.s7|165-167|its|drug
DDI-DrugBank.d318.s7|169-176|cellular|drug
DDI-DrugBank.d318.s7|178-183|uptake|drug
DDI-DrugBank.d318.s7|185-190|and/or|drug
DDI-DrugBank.d318.s7|192-200|impairing|drug
DDI-DrugBank.d318.s7|202-204|its|drug
DDI-DrugBank.d318.s7|206-210|renal|drug
DDI-DrugBank.d318.s7|212-220|excretion|drug
DDI-DrugBank.d318.s7|221-221|.|drug
DDI-DrugBank.d318.s8|0-9|Imidazoles|group
DDI-DrugBank.d318.s8|11-11|(|drug
DDI-DrugBank.d318.s8|12-13|e.|drug
DDI-DrugBank.d318.s8|15-16|g.|drug
DDI-DrugBank.d318.s8|17-17|,|drug
DDI-DrugBank.d318.s8|19-30|ketoconazole|drug
DDI-DrugBank.d318.s8|31-31|,|drug
DDI-DrugBank.d318.s8|33-42|miconazole|drug
DDI-DrugBank.d318.s8|43-43|,|drug
DDI-DrugBank.d318.s8|45-56|clotrimazole|drug
DDI-DrugBank.d318.s8|57-57|,|drug
DDI-DrugBank.d318.s8|59-69|fluconazole|drug
DDI-DrugBank.d318.s8|70-70|,|drug
DDI-DrugBank.d318.s8|72-75|etc|drug
DDI-DrugBank.d318.s8|76-76|.|drug
DDI-DrugBank.d318.s8|77-77|)|drug
DDI-DrugBank.d318.s8|79-80|:|drug
DDI-DrugBank.d318.s8|82-86|in|drug
DDI-DrugBank.d318.s8|88-90|vitro|drug
DDI-DrugBank.d318.s8|92-97|and|drug
DDI-DrugBank.d318.s8|99-105|animal|drug
DDI-DrugBank.d318.s8|107-110|studies|drug
DDI-DrugBank.d318.s8|112-114|with|drug
DDI-DrugBank.d318.s8|116-126|the|drug
DDI-DrugBank.d318.s8|128-129|combination|drug
DDI-DrugBank.d318.s8|131-142|of|drug
DDI-DrugBank.d318.s8|144-144|amphotericin|drug
DDI-DrugBank.d318.s8|146-148|B|drug
DDI-DrugBank.d318.s8|150-159|and|drug
DDI-DrugBank.d318.s8|161-167|imidazoles|drug
DDI-DrugBank.d318.s8|169-172|suggest|drug
DDI-DrugBank.d318.s8|174-183|that|drug
DDI-DrugBank.d318.s8|185-187|imidazoles|drug
DDI-DrugBank.d318.s8|189-194|may|drug
DDI-DrugBank.d318.s8|196-201|induce|drug
DDI-DrugBank.d318.s8|203-212|fungal|drug
DDI-DrugBank.d318.s8|214-215|resistance|drug
DDI-DrugBank.d318.s8|217-228|to|drug
DDI-DrugBank.d318.s8|230-230|amphotericin|drug
DDI-DrugBank.d318.s8|231-231|B|drug
DDI-DrugBank.d318.s9|0-10|Combination|drug
DDI-DrugBank.d318.s9|12-18|therapy|drug
DDI-DrugBank.d318.s9|20-25|should|drug
DDI-DrugBank.d318.s9|27-28|be|drug
DDI-DrugBank.d318.s9|30-41|administered|drug
DDI-DrugBank.d318.s9|43-46|with|drug
DDI-DrugBank.d318.s9|48-54|caution|drug
DDI-DrugBank.d318.s9|55-55|,|drug
DDI-DrugBank.d318.s9|57-66|especially|drug
DDI-DrugBank.d318.s9|68-69|in|drug
DDI-DrugBank.d318.s9|71-87|immunocompromised|drug
DDI-DrugBank.d318.s9|89-96|patients|drug
DDI-DrugBank.d318.s9|97-97|.|drug
DDI-DrugBank.d318.s10|0-4|Other|drug
DDI-DrugBank.d318.s10|6-16|nephrotoxic|drug
DDI-DrugBank.d318.s10|18-28|medications|drug
DDI-DrugBank.d318.s10|29-29|:|drug
DDI-DrugBank.d318.s10|31-36|agents|drug
DDI-DrugBank.d318.s10|38-41|such|drug
DDI-DrugBank.d318.s10|43-44|as|drug
DDI-DrugBank.d318.s10|46-60|aminoglycosides|drug
DDI-DrugBank.d318.s10|61-61|,|drug
DDI-DrugBank.d318.s10|63-74|cyclosporine|drug
DDI-DrugBank.d318.s10|75-75|,|drug
DDI-DrugBank.d318.s10|77-79|and|drug
DDI-DrugBank.d318.s10|81-91|pentamidine|drug
DDI-DrugBank.d318.s10|93-95|may|drug
DDI-DrugBank.d318.s10|97-103|enhance|drug
DDI-DrugBank.d318.s10|105-107|the|drug
DDI-DrugBank.d318.s10|109-117|potential|drug
DDI-DrugBank.d318.s10|119-121|for|drug
DDI-DrugBank.d318.s10|123-134|drug-induced|drug
DDI-DrugBank.d318.s10|136-140|renal|drug
DDI-DrugBank.d318.s10|142-149|toxicity|drug
DDI-DrugBank.d318.s10|150-150|,|drug
DDI-DrugBank.d318.s10|152-154|and|drug
DDI-DrugBank.d318.s10|156-161|should|drug
DDI-DrugBank.d318.s10|163-164|be|drug
DDI-DrugBank.d318.s10|166-169|used|drug
DDI-DrugBank.d318.s10|171-183|concomitantly|drug
DDI-DrugBank.d318.s10|185-188|only|drug
DDI-DrugBank.d318.s10|190-193|with|drug
DDI-DrugBank.d318.s10|195-199|great|drug
DDI-DrugBank.d318.s10|201-207|caution|drug
DDI-DrugBank.d318.s10|208-208|.|drug
DDI-DrugBank.d318.s11|0-8|Intensive|drug
DDI-DrugBank.d318.s11|10-19|monitoring|drug
DDI-DrugBank.d318.s11|21-22|of|drug
DDI-DrugBank.d318.s11|24-28|renal|drug
DDI-DrugBank.d318.s11|30-37|function|drug
DDI-DrugBank.d318.s11|39-40|is|drug
DDI-DrugBank.d318.s11|42-52|recommended|drug
DDI-DrugBank.d318.s11|54-55|in|drug
DDI-DrugBank.d318.s11|57-64|patients|drug
DDI-DrugBank.d318.s11|66-74|requiring|drug
DDI-DrugBank.d318.s11|76-78|any|drug
DDI-DrugBank.d318.s11|80-90|combination|drug
DDI-DrugBank.d318.s11|92-93|of|drug
DDI-DrugBank.d318.s11|95-105|nephrotoxic|drug
DDI-DrugBank.d318.s11|107-117|medications|drug
DDI-DrugBank.d318.s11|119-119|.|drug
DDI-DrugBank.d318.s12|0-7|Skeletal|drug
DDI-DrugBank.d318.s12|9-14|muscle|drug
DDI-DrugBank.d318.s12|16-24|relaxants|drug
DDI-DrugBank.d318.s12|25-25|:|drug
DDI-DrugBank.d318.s12|27-38|amphotericin|drug
DDI-DrugBank.d318.s12|40-48|B-induced|drug
DDI-DrugBank.d318.s12|50-60|hypokalemia|drug
DDI-DrugBank.d318.s12|62-64|may|drug
DDI-DrugBank.d318.s12|66-72|enhance|drug
DDI-DrugBank.d318.s12|74-76|the|drug
DDI-DrugBank.d318.s12|78-87|curariform|drug
DDI-DrugBank.d318.s12|89-94|effect|drug
DDI-DrugBank.d318.s12|96-97|of|drug
DDI-DrugBank.d318.s12|99-106|skeletal|drug
DDI-DrugBank.d318.s12|108-113|muscle|drug
DDI-DrugBank.d318.s12|115-123|relaxants|drug
DDI-DrugBank.d318.s12|125-125|(|drug
DDI-DrugBank.d318.s12|126-129|e.g.|drug
DDI-DrugBank.d318.s12|130-130|,|drug
DDI-DrugBank.d318.s12|132-143|tubocurarine|drug
DDI-DrugBank.d318.s12|144-144|)|drug
DDI-DrugBank.d318.s12|145-145|.|drug
DDI-DrugBank.d318.s13|0-4|Serum|group
DDI-DrugBank.d318.s13|6-14|potassium|drug
DDI-DrugBank.d318.s13|16-21|levels|drug
DDI-DrugBank.d318.s13|23-28|should|drug
DDI-DrugBank.d318.s13|30-31|be|drug
DDI-DrugBank.d318.s13|33-41|monitored|drug
DDI-DrugBank.d318.s13|43-45|and|drug
DDI-DrugBank.d318.s13|47-58|deficiencies|drug
DDI-DrugBank.d318.s13|60-68|corrected|drug
DDI-DrugBank.d318.s13|69-69|.|drug
DDI-DrugBank.d318.s14|0-8|Leukocyte|drug
DDI-DrugBank.d318.s14|10-21|transfusions|drug
DDI-DrugBank.d318.s14|22-22|:|drug
DDI-DrugBank.d318.s14|24-28|acute|drug
DDI-DrugBank.d318.s14|30-38|pulmonary|drug
DDI-DrugBank.d318.s14|40-47|toxicity|drug
DDI-DrugBank.d318.s14|49-51|has|drug
DDI-DrugBank.d318.s14|53-56|been|drug
DDI-DrugBank.d318.s14|58-65|reported|drug
DDI-DrugBank.d318.s14|67-68|in|drug
DDI-DrugBank.d318.s14|70-77|patients|drug
DDI-DrugBank.d318.s14|79-87|receiving|drug
DDI-DrugBank.d318.s14|89-99|intravenous|drug
DDI-DrugBank.d318.s14|101-112|amphotericin|drug
DDI-DrugBank.d318.s14|114-114|B|drug
DDI-DrugBank.d318.s14|116-118|and|drug
DDI-DrugBank.d318.s14|120-128|leukocyte|drug
DDI-DrugBank.d318.s14|130-141|transfusions|drug
DDI-DrugBank.d318.s14|142-142|.|drug
DDI-MedLine.d23.s0|0-2|The|drug
DDI-MedLine.d23.s0|4-10|effects|drug
DDI-MedLine.d23.s0|12-13|of|drug
DDI-MedLine.d23.s0|15-22|ketamine|drug
DDI-MedLine.d23.s0|24-26|and|drug
DDI-MedLine.d23.s0|28-29|of|drug
DDI-MedLine.d23.s0|31-37|Innovar|drug
DDI-MedLine.d23.s0|39-48|anesthesia|drug
DDI-MedLine.d23.s0|50-51|on|drug
DDI-MedLine.d23.s0|53-61|digitalis|drug
DDI-MedLine.d23.s0|63-71|tolerance|drug
DDI-MedLine.d23.s0|73-74|in|drug
DDI-MedLine.d23.s0|76-79|dogs|drug
DDI-MedLine.d23.s0|80-80|.|drug
DDI-MedLine.d23.s1|0-1|In|drug
DDI-MedLine.d23.s1|3-3|a|drug
DDI-MedLine.d23.s1|5-14|comparison|drug
DDI-MedLine.d23.s1|16-17|of|drug
DDI-MedLine.d23.s1|19-27|digitalis|drug
DDI-MedLine.d23.s1|29-37|tolerance|drug
DDI-MedLine.d23.s1|39-40|in|drug
DDI-MedLine.d23.s1|42-45|dogs|drug
DDI-MedLine.d23.s1|47-58|anesthetized|drug
DDI-MedLine.d23.s1|60-63|with|drug
DDI-MedLine.d23.s1|65-72|ketamine|drug
DDI-MedLine.d23.s1|73-73|,|drug
DDI-MedLine.d23.s1|75-81|Innovar|drug
DDI-MedLine.d23.s1|83-85|Vet|drug
DDI-MedLine.d23.s1|86-86|,|drug
DDI-MedLine.d23.s1|88-89|or|drug
DDI-MedLine.d23.s1|91-103|pentobarbital|drug
DDI-MedLine.d23.s1|104-104|,|drug
DDI-MedLine.d23.s1|106-108|the|drug
DDI-MedLine.d23.s1|110-115|dosage|drug
DDI-MedLine.d23.s1|117-118|of|drug
DDI-MedLine.d23.s1|120-126|ouabain|drug
DDI-MedLine.d23.s1|128-133|needed|drug
DDI-MedLine.d23.s1|135-136|to|drug
DDI-MedLine.d23.s1|138-142|cause|drug
DDI-MedLine.d23.s1|144-154|ventricular|drug
DDI-MedLine.d23.s1|156-166|tachycardia|drug
DDI-MedLine.d23.s1|168-170|was|drug
DDI-MedLine.d23.s1|172-184|significantly|drug
DDI-MedLine.d23.s1|186-191|higher|drug
DDI-MedLine.d23.s1|192-192|,|drug
DDI-MedLine.d23.s1|194-195|as|drug
DDI-MedLine.d23.s1|197-199|was|drug
DDI-MedLine.d23.s1|201-203|the|drug
DDI-MedLine.d23.s1|205-208|LD50|drug
DDI-MedLine.d23.s1|210-211|of|drug
DDI-MedLine.d23.s1|213-219|ouabain|drug
DDI-MedLine.d23.s1|220-220|,|drug
DDI-MedLine.d23.s1|222-225|with|drug
DDI-MedLine.d23.s1|227-234|ketamine|drug
DDI-MedLine.d23.s1|236-237|or|drug
DDI-MedLine.d23.s1|239-245|Innovar|drug
DDI-MedLine.d23.s1|247-250|than|drug
DDI-MedLine.d23.s1|252-255|with|drug
DDI-MedLine.d23.s1|257-269|pentobarbital|drug
DDI-MedLine.d23.s1|270-270|.|drug
DDI-MedLine.d23.s2|0-10|Ventricular|drug
DDI-MedLine.d23.s2|12-22|tachycardia|drug
DDI-MedLine.d23.s2|24-30|induced|drug
DDI-MedLine.d23.s2|32-33|by|drug
DDI-MedLine.d23.s2|35-41|ouabain|drug
DDI-MedLine.d23.s2|43-45|was|drug
DDI-MedLine.d23.s2|47-55|generally|drug
DDI-MedLine.d23.s2|57-65|converted|drug
DDI-MedLine.d23.s2|67-68|to|drug
DDI-MedLine.d23.s2|70-74|sinus|drug
DDI-MedLine.d23.s2|76-81|rhythm|drug
DDI-MedLine.d23.s2|83-91|following|drug
DDI-MedLine.d23.s2|93-106|administration|drug
DDI-MedLine.d23.s2|108-109|of|drug
DDI-MedLine.d23.s2|111-117|Innovar|drug
DDI-MedLine.d23.s2|118-118|,|drug
DDI-MedLine.d23.s2|120-127|ketamine|drug
DDI-MedLine.d23.s2|128-128|,|drug
DDI-MedLine.d23.s2|130-131|or|drug
DDI-MedLine.d23.s2|133-142|droperidol|drug
DDI-MedLine.d23.s2|144-146|but|drug
DDI-MedLine.d23.s2|148-150|not|drug
DDI-MedLine.d23.s2|152-156|after|drug
DDI-MedLine.d23.s2|158-171|administration|drug
DDI-MedLine.d23.s2|173-174|of|drug
DDI-MedLine.d23.s2|176-182|fentayl|drug
DDI-MedLine.d23.s2|184-188|alone|drug
DDI-MedLine.d23.s2|190-191|or|drug
DDI-MedLine.d23.s2|193-197|after|drug
DDI-MedLine.d23.s2|199-211|pentobarbital|drug
DDI-MedLine.d23.s2|212-212|.|drug
DDI-DrugBank.d141.s0|0-16|Immunosuppressive|drug
DDI-DrugBank.d141.s0|18-22|Drugs|drug
DDI-DrugBank.d141.s0|23-23|,|drug
DDI-DrugBank.d141.s0|25-30|Fibric|drug
DDI-DrugBank.d141.s0|32-35|Acid|drug
DDI-DrugBank.d141.s0|37-47|Derivatives|drug
DDI-DrugBank.d141.s0|48-48|,|drug
DDI-DrugBank.d141.s0|50-55|Niacin|brand
DDI-DrugBank.d141.s0|57-57|(|drug
DDI-DrugBank.d141.s0|58-66|Nicotinic|drug
DDI-DrugBank.d141.s0|68-71|Acid|drug
DDI-DrugBank.d141.s0|72-72|,|drug
DDI-DrugBank.d141.s0|74-85|Erythromycin|brand
DDI-DrugBank.d141.s0|86-86|,|drug
DDI-DrugBank.d141.s0|88-92|Azole|drug
DDI-DrugBank.d141.s0|94-104|Antifungals|drug
DDI-DrugBank.d141.s0|105-105|:|drug
DDI-DrugBank.d141.s0|107-114|Skeletal|drug
DDI-DrugBank.d141.s0|116-121|Muscle|brand
DDI-DrugBank.d141.s0|122-122|.|drug
DDI-DrugBank.d141.s1|0-6|ANTACID|drug
DDI-DrugBank.d141.s1|8-8|(|drug
DDI-DrugBank.d141.s1|9-26|Magnesium-Aluminum|drug
DDI-DrugBank.d141.s1|28-36|Hydroxide|drug
DDI-DrugBank.d141.s1|37-37|)|drug
DDI-DrugBank.d141.s1|38-38|:|drug
DDI-DrugBank.d141.s1|40-51|Cerivastatin|drug
DDI-DrugBank.d141.s1|53-58|plasma|drug
DDI-DrugBank.d141.s1|60-73|concentrations|drug
DDI-DrugBank.d141.s1|75-78|were|drug
DDI-DrugBank.d141.s1|80-82|not|drug
DDI-DrugBank.d141.s1|84-91|affected|drug
DDI-DrugBank.d141.s1|93-94|by|drug
DDI-DrugBank.d141.s1|96-112|co-administration|drug
DDI-DrugBank.d141.s1|114-115|of|drug
DDI-DrugBank.d141.s1|117-123|antacid|drug
DDI-DrugBank.d141.s1|124-124|.|drug
DDI-DrugBank.d141.s2|0-9|CIMETlDINE|drug
DDI-DrugBank.d141.s2|10-10|:|drug
DDI-DrugBank.d141.s2|12-23|Cerivastatin|drug
DDI-DrugBank.d141.s2|25-30|plasma|drug
DDI-DrugBank.d141.s2|32-45|concentrations|drug
DDI-DrugBank.d141.s2|47-50|were|drug
DDI-DrugBank.d141.s2|52-54|not|drug
DDI-DrugBank.d141.s2|56-63|affected|drug
DDI-DrugBank.d141.s2|65-66|by|drug
DDI-DrugBank.d141.s2|68-84|co-administration|drug
DDI-DrugBank.d141.s2|86-87|of|drug
DDI-DrugBank.d141.s2|89-98|cimetidine|drug
DDI-DrugBank.d141.s2|99-99|.|drug
DDI-DrugBank.d141.s3|0-13|CHOLESTYRAMINE|drug
DDI-DrugBank.d141.s3|14-14|:|drug
DDI-DrugBank.d141.s3|16-18|The|drug
DDI-DrugBank.d141.s3|20-28|influence|drug
DDI-DrugBank.d141.s3|30-31|of|drug
DDI-DrugBank.d141.s3|33-35|the|drug
DDI-DrugBank.d141.s3|37-57|bile-acidsequestering|drug
DDI-DrugBank.d141.s3|59-63|agent|drug
DDI-DrugBank.d141.s3|65-78|cholestyramine|drug
DDI-DrugBank.d141.s3|80-81|on|drug
DDI-DrugBank.d141.s3|83-85|the|drug
DDI-DrugBank.d141.s3|87-102|pharmacokinetits|drug
DDI-DrugBank.d141.s3|104-105|of|drug
DDI-DrugBank.d141.s3|107-118|cerivastatin|drug
DDI-DrugBank.d141.s3|120-125|sodium|drug
DDI-DrugBank.d141.s3|127-129|was|drug
DDI-DrugBank.d141.s3|131-139|evaluated|drug
DDI-DrugBank.d141.s3|141-142|in|drug
DDI-DrugBank.d141.s3|144-145|12|drug
DDI-DrugBank.d141.s3|147-153|healthy|drug
DDI-DrugBank.d141.s3|155-159|males|drug
DDI-DrugBank.d141.s3|161-162|in|drug
DDI-DrugBank.d141.s3|164-164|2|drug
DDI-DrugBank.d141.s3|166-173|separate|drug
DDI-DrugBank.d141.s3|175-184|randomized|drug
DDI-DrugBank.d141.s3|186-194|crossover|drug
DDI-DrugBank.d141.s3|196-202|studies|drug
DDI-DrugBank.d141.s3|203-203|.|drug
DDI-DrugBank.d141.s4|0-1|In|drug
DDI-DrugBank.d141.s4|3-5|the|drug
DDI-DrugBank.d141.s4|7-11|first|drug
DDI-DrugBank.d141.s4|13-17|study|drug
DDI-DrugBank.d141.s4|18-18|,|drug
DDI-DrugBank.d141.s4|20-30|concomitant|drug
DDI-DrugBank.d141.s4|32-45|administration|drug
DDI-DrugBank.d141.s4|47-48|of|drug
DDI-DrugBank.d141.s4|50-52|0.2|drug
DDI-DrugBank.d141.s4|54-55|mg|drug
DDI-DrugBank.d141.s4|57-68|cerivastatin|drug
DDI-DrugBank.d141.s4|70-75|sodium|drug
DDI-DrugBank.d141.s4|77-79|and|drug
DDI-DrugBank.d141.s4|81-82|12|drug
DDI-DrugBank.d141.s4|84-84|g|drug
DDI-DrugBank.d141.s4|86-99|cholestyramine|drug
DDI-DrugBank.d141.s4|101-108|resulted|drug
DDI-DrugBank.d141.s4|110-111|in|drug
DDI-DrugBank.d141.s4|113-121|decreases|drug
DDI-DrugBank.d141.s4|123-124|of|drug
DDI-DrugBank.d141.s4|126-129|more|drug
DDI-DrugBank.d141.s4|131-134|than|drug
DDI-DrugBank.d141.s4|136-137|22|drug
DDI-DrugBank.d141.s4|138-138|%|drug
DDI-DrugBank.d141.s4|140-142|for|drug
DDI-DrugBank.d141.s4|144-146|AUC|drug
DDI-DrugBank.d141.s4|148-150|and|drug
DDI-DrugBank.d141.s4|152-153|40|drug
DDI-DrugBank.d141.s4|154-154|%|drug
DDI-DrugBank.d141.s4|156-158|for|drug
DDI-DrugBank.d141.s4|160-163|Cmax|drug
DDI-DrugBank.d141.s4|165-168|when|drug
DDI-DrugBank.d141.s4|170-177|compared|drug
DDI-DrugBank.d141.s4|179-180|to|drug
DDI-DrugBank.d141.s4|182-187|dosing|drug
DDI-DrugBank.d141.s4|189-200|cerivastatin|drug
DDI-DrugBank.d141.s4|202-207|sodium|drug
DDI-DrugBank.d141.s4|209-213|alone|drug
DDI-DrugBank.d141.s4|214-214|.|drug
DDI-DrugBank.d141.s5|0-6|However|drug
DDI-DrugBank.d141.s5|7-7|,|drug
DDI-DrugBank.d141.s5|9-10|in|drug
DDI-DrugBank.d141.s5|12-14|the|drug
DDI-DrugBank.d141.s5|16-21|second|drug
DDI-DrugBank.d141.s5|23-27|study|drug
DDI-DrugBank.d141.s5|28-28|,|drug
DDI-DrugBank.d141.s5|30-43|administration|drug
DDI-DrugBank.d141.s5|45-46|of|drug
DDI-DrugBank.d141.s5|48-49|12|drug
DDI-DrugBank.d141.s5|51-51|g|drug
DDI-DrugBank.d141.s5|53-66|cholestyramine|drug
DDI-DrugBank.d141.s5|68-68|1|drug
DDI-DrugBank.d141.s5|70-73|hour|drug
DDI-DrugBank.d141.s5|75-80|before|drug
DDI-DrugBank.d141.s5|82-84|the|drug
DDI-DrugBank.d141.s5|86-92|evening|drug
DDI-DrugBank.d141.s5|94-97|meal|drug
DDI-DrugBank.d141.s5|99-101|and|drug
DDI-DrugBank.d141.s5|103-105|0.3|drug
DDI-DrugBank.d141.s5|107-108|mg|drug
DDI-DrugBank.d141.s5|110-121|cerivastatin|drug
DDI-DrugBank.d141.s5|123-128|sodium|drug
DDI-DrugBank.d141.s5|130-142|approximately|drug
DDI-DrugBank.d141.s5|144-144|4|drug
DDI-DrugBank.d141.s5|146-150|hours|drug
DDI-DrugBank.d141.s5|152-156|after|drug
DDI-DrugBank.d141.s5|158-160|the|drug
DDI-DrugBank.d141.s5|162-165|same|drug
DDI-DrugBank.d141.s5|167-173|evening|drug
DDI-DrugBank.d141.s5|175-178|meal|drug
DDI-DrugBank.d141.s5|180-187|resulted|drug
DDI-DrugBank.d141.s5|189-190|in|drug
DDI-DrugBank.d141.s5|192-192|a|drug
DDI-DrugBank.d141.s5|194-201|decrease|drug
DDI-DrugBank.d141.s5|203-204|in|drug
DDI-DrugBank.d141.s5|206-208|the|drug
DDI-DrugBank.d141.s5|210-221|cerivastatin|drug
DDI-DrugBank.d141.s5|223-225|AUC|drug
DDI-DrugBank.d141.s5|227-228|of|drug
DDI-DrugBank.d141.s5|230-233|less|drug
DDI-DrugBank.d141.s5|235-238|than|drug
DDI-DrugBank.d141.s5|240-240|8|drug
DDI-DrugBank.d141.s5|241-241|%|drug
DDI-DrugBank.d141.s5|242-242|,|drug
DDI-DrugBank.d141.s5|244-246|and|drug
DDI-DrugBank.d141.s5|248-248|a|drug
DDI-DrugBank.d141.s5|250-257|decrease|drug
DDI-DrugBank.d141.s5|259-260|in|drug
DDI-DrugBank.d141.s5|262-265|Cmax|drug
DDI-DrugBank.d141.s5|267-268|of|drug
DDI-DrugBank.d141.s5|270-274|about|drug
DDI-DrugBank.d141.s5|276-277|30|drug
DDI-DrugBank.d141.s5|278-278|%|drug
DDI-DrugBank.d141.s5|280-283|when|drug
DDI-DrugBank.d141.s5|285-292|compared|drug
DDI-DrugBank.d141.s5|294-295|to|drug
DDI-DrugBank.d141.s5|297-302|dosing|drug
DDI-DrugBank.d141.s5|304-315|cerivastatin|drug
DDI-DrugBank.d141.s5|317-322|sodium|drug
DDI-DrugBank.d141.s5|324-328|alone|drug
DDI-DrugBank.d141.s5|329-329|.|drug
DDI-DrugBank.d141.s6|0-8|Therefore|drug
DDI-DrugBank.d141.s6|9-9|,|drug
DDI-DrugBank.d141.s6|11-12|it|drug
DDI-DrugBank.d141.s6|14-18|would|drug
DDI-DrugBank.d141.s6|20-21|be|drug
DDI-DrugBank.d141.s6|23-30|expected|drug
DDI-DrugBank.d141.s6|32-35|that|drug
DDI-DrugBank.d141.s6|37-37|a|drug
DDI-DrugBank.d141.s6|39-44|dosing|drug
DDI-DrugBank.d141.s6|46-53|schedule|drug
DDI-DrugBank.d141.s6|55-56|of|drug
DDI-DrugBank.d141.s6|58-69|cerivastatin|drug
DDI-DrugBank.d141.s6|71-76|sodium|drug
DDI-DrugBank.d141.s6|78-82|given|drug
DDI-DrugBank.d141.s6|84-85|at|drug
DDI-DrugBank.d141.s6|87-93|bedtime|drug
DDI-DrugBank.d141.s6|95-97|and|drug
DDI-DrugBank.d141.s6|99-112|cholestyramine|drug
DDI-DrugBank.d141.s6|114-118|given|drug
DDI-DrugBank.d141.s6|120-125|before|drug
DDI-DrugBank.d141.s6|127-129|the|drug
DDI-DrugBank.d141.s6|131-137|evening|drug
DDI-DrugBank.d141.s6|139-142|meal|drug
DDI-DrugBank.d141.s6|144-148|would|drug
DDI-DrugBank.d141.s6|150-152|not|drug
DDI-DrugBank.d141.s6|154-159|result|drug
DDI-DrugBank.d141.s6|161-162|in|drug
DDI-DrugBank.d141.s6|164-164|a|drug
DDI-DrugBank.d141.s6|166-176|significant|drug
DDI-DrugBank.d141.s6|178-185|decrease|drug
DDI-DrugBank.d141.s6|187-188|in|drug
DDI-DrugBank.d141.s6|190-192|the|drug
DDI-DrugBank.d141.s6|194-201|clinical|drug
DDI-DrugBank.d141.s6|203-208|effect|drug
DDI-DrugBank.d141.s6|210-211|of|drug
DDI-DrugBank.d141.s6|213-224|cerivastatin|drug
DDI-DrugBank.d141.s6|226-231|sodium|drug
DDI-DrugBank.d141.s6|232-232|.|drug
DDI-DrugBank.d141.s7|0-6|DIGOXIN|drug
DDI-DrugBank.d141.s7|7-7|:|drug
DDI-DrugBank.d141.s7|9-14|Plasma|drug
DDI-DrugBank.d141.s7|16-22|digoxin|drug
DDI-DrugBank.d141.s7|24-29|levels|drug
DDI-DrugBank.d141.s7|31-33|and|drug
DDI-DrugBank.d141.s7|35-41|digoxin|drug
DDI-DrugBank.d141.s7|43-51|clearance|drug
DDI-DrugBank.d141.s7|53-54|at|drug
DDI-DrugBank.d141.s7|56-67|steady-state|drug
DDI-DrugBank.d141.s7|69-72|were|drug
DDI-DrugBank.d141.s7|74-76|not|drug
DDI-DrugBank.d141.s7|78-85|affected|drug
DDI-DrugBank.d141.s7|87-88|by|drug
DDI-DrugBank.d141.s7|90-106|co-administration|drug
DDI-DrugBank.d141.s7|108-109|of|drug
DDI-DrugBank.d141.s7|111-113|0.2|drug
DDI-DrugBank.d141.s7|115-116|mg|drug
DDI-DrugBank.d141.s7|118-129|cerivastatin|drug
DDI-DrugBank.d141.s7|131-136|sodium|drug
DDI-DrugBank.d141.s7|137-137|.|drug
DDI-DrugBank.d141.s8|0-11|Cerivastatin|drug
DDI-DrugBank.d141.s8|13-18|plasma|drug
DDI-DrugBank.d141.s8|20-33|concentrations|drug
DDI-DrugBank.d141.s8|35-38|were|drug
DDI-DrugBank.d141.s8|40-43|also|drug
DDI-DrugBank.d141.s8|45-47|not|drug
DDI-DrugBank.d141.s8|49-56|affected|drug
DDI-DrugBank.d141.s8|58-59|by|drug
DDI-DrugBank.d141.s8|61-77|co-administration|drug
DDI-DrugBank.d141.s8|79-80|of|drug
DDI-DrugBank.d141.s8|82-88|digoxin|drug
DDI-DrugBank.d141.s8|89-89|.|drug
DDI-DrugBank.d141.s9|0-7|WARFARIN|drug
DDI-DrugBank.d141.s9|8-8|:|drug
DDI-DrugBank.d141.s9|10-12|Co-|drug
DDI-DrugBank.d141.s9|14-27|administration|drug
DDI-DrugBank.d141.s9|29-30|of|drug
DDI-DrugBank.d141.s9|32-39|warfarin|drug
DDI-DrugBank.d141.s9|41-43|and|drug
DDI-DrugBank.d141.s9|45-56|cerivastatin|drug
DDI-DrugBank.d141.s9|58-59|to|drug
DDI-DrugBank.d141.s9|61-67|healthy|drug
DDI-DrugBank.d141.s9|69-78|volunteers|drug
DDI-DrugBank.d141.s9|80-82|did|drug
DDI-DrugBank.d141.s9|84-86|not|drug
DDI-DrugBank.d141.s9|88-93|result|drug
DDI-DrugBank.d141.s9|95-96|in|drug
DDI-DrugBank.d141.s9|98-100|any|drug
DDI-DrugBank.d141.s9|102-108|changes|drug
DDI-DrugBank.d141.s9|110-111|in|drug
DDI-DrugBank.d141.s9|113-123|prothrombin|drug
DDI-DrugBank.d141.s9|125-128|time|drug
DDI-DrugBank.d141.s9|130-131|or|drug
DDI-DrugBank.d141.s9|133-140|clotting|drug
DDI-DrugBank.d141.s9|142-147|factor|drug
DDI-DrugBank.d141.s9|149-151|VII|drug
DDI-DrugBank.d141.s9|153-156|when|drug
DDI-DrugBank.d141.s9|158-165|compared|drug
DDI-DrugBank.d141.s9|167-168|to|drug
DDI-DrugBank.d141.s9|170-186|co-administration|drug
DDI-DrugBank.d141.s9|188-189|of|drug
DDI-DrugBank.d141.s9|191-198|warfarin|drug
DDI-DrugBank.d141.s9|200-202|and|drug
DDI-DrugBank.d141.s9|204-210|placebo|drug
DDI-DrugBank.d141.s9|211-211|.|drug
DDI-DrugBank.d141.s10|0-2|The|drug
DDI-DrugBank.d141.s10|4-6|AUC|drug
DDI-DrugBank.d141.s10|8-10|and|drug
DDI-DrugBank.d141.s10|12-15|Cmax|drug
DDI-DrugBank.d141.s10|17-18|of|drug
DDI-DrugBank.d141.s10|20-23|both|drug
DDI-DrugBank.d141.s10|25-27|the|drug
DDI-DrugBank.d141.s10|29-29|(|drug
DDI-DrugBank.d141.s10|30-30|R|drug
DDI-DrugBank.d141.s10|31-31|)|drug
DDI-DrugBank.d141.s10|33-35|and|drug
DDI-DrugBank.d141.s10|37-37|(|drug
DDI-DrugBank.d141.s10|38-38|S|drug
DDI-DrugBank.d141.s10|39-39|)|drug
DDI-DrugBank.d141.s10|41-47|isomers|drug
DDI-DrugBank.d141.s10|49-50|of|drug
DDI-DrugBank.d141.s10|52-59|warfarin|drug
DDI-DrugBank.d141.s10|61-64|were|drug
DDI-DrugBank.d141.s10|66-75|unaffected|drug
DDI-DrugBank.d141.s10|77-78|by|drug
DDI-DrugBank.d141.s10|80-89|concurrent|drug
DDI-DrugBank.d141.s10|91-96|dosing|drug
DDI-DrugBank.d141.s10|98-99|of|drug
DDI-DrugBank.d141.s10|101-103|0.3|drug
DDI-DrugBank.d141.s10|105-106|mg|drug
DDI-DrugBank.d141.s10|108-119|cerivastatin|drug
DDI-DrugBank.d141.s10|121-126|sodium|drug
DDI-DrugBank.d141.s10|127-127|.|drug
DDI-DrugBank.d141.s11|0-16|Co-administration|drug
DDI-DrugBank.d141.s11|18-19|of|drug
DDI-DrugBank.d141.s11|21-28|warfarin|drug
DDI-DrugBank.d141.s11|30-32|and|drug
DDI-DrugBank.d141.s11|34-45|cerivastatin|drug
DDI-DrugBank.d141.s11|47-49|did|drug
DDI-DrugBank.d141.s11|51-53|not|drug
DDI-DrugBank.d141.s11|55-59|alter|drug
DDI-DrugBank.d141.s11|61-63|the|drug
DDI-DrugBank.d141.s11|65-80|pharmacokinetics|drug
DDI-DrugBank.d141.s11|82-83|of|drug
DDI-DrugBank.d141.s11|85-96|cerivastatin|drug
DDI-DrugBank.d141.s11|98-103|sodium|drug
DDI-DrugBank.d141.s11|104-104|.|drug
DDI-DrugBank.d141.s12|0-11|ERYTHROMYCIN|drug
DDI-DrugBank.d141.s12|12-12|:|drug
DDI-DrugBank.d141.s12|14-15|In|drug
DDI-DrugBank.d141.s12|17-36|hypercholesterolemic|drug
DDI-DrugBank.d141.s12|38-45|patients|drug
DDI-DrugBank.d141.s12|46-46|,|drug
DDI-DrugBank.d141.s12|48-59|steady-state|drug
DDI-DrugBank.d141.s12|61-72|cerivastatin|drug
DDI-DrugBank.d141.s12|74-76|AUC|drug
DDI-DrugBank.d141.s12|78-80|and|drug
DDI-DrugBank.d141.s12|82-85|Cmax|drug
DDI-DrugBank.d141.s12|87-95|increased|drug
DDI-DrugBank.d141.s12|97-109|approximately|drug
DDI-DrugBank.d141.s12|111-112|50|drug
DDI-DrugBank.d141.s12|113-113|%|drug
DDI-DrugBank.d141.s12|115-117|and|drug
DDI-DrugBank.d141.s12|119-120|24|drug
DDI-DrugBank.d141.s12|121-121|%|drug
DDI-DrugBank.d141.s12|123-134|respectively|drug
DDI-DrugBank.d141.s12|136-140|after|drug
DDI-DrugBank.d141.s12|142-143|10|drug
DDI-DrugBank.d141.s12|145-148|days|drug
DDI-DrugBank.d141.s12|150-153|with|drug
DDI-DrugBank.d141.s12|155-171|co-administration|drug
DDI-DrugBank.d141.s12|173-174|of|drug
DDI-DrugBank.d141.s12|176-187|erythromycin|drug
DDI-DrugBank.d141.s12|188-188|,|drug
DDI-DrugBank.d141.s12|190-190|a|drug
DDI-DrugBank.d141.s12|192-196|known|drug
DDI-DrugBank.d141.s12|198-206|inhibitor|drug
DDI-DrugBank.d141.s12|208-209|of|drug
DDI-DrugBank.d141.s12|211-220|cytochrome|drug
DDI-DrugBank.d141.s12|222-225|P450|drug
DDI-DrugBank.d141.s12|227-229|3A4|drug
DDI-DrugBank.d141.s12|230-230|.|drug
DDI-DrugBank.d141.s13|0-4|OTHER|drug
DDI-DrugBank.d141.s13|6-16|CONCOMITANT|drug
DDI-DrugBank.d141.s13|18-24|THERAPY|drug
DDI-DrugBank.d141.s13|25-25|:|drug
DDI-DrugBank.d141.s13|27-34|Although|drug
DDI-DrugBank.d141.s13|36-43|specific|drug
DDI-DrugBank.d141.s13|45-55|interaction|drug
DDI-DrugBank.d141.s13|57-63|studies|drug
DDI-DrugBank.d141.s13|65-68|were|drug
DDI-DrugBank.d141.s13|70-72|not|drug
DDI-DrugBank.d141.s13|74-82|performed|drug
DDI-DrugBank.d141.s13|83-83|,|drug
DDI-DrugBank.d141.s13|85-86|in|drug
DDI-DrugBank.d141.s13|88-95|clinical|drug
DDI-DrugBank.d141.s13|97-103|studies|drug
DDI-DrugBank.d141.s13|104-104|,|drug
DDI-DrugBank.d141.s13|106-117|cerivastatin|drug
DDI-DrugBank.d141.s13|119-124|sodium|drug
DDI-DrugBank.d141.s13|126-128|was|drug
DDI-DrugBank.d141.s13|130-133|used|drug
DDI-DrugBank.d141.s13|135-147|concomitantly|drug
DDI-DrugBank.d141.s13|149-152|with|drug
DDI-DrugBank.d141.s13|154-165|angiotensin-|drug
DDI-DrugBank.d141.s13|167-176|converting|drug
DDI-DrugBank.d141.s13|178-183|enzyme|drug
DDI-DrugBank.d141.s13|185-185|(|drug
DDI-DrugBank.d141.s13|186-188|ACE|drug
DDI-DrugBank.d141.s13|189-189|)|drug
DDI-DrugBank.d141.s13|191-200|inhibitors|drug
DDI-DrugBank.d141.s13|201-201|,|drug
DDI-DrugBank.d141.s13|203-214|betablockers|drug
DDI-DrugBank.d141.s13|215-215|,|drug
DDI-DrugBank.d141.s13|217-231|calcium-channel|drug
DDI-DrugBank.d141.s13|233-240|blockers|drug
DDI-DrugBank.d141.s13|241-241|,|drug
DDI-DrugBank.d141.s13|243-251|diuretics|drug
DDI-DrugBank.d141.s13|252-252|,|drug
DDI-DrugBank.d141.s13|254-256|and|drug
DDI-DrugBank.d141.s13|258-269|nonsteroidal|drug
DDI-DrugBank.d141.s13|271-287|anti-inflammatory|drug
DDI-DrugBank.d141.s13|289-293|drugs|drug
DDI-DrugBank.d141.s13|295-295|(|drug
DDI-DrugBank.d141.s13|296-301|NSAIDs|drug
DDI-DrugBank.d141.s13|302-302|)|drug
DDI-DrugBank.d141.s13|304-310|without|drug
DDI-DrugBank.d141.s13|312-319|evidence|drug
DDI-DrugBank.d141.s13|321-322|of|drug
DDI-DrugBank.d141.s13|324-333|clinically|drug
DDI-DrugBank.d141.s13|335-345|significant|drug
DDI-DrugBank.d141.s13|347-353|adverse|drug
DDI-DrugBank.d141.s13|355-366|interactions|drug
DDI-DrugBank.d141.s13|367-367|.|drug
DDI-MedLine.d132.s0|0-2|The|drug
DDI-MedLine.d132.s0|4-11|emerging|drug
DDI-MedLine.d132.s0|13-17|roles|drug
DDI-MedLine.d132.s0|19-20|of|drug
DDI-MedLine.d132.s0|22-35|non-nucleoside|drug
DDI-MedLine.d132.s0|37-43|reverse|drug
DDI-MedLine.d132.s0|45-57|transcriptase|drug
DDI-MedLine.d132.s0|59-68|inhibitors|drug
DDI-MedLine.d132.s0|70-71|in|drug
DDI-MedLine.d132.s0|73-86|antiretroviral|drug
DDI-MedLine.d132.s0|88-94|therapy|drug
DDI-MedLine.d132.s0|95-95|.|drug
DDI-MedLine.d132.s1|0-2|The|drug
DDI-MedLine.d132.s1|4-15|availability|drug
DDI-MedLine.d132.s1|17-18|of|drug
DDI-MedLine.d132.s1|20-25|potent|drug
DDI-MedLine.d132.s1|27-40|non-nucleoside|drug
DDI-MedLine.d132.s1|42-48|reverse|drug
DDI-MedLine.d132.s1|50-62|transcriptase|drug
DDI-MedLine.d132.s1|64-72|inhibitor|drug
DDI-MedLine.d132.s1|74-74|(|drug
DDI-MedLine.d132.s1|75-79|NNRTI|drug
DDI-MedLine.d132.s1|80-80|)|drug
DDI-MedLine.d132.s1|81-86|-based|drug
DDI-MedLine.d132.s1|88-95|regimens|drug
DDI-MedLine.d132.s1|97-99|for|drug
DDI-MedLine.d132.s1|101-114|antiretroviral|drug
DDI-MedLine.d132.s1|116-122|therapy|drug
DDI-MedLine.d132.s1|124-126|and|drug
DDI-MedLine.d132.s1|128-135|concerns|drug
DDI-MedLine.d132.s1|137-145|regarding|drug
DDI-MedLine.d132.s1|147-154|protease|drug
DDI-MedLine.d132.s1|156-164|inhibitor|drug
DDI-MedLine.d132.s1|166-166|(|drug
DDI-MedLine.d132.s1|167-168|PI|drug
DDI-MedLine.d132.s1|169-169|)|drug
DDI-MedLine.d132.s1|170-177|-related|drug
DDI-MedLine.d132.s1|179-187|metabolic|drug
DDI-MedLine.d132.s1|189-200|disturbances|drug
DDI-MedLine.d132.s1|202-205|have|drug
DDI-MedLine.d132.s1|207-209|led|drug
DDI-MedLine.d132.s1|211-212|to|drug
DDI-MedLine.d132.s1|214-224|significant|drug
DDI-MedLine.d132.s1|226-231|shifts|drug
DDI-MedLine.d132.s1|233-234|in|drug
DDI-MedLine.d132.s1|236-244|treatment|drug
DDI-MedLine.d132.s1|246-254|practices|drug
DDI-MedLine.d132.s1|256-257|in|drug
DDI-MedLine.d132.s1|259-261|HIV|drug
DDI-MedLine.d132.s1|263-271|infection|drug
DDI-MedLine.d132.s1|272-272|.|drug
DDI-MedLine.d132.s2|0-10|NNRTI-based|drug
DDI-MedLine.d132.s2|12-19|regimens|drug
DDI-MedLine.d132.s2|21-23|may|drug
DDI-MedLine.d132.s2|25-28|have|drug
DDI-MedLine.d132.s2|30-36|several|drug
DDI-MedLine.d132.s2|38-47|advantages|drug
DDI-MedLine.d132.s2|49-52|over|drug
DDI-MedLine.d132.s2|54-61|PI-based|drug
DDI-MedLine.d132.s2|63-69|therapy|drug
DDI-MedLine.d132.s2|71-73|for|drug
DDI-MedLine.d132.s2|75-81|initial|drug
DDI-MedLine.d132.s2|83-84|or|drug
DDI-MedLine.d132.s2|86-94|prolonged|drug
DDI-MedLine.d132.s2|96-102|therapy|drug
DDI-MedLine.d132.s2|103-103|,|drug
DDI-MedLine.d132.s2|105-113|including|drug
DDI-MedLine.d132.s2|115-118|more|drug
DDI-MedLine.d132.s2|120-129|convenient|drug
DDI-MedLine.d132.s2|131-144|administration|drug
DDI-MedLine.d132.s2|146-153|regimens|drug
DDI-MedLine.d132.s2|154-154|,|drug
DDI-MedLine.d132.s2|156-160|lower|drug
DDI-MedLine.d132.s2|162-167|tablet|drug
DDI-MedLine.d132.s2|169-174|volume|drug
DDI-MedLine.d132.s2|175-175|,|drug
DDI-MedLine.d132.s2|177-181|fewer|drug
DDI-MedLine.d132.s2|183-186|drug|drug
DDI-MedLine.d132.s2|188-199|interactions|drug
DDI-MedLine.d132.s2|200-200|,|drug
DDI-MedLine.d132.s2|202-204|and|drug
DDI-MedLine.d132.s2|206-212|central|drug
DDI-MedLine.d132.s2|214-220|nervous|drug
DDI-MedLine.d132.s2|222-227|system|drug
DDI-MedLine.d132.s2|229-239|penetration|drug
DDI-MedLine.d132.s2|240-240|.|drug
DDI-MedLine.d132.s3|0-1|No|drug
DDI-MedLine.d132.s3|3-6|data|drug
DDI-MedLine.d132.s3|8-11|from|drug
DDI-MedLine.d132.s3|13-23|prospective|drug
DDI-MedLine.d132.s3|25-32|clinical|drug
DDI-MedLine.d132.s3|34-39|trials|drug
DDI-MedLine.d132.s3|41-49|currently|drug
DDI-MedLine.d132.s3|51-55|exist|drug
DDI-MedLine.d132.s3|57-65|comparing|drug
DDI-MedLine.d132.s3|67-69|the|drug
DDI-MedLine.d132.s3|71-71|3|drug
DDI-MedLine.d132.s3|73-80|approved|drug
DDI-MedLine.d132.s3|82-87|agents|drug
DDI-MedLine.d132.s3|89-89|(|drug
DDI-MedLine.d132.s3|90-98|efavirenz|drug
DDI-MedLine.d132.s3|99-99|,|drug
DDI-MedLine.d132.s3|101-110|nevirapine|drug
DDI-MedLine.d132.s3|112-113|or|drug
DDI-MedLine.d132.s3|115-125|delavirdine|drug
DDI-MedLine.d132.s3|126-126|)|drug
DDI-MedLine.d132.s3|127-127|.|drug
DDI-MedLine.d132.s4|0-3|Both|drug
DDI-MedLine.d132.s4|5-13|efavirenz|drug
DDI-MedLine.d132.s4|15-17|and|drug
DDI-MedLine.d132.s4|19-28|nevirapine|drug
DDI-MedLine.d132.s4|30-33|have|drug
DDI-MedLine.d132.s4|35-38|been|drug
DDI-MedLine.d132.s4|40-47|compared|drug
DDI-MedLine.d132.s4|49-50|to|drug
DDI-MedLine.d132.s4|52-57|triple|drug
DDI-MedLine.d132.s4|59-65|therapy|drug
DDI-MedLine.d132.s4|67-70|with|drug
DDI-MedLine.d132.s4|72-74|the|drug
DDI-MedLine.d132.s4|76-77|PI|drug
DDI-MedLine.d132.s4|79-87|indinavir|drug
DDI-MedLine.d132.s4|89-92|over|drug
DDI-MedLine.d132.s4|94-95|48|drug
DDI-MedLine.d132.s4|97-101|weeks|drug
DDI-MedLine.d132.s4|103-104|as|drug
DDI-MedLine.d132.s4|106-112|initial|drug
DDI-MedLine.d132.s4|114-120|therapy|drug
DDI-MedLine.d132.s4|121-121|,|drug
DDI-MedLine.d132.s4|123-126|with|drug
DDI-MedLine.d132.s4|128-134|similar|drug
DDI-MedLine.d132.s4|136-144|responses|drug
DDI-MedLine.d132.s4|146-150|being|drug
DDI-MedLine.d132.s4|152-159|observed|drug
DDI-MedLine.d132.s4|161-164|with|drug
DDI-MedLine.d132.s4|166-175|nevirapine|drug
DDI-MedLine.d132.s4|177-184|regimens|drug
DDI-MedLine.d132.s4|186-188|and|drug
DDI-MedLine.d132.s4|190-200|superiority|drug
DDI-MedLine.d132.s4|202-209|observed|drug
DDI-MedLine.d132.s4|211-214|with|drug
DDI-MedLine.d132.s4|216-224|efavirenz|drug
DDI-MedLine.d132.s4|225-225|.|drug
DDI-MedLine.d132.s5|0-0|A|drug
DDI-MedLine.d132.s5|2-8|smaller|drug
DDI-MedLine.d132.s5|10-16|24-week|drug
DDI-MedLine.d132.s5|18-22|study|drug
DDI-MedLine.d132.s5|24-26|has|drug
DDI-MedLine.d132.s5|28-36|suggested|drug
DDI-MedLine.d132.s5|38-47|nevirapine|drug
DDI-MedLine.d132.s5|49-51|may|drug
DDI-MedLine.d132.s5|53-54|be|drug
DDI-MedLine.d132.s5|56-63|superior|drug
DDI-MedLine.d132.s5|65-66|to|drug
DDI-MedLine.d132.s5|68-70|the|drug
DDI-MedLine.d132.s5|72-73|PI|drug
DDI-MedLine.d132.s5|75-84|nelfinavir|drug
DDI-MedLine.d132.s5|85-85|.|drug
DDI-MedLine.d132.s6|0-6|Limited|drug
DDI-MedLine.d132.s6|8-18|comparative|drug
DDI-MedLine.d132.s6|20-23|data|drug
DDI-MedLine.d132.s6|25-26|in|drug
DDI-MedLine.d132.s6|28-35|patients|drug
DDI-MedLine.d132.s6|37-40|with|drug
DDI-MedLine.d132.s6|42-45|high|drug
DDI-MedLine.d132.s6|47-51|viral|drug
DDI-MedLine.d132.s6|53-57|loads|drug
DDI-MedLine.d132.s6|59-65|treated|drug
DDI-MedLine.d132.s6|67-70|with|drug
DDI-MedLine.d132.s6|72-82|nevirapine-|drug
DDI-MedLine.d132.s6|84-85|or|drug
DDI-MedLine.d132.s6|87-103|delavirdine-based|drug
DDI-MedLine.d132.s6|105-112|regimens|drug
DDI-MedLine.d132.s6|114-122|currently|drug
DDI-MedLine.d132.s6|124-128|exist|drug
DDI-MedLine.d132.s6|129-129|.|drug
DDI-MedLine.d132.s7|0-6|However|drug
DDI-MedLine.d132.s7|7-7|,|drug
DDI-MedLine.d132.s7|9-14|cohort|drug
DDI-MedLine.d132.s7|16-19|data|drug
DDI-MedLine.d132.s7|21-23|and|drug
DDI-MedLine.d132.s7|25-32|selected|drug
DDI-MedLine.d132.s7|34-40|patient|drug
DDI-MedLine.d132.s7|42-45|data|drug
DDI-MedLine.d132.s7|47-50|from|drug
DDI-MedLine.d132.s7|52-59|clinical|drug
DDI-MedLine.d132.s7|61-66|trials|drug
DDI-MedLine.d132.s7|68-74|suggest|drug
DDI-MedLine.d132.s7|76-85|comparable|drug
DDI-MedLine.d132.s7|87-94|activity|drug
DDI-MedLine.d132.s7|96-97|to|drug
DDI-MedLine.d132.s7|99-106|PI-based|drug
DDI-MedLine.d132.s7|108-115|regimens|drug
DDI-MedLine.d132.s7|117-118|in|drug
DDI-MedLine.d132.s7|120-124|these|drug
DDI-MedLine.d132.s7|126-133|patients|drug
DDI-MedLine.d132.s7|134-134|.|drug
DDI-MedLine.d132.s8|0-2|The|drug
DDI-MedLine.d132.s8|4-14|superiority|drug
DDI-MedLine.d132.s8|16-17|of|drug
DDI-MedLine.d132.s8|19-27|efavirenz|drug
DDI-MedLine.d132.s8|29-32|over|drug
DDI-MedLine.d132.s8|34-48|indinavir-based|drug
DDI-MedLine.d132.s8|50-57|regimens|drug
DDI-MedLine.d132.s8|59-61|has|drug
DDI-MedLine.d132.s8|63-66|been|drug
DDI-MedLine.d132.s8|68-75|observed|drug
DDI-MedLine.d132.s8|77-78|in|drug
DDI-MedLine.d132.s8|80-90|comparative|drug
DDI-MedLine.d132.s8|92-95|data|drug
DDI-MedLine.d132.s8|97-98|in|drug
DDI-MedLine.d132.s8|100-100|a|drug
DDI-MedLine.d132.s8|102-107|subset|drug
DDI-MedLine.d132.s8|109-110|of|drug
DDI-MedLine.d132.s8|112-119|patients|drug
DDI-MedLine.d132.s8|121-124|with|drug
DDI-MedLine.d132.s8|126-129|high|drug
DDI-MedLine.d132.s8|131-135|viral|drug
DDI-MedLine.d132.s8|137-141|loads|drug
DDI-MedLine.d132.s8|142-142|.|drug
DDI-MedLine.d132.s9|0-1|In|drug
DDI-MedLine.d132.s9|3-23|treatment-experienced|drug
DDI-MedLine.d132.s9|25-32|patients|drug
DDI-MedLine.d132.s9|33-33|,|drug
DDI-MedLine.d132.s9|35-43|available|drug
DDI-MedLine.d132.s9|45-56|uncontrolled|drug
DDI-MedLine.d132.s9|58-61|data|drug
DDI-MedLine.d132.s9|63-69|suggest|drug
DDI-MedLine.d132.s9|71-75|these|drug
DDI-MedLine.d132.s9|77-82|agents|drug
DDI-MedLine.d132.s9|84-93|contribute|drug
DDI-MedLine.d132.s9|95-96|to|drug
DDI-MedLine.d132.s9|98-104|regimen|drug
DDI-MedLine.d132.s9|106-113|efficacy|drug
DDI-MedLine.d132.s9|115-116|in|drug
DDI-MedLine.d132.s9|118-125|NNRTI-na|drug
DDI-MedLine.d132.s9|128-129|ve|drug
DDI-MedLine.d132.s9|130-130|,|drug
DDI-MedLine.d132.s9|132-152|treatment-experienced|drug
DDI-MedLine.d132.s9|154-161|patients|drug
DDI-MedLine.d132.s9|162-162|.|drug
DDI-MedLine.d132.s10|0-8|Efavirenz|brand
DDI-MedLine.d132.s10|10-12|has|drug
DDI-MedLine.d132.s10|14-25|demonstrated|drug
DDI-MedLine.d132.s10|27-37|superiority|drug
DDI-MedLine.d132.s10|39-42|over|drug
DDI-MedLine.d132.s10|44-53|nelfinavir|drug
DDI-MedLine.d132.s10|55-56|in|drug
DDI-MedLine.d132.s10|58-79|nucleoside-experienced|drug
DDI-MedLine.d132.s10|81-88|patients|drug
DDI-MedLine.d132.s10|89-89|,|drug
DDI-MedLine.d132.s10|91-98|although|drug
DDI-MedLine.d132.s10|100-108|combining|drug
DDI-MedLine.d132.s10|110-114|these|drug
DDI-MedLine.d132.s10|116-116|2|drug
DDI-MedLine.d132.s10|118-123|agents|drug
DDI-MedLine.d132.s10|125-127|may|drug
DDI-MedLine.d132.s10|129-137|represent|drug
DDI-MedLine.d132.s10|139-141|the|drug
DDI-MedLine.d132.s10|143-146|best|drug
DDI-MedLine.d132.s10|148-155|approach|drug
DDI-MedLine.d132.s10|157-158|in|drug
DDI-MedLine.d132.s10|160-164|these|drug
DDI-MedLine.d132.s10|166-178|circumstances|drug
DDI-MedLine.d132.s10|179-179|.|drug
DDI-MedLine.d132.s11|0-2|The|drug
DDI-MedLine.d132.s11|4-15|tolerability|drug
DDI-MedLine.d132.s11|17-18|of|drug
DDI-MedLine.d132.s11|20-25|NNRTIs|drug
DDI-MedLine.d132.s11|27-33|appears|drug
DDI-MedLine.d132.s11|35-43|generally|drug
DDI-MedLine.d132.s11|45-48|good|drug
DDI-MedLine.d132.s11|50-53|with|drug
DDI-MedLine.d132.s11|55-57|few|drug
DDI-MedLine.d132.s11|59-69|individuals|drug
DDI-MedLine.d132.s11|71-83|discontinuing|drug
DDI-MedLine.d132.s11|85-86|in|drug
DDI-MedLine.d132.s11|88-95|clinical|drug
DDI-MedLine.d132.s11|97-103|studies|drug
DDI-MedLine.d132.s11|105-106|as|drug
DDI-MedLine.d132.s11|108-108|a|drug
DDI-MedLine.d132.s11|110-115|result|drug
DDI-MedLine.d132.s11|117-118|of|drug
DDI-MedLine.d132.s11|120-126|adverse|drug
DDI-MedLine.d132.s11|128-131|drug|drug
DDI-MedLine.d132.s11|133-138|events|drug
DDI-MedLine.d132.s11|139-139|.|drug
DDI-MedLine.d132.s12|0-2|The|drug
DDI-MedLine.d132.s12|4-11|majority|drug
DDI-MedLine.d132.s12|13-14|of|drug
DDI-MedLine.d132.s12|16-22|adverse|drug
DDI-MedLine.d132.s12|24-29|events|drug
DDI-MedLine.d132.s12|31-34|with|drug
DDI-MedLine.d132.s12|36-41|NNRTIs|drug
DDI-MedLine.d132.s12|43-47|occur|drug
DDI-MedLine.d132.s12|49-54|within|drug
DDI-MedLine.d132.s12|56-58|the|drug
DDI-MedLine.d132.s12|60-64|first|drug
DDI-MedLine.d132.s12|66-70|month|drug
DDI-MedLine.d132.s12|71-71|,|drug
DDI-MedLine.d132.s12|73-75|and|drug
DDI-MedLine.d132.s12|77-79|are|drug
DDI-MedLine.d132.s12|81-91|predictable|drug
DDI-MedLine.d132.s12|93-95|and|drug
DDI-MedLine.d132.s12|97-106|manageable|drug
DDI-MedLine.d132.s12|108-114|without|drug
DDI-MedLine.d132.s12|116-122|therapy|drug
DDI-MedLine.d132.s12|124-135|interruption|drug
DDI-MedLine.d132.s12|136-136|.|drug
DDI-DrugBank.d497.s0|0-4|AZOPT|drug
DDI-DrugBank.d497.s0|6-6|(|drug
DDI-DrugBank.d497.s0|7-18|brinzolamide|drug
DDI-DrugBank.d497.s0|20-29|ophthalmic|drug
DDI-DrugBank.d497.s0|31-40|suspension|drug
DDI-DrugBank.d497.s0|41-41|)|drug
DDI-DrugBank.d497.s0|43-43|1|drug
DDI-DrugBank.d497.s0|44-44|%|drug
DDI-DrugBank.d497.s0|46-53|contains|drug
DDI-DrugBank.d497.s0|55-55|a|drug
DDI-DrugBank.d497.s0|57-64|carbonic|drug
DDI-DrugBank.d497.s0|66-74|anhydrase|drug
DDI-DrugBank.d497.s0|76-84|inhibitor|drug
DDI-DrugBank.d497.s0|85-85|.|drug
DDI-DrugBank.d497.s1|0-8|Acid-base|drug
DDI-DrugBank.d497.s1|10-12|and|drug
DDI-DrugBank.d497.s1|14-24|electrolyte|drug
DDI-DrugBank.d497.s1|26-36|alterations|drug
DDI-DrugBank.d497.s1|38-41|were|drug
DDI-DrugBank.d497.s1|43-45|not|drug
DDI-DrugBank.d497.s1|47-54|reported|drug
DDI-DrugBank.d497.s1|56-57|in|drug
DDI-DrugBank.d497.s1|59-61|the|drug
DDI-DrugBank.d497.s1|63-70|clinical|drug
DDI-DrugBank.d497.s1|72-77|trials|drug
DDI-DrugBank.d497.s1|79-82|with|drug
DDI-DrugBank.d497.s1|84-95|brinzolamide|drug
DDI-DrugBank.d497.s1|96-96|.|drug
DDI-DrugBank.d497.s2|0-6|However|drug
DDI-DrugBank.d497.s2|7-7|,|drug
DDI-DrugBank.d497.s2|9-10|in|drug
DDI-DrugBank.d497.s2|12-19|patients|drug
DDI-DrugBank.d497.s2|21-27|treated|drug
DDI-DrugBank.d497.s2|29-32|with|drug
DDI-DrugBank.d497.s2|34-37|oral|drug
DDI-DrugBank.d497.s2|39-46|carbonic|drug
DDI-DrugBank.d497.s2|48-56|anhydrase|drug
DDI-DrugBank.d497.s2|58-67|inhibitors|drug
DDI-DrugBank.d497.s2|68-68|,|drug
DDI-DrugBank.d497.s2|70-73|rare|drug
DDI-DrugBank.d497.s2|75-83|instances|drug
DDI-DrugBank.d497.s2|85-86|of|drug
DDI-DrugBank.d497.s2|88-91|drug|drug
DDI-DrugBank.d497.s2|93-104|interactions|drug
DDI-DrugBank.d497.s2|106-109|have|drug
DDI-DrugBank.d497.s2|111-118|occurred|drug
DDI-DrugBank.d497.s2|120-123|with|drug
DDI-DrugBank.d497.s2|125-133|high-dose|drug
DDI-DrugBank.d497.s2|135-144|salicylate|drug
DDI-DrugBank.d497.s2|146-152|therapy|drug
DDI-DrugBank.d497.s2|153-153|.|drug
DDI-DrugBank.d497.s3|0-8|Therefore|drug
DDI-DrugBank.d497.s3|9-9|,|drug
DDI-DrugBank.d497.s3|11-13|the|drug
DDI-DrugBank.d497.s3|15-23|potential|drug
DDI-DrugBank.d497.s3|25-27|for|drug
DDI-DrugBank.d497.s3|29-32|such|drug
DDI-DrugBank.d497.s3|34-37|drug|drug
DDI-DrugBank.d497.s3|39-49|interaction|drug
DDI-DrugBank.d497.s3|51-56|should|drug
DDI-DrugBank.d497.s3|58-59|be|drug
DDI-DrugBank.d497.s3|61-70|considered|drug
DDI-DrugBank.d497.s3|72-73|in|drug
DDI-DrugBank.d497.s3|75-82|patients|drug
DDI-DrugBank.d497.s3|84-92|receiving|drug
DDI-DrugBank.d497.s3|94-98|AZOPT|drug
DDI-DrugBank.d497.s3|100-100|(|drug
DDI-DrugBank.d497.s3|101-112|brinzolamide|drug
DDI-DrugBank.d497.s3|114-123|ophthalmic|drug
DDI-DrugBank.d497.s3|125-134|suspension|drug
DDI-DrugBank.d497.s3|135-135|)|drug
DDI-DrugBank.d497.s3|137-137|1|drug
DDI-DrugBank.d497.s3|138-138|%|drug
DDI-DrugBank.d497.s3|139-139|.|drug
DDI-DrugBank.d776.s0|0-9|Clinically|drug
DDI-DrugBank.d776.s0|11-12|or|drug
DDI-DrugBank.d776.s0|14-24|potentially|drug
DDI-DrugBank.d776.s0|26-36|significant|drug
DDI-DrugBank.d776.s0|38-41|drug|drug
DDI-DrugBank.d776.s0|43-54|interactions|drug
DDI-DrugBank.d776.s0|56-62|between|drug
DDI-DrugBank.d776.s0|64-71|DIFLUCAN|drug
DDI-DrugBank.d776.s0|73-75|and|drug
DDI-DrugBank.d776.s0|77-79|the|drug
DDI-DrugBank.d776.s0|81-89|following|drug
DDI-DrugBank.d776.s0|91-104|agents/classes|drug
DDI-DrugBank.d776.s0|106-109|have|drug
DDI-DrugBank.d776.s0|111-114|been|drug
DDI-DrugBank.d776.s0|116-123|observed|drug
DDI-DrugBank.d776.s0|124-124|.|drug
DDI-DrugBank.d776.s1|0-4|These|drug
DDI-DrugBank.d776.s1|6-8|are|drug
DDI-DrugBank.d776.s1|10-18|described|drug
DDI-DrugBank.d776.s1|20-21|in|drug
DDI-DrugBank.d776.s1|23-29|greater|drug
DDI-DrugBank.d776.s1|31-36|detail|drug
DDI-DrugBank.d776.s1|38-42|below|drug
DDI-DrugBank.d776.s1|43-43|:|drug
DDI-DrugBank.d776.s1|45-52|DIFLUCAN|drug
DDI-DrugBank.d776.s1|54-56|and|drug
DDI-DrugBank.d776.s1|58-60|the|drug
DDI-DrugBank.d776.s1|62-70|following|drug
DDI-DrugBank.d776.s1|72-85|agents/classes|drug
DDI-DrugBank.d776.s1|87-90|have|drug
DDI-DrugBank.d776.s1|92-95|been|drug
DDI-DrugBank.d776.s1|97-104|observed|drug
DDI-DrugBank.d776.s1|105-105|.|drug
DDI-DrugBank.d776.s2|0-4|These|drug
DDI-DrugBank.d776.s2|6-8|are|drug
DDI-DrugBank.d776.s2|10-18|described|drug
DDI-DrugBank.d776.s2|20-21|in|drug
DDI-DrugBank.d776.s2|23-29|greater|drug
DDI-DrugBank.d776.s2|31-36|detail|drug
DDI-DrugBank.d776.s2|38-42|below|drug
DDI-DrugBank.d776.s2|43-43|:|drug
DDI-DrugBank.d776.s2|46-49|Oral|drug
DDI-DrugBank.d776.s2|51-63|hypoglycemics|drug
DDI-DrugBank.d776.s2|64-64|,|drug
DDI-DrugBank.d776.s2|66-78|Coumarin-type|drug
DDI-DrugBank.d776.s2|80-93|anticoagulants|drug
DDI-DrugBank.d776.s2|94-94|,|drug
DDI-DrugBank.d776.s2|96-104|Phenytoin|brand
DDI-DrugBank.d776.s2|105-105|,|drug
DDI-DrugBank.d776.s2|107-118|Cyclosporine|brand
DDI-DrugBank.d776.s2|119-119|,|drug
DDI-DrugBank.d776.s2|121-128|Rifampin|brand
DDI-DrugBank.d776.s2|129-129|,|drug
DDI-DrugBank.d776.s2|131-142|Theophylline|brand
DDI-DrugBank.d776.s2|143-143|,|drug
DDI-DrugBank.d776.s2|145-155|Terfenadine|drug
DDI-DrugBank.d776.s2|156-156|,|drug
DDI-DrugBank.d776.s2|158-166|Cisapride|drug
DDI-DrugBank.d776.s2|167-167|,|drug
DDI-DrugBank.d776.s2|169-178|Astemizole|drug
DDI-DrugBank.d776.s2|179-179|,|drug
DDI-DrugBank.d776.s2|181-189|Rifabutin|brand
DDI-DrugBank.d776.s2|190-190|,|drug
DDI-DrugBank.d776.s2|192-201|Tacrolimus|brand
DDI-DrugBank.d776.s2|202-202|,|drug
DDI-DrugBank.d776.s2|204-215|Short-acting|drug
DDI-DrugBank.d776.s2|217-231|benzodiazepines|drug
DDI-DrugBank.d776.s2|232-232|,|drug
DDI-DrugBank.d776.s2|235-238|Oral|drug
DDI-DrugBank.d776.s2|240-252|hypoglycemics|drug
DDI-DrugBank.d776.s2|253-253|:|drug
DDI-DrugBank.d776.s2|255-264|Clinically|drug
DDI-DrugBank.d776.s2|266-276|significant|drug
DDI-DrugBank.d776.s2|278-289|hypoglycemia|drug
DDI-DrugBank.d776.s2|291-293|may|drug
DDI-DrugBank.d776.s2|295-296|be|drug
DDI-DrugBank.d776.s2|298-309|precipitated|drug
DDI-DrugBank.d776.s2|311-312|by|drug
DDI-DrugBank.d776.s2|314-316|the|drug
DDI-DrugBank.d776.s2|318-320|use|drug
DDI-DrugBank.d776.s2|322-323|of|drug
DDI-DrugBank.d776.s2|325-332|DIFLUCAN|drug
DDI-DrugBank.d776.s2|334-337|with|drug
DDI-DrugBank.d776.s2|339-342|oral|drug
DDI-DrugBank.d776.s2|344-355|hypoglycemic|drug
DDI-DrugBank.d776.s2|357-362|agents|drug
DDI-DrugBank.d776.s2|363-363|;|drug
DDI-DrugBank.d776.s3|0-2|one|drug
DDI-DrugBank.d776.s3|4-11|fatality|drug
DDI-DrugBank.d776.s3|13-15|has|drug
DDI-DrugBank.d776.s3|17-20|been|drug
DDI-DrugBank.d776.s3|22-29|reported|drug
DDI-DrugBank.d776.s3|31-34|from|drug
DDI-DrugBank.d776.s3|36-47|hypoglycemia|drug
DDI-DrugBank.d776.s3|49-50|in|drug
DDI-DrugBank.d776.s3|52-62|association|drug
DDI-DrugBank.d776.s3|64-67|with|drug
DDI-DrugBank.d776.s3|69-76|combined|drug
DDI-DrugBank.d776.s3|78-85|DIFLUCAN|drug
DDI-DrugBank.d776.s3|87-89|and|drug
DDI-DrugBank.d776.s3|91-99|glyburide|drug
DDI-DrugBank.d776.s3|101-103|use|drug
DDI-DrugBank.d776.s3|104-104|.|drug
DDI-DrugBank.d776.s4|0-7|DIFLUCAN|drug
DDI-DrugBank.d776.s4|9-15|reduces|drug
DDI-DrugBank.d776.s4|17-19|the|drug
DDI-DrugBank.d776.s4|21-30|metabolism|drug
DDI-DrugBank.d776.s4|32-33|of|drug
DDI-DrugBank.d776.s4|35-45|tolbutamide|drug
DDI-DrugBank.d776.s4|46-46|,|drug
DDI-DrugBank.d776.s4|48-56|glyburide|drug
DDI-DrugBank.d776.s4|57-57|,|drug
DDI-DrugBank.d776.s4|59-61|and|drug
DDI-DrugBank.d776.s4|63-71|glipizide|drug
DDI-DrugBank.d776.s4|73-75|and|drug
DDI-DrugBank.d776.s4|77-85|increases|drug
DDI-DrugBank.d776.s4|87-89|the|drug
DDI-DrugBank.d776.s4|91-96|plasma|drug
DDI-DrugBank.d776.s4|98-110|concentration|drug
DDI-DrugBank.d776.s4|112-113|of|drug
DDI-DrugBank.d776.s4|115-119|these|drug
DDI-DrugBank.d776.s4|121-126|agents|drug
DDI-DrugBank.d776.s4|127-127|.|drug
DDI-DrugBank.d776.s5|0-3|When|drug
DDI-DrugBank.d776.s5|5-12|DIFLUCAN|drug
DDI-DrugBank.d776.s5|14-15|is|drug
DDI-DrugBank.d776.s5|17-20|used|drug
DDI-DrugBank.d776.s5|22-34|concomitantly|drug
DDI-DrugBank.d776.s5|36-39|with|drug
DDI-DrugBank.d776.s5|41-45|these|drug
DDI-DrugBank.d776.s5|47-48|or|drug
DDI-DrugBank.d776.s5|50-54|other|drug
DDI-DrugBank.d776.s5|56-67|sulfonylurea|drug
DDI-DrugBank.d776.s5|69-72|oral|drug
DDI-DrugBank.d776.s5|74-85|hypoglycemic|drug
DDI-DrugBank.d776.s5|87-92|agents|drug
DDI-DrugBank.d776.s5|93-93|,|drug
DDI-DrugBank.d776.s5|95-99|blood|drug
DDI-DrugBank.d776.s5|101-107|glucose|drug
DDI-DrugBank.d776.s5|109-122|concentrations|drug
DDI-DrugBank.d776.s5|124-129|should|drug
DDI-DrugBank.d776.s5|131-132|be|drug
DDI-DrugBank.d776.s5|134-142|carefully|drug
DDI-DrugBank.d776.s5|144-152|monitored|drug
DDI-DrugBank.d776.s5|154-156|and|drug
DDI-DrugBank.d776.s5|158-160|the|drug
DDI-DrugBank.d776.s5|162-165|dose|drug
DDI-DrugBank.d776.s5|167-168|of|drug
DDI-DrugBank.d776.s5|170-172|the|drug
DDI-DrugBank.d776.s5|174-185|sulfonylurea|drug
DDI-DrugBank.d776.s5|187-192|should|drug
DDI-DrugBank.d776.s5|194-195|be|drug
DDI-DrugBank.d776.s5|197-204|adjusted|drug
DDI-DrugBank.d776.s5|206-207|as|drug
DDI-DrugBank.d776.s5|209-217|necessary|drug
DDI-DrugBank.d776.s5|218-218|.|drug
DDI-DrugBank.d776.s6|0-12|Coumarin-type|drug
DDI-DrugBank.d776.s6|14-27|anticoagulants|drug
DDI-DrugBank.d776.s6|28-28|:|drug
DDI-DrugBank.d776.s6|30-40|Prothrombin|drug
DDI-DrugBank.d776.s6|42-45|time|drug
DDI-DrugBank.d776.s6|47-49|may|drug
DDI-DrugBank.d776.s6|51-52|be|drug
DDI-DrugBank.d776.s6|54-62|increased|drug
DDI-DrugBank.d776.s6|64-65|in|drug
DDI-DrugBank.d776.s6|67-74|patients|drug
DDI-DrugBank.d776.s6|76-84|receiving|drug
DDI-DrugBank.d776.s6|86-96|concomitant|drug
DDI-DrugBank.d776.s6|98-105|DIFLUCAN|drug
DDI-DrugBank.d776.s6|107-109|and|drug
DDI-DrugBank.d776.s6|111-123|coumarin-type|drug
DDI-DrugBank.d776.s6|125-138|anticoagulants|drug
DDI-DrugBank.d776.s6|139-139|.|drug
DDI-DrugBank.d776.s7|0-1|In|drug
DDI-DrugBank.d776.s7|3-16|post-marketing|drug
DDI-DrugBank.d776.s7|18-27|experience|drug
DDI-DrugBank.d776.s7|28-28|,|drug
DDI-DrugBank.d776.s7|30-31|as|drug
DDI-DrugBank.d776.s7|33-36|with|drug
DDI-DrugBank.d776.s7|38-42|other|drug
DDI-DrugBank.d776.s7|44-48|azole|drug
DDI-DrugBank.d776.s7|50-60|antifungals|drug
DDI-DrugBank.d776.s7|61-61|,|drug
DDI-DrugBank.d776.s7|63-70|bleeding|drug
DDI-DrugBank.d776.s7|72-77|events|drug
DDI-DrugBank.d776.s7|79-79|(|drug
DDI-DrugBank.d776.s7|80-87|bruising|drug
DDI-DrugBank.d776.s7|88-88|,|drug
DDI-DrugBank.d776.s7|90-98|epistaxis|drug
DDI-DrugBank.d776.s7|99-99|,|drug
DDI-DrugBank.d776.s7|101-116|gastrointestinal|drug
DDI-DrugBank.d776.s7|118-125|bleeding|drug
DDI-DrugBank.d776.s7|126-126|,|drug
DDI-DrugBank.d776.s7|128-136|hematuria|drug
DDI-DrugBank.d776.s7|137-137|,|drug
DDI-DrugBank.d776.s7|139-141|and|drug
DDI-DrugBank.d776.s7|143-148|melena|drug
DDI-DrugBank.d776.s7|149-149|)|drug
DDI-DrugBank.d776.s7|151-154|have|drug
DDI-DrugBank.d776.s7|156-159|been|drug
DDI-DrugBank.d776.s7|161-168|reported|drug
DDI-DrugBank.d776.s7|170-171|in|drug
DDI-DrugBank.d776.s7|173-183|association|drug
DDI-DrugBank.d776.s7|185-188|with|drug
DDI-DrugBank.d776.s7|190-198|increases|drug
DDI-DrugBank.d776.s7|200-201|in|drug
DDI-DrugBank.d776.s7|203-213|prothrombin|drug
DDI-DrugBank.d776.s7|215-218|time|drug
DDI-DrugBank.d776.s7|220-221|in|drug
DDI-DrugBank.d776.s7|223-230|patients|drug
DDI-DrugBank.d776.s7|232-240|receiving|drug
DDI-DrugBank.d776.s7|242-252|fluconazole|drug
DDI-DrugBank.d776.s7|254-265|concurrently|drug
DDI-DrugBank.d776.s7|267-270|with|drug
DDI-DrugBank.d776.s7|272-279|warfarin|drug
DDI-DrugBank.d776.s7|280-280|.|drug
DDI-DrugBank.d776.s8|0-6|Careful|drug
DDI-DrugBank.d776.s8|8-17|monitoring|drug
DDI-DrugBank.d776.s8|19-20|of|drug
DDI-DrugBank.d776.s8|22-32|prothrombin|drug
DDI-DrugBank.d776.s8|34-37|time|drug
DDI-DrugBank.d776.s8|39-40|in|drug
DDI-DrugBank.d776.s8|42-49|patients|drug
DDI-DrugBank.d776.s8|51-59|receiving|drug
DDI-DrugBank.d776.s8|61-68|DIFLUCAN|drug
DDI-DrugBank.d776.s8|70-72|and|drug
DDI-DrugBank.d776.s8|74-86|coumarin-type|drug
DDI-DrugBank.d776.s8|88-101|anticoagulants|drug
DDI-DrugBank.d776.s8|103-104|is|drug
DDI-DrugBank.d776.s8|106-116|recommended|drug
DDI-DrugBank.d776.s8|117-117|.|drug
DDI-DrugBank.d776.s9|0-0|(|drug
DDI-DrugBank.d776.s9|1-3|See|drug
DDI-DrugBank.d776.s9|5-5|<|drug
DDI-DrugBank.d776.s9|6-6|a|drug
DDI-DrugBank.d776.s9|8-12|href=|drug
DDI-DrugBank.d776.s9|14-14|``|drug
DDI-DrugBank.d776.s9|15-27|flucon_cp.htm|drug
DDI-DrugBank.d776.s9|28-28|#|drug
DDI-DrugBank.d776.s9|29-30|CP|drug
DDI-DrugBank.d776.s9|31-31|''|drug
DDI-DrugBank.d776.s9|32-32|>|drug
DDI-DrugBank.d776.s9|33-40|CLINICAL|drug
DDI-DrugBank.d776.s9|42-53|PHARMACOLOGY|drug
DDI-DrugBank.d776.s9|54-54|:|drug
DDI-DrugBank.d776.s9|56-59|Drug|drug
DDI-DrugBank.d776.s9|61-71|Interaction|drug
DDI-DrugBank.d776.s9|73-79|Studies|drug
DDI-DrugBank.d776.s9|80-80|.|drug
DDI-DrugBank.d776.s9|81-81|)|drug
DDI-DrugBank.d776.s10|0-8|Phenytoin|brand
DDI-DrugBank.d776.s10|9-9|:|drug
DDI-DrugBank.d776.s10|11-18|DIFLUCAN|drug
DDI-DrugBank.d776.s10|20-28|increases|drug
DDI-DrugBank.d776.s10|30-32|the|drug
DDI-DrugBank.d776.s10|34-39|plasma|drug
DDI-DrugBank.d776.s10|41-54|concentrations|drug
DDI-DrugBank.d776.s10|56-57|of|drug
DDI-DrugBank.d776.s10|59-67|phenytoin|drug
DDI-DrugBank.d776.s10|68-68|.|drug
DDI-DrugBank.d776.s11|0-6|Careful|drug
DDI-DrugBank.d776.s11|8-17|monitoring|drug
DDI-DrugBank.d776.s11|19-20|of|drug
DDI-DrugBank.d776.s11|22-30|phenytoin|drug
DDI-DrugBank.d776.s11|32-45|concentrations|drug
DDI-DrugBank.d776.s11|47-48|in|drug
DDI-DrugBank.d776.s11|50-57|patients|drug
DDI-DrugBank.d776.s11|59-67|receiving|drug
DDI-DrugBank.d776.s11|69-76|DIFLUCAN|drug
DDI-DrugBank.d776.s11|78-80|and|drug
DDI-DrugBank.d776.s11|82-90|phenytoin|drug
DDI-DrugBank.d776.s11|92-93|is|drug
DDI-DrugBank.d776.s11|95-105|recommended|drug
DDI-DrugBank.d776.s11|106-106|.|drug
DDI-DrugBank.d776.s12|0-0|(|drug
DDI-DrugBank.d776.s12|1-3|See|drug
DDI-DrugBank.d776.s12|5-5|<|drug
DDI-DrugBank.d776.s12|6-6|a|drug
DDI-DrugBank.d776.s12|8-12|href=|drug
DDI-DrugBank.d776.s12|14-14|``|drug
DDI-DrugBank.d776.s12|15-27|flucon_cp.htm|drug
DDI-DrugBank.d776.s12|28-28|#|drug
DDI-DrugBank.d776.s12|29-30|CP|drug
DDI-DrugBank.d776.s12|31-31|''|drug
DDI-DrugBank.d776.s12|32-32|>|drug
DDI-DrugBank.d776.s12|33-40|CLINICAL|drug
DDI-DrugBank.d776.s12|42-53|PHARMACOLOGY|drug
DDI-DrugBank.d776.s12|54-54|:|drug
DDI-DrugBank.d776.s12|56-59|Drug|drug
DDI-DrugBank.d776.s12|61-71|Interaction|drug
DDI-DrugBank.d776.s12|73-79|Studies|drug
DDI-DrugBank.d776.s12|80-80|.|drug
DDI-DrugBank.d776.s12|81-81|)|drug
DDI-DrugBank.d776.s13|0-11|Cyclosporine|brand
DDI-DrugBank.d776.s13|12-12|:|drug
DDI-DrugBank.d776.s13|14-21|DIFLUCAN|drug
DDI-DrugBank.d776.s13|23-25|may|drug
DDI-DrugBank.d776.s13|27-39|significantly|drug
DDI-DrugBank.d776.s13|41-48|increase|drug
DDI-DrugBank.d776.s13|50-61|cyclosporine|drug
DDI-DrugBank.d776.s13|63-68|levels|drug
DDI-DrugBank.d776.s13|70-71|in|drug
DDI-DrugBank.d776.s13|73-77|renal|drug
DDI-DrugBank.d776.s13|79-88|transplant|drug
DDI-DrugBank.d776.s13|90-97|patients|drug
DDI-DrugBank.d776.s13|99-102|with|drug
DDI-DrugBank.d776.s13|104-105|or|drug
DDI-DrugBank.d776.s13|107-113|without|drug
DDI-DrugBank.d776.s13|115-119|renal|drug
DDI-DrugBank.d776.s13|121-130|impairment|drug
DDI-DrugBank.d776.s13|131-131|.|drug
DDI-DrugBank.d776.s14|0-6|Careful|drug
DDI-DrugBank.d776.s14|8-17|monitoring|drug
DDI-DrugBank.d776.s14|19-20|of|drug
DDI-DrugBank.d776.s14|22-33|cyclosporine|drug
DDI-DrugBank.d776.s14|35-48|concentrations|drug
DDI-DrugBank.d776.s14|50-52|and|drug
DDI-DrugBank.d776.s14|54-58|serum|drug
DDI-DrugBank.d776.s14|60-69|creatinine|drug
DDI-DrugBank.d776.s14|71-72|is|drug
DDI-DrugBank.d776.s14|74-84|recommended|drug
DDI-DrugBank.d776.s14|86-87|in|drug
DDI-DrugBank.d776.s14|89-96|patients|drug
DDI-DrugBank.d776.s14|98-106|receiving|drug
DDI-DrugBank.d776.s14|108-115|DIFLUCAN|drug
DDI-DrugBank.d776.s14|117-119|and|drug
DDI-DrugBank.d776.s14|121-132|cyclosporine|drug
DDI-DrugBank.d776.s14|133-133|.|drug
DDI-DrugBank.d776.s15|0-0|(|drug
DDI-DrugBank.d776.s15|1-3|See|drug
DDI-DrugBank.d776.s15|5-12|CLINICAL|drug
DDI-DrugBank.d776.s15|14-25|PHARMACOLOGY|drug
DDI-DrugBank.d776.s15|26-26|:|drug
DDI-DrugBank.d776.s15|28-31|Drug|drug
DDI-DrugBank.d776.s15|33-43|Interaction|drug
DDI-DrugBank.d776.s15|45-51|Studies|drug
DDI-DrugBank.d776.s15|52-52|.|drug
DDI-DrugBank.d776.s15|53-53|)|drug
DDI-DrugBank.d776.s16|0-7|Rifampin|brand
DDI-DrugBank.d776.s16|8-8|:|drug
DDI-DrugBank.d776.s16|10-17|Rifampin|brand
DDI-DrugBank.d776.s16|19-26|enhances|drug
DDI-DrugBank.d776.s16|28-30|the|drug
DDI-DrugBank.d776.s16|32-41|metabolism|drug
DDI-DrugBank.d776.s16|43-44|of|drug
DDI-DrugBank.d776.s16|46-57|concurrently|drug
DDI-DrugBank.d776.s16|59-70|administered|drug
DDI-DrugBank.d776.s16|72-79|DIFLUCAN|drug
DDI-DrugBank.d776.s16|80-80|.|drug
DDI-DrugBank.d776.s17|0-8|Depending|drug
DDI-DrugBank.d776.s17|10-11|on|drug
DDI-DrugBank.d776.s17|13-20|clinical|drug
DDI-DrugBank.d776.s17|22-34|circumstances|drug
DDI-DrugBank.d776.s17|35-35|,|drug
DDI-DrugBank.d776.s17|37-49|consideration|drug
DDI-DrugBank.d776.s17|51-56|should|drug
DDI-DrugBank.d776.s17|58-59|be|drug
DDI-DrugBank.d776.s17|61-65|given|drug
DDI-DrugBank.d776.s17|67-68|to|drug
DDI-DrugBank.d776.s17|70-79|increasing|drug
DDI-DrugBank.d776.s17|81-83|the|drug
DDI-DrugBank.d776.s17|85-88|dose|drug
DDI-DrugBank.d776.s17|90-91|of|drug
DDI-DrugBank.d776.s17|93-100|DIFLUCAN|drug
DDI-DrugBank.d776.s17|102-105|when|drug
DDI-DrugBank.d776.s17|107-108|it|drug
DDI-DrugBank.d776.s17|110-111|is|drug
DDI-DrugBank.d776.s17|113-124|administered|drug
DDI-DrugBank.d776.s17|126-129|with|drug
DDI-DrugBank.d776.s17|131-138|rifampin|drug
DDI-DrugBank.d776.s17|139-139|.|drug
DDI-DrugBank.d776.s18|0-11|Theophylline|brand
DDI-DrugBank.d776.s18|12-12|:|drug
DDI-DrugBank.d776.s18|14-21|DIFLUCAN|drug
DDI-DrugBank.d776.s18|23-31|increases|drug
DDI-DrugBank.d776.s18|33-35|the|drug
DDI-DrugBank.d776.s18|37-41|serum|drug
DDI-DrugBank.d776.s18|43-56|concentrations|drug
DDI-DrugBank.d776.s18|58-59|of|drug
DDI-DrugBank.d776.s18|61-72|theophylline|drug
DDI-DrugBank.d776.s18|73-73|.|drug
DDI-DrugBank.d776.s19|0-6|Careful|drug
DDI-DrugBank.d776.s19|8-17|monitoring|drug
DDI-DrugBank.d776.s19|19-20|of|drug
DDI-DrugBank.d776.s19|22-26|serum|drug
DDI-DrugBank.d776.s19|28-39|theophylline|drug
DDI-DrugBank.d776.s19|41-54|concentrations|drug
DDI-DrugBank.d776.s19|56-57|in|drug
DDI-DrugBank.d776.s19|59-66|patients|drug
DDI-DrugBank.d776.s19|68-76|receiving|drug
DDI-DrugBank.d776.s19|78-85|DIFLUCAN|drug
DDI-DrugBank.d776.s19|87-89|and|drug
DDI-DrugBank.d776.s19|91-102|theophylline|drug
DDI-DrugBank.d776.s19|104-105|is|drug
DDI-DrugBank.d776.s19|107-117|recommended|drug
DDI-DrugBank.d776.s19|118-118|.|drug
DDI-DrugBank.d776.s20|0-10|Terfenadine|drug
DDI-DrugBank.d776.s20|11-11|:|drug
DDI-DrugBank.d776.s20|13-19|Because|drug
DDI-DrugBank.d776.s20|21-22|of|drug
DDI-DrugBank.d776.s20|24-26|the|drug
DDI-DrugBank.d776.s20|28-37|occurrence|drug
DDI-DrugBank.d776.s20|39-40|of|drug
DDI-DrugBank.d776.s20|42-48|serious|drug
DDI-DrugBank.d776.s20|50-56|cardiac|drug
DDI-DrugBank.d776.s20|58-69|dysrhythmias|drug
DDI-DrugBank.d776.s20|71-79|secondary|drug
DDI-DrugBank.d776.s20|81-82|to|drug
DDI-DrugBank.d776.s20|84-95|prolongation|drug
DDI-DrugBank.d776.s20|97-98|of|drug
DDI-DrugBank.d776.s20|100-102|the|drug
DDI-DrugBank.d776.s20|104-106|QTc|drug
DDI-DrugBank.d776.s20|108-115|interval|drug
DDI-DrugBank.d776.s20|117-118|in|drug
DDI-DrugBank.d776.s20|120-127|patients|drug
DDI-DrugBank.d776.s20|129-137|receiving|drug
DDI-DrugBank.d776.s20|139-143|azole|drug
DDI-DrugBank.d776.s20|145-155|antifungals|drug
DDI-DrugBank.d776.s20|157-158|in|drug
DDI-DrugBank.d776.s20|160-170|conjunction|drug
DDI-DrugBank.d776.s20|172-175|with|drug
DDI-DrugBank.d776.s20|177-187|terfenadine|drug
DDI-DrugBank.d776.s20|188-188|,|drug
DDI-DrugBank.d776.s20|190-200|interaction|drug
DDI-DrugBank.d776.s20|202-208|studies|drug
DDI-DrugBank.d776.s20|210-213|have|drug
DDI-DrugBank.d776.s20|215-218|been|drug
DDI-DrugBank.d776.s20|220-228|performed|drug
DDI-DrugBank.d776.s20|229-229|.|drug
DDI-DrugBank.d776.s21|0-2|One|drug
DDI-DrugBank.d776.s21|4-8|study|drug
DDI-DrugBank.d776.s21|10-11|at|drug
DDI-DrugBank.d776.s21|13-13|a|drug
DDI-DrugBank.d776.s21|15-20|200-mg|drug
DDI-DrugBank.d776.s21|22-26|daily|drug
DDI-DrugBank.d776.s21|28-31|dose|drug
DDI-DrugBank.d776.s21|33-34|of|drug
DDI-DrugBank.d776.s21|36-46|fluconazole|drug
DDI-DrugBank.d776.s21|48-53|failed|drug
DDI-DrugBank.d776.s21|55-56|to|drug
DDI-DrugBank.d776.s21|58-68|demonstrate|drug
DDI-DrugBank.d776.s21|70-70|a|drug
DDI-DrugBank.d776.s21|72-83|prolongation|drug
DDI-DrugBank.d776.s21|85-86|in|drug
DDI-DrugBank.d776.s21|88-90|QTc|drug
DDI-DrugBank.d776.s21|92-99|interval|drug
DDI-DrugBank.d776.s21|100-100|.|drug
DDI-DrugBank.d776.s22|0-6|Another|drug
DDI-DrugBank.d776.s22|8-12|study|drug
DDI-DrugBank.d776.s22|14-15|at|drug
DDI-DrugBank.d776.s22|17-17|a|drug
DDI-DrugBank.d776.s22|19-24|400-mg|drug
DDI-DrugBank.d776.s22|26-28|and|drug
DDI-DrugBank.d776.s22|30-35|800-mg|drug
DDI-DrugBank.d776.s22|37-41|daily|drug
DDI-DrugBank.d776.s22|43-46|dose|drug
DDI-DrugBank.d776.s22|48-49|of|drug
DDI-DrugBank.d776.s22|51-61|fluconazole|drug
DDI-DrugBank.d776.s22|63-74|demonstrated|drug
DDI-DrugBank.d776.s22|76-79|that|drug
DDI-DrugBank.d776.s22|81-88|DIFLUCAN|drug
DDI-DrugBank.d776.s22|90-94|taken|drug
DDI-DrugBank.d776.s22|96-97|in|drug
DDI-DrugBank.d776.s22|99-103|doses|drug
DDI-DrugBank.d776.s22|105-106|of|drug
DDI-DrugBank.d776.s22|108-110|400|drug
DDI-DrugBank.d776.s22|112-113|mg|drug
DDI-DrugBank.d776.s22|115-117|per|drug
DDI-DrugBank.d776.s22|119-121|day|drug
DDI-DrugBank.d776.s22|123-124|or|drug
DDI-DrugBank.d776.s22|126-132|greater|drug
DDI-DrugBank.d776.s22|134-146|significantly|drug
DDI-DrugBank.d776.s22|148-156|increases|drug
DDI-DrugBank.d776.s22|158-163|plasma|drug
DDI-DrugBank.d776.s22|165-170|levels|drug
DDI-DrugBank.d776.s22|172-173|of|drug
DDI-DrugBank.d776.s22|175-185|terfenadine|drug
DDI-DrugBank.d776.s22|187-190|when|drug
DDI-DrugBank.d776.s22|192-196|taken|drug
DDI-DrugBank.d776.s22|198-210|concomitantly|drug
DDI-DrugBank.d776.s22|211-211|.|drug
DDI-DrugBank.d776.s23|0-2|The|drug
DDI-DrugBank.d776.s23|4-11|combined|drug
DDI-DrugBank.d776.s23|13-15|use|drug
DDI-DrugBank.d776.s23|17-18|of|drug
DDI-DrugBank.d776.s23|20-30|fluconazole|drug
DDI-DrugBank.d776.s23|32-33|at|drug
DDI-DrugBank.d776.s23|35-39|doses|drug
DDI-DrugBank.d776.s23|41-42|of|drug
DDI-DrugBank.d776.s23|44-46|400|drug
DDI-DrugBank.d776.s23|48-49|mg|drug
DDI-DrugBank.d776.s23|51-52|or|drug
DDI-DrugBank.d776.s23|54-60|greater|drug
DDI-DrugBank.d776.s23|62-65|with|drug
DDI-DrugBank.d776.s23|67-77|terfenadine|drug
DDI-DrugBank.d776.s23|79-80|is|drug
DDI-DrugBank.d776.s23|82-96|contraindicated|drug
DDI-DrugBank.d776.s23|97-97|.|drug
DDI-DrugBank.d776.s24|0-2|The|drug
DDI-DrugBank.d776.s24|4-19|coadministration|drug
DDI-DrugBank.d776.s24|21-22|of|drug
DDI-DrugBank.d776.s24|24-34|fluconazole|drug
DDI-DrugBank.d776.s24|36-37|at|drug
DDI-DrugBank.d776.s24|39-43|doses|drug
DDI-DrugBank.d776.s24|45-49|lower|drug
DDI-DrugBank.d776.s24|51-54|than|drug
DDI-DrugBank.d776.s24|56-58|400|drug
DDI-DrugBank.d776.s24|60-65|mg/day|drug
DDI-DrugBank.d776.s24|67-70|with|drug
DDI-DrugBank.d776.s24|72-82|terfenadine|drug
DDI-DrugBank.d776.s24|84-89|should|drug
DDI-DrugBank.d776.s24|91-92|be|drug
DDI-DrugBank.d776.s24|94-102|carefully|drug
DDI-DrugBank.d776.s24|104-112|monitored|drug
DDI-DrugBank.d776.s24|113-113|.|drug
DDI-DrugBank.d776.s25|0-8|Cisapride|drug
DDI-DrugBank.d776.s25|9-9|:|drug
DDI-DrugBank.d776.s25|11-15|There|drug
DDI-DrugBank.d776.s25|17-20|have|drug
DDI-DrugBank.d776.s25|22-25|been|drug
DDI-DrugBank.d776.s25|27-33|reports|drug
DDI-DrugBank.d776.s25|35-36|of|drug
DDI-DrugBank.d776.s25|38-44|cardiac|drug
DDI-DrugBank.d776.s25|46-51|events|drug
DDI-DrugBank.d776.s25|52-52|,|drug
DDI-DrugBank.d776.s25|54-62|including|drug
DDI-DrugBank.d776.s25|64-70|torsade|drug
DDI-DrugBank.d776.s25|72-73|de|drug
DDI-DrugBank.d776.s25|75-81|pointes|drug
DDI-DrugBank.d776.s25|83-84|in|drug
DDI-DrugBank.d776.s25|86-93|patients|drug
DDI-DrugBank.d776.s25|95-96|to|drug
DDI-DrugBank.d776.s25|98-101|whom|drug
DDI-DrugBank.d776.s25|103-113|fluconazole|drug
DDI-DrugBank.d776.s25|115-117|and|drug
DDI-DrugBank.d776.s25|119-127|cisapride|drug
DDI-DrugBank.d776.s25|129-132|were|drug
DDI-DrugBank.d776.s25|134-147|coadministered|drug
DDI-DrugBank.d776.s25|148-148|.|drug
DDI-DrugBank.d776.s26|0-0|A|drug
DDI-DrugBank.d776.s26|2-11|controlled|drug
DDI-DrugBank.d776.s26|13-17|study|drug
DDI-DrugBank.d776.s26|19-23|found|drug
DDI-DrugBank.d776.s26|25-28|that|drug
DDI-DrugBank.d776.s26|30-40|concomitant|drug
DDI-DrugBank.d776.s26|42-52|fluconazole|drug
DDI-DrugBank.d776.s26|54-56|200|drug
DDI-DrugBank.d776.s26|58-59|mg|drug
DDI-DrugBank.d776.s26|61-64|once|drug
DDI-DrugBank.d776.s26|66-70|daily|drug
DDI-DrugBank.d776.s26|72-74|and|drug
DDI-DrugBank.d776.s26|76-84|cisapride|drug
DDI-DrugBank.d776.s26|86-87|20|drug
DDI-DrugBank.d776.s26|89-90|mg|drug
DDI-DrugBank.d776.s26|92-95|four|drug
DDI-DrugBank.d776.s26|97-101|times|drug
DDI-DrugBank.d776.s26|103-103|a|drug
DDI-DrugBank.d776.s26|105-107|day|drug
DDI-DrugBank.d776.s26|109-115|yielded|drug
DDI-DrugBank.d776.s26|117-117|a|drug
DDI-DrugBank.d776.s26|119-129|significant|drug
DDI-DrugBank.d776.s26|131-138|increase|drug
DDI-DrugBank.d776.s26|140-141|in|drug
DDI-DrugBank.d776.s26|143-151|cisapride|drug
DDI-DrugBank.d776.s26|153-158|plasma|drug
DDI-DrugBank.d776.s26|160-165|levels|drug
DDI-DrugBank.d776.s26|167-169|and|drug
DDI-DrugBank.d776.s26|171-182|prolongation|drug
DDI-DrugBank.d776.s26|184-185|of|drug
DDI-DrugBank.d776.s26|187-189|QTc|drug
DDI-DrugBank.d776.s26|191-198|interval|drug
DDI-DrugBank.d776.s26|199-199|.|drug
DDI-DrugBank.d776.s27|0-2|The|drug
DDI-DrugBank.d776.s27|4-11|combined|drug
DDI-DrugBank.d776.s27|13-15|use|drug
DDI-DrugBank.d776.s27|17-18|of|drug
DDI-DrugBank.d776.s27|20-30|fluconazole|drug
DDI-DrugBank.d776.s27|32-35|with|drug
DDI-DrugBank.d776.s27|37-45|cisapride|drug
DDI-DrugBank.d776.s27|47-48|is|drug
DDI-DrugBank.d776.s27|50-64|contraindicated|drug
DDI-DrugBank.d776.s27|65-65|.|drug
DDI-DrugBank.d776.s28|0-9|Astemizole|drug
DDI-DrugBank.d776.s28|10-10|:|drug
DDI-DrugBank.d776.s28|12-14|The|drug
DDI-DrugBank.d776.s28|16-18|use|drug
DDI-DrugBank.d776.s28|20-21|of|drug
DDI-DrugBank.d776.s28|23-33|fluconazole|drug
DDI-DrugBank.d776.s28|35-36|in|drug
DDI-DrugBank.d776.s28|38-45|patients|drug
DDI-DrugBank.d776.s28|47-58|concurrently|drug
DDI-DrugBank.d776.s28|60-65|taking|drug
DDI-DrugBank.d776.s28|67-76|astemizole|drug
DDI-DrugBank.d776.s28|78-79|or|drug
DDI-DrugBank.d776.s28|81-85|other|drug
DDI-DrugBank.d776.s28|87-91|drugs|drug
DDI-DrugBank.d776.s28|93-103|metabolized|drug
DDI-DrugBank.d776.s28|105-106|by|drug
DDI-DrugBank.d776.s28|108-110|the|drug
DDI-DrugBank.d776.s28|112-121|cytochrome|drug
DDI-DrugBank.d776.s28|123-126|P450|drug
DDI-DrugBank.d776.s28|128-133|system|drug
DDI-DrugBank.d776.s28|135-137|may|drug
DDI-DrugBank.d776.s28|139-140|be|drug
DDI-DrugBank.d776.s28|142-151|associated|drug
DDI-DrugBank.d776.s28|153-156|with|drug
DDI-DrugBank.d776.s28|158-167|elevations|drug
DDI-DrugBank.d776.s28|169-170|in|drug
DDI-DrugBank.d776.s28|172-176|serum|drug
DDI-DrugBank.d776.s28|178-183|levels|drug
DDI-DrugBank.d776.s28|185-186|of|drug
DDI-DrugBank.d776.s28|188-192|these|drug
DDI-DrugBank.d776.s28|194-198|drugs|drug
DDI-DrugBank.d776.s28|199-199|.|drug
DDI-DrugBank.d776.s29|0-1|In|drug
DDI-DrugBank.d776.s29|3-5|the|drug
DDI-DrugBank.d776.s29|7-13|absence|drug
DDI-DrugBank.d776.s29|15-16|of|drug
DDI-DrugBank.d776.s29|18-27|definitive|drug
DDI-DrugBank.d776.s29|29-39|information|drug
DDI-DrugBank.d776.s29|40-40|,|drug
DDI-DrugBank.d776.s29|42-48|caution|drug
DDI-DrugBank.d776.s29|50-55|should|drug
DDI-DrugBank.d776.s29|57-58|be|drug
DDI-DrugBank.d776.s29|60-63|used|drug
DDI-DrugBank.d776.s29|65-68|when|drug
DDI-DrugBank.d776.s29|70-84|coadministering|drug
DDI-DrugBank.d776.s29|86-96|fluconazole|drug
DDI-DrugBank.d776.s29|97-97|.|drug
DDI-DrugBank.d776.s30|0-7|Patients|drug
DDI-DrugBank.d776.s30|9-14|should|drug
DDI-DrugBank.d776.s30|16-17|be|drug
DDI-DrugBank.d776.s30|19-27|carefully|drug
DDI-DrugBank.d776.s30|29-37|monitored|drug
DDI-DrugBank.d776.s30|38-38|.|drug
DDI-DrugBank.d776.s31|0-8|Rifabutin|brand
DDI-DrugBank.d776.s31|9-9|:|drug
DDI-DrugBank.d776.s31|11-15|There|drug
DDI-DrugBank.d776.s31|17-20|have|drug
DDI-DrugBank.d776.s31|22-25|been|drug
DDI-DrugBank.d776.s31|27-33|reports|drug
DDI-DrugBank.d776.s31|35-36|of|drug
DDI-DrugBank.d776.s31|38-44|uveitis|drug
DDI-DrugBank.d776.s31|46-47|in|drug
DDI-DrugBank.d776.s31|49-56|patients|drug
DDI-DrugBank.d776.s31|58-59|to|drug
DDI-DrugBank.d776.s31|61-64|whom|drug
DDI-DrugBank.d776.s31|66-76|fluconazole|drug
DDI-DrugBank.d776.s31|78-80|and|drug
DDI-DrugBank.d776.s31|82-90|rifabutin|drug
DDI-DrugBank.d776.s31|92-95|were|drug
DDI-DrugBank.d776.s31|97-110|coadministered|drug
DDI-DrugBank.d776.s31|111-111|.|drug
DDI-DrugBank.d776.s32|0-7|Patients|drug
DDI-DrugBank.d776.s32|9-17|receiving|drug
DDI-DrugBank.d776.s32|19-27|rifabutin|drug
DDI-DrugBank.d776.s32|29-31|and|drug
DDI-DrugBank.d776.s32|33-43|fluconazole|drug
DDI-DrugBank.d776.s32|45-57|concomitantly|drug
DDI-DrugBank.d776.s32|59-64|should|drug
DDI-DrugBank.d776.s32|66-67|be|drug
DDI-DrugBank.d776.s32|69-77|carefully|drug
DDI-DrugBank.d776.s32|79-87|monitored|drug
DDI-DrugBank.d776.s32|88-88|.|drug
DDI-DrugBank.d776.s33|0-9|Tacrolimus|brand
DDI-DrugBank.d776.s33|10-10|:|drug
DDI-DrugBank.d776.s33|12-16|There|drug
DDI-DrugBank.d776.s33|18-21|have|drug
DDI-DrugBank.d776.s33|23-26|been|drug
DDI-DrugBank.d776.s33|28-34|reports|drug
DDI-DrugBank.d776.s33|36-37|of|drug
DDI-DrugBank.d776.s33|39-52|nephrotoxicity|drug
DDI-DrugBank.d776.s33|54-55|in|drug
DDI-DrugBank.d776.s33|57-64|patients|drug
DDI-DrugBank.d776.s33|66-67|to|drug
DDI-DrugBank.d776.s33|69-72|whom|drug
DDI-DrugBank.d776.s33|74-84|fluconazole|drug
DDI-DrugBank.d776.s33|86-88|and|drug
DDI-DrugBank.d776.s33|90-99|tacrolimus|drug
DDI-DrugBank.d776.s33|101-104|were|drug
DDI-DrugBank.d776.s33|106-119|coadministered|drug
DDI-DrugBank.d776.s33|120-120|.|drug
DDI-DrugBank.d776.s34|0-7|Patients|drug
DDI-DrugBank.d776.s34|9-17|receiving|drug
DDI-DrugBank.d776.s34|19-28|tacrolimus|drug
DDI-DrugBank.d776.s34|30-32|and|drug
DDI-DrugBank.d776.s34|34-44|fluconazole|drug
DDI-DrugBank.d776.s34|46-58|concomitantly|drug
DDI-DrugBank.d776.s34|60-65|should|drug
DDI-DrugBank.d776.s34|67-68|be|drug
DDI-DrugBank.d776.s34|70-78|carefully|drug
DDI-DrugBank.d776.s34|80-88|monitored|drug
DDI-DrugBank.d776.s34|89-89|.|drug
DDI-DrugBank.d776.s35|0-11|Short-acting|drug
DDI-DrugBank.d776.s35|13-27|Benzodiazepines|drug
DDI-DrugBank.d776.s35|28-28|:|drug
DDI-DrugBank.d776.s35|30-38|Following|drug
DDI-DrugBank.d776.s35|40-43|oral|drug
DDI-DrugBank.d776.s35|45-58|administration|drug
DDI-DrugBank.d776.s35|60-61|of|drug
DDI-DrugBank.d776.s35|63-71|midazolam|drug
DDI-DrugBank.d776.s35|72-72|,|drug
DDI-DrugBank.d776.s35|74-84|fluconazole|drug
DDI-DrugBank.d776.s35|86-93|resulted|drug
DDI-DrugBank.d776.s35|95-96|in|drug
DDI-DrugBank.d776.s35|98-108|substantial|drug
DDI-DrugBank.d776.s35|110-118|increases|drug
DDI-DrugBank.d776.s35|120-121|in|drug
DDI-DrugBank.d776.s35|123-131|midazolam|drug
DDI-DrugBank.d776.s35|133-146|concentrations|drug
DDI-DrugBank.d776.s35|148-150|and|drug
DDI-DrugBank.d776.s35|152-162|psychomotor|drug
DDI-DrugBank.d776.s35|164-170|effects|drug
DDI-DrugBank.d776.s35|171-171|.|drug
DDI-DrugBank.d776.s36|0-3|This|drug
DDI-DrugBank.d776.s36|5-10|effect|drug
DDI-DrugBank.d776.s36|12-13|on|drug
DDI-DrugBank.d776.s36|15-23|midazolam|drug
DDI-DrugBank.d776.s36|25-31|appears|drug
DDI-DrugBank.d776.s36|33-34|to|drug
DDI-DrugBank.d776.s36|36-37|be|drug
DDI-DrugBank.d776.s36|39-42|more|drug
DDI-DrugBank.d776.s36|44-53|pronounced|drug
DDI-DrugBank.d776.s36|55-63|following|drug
DDI-DrugBank.d776.s36|65-68|oral|drug
DDI-DrugBank.d776.s36|70-83|administration|drug
DDI-DrugBank.d776.s36|85-86|of|drug
DDI-DrugBank.d776.s36|88-98|fluconazole|drug
DDI-DrugBank.d776.s36|100-103|than|drug
DDI-DrugBank.d776.s36|105-108|with|drug
DDI-DrugBank.d776.s36|110-120|fluconazole|drug
DDI-DrugBank.d776.s36|122-133|administered|drug
DDI-DrugBank.d776.s36|135-147|intravenously|drug
DDI-DrugBank.d776.s36|148-148|.|drug
DDI-DrugBank.d776.s37|0-1|If|drug
DDI-DrugBank.d776.s37|3-14|short-acting|drug
DDI-DrugBank.d776.s37|16-30|benzodiazepines|drug
DDI-DrugBank.d776.s37|31-31|,|drug
DDI-DrugBank.d776.s37|33-37|which|drug
DDI-DrugBank.d776.s37|39-41|are|drug
DDI-DrugBank.d776.s37|43-53|metabolized|drug
DDI-DrugBank.d776.s37|55-56|by|drug
DDI-DrugBank.d776.s37|58-60|the|drug
DDI-DrugBank.d776.s37|62-71|cytochrome|drug
DDI-DrugBank.d776.s37|73-76|P450|drug
DDI-DrugBank.d776.s37|78-83|system|drug
DDI-DrugBank.d776.s37|84-84|,|drug
DDI-DrugBank.d776.s37|86-88|are|drug
DDI-DrugBank.d776.s37|90-102|concomitantly|drug
DDI-DrugBank.d776.s37|104-115|administered|drug
DDI-DrugBank.d776.s37|117-120|with|drug
DDI-DrugBank.d776.s37|122-132|fluconazole|drug
DDI-DrugBank.d776.s37|133-133|,|drug
DDI-DrugBank.d776.s37|135-147|consideration|drug
DDI-DrugBank.d776.s37|149-154|should|drug
DDI-DrugBank.d776.s37|156-157|be|drug
DDI-DrugBank.d776.s37|159-163|given|drug
DDI-DrugBank.d776.s37|165-166|to|drug
DDI-DrugBank.d776.s37|168-177|decreasing|drug
DDI-DrugBank.d776.s37|179-181|the|drug
DDI-DrugBank.d776.s37|183-196|benzodiazepine|drug
DDI-DrugBank.d776.s37|198-203|dosage|drug
DDI-DrugBank.d776.s37|204-204|,|drug
DDI-DrugBank.d776.s37|206-208|and|drug
DDI-DrugBank.d776.s37|210-212|the|drug
DDI-DrugBank.d776.s37|214-221|patients|drug
DDI-DrugBank.d776.s37|223-228|should|drug
DDI-DrugBank.d776.s37|230-231|be|drug
DDI-DrugBank.d776.s37|233-245|appropriately|drug
DDI-DrugBank.d776.s37|247-255|monitored|drug
DDI-DrugBank.d776.s37|256-256|.|drug
DDI-DrugBank.d776.s38|0-10|Fluconazole|brand
DDI-DrugBank.d776.s38|12-18|tablets|drug
DDI-DrugBank.d776.s38|20-33|coadministered|drug
DDI-DrugBank.d776.s38|35-38|with|drug
DDI-DrugBank.d776.s38|40-46|ethinyl|drug
DDI-DrugBank.d776.s38|48-57|estradiol-|drug
DDI-DrugBank.d776.s38|59-61|and|drug
DDI-DrugBank.d776.s38|63-87|levonorgestrel-containing|drug
DDI-DrugBank.d776.s38|89-92|oral|drug
DDI-DrugBank.d776.s38|94-107|contraceptives|drug
DDI-DrugBank.d776.s38|109-116|produced|drug
DDI-DrugBank.d776.s38|118-119|an|drug
DDI-DrugBank.d776.s38|121-127|overall|drug
DDI-DrugBank.d776.s38|129-132|mean|drug
DDI-DrugBank.d776.s38|134-141|increase|drug
DDI-DrugBank.d776.s38|143-144|in|drug
DDI-DrugBank.d776.s38|146-152|ethinyl|drug
DDI-DrugBank.d776.s38|154-162|estradiol|drug
DDI-DrugBank.d776.s38|164-166|and|drug
DDI-DrugBank.d776.s38|168-181|levonorgestrel|drug
DDI-DrugBank.d776.s38|183-188|levels|drug
DDI-DrugBank.d776.s38|189-189|;|drug
DDI-DrugBank.d776.s39|0-6|however|drug
DDI-DrugBank.d776.s39|7-7|,|drug
DDI-DrugBank.d776.s39|9-10|in|drug
DDI-DrugBank.d776.s39|12-15|some|drug
DDI-DrugBank.d776.s39|17-24|patients|drug
DDI-DrugBank.d776.s39|26-30|there|drug
DDI-DrugBank.d776.s39|32-35|were|drug
DDI-DrugBank.d776.s39|37-45|decreases|drug
DDI-DrugBank.d776.s39|47-48|up|drug
DDI-DrugBank.d776.s39|50-51|to|drug
DDI-DrugBank.d776.s39|53-54|47|drug
DDI-DrugBank.d776.s39|55-55|%|drug
DDI-DrugBank.d776.s39|57-59|and|drug
DDI-DrugBank.d776.s39|61-62|33|drug
DDI-DrugBank.d776.s39|63-63|%|drug
DDI-DrugBank.d776.s39|65-66|of|drug
DDI-DrugBank.d776.s39|68-74|ethinyl|drug
DDI-DrugBank.d776.s39|76-84|estradiol|drug
DDI-DrugBank.d776.s39|86-88|and|drug
DDI-DrugBank.d776.s39|90-103|levonorgestrel|drug
DDI-DrugBank.d776.s39|105-110|levels|drug
DDI-DrugBank.d776.s39|111-111|.|drug
DDI-DrugBank.d776.s40|0-2|The|drug
DDI-DrugBank.d776.s40|4-7|data|drug
DDI-DrugBank.d776.s40|9-17|presently|drug
DDI-DrugBank.d776.s40|19-27|available|drug
DDI-DrugBank.d776.s40|29-36|indicate|drug
DDI-DrugBank.d776.s40|38-41|that|drug
DDI-DrugBank.d776.s40|43-45|the|drug
DDI-DrugBank.d776.s40|47-55|decreases|drug
DDI-DrugBank.d776.s40|57-58|in|drug
DDI-DrugBank.d776.s40|60-63|some|drug
DDI-DrugBank.d776.s40|65-74|individual|drug
DDI-DrugBank.d776.s40|76-82|ethinyl|drug
DDI-DrugBank.d776.s40|84-92|estradiol|drug
DDI-DrugBank.d776.s40|94-96|and|drug
DDI-DrugBank.d776.s40|98-111|levonorgestrel|drug
DDI-DrugBank.d776.s40|113-115|AUC|drug
DDI-DrugBank.d776.s40|117-122|values|drug
DDI-DrugBank.d776.s40|124-127|with|drug
DDI-DrugBank.d776.s40|129-139|fluconazole|drug
DDI-DrugBank.d776.s40|141-149|treatment|drug
DDI-DrugBank.d776.s40|151-153|are|drug
DDI-DrugBank.d776.s40|155-160|likely|drug
DDI-DrugBank.d776.s40|162-164|the|drug
DDI-DrugBank.d776.s40|166-171|result|drug
DDI-DrugBank.d776.s40|173-174|of|drug
DDI-DrugBank.d776.s40|176-181|random|drug
DDI-DrugBank.d776.s40|183-191|variation|drug
DDI-DrugBank.d776.s40|192-192|.|drug
DDI-DrugBank.d776.s41|0-4|While|drug
DDI-DrugBank.d776.s41|6-10|there|drug
DDI-DrugBank.d776.s41|12-13|is|drug
DDI-DrugBank.d776.s41|15-22|evidence|drug
DDI-DrugBank.d776.s41|24-27|that|drug
DDI-DrugBank.d776.s41|29-39|fluconazole|drug
DDI-DrugBank.d776.s41|41-43|can|drug
DDI-DrugBank.d776.s41|45-51|inhibit|drug
DDI-DrugBank.d776.s41|53-55|the|drug
DDI-DrugBank.d776.s41|57-66|metabolism|drug
DDI-DrugBank.d776.s41|68-69|of|drug
DDI-DrugBank.d776.s41|71-77|ethinyl|drug
DDI-DrugBank.d776.s41|79-87|estradiol|drug
DDI-DrugBank.d776.s41|89-91|and|drug
DDI-DrugBank.d776.s41|93-106|levonorgestrel|drug
DDI-DrugBank.d776.s41|107-107|,|drug
DDI-DrugBank.d776.s41|109-113|there|drug
DDI-DrugBank.d776.s41|115-116|is|drug
DDI-DrugBank.d776.s41|118-119|no|drug
DDI-DrugBank.d776.s41|121-128|evidence|drug
DDI-DrugBank.d776.s41|130-133|that|drug
DDI-DrugBank.d776.s41|135-145|fluconazole|drug
DDI-DrugBank.d776.s41|147-148|is|drug
DDI-DrugBank.d776.s41|150-150|a|drug
DDI-DrugBank.d776.s41|152-154|net|drug
DDI-DrugBank.d776.s41|156-162|inducer|drug
DDI-DrugBank.d776.s41|164-165|of|drug
DDI-DrugBank.d776.s41|167-173|ethinyl|drug
DDI-DrugBank.d776.s41|175-183|estradiol|drug
DDI-DrugBank.d776.s41|185-186|or|drug
DDI-DrugBank.d776.s41|188-201|levonorgestrel|drug
DDI-DrugBank.d776.s41|203-212|metabolism|drug
DDI-DrugBank.d776.s41|213-213|.|drug
DDI-DrugBank.d776.s42|0-2|The|drug
DDI-DrugBank.d776.s42|4-11|clinical|drug
DDI-DrugBank.d776.s42|13-24|significance|drug
DDI-DrugBank.d776.s42|26-27|of|drug
DDI-DrugBank.d776.s42|29-33|these|drug
DDI-DrugBank.d776.s42|35-41|effects|drug
DDI-DrugBank.d776.s42|43-44|is|drug
DDI-DrugBank.d776.s42|46-54|presently|drug
DDI-DrugBank.d776.s42|56-62|unknown|drug
DDI-DrugBank.d776.s42|63-63|.|drug
DDI-DrugBank.d776.s43|0-9|Physicians|drug
DDI-DrugBank.d776.s43|11-16|should|drug
DDI-DrugBank.d776.s43|18-19|be|drug
DDI-DrugBank.d776.s43|21-25|aware|drug
DDI-DrugBank.d776.s43|27-30|that|drug
DDI-DrugBank.d776.s43|32-42|interaction|drug
DDI-DrugBank.d776.s43|44-50|studies|drug
DDI-DrugBank.d776.s43|52-55|with|drug
DDI-DrugBank.d776.s43|57-67|medications|drug
DDI-DrugBank.d776.s43|69-73|other|drug
DDI-DrugBank.d776.s43|75-78|than|drug
DDI-DrugBank.d776.s43|80-84|those|drug
DDI-DrugBank.d776.s43|86-91|listed|drug
DDI-DrugBank.d776.s43|93-94|in|drug
DDI-DrugBank.d776.s43|96-98|the|drug
DDI-DrugBank.d776.s43|100-100|<|drug
DDI-DrugBank.d776.s43|101-101|a|drug
DDI-DrugBank.d776.s43|103-107|href=|drug
DDI-DrugBank.d776.s43|109-109|``|drug
DDI-DrugBank.d776.s43|110-122|flucon_cp.htm|drug
DDI-DrugBank.d776.s43|123-123|#|drug
DDI-DrugBank.d776.s43|124-125|CP|drug
DDI-DrugBank.d776.s43|126-126|''|drug
DDI-DrugBank.d776.s43|127-127|>|drug
DDI-DrugBank.d776.s43|128-135|CLINICAL|drug
DDI-DrugBank.d776.s43|137-148|PHARMACOLOGY|drug
DDI-DrugBank.d776.s43|150-156|section|drug
DDI-DrugBank.d776.s43|158-161|have|drug
DDI-DrugBank.d776.s43|163-165|not|drug
DDI-DrugBank.d776.s43|167-170|been|drug
DDI-DrugBank.d776.s43|172-180|conducted|drug
DDI-DrugBank.d776.s43|181-181|,|drug
DDI-DrugBank.d776.s43|183-185|but|drug
DDI-DrugBank.d776.s43|187-190|such|drug
DDI-DrugBank.d776.s43|192-203|interactions|drug
DDI-DrugBank.d776.s43|205-207|may|drug
DDI-DrugBank.d776.s43|209-213|occur|drug
DDI-DrugBank.d776.s43|214-214|.|drug
DDI-DrugBank.d219.s0|0-13|ACE-inhibitors|drug
DDI-DrugBank.d219.s0|15-21|Reports|drug
DDI-DrugBank.d219.s0|23-29|suggest|drug
DDI-DrugBank.d219.s0|31-34|that|drug
DDI-DrugBank.d219.s0|36-41|NSAIDs|drug
DDI-DrugBank.d219.s0|43-45|may|drug
DDI-DrugBank.d219.s0|47-54|diminish|drug
DDI-DrugBank.d219.s0|56-58|the|drug
DDI-DrugBank.d219.s0|60-75|antihypertensive|drug
DDI-DrugBank.d219.s0|77-82|effect|drug
DDI-DrugBank.d219.s0|84-85|of|drug
DDI-DrugBank.d219.s0|87-100|ACE-inhibitors|drug
DDI-DrugBank.d219.s0|101-101|.|drug
DDI-DrugBank.d219.s1|0-3|This|drug
DDI-DrugBank.d219.s1|5-15|interaction|drug
DDI-DrugBank.d219.s1|17-22|should|drug
DDI-DrugBank.d219.s1|24-25|be|drug
DDI-DrugBank.d219.s1|27-31|given|drug
DDI-DrugBank.d219.s1|33-45|consideration|drug
DDI-DrugBank.d219.s1|47-48|in|drug
DDI-DrugBank.d219.s1|50-57|patients|drug
DDI-DrugBank.d219.s1|59-64|taking|drug
DDI-DrugBank.d219.s1|66-71|NSAIDs|drug
DDI-DrugBank.d219.s1|73-85|concomitantly|drug
DDI-DrugBank.d219.s1|87-90|with|drug
DDI-DrugBank.d219.s1|92-105|ACE-inhibitors|drug
DDI-DrugBank.d219.s1|106-106|.|drug
DDI-DrugBank.d219.s2|0-7|Antacids|group
DDI-DrugBank.d219.s2|8-8|:|drug
DDI-DrugBank.d219.s2|10-12|The|drug
DDI-DrugBank.d219.s2|14-24|concomitant|drug
DDI-DrugBank.d219.s2|26-39|administration|drug
DDI-DrugBank.d219.s2|41-42|of|drug
DDI-DrugBank.d219.s2|44-51|antacids|drug
DDI-DrugBank.d219.s2|53-55|has|drug
DDI-DrugBank.d219.s2|57-58|no|drug
DDI-DrugBank.d219.s2|60-67|apparent|drug
DDI-DrugBank.d219.s2|69-74|effect|drug
DDI-DrugBank.d219.s2|76-77|on|drug
DDI-DrugBank.d219.s2|79-81|the|drug
DDI-DrugBank.d219.s2|83-88|extent|drug
DDI-DrugBank.d219.s2|90-91|of|drug
DDI-DrugBank.d219.s2|93-102|absorption|drug
DDI-DrugBank.d219.s2|104-105|of|drug
DDI-DrugBank.d219.s2|107-112|Lodine|brand
DDI-DrugBank.d219.s2|113-113|.|drug
DDI-DrugBank.d219.s3|0-6|However|drug
DDI-DrugBank.d219.s3|7-7|,|drug
DDI-DrugBank.d219.s3|9-16|antacids|drug
DDI-DrugBank.d219.s3|18-20|can|drug
DDI-DrugBank.d219.s3|22-29|decrease|drug
DDI-DrugBank.d219.s3|31-33|the|drug
DDI-DrugBank.d219.s3|35-38|peak|drug
DDI-DrugBank.d219.s3|40-52|concentration|drug
DDI-DrugBank.d219.s3|54-60|reached|drug
DDI-DrugBank.d219.s3|62-63|by|drug
DDI-DrugBank.d219.s3|65-66|15|drug
DDI-DrugBank.d219.s3|67-67|%|drug
DDI-DrugBank.d219.s3|69-70|to|drug
DDI-DrugBank.d219.s3|72-73|20|drug
DDI-DrugBank.d219.s3|74-74|%|drug
DDI-DrugBank.d219.s3|76-78|but|drug
DDI-DrugBank.d219.s3|80-83|have|drug
DDI-DrugBank.d219.s3|85-86|no|drug
DDI-DrugBank.d219.s3|88-97|detectable|drug
DDI-DrugBank.d219.s3|99-104|effect|drug
DDI-DrugBank.d219.s3|106-107|on|drug
DDI-DrugBank.d219.s3|109-111|the|drug
DDI-DrugBank.d219.s3|113-124|time-to-peak|drug
DDI-DrugBank.d219.s3|125-125|.|drug
DDI-DrugBank.d219.s4|0-6|Aspirin|brand
DDI-DrugBank.d219.s4|7-7|:|drug
DDI-DrugBank.d219.s4|9-12|When|drug
DDI-DrugBank.d219.s4|14-19|Lodine|brand
DDI-DrugBank.d219.s4|21-22|is|drug
DDI-DrugBank.d219.s4|24-35|administered|drug
DDI-DrugBank.d219.s4|37-40|with|drug
DDI-DrugBank.d219.s4|42-48|aspirin|drug
DDI-DrugBank.d219.s4|49-49|,|drug
DDI-DrugBank.d219.s4|51-53|its|drug
DDI-DrugBank.d219.s4|55-61|protein|drug
DDI-DrugBank.d219.s4|63-69|binding|drug
DDI-DrugBank.d219.s4|71-72|is|drug
DDI-DrugBank.d219.s4|74-80|reduced|drug
DDI-DrugBank.d219.s4|81-81|,|drug
DDI-DrugBank.d219.s4|83-90|although|drug
DDI-DrugBank.d219.s4|92-94|the|drug
DDI-DrugBank.d219.s4|96-104|clearance|drug
DDI-DrugBank.d219.s4|106-107|of|drug
DDI-DrugBank.d219.s4|109-112|free|drug
DDI-DrugBank.d219.s4|114-121|etodolac|drug
DDI-DrugBank.d219.s4|123-124|is|drug
DDI-DrugBank.d219.s4|126-128|not|drug
DDI-DrugBank.d219.s4|130-136|altered|drug
DDI-DrugBank.d219.s4|137-137|.|drug
DDI-DrugBank.d219.s5|0-2|The|drug
DDI-DrugBank.d219.s5|4-11|clinical|drug
DDI-DrugBank.d219.s5|13-24|significance|drug
DDI-DrugBank.d219.s5|26-27|of|drug
DDI-DrugBank.d219.s5|29-32|this|drug
DDI-DrugBank.d219.s5|34-44|interaction|drug
DDI-DrugBank.d219.s5|46-47|is|drug
DDI-DrugBank.d219.s5|49-51|not|drug
DDI-DrugBank.d219.s5|53-57|known|drug
DDI-DrugBank.d219.s5|58-58|;|drug
DDI-DrugBank.d219.s6|0-6|however|drug
DDI-DrugBank.d219.s6|7-7|,|drug
DDI-DrugBank.d219.s6|9-10|as|drug
DDI-DrugBank.d219.s6|12-15|with|drug
DDI-DrugBank.d219.s6|17-21|other|drug
DDI-DrugBank.d219.s6|23-28|NSAIDs|drug
DDI-DrugBank.d219.s6|29-29|,|drug
DDI-DrugBank.d219.s6|31-41|concomitant|drug
DDI-DrugBank.d219.s6|43-56|administration|drug
DDI-DrugBank.d219.s6|58-59|of|drug
DDI-DrugBank.d219.s6|61-66|Lodine|brand
DDI-DrugBank.d219.s6|68-70|and|drug
DDI-DrugBank.d219.s6|72-78|aspirin|drug
DDI-DrugBank.d219.s6|80-81|is|drug
DDI-DrugBank.d219.s6|83-85|not|drug
DDI-DrugBank.d219.s6|87-95|generally|drug
DDI-DrugBank.d219.s6|97-107|recommended|drug
DDI-DrugBank.d219.s6|109-115|because|drug
DDI-DrugBank.d219.s6|117-118|of|drug
DDI-DrugBank.d219.s6|120-122|the|drug
DDI-DrugBank.d219.s6|124-132|potential|drug
DDI-DrugBank.d219.s6|134-135|of|drug
DDI-DrugBank.d219.s6|137-145|increased|drug
DDI-DrugBank.d219.s6|147-153|adverse|drug
DDI-DrugBank.d219.s6|155-161|effects|drug
DDI-DrugBank.d219.s6|162-162|.|drug
DDI-DrugBank.d219.s7|0-11|Cyclosporine|brand
DDI-DrugBank.d219.s7|12-12|,|drug
DDI-DrugBank.d219.s7|14-20|Digoxin|brand
DDI-DrugBank.d219.s7|21-21|,|drug
DDI-DrugBank.d219.s7|23-34|Methotrexate|brand
DDI-DrugBank.d219.s7|36-41|Lodine|brand
DDI-DrugBank.d219.s7|42-42|,|drug
DDI-DrugBank.d219.s7|44-47|like|drug
DDI-DrugBank.d219.s7|49-53|other|drug
DDI-DrugBank.d219.s7|55-60|NSAIDs|drug
DDI-DrugBank.d219.s7|61-61|,|drug
DDI-DrugBank.d219.s7|63-69|through|drug
DDI-DrugBank.d219.s7|71-77|effects|drug
DDI-DrugBank.d219.s7|79-80|on|drug
DDI-DrugBank.d219.s7|82-86|renal|drug
DDI-DrugBank.d219.s7|88-101|prostaglandins|drug
DDI-DrugBank.d219.s7|102-102|,|drug
DDI-DrugBank.d219.s7|104-106|may|drug
DDI-DrugBank.d219.s7|108-112|cause|drug
DDI-DrugBank.d219.s7|114-120|changes|drug
DDI-DrugBank.d219.s7|122-123|in|drug
DDI-DrugBank.d219.s7|125-127|the|drug
DDI-DrugBank.d219.s7|129-139|elimination|drug
DDI-DrugBank.d219.s7|141-142|of|drug
DDI-DrugBank.d219.s7|144-148|these|drug
DDI-DrugBank.d219.s7|150-154|drugs|drug
DDI-DrugBank.d219.s7|156-162|leading|drug
DDI-DrugBank.d219.s7|164-165|to|drug
DDI-DrugBank.d219.s7|167-174|elevated|drug
DDI-DrugBank.d219.s7|176-180|serum|drug
DDI-DrugBank.d219.s7|182-187|levels|drug
DDI-DrugBank.d219.s7|189-190|of|drug
DDI-DrugBank.d219.s7|192-203|cyclosporine|drug
DDI-DrugBank.d219.s7|204-204|,|drug
DDI-DrugBank.d219.s7|206-212|digoxin|drug
DDI-DrugBank.d219.s7|213-213|,|drug
DDI-DrugBank.d219.s7|215-226|methotrexate|drug
DDI-DrugBank.d219.s7|227-227|,|drug
DDI-DrugBank.d219.s7|229-231|and|drug
DDI-DrugBank.d219.s7|233-241|increased|drug
DDI-DrugBank.d219.s7|243-250|toxicity|drug
DDI-DrugBank.d219.s7|251-251|.|drug
DDI-DrugBank.d219.s8|0-13|Nephrotoxicity|drug
DDI-DrugBank.d219.s8|15-24|associated|drug
DDI-DrugBank.d219.s8|26-29|with|drug
DDI-DrugBank.d219.s8|31-42|cyclosporine|drug
DDI-DrugBank.d219.s8|44-46|may|drug
DDI-DrugBank.d219.s8|48-51|also|drug
DDI-DrugBank.d219.s8|53-54|be|drug
DDI-DrugBank.d219.s8|56-63|enhanced|drug
DDI-DrugBank.d219.s8|64-64|.|drug
DDI-DrugBank.d219.s9|0-7|Patients|drug
DDI-DrugBank.d219.s9|9-17|receiving|drug
DDI-DrugBank.d219.s9|19-23|these|drug
DDI-DrugBank.d219.s9|25-29|drugs|drug
DDI-DrugBank.d219.s9|31-33|who|drug
DDI-DrugBank.d219.s9|35-37|are|drug
DDI-DrugBank.d219.s9|39-43|given|drug
DDI-DrugBank.d219.s9|45-50|Lodine|brand
DDI-DrugBank.d219.s9|51-51|,|drug
DDI-DrugBank.d219.s9|53-54|or|drug
DDI-DrugBank.d219.s9|56-58|any|drug
DDI-DrugBank.d219.s9|60-64|other|drug
DDI-DrugBank.d219.s9|66-70|NSAID|drug
DDI-DrugBank.d219.s9|71-71|,|drug
DDI-DrugBank.d219.s9|73-75|and|drug
DDI-DrugBank.d219.s9|77-88|particularly|drug
DDI-DrugBank.d219.s9|90-94|those|drug
DDI-DrugBank.d219.s9|96-103|patients|drug
DDI-DrugBank.d219.s9|105-108|with|drug
DDI-DrugBank.d219.s9|110-116|altered|drug
DDI-DrugBank.d219.s9|118-122|renal|drug
DDI-DrugBank.d219.s9|124-131|function|drug
DDI-DrugBank.d219.s9|132-132|,|drug
DDI-DrugBank.d219.s9|134-139|should|drug
DDI-DrugBank.d219.s9|141-142|be|drug
DDI-DrugBank.d219.s9|144-151|observed|drug
DDI-DrugBank.d219.s9|153-155|for|drug
DDI-DrugBank.d219.s9|157-159|the|drug
DDI-DrugBank.d219.s9|161-171|development|drug
DDI-DrugBank.d219.s9|173-174|of|drug
DDI-DrugBank.d219.s9|176-178|the|drug
DDI-DrugBank.d219.s9|180-187|specific|drug
DDI-DrugBank.d219.s9|189-198|toxicities|drug
DDI-DrugBank.d219.s9|200-201|of|drug
DDI-DrugBank.d219.s9|203-207|these|drug
DDI-DrugBank.d219.s9|209-213|drugs|drug
DDI-DrugBank.d219.s9|214-214|.|drug
DDI-DrugBank.d219.s10|0-8|Diuretics|group
DDI-DrugBank.d219.s10|9-9|:|drug
DDI-DrugBank.d219.s10|11-18|Etodolac|brand
DDI-DrugBank.d219.s10|20-22|has|drug
DDI-DrugBank.d219.s10|24-25|no|drug
DDI-DrugBank.d219.s10|27-34|apparent|drug
DDI-DrugBank.d219.s10|36-50|pharmacokinetic|drug
DDI-DrugBank.d219.s10|52-62|interaction|drug
DDI-DrugBank.d219.s10|64-67|when|drug
DDI-DrugBank.d219.s10|69-80|administered|drug
DDI-DrugBank.d219.s10|82-85|with|drug
DDI-DrugBank.d219.s10|87-96|furosemide|drug
DDI-DrugBank.d219.s10|98-99|or|drug
DDI-DrugBank.d219.s10|101-119|hydrochlorothiazide|drug
DDI-DrugBank.d219.s10|120-120|.|drug
DDI-DrugBank.d219.s11|0-11|Nevertheless|drug
DDI-DrugBank.d219.s11|12-12|,|drug
DDI-DrugBank.d219.s11|14-21|clinical|drug
DDI-DrugBank.d219.s11|23-29|studies|drug
DDI-DrugBank.d219.s11|30-30|,|drug
DDI-DrugBank.d219.s11|32-33|as|drug
DDI-DrugBank.d219.s11|35-38|well|drug
DDI-DrugBank.d219.s11|40-41|as|drug
DDI-DrugBank.d219.s11|43-55|postmarketing|drug
DDI-DrugBank.d219.s11|57-68|observations|drug
DDI-DrugBank.d219.s11|70-73|have|drug
DDI-DrugBank.d219.s11|75-79|shown|drug
DDI-DrugBank.d219.s11|81-84|that|drug
DDI-DrugBank.d219.s11|86-91|Lodine|brand
DDI-DrugBank.d219.s11|93-95|can|drug
DDI-DrugBank.d219.s11|97-102|reduce|drug
DDI-DrugBank.d219.s11|104-106|the|drug
DDI-DrugBank.d219.s11|108-118|natriuretic|drug
DDI-DrugBank.d219.s11|120-125|effect|drug
DDI-DrugBank.d219.s11|127-128|of|drug
DDI-DrugBank.d219.s11|130-139|furosemide|drug
DDI-DrugBank.d219.s11|141-143|and|drug
DDI-DrugBank.d219.s11|145-153|thiazides|drug
DDI-DrugBank.d219.s11|155-156|in|drug
DDI-DrugBank.d219.s11|158-161|some|drug
DDI-DrugBank.d219.s11|163-170|patients|drug
DDI-DrugBank.d219.s11|171-171|.|drug
DDI-DrugBank.d219.s12|0-3|This|drug
DDI-DrugBank.d219.s12|5-12|response|drug
DDI-DrugBank.d219.s12|14-16|has|drug
DDI-DrugBank.d219.s12|18-21|been|drug
DDI-DrugBank.d219.s12|23-32|attributed|drug
DDI-DrugBank.d219.s12|34-35|to|drug
DDI-DrugBank.d219.s12|37-46|inhibition|drug
DDI-DrugBank.d219.s12|48-49|of|drug
DDI-DrugBank.d219.s12|51-55|renal|drug
DDI-DrugBank.d219.s12|57-69|prostaglandin|drug
DDI-DrugBank.d219.s12|71-79|synthesis|drug
DDI-DrugBank.d219.s12|80-80|.|drug
DDI-DrugBank.d219.s13|0-5|During|drug
DDI-DrugBank.d219.s13|7-17|concomitant|drug
DDI-DrugBank.d219.s13|19-25|therapy|drug
DDI-DrugBank.d219.s13|27-30|with|drug
DDI-DrugBank.d219.s13|32-37|NSAIDs|drug
DDI-DrugBank.d219.s13|38-38|,|drug
DDI-DrugBank.d219.s13|40-42|the|drug
DDI-DrugBank.d219.s13|44-50|patient|drug
DDI-DrugBank.d219.s13|52-57|should|drug
DDI-DrugBank.d219.s13|59-60|be|drug
DDI-DrugBank.d219.s13|62-69|observed|drug
DDI-DrugBank.d219.s13|71-77|closely|drug
DDI-DrugBank.d219.s13|79-81|for|drug
DDI-DrugBank.d219.s13|83-87|signs|drug
DDI-DrugBank.d219.s13|89-90|of|drug
DDI-DrugBank.d219.s13|92-96|renal|drug
DDI-DrugBank.d219.s13|98-104|failure|drug
DDI-DrugBank.d219.s13|105-105|,|drug
DDI-DrugBank.d219.s13|107-108|as|drug
DDI-DrugBank.d219.s13|110-113|well|drug
DDI-DrugBank.d219.s13|115-116|as|drug
DDI-DrugBank.d219.s13|118-119|to|drug
DDI-DrugBank.d219.s13|121-126|assure|drug
DDI-DrugBank.d219.s13|128-135|diuretic|drug
DDI-DrugBank.d219.s13|137-144|efficacy|drug
DDI-DrugBank.d219.s13|145-145|.|drug
DDI-DrugBank.d219.s14|0-8|Glyburide|brand
DDI-DrugBank.d219.s14|9-9|:|drug
DDI-DrugBank.d219.s14|11-18|Etodolac|brand
DDI-DrugBank.d219.s14|20-22|has|drug
DDI-DrugBank.d219.s14|24-25|no|drug
DDI-DrugBank.d219.s14|27-34|apparent|drug
DDI-DrugBank.d219.s14|36-50|pharmacokinetic|drug
DDI-DrugBank.d219.s14|52-62|interaction|drug
DDI-DrugBank.d219.s14|64-67|when|drug
DDI-DrugBank.d219.s14|69-80|administered|drug
DDI-DrugBank.d219.s14|82-85|with|drug
DDI-DrugBank.d219.s14|87-95|glyburide|drug
DDI-DrugBank.d219.s14|96-96|.|drug
DDI-DrugBank.d219.s15|0-6|Lithium|brand
DDI-DrugBank.d219.s15|7-7|:|drug
DDI-DrugBank.d219.s15|9-14|NSAIDs|drug
DDI-DrugBank.d219.s15|16-19|have|drug
DDI-DrugBank.d219.s15|21-28|produced|drug
DDI-DrugBank.d219.s15|30-31|an|drug
DDI-DrugBank.d219.s15|33-41|elevation|drug
DDI-DrugBank.d219.s15|43-44|of|drug
DDI-DrugBank.d219.s15|46-51|plasma|drug
DDI-DrugBank.d219.s15|53-59|lithium|drug
DDI-DrugBank.d219.s15|61-66|levels|drug
DDI-DrugBank.d219.s15|68-70|and|drug
DDI-DrugBank.d219.s15|72-72|a|drug
DDI-DrugBank.d219.s15|74-82|reduction|drug
DDI-DrugBank.d219.s15|84-85|in|drug
DDI-DrugBank.d219.s15|87-91|renal|drug
DDI-DrugBank.d219.s15|93-99|lithium|drug
DDI-DrugBank.d219.s15|101-109|clearance|drug
DDI-DrugBank.d219.s15|110-110|.|drug
DDI-DrugBank.d219.s16|0-2|The|drug
DDI-DrugBank.d219.s16|4-7|mean|drug
DDI-DrugBank.d219.s16|9-15|minimum|drug
DDI-DrugBank.d219.s16|17-23|lithium|drug
DDI-DrugBank.d219.s16|25-37|concentration|drug
DDI-DrugBank.d219.s16|39-47|increased|drug
DDI-DrugBank.d219.s16|49-50|15|drug
DDI-DrugBank.d219.s16|51-51|%|drug
DDI-DrugBank.d219.s16|53-55|and|drug
DDI-DrugBank.d219.s16|57-59|the|drug
DDI-DrugBank.d219.s16|61-65|renal|drug
DDI-DrugBank.d219.s16|67-75|clearance|drug
DDI-DrugBank.d219.s16|77-79|was|drug
DDI-DrugBank.d219.s16|81-89|decreased|drug
DDI-DrugBank.d219.s16|91-92|by|drug
DDI-DrugBank.d219.s16|94-106|approximately|drug
DDI-DrugBank.d219.s16|108-109|20|drug
DDI-DrugBank.d219.s16|110-110|%|drug
DDI-DrugBank.d219.s16|111-111|.|drug
DDI-DrugBank.d219.s17|0-4|These|drug
DDI-DrugBank.d219.s17|6-12|effects|drug
DDI-DrugBank.d219.s17|14-17|have|drug
DDI-DrugBank.d219.s17|19-22|been|drug
DDI-DrugBank.d219.s17|24-33|attributed|drug
DDI-DrugBank.d219.s17|35-36|to|drug
DDI-DrugBank.d219.s17|38-47|inhibition|drug
DDI-DrugBank.d219.s17|49-50|of|drug
DDI-DrugBank.d219.s17|52-56|renal|drug
DDI-DrugBank.d219.s17|58-70|prostaglandin|drug
DDI-DrugBank.d219.s17|72-80|synthesis|drug
DDI-DrugBank.d219.s17|82-83|by|drug
DDI-DrugBank.d219.s17|85-87|the|drug
DDI-DrugBank.d219.s17|89-93|NSAID|drug
DDI-DrugBank.d219.s17|94-94|.|drug
DDI-DrugBank.d219.s18|0-3|Thus|drug
DDI-DrugBank.d219.s18|4-4|,|drug
DDI-DrugBank.d219.s18|6-9|when|drug
DDI-DrugBank.d219.s18|11-16|NSAIDs|drug
DDI-DrugBank.d219.s18|18-20|and|drug
DDI-DrugBank.d219.s18|22-28|lithium|drug
DDI-DrugBank.d219.s18|30-32|are|drug
DDI-DrugBank.d219.s18|34-45|administered|drug
DDI-DrugBank.d219.s18|47-58|concurrently|drug
DDI-DrugBank.d219.s18|59-59|,|drug
DDI-DrugBank.d219.s18|61-68|subjects|drug
DDI-DrugBank.d219.s18|70-75|should|drug
DDI-DrugBank.d219.s18|77-78|be|drug
DDI-DrugBank.d219.s18|80-87|observed|drug
DDI-DrugBank.d219.s18|89-97|carefully|drug
DDI-DrugBank.d219.s18|99-101|for|drug
DDI-DrugBank.d219.s18|103-107|signs|drug
DDI-DrugBank.d219.s18|109-110|of|drug
DDI-DrugBank.d219.s18|112-118|lithium|drug
DDI-DrugBank.d219.s18|120-127|toxicity|drug
DDI-DrugBank.d219.s18|128-128|.|drug
DDI-DrugBank.d219.s19|0-13|Phenylbutazone|drug
DDI-DrugBank.d219.s19|14-14|:|drug
DDI-DrugBank.d219.s19|16-29|Phenylbutazone|drug
DDI-DrugBank.d219.s19|31-36|causes|drug
DDI-DrugBank.d219.s19|38-45|increase|drug
DDI-DrugBank.d219.s19|47-47|(|drug
DDI-DrugBank.d219.s19|48-49|by|drug
DDI-DrugBank.d219.s19|51-55|about|drug
DDI-DrugBank.d219.s19|57-58|80|drug
DDI-DrugBank.d219.s19|59-59|%|drug
DDI-DrugBank.d219.s19|60-60|)|drug
DDI-DrugBank.d219.s19|62-63|in|drug
DDI-DrugBank.d219.s19|65-67|the|drug
DDI-DrugBank.d219.s19|69-72|free|drug
DDI-DrugBank.d219.s19|74-81|fraction|drug
DDI-DrugBank.d219.s19|83-84|of|drug
DDI-DrugBank.d219.s19|86-93|etodolac|drug
DDI-DrugBank.d219.s19|94-94|.|drug
DDI-DrugBank.d219.s20|0-7|Although|drug
DDI-DrugBank.d219.s20|9-10|in|drug
DDI-DrugBank.d219.s20|12-15|vivo|drug
DDI-DrugBank.d219.s20|17-23|studies|drug
DDI-DrugBank.d219.s20|25-28|have|drug
DDI-DrugBank.d219.s20|30-32|not|drug
DDI-DrugBank.d219.s20|34-37|been|drug
DDI-DrugBank.d219.s20|39-42|done|drug
DDI-DrugBank.d219.s20|44-45|to|drug
DDI-DrugBank.d219.s20|47-49|see|drug
DDI-DrugBank.d219.s20|51-52|if|drug
DDI-DrugBank.d219.s20|54-61|etodolac|drug
DDI-DrugBank.d219.s20|63-71|clearance|drug
DDI-DrugBank.d219.s20|73-74|is|drug
DDI-DrugBank.d219.s20|76-82|changed|drug
DDI-DrugBank.d219.s20|84-85|by|drug
DDI-DrugBank.d219.s20|87-102|coadministration|drug
DDI-DrugBank.d219.s20|104-105|of|drug
DDI-DrugBank.d219.s20|107-120|phenylbutazone|drug
DDI-DrugBank.d219.s20|121-121|,|drug
DDI-DrugBank.d219.s20|123-124|it|drug
DDI-DrugBank.d219.s20|126-127|is|drug
DDI-DrugBank.d219.s20|129-131|not|drug
DDI-DrugBank.d219.s20|133-143|recommended|drug
DDI-DrugBank.d219.s20|145-148|that|drug
DDI-DrugBank.d219.s20|150-153|they|drug
DDI-DrugBank.d219.s20|155-156|be|drug
DDI-DrugBank.d219.s20|158-171|coadministered|drug
DDI-DrugBank.d219.s20|172-172|.|drug
DDI-DrugBank.d219.s21|0-8|Phenytoin|brand
DDI-DrugBank.d219.s21|9-9|:|drug
DDI-DrugBank.d219.s21|11-18|Etodolac|brand
DDI-DrugBank.d219.s21|20-22|has|drug
DDI-DrugBank.d219.s21|24-25|no|drug
DDI-DrugBank.d219.s21|27-34|apparent|drug
DDI-DrugBank.d219.s21|36-50|pharmacokinetic|drug
DDI-DrugBank.d219.s21|52-62|interaction|drug
DDI-DrugBank.d219.s21|64-67|when|drug
DDI-DrugBank.d219.s21|69-80|administered|drug
DDI-DrugBank.d219.s21|82-85|with|drug
DDI-DrugBank.d219.s21|87-95|phenytoin|drug
DDI-DrugBank.d219.s21|96-96|.|drug
DDI-DrugBank.d219.s22|0-7|Warfarin|brand
DDI-DrugBank.d219.s22|8-8|:|drug
DDI-DrugBank.d219.s22|10-12|The|drug
DDI-DrugBank.d219.s22|14-20|effects|drug
DDI-DrugBank.d219.s22|22-23|of|drug
DDI-DrugBank.d219.s22|25-32|warfarin|drug
DDI-DrugBank.d219.s22|34-36|and|drug
DDI-DrugBank.d219.s22|38-43|NSAIDs|drug
DDI-DrugBank.d219.s22|45-46|on|drug
DDI-DrugBank.d219.s22|48-49|GI|drug
DDI-DrugBank.d219.s22|51-58|bleeding|drug
DDI-DrugBank.d219.s22|60-62|are|drug
DDI-DrugBank.d219.s22|64-74|synergistic|drug
DDI-DrugBank.d219.s22|75-75|,|drug
DDI-DrugBank.d219.s22|77-80|such|drug
DDI-DrugBank.d219.s22|82-85|that|drug
DDI-DrugBank.d219.s22|87-91|users|drug
DDI-DrugBank.d219.s22|93-94|of|drug
DDI-DrugBank.d219.s22|96-99|both|drug
DDI-DrugBank.d219.s22|101-105|drugs|drug
DDI-DrugBank.d219.s22|107-114|together|drug
DDI-DrugBank.d219.s22|116-119|have|drug
DDI-DrugBank.d219.s22|121-121|a|drug
DDI-DrugBank.d219.s22|123-126|risk|drug
DDI-DrugBank.d219.s22|128-129|of|drug
DDI-DrugBank.d219.s22|131-137|serious|drug
DDI-DrugBank.d219.s22|139-140|GI|drug
DDI-DrugBank.d219.s22|142-149|bleeding|drug
DDI-DrugBank.d219.s22|151-156|higher|drug
DDI-DrugBank.d219.s22|158-161|than|drug
DDI-DrugBank.d219.s22|163-166|that|drug
DDI-DrugBank.d219.s22|168-169|of|drug
DDI-DrugBank.d219.s22|171-175|users|drug
DDI-DrugBank.d219.s22|177-178|of|drug
DDI-DrugBank.d219.s22|180-185|either|drug
DDI-DrugBank.d219.s22|187-190|drug|drug
DDI-DrugBank.d219.s22|192-196|alone|drug
DDI-DrugBank.d219.s22|197-197|.|drug
DDI-DrugBank.d219.s23|0-9|Short-term|drug
DDI-DrugBank.d219.s23|11-25|pharmacokinetic|drug
DDI-DrugBank.d219.s23|27-33|studies|drug
DDI-DrugBank.d219.s23|35-38|have|drug
DDI-DrugBank.d219.s23|40-51|demonstrated|drug
DDI-DrugBank.d219.s23|53-56|that|drug
DDI-DrugBank.d219.s23|58-68|concomitant|drug
DDI-DrugBank.d219.s23|70-83|administration|drug
DDI-DrugBank.d219.s23|85-86|of|drug
DDI-DrugBank.d219.s23|88-95|warfarin|drug
DDI-DrugBank.d219.s23|97-99|and|drug
DDI-DrugBank.d219.s23|101-106|Lodine|brand
DDI-DrugBank.d219.s23|109-109|(|drug
DDI-DrugBank.d219.s23|110-117|etodolac|drug
DDI-DrugBank.d219.s23|119-126|capsules|drug
DDI-DrugBank.d219.s23|128-130|and|drug
DDI-DrugBank.d219.s23|132-138|tablets|drug
DDI-DrugBank.d219.s23|139-139|)|drug
DDI-DrugBank.d219.s23|141-147|results|drug
DDI-DrugBank.d219.s23|149-150|in|drug
DDI-DrugBank.d219.s23|152-158|reduced|drug
DDI-DrugBank.d219.s23|160-166|protein|drug
DDI-DrugBank.d219.s23|168-174|binding|drug
DDI-DrugBank.d219.s23|176-177|of|drug
DDI-DrugBank.d219.s23|179-186|warfarin|drug
DDI-DrugBank.d219.s23|187-187|,|drug
DDI-DrugBank.d219.s23|189-191|but|drug
DDI-DrugBank.d219.s23|193-197|there|drug
DDI-DrugBank.d219.s23|199-201|was|drug
DDI-DrugBank.d219.s23|203-204|no|drug
DDI-DrugBank.d219.s23|206-211|change|drug
DDI-DrugBank.d219.s23|213-214|in|drug
DDI-DrugBank.d219.s23|216-218|the|drug
DDI-DrugBank.d219.s23|220-228|clearance|drug
DDI-DrugBank.d219.s23|230-231|of|drug
DDI-DrugBank.d219.s23|233-236|free|drug
DDI-DrugBank.d219.s23|238-245|warfarin|drug
DDI-DrugBank.d219.s23|246-246|.|drug
DDI-DrugBank.d219.s24|0-4|There|drug
DDI-DrugBank.d219.s24|6-8|was|drug
DDI-DrugBank.d219.s24|10-11|no|drug
DDI-DrugBank.d219.s24|13-23|significant|drug
DDI-DrugBank.d219.s24|25-34|difference|drug
DDI-DrugBank.d219.s24|36-37|in|drug
DDI-DrugBank.d219.s24|39-41|the|drug
DDI-DrugBank.d219.s24|43-57|pharmacodynamic|drug
DDI-DrugBank.d219.s24|59-64|effect|drug
DDI-DrugBank.d219.s24|66-67|of|drug
DDI-DrugBank.d219.s24|69-76|warfarin|drug
DDI-DrugBank.d219.s24|78-89|administered|drug
DDI-DrugBank.d219.s24|91-95|alone|drug
DDI-DrugBank.d219.s24|97-99|and|drug
DDI-DrugBank.d219.s24|101-108|warfarin|drug
DDI-DrugBank.d219.s24|110-121|administered|drug
DDI-DrugBank.d219.s24|123-126|with|drug
DDI-DrugBank.d219.s24|128-133|Lodine|brand
DDI-DrugBank.d219.s24|135-136|as|drug
DDI-DrugBank.d219.s24|138-145|measured|drug
DDI-DrugBank.d219.s24|147-148|by|drug
DDI-DrugBank.d219.s24|150-160|prothrombin|drug
DDI-DrugBank.d219.s24|162-165|time|drug
DDI-DrugBank.d219.s24|166-166|.|drug
DDI-DrugBank.d219.s25|0-3|Thus|drug
DDI-DrugBank.d219.s25|4-4|,|drug
DDI-DrugBank.d219.s25|6-16|concomitant|drug
DDI-DrugBank.d219.s25|18-24|therapy|drug
DDI-DrugBank.d219.s25|26-29|with|drug
DDI-DrugBank.d219.s25|31-38|warfarin|drug
DDI-DrugBank.d219.s25|40-42|and|drug
DDI-DrugBank.d219.s25|44-49|Lodine|brand
DDI-DrugBank.d219.s25|51-56|should|drug
DDI-DrugBank.d219.s25|58-60|not|drug
DDI-DrugBank.d219.s25|62-68|require|drug
DDI-DrugBank.d219.s25|70-75|dosage|drug
DDI-DrugBank.d219.s25|77-86|adjustment|drug
DDI-DrugBank.d219.s25|88-89|of|drug
DDI-DrugBank.d219.s25|91-96|either|drug
DDI-DrugBank.d219.s25|98-101|drug|drug
DDI-DrugBank.d219.s25|102-102|.|drug
DDI-DrugBank.d219.s26|0-6|However|drug
DDI-DrugBank.d219.s26|7-7|,|drug
DDI-DrugBank.d219.s26|9-15|caution|drug
DDI-DrugBank.d219.s26|17-22|should|drug
DDI-DrugBank.d219.s26|24-25|be|drug
DDI-DrugBank.d219.s26|27-35|exercised|drug
DDI-DrugBank.d219.s26|37-43|because|drug
DDI-DrugBank.d219.s26|45-49|there|drug
DDI-DrugBank.d219.s26|51-54|have|drug
DDI-DrugBank.d219.s26|56-59|been|drug
DDI-DrugBank.d219.s26|61-61|a|drug
DDI-DrugBank.d219.s26|63-65|few|drug
DDI-DrugBank.d219.s26|67-77|spontaneous|drug
DDI-DrugBank.d219.s26|79-85|reports|drug
DDI-DrugBank.d219.s26|87-88|of|drug
DDI-DrugBank.d219.s26|90-98|prolonged|drug
DDI-DrugBank.d219.s26|100-110|prothrombin|drug
DDI-DrugBank.d219.s26|112-116|times|drug
DDI-DrugBank.d219.s26|117-117|,|drug
DDI-DrugBank.d219.s26|119-122|with|drug
DDI-DrugBank.d219.s26|124-125|or|drug
DDI-DrugBank.d219.s26|127-133|without|drug
DDI-DrugBank.d219.s26|135-142|bleeding|drug
DDI-DrugBank.d219.s26|143-143|,|drug
DDI-DrugBank.d219.s26|145-146|in|drug
DDI-DrugBank.d219.s26|148-163|etodolac-treated|drug
DDI-DrugBank.d219.s26|165-172|patients|drug
DDI-DrugBank.d219.s26|174-182|receiving|drug
DDI-DrugBank.d219.s26|184-194|concomitant|drug
DDI-DrugBank.d219.s26|196-203|warfarin|drug
DDI-DrugBank.d219.s26|205-211|therapy|drug
DDI-DrugBank.d219.s26|212-212|.|drug
DDI-DrugBank.d219.s27|0-14|Drug/Laboratory|drug
DDI-DrugBank.d219.s27|16-19|Test|drug
DDI-DrugBank.d219.s27|21-32|Interactions|drug
DDI-DrugBank.d219.s27|34-36|The|drug
DDI-DrugBank.d219.s27|38-42|urine|drug
DDI-DrugBank.d219.s27|44-45|of|drug
DDI-DrugBank.d219.s27|47-54|patients|drug
DDI-DrugBank.d219.s27|56-58|who|drug
DDI-DrugBank.d219.s27|60-63|take|drug
DDI-DrugBank.d219.s27|65-70|Lodine|brand
DDI-DrugBank.d219.s27|72-74|can|drug
DDI-DrugBank.d219.s27|76-79|give|drug
DDI-DrugBank.d219.s27|81-81|a|drug
DDI-DrugBank.d219.s27|83-96|false-positive|drug
DDI-DrugBank.d219.s27|98-105|reaction|drug
DDI-DrugBank.d219.s27|107-109|for|drug
DDI-DrugBank.d219.s27|111-117|urinary|drug
DDI-DrugBank.d219.s27|119-127|bilirubin|drug
DDI-DrugBank.d219.s27|129-129|(|drug
DDI-DrugBank.d219.s27|130-137|urobilin|drug
DDI-DrugBank.d219.s27|138-138|)|drug
DDI-DrugBank.d219.s27|140-142|due|drug
DDI-DrugBank.d219.s27|144-145|to|drug
DDI-DrugBank.d219.s27|147-149|the|drug
DDI-DrugBank.d219.s27|151-158|presence|drug
DDI-DrugBank.d219.s27|160-161|of|drug
DDI-DrugBank.d219.s27|163-170|phenolic|drug
DDI-DrugBank.d219.s27|172-182|metabolites|drug
DDI-DrugBank.d219.s27|184-185|of|drug
DDI-DrugBank.d219.s27|187-194|etodolac|drug
DDI-DrugBank.d219.s27|195-195|.|drug
DDI-DrugBank.d219.s28|0-9|Diagnostic|drug
DDI-DrugBank.d219.s28|11-19|dip-stick|drug
DDI-DrugBank.d219.s28|21-31|methodology|drug
DDI-DrugBank.d219.s28|32-32|,|drug
DDI-DrugBank.d219.s28|34-37|used|drug
DDI-DrugBank.d219.s28|39-40|to|drug
DDI-DrugBank.d219.s28|42-47|detect|drug
DDI-DrugBank.d219.s28|49-54|ketone|drug
DDI-DrugBank.d219.s28|56-61|bodies|drug
DDI-DrugBank.d219.s28|63-64|in|drug
DDI-DrugBank.d219.s28|66-70|urine|drug
DDI-DrugBank.d219.s28|71-71|,|drug
DDI-DrugBank.d219.s28|73-75|has|drug
DDI-DrugBank.d219.s28|77-84|resulted|drug
DDI-DrugBank.d219.s28|86-87|in|drug
DDI-DrugBank.d219.s28|89-102|false-positive|drug
DDI-DrugBank.d219.s28|104-111|findings|drug
DDI-DrugBank.d219.s28|113-114|in|drug
DDI-DrugBank.d219.s28|116-119|some|drug
DDI-DrugBank.d219.s28|121-128|patients|drug
DDI-DrugBank.d219.s28|130-136|treated|drug
DDI-DrugBank.d219.s28|138-141|with|drug
DDI-DrugBank.d219.s28|143-148|Lodine|brand
DDI-DrugBank.d219.s28|149-149|.|drug
DDI-DrugBank.d219.s29|0-8|Generally|drug
DDI-DrugBank.d219.s29|9-9|,|drug
DDI-DrugBank.d219.s29|11-14|this|drug
DDI-DrugBank.d219.s29|16-25|phenomenon|drug
DDI-DrugBank.d219.s29|27-29|has|drug
DDI-DrugBank.d219.s29|31-33|not|drug
DDI-DrugBank.d219.s29|35-38|been|drug
DDI-DrugBank.d219.s29|40-49|associated|drug
DDI-DrugBank.d219.s29|51-54|with|drug
DDI-DrugBank.d219.s29|56-60|other|drug
DDI-DrugBank.d219.s29|62-71|clinically|drug
DDI-DrugBank.d219.s29|73-83|significant|drug
DDI-DrugBank.d219.s29|85-90|events|drug
DDI-DrugBank.d219.s29|91-91|.|drug
DDI-DrugBank.d219.s30|0-1|No|drug
DDI-DrugBank.d219.s30|3-6|dose|drug
DDI-DrugBank.d219.s30|8-19|relationship|drug
DDI-DrugBank.d219.s30|21-23|has|drug
DDI-DrugBank.d219.s30|25-28|been|drug
DDI-DrugBank.d219.s30|30-37|observed|drug
DDI-DrugBank.d219.s30|38-38|.|drug
DDI-DrugBank.d219.s31|0-5|Lodine|brand
DDI-DrugBank.d219.s31|7-15|treatment|drug
DDI-DrugBank.d219.s31|17-18|is|drug
DDI-DrugBank.d219.s31|20-29|associated|drug
DDI-DrugBank.d219.s31|31-34|with|drug
DDI-DrugBank.d219.s31|36-36|a|drug
DDI-DrugBank.d219.s31|38-42|small|drug
DDI-DrugBank.d219.s31|44-51|decrease|drug
DDI-DrugBank.d219.s31|53-54|in|drug
DDI-DrugBank.d219.s31|56-60|serum|drug
DDI-DrugBank.d219.s31|62-65|uric|drug
DDI-DrugBank.d219.s31|67-70|acid|drug
DDI-DrugBank.d219.s31|72-77|levels|drug
DDI-DrugBank.d219.s31|78-78|.|drug
DDI-DrugBank.d219.s32|0-1|In|drug
DDI-DrugBank.d219.s32|3-10|clinical|drug
DDI-DrugBank.d219.s32|12-17|trials|drug
DDI-DrugBank.d219.s32|18-18|,|drug
DDI-DrugBank.d219.s32|20-23|mean|drug
DDI-DrugBank.d219.s32|25-33|decreases|drug
DDI-DrugBank.d219.s32|35-36|of|drug
DDI-DrugBank.d219.s32|38-38|1|drug
DDI-DrugBank.d219.s32|40-41|to|drug
DDI-DrugBank.d219.s32|43-43|2|drug
DDI-DrugBank.d219.s32|45-49|mg/dL|drug
DDI-DrugBank.d219.s32|51-54|were|drug
DDI-DrugBank.d219.s32|56-63|observed|drug
DDI-DrugBank.d219.s32|65-66|in|drug
DDI-DrugBank.d219.s32|68-76|arthritic|drug
DDI-DrugBank.d219.s32|78-85|patients|drug
DDI-DrugBank.d219.s32|87-95|receiving|drug
DDI-DrugBank.d219.s32|97-104|etodolac|drug
DDI-DrugBank.d219.s32|106-106|(|drug
DDI-DrugBank.d219.s32|107-109|600|drug
DDI-DrugBank.d219.s32|111-112|mg|drug
DDI-DrugBank.d219.s32|114-115|to|drug
DDI-DrugBank.d219.s32|117-120|1000|drug
DDI-DrugBank.d219.s32|122-127|mg/day|drug
DDI-DrugBank.d219.s32|128-128|)|drug
DDI-DrugBank.d219.s32|130-134|after|drug
DDI-DrugBank.d219.s32|136-136|4|drug
DDI-DrugBank.d219.s32|138-142|weeks|drug
DDI-DrugBank.d219.s32|144-145|of|drug
DDI-DrugBank.d219.s32|147-153|therapy|drug
DDI-DrugBank.d219.s32|154-154|.|drug
DDI-DrugBank.d219.s33|0-4|These|drug
DDI-DrugBank.d219.s33|6-11|levels|drug
DDI-DrugBank.d219.s33|13-16|then|drug
DDI-DrugBank.d219.s33|18-25|remained|drug
DDI-DrugBank.d219.s33|27-32|stable|drug
DDI-DrugBank.d219.s33|34-36|for|drug
DDI-DrugBank.d219.s33|38-39|up|drug
DDI-DrugBank.d219.s33|41-42|to|drug
DDI-DrugBank.d219.s33|44-44|1|drug
DDI-DrugBank.d219.s33|46-49|year|drug
DDI-DrugBank.d219.s33|51-52|of|drug
DDI-DrugBank.d219.s33|54-60|therapy|drug
DDI-DrugBank.d219.s33|61-61|.|drug
DDI-MedLine.d185.s0|0-5|Effect|drug
DDI-MedLine.d185.s0|7-8|of|drug
DDI-MedLine.d185.s0|10-30|ketoconazole-mediated|drug
DDI-MedLine.d185.s0|32-37|CYP3A4|drug
DDI-MedLine.d185.s0|39-48|inhibition|drug
DDI-MedLine.d185.s0|50-51|on|drug
DDI-MedLine.d185.s0|53-60|clinical|drug
DDI-MedLine.d185.s0|62-77|pharmacokinetics|drug
DDI-MedLine.d185.s0|79-80|of|drug
DDI-MedLine.d185.s0|82-93|panobinostat|drug
DDI-MedLine.d185.s0|95-95|(|drug
DDI-MedLine.d185.s0|96-101|LBH589|drug
DDI-MedLine.d185.s0|102-102|)|drug
DDI-MedLine.d185.s0|103-103|,|drug
DDI-MedLine.d185.s0|105-106|an|drug
DDI-MedLine.d185.s0|108-113|orally|drug
DDI-MedLine.d185.s0|115-120|active|drug
DDI-MedLine.d185.s0|122-128|histone|drug
DDI-MedLine.d185.s0|130-140|deacetylase|drug
DDI-MedLine.d185.s0|142-150|inhibitor|drug
DDI-MedLine.d185.s0|151-151|.|drug
DDI-MedLine.d185.s1|0-11|Panobinostat|drug
DDI-MedLine.d185.s1|13-14|is|drug
DDI-MedLine.d185.s1|16-21|partly|drug
DDI-MedLine.d185.s1|23-33|metabolized|drug
DDI-MedLine.d185.s1|35-36|by|drug
DDI-MedLine.d185.s1|38-43|CYP3A4|drug
DDI-MedLine.d185.s1|45-46|in|drug
DDI-MedLine.d185.s1|48-52|vitro|drug
DDI-MedLine.d185.s1|53-53|.|drug
DDI-MedLine.d185.s2|0-3|This|drug
DDI-MedLine.d185.s2|5-9|study|drug
DDI-MedLine.d185.s2|11-19|evaluated|drug
DDI-MedLine.d185.s2|21-23|the|drug
DDI-MedLine.d185.s2|25-30|effect|drug
DDI-MedLine.d185.s2|32-33|of|drug
DDI-MedLine.d185.s2|35-35|a|drug
DDI-MedLine.d185.s2|37-42|potent|drug
DDI-MedLine.d185.s2|44-48|CYP3A|drug
DDI-MedLine.d185.s2|50-58|inhibitor|drug
DDI-MedLine.d185.s2|59-59|,|drug
DDI-MedLine.d185.s2|61-72|ketoconazole|drug
DDI-MedLine.d185.s2|73-73|,|drug
DDI-MedLine.d185.s2|75-76|on|drug
DDI-MedLine.d185.s2|78-80|the|drug
DDI-MedLine.d185.s2|82-97|pharmacokinetics|drug
DDI-MedLine.d185.s2|99-101|and|drug
DDI-MedLine.d185.s2|103-108|safety|drug
DDI-MedLine.d185.s2|110-111|of|drug
DDI-MedLine.d185.s2|113-124|panobinostat|drug
DDI-MedLine.d185.s2|125-125|.|drug
DDI-MedLine.d185.s3|0-7|Patients|drug
DDI-MedLine.d185.s3|9-16|received|drug
DDI-MedLine.d185.s3|18-18|a|drug
DDI-MedLine.d185.s3|20-25|single|drug
DDI-MedLine.d185.s3|27-38|panobinostat|drug
DDI-MedLine.d185.s3|40-43|oral|drug
DDI-MedLine.d185.s3|45-48|dose|drug
DDI-MedLine.d185.s3|50-51|on|drug
DDI-MedLine.d185.s3|53-55|day|drug
DDI-MedLine.d185.s3|57-57|1|drug
DDI-MedLine.d185.s3|58-58|,|drug
DDI-MedLine.d185.s3|60-67|followed|drug
DDI-MedLine.d185.s3|69-70|by|drug
DDI-MedLine.d185.s3|72-72|4|drug
DDI-MedLine.d185.s3|75-78|days|drug
DDI-MedLine.d185.s3|80-87|wash-out|drug
DDI-MedLine.d185.s3|89-94|period|drug
DDI-MedLine.d185.s3|95-95|.|drug
DDI-MedLine.d185.s4|0-1|On|drug
DDI-MedLine.d185.s4|3-6|days|drug
DDI-MedLine.d185.s4|8-10|5-9|drug
DDI-MedLine.d185.s4|11-11|,|drug
DDI-MedLine.d185.s4|13-24|ketoconazole|drug
DDI-MedLine.d185.s4|26-28|was|drug
DDI-MedLine.d185.s4|30-41|administered|drug
DDI-MedLine.d185.s4|42-42|.|drug
DDI-MedLine.d185.s5|0-1|On|drug
DDI-MedLine.d185.s5|3-5|day|drug
DDI-MedLine.d185.s5|7-7|8|drug
DDI-MedLine.d185.s5|8-8|,|drug
DDI-MedLine.d185.s5|10-10|a|drug
DDI-MedLine.d185.s5|12-17|single|drug
DDI-MedLine.d185.s5|19-30|panobinostat|drug
DDI-MedLine.d185.s5|32-35|dose|drug
DDI-MedLine.d185.s5|37-39|was|drug
DDI-MedLine.d185.s5|41-55|co-administered|drug
DDI-MedLine.d185.s5|57-60|with|drug
DDI-MedLine.d185.s5|62-73|ketoconazole|drug
DDI-MedLine.d185.s5|74-74|.|drug
DDI-MedLine.d185.s6|0-11|Panobinostat|drug
DDI-MedLine.d185.s6|13-15|was|drug
DDI-MedLine.d185.s6|17-28|administered|drug
DDI-MedLine.d185.s6|30-31|as|drug
DDI-MedLine.d185.s6|33-38|single|drug
DDI-MedLine.d185.s6|40-44|agent|drug
DDI-MedLine.d185.s6|46-50|three|drug
DDI-MedLine.d185.s6|52-56|times|drug
DDI-MedLine.d185.s6|58-58|a|drug
DDI-MedLine.d185.s6|60-63|week|drug
DDI-MedLine.d185.s6|65-66|on|drug
DDI-MedLine.d185.s6|68-70|day|drug
DDI-MedLine.d185.s6|72-73|15|drug
DDI-MedLine.d185.s6|75-77|and|drug
DDI-MedLine.d185.s6|79-84|onward|drug
DDI-MedLine.d185.s6|85-85|.|drug
DDI-MedLine.d185.s7|0-1|In|drug
DDI-MedLine.d185.s7|3-5|the|drug
DDI-MedLine.d185.s7|7-14|presence|drug
DDI-MedLine.d185.s7|16-17|of|drug
DDI-MedLine.d185.s7|19-30|ketoconazole|drug
DDI-MedLine.d185.s7|31-31|,|drug
DDI-MedLine.d185.s7|33-37|there|drug
DDI-MedLine.d185.s7|39-41|was|drug
DDI-MedLine.d185.s7|43-46|1.6-|drug
DDI-MedLine.d185.s7|48-50|and|drug
DDI-MedLine.d185.s7|52-59|1.8-fold|drug
DDI-MedLine.d185.s7|61-68|increase|drug
DDI-MedLine.d185.s7|70-71|in|drug
DDI-MedLine.d185.s7|73-73|C|drug
DDI-MedLine.d185.s7|75-75|(|drug
DDI-MedLine.d185.s7|76-78|max|drug
DDI-MedLine.d185.s7|79-79|)|drug
DDI-MedLine.d185.s7|81-83|and|drug
DDI-MedLine.d185.s7|85-87|AUC|drug
DDI-MedLine.d185.s7|89-90|of|drug
DDI-MedLine.d185.s7|92-103|panobinostat|drug
DDI-MedLine.d185.s7|104-104|,|drug
DDI-MedLine.d185.s7|106-117|respectively|drug
DDI-MedLine.d185.s7|118-118|.|drug
DDI-MedLine.d185.s8|0-1|No|drug
DDI-MedLine.d185.s8|3-13|substantial|drug
DDI-MedLine.d185.s8|15-20|change|drug
DDI-MedLine.d185.s8|22-23|in|drug
DDI-MedLine.d185.s8|25-25|T|drug
DDI-MedLine.d185.s8|27-27|(|drug
DDI-MedLine.d185.s8|28-30|max|drug
DDI-MedLine.d185.s8|31-31|)|drug
DDI-MedLine.d185.s8|33-34|or|drug
DDI-MedLine.d185.s8|36-44|half-life|drug
DDI-MedLine.d185.s8|46-48|was|drug
DDI-MedLine.d185.s8|50-57|observed|drug
DDI-MedLine.d185.s8|58-58|.|drug
DDI-MedLine.d185.s9|0-1|No|drug
DDI-MedLine.d185.s9|3-12|difference|drug
DDI-MedLine.d185.s9|14-15|in|drug
DDI-MedLine.d185.s9|17-45|panobinostat-pharmacokinetics|drug
DDI-MedLine.d185.s9|47-53|between|drug
DDI-MedLine.d185.s9|55-62|patients|drug
DDI-MedLine.d185.s9|64-71|carrying|drug
DDI-MedLine.d185.s9|73-83|CYP3A5|drug
DDI-MedLine.d185.s9|85-87|*|drug
DDI-MedLine.d185.s9|89-99|1/|drug
DDI-MedLine.d185.s9|101-107|*|drug
DDI-MedLine.d185.s9|109-111|3|drug
DDI-MedLine.d185.s9|113-120|and|drug
DDI-MedLine.d185.s9|121-121|CYP3A5|drug
DDI-MedLine.d185.s10|0-3|Most|drug
DDI-MedLine.d185.s10|5-14|frequently|drug
DDI-MedLine.d185.s10|16-23|reported|drug
DDI-MedLine.d185.s10|25-31|adverse|drug
DDI-MedLine.d185.s10|33-38|events|drug
DDI-MedLine.d185.s10|40-43|were|drug
DDI-MedLine.d185.s10|45-60|gastrointestinal|drug
DDI-MedLine.d185.s10|62-68|related|drug
DDI-MedLine.d185.s10|69-69|.|drug
DDI-MedLine.d185.s11|0-7|Patients|drug
DDI-MedLine.d185.s11|9-11|had|drug
DDI-MedLine.d185.s11|13-24|asymptomatic|drug
DDI-MedLine.d185.s11|26-41|hypophosphatemia|drug
DDI-MedLine.d185.s11|43-43|(|drug
DDI-MedLine.d185.s11|44-45|64|drug
DDI-MedLine.d185.s11|46-46|%|drug
DDI-MedLine.d185.s11|47-47|)|drug
DDI-MedLine.d185.s11|48-48|,|drug
DDI-MedLine.d185.s11|50-52|and|drug
DDI-MedLine.d185.s11|54-58|urine|drug
DDI-MedLine.d185.s11|60-67|analysis|drug
DDI-MedLine.d185.s11|69-77|suggested|drug
DDI-MedLine.d185.s11|79-83|renal|drug
DDI-MedLine.d185.s11|85-93|phosphate|drug
DDI-MedLine.d185.s11|95-101|wasting|drug
DDI-MedLine.d185.s11|102-102|.|drug
DDI-MedLine.d185.s12|0-16|Co-administration|drug
DDI-MedLine.d185.s12|18-19|of|drug
DDI-MedLine.d185.s12|21-32|panobinostat|drug
DDI-MedLine.d185.s12|34-37|with|drug
DDI-MedLine.d185.s12|39-43|CYP3A|drug
DDI-MedLine.d185.s12|45-54|inhibitors|drug
DDI-MedLine.d185.s12|56-57|is|drug
DDI-MedLine.d185.s12|59-66|feasible|drug
DDI-MedLine.d185.s12|68-69|as|drug
DDI-MedLine.d185.s12|71-73|the|drug
DDI-MedLine.d185.s12|75-82|observed|drug
DDI-MedLine.d185.s12|84-91|increase|drug
DDI-MedLine.d185.s12|93-94|in|drug
DDI-MedLine.d185.s12|96-107|panobinostat|drug
DDI-MedLine.d185.s12|109-110|PK|drug
DDI-MedLine.d185.s12|112-121|parameters|drug
DDI-MedLine.d185.s12|123-125|was|drug
DDI-MedLine.d185.s12|127-129|not|drug
DDI-MedLine.d185.s12|131-140|considered|drug
DDI-MedLine.d185.s12|142-151|clinically|drug
DDI-MedLine.d185.s12|153-160|relevant|drug
DDI-MedLine.d185.s12|161-161|.|drug
DDI-MedLine.d185.s13|0-10|Considering|drug
DDI-MedLine.d185.s13|12-14|the|drug
DDI-MedLine.d185.s13|16-26|variability|drug
DDI-MedLine.d185.s13|28-29|in|drug
DDI-MedLine.d185.s13|31-38|exposure|drug
DDI-MedLine.d185.s13|40-48|following|drug
DDI-MedLine.d185.s13|50-55|enzyme|drug
DDI-MedLine.d185.s13|57-66|inhibition|drug
DDI-MedLine.d185.s13|68-70|and|drug
DDI-MedLine.d185.s13|72-74|the|drug
DDI-MedLine.d185.s13|76-79|fact|drug
DDI-MedLine.d185.s13|81-84|that|drug
DDI-MedLine.d185.s13|86-92|chronic|drug
DDI-MedLine.d185.s13|94-99|dosing|drug
DDI-MedLine.d185.s13|101-102|of|drug
DDI-MedLine.d185.s13|104-115|panobinostat|drug
DDI-MedLine.d185.s13|117-119|was|drug
DDI-MedLine.d185.s13|121-123|not|drug
DDI-MedLine.d185.s13|125-131|studied|drug
DDI-MedLine.d185.s13|133-136|with|drug
DDI-MedLine.d185.s13|138-142|CYP3A|drug
DDI-MedLine.d185.s13|144-153|inhibitors|drug
DDI-MedLine.d185.s13|154-154|,|drug
DDI-MedLine.d185.s13|156-160|close|drug
DDI-MedLine.d185.s13|162-171|monitoring|drug
DDI-MedLine.d185.s13|173-174|of|drug
DDI-MedLine.d185.s13|176-195|panobinostat-related|drug
DDI-MedLine.d185.s13|197-203|adverse|drug
DDI-MedLine.d185.s13|205-210|events|drug
DDI-MedLine.d185.s13|212-213|is|drug
DDI-MedLine.d185.s13|215-223|necessary|drug
DDI-MedLine.d185.s13|224-224|.|drug
DDI-DrugBank.d658.s0|0-3|When|drug
DDI-DrugBank.d658.s0|5-16|administered|drug
DDI-DrugBank.d658.s0|18-29|concurrently|drug
DDI-DrugBank.d658.s0|30-30|,|drug
DDI-DrugBank.d658.s0|32-43|testolactone|drug
DDI-DrugBank.d658.s0|45-47|may|drug
DDI-DrugBank.d658.s0|49-56|increase|drug
DDI-DrugBank.d658.s0|58-60|the|drug
DDI-DrugBank.d658.s0|62-68|effects|drug
DDI-DrugBank.d658.s0|70-71|of|drug
DDI-DrugBank.d658.s0|73-76|oral|drug
DDI-DrugBank.d658.s0|78-91|anticoagulants|drug
DDI-DrugBank.d658.s0|92-92|;|drug
DDI-DrugBank.d658.s1|0-6|monitor|drug
DDI-DrugBank.d658.s1|8-10|and|drug
DDI-DrugBank.d658.s1|12-17|adjust|drug
DDI-DrugBank.d658.s1|19-31|anticoagulant|drug
DDI-DrugBank.d658.s1|33-38|dosage|drug
DDI-DrugBank.d658.s1|40-50|accordingly|drug
DDI-DrugBank.d658.s1|51-51|.|drug
DDI-DrugBank.d658.s2|0-14|Drug/Laboratory|drug
DDI-DrugBank.d658.s2|16-19|Test|drug
DDI-DrugBank.d658.s2|21-32|Interactions|drug
DDI-DrugBank.d658.s2|33-33|:|drug
DDI-DrugBank.d658.s2|35-45|Physiologic|drug
DDI-DrugBank.d658.s2|47-53|effects|drug
DDI-DrugBank.d658.s2|55-56|of|drug
DDI-DrugBank.d658.s2|58-69|testolactone|drug
DDI-DrugBank.d658.s2|71-73|may|drug
DDI-DrugBank.d658.s2|75-80|result|drug
DDI-DrugBank.d658.s2|82-83|in|drug
DDI-DrugBank.d658.s2|85-93|decreased|drug
DDI-DrugBank.d658.s2|95-103|estradiol|drug
DDI-DrugBank.d658.s2|105-118|concentrations|drug
DDI-DrugBank.d658.s2|120-123|with|drug
DDI-DrugBank.d658.s2|125-141|radioimmunoassays|drug
DDI-DrugBank.d658.s2|143-145|for|drug
DDI-DrugBank.d658.s2|147-155|estradiol|drug
DDI-DrugBank.d658.s2|156-156|,|drug
DDI-DrugBank.d658.s2|158-166|increased|drug
DDI-DrugBank.d658.s2|168-173|plasma|drug
DDI-DrugBank.d658.s2|175-181|calcium|drug
DDI-DrugBank.d658.s2|183-196|concentrations|drug
DDI-DrugBank.d658.s2|197-197|,|drug
DDI-DrugBank.d658.s2|199-201|and|drug
DDI-DrugBank.d658.s2|203-211|increased|drug
DDI-DrugBank.d658.s2|213-219|24-hour|drug
DDI-DrugBank.d658.s2|221-227|urinary|drug
DDI-DrugBank.d658.s2|229-237|excretion|drug
DDI-DrugBank.d658.s2|239-240|of|drug
DDI-DrugBank.d658.s2|242-249|creatine|drug
DDI-DrugBank.d658.s2|251-253|and|drug
DDI-DrugBank.d658.s2|255-269|17-ketosteroids|drug
DDI-DrugBank.d658.s2|270-270|.|drug
DDI-DrugBank.d168.s0|0-3|This|drug
DDI-DrugBank.d168.s0|5-8|drug|drug
DDI-DrugBank.d168.s0|10-12|may|drug
DDI-DrugBank.d168.s0|14-21|interact|drug
DDI-DrugBank.d168.s0|23-26|with|drug
DDI-DrugBank.d168.s0|28-34|alcohol|drug
DDI-DrugBank.d168.s0|36-37|or|drug
DDI-DrugBank.d168.s0|39-43|other|drug
DDI-DrugBank.d168.s0|45-47|CNS|drug
DDI-DrugBank.d168.s0|49-59|depressants|drug
DDI-DrugBank.d168.s0|61-61|(|drug
DDI-DrugBank.d168.s0|62-64|may|drug
DDI-DrugBank.d168.s0|66-75|potentiate|drug
DDI-DrugBank.d168.s0|77-79|the|drug
DDI-DrugBank.d168.s0|81-83|CNS|drug
DDI-DrugBank.d168.s0|85-94|depressant|drug
DDI-DrugBank.d168.s0|96-102|effects|drug
DDI-DrugBank.d168.s0|104-105|of|drug
DDI-DrugBank.d168.s0|107-112|either|drug
DDI-DrugBank.d168.s0|114-118|these|drug
DDI-DrugBank.d168.s0|120-130|medications|drug
DDI-DrugBank.d168.s0|132-133|or|drug
DDI-DrugBank.d168.s0|135-148|antihistamines|drug
DDI-DrugBank.d168.s0|149-149|)|drug
DDI-DrugBank.d168.s0|150-150|,|drug
DDI-DrugBank.d168.s0|152-167|anticholinergics|drug
DDI-DrugBank.d168.s0|169-170|or|drug
DDI-DrugBank.d168.s0|172-176|other|drug
DDI-DrugBank.d168.s0|178-188|medications|drug
DDI-DrugBank.d168.s0|190-193|with|drug
DDI-DrugBank.d168.s0|195-209|anticholinergic|drug
DDI-DrugBank.d168.s0|211-218|activity|drug
DDI-DrugBank.d168.s0|220-220|(|drug
DDI-DrugBank.d168.s0|221-235|anticholinergic|drug
DDI-DrugBank.d168.s0|237-243|effects|drug
DDI-DrugBank.d168.s0|245-247|may|drug
DDI-DrugBank.d168.s0|249-250|be|drug
DDI-DrugBank.d168.s0|252-262|potentiated|drug
DDI-DrugBank.d168.s0|264-267|when|drug
DDI-DrugBank.d168.s0|269-273|these|drug
DDI-DrugBank.d168.s0|275-285|medications|drug
DDI-DrugBank.d168.s0|287-289|are|drug
DDI-DrugBank.d168.s0|291-294|used|drug
DDI-DrugBank.d168.s0|296-307|concurrently|drug
DDI-DrugBank.d168.s0|309-312|with|drug
DDI-DrugBank.d168.s0|314-327|antihistamines|drug
DDI-DrugBank.d168.s0|328-328|)|drug
DDI-DrugBank.d168.s0|329-329|,|drug
DDI-DrugBank.d168.s0|331-333|and|drug
DDI-DrugBank.d168.s0|335-343|monoamine|drug
DDI-DrugBank.d168.s0|345-351|oxidase|drug
DDI-DrugBank.d168.s0|353-353|(|drug
DDI-DrugBank.d168.s0|354-356|MAO|drug
DDI-DrugBank.d168.s0|357-357|)|drug
DDI-DrugBank.d168.s0|359-368|inhibitors|drug
DDI-DrugBank.d168.s0|370-370|(|drug
DDI-DrugBank.d168.s0|371-380|concurrent|drug
DDI-DrugBank.d168.s0|382-384|use|drug
DDI-DrugBank.d168.s0|386-389|with|drug
DDI-DrugBank.d168.s0|391-404|antihistamines|drug
DDI-DrugBank.d168.s0|406-408|may|drug
DDI-DrugBank.d168.s0|410-416|prolong|drug
DDI-DrugBank.d168.s0|418-420|and|drug
DDI-DrugBank.d168.s0|422-430|intensify|drug
DDI-DrugBank.d168.s0|432-434|the|drug
DDI-DrugBank.d168.s0|436-450|anticholinergic|drug
DDI-DrugBank.d168.s0|452-454|and|drug
DDI-DrugBank.d168.s0|456-458|CNS|drug
DDI-DrugBank.d168.s0|460-469|depressant|drug
DDI-DrugBank.d168.s0|471-477|effects|drug
DDI-DrugBank.d168.s0|479-480|of|drug
DDI-DrugBank.d168.s0|482-495|antihistamines|drug
DDI-DrugBank.d168.s0|496-496|)|drug
DDI-DrugBank.d168.s0|497-497|.|drug
DDI-DrugBank.d73.s0|0-22|Catecholamine-depleting|drug
DDI-DrugBank.d73.s0|24-28|drugs|drug
DDI-DrugBank.d73.s0|30-30|(|drug
DDI-DrugBank.d73.s0|31-32|eg|drug
DDI-DrugBank.d73.s0|33-33|,|drug
DDI-DrugBank.d73.s0|35-43|reserpine|drug
DDI-DrugBank.d73.s0|44-44|)|drug
DDI-DrugBank.d73.s0|46-48|may|drug
DDI-DrugBank.d73.s0|50-53|have|drug
DDI-DrugBank.d73.s0|55-56|an|drug
DDI-DrugBank.d73.s0|58-65|additive|drug
DDI-DrugBank.d73.s0|67-72|effect|drug
DDI-DrugBank.d73.s0|74-77|when|drug
DDI-DrugBank.d73.s0|79-83|given|drug
DDI-DrugBank.d73.s0|85-88|with|drug
DDI-DrugBank.d73.s0|90-102|beta-blocking|drug
DDI-DrugBank.d73.s0|104-109|agents|drug
DDI-DrugBank.d73.s0|110-110|.|drug
DDI-DrugBank.d73.s1|0-7|Patients|drug
DDI-DrugBank.d73.s1|9-15|treated|drug
DDI-DrugBank.d73.s1|17-20|with|drug
DDI-DrugBank.d73.s1|22-29|TENORMIN|drug
DDI-DrugBank.d73.s1|31-34|plus|drug
DDI-DrugBank.d73.s1|36-36|a|drug
DDI-DrugBank.d73.s1|38-50|catecholamine|drug
DDI-DrugBank.d73.s1|52-59|depletor|drug
DDI-DrugBank.d73.s1|61-66|should|drug
DDI-DrugBank.d73.s1|68-76|therefore|drug
DDI-DrugBank.d73.s1|78-79|be|drug
DDI-DrugBank.d73.s1|81-87|closely|drug
DDI-DrugBank.d73.s1|89-96|observed|drug
DDI-DrugBank.d73.s1|98-100|for|drug
DDI-DrugBank.d73.s1|102-109|evidence|drug
DDI-DrugBank.d73.s1|111-112|of|drug
DDI-DrugBank.d73.s1|114-124|hypotension|drug
DDI-DrugBank.d73.s1|126-131|and/or|drug
DDI-DrugBank.d73.s1|133-138|marked|drug
DDI-DrugBank.d73.s1|140-150|bradycardia|drug
DDI-DrugBank.d73.s1|152-156|which|drug
DDI-DrugBank.d73.s1|158-160|may|drug
DDI-DrugBank.d73.s1|162-168|produce|drug
DDI-DrugBank.d73.s1|170-176|vertigo|drug
DDI-DrugBank.d73.s1|177-177|,|drug
DDI-DrugBank.d73.s1|179-185|syncope|drug
DDI-DrugBank.d73.s1|186-186|,|drug
DDI-DrugBank.d73.s1|188-189|or|drug
DDI-DrugBank.d73.s1|191-198|postural|drug
DDI-DrugBank.d73.s1|200-210|hypotension|drug
DDI-DrugBank.d73.s1|211-211|.|drug
DDI-DrugBank.d73.s2|0-6|Calcium|brand
DDI-DrugBank.d73.s2|8-14|channel|drug
DDI-DrugBank.d73.s2|16-23|blockers|drug
DDI-DrugBank.d73.s2|25-27|may|drug
DDI-DrugBank.d73.s2|29-32|also|drug
DDI-DrugBank.d73.s2|34-37|have|drug
DDI-DrugBank.d73.s2|39-40|an|drug
DDI-DrugBank.d73.s2|42-49|additive|drug
DDI-DrugBank.d73.s2|51-56|effect|drug
DDI-DrugBank.d73.s2|58-61|when|drug
DDI-DrugBank.d73.s2|63-67|given|drug
DDI-DrugBank.d73.s2|69-72|with|drug
DDI-DrugBank.d73.s2|74-81|TENORMIN|drug
DDI-DrugBank.d73.s2|83-83|.|drug
DDI-DrugBank.d73.s3|0-3|Beta|drug
DDI-DrugBank.d73.s3|5-12|blockers|drug
DDI-DrugBank.d73.s3|14-16|may|drug
DDI-DrugBank.d73.s3|18-27|exacerbate|drug
DDI-DrugBank.d73.s3|29-31|the|drug
DDI-DrugBank.d73.s3|33-39|rebound|drug
DDI-DrugBank.d73.s3|41-52|hypertension|drug
DDI-DrugBank.d73.s3|54-58|which|drug
DDI-DrugBank.d73.s3|60-62|can|drug
DDI-DrugBank.d73.s3|64-69|follow|drug
DDI-DrugBank.d73.s3|71-73|the|drug
DDI-DrugBank.d73.s3|75-84|withdrawal|drug
DDI-DrugBank.d73.s3|86-87|of|drug
DDI-DrugBank.d73.s3|89-97|clonidine|drug
DDI-DrugBank.d73.s3|98-98|.|drug
DDI-DrugBank.d73.s4|0-1|If|drug
DDI-DrugBank.d73.s4|3-5|the|drug
DDI-DrugBank.d73.s4|7-9|two|drug
DDI-DrugBank.d73.s4|11-15|drugs|drug
DDI-DrugBank.d73.s4|17-19|are|drug
DDI-DrugBank.d73.s4|21-34|coadministered|drug
DDI-DrugBank.d73.s4|35-35|,|drug
DDI-DrugBank.d73.s4|37-39|the|drug
DDI-DrugBank.d73.s4|41-44|beta|drug
DDI-DrugBank.d73.s4|46-52|blocker|drug
DDI-DrugBank.d73.s4|54-59|should|drug
DDI-DrugBank.d73.s4|61-62|be|drug
DDI-DrugBank.d73.s4|64-72|withdrawn|drug
DDI-DrugBank.d73.s4|74-80|several|drug
DDI-DrugBank.d73.s4|82-85|days|drug
DDI-DrugBank.d73.s4|87-92|before|drug
DDI-DrugBank.d73.s4|94-96|the|drug
DDI-DrugBank.d73.s4|98-104|gradual|drug
DDI-DrugBank.d73.s4|106-115|withdrawal|drug
DDI-DrugBank.d73.s4|117-118|of|drug
DDI-DrugBank.d73.s4|120-128|clonidine|drug
DDI-DrugBank.d73.s4|129-129|.|drug
DDI-DrugBank.d73.s5|0-1|If|drug
DDI-DrugBank.d73.s5|3-11|replacing|drug
DDI-DrugBank.d73.s5|13-21|clonidine|drug
DDI-DrugBank.d73.s5|23-24|by|drug
DDI-DrugBank.d73.s5|26-37|beta-blocker|drug
DDI-DrugBank.d73.s5|39-45|therapy|drug
DDI-DrugBank.d73.s5|46-46|,|drug
DDI-DrugBank.d73.s5|48-50|the|drug
DDI-DrugBank.d73.s5|52-63|introduction|drug
DDI-DrugBank.d73.s5|65-66|of|drug
DDI-DrugBank.d73.s5|68-71|beta|drug
DDI-DrugBank.d73.s5|73-80|blockers|drug
DDI-DrugBank.d73.s5|82-87|should|drug
DDI-DrugBank.d73.s5|89-90|be|drug
DDI-DrugBank.d73.s5|92-98|delayed|drug
DDI-DrugBank.d73.s5|100-102|for|drug
DDI-DrugBank.d73.s5|104-110|several|drug
DDI-DrugBank.d73.s5|112-115|days|drug
DDI-DrugBank.d73.s5|117-121|after|drug
DDI-DrugBank.d73.s5|123-131|clonidine|drug
DDI-DrugBank.d73.s5|133-146|administration|drug
DDI-DrugBank.d73.s5|148-150|has|drug
DDI-DrugBank.d73.s5|152-158|stopped|drug
DDI-DrugBank.d73.s5|159-159|.|drug
DDI-DrugBank.d73.s6|0-10|Concomitant|drug
DDI-DrugBank.d73.s6|12-14|use|drug
DDI-DrugBank.d73.s6|16-17|of|drug
DDI-DrugBank.d73.s6|19-31|prostaglandin|drug
DDI-DrugBank.d73.s6|33-40|synthase|drug
DDI-DrugBank.d73.s6|42-51|inhibiting|drug
DDI-DrugBank.d73.s6|53-57|drugs|drug
DDI-DrugBank.d73.s6|58-58|,|drug
DDI-DrugBank.d73.s6|60-61|eg|drug
DDI-DrugBank.d73.s6|62-62|,|drug
DDI-DrugBank.d73.s6|64-75|indomethacin|drug
DDI-DrugBank.d73.s6|76-76|,|drug
DDI-DrugBank.d73.s6|78-80|may|drug
DDI-DrugBank.d73.s6|82-89|decrease|drug
DDI-DrugBank.d73.s6|91-93|the|drug
DDI-DrugBank.d73.s6|95-105|hypotensive|drug
DDI-DrugBank.d73.s6|107-113|effects|drug
DDI-DrugBank.d73.s6|115-116|of|drug
DDI-DrugBank.d73.s6|118-121|beta|drug
DDI-DrugBank.d73.s6|123-130|blockers|drug
DDI-DrugBank.d73.s6|131-131|.|drug
DDI-DrugBank.d73.s7|0-10|Information|drug
DDI-DrugBank.d73.s7|12-13|on|drug
DDI-DrugBank.d73.s7|15-24|concurrent|drug
DDI-DrugBank.d73.s7|26-30|usage|drug
DDI-DrugBank.d73.s7|32-33|of|drug
DDI-DrugBank.d73.s7|35-42|atenolol|drug
DDI-DrugBank.d73.s7|44-46|and|drug
DDI-DrugBank.d73.s7|48-54|aspirin|drug
DDI-DrugBank.d73.s7|56-57|is|drug
DDI-DrugBank.d73.s7|59-65|limited|drug
DDI-DrugBank.d73.s7|66-66|.|drug
DDI-DrugBank.d73.s8|0-3|Data|drug
DDI-DrugBank.d73.s8|5-8|from|drug
DDI-DrugBank.d73.s8|10-16|several|drug
DDI-DrugBank.d73.s8|18-24|studies|drug
DDI-DrugBank.d73.s8|25-25|,|drug
DDI-DrugBank.d73.s8|27-28|ie|drug
DDI-DrugBank.d73.s8|29-29|,|drug
DDI-DrugBank.d73.s8|31-37|TIMI-II|drug
DDI-DrugBank.d73.s8|38-38|,|drug
DDI-DrugBank.d73.s8|40-45|ISIS-2|drug
DDI-DrugBank.d73.s8|46-46|,|drug
DDI-DrugBank.d73.s8|48-56|currently|drug
DDI-DrugBank.d73.s8|58-59|do|drug
DDI-DrugBank.d73.s8|61-63|not|drug
DDI-DrugBank.d73.s8|65-71|suggest|drug
DDI-DrugBank.d73.s8|73-75|any|drug
DDI-DrugBank.d73.s8|77-84|clinical|drug
DDI-DrugBank.d73.s8|86-96|interaction|drug
DDI-DrugBank.d73.s8|98-104|between|drug
DDI-DrugBank.d73.s8|106-112|aspirin|drug
DDI-DrugBank.d73.s8|114-116|and|drug
DDI-DrugBank.d73.s8|118-121|beta|drug
DDI-DrugBank.d73.s8|123-130|blockers|drug
DDI-DrugBank.d73.s8|132-133|in|drug
DDI-DrugBank.d73.s8|135-137|the|drug
DDI-DrugBank.d73.s8|139-143|acute|drug
DDI-DrugBank.d73.s8|145-154|myocardial|drug
DDI-DrugBank.d73.s8|156-165|infarction|drug
DDI-DrugBank.d73.s8|167-173|setting|drug
DDI-DrugBank.d73.s8|174-174|.|drug
DDI-DrugBank.d73.s9|0-4|While|drug
DDI-DrugBank.d73.s9|6-11|taking|drug
DDI-DrugBank.d73.s9|13-16|beta|drug
DDI-DrugBank.d73.s9|18-25|blockers|drug
DDI-DrugBank.d73.s9|26-26|,|drug
DDI-DrugBank.d73.s9|28-35|patients|drug
DDI-DrugBank.d73.s9|37-40|with|drug
DDI-DrugBank.d73.s9|42-42|a|drug
DDI-DrugBank.d73.s9|44-50|history|drug
DDI-DrugBank.d73.s9|52-53|of|drug
DDI-DrugBank.d73.s9|55-66|anaphylactic|drug
DDI-DrugBank.d73.s9|68-75|reaction|drug
DDI-DrugBank.d73.s9|77-78|to|drug
DDI-DrugBank.d73.s9|80-80|a|drug
DDI-DrugBank.d73.s9|82-88|variety|drug
DDI-DrugBank.d73.s9|90-91|of|drug
DDI-DrugBank.d73.s9|93-101|allergens|drug
DDI-DrugBank.d73.s9|103-105|may|drug
DDI-DrugBank.d73.s9|107-110|have|drug
DDI-DrugBank.d73.s9|112-112|a|drug
DDI-DrugBank.d73.s9|114-117|more|drug
DDI-DrugBank.d73.s9|119-124|severe|drug
DDI-DrugBank.d73.s9|126-133|reaction|drug
DDI-DrugBank.d73.s9|135-136|on|drug
DDI-DrugBank.d73.s9|138-145|repeated|drug
DDI-DrugBank.d73.s9|147-155|challenge|drug
DDI-DrugBank.d73.s9|156-156|,|drug
DDI-DrugBank.d73.s9|158-163|either|drug
DDI-DrugBank.d73.s9|165-174|accidental|drug
DDI-DrugBank.d73.s9|175-175|,|drug
DDI-DrugBank.d73.s9|177-186|diagnostic|drug
DDI-DrugBank.d73.s9|188-189|or|drug
DDI-DrugBank.d73.s9|191-201|therapeutic|drug
DDI-DrugBank.d73.s9|202-202|.|drug
DDI-DrugBank.d73.s10|0-3|Such|drug
DDI-DrugBank.d73.s10|5-12|patients|drug
DDI-DrugBank.d73.s10|14-16|may|drug
DDI-DrugBank.d73.s10|18-19|be|drug
DDI-DrugBank.d73.s10|21-32|unresponsive|drug
DDI-DrugBank.d73.s10|34-35|to|drug
DDI-DrugBank.d73.s10|37-39|the|drug
DDI-DrugBank.d73.s10|41-45|usual|drug
DDI-DrugBank.d73.s10|47-51|doses|drug
DDI-DrugBank.d73.s10|53-54|of|drug
DDI-DrugBank.d73.s10|56-66|epinephrine|drug
DDI-DrugBank.d73.s10|68-71|used|drug
DDI-DrugBank.d73.s10|73-74|to|drug
DDI-DrugBank.d73.s10|76-80|treat|drug
DDI-DrugBank.d73.s10|82-84|the|drug
DDI-DrugBank.d73.s10|86-93|allergic|drug
DDI-DrugBank.d73.s10|95-102|reaction|drug
DDI-DrugBank.d73.s10|103-103|.|drug
DDI-DrugBank.d640.s0|0-8|Diuretics|group
DDI-DrugBank.d640.s0|9-9|:|drug
DDI-DrugBank.d640.s0|11-19|Excessive|drug
DDI-DrugBank.d640.s0|21-30|reductions|drug
DDI-DrugBank.d640.s0|32-33|in|drug
DDI-DrugBank.d640.s0|35-39|blood|drug
DDI-DrugBank.d640.s0|41-48|pressure|drug
DDI-DrugBank.d640.s0|50-52|may|drug
DDI-DrugBank.d640.s0|54-58|occur|drug
DDI-DrugBank.d640.s0|60-61|in|drug
DDI-DrugBank.d640.s0|63-70|patients|drug
DDI-DrugBank.d640.s0|72-73|on|drug
DDI-DrugBank.d640.s0|75-82|diuretic|drug
DDI-DrugBank.d640.s0|84-90|therapy|drug
DDI-DrugBank.d640.s0|92-95|when|drug
DDI-DrugBank.d640.s0|97-99|ACE|drug
DDI-DrugBank.d640.s0|101-110|inhibitors|drug
DDI-DrugBank.d640.s0|112-114|are|drug
DDI-DrugBank.d640.s0|116-122|started|drug
DDI-DrugBank.d640.s0|123-123|.|drug
DDI-DrugBank.d640.s1|0-2|The|drug
DDI-DrugBank.d640.s1|4-14|possibility|drug
DDI-DrugBank.d640.s1|16-17|of|drug
DDI-DrugBank.d640.s1|19-29|hypotensive|drug
DDI-DrugBank.d640.s1|31-37|effects|drug
DDI-DrugBank.d640.s1|39-42|with|drug
DDI-DrugBank.d640.s1|44-50|UNIVASC|drug
DDI-DrugBank.d640.s1|55-57|can|drug
DDI-DrugBank.d640.s1|59-60|be|drug
DDI-DrugBank.d640.s1|62-70|minimized|drug
DDI-DrugBank.d640.s1|72-73|by|drug
DDI-DrugBank.d640.s1|75-87|discontinuing|drug
DDI-DrugBank.d640.s1|89-96|diuretic|drug
DDI-DrugBank.d640.s1|98-104|therapy|drug
DDI-DrugBank.d640.s1|106-108|for|drug
DDI-DrugBank.d640.s1|110-116|several|drug
DDI-DrugBank.d640.s1|118-121|days|drug
DDI-DrugBank.d640.s1|123-124|or|drug
DDI-DrugBank.d640.s1|126-135|cautiously|drug
DDI-DrugBank.d640.s1|137-146|increasing|drug
DDI-DrugBank.d640.s1|148-151|salt|drug
DDI-DrugBank.d640.s1|153-158|intake|drug
DDI-DrugBank.d640.s1|160-165|before|drug
DDI-DrugBank.d640.s1|167-176|initiation|drug
DDI-DrugBank.d640.s1|178-179|of|drug
DDI-DrugBank.d640.s1|181-189|treatment|drug
DDI-DrugBank.d640.s1|191-194|with|drug
DDI-DrugBank.d640.s1|196-202|UNIVASC|drug
DDI-DrugBank.d640.s1|206-206|.|drug
DDI-DrugBank.d640.s1|208-209|If|drug
DDI-DrugBank.d640.s1|211-214|this|drug
DDI-DrugBank.d640.s1|216-217|is|drug
DDI-DrugBank.d640.s1|219-221|not|drug
DDI-DrugBank.d640.s1|223-230|possible|drug
DDI-DrugBank.d640.s1|231-231|,|drug
DDI-DrugBank.d640.s1|233-235|the|drug
DDI-DrugBank.d640.s1|237-244|starting|drug
DDI-DrugBank.d640.s1|246-249|dose|drug
DDI-DrugBank.d640.s1|251-252|of|drug
DDI-DrugBank.d640.s1|254-261|moexpril|drug
DDI-DrugBank.d640.s1|263-268|should|drug
DDI-DrugBank.d640.s1|270-271|be|drug
DDI-DrugBank.d640.s1|273-281|reduced|drug
DDI-DrugBank.d640.s2|0-8|Potassium|drug
DDI-DrugBank.d640.s2|10-20|Supplements|group
DDI-DrugBank.d640.s2|22-24|and|drug
DDI-DrugBank.d640.s2|26-42|Potassium-Sparing|drug
DDI-DrugBank.d640.s2|44-52|Diuretics|group
DDI-DrugBank.d640.s2|53-53|:|drug
DDI-DrugBank.d640.s2|55-61|UNIVASC|drug
DDI-DrugBank.d640.s2|66-68|can|drug
DDI-DrugBank.d640.s2|70-77|increase|drug
DDI-DrugBank.d640.s2|79-83|serum|drug
DDI-DrugBank.d640.s2|85-93|potassium|drug
DDI-DrugBank.d640.s2|95-101|because|drug
DDI-DrugBank.d640.s2|103-104|it|drug
DDI-DrugBank.d640.s2|106-114|decreases|drug
DDI-DrugBank.d640.s2|116-126|aldosterone|drug
DDI-DrugBank.d640.s2|128-136|secretion|drug
DDI-DrugBank.d640.s2|137-137|.|drug
DDI-DrugBank.d640.s3|0-2|Use|drug
DDI-DrugBank.d640.s3|4-5|of|drug
DDI-DrugBank.d640.s3|7-23|potassium-sparing|drug
DDI-DrugBank.d640.s3|25-33|diuretics|drug
DDI-DrugBank.d640.s3|35-35|(|drug
DDI-DrugBank.d640.s3|36-49|spironolactone|drug
DDI-DrugBank.d640.s3|50-50|,|drug
DDI-DrugBank.d640.s3|52-62|triamterene|drug
DDI-DrugBank.d640.s3|63-63|,|drug
DDI-DrugBank.d640.s3|65-73|amiloride|drug
DDI-DrugBank.d640.s3|74-74|)|drug
DDI-DrugBank.d640.s3|76-77|or|drug
DDI-DrugBank.d640.s3|79-87|potassium|drug
DDI-DrugBank.d640.s3|89-99|supplements|drug
DDI-DrugBank.d640.s3|101-113|concomitantly|drug
DDI-DrugBank.d640.s3|115-118|with|drug
DDI-DrugBank.d640.s3|120-122|ACE|drug
DDI-DrugBank.d640.s3|124-133|inhibitors|drug
DDI-DrugBank.d640.s3|135-137|can|drug
DDI-DrugBank.d640.s3|139-146|increase|drug
DDI-DrugBank.d640.s3|148-150|the|drug
DDI-DrugBank.d640.s3|152-155|risk|drug
DDI-DrugBank.d640.s3|157-158|of|drug
DDI-DrugBank.d640.s3|160-171|hyperkalemia|drug
DDI-DrugBank.d640.s3|172-172|.|drug
DDI-DrugBank.d640.s4|0-8|Therefore|drug
DDI-DrugBank.d640.s4|9-9|,|drug
DDI-DrugBank.d640.s4|11-12|if|drug
DDI-DrugBank.d640.s4|14-24|concomitant|drug
DDI-DrugBank.d640.s4|26-28|use|drug
DDI-DrugBank.d640.s4|30-31|of|drug
DDI-DrugBank.d640.s4|33-36|such|drug
DDI-DrugBank.d640.s4|38-43|agents|drug
DDI-DrugBank.d640.s4|45-46|is|drug
DDI-DrugBank.d640.s4|48-56|indicated|drug
DDI-DrugBank.d640.s4|57-57|,|drug
DDI-DrugBank.d640.s4|59-62|they|drug
DDI-DrugBank.d640.s4|64-69|should|drug
DDI-DrugBank.d640.s4|71-72|be|drug
DDI-DrugBank.d640.s4|74-78|given|drug
DDI-DrugBank.d640.s4|80-83|with|drug
DDI-DrugBank.d640.s4|85-91|caution|drug
DDI-DrugBank.d640.s4|93-95|and|drug
DDI-DrugBank.d640.s4|97-99|the|drug
DDI-DrugBank.d640.s4|101-107|patient|drug
DDI-DrugBank.d640.s4|108-109|'s|drug
DDI-DrugBank.d640.s4|111-115|serum|drug
DDI-DrugBank.d640.s4|117-125|potassium|drug
DDI-DrugBank.d640.s4|127-132|should|drug
DDI-DrugBank.d640.s4|134-135|be|drug
DDI-DrugBank.d640.s4|137-145|monitored|drug
DDI-DrugBank.d640.s4|146-146|.|drug
DDI-DrugBank.d640.s5|0-3|Oral|drug
DDI-DrugBank.d640.s5|5-18|Anticoagulants|group
DDI-DrugBank.d640.s5|19-19|:|drug
DDI-DrugBank.d640.s5|21-31|Interaction|drug
DDI-DrugBank.d640.s5|33-39|studies|drug
DDI-DrugBank.d640.s5|41-44|with|drug
DDI-DrugBank.d640.s5|46-53|warfarin|drug
DDI-DrugBank.d640.s5|55-60|failed|drug
DDI-DrugBank.d640.s5|62-63|to|drug
DDI-DrugBank.d640.s5|65-72|identify|drug
DDI-DrugBank.d640.s5|74-76|any|drug
DDI-DrugBank.d640.s5|78-87|clinically|drug
DDI-DrugBank.d640.s5|89-97|important|drug
DDI-DrugBank.d640.s5|99-104|effect|drug
DDI-DrugBank.d640.s5|106-107|on|drug
DDI-DrugBank.d640.s5|109-111|the|drug
DDI-DrugBank.d640.s5|113-117|serum|drug
DDI-DrugBank.d640.s5|119-132|concentrations|drug
DDI-DrugBank.d640.s5|134-135|of|drug
DDI-DrugBank.d640.s5|137-139|the|drug
DDI-DrugBank.d640.s5|141-153|anticoagulant|drug
DDI-DrugBank.d640.s5|155-156|or|drug
DDI-DrugBank.d640.s5|158-159|on|drug
DDI-DrugBank.d640.s5|161-163|its|drug
DDI-DrugBank.d640.s5|165-177|anticoagulant|drug
DDI-DrugBank.d640.s5|179-184|effect|drug
DDI-DrugBank.d640.s5|185-185|.|drug
DDI-DrugBank.d640.s6|0-6|Lithium|brand
DDI-DrugBank.d640.s6|7-7|:|drug
DDI-DrugBank.d640.s6|9-17|Increased|drug
DDI-DrugBank.d640.s6|19-23|serum|drug
DDI-DrugBank.d640.s6|25-31|lithium|drug
DDI-DrugBank.d640.s6|33-38|levels|drug
DDI-DrugBank.d640.s6|40-42|and|drug
DDI-DrugBank.d640.s6|44-51|symptoms|drug
DDI-DrugBank.d640.s6|53-54|of|drug
DDI-DrugBank.d640.s6|56-62|lithium|drug
DDI-DrugBank.d640.s6|64-71|toxicity|drug
DDI-DrugBank.d640.s6|73-76|have|drug
DDI-DrugBank.d640.s6|78-81|been|drug
DDI-DrugBank.d640.s6|83-90|reported|drug
DDI-DrugBank.d640.s6|92-93|in|drug
DDI-DrugBank.d640.s6|95-102|patients|drug
DDI-DrugBank.d640.s6|104-112|receiving|drug
DDI-DrugBank.d640.s6|114-116|ACE|drug
DDI-DrugBank.d640.s6|118-127|inhibitors|drug
DDI-DrugBank.d640.s6|129-134|during|drug
DDI-DrugBank.d640.s6|136-142|therapy|drug
DDI-DrugBank.d640.s6|144-147|with|drug
DDI-DrugBank.d640.s6|149-155|lithium|drug
DDI-DrugBank.d640.s6|156-156|.|drug
DDI-DrugBank.d640.s7|0-4|These|drug
DDI-DrugBank.d640.s7|6-10|drugs|drug
DDI-DrugBank.d640.s7|12-17|should|drug
DDI-DrugBank.d640.s7|19-20|be|drug
DDI-DrugBank.d640.s7|22-35|coadministered|drug
DDI-DrugBank.d640.s7|37-40|with|drug
DDI-DrugBank.d640.s7|42-48|caution|drug
DDI-DrugBank.d640.s7|49-49|,|drug
DDI-DrugBank.d640.s7|51-53|and|drug
DDI-DrugBank.d640.s7|55-62|frequent|drug
DDI-DrugBank.d640.s7|64-73|monitoring|drug
DDI-DrugBank.d640.s7|75-76|of|drug
DDI-DrugBank.d640.s7|78-82|serum|drug
DDI-DrugBank.d640.s7|84-90|lithium|drug
DDI-DrugBank.d640.s7|92-97|levels|drug
DDI-DrugBank.d640.s7|99-100|is|drug
DDI-DrugBank.d640.s7|102-112|recommended|drug
DDI-DrugBank.d640.s7|113-113|.|drug
DDI-DrugBank.d640.s8|0-1|If|drug
DDI-DrugBank.d640.s8|3-3|a|drug
DDI-DrugBank.d640.s8|5-12|diuretic|drug
DDI-DrugBank.d640.s8|14-15|is|drug
DDI-DrugBank.d640.s8|17-20|also|drug
DDI-DrugBank.d640.s8|22-25|used|drug
DDI-DrugBank.d640.s8|26-26|,|drug
DDI-DrugBank.d640.s8|28-30|the|drug
DDI-DrugBank.d640.s8|32-35|risk|drug
DDI-DrugBank.d640.s8|37-38|of|drug
DDI-DrugBank.d640.s8|40-46|lithium|drug
DDI-DrugBank.d640.s8|48-55|toxicity|drug
DDI-DrugBank.d640.s8|57-59|may|drug
DDI-DrugBank.d640.s8|61-62|be|drug
DDI-DrugBank.d640.s8|64-72|increased|drug
DDI-DrugBank.d640.s8|73-73|.|drug
DDI-DrugBank.d640.s9|0-4|Other|drug
DDI-DrugBank.d640.s9|6-11|Agents|drug
DDI-DrugBank.d640.s9|12-12|:|drug
DDI-DrugBank.d640.s9|14-15|No|drug
DDI-DrugBank.d640.s9|17-26|clinically|drug
DDI-DrugBank.d640.s9|28-36|important|drug
DDI-DrugBank.d640.s9|38-52|pharmacokinetic|drug
DDI-DrugBank.d640.s9|54-65|interactions|drug
DDI-DrugBank.d640.s9|67-74|occurred|drug
DDI-DrugBank.d640.s9|76-79|when|drug
DDI-DrugBank.d640.s9|81-87|UNIVASC|drug
DDI-DrugBank.d640.s9|92-94|was|drug
DDI-DrugBank.d640.s9|96-107|administered|drug
DDI-DrugBank.d640.s9|109-121|concomitantly|drug
DDI-DrugBank.d640.s9|123-126|with|drug
DDI-DrugBank.d640.s9|128-146|hydrochlorothiazide|drug
DDI-DrugBank.d640.s9|147-147|,|drug
DDI-DrugBank.d640.s9|149-155|digoxin|drug
DDI-DrugBank.d640.s9|156-156|,|drug
DDI-DrugBank.d640.s9|158-159|or|drug
DDI-DrugBank.d640.s9|161-170|cimetidine|drug
DDI-DrugBank.d640.s9|171-171|.|drug
DDI-DrugBank.d640.s10|0-6|UNIVASC|drug
DDI-DrugBank.d640.s10|11-13|has|drug
DDI-DrugBank.d640.s10|15-18|been|drug
DDI-DrugBank.d640.s10|20-23|used|drug
DDI-DrugBank.d640.s10|25-26|in|drug
DDI-DrugBank.d640.s10|28-35|clinical|drug
DDI-DrugBank.d640.s10|37-42|trials|drug
DDI-DrugBank.d640.s10|44-56|concomitantly|drug
DDI-DrugBank.d640.s10|58-61|with|drug
DDI-DrugBank.d640.s10|63-86|calcium-channel-blocking|drug
DDI-DrugBank.d640.s10|88-93|agents|drug
DDI-DrugBank.d640.s10|94-94|,|drug
DDI-DrugBank.d640.s10|96-104|diuretics|drug
DDI-DrugBank.d640.s10|105-105|,|drug
DDI-DrugBank.d640.s10|107-108|H2|drug
DDI-DrugBank.d640.s10|110-117|blockers|drug
DDI-DrugBank.d640.s10|118-118|,|drug
DDI-DrugBank.d640.s10|120-126|digoxin|drug
DDI-DrugBank.d640.s10|127-127|,|drug
DDI-DrugBank.d640.s10|129-132|oral|drug
DDI-DrugBank.d640.s10|134-145|hypoglycemic|drug
DDI-DrugBank.d640.s10|147-152|agents|drug
DDI-DrugBank.d640.s10|153-153|,|drug
DDI-DrugBank.d640.s10|155-157|and|drug
DDI-DrugBank.d640.s10|159-178|cholesterol-lowering|drug
DDI-DrugBank.d640.s10|180-185|agents|drug
DDI-DrugBank.d640.s10|186-186|.|drug
DDI-DrugBank.d640.s11|0-4|There|drug
DDI-DrugBank.d640.s11|6-8|was|drug
DDI-DrugBank.d640.s11|10-11|no|drug
DDI-DrugBank.d640.s11|13-20|evidence|drug
DDI-DrugBank.d640.s11|22-23|of|drug
DDI-DrugBank.d640.s11|25-34|clinically|drug
DDI-DrugBank.d640.s11|36-44|important|drug
DDI-DrugBank.d640.s11|46-52|adverse|drug
DDI-DrugBank.d640.s11|54-65|interactions|drug
DDI-DrugBank.d640.s11|66-66|.|drug
DDI-DrugBank.d630.s0|0-12|Methazolamide|brand
DDI-DrugBank.d630.s0|14-19|should|drug
DDI-DrugBank.d630.s0|21-22|be|drug
DDI-DrugBank.d630.s0|24-27|used|drug
DDI-DrugBank.d630.s0|29-32|with|drug
DDI-DrugBank.d630.s0|34-40|caution|drug
DDI-DrugBank.d630.s0|42-43|in|drug
DDI-DrugBank.d630.s0|45-52|patients|drug
DDI-DrugBank.d630.s0|54-55|on|drug
DDI-DrugBank.d630.s0|57-63|steroid|drug
DDI-DrugBank.d630.s0|65-71|therapy|drug
DDI-DrugBank.d630.s0|73-79|because|drug
DDI-DrugBank.d630.s0|81-82|of|drug
DDI-DrugBank.d630.s0|84-86|the|drug
DDI-DrugBank.d630.s0|88-96|potential|drug
DDI-DrugBank.d630.s0|98-100|for|drug
DDI-DrugBank.d630.s0|102-111|developing|drug
DDI-DrugBank.d630.s0|113-123|hypokalemia|drug
DDI-DrugBank.d630.s0|124-124|.|drug
DDI-DrugBank.d630.s1|0-6|Caution|drug
DDI-DrugBank.d630.s1|8-9|is|drug
DDI-DrugBank.d630.s1|11-17|advised|drug
DDI-DrugBank.d630.s1|19-21|for|drug
DDI-DrugBank.d630.s1|23-30|patients|drug
DDI-DrugBank.d630.s1|32-40|receiving|drug
DDI-DrugBank.d630.s1|42-50|high-dose|drug
DDI-DrugBank.d630.s1|52-58|aspirin|drug
DDI-DrugBank.d630.s1|60-62|and|drug
DDI-DrugBank.d630.s1|64-76|methazolamide|drug
DDI-DrugBank.d630.s1|78-90|concomitantly|drug
DDI-DrugBank.d630.s1|91-91|,|drug
DDI-DrugBank.d630.s1|93-94|as|drug
DDI-DrugBank.d630.s1|96-103|anorexia|drug
DDI-DrugBank.d630.s1|104-104|,|drug
DDI-DrugBank.d630.s1|106-114|tachypnea|drug
DDI-DrugBank.d630.s1|115-115|,|drug
DDI-DrugBank.d630.s1|117-124|lethargy|drug
DDI-DrugBank.d630.s1|125-125|,|drug
DDI-DrugBank.d630.s1|127-130|coma|drug
DDI-DrugBank.d630.s1|132-134|and|drug
DDI-DrugBank.d630.s1|136-140|death|drug
DDI-DrugBank.d630.s1|142-145|have|drug
DDI-DrugBank.d630.s1|147-150|been|drug
DDI-DrugBank.d630.s1|152-159|reported|drug
DDI-DrugBank.d630.s1|161-164|with|drug
DDI-DrugBank.d630.s1|166-176|concomitant|drug
DDI-DrugBank.d630.s1|178-180|use|drug
DDI-DrugBank.d630.s1|182-183|of|drug
DDI-DrugBank.d630.s1|185-193|high-dose|drug
DDI-DrugBank.d630.s1|195-201|aspirin|drug
DDI-DrugBank.d630.s1|203-205|and|drug
DDI-DrugBank.d630.s1|207-214|carbonic|drug
DDI-DrugBank.d630.s1|216-224|anhydrase|drug
DDI-DrugBank.d630.s1|226-235|inhibitors|drug
DDI-DrugBank.d630.s1|236-236|.|drug
DDI-MedLine.d164.s0|0-8|Lapatinib|drug
DDI-MedLine.d164.s0|10-17|enhances|drug
DDI-MedLine.d164.s0|19-36|herceptin-mediated|drug
DDI-MedLine.d164.s0|38-55|antibody-dependent|drug
DDI-MedLine.d164.s0|57-64|cellular|drug
DDI-MedLine.d164.s0|66-77|cytotoxicity|drug
DDI-MedLine.d164.s0|79-80|by|drug
DDI-MedLine.d164.s0|82-94|up-regulation|drug
DDI-MedLine.d164.s0|96-97|of|drug
DDI-MedLine.d164.s0|99-102|cell|drug
DDI-MedLine.d164.s0|104-110|surface|drug
DDI-MedLine.d164.s0|112-115|HER2|drug
DDI-MedLine.d164.s0|117-126|expression|drug
DDI-MedLine.d164.s0|127-127|.|drug
DDI-MedLine.d164.s1|0-7|Although|drug
DDI-MedLine.d164.s1|9-10|it|drug
DDI-MedLine.d164.s1|12-14|was|drug
DDI-MedLine.d164.s1|16-25|previously|drug
DDI-MedLine.d164.s1|27-34|reported|drug
DDI-MedLine.d164.s1|36-39|that|drug
DDI-MedLine.d164.s1|41-49|lapatinib|drug
DDI-MedLine.d164.s1|51-58|combined|drug
DDI-MedLine.d164.s1|60-63|with|drug
DDI-MedLine.d164.s1|65-73|Herceptin|brand
DDI-MedLine.d164.s1|75-82|improved|drug
DDI-MedLine.d164.s1|84-86|the|drug
DDI-MedLine.d164.s1|88-103|progression-free|drug
DDI-MedLine.d164.s1|105-112|survival|drug
DDI-MedLine.d164.s1|114-117|rate|drug
DDI-MedLine.d164.s1|119-126|compared|drug
DDI-MedLine.d164.s1|128-131|with|drug
DDI-MedLine.d164.s1|133-141|lapatinib|drug
DDI-MedLine.d164.s1|143-147|alone|drug
DDI-MedLine.d164.s1|149-151|for|drug
DDI-MedLine.d164.s1|153-160|patients|drug
DDI-MedLine.d164.s1|162-165|with|drug
DDI-MedLine.d164.s1|167-186|Herceptin-refractory|drug
DDI-MedLine.d164.s1|188-200|HER2-positive|drug
DDI-MedLine.d164.s1|202-211|metastatic|drug
DDI-MedLine.d164.s1|213-218|breast|drug
DDI-MedLine.d164.s1|220-225|cancer|drug
DDI-MedLine.d164.s1|226-226|,|drug
DDI-MedLine.d164.s1|228-230|the|drug
DDI-MedLine.d164.s1|232-240|mechanism|drug
DDI-MedLine.d164.s1|242-243|is|drug
DDI-MedLine.d164.s1|245-253|purported|drug
DDI-MedLine.d164.s1|255-256|to|drug
DDI-MedLine.d164.s1|258-259|be|drug
DDI-MedLine.d164.s1|261-262|an|drug
DDI-MedLine.d164.s1|264-280|antiproliferative|drug
DDI-MedLine.d164.s1|282-287|effect|drug
DDI-MedLine.d164.s1|289-296|relating|drug
DDI-MedLine.d164.s1|298-299|to|drug
DDI-MedLine.d164.s1|301-303|the|drug
DDI-MedLine.d164.s1|305-313|synergism|drug
DDI-MedLine.d164.s1|315-316|of|drug
DDI-MedLine.d164.s1|318-322|these|drug
DDI-MedLine.d164.s1|324-326|two|drug
DDI-MedLine.d164.s1|328-333|agents|drug
DDI-MedLine.d164.s1|334-334|.|drug
DDI-MedLine.d164.s2|0-1|We|drug
DDI-MedLine.d164.s2|3-11|evaluated|drug
DDI-MedLine.d164.s2|13-15|how|drug
DDI-MedLine.d164.s2|17-25|lapatinib|drug
DDI-MedLine.d164.s2|27-35|interacts|drug
DDI-MedLine.d164.s2|37-40|with|drug
DDI-MedLine.d164.s2|42-50|Herceptin|brand
DDI-MedLine.d164.s2|52-53|in|drug
DDI-MedLine.d164.s2|55-67|HER2-positive|drug
DDI-MedLine.d164.s2|69-74|breast|drug
DDI-MedLine.d164.s2|76-81|cancer|drug
DDI-MedLine.d164.s2|82-82|,|drug
DDI-MedLine.d164.s2|84-87|with|drug
DDI-MedLine.d164.s2|89-89|a|drug
DDI-MedLine.d164.s2|91-100|particular|drug
DDI-MedLine.d164.s2|102-106|focus|drug
DDI-MedLine.d164.s2|108-109|on|drug
DDI-MedLine.d164.s2|111-128|Herceptin-mediated|drug
DDI-MedLine.d164.s2|130-147|antibody-dependent|drug
DDI-MedLine.d164.s2|149-156|cellular|drug
DDI-MedLine.d164.s2|158-169|cytotoxicity|drug
DDI-MedLine.d164.s2|171-171|(|drug
DDI-MedLine.d164.s2|172-175|ADCC|drug
DDI-MedLine.d164.s2|176-176|)|drug
DDI-MedLine.d164.s2|177-177|.|drug
DDI-MedLine.d164.s3|0-1|In|drug
DDI-MedLine.d164.s3|3-4|an|drug
DDI-MedLine.d164.s3|6-7|in|drug
DDI-MedLine.d164.s3|9-13|vitro|drug
DDI-MedLine.d164.s3|15-19|assay|drug
DDI-MedLine.d164.s3|20-20|,|drug
DDI-MedLine.d164.s3|22-30|lapatinib|drug
DDI-MedLine.d164.s3|32-38|induced|drug
DDI-MedLine.d164.s3|40-43|HER2|drug
DDI-MedLine.d164.s3|45-54|expression|drug
DDI-MedLine.d164.s3|56-57|at|drug
DDI-MedLine.d164.s3|59-61|the|drug
DDI-MedLine.d164.s3|63-66|cell|drug
DDI-MedLine.d164.s3|68-74|surface|drug
DDI-MedLine.d164.s3|76-77|of|drug
DDI-MedLine.d164.s3|79-91|HER2-positive|drug
DDI-MedLine.d164.s3|93-98|breast|drug
DDI-MedLine.d164.s3|100-105|cancer|drug
DDI-MedLine.d164.s3|107-110|cell|drug
DDI-MedLine.d164.s3|112-116|lines|drug
DDI-MedLine.d164.s3|117-117|,|drug
DDI-MedLine.d164.s3|119-125|leading|drug
DDI-MedLine.d164.s3|127-128|to|drug
DDI-MedLine.d164.s3|130-132|the|drug
DDI-MedLine.d164.s3|134-144|enhancement|drug
DDI-MedLine.d164.s3|146-147|of|drug
DDI-MedLine.d164.s3|149-166|Herceptin-mediated|drug
DDI-MedLine.d164.s3|168-171|ADCC|drug
DDI-MedLine.d164.s3|172-172|.|drug
DDI-MedLine.d164.s4|0-10|Furthermore|drug
DDI-MedLine.d164.s4|11-11|,|drug
DDI-MedLine.d164.s4|13-14|we|drug
DDI-MedLine.d164.s4|16-22|present|drug
DDI-MedLine.d164.s4|24-24|a|drug
DDI-MedLine.d164.s4|26-29|case|drug
DDI-MedLine.d164.s4|31-36|report|drug
DDI-MedLine.d164.s4|38-39|in|drug
DDI-MedLine.d164.s4|41-45|which|drug
DDI-MedLine.d164.s4|47-47|a|drug
DDI-MedLine.d164.s4|49-54|second|drug
DDI-MedLine.d164.s4|56-64|Herceptin|brand
DDI-MedLine.d164.s4|66-74|treatment|drug
DDI-MedLine.d164.s4|76-84|following|drug
DDI-MedLine.d164.s4|86-94|lapatinib|drug
DDI-MedLine.d164.s4|96-103|resulted|drug
DDI-MedLine.d164.s4|105-106|in|drug
DDI-MedLine.d164.s4|108-110|the|drug
DDI-MedLine.d164.s4|112-117|marked|drug
DDI-MedLine.d164.s4|119-127|shrinkage|drug
DDI-MedLine.d164.s4|129-130|of|drug
DDI-MedLine.d164.s4|132-139|multiple|drug
DDI-MedLine.d164.s4|141-150|metastatic|drug
DDI-MedLine.d164.s4|152-157|tumors|drug
DDI-MedLine.d164.s4|159-160|in|drug
DDI-MedLine.d164.s4|162-174|HER2-positive|drug
DDI-MedLine.d164.s4|176-181|breast|drug
DDI-MedLine.d164.s4|183-188|cancer|drug
DDI-MedLine.d164.s4|189-189|.|drug
DDI-MedLine.d164.s5|0-8|Lapatinib|drug
DDI-MedLine.d164.s5|10-12|may|drug
DDI-MedLine.d164.s5|14-17|have|drug
DDI-MedLine.d164.s5|19-21|the|drug
DDI-MedLine.d164.s5|23-31|potential|drug
DDI-MedLine.d164.s5|33-34|to|drug
DDI-MedLine.d164.s5|36-42|convert|drug
DDI-MedLine.d164.s5|44-63|Herceptin-refractory|drug
DDI-MedLine.d164.s5|65-66|to|drug
DDI-MedLine.d164.s5|68-86|Herceptin-sensitive|drug
DDI-MedLine.d164.s5|88-93|tumors|drug
DDI-MedLine.d164.s5|95-96|in|drug
DDI-MedLine.d164.s5|98-110|HER2-positive|drug
DDI-MedLine.d164.s5|112-117|breast|drug
DDI-MedLine.d164.s5|119-124|cancer|drug
DDI-MedLine.d164.s5|126-127|by|drug
DDI-MedLine.d164.s5|129-141|up-regulation|drug
DDI-MedLine.d164.s5|143-144|of|drug
DDI-MedLine.d164.s5|146-148|the|drug
DDI-MedLine.d164.s5|150-153|cell|drug
DDI-MedLine.d164.s5|155-161|surface|drug
DDI-MedLine.d164.s5|163-172|expression|drug
DDI-MedLine.d164.s5|174-175|of|drug
DDI-MedLine.d164.s5|177-180|HER2|drug
DDI-MedLine.d164.s5|181-181|.|drug
DDI-DrugBank.d179.s0|0-10|Interations|drug
DDI-DrugBank.d179.s1|0-12|Sulfapyridine|drug
DDI-DrugBank.d179.s1|14-16|may|drug
DDI-DrugBank.d179.s1|18-25|interact|drug
DDI-DrugBank.d179.s1|27-30|with|drug
DDI-DrugBank.d179.s1|32-34|any|drug
DDI-DrugBank.d179.s1|36-37|of|drug
DDI-DrugBank.d179.s1|39-41|the|drug
DDI-DrugBank.d179.s1|43-51|following|drug
DDI-DrugBank.d179.s1|52-52|:|drug
DDI-DrugBank.d179.s1|54-54|-|drug
DDI-DrugBank.d179.s1|56-68|Acetaminophen|brand
DDI-DrugBank.d179.s1|70-70|(|drug
DDI-DrugBank.d179.s1|71-74|e.g.|drug
DDI-DrugBank.d179.s1|75-75|,|drug
DDI-DrugBank.d179.s1|77-83|Tylenol|brand
DDI-DrugBank.d179.s1|84-84|)|drug
DDI-DrugBank.d179.s1|86-86|(|drug
DDI-DrugBank.d179.s1|87-90|with|drug
DDI-DrugBank.d179.s1|92-100|long-term|drug
DDI-DrugBank.d179.s1|101-101|,|drug
DDI-DrugBank.d179.s1|103-111|high-dose|drug
DDI-DrugBank.d179.s1|113-115|use|drug
DDI-DrugBank.d179.s1|116-116|)|drug
DDI-DrugBank.d179.s1|118-119|or|drug
DDI-DrugBank.d179.s2|0-0|-|drug
DDI-DrugBank.d179.s2|2-11|Amiodarone|brand
DDI-DrugBank.d179.s2|13-13|(|drug
DDI-DrugBank.d179.s2|14-17|e.g.|drug
DDI-DrugBank.d179.s2|18-18|,|drug
DDI-DrugBank.d179.s2|20-28|Cordarone|brand
DDI-DrugBank.d179.s2|29-29|)|drug
DDI-DrugBank.d179.s2|31-32|or|drug
DDI-DrugBank.d179.s3|0-0|-|drug
DDI-DrugBank.d179.s3|2-9|Anabolic|drug
DDI-DrugBank.d179.s3|11-18|steroids|drug
DDI-DrugBank.d179.s3|20-20|(|drug
DDI-DrugBank.d179.s3|21-30|nandrolone|drug
DDI-DrugBank.d179.s3|32-32|[|drug
DDI-DrugBank.d179.s3|33-36|e.g.|drug
DDI-DrugBank.d179.s3|37-37|,|drug
DDI-DrugBank.d179.s3|39-46|Anabolin|drug
DDI-DrugBank.d179.s3|47-47|]|drug
DDI-DrugBank.d179.s3|48-48|,|drug
DDI-DrugBank.d179.s3|50-60|oxandrolone|drug
DDI-DrugBank.d179.s3|62-62|[|drug
DDI-DrugBank.d179.s3|63-66|e.g.|drug
DDI-DrugBank.d179.s3|67-67|,|drug
DDI-DrugBank.d179.s3|69-74|Anavar|drug
DDI-DrugBank.d179.s3|75-75|]|drug
DDI-DrugBank.d179.s3|76-76|,|drug
DDI-DrugBank.d179.s3|78-89|oxymetholone|drug
DDI-DrugBank.d179.s3|91-91|[|drug
DDI-DrugBank.d179.s3|92-95|e.g.|drug
DDI-DrugBank.d179.s3|96-96|,|drug
DDI-DrugBank.d179.s3|98-104|Anadrol|brand
DDI-DrugBank.d179.s3|105-105|]|drug
DDI-DrugBank.d179.s3|106-106|,|drug
DDI-DrugBank.d179.s3|108-117|stanozolol|drug
DDI-DrugBank.d179.s3|119-119|[|drug
DDI-DrugBank.d179.s3|120-123|e.g.|drug
DDI-DrugBank.d179.s3|124-124|,|drug
DDI-DrugBank.d179.s3|126-133|Winstrol|drug
DDI-DrugBank.d179.s3|134-134|]|drug
DDI-DrugBank.d179.s3|135-135|)|drug
DDI-DrugBank.d179.s3|137-138|or|drug
DDI-DrugBank.d179.s4|0-0|-|drug
DDI-DrugBank.d179.s4|2-10|Androgens|group
DDI-DrugBank.d179.s4|12-12|(|drug
DDI-DrugBank.d179.s4|13-16|male|drug
DDI-DrugBank.d179.s4|18-25|hormones|drug
DDI-DrugBank.d179.s4|26-26|)|drug
DDI-DrugBank.d179.s4|28-29|or|drug
DDI-DrugBank.d179.s5|0-0|-|drug
DDI-DrugBank.d179.s5|2-12|Antithyroid|drug
DDI-DrugBank.d179.s5|14-19|agents|drug
DDI-DrugBank.d179.s5|21-21|(|drug
DDI-DrugBank.d179.s5|22-29|medicine|drug
DDI-DrugBank.d179.s5|31-33|for|drug
DDI-DrugBank.d179.s5|35-44|overactive|drug
DDI-DrugBank.d179.s5|46-52|thyroid|drug
DDI-DrugBank.d179.s5|53-53|)|drug
DDI-DrugBank.d179.s5|55-56|or|drug
DDI-DrugBank.d179.s6|0-0|-|drug
DDI-DrugBank.d179.s6|2-14|Carbamazepine|brand
DDI-DrugBank.d179.s6|16-16|(|drug
DDI-DrugBank.d179.s6|17-20|e.g.|drug
DDI-DrugBank.d179.s6|21-21|,|drug
DDI-DrugBank.d179.s6|23-30|Tegretol|brand
DDI-DrugBank.d179.s6|31-31|)|drug
DDI-DrugBank.d179.s6|33-34|or|drug
DDI-DrugBank.d179.s7|0-0|-|drug
DDI-DrugBank.d179.s7|2-11|Carmustine|brand
DDI-DrugBank.d179.s7|13-13|(|drug
DDI-DrugBank.d179.s7|14-17|e.g.|drug
DDI-DrugBank.d179.s7|18-18|,|drug
DDI-DrugBank.d179.s7|20-24|BiCNU|brand
DDI-DrugBank.d179.s7|25-25|)|drug
DDI-DrugBank.d179.s7|27-28|or|drug
DDI-DrugBank.d179.s8|0-0|-|drug
DDI-DrugBank.d179.s8|2-12|Chloroquine|brand
DDI-DrugBank.d179.s8|14-14|(|drug
DDI-DrugBank.d179.s8|15-18|e.g.|drug
DDI-DrugBank.d179.s8|19-19|,|drug
DDI-DrugBank.d179.s8|21-26|Aralen|brand
DDI-DrugBank.d179.s8|27-27|)|drug
DDI-DrugBank.d179.s8|29-30|or|drug
DDI-DrugBank.d179.s9|0-0|-|drug
DDI-DrugBank.d179.s9|2-11|Dantrolene|brand
DDI-DrugBank.d179.s9|13-13|(|drug
DDI-DrugBank.d179.s9|14-17|e.g.|drug
DDI-DrugBank.d179.s9|18-18|,|drug
DDI-DrugBank.d179.s9|20-27|Dantrium|brand
DDI-DrugBank.d179.s9|28-28|)|drug
DDI-DrugBank.d179.s9|30-31|or|drug
DDI-DrugBank.d179.s10|0-0|-|drug
DDI-DrugBank.d179.s10|2-13|Daunorubicin|drug
DDI-DrugBank.d179.s10|15-15|(|drug
DDI-DrugBank.d179.s10|16-19|e.g.|drug
DDI-DrugBank.d179.s10|20-20|,|drug
DDI-DrugBank.d179.s10|22-31|Cerubidine|brand
DDI-DrugBank.d179.s10|32-32|)|drug
DDI-DrugBank.d179.s10|34-35|or|drug
DDI-DrugBank.d179.s11|0-0|-|drug
DDI-DrugBank.d179.s11|2-11|Disulfiram|brand
DDI-DrugBank.d179.s11|13-13|(|drug
DDI-DrugBank.d179.s11|14-17|e.g.|drug
DDI-DrugBank.d179.s11|18-18|,|drug
DDI-DrugBank.d179.s11|20-27|Antabuse|brand
DDI-DrugBank.d179.s11|28-28|)|drug
DDI-DrugBank.d179.s11|30-31|or|drug
DDI-DrugBank.d179.s12|0-0|-|drug
DDI-DrugBank.d179.s12|2-11|Divalproex|brand
DDI-DrugBank.d179.s12|13-13|(|drug
DDI-DrugBank.d179.s12|14-17|e.g.|drug
DDI-DrugBank.d179.s12|18-18|,|drug
DDI-DrugBank.d179.s12|20-27|Depakote|brand
DDI-DrugBank.d179.s12|28-28|)|drug
DDI-DrugBank.d179.s12|30-31|or|drug
DDI-DrugBank.d179.s13|0-0|-|drug
DDI-DrugBank.d179.s13|2-10|Estrogens|group
DDI-DrugBank.d179.s13|12-12|(|drug
DDI-DrugBank.d179.s13|13-18|female|drug
DDI-DrugBank.d179.s13|20-27|hormones|drug
DDI-DrugBank.d179.s13|28-28|)|drug
DDI-DrugBank.d179.s13|30-31|or|drug
DDI-DrugBank.d179.s14|0-0|-|drug
DDI-DrugBank.d179.s14|2-11|Etretinate|drug
DDI-DrugBank.d179.s14|13-13|(|drug
DDI-DrugBank.d179.s14|14-17|e.g.|drug
DDI-DrugBank.d179.s14|18-18|,|drug
DDI-DrugBank.d179.s14|20-26|Tegison|drug
DDI-DrugBank.d179.s14|27-27|)|drug
DDI-DrugBank.d179.s14|29-30|or|drug
DDI-DrugBank.d179.s15|0-0|-|drug
DDI-DrugBank.d179.s15|2-5|Gold|drug
DDI-DrugBank.d179.s15|7-11|salts|drug
DDI-DrugBank.d179.s15|13-13|(|drug
DDI-DrugBank.d179.s15|14-21|medicine|drug
DDI-DrugBank.d179.s15|23-25|for|drug
DDI-DrugBank.d179.s15|27-35|arthritis|drug
DDI-DrugBank.d179.s15|36-36|)|drug
DDI-DrugBank.d179.s15|38-39|or|drug
DDI-DrugBank.d179.s16|0-0|-|drug
DDI-DrugBank.d179.s16|2-19|Hydroxychloroquine|drug
DDI-DrugBank.d179.s16|21-21|(|drug
DDI-DrugBank.d179.s16|22-25|e.g.|drug
DDI-DrugBank.d179.s16|26-26|,|drug
DDI-DrugBank.d179.s16|28-36|Plaquenil|brand
DDI-DrugBank.d179.s16|37-37|)|drug
DDI-DrugBank.d179.s16|39-40|or|drug
DDI-DrugBank.d179.s17|0-0|-|drug
DDI-DrugBank.d179.s17|2-15|Mercaptopurine|brand
DDI-DrugBank.d179.s17|17-17|(|drug
DDI-DrugBank.d179.s17|18-21|e.g.|drug
DDI-DrugBank.d179.s17|22-22|,|drug
DDI-DrugBank.d179.s17|24-33|Purinethol|brand
DDI-DrugBank.d179.s17|34-34|)|drug
DDI-DrugBank.d179.s17|36-37|or|drug
DDI-DrugBank.d179.s18|0-0|-|drug
DDI-DrugBank.d179.s18|2-11|Naltrexone|brand
DDI-DrugBank.d179.s18|13-13|(|drug
DDI-DrugBank.d179.s18|14-17|e.g.|drug
DDI-DrugBank.d179.s18|18-18|,|drug
DDI-DrugBank.d179.s18|20-25|Trexan|drug
DDI-DrugBank.d179.s18|26-26|)|drug
DDI-DrugBank.d179.s18|28-28|(|drug
DDI-DrugBank.d179.s18|29-32|with|drug
DDI-DrugBank.d179.s18|34-42|long-term|drug
DDI-DrugBank.d179.s18|43-43|,|drug
DDI-DrugBank.d179.s18|45-53|high-dose|drug
DDI-DrugBank.d179.s18|55-57|use|drug
DDI-DrugBank.d179.s18|58-58|)|drug
DDI-DrugBank.d179.s18|60-61|or|drug
DDI-DrugBank.d179.s19|0-0|-|drug
DDI-DrugBank.d179.s19|2-5|Oral|drug
DDI-DrugBank.d179.s19|7-20|contraceptives|drug
DDI-DrugBank.d179.s19|22-22|(|drug
DDI-DrugBank.d179.s19|23-27|birth|drug
DDI-DrugBank.d179.s19|29-35|control|drug
DDI-DrugBank.d179.s19|37-41|pills|drug
DDI-DrugBank.d179.s19|42-42|)|drug
DDI-DrugBank.d179.s19|44-53|containing|drug
DDI-DrugBank.d179.s19|55-62|estrogen|drug
DDI-DrugBank.d179.s19|64-65|or|drug
DDI-DrugBank.d179.s20|0-0|-|drug
DDI-DrugBank.d179.s20|2-6|Other|drug
DDI-DrugBank.d179.s20|8-22|anti-infectives|drug
DDI-DrugBank.d179.s20|24-25|by|drug
DDI-DrugBank.d179.s20|27-31|mouth|drug
DDI-DrugBank.d179.s20|33-34|or|drug
DDI-DrugBank.d179.s20|36-37|by|drug
DDI-DrugBank.d179.s20|39-47|injection|drug
DDI-DrugBank.d179.s20|49-49|(|drug
DDI-DrugBank.d179.s20|50-57|medicine|drug
DDI-DrugBank.d179.s20|59-61|for|drug
DDI-DrugBank.d179.s20|63-71|infection|drug
DDI-DrugBank.d179.s20|72-72|)|drug
DDI-DrugBank.d179.s20|74-75|or|drug
DDI-DrugBank.d179.s21|0-0|-|drug
DDI-DrugBank.d179.s21|2-15|Phenothiazines|group
DDI-DrugBank.d179.s21|17-17|(|drug
DDI-DrugBank.d179.s21|18-31|acetophenazine|drug
DDI-DrugBank.d179.s21|33-33|[|drug
DDI-DrugBank.d179.s21|34-37|e.g.|drug
DDI-DrugBank.d179.s21|38-38|,|drug
DDI-DrugBank.d179.s21|40-45|Tindal|drug
DDI-DrugBank.d179.s21|46-46|]|drug
DDI-DrugBank.d179.s21|47-47|,|drug
DDI-DrugBank.d179.s21|49-62|chlorpromazine|drug
DDI-DrugBank.d179.s21|64-64|[|drug
DDI-DrugBank.d179.s21|65-68|e.g.|drug
DDI-DrugBank.d179.s21|69-69|,|drug
DDI-DrugBank.d179.s21|71-79|Thorazine|brand
DDI-DrugBank.d179.s21|80-80|]|drug
DDI-DrugBank.d179.s21|81-81|,|drug
DDI-DrugBank.d179.s21|83-94|fluphenazine|drug
DDI-DrugBank.d179.s21|96-96|[|drug
DDI-DrugBank.d179.s21|97-100|e.g.|drug
DDI-DrugBank.d179.s21|101-101|,|drug
DDI-DrugBank.d179.s21|103-110|Prolixin|brand
DDI-DrugBank.d179.s21|111-111|]|drug
DDI-DrugBank.d179.s21|112-112|,|drug
DDI-DrugBank.d179.s21|114-125|mesoridazine|drug
DDI-DrugBank.d179.s21|127-127|[|drug
DDI-DrugBank.d179.s21|128-131|e.g.|drug
DDI-DrugBank.d179.s21|132-132|,|drug
DDI-DrugBank.d179.s21|134-141|Serentil|brand
DDI-DrugBank.d179.s21|142-142|]|drug
DDI-DrugBank.d179.s21|143-143|,|drug
DDI-DrugBank.d179.s21|145-156|perphenazine|drug
DDI-DrugBank.d179.s21|158-158|[|drug
DDI-DrugBank.d179.s21|159-162|e.g.|drug
DDI-DrugBank.d179.s21|163-163|,|drug
DDI-DrugBank.d179.s21|165-172|Trilafon|drug
DDI-DrugBank.d179.s21|173-173|]|drug
DDI-DrugBank.d179.s21|174-174|,|drug
DDI-DrugBank.d179.s21|176-191|prochlorperazine|drug
DDI-DrugBank.d179.s21|193-193|[|drug
DDI-DrugBank.d179.s21|194-197|e.g.|drug
DDI-DrugBank.d179.s21|198-198|,|drug
DDI-DrugBank.d179.s21|200-208|Compazine|brand
DDI-DrugBank.d179.s21|209-209|]|drug
DDI-DrugBank.d179.s21|210-210|,|drug
DDI-DrugBank.d179.s21|212-220|promazine|drug
DDI-DrugBank.d179.s21|222-222|[|drug
DDI-DrugBank.d179.s21|223-226|e.g.|drug
DDI-DrugBank.d179.s21|227-227|,|drug
DDI-DrugBank.d179.s21|229-235|Sparine|drug
DDI-DrugBank.d179.s21|236-236|]|drug
DDI-DrugBank.d179.s21|237-237|,|drug
DDI-DrugBank.d179.s21|239-250|promethazine|drug
DDI-DrugBank.d179.s21|252-252|[|drug
DDI-DrugBank.d179.s21|253-256|e.g.|drug
DDI-DrugBank.d179.s21|257-257|,|drug
DDI-DrugBank.d179.s21|259-267|Phenergan|brand
DDI-DrugBank.d179.s21|268-268|]|drug
DDI-DrugBank.d179.s21|269-269|,|drug
DDI-DrugBank.d179.s21|271-282|thioridazine|drug
DDI-DrugBank.d179.s21|284-284|[|drug
DDI-DrugBank.d179.s21|285-288|e.g.|drug
DDI-DrugBank.d179.s21|289-289|,|drug
DDI-DrugBank.d179.s21|291-298|Mellaril|brand
DDI-DrugBank.d179.s21|299-299|]|drug
DDI-DrugBank.d179.s21|300-300|,|drug
DDI-DrugBank.d179.s21|302-316|trifluoperazine|drug
DDI-DrugBank.d179.s21|318-318|[|drug
DDI-DrugBank.d179.s21|319-322|e.g.|drug
DDI-DrugBank.d179.s21|323-323|,|drug
DDI-DrugBank.d179.s21|325-333|Stelazine|drug
DDI-DrugBank.d179.s21|334-334|]|drug
DDI-DrugBank.d179.s21|335-335|,|drug
DDI-DrugBank.d179.s21|337-351|triflupromazine|drug
DDI-DrugBank.d179.s21|353-353|[|drug
DDI-DrugBank.d179.s21|354-357|e.g.|drug
DDI-DrugBank.d179.s21|358-358|,|drug
DDI-DrugBank.d179.s21|360-366|Vesprin|drug
DDI-DrugBank.d179.s21|367-367|]|drug
DDI-DrugBank.d179.s21|368-368|,|drug
DDI-DrugBank.d179.s21|370-381|trimeprazine|drug
DDI-DrugBank.d179.s21|383-383|[|drug
DDI-DrugBank.d179.s21|384-387|e.g.|drug
DDI-DrugBank.d179.s21|388-388|,|drug
DDI-DrugBank.d179.s21|390-396|Temaril|drug
DDI-DrugBank.d179.s21|397-397|]|drug
DDI-DrugBank.d179.s21|398-398|)|drug
DDI-DrugBank.d179.s21|400-401|or|drug
DDI-DrugBank.d179.s22|0-0|-|drug
DDI-DrugBank.d179.s22|2-11|Plicamycin|drug
DDI-DrugBank.d179.s22|13-13|(|drug
DDI-DrugBank.d179.s22|14-17|e.g.|drug
DDI-DrugBank.d179.s22|18-18|,|drug
DDI-DrugBank.d179.s22|20-28|Mithracin|drug
DDI-DrugBank.d179.s22|29-29|)|drug
DDI-DrugBank.d179.s22|31-32|or|drug
DDI-DrugBank.d179.s23|0-0|-|drug
DDI-DrugBank.d179.s23|2-9|Valproic|brand
DDI-DrugBank.d179.s23|11-14|acid|drug
DDI-DrugBank.d179.s23|16-16|(|drug
DDI-DrugBank.d179.s23|17-20|e.g.|drug
DDI-DrugBank.d179.s23|21-21|,|drug
DDI-DrugBank.d179.s23|23-30|Depakene|brand
DDI-DrugBank.d179.s23|31-31|)|drug
DDI-DrugBank.d179.s23|33-35|Use|drug
DDI-DrugBank.d179.s23|37-38|of|drug
DDI-DrugBank.d179.s23|40-52|sulfapyridine|drug
DDI-DrugBank.d179.s23|54-57|with|drug
DDI-DrugBank.d179.s23|59-63|these|drug
DDI-DrugBank.d179.s23|65-73|medicines|drug
DDI-DrugBank.d179.s23|75-77|may|drug
DDI-DrugBank.d179.s23|79-86|increase|drug
DDI-DrugBank.d179.s23|88-90|the|drug
DDI-DrugBank.d179.s23|92-97|chance|drug
DDI-DrugBank.d179.s23|99-100|of|drug
DDI-DrugBank.d179.s23|102-105|side|drug
DDI-DrugBank.d179.s23|107-113|effects|drug
DDI-DrugBank.d179.s23|115-123|affecting|drug
DDI-DrugBank.d179.s23|125-127|the|drug
DDI-DrugBank.d179.s23|129-133|liver|drug
DDI-DrugBank.d179.s24|0-0|-|drug
DDI-DrugBank.d179.s24|2-16|Acetohydroxamic|drug
DDI-DrugBank.d179.s24|18-21|acid|drug
DDI-DrugBank.d179.s24|23-23|(|drug
DDI-DrugBank.d179.s24|24-27|e.g.|drug
DDI-DrugBank.d179.s24|28-28|,|drug
DDI-DrugBank.d179.s24|30-38|Lithostat|brand
DDI-DrugBank.d179.s24|39-39|)|drug
DDI-DrugBank.d179.s24|41-42|or|drug
DDI-DrugBank.d179.s25|0-0|-|drug
DDI-DrugBank.d179.s25|2-8|Dapsone|brand
DDI-DrugBank.d179.s25|10-11|or|drug
DDI-DrugBank.d179.s26|0-0|-|drug
DDI-DrugBank.d179.s26|2-13|Furazolidone|drug
DDI-DrugBank.d179.s26|15-15|(|drug
DDI-DrugBank.d179.s26|16-19|e.g.|drug
DDI-DrugBank.d179.s26|20-20|,|drug
DDI-DrugBank.d179.s26|22-29|Furoxone|drug
DDI-DrugBank.d179.s26|30-30|)|drug
DDI-DrugBank.d179.s26|32-33|or|drug
DDI-DrugBank.d179.s27|0-0|-|drug
DDI-DrugBank.d179.s27|2-15|Nitrofurantoin|brand
DDI-DrugBank.d179.s27|17-17|(|drug
DDI-DrugBank.d179.s27|18-21|e.g.|drug
DDI-DrugBank.d179.s27|22-22|,|drug
DDI-DrugBank.d179.s27|24-33|Furadantin|brand
DDI-DrugBank.d179.s27|34-34|)|drug
DDI-DrugBank.d179.s27|36-37|or|drug
DDI-DrugBank.d179.s28|0-0|-|drug
DDI-DrugBank.d179.s28|2-11|Primaquine|brand
DDI-DrugBank.d179.s28|13-14|or|drug
DDI-DrugBank.d179.s29|0-0|-|drug
DDI-DrugBank.d179.s29|2-13|Procainamide|drug
DDI-DrugBank.d179.s29|15-15|(|drug
DDI-DrugBank.d179.s29|16-19|e.g.|drug
DDI-DrugBank.d179.s29|20-20|,|drug
DDI-DrugBank.d179.s29|22-30|Pronestyl|brand
DDI-DrugBank.d179.s29|31-31|)|drug
DDI-DrugBank.d179.s29|33-34|or|drug
DDI-DrugBank.d179.s30|0-0|-|drug
DDI-DrugBank.d179.s30|2-10|Quinidine|drug
DDI-DrugBank.d179.s30|12-12|(|drug
DDI-DrugBank.d179.s30|13-16|e.g.|drug
DDI-DrugBank.d179.s30|17-17|,|drug
DDI-DrugBank.d179.s30|19-26|Quinidex|drug
DDI-DrugBank.d179.s30|27-27|)|drug
DDI-DrugBank.d179.s30|29-30|or|drug
DDI-DrugBank.d179.s31|0-0|-|drug
DDI-DrugBank.d179.s31|2-8|Quinine|drug
DDI-DrugBank.d179.s31|10-10|(|drug
DDI-DrugBank.d179.s31|11-14|e.g.|drug
DDI-DrugBank.d179.s31|15-15|,|drug
DDI-DrugBank.d179.s31|17-23|Quinamm|drug
DDI-DrugBank.d179.s31|24-24|)|drug
DDI-DrugBank.d179.s31|26-27|or|drug
DDI-DrugBank.d179.s32|0-0|-|drug
DDI-DrugBank.d179.s32|2-10|Sulfoxone|drug
DDI-DrugBank.d179.s32|12-12|(|drug
DDI-DrugBank.d179.s32|13-16|e.g.|drug
DDI-DrugBank.d179.s32|17-17|,|drug
DDI-DrugBank.d179.s32|19-25|Diasone|drug
DDI-DrugBank.d179.s32|26-26|)|drug
DDI-DrugBank.d179.s32|28-29|or|drug
DDI-DrugBank.d179.s33|0-0|-|drug
DDI-DrugBank.d179.s33|2-8|Vitamin|drug
DDI-DrugBank.d179.s33|10-10|K|drug
DDI-DrugBank.d179.s33|12-12|(|drug
DDI-DrugBank.d179.s33|13-16|e.g.|drug
DDI-DrugBank.d179.s33|17-17|,|drug
DDI-DrugBank.d179.s33|19-30|AquaMEPHYTON|brand
DDI-DrugBank.d179.s33|31-31|,|drug
DDI-DrugBank.d179.s33|33-42|Synkayvite|drug
DDI-DrugBank.d179.s33|43-43|)|drug
DDI-DrugBank.d179.s33|45-47|Use|drug
DDI-DrugBank.d179.s33|49-50|of|drug
DDI-DrugBank.d179.s33|52-64|sulfapyridine|drug
DDI-DrugBank.d179.s33|66-69|with|drug
DDI-DrugBank.d179.s33|71-75|these|drug
DDI-DrugBank.d179.s33|77-85|medicines|drug
DDI-DrugBank.d179.s33|87-89|may|drug
DDI-DrugBank.d179.s33|91-98|increase|drug
DDI-DrugBank.d179.s33|100-102|the|drug
DDI-DrugBank.d179.s33|104-109|chance|drug
DDI-DrugBank.d179.s33|111-112|of|drug
DDI-DrugBank.d179.s33|114-117|side|drug
DDI-DrugBank.d179.s33|119-125|effects|drug
DDI-DrugBank.d179.s33|127-135|affecting|drug
DDI-DrugBank.d179.s33|137-139|the|drug
DDI-DrugBank.d179.s33|141-145|blood|drug
DDI-DrugBank.d179.s34|0-0|-|drug
DDI-DrugBank.d179.s34|2-15|Anticoagulants|group
DDI-DrugBank.d179.s34|17-17|(|drug
DDI-DrugBank.d179.s34|18-22|blood|drug
DDI-DrugBank.d179.s34|24-31|thinners|drug
DDI-DrugBank.d179.s34|32-32|)|drug
DDI-DrugBank.d179.s34|34-35|or|drug
DDI-DrugBank.d179.s35|0-0|-|drug
DDI-DrugBank.d179.s35|2-9|Ethotoin|drug
DDI-DrugBank.d179.s35|11-11|(|drug
DDI-DrugBank.d179.s35|12-15|e.g.|drug
DDI-DrugBank.d179.s35|16-16|,|drug
DDI-DrugBank.d179.s35|18-25|Peganone|brand
DDI-DrugBank.d179.s35|26-26|)|drug
DDI-DrugBank.d179.s35|28-29|or|drug
DDI-DrugBank.d179.s36|0-0|-|drug
DDI-DrugBank.d179.s36|2-12|Mephenytoin|drug
DDI-DrugBank.d179.s36|14-14|(|drug
DDI-DrugBank.d179.s36|15-18|e.g.|drug
DDI-DrugBank.d179.s36|19-19|,|drug
DDI-DrugBank.d179.s36|21-29|Mesantoin|brand
DDI-DrugBank.d179.s36|30-30|)|drug
DDI-DrugBank.d179.s36|32-34|Use|drug
DDI-DrugBank.d179.s36|36-37|of|drug
DDI-DrugBank.d179.s36|39-51|sulfapyridine|drug
DDI-DrugBank.d179.s36|53-56|with|drug
DDI-DrugBank.d179.s36|58-62|these|drug
DDI-DrugBank.d179.s36|64-72|medicines|drug
DDI-DrugBank.d179.s36|74-76|may|drug
DDI-DrugBank.d179.s36|78-85|increase|drug
DDI-DrugBank.d179.s36|87-89|the|drug
DDI-DrugBank.d179.s36|91-96|chance|drug
DDI-DrugBank.d179.s36|98-99|of|drug
DDI-DrugBank.d179.s36|101-104|side|drug
DDI-DrugBank.d179.s36|106-112|effects|drug
DDI-DrugBank.d179.s36|114-115|of|drug
DDI-DrugBank.d179.s36|117-121|these|drug
DDI-DrugBank.d179.s36|123-131|medicines|drug
DDI-DrugBank.d179.s37|0-0|-|drug
DDI-DrugBank.d179.s37|2-14|Antidiabetics|drug
DDI-DrugBank.d179.s37|15-15|,|drug
DDI-DrugBank.d179.s37|17-20|oral|drug
DDI-DrugBank.d179.s37|22-22|(|drug
DDI-DrugBank.d179.s37|23-30|diabetes|drug
DDI-DrugBank.d179.s37|32-39|medicine|drug
DDI-DrugBank.d179.s37|41-43|you|drug
DDI-DrugBank.d179.s37|45-48|take|drug
DDI-DrugBank.d179.s37|50-51|by|drug
DDI-DrugBank.d179.s37|53-57|mouth|drug
DDI-DrugBank.d179.s37|58-58|)|drug
DDI-DrugBank.d179.s37|60-62|Use|drug
DDI-DrugBank.d179.s37|64-65|of|drug
DDI-DrugBank.d179.s37|67-70|oral|drug
DDI-DrugBank.d179.s37|72-84|antidiabetics|drug
DDI-DrugBank.d179.s37|86-89|with|drug
DDI-DrugBank.d179.s37|91-103|sulfapyridine|drug
DDI-DrugBank.d179.s37|105-107|may|drug
DDI-DrugBank.d179.s37|109-116|increase|drug
DDI-DrugBank.d179.s37|118-120|the|drug
DDI-DrugBank.d179.s37|122-127|chance|drug
DDI-DrugBank.d179.s37|129-130|of|drug
DDI-DrugBank.d179.s37|132-135|side|drug
DDI-DrugBank.d179.s37|137-143|effects|drug
DDI-DrugBank.d179.s37|145-153|affecting|drug
DDI-DrugBank.d179.s37|155-157|the|drug
DDI-DrugBank.d179.s37|159-163|blood|drug
DDI-DrugBank.d179.s37|165-170|and/or|drug
DDI-DrugBank.d179.s37|172-174|the|drug
DDI-DrugBank.d179.s37|176-179|side|drug
DDI-DrugBank.d179.s37|181-187|effects|drug
DDI-DrugBank.d179.s37|189-190|or|drug
DDI-DrugBank.d179.s37|192-195|oral|drug
DDI-DrugBank.d179.s37|197-209|antidiabetics|drug
DDI-DrugBank.d179.s38|0-0|-|drug
DDI-DrugBank.d179.s38|2-13|Methotrexate|brand
DDI-DrugBank.d179.s38|15-15|(|drug
DDI-DrugBank.d179.s38|16-19|e.g.|drug
DDI-DrugBank.d179.s38|20-20|,|drug
DDI-DrugBank.d179.s38|22-27|Mexate|drug
DDI-DrugBank.d179.s38|28-28|)|drug
DDI-DrugBank.d179.s38|30-32|Use|drug
DDI-DrugBank.d179.s38|34-35|of|drug
DDI-DrugBank.d179.s38|37-48|methotrexate|drug
DDI-DrugBank.d179.s38|50-53|with|drug
DDI-DrugBank.d179.s38|55-67|sulfapyridine|drug
DDI-DrugBank.d179.s38|69-71|may|drug
DDI-DrugBank.d179.s38|73-80|increase|drug
DDI-DrugBank.d179.s38|82-84|the|drug
DDI-DrugBank.d179.s38|86-91|chance|drug
DDI-DrugBank.d179.s38|93-94|of|drug
DDI-DrugBank.d179.s38|96-99|side|drug
DDI-DrugBank.d179.s38|101-107|effects|drug
DDI-DrugBank.d179.s38|109-117|affecting|drug
DDI-DrugBank.d179.s38|119-121|the|drug
DDI-DrugBank.d179.s38|123-127|liver|drug
DDI-DrugBank.d179.s38|129-134|and/or|drug
DDI-DrugBank.d179.s38|136-138|the|drug
DDI-DrugBank.d179.s38|140-143|side|drug
DDI-DrugBank.d179.s38|145-151|effects|drug
DDI-DrugBank.d179.s38|153-154|of|drug
DDI-DrugBank.d179.s38|156-167|methotrexate|drug
DDI-DrugBank.d179.s39|0-0|-|drug
DDI-DrugBank.d179.s39|2-11|Methyldopa|brand
DDI-DrugBank.d179.s39|13-13|(|drug
DDI-DrugBank.d179.s39|14-17|e.g.|drug
DDI-DrugBank.d179.s39|18-18|,|drug
DDI-DrugBank.d179.s39|20-26|Aldomet|drug
DDI-DrugBank.d179.s39|27-27|)|drug
DDI-DrugBank.d179.s39|29-31|Use|drug
DDI-DrugBank.d179.s39|33-34|of|drug
DDI-DrugBank.d179.s39|36-45|methyldopa|drug
DDI-DrugBank.d179.s39|47-50|with|drug
DDI-DrugBank.d179.s39|52-64|sulfapyridine|drug
DDI-DrugBank.d179.s39|66-68|may|drug
DDI-DrugBank.d179.s39|70-77|increase|drug
DDI-DrugBank.d179.s39|79-81|the|drug
DDI-DrugBank.d179.s39|83-88|chance|drug
DDI-DrugBank.d179.s39|90-91|of|drug
DDI-DrugBank.d179.s39|93-96|side|drug
DDI-DrugBank.d179.s39|98-104|effects|drug
DDI-DrugBank.d179.s39|106-114|affecting|drug
DDI-DrugBank.d179.s39|116-118|the|drug
DDI-DrugBank.d179.s39|120-124|liver|drug
DDI-DrugBank.d179.s39|126-131|and/or|drug
DDI-DrugBank.d179.s39|133-135|the|drug
DDI-DrugBank.d179.s39|137-141|blood|drug
DDI-DrugBank.d179.s40|0-0|-|drug
DDI-DrugBank.d179.s40|2-10|Phenytoin|brand
DDI-DrugBank.d179.s40|12-12|(|drug
DDI-DrugBank.d179.s40|13-16|e.g.|drug
DDI-DrugBank.d179.s40|17-17|,|drug
DDI-DrugBank.d179.s40|19-26|Dilantin|brand
DDI-DrugBank.d179.s40|27-27|)|drug
DDI-DrugBank.d179.s40|29-31|Use|drug
DDI-DrugBank.d179.s40|33-34|of|drug
DDI-DrugBank.d179.s40|36-44|phenytoin|drug
DDI-DrugBank.d179.s40|46-49|with|drug
DDI-DrugBank.d179.s40|51-63|sulfapyridine|drug
DDI-DrugBank.d179.s40|65-67|may|drug
DDI-DrugBank.d179.s40|69-76|increase|drug
DDI-DrugBank.d179.s40|78-80|the|drug
DDI-DrugBank.d179.s40|82-87|chance|drug
DDI-DrugBank.d179.s40|89-90|of|drug
DDI-DrugBank.d179.s40|92-95|side|drug
DDI-DrugBank.d179.s40|97-103|effects|drug
DDI-DrugBank.d179.s40|105-113|affecting|drug
DDI-DrugBank.d179.s40|115-117|the|drug
DDI-DrugBank.d179.s40|119-123|liver|drug
DDI-DrugBank.d179.s40|125-130|and/or|drug
DDI-DrugBank.d179.s40|132-134|the|drug
DDI-DrugBank.d179.s40|136-139|side|drug
DDI-DrugBank.d179.s40|141-147|effects|drug
DDI-DrugBank.d179.s40|149-150|of|drug
DDI-DrugBank.d179.s40|152-160|phenytoin|drug
DDI-MedLine.d159.s0|0-9|Protective|drug
DDI-MedLine.d159.s0|11-16|effect|drug
DDI-MedLine.d159.s0|18-19|of|drug
DDI-MedLine.d159.s0|21-38|acetyl-l-carnitine|drug
DDI-MedLine.d159.s0|40-42|and|drug
DDI-MedLine.d159.s0|45-49|alpha|drug
DDI-MedLine.d159.s0|51-56|lipoic|drug
DDI-MedLine.d159.s0|58-61|acid|drug
DDI-MedLine.d159.s0|63-69|against|drug
DDI-MedLine.d159.s0|71-73|the|drug
DDI-MedLine.d159.s0|75-79|acute|drug
DDI-MedLine.d159.s0|81-88|toxicity|drug
DDI-MedLine.d159.s0|90-91|of|drug
DDI-MedLine.d159.s0|93-105|diepoxybutane|drug
DDI-MedLine.d159.s0|107-108|to|drug
DDI-MedLine.d159.s0|110-114|human|drug
DDI-MedLine.d159.s0|116-126|lymphocytes|drug
DDI-MedLine.d159.s0|127-127|.|drug
DDI-MedLine.d159.s1|0-2|The|drug
DDI-MedLine.d159.s1|4-20|biotransformation|drug
DDI-MedLine.d159.s1|22-24|and|drug
DDI-MedLine.d159.s1|26-34|oxidative|drug
DDI-MedLine.d159.s1|36-41|stress|drug
DDI-MedLine.d159.s1|43-45|may|drug
DDI-MedLine.d159.s1|47-56|contribute|drug
DDI-MedLine.d159.s1|58-59|to|drug
DDI-MedLine.d159.s1|61-81|1,2:3,4-diepoxybutane|drug
DDI-MedLine.d159.s1|83-83|(|drug
DDI-MedLine.d159.s1|84-86|DEB|drug
DDI-MedLine.d159.s1|87-87|)|drug
DDI-MedLine.d159.s1|88-95|-induced|drug
DDI-MedLine.d159.s1|97-104|toxicity|drug
DDI-MedLine.d159.s1|106-107|to|drug
DDI-MedLine.d159.s1|109-113|human|drug
DDI-MedLine.d159.s1|115-125|lymphocytes|drug
DDI-MedLine.d159.s1|127-128|of|drug
DDI-MedLine.d159.s1|130-136|Fanconi|drug
DDI-MedLine.d159.s1|138-143|Anemia|drug
DDI-MedLine.d159.s1|145-145|(|drug
DDI-MedLine.d159.s1|146-147|FA|drug
DDI-MedLine.d159.s1|148-148|)|drug
DDI-MedLine.d159.s1|150-157|patients|drug
DDI-MedLine.d159.s1|158-158|.|drug
DDI-MedLine.d159.s2|0-3|Thus|drug
DDI-MedLine.d159.s2|4-4|,|drug
DDI-MedLine.d159.s2|6-8|the|drug
DDI-MedLine.d159.s2|10-23|identification|drug
DDI-MedLine.d159.s2|25-26|of|drug
DDI-MedLine.d159.s2|28-35|putative|drug
DDI-MedLine.d159.s2|37-46|inhibitors|drug
DDI-MedLine.d159.s2|48-49|of|drug
DDI-MedLine.d159.s2|51-63|bioactivation|drug
DDI-MedLine.d159.s2|64-64|,|drug
DDI-MedLine.d159.s2|66-67|as|drug
DDI-MedLine.d159.s2|69-72|well|drug
DDI-MedLine.d159.s2|74-75|as|drug
DDI-MedLine.d159.s2|77-79|the|drug
DDI-MedLine.d159.s2|81-93|determination|drug
DDI-MedLine.d159.s2|95-96|of|drug
DDI-MedLine.d159.s2|98-100|the|drug
DDI-MedLine.d159.s2|102-111|protective|drug
DDI-MedLine.d159.s2|113-116|role|drug
DDI-MedLine.d159.s2|118-119|of|drug
DDI-MedLine.d159.s2|121-127|oxidant|drug
DDI-MedLine.d159.s2|129-136|defenses|drug
DDI-MedLine.d159.s2|137-137|,|drug
DDI-MedLine.d159.s2|139-140|on|drug
DDI-MedLine.d159.s2|142-152|DEB-induced|drug
DDI-MedLine.d159.s2|154-161|toxicity|drug
DDI-MedLine.d159.s2|162-162|,|drug
DDI-MedLine.d159.s2|164-166|can|drug
DDI-MedLine.d159.s2|168-171|help|drug
DDI-MedLine.d159.s2|173-174|to|drug
DDI-MedLine.d159.s2|176-185|understand|drug
DDI-MedLine.d159.s2|187-190|what|drug
DDI-MedLine.d159.s2|192-193|is|drug
DDI-MedLine.d159.s2|195-201|failing|drug
DDI-MedLine.d159.s2|203-204|in|drug
DDI-MedLine.d159.s2|206-207|FA|drug
DDI-MedLine.d159.s2|209-213|cells|drug
DDI-MedLine.d159.s2|214-214|.|drug
DDI-MedLine.d159.s3|0-1|In|drug
DDI-MedLine.d159.s3|3-5|the|drug
DDI-MedLine.d159.s3|7-13|present|drug
DDI-MedLine.d159.s3|15-18|work|drug
DDI-MedLine.d159.s3|20-21|we|drug
DDI-MedLine.d159.s3|23-29|studied|drug
DDI-MedLine.d159.s3|31-33|the|drug
DDI-MedLine.d159.s3|35-46|contribution|drug
DDI-MedLine.d159.s3|48-49|of|drug
DDI-MedLine.d159.s3|51-57|several|drug
DDI-MedLine.d159.s3|59-69|biochemical|drug
DDI-MedLine.d159.s3|71-78|pathways|drug
DDI-MedLine.d159.s3|80-82|for|drug
DDI-MedLine.d159.s3|84-94|DEB-induced|drug
DDI-MedLine.d159.s3|96-100|acute|drug
DDI-MedLine.d159.s3|102-109|toxicity|drug
DDI-MedLine.d159.s3|111-112|in|drug
DDI-MedLine.d159.s3|114-118|human|drug
DDI-MedLine.d159.s3|120-129|lymphocyte|drug
DDI-MedLine.d159.s3|131-141|suspensions|drug
DDI-MedLine.d159.s3|142-142|,|drug
DDI-MedLine.d159.s3|144-145|by|drug
DDI-MedLine.d159.s3|147-151|using|drug
DDI-MedLine.d159.s3|153-162|inhibitors|drug
DDI-MedLine.d159.s3|164-165|of|drug
DDI-MedLine.d159.s3|167-173|epoxide|drug
DDI-MedLine.d159.s3|175-184|hydrolases|drug
DDI-MedLine.d159.s3|185-185|,|drug
DDI-MedLine.d159.s3|187-196|inhibitors|drug
DDI-MedLine.d159.s3|198-199|of|drug
DDI-MedLine.d159.s3|201-210|protective|drug
DDI-MedLine.d159.s3|212-218|enzymes|drug
DDI-MedLine.d159.s3|220-221|as|drug
DDI-MedLine.d159.s3|223-233|glutathione|drug
DDI-MedLine.d159.s3|235-247|S-transferase|drug
DDI-MedLine.d159.s3|249-251|and|drug
DDI-MedLine.d159.s3|253-260|catalase|drug
DDI-MedLine.d159.s3|261-261|,|drug
DDI-MedLine.d159.s3|263-265|the|drug
DDI-MedLine.d159.s3|267-275|depletion|drug
DDI-MedLine.d159.s3|277-278|of|drug
DDI-MedLine.d159.s3|280-290|glutathione|drug
DDI-MedLine.d159.s3|292-292|(|drug
DDI-MedLine.d159.s3|293-295|GSH|drug
DDI-MedLine.d159.s3|296-296|)|drug
DDI-MedLine.d159.s3|297-297|,|drug
DDI-MedLine.d159.s3|299-301|and|drug
DDI-MedLine.d159.s3|303-305|the|drug
DDI-MedLine.d159.s3|307-316|inhibition|drug
DDI-MedLine.d159.s3|318-319|of|drug
DDI-MedLine.d159.s3|321-327|protein|drug
DDI-MedLine.d159.s3|329-337|synthesis|drug
DDI-MedLine.d159.s3|338-338|;|drug
DDI-MedLine.d159.s4|0-2|and|drug
DDI-MedLine.d159.s4|4-4|a|drug
DDI-MedLine.d159.s4|6-12|variety|drug
DDI-MedLine.d159.s4|14-15|of|drug
DDI-MedLine.d159.s4|17-24|putative|drug
DDI-MedLine.d159.s4|26-35|protective|drug
DDI-MedLine.d159.s4|37-45|compounds|drug
DDI-MedLine.d159.s4|46-46|,|drug
DDI-MedLine.d159.s4|48-56|including|drug
DDI-MedLine.d159.s4|58-69|antioxidants|drug
DDI-MedLine.d159.s4|70-70|,|drug
DDI-MedLine.d159.s4|72-74|and|drug
DDI-MedLine.d159.s4|76-88|mitochondrial|drug
DDI-MedLine.d159.s4|90-99|protective|drug
DDI-MedLine.d159.s4|101-106|agents|drug
DDI-MedLine.d159.s4|107-107|.|drug
DDI-MedLine.d159.s5|0-2|The|drug
DDI-MedLine.d159.s5|4-10|present|drug
DDI-MedLine.d159.s5|12-16|study|drug
DDI-MedLine.d159.s5|18-24|reports|drug
DDI-MedLine.d159.s5|26-28|two|drug
DDI-MedLine.d159.s5|30-34|novel|drug
DDI-MedLine.d159.s5|36-43|findings|drug
DDI-MedLine.d159.s5|44-44|:|drug
DDI-MedLine.d159.s5|46-46|(|drug
DDI-MedLine.d159.s5|47-47|i|drug
DDI-MedLine.d159.s5|48-48|)|drug
DDI-MedLine.d159.s5|50-51|it|drug
DDI-MedLine.d159.s5|53-55|was|drug
DDI-MedLine.d159.s5|57-63|clearly|drug
DDI-MedLine.d159.s5|65-73|evidenced|drug
DDI-MedLine.d159.s5|74-74|,|drug
DDI-MedLine.d159.s5|76-78|for|drug
DDI-MedLine.d159.s5|80-82|the|drug
DDI-MedLine.d159.s5|84-88|first|drug
DDI-MedLine.d159.s5|90-93|time|drug
DDI-MedLine.d159.s5|94-94|,|drug
DDI-MedLine.d159.s5|96-99|that|drug
DDI-MedLine.d159.s5|101-103|the|drug
DDI-MedLine.d159.s5|105-109|acute|drug
DDI-MedLine.d159.s5|111-118|exposure|drug
DDI-MedLine.d159.s5|120-121|of|drug
DDI-MedLine.d159.s5|123-129|freshly|drug
DDI-MedLine.d159.s5|131-138|isolated|drug
DDI-MedLine.d159.s5|140-144|human|drug
DDI-MedLine.d159.s5|146-156|lymphocytes|drug
DDI-MedLine.d159.s5|158-159|to|drug
DDI-MedLine.d159.s5|161-163|DEB|drug
DDI-MedLine.d159.s5|165-171|results|drug
DDI-MedLine.d159.s5|173-174|in|drug
DDI-MedLine.d159.s5|176-181|severe|drug
DDI-MedLine.d159.s5|183-185|GSH|drug
DDI-MedLine.d159.s5|187-195|depletion|drug
DDI-MedLine.d159.s5|197-199|and|drug
DDI-MedLine.d159.s5|201-204|loss|drug
DDI-MedLine.d159.s5|206-207|of|drug
DDI-MedLine.d159.s5|209-211|ATP|drug
DDI-MedLine.d159.s5|212-212|,|drug
DDI-MedLine.d159.s5|214-221|followed|drug
DDI-MedLine.d159.s5|223-224|by|drug
DDI-MedLine.d159.s5|226-229|cell|drug
DDI-MedLine.d159.s5|231-235|death|drug
DDI-MedLine.d159.s5|236-236|;|drug
DDI-MedLine.d159.s6|0-0|(|drug
DDI-MedLine.d159.s6|1-2|ii|drug
DDI-MedLine.d159.s6|3-3|)|drug
DDI-MedLine.d159.s6|5-22|acetyl-l-carnitine|drug
DDI-MedLine.d159.s6|24-30|elicits|drug
DDI-MedLine.d159.s6|32-32|a|drug
DDI-MedLine.d159.s6|34-44|significant|drug
DDI-MedLine.d159.s6|46-55|protective|drug
DDI-MedLine.d159.s6|57-62|effect|drug
DDI-MedLine.d159.s6|64-65|on|drug
DDI-MedLine.d159.s6|67-69|DEB|drug
DDI-MedLine.d159.s6|71-77|induced|drug
DDI-MedLine.d159.s6|79-86|toxicity|drug
DDI-MedLine.d159.s6|87-87|,|drug
DDI-MedLine.d159.s6|89-93|which|drug
DDI-MedLine.d159.s6|95-97|was|drug
DDI-MedLine.d159.s6|99-109|potentiated|drug
DDI-MedLine.d159.s6|111-112|by|drug
DDI-MedLine.d159.s6|115-126|alpha-lipoic|drug
DDI-MedLine.d159.s6|128-131|acid|drug
DDI-MedLine.d159.s6|132-132|.|drug
DDI-MedLine.d159.s7|0-11|Collectively|drug
DDI-MedLine.d159.s7|12-12|,|drug
DDI-MedLine.d159.s7|14-18|these|drug
DDI-MedLine.d159.s7|20-27|findings|drug
DDI-MedLine.d159.s7|29-38|contribute|drug
DDI-MedLine.d159.s7|40-41|to|drug
DDI-MedLine.d159.s7|43-50|increase|drug
DDI-MedLine.d159.s7|52-54|our|drug
DDI-MedLine.d159.s7|56-64|knowledge|drug
DDI-MedLine.d159.s7|66-67|of|drug
DDI-MedLine.d159.s7|69-78|DEB-induce|drug
DDI-MedLine.d159.s7|80-87|toxicity|drug
DDI-MedLine.d159.s7|89-91|and|drug
DDI-MedLine.d159.s7|93-96|will|drug
DDI-MedLine.d159.s7|98-99|be|drug
DDI-MedLine.d159.s7|101-104|very|drug
DDI-MedLine.d159.s7|106-111|useful|drug
DDI-MedLine.d159.s7|113-116|when|drug
DDI-MedLine.d159.s7|118-124|applied|drug
DDI-MedLine.d159.s7|126-127|in|drug
DDI-MedLine.d159.s7|129-135|studies|drug
DDI-MedLine.d159.s7|137-140|with|drug
DDI-MedLine.d159.s7|142-152|lymphocytes|drug
DDI-MedLine.d159.s7|154-157|from|drug
DDI-MedLine.d159.s7|159-160|FA|drug
DDI-MedLine.d159.s7|162-169|patients|drug
DDI-MedLine.d159.s7|170-170|,|drug
DDI-MedLine.d159.s7|172-173|in|drug
DDI-MedLine.d159.s7|175-179|order|drug
DDI-MedLine.d159.s7|181-182|to|drug
DDI-MedLine.d159.s7|184-187|find|drug
DDI-MedLine.d159.s7|189-191|out|drug
DDI-MedLine.d159.s7|193-193|a|drug
DDI-MedLine.d159.s7|195-204|protective|drug
DDI-MedLine.d159.s7|206-210|agent|drug
DDI-MedLine.d159.s7|212-218|against|drug
DDI-MedLine.d159.s7|220-230|spontaneous|drug
DDI-MedLine.d159.s7|232-234|and|drug
DDI-MedLine.d159.s7|236-246|DEB-induced|drug
DDI-MedLine.d159.s7|248-257|chromosome|drug
DDI-MedLine.d159.s7|259-269|instability|drug
DDI-MedLine.d159.s7|270-270|.|drug
DDI-DrugBank.d339.s0|0-12|Carbamazepine|brand
DDI-DrugBank.d339.s0|13-13|:|drug
DDI-DrugBank.d339.s0|15-22|Elevated|drug
DDI-DrugBank.d339.s0|24-36|carbamazepine|drug
DDI-DrugBank.d339.s0|38-43|levels|drug
DDI-DrugBank.d339.s0|45-48|have|drug
DDI-DrugBank.d339.s0|50-53|been|drug
DDI-DrugBank.d339.s0|55-62|reported|drug
DDI-DrugBank.d339.s0|64-65|in|drug
DDI-DrugBank.d339.s0|67-79|postmarketing|drug
DDI-DrugBank.d339.s0|81-90|experience|drug
DDI-DrugBank.d339.s0|92-95|when|drug
DDI-DrugBank.d339.s0|97-102|SUPRAX|drug
DDI-DrugBank.d339.s0|104-105|is|drug
DDI-DrugBank.d339.s0|107-118|administered|drug
DDI-DrugBank.d339.s0|120-132|concomitantly|drug
DDI-DrugBank.d339.s0|133-133|.|drug
DDI-DrugBank.d339.s1|0-3|Drug|drug
DDI-DrugBank.d339.s1|5-14|monitoring|drug
DDI-DrugBank.d339.s1|16-18|may|drug
DDI-DrugBank.d339.s1|20-21|be|drug
DDI-DrugBank.d339.s1|23-24|of|drug
DDI-DrugBank.d339.s1|26-35|assistance|drug
DDI-DrugBank.d339.s1|37-38|in|drug
DDI-DrugBank.d339.s1|40-48|detecting|drug
DDI-DrugBank.d339.s1|50-60|alterations|drug
DDI-DrugBank.d339.s1|62-63|in|drug
DDI-DrugBank.d339.s1|65-77|carbamazepine|drug
DDI-DrugBank.d339.s1|79-84|plasma|drug
DDI-DrugBank.d339.s1|86-99|concentrations|drug
DDI-DrugBank.d339.s1|100-100|.|drug
DDI-DrugBank.d339.s2|0-7|Warfarin|brand
DDI-DrugBank.d339.s2|9-11|and|drug
DDI-DrugBank.d339.s2|13-26|Anticoagulants|group
DDI-DrugBank.d339.s2|27-27|:|drug
DDI-DrugBank.d339.s2|29-37|Increased|drug
DDI-DrugBank.d339.s2|39-49|prothrombin|drug
DDI-DrugBank.d339.s2|51-54|time|drug
DDI-DrugBank.d339.s2|55-55|,|drug
DDI-DrugBank.d339.s2|57-60|with|drug
DDI-DrugBank.d339.s2|62-63|or|drug
DDI-DrugBank.d339.s2|65-71|without|drug
DDI-DrugBank.d339.s2|73-80|clinical|drug
DDI-DrugBank.d339.s2|82-89|bleeding|drug
DDI-DrugBank.d339.s2|90-90|,|drug
DDI-DrugBank.d339.s2|92-94|has|drug
DDI-DrugBank.d339.s2|96-99|been|drug
DDI-DrugBank.d339.s2|101-108|reported|drug
DDI-DrugBank.d339.s2|110-113|when|drug
DDI-DrugBank.d339.s2|115-122|cefixime|drug
DDI-DrugBank.d339.s2|124-125|is|drug
DDI-DrugBank.d339.s2|127-138|administered|drug
DDI-DrugBank.d339.s2|140-152|concomitantly|drug
DDI-DrugBank.d339.s2|153-153|.|drug
DDI-DrugBank.d339.s3|0-14|Drug/Laboratory|drug
DDI-DrugBank.d339.s3|16-19|Test|drug
DDI-DrugBank.d339.s3|21-32|Interactions|drug
DDI-DrugBank.d339.s3|34-34|A|drug
DDI-DrugBank.d339.s3|36-49|false-positive|drug
DDI-DrugBank.d339.s3|51-58|reaction|drug
DDI-DrugBank.d339.s3|60-62|for|drug
DDI-DrugBank.d339.s3|64-70|ketones|drug
DDI-DrugBank.d339.s3|72-73|in|drug
DDI-DrugBank.d339.s3|75-77|the|drug
DDI-DrugBank.d339.s3|79-83|urine|drug
DDI-DrugBank.d339.s3|85-87|may|drug
DDI-DrugBank.d339.s3|89-93|occur|drug
DDI-DrugBank.d339.s3|95-98|with|drug
DDI-DrugBank.d339.s3|100-104|tests|drug
DDI-DrugBank.d339.s3|106-110|using|drug
DDI-DrugBank.d339.s3|112-124|nitroprusside|drug
DDI-DrugBank.d339.s3|126-128|but|drug
DDI-DrugBank.d339.s3|130-132|not|drug
DDI-DrugBank.d339.s3|134-137|with|drug
DDI-DrugBank.d339.s3|139-143|those|drug
DDI-DrugBank.d339.s3|145-149|using|drug
DDI-DrugBank.d339.s3|151-167|nitroferricyanide|drug
DDI-DrugBank.d339.s3|168-168|.|drug
DDI-DrugBank.d339.s4|0-2|The|drug
DDI-DrugBank.d339.s4|4-17|administration|drug
DDI-DrugBank.d339.s4|19-20|of|drug
DDI-DrugBank.d339.s4|22-27|SUPRAX|drug
DDI-DrugBank.d339.s4|29-31|may|drug
DDI-DrugBank.d339.s4|33-38|result|drug
DDI-DrugBank.d339.s4|40-41|in|drug
DDI-DrugBank.d339.s4|43-43|a|drug
DDI-DrugBank.d339.s4|45-58|false-positive|drug
DDI-DrugBank.d339.s4|60-67|reaction|drug
DDI-DrugBank.d339.s4|69-71|for|drug
DDI-DrugBank.d339.s4|73-79|glucose|drug
DDI-DrugBank.d339.s4|81-82|in|drug
DDI-DrugBank.d339.s4|84-86|the|drug
DDI-DrugBank.d339.s4|88-92|urine|drug
DDI-DrugBank.d339.s4|94-98|using|drug
DDI-DrugBank.d339.s4|100-108|Clinitest|drug
DDI-DrugBank.d339.s4|110-111|*|drug
DDI-DrugBank.d339.s4|112-112|*|drug
DDI-DrugBank.d339.s4|114-121|,|drug
DDI-DrugBank.d339.s4|123-123|Benedict|drug
DDI-DrugBank.d339.s4|125-132|s|drug
DDI-DrugBank.d339.s4|133-133|solution|drug
DDI-DrugBank.d339.s4|135-136|,|drug
DDI-DrugBank.d339.s4|138-144|or|drug
DDI-DrugBank.d339.s4|146-146|Fehling|drug
DDI-DrugBank.d339.s4|148-155|s|drug
DDI-DrugBank.d339.s4|156-156|solution|drug
DDI-DrugBank.d339.s5|0-1|It|drug
DDI-DrugBank.d339.s5|3-4|is|drug
DDI-DrugBank.d339.s5|6-16|recommended|drug
DDI-DrugBank.d339.s5|18-21|that|drug
DDI-DrugBank.d339.s5|23-29|glucose|drug
DDI-DrugBank.d339.s5|31-35|tests|drug
DDI-DrugBank.d339.s5|37-41|based|drug
DDI-DrugBank.d339.s5|43-44|on|drug
DDI-DrugBank.d339.s5|46-54|enzymatic|drug
DDI-DrugBank.d339.s5|56-62|glucose|drug
DDI-DrugBank.d339.s5|64-70|oxidase|drug
DDI-DrugBank.d339.s5|72-80|reactions|drug
DDI-DrugBank.d339.s5|82-82|(|drug
DDI-DrugBank.d339.s5|83-86|such|drug
DDI-DrugBank.d339.s5|88-89|as|drug
DDI-DrugBank.d339.s5|91-99|Clinistix|drug
DDI-DrugBank.d339.s5|101-102|*|drug
DDI-DrugBank.d339.s5|104-105|*|drug
DDI-DrugBank.d339.s5|107-114|or|drug
DDI-DrugBank.d339.s5|116-117|Tes-Tape|drug
DDI-DrugBank.d339.s5|118-118|*|drug
DDI-DrugBank.d339.s5|120-121|*|drug
DDI-DrugBank.d339.s5|123-126|)|drug
DDI-DrugBank.d339.s5|127-127|be|drug
DDI-DrugBank.d339.s6|0-0|A|drug
DDI-DrugBank.d339.s6|2-15|false-positive|drug
DDI-DrugBank.d339.s6|17-22|direct|drug
DDI-DrugBank.d339.s6|24-29|Coombs|drug
DDI-DrugBank.d339.s6|31-34|test|drug
DDI-DrugBank.d339.s6|36-38|has|drug
DDI-DrugBank.d339.s6|40-43|been|drug
DDI-DrugBank.d339.s6|45-52|reported|drug
DDI-DrugBank.d339.s6|54-59|during|drug
DDI-DrugBank.d339.s6|61-69|treatment|drug
DDI-DrugBank.d339.s6|71-74|with|drug
DDI-DrugBank.d339.s6|76-80|other|drug
DDI-DrugBank.d339.s6|82-94|cephalosporin|drug
DDI-DrugBank.d339.s6|96-106|antibiotics|drug
DDI-DrugBank.d339.s6|107-107|;|drug
DDI-DrugBank.d339.s7|0-8|therefore|drug
DDI-DrugBank.d339.s7|9-9|,|drug
DDI-DrugBank.d339.s7|11-12|it|drug
DDI-DrugBank.d339.s7|14-19|should|drug
DDI-DrugBank.d339.s7|21-22|be|drug
DDI-DrugBank.d339.s7|24-33|recognized|drug
DDI-DrugBank.d339.s7|35-38|that|drug
DDI-DrugBank.d339.s7|40-40|a|drug
DDI-DrugBank.d339.s7|42-49|positive|drug
DDI-DrugBank.d339.s7|51-56|Coombs|drug
DDI-DrugBank.d339.s7|58-61|test|drug
DDI-DrugBank.d339.s7|63-65|may|drug
DDI-DrugBank.d339.s7|67-68|be|drug
DDI-DrugBank.d339.s7|70-72|due|drug
DDI-DrugBank.d339.s7|74-75|to|drug
DDI-DrugBank.d339.s7|77-79|the|drug
DDI-DrugBank.d339.s7|81-84|drug|drug
DDI-DrugBank.d339.s7|85-85|.|drug
DDI-DrugBank.d475.s0|0-1|No|drug
DDI-DrugBank.d475.s0|3-14|interactions|drug
DDI-DrugBank.d475.s0|16-19|have|drug
DDI-DrugBank.d475.s0|21-24|been|drug
DDI-DrugBank.d475.s0|26-33|observed|drug
DDI-DrugBank.d475.s0|35-41|between|drug
DDI-DrugBank.d475.s0|43-52|nizatidine|drug
DDI-DrugBank.d475.s0|54-56|and|drug
DDI-DrugBank.d475.s0|58-69|theophylline|drug
DDI-DrugBank.d475.s0|70-70|,|drug
DDI-DrugBank.d475.s0|72-87|chlordiazepoxide|drug
DDI-DrugBank.d475.s0|88-88|,|drug
DDI-DrugBank.d475.s0|90-98|lorazepam|drug
DDI-DrugBank.d475.s0|99-99|,|drug
DDI-DrugBank.d475.s0|101-109|lidocaine|drug
DDI-DrugBank.d475.s0|110-110|,|drug
DDI-DrugBank.d475.s0|112-120|phenytoin|drug
DDI-DrugBank.d475.s0|121-121|,|drug
DDI-DrugBank.d475.s0|123-125|and|drug
DDI-DrugBank.d475.s0|127-134|warfarin|drug
DDI-DrugBank.d475.s0|135-135|.|drug
DDI-DrugBank.d475.s1|0-9|Nizatidine|brand
DDI-DrugBank.d475.s1|11-14|does|drug
DDI-DrugBank.d475.s1|16-18|not|drug
DDI-DrugBank.d475.s1|20-26|inhibit|drug
DDI-DrugBank.d475.s1|28-30|the|drug
DDI-DrugBank.d475.s1|32-41|cytochrome|drug
DDI-DrugBank.d475.s1|43-54|P-450-linked|drug
DDI-DrugBank.d475.s1|56-72|drug-metabolizing|drug
DDI-DrugBank.d475.s1|74-79|enzyme|drug
DDI-DrugBank.d475.s1|81-86|system|drug
DDI-DrugBank.d475.s1|87-87|;|drug
DDI-DrugBank.d475.s2|0-8|therefore|drug
DDI-DrugBank.d475.s2|9-9|,|drug
DDI-DrugBank.d475.s2|11-14|drug|drug
DDI-DrugBank.d475.s2|16-27|interactions|drug
DDI-DrugBank.d475.s2|29-36|mediated|drug
DDI-DrugBank.d475.s2|38-39|by|drug
DDI-DrugBank.d475.s2|41-50|inhibition|drug
DDI-DrugBank.d475.s2|52-53|of|drug
DDI-DrugBank.d475.s2|55-61|hepatic|drug
DDI-DrugBank.d475.s2|63-72|metabolism|drug
DDI-DrugBank.d475.s2|74-76|are|drug
DDI-DrugBank.d475.s2|78-80|not|drug
DDI-DrugBank.d475.s2|82-89|expected|drug
DDI-DrugBank.d475.s2|91-92|to|drug
DDI-DrugBank.d475.s2|94-98|occur|drug
DDI-DrugBank.d475.s2|99-99|.|drug
DDI-DrugBank.d475.s3|0-1|In|drug
DDI-DrugBank.d475.s3|3-10|patients|drug
DDI-DrugBank.d475.s3|12-16|given|drug
DDI-DrugBank.d475.s3|18-21|very|drug
DDI-DrugBank.d475.s3|23-26|high|drug
DDI-DrugBank.d475.s3|28-32|doses|drug
DDI-DrugBank.d475.s3|34-34|(|drug
DDI-DrugBank.d475.s3|35-38|3900|drug
DDI-DrugBank.d475.s3|40-41|mg|drug
DDI-DrugBank.d475.s3|42-42|)|drug
DDI-DrugBank.d475.s3|44-45|of|drug
DDI-DrugBank.d475.s3|47-53|aspirin|drug
DDI-DrugBank.d475.s3|55-59|daily|drug
DDI-DrugBank.d475.s3|60-60|,|drug
DDI-DrugBank.d475.s3|62-70|increases|drug
DDI-DrugBank.d475.s3|72-73|in|drug
DDI-DrugBank.d475.s3|75-79|serum|drug
DDI-DrugBank.d475.s3|81-90|salicylate|drug
DDI-DrugBank.d475.s3|92-97|levels|drug
DDI-DrugBank.d475.s3|99-102|were|drug
DDI-DrugBank.d475.s3|104-107|seen|drug
DDI-DrugBank.d475.s3|109-112|when|drug
DDI-DrugBank.d475.s3|114-123|nizatidine|drug
DDI-DrugBank.d475.s3|124-124|,|drug
DDI-DrugBank.d475.s3|126-128|150|drug
DDI-DrugBank.d475.s3|130-131|mg|drug
DDI-DrugBank.d475.s3|133-138|b.i.d.|drug
DDI-DrugBank.d475.s3|139-139|,|drug
DDI-DrugBank.d475.s3|141-143|was|drug
DDI-DrugBank.d475.s3|145-156|administered|drug
DDI-DrugBank.d475.s3|158-169|concurrently|drug
DDI-DrugBank.d475.s3|170-170|.|drug
DDI-DrugBank.d706.s0|0-22|Catecholamine-depleting|drug
DDI-DrugBank.d706.s0|24-28|drugs|drug
DDI-DrugBank.d706.s0|30-30|(|drug
DDI-DrugBank.d706.s0|31-34|e.g.|drug
DDI-DrugBank.d706.s0|35-35|,|drug
DDI-DrugBank.d706.s0|37-45|reserpine|drug
DDI-DrugBank.d706.s0|46-46|)|drug
DDI-DrugBank.d706.s0|48-50|may|drug
DDI-DrugBank.d706.s0|52-55|have|drug
DDI-DrugBank.d706.s0|57-58|an|drug
DDI-DrugBank.d706.s0|60-67|additive|drug
DDI-DrugBank.d706.s0|69-74|effect|drug
DDI-DrugBank.d706.s0|76-79|when|drug
DDI-DrugBank.d706.s0|81-85|given|drug
DDI-DrugBank.d706.s0|87-90|with|drug
DDI-DrugBank.d706.s0|92-104|beta-blocking|drug
DDI-DrugBank.d706.s0|106-111|agents|drug
DDI-DrugBank.d706.s0|112-112|.|drug
DDI-DrugBank.d706.s1|0-7|Patients|drug
DDI-DrugBank.d706.s1|9-15|treated|drug
DDI-DrugBank.d706.s1|17-20|with|drug
DDI-DrugBank.d706.s1|22-29|extended|drug
DDI-DrugBank.d706.s1|31-37|release|drug
DDI-DrugBank.d706.s1|39-48|metoprolol|drug
DDI-DrugBank.d706.s1|50-58|succinate|drug
DDI-DrugBank.d706.s1|60-63|plus|drug
DDI-DrugBank.d706.s1|65-65|a|drug
DDI-DrugBank.d706.s1|67-79|catecholamine|drug
DDI-DrugBank.d706.s1|81-88|depletor|drug
DDI-DrugBank.d706.s1|90-95|should|drug
DDI-DrugBank.d706.s1|97-105|therefore|drug
DDI-DrugBank.d706.s1|107-108|be|drug
DDI-DrugBank.d706.s1|110-116|closely|drug
DDI-DrugBank.d706.s1|118-125|observed|drug
DDI-DrugBank.d706.s1|127-129|for|drug
DDI-DrugBank.d706.s1|131-138|evidence|drug
DDI-DrugBank.d706.s1|140-141|of|drug
DDI-DrugBank.d706.s1|143-153|hypotension|drug
DDI-DrugBank.d706.s1|155-156|or|drug
DDI-DrugBank.d706.s1|158-163|marked|drug
DDI-DrugBank.d706.s1|165-175|bradycardia|drug
DDI-DrugBank.d706.s1|176-176|,|drug
DDI-DrugBank.d706.s1|178-182|which|drug
DDI-DrugBank.d706.s1|184-186|may|drug
DDI-DrugBank.d706.s1|188-194|produce|drug
DDI-DrugBank.d706.s1|196-202|vertigo|drug
DDI-DrugBank.d706.s1|203-203|,|drug
DDI-DrugBank.d706.s1|205-211|syncope|drug
DDI-DrugBank.d706.s1|212-212|,|drug
DDI-DrugBank.d706.s1|214-215|or|drug
DDI-DrugBank.d706.s1|217-224|postural|drug
DDI-DrugBank.d706.s1|226-236|hypotension|drug
DDI-DrugBank.d706.s1|237-237|.|drug
DDI-DrugBank.d163.s0|0-6|Vitamin|drug
DDI-DrugBank.d163.s0|8-8|A|drug
DDI-DrugBank.d163.s0|9-9|:|drug
DDI-DrugBank.d163.s0|11-17|Because|drug
DDI-DrugBank.d163.s0|19-20|of|drug
DDI-DrugBank.d163.s0|22-24|the|drug
DDI-DrugBank.d163.s0|26-37|relationship|drug
DDI-DrugBank.d163.s0|39-40|of|drug
DDI-DrugBank.d163.s0|42-49|Accutane|brand
DDI-DrugBank.d163.s0|51-52|to|drug
DDI-DrugBank.d163.s0|54-60|vitamin|drug
DDI-DrugBank.d163.s0|62-62|A|drug
DDI-DrugBank.d163.s0|63-63|,|drug
DDI-DrugBank.d163.s0|65-72|patients|drug
DDI-DrugBank.d163.s0|74-79|should|drug
DDI-DrugBank.d163.s0|81-82|be|drug
DDI-DrugBank.d163.s0|84-90|advised|drug
DDI-DrugBank.d163.s0|92-98|against|drug
DDI-DrugBank.d163.s0|100-105|taking|drug
DDI-DrugBank.d163.s0|107-113|vitamin|drug
DDI-DrugBank.d163.s0|115-125|supplements|drug
DDI-DrugBank.d163.s0|127-136|containing|drug
DDI-DrugBank.d163.s0|138-144|vitamin|drug
DDI-DrugBank.d163.s0|146-146|A|drug
DDI-DrugBank.d163.s0|148-149|to|drug
DDI-DrugBank.d163.s0|151-155|avoid|drug
DDI-DrugBank.d163.s0|157-164|additive|drug
DDI-DrugBank.d163.s0|166-170|toxic|drug
DDI-DrugBank.d163.s0|172-178|effects|drug
DDI-DrugBank.d163.s1|0-0|.|drug
DDI-DrugBank.d163.s2|0-12|Tetracyclines|group
DDI-DrugBank.d163.s2|13-13|:|drug
DDI-DrugBank.d163.s2|15-25|Concomitant|drug
DDI-DrugBank.d163.s2|27-35|treatment|drug
DDI-DrugBank.d163.s2|37-40|with|drug
DDI-DrugBank.d163.s2|42-49|Accutane|brand
DDI-DrugBank.d163.s2|51-53|and|drug
DDI-DrugBank.d163.s2|55-67|tetracyclines|drug
DDI-DrugBank.d163.s2|69-74|should|drug
DDI-DrugBank.d163.s2|76-77|be|drug
DDI-DrugBank.d163.s2|79-85|avoided|drug
DDI-DrugBank.d163.s2|87-93|because|drug
DDI-DrugBank.d163.s2|95-102|Accutane|brand
DDI-DrugBank.d163.s2|104-106|use|drug
DDI-DrugBank.d163.s2|108-110|has|drug
DDI-DrugBank.d163.s2|112-115|been|drug
DDI-DrugBank.d163.s2|117-126|associated|drug
DDI-DrugBank.d163.s2|128-131|with|drug
DDI-DrugBank.d163.s2|133-133|a|drug
DDI-DrugBank.d163.s2|135-140|number|drug
DDI-DrugBank.d163.s2|142-143|of|drug
DDI-DrugBank.d163.s2|145-149|cases|drug
DDI-DrugBank.d163.s2|151-152|of|drug
DDI-DrugBank.d163.s2|154-164|pseudotumor|drug
DDI-DrugBank.d163.s2|166-172|cerebri|drug
DDI-DrugBank.d163.s2|174-174|(|drug
DDI-DrugBank.d163.s2|175-180|benign|drug
DDI-DrugBank.d163.s2|182-193|intracranial|drug
DDI-DrugBank.d163.s2|195-206|hypertension|drug
DDI-DrugBank.d163.s2|207-207|)|drug
DDI-DrugBank.d163.s2|208-208|,|drug
DDI-DrugBank.d163.s2|210-213|some|drug
DDI-DrugBank.d163.s2|215-216|of|drug
DDI-DrugBank.d163.s2|218-222|which|drug
DDI-DrugBank.d163.s2|224-231|involved|drug
DDI-DrugBank.d163.s2|233-243|concomitant|drug
DDI-DrugBank.d163.s2|245-247|use|drug
DDI-DrugBank.d163.s2|249-250|of|drug
DDI-DrugBank.d163.s2|252-264|tetracyclines|drug
DDI-DrugBank.d163.s3|0-0|.|drug
DDI-DrugBank.d163.s4|0-10|Micro-dosed|drug
DDI-DrugBank.d163.s4|12-23|Progesterone|brand
DDI-DrugBank.d163.s4|25-36|Preparations|drug
DDI-DrugBank.d163.s4|37-37|:|drug
DDI-DrugBank.d163.s4|39-49|Micro-dosed|drug
DDI-DrugBank.d163.s4|51-62|progesterone|drug
DDI-DrugBank.d163.s4|64-75|preparations|drug
DDI-DrugBank.d163.s4|77-77|(|drug
DDI-DrugBank.d163.s4|78-86|minipills|drug
DDI-DrugBank.d163.s4|88-91|that|drug
DDI-DrugBank.d163.s4|93-94|do|drug
DDI-DrugBank.d163.s4|96-98|not|drug
DDI-DrugBank.d163.s4|100-106|contain|drug
DDI-DrugBank.d163.s4|108-109|an|drug
DDI-DrugBank.d163.s4|111-118|estrogen|drug
DDI-DrugBank.d163.s4|119-119|)|drug
DDI-DrugBank.d163.s4|121-123|may|drug
DDI-DrugBank.d163.s4|125-126|be|drug
DDI-DrugBank.d163.s4|128-129|an|drug
DDI-DrugBank.d163.s4|131-140|inadequate|drug
DDI-DrugBank.d163.s4|142-147|method|drug
DDI-DrugBank.d163.s4|149-150|of|drug
DDI-DrugBank.d163.s4|152-164|contraception|drug
DDI-DrugBank.d163.s4|166-171|during|drug
DDI-DrugBank.d163.s4|173-180|Accutane|brand
DDI-DrugBank.d163.s4|182-188|therapy|drug
DDI-DrugBank.d163.s4|189-189|.|drug
DDI-DrugBank.d163.s5|0-7|Although|drug
DDI-DrugBank.d163.s5|9-13|other|drug
DDI-DrugBank.d163.s5|15-22|hormonal|drug
DDI-DrugBank.d163.s5|24-37|contraceptives|drug
DDI-DrugBank.d163.s5|39-41|are|drug
DDI-DrugBank.d163.s5|43-48|highly|drug
DDI-DrugBank.d163.s5|50-58|effective|drug
DDI-DrugBank.d163.s5|59-59|,|drug
DDI-DrugBank.d163.s5|61-65|there|drug
DDI-DrugBank.d163.s5|67-70|have|drug
DDI-DrugBank.d163.s5|72-75|been|drug
DDI-DrugBank.d163.s5|77-83|reports|drug
DDI-DrugBank.d163.s5|85-86|of|drug
DDI-DrugBank.d163.s5|88-96|pregnancy|drug
DDI-DrugBank.d163.s5|98-101|from|drug
DDI-DrugBank.d163.s5|103-107|women|drug
DDI-DrugBank.d163.s5|109-111|who|drug
DDI-DrugBank.d163.s5|113-116|have|drug
DDI-DrugBank.d163.s5|118-121|used|drug
DDI-DrugBank.d163.s5|123-130|combined|drug
DDI-DrugBank.d163.s5|132-135|oral|drug
DDI-DrugBank.d163.s5|137-150|contraceptives|drug
DDI-DrugBank.d163.s5|151-151|,|drug
DDI-DrugBank.d163.s5|153-154|as|drug
DDI-DrugBank.d163.s5|156-159|well|drug
DDI-DrugBank.d163.s5|161-162|as|drug
DDI-DrugBank.d163.s5|164-204|topical/injectable/implantable/insertable|drug
DDI-DrugBank.d163.s5|206-213|hormonal|drug
DDI-DrugBank.d163.s5|215-219|birth|drug
DDI-DrugBank.d163.s5|221-227|control|drug
DDI-DrugBank.d163.s5|229-236|products|drug
DDI-DrugBank.d163.s5|237-237|.|drug
DDI-DrugBank.d163.s6|0-4|These|drug
DDI-DrugBank.d163.s6|6-12|reports|drug
DDI-DrugBank.d163.s6|14-16|are|drug
DDI-DrugBank.d163.s6|18-21|more|drug
DDI-DrugBank.d163.s6|23-30|frequent|drug
DDI-DrugBank.d163.s6|32-34|for|drug
DDI-DrugBank.d163.s6|36-40|women|drug
DDI-DrugBank.d163.s6|42-44|who|drug
DDI-DrugBank.d163.s6|46-48|use|drug
DDI-DrugBank.d163.s6|50-53|only|drug
DDI-DrugBank.d163.s6|55-55|a|drug
DDI-DrugBank.d163.s6|57-62|single|drug
DDI-DrugBank.d163.s6|64-69|method|drug
DDI-DrugBank.d163.s6|71-72|of|drug
DDI-DrugBank.d163.s6|74-86|contraception|drug
DDI-DrugBank.d163.s6|87-87|.|drug
DDI-DrugBank.d163.s7|0-1|It|drug
DDI-DrugBank.d163.s7|3-4|is|drug
DDI-DrugBank.d163.s7|6-8|not|drug
DDI-DrugBank.d163.s7|10-14|known|drug
DDI-DrugBank.d163.s7|16-17|if|drug
DDI-DrugBank.d163.s7|19-26|hormonal|drug
DDI-DrugBank.d163.s7|28-41|contraceptives|drug
DDI-DrugBank.d163.s7|43-48|differ|drug
DDI-DrugBank.d163.s7|50-51|in|drug
DDI-DrugBank.d163.s7|53-57|their|drug
DDI-DrugBank.d163.s7|59-71|effectiveness|drug
DDI-DrugBank.d163.s7|73-76|when|drug
DDI-DrugBank.d163.s7|78-81|used|drug
DDI-DrugBank.d163.s7|83-86|with|drug
DDI-DrugBank.d163.s7|88-95|Accutane|brand
DDI-DrugBank.d163.s7|96-96|.|drug
DDI-DrugBank.d163.s8|0-8|Therefore|drug
DDI-DrugBank.d163.s8|9-9|,|drug
DDI-DrugBank.d163.s8|11-12|it|drug
DDI-DrugBank.d163.s8|14-15|is|drug
DDI-DrugBank.d163.s8|17-26|critically|drug
DDI-DrugBank.d163.s8|28-36|important|drug
DDI-DrugBank.d163.s8|38-40|for|drug
DDI-DrugBank.d163.s8|42-46|women|drug
DDI-DrugBank.d163.s8|48-49|of|drug
DDI-DrugBank.d163.s8|51-62|childbearing|drug
DDI-DrugBank.d163.s8|64-72|potential|drug
DDI-DrugBank.d163.s8|74-75|to|drug
DDI-DrugBank.d163.s8|77-82|select|drug
DDI-DrugBank.d163.s8|84-86|and|drug
DDI-DrugBank.d163.s8|88-93|commit|drug
DDI-DrugBank.d163.s8|95-96|to|drug
DDI-DrugBank.d163.s8|98-100|use|drug
DDI-DrugBank.d163.s8|102-102|2|drug
DDI-DrugBank.d163.s8|104-108|forms|drug
DDI-DrugBank.d163.s8|110-111|of|drug
DDI-DrugBank.d163.s8|113-121|effective|drug
DDI-DrugBank.d163.s8|123-135|contraception|drug
DDI-DrugBank.d163.s8|137-150|simultaneously|drug
DDI-DrugBank.d163.s8|151-151|,|drug
DDI-DrugBank.d163.s8|153-154|at|drug
DDI-DrugBank.d163.s8|156-160|least|drug
DDI-DrugBank.d163.s8|162-162|1|drug
DDI-DrugBank.d163.s8|164-165|of|drug
DDI-DrugBank.d163.s8|167-171|which|drug
DDI-DrugBank.d163.s8|173-176|must|drug
DDI-DrugBank.d163.s8|178-179|be|drug
DDI-DrugBank.d163.s8|181-181|a|drug
DDI-DrugBank.d163.s8|183-189|primary|drug
DDI-DrugBank.d163.s8|191-194|form|drug
DDI-DrugBank.d163.s8|195-195|,|drug
DDI-DrugBank.d163.s8|197-202|unless|drug
DDI-DrugBank.d163.s8|204-211|absolute|drug
DDI-DrugBank.d163.s8|213-222|abstinence|drug
DDI-DrugBank.d163.s8|224-225|is|drug
DDI-DrugBank.d163.s8|227-229|the|drug
DDI-DrugBank.d163.s8|231-236|chosen|drug
DDI-DrugBank.d163.s8|238-243|method|drug
DDI-DrugBank.d163.s8|244-244|,|drug
DDI-DrugBank.d163.s8|246-247|or|drug
DDI-DrugBank.d163.s8|249-251|the|drug
DDI-DrugBank.d163.s8|253-259|patient|drug
DDI-DrugBank.d163.s8|261-263|has|drug
DDI-DrugBank.d163.s8|265-273|undergone|drug
DDI-DrugBank.d163.s8|275-275|a|drug
DDI-DrugBank.d163.s8|277-288|hysterectomy|drug
DDI-DrugBank.d163.s9|0-0|.|drug
DDI-DrugBank.d163.s10|0-8|Phenytoin|brand
DDI-DrugBank.d163.s10|9-9|:|drug
DDI-DrugBank.d163.s10|11-18|Accutane|brand
DDI-DrugBank.d163.s10|20-22|has|drug
DDI-DrugBank.d163.s10|24-26|not|drug
DDI-DrugBank.d163.s10|28-31|been|drug
DDI-DrugBank.d163.s10|33-37|shown|drug
DDI-DrugBank.d163.s10|39-40|to|drug
DDI-DrugBank.d163.s10|42-46|alter|drug
DDI-DrugBank.d163.s10|48-50|the|drug
DDI-DrugBank.d163.s10|52-67|pharmacokinetics|drug
DDI-DrugBank.d163.s10|69-70|of|drug
DDI-DrugBank.d163.s10|72-80|phenytoin|drug
DDI-DrugBank.d163.s10|82-83|in|drug
DDI-DrugBank.d163.s10|85-85|a|drug
DDI-DrugBank.d163.s10|87-91|study|drug
DDI-DrugBank.d163.s10|93-94|in|drug
DDI-DrugBank.d163.s10|96-100|seven|drug
DDI-DrugBank.d163.s10|102-108|healthy|drug
DDI-DrugBank.d163.s10|110-119|volunteers|drug
DDI-DrugBank.d163.s10|120-120|.|drug
DDI-DrugBank.d163.s11|0-4|These|drug
DDI-DrugBank.d163.s11|6-12|results|drug
DDI-DrugBank.d163.s11|14-16|are|drug
DDI-DrugBank.d163.s11|18-27|consistent|drug
DDI-DrugBank.d163.s11|29-32|with|drug
DDI-DrugBank.d163.s11|34-36|the|drug
DDI-DrugBank.d163.s11|38-39|in|drug
DDI-DrugBank.d163.s11|41-45|vitro|drug
DDI-DrugBank.d163.s11|47-53|finding|drug
DDI-DrugBank.d163.s11|55-58|that|drug
DDI-DrugBank.d163.s11|60-66|neither|drug
DDI-DrugBank.d163.s11|68-79|isotretinoin|drug
DDI-DrugBank.d163.s11|81-83|nor|drug
DDI-DrugBank.d163.s11|85-87|its|drug
DDI-DrugBank.d163.s11|89-99|metabolites|drug
DDI-DrugBank.d163.s11|101-106|induce|drug
DDI-DrugBank.d163.s11|108-109|or|drug
DDI-DrugBank.d163.s11|111-117|inhibit|drug
DDI-DrugBank.d163.s11|119-121|the|drug
DDI-DrugBank.d163.s11|123-130|activity|drug
DDI-DrugBank.d163.s11|132-133|of|drug
DDI-DrugBank.d163.s11|135-137|the|drug
DDI-DrugBank.d163.s11|139-141|CYP|drug
DDI-DrugBank.d163.s11|143-145|2C9|drug
DDI-DrugBank.d163.s11|147-151|human|drug
DDI-DrugBank.d163.s11|153-159|hepatic|drug
DDI-DrugBank.d163.s11|161-164|P450|drug
DDI-DrugBank.d163.s11|166-171|enzyme|drug
DDI-DrugBank.d163.s11|172-172|.|drug
DDI-DrugBank.d163.s12|0-8|Phenytoin|brand
DDI-DrugBank.d163.s12|10-11|is|drug
DDI-DrugBank.d163.s12|13-17|known|drug
DDI-DrugBank.d163.s12|19-20|to|drug
DDI-DrugBank.d163.s12|22-26|cause|drug
DDI-DrugBank.d163.s12|28-39|osteomalacia|drug
DDI-DrugBank.d163.s12|40-40|.|drug
DDI-DrugBank.d163.s13|0-1|No|drug
DDI-DrugBank.d163.s13|3-8|formal|drug
DDI-DrugBank.d163.s13|10-17|clinical|drug
DDI-DrugBank.d163.s13|19-25|studies|drug
DDI-DrugBank.d163.s13|27-30|have|drug
DDI-DrugBank.d163.s13|32-35|been|drug
DDI-DrugBank.d163.s13|37-45|conducted|drug
DDI-DrugBank.d163.s13|47-48|to|drug
DDI-DrugBank.d163.s13|50-55|assess|drug
DDI-DrugBank.d163.s13|57-58|if|drug
DDI-DrugBank.d163.s13|60-64|there|drug
DDI-DrugBank.d163.s13|66-67|is|drug
DDI-DrugBank.d163.s13|69-70|an|drug
DDI-DrugBank.d163.s13|72-82|interactive|drug
DDI-DrugBank.d163.s13|84-89|effect|drug
DDI-DrugBank.d163.s13|91-92|on|drug
DDI-DrugBank.d163.s13|94-97|bone|drug
DDI-DrugBank.d163.s13|99-102|loss|drug
DDI-DrugBank.d163.s13|104-110|between|drug
DDI-DrugBank.d163.s13|112-120|phenytoin|drug
DDI-DrugBank.d163.s13|122-124|and|drug
DDI-DrugBank.d163.s13|126-133|Accutane|brand
DDI-DrugBank.d163.s13|134-134|.|drug
DDI-DrugBank.d163.s14|0-8|Therefore|drug
DDI-DrugBank.d163.s14|9-9|,|drug
DDI-DrugBank.d163.s14|11-17|caution|drug
DDI-DrugBank.d163.s14|19-24|should|drug
DDI-DrugBank.d163.s14|26-27|be|drug
DDI-DrugBank.d163.s14|29-37|exercised|drug
DDI-DrugBank.d163.s14|39-42|when|drug
DDI-DrugBank.d163.s14|44-48|using|drug
DDI-DrugBank.d163.s14|50-54|these|drug
DDI-DrugBank.d163.s14|56-60|drugs|drug
DDI-DrugBank.d163.s14|62-69|together|drug
DDI-DrugBank.d163.s15|0-0|.|drug
DDI-DrugBank.d163.s16|0-7|Systemic|drug
DDI-DrugBank.d163.s16|9-23|Corticosteroids|group
DDI-DrugBank.d163.s16|24-24|:|drug
DDI-DrugBank.d163.s16|26-33|Systemic|drug
DDI-DrugBank.d163.s16|35-49|corticosteroids|drug
DDI-DrugBank.d163.s16|51-53|are|drug
DDI-DrugBank.d163.s16|55-59|known|drug
DDI-DrugBank.d163.s16|61-62|to|drug
DDI-DrugBank.d163.s16|64-68|cause|drug
DDI-DrugBank.d163.s16|70-81|osteoporosis|drug
DDI-DrugBank.d163.s16|82-82|.|drug
DDI-DrugBank.d163.s17|0-1|No|drug
DDI-DrugBank.d163.s17|3-8|formal|drug
DDI-DrugBank.d163.s17|10-17|clinical|drug
DDI-DrugBank.d163.s17|19-25|studies|drug
DDI-DrugBank.d163.s17|27-30|have|drug
DDI-DrugBank.d163.s17|32-35|been|drug
DDI-DrugBank.d163.s17|37-45|conducted|drug
DDI-DrugBank.d163.s17|47-48|to|drug
DDI-DrugBank.d163.s17|50-55|assess|drug
DDI-DrugBank.d163.s17|57-58|if|drug
DDI-DrugBank.d163.s17|60-64|there|drug
DDI-DrugBank.d163.s17|66-67|is|drug
DDI-DrugBank.d163.s17|69-70|an|drug
DDI-DrugBank.d163.s17|72-82|interactive|drug
DDI-DrugBank.d163.s17|84-89|effect|drug
DDI-DrugBank.d163.s17|91-92|on|drug
DDI-DrugBank.d163.s17|94-97|bone|drug
DDI-DrugBank.d163.s17|99-102|loss|drug
DDI-DrugBank.d163.s17|104-110|between|drug
DDI-DrugBank.d163.s17|112-119|systemic|drug
DDI-DrugBank.d163.s17|121-135|corticosteroids|drug
DDI-DrugBank.d163.s17|137-139|and|drug
DDI-DrugBank.d163.s17|141-148|Accutane|brand
DDI-DrugBank.d163.s17|149-149|.|drug
DDI-DrugBank.d163.s18|0-8|Therefore|drug
DDI-DrugBank.d163.s18|9-9|,|drug
DDI-DrugBank.d163.s18|11-17|caution|drug
DDI-DrugBank.d163.s18|19-24|should|drug
DDI-DrugBank.d163.s18|26-27|be|drug
DDI-DrugBank.d163.s18|29-37|exercised|drug
DDI-DrugBank.d163.s18|39-42|when|drug
DDI-DrugBank.d163.s18|44-48|using|drug
DDI-DrugBank.d163.s18|50-54|these|drug
DDI-DrugBank.d163.s18|56-60|drugs|drug
DDI-DrugBank.d163.s18|62-69|together|drug
DDI-DrugBank.d163.s18|70-70|.|drug
DDI-DrugBank.d163.s19|0-10|Prescribers|drug
DDI-DrugBank.d163.s19|12-14|are|drug
DDI-DrugBank.d163.s19|16-22|advised|drug
DDI-DrugBank.d163.s19|24-25|to|drug
DDI-DrugBank.d163.s19|27-33|consult|drug
DDI-DrugBank.d163.s19|35-37|the|drug
DDI-DrugBank.d163.s19|39-45|package|drug
DDI-DrugBank.d163.s19|47-52|insert|drug
DDI-DrugBank.d163.s19|54-55|of|drug
DDI-DrugBank.d163.s19|57-66|medication|drug
DDI-DrugBank.d163.s19|68-79|administered|drug
DDI-DrugBank.d163.s19|81-93|concomitantly|drug
DDI-DrugBank.d163.s19|95-98|with|drug
DDI-DrugBank.d163.s19|100-107|hormonal|drug
DDI-DrugBank.d163.s19|109-122|contraceptives|drug
DDI-DrugBank.d163.s19|123-123|,|drug
DDI-DrugBank.d163.s19|125-129|since|drug
DDI-DrugBank.d163.s19|131-134|some|drug
DDI-DrugBank.d163.s19|136-146|medications|drug
DDI-DrugBank.d163.s19|148-150|may|drug
DDI-DrugBank.d163.s19|152-159|decrease|drug
DDI-DrugBank.d163.s19|161-163|the|drug
DDI-DrugBank.d163.s19|165-177|effectiveness|drug
DDI-DrugBank.d163.s19|179-180|of|drug
DDI-DrugBank.d163.s19|182-186|these|drug
DDI-DrugBank.d163.s19|188-192|birth|drug
DDI-DrugBank.d163.s19|194-200|control|drug
DDI-DrugBank.d163.s19|202-209|products|drug
DDI-DrugBank.d163.s19|210-210|.|drug
DDI-DrugBank.d163.s20|0-7|Accutane|brand
DDI-DrugBank.d163.s20|9-11|use|drug
DDI-DrugBank.d163.s20|13-14|is|drug
DDI-DrugBank.d163.s20|16-25|associated|drug
DDI-DrugBank.d163.s20|27-30|with|drug
DDI-DrugBank.d163.s20|32-41|depression|drug
DDI-DrugBank.d163.s20|43-44|in|drug
DDI-DrugBank.d163.s20|46-49|some|drug
DDI-DrugBank.d163.s20|51-58|patients|drug
DDI-DrugBank.d163.s20|59-59|.|drug
DDI-DrugBank.d163.s21|0-10|Pregnancies|drug
DDI-DrugBank.d163.s21|12-15|have|drug
DDI-DrugBank.d163.s21|17-20|been|drug
DDI-DrugBank.d163.s21|22-29|reported|drug
DDI-DrugBank.d163.s21|31-32|by|drug
DDI-DrugBank.d163.s21|34-38|users|drug
DDI-DrugBank.d163.s21|40-41|of|drug
DDI-DrugBank.d163.s21|43-50|combined|drug
DDI-DrugBank.d163.s21|52-59|hormonal|drug
DDI-DrugBank.d163.s21|61-74|contraceptives|drug
DDI-DrugBank.d163.s21|76-78|who|drug
DDI-DrugBank.d163.s21|80-83|also|drug
DDI-DrugBank.d163.s21|85-88|used|drug
DDI-DrugBank.d163.s21|90-93|some|drug
DDI-DrugBank.d163.s21|95-98|form|drug
DDI-DrugBank.d163.s21|100-101|of|drug
DDI-DrugBank.d163.s21|103-105|St.|drug
DDI-DrugBank.d163.s21|107-111|Johns|drug
DDI-DrugBank.d163.s21|113-116|Wort|drug
DDI-DrugBank.d163.s21|117-117|.|drug
DDI-DrugBank.d163.s22|0-9|Laboratory|drug
DDI-DrugBank.d163.s22|11-15|Tests|drug
DDI-DrugBank.d163.s22|17-25|Pregnancy|drug
DDI-DrugBank.d163.s22|27-30|Test|drug
DDI-DrugBank.d163.s22|32-37|Female|drug
DDI-DrugBank.d163.s22|39-46|patients|drug
DDI-DrugBank.d163.s22|48-49|of|drug
DDI-DrugBank.d163.s22|51-62|childbearing|drug
DDI-DrugBank.d163.s22|64-72|potential|drug
DDI-DrugBank.d163.s22|74-77|must|drug
DDI-DrugBank.d163.s22|79-82|have|drug
DDI-DrugBank.d163.s22|84-91|negative|drug
DDI-DrugBank.d163.s22|93-99|results|drug
DDI-DrugBank.d163.s22|101-104|from|drug
DDI-DrugBank.d163.s22|106-106|2|drug
DDI-DrugBank.d163.s22|108-112|urine|drug
DDI-DrugBank.d163.s22|114-115|or|drug
DDI-DrugBank.d163.s22|117-121|serum|drug
DDI-DrugBank.d163.s22|123-131|pregnancy|drug
DDI-DrugBank.d163.s22|133-137|tests|drug
DDI-DrugBank.d163.s22|139-142|with|drug
DDI-DrugBank.d163.s22|144-144|a|drug
DDI-DrugBank.d163.s22|146-156|sensitivity|drug
DDI-DrugBank.d163.s22|158-159|of|drug
DDI-DrugBank.d163.s22|161-162|at|drug
DDI-DrugBank.d163.s22|164-168|least|drug
DDI-DrugBank.d163.s22|170-171|25|drug
DDI-DrugBank.d163.s22|173-178|mIU/mL|drug
DDI-DrugBank.d163.s22|180-185|before|drug
DDI-DrugBank.d163.s22|187-195|receiving|drug
DDI-DrugBank.d163.s22|197-199|the|drug
DDI-DrugBank.d163.s22|201-207|initial|drug
DDI-DrugBank.d163.s22|209-216|Accutane|brand
DDI-DrugBank.d163.s22|218-229|prescription|drug
DDI-DrugBank.d163.s22|230-230|.|drug
DDI-DrugBank.d163.s23|0-2|The|drug
DDI-DrugBank.d163.s23|4-8|first|drug
DDI-DrugBank.d163.s23|10-13|test|drug
DDI-DrugBank.d163.s23|15-16|is|drug
DDI-DrugBank.d163.s23|18-25|obtained|drug
DDI-DrugBank.d163.s23|27-28|by|drug
DDI-DrugBank.d163.s23|30-32|the|drug
DDI-DrugBank.d163.s23|34-43|prescriber|drug
DDI-DrugBank.d163.s23|45-48|when|drug
DDI-DrugBank.d163.s23|50-52|the|drug
DDI-DrugBank.d163.s23|54-61|decision|drug
DDI-DrugBank.d163.s23|63-64|is|drug
DDI-DrugBank.d163.s23|66-69|made|drug
DDI-DrugBank.d163.s23|71-72|to|drug
DDI-DrugBank.d163.s23|74-79|pursue|drug
DDI-DrugBank.d163.s23|81-93|qualification|drug
DDI-DrugBank.d163.s23|95-96|of|drug
DDI-DrugBank.d163.s23|98-100|the|drug
DDI-DrugBank.d163.s23|102-108|patient|drug
DDI-DrugBank.d163.s23|110-112|for|drug
DDI-DrugBank.d163.s23|114-121|Accutane|brand
DDI-DrugBank.d163.s23|123-123|(|drug
DDI-DrugBank.d163.s23|124-124|a|drug
DDI-DrugBank.d163.s23|126-134|screening|drug
DDI-DrugBank.d163.s23|136-139|test|drug
DDI-DrugBank.d163.s23|140-140|)|drug
DDI-DrugBank.d163.s23|141-141|.|drug
DDI-DrugBank.d163.s24|0-2|The|drug
DDI-DrugBank.d163.s24|4-9|second|drug
DDI-DrugBank.d163.s24|11-19|pregnancy|drug
DDI-DrugBank.d163.s24|21-24|test|drug
DDI-DrugBank.d163.s24|26-26|(|drug
DDI-DrugBank.d163.s24|27-27|a|drug
DDI-DrugBank.d163.s24|29-40|confirmation|drug
DDI-DrugBank.d163.s24|42-45|test|drug
DDI-DrugBank.d163.s24|46-46|)|drug
DDI-DrugBank.d163.s24|48-53|should|drug
DDI-DrugBank.d163.s24|55-56|be|drug
DDI-DrugBank.d163.s24|58-61|done|drug
DDI-DrugBank.d163.s24|63-68|during|drug
DDI-DrugBank.d163.s24|70-72|the|drug
DDI-DrugBank.d163.s24|74-78|first|drug
DDI-DrugBank.d163.s24|80-80|5|drug
DDI-DrugBank.d163.s24|82-85|days|drug
DDI-DrugBank.d163.s24|87-88|of|drug
DDI-DrugBank.d163.s24|90-92|the|drug
DDI-DrugBank.d163.s24|94-102|menstrual|drug
DDI-DrugBank.d163.s24|104-109|period|drug
DDI-DrugBank.d163.s24|111-121|immediately|drug
DDI-DrugBank.d163.s24|123-131|preceding|drug
DDI-DrugBank.d163.s24|133-135|the|drug
DDI-DrugBank.d163.s24|137-145|beginning|drug
DDI-DrugBank.d163.s24|147-148|of|drug
DDI-DrugBank.d163.s24|150-157|Accutane|brand
DDI-DrugBank.d163.s24|159-165|therapy|drug
DDI-DrugBank.d163.s24|166-166|.|drug
DDI-DrugBank.d163.s25|0-2|For|drug
DDI-DrugBank.d163.s25|4-11|patients|drug
DDI-DrugBank.d163.s25|13-16|with|drug
DDI-DrugBank.d163.s25|18-27|amenorrhea|drug
DDI-DrugBank.d163.s25|28-28|,|drug
DDI-DrugBank.d163.s25|30-32|the|drug
DDI-DrugBank.d163.s25|34-39|second|drug
DDI-DrugBank.d163.s25|41-44|test|drug
DDI-DrugBank.d163.s25|46-51|should|drug
DDI-DrugBank.d163.s25|53-54|be|drug
DDI-DrugBank.d163.s25|56-59|done|drug
DDI-DrugBank.d163.s25|61-62|at|drug
DDI-DrugBank.d163.s25|64-68|least|drug
DDI-DrugBank.d163.s25|70-71|11|drug
DDI-DrugBank.d163.s25|73-76|days|drug
DDI-DrugBank.d163.s25|78-82|after|drug
DDI-DrugBank.d163.s25|84-86|the|drug
DDI-DrugBank.d163.s25|88-91|last|drug
DDI-DrugBank.d163.s25|93-95|act|drug
DDI-DrugBank.d163.s25|97-98|of|drug
DDI-DrugBank.d163.s25|100-110|unprotected|drug
DDI-DrugBank.d163.s25|112-117|sexual|drug
DDI-DrugBank.d163.s25|119-129|intercourse|drug
DDI-DrugBank.d163.s25|131-131|(|drug
DDI-DrugBank.d163.s25|132-138|without|drug
DDI-DrugBank.d163.s25|140-144|using|drug
DDI-DrugBank.d163.s25|146-146|2|drug
DDI-DrugBank.d163.s25|148-156|effective|drug
DDI-DrugBank.d163.s25|158-162|forms|drug
DDI-DrugBank.d163.s25|164-165|of|drug
DDI-DrugBank.d163.s25|167-179|contraception|drug
DDI-DrugBank.d163.s25|180-180|)|drug
DDI-DrugBank.d163.s25|181-181|.|drug
DDI-DrugBank.d163.s26|0-3|Each|drug
DDI-DrugBank.d163.s26|5-9|month|drug
DDI-DrugBank.d163.s26|11-12|of|drug
DDI-DrugBank.d163.s26|14-20|therapy|drug
DDI-DrugBank.d163.s26|21-21|,|drug
DDI-DrugBank.d163.s26|23-25|the|drug
DDI-DrugBank.d163.s26|27-33|patient|drug
DDI-DrugBank.d163.s26|35-38|must|drug
DDI-DrugBank.d163.s26|40-43|have|drug
DDI-DrugBank.d163.s26|45-45|a|drug
DDI-DrugBank.d163.s26|47-54|negative|drug
DDI-DrugBank.d163.s26|56-61|result|drug
DDI-DrugBank.d163.s26|63-66|from|drug
DDI-DrugBank.d163.s26|68-68|a|drug
DDI-DrugBank.d163.s26|70-74|urine|drug
DDI-DrugBank.d163.s26|76-77|or|drug
DDI-DrugBank.d163.s26|79-83|serum|drug
DDI-DrugBank.d163.s26|85-93|pregnancy|drug
DDI-DrugBank.d163.s26|95-98|test|drug
DDI-DrugBank.d163.s26|99-99|.|drug
DDI-DrugBank.d163.s27|0-0|A|drug
DDI-DrugBank.d163.s27|2-10|pregnancy|drug
DDI-DrugBank.d163.s27|12-15|test|drug
DDI-DrugBank.d163.s27|17-20|must|drug
DDI-DrugBank.d163.s27|22-23|be|drug
DDI-DrugBank.d163.s27|25-32|repeated|drug
DDI-DrugBank.d163.s27|34-37|each|drug
DDI-DrugBank.d163.s27|39-43|month|drug
DDI-DrugBank.d163.s27|45-49|prior|drug
DDI-DrugBank.d163.s27|51-52|to|drug
DDI-DrugBank.d163.s27|54-56|the|drug
DDI-DrugBank.d163.s27|58-63|female|drug
DDI-DrugBank.d163.s27|65-71|patient|drug
DDI-DrugBank.d163.s27|73-81|receiving|drug
DDI-DrugBank.d163.s27|83-86|each|drug
DDI-DrugBank.d163.s27|88-99|prescription|drug
DDI-DrugBank.d163.s28|0-0|.|drug
DDI-DrugBank.d163.s29|0-5|Lipids|group
DDI-DrugBank.d163.s29|6-6|:|drug
DDI-DrugBank.d163.s29|8-19|Pretreatment|drug
DDI-DrugBank.d163.s29|21-23|and|drug
DDI-DrugBank.d163.s29|25-33|follow-up|drug
DDI-DrugBank.d163.s29|35-39|blood|drug
DDI-DrugBank.d163.s29|41-46|lipids|drug
DDI-DrugBank.d163.s29|48-53|should|drug
DDI-DrugBank.d163.s29|55-56|be|drug
DDI-DrugBank.d163.s29|58-65|obtained|drug
DDI-DrugBank.d163.s29|67-71|under|drug
DDI-DrugBank.d163.s29|73-79|fasting|drug
DDI-DrugBank.d163.s29|81-90|conditions|drug
DDI-DrugBank.d163.s29|91-91|.|drug
DDI-DrugBank.d163.s30|0-4|After|drug
DDI-DrugBank.d163.s30|6-16|consumption|drug
DDI-DrugBank.d163.s30|18-19|of|drug
DDI-DrugBank.d163.s30|21-27|alcohol|drug
DDI-DrugBank.d163.s30|28-28|,|drug
DDI-DrugBank.d163.s30|30-31|at|drug
DDI-DrugBank.d163.s30|33-37|least|drug
DDI-DrugBank.d163.s30|39-40|36|drug
DDI-DrugBank.d163.s30|42-46|hours|drug
DDI-DrugBank.d163.s30|48-53|should|drug
DDI-DrugBank.d163.s30|55-60|elapse|drug
DDI-DrugBank.d163.s30|62-67|before|drug
DDI-DrugBank.d163.s30|69-73|these|drug
DDI-DrugBank.d163.s30|75-88|determinations|drug
DDI-DrugBank.d163.s30|90-92|are|drug
DDI-DrugBank.d163.s30|94-97|made|drug
DDI-DrugBank.d163.s30|98-98|.|drug
DDI-DrugBank.d163.s31|0-1|It|drug
DDI-DrugBank.d163.s31|3-4|is|drug
DDI-DrugBank.d163.s31|6-16|recommended|drug
DDI-DrugBank.d163.s31|18-21|that|drug
DDI-DrugBank.d163.s31|23-27|these|drug
DDI-DrugBank.d163.s31|29-33|tests|drug
DDI-DrugBank.d163.s31|35-36|be|drug
DDI-DrugBank.d163.s31|38-46|performed|drug
DDI-DrugBank.d163.s31|48-49|at|drug
DDI-DrugBank.d163.s31|51-56|weekly|drug
DDI-DrugBank.d163.s31|58-59|or|drug
DDI-DrugBank.d163.s31|61-68|biweekly|drug
DDI-DrugBank.d163.s31|70-78|intervals|drug
DDI-DrugBank.d163.s31|80-84|until|drug
DDI-DrugBank.d163.s31|86-88|the|drug
DDI-DrugBank.d163.s31|90-94|lipid|drug
DDI-DrugBank.d163.s31|96-103|response|drug
DDI-DrugBank.d163.s31|105-106|to|drug
DDI-DrugBank.d163.s31|108-115|Accutane|brand
DDI-DrugBank.d163.s31|117-118|is|drug
DDI-DrugBank.d163.s31|120-130|established|drug
DDI-DrugBank.d163.s31|131-131|.|drug
DDI-DrugBank.d163.s32|0-2|The|drug
DDI-DrugBank.d163.s32|4-12|incidence|drug
DDI-DrugBank.d163.s32|14-15|of|drug
DDI-DrugBank.d163.s32|17-36|hypertriglyceridemia|drug
DDI-DrugBank.d163.s32|38-39|is|drug
DDI-DrugBank.d163.s32|41-41|1|drug
DDI-DrugBank.d163.s32|43-49|patient|drug
DDI-DrugBank.d163.s32|51-52|in|drug
DDI-DrugBank.d163.s32|54-54|4|drug
DDI-DrugBank.d163.s32|56-57|on|drug
DDI-DrugBank.d163.s32|59-66|Accutane|brand
DDI-DrugBank.d163.s32|68-74|therapy|drug
DDI-DrugBank.d163.s33|0-0|.|drug
DDI-DrugBank.d163.s34|0-4|Liver|drug
DDI-DrugBank.d163.s34|6-13|Function|drug
DDI-DrugBank.d163.s34|15-19|Tests|drug
DDI-DrugBank.d163.s34|20-20|:|drug
DDI-DrugBank.d163.s34|22-26|Since|drug
DDI-DrugBank.d163.s34|28-37|elevations|drug
DDI-DrugBank.d163.s34|39-40|of|drug
DDI-DrugBank.d163.s34|42-46|liver|drug
DDI-DrugBank.d163.s34|48-54|enzymes|drug
DDI-DrugBank.d163.s34|56-59|have|drug
DDI-DrugBank.d163.s34|61-64|been|drug
DDI-DrugBank.d163.s34|66-73|observed|drug
DDI-DrugBank.d163.s34|75-80|during|drug
DDI-DrugBank.d163.s34|82-89|clinical|drug
DDI-DrugBank.d163.s34|91-96|trials|drug
DDI-DrugBank.d163.s34|97-97|,|drug
DDI-DrugBank.d163.s34|99-101|and|drug
DDI-DrugBank.d163.s34|103-111|hepatitis|drug
DDI-DrugBank.d163.s34|113-115|has|drug
DDI-DrugBank.d163.s34|117-120|been|drug
DDI-DrugBank.d163.s34|122-129|reported|drug
DDI-DrugBank.d163.s34|130-130|,|drug
DDI-DrugBank.d163.s34|132-143|pretreatment|drug
DDI-DrugBank.d163.s34|145-147|and|drug
DDI-DrugBank.d163.s34|149-157|follow-up|drug
DDI-DrugBank.d163.s34|159-163|liver|drug
DDI-DrugBank.d163.s34|165-172|function|drug
DDI-DrugBank.d163.s34|174-178|tests|drug
DDI-DrugBank.d163.s34|180-185|should|drug
DDI-DrugBank.d163.s34|187-188|be|drug
DDI-DrugBank.d163.s34|190-198|performed|drug
DDI-DrugBank.d163.s34|200-201|at|drug
DDI-DrugBank.d163.s34|203-208|weekly|drug
DDI-DrugBank.d163.s34|210-211|or|drug
DDI-DrugBank.d163.s34|213-220|biweekly|drug
DDI-DrugBank.d163.s34|222-230|intervals|drug
DDI-DrugBank.d163.s34|232-236|until|drug
DDI-DrugBank.d163.s34|238-240|the|drug
DDI-DrugBank.d163.s34|242-249|response|drug
DDI-DrugBank.d163.s34|251-252|to|drug
DDI-DrugBank.d163.s34|254-261|Accutane|brand
DDI-DrugBank.d163.s34|263-265|has|drug
DDI-DrugBank.d163.s34|267-270|been|drug
DDI-DrugBank.d163.s34|272-282|established|drug
DDI-DrugBank.d163.s35|0-0|.|drug
DDI-DrugBank.d163.s36|0-6|Glucose|brand
DDI-DrugBank.d163.s36|7-7|:|drug
DDI-DrugBank.d163.s36|9-12|Some|drug
DDI-DrugBank.d163.s36|14-21|patients|drug
DDI-DrugBank.d163.s36|23-31|receiving|drug
DDI-DrugBank.d163.s36|33-40|Accutane|brand
DDI-DrugBank.d163.s36|42-45|have|drug
DDI-DrugBank.d163.s36|47-57|experienced|drug
DDI-DrugBank.d163.s36|59-66|problems|drug
DDI-DrugBank.d163.s36|68-69|in|drug
DDI-DrugBank.d163.s36|71-73|the|drug
DDI-DrugBank.d163.s36|75-81|control|drug
DDI-DrugBank.d163.s36|83-84|of|drug
DDI-DrugBank.d163.s36|86-90|their|drug
DDI-DrugBank.d163.s36|92-96|blood|drug
DDI-DrugBank.d163.s36|98-102|sugar|drug
DDI-DrugBank.d163.s36|103-103|.|drug
DDI-DrugBank.d163.s37|0-1|In|drug
DDI-DrugBank.d163.s37|3-10|addition|drug
DDI-DrugBank.d163.s37|11-11|,|drug
DDI-DrugBank.d163.s37|13-15|new|drug
DDI-DrugBank.d163.s37|17-21|cases|drug
DDI-DrugBank.d163.s37|23-24|of|drug
DDI-DrugBank.d163.s37|26-33|diabetes|drug
DDI-DrugBank.d163.s37|35-38|have|drug
DDI-DrugBank.d163.s37|40-43|been|drug
DDI-DrugBank.d163.s37|45-53|diagnosed|drug
DDI-DrugBank.d163.s37|55-60|during|drug
DDI-DrugBank.d163.s37|62-69|Accutane|brand
DDI-DrugBank.d163.s37|71-77|therapy|drug
DDI-DrugBank.d163.s37|78-78|,|drug
DDI-DrugBank.d163.s37|80-87|although|drug
DDI-DrugBank.d163.s37|89-90|no|drug
DDI-DrugBank.d163.s37|92-97|causal|drug
DDI-DrugBank.d163.s37|99-110|relationship|drug
DDI-DrugBank.d163.s37|112-114|has|drug
DDI-DrugBank.d163.s37|116-119|been|drug
DDI-DrugBank.d163.s37|121-131|established|drug
DDI-DrugBank.d163.s38|0-0|.|drug
DDI-DrugBank.d163.s39|0-2|CPK|drug
DDI-DrugBank.d163.s39|3-3|:|drug
DDI-DrugBank.d163.s39|5-8|Some|drug
DDI-DrugBank.d163.s39|10-17|patients|drug
DDI-DrugBank.d163.s39|19-28|undergoing|drug
DDI-DrugBank.d163.s39|30-37|vigorous|drug
DDI-DrugBank.d163.s39|39-46|physical|drug
DDI-DrugBank.d163.s39|48-55|activity|drug
DDI-DrugBank.d163.s39|57-61|while|drug
DDI-DrugBank.d163.s39|63-64|on|drug
DDI-DrugBank.d163.s39|66-73|Accutane|brand
DDI-DrugBank.d163.s39|75-81|therapy|drug
DDI-DrugBank.d163.s39|83-86|have|drug
DDI-DrugBank.d163.s39|88-98|experienced|drug
DDI-DrugBank.d163.s39|100-107|elevated|drug
DDI-DrugBank.d163.s39|109-111|CPK|drug
DDI-DrugBank.d163.s39|113-118|levels|drug
DDI-DrugBank.d163.s39|119-119|;|drug
DDI-DrugBank.d163.s40|0-6|however|drug
DDI-DrugBank.d163.s40|7-7|,|drug
DDI-DrugBank.d163.s40|9-11|the|drug
DDI-DrugBank.d163.s40|13-20|clinical|drug
DDI-DrugBank.d163.s40|22-33|significance|drug
DDI-DrugBank.d163.s40|35-36|is|drug
DDI-DrugBank.d163.s40|38-44|unknown|drug
DDI-DrugBank.d163.s40|45-45|.|drug
DDI-DrugBank.d163.s41|0-4|There|drug
DDI-DrugBank.d163.s41|6-9|have|drug
DDI-DrugBank.d163.s41|11-14|been|drug
DDI-DrugBank.d163.s41|16-19|rare|drug
DDI-DrugBank.d163.s41|21-33|postmarketing|drug
DDI-DrugBank.d163.s41|35-41|reports|drug
DDI-DrugBank.d163.s41|43-44|of|drug
DDI-DrugBank.d163.s41|46-59|rhabdomyolysis|drug
DDI-DrugBank.d163.s41|60-60|,|drug
DDI-DrugBank.d163.s41|62-65|some|drug
DDI-DrugBank.d163.s41|67-76|associated|drug
DDI-DrugBank.d163.s41|78-81|with|drug
DDI-DrugBank.d163.s41|83-91|strenuous|drug
DDI-DrugBank.d163.s41|93-100|physical|drug
DDI-DrugBank.d163.s41|102-109|activity|drug
DDI-DrugBank.d163.s41|110-110|.|drug
DDI-DrugBank.d163.s42|0-1|In|drug
DDI-DrugBank.d163.s42|3-3|a|drug
DDI-DrugBank.d163.s42|5-12|clinical|drug
DDI-DrugBank.d163.s42|14-18|trial|drug
DDI-DrugBank.d163.s42|20-21|of|drug
DDI-DrugBank.d163.s42|23-25|217|brand
DDI-DrugBank.d163.s42|27-35|pediatric|drug
DDI-DrugBank.d163.s42|37-44|patients|drug
DDI-DrugBank.d163.s42|46-46|(|drug
DDI-DrugBank.d163.s42|47-48|12|drug
DDI-DrugBank.d163.s42|50-51|to|drug
DDI-DrugBank.d163.s42|53-54|17|drug
DDI-DrugBank.d163.s42|56-60|years|drug
DDI-DrugBank.d163.s42|61-61|)|drug
DDI-DrugBank.d163.s42|63-66|with|drug
DDI-DrugBank.d163.s42|68-73|severe|drug
DDI-DrugBank.d163.s42|75-86|recalcitrant|drug
DDI-DrugBank.d163.s42|88-94|nodular|drug
DDI-DrugBank.d163.s42|96-99|acne|drug
DDI-DrugBank.d163.s42|100-100|,|drug
DDI-DrugBank.d163.s42|102-110|transient|drug
DDI-DrugBank.d163.s42|112-121|elevations|drug
DDI-DrugBank.d163.s42|123-124|in|drug
DDI-DrugBank.d163.s42|126-128|CPK|drug
DDI-DrugBank.d163.s42|130-133|were|drug
DDI-DrugBank.d163.s42|135-142|observed|drug
DDI-DrugBank.d163.s42|144-145|in|drug
DDI-DrugBank.d163.s42|147-148|12|drug
DDI-DrugBank.d163.s42|149-149|%|drug
DDI-DrugBank.d163.s42|151-152|of|drug
DDI-DrugBank.d163.s42|154-161|patients|drug
DDI-DrugBank.d163.s42|162-162|,|drug
DDI-DrugBank.d163.s42|164-172|including|drug
DDI-DrugBank.d163.s42|174-178|those|drug
DDI-DrugBank.d163.s42|180-189|undergoing|drug
DDI-DrugBank.d163.s42|191-199|strenuous|drug
DDI-DrugBank.d163.s42|201-208|physical|drug
DDI-DrugBank.d163.s42|210-217|activity|drug
DDI-DrugBank.d163.s42|219-220|in|drug
DDI-DrugBank.d163.s42|222-232|association|drug
DDI-DrugBank.d163.s42|234-237|with|drug
DDI-DrugBank.d163.s42|239-246|reported|drug
DDI-DrugBank.d163.s42|248-262|musculoskeletal|drug
DDI-DrugBank.d163.s42|264-270|adverse|drug
DDI-DrugBank.d163.s42|272-277|events|drug
DDI-DrugBank.d163.s42|279-282|such|drug
DDI-DrugBank.d163.s42|284-285|as|drug
DDI-DrugBank.d163.s42|287-290|back|drug
DDI-DrugBank.d163.s42|292-295|pain|drug
DDI-DrugBank.d163.s42|296-296|,|drug
DDI-DrugBank.d163.s42|298-307|arthralgia|drug
DDI-DrugBank.d163.s42|308-308|,|drug
DDI-DrugBank.d163.s42|310-313|limb|drug
DDI-DrugBank.d163.s42|315-320|injury|drug
DDI-DrugBank.d163.s42|321-321|,|drug
DDI-DrugBank.d163.s42|323-324|or|drug
DDI-DrugBank.d163.s42|326-331|muscle|drug
DDI-DrugBank.d163.s42|333-338|sprain|drug
DDI-DrugBank.d163.s42|339-339|.|drug
DDI-DrugBank.d163.s43|0-1|In|drug
DDI-DrugBank.d163.s43|3-7|these|drug
DDI-DrugBank.d163.s43|9-16|patients|drug
DDI-DrugBank.d163.s43|17-17|,|drug
DDI-DrugBank.d163.s43|19-31|approximately|drug
DDI-DrugBank.d163.s43|33-36|half|drug
DDI-DrugBank.d163.s43|38-39|of|drug
DDI-DrugBank.d163.s43|41-43|the|drug
DDI-DrugBank.d163.s43|45-47|CPK|drug
DDI-DrugBank.d163.s43|49-58|elevations|drug
DDI-DrugBank.d163.s43|60-67|returned|drug
DDI-DrugBank.d163.s43|69-70|to|drug
DDI-DrugBank.d163.s43|72-77|normal|drug
DDI-DrugBank.d163.s43|79-84|within|drug
DDI-DrugBank.d163.s43|86-86|2|drug
DDI-DrugBank.d163.s43|88-92|weeks|drug
DDI-DrugBank.d163.s43|94-96|and|drug
DDI-DrugBank.d163.s43|98-101|half|drug
DDI-DrugBank.d163.s43|103-110|returned|drug
DDI-DrugBank.d163.s43|112-113|to|drug
DDI-DrugBank.d163.s43|115-120|normal|drug
DDI-DrugBank.d163.s43|122-127|within|drug
DDI-DrugBank.d163.s43|129-129|4|drug
DDI-DrugBank.d163.s43|131-135|weeks|drug
DDI-DrugBank.d163.s43|136-136|.|drug
DDI-DrugBank.d163.s44|0-1|No|drug
DDI-DrugBank.d163.s44|3-7|cases|drug
DDI-DrugBank.d163.s44|9-10|of|drug
DDI-DrugBank.d163.s44|12-25|rhabdomyolysis|drug
DDI-DrugBank.d163.s44|27-30|were|drug
DDI-DrugBank.d163.s44|32-39|reported|drug
DDI-DrugBank.d163.s44|41-42|in|drug
DDI-DrugBank.d163.s44|44-47|this|drug
DDI-DrugBank.d163.s44|49-53|trial|drug
DDI-DrugBank.d163.s44|54-54|.|drug
DDI-MedLine.d180.s0|0-11|Determinants|drug
DDI-MedLine.d180.s0|13-14|of|drug
DDI-MedLine.d180.s0|16-26|sensitivity|drug
DDI-MedLine.d180.s0|28-29|to|drug
DDI-MedLine.d180.s0|31-35|DZNep|drug
DDI-MedLine.d180.s0|37-43|induced|drug
DDI-MedLine.d180.s0|45-53|apoptosis|drug
DDI-MedLine.d180.s0|55-56|in|drug
DDI-MedLine.d180.s0|58-65|multiple|drug
DDI-MedLine.d180.s0|67-73|myeloma|drug
DDI-MedLine.d180.s0|75-79|cells|drug
DDI-MedLine.d180.s0|80-80|.|drug
DDI-MedLine.d180.s1|0-2|The|drug
DDI-MedLine.d180.s1|4-20|3-Deazaneplanocin|drug
DDI-MedLine.d180.s1|22-22|A|drug
DDI-MedLine.d180.s1|24-24|(|drug
DDI-MedLine.d180.s1|25-29|DZNep|drug
DDI-MedLine.d180.s1|30-30|)|drug
DDI-MedLine.d180.s1|31-31|,|drug
DDI-MedLine.d180.s1|33-35|one|drug
DDI-MedLine.d180.s1|37-38|of|drug
DDI-MedLine.d180.s1|40-61|S-adenosylhomocysteine|drug
DDI-MedLine.d180.s1|63-63|(|drug
DDI-MedLine.d180.s1|64-69|AdoHcy|drug
DDI-MedLine.d180.s1|70-70|)|drug
DDI-MedLine.d180.s1|72-80|hydrolase|drug
DDI-MedLine.d180.s1|82-91|inhibitors|drug
DDI-MedLine.d180.s1|92-92|,|drug
DDI-MedLine.d180.s1|94-96|has|drug
DDI-MedLine.d180.s1|98-102|shown|drug
DDI-MedLine.d180.s1|104-112|antitumor|drug
DDI-MedLine.d180.s1|114-123|activities|drug
DDI-MedLine.d180.s1|125-126|in|drug
DDI-MedLine.d180.s1|128-128|a|drug
DDI-MedLine.d180.s1|130-134|broad|drug
DDI-MedLine.d180.s1|136-140|range|drug
DDI-MedLine.d180.s1|142-143|of|drug
DDI-MedLine.d180.s1|145-149|solid|drug
DDI-MedLine.d180.s1|151-156|tumors|drug
DDI-MedLine.d180.s1|158-160|and|drug
DDI-MedLine.d180.s1|162-166|acute|drug
DDI-MedLine.d180.s1|168-174|myeloid|drug
DDI-MedLine.d180.s1|176-183|leukemia|drug
DDI-MedLine.d180.s1|184-184|.|drug
DDI-MedLine.d180.s2|0-3|Here|drug
DDI-MedLine.d180.s2|4-4|,|drug
DDI-MedLine.d180.s2|6-7|we|drug
DDI-MedLine.d180.s2|9-16|examined|drug
DDI-MedLine.d180.s2|18-20|its|drug
DDI-MedLine.d180.s2|22-28|effects|drug
DDI-MedLine.d180.s2|30-31|on|drug
DDI-MedLine.d180.s2|33-40|multiple|drug
DDI-MedLine.d180.s2|42-48|myeloma|drug
DDI-MedLine.d180.s2|50-50|(|drug
DDI-MedLine.d180.s2|51-52|MM|drug
DDI-MedLine.d180.s2|53-53|)|drug
DDI-MedLine.d180.s2|55-59|cells|drug
DDI-MedLine.d180.s2|61-63|and|drug
DDI-MedLine.d180.s2|65-69|found|drug
DDI-MedLine.d180.s2|71-74|that|drug
DDI-MedLine.d180.s2|75-75|,|drug
DDI-MedLine.d180.s2|77-78|at|drug
DDI-MedLine.d180.s2|80-82|500|drug
DDI-MedLine.d180.s2|84-85|nM|drug
DDI-MedLine.d180.s2|86-86|,|drug
DDI-MedLine.d180.s2|88-89|it|drug
DDI-MedLine.d180.s2|91-98|potently|drug
DDI-MedLine.d180.s2|100-108|inhibited|drug
DDI-MedLine.d180.s2|110-115|growth|drug
DDI-MedLine.d180.s2|117-119|and|drug
DDI-MedLine.d180.s2|121-127|induced|drug
DDI-MedLine.d180.s2|129-137|apoptosis|drug
DDI-MedLine.d180.s2|139-140|in|drug
DDI-MedLine.d180.s2|142-142|2|drug
DDI-MedLine.d180.s2|144-145|of|drug
DDI-MedLine.d180.s2|147-147|8|drug
DDI-MedLine.d180.s2|149-150|MM|drug
DDI-MedLine.d180.s2|152-155|cell|drug
DDI-MedLine.d180.s2|157-161|lines|drug
DDI-MedLine.d180.s2|162-162|.|drug
DDI-MedLine.d180.s3|0-2|RNA|drug
DDI-MedLine.d180.s3|4-7|from|drug
DDI-MedLine.d180.s3|9-18|un-treated|drug
DDI-MedLine.d180.s3|20-22|and|drug
DDI-MedLine.d180.s3|24-28|DZNep|drug
DDI-MedLine.d180.s3|30-36|treated|drug
DDI-MedLine.d180.s3|38-42|cells|drug
DDI-MedLine.d180.s3|44-46|was|drug
DDI-MedLine.d180.s3|48-55|profiled|drug
DDI-MedLine.d180.s3|57-58|by|drug
DDI-MedLine.d180.s3|60-69|Affymetrix|drug
DDI-MedLine.d180.s3|71-77|HG-U133|drug
DDI-MedLine.d180.s3|79-82|Plus|drug
DDI-MedLine.d180.s3|84-86|2.0|drug
DDI-MedLine.d180.s3|88-97|microarray|drug
DDI-MedLine.d180.s3|99-101|and|drug
DDI-MedLine.d180.s3|103-107|genes|drug
DDI-MedLine.d180.s3|109-112|with|drug
DDI-MedLine.d180.s3|114-114|a|drug
DDI-MedLine.d180.s3|116-126|significant|drug
DDI-MedLine.d180.s3|128-133|change|drug
DDI-MedLine.d180.s3|135-136|in|drug
DDI-MedLine.d180.s3|138-141|gene|drug
DDI-MedLine.d180.s3|143-152|expression|drug
DDI-MedLine.d180.s3|154-157|were|drug
DDI-MedLine.d180.s3|159-168|determined|drug
DDI-MedLine.d180.s3|170-171|by|drug
DDI-MedLine.d180.s3|173-184|significance|drug
DDI-MedLine.d180.s3|186-193|analysis|drug
DDI-MedLine.d180.s3|195-196|of|drug
DDI-MedLine.d180.s3|198-207|microarray|drug
DDI-MedLine.d180.s3|209-209|(|drug
DDI-MedLine.d180.s3|210-212|SAM|drug
DDI-MedLine.d180.s3|213-213|)|drug
DDI-MedLine.d180.s3|215-221|testing|drug
DDI-MedLine.d180.s3|222-222|.|drug
DDI-MedLine.d180.s4|0-4|ALOX5|drug
DDI-MedLine.d180.s4|6-8|was|drug
DDI-MedLine.d180.s4|10-12|the|drug
DDI-MedLine.d180.s4|14-17|most|drug
DDI-MedLine.d180.s4|19-32|down-regulated|drug
DDI-MedLine.d180.s4|34-37|gene|drug
DDI-MedLine.d180.s4|39-39|(|drug
DDI-MedLine.d180.s4|40-47|5.8-fold|drug
DDI-MedLine.d180.s4|48-48|)|drug
DDI-MedLine.d180.s4|50-51|in|drug
DDI-MedLine.d180.s4|53-61|sensitive|drug
DDI-MedLine.d180.s4|63-67|cells|drug
DDI-MedLine.d180.s4|69-71|and|drug
DDI-MedLine.d180.s4|73-75|was|drug
DDI-MedLine.d180.s4|77-85|expressed|drug
DDI-MedLine.d180.s4|87-88|at|drug
DDI-MedLine.d180.s4|90-92|low|drug
DDI-MedLine.d180.s4|94-98|level|drug
DDI-MedLine.d180.s4|100-101|in|drug
DDI-MedLine.d180.s4|103-111|resistant|drug
DDI-MedLine.d180.s4|113-117|cells|drug
DDI-MedLine.d180.s4|118-118|.|drug
DDI-MedLine.d180.s5|0-2|The|drug
DDI-MedLine.d180.s5|4-10|results|drug
DDI-MedLine.d180.s5|12-15|were|drug
DDI-MedLine.d180.s5|17-28|corroborated|drug
DDI-MedLine.d180.s5|30-31|by|drug
DDI-MedLine.d180.s5|33-44|quantitative|drug
DDI-MedLine.d180.s5|46-51|RT-PCR|drug
DDI-MedLine.d180.s5|52-52|.|drug
DDI-MedLine.d180.s6|0-11|Western-blot|drug
DDI-MedLine.d180.s6|13-20|analysis|drug
DDI-MedLine.d180.s6|22-30|indicated|drug
DDI-MedLine.d180.s6|32-36|ALOX5|drug
DDI-MedLine.d180.s6|38-40|was|drug
DDI-MedLine.d180.s6|42-47|highly|drug
DDI-MedLine.d180.s6|49-57|expressed|drug
DDI-MedLine.d180.s6|59-62|only|drug
DDI-MedLine.d180.s6|64-65|in|drug
DDI-MedLine.d180.s6|67-75|sensitive|drug
DDI-MedLine.d180.s6|77-80|cell|drug
DDI-MedLine.d180.s6|82-85|line|drug
DDI-MedLine.d180.s6|87-90|H929|drug
DDI-MedLine.d180.s6|92-94|and|drug
DDI-MedLine.d180.s6|96-102|greatly|drug
DDI-MedLine.d180.s6|104-112|decreased|drug
DDI-MedLine.d180.s6|114-117|upon|drug
DDI-MedLine.d180.s6|119-123|DZNep|drug
DDI-MedLine.d180.s6|125-133|treatment|drug
DDI-MedLine.d180.s6|134-134|.|drug
DDI-MedLine.d180.s7|0-6|Ectopic|drug
DDI-MedLine.d180.s7|8-17|expression|drug
DDI-MedLine.d180.s7|19-20|of|drug
DDI-MedLine.d180.s7|22-26|ALOX5|drug
DDI-MedLine.d180.s7|28-34|reduced|drug
DDI-MedLine.d180.s7|36-46|sensitivity|drug
DDI-MedLine.d180.s7|48-49|to|drug
DDI-MedLine.d180.s7|51-55|DZNep|drug
DDI-MedLine.d180.s7|57-58|in|drug
DDI-MedLine.d180.s7|60-63|H929|drug
DDI-MedLine.d180.s7|65-69|cells|drug
DDI-MedLine.d180.s7|70-70|.|drug
DDI-MedLine.d180.s8|0-10|Furthermore|drug
DDI-MedLine.d180.s8|11-11|,|drug
DDI-MedLine.d180.s8|13-27|down-regulation|drug
DDI-MedLine.d180.s8|29-30|of|drug
DDI-MedLine.d180.s8|32-36|ALOX5|drug
DDI-MedLine.d180.s8|38-39|by|drug
DDI-MedLine.d180.s8|41-43|RNA|drug
DDI-MedLine.d180.s8|45-56|interference|drug
DDI-MedLine.d180.s8|58-62|could|drug
DDI-MedLine.d180.s8|64-67|also|drug
DDI-MedLine.d180.s8|69-74|induce|drug
DDI-MedLine.d180.s8|76-84|apoptosis|drug
DDI-MedLine.d180.s8|86-87|in|drug
DDI-MedLine.d180.s8|89-92|H929|drug
DDI-MedLine.d180.s8|93-93|.|drug
DDI-MedLine.d180.s9|0-3|Gene|drug
DDI-MedLine.d180.s9|5-14|expression|drug
DDI-MedLine.d180.s9|16-23|analysis|drug
DDI-MedLine.d180.s9|25-26|on|drug
DDI-MedLine.d180.s9|28-29|MM|drug
DDI-MedLine.d180.s9|31-37|patient|drug
DDI-MedLine.d180.s9|39-45|dataset|drug
DDI-MedLine.d180.s9|47-55|indicated|drug
DDI-MedLine.d180.s9|57-61|ALOX5|drug
DDI-MedLine.d180.s9|63-72|expression|drug
DDI-MedLine.d180.s9|74-76|was|drug
DDI-MedLine.d180.s9|78-90|significantly|drug
DDI-MedLine.d180.s9|92-97|higher|drug
DDI-MedLine.d180.s9|99-100|in|drug
DDI-MedLine.d180.s9|102-103|MM|drug
DDI-MedLine.d180.s9|105-112|patients|drug
DDI-MedLine.d180.s9|114-121|compared|drug
DDI-MedLine.d180.s9|123-124|to|drug
DDI-MedLine.d180.s9|126-131|normal|drug
DDI-MedLine.d180.s9|133-138|plasma|drug
DDI-MedLine.d180.s9|140-144|cells|drug
DDI-MedLine.d180.s9|145-145|.|drug
DDI-MedLine.d180.s10|0-1|We|drug
DDI-MedLine.d180.s10|3-6|also|drug
DDI-MedLine.d180.s10|8-12|found|drug
DDI-MedLine.d180.s10|14-17|that|drug
DDI-MedLine.d180.s10|19-23|Bcl-2|drug
DDI-MedLine.d180.s10|25-27|was|drug
DDI-MedLine.d180.s10|29-41|overexpressed|drug
DDI-MedLine.d180.s10|43-44|in|drug
DDI-MedLine.d180.s10|46-50|DZNep|drug
DDI-MedLine.d180.s10|52-62|insensitive|drug
DDI-MedLine.d180.s10|64-68|cells|drug
DDI-MedLine.d180.s10|69-69|,|drug
DDI-MedLine.d180.s10|71-73|and|drug
DDI-MedLine.d180.s10|75-85|cotreatment|drug
DDI-MedLine.d180.s10|87-90|with|drug
DDI-MedLine.d180.s10|92-96|DZNep|drug
DDI-MedLine.d180.s10|98-100|and|drug
DDI-MedLine.d180.s10|102-108|ABT-737|drug
DDI-MedLine.d180.s10|109-109|,|drug
DDI-MedLine.d180.s10|111-111|a|drug
DDI-MedLine.d180.s10|113-117|Bcl-2|drug
DDI-MedLine.d180.s10|119-124|family|drug
DDI-MedLine.d180.s10|126-134|inhibitor|drug
DDI-MedLine.d180.s10|135-135|,|drug
DDI-MedLine.d180.s10|137-151|synergistically|drug
DDI-MedLine.d180.s10|153-161|inhibited|drug
DDI-MedLine.d180.s10|163-168|growth|drug
DDI-MedLine.d180.s10|170-172|and|drug
DDI-MedLine.d180.s10|174-180|induced|drug
DDI-MedLine.d180.s10|182-190|apoptosis|drug
DDI-MedLine.d180.s10|192-193|of|drug
DDI-MedLine.d180.s10|195-199|DZNep|drug
DDI-MedLine.d180.s10|201-211|insensitive|drug
DDI-MedLine.d180.s10|213-214|MM|drug
DDI-MedLine.d180.s10|216-220|cells|drug
DDI-MedLine.d180.s10|221-221|.|drug
DDI-MedLine.d180.s11|0-4|Taken|drug
DDI-MedLine.d180.s11|6-13|together|drug
DDI-MedLine.d180.s11|14-14|,|drug
DDI-MedLine.d180.s11|16-19|this|drug
DDI-MedLine.d180.s11|21-25|study|drug
DDI-MedLine.d180.s11|27-31|shows|drug
DDI-MedLine.d180.s11|33-35|one|drug
DDI-MedLine.d180.s11|37-38|of|drug
DDI-MedLine.d180.s11|40-49|mechanisms|drug
DDI-MedLine.d180.s11|51-52|of|drug
DDI-MedLine.d180.s11|54-56|the|drug
DDI-MedLine.d180.s11|58-62|DZNep|drug
DDI-MedLine.d180.s11|64-71|efficacy|drug
DDI-MedLine.d180.s11|73-74|on|drug
DDI-MedLine.d180.s11|76-77|MM|drug
DDI-MedLine.d180.s11|79-88|correlates|drug
DDI-MedLine.d180.s11|90-93|with|drug
DDI-MedLine.d180.s11|95-97|its|drug
DDI-MedLine.d180.s11|99-105|ability|drug
DDI-MedLine.d180.s11|107-108|to|drug
DDI-MedLine.d180.s11|110-122|down-regulate|drug
DDI-MedLine.d180.s11|124-126|the|drug
DDI-MedLine.d180.s11|128-132|ALOX5|drug
DDI-MedLine.d180.s11|134-139|levels|drug
DDI-MedLine.d180.s11|140-140|.|drug
DDI-MedLine.d180.s12|0-1|In|drug
DDI-MedLine.d180.s12|3-10|addition|drug
DDI-MedLine.d180.s12|11-11|,|drug
DDI-MedLine.d180.s12|13-17|DZNep|drug
DDI-MedLine.d180.s12|19-31|insensitivity|drug
DDI-MedLine.d180.s12|33-37|might|drug
DDI-MedLine.d180.s12|39-40|be|drug
DDI-MedLine.d180.s12|42-51|associated|drug
DDI-MedLine.d180.s12|53-56|with|drug
DDI-MedLine.d180.s12|58-71|overexpression|drug
DDI-MedLine.d180.s12|73-74|of|drug
DDI-MedLine.d180.s12|76-80|Bcl-2|drug
DDI-MedLine.d180.s12|81-81|,|drug
DDI-MedLine.d180.s12|83-85|and|drug
DDI-MedLine.d180.s12|87-89|the|drug
DDI-MedLine.d180.s12|91-101|combination|drug
DDI-MedLine.d180.s12|103-104|of|drug
DDI-MedLine.d180.s12|106-112|ABT-737|drug
DDI-MedLine.d180.s12|114-116|and|drug
DDI-MedLine.d180.s12|118-122|DZNep|drug
DDI-MedLine.d180.s12|124-128|could|drug
DDI-MedLine.d180.s12|130-144|synergistically|drug
DDI-MedLine.d180.s12|146-152|induced|drug
DDI-MedLine.d180.s12|154-162|apoptosis|drug
DDI-MedLine.d180.s12|163-163|.|drug
DDI-MedLine.d180.s13|0-4|These|drug
DDI-MedLine.d180.s13|6-12|results|drug
DDI-MedLine.d180.s13|14-20|suggest|drug
DDI-MedLine.d180.s13|22-25|that|drug
DDI-MedLine.d180.s13|27-31|DZNep|drug
DDI-MedLine.d180.s13|33-35|may|drug
DDI-MedLine.d180.s13|37-38|be|drug
DDI-MedLine.d180.s13|40-48|exploited|drug
DDI-MedLine.d180.s13|50-64|therapeutically|drug
DDI-MedLine.d180.s13|66-68|for|drug
DDI-MedLine.d180.s13|70-70|a|drug
DDI-MedLine.d180.s13|72-77|subset|drug
DDI-MedLine.d180.s13|79-80|of|drug
DDI-MedLine.d180.s13|82-83|MM|drug
DDI-MedLine.d180.s13|84-84|.|drug
DDI-DrugBank.d509.s0|0-8|Drug-Drug|drug
DDI-DrugBank.d509.s0|10-21|Interactions|drug
DDI-DrugBank.d509.s0|23-27|Given|drug
DDI-DrugBank.d509.s0|29-31|the|drug
DDI-DrugBank.d509.s0|33-39|primary|drug
DDI-DrugBank.d509.s0|41-43|CNS|drug
DDI-DrugBank.d509.s0|45-51|effects|drug
DDI-DrugBank.d509.s0|53-54|of|drug
DDI-DrugBank.d509.s0|56-67|aripiprazole|drug
DDI-DrugBank.d509.s0|68-68|,|drug
DDI-DrugBank.d509.s0|70-76|caution|drug
DDI-DrugBank.d509.s0|78-83|should|drug
DDI-DrugBank.d509.s0|85-86|be|drug
DDI-DrugBank.d509.s0|88-91|used|drug
DDI-DrugBank.d509.s0|93-96|when|drug
DDI-DrugBank.d509.s0|98-104|ABILIFY|drug
DDI-DrugBank.d509.s0|106-107|is|drug
DDI-DrugBank.d509.s0|109-113|taken|drug
DDI-DrugBank.d509.s0|115-116|in|drug
DDI-DrugBank.d509.s0|118-128|combination|drug
DDI-DrugBank.d509.s0|130-133|with|drug
DDI-DrugBank.d509.s0|135-139|other|drug
DDI-DrugBank.d509.s0|141-149|centrally|drug
DDI-DrugBank.d509.s0|151-156|acting|drug
DDI-DrugBank.d509.s0|158-162|drugs|drug
DDI-DrugBank.d509.s0|164-166|and|drug
DDI-DrugBank.d509.s0|168-174|alcohol|drug
DDI-DrugBank.d509.s0|175-175|.|drug
DDI-DrugBank.d509.s1|0-2|Due|drug
DDI-DrugBank.d509.s1|4-5|to|drug
DDI-DrugBank.d509.s1|7-9|its|drug
DDI-DrugBank.d509.s2|0-1|1-|drug
DDI-DrugBank.d509.s2|3-12|adrenergic|drug
DDI-DrugBank.d509.s2|14-21|receptor|drug
DDI-DrugBank.d509.s2|23-32|antagonism|drug
DDI-DrugBank.d509.s2|33-33|,|drug
DDI-DrugBank.d509.s2|35-46|aripiprazole|drug
DDI-DrugBank.d509.s2|48-50|has|drug
DDI-DrugBank.d509.s2|52-54|the|drug
DDI-DrugBank.d509.s2|56-64|potential|drug
DDI-DrugBank.d509.s2|66-67|to|drug
DDI-DrugBank.d509.s2|69-75|enhance|drug
DDI-DrugBank.d509.s2|77-79|the|drug
DDI-DrugBank.d509.s2|81-86|effect|drug
DDI-DrugBank.d509.s2|88-89|of|drug
DDI-DrugBank.d509.s2|91-97|certain|drug
DDI-DrugBank.d509.s2|99-114|antihypertensive|drug
DDI-DrugBank.d509.s2|116-121|agents|drug
DDI-DrugBank.d509.s2|122-122|.|drug
DDI-DrugBank.d509.s3|0-8|Potential|drug
DDI-DrugBank.d509.s3|10-12|for|drug
DDI-DrugBank.d509.s3|14-18|Other|drug
DDI-DrugBank.d509.s3|20-24|Drugs|drug
DDI-DrugBank.d509.s3|26-27|to|drug
DDI-DrugBank.d509.s3|29-34|Affect|drug
DDI-DrugBank.d509.s3|36-42|ABILIFY|drug
DDI-DrugBank.d509.s3|44-55|Aripiprazole|brand
DDI-DrugBank.d509.s3|57-58|is|drug
DDI-DrugBank.d509.s3|60-62|not|drug
DDI-DrugBank.d509.s3|64-64|a|drug
DDI-DrugBank.d509.s3|66-74|substrate|drug
DDI-DrugBank.d509.s3|76-77|of|drug
DDI-DrugBank.d509.s3|79-84|CYP1A1|drug
DDI-DrugBank.d509.s3|85-85|,|drug
DDI-DrugBank.d509.s3|87-92|CYP1A2|drug
DDI-DrugBank.d509.s3|93-93|,|drug
DDI-DrugBank.d509.s3|95-100|CYP2A6|drug
DDI-DrugBank.d509.s3|101-101|,|drug
DDI-DrugBank.d509.s3|103-108|CYP2B6|drug
DDI-DrugBank.d509.s3|109-109|,|drug
DDI-DrugBank.d509.s3|111-116|CYP2C8|drug
DDI-DrugBank.d509.s3|117-117|,|drug
DDI-DrugBank.d509.s3|119-124|CYP2C9|drug
DDI-DrugBank.d509.s3|125-125|,|drug
DDI-DrugBank.d509.s3|127-133|CYP2C19|drug
DDI-DrugBank.d509.s3|134-134|,|drug
DDI-DrugBank.d509.s3|136-137|or|drug
DDI-DrugBank.d509.s3|139-144|CYP2E1|drug
DDI-DrugBank.d509.s3|146-152|enzymes|drug
DDI-DrugBank.d509.s3|153-153|.|drug
DDI-DrugBank.d509.s4|0-11|Aripiprazole|brand
DDI-DrugBank.d509.s4|13-16|also|drug
DDI-DrugBank.d509.s4|18-21|does|drug
DDI-DrugBank.d509.s4|23-25|not|drug
DDI-DrugBank.d509.s4|27-33|undergo|drug
DDI-DrugBank.d509.s4|35-40|direct|drug
DDI-DrugBank.d509.s4|42-56|glucuronidation|drug
DDI-DrugBank.d509.s4|57-57|.|drug
DDI-DrugBank.d509.s5|0-3|This|drug
DDI-DrugBank.d509.s5|5-12|suggests|drug
DDI-DrugBank.d509.s5|14-17|that|drug
DDI-DrugBank.d509.s5|19-20|an|drug
DDI-DrugBank.d509.s5|22-32|interaction|drug
DDI-DrugBank.d509.s5|34-35|of|drug
DDI-DrugBank.d509.s5|37-48|aripiprazole|drug
DDI-DrugBank.d509.s5|50-53|with|drug
DDI-DrugBank.d509.s5|55-64|inhibitors|drug
DDI-DrugBank.d509.s5|66-67|or|drug
DDI-DrugBank.d509.s5|69-76|inducers|drug
DDI-DrugBank.d509.s5|78-79|of|drug
DDI-DrugBank.d509.s5|81-85|these|drug
DDI-DrugBank.d509.s5|87-93|enzymes|drug
DDI-DrugBank.d509.s5|94-94|,|drug
DDI-DrugBank.d509.s5|96-97|or|drug
DDI-DrugBank.d509.s5|99-103|other|drug
DDI-DrugBank.d509.s5|105-111|factors|drug
DDI-DrugBank.d509.s5|112-112|,|drug
DDI-DrugBank.d509.s5|114-117|like|drug
DDI-DrugBank.d509.s5|119-125|smoking|drug
DDI-DrugBank.d509.s5|126-126|,|drug
DDI-DrugBank.d509.s5|128-129|is|drug
DDI-DrugBank.d509.s5|131-138|unlikely|drug
DDI-DrugBank.d509.s5|139-139|.|drug
DDI-DrugBank.d509.s6|0-3|Both|drug
DDI-DrugBank.d509.s6|5-10|CYP3A4|drug
DDI-DrugBank.d509.s6|12-14|and|drug
DDI-DrugBank.d509.s6|16-21|CYP2D6|drug
DDI-DrugBank.d509.s6|23-25|are|drug
DDI-DrugBank.d509.s6|27-37|responsible|drug
DDI-DrugBank.d509.s6|39-41|for|drug
DDI-DrugBank.d509.s6|43-54|aripiprazole|drug
DDI-DrugBank.d509.s6|56-65|metabolism|drug
DDI-DrugBank.d509.s6|66-66|.|drug
DDI-DrugBank.d509.s7|0-5|Agents|drug
DDI-DrugBank.d509.s7|7-10|that|drug
DDI-DrugBank.d509.s7|12-17|induce|drug
DDI-DrugBank.d509.s7|19-24|CYP3A4|drug
DDI-DrugBank.d509.s7|26-26|(|drug
DDI-DrugBank.d509.s7|27-28|eg|drug
DDI-DrugBank.d509.s7|29-29|,|drug
DDI-DrugBank.d509.s7|31-43|carbamazepine|drug
DDI-DrugBank.d509.s7|44-44|)|drug
DDI-DrugBank.d509.s7|46-50|could|drug
DDI-DrugBank.d509.s7|52-56|cause|drug
DDI-DrugBank.d509.s7|58-59|an|drug
DDI-DrugBank.d509.s7|61-68|increase|drug
DDI-DrugBank.d509.s7|70-71|in|drug
DDI-DrugBank.d509.s7|73-84|aripiprazole|drug
DDI-DrugBank.d509.s7|86-94|clearance|drug
DDI-DrugBank.d509.s7|96-98|and|drug
DDI-DrugBank.d509.s7|100-104|lower|drug
DDI-DrugBank.d509.s7|106-110|blood|drug
DDI-DrugBank.d509.s7|112-117|levels|drug
DDI-DrugBank.d509.s7|118-118|.|drug
DDI-DrugBank.d509.s8|0-9|Inhibitors|drug
DDI-DrugBank.d509.s8|11-12|of|drug
DDI-DrugBank.d509.s8|14-19|CYP3A4|drug
DDI-DrugBank.d509.s8|21-21|(|drug
DDI-DrugBank.d509.s8|22-23|eg|drug
DDI-DrugBank.d509.s8|24-24|,|drug
DDI-DrugBank.d509.s8|26-37|ketoconazole|drug
DDI-DrugBank.d509.s8|38-38|)|drug
DDI-DrugBank.d509.s8|40-41|or|drug
DDI-DrugBank.d509.s8|43-48|CYP2D6|drug
DDI-DrugBank.d509.s8|50-50|(|drug
DDI-DrugBank.d509.s8|51-52|eg|drug
DDI-DrugBank.d509.s8|53-53|,|drug
DDI-DrugBank.d509.s8|55-63|quinidine|drug
DDI-DrugBank.d509.s8|64-64|,|drug
DDI-DrugBank.d509.s8|66-75|fluoxetine|drug
DDI-DrugBank.d509.s8|76-76|,|drug
DDI-DrugBank.d509.s8|78-79|or|drug
DDI-DrugBank.d509.s8|81-90|paroxetine|drug
DDI-DrugBank.d509.s8|91-91|)|drug
DDI-DrugBank.d509.s8|93-95|can|drug
DDI-DrugBank.d509.s8|97-103|inhibit|drug
DDI-DrugBank.d509.s8|105-116|aripiprazole|drug
DDI-DrugBank.d509.s8|118-128|elimination|drug
DDI-DrugBank.d509.s8|130-132|and|drug
DDI-DrugBank.d509.s8|134-138|cause|drug
DDI-DrugBank.d509.s8|140-148|increased|drug
DDI-DrugBank.d509.s8|150-154|blood|drug
DDI-DrugBank.d509.s8|156-161|levels|drug
DDI-DrugBank.d509.s8|162-162|.|drug
DDI-DrugBank.d509.s9|0-11|Ketoconazole|brand
DDI-DrugBank.d509.s9|12-12|:|drug
DDI-DrugBank.d509.s9|14-29|Coadministration|drug
DDI-DrugBank.d509.s9|31-32|of|drug
DDI-DrugBank.d509.s9|34-45|ketoconazole|drug
DDI-DrugBank.d509.s9|47-47|(|drug
DDI-DrugBank.d509.s9|48-50|200|drug
DDI-DrugBank.d509.s9|52-57|mg/day|drug
DDI-DrugBank.d509.s9|59-61|for|drug
DDI-DrugBank.d509.s9|63-64|14|drug
DDI-DrugBank.d509.s9|66-69|days|drug
DDI-DrugBank.d509.s9|70-70|)|drug
DDI-DrugBank.d509.s9|72-75|with|drug
DDI-DrugBank.d509.s9|77-77|a|drug
DDI-DrugBank.d509.s9|79-83|15-mg|drug
DDI-DrugBank.d509.s9|85-90|single|drug
DDI-DrugBank.d509.s9|92-95|dose|drug
DDI-DrugBank.d509.s9|97-98|of|drug
DDI-DrugBank.d509.s9|100-111|aripiprazole|drug
DDI-DrugBank.d509.s9|113-121|increased|drug
DDI-DrugBank.d509.s9|123-125|the|drug
DDI-DrugBank.d509.s9|127-129|AUC|drug
DDI-DrugBank.d509.s9|131-132|of|drug
DDI-DrugBank.d509.s9|134-145|aripiprazole|drug
DDI-DrugBank.d509.s9|147-149|and|drug
DDI-DrugBank.d509.s9|151-153|its|drug
DDI-DrugBank.d509.s9|155-160|active|drug
DDI-DrugBank.d509.s9|162-171|metabolite|drug
DDI-DrugBank.d509.s9|173-174|by|drug
DDI-DrugBank.d509.s9|176-177|63|drug
DDI-DrugBank.d509.s9|178-178|%|drug
DDI-DrugBank.d509.s9|180-182|and|drug
DDI-DrugBank.d509.s9|184-185|77|drug
DDI-DrugBank.d509.s9|186-186|%|drug
DDI-DrugBank.d509.s9|187-187|,|drug
DDI-DrugBank.d509.s9|189-200|respectively|drug
DDI-DrugBank.d509.s9|201-201|.|drug
DDI-DrugBank.d509.s10|0-2|The|drug
DDI-DrugBank.d509.s10|4-9|effect|drug
DDI-DrugBank.d509.s10|11-12|of|drug
DDI-DrugBank.d509.s10|14-14|a|drug
DDI-DrugBank.d509.s10|16-21|higher|drug
DDI-DrugBank.d509.s10|23-34|ketoconazole|drug
DDI-DrugBank.d509.s10|36-39|dose|drug
DDI-DrugBank.d509.s10|41-41|(|drug
DDI-DrugBank.d509.s10|42-44|400|drug
DDI-DrugBank.d509.s10|46-51|mg/day|drug
DDI-DrugBank.d509.s10|52-52|)|drug
DDI-DrugBank.d509.s10|54-56|has|drug
DDI-DrugBank.d509.s10|58-60|not|drug
DDI-DrugBank.d509.s10|62-65|been|drug
DDI-DrugBank.d509.s10|67-73|studied|drug
DDI-DrugBank.d509.s10|74-74|.|drug
DDI-DrugBank.d509.s11|0-3|When|drug
DDI-DrugBank.d509.s11|5-15|concomitant|drug
DDI-DrugBank.d509.s11|17-30|administration|drug
DDI-DrugBank.d509.s11|32-33|of|drug
DDI-DrugBank.d509.s11|35-46|ketoconazole|drug
DDI-DrugBank.d509.s11|48-51|with|drug
DDI-DrugBank.d509.s11|53-64|aripiprazole|drug
DDI-DrugBank.d509.s11|66-71|occurs|drug
DDI-DrugBank.d509.s11|72-72|,|drug
DDI-DrugBank.d509.s11|74-85|aripiprazole|drug
DDI-DrugBank.d509.s11|87-90|dose|drug
DDI-DrugBank.d509.s11|92-97|should|drug
DDI-DrugBank.d509.s11|99-100|be|drug
DDI-DrugBank.d509.s11|102-108|reduced|drug
DDI-DrugBank.d509.s11|110-111|to|drug
DDI-DrugBank.d509.s11|113-120|one-half|drug
DDI-DrugBank.d509.s11|122-123|of|drug
DDI-DrugBank.d509.s11|125-127|its|drug
DDI-DrugBank.d509.s11|129-134|normal|drug
DDI-DrugBank.d509.s11|136-139|dose|drug
DDI-DrugBank.d509.s11|140-140|.|drug
DDI-DrugBank.d509.s12|0-4|Other|drug
DDI-DrugBank.d509.s12|6-11|strong|drug
DDI-DrugBank.d509.s12|13-22|inhibitors|drug
DDI-DrugBank.d509.s12|24-25|of|drug
DDI-DrugBank.d509.s12|27-32|CYP3A4|drug
DDI-DrugBank.d509.s12|34-34|(|drug
DDI-DrugBank.d509.s12|35-46|itraconazole|drug
DDI-DrugBank.d509.s12|47-47|)|drug
DDI-DrugBank.d509.s12|49-53|would|drug
DDI-DrugBank.d509.s12|55-56|be|drug
DDI-DrugBank.d509.s12|58-65|expected|drug
DDI-DrugBank.d509.s12|67-68|to|drug
DDI-DrugBank.d509.s12|70-73|have|drug
DDI-DrugBank.d509.s12|75-81|similar|drug
DDI-DrugBank.d509.s12|83-89|effects|drug
DDI-DrugBank.d509.s12|91-93|and|drug
DDI-DrugBank.d509.s12|95-98|need|drug
DDI-DrugBank.d509.s12|100-106|similar|drug
DDI-DrugBank.d509.s12|108-111|dose|drug
DDI-DrugBank.d509.s12|113-122|reductions|drug
DDI-DrugBank.d509.s12|123-123|;|drug
DDI-DrugBank.d509.s13|0-5|weaker|drug
DDI-DrugBank.d509.s13|7-16|inhibitors|drug
DDI-DrugBank.d509.s13|18-18|(|drug
DDI-DrugBank.d509.s13|19-30|erythromycin|drug
DDI-DrugBank.d509.s13|31-31|,|drug
DDI-DrugBank.d509.s13|33-42|grapefruit|drug
DDI-DrugBank.d509.s13|44-48|juice|drug
DDI-DrugBank.d509.s13|49-49|)|drug
DDI-DrugBank.d509.s13|51-54|have|drug
DDI-DrugBank.d509.s13|56-58|not|drug
DDI-DrugBank.d509.s13|60-63|been|drug
DDI-DrugBank.d509.s13|65-71|studied|drug
DDI-DrugBank.d509.s13|72-72|.|drug
DDI-DrugBank.d509.s14|0-3|When|drug
DDI-DrugBank.d509.s14|5-7|the|drug
DDI-DrugBank.d509.s14|9-14|CYP3A4|drug
DDI-DrugBank.d509.s14|16-24|inhibitor|drug
DDI-DrugBank.d509.s14|26-27|is|drug
DDI-DrugBank.d509.s14|29-37|withdrawn|drug
DDI-DrugBank.d509.s14|39-42|from|drug
DDI-DrugBank.d509.s14|44-46|the|drug
DDI-DrugBank.d509.s14|48-58|combination|drug
DDI-DrugBank.d509.s14|60-66|therapy|drug
DDI-DrugBank.d509.s14|67-67|,|drug
DDI-DrugBank.d509.s14|69-80|aripiprazole|drug
DDI-DrugBank.d509.s14|82-85|dose|drug
DDI-DrugBank.d509.s14|87-92|should|drug
DDI-DrugBank.d509.s14|94-97|then|drug
DDI-DrugBank.d509.s14|99-100|be|drug
DDI-DrugBank.d509.s14|102-110|increased|drug
DDI-DrugBank.d509.s14|111-111|.|drug
DDI-DrugBank.d509.s15|0-8|Quinidine|drug
DDI-DrugBank.d509.s15|9-9|:|drug
DDI-DrugBank.d509.s15|11-26|Coadministration|drug
DDI-DrugBank.d509.s15|28-29|of|drug
DDI-DrugBank.d509.s15|31-31|a|drug
DDI-DrugBank.d509.s15|33-37|10-mg|drug
DDI-DrugBank.d509.s15|39-44|single|drug
DDI-DrugBank.d509.s15|46-49|dose|drug
DDI-DrugBank.d509.s15|51-52|of|drug
DDI-DrugBank.d509.s15|54-65|aripiprazole|drug
DDI-DrugBank.d509.s15|67-70|with|drug
DDI-DrugBank.d509.s15|72-80|quinidine|drug
DDI-DrugBank.d509.s15|82-82|(|drug
DDI-DrugBank.d509.s15|83-85|166|drug
DDI-DrugBank.d509.s15|87-92|mg/day|drug
DDI-DrugBank.d509.s15|94-96|for|drug
DDI-DrugBank.d509.s15|98-99|13|drug
DDI-DrugBank.d509.s15|101-104|days|drug
DDI-DrugBank.d509.s15|105-105|)|drug
DDI-DrugBank.d509.s15|106-106|,|drug
DDI-DrugBank.d509.s15|108-108|a|drug
DDI-DrugBank.d509.s15|110-115|potent|drug
DDI-DrugBank.d509.s15|117-125|inhibitor|drug
DDI-DrugBank.d509.s15|127-128|of|drug
DDI-DrugBank.d509.s15|130-135|CYP2D6|drug
DDI-DrugBank.d509.s15|136-136|,|drug
DDI-DrugBank.d509.s15|138-146|increased|drug
DDI-DrugBank.d509.s15|148-150|the|drug
DDI-DrugBank.d509.s15|152-154|AUC|drug
DDI-DrugBank.d509.s15|156-157|of|drug
DDI-DrugBank.d509.s15|159-170|aripiprazole|drug
DDI-DrugBank.d509.s15|172-173|by|drug
DDI-DrugBank.d509.s15|175-177|112|drug
DDI-DrugBank.d509.s15|178-178|%|drug
DDI-DrugBank.d509.s15|180-182|but|drug
DDI-DrugBank.d509.s15|184-192|decreased|drug
DDI-DrugBank.d509.s15|194-196|the|drug
DDI-DrugBank.d509.s15|198-200|AUC|drug
DDI-DrugBank.d509.s15|202-203|of|drug
DDI-DrugBank.d509.s15|205-207|its|drug
DDI-DrugBank.d509.s15|209-214|active|drug
DDI-DrugBank.d509.s15|216-225|metabolite|drug
DDI-DrugBank.d509.s15|226-226|,|drug
DDI-DrugBank.d509.s15|228-246|dehydroaripiprazole|drug
DDI-DrugBank.d509.s15|247-247|,|drug
DDI-DrugBank.d509.s15|249-250|by|drug
DDI-DrugBank.d509.s15|252-253|35|drug
DDI-DrugBank.d509.s15|254-254|%|drug
DDI-DrugBank.d509.s15|255-255|.|drug
DDI-DrugBank.d509.s16|0-11|Aripiprazole|brand
DDI-DrugBank.d509.s16|13-16|dose|drug
DDI-DrugBank.d509.s16|18-23|should|drug
DDI-DrugBank.d509.s16|25-26|be|drug
DDI-DrugBank.d509.s16|28-34|reduced|drug
DDI-DrugBank.d509.s16|36-37|to|drug
DDI-DrugBank.d509.s16|39-46|one-half|drug
DDI-DrugBank.d509.s16|48-49|of|drug
DDI-DrugBank.d509.s16|51-53|its|drug
DDI-DrugBank.d509.s16|55-60|normal|drug
DDI-DrugBank.d509.s16|62-65|dose|drug
DDI-DrugBank.d509.s16|67-70|when|drug
DDI-DrugBank.d509.s16|72-82|concomitant|drug
DDI-DrugBank.d509.s16|84-97|administration|drug
DDI-DrugBank.d509.s16|99-100|of|drug
DDI-DrugBank.d509.s16|102-110|quinidine|drug
DDI-DrugBank.d509.s16|112-115|with|drug
DDI-DrugBank.d509.s16|117-128|aripiprazole|drug
DDI-DrugBank.d509.s16|130-135|occurs|drug
DDI-DrugBank.d509.s16|136-136|.|drug
DDI-DrugBank.d509.s17|0-4|Other|drug
DDI-DrugBank.d509.s17|6-16|significant|drug
DDI-DrugBank.d509.s17|18-27|inhibitors|drug
DDI-DrugBank.d509.s17|29-30|of|drug
DDI-DrugBank.d509.s17|32-37|CYP2D6|drug
DDI-DrugBank.d509.s17|38-38|,|drug
DDI-DrugBank.d509.s17|40-43|such|drug
DDI-DrugBank.d509.s17|45-46|as|drug
DDI-DrugBank.d509.s17|48-57|fluoxetine|drug
DDI-DrugBank.d509.s17|59-60|or|drug
DDI-DrugBank.d509.s17|62-71|paroxetine|drug
DDI-DrugBank.d509.s17|72-72|,|drug
DDI-DrugBank.d509.s17|74-78|would|drug
DDI-DrugBank.d509.s17|80-81|be|drug
DDI-DrugBank.d509.s17|83-90|expected|drug
DDI-DrugBank.d509.s17|92-93|to|drug
DDI-DrugBank.d509.s17|95-98|have|drug
DDI-DrugBank.d509.s17|100-106|similar|drug
DDI-DrugBank.d509.s17|108-114|effects|drug
DDI-DrugBank.d509.s17|116-118|and|drug
DDI-DrugBank.d509.s17|119-119|,|drug
DDI-DrugBank.d509.s17|121-129|therefore|drug
DDI-DrugBank.d509.s17|130-130|,|drug
DDI-DrugBank.d509.s17|132-137|should|drug
DDI-DrugBank.d509.s17|139-140|be|drug
DDI-DrugBank.d509.s17|142-152|accompanied|drug
DDI-DrugBank.d509.s17|154-155|by|drug
DDI-DrugBank.d509.s17|157-163|similar|drug
DDI-DrugBank.d509.s17|165-168|dose|drug
DDI-DrugBank.d509.s17|170-179|reductions|drug
DDI-DrugBank.d509.s17|180-180|.|drug
DDI-DrugBank.d509.s18|0-3|When|drug
DDI-DrugBank.d509.s18|5-7|the|drug
DDI-DrugBank.d509.s18|9-14|CYP2D6|drug
DDI-DrugBank.d509.s18|16-24|inhibitor|drug
DDI-DrugBank.d509.s18|26-27|is|drug
DDI-DrugBank.d509.s18|29-37|withdrawn|drug
DDI-DrugBank.d509.s18|39-42|from|drug
DDI-DrugBank.d509.s18|44-46|the|drug
DDI-DrugBank.d509.s18|48-58|combination|drug
DDI-DrugBank.d509.s18|60-66|therapy|drug
DDI-DrugBank.d509.s18|67-67|,|drug
DDI-DrugBank.d509.s18|69-80|aripiprazole|drug
DDI-DrugBank.d509.s18|82-85|dose|drug
DDI-DrugBank.d509.s18|87-92|should|drug
DDI-DrugBank.d509.s18|94-97|then|drug
DDI-DrugBank.d509.s18|99-100|be|drug
DDI-DrugBank.d509.s18|102-110|increased|drug
DDI-DrugBank.d509.s18|111-111|.|drug
DDI-DrugBank.d509.s19|0-12|Carbamazepine|brand
DDI-DrugBank.d509.s19|13-13|:|drug
DDI-DrugBank.d509.s19|15-30|Coadministration|drug
DDI-DrugBank.d509.s19|32-33|of|drug
DDI-DrugBank.d509.s19|35-47|carbamazepine|drug
DDI-DrugBank.d509.s19|49-49|(|drug
DDI-DrugBank.d509.s19|50-52|200|drug
DDI-DrugBank.d509.s19|54-55|mg|drug
DDI-DrugBank.d509.s19|57-59|BID|drug
DDI-DrugBank.d509.s19|60-60|)|drug
DDI-DrugBank.d509.s19|61-61|,|drug
DDI-DrugBank.d509.s19|63-63|a|drug
DDI-DrugBank.d509.s19|65-70|potent|drug
DDI-DrugBank.d509.s19|72-77|CYP3A4|drug
DDI-DrugBank.d509.s19|79-85|inducer|drug
DDI-DrugBank.d509.s19|86-86|,|drug
DDI-DrugBank.d509.s19|88-91|with|drug
DDI-DrugBank.d509.s19|93-104|aripiprazole|drug
DDI-DrugBank.d509.s19|106-106|(|drug
DDI-DrugBank.d509.s19|107-108|30|drug
DDI-DrugBank.d509.s19|110-111|mg|drug
DDI-DrugBank.d509.s19|113-114|QD|drug
DDI-DrugBank.d509.s19|115-115|)|drug
DDI-DrugBank.d509.s19|117-124|resulted|drug
DDI-DrugBank.d509.s19|126-127|in|drug
DDI-DrugBank.d509.s19|129-130|an|drug
DDI-DrugBank.d509.s19|132-142|approximate|drug
DDI-DrugBank.d509.s19|144-145|70|drug
DDI-DrugBank.d509.s19|146-146|%|drug
DDI-DrugBank.d509.s19|148-155|decrease|drug
DDI-DrugBank.d509.s19|157-158|in|drug
DDI-DrugBank.d509.s19|160-163|Cmax|drug
DDI-DrugBank.d509.s19|165-167|and|drug
DDI-DrugBank.d509.s19|169-171|AUC|drug
DDI-DrugBank.d509.s19|173-178|values|drug
DDI-DrugBank.d509.s19|180-181|of|drug
DDI-DrugBank.d509.s19|183-186|both|drug
DDI-DrugBank.d509.s19|188-199|aripiprazole|drug
DDI-DrugBank.d509.s19|201-203|and|drug
DDI-DrugBank.d509.s19|205-207|its|drug
DDI-DrugBank.d509.s19|209-214|active|drug
DDI-DrugBank.d509.s19|216-225|metabolite|drug
DDI-DrugBank.d509.s19|226-226|,|drug
DDI-DrugBank.d509.s19|228-247|dehydro-aripiprazole|drug
DDI-DrugBank.d509.s19|248-248|.|drug
DDI-DrugBank.d509.s20|0-3|When|drug
DDI-DrugBank.d509.s20|5-17|carbamazepine|drug
DDI-DrugBank.d509.s20|19-20|is|drug
DDI-DrugBank.d509.s20|22-26|added|drug
DDI-DrugBank.d509.s20|28-29|to|drug
DDI-DrugBank.d509.s20|31-42|aripiprazole|drug
DDI-DrugBank.d509.s20|44-50|therapy|drug
DDI-DrugBank.d509.s20|51-51|,|drug
DDI-DrugBank.d509.s20|53-64|aripiprazole|drug
DDI-DrugBank.d509.s20|66-69|dose|drug
DDI-DrugBank.d509.s20|71-76|should|drug
DDI-DrugBank.d509.s20|78-79|be|drug
DDI-DrugBank.d509.s20|81-87|doubled|drug
DDI-DrugBank.d509.s20|88-88|.|drug
DDI-DrugBank.d509.s21|0-9|Additional|drug
DDI-DrugBank.d509.s21|11-14|dose|drug
DDI-DrugBank.d509.s21|16-24|increases|drug
DDI-DrugBank.d509.s21|26-31|should|drug
DDI-DrugBank.d509.s21|33-34|be|drug
DDI-DrugBank.d509.s21|36-40|based|drug
DDI-DrugBank.d509.s21|42-43|on|drug
DDI-DrugBank.d509.s21|45-52|clinical|drug
DDI-DrugBank.d509.s21|54-63|evaluation|drug
DDI-DrugBank.d509.s21|64-64|.|drug
DDI-DrugBank.d509.s22|0-3|When|drug
DDI-DrugBank.d509.s22|5-17|carbamazepine|drug
DDI-DrugBank.d509.s22|19-20|is|drug
DDI-DrugBank.d509.s22|22-30|withdrawn|drug
DDI-DrugBank.d509.s22|32-35|from|drug
DDI-DrugBank.d509.s22|37-39|the|drug
DDI-DrugBank.d509.s22|41-51|combination|drug
DDI-DrugBank.d509.s22|53-59|therapy|drug
DDI-DrugBank.d509.s22|60-60|,|drug
DDI-DrugBank.d509.s22|62-73|aripiprazole|drug
DDI-DrugBank.d509.s22|75-78|dose|drug
DDI-DrugBank.d509.s22|80-85|should|drug
DDI-DrugBank.d509.s22|87-90|then|drug
DDI-DrugBank.d509.s22|92-93|be|drug
DDI-DrugBank.d509.s22|95-101|reduced|drug
DDI-DrugBank.d509.s22|102-102|.|drug
DDI-DrugBank.d509.s23|0-1|No|drug
DDI-DrugBank.d509.s23|3-12|clinically|drug
DDI-DrugBank.d509.s23|14-24|significant|drug
DDI-DrugBank.d509.s23|26-31|effect|drug
DDI-DrugBank.d509.s23|33-34|of|drug
DDI-DrugBank.d509.s23|36-45|famotidine|drug
DDI-DrugBank.d509.s23|46-46|,|drug
DDI-DrugBank.d509.s23|48-56|valproate|drug
DDI-DrugBank.d509.s23|57-57|,|drug
DDI-DrugBank.d509.s23|59-60|or|drug
DDI-DrugBank.d509.s23|62-68|lithium|drug
DDI-DrugBank.d509.s23|70-72|was|drug
DDI-DrugBank.d509.s23|74-77|seen|drug
DDI-DrugBank.d509.s23|79-80|on|drug
DDI-DrugBank.d509.s23|82-84|the|drug
DDI-DrugBank.d509.s23|86-101|pharmacokinetics|drug
DDI-DrugBank.d509.s23|103-104|of|drug
DDI-DrugBank.d509.s23|106-117|aripiprazole|drug
DDI-DrugBank.d509.s23|119-119|(|drug
DDI-DrugBank.d509.s23|120-122|see|drug
DDI-DrugBank.d509.s23|124-131|CLINICAL|drug
DDI-DrugBank.d509.s23|133-144|PHARMACOLOGY|drug
DDI-DrugBank.d509.s23|145-145|:|drug
DDI-DrugBank.d509.s23|147-151|Drug-|drug
DDI-DrugBank.d509.s23|153-156|Drug|drug
DDI-DrugBank.d509.s23|158-169|Interactions|drug
DDI-DrugBank.d509.s23|170-170|)|drug
DDI-DrugBank.d509.s23|171-171|.|drug
DDI-DrugBank.d509.s24|0-8|Potential|drug
DDI-DrugBank.d509.s24|10-12|for|drug
DDI-DrugBank.d509.s24|14-20|ABILIFY|drug
DDI-DrugBank.d509.s24|22-23|to|drug
DDI-DrugBank.d509.s24|25-30|Affect|drug
DDI-DrugBank.d509.s24|32-36|Other|drug
DDI-DrugBank.d509.s24|38-42|Drugs|drug
DDI-DrugBank.d509.s24|44-55|Aripiprazole|brand
DDI-DrugBank.d509.s24|57-58|is|drug
DDI-DrugBank.d509.s24|60-67|unlikely|drug
DDI-DrugBank.d509.s24|69-70|to|drug
DDI-DrugBank.d509.s24|72-76|cause|drug
DDI-DrugBank.d509.s24|78-87|clinically|drug
DDI-DrugBank.d509.s24|89-97|important|drug
DDI-DrugBank.d509.s24|99-113|pharmacokinetic|drug
DDI-DrugBank.d509.s24|115-126|interactions|drug
DDI-DrugBank.d509.s24|128-131|with|drug
DDI-DrugBank.d509.s24|133-137|drugs|drug
DDI-DrugBank.d509.s24|139-149|metabolized|drug
DDI-DrugBank.d509.s24|151-152|by|drug
DDI-DrugBank.d509.s24|154-163|cytochrome|drug
DDI-DrugBank.d509.s24|165-168|P450|drug
DDI-DrugBank.d509.s24|170-176|enzymes|drug
DDI-DrugBank.d509.s24|177-177|.|drug
DDI-DrugBank.d509.s25|0-1|In|drug
DDI-DrugBank.d509.s25|3-4|in|drug
DDI-DrugBank.d509.s25|6-9|vivo|drug
DDI-DrugBank.d509.s25|11-17|studies|drug
DDI-DrugBank.d509.s25|18-18|,|drug
DDI-DrugBank.d509.s25|20-22|10-|drug
DDI-DrugBank.d509.s25|24-25|to|drug
DDI-DrugBank.d509.s25|27-35|30-mg/day|drug
DDI-DrugBank.d509.s25|37-41|doses|drug
DDI-DrugBank.d509.s25|43-44|of|drug
DDI-DrugBank.d509.s25|46-57|aripiprazole|drug
DDI-DrugBank.d509.s25|59-61|had|drug
DDI-DrugBank.d509.s25|63-64|no|drug
DDI-DrugBank.d509.s25|66-76|significant|drug
DDI-DrugBank.d509.s25|78-83|effect|drug
DDI-DrugBank.d509.s25|85-86|on|drug
DDI-DrugBank.d509.s25|88-97|metabolism|drug
DDI-DrugBank.d509.s25|99-100|by|drug
DDI-DrugBank.d509.s25|102-107|CYP2D6|drug
DDI-DrugBank.d509.s25|109-109|(|drug
DDI-DrugBank.d509.s25|110-125|dextromethorphan|drug
DDI-DrugBank.d509.s25|126-126|)|drug
DDI-DrugBank.d509.s25|127-127|,|drug
DDI-DrugBank.d509.s25|129-134|CYP2C9|drug
DDI-DrugBank.d509.s25|136-136|(|drug
DDI-DrugBank.d509.s25|137-144|warfarin|drug
DDI-DrugBank.d509.s25|145-145|)|drug
DDI-DrugBank.d509.s25|146-146|,|drug
DDI-DrugBank.d509.s25|148-154|CYP2C19|drug
DDI-DrugBank.d509.s25|156-156|(|drug
DDI-DrugBank.d509.s25|157-166|omeprazole|drug
DDI-DrugBank.d509.s25|167-167|,|drug
DDI-DrugBank.d509.s25|169-176|warfarin|drug
DDI-DrugBank.d509.s25|177-177|)|drug
DDI-DrugBank.d509.s25|178-178|,|drug
DDI-DrugBank.d509.s25|180-182|and|drug
DDI-DrugBank.d509.s25|184-189|CYP3A4|drug
DDI-DrugBank.d509.s25|191-191|(|drug
DDI-DrugBank.d509.s25|192-207|dextromethorphan|drug
DDI-DrugBank.d509.s25|208-208|)|drug
DDI-DrugBank.d509.s25|210-219|substrates|drug
DDI-DrugBank.d509.s25|220-220|.|drug
DDI-DrugBank.d509.s26|0-11|Additionally|drug
DDI-DrugBank.d509.s26|12-12|,|drug
DDI-DrugBank.d509.s26|14-25|aripiprazole|drug
DDI-DrugBank.d509.s26|27-29|and|drug
DDI-DrugBank.d509.s26|31-49|dehydroaripiprazole|drug
DDI-DrugBank.d509.s26|51-53|did|drug
DDI-DrugBank.d509.s26|55-57|not|drug
DDI-DrugBank.d509.s26|59-62|show|drug
DDI-DrugBank.d509.s26|64-72|potential|drug
DDI-DrugBank.d509.s26|74-76|for|drug
DDI-DrugBank.d509.s26|78-85|altering|drug
DDI-DrugBank.d509.s26|87-101|CYP1A2-mediated|drug
DDI-DrugBank.d509.s26|103-112|metabolism|drug
DDI-DrugBank.d509.s26|114-115|in|drug
DDI-DrugBank.d509.s26|117-121|vitro|drug
DDI-DrugBank.d509.s26|122-122|.|drug
DDI-DrugBank.d509.s27|0-6|Alcohol|brand
DDI-DrugBank.d509.s27|7-7|:|drug
DDI-DrugBank.d509.s27|9-13|There|drug
DDI-DrugBank.d509.s27|15-17|was|drug
DDI-DrugBank.d509.s27|19-20|no|drug
DDI-DrugBank.d509.s27|22-32|significant|drug
DDI-DrugBank.d509.s27|34-43|difference|drug
DDI-DrugBank.d509.s27|45-51|between|drug
DDI-DrugBank.d509.s27|53-64|aripiprazole|drug
DDI-DrugBank.d509.s27|66-79|coadministered|drug
DDI-DrugBank.d509.s27|81-84|with|drug
DDI-DrugBank.d509.s27|86-92|ethanol|drug
DDI-DrugBank.d509.s27|94-96|and|drug
DDI-DrugBank.d509.s27|98-104|placebo|drug
DDI-DrugBank.d509.s27|106-119|coadministered|drug
DDI-DrugBank.d509.s27|121-124|with|drug
DDI-DrugBank.d509.s27|126-132|ethanol|drug
DDI-DrugBank.d509.s27|134-135|on|drug
DDI-DrugBank.d509.s27|137-147|performance|drug
DDI-DrugBank.d509.s27|149-150|of|drug
DDI-DrugBank.d509.s27|152-156|gross|drug
DDI-DrugBank.d509.s27|158-162|motor|drug
DDI-DrugBank.d509.s27|164-169|skills|drug
DDI-DrugBank.d509.s27|171-172|or|drug
DDI-DrugBank.d509.s27|174-181|stimulus|drug
DDI-DrugBank.d509.s27|183-190|response|drug
DDI-DrugBank.d509.s27|192-193|in|drug
DDI-DrugBank.d509.s27|195-201|healthy|drug
DDI-DrugBank.d509.s27|203-210|subjects|drug
DDI-DrugBank.d509.s27|211-211|.|drug
DDI-DrugBank.d509.s28|0-1|As|drug
DDI-DrugBank.d509.s28|3-6|with|drug
DDI-DrugBank.d509.s28|8-11|most|drug
DDI-DrugBank.d509.s28|13-24|psychoactive|drug
DDI-DrugBank.d509.s28|26-36|medications|drug
DDI-DrugBank.d509.s28|37-37|,|drug
DDI-DrugBank.d509.s28|39-46|patients|drug
DDI-DrugBank.d509.s28|48-53|should|drug
DDI-DrugBank.d509.s28|55-56|be|drug
DDI-DrugBank.d509.s28|58-64|advised|drug
DDI-DrugBank.d509.s28|66-67|to|drug
DDI-DrugBank.d509.s28|69-73|avoid|drug
DDI-DrugBank.d509.s28|75-81|alcohol|drug
DDI-DrugBank.d509.s28|83-87|while|drug
DDI-DrugBank.d509.s28|89-94|taking|drug
DDI-DrugBank.d509.s28|96-102|ABILIFY|drug
DDI-DrugBank.d509.s29|0-0|.|drug
DDI-MedLine.d179.s0|0-10|Synergistic|drug
DDI-MedLine.d179.s0|12-22|interaction|drug
DDI-MedLine.d179.s0|24-30|between|drug
DDI-MedLine.d179.s0|32-40|sunitinib|drug
DDI-MedLine.d179.s0|42-44|and|drug
DDI-MedLine.d179.s0|46-54|docetaxel|drug
DDI-MedLine.d179.s0|56-57|is|drug
DDI-MedLine.d179.s0|59-66|sequence|drug
DDI-MedLine.d179.s0|68-76|dependent|drug
DDI-MedLine.d179.s0|78-79|in|drug
DDI-MedLine.d179.s0|81-85|human|drug
DDI-MedLine.d179.s0|87-95|non-small|drug
DDI-MedLine.d179.s0|97-100|lung|drug
DDI-MedLine.d179.s0|102-107|cancer|drug
DDI-MedLine.d179.s0|109-112|with|drug
DDI-MedLine.d179.s0|114-117|EGFR|drug
DDI-MedLine.d179.s0|119-132|TKIs-resistant|drug
DDI-MedLine.d179.s0|134-141|mutation|drug
DDI-MedLine.d179.s0|142-142|.|drug
DDI-MedLine.d179.s1|0-7|Previous|drug
DDI-MedLine.d179.s1|9-15|studies|drug
DDI-MedLine.d179.s1|17-20|have|drug
DDI-MedLine.d179.s1|22-33|demonstrated|drug
DDI-MedLine.d179.s1|35-38|that|drug
DDI-MedLine.d179.s1|40-48|sunitinib|drug
DDI-MedLine.d179.s1|50-52|has|drug
DDI-MedLine.d179.s1|54-56|the|drug
DDI-MedLine.d179.s1|58-67|anti-tumor|drug
DDI-MedLine.d179.s1|69-76|activity|drug
DDI-MedLine.d179.s1|78-79|in|drug
DDI-MedLine.d179.s1|81-85|human|drug
DDI-MedLine.d179.s1|87-95|non-small|drug
DDI-MedLine.d179.s1|97-100|cell|drug
DDI-MedLine.d179.s1|102-105|lung|drug
DDI-MedLine.d179.s1|107-112|cancer|drug
DDI-MedLine.d179.s1|114-114|(|drug
DDI-MedLine.d179.s1|115-119|NSCLC|drug
DDI-MedLine.d179.s1|120-120|)|drug
DDI-MedLine.d179.s1|121-121|.|drug
DDI-MedLine.d179.s2|0-3|This|drug
DDI-MedLine.d179.s2|5-9|study|drug
DDI-MedLine.d179.s2|11-13|was|drug
DDI-MedLine.d179.s2|15-19|aimed|drug
DDI-MedLine.d179.s2|21-22|to|drug
DDI-MedLine.d179.s2|24-34|investigate|drug
DDI-MedLine.d179.s2|36-38|the|drug
DDI-MedLine.d179.s2|40-47|efficacy|drug
DDI-MedLine.d179.s2|49-50|of|drug
DDI-MedLine.d179.s2|52-57|single|drug
DDI-MedLine.d179.s2|59-61|use|drug
DDI-MedLine.d179.s2|63-64|of|drug
DDI-MedLine.d179.s2|66-74|sunitinib|drug
DDI-MedLine.d179.s2|76-78|and|drug
DDI-MedLine.d179.s2|80-83|that|drug
DDI-MedLine.d179.s2|85-86|of|drug
DDI-MedLine.d179.s2|88-97|concurrent|drug
DDI-MedLine.d179.s2|99-100|or|drug
DDI-MedLine.d179.s2|102-111|sequential|drug
DDI-MedLine.d179.s2|113-126|administration|drug
DDI-MedLine.d179.s2|128-129|of|drug
DDI-MedLine.d179.s2|131-139|sunitinib|drug
DDI-MedLine.d179.s2|141-143|and|drug
DDI-MedLine.d179.s2|145-153|docetaxel|drug
DDI-MedLine.d179.s2|155-156|in|drug
DDI-MedLine.d179.s2|158-162|NSCLC|drug
DDI-MedLine.d179.s2|164-167|cell|drug
DDI-MedLine.d179.s2|169-173|lines|drug
DDI-MedLine.d179.s2|175-178|that|drug
DDI-MedLine.d179.s2|180-182|are|drug
DDI-MedLine.d179.s2|184-192|resistant|drug
DDI-MedLine.d179.s2|194-195|to|drug
DDI-MedLine.d179.s2|197-200|EGFR|drug
DDI-MedLine.d179.s2|202-205|TKIs|drug
DDI-MedLine.d179.s2|206-206|.|drug
DDI-MedLine.d179.s3|0-4|NSCLC|drug
DDI-MedLine.d179.s3|6-9|cell|drug
DDI-MedLine.d179.s3|11-15|lines|drug
DDI-MedLine.d179.s3|17-20|with|drug
DDI-MedLine.d179.s3|22-25|EGFR|drug
DDI-MedLine.d179.s3|27-31|T790M|drug
DDI-MedLine.d179.s3|33-40|mutation|drug
DDI-MedLine.d179.s3|42-44|and|drug
DDI-MedLine.d179.s3|46-50|K-ras|drug
DDI-MedLine.d179.s3|52-59|mutation|drug
DDI-MedLine.d179.s3|61-64|were|drug
DDI-MedLine.d179.s3|66-72|exposed|drug
DDI-MedLine.d179.s3|74-75|to|drug
DDI-MedLine.d179.s3|77-82|either|drug
DDI-MedLine.d179.s3|84-92|sunitinib|drug
DDI-MedLine.d179.s3|94-95|or|drug
DDI-MedLine.d179.s3|97-105|docetaxel|drug
DDI-MedLine.d179.s3|107-108|or|drug
DDI-MedLine.d179.s3|110-113|both|drug
DDI-MedLine.d179.s3|115-119|based|drug
DDI-MedLine.d179.s3|121-122|on|drug
DDI-MedLine.d179.s3|124-130|various|drug
DDI-MedLine.d179.s3|132-141|sequential|drug
DDI-MedLine.d179.s3|143-157|administrations|drug
DDI-MedLine.d179.s3|158-158|.|drug
DDI-MedLine.d179.s4|0-4|After|drug
DDI-MedLine.d179.s4|6-13|exposure|drug
DDI-MedLine.d179.s4|14-14|,|drug
DDI-MedLine.d179.s4|16-18|the|drug
DDI-MedLine.d179.s4|20-23|cell|drug
DDI-MedLine.d179.s4|25-33|viability|drug
DDI-MedLine.d179.s4|35-37|was|drug
DDI-MedLine.d179.s4|39-46|measured|drug
DDI-MedLine.d179.s4|48-49|by|drug
DDI-MedLine.d179.s4|51-53|MTT|drug
DDI-MedLine.d179.s4|55-59|assay|drug
DDI-MedLine.d179.s4|60-60|,|drug
DDI-MedLine.d179.s4|62-65|cell|drug
DDI-MedLine.d179.s4|67-71|cycle|drug
DDI-MedLine.d179.s4|73-84|distribution|drug
DDI-MedLine.d179.s4|86-88|was|drug
DDI-MedLine.d179.s4|90-97|analyzed|drug
DDI-MedLine.d179.s4|99-100|by|drug
DDI-MedLine.d179.s4|102-105|flow|drug
DDI-MedLine.d179.s4|107-115|cytometry|drug
DDI-MedLine.d179.s4|116-116|,|drug
DDI-MedLine.d179.s4|118-120|and|drug
DDI-MedLine.d179.s4|122-132|alterations|drug
DDI-MedLine.d179.s4|134-135|in|drug
DDI-MedLine.d179.s4|137-145|signaling|drug
DDI-MedLine.d179.s4|147-153|pathway|drug
DDI-MedLine.d179.s4|155-158|were|drug
DDI-MedLine.d179.s4|160-169|determined|drug
DDI-MedLine.d179.s4|171-172|by|drug
DDI-MedLine.d179.s4|174-187|immunoblotting|drug
DDI-MedLine.d179.s4|188-188|.|drug
DDI-MedLine.d179.s5|0-8|Sunitinib|drug
DDI-MedLine.d179.s5|10-18|exhibited|drug
DDI-MedLine.d179.s5|20-33|dose-dependent|drug
DDI-MedLine.d179.s5|35-40|growth|drug
DDI-MedLine.d179.s5|42-51|inhibition|drug
DDI-MedLine.d179.s5|53-54|in|drug
DDI-MedLine.d179.s5|56-60|NSCLC|drug
DDI-MedLine.d179.s5|62-65|cell|drug
DDI-MedLine.d179.s5|67-71|lines|drug
DDI-MedLine.d179.s5|73-75|and|drug
DDI-MedLine.d179.s5|77-84|arrested|drug
DDI-MedLine.d179.s5|86-89|cell|drug
DDI-MedLine.d179.s5|91-95|cycle|drug
DDI-MedLine.d179.s5|97-98|at|drug
DDI-MedLine.d179.s5|100-101|G1|drug
DDI-MedLine.d179.s5|103-107|phase|drug
DDI-MedLine.d179.s5|108-108|,|drug
DDI-MedLine.d179.s5|110-116|whereas|drug
DDI-MedLine.d179.s5|118-126|docetaxel|drug
DDI-MedLine.d179.s5|128-135|arrested|drug
DDI-MedLine.d179.s5|137-138|at|drug
DDI-MedLine.d179.s5|140-140|S|drug
DDI-MedLine.d179.s5|142-146|phase|drug
DDI-MedLine.d179.s5|147-147|.|drug
DDI-MedLine.d179.s6|0-7|Although|drug
DDI-MedLine.d179.s6|9-14|single|drug
DDI-MedLine.d179.s6|16-17|or|drug
DDI-MedLine.d179.s6|19-28|concurrent|drug
DDI-MedLine.d179.s6|30-32|use|drug
DDI-MedLine.d179.s6|34-35|of|drug
DDI-MedLine.d179.s6|37-45|sunitinib|drug
DDI-MedLine.d179.s6|47-49|and|drug
DDI-MedLine.d179.s6|51-59|docetaxel|drug
DDI-MedLine.d179.s6|61-63|has|drug
DDI-MedLine.d179.s6|65-68|some|drug
DDI-MedLine.d179.s6|70-87|anti-proliferative|drug
DDI-MedLine.d179.s6|89-95|effects|drug
DDI-MedLine.d179.s6|96-96|,|drug
DDI-MedLine.d179.s6|98-100|the|drug
DDI-MedLine.d179.s6|102-111|sequential|drug
DDI-MedLine.d179.s6|113-127|administrations|drug
DDI-MedLine.d179.s6|129-130|of|drug
DDI-MedLine.d179.s6|132-135|both|drug
DDI-MedLine.d179.s6|137-141|drugs|drug
DDI-MedLine.d179.s6|143-152|remarkably|drug
DDI-MedLine.d179.s6|154-161|enhanced|drug
DDI-MedLine.d179.s6|163-172|anti-tumor|drug
DDI-MedLine.d179.s6|174-181|activity|drug
DDI-MedLine.d179.s6|182-182|.|drug
DDI-MedLine.d179.s7|0-3|When|drug
DDI-MedLine.d179.s7|5-9|cells|drug
DDI-MedLine.d179.s7|11-14|were|drug
DDI-MedLine.d179.s7|16-22|exposed|drug
DDI-MedLine.d179.s7|24-25|to|drug
DDI-MedLine.d179.s7|27-35|docetaxel|drug
DDI-MedLine.d179.s7|37-44|followed|drug
DDI-MedLine.d179.s7|46-47|by|drug
DDI-MedLine.d179.s7|49-57|sunitinib|drug
DDI-MedLine.d179.s7|58-58|,|drug
DDI-MedLine.d179.s7|60-68|synergism|drug
DDI-MedLine.d179.s7|70-72|was|drug
DDI-MedLine.d179.s7|74-81|observed|drug
DDI-MedLine.d179.s7|82-82|.|drug
DDI-MedLine.d179.s8|0-2|The|drug
DDI-MedLine.d179.s8|4-12|molecular|drug
DDI-MedLine.d179.s8|14-18|basis|drug
DDI-MedLine.d179.s8|20-21|of|drug
DDI-MedLine.d179.s8|23-26|this|drug
DDI-MedLine.d179.s8|28-36|synergism|drug
DDI-MedLine.d179.s8|38-39|is|drug
DDI-MedLine.d179.s8|41-44|that|drug
DDI-MedLine.d179.s8|46-48|the|drug
DDI-MedLine.d179.s8|50-58|signaling|drug
DDI-MedLine.d179.s8|60-67|pathways|drug
DDI-MedLine.d179.s8|69-72|that|drug
DDI-MedLine.d179.s8|74-77|were|drug
DDI-MedLine.d179.s8|79-87|initially|drug
DDI-MedLine.d179.s8|89-97|activated|drug
DDI-MedLine.d179.s8|99-100|by|drug
DDI-MedLine.d179.s8|102-110|docetaxel|drug
DDI-MedLine.d179.s8|112-119|exposure|drug
DDI-MedLine.d179.s8|121-124|were|drug
DDI-MedLine.d179.s8|126-136|efficiently|drug
DDI-MedLine.d179.s8|138-147|suppressed|drug
DDI-MedLine.d179.s8|149-150|by|drug
DDI-MedLine.d179.s8|152-154|the|drug
DDI-MedLine.d179.s8|156-165|subsequent|drug
DDI-MedLine.d179.s8|167-174|exposure|drug
DDI-MedLine.d179.s8|176-177|to|drug
DDI-MedLine.d179.s8|179-187|sunitinib|drug
DDI-MedLine.d179.s8|188-188|.|drug
DDI-MedLine.d179.s9|0-1|In|drug
DDI-MedLine.d179.s9|3-10|contrast|drug
DDI-MedLine.d179.s9|11-11|,|drug
DDI-MedLine.d179.s9|13-15|the|drug
DDI-MedLine.d179.s9|17-23|reverse|drug
DDI-MedLine.d179.s9|25-26|of|drug
DDI-MedLine.d179.s9|28-31|this|drug
DDI-MedLine.d179.s9|33-42|sequential|drug
DDI-MedLine.d179.s9|44-57|administration|drug
DDI-MedLine.d179.s9|59-66|resulted|drug
DDI-MedLine.d179.s9|68-69|in|drug
DDI-MedLine.d179.s9|71-80|antagonism|drug
DDI-MedLine.d179.s9|81-81|,|drug
DDI-MedLine.d179.s9|83-87|which|drug
DDI-MedLine.d179.s9|89-91|may|drug
DDI-MedLine.d179.s9|93-94|be|drug
DDI-MedLine.d179.s9|96-98|due|drug
DDI-MedLine.d179.s9|100-101|to|drug
DDI-MedLine.d179.s9|103-114|differential|drug
DDI-MedLine.d179.s9|116-122|effects|drug
DDI-MedLine.d179.s9|124-125|on|drug
DDI-MedLine.d179.s9|127-130|cell|drug
DDI-MedLine.d179.s9|132-136|cycle|drug
DDI-MedLine.d179.s9|138-143|arrest|drug
DDI-MedLine.d179.s9|144-144|.|drug
DDI-MedLine.d179.s10|0-8|Sunitinib|drug
DDI-MedLine.d179.s10|10-11|as|drug
DDI-MedLine.d179.s10|13-13|a|drug
DDI-MedLine.d179.s10|15-20|single|drug
DDI-MedLine.d179.s10|22-26|agent|drug
DDI-MedLine.d179.s10|28-35|exhibits|drug
DDI-MedLine.d179.s10|37-54|anti-proliferative|drug
DDI-MedLine.d179.s10|56-62|effects|drug
DDI-MedLine.d179.s10|64-65|in|drug
DDI-MedLine.d179.s10|67-71|vitro|drug
DDI-MedLine.d179.s10|73-74|in|drug
DDI-MedLine.d179.s10|76-80|NSCLC|drug
DDI-MedLine.d179.s10|82-85|cell|drug
DDI-MedLine.d179.s10|87-91|lines|drug
DDI-MedLine.d179.s10|93-96|with|drug
DDI-MedLine.d179.s10|98-101|EGFR|drug
DDI-MedLine.d179.s10|103-107|T790M|drug
DDI-MedLine.d179.s10|109-111|and|drug
DDI-MedLine.d179.s10|113-117|K-ras|drug
DDI-MedLine.d179.s10|119-127|mutations|drug
DDI-MedLine.d179.s10|129-131|but|drug
DDI-MedLine.d179.s10|133-135|the|drug
DDI-MedLine.d179.s10|137-146|sequential|drug
DDI-MedLine.d179.s10|148-161|administration|drug
DDI-MedLine.d179.s10|163-164|of|drug
DDI-MedLine.d179.s10|166-174|docetaxel|drug
DDI-MedLine.d179.s10|176-183|followed|drug
DDI-MedLine.d179.s10|185-186|by|drug
DDI-MedLine.d179.s10|188-196|sunitinib|drug
DDI-MedLine.d179.s10|198-199|is|drug
DDI-MedLine.d179.s10|201-208|superior|drug
DDI-MedLine.d179.s10|210-211|to|drug
DDI-MedLine.d179.s10|213-221|sunitinib|drug
DDI-MedLine.d179.s10|223-230|followed|drug
DDI-MedLine.d179.s10|232-233|by|drug
DDI-MedLine.d179.s10|235-243|docetaxel|drug
DDI-MedLine.d179.s10|245-247|and|drug
DDI-MedLine.d179.s10|249-258|concurrent|drug
DDI-MedLine.d179.s10|260-273|administration|drug
DDI-MedLine.d179.s10|274-274|.|drug
DDI-DrugBank.d464.s0|0-6|Codeine|drug
DDI-DrugBank.d464.s0|8-9|in|drug
DDI-DrugBank.d464.s0|11-21|combination|drug
DDI-DrugBank.d464.s0|23-26|with|drug
DDI-DrugBank.d464.s0|28-32|other|drug
DDI-DrugBank.d464.s0|34-41|narcotic|drug
DDI-DrugBank.d464.s0|43-52|analgesics|drug
DDI-DrugBank.d464.s0|53-53|,|drug
DDI-DrugBank.d464.s0|55-61|general|drug
DDI-DrugBank.d464.s0|63-73|anesthetics|drug
DDI-DrugBank.d464.s0|74-74|,|drug
DDI-DrugBank.d464.s0|76-89|phenothiazines|drug
DDI-DrugBank.d464.s0|90-90|,|drug
DDI-DrugBank.d464.s0|92-104|tranquilizers|drug
DDI-DrugBank.d464.s0|105-105|,|drug
DDI-DrugBank.d464.s0|107-124|sedative-hypnotics|drug
DDI-DrugBank.d464.s0|125-125|,|drug
DDI-DrugBank.d464.s0|127-128|or|drug
DDI-DrugBank.d464.s0|130-134|other|drug
DDI-DrugBank.d464.s0|136-138|CNS|drug
DDI-DrugBank.d464.s0|140-150|depressants|drug
DDI-DrugBank.d464.s0|152-152|(|drug
DDI-DrugBank.d464.s0|153-161|including|drug
DDI-DrugBank.d464.s0|163-169|alcohol|drug
DDI-DrugBank.d464.s0|170-170|)|drug
DDI-DrugBank.d464.s0|172-174|has|drug
DDI-DrugBank.d464.s0|176-183|additive|drug
DDI-DrugBank.d464.s0|185-194|depressant|drug
DDI-DrugBank.d464.s0|196-202|effects|drug
DDI-DrugBank.d464.s0|203-203|.|drug
DDI-DrugBank.d464.s1|0-3|When|drug
DDI-DrugBank.d464.s1|5-7|s.c|drug
DDI-DrugBank.d464.s1|8-8|.|drug
DDI-DrugBank.d464.s2|0-10|combination|drug
DDI-DrugBank.d464.s2|12-18|therapy|drug
DDI-DrugBank.d464.s2|20-21|is|drug
DDI-DrugBank.d464.s2|23-34|contemplated|drug
DDI-DrugBank.d464.s2|35-35|,|drug
DDI-DrugBank.d464.s2|37-39|the|drug
DDI-DrugBank.d464.s2|41-46|dosage|drug
DDI-DrugBank.d464.s2|48-49|of|drug
DDI-DrugBank.d464.s2|51-53|one|drug
DDI-DrugBank.d464.s2|55-56|or|drug
DDI-DrugBank.d464.s2|58-61|both|drug
DDI-DrugBank.d464.s2|63-68|agents|drug
DDI-DrugBank.d464.s2|70-75|should|drug
DDI-DrugBank.d464.s2|77-78|be|drug
DDI-DrugBank.d464.s2|80-86|reduced|drug
DDI-DrugBank.d464.s2|87-87|.|drug
DDI-DrugBank.d383.s0|0-1|No|drug
DDI-DrugBank.d383.s0|3-13|information|drug
DDI-DrugBank.d383.s0|15-22|provided|drug
DDI-MedLine.d65.s0|0-3|Drug|drug
DDI-MedLine.d65.s0|5-16|interactions|drug
DDI-MedLine.d65.s0|17-17|:|drug
DDI-MedLine.d65.s0|19-21|How|drug
DDI-MedLine.d65.s0|23-24|to|drug
DDI-MedLine.d65.s0|26-33|identify|drug
DDI-MedLine.d65.s0|35-38|them|drug
DDI-MedLine.d65.s0|39-39|.|drug
DDI-MedLine.d65.s1|0-11|Interactions|drug
DDI-MedLine.d65.s1|13-19|between|drug
DDI-MedLine.d65.s1|21-30|theraputic|drug
DDI-MedLine.d65.s1|32-37|agents|drug
DDI-MedLine.d65.s1|39-42|have|drug
DDI-MedLine.d65.s1|44-47|been|drug
DDI-MedLine.d65.s1|49-58|recognized|drug
DDI-MedLine.d65.s1|60-61|as|drug
DDI-MedLine.d65.s1|63-74|increasingly|drug
DDI-MedLine.d65.s1|76-84|important|drug
DDI-MedLine.d65.s1|86-91|causes|drug
DDI-MedLine.d65.s1|93-94|of|drug
DDI-MedLine.d65.s1|96-99|drug|drug
DDI-MedLine.d65.s1|101-102|at|drug
DDI-MedLine.d65.s1|104-108|their|drug
DDI-MedLine.d65.s1|110-114|usual|drug
DDI-MedLine.d65.s1|116-126|recommended|drug
DDI-MedLine.d65.s1|128-131|dose|drug
DDI-MedLine.d65.s1|133-135|may|drug
DDI-MedLine.d65.s1|136-136|,|drug
DDI-MedLine.d65.s1|138-142|under|drug
DDI-MedLine.d65.s1|144-150|certain|drug
DDI-MedLine.d65.s1|152-161|conditions|drug
DDI-MedLine.d65.s1|162-162|,|drug
DDI-MedLine.d65.s1|164-170|produce|drug
DDI-MedLine.d65.s1|172-179|toxicity|drug
DDI-MedLine.d65.s1|181-182|of|drug
DDI-MedLine.d65.s1|184-199|life-endangering|drug
DDI-MedLine.d65.s1|201-211|proportions|drug
DDI-MedLine.d65.s1|212-212|.|drug
DDI-MedLine.d65.s2|0-4|While|drug
DDI-MedLine.d65.s2|6-8|the|drug
DDI-MedLine.d65.s2|10-20|recognition|drug
DDI-MedLine.d65.s2|22-23|of|drug
DDI-MedLine.d65.s2|25-28|drug|drug
DDI-MedLine.d65.s2|30-37|toxicity|drug
DDI-MedLine.d65.s2|39-47|resulting|drug
DDI-MedLine.d65.s2|49-52|from|drug
DDI-MedLine.d65.s2|54-65|interactions|drug
DDI-MedLine.d65.s2|67-68|is|drug
DDI-MedLine.d65.s2|70-71|of|drug
DDI-MedLine.d65.s2|73-82|importance|drug
DDI-MedLine.d65.s2|84-85|to|drug
DDI-MedLine.d65.s2|87-89|all|drug
DDI-MedLine.d65.s2|91-100|physciains|drug
DDI-MedLine.d65.s2|101-101|,|drug
DDI-MedLine.d65.s2|103-104|it|drug
DDI-MedLine.d65.s2|106-107|is|drug
DDI-MedLine.d65.s2|109-118|especially|drug
DDI-MedLine.d65.s2|120-121|so|drug
DDI-MedLine.d65.s2|123-125|for|drug
DDI-MedLine.d65.s2|127-129|the|drug
DDI-MedLine.d65.s2|131-139|clinician|drug
DDI-MedLine.d65.s2|141-151|responsible|drug
DDI-MedLine.d65.s2|153-155|for|drug
DDI-MedLine.d65.s2|157-159|the|drug
DDI-MedLine.d65.s2|161-167|welfare|drug
DDI-MedLine.d65.s2|169-170|of|drug
DDI-MedLine.d65.s2|172-176|those|drug
DDI-MedLine.d65.s2|178-179|in|drug
DDI-MedLine.d65.s2|181-183|the|drug
DDI-MedLine.d65.s2|185-193|aerospace|drug
DDI-MedLine.d65.s2|195-205|environment|drug
DDI-MedLine.d65.s2|206-206|.|drug
DDI-MedLine.d65.s3|0-3|This|drug
DDI-MedLine.d65.s3|5-9|paper|drug
DDI-MedLine.d65.s3|11-18|attempts|drug
DDI-MedLine.d65.s3|20-21|to|drug
DDI-MedLine.d65.s3|23-29|provide|drug
DDI-MedLine.d65.s3|31-31|a|drug
DDI-MedLine.d65.s3|33-37|basis|drug
DDI-MedLine.d65.s3|39-41|for|drug
DDI-MedLine.d65.s3|43-45|the|drug
DDI-MedLine.d65.s3|47-59|understanding|drug
DDI-MedLine.d65.s3|61-63|and|drug
DDI-MedLine.d65.s3|65-79|identifications|drug
DDI-MedLine.d65.s3|81-82|of|drug
DDI-MedLine.d65.s3|84-92|important|drug
DDI-MedLine.d65.s3|94-97|drug|drug
DDI-MedLine.d65.s3|99-110|interactions|drug
DDI-MedLine.d65.s3|111-111|.|drug
DDI-MedLine.d65.s4|0-9|Guidelines|drug
DDI-MedLine.d65.s4|11-13|are|drug
DDI-MedLine.d65.s4|15-22|provided|drug
DDI-MedLine.d65.s4|24-25|to|drug
DDI-MedLine.d65.s4|27-32|assist|drug
DDI-MedLine.d65.s4|34-36|the|drug
DDI-MedLine.d65.s4|38-46|clinician|drug
DDI-MedLine.d65.s4|48-49|in|drug
DDI-MedLine.d65.s4|51-53|his|drug
DDI-MedLine.d65.s4|55-61|logical|drug
DDI-MedLine.d65.s4|63-70|approach|drug
DDI-MedLine.d65.s4|72-73|to|drug
DDI-MedLine.d65.s4|75-77|the|drug
DDI-MedLine.d65.s4|79-92|identification|drug
DDI-MedLine.d65.s4|94-95|of|drug
DDI-MedLine.d65.s4|97-100|drug|drug
DDI-MedLine.d65.s4|102-113|interactions|drug
DDI-MedLine.d65.s4|115-118|when|drug
DDI-MedLine.d65.s4|120-126|serious|drug
DDI-MedLine.d65.s4|128-131|drug|drug
DDI-MedLine.d65.s4|133-140|toxicity|drug
DDI-MedLine.d65.s4|142-143|is|drug
DDI-MedLine.d65.s4|145-155|encountered|drug
DDI-MedLine.d65.s4|157-158|in|drug
DDI-MedLine.d65.s4|160-160|a|drug
DDI-MedLine.d65.s4|162-168|pateint|drug
DDI-MedLine.d65.s4|169-169|.|drug
DDI-MedLine.d65.s5|0-3|Only|drug
DDI-MedLine.d65.s5|5-8|with|drug
DDI-MedLine.d65.s5|10-18|knowledge|drug
DDI-MedLine.d65.s5|20-21|of|drug
DDI-MedLine.d65.s5|23-25|the|drug
DDI-MedLine.d65.s5|27-37|interaction|drug
DDI-MedLine.d65.s5|39-41|can|drug
DDI-MedLine.d65.s5|43-45|the|drug
DDI-MedLine.d65.s5|47-57|therapeutic|drug
DDI-MedLine.d65.s5|59-65|regimen|drug
DDI-MedLine.d65.s5|67-68|be|drug
DDI-MedLine.d65.s5|70-76|altered|drug
DDI-MedLine.d65.s5|78-79|so|drug
DDI-MedLine.d65.s5|81-82|as|drug
DDI-MedLine.d65.s5|84-85|to|drug
DDI-MedLine.d65.s5|87-93|provide|drug
DDI-MedLine.d65.s5|95-105|therapeutic|drug
DDI-MedLine.d65.s5|107-112|levels|drug
DDI-MedLine.d65.s5|114-115|of|drug
DDI-MedLine.d65.s5|117-125|necessary|drug
DDI-MedLine.d65.s5|127-131|drugs|drug
DDI-MedLine.d65.s5|133-137|while|drug
DDI-MedLine.d65.s5|139-146|avoiding|drug
DDI-MedLine.d65.s5|148-155|toxicity|drug
DDI-MedLine.d65.s5|156-156|.|drug
DDI-DrugBank.d515.s0|0-2|The|drug
DDI-DrugBank.d515.s0|4-12|physician|drug
DDI-DrugBank.d515.s0|14-19|should|drug
DDI-DrugBank.d515.s0|21-22|be|drug
DDI-DrugBank.d515.s0|24-28|alert|drug
DDI-DrugBank.d515.s0|30-32|for|drug
DDI-DrugBank.d515.s0|34-41|possible|drug
DDI-DrugBank.d515.s0|43-50|combined|drug
DDI-DrugBank.d515.s0|52-55|drug|drug
DDI-DrugBank.d515.s0|57-63|actions|drug
DDI-DrugBank.d515.s0|64-64|,|drug
DDI-DrugBank.d515.s0|66-74|desirable|drug
DDI-DrugBank.d515.s0|76-77|or|drug
DDI-DrugBank.d515.s0|79-89|undesirable|drug
DDI-DrugBank.d515.s0|90-90|,|drug
DDI-DrugBank.d515.s0|92-100|involving|drug
DDI-DrugBank.d515.s0|102-111|ifosfamide|drug
DDI-DrugBank.d515.s0|113-116|even|drug
DDI-DrugBank.d515.s0|118-123|though|drug
DDI-DrugBank.d515.s0|125-134|ifosfamide|drug
DDI-DrugBank.d515.s0|136-138|has|drug
DDI-DrugBank.d515.s0|140-143|been|drug
DDI-DrugBank.d515.s0|145-148|used|drug
DDI-DrugBank.d515.s0|150-161|successfully|drug
DDI-DrugBank.d515.s0|163-174|concurrently|drug
DDI-DrugBank.d515.s0|176-179|with|drug
DDI-DrugBank.d515.s0|181-185|other|drug
DDI-DrugBank.d515.s0|187-191|drugs|drug
DDI-DrugBank.d515.s0|192-192|,|drug
DDI-DrugBank.d515.s0|194-202|including|drug
DDI-DrugBank.d515.s0|204-208|other|drug
DDI-DrugBank.d515.s0|210-218|cytotoxic|drug
DDI-DrugBank.d515.s0|220-224|drugs|drug
DDI-DrugBank.d515.s0|225-225|.|drug
DDI-DrugBank.d734.s0|0-7|Thiazide|drug
DDI-DrugBank.d734.s0|9-17|diuretics|drug
DDI-DrugBank.d734.s0|19-21|may|drug
DDI-DrugBank.d734.s0|23-32|accentuate|drug
DDI-DrugBank.d734.s0|34-36|the|drug
DDI-DrugBank.d734.s0|38-48|orthostatic|drug
DDI-DrugBank.d734.s0|50-60|hypotension|drug
DDI-DrugBank.d734.s0|62-65|that|drug
DDI-DrugBank.d734.s0|67-69|may|drug
DDI-DrugBank.d734.s0|71-75|occur|drug
DDI-DrugBank.d734.s0|77-80|with|drug
DDI-DrugBank.d734.s0|82-95|phenothiazines|drug
DDI-DrugBank.d734.s0|96-96|.|drug
DDI-DrugBank.d734.s1|0-15|Antihypertensive|drug
DDI-DrugBank.d734.s1|17-23|effects|drug
DDI-DrugBank.d734.s1|25-26|of|drug
DDI-DrugBank.d734.s1|28-39|guanethidine|drug
DDI-DrugBank.d734.s1|41-43|and|drug
DDI-DrugBank.d734.s1|45-51|related|drug
DDI-DrugBank.d734.s1|53-61|compounds|drug
DDI-DrugBank.d734.s1|63-65|may|drug
DDI-DrugBank.d734.s1|67-68|be|drug
DDI-DrugBank.d734.s1|70-81|counteracted|drug
DDI-DrugBank.d734.s1|83-86|when|drug
DDI-DrugBank.d734.s1|88-101|phenothiazines|drug
DDI-DrugBank.d734.s1|103-105|are|drug
DDI-DrugBank.d734.s1|107-110|used|drug
DDI-DrugBank.d734.s1|112-124|concomitantly|drug
DDI-DrugBank.d734.s1|125-125|.|drug
DDI-DrugBank.d734.s2|0-10|Concomitant|drug
DDI-DrugBank.d734.s2|12-25|administration|drug
DDI-DrugBank.d734.s2|27-28|of|drug
DDI-DrugBank.d734.s2|30-40|propranolol|drug
DDI-DrugBank.d734.s2|42-45|with|drug
DDI-DrugBank.d734.s2|47-60|phenothiazines|drug
DDI-DrugBank.d734.s2|62-68|results|drug
DDI-DrugBank.d734.s2|70-71|in|drug
DDI-DrugBank.d734.s2|73-81|increased|drug
DDI-DrugBank.d734.s2|83-88|plasma|drug
DDI-DrugBank.d734.s2|90-95|levels|drug
DDI-DrugBank.d734.s2|97-98|of|drug
DDI-DrugBank.d734.s2|100-103|both|drug
DDI-DrugBank.d734.s2|105-109|drugs|drug
DDI-DrugBank.d734.s2|110-110|.|drug
DDI-MedLine.d169.s0|0-6|Calcium|brand
DDI-MedLine.d169.s0|8-11|does|drug
DDI-MedLine.d169.s0|13-15|not|drug
DDI-MedLine.d169.s0|17-23|inhibit|drug
DDI-MedLine.d169.s0|25-27|the|drug
DDI-MedLine.d169.s0|29-38|absorption|drug
DDI-MedLine.d169.s0|40-41|of|drug
DDI-MedLine.d169.s0|43-43|5|drug
DDI-MedLine.d169.s0|45-54|milligrams|drug
DDI-MedLine.d169.s0|56-57|of|drug
DDI-MedLine.d169.s0|59-65|nonheme|drug
DDI-MedLine.d169.s0|67-68|or|drug
DDI-MedLine.d169.s0|70-73|heme|drug
DDI-MedLine.d169.s0|75-78|iron|drug
DDI-MedLine.d169.s0|80-81|at|drug
DDI-MedLine.d169.s0|83-87|doses|drug
DDI-MedLine.d169.s0|89-92|less|drug
DDI-MedLine.d169.s0|94-97|than|drug
DDI-MedLine.d169.s0|99-101|800|drug
DDI-MedLine.d169.s0|103-112|milligrams|drug
DDI-MedLine.d169.s0|114-115|in|drug
DDI-MedLine.d169.s0|117-127|nonpregnant|drug
DDI-MedLine.d169.s0|129-133|women|drug
DDI-MedLine.d169.s0|134-134|.|drug
DDI-MedLine.d169.s1|0-6|Calcium|brand
DDI-MedLine.d169.s1|8-9|is|drug
DDI-MedLine.d169.s1|11-13|the|drug
DDI-MedLine.d169.s1|15-18|only|drug
DDI-MedLine.d169.s1|20-24|known|drug
DDI-MedLine.d169.s1|26-34|component|drug
DDI-MedLine.d169.s1|36-37|in|drug
DDI-MedLine.d169.s1|39-41|the|drug
DDI-MedLine.d169.s1|43-46|diet|drug
DDI-MedLine.d169.s1|48-51|that|drug
DDI-MedLine.d169.s1|53-55|may|drug
DDI-MedLine.d169.s1|57-62|affect|drug
DDI-MedLine.d169.s1|64-73|absorption|drug
DDI-MedLine.d169.s1|75-76|of|drug
DDI-MedLine.d169.s1|78-81|both|drug
DDI-MedLine.d169.s1|83-89|nonheme|drug
DDI-MedLine.d169.s1|91-93|and|drug
DDI-MedLine.d169.s1|95-98|heme|drug
DDI-MedLine.d169.s1|100-103|iron|drug
DDI-MedLine.d169.s1|104-104|.|drug
DDI-MedLine.d169.s2|0-6|However|drug
DDI-MedLine.d169.s2|7-7|,|drug
DDI-MedLine.d169.s2|9-11|the|drug
DDI-MedLine.d169.s2|13-20|evidence|drug
DDI-MedLine.d169.s2|22-24|for|drug
DDI-MedLine.d169.s2|26-26|a|drug
DDI-MedLine.d169.s2|28-34|calcium|drug
DDI-MedLine.d169.s2|36-41|effect|drug
DDI-MedLine.d169.s2|43-44|on|drug
DDI-MedLine.d169.s2|46-49|iron|drug
DDI-MedLine.d169.s2|51-60|absorption|drug
DDI-MedLine.d169.s2|62-67|mainly|drug
DDI-MedLine.d169.s2|69-73|comes|drug
DDI-MedLine.d169.s2|75-78|from|drug
DDI-MedLine.d169.s2|80-86|studies|drug
DDI-MedLine.d169.s2|88-91|that|drug
DDI-MedLine.d169.s2|93-95|did|drug
DDI-MedLine.d169.s2|97-99|not|drug
DDI-MedLine.d169.s2|101-107|isolate|drug
DDI-MedLine.d169.s2|109-111|the|drug
DDI-MedLine.d169.s2|113-118|effect|drug
DDI-MedLine.d169.s2|120-121|of|drug
DDI-MedLine.d169.s2|123-129|calcium|drug
DDI-MedLine.d169.s2|131-134|from|drug
DDI-MedLine.d169.s2|136-139|that|drug
DDI-MedLine.d169.s2|141-142|of|drug
DDI-MedLine.d169.s2|144-148|other|drug
DDI-MedLine.d169.s2|150-156|dietary|drug
DDI-MedLine.d169.s2|158-167|components|drug
DDI-MedLine.d169.s2|168-168|,|drug
DDI-MedLine.d169.s2|170-176|because|drug
DDI-MedLine.d169.s2|178-179|it|drug
DDI-MedLine.d169.s2|181-183|was|drug
DDI-MedLine.d169.s2|185-192|detected|drug
DDI-MedLine.d169.s2|194-195|in|drug
DDI-MedLine.d169.s2|197-207|single-meal|drug
DDI-MedLine.d169.s2|209-215|studies|drug
DDI-MedLine.d169.s2|216-216|.|drug
DDI-MedLine.d169.s3|0-2|Our|drug
DDI-MedLine.d169.s3|4-12|objective|drug
DDI-MedLine.d169.s3|14-16|was|drug
DDI-MedLine.d169.s3|18-19|to|drug
DDI-MedLine.d169.s3|21-29|establish|drug
DDI-MedLine.d169.s3|31-39|potential|drug
DDI-MedLine.d169.s3|41-47|effects|drug
DDI-MedLine.d169.s3|49-50|of|drug
DDI-MedLine.d169.s3|52-58|calcium|drug
DDI-MedLine.d169.s3|60-61|on|drug
DDI-MedLine.d169.s3|63-72|absorption|drug
DDI-MedLine.d169.s3|74-75|of|drug
DDI-MedLine.d169.s3|77-83|nonheme|drug
DDI-MedLine.d169.s3|85-87|and|drug
DDI-MedLine.d169.s3|89-92|heme|drug
DDI-MedLine.d169.s3|94-97|iron|drug
DDI-MedLine.d169.s3|99-101|and|drug
DDI-MedLine.d169.s3|103-105|the|drug
DDI-MedLine.d169.s3|107-110|dose|drug
DDI-MedLine.d169.s3|112-119|response|drug
DDI-MedLine.d169.s3|121-123|for|drug
DDI-MedLine.d169.s3|125-128|this|drug
DDI-MedLine.d169.s3|130-135|effect|drug
DDI-MedLine.d169.s3|137-138|in|drug
DDI-MedLine.d169.s3|140-142|the|drug
DDI-MedLine.d169.s3|144-150|absence|drug
DDI-MedLine.d169.s3|152-153|of|drug
DDI-MedLine.d169.s3|155-155|a|drug
DDI-MedLine.d169.s3|157-160|meal|drug
DDI-MedLine.d169.s3|161-161|.|drug
DDI-MedLine.d169.s4|0-9|Fifty-four|drug
DDI-MedLine.d169.s4|11-17|healthy|drug
DDI-MedLine.d169.s4|18-18|,|drug
DDI-MedLine.d169.s4|20-30|nonpregnant|drug
DDI-MedLine.d169.s4|32-36|women|drug
DDI-MedLine.d169.s4|38-41|were|drug
DDI-MedLine.d169.s4|43-50|selected|drug
DDI-MedLine.d169.s4|52-53|to|drug
DDI-MedLine.d169.s4|55-65|participate|drug
DDI-MedLine.d169.s4|67-68|in|drug
DDI-MedLine.d169.s4|70-70|4|drug
DDI-MedLine.d169.s4|72-75|iron|drug
DDI-MedLine.d169.s4|77-86|absorption|drug
DDI-MedLine.d169.s4|88-94|studies|drug
DDI-MedLine.d169.s4|96-100|using|drug
DDI-MedLine.d169.s4|102-105|iron|drug
DDI-MedLine.d169.s4|107-117|radioactive|drug
DDI-MedLine.d169.s4|119-125|tracers|drug
DDI-MedLine.d169.s4|126-126|.|drug
DDI-MedLine.d169.s5|0-1|We|drug
DDI-MedLine.d169.s5|3-11|evaluated|drug
DDI-MedLine.d169.s5|13-15|the|drug
DDI-MedLine.d169.s5|17-23|effects|drug
DDI-MedLine.d169.s5|25-26|of|drug
DDI-MedLine.d169.s5|28-34|calcium|drug
DDI-MedLine.d169.s5|36-40|doses|drug
DDI-MedLine.d169.s5|42-48|between|drug
DDI-MedLine.d169.s5|50-52|200|drug
DDI-MedLine.d169.s5|54-56|and|drug
DDI-MedLine.d169.s5|58-61|1500|drug
DDI-MedLine.d169.s5|63-64|mg|drug
DDI-MedLine.d169.s5|66-67|on|drug
DDI-MedLine.d169.s5|69-78|absorption|drug
DDI-MedLine.d169.s5|80-81|of|drug
DDI-MedLine.d169.s5|83-83|5|drug
DDI-MedLine.d169.s5|85-86|mg|drug
DDI-MedLine.d169.s5|88-94|nonheme|drug
DDI-MedLine.d169.s5|96-99|iron|drug
DDI-MedLine.d169.s5|101-101|(|drug
DDI-MedLine.d169.s5|102-103|as|drug
DDI-MedLine.d169.s5|105-111|ferrous|drug
DDI-MedLine.d169.s5|113-119|sulfate|drug
DDI-MedLine.d169.s5|120-120|)|drug
DDI-MedLine.d169.s5|121-121|.|drug
DDI-MedLine.d169.s6|0-1|We|drug
DDI-MedLine.d169.s6|3-6|also|drug
DDI-MedLine.d169.s6|8-16|evaluated|drug
DDI-MedLine.d169.s6|18-20|the|drug
DDI-MedLine.d169.s6|22-28|effects|drug
DDI-MedLine.d169.s6|30-31|of|drug
DDI-MedLine.d169.s6|33-39|calcium|drug
DDI-MedLine.d169.s6|41-45|doses|drug
DDI-MedLine.d169.s6|47-53|between|drug
DDI-MedLine.d169.s6|55-57|200|drug
DDI-MedLine.d169.s6|59-61|and|drug
DDI-MedLine.d169.s6|63-65|800|drug
DDI-MedLine.d169.s6|67-68|mg|drug
DDI-MedLine.d169.s6|70-71|on|drug
DDI-MedLine.d169.s6|73-82|absorption|drug
DDI-MedLine.d169.s6|84-85|of|drug
DDI-MedLine.d169.s6|87-87|5|drug
DDI-MedLine.d169.s6|89-90|mg|drug
DDI-MedLine.d169.s6|92-95|heme|drug
DDI-MedLine.d169.s6|97-100|iron|drug
DDI-MedLine.d169.s6|102-102|[|drug
DDI-MedLine.d169.s6|103-104|as|drug
DDI-MedLine.d169.s6|106-117|concentrated|drug
DDI-MedLine.d169.s6|119-121|RBC|drug
DDI-MedLine.d169.s6|123-123|(|drug
DDI-MedLine.d169.s6|124-127|CRBC|drug
DDI-MedLine.d169.s6|128-128|)|drug
DDI-MedLine.d169.s6|129-129|]|drug
DDI-MedLine.d169.s6|130-130|.|drug
DDI-MedLine.d169.s7|0-6|Calcium|brand
DDI-MedLine.d169.s7|8-10|was|drug
DDI-MedLine.d169.s7|12-23|administered|drug
DDI-MedLine.d169.s7|25-26|as|drug
DDI-MedLine.d169.s7|28-34|calcium|drug
DDI-MedLine.d169.s7|36-43|chloride|drug
DDI-MedLine.d169.s7|45-46|in|drug
DDI-MedLine.d169.s7|48-50|all|drug
DDI-MedLine.d169.s7|52-58|studies|drug
DDI-MedLine.d169.s7|60-62|and|drug
DDI-MedLine.d169.s7|64-71|minerals|drug
DDI-MedLine.d169.s7|73-76|were|drug
DDI-MedLine.d169.s7|78-85|ingested|drug
DDI-MedLine.d169.s7|87-88|on|drug
DDI-MedLine.d169.s7|90-91|an|drug
DDI-MedLine.d169.s7|93-97|empty|drug
DDI-MedLine.d169.s7|99-105|stomach|drug
DDI-MedLine.d169.s7|106-106|.|drug
DDI-MedLine.d169.s8|0-6|Calcium|brand
DDI-MedLine.d169.s8|8-12|doses|drug
DDI-MedLine.d169.s8|16-19|1000|drug
DDI-MedLine.d169.s8|21-22|mg|drug
DDI-MedLine.d169.s8|24-33|diminished|drug
DDI-MedLine.d169.s8|35-41|nonheme|drug
DDI-MedLine.d169.s8|43-46|iron|drug
DDI-MedLine.d169.s8|48-57|absorption|drug
DDI-MedLine.d169.s8|59-60|by|drug
DDI-MedLine.d169.s8|62-63|an|drug
DDI-MedLine.d169.s8|65-71|average|drug
DDI-MedLine.d169.s8|73-74|of|drug
DDI-MedLine.d169.s8|76-79|49.6|drug
DDI-MedLine.d169.s8|80-80|%|drug
DDI-MedLine.d169.s8|81-81|.|drug
DDI-MedLine.d169.s9|0-0|A|drug
DDI-MedLine.d169.s9|2-8|calcium|drug
DDI-MedLine.d169.s9|10-13|dose|drug
DDI-MedLine.d169.s9|15-16|of|drug
DDI-MedLine.d169.s9|18-20|800|drug
DDI-MedLine.d169.s9|22-23|mg|drug
DDI-MedLine.d169.s9|25-34|diminished|drug
DDI-MedLine.d169.s9|36-45|absorption|drug
DDI-MedLine.d169.s9|47-48|of|drug
DDI-MedLine.d169.s9|50-50|5|drug
DDI-MedLine.d169.s9|52-53|mg|drug
DDI-MedLine.d169.s9|55-58|heme|drug
DDI-MedLine.d169.s9|60-63|iron|drug
DDI-MedLine.d169.s9|65-66|by|drug
DDI-MedLine.d169.s9|68-71|37.7|drug
DDI-MedLine.d169.s9|72-72|%|drug
DDI-MedLine.d169.s9|73-73|.|drug
DDI-MedLine.d169.s10|0-1|In|drug
DDI-MedLine.d169.s10|3-12|conclusion|drug
DDI-MedLine.d169.s10|13-13|,|drug
DDI-MedLine.d169.s10|15-16|we|drug
DDI-MedLine.d169.s10|18-29|demonstrated|drug
DDI-MedLine.d169.s10|31-32|an|drug
DDI-MedLine.d169.s10|34-41|isolated|drug
DDI-MedLine.d169.s10|43-48|effect|drug
DDI-MedLine.d169.s10|50-51|of|drug
DDI-MedLine.d169.s10|53-59|calcium|drug
DDI-MedLine.d169.s10|61-61|(|drug
DDI-MedLine.d169.s10|62-63|as|drug
DDI-MedLine.d169.s10|65-72|chloride|drug
DDI-MedLine.d169.s10|73-73|)|drug
DDI-MedLine.d169.s10|75-76|on|drug
DDI-MedLine.d169.s10|78-87|absorption|drug
DDI-MedLine.d169.s10|89-90|of|drug
DDI-MedLine.d169.s10|92-92|5|drug
DDI-MedLine.d169.s10|94-95|mg|drug
DDI-MedLine.d169.s10|97-98|of|drug
DDI-MedLine.d169.s10|100-103|iron|drug
DDI-MedLine.d169.s10|105-112|provided|drug
DDI-MedLine.d169.s10|114-115|as|drug
DDI-MedLine.d169.s10|117-123|nonheme|drug
DDI-MedLine.d169.s10|125-125|(|drug
DDI-MedLine.d169.s10|126-127|as|drug
DDI-MedLine.d169.s10|129-135|sulfate|drug
DDI-MedLine.d169.s10|136-136|)|drug
DDI-MedLine.d169.s10|138-140|and|drug
DDI-MedLine.d169.s10|142-145|heme|drug
DDI-MedLine.d169.s10|147-147|(|drug
DDI-MedLine.d169.s10|148-149|as|drug
DDI-MedLine.d169.s10|151-154|CRBC|drug
DDI-MedLine.d169.s10|155-155|)|drug
DDI-MedLine.d169.s10|157-160|iron|drug
DDI-MedLine.d169.s10|161-161|.|drug
DDI-MedLine.d169.s11|0-3|This|drug
DDI-MedLine.d169.s11|5-10|effect|drug
DDI-MedLine.d169.s11|12-14|was|drug
DDI-MedLine.d169.s11|16-23|observed|drug
DDI-MedLine.d169.s11|25-26|at|drug
DDI-MedLine.d169.s11|28-32|doses|drug
DDI-MedLine.d169.s11|34-39|higher|drug
DDI-MedLine.d169.s11|41-44|than|drug
DDI-MedLine.d169.s11|46-55|previously|drug
DDI-MedLine.d169.s11|57-64|reported|drug
DDI-MedLine.d169.s11|66-69|from|drug
DDI-MedLine.d169.s11|71-81|single-meal|drug
DDI-MedLine.d169.s11|83-89|studies|drug
DDI-MedLine.d169.s11|90-90|,|drug
DDI-MedLine.d169.s11|92-99|starting|drug
DDI-MedLine.d169.s11|101-102|at|drug
DDI-MedLine.d169.s11|104-107|~800|drug
DDI-MedLine.d169.s11|109-110|mg|drug
DDI-MedLine.d169.s11|112-113|of|drug
DDI-MedLine.d169.s11|115-121|calcium|drug
DDI-MedLine.d169.s11|122-122|.|drug
DDI-DrugBank.d514.s0|0-6|Opioids|group
DDI-DrugBank.d514.s0|8-10|are|drug
DDI-DrugBank.d514.s0|12-17|strong|drug
DDI-DrugBank.d514.s0|19-25|central|drug
DDI-DrugBank.d514.s0|27-33|nervous|drug
DDI-DrugBank.d514.s0|35-40|system|drug
DDI-DrugBank.d514.s0|42-52|depressants|drug
DDI-DrugBank.d514.s0|53-53|,|drug
DDI-DrugBank.d514.s0|55-57|but|drug
DDI-DrugBank.d514.s0|59-65|regular|drug
DDI-DrugBank.d514.s0|67-71|users|drug
DDI-DrugBank.d514.s0|73-79|develop|drug
DDI-DrugBank.d514.s0|81-93|physiological|drug
DDI-DrugBank.d514.s0|95-103|tolerance|drug
DDI-DrugBank.d514.s0|105-112|allowing|drug
DDI-DrugBank.d514.s0|114-122|gradually|drug
DDI-DrugBank.d514.s0|124-132|increased|drug
DDI-DrugBank.d514.s0|134-140|dosages|drug
DDI-DrugBank.d514.s0|141-141|.|drug
DDI-DrugBank.d514.s1|0-1|In|drug
DDI-DrugBank.d514.s1|3-13|combination|drug
DDI-DrugBank.d514.s1|15-18|with|drug
DDI-DrugBank.d514.s1|20-24|other|drug
DDI-DrugBank.d514.s1|26-32|central|drug
DDI-DrugBank.d514.s1|34-40|nervous|drug
DDI-DrugBank.d514.s1|42-47|system|drug
DDI-DrugBank.d514.s1|49-59|depressants|drug
DDI-DrugBank.d514.s1|60-60|,|drug
DDI-DrugBank.d514.s1|62-67|heroin|drug
DDI-DrugBank.d514.s1|69-71|may|drug
DDI-DrugBank.d514.s1|73-77|still|drug
DDI-DrugBank.d514.s1|79-82|kill|drug
DDI-DrugBank.d514.s1|84-87|even|drug
DDI-DrugBank.d514.s1|89-99|experienced|drug
DDI-DrugBank.d514.s1|101-105|users|drug
DDI-DrugBank.d514.s1|106-106|,|drug
DDI-DrugBank.d514.s1|108-119|particularly|drug
DDI-DrugBank.d514.s1|121-122|if|drug
DDI-DrugBank.d514.s1|124-128|their|drug
DDI-DrugBank.d514.s1|130-138|tolerance|drug
DDI-DrugBank.d514.s1|140-141|to|drug
DDI-DrugBank.d514.s1|143-145|the|drug
DDI-DrugBank.d514.s1|147-150|drug|drug
DDI-DrugBank.d514.s1|152-154|has|drug
DDI-DrugBank.d514.s1|156-162|reduced|drug
DDI-DrugBank.d514.s1|164-165|or|drug
DDI-DrugBank.d514.s1|167-169|the|drug
DDI-DrugBank.d514.s1|171-178|strength|drug
DDI-DrugBank.d514.s1|180-181|of|drug
DDI-DrugBank.d514.s1|183-187|their|drug
DDI-DrugBank.d514.s1|189-193|usual|drug
DDI-DrugBank.d514.s1|195-198|dose|drug
DDI-DrugBank.d514.s1|200-202|has|drug
DDI-DrugBank.d514.s1|204-212|increased|drug
DDI-DrugBank.d514.s1|213-213|.|drug
DDI-DrugBank.d514.s2|0-9|Toxicology|drug
DDI-DrugBank.d514.s2|11-17|studies|drug
DDI-DrugBank.d514.s2|19-20|of|drug
DDI-DrugBank.d514.s2|22-35|heroin-related|drug
DDI-DrugBank.d514.s2|37-42|deaths|drug
DDI-DrugBank.d514.s2|44-49|reveal|drug
DDI-DrugBank.d514.s2|51-58|frequent|drug
DDI-DrugBank.d514.s2|60-70|involvement|drug
DDI-DrugBank.d514.s2|72-73|of|drug
DDI-DrugBank.d514.s2|75-79|other|drug
DDI-DrugBank.d514.s2|81-87|central|drug
DDI-DrugBank.d514.s2|89-95|nervous|drug
DDI-DrugBank.d514.s2|97-102|system|drug
DDI-DrugBank.d514.s2|104-114|depressants|drug
DDI-DrugBank.d514.s2|115-115|,|drug
DDI-DrugBank.d514.s2|117-125|including|drug
DDI-DrugBank.d514.s2|127-133|alcohol|drug
DDI-DrugBank.d514.s2|134-134|,|drug
DDI-DrugBank.d514.s2|136-150|benzodiazepines|drug
DDI-DrugBank.d514.s2|152-155|such|drug
DDI-DrugBank.d514.s2|157-158|as|drug
DDI-DrugBank.d514.s2|160-167|diazepam|drug
DDI-DrugBank.d514.s2|169-169|(|drug
DDI-DrugBank.d514.s2|170-175|Valium|brand
DDI-DrugBank.d514.s2|176-176|)|drug
DDI-DrugBank.d514.s2|177-177|,|drug
DDI-DrugBank.d514.s2|179-181|and|drug
DDI-DrugBank.d514.s2|182-182|,|drug
DDI-DrugBank.d514.s2|184-185|to|drug
DDI-DrugBank.d514.s2|187-187|a|drug
DDI-DrugBank.d514.s2|189-194|rising|drug
DDI-DrugBank.d514.s2|196-201|degree|drug
DDI-DrugBank.d514.s2|202-202|,|drug
DDI-DrugBank.d514.s2|204-212|methadone|drug
DDI-DrugBank.d514.s2|213-213|.|drug
DDI-DrugBank.d514.s3|0-9|Ironically|drug
DDI-DrugBank.d514.s3|10-10|,|drug
DDI-DrugBank.d514.s3|12-26|benzodiazepines|drug
DDI-DrugBank.d514.s3|28-30|are|drug
DDI-DrugBank.d514.s3|32-36|often|drug
DDI-DrugBank.d514.s3|38-41|used|drug
DDI-DrugBank.d514.s3|43-44|in|drug
DDI-DrugBank.d514.s3|46-48|the|drug
DDI-DrugBank.d514.s3|50-58|treatment|drug
DDI-DrugBank.d514.s3|60-61|of|drug
DDI-DrugBank.d514.s3|63-68|heroin|drug
DDI-DrugBank.d514.s3|70-78|addiction|drug
DDI-DrugBank.d514.s3|80-84|while|drug
DDI-DrugBank.d514.s3|86-89|they|drug
DDI-DrugBank.d514.s3|91-95|cause|drug
DDI-DrugBank.d514.s3|97-100|much|drug
DDI-DrugBank.d514.s3|102-105|more|drug
DDI-DrugBank.d514.s3|107-112|severe|drug
DDI-DrugBank.d514.s3|114-123|withdrawal|drug
DDI-DrugBank.d514.s3|125-132|symptoms|drug
DDI-DrugBank.d514.s3|133-133|.|drug
DDI-DrugBank.d514.s4|0-6|Cocaine|drug
DDI-DrugBank.d514.s4|8-16|sometimes|drug
DDI-DrugBank.d514.s4|18-23|proves|drug
DDI-DrugBank.d514.s4|25-26|to|drug
DDI-DrugBank.d514.s4|28-29|be|drug
DDI-DrugBank.d514.s4|31-35|fatal|drug
DDI-DrugBank.d514.s4|37-40|when|drug
DDI-DrugBank.d514.s4|42-45|used|drug
DDI-DrugBank.d514.s4|47-48|in|drug
DDI-DrugBank.d514.s4|50-60|combination|drug
DDI-DrugBank.d514.s4|62-65|with|drug
DDI-DrugBank.d514.s4|67-72|heroin|drug
DDI-DrugBank.d514.s4|73-73|.|drug
DDI-MedLine.d100.s0|0-8|Influence|drug
DDI-MedLine.d100.s0|10-11|of|drug
DDI-MedLine.d100.s0|13-27|calcium-channel|drug
DDI-MedLine.d100.s0|29-36|blockers|drug
DDI-MedLine.d100.s0|38-39|on|drug
DDI-MedLine.d100.s0|41-48|platelet|drug
DDI-MedLine.d100.s0|50-57|function|drug
DDI-MedLine.d100.s0|59-61|and|drug
DDI-MedLine.d100.s0|63-73|arachidonic|drug
DDI-MedLine.d100.s0|75-78|acid|drug
DDI-MedLine.d100.s0|80-89|metabolism|drug
DDI-MedLine.d100.s0|90-90|.|drug
DDI-MedLine.d100.s1|0-8|Available|drug
DDI-MedLine.d100.s1|10-13|data|drug
DDI-MedLine.d100.s1|15-22|indicate|drug
DDI-MedLine.d100.s1|24-27|that|drug
DDI-MedLine.d100.s1|29-36|platelet|drug
DDI-MedLine.d100.s1|38-45|function|drug
DDI-MedLine.d100.s1|47-49|and|drug
DDI-MedLine.d100.s1|51-61|arachidonic|drug
DDI-MedLine.d100.s1|63-66|acid|drug
DDI-MedLine.d100.s1|68-77|metabolism|drug
DDI-MedLine.d100.s1|79-81|are|drug
DDI-MedLine.d100.s1|83-91|important|drug
DDI-MedLine.d100.s1|93-99|factors|drug
DDI-MedLine.d100.s1|101-102|in|drug
DDI-MedLine.d100.s1|104-113|hemostasis|drug
DDI-MedLine.d100.s1|115-117|and|drug
DDI-MedLine.d100.s1|119-128|regulation|drug
DDI-MedLine.d100.s1|130-131|of|drug
DDI-MedLine.d100.s1|133-140|vascular|drug
DDI-MedLine.d100.s1|142-145|tone|drug
DDI-MedLine.d100.s1|146-146|.|drug
DDI-MedLine.d100.s2|0-5|Plasma|drug
DDI-MedLine.d100.s2|7-14|membrane|drug
DDI-MedLine.d100.s2|16-18|and|drug
DDI-MedLine.d100.s2|20-32|intracellular|drug
DDI-MedLine.d100.s2|34-45|mobilization|drug
DDI-MedLine.d100.s2|47-48|of|drug
DDI-MedLine.d100.s2|50-56|calcium|drug
DDI-MedLine.d100.s2|58-61|ions|drug
DDI-MedLine.d100.s2|63-65|are|drug
DDI-MedLine.d100.s2|67-76|intimately|drug
DDI-MedLine.d100.s2|78-84|related|drug
DDI-MedLine.d100.s2|86-87|to|drug
DDI-MedLine.d100.s2|89-96|platelet|drug
DDI-MedLine.d100.s2|98-107|activation|drug
DDI-MedLine.d100.s2|109-111|and|drug
DDI-MedLine.d100.s2|113-119|release|drug
DDI-MedLine.d100.s2|121-122|of|drug
DDI-MedLine.d100.s2|124-131|platelet|drug
DDI-MedLine.d100.s2|133-140|contents|drug
DDI-MedLine.d100.s2|141-141|.|drug
DDI-MedLine.d100.s3|0-6|Release|brand
DDI-MedLine.d100.s3|8-9|of|drug
DDI-MedLine.d100.s3|11-21|arachidonic|drug
DDI-MedLine.d100.s3|23-26|acid|drug
DDI-MedLine.d100.s3|28-31|from|drug
DDI-MedLine.d100.s3|33-40|membrane|drug
DDI-MedLine.d100.s3|42-54|phospholipids|drug
DDI-MedLine.d100.s3|56-57|as|drug
DDI-MedLine.d100.s3|59-62|well|drug
DDI-MedLine.d100.s3|64-65|as|drug
DDI-MedLine.d100.s3|67-76|subsequent|drug
DDI-MedLine.d100.s3|78-86|synthesis|drug
DDI-MedLine.d100.s3|88-90|and|drug
DDI-MedLine.d100.s3|92-98|release|drug
DDI-MedLine.d100.s3|100-101|of|drug
DDI-MedLine.d100.s3|103-117|vasoconstrictor|drug
DDI-MedLine.d100.s3|119-129|thromboxane|drug
DDI-MedLine.d100.s3|131-132|A2|drug
DDI-MedLine.d100.s3|134-136|are|drug
DDI-MedLine.d100.s3|138-141|also|drug
DDI-MedLine.d100.s3|143-151|regulated|drug
DDI-MedLine.d100.s3|153-154|by|drug
DDI-MedLine.d100.s3|156-163|movement|drug
DDI-MedLine.d100.s3|165-166|of|drug
DDI-MedLine.d100.s3|168-174|calcium|drug
DDI-MedLine.d100.s3|176-179|ions|drug
DDI-MedLine.d100.s3|180-180|.|drug
DDI-MedLine.d100.s4|0-8|Adenosine|brand
DDI-MedLine.d100.s4|10-21|3':5'-cyclic|drug
DDI-MedLine.d100.s4|23-31|phosphate|drug
DDI-MedLine.d100.s4|33-34|in|drug
DDI-MedLine.d100.s4|36-39|turn|drug
DDI-MedLine.d100.s4|41-48|controls|drug
DDI-MedLine.d100.s4|50-55|levels|drug
DDI-MedLine.d100.s4|57-58|of|drug
DDI-MedLine.d100.s4|60-63|free|drug
DDI-MedLine.d100.s4|65-71|calcium|drug
DDI-MedLine.d100.s4|73-76|ions|drug
DDI-MedLine.d100.s4|78-79|in|drug
DDI-MedLine.d100.s4|81-89|platelets|drug
DDI-MedLine.d100.s4|91-93|and|drug
DDI-MedLine.d100.s4|95-103|regulates|drug
DDI-MedLine.d100.s4|105-121|calcium-dependent|drug
DDI-MedLine.d100.s4|123-131|reactions|drug
DDI-MedLine.d100.s4|132-132|.|drug
DDI-MedLine.d100.s5|0-11|Slow-channel|drug
DDI-MedLine.d100.s5|13-19|calcium|drug
DDI-MedLine.d100.s5|21-28|blockers|drug
DDI-MedLine.d100.s5|29-29|,|drug
DDI-MedLine.d100.s5|31-34|such|drug
DDI-MedLine.d100.s5|36-37|as|drug
DDI-MedLine.d100.s5|39-47|verapamil|drug
DDI-MedLine.d100.s5|48-48|,|drug
DDI-MedLine.d100.s5|50-58|diltiazem|drug
DDI-MedLine.d100.s5|60-62|and|drug
DDI-MedLine.d100.s5|64-73|nifedipine|drug
DDI-MedLine.d100.s5|74-74|,|drug
DDI-MedLine.d100.s5|76-82|inhibit|drug
DDI-MedLine.d100.s5|84-91|platelet|drug
DDI-MedLine.d100.s5|93-102|activation|drug
DDI-MedLine.d100.s5|104-105|in|drug
DDI-MedLine.d100.s5|107-111|vitro|drug
DDI-MedLine.d100.s5|112-112|,|drug
DDI-MedLine.d100.s5|114-116|and|drug
DDI-MedLine.d100.s5|118-125|decrease|drug
DDI-MedLine.d100.s5|127-134|platelet|drug
DDI-MedLine.d100.s5|136-143|adhesion|drug
DDI-MedLine.d100.s5|145-159|intravascularly|drug
DDI-MedLine.d100.s5|160-160|.|drug
DDI-MedLine.d100.s6|0-4|These|drug
DDI-MedLine.d100.s6|6-11|agents|drug
DDI-MedLine.d100.s6|13-16|have|drug
DDI-MedLine.d100.s6|18-21|also|drug
DDI-MedLine.d100.s6|23-26|been|drug
DDI-MedLine.d100.s6|28-32|shown|drug
DDI-MedLine.d100.s6|34-35|to|drug
DDI-MedLine.d100.s6|37-44|decrease|drug
DDI-MedLine.d100.s6|46-53|platelet|drug
DDI-MedLine.d100.s6|55-64|nucleotide|drug
DDI-MedLine.d100.s6|66-72|release|drug
DDI-MedLine.d100.s6|74-76|and|drug
DDI-MedLine.d100.s6|78-88|thromboxane|drug
DDI-MedLine.d100.s6|90-91|A2|drug
DDI-MedLine.d100.s6|93-102|generation|drug
DDI-MedLine.d100.s6|103-103|.|drug
DDI-MedLine.d100.s7|0-3|Some|drug
DDI-MedLine.d100.s7|5-15|preliminary|drug
DDI-MedLine.d100.s7|17-20|data|drug
DDI-MedLine.d100.s7|22-28|suggest|drug
DDI-MedLine.d100.s7|30-33|that|drug
DDI-MedLine.d100.s7|35-41|calcium|drug
DDI-MedLine.d100.s7|43-50|blockers|drug
DDI-MedLine.d100.s7|52-55|also|drug
DDI-MedLine.d100.s7|57-64|increase|drug
DDI-MedLine.d100.s7|66-75|generation|drug
DDI-MedLine.d100.s7|77-78|of|drug
DDI-MedLine.d100.s7|80-90|vasodilator|drug
DDI-MedLine.d100.s7|92-94|and|drug
DDI-MedLine.d100.s7|96-103|platelet|drug
DDI-MedLine.d100.s7|105-117|antiaggregant|drug
DDI-MedLine.d100.s7|119-130|prostacyclin|drug
DDI-MedLine.d100.s7|131-131|,|drug
DDI-MedLine.d100.s7|133-137|which|drug
DDI-MedLine.d100.s7|139-143|could|drug
DDI-MedLine.d100.s7|145-154|contribute|drug
DDI-MedLine.d100.s7|156-157|to|drug
DDI-MedLine.d100.s7|159-166|decrease|drug
DDI-MedLine.d100.s7|168-169|in|drug
DDI-MedLine.d100.s7|171-178|platelet|drug
DDI-MedLine.d100.s7|180-187|function|drug
DDI-MedLine.d100.s7|188-188|.|drug
DDI-MedLine.d100.s8|0-4|These|drug
DDI-MedLine.d100.s8|6-12|effects|drug
DDI-MedLine.d100.s8|14-15|of|drug
DDI-MedLine.d100.s8|17-23|calcium|drug
DDI-MedLine.d100.s8|25-32|blockers|drug
DDI-MedLine.d100.s8|34-35|on|drug
DDI-MedLine.d100.s8|37-44|platelet|drug
DDI-MedLine.d100.s8|46-53|function|drug
DDI-MedLine.d100.s8|55-57|and|drug
DDI-MedLine.d100.s8|59-69|arachidonic|drug
DDI-MedLine.d100.s8|71-74|acid|drug
DDI-MedLine.d100.s8|76-85|metabolism|drug
DDI-MedLine.d100.s8|87-91|could|drug
DDI-MedLine.d100.s8|93-102|contribute|drug
DDI-MedLine.d100.s8|104-105|in|drug
DDI-MedLine.d100.s8|107-110|part|drug
DDI-MedLine.d100.s8|112-113|to|drug
DDI-MedLine.d100.s8|115-119|their|drug
DDI-MedLine.d100.s8|121-128|efficacy|drug
DDI-MedLine.d100.s8|130-131|in|drug
DDI-MedLine.d100.s8|133-140|patients|drug
DDI-MedLine.d100.s8|142-145|with|drug
DDI-MedLine.d100.s8|147-154|ischemic|drug
DDI-MedLine.d100.s8|156-160|heart|drug
DDI-MedLine.d100.s8|162-168|disease|drug
DDI-MedLine.d100.s8|169-169|.|drug
DDI-MedLine.d62.s0|0-9|Activation|drug
DDI-MedLine.d62.s0|11-12|of|drug
DDI-MedLine.d62.s0|14-15|an|drug
DDI-MedLine.d62.s0|17-24|effector|drug
DDI-MedLine.d62.s0|26-40|immediate-early|drug
DDI-MedLine.d62.s0|42-45|gene|drug
DDI-MedLine.d62.s0|47-49|arc|drug
DDI-MedLine.d62.s0|51-52|by|drug
DDI-MedLine.d62.s0|54-68|methamphetamine|drug
DDI-MedLine.d62.s0|69-69|.|drug
DDI-MedLine.d62.s1|0-1|As|drug
DDI-MedLine.d62.s1|3-17|immediate-early|drug
DDI-MedLine.d62.s1|19-23|genes|drug
DDI-MedLine.d62.s1|25-25|(|drug
DDI-MedLine.d62.s1|26-29|IEGs|drug
DDI-MedLine.d62.s1|30-30|)|drug
DDI-MedLine.d62.s1|32-34|are|drug
DDI-MedLine.d62.s1|36-42|thought|drug
DDI-MedLine.d62.s1|44-45|to|drug
DDI-MedLine.d62.s1|47-50|play|drug
DDI-MedLine.d62.s1|52-52|a|drug
DDI-MedLine.d62.s1|54-61|critical|drug
DDI-MedLine.d62.s1|63-66|role|drug
DDI-MedLine.d62.s1|68-69|in|drug
DDI-MedLine.d62.s1|71-79|mediating|drug
DDI-MedLine.d62.s1|81-96|stimulus-induced|drug
DDI-MedLine.d62.s1|98-103|neural|drug
DDI-MedLine.d62.s1|105-114|plasticity|drug
DDI-MedLine.d62.s1|115-115|,|drug
DDI-MedLine.d62.s1|117-119|IEG|drug
DDI-MedLine.d62.s1|121-128|response|drug
DDI-MedLine.d62.s1|130-136|induced|drug
DDI-MedLine.d62.s1|138-139|by|drug
DDI-MedLine.d62.s1|141-155|methamphetamine|drug
DDI-MedLine.d62.s1|157-157|(|drug
DDI-MedLine.d62.s1|158-161|METH|drug
DDI-MedLine.d62.s1|162-162|)|drug
DDI-MedLine.d62.s1|164-166|has|drug
DDI-MedLine.d62.s1|168-171|been|drug
DDI-MedLine.d62.s1|173-185|characterized|drug
DDI-MedLine.d62.s1|187-188|to|drug
DDI-MedLine.d62.s1|190-195|define|drug
DDI-MedLine.d62.s1|197-199|the|drug
DDI-MedLine.d62.s1|201-207|changes|drug
DDI-MedLine.d62.s1|209-210|in|drug
DDI-MedLine.d62.s1|212-215|gene|drug
DDI-MedLine.d62.s1|217-226|expression|drug
DDI-MedLine.d62.s1|228-231|that|drug
DDI-MedLine.d62.s1|233-235|may|drug
DDI-MedLine.d62.s1|237-244|underlie|drug
DDI-MedLine.d62.s1|246-248|its|drug
DDI-MedLine.d62.s1|250-261|long-lasting|drug
DDI-MedLine.d62.s1|263-272|behavioral|drug
DDI-MedLine.d62.s1|274-280|effects|drug
DDI-MedLine.d62.s1|281-281|.|drug
DDI-MedLine.d62.s2|0-7|Although|drug
DDI-MedLine.d62.s2|9-18|activation|drug
DDI-MedLine.d62.s2|20-21|of|drug
DDI-MedLine.d62.s2|23-29|several|drug
DDI-MedLine.d62.s2|31-43|transcription|drug
DDI-MedLine.d62.s2|45-50|factor|drug
DDI-MedLine.d62.s2|52-55|IEGs|drug
DDI-MedLine.d62.s2|57-59|has|drug
DDI-MedLine.d62.s2|61-64|been|drug
DDI-MedLine.d62.s2|66-74|described|drug
DDI-MedLine.d62.s2|75-75|,|drug
DDI-MedLine.d62.s2|77-82|little|drug
DDI-MedLine.d62.s2|84-85|is|drug
DDI-MedLine.d62.s2|87-91|known|drug
DDI-MedLine.d62.s2|93-97|about|drug
DDI-MedLine.d62.s2|99-106|effector|drug
DDI-MedLine.d62.s2|108-111|IEGs|drug
DDI-MedLine.d62.s2|112-112|.|drug
DDI-MedLine.d62.s3|0-3|Here|drug
DDI-MedLine.d62.s3|4-4|,|drug
DDI-MedLine.d62.s3|6-7|we|drug
DDI-MedLine.d62.s3|9-12|have|drug
DDI-MedLine.d62.s3|14-21|examined|drug
DDI-MedLine.d62.s3|23-29|whether|drug
DDI-MedLine.d62.s3|31-34|METH|drug
DDI-MedLine.d62.s3|36-49|administration|drug
DDI-MedLine.d62.s3|51-57|affects|drug
DDI-MedLine.d62.s3|59-68|expression|drug
DDI-MedLine.d62.s3|70-71|of|drug
DDI-MedLine.d62.s3|73-74|an|drug
DDI-MedLine.d62.s3|76-83|effector|drug
DDI-MedLine.d62.s3|85-87|IEG|drug
DDI-MedLine.d62.s3|89-91|arc|drug
DDI-MedLine.d62.s3|93-93|(|drug
DDI-MedLine.d62.s3|94-111|activity-regulated|drug
DDI-MedLine.d62.s3|112-112|,|drug
DDI-MedLine.d62.s3|114-136|cytoskeleton-associated|drug
DDI-MedLine.d62.s3|137-137|)|drug
DDI-MedLine.d62.s3|139-142|that|drug
DDI-MedLine.d62.s3|144-150|encodes|drug
DDI-MedLine.d62.s3|152-152|a|drug
DDI-MedLine.d62.s3|154-160|protein|drug
DDI-MedLine.d62.s3|162-165|with|drug
DDI-MedLine.d62.s3|167-174|homology|drug
DDI-MedLine.d62.s3|176-177|to|drug
DDI-MedLine.d62.s3|179-186|spectrin|drug
DDI-MedLine.d62.s3|187-187|.|drug
DDI-MedLine.d62.s4|0-4|Using|drug
DDI-MedLine.d62.s4|6-7|in|drug
DDI-MedLine.d62.s4|9-12|situ|drug
DDI-MedLine.d62.s4|14-26|hybridization|drug
DDI-MedLine.d62.s4|27-27|,|drug
DDI-MedLine.d62.s4|29-30|we|drug
DDI-MedLine.d62.s4|32-39|observed|drug
DDI-MedLine.d62.s4|41-44|that|drug
DDI-MedLine.d62.s4|46-49|METH|drug
DDI-MedLine.d62.s4|51-56|caused|drug
DDI-MedLine.d62.s4|58-58|a|drug
DDI-MedLine.d62.s4|60-64|rapid|drug
DDI-MedLine.d62.s4|66-68|and|drug
DDI-MedLine.d62.s4|70-78|transient|drug
DDI-MedLine.d62.s4|80-93|dose-dependent|drug
DDI-MedLine.d62.s4|95-102|increase|drug
DDI-MedLine.d62.s4|104-105|in|drug
DDI-MedLine.d62.s4|107-109|arc|drug
DDI-MedLine.d62.s4|111-114|mRNA|drug
DDI-MedLine.d62.s4|116-120|level|drug
DDI-MedLine.d62.s4|122-123|in|drug
DDI-MedLine.d62.s4|125-127|the|drug
DDI-MedLine.d62.s4|129-136|striatum|drug
DDI-MedLine.d62.s4|138-140|and|drug
DDI-MedLine.d62.s4|142-147|cortex|drug
DDI-MedLine.d62.s4|149-152|that|drug
DDI-MedLine.d62.s4|154-156|was|drug
DDI-MedLine.d62.s4|158-166|abolished|drug
DDI-MedLine.d62.s4|168-169|by|drug
DDI-MedLine.d62.s4|171-182|pretreatment|drug
DDI-MedLine.d62.s4|184-187|with|drug
DDI-MedLine.d62.s4|189-191|the|drug
DDI-MedLine.d62.s4|193-200|specific|drug
DDI-MedLine.d62.s4|202-209|dopamine|drug
DDI-MedLine.d62.s4|211-212|D1|drug
DDI-MedLine.d62.s4|214-221|receptor|drug
DDI-MedLine.d62.s4|223-232|antagonist|drug
DDI-MedLine.d62.s4|234-242|SCH-23390|drug
DDI-MedLine.d62.s4|244-246|but|drug
DDI-MedLine.d62.s4|248-250|not|drug
DDI-MedLine.d62.s4|252-253|by|drug
DDI-MedLine.d62.s4|255-256|an|drug
DDI-MedLine.d62.s4|258-265|atypical|drug
DDI-MedLine.d62.s4|267-277|neuroleptic|drug
DDI-MedLine.d62.s4|279-287|clozapine|drug
DDI-MedLine.d62.s4|288-288|.|drug
DDI-MedLine.d62.s5|0-3|METH|drug
DDI-MedLine.d62.s5|5-11|induced|drug
DDI-MedLine.d62.s5|13-15|arc|drug
DDI-MedLine.d62.s5|17-20|mRNA|drug
DDI-MedLine.d62.s5|22-23|in|drug
DDI-MedLine.d62.s5|25-30|layers|drug
DDI-MedLine.d62.s5|32-33|IV|drug
DDI-MedLine.d62.s5|35-37|and|drug
DDI-MedLine.d62.s5|39-40|VI|drug
DDI-MedLine.d62.s5|42-43|of|drug
DDI-MedLine.d62.s5|45-47|the|drug
DDI-MedLine.d62.s5|49-54|cortex|drug
DDI-MedLine.d62.s5|56-60|which|drug
DDI-MedLine.d62.s5|62-69|dopamine|drug
DDI-MedLine.d62.s5|71-78|receptor|drug
DDI-MedLine.d62.s5|80-82|are|drug
DDI-MedLine.d62.s5|84-92|localized|drug
DDI-MedLine.d62.s5|94-95|to|drug
DDI-MedLine.d62.s5|96-96|.|drug
DDI-MedLine.d62.s6|0-4|These|drug
DDI-MedLine.d62.s6|6-12|results|drug
DDI-MedLine.d62.s6|14-20|suggest|drug
DDI-MedLine.d62.s6|22-25|that|drug
DDI-MedLine.d62.s6|27-28|D1|drug
DDI-MedLine.d62.s6|30-38|receptors|drug
DDI-MedLine.d62.s6|40-42|are|drug
DDI-MedLine.d62.s6|44-50|coupled|drug
DDI-MedLine.d62.s6|52-53|to|drug
DDI-MedLine.d62.s6|55-64|activation|drug
DDI-MedLine.d62.s6|66-67|of|drug
DDI-MedLine.d62.s6|69-71|arc|drug
DDI-MedLine.d62.s6|73-76|gene|drug
DDI-MedLine.d62.s6|77-77|,|drug
DDI-MedLine.d62.s6|79-83|which|drug
DDI-MedLine.d62.s6|85-87|may|drug
DDI-MedLine.d62.s6|89-90|be|drug
DDI-MedLine.d62.s6|92-99|involved|drug
DDI-MedLine.d62.s6|101-102|in|drug
DDI-MedLine.d62.s6|104-113|functional|drug
DDI-MedLine.d62.s6|115-116|or|drug
DDI-MedLine.d62.s6|118-127|structural|drug
DDI-MedLine.d62.s6|129-139|alterations|drug
DDI-MedLine.d62.s6|141-150|underlying|drug
DDI-MedLine.d62.s6|152-157|neural|drug
DDI-MedLine.d62.s6|159-168|plasticity|drug
DDI-MedLine.d62.s6|170-178|triggered|drug
DDI-MedLine.d62.s6|180-181|by|drug
DDI-MedLine.d62.s6|183-186|METH|drug
DDI-MedLine.d62.s6|187-187|.|drug
DDI-DrugBank.d346.s0|0-6|Studies|drug
DDI-DrugBank.d346.s0|8-9|to|drug
DDI-DrugBank.d346.s0|11-18|evaluate|drug
DDI-DrugBank.d346.s0|20-27|possible|drug
DDI-DrugBank.d346.s0|29-40|interactions|drug
DDI-DrugBank.d346.s0|42-48|between|drug
DDI-DrugBank.d346.s0|50-54|REVIA|drug
DDI-DrugBank.d346.s0|56-58|and|drug
DDI-DrugBank.d346.s0|60-64|drugs|drug
DDI-DrugBank.d346.s0|66-70|other|drug
DDI-DrugBank.d346.s0|72-75|than|drug
DDI-DrugBank.d346.s0|77-83|opiates|drug
DDI-DrugBank.d346.s0|85-88|have|drug
DDI-DrugBank.d346.s0|90-92|not|drug
DDI-DrugBank.d346.s0|94-97|been|drug
DDI-DrugBank.d346.s0|99-107|performed|drug
DDI-DrugBank.d346.s0|108-108|.|drug
DDI-DrugBank.d346.s1|0-11|Consequently|drug
DDI-DrugBank.d346.s1|12-12|,|drug
DDI-DrugBank.d346.s1|14-20|caution|drug
DDI-DrugBank.d346.s1|22-23|is|drug
DDI-DrugBank.d346.s1|25-31|advised|drug
DDI-DrugBank.d346.s1|33-34|if|drug
DDI-DrugBank.d346.s1|36-38|the|drug
DDI-DrugBank.d346.s1|40-50|concomitant|drug
DDI-DrugBank.d346.s1|52-65|administration|drug
DDI-DrugBank.d346.s1|67-68|of|drug
DDI-DrugBank.d346.s1|70-74|REVIA|drug
DDI-DrugBank.d346.s1|76-78|and|drug
DDI-DrugBank.d346.s1|80-84|other|drug
DDI-DrugBank.d346.s1|86-90|drugs|drug
DDI-DrugBank.d346.s1|92-93|is|drug
DDI-DrugBank.d346.s1|95-102|required|drug
DDI-DrugBank.d346.s1|103-103|.|drug
DDI-DrugBank.d346.s2|0-2|The|drug
DDI-DrugBank.d346.s2|4-9|safety|drug
DDI-DrugBank.d346.s2|11-13|and|drug
DDI-DrugBank.d346.s2|15-22|efficacy|drug
DDI-DrugBank.d346.s2|24-25|of|drug
DDI-DrugBank.d346.s2|27-37|concomitant|drug
DDI-DrugBank.d346.s2|39-41|use|drug
DDI-DrugBank.d346.s2|43-44|of|drug
DDI-DrugBank.d346.s2|46-50|REVIA|drug
DDI-DrugBank.d346.s2|52-54|and|drug
DDI-DrugBank.d346.s2|56-65|disulfiram|drug
DDI-DrugBank.d346.s2|67-68|is|drug
DDI-DrugBank.d346.s2|70-76|unknown|drug
DDI-DrugBank.d346.s2|77-77|,|drug
DDI-DrugBank.d346.s2|79-81|and|drug
DDI-DrugBank.d346.s2|83-85|the|drug
DDI-DrugBank.d346.s2|87-97|concomitant|drug
DDI-DrugBank.d346.s2|99-101|use|drug
DDI-DrugBank.d346.s2|103-104|of|drug
DDI-DrugBank.d346.s2|106-108|two|drug
DDI-DrugBank.d346.s2|110-120|potentially|drug
DDI-DrugBank.d346.s2|122-132|hepatotoxic|drug
DDI-DrugBank.d346.s2|134-144|medications|drug
DDI-DrugBank.d346.s2|146-147|is|drug
DDI-DrugBank.d346.s2|149-151|not|drug
DDI-DrugBank.d346.s2|153-162|ordinarily|drug
DDI-DrugBank.d346.s2|164-174|recommended|drug
DDI-DrugBank.d346.s2|176-181|unless|drug
DDI-DrugBank.d346.s2|183-185|the|drug
DDI-DrugBank.d346.s2|187-194|probable|drug
DDI-DrugBank.d346.s2|196-203|benefits|drug
DDI-DrugBank.d346.s2|205-212|outweigh|drug
DDI-DrugBank.d346.s2|214-216|the|drug
DDI-DrugBank.d346.s2|218-222|known|drug
DDI-DrugBank.d346.s2|224-228|risks|drug
DDI-DrugBank.d346.s2|229-229|.|drug
DDI-DrugBank.d346.s3|0-7|Lethargy|drug
DDI-DrugBank.d346.s3|9-11|and|drug
DDI-DrugBank.d346.s3|13-22|somnolence|drug
DDI-DrugBank.d346.s3|24-27|have|drug
DDI-DrugBank.d346.s3|29-32|been|drug
DDI-DrugBank.d346.s3|34-41|reported|drug
DDI-DrugBank.d346.s3|43-51|following|drug
DDI-DrugBank.d346.s3|53-57|doses|drug
DDI-DrugBank.d346.s3|59-60|of|drug
DDI-DrugBank.d346.s3|62-66|REVIA|drug
DDI-DrugBank.d346.s3|68-70|and|drug
DDI-DrugBank.d346.s3|72-83|thioridazine|drug
DDI-DrugBank.d346.s3|84-84|.|drug
DDI-DrugBank.d346.s4|0-7|Patients|drug
DDI-DrugBank.d346.s4|9-14|taking|drug
DDI-DrugBank.d346.s4|16-20|REVIA|drug
DDI-DrugBank.d346.s4|22-24|may|drug
DDI-DrugBank.d346.s4|26-28|not|drug
DDI-DrugBank.d346.s4|30-36|benefit|drug
DDI-DrugBank.d346.s4|38-41|from|drug
DDI-DrugBank.d346.s4|43-48|opioid|drug
DDI-DrugBank.d346.s4|50-59|containing|drug
DDI-DrugBank.d346.s4|61-69|medicines|drug
DDI-DrugBank.d346.s4|70-70|,|drug
DDI-DrugBank.d346.s4|72-75|such|drug
DDI-DrugBank.d346.s4|77-78|as|drug
DDI-DrugBank.d346.s4|80-84|cough|drug
DDI-DrugBank.d346.s4|86-88|and|drug
DDI-DrugBank.d346.s4|90-93|cold|drug
DDI-DrugBank.d346.s4|95-106|preparations|drug
DDI-DrugBank.d346.s4|107-107|,|drug
DDI-DrugBank.d346.s4|109-121|antidiarrheal|drug
DDI-DrugBank.d346.s4|123-134|preparations|drug
DDI-DrugBank.d346.s4|135-135|,|drug
DDI-DrugBank.d346.s4|137-139|and|drug
DDI-DrugBank.d346.s4|141-146|opioid|drug
DDI-DrugBank.d346.s4|148-157|analgesics|drug
DDI-DrugBank.d346.s4|158-158|.|drug
DDI-DrugBank.d346.s5|0-1|In|drug
DDI-DrugBank.d346.s5|3-4|an|drug
DDI-DrugBank.d346.s5|6-14|emergency|drug
DDI-DrugBank.d346.s5|16-24|situation|drug
DDI-DrugBank.d346.s5|26-29|when|drug
DDI-DrugBank.d346.s5|31-36|opioid|drug
DDI-DrugBank.d346.s5|38-46|analgesia|drug
DDI-DrugBank.d346.s5|48-51|must|drug
DDI-DrugBank.d346.s5|53-54|be|drug
DDI-DrugBank.d346.s5|56-67|administered|drug
DDI-DrugBank.d346.s5|69-70|to|drug
DDI-DrugBank.d346.s5|72-72|a|drug
DDI-DrugBank.d346.s5|74-80|patient|drug
DDI-DrugBank.d346.s5|82-90|receiving|drug
DDI-DrugBank.d346.s5|92-96|REVIA|drug
DDI-DrugBank.d346.s5|97-97|,|drug
DDI-DrugBank.d346.s5|99-101|the|drug
DDI-DrugBank.d346.s5|103-108|amount|drug
DDI-DrugBank.d346.s5|110-111|of|drug
DDI-DrugBank.d346.s5|113-118|opioid|drug
DDI-DrugBank.d346.s5|120-127|required|drug
DDI-DrugBank.d346.s5|129-131|may|drug
DDI-DrugBank.d346.s5|133-134|be|drug
DDI-DrugBank.d346.s5|136-142|greater|drug
DDI-DrugBank.d346.s5|144-147|than|drug
DDI-DrugBank.d346.s5|149-153|usual|drug
DDI-DrugBank.d346.s5|154-154|,|drug
DDI-DrugBank.d346.s5|156-158|and|drug
DDI-DrugBank.d346.s5|160-162|the|drug
DDI-DrugBank.d346.s5|164-172|resulting|drug
DDI-DrugBank.d346.s5|174-184|respiratory|drug
DDI-DrugBank.d346.s5|186-195|depression|drug
DDI-DrugBank.d346.s5|197-199|may|drug
DDI-DrugBank.d346.s5|201-202|be|drug
DDI-DrugBank.d346.s5|204-209|deeper|drug
DDI-DrugBank.d346.s5|211-213|and|drug
DDI-DrugBank.d346.s5|215-218|more|drug
DDI-DrugBank.d346.s5|220-228|prolonged|drug
DDI-DrugBank.d346.s5|229-229|.|drug
DDI-DrugBank.d737.s0|0-17|Carbidopa/Levodopa|drug
DDI-DrugBank.d737.s0|18-18|:|drug
DDI-DrugBank.d737.s0|20-37|Carbidopa/Levodopa|drug
DDI-DrugBank.d737.s0|39-42|does|drug
DDI-DrugBank.d737.s0|44-46|not|drug
DDI-DrugBank.d737.s0|48-56|influence|drug
DDI-DrugBank.d737.s0|58-60|the|drug
DDI-DrugBank.d737.s0|62-77|pharmacokinetics|drug
DDI-DrugBank.d737.s0|79-80|of|drug
DDI-DrugBank.d737.s0|82-92|pramipexole|drug
DDI-DrugBank.d737.s0|94-95|in|drug
DDI-DrugBank.d737.s0|97-103|healthy|drug
DDI-DrugBank.d737.s0|105-114|volunteers|drug
DDI-DrugBank.d737.s0|116-116|(|drug
DDI-DrugBank.d737.s0|117-118|N=|drug
DDI-DrugBank.d737.s0|120-121|10|drug
DDI-DrugBank.d737.s0|122-122|)|drug
DDI-DrugBank.d737.s0|123-123|.|drug
DDI-DrugBank.d737.s1|0-0|5|drug
DDI-DrugBank.d737.s1|2-6|hours|drug
DDI-DrugBank.d737.s1|7-7|.|drug
DDI-DrugBank.d737.s2|0-9|Selegiline|brand
DDI-DrugBank.d737.s2|10-10|:|drug
DDI-DrugBank.d737.s2|12-13|In|drug
DDI-DrugBank.d737.s2|15-21|healthy|drug
DDI-DrugBank.d737.s2|23-32|volunteers|drug
DDI-DrugBank.d737.s2|34-34|(|drug
DDI-DrugBank.d737.s2|35-36|N=|drug
DDI-DrugBank.d737.s2|38-39|11|drug
DDI-DrugBank.d737.s2|40-40|)|drug
DDI-DrugBank.d737.s2|41-41|,|drug
DDI-DrugBank.d737.s2|43-52|selegiline|drug
DDI-DrugBank.d737.s2|54-56|did|drug
DDI-DrugBank.d737.s2|58-60|not|drug
DDI-DrugBank.d737.s2|62-70|influence|drug
DDI-DrugBank.d737.s2|72-74|the|drug
DDI-DrugBank.d737.s2|76-91|pharmacokinetics|drug
DDI-DrugBank.d737.s2|93-94|of|drug
DDI-DrugBank.d737.s2|96-106|pramipexole|drug
DDI-DrugBank.d737.s2|107-107|.|drug
DDI-DrugBank.d737.s3|0-9|Amantadine|brand
DDI-DrugBank.d737.s3|10-10|:|drug
DDI-DrugBank.d737.s3|12-21|Population|drug
DDI-DrugBank.d737.s3|23-37|pharmacokinetic|drug
DDI-DrugBank.d737.s3|39-46|analysis|drug
DDI-DrugBank.d737.s3|48-55|suggests|drug
DDI-DrugBank.d737.s3|57-60|that|drug
DDI-DrugBank.d737.s3|62-71|amantadine|drug
DDI-DrugBank.d737.s3|73-74|is|drug
DDI-DrugBank.d737.s3|76-83|unlikely|drug
DDI-DrugBank.d737.s3|85-86|to|drug
DDI-DrugBank.d737.s3|88-92|alter|drug
DDI-DrugBank.d737.s3|94-96|the|drug
DDI-DrugBank.d737.s3|98-101|oral|drug
DDI-DrugBank.d737.s3|103-111|clearance|drug
DDI-DrugBank.d737.s3|113-114|of|drug
DDI-DrugBank.d737.s3|116-126|pramipexole|drug
DDI-DrugBank.d737.s3|128-128|(|drug
DDI-DrugBank.d737.s3|129-130|N=|drug
DDI-DrugBank.d737.s3|132-133|54|drug
DDI-DrugBank.d737.s3|134-134|)|drug
DDI-DrugBank.d737.s3|135-135|.|drug
DDI-DrugBank.d737.s4|0-9|Cimetidine|brand
DDI-DrugBank.d737.s4|10-10|:|drug
DDI-DrugBank.d737.s4|12-21|Cimetidine|brand
DDI-DrugBank.d737.s4|22-22|,|drug
DDI-DrugBank.d737.s4|24-24|a|drug
DDI-DrugBank.d737.s4|26-30|known|drug
DDI-DrugBank.d737.s4|32-40|inhibitor|drug
DDI-DrugBank.d737.s4|42-43|of|drug
DDI-DrugBank.d737.s4|45-49|renal|drug
DDI-DrugBank.d737.s4|51-57|tubular|drug
DDI-DrugBank.d737.s4|59-67|secretion|drug
DDI-DrugBank.d737.s4|69-70|of|drug
DDI-DrugBank.d737.s4|72-78|organic|drug
DDI-DrugBank.d737.s4|80-84|bases|drug
DDI-DrugBank.d737.s4|86-88|via|drug
DDI-DrugBank.d737.s4|90-92|the|drug
DDI-DrugBank.d737.s4|94-101|cationic|drug
DDI-DrugBank.d737.s4|103-111|transport|drug
DDI-DrugBank.d737.s4|113-118|system|drug
DDI-DrugBank.d737.s4|119-119|,|drug
DDI-DrugBank.d737.s4|121-126|caused|drug
DDI-DrugBank.d737.s4|128-128|a|drug
DDI-DrugBank.d737.s4|130-131|50|drug
DDI-DrugBank.d737.s4|132-132|%|drug
DDI-DrugBank.d737.s4|134-141|increase|drug
DDI-DrugBank.d737.s4|143-144|in|drug
DDI-DrugBank.d737.s4|146-156|pramipexole|drug
DDI-DrugBank.d737.s4|158-160|AUC|drug
DDI-DrugBank.d737.s4|162-164|and|drug
DDI-DrugBank.d737.s4|166-166|a|drug
DDI-DrugBank.d737.s4|168-169|40|drug
DDI-DrugBank.d737.s4|170-170|%|drug
DDI-DrugBank.d737.s4|172-179|increase|drug
DDI-DrugBank.d737.s4|181-182|in|drug
DDI-DrugBank.d737.s4|184-192|half-life|drug
DDI-DrugBank.d737.s4|194-194|(|drug
DDI-DrugBank.d737.s4|195-196|N=|drug
DDI-DrugBank.d737.s4|198-199|12|drug
DDI-DrugBank.d737.s4|200-200|)|drug
DDI-DrugBank.d737.s4|201-201|.|drug
DDI-DrugBank.d737.s5|0-9|Probenecid|brand
DDI-DrugBank.d737.s5|10-10|:|drug
DDI-DrugBank.d737.s5|12-21|Probenecid|brand
DDI-DrugBank.d737.s5|22-22|,|drug
DDI-DrugBank.d737.s5|24-24|a|drug
DDI-DrugBank.d737.s5|26-30|known|drug
DDI-DrugBank.d737.s5|32-40|inhibitor|drug
DDI-DrugBank.d737.s5|42-43|of|drug
DDI-DrugBank.d737.s5|45-49|renal|drug
DDI-DrugBank.d737.s5|51-57|tubular|drug
DDI-DrugBank.d737.s5|59-67|secretion|drug
DDI-DrugBank.d737.s5|69-70|of|drug
DDI-DrugBank.d737.s5|72-78|organic|drug
DDI-DrugBank.d737.s5|80-84|acids|drug
DDI-DrugBank.d737.s5|86-88|via|drug
DDI-DrugBank.d737.s5|90-92|the|drug
DDI-DrugBank.d737.s5|94-100|aruonic|drug
DDI-DrugBank.d737.s5|102-112|transporter|drug
DDI-DrugBank.d737.s5|113-113|,|drug
DDI-DrugBank.d737.s5|115-117|did|drug
DDI-DrugBank.d737.s5|119-121|not|drug
DDI-DrugBank.d737.s5|123-132|noticeably|drug
DDI-DrugBank.d737.s5|134-142|influence|drug
DDI-DrugBank.d737.s5|144-154|pramipexole|drug
DDI-DrugBank.d737.s5|156-171|pharmacokinetics|drug
DDI-DrugBank.d737.s5|173-173|(|drug
DDI-DrugBank.d737.s5|174-175|N=|drug
DDI-DrugBank.d737.s5|177-178|12|drug
DDI-DrugBank.d737.s5|179-179|)|drug
DDI-DrugBank.d737.s5|180-180|.|drug
DDI-DrugBank.d737.s6|0-4|Other|drug
DDI-DrugBank.d737.s6|6-10|drugs|drug
DDI-DrugBank.d737.s6|12-21|eliminated|drug
DDI-DrugBank.d737.s6|23-25|via|drug
DDI-DrugBank.d737.s6|27-31|renal|drug
DDI-DrugBank.d737.s6|33-41|secretion|drug
DDI-DrugBank.d737.s6|42-42|:|drug
DDI-DrugBank.d737.s6|44-53|Population|drug
DDI-DrugBank.d737.s6|55-69|pharmacokinetic|drug
DDI-DrugBank.d737.s6|71-78|analysis|drug
DDI-DrugBank.d737.s6|80-87|suggests|drug
DDI-DrugBank.d737.s6|89-92|that|drug
DDI-DrugBank.d737.s6|94-109|coadministration|drug
DDI-DrugBank.d737.s6|111-112|of|drug
DDI-DrugBank.d737.s6|114-118|drugs|drug
DDI-DrugBank.d737.s6|120-123|that|drug
DDI-DrugBank.d737.s6|125-127|are|drug
DDI-DrugBank.d737.s6|129-136|secreted|drug
DDI-DrugBank.d737.s6|138-139|by|drug
DDI-DrugBank.d737.s6|141-143|the|drug
DDI-DrugBank.d737.s6|145-152|cationic|drug
DDI-DrugBank.d737.s6|154-162|transport|drug
DDI-DrugBank.d737.s6|164-169|system|drug
DDI-DrugBank.d737.s6|171-171|(|drug
DDI-DrugBank.d737.s6|172-175|e.g.|drug
DDI-DrugBank.d737.s6|176-176|,|drug
DDI-DrugBank.d737.s6|178-187|cimetidine|drug
DDI-DrugBank.d737.s6|188-188|,|drug
DDI-DrugBank.d737.s6|190-199|ranitidine|drug
DDI-DrugBank.d737.s6|200-200|,|drug
DDI-DrugBank.d737.s6|202-210|diltiazem|drug
DDI-DrugBank.d737.s6|211-211|,|drug
DDI-DrugBank.d737.s6|213-223|triamterene|drug
DDI-DrugBank.d737.s6|224-224|,|drug
DDI-DrugBank.d737.s6|226-234|verapamil|drug
DDI-DrugBank.d737.s6|235-235|,|drug
DDI-DrugBank.d737.s6|237-245|quinidine|drug
DDI-DrugBank.d737.s6|246-246|,|drug
DDI-DrugBank.d737.s6|248-250|and|drug
DDI-DrugBank.d737.s6|252-258|quinine|drug
DDI-DrugBank.d737.s6|259-259|)|drug
DDI-DrugBank.d737.s6|261-269|decreases|drug
DDI-DrugBank.d737.s6|271-273|the|drug
DDI-DrugBank.d737.s6|275-278|oral|drug
DDI-DrugBank.d737.s6|280-288|clearance|drug
DDI-DrugBank.d737.s6|290-291|of|drug
DDI-DrugBank.d737.s6|293-303|pramipexole|drug
DDI-DrugBank.d737.s6|305-306|by|drug
DDI-DrugBank.d737.s6|308-312|about|drug
DDI-DrugBank.d737.s6|314-315|20|drug
DDI-DrugBank.d737.s6|316-316|%|drug
DDI-DrugBank.d737.s6|317-317|,|drug
DDI-DrugBank.d737.s6|319-323|while|drug
DDI-DrugBank.d737.s6|325-329|those|drug
DDI-DrugBank.d737.s6|331-338|secreted|drug
DDI-DrugBank.d737.s6|340-341|by|drug
DDI-DrugBank.d737.s6|343-345|the|drug
DDI-DrugBank.d737.s6|347-353|anionic|drug
DDI-DrugBank.d737.s6|355-363|transport|drug
DDI-DrugBank.d737.s6|365-370|system|drug
DDI-DrugBank.d737.s6|372-372|(|drug
DDI-DrugBank.d737.s6|373-376|e.g.|drug
DDI-DrugBank.d737.s6|377-377|,|drug
DDI-DrugBank.d737.s6|379-392|cephalosporins|drug
DDI-DrugBank.d737.s6|393-393|,|drug
DDI-DrugBank.d737.s6|395-405|penicillins|drug
DDI-DrugBank.d737.s6|406-406|,|drug
DDI-DrugBank.d737.s6|408-419|indomethacin|drug
DDI-DrugBank.d737.s6|420-420|,|drug
DDI-DrugBank.d737.s6|422-440|hydrochlorothiazide|drug
DDI-DrugBank.d737.s6|441-441|,|drug
DDI-DrugBank.d737.s6|443-445|and|drug
DDI-DrugBank.d737.s6|447-460|chlorpropamide|drug
DDI-DrugBank.d737.s6|461-461|)|drug
DDI-DrugBank.d737.s6|463-465|are|drug
DDI-DrugBank.d737.s6|467-472|likely|drug
DDI-DrugBank.d737.s6|474-475|to|drug
DDI-DrugBank.d737.s6|477-480|have|drug
DDI-DrugBank.d737.s6|482-487|little|drug
DDI-DrugBank.d737.s6|489-494|effect|drug
DDI-DrugBank.d737.s6|496-497|on|drug
DDI-DrugBank.d737.s6|499-501|the|drug
DDI-DrugBank.d737.s6|503-506|oral|drug
DDI-DrugBank.d737.s6|508-516|clearance|drug
DDI-DrugBank.d737.s6|518-519|of|drug
DDI-DrugBank.d737.s6|521-531|pramipexole|drug
DDI-DrugBank.d737.s6|532-532|.|drug
DDI-DrugBank.d737.s7|0-2|CYP|drug
DDI-DrugBank.d737.s7|4-15|interactions|drug
DDI-DrugBank.d737.s7|16-16|:|drug
DDI-DrugBank.d737.s7|18-27|Inhibitors|drug
DDI-DrugBank.d737.s7|29-30|of|drug
DDI-DrugBank.d737.s7|32-41|cytochrome|drug
DDI-DrugBank.d737.s7|43-46|P450|drug
DDI-DrugBank.d737.s7|48-54|enzymes|drug
DDI-DrugBank.d737.s7|56-60|would|drug
DDI-DrugBank.d737.s7|62-64|not|drug
DDI-DrugBank.d737.s7|66-67|be|drug
DDI-DrugBank.d737.s7|69-76|expected|drug
DDI-DrugBank.d737.s7|78-79|to|drug
DDI-DrugBank.d737.s7|81-86|affect|drug
DDI-DrugBank.d737.s7|88-98|pramipexole|drug
DDI-DrugBank.d737.s7|100-110|elimination|drug
DDI-DrugBank.d737.s7|112-118|because|drug
DDI-DrugBank.d737.s7|120-130|pramipexole|drug
DDI-DrugBank.d737.s7|132-133|is|drug
DDI-DrugBank.d737.s7|135-137|not|drug
DDI-DrugBank.d737.s7|139-149|appreciably|drug
DDI-DrugBank.d737.s7|151-161|metabolized|drug
DDI-DrugBank.d737.s7|163-164|by|drug
DDI-DrugBank.d737.s7|166-170|these|drug
DDI-DrugBank.d737.s7|172-178|enzymes|drug
DDI-DrugBank.d737.s7|180-181|in|drug
DDI-DrugBank.d737.s7|183-186|vivo|drug
DDI-DrugBank.d737.s7|188-189|or|drug
DDI-DrugBank.d737.s7|191-192|in|drug
DDI-DrugBank.d737.s7|194-198|vitro|drug
DDI-DrugBank.d737.s7|199-199|.|drug
DDI-DrugBank.d737.s8|0-10|Pramipexole|brand
DDI-DrugBank.d737.s8|12-15|does|drug
DDI-DrugBank.d737.s8|17-19|not|drug
DDI-DrugBank.d737.s8|21-27|inhibit|drug
DDI-DrugBank.d737.s8|29-31|CYP|drug
DDI-DrugBank.d737.s8|33-39|enzymes|drug
DDI-DrugBank.d737.s8|41-46|CYPIA2|drug
DDI-DrugBank.d737.s8|47-47|,|drug
DDI-DrugBank.d737.s8|49-54|CYP2C9|drug
DDI-DrugBank.d737.s8|55-55|,|drug
DDI-DrugBank.d737.s8|57-63|CYP2CI9|drug
DDI-DrugBank.d737.s8|64-64|,|drug
DDI-DrugBank.d737.s8|66-71|CYP2EI|drug
DDI-DrugBank.d737.s8|72-72|,|drug
DDI-DrugBank.d737.s8|74-76|and|drug
DDI-DrugBank.d737.s8|78-83|CYP3A4|drug
DDI-DrugBank.d737.s8|84-84|.|drug
DDI-DrugBank.d737.s9|0-9|Inhibition|drug
DDI-DrugBank.d737.s9|11-12|of|drug
DDI-DrugBank.d737.s9|14-19|CYP2D6|drug
DDI-DrugBank.d737.s9|21-23|was|drug
DDI-DrugBank.d737.s9|25-32|observed|drug
DDI-DrugBank.d737.s9|34-37|with|drug
DDI-DrugBank.d737.s9|39-40|an|drug
DDI-DrugBank.d737.s9|42-49|apparent|drug
DDI-DrugBank.d737.s9|51-52|Ki|drug
DDI-DrugBank.d737.s9|54-55|of|drug
DDI-DrugBank.d737.s9|57-58|30|drug
DDI-DrugBank.d737.s9|60-61|uM|drug
DDI-DrugBank.d737.s9|62-62|,|drug
DDI-DrugBank.d737.s9|64-73|indicating|drug
DDI-DrugBank.d737.s9|75-78|that|drug
DDI-DrugBank.d737.s9|80-90|pramipexole|drug
DDI-DrugBank.d737.s9|92-95|will|drug
DDI-DrugBank.d737.s9|97-99|not|drug
DDI-DrugBank.d737.s9|101-107|inhibit|drug
DDI-DrugBank.d737.s9|109-111|CYP|drug
DDI-DrugBank.d737.s9|113-119|enzymes|drug
DDI-DrugBank.d737.s9|121-122|at|drug
DDI-DrugBank.d737.s9|124-129|plasma|drug
DDI-DrugBank.d737.s9|131-144|concentrations|drug
DDI-DrugBank.d737.s9|146-153|observed|drug
DDI-DrugBank.d737.s9|155-163|following|drug
DDI-DrugBank.d737.s9|165-167|the|drug
DDI-DrugBank.d737.s9|169-175|highest|drug
DDI-DrugBank.d737.s9|177-187|recommended|drug
DDI-DrugBank.d737.s9|189-196|clinical|drug
DDI-DrugBank.d737.s9|198-201|dose|drug
DDI-DrugBank.d737.s9|203-203|(|drug
DDI-DrugBank.d737.s9|204-206|1.5|drug
DDI-DrugBank.d737.s9|208-209|mg|drug
DDI-DrugBank.d737.s9|211-213|tid|drug
DDI-DrugBank.d737.s9|214-214|)|drug
DDI-DrugBank.d737.s9|215-215|.|drug
DDI-DrugBank.d737.s10|0-7|Dopamine|brand
DDI-DrugBank.d737.s10|9-19|antagonists|drug
DDI-DrugBank.d737.s10|20-20|:|drug
DDI-DrugBank.d737.s10|22-26|Since|drug
DDI-DrugBank.d737.s10|28-38|pramipexole|drug
DDI-DrugBank.d737.s10|40-41|is|drug
DDI-DrugBank.d737.s10|43-43|a|drug
DDI-DrugBank.d737.s10|45-52|dopamine|drug
DDI-DrugBank.d737.s10|54-60|agonist|drug
DDI-DrugBank.d737.s10|61-61|,|drug
DDI-DrugBank.d737.s10|63-64|it|drug
DDI-DrugBank.d737.s10|66-67|is|drug
DDI-DrugBank.d737.s10|69-76|possible|drug
DDI-DrugBank.d737.s10|78-81|that|drug
DDI-DrugBank.d737.s10|83-90|dopamine|drug
DDI-DrugBank.d737.s10|92-102|antagonists|drug
DDI-DrugBank.d737.s10|103-103|,|drug
DDI-DrugBank.d737.s10|105-108|such|drug
DDI-DrugBank.d737.s10|110-111|as|drug
DDI-DrugBank.d737.s10|113-115|the|drug
DDI-DrugBank.d737.s10|117-128|neuroleptics|drug
DDI-DrugBank.d737.s10|130-130|(|drug
DDI-DrugBank.d737.s10|131-144|phenothiazines|drug
DDI-DrugBank.d737.s10|145-145|,|drug
DDI-DrugBank.d737.s10|147-160|butyrophenones|drug
DDI-DrugBank.d737.s10|161-161|,|drug
DDI-DrugBank.d737.s10|163-175|thioxanthenes|drug
DDI-DrugBank.d737.s10|176-176|)|drug
DDI-DrugBank.d737.s10|178-179|or|drug
DDI-DrugBank.d737.s10|181-194|metoclopramide|drug
DDI-DrugBank.d737.s10|195-195|,|drug
DDI-DrugBank.d737.s10|197-199|may|drug
DDI-DrugBank.d737.s10|201-208|diminish|drug
DDI-DrugBank.d737.s10|210-212|the|drug
DDI-DrugBank.d737.s10|214-226|effectiveness|drug
DDI-DrugBank.d737.s10|228-229|of|drug
DDI-DrugBank.d737.s10|231-237|MIRAPEX|drug
DDI-DrugBank.d737.s10|238-238|.|drug
DDI-DrugBank.d737.s11|0-4|Drug/|drug
DDI-DrugBank.d737.s11|6-15|Laboratory|drug
DDI-DrugBank.d737.s11|17-20|Test|drug
DDI-DrugBank.d737.s11|22-33|Interactions|drug
DDI-DrugBank.d737.s11|35-39|There|drug
DDI-DrugBank.d737.s11|41-43|are|drug
DDI-DrugBank.d737.s11|45-46|no|drug
DDI-DrugBank.d737.s11|48-52|known|drug
DDI-DrugBank.d737.s11|54-65|interactions|drug
DDI-DrugBank.d737.s11|67-73|between|drug
DDI-DrugBank.d737.s11|75-81|MIRAPEX|drug
DDI-DrugBank.d737.s11|83-85|and|drug
DDI-DrugBank.d737.s11|87-96|laboratory|drug
DDI-DrugBank.d737.s11|98-102|tests|drug
DDI-DrugBank.d737.s11|103-103|.|drug
